PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kreis, NN; Steinhauser, K; Ritter, A; Kloble, P; Hoock, SC; Roth, S; Louwen, F; Oswald, F; Yuan, JP				Kreis, Nina-Naomi; Steinhaeuser, Kerstin; Ritter, Andreas; Kloeble, Patricia; Hoock, Samira Catharina; Roth, Susanne; Louwen, Frank; Oswald, Franz; Yuan, Juping			Potential involvement of RITA in the activation of Aurora A at spindle poles during mitosis	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; MICROTUBULE-ASSOCIATED PROTEIN; CELL LYMPHOMA 6; A KINASE; CENTROSOME AMPLIFICATION; MITOTIC DEFECTS; TPX2; NUCLEATION; TUBULIN; HURP	The mitotic kinase Aurora A is crucial for various mitotic events. Its activation has been intensively investigated and is not yet completely understood. RITA, the RBP-J interacting and tubulin-associated protein, has been shown to modulate microtubule dynamics in mitosis. We asked if RITA could be related to the activation of Aurora A. We show here that RITA is colocalized with Aurora A and its activator TPX2 at spindle poles during mitosis. FLAG-RITA is precipitated with the complex of Aurora A, TPX2 and tubulin. Depletion of RITA increases exclusively active Aurora A and TPX2 at spindle poles in diverse cancer cell lines and in RITA knockout mouse embryonic fibroblasts. The enhanced active Aurora A, its substrate p-TACC3 and TPX2 are restored by adding back of RITA but not its Delta tub mutant with an impaired tubulin-binding capability, indicating that RITA' s role as Aurora A's modulator is mediated through its interaction with tubulin. Also, the mitotic failures in cells depleted of RITA are rescued by the inhibition of Aurora A. RITA itself does not directly interfere with the catalytic activity of Aurora A, instead, affects the microtubule binding of its activator TPX2. Moreover, Aurora A's activation correlates with microtubule stabilization induced by the microtubule stabilizer paclitaxel, implicating that stabilized microtubules caused by RITA depletion could also account for increased active Aurora A. Our data suggest a potential role for RITA in the activation of Aurora A at spindle poles by modulating the microtubule binding of TPX2 and the microtubule stability during mitosis.	[Kreis, Nina-Naomi; Steinhaeuser, Kerstin; Ritter, Andreas; Hoock, Samira Catharina; Roth, Susanne; Louwen, Frank; Yuan, Juping] Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany; [Kloeble, Patricia; Oswald, Franz] Univ Med Ctr Ulm, Ctr Internal Med, Dept Internal Med 1, Albert Einstein Allee 23, D-89081 Ulm, Germany; [Steinhaeuser, Kerstin] Solvadis Distribut GmbH, Hafen 4, D-64579 Gernsheim, Germany	Goethe University Frankfurt; Ulm University	Yuan, JP (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Gynecol & Obstet, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	yuan@em.uni-frankfurt.de	Ritter, Andreas/AAX-3938-2020; Ritter, Andreas/ABB-6348-2020; Kreis, Nina-Naomi/AAF-5407-2019; Oswald, Franz/AAO-9584-2020	Ritter, Andreas/0000-0002-5955-859X; Kreis, Nina-Naomi/0000-0003-4304-0160; Yuan, Juping/0000-0003-0694-0565	Deutsche Forschungsgemeinschaft [SFB1074/A3, Yu 156/7-1]; BMBF (research nucleus SyStAR); International Graduate School in Molecular Medicine, Ulm [GSC270]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); BMBF (research nucleus SyStAR)(Federal Ministry of Education & Research (BMBF)); International Graduate School in Molecular Medicine, Ulm	We gratefully thank Ms. Friemel (Frankfurt) and Ms. Schirmer (Ulm) for their technical assistance. The work was partially supported by the Deutsche Forschungsgemeinschaft (SFB1074/A3 to FO, Yu 156/7-1 to JY) and the BMBF (research nucleus SyStAR to FO). PK was supported by the International Graduate School in Molecular Medicine, Ulm (GSC270).	Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Asteriti IA, 2010, BBA-REV CANCER, V1806, P230, DOI 10.1016/j.bbcan.2010.08.001; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Brunet S, 2004, MOL BIOL CELL, V15, P5318, DOI 10.1091/mbc.E04-05-0385; Burgess SG, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005345; Carmena M, 2009, CURR OPIN CELL BIOL, V21, P796, DOI 10.1016/j.ceb.2009.09.008; D'Assoro AB, 2016, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00295; Dodson CA, 2012, J BIOL CHEM, V287, P1150, DOI 10.1074/jbc.M111.312090; Ertych N, 2014, NAT CELL BIOL, V16, P779, DOI 10.1038/ncb2994; Eyers PA, 2004, J BIOL CHEM, V279, P9008, DOI 10.1074/jbc.M312424200; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Garrett S, 2002, CURR BIOL, V12, P2055, DOI 10.1016/S0960-9822(02)01277-0; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; Goepfert TM, 2002, CANCER RES, V62, P4115; Gruss OJ, 2004, J CELL BIOL, V166, P949, DOI 10.1083/jcb.200312112; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Hochegger H, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120185; Jasmer B, 2017, ONCOTARGET, V8, P108643, DOI 10.18632/oncotarget.20586; Karthigeyan D, 2011, MED RES REV, V31, P757, DOI 10.1002/med.20203; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Kreis NN, 2014, ONCOGENE, V33, P5716, DOI 10.1038/onc.2013.518; Kreis NN, 2016, ONCOTARGET, V7, P50215, DOI 10.18632/oncotarget.10330; Kreis NN, 2015, ONCOTARGET, V6, P6611, DOI 10.18632/oncotarget.2844; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Magiera MM, 2013, METHOD CELL BIOL, V115, P247, DOI 10.1016/B978-0-12-407757-7.00016-5; Manfredi MG, 2007, P NATL ACAD SCI USA, V104, P4106, DOI 10.1073/pnas.0608798104; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Muschol-Steinmetz C, 2016, CELL CYCLE, V15, P827, DOI 10.1080/15384101.2016.1149273; Nguyen HL, 1999, J CELL SCI, V112, P1813; Noujaim M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086786; Ritter A, 2018, STEM CELL REP, V10, P583, DOI 10.1016/j.stemcr.2017.12.022; Ritter A, 2016, CRIT REV BIOCHEM MOL, V51, P228, DOI 10.1080/10409238.2016.1178705; Ritter A, 2015, CELL CYCLE, V14, P3755, DOI 10.1080/15384101.2015.1068481; Rodel F, 2018, RADIOTHER ONCOL, V126, P214, DOI 10.1016/j.radonc.2017.10.028; Rohena CC, 2013, BIOCHEM PHARMACOL, V85, P1104, DOI 10.1016/j.bcp.2013.01.030; Rosasco-Nitcher SE, 2008, SCIENCE, V319, P469, DOI 10.1126/science.1148980; Sanhaji M, 2010, MOL CELL BIOL, V30, P2594, DOI 10.1128/MCB.00098-10; Sardon T, 2008, EMBO J, V27, P2567, DOI 10.1038/emboj.2008.173; Sardon T, 2010, EMBO REP, V11, P977, DOI 10.1038/embor.2010.171; Schatz CA, 2003, EMBO J, V22, P2060, DOI 10.1093/emboj/cdg195; Silva VC, 2013, MOL BIOL CELL, V24, P3819, DOI 10.1091/mbc.E13-02-0108; Steinhauser K, 2017, ONCOGENE, V36, P2146, DOI 10.1038/onc.2016.372; Tang AQ, 2017, ONCOTARGET, V8, P23937, DOI 10.18632/oncotarget.14893; Thakur HC, 2013, BIOL CHEM, V394, P1411, DOI 10.1515/hsz-2013-0184; Tsai MY, 2005, CURR BIOL, V15, P2156, DOI 10.1016/j.cub.2005.10.054; Wacker SA, 2011, EMBO J, V30, P43, DOI 10.1038/emboj.2010.289; Wang HH, 2014, BIOCHEM BIOPH RES CO, V454, P71, DOI 10.1016/j.bbrc.2014.10.023; Wang HH, 2012, ONCOL RES, V20, P437, DOI 10.3727/096504013X13685487925059; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673; Wong J, 2008, MOL BIOL CELL, V19, P2083, DOI 10.1091/mbc.E07-10-1088; Wu JM, 2013, P NATL ACAD SCI USA, V110, pE1779, DOI 10.1073/pnas.1220523110; Zhang R, 2017, ELIFE, V6, DOI 10.7554/eLife.30959; Zhang X, 2008, MOL BIOL CELL, V19, P2752, DOI 10.1091/mbc.E08-02-0198	57	3	3	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4199	4214		10.1038/s41388-019-0716-7	http://dx.doi.org/10.1038/s41388-019-0716-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30705408				2022-12-17	WOS:000469339100001
J	Dong, PX; Xiong, Y; Yu, JH; Chen, L; Tao, T; Yi, S; Hanley, SJB; Yue, JM; Watari, H; Sakuragi, N				Dong, Peixin; Xiong, Ying; Yu, Jiehai; Chen, Lin; Tao, Tang; Yi, Song; Hanley, Sharon J. B.; Yue, Junming; Watari, Hidemichi; Sakuragi, Noriaki			Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer (vol 37, pg 5257, 2018)	ONCOGENE			English	Correction									[Dong, Peixin; Hanley, Sharon J. B.; Sakuragi, Noriaki] Hokkaido Univ, Dept Womens Hlth Educ Syst, Sch Med, Sapporo, Hokkaido 0608638, Japan; [Dong, Peixin; Watari, Hidemichi] Hokkaido Univ, Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido 0608638, Japan; [Xiong, Ying; Yu, Jiehai; Chen, Lin] Sun Yat Sen Univ, State Key Lab Oncol South China, Dept Gynecol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China; [Tao, Tang; Yi, Song] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Fac Med, Shatin, Hong Kong, Peoples R China; [Yue, Junming] Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN 38163 USA; [Yue, Junming] Univ Tennessee, Hlth Sci Ctr, Ctr Canc Res, Memphis, TN 38163 USA	Hokkaido University; Hokkaido University; State Key Lab Oncology South China; Sun Yat Sen University; Chinese University of Hong Kong; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Dong, PX (corresponding author), Hokkaido Univ, Dept Womens Hlth Educ Syst, Sch Med, Sapporo, Hokkaido 0608638, Japan.; Dong, PX; Watari, H (corresponding author), Hokkaido Univ, Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido 0608638, Japan.; Yue, JM (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN 38163 USA.; Yue, JM (corresponding author), Univ Tennessee, Hlth Sci Ctr, Ctr Canc Res, Memphis, TN 38163 USA.	dpx1cn@gmail.com; jyue@uthsc.edu; watarih@med.hokudai.ac.jp						Dong PX, 2018, ONCOGENE, V37, P5257, DOI 10.1038/s41388-018-0347-4	1	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3972	3972		10.1038/s41388-019-0677-x	http://dx.doi.org/10.1038/s41388-019-0677-x			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30679789	hybrid, Green Published			2022-12-17	WOS:000468035600016
J	Arafeh, R; Di Pizio, A; Elkahloun, AG; Dym, O; Niv, MY; Samuels, Y				Arafeh, Rand; Di Pizio, Antonella; Elkahloun, Abdel G.; Dym, Orly; Niv, Masha Y.; Samuels, Yardena			RASA2 and NF1; two-negative regulators of Ras with complementary functions in melanoma	ONCOGENE			English	Letter							MUTATIONS		[Arafeh, Rand; Dym, Orly; Samuels, Yardena] Weizmann Inst Sci, Rehovot, Israel; [Di Pizio, Antonella; Niv, Masha Y.] Hebrew Univ Jerusalem, Robert H Smith Fac Agr Food & Environm, Inst Biochem Food Sci & Nutr, Rehovot, Israel; [Elkahloun, Abdel G.] NHGRI, US Natl Inst Hlth, Bethesda, MD 20892 USA	Weizmann Institute of Science; Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Samuels, Y (corresponding author), Weizmann Inst Sci, Rehovot, Israel.	Yardena.Samuels@weizmann.ac.il	Niv, Masha/AAL-1123-2020; Di Pizio, Antonella/ABC-6792-2020	Di Pizio, Antonella/0000-0002-8520-5165; Arafeh, Rand/0000-0001-7107-2982; Niv, Masha/0000-0001-8275-8795	Intramural Research Program of the National Cancer Institute; Israel Science Foundation [696/17]; European Research Council (ERC) under the European Union's Horizon 2020 research and innovation Programme [754282]; ERC [StG-335377]; Minerva Foundation Grant; Henry Chanoch Krenter Institute for Biomedical Imaging and Genomics; estate of Alice Schwarz-Gardos; estate of John Hunter; Knell Family; Peter and Patricia Gruber Award; Hamburger Family; Clore foundation; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZICHG200365] Funding Source: NIH RePORTER	Intramural Research Program of the National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Israel Science Foundation(Israel Science Foundation); European Research Council (ERC) under the European Union's Horizon 2020 research and innovation Programme(European Research Council (ERC)); ERC(European Research Council (ERC)European Commission); Minerva Foundation Grant; Henry Chanoch Krenter Institute for Biomedical Imaging and Genomics; estate of Alice Schwarz-Gardos; estate of John Hunter; Knell Family; Peter and Patricia Gruber Award; Hamburger Family; Clore foundation; NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank T. Wiesel for graphical assistance. This work was supported by the Intramural Research Program of the National Cancer Institute. Y.S. is supported by the Israel Science Foundation grant number 696/17. This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation Programme (grant agreement No 754282), the ERC (StG-335377), the Minerva Foundation Grant, the Henry Chanoch Krenter Institute for Biomedical Imaging and Genomics, the estate of Alice Schwarz-Gardos, the estate of John Hunter, the Knell Family, the Peter and Patricia Gruber Award, and the Hamburger Family. R.A. is supported by Clore foundation. A.D.P is a Lady Davis postdoctoral fellow.	Arafeh R, 2015, NAT GENET, V47, P1408, DOI 10.1038/ng.3427; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313	3	3	3	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2432	2434		10.1038/s41388-018-0578-4	http://dx.doi.org/10.1038/s41388-018-0578-4			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30478445				2022-12-17	WOS:000462588000015
J	Stylianou, N; Lehman, ML; Wang, CW; Fard, AT; Rockstroh, A; Fazli, L; Jovanovic, L; Ward, M; Sadowski, MC; Kashyap, AS; Buttyan, R; Gleave, ME; Westbrook, TF; Williams, ED; Gunter, JH; Nelson, CC; Hollier, BG				Stylianou, Nataly; Lehman, Melanie L.; Wang, Chenwei; Fard, Atefeh Taherian; Rockstroh, Anja; Fazli, Ladan; Jovanovic, Lidija; Ward, Micheal; Sadowski, Martin C.; Kashyap, Abhishek S.; Buttyan, Ralph; Gleave, Martin E.; Westbrook, Thomas F.; Williams, Elizabeth D.; Gunter, Jennifer H.; Nelson, Colleen C.; Hollier, Brett G.			A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome (vol 38, pg 913, 2019)	ONCOGENE			English	Correction									[Stylianou, Nataly; Lehman, Melanie L.; Wang, Chenwei; Fard, Atefeh Taherian; Rockstroh, Anja; Jovanovic, Lidija; Sadowski, Martin C.; Williams, Elizabeth D.; Gunter, Jennifer H.; Nelson, Colleen C.; Hollier, Brett G.] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Princess Alexandra Hosp, Fac Hlth,Sch Biomed Sci,Translat Res Inst,Inst Hl, Brisbane, Qld, Australia; [Lehman, Melanie L.; Fazli, Ladan; Buttyan, Ralph; Gleave, Martin E.] Univ British Columbia, Dept Urol Sci, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Ward, Micheal] Univ Queensland, Sch Med, Glycat & Diabet Complicat Grp, Mater Res Inst,Translat Res Inst, Brisbane, Qld, Australia; [Kashyap, Abhishek S.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Tissue Repair & Regenerat Program, Brisbane, Qld, Australia; [Westbrook, Thomas F.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Queensland University of Technology (QUT); University of British Columbia; Mater Research; University of Queensland; Queensland University of Technology (QUT); Baylor College of Medicine	Hollier, BG (corresponding author), Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Princess Alexandra Hosp, Fac Hlth,Sch Biomed Sci,Translat Res Inst,Inst Hl, Brisbane, Qld, Australia.	b.hollier@qut.edu.au	Stylianou, Nataly/GOP-1782-2022; Fard, Ati/AAX-4092-2021; Williams, Elizabeth D/B-1538-2008; Gunter, Jennifer H/B-8960-2016	Williams, Elizabeth D/0000-0002-3364-6655; Gunter, Jennifer H/0000-0003-2447-5732; Gleave, Martin/0000-0003-4235-0167; Sadowski, Martin/0000-0002-5267-1442; Stylianou, Nataly/0000-0002-8006-5730				Stylianou N, 2019, ONCOGENE, V38, P913, DOI 10.1038/s41388-018-0488-5	1	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2436	2436		10.1038/s41388-018-0587-3	http://dx.doi.org/10.1038/s41388-018-0587-3			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30510231	Green Published, hybrid			2022-12-17	WOS:000462588000017
J	Lubrano, S; Comelli, L; Piccirilli, C; Marranci, A; Dapporto, F; Tantillo, E; Gemignani, F; Gutkind, JS; Salvetti, A; Chiorino, G; Cozza, G; Chiariello, M; Galli, A; Poliseno, L; Cervelli, T				Lubrano, Simone; Comelli, Laura; Piccirilli, Chiara; Marranci, Andrea; Dapporto, Francesca; Tantillo, Elena; Gemignani, Federica; Gutkind, J. Silvio; Salvetti, Alessandra; Chiorino, Giovanna; Cozza, Giorgio; Chiariello, Mario; Galli, Alvaro; Poliseno, Laura; Cervelli, Tiziana			Development of a yeast-based system to identify new hBRAFV600E functional interactors	ONCOGENE			English	Article							B-RAF; MOLECULAR-DYNAMICS; PROTEIN-KINASES; BRAF; PHOSPHORYLATION; PROGRESSION; MUTATIONS; PATHWAY; GROWTH; PTP2	BRAFV600E is a mutant Ser-Thr protein kinase that plays a crucial role in many types of cancer, including melanoma. Despite several aspects of BRAFV600E biology have been already elucidated, the proteins that regulate its expression and activity remain largely unknown, hampering our capacity to control its unrestrained effects. Here, we propose yeast Saccharomyces cerevisiae as a model system that can be used to achieve a better understanding of the regulation of human BRAFV600E. By showing that in osmotic stress conditions hBRAFV600E can rescue the growth of strains carrying a double or triple deletion in MAPKKK belonging to the HOG pathway, we demonstrate that this oncogenic kinase is active in yeast even if it does not have an ortholog. Moreover, we report that, in the yeast ptp3 Delta ptc1 Delta strain that is deleted in the genes encoding for two phosphatases responsible for Hog1 de-phoshorylation, hBRAFV600E mimics the toxicity observed in the presence of constitutive Hog1 activation. Finally, we exploit such a toxicity to perform a functional screening of a human cDNA library, looking for cDNAs able to rescue yeast growth. In this way, we identify SMIM10, a mitochondrial protein that in melanoma cells selectively downregulates BRAFV600E RNA and protein levels, by acting indirectly at the post-transcriptional level. Upon SMIM10 overexpression, BRAFV600E melanoma cells show disrupted mitochondrial structure/function and undergo senescence. They also show decreased ability to proliferate and form colonies, as well as increased sensitivity to the BRAF inhibitor vemurafenib. Interestingly, the analysis of TCGA melanoma samples indicates that patients with higher SMIM10 levels have a better prognosis. Therefore, these data suggest that SMIM10 exerts an oncosuppressive role in melanoma cells. Taken together, our results unveil the potential of S. cerevisiae to study hBRAFV600E, to populate the network of its functional interactors and, in doing so, to uncover new cancer-associated genes with therapeutic potential.	[Lubrano, Simone; Marranci, Andrea; Poliseno, Laura] ISPRO, Core Res Lab, Oncogen Unit, Pisa, Italy; [Lubrano, Simone; Comelli, Laura; Piccirilli, Chiara; Marranci, Andrea; Chiariello, Mario; Galli, Alvaro; Poliseno, Laura; Cervelli, Tiziana] IFC CNR, Inst Clin Physiol, Pisa, Italy; [Lubrano, Simone; Gemignani, Federica] Univ Pisa, Dept Biol, Pisa, Italy; [Dapporto, Francesca; Chiariello, Mario] ISPRO, Core Res Lab, Signal Transduct Unit, Siena, Italy; [Tantillo, Elena] Scuola Normale Super Pisa, Pisa, Italy; [Tantillo, Elena] FPS Pisa Sci Fdn, Pisa, Italy; [Gutkind, J. Silvio] UC San Diego Moores Canc Ctr, Dept Pharmacol, La Jolla, CA USA; [Salvetti, Alessandra] Univ Pisa, Dept Clin & Expt Med, Unit Expt Biol & Genet, Pisa, Italy; [Chiorino, Giovanna] Fdn Edo & Elvo Tempia, Lab Canc Genom, Biella, Italy; [Cozza, Giorgio] Univ Padua, Dept Mol Med, Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Pisa; Scuola Normale Superiore di Pisa; University of Pisa; University of Padua	Poliseno, L (corresponding author), ISPRO, Core Res Lab, Oncogen Unit, Pisa, Italy.; Galli, A; Poliseno, L; Cervelli, T (corresponding author), IFC CNR, Inst Clin Physiol, Pisa, Italy.	alvaro.galli@ifc.cnr.it; laura.poliseno@gmail.com; tizicerv@ifc.cnr.it	Marranci, Andrea/AAA-7874-2019; Gutkind, J. Silvio/J-1201-2016; Galli, Alvaro/K-3146-2018; Chiorino, Giovanna/K-5037-2016; Chiariello, Mario/O-3642-2014; Lubrano, Simone/AAF-1964-2021; Galli, Alvaro/AAL-7247-2020; Poliseno, Laura/B-5711-2012	Marranci, Andrea/0000-0002-8334-8795; Gutkind, J. Silvio/0000-0002-5150-4482; Galli, Alvaro/0000-0002-9091-5639; Chiorino, Giovanna/0000-0002-9502-6400; Chiariello, Mario/0000-0001-8434-5177; Lubrano, Simone/0000-0003-4779-5632; GEMIGNANI, Federica/0000-0003-1297-0701; COZZA, GIORGIO/0000-0002-5155-4682; Poliseno, Laura/0000-0001-6557-955X	Progetto Giovani Ricercatori (University of Padova); ITT; Progetto Giovani Ricercatori (Ministero della Salute) [GR-2011-02348535]; AIRC [MFAG 17095, IG 14477]; Fondazione Pisa grant [127/16]	Progetto Giovani Ricercatori (University of Padova); ITT; Progetto Giovani Ricercatori (Ministero della Salute); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Pisa grant	The authors would like to thank all the Poliseno and Galli lab members, as well as A. Tuccoli, for helpful discussions. They also thank E. O'Shea (Department of Molecular and Cellular Biology, Harvard University, Cambridge, United States, USA) for providing the ECY46 yeast strain. This work was supported by: Progetto Giovani Ricercatori (University of Padova) to GC; Start up funding ITT and Progetto Giovani Ricercatori #GR-2011-02348535 (Ministero della Salute) to LP. It was also partially supported by AIRC grant #MFAG 17095 to LP; Fondazione Pisa grant #127/16 as well as AIRC grant #IG 14477 to AG.	Ascierto PA, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1341-2; Atienza JM, 2000, J BIOL CHEM, V275, P20638, DOI 10.1074/jbc.M910024199; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Collavoli A, 2008, FEMS YEAST RES, V8, P351, DOI 10.1111/j.1567-1364.2007.00343.x; Condelli V, 2014, CANCER RES, V74, P6693, DOI 10.1158/0008-5472.CAN-14-1331; Cozza G, 2017, FREE RADICAL BIO MED, V112, P1, DOI 10.1016/j.freeradbiomed.2017.07.010; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Gietz RD, 2007, NAT PROTOC, V2, P38, DOI 10.1038/nprot.2007.15; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Harvey MJ, 2009, J CHEM THEORY COMPUT, V5, P1632, DOI 10.1021/ct9000685; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Jain A, 2017, ONCOGENE, V36, P4585, DOI 10.1038/onc.2017.76; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Laurent JM, 2016, BRIEF FUNCT GENOMICS, V15, P155, DOI 10.1093/bfgp/elv041; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; Marranci A, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0645-4; Marranci A, 2015, J INVEST DERMATOL, V135, P1694, DOI 10.1038/jid.2015.47; O'Rourke SM, 2004, MOL BIOL CELL, V15, P532, DOI 10.1091/mbc.E03-07-0521; O'Shaughnessy EC, 2011, CELL, V144, P119, DOI 10.1016/j.cell.2010.12.014; Papin C, 1996, ONCOGENE, V12, P2213; Park S, 2005, ONCOGENE, V24, P3535, DOI 10.1038/sj.onc.1208435; PASTOR RW, 1988, MOL PHYS, V65, P1409, DOI 10.1080/00268978800101881; Perkins E, 2001, CANCER RES, V61, P4175; Piper PW, 2006, BIOCHEM SOC T, V34, P783, DOI 10.1042/BST0340783; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Rohl CA, 2004, METHOD ENZYMOL, V383, P66; Saei A, 2018, J EXP MED, V215, P1913, DOI 10.1084/jem.20171960; Saito H, 2010, CURR OPIN MICROBIOL, V13, P677, DOI 10.1016/j.mib.2010.09.001; Schmidt O, 2010, NAT REV MOL CELL BIO, V11, P655, DOI 10.1038/nrm2959; Shen CH, 2013, MOL CELL, V52, P161, DOI 10.1016/j.molcel.2013.08.044; Stuckey S, 2013, METHOD ENZYMOL, V533, P103, DOI 10.1016/B978-0-12-420067-8.00008-8; Vitiello M, 2017, ONCOTARGET, V8, P25395, DOI 10.18632/oncotarget.15915; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zhi H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054867	38	3	3	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1355	1366		10.1038/s41388-018-0496-5	http://dx.doi.org/10.1038/s41388-018-0496-5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30237439				2022-12-17	WOS:000459249800016
J	Chen-Wichmann, L; Shvartsman, M; Preiss, C; Hockings, C; Windisch, R; Monte, ER; Leubolt, G; Spiekermann, K; Lausen, J; Brendel, C; Grez, M; Greif, PA; Wichmann, C				Chen-Wichmann, Linping; Shvartsman, Marina; Preiss, Caro; Hockings, Colin; Windisch, Roland; Monte, Enric Redondo; Leubolt, Georg; Spiekermann, Karsten; Lausen, Jorn; Brendel, Christian; Grez, Manuel; Greif, Philipp A.; Wichmann, Christian			Compatibility of RUNX1/ETO fusion protein modules driving CD34+human progenitor cell expansion	ONCOGENE			English	Article							ETO HOMOLOGS; AML1-ETO; DOMAIN; LEUKEMIA; PROMOTES; COMPLEX; GENE; TRANSCRIPTION; REPRESSION; PARTNER	Chromosomal translocations represent frequent events in leukemia. In t(8;21)+ acute myeloid leukemia, RUNX1 is fused to nearly the entire ETO protein, which contains four conserved nervy homology regions, NHR1-4. Furthermore RUNX1/ETO interacts with ETO-homologous proteins via NHR2, thereby multiplying NHR domain contacts. As shown recently, RUNX1/ETO retains oncogenic activity upon either deletion of the NHR3 + 4 N-CoR/SMRT interaction domain or substitution of the NHR2 tetramer domain. Thus, we aimed to clarify the specificities of the NHR domains. A C-terminally NHR3 + 4 truncated RUNX1/ETO containing a heterologous, structurally highly related non-NHR2 tetramer interface translocated into the nucleus and bound to RUNX1 consensus motifs. However, it failed to interact with ETO-homologues, repress RUNX1 targets, and transform progenitors. Surprisingly, transforming capacity was fully restored by C-terminal fusion with ETO's NHR4 zinc-finger or the repressor domain 3 of N-CoR, while other repression domains failed. With an inducible protein assembly system, we further demonstrated that NHR4 domain activity is critically required early in the establishment of progenitor cultures expressing the NHR2 exchanged truncated RUNX1/ETO. Together, we can show that NHR2 and NHR4 domains can be replaced by heterologous protein domains conferring tetramerization and repressor functions, thus showing that the NHR2 and NHR4 domain structures do not have irreplaceable functions concerning RUNX1/ETO activity for the establishment of human CD34+ cell expansion. We could resemble the function of RUNX1/ETO through modular recomposition with protein domains from RUNX1, ETO, BCR and N-CoR without any NHR2 and NHR4 sequences. As most transcriptional repressor proteins do not comprise tetramerization domains, our results provide a possible explanation as to the reason that RUNX1 is recurrently found translocated to ETO family members, which all contain tetramer together with transcriptional repressor moieties.	[Chen-Wichmann, Linping; Shvartsman, Marina; Preiss, Caro; Windisch, Roland; Wichmann, Christian] Ludwig Maximilians Univ Munchen, Hosp Munich, Dept Transfus Med Cell Therapeut & Hemostaseol, Munich, Germany; [Hockings, Colin] Univ Cambridge, Dept Chem Engn & Biotechnol, Cambridge, England; [Monte, Enric Redondo; Leubolt, Georg; Spiekermann, Karsten; Greif, Philipp A.] Ludwig Maximilians Univ Hosp Munich, Dept Internal Med 3, Munich, Germany; [Spiekermann, Karsten; Greif, Philipp A.] German Canc Consortium DKTK, Heidelberg, Germany; [Spiekermann, Karsten; Greif, Philipp A.] German Canc Res Ctr, Heidelberg, Germany; [Lausen, Jorn] Goethe Univ Frankfurt, Inst Transfus Med & Immunohematol, Frankfurt, Germany; [Lausen, Jorn] German Red Cross Blood Serv, Frankfurt, Germany; [Brendel, Christian] Harvard Med Sch, Dana Farber Canc Inst, Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA USA; [Grez, Manuel] Inst Tumor Biol & Expt Therapy, Georg Speyer Haus, Frankfurt, Germany	University of Munich; University of Cambridge; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Wichmann, C (corresponding author), Ludwig Maximilians Univ Munchen, Hosp Munich, Dept Transfus Med Cell Therapeut & Hemostaseol, Munich, Germany.	christian.wichmann@med.uni-muenchen.de	Wichmann, Christian/H-2491-2017; Brendel, Christian/HDN-6077-2022	Greif, Philipp/0000-0002-3744-7936; Redondo Monte, Enric/0000-0002-3588-223X; Brendel, Christian/0000-0003-4081-4351; Hockings, Colin/0000-0002-0248-0517	Jose Carreras Leukemia Foundation [DJCLS R 12/28]; Wilhelm Sander-Foundation [2014.162.2]; Friedrich-Baur Foundation; Deutsche Forschungsgemeinschaft [DFG LA 1389/6-1]	Jose Carreras Leukemia Foundation; Wilhelm Sander-Foundation; Friedrich-Baur Foundation; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Simone Schwarz for expert technical assistance and Sandra Moore for critical comments on the manuscript. We are supported by research grants from the Jose Carreras Leukemia Foundation (DJCLS R 12/28, CW), the Wilhelm Sander-Foundation (2014.162.2, PG & CW) the Friedrich-Baur Foundation (CW) and the Deutsche Forschungsgemeinschaft (DFG LA 1389/6-1, JL).	Ahn EY, 2008, P NATL ACAD SCI USA, V105, P17103, DOI 10.1073/pnas.0802696105; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; DeKelver RC, 2013, BLOOD, V121, P3714, DOI 10.1182/blood-2012-11-465641; Graef IA, 1997, EMBO J, V16, P5618, DOI 10.1093/emboj/16.18.5618; Guastadisegni MC, 2010, LEUKEMIA, V24, P1516, DOI 10.1038/leu.2010.106; Huang EY, 2000, GENE DEV, V14, P45; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Kohrs N, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005946; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Kwok C, 2009, P NATL ACAD SCI USA, V106, P2853, DOI 10.1073/pnas.0810558106; Lausen J, 2004, J BIOL CHEM, V279, P49281, DOI 10.1074/jbc.M407239200; Lindberg SR, 2003, EUR J HAEMATOL, V71, P439, DOI 10.1046/j.0902-4441.2003.00166.x; Lindberg SR, 2005, EXP HEMATOL, V33, P189, DOI 10.1016/j.exphem.2004.10.011; Link KA, 2016, P NATL ACAD SCI USA, V113, P9075, DOI 10.1073/pnas.1524225113; Liu YZ, 2007, CANCER CELL, V11, P483, DOI 10.1016/j.ccr.2007.04.010; Liu YZ, 2006, CANCER CELL, V9, P249, DOI 10.1016/j.ccr.2006.03.012; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Okumura AJ, 2008, BLOOD, V112, P1392, DOI 10.1182/blood-2007-11-124735; Okumura AJ, 2007, EXP HEMATOL, V35, P978, DOI 10.1016/j.exphem.2007.03.002; Park S, 2009, BLOOD, V113, P3558, DOI 10.1182/blood-2008-06-161307; Ponnusamy K, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.6; Pownall ME, 2003, DEV BIOL, V256, P89, DOI 10.1016/S0012-1606(02)00120-3; Salomon-Nguyen F, 2000, LEUKEMIA, V14, P1704, DOI 10.1038/sj.leu.2401885; Sun XJ, 2013, NATURE, V500, P93, DOI 10.1038/nature12287; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662; Wichmann C, 2015, LEUKEMIA, V29, P279, DOI 10.1038/leu.2014.179; Wichmann C, 2010, BLOOD, V116, P603, DOI 10.1182/blood-2009-10-248047; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Zhao X, 2002, NAT STRUCT BIOL, V9, P117	31	3	3	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					261	272		10.1038/s41388-018-0441-7	http://dx.doi.org/10.1038/s41388-018-0441-7			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30093631				2022-12-17	WOS:000455366700008
J	Zhu, J; Zhao, C; Kharman-Biz, A; Zhuang, T; Jonsson, P; Liang, N; Williams, C; Lin, CY; Qiao, Y; Zendehdel, K; Stromblad, S; Treuter, E; Dahlman-Wright, K				Zhu, J.; Zhao, C.; Kharman-Biz, A.; Zhuang, T.; Jonsson, P.; Liang, N.; Williams, C.; Lin, C. -Y.; Qiao, Y.; Zendehdel, K.; Stromblad, S.; Treuter, E.; Dahlman-Wright, K.			The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor alpha and modulates estrogen-stimulated breast cancer cell proliferation (vol 33, pg 4340, 2018)	ONCOGENE			English	Correction									[Zhu, J.; Zhao, C.; Kharman-Biz, A.; Zhuang, T.; Liang, N.; Qiao, Y.; Stromblad, S.; Treuter, E.; Dahlman-Wright, K.] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden; [Kharman-Biz, A.; Zendehdel, K.] Univ Tehran Med Sci, Canc Inst Iran, Canc Res Ctr, Tehran, Iran; [Jonsson, P.; Williams, C.; Lin, C. -Y.] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX USA	Karolinska Institutet; Tehran University of Medical Sciences; University of Houston System; University of Houston	Dahlman-Wright, K (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden.	karin.dahlman-wright@ki.se		Liang, Ning/0000-0002-7848-2893; Zendehdel, Kazem/0000-0002-0269-4945				Zhu J, 2014, ONCOGENE, V33, P4340, DOI 10.1038/onc.2013.573	1	3	3	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					299	300		10.1038/s41388-018-0502-y	http://dx.doi.org/10.1038/s41388-018-0502-y			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30262864	Bronze, Green Published			2022-12-17	WOS:000455366700011
J	Elias, D; Vever, H; Laenkholm, AV; Gjerstorff, MF; Yde, CW; Lykkesfeldt, AE; Ditzel, HJ				Elias, D.; Vever, H.; Laenkholm, A. -V.; Gjerstorff, M. F.; Yde, C. W.; Lykkesfeldt, A. E.; Ditzel, H. J.			Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (vol 34, pg 1919, 2015)	ONCOGENE			English	Correction									[Elias, D.; Vever, H.; Gjerstorff, M. F.; Ditzel, H. J.] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, Odense C, Denmark; [Laenkholm, A. -V.] Slagelse Hosp, Dept Pathol, Slagelse, Denmark; [Yde, C. W.; Lykkesfeldt, A. E.] Danish Canc Soc Res Ctr, Breast Canc Grp, Cell Death & Metab, Copenhagen, Denmark; [Ditzel, H. J.] Odense Univ Hosp, Dept Oncol, Odense, Denmark	University of Southern Denmark; Danish Cancer Society; University of Southern Denmark; Odense University Hospital	Elias, D; Ditzel, HJ (corresponding author), Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, Odense C, Denmark.; Ditzel, HJ (corresponding author), Odense Univ Hosp, Dept Oncol, Odense, Denmark.	delias@health.sdu.dk; hditzel@health.sdu.dk		Laenkholm, Anne-Vibeke/0000-0003-2166-8686				Elias D, 2015, ONCOGENE, V34, P1919, DOI 10.1038/onc.2014.138	1	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5585	5586		10.1038/s41388-018-0495-6	http://dx.doi.org/10.1038/s41388-018-0495-6			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	30242243	Green Published, hybrid			2022-12-17	WOS:000446991200008
J	Stantic, M; Wolfsberger, J; Sakil, HAM; Wilhelm, MT				Stantic, Marina; Wolfsberger, Johanna; Sakil, Habib A. M.; Wilhelm, Margareta T.			Delta Np73 enhances HIF-1 alpha protein stability through repression of the ECV complex	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BREAST-CANCER; TUMOR ANGIOGENESIS; UNFAVORABLE PROGNOSIS; FACTOR 1-ALPHA; UBIQUITIN LIGASES; POOR-PROGNOSIS; LUNG-CANCER; FACTOR-I; EXPRESSION	Cellular responses to low oxygen conditions are mainly regulated by the Hypoxia-inducible factors (HIFs). Induction of HIF-1 beta in tumor cells activates the angiogenic switch and allows for metabolic adaptations. HIF-1 alpha protein levels are tightly regulated through ubiquitin-mediated proteosomal degradation; however, high levels of HIF-1 alpha is a common feature in many solid tumors and is thought to enhance cancer cell proliferation, migration, and survival. Here, we report that the oncogenic p73 isoform, Delta Np73, increases HIF-1 alpha protein stability. We found that Delta Np73 represses expression of genes encoding subunits of the ECV complex, in particular Elongin C, Elongin B, Cullin 2, and Rbx1. The ECV complex is an E3 ligase complex responsible for polyubiquitinating HIF-1 alpha. Loss of Delta Np73 increases ubiquitination of HIF-1 alpha, leading to its degradation via the proteosomal pathway, and subsequent decrease of HIF-1 alpha target genes. Taken together, our data demonstrates that high levels of Delta Np73 stabilize HIF-1 alpha protein, allowing for it to accumulate and further potentiating its transcriptional activity and supporting tumor progression.	[Stantic, Marina; Wolfsberger, Johanna; Sakil, Habib A. M.; Wilhelm, Margareta T.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, S-17177 Stockholm, Sweden	Karolinska Institutet	Wilhelm, MT (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, S-17177 Stockholm, Sweden.	margareta.wilhelm@ki.se		Stantic, Marina/0000-0002-2800-5538; Wilhelm, Margareta/0000-0002-0516-9724	Swedish Cancer Society; Swedish Research Council; Swedish Childhood Cancer Society; Karolinska Institutet doctoral grants (KID); Young Investigator Award from the Swedish Cancer Society	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Childhood Cancer Society; Karolinska Institutet doctoral grants (KID); Young Investigator Award from the Swedish Cancer Society	This work was supported by grants from the Swedish Cancer Society and the Swedish Research Council. MS is supported by a postdoctoral fellowship from the Swedish Childhood Cancer Society. JW and HAMS are funded by Karolinska Institutet doctoral grants (KID). MW is supported by a Young Investigator Award from the Swedish Cancer Society.	Amelio I, 2015, P NATL ACAD SCI USA, V112, P226, DOI 10.1073/pnas.1410609111; Birner P, 2000, CANCER RES, V60, P4693; Cardote TAF, 2017, STRUCTURE, V25, P901, DOI 10.1016/j.str.2017.04.009; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Dulloo I, 2015, CELL CYCLE, V14, P3533, DOI 10.1080/15384101.2015.1078038; Fernandez-Alonso R, 2015, CELL DEATH DIFFER, V22, P1287, DOI 10.1038/cdd.2014.214; Generali D, 2006, CLIN CANCER RES, V12, P4562, DOI 10.1158/1078-0432.CCR-05-2690; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Gruber G, 2004, BREAST CANCER RES, V6, pR191, DOI 10.1186/bcr775; Ivan M, 2017, MOL CELL, V66, P772, DOI 10.1016/j.molcel.2017.06.002; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Koeppel M, 2011, NUCLEIC ACIDS RES, V39, P6069, DOI 10.1093/nar/gkr028; Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654; Kuschel A, 2012, J CELL PHYSIOL, V227, P514, DOI 10.1002/jcp.22798; Leung THY, 2013, BRIT J CANCER, V109, P965, DOI 10.1038/bjc.2013.397; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Madden SL, 1996, CANCER RES, V56, P5384; Mahrour N, 2008, J BIOL CHEM, V283, P8005, DOI 10.1074/jbc.M706987200; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736; Mohlin S, 2017, EXP CELL RES, V356, P192, DOI 10.1016/j.yexcr.2017.03.007; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413; Osada R, 2007, HUM PATHOL, V38, P1310, DOI 10.1016/j.humpath.2007.02.010; Sakil HAM, 2017, CELL ONCOL, V40, P631, DOI 10.1007/s13402-017-0340-x; Schindl M, 2002, CLIN CANCER RES, V8, P1831; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Shibaji T, 2003, ANTICANCER RES, V23, P4721; Soldevilla B, 2014, HUM MOL GENET, V23, P467, DOI 10.1093/hmg/ddt437; Stantic M, 2015, P NATL ACAD SCI USA, V112, P220, DOI 10.1073/pnas.1421697112; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Theodoropoulos VE, 2004, EUR UROL, V46, P200, DOI 10.1016/j.eururo.2004.04.008; Uramoto H, 2004, CLIN CANCER RES, V10, P6905, DOI 10.1158/1078-0432.CCR-04-0290; Uramoto H, 2006, ANTICANCER RES, V26, P1785; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wang RH, 2016, BIOCHEM BIOPH RES CO, V470, P117, DOI 10.1016/j.bbrc.2016.01.005; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Yamamoto Y, 2008, BREAST CANCER RES TR, V110, P465, DOI 10.1007/s10549-007-9742-1; Yoshimura H, 2004, CLIN CANCER RES, V10, P8554, DOI 10.1158/1078-0432.CCR-0946-03; Zambelli F, 2009, NUCLEIC ACIDS RES, V37, pW247, DOI 10.1093/nar/gkp464; Zhong H, 1999, CANCER RES, V59, P5830; Zhou WH, 2013, CELL RES, V23, P599, DOI 10.1038/cr.2013.44; Zitterbart K, 2007, ACTA NEUROPATHOL, V114, P641, DOI 10.1007/s00401-007-0298-2	47	3	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3729	3739		10.1038/s41388-018-0195-2	http://dx.doi.org/10.1038/s41388-018-0195-2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29628507	hybrid, Green Published			2022-12-17	WOS:000437975200009
J	Babbar, M; Huang, Y; An, J; Landas, SK; Sheikh, MS				Babbar, Mansi; Huang, Ying; An, Jie; Landas, Steve K.; Sheikh, M. Saeed			CHTM1, a novel metabolic marker deregulated in human malignancies	ONCOGENE			English	Article							CREB; ACTIVATION; COACTIVATOR; OXIDATION; COMPLEX; CELLS	A better understanding of the link between cellular metabolism and tumorigenesis is needed. Here, we report characterization of a novel protein named coiled-coil helix tumor and metabolism 1 (CHTM1). We have found that CHTM1 is associated with cancer and cellular metabolism. CHTM1 localizes to mitochondria and cytosol, and its deficiency in cancer cells results in decreased mitochondrial oxygen consumption and ATP levels as well as oxidative stress indicating mitochondrial dysfunction. CHTM1-deficient cancer cells display poor growth under glucose/glutamine-deprived conditions, whereas cells expressing increased levels of exogenous CHTM1 exhibit enhanced proliferation and survival under similar conditions. CHTM1 deficiency also leads to defects in lipid metabolism resulting in fatty acid accumulation, which explains poor growth of CHTM1-deficient cells under glucose/glutamine deprivation since nutrient deprivation increases dependency on lipids for energy generation. We also demonstrate that CHTM1 mediates its effect via the PKC, CREB, and PGC-1alpha signaling axis, and cytosolic accumulation of CHTM1 during nutrient deprivation appears to be important for its effect on cellular signaling events. Furthermore, analyses of tissue specimens from 71 breast and 97 colon cancer patients show CHTM1 expression to be upregulated in the majority of tumor specimens representing these malignancies. Collectively, our findings are highly significant because CHTM1 is a novel metabolic marker that is important for the growth of tumorigenic cells under limiting nutrient supplies and thus, links cellular metabolism and tumorigenesis.	[Babbar, Mansi; Huang, Ying; An, Jie; Sheikh, M. Saeed] SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; [Landas, Steve K.] SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA; [An, Jie] Gulfstream Diagnost Genom, Dallas, TX USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.	sheikhm@upstate.edu	Babbar, Mansi/AAP-7320-2020; Babbar, Mansi/P-1698-2019	BABBAR, MANSI/0000-0002-9690-8974	Carol M. Baldwin breast cancer fund; NIH [CA150132]; NATIONAL CANCER INSTITUTE [R03CA150132] Funding Source: NIH RePORTER	Carol M. Baldwin breast cancer fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Daniel P. Kelly, Sanford- Burnham Medical Research Institute, FL for providing the anti-PGC-1 alpha anti-body and Dr. Michael Shuen, York University, Ontario, Canada for pGL3-PGC-1 alpha promoter construct. Dr. David M. Markovitz (Department of Internal Medicine, University of Michigan Medical Center) kindly provided UACC-62 melanoma cells (originally from Dr. Maria S. Soengas, Melanoma Laboratory, Spanish National Cancer Research Center). This work was supported in part by Carol M. Baldwin breast cancer fund and NIH grant CA150132.	Agarwal NR, 2016, CELL BIOL INT, V40, P821, DOI 10.1002/cbin.10619; An J, 2012, J BIOL CHEM, V287, P7411, DOI 10.1074/jbc.M111.277103; Babbar Mansi, 2013, Mol Cell Pharmacol, V5, P109; Banci L, 2012, J STRUCT BIOL, V180, P190, DOI 10.1016/j.jsb.2012.07.007; Burri L, 2005, MOL BIOL CELL, V16, P2926, DOI 10.1091/mbc.E04-12-1086; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Canto C, 2009, CURR OPIN LIPIDOL, V20, P98, DOI 10.1097/MOL.0b013e328328d0a4; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354; Delghandi MP, 2005, CELL SIGNAL, V17, P1343, DOI 10.1016/j.cellsig.2005.02.003; Fath MA, 2009, CANCER BIOL THER, V8, P1228, DOI 10.4161/cbt.8.13.8631; Fernandez-Marcos PJ, 2011, AM J CLIN NUTR, V93, p884S, DOI 10.3945/ajcn.110.001917; Hao YJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11971; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Herzig S, 2003, NATURE, V426, P190, DOI 10.1038/nature02110; Kamarajugadda S, 2012, MOL CELL BIOL, V32, P1893, DOI 10.1128/MCB.06248-11; Landor SKJ, 2011, P NATL ACAD SCI USA, V108, P18814, DOI 10.1073/pnas.1104943108; Lehman JJ, 2002, CLIN EXP PHARMACOL P, V29, P339, DOI 10.1046/j.1440-1681.2002.03655.x; Li BL, 2006, BIOCHEM BIOPH RES CO, V350, P179, DOI 10.1016/j.bbrc.2006.09.016; Lucchesi C, 2016, ONCOGENE, V35, P2565, DOI 10.1038/onc.2015.339; Luo XJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0646-3; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Simoes RV, 2015, NEOPLASIA, V17, P671, DOI 10.1016/j.neo.2015.08.005; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Yang J, 2012, J CLIN INVEST, V122, P600, DOI 10.1172/JCI58780; Zhang Q, 2006, J BIOL CHEM, V281, P10174, DOI 10.1074/jbc.M513008200	29	3	3	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					2052	2066		10.1038/s41388-017-0051-9	http://dx.doi.org/10.1038/s41388-017-0051-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29371680	Green Accepted			2022-12-17	WOS:000429899400008
J	Kwun, HJ; Wendzicki, JA; Shuda, Y; Moore, PS; Chang, Y				Kwun, H. J.; Wendzicki, J. A.; Shuda, Y.; Moore, P. S.; Chang, Y.			Merkel cell polyomavirus small T antigen induces genome instability by E3 ubiquitin ligase targeting (vol 36, pg 6784, 2017)	ONCOGENE			English	Correction													Kwun, Hyun jin/AAJ-3365-2020; Moore, Patrick/GVR-8294-2022	Kwun, Hyun jin/0000-0002-8926-746X; 	NCI NIH HHS [R01 CA170354] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA170354] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Kwun HJ, 2017, ONCOGENE, V36, P6784, DOI 10.1038/onc.2017.277	1	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6838	6838		10.1038/onc.2017.389	http://dx.doi.org/10.1038/onc.2017.389			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28991223	hybrid, Green Published			2022-12-17	WOS:000417282500010
J	Wang, G; Fu, Y; Yang, X; Luo, X; Wang, J; Gong, J; Hu, J				Wang, G.; Fu, Y.; Yang, X.; Luo, X.; Wang, J.; Gong, J.; Hu, J.			Brg-1 targeting of novel miR550a-5p/RNF43/Wnt signaling axis regulates colorectal cancer metastasis (vol 35, pg 651, 2016)	ONCOGENE			English	Correction									[Wang, G.] Huazhong Univ Sci & Technol, Canc Res Inst, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China	Huazhong University of Science & Technology	Wang, G (corresponding author), Huazhong Univ Sci & Technol, Canc Res Inst, Tongji Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.							Wang G, 2016, ONCOGENE, V35, P651, DOI 10.1038/onc.2015.124	1	3	3	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5915	5915		10.1038/onc.2017.317	http://dx.doi.org/10.1038/onc.2017.317			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28846106	Bronze			2022-12-17	WOS:000413292900014
J	Joseph, B; Marchetti, P; Formstecher, P; Kroemer, G; Lewensohn, R; Zhivotovsky, B				Joseph, B.; Marchetti, P.; Formstecher, P.; Kroemer, G.; Lewensohn, R.; Zhivotovsky, B.			Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment (vol 21, pg 65, 2002)	ONCOGENE			English	Correction													Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	KROEMER, Guido/0000-0002-9334-4405				Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018	1	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4818	4818		10.1038/onc.2017.78	http://dx.doi.org/10.1038/onc.2017.78			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28394341	Bronze			2022-12-17	WOS:000407702400015
J	Pandita, TK				Pandita, T. K.			Critical role of the POT1 OB domain in maintaining genomic stability	ONCOGENE			English	Editorial Material							DNA-DAMAGE RESPONSE; TELOMERE DYSFUNCTION; DYSKERATOSIS-CONGENITA; BINDING PROTEIN; ATM; MUTATIONS; PREDISPOSE; PROTECTION; COMPONENT; VARIANTS	Oligonucleotide/oligosaccharide-binding (OB) domain-containing proteins have been identified as critical for telomere maintenance, DNA repair, transcription and other DNA metabolism processes. Protection of telomere 1 (POT1), a telomere binding protein, has an OB domain like single-strand binding protein (SSB1). In this issue of Oncogene, Gu et al. present evidence that POT1, like SSB1, is required to maintain genomic stability. This work, in conjunction with results from previous investigators, highlights the importance of POT1 in telomere metabolism. Inactivation of POT1 telomere protective functions in mouse models lacking p53 expression in the breast epithelium unleashes a torrent of DNA damage responses (DDRs) at the telomeres, culminating in karyotypic alterations with massive arrays of telomere fusions. Therefore, POT1 is not only required to promote telomere homeostasis, but also plays an essential role in maintaining a stable genome.	[Pandita, T. K.] Houston Methodist Hosp, Weill Cornell Med Coll, Houston Methodist Res Inst, Dept Radiat Oncol, Houston, TX USA	Cornell University; The Methodist Hospital System; The Methodist Hospital - Houston	Pandita, TK (corresponding author), Houston Methodist Res Inst, Dept Radiat Oncol, 6550 Fannin St, Houston, TX 77030 USA.	tpandita@houstonmethodist.org	Pandita, Tej K/AAM-9188-2020		National Institute of Health [CA129537, GM109768]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The research in the author's laboratory is funded by the National Institute of Health Grants CA129537 and GM109768.	Alter BP, 2009, BLOOD, V113, P6549, DOI 10.1182/blood-2008-12-192880; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Attwooll CL, 2009, MOL CELL BIOL, V29, P5540, DOI 10.1128/MCB.00479-09; Bainbridge MN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju384; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Calado RT, 2009, NEW ENGL J MED, V361, P2353, DOI 10.1056/NEJMra0903373; Calvete O, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9383; Chan SS, 2010, FEBS LETT, V584, P3773, DOI 10.1016/j.febslet.2010.06.016; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Deng YB, 2009, NATURE, V460, P914, DOI 10.1038/nature08196; Dimitrova N, 2009, MOL CELL BIOL, V29, P5552, DOI 10.1128/MCB.00476-09; Flynn RL, 2011, NATURE, V471, P532, DOI 10.1038/nature09772; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Guo X, 2007, EMBO J, V26, P4709, DOI 10.1038/sj.emboj.7601893; He H, 2006, EMBO J, V25, P5180, DOI 10.1038/sj.emboj.7601294; He H, 2009, MOL CELL BIOL, V29, P229, DOI 10.1128/MCB.01400-08; Hills M, 2009, ANN NY ACAD SCI, V1176, P178, DOI 10.1111/j.1749-6632.2009.04565.x; Hockemeyer D, 2008, GENE DEV, V22, P1773, DOI 10.1101/gad.1679208; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Lei M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Maser RS, 2004, DNA REPAIR, V3, P979, DOI 10.1016/j.dnarep.2004.05.009; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Pandita RK, 2015, CANCER RES, V75, P858, DOI 10.1158/0008-5472.CAN-14-2289; Pandita TK, 2009, NUCLEIC ACIDS RES, V37, P1363, DOI 10.1093/nar/gkn1071; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; Rai R, 2010, EMBO J, V29, P2598, DOI 10.1038/emboj.2010.142; Ramsay AJ, 2013, NAT GENET, V45, P526, DOI 10.1038/ng.2584; Robles-Espinoza CD, 2014, NAT GENET, V46, P478, DOI 10.1038/ng.2947; Savage SA, 2008, AM J HUM GENET, V82, P501, DOI 10.1016/j.ajhg.2007.10.004; Scott SP, 2006, J CELL BIOCHEM, V99, P1463, DOI 10.1002/jcb.21067; Sfeir A, 2012, SCIENCE, V336, P593, DOI 10.1126/science.1218498; Shakirov EV, 2005, MOL CELL BIOL, V25, P7725, DOI 10.1128/MCB.25.17.7725-7733.2005; Shi JX, 2014, NAT GENET, V46, P482, DOI 10.1038/ng.2941; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Veldman T, 2004, CURR BIOL, V14, P2264, DOI 10.1016/j.cub.2004.12.031; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy T, 2004, NAT GENET, V36, P447, DOI 10.1038/ng1346; Walne AJ, 2008, BLOOD, V112, P3594, DOI 10.1182/blood-2008-05-153445; Wang Y, 2011, BLOOD, V118, P6068, DOI 10.1182/blood-2011-06-361527; Wu L, 2006, CELL, V126, P49, DOI 10.1016/j.cell.2006.05.037; Yang Q, 2005, MOL CELL BIOL, V25, P1070, DOI 10.1128/MCB.25.3.1070-1080.2005	48	3	3	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1908	1910		10.1038/onc.2016.365	http://dx.doi.org/10.1038/onc.2016.365			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27869169				2022-12-17	WOS:000398898500002
J	Worrillow, L; Baskaran, P; Care, MA; Varghese, A; Munir, T; Evans, PA; O'Connor, SJ; Rawstron, A; Hazelwood, L; Tooze, RM; Hillmen, P; Newton, DJ				Worrillow, L.; Baskaran, P.; Care, M. A.; Varghese, A.; Munir, T.; Evans, P. A.; O'Connor, S. J.; Rawstron, A.; Hazelwood, L.; Tooze, R. M.; Hillmen, P.; Newton, D. J.			An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases	ONCOGENE			English	Article							SUBCLONAL MUTATIONS; 17P DELETION; MUTANT P53; EVOLUTION; THERAPY; ALEMTUZUMAB; FLUDARABINE; RESISTANCE; SURVIVAL; IMPACT	Chronic lymphocytic leukaemia (CLL) is the most common clonal B-cell disorder characterized by clonal diversity, a relapsing and remitting course, and in its aggressive forms remains largely incurable. Current front-line regimes include agents such as fludarabine, which act primarily via the DNA damage response pathway. Key to this is the transcription factor p53. Mutations in the TP53 gene, altering p53 functionality, are associated with genetic instability, and are present in aggressive CLL. Furthermore, the emergence of clonal TP53 mutations in relapsed CLL, refractory to DNA-damaging therapy, suggests that accurate detection of sub-clonal TP53 mutations prior to and during treatment may be indicative of early relapse. In this study, we describe a novel deep sequencing workflow using multiple polymerases to generate sequencing libraries (MuPol-Seq), facilitating accurate detection of TP53 mutations at a frequency as low as 0.3%, in presentation CLL cases tested. As these mutations were mostly clustered within the regions of TP53 encoding DNA-binding domains, essential for DNA contact and structural architecture, they are likely to be of prognostic relevance in disease progression. The workflow described here has the potential to be implemented routinely to identify rare mutations across a range of diseases.	[Worrillow, L.; Care, M. A.; Tooze, R. M.; Hillmen, P.; Newton, D. J.] Univ Leeds, Leeds Inst Canc & Pathol, Sect Expt Haematol, Leeds LS9 7TF, W Yorkshire, England; [Baskaran, P.] Max Planck Inst Dev Biol, Dept Evolutionary Biol, Tubingen, Germany; [Varghese, A.; Munir, T.; Evans, P. A.; O'Connor, S. J.; Rawstron, A.] Leeds Teaching Hosp Natl Hlth Serv Trust, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England; [Hazelwood, L.] Univ Cambridge, Canc Res UK, Ling Ka Shing Ctr, Cambridge, England	University of Leeds; Max Planck Society; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Newton, DJ (corresponding author), Univ Leeds, Leeds Inst Canc & Pathol, Sect Expt Haematol, Leeds LS9 7TF, W Yorkshire, England.	D.J.Newton@leeds.ac.uk	Newton, Darren/CAA-0475-2022; Care, Matthew/P-2987-2019	Care, Matthew/0000-0001-6584-5889; Tooze, Reuben/0000-0003-2915-7119; Baskaran, Praveen/0000-0003-2275-3516	Kay Kendall Leukaemia Fund	Kay Kendall Leukaemia Fund	This project was funded by the Kay Kendall Leukaemia Fund (www.kklf.org.uk). We would also like to thank the staff in the Haematological Malignancy Diagnostic Services Unit at Leeds Teaching Hospital who provided information on diagnostic patient data and samples for the study, and the sequencing facility at the University of Leeds who provided a technical service running the Illumina next-generation sequencing systems.	Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Campbell PJ, 2008, P NATL ACAD SCI USA, V105, P13081, DOI 10.1073/pnas.0801523105; Delgado J, 2012, BRIT J HAEMATOL, V157, P67, DOI 10.1111/j.1365-2141.2011.09000.x; Dicker F, 2009, LEUKEMIA, V23, P117, DOI 10.1038/leu.2008.274; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784; Gonzalez D, 2011, J CLIN ONCOL, V29, P2223, DOI 10.1200/JCO.2010.32.0838; Gravanis I, 2010, ONCOLOGIST, V15, P1335, DOI 10.1634/theoncologist.2010-0255; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grollman AP, 2007, P NATL ACAD SCI USA, V104, P12129, DOI 10.1073/pnas.0701248104; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Huggett JF, 2015, CLIN CHEM, V61, P79, DOI 10.1373/clinchem.2014.221366; Huse SM, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r143; Jethwa A, 2013, BRIT J HAEMATOL, V163, P496, DOI 10.1111/bjh.12539; Joerger AC, 2008, ANNU REV BIOCHEM, V77, P557, DOI 10.1146/annurev.biochem.77.060806.091238; Joerger AC, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000919; KNUDSON AG, 1991, MUTAT RES, V247, P185, DOI 10.1016/0027-5107(91)90013-E; Komarova NL, 2014, P NATL ACAD SCI USA, V111, P13906, DOI 10.1073/pnas.1409362111; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lozanski G, 2004, BLOOD, V103, P3278, DOI 10.1182/blood-2003-10-3729; Malcikova J, 2015, LEUKEMIA, V29, P877, DOI 10.1038/leu.2014.297; Mclnerney P, 2014, MOL BIOL INT, V2014; Mohr J, 2011, BLOOD, V117, P1622, DOI 10.1182/blood-2010-08-300160; Nakamura S, 2011, EXP BIOL MED, V236, P968, DOI 10.1258/ebm.2011.010378; Ojha J, 2015, BLOOD, V125, P492, DOI 10.1182/blood-2014-06-580563; Olivier M, 2009, CANCER GENE THER, V16, P1, DOI 10.1038/cgt.2008.69; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Rossi D, 2014, BLOOD, V123, P2139, DOI 10.1182/blood-2013-11-539726; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Schuh A, 2012, BLOOD, V120, P4191, DOI 10.1182/blood-2012-05-433540; Stieglitz E, 2015, BLOOD, V125, P516, DOI 10.1182/blood-2014-09-601690; Stilgenbauer S, 2009, J CLIN ONCOL, V27, P3994, DOI 10.1200/JCO.2008.21.1128; Stocks MB, 2012, BIOINFORMATICS, V28, P2059, DOI 10.1093/bioinformatics/bts311; Tian K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072303; Tsao SCH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11198; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Wang J, 2014, ELIFE, V3, DOI 10.7554/eLife.03496; Wawrzyniak E, 2014, EUR J HAEMATOL, V92, P91, DOI 10.1111/ejh.12215; Wong TN, 2015, NATURE, V518, P552, DOI 10.1038/nature13968; Woyach JA, 2014, NEW ENGL J MED, V370, P2286, DOI 10.1056/NEJMoa1400029; Zenz T, 2010, J CLIN ONCOL, V28, P4473, DOI 10.1200/JCO.2009.27.8762; Zenz T, 2009, BLOOD, V114, P2589, DOI 10.1182/blood-2009-05-224071; Zenz T, 2008, CELL CYCLE, V7, P3810, DOI 10.4161/cc.7.24.7245	48	3	3	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5328	5336		10.1038/onc.2016.73	http://dx.doi.org/10.1038/onc.2016.73			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	27041575	Green Accepted			2022-12-17	WOS:000386053000011
J	Kanu, N; Zhang, T; Burrell, RA; Chakraborty, A; Cronshaw, J; DaCosta, C; Gronroos, E; Pemberton, HN; Anderton, E; Gonzalez, L; Sabbioneda, S; Ulrich, HD; Swanton, C; Behrens, A				Kanu, N.; Zhang, T.; Burrell, R. A.; Chakraborty, A.; Cronshaw, J.; DaCosta, C.; Gronroos, E.; Pemberton, H. N.; Anderton, E.; Gonzalez, L.; Sabbioneda, S.; Ulrich, H. D.; Swanton, C.; Behrens, A.			RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress (vol 35, pg 4009, 2016)	ONCOGENE			English	Correction													Sabbioneda, Simone/N-7017-2015	Sabbioneda, Simone/0000-0001-8551-5465; Behrens, Axel/0000-0002-1557-1143; Gronroos, Eva/0000-0001-8303-5409; Ulrich, Helle D./0000-0003-0431-2223	Novo Nordisk Fonden [NNF15OC0016584] Funding Source: researchfish; The Francis Crick Institute [10169] Funding Source: researchfish	Novo Nordisk Fonden(Novo Nordisk Foundation); The Francis Crick Institute		Kanu N, 2016, ONCOGENE, V35, P4009, DOI 10.1038/onc.2015.427	1	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					4020	4020		10.1038/onc.2015.500	http://dx.doi.org/10.1038/onc.2015.500			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	27345393	Bronze			2022-12-17	WOS:000381013100013
J	Joly, AL; Deepti, A; Seignez, A; Goloudina, A; Hebrard, S; Schmitt, E; Richaud, S; Fourmaux, E; Hammann, A; Collura, A; Svrcek, M; Jego, G; Robinet, E; Solary, E; Demidov, O; Kohli, E; Garrido, C				Joly, A-L; Deepti, A.; Seignez, A.; Goloudina, A.; Hebrard, S.; Schmitt, E.; Richaud, S.; Fourmaux, E.; Hammann, A.; Collura, A.; Svrcek, M.; Jego, G.; Robinet, E.; Solary, E.; Demidov, O.; Kohli, E.; Garrido, C.			The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development (vol 35, pg 2842, 2016)	ONCOGENE			English	Correction									[Joly, A-L] INSERM, UMR 866, Equipe Labellisee Ligue Natl Canc, Dijon, France; [Joly, A-L] Lab Excellence LipSTIC, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Joly, AL (corresponding author), INSERM, UMR 866, Equipe Labellisee Ligue Natl Canc, Dijon, France.; Joly, AL (corresponding author), Lab Excellence LipSTIC, Dijon, France.		Garrido, Carolina/GWM-5557-2022; Demidov, Oleg/AAC-4462-2021; Demidov, Oleg/U-2050-2017; Garrido, carmen/G-1633-2018	Demidov, Oleg/0000-0003-4323-7174; Demidov, Oleg/0000-0003-4323-7174; Garrido, carmen/0000-0003-1368-1493; Solary, Eric/0000-0002-8629-1341				Joly AL, 2016, ONCOGENE, V35, P2842, DOI 10.1038/onc.2015.242	1	3	3	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2948	2948		10.1038/onc.2016.63	http://dx.doi.org/10.1038/onc.2016.63			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	27251741	Bronze			2022-12-17	WOS:000377473700015
J	Horikoshi, N; Hunt, CR; Pandita, TK				Horikoshi, N.; Hunt, C. R.; Pandita, T. K.			More complex transcriptional regulation and stress response by MOF	ONCOGENE			English	Editorial Material							H4 LYSINE 16; MALES ABSENT; MSL COMPLEX; DROSOPHILA; DELETION; MICE	MOF (males absent on the first) was initially discovered as a dosage compensation factor that regulates the epigenetic acetylation of histone H4 lysine 16. In this issue, Sheikh et al. demonstrate that MOF expression is not required for normal kidney tissue function but is required for maintaining transcriptional regulation under conditions of stress. This work along with results from previous investigators highlights the importance of the cell lineage-chromatin modification interaction in determining transcriptional programs and physiological outcomes under normal and stress conditions.	[Horikoshi, N.; Hunt, C. R.; Pandita, T. K.] Houston Methodist Res Inst, Dept Radiat Oncol, 6550 Fannin St, Houston, TX 77030 USA	The Methodist Hospital System; The Methodist Hospital - Houston	Pandita, TK (corresponding author), Houston Methodist Res Inst, Dept Radiat Oncol, 6550 Fannin St, Houston, TX 77030 USA.	tpandita@houstonmethodist.org	Pandita, Tej K/AAM-9188-2020; Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178	NATIONAL CANCER INSTITUTE [R01CA154320, R01CA129537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM109768] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA129537, R01 CA154320] Funding Source: Medline; NIGMS NIH HHS [R01 GM109768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhadra MP, 2012, CHROMOSOMA, V121, P79, DOI 10.1007/s00412-011-0344-7; Cai Y, 2010, J BIOL CHEM, V285, P4268, DOI 10.1074/jbc.C109.087981; Chelmicki T, 2014, ELIFE, V3, DOI 10.7554/eLife.02024; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Gupta A, 2008, MOL CELL BIOL, V28, P397, DOI 10.1128/MCB.01045-07; Gupta A, 2013, MUTAGENESIS, V28, P263, DOI 10.1093/mutage/ges080; Horikoshi Nobuo, 2013, Genome Integr, V4, P3, DOI 10.1186/2041-9414-4-3; Hunt CR, 2013, RADIAT RES, V179, P383, DOI 10.1667/RR3308.2; Kumar R, 2011, P NATL ACAD SCI USA, V108, P3636, DOI 10.1073/pnas.1016524108; Laverty C, 2010, CURR OPIN GENET DEV, V20, P171, DOI 10.1016/j.gde.2010.01.007; Li XZ, 2012, CELL STEM CELL, V11, P163, DOI 10.1016/j.stem.2012.04.023; Lucchesi J. C., 2015, COLD SPRING HARB PER, V7; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Pandita TK, 2013, PROTEOMICS, V13, P1546, DOI 10.1002/pmic.201300145; Pandita TK, 2009, NUCLEIC ACIDS RES, V37, P1363, DOI 10.1093/nar/gkn1071; Raja SJ, 2010, MOL CELL, V38, P827, DOI 10.1016/j.molcel.2010.05.021; Ravens S, 2014, ELIFE, V3, DOI 10.7554/eLife.02104; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; Sheikh BN, 2016, ONCOGENE, V35, P2698, DOI 10.1038/onc.2015.335; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Taylor GCA, 2013, GENOME RES, V23, P2053, DOI 10.1101/gr.155028.113	21	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2681	2683		10.1038/onc.2015.373	http://dx.doi.org/10.1038/onc.2015.373			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26434593				2022-12-17	WOS:000377472700001
J	Wiel, C; Gras, B; Vindrieux, D; Warnier, M; Gitenay, D; Le Calve, B; Ferrand, M; Augert, A; Bernard, D				Wiel, C.; Gras, B.; Vindrieux, D.; Warnier, M.; Gitenay, D.; Le Calve, B.; Ferrand, M.; Augert, A.; Bernard, D.			Multidrug resistance protein 3 loss promotes tumor formation by inducing senescence escape	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; TRANSPORT; CANCER; SUPPRESSION; MRP3; MICE	Oncogenic-stress-induced senescence (OIS) is a stress response allowing normal cells, when receiving oncogenic signals, to stably arrest their proliferation. OIS thus acts to prevent aberrant cell proliferation and tumor formation. To identify novel tumor suppressive pathways, we have recently completed a loss-of-function genetic screen to identify novel genes promoting escape from OIS and thus, potentially, tumor formation when their functions are lost. Using this approach, we unexpectedly found that loss of function of the multidrug resistance protein 3 (MRP3 or ABCC3) promotes escape from OIS in human epithelial cells. Importantly, ABCC3 expression is reduced in human skin tumors, and ABCC3-knockout mice display increased sensitivity to RAS-induced skin carcinogenesis, concomitantly with decreased OIS. ABCC3 participates in resistance to chemotherapy via its transporter activity. Our data show that this transporter activity is involved in ABCC3-induced senescence, demonstrating that this protein has a complex role in cancer, since its loss of function may promote escape from OIS and tumor formation whereas its gain of function promotes resistance to chemotherapy.	[Wiel, C.; Gras, B.; Vindrieux, D.; Warnier, M.; Gitenay, D.; Le Calve, B.; Ferrand, M.; Augert, A.; Bernard, D.] Ctr Rech Cancerol Lyon, INSERM, U1052, Senescence Escape Mech Lab Tumoral Escape Dept, Lyon, France; [Wiel, C.; Gras, B.; Vindrieux, D.; Warnier, M.; Gitenay, D.; Le Calve, B.; Ferrand, M.; Augert, A.; Bernard, D.] CNRS, UMR5286, Lyon, France; [Wiel, C.; Gras, B.; Vindrieux, D.; Warnier, M.; Gitenay, D.; Le Calve, B.; Ferrand, M.; Augert, A.; Bernard, D.] Ctr Leon Berard, F-69373 Lyon, France; [Wiel, C.; Gras, B.; Vindrieux, D.; Warnier, M.; Gitenay, D.; Le Calve, B.; Ferrand, M.; Augert, A.; Bernard, D.] Univ Lyon, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Centre Leon Berard	Bernard, D (corresponding author), Ctr Leon Berard, INSERM, CRCL, U1052,CNRS,UMR 5286, 28 Rue Laennec, F-69373 Lyon 08, France.	david.bernard@lyon.unicancer.fr	; Bernard, David/D-6265-2018	Gitenay, Delphine/0000-0002-6043-4519; Vindrieux, David/0000-0002-4713-5768; Bernard, David/0000-0002-1557-2074	French National Cancer Institute [plbio 2010-181]; Ligue contre le Cancer, comite de la Savoie; Fondation ARC; RTRS Fondation Synergie Lyon Cancer; Ligue Nationale contre le Cancer; Fondation pour la Recherche Medicale	French National Cancer Institute(Institut National du Cancer (INCA) France); Ligue contre le Cancer, comite de la Savoie; Fondation ARC; RTRS Fondation Synergie Lyon Cancer; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	We thank Lea Payen for advice and Sarah Kabani for critical reading of the manuscript. This work was carried out with the support of the French National Cancer Institute (grants plbio 2010-181), the 'Ligue contre le Cancer, comite de la Savoie', the 'Fondation ARC', and the 'RTRS Fondation Synergie Lyon Cancer'. CW is supported by the 'Ligue Nationale contre le Cancer' and the 'Fondation pour la Recherche Medicale'.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Bianchi-Smiraglia A, 2012, CELL CYCLE, V11, P4147, DOI 10.4161/cc.22589; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; Chen ZS, 2011, FEBS J, V278, P3226, DOI 10.1111/j.1742-4658.2011.08235.x; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; Cipriano R, 2011, P NATL ACAD SCI USA, V108, P8668, DOI 10.1073/pnas.1015022108; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Deeley RG, 2006, PHYSIOL REV, V86, P849, DOI 10.1152/physrev.00035.2005; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789; Gitenay D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.63; Gitenay D, 2014, ONCOTARGET, V5, P5845, DOI 10.18632/oncotarget.2286; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henderson MJ, 2011, J NATL CANCER I, V103, P1236, DOI 10.1093/jnci/djr256; Humbert N, 2010, EMBO J, V29, P376, DOI 10.1038/emboj.2009.342; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Lallet-Daher H, 2013, CANCER RES, V73, P5253, DOI 10.1158/0008-5472.CAN-12-3690; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Nelson DM, 2014, AGE, V36, P1049, DOI 10.1007/s11357-014-9637-0; Scurr LL, 2010, CELL, V141, P717, DOI 10.1016/j.cell.2010.04.021; Van De Wetering K, 2009, GASTROENTEROLOGY, V137, P1725, DOI 10.1053/j.gastro.2009.06.052; Vindrieux D, 2013, CANCER RES, V73, P6334, DOI 10.1158/0008-5472.CAN-13-0318; Wiel C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.382; Wiel C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4792; Zelcer N, 2006, J HEPATOL, V44, P768, DOI 10.1016/j.jhep.2005.07.022; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100	34	3	3	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1596	1601		10.1038/onc.2015.218	http://dx.doi.org/10.1038/onc.2015.218			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26073088				2022-12-17	WOS:000373063600012
J	Guan, D; Factor, D; Liu, Y; Wang, Z; Kao, HY				Guan, D.; Factor, D.; Liu, Yu; Wang, Z.; Kao, H-Y			The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein (vol 32, pg 3819, 2013)	ONCOGENE			English	Correction																		Guan D, 2013, ONCOGENE, V32, P3819, DOI 10.1038/onc.2012.406	1	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5206	5206		10.1038/onc.2015.314	http://dx.doi.org/10.1038/onc.2015.314			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	26424573	Bronze			2022-12-17	WOS:000362233400010
J	Gilan, O; Diesch, J; Amalia, M; Jastrzebski, K; Chueh, AC; Verrills, NM; Pearson, RB; Mariadason, JM; Tulchinsky, E; Hannan, RD; Dhillon, AS				Gilan, O.; Diesch, J.; Amalia, M.; Jastrzebski, K.; Chueh, A. C.; Verrills, N. M.; Pearson, R. B.; Mariadason, J. M.; Tulchinsky, E.; Hannan, R. D.; Dhillon, A. S.			PR55 alpha-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity (vol 34, pg 1333, 2015)	ONCOGENE			English	Correction													Tulchinsky, Eugene/ABD-7070-2021; Chueh, Anderly/AAF-9375-2022; Chueh, Anderly C./D-8615-2015; Diesch, Jeannine/J-8558-2017; Pearson, Richard Bruce/I-1451-2013; Chüeh, Anderly C/AFC-2076-2022	Chueh, Anderly C./0000-0003-1140-5516; Diesch, Jeannine/0000-0002-4667-3468; Pearson, Richard Bruce/0000-0001-5919-5090; Chüeh, Anderly C/0000-0003-1140-5516; Jastrzesbki, Katarzyna/0000-0002-3062-9016; Hannan, Ross/0000-0002-2166-4493; Dhillon, Amardeep/0000-0002-6065-663X; Verrills, Nicole/0000-0002-7894-0137				Gilan O, 2015, ONCOGENE, V34, P1333, DOI 10.1038/onc.2014.26	1	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1340	1340		10.1038/onc.2014.460	http://dx.doi.org/10.1038/onc.2014.460			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	25740609	Bronze			2022-12-17	WOS:000350687100014
J	Carpenter, EL; Haglund, EA; Mace, EM; Deng, D; Martinez, D; Wood, AC; Chow, AK; Weiser, DA; Belcastro, LT; Winter, C; Bresler, SC; Vigny, M; Mazot, P; Asgharzadeh, S; Seeger, RC; Zhao, H; Guo, R; Christensen, JG; Orange, JS; Pawel, BR; Lemmon, MA; Mosse, YP				Carpenter, E. L.; Haglund, E. A.; Mace, E. M.; Deng, D.; Martinez, D.; Wood, A. C.; Chow, A. K.; Weiser, D. A.; Belcastro, L. T.; Winter, C.; Bresler, S. C.; Vigny, M.; Mazot, P.; Asgharzadeh, S.; Seeger, R. C.; Zhao, H.; Guo, R.; Christensen, J. G.; Orange, J. S.; Pawel, B. R.; Lemmon, M. A.; Mosse, Y. P.			Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma (vol 31, pg 4859, 2012)	ONCOGENE			English	Correction									[Vigny, M.; Mazot, P.] Univ Paris 06, INSERM UMRS 839, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite				Mace, Emily/0000-0003-0226-7393; orange, jordan/0000-0001-7117-7725				Carpenter EL, 2012, ONCOGENE, V31, P4859, DOI 10.1038/onc.2011.647	1	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	46					4888	4888		10.1038/onc.2012.208	http://dx.doi.org/10.1038/onc.2012.208			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT		Bronze			2022-12-17	WOS:000311210700009
J	Djavaheri-Mergny, M; Maiuri, MC; Kroemer, G				Djavaheri-Mergny, M.; Maiuri, M. C.; Kroemer, G.			Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1 (vol 29, pg 1717, 2010)	ONCOGENE			English	Correction													Kroemer, Guido/AAY-9859-2020; Djavaheri-Mergny, Mojgan/N-6315-2017; KROEMER, Guido/B-4263-2013	Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; KROEMER, Guido/0000-0002-9334-4405				Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519	1	3	4	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2010	29	49					6508	6508		10.1038/onc.2010.514	http://dx.doi.org/10.1038/onc.2010.514			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP		Bronze			2022-12-17	WOS:000285138900010
J	Castedo, M; Vitale, I; Kroemer, G				Castedo, M.; Vitale, I.; Kroemer, G.			A novel source of tetraploid cancer cell precursors: telomere insufficiency links aging to oncogenesis	ONCOGENE			English	Review						tetraploidy; oncogenesis; telomere; aging	CHROMOSOMAL INSTABILITY; CARCINOGENESIS; APOPTOSIS; LENGTH; P53; MITOSIS	Epithelial cancers of the elderly are caused by a combination of telomere dysfunction and the mutational invalidation of major tumor suppressors including p53. A recent article published in Cell by Davoli et al. shows that the simultaneous elimination of p53 and telomerase causes a state of chronic DNA damage that results in tetraploidization through endoreplication, that is, two consecutive S phases that are not separated by mitosis. As tetraploid cells represent a metastable intermediate between normal diploidy and cancer-associated aneuploidy, this novel route to tetraploidization may constitute (one of) the functional link(s) between aging and carcinogenesis. Oncogene (2010) 29, 5869-5872; doi:10.1038/onc.2010.392; published online 30 August 2010	[Castedo, M.; Vitale, I.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Castedo, M.; Vitale, I.; Kroemer, G.] Univ Paris 11, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Castedo, M (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	castedo@igr.fr; kroemer@orange.fr	Vitale, Ilio/M-3960-2017; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	Vitale, Ilio/0000-0002-5918-1841; KROEMER, Guido/0000-0002-9334-4405	Ligue Nationale contre le Cancer; Agence Nationale pour la Recherche (ANR); European Commission; Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); Canceropole Ile-de-France	Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France)	GK was supported by the Ligue Nationale contre le Cancer (Equipes labellisee), Agence Nationale pour la Recherche (ANR), European Commission (Active p53, Apo-Sys, Chemo Res, ApopTrain), Fondation pour la Recherche Medicale (FRM), Institut National du Cancer (INCa) and Canceropole Ile-de-France. IV was supported by the Ligue Nationale contre le Cancer.	Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; DANES BS, 1978, CANCER-AM CANCER SOC, V41, P2330, DOI 10.1002/1097-0142(197806)41:6<2330::AID-CNCR2820410635>3.0.CO;2-X; Davoli T, 2010, CELL, V141, P81, DOI 10.1016/j.cell.2010.01.031; Duelli DM, 2007, CURR BIOL, V17, P431, DOI 10.1016/j.cub.2007.01.049; DUTRILLAUX B, 1991, BREAST CANCER RES TR, V19, P245, DOI 10.1007/BF01961161; Engelhardt M, 1997, CLIN CANCER RES, V3, P1849; Finley JC, 2006, CANCER EPIDEM BIOMAR, V15, P1451, DOI 10.1158/1055-9965.EPI-05-0837; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lantuejoul S, 2005, CLIN CANCER RES, V11, P2074, DOI 10.1158/1078-0432.CCR-04-1376; Margolis RL, 2005, CANCER CELL, V8, P353, DOI 10.1016/j.ccr.2005.10.017; Maruyama Y, 1997, JPN J CLIN ONCOL, V27, P216, DOI 10.1093/jjco/27.4.216; Meeker AK, 2004, CLIN CANCER RES, V10, P3317, DOI 10.1158/1078-0432.CCR-0984-03; Olaharski AJ, 2006, CARCINOGENESIS, V27, P337, DOI 10.1093/carcin/bgi218; Rello-Varona S, 2009, CELL CYCLE, V8, P1030, DOI 10.4161/cc.8.7.7950; Roumier T, 2005, CELL DEATH DIFFER, V12, P91, DOI 10.1038/sj.cdd.4401521; Sahin E, 2010, NATURE, V464, P520, DOI 10.1038/nature08982; Senovilla L, 2009, CELL CYCLE, V8, P1380, DOI 10.4161/cc.8.9.8305; Skyldberg BM, 1999, MODERN PATHOL, V12, P675; Vitale I, 2010, EMBO J, V29, P1272, DOI 10.1038/emboj.2010.11	25	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	44					5869	5872		10.1038/onc.2010.392	http://dx.doi.org/10.1038/onc.2010.392			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20802535				2022-12-17	WOS:000283843400001
J	Rabson, AB				Rabson, A. B.			Trisomy 21 leukemias: finding the hits that matter	ONCOGENE			English	Editorial Material							DOWN-SYNDROME; MOUSE MODEL; LEUKEMOGENESIS; GATA1; ERG	Down syndrome is associated with a markedly increased risk of childhood leukemias, and identification of chromosome 21 sequences that have a role in leukemogenesis may provide insights into critical pathways and suggest targets for therapy and prevention. A study in this issue of Oncogene, defines human chromosome 21 sequences that alter hematopoiesis and induce expression of leukemia-associated markers. Oncogene (2010) 29, 6099-6101; doi:10.1038/onc.2010.353; published online 16 August 2010	[Rabson, A. B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ 08901 USA; [Rabson, A. B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08901 USA; [Rabson, A. B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, New Brunswick, NJ 08901 USA; [Rabson, A. B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, New Brunswick, NJ 08901 USA; [Rabson, A. B.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Rabson, AB (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, 89 French St, New Brunswick, NJ 08901 USA.	rabsonab@umdnj.edu						Alford KA, 2010, BLOOD, V115, P2928, DOI 10.1182/blood-2009-06-227629; Chou ST, 2008, BLOOD, V112, P4503, DOI 10.1182/blood-2008-05-157859; De Vita S, 2010, ONCOGENE, V29, P6102, DOI 10.1038/onc.2010.351; Izraeli S, 2007, BLOOD CELL MOL DIS, V39, P156, DOI 10.1016/j.bcmd.2007.04.004; Kirsammer G, 2008, BLOOD, V111, P767, DOI 10.1182/blood-2007-04-085670; Klusmann JH, 2010, GENE DEV, V24, P478, DOI 10.1101/gad.1856210; Li Z, 2005, NAT GENET, V37, P613, DOI 10.1038/ng1566; Malinge S, 2009, BLOOD, V113, P2619, DOI 10.1182/blood-2008-11-163501; Ng AP, 2010, BLOOD, V115, P3966, DOI 10.1182/blood-2009-09-242107; Salek-Ardakani S, 2009, CANCER RES, V69, P4665, DOI 10.1158/0008-5472.CAN-09-0075; Tunstall-Pedoe O, 2008, BLOOD, V112, P4507, DOI 10.1182/blood-2008-04-152967; Yanagida M, 2005, ONCOGENE, V24, P4477, DOI 10.1038/sj.onc.1208675	12	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	46					6099	6101		10.1038/onc.2010.353	http://dx.doi.org/10.1038/onc.2010.353			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20711238				2022-12-17	WOS:000284356500002
J	Jones, RA; Petrik, JJ; Moorehead, RA				Jones, R. A.; Petrik, J. J.; Moorehead, R. A.			Preneoplastic changes persist after IGF-IR downregulation and tumor regression	ONCOGENE			English	Article						mammary tumorigenesis; IGF-IR; tumor regression; tumor recurrence; dormant tumor cells	BREAST-CANCER-CELLS; TRANSGENIC MICE; NEOADJUVANT CHEMOTHERAPY; SOMATOMEDIN RECEPTOR; MAMMARY-TUMORS; GROWTH; OVEREXPRESSION; TUMORIGENESIS; EXPRESSION; RESISTANCE	Despite our incomplete understanding of the function of the type I insulin-like growth factor receptor (IGF-IR) in tumorigenesis, IGF-IR targeting agents have entered clinical trials for the treatment of human cancers. Previously, we have shown that downregulation of IGF-IR transgene in mammary tumors in MTB-IGFIR transengic mice results in tumor regression in a majority of the mice and most of these mice do not develop recurrent mammary tumors. In this study, we examined mammary tissue of mice that did not develop recurrent tumors. Areas of tumor regression were visible macroscopically and microscopically these lesions contained cell debris, individual cells, lipofuscin and doxycycline crystals. Three of the 12 mice also presented with considerable lobuloalveolar development. The re-expression of the IGF-IR transgene in mammary tissue with stably regressed tumors resulted in the rapid re-emergence of mammary tumors, some of which seemed to originate from the regressed mammary lesions. Thus, despite stable tumor regression after IGF-IR downregulation, mammary tissue contained preneoplastic lesions and tumors rapidly re-appear upon re-overexpression of IGF-IR transgene. Therefore, IGF-IR-targeting agents may be effective at regressing mammary tumors expressing IGF-IR, but these agents will not completely eradicate all tumor cells or restore the mammary stromal environment. Oncogene (2010) 29, 4779-4786; doi:10.1038/onc.2010.231; published online 14 June 2010	[Jones, R. A.; Petrik, J. J.; Moorehead, R. A.] Univ Guelph, Dept Biomed Sci, Ontario Vet Coll, Guelph, ON N5A 7Z1, Canada	University of Guelph	Moorehead, RA (corresponding author), Univ Guelph, Dept Biomed Sci, Ontario Vet Coll, 50 Stone Rd E, Guelph, ON N5A 7Z1, Canada.	rmoorehe@uoguelph.ca		, Roger/0000-0001-9539-6295; Jones, Robert/0000-0001-7665-9301	Cancer Research Society; Canadian Institutes of Health Research	Cancer Research Society; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This study was funded by a Cancer Research Society grant and a Canadian Institutes of Health Research grant to RAM.	ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; ARTEAGA CL, 1989, CANCER RES, V49, P6237; Bahri S, 2009, ANN SURG ONCOL, V16, P1619, DOI 10.1245/s10434-009-0441-5; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; Carboni JM, 2005, CANCER RES, V65, P3781, DOI 10.1158/0008-5472.CAN-04-4602; Chernicky CL, 2002, J CLIN PATHOL-MOL PA, V55, P102, DOI 10.1136/mp.55.2.102; Denys H, 2009, CURR PHARM DESIGN, V15, P1373, DOI 10.2174/138161209787846711; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Ghajar CM, 2008, HISTOCHEM CELL BIOL, V130, P1105, DOI 10.1007/s00418-008-0537-1; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jones RA, 2007, ONCOGENE, V26, P1636, DOI 10.1038/sj.onc.1209955; Jones RA, 2009, ONCOGENE, V28, P2152, DOI 10.1038/onc.2009.79; Kaplan-Lefko PJ, 2008, ONCOGENE, V27, P2868, DOI 10.1038/sj.onc.1210943; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Linnerth NM, 2009, NEOPLASIA, V11, P672, DOI 10.1593/neo.09310; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Miranda MB, 2008, LEUKEMIA, V22, P1624, DOI 10.1038/leu.2008.28; Moorehead RA, 2003, ONCOGENE, V22, P853, DOI 10.1038/sj.onc.1206188; Morris GJ, 2010, SEMIN ONCOL, V37, P1, DOI 10.1053/j.seminoncol.2009.12.001; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Peintinger F, 2008, BRIT J SURG, V95, P433, DOI 10.1002/bjs.6044; Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.3.CO;2-3; Pure E, 2009, EXPERT OPIN THER TAR, V13, P967, DOI 10.1517/14728220903103841; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Wilker E, 2005, MOL CARCINOGEN, V44, P137, DOI 10.1002/mc.20132; Wise TL, 2006, CANCER RES, V66, P1327, DOI 10.1158/0008-5472.CAN-05-3107; Zhang DW, 2009, CLIN CANCER RES, V15, P6639, DOI 10.1158/1078-0432.CCR-09-0951	36	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	34					4779	4786		10.1038/onc.2010.231	http://dx.doi.org/10.1038/onc.2010.231			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20543862				2022-12-17	WOS:000281326400004
J	Morawska-Onyszczuk, M; Bienkowska-Szewczyk, K; Dobbelstein, M				Morawska-Onyszczuk, M.; Bienkowska-Szewczyk, K.; Dobbelstein, M.			Self-association of adenovirus type 5 E1B-55kDa as well as p53 is essential for their mutual interaction	ONCOGENE			English	Article						p53; E1B-55kDa; oligomerization; adenovirus	E1B 55-KILODALTON PROTEIN; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; E4ORF3 PROTEIN; TUMOR-ANTIGEN; DNA; DEGRADATION; BINDING; ONCOPROTEINS; IDENTIFICATION	The adenovirus type 5 E1B-55kDa oncoprotein forms a complex with the tumor suppressor p53 and inactivates it. E1B-55kDa and p53 are each capable of forming oligomers. We mapped the oligomerization domain of E1B-55kDa to the central portion of the protein. Disturbing E1B-55kDa self-association by point mutations at residues 285/286 or 307 not only impairs its intracellular localization to the cytoplasmic clusters, but in addition, its association with p53. Strikingly, tetramerization of p53 is also required for efficient association with E1B-55kDa. Moreover, two different E1B-55kDa mutants defective for p53 binding but proficient for oligomerization can trans-complement each other for p53 relocalization. We propose that the homo-oligomerization of each component enables efficient interaction between E1B-55kDa and p53 through increased avidity. Oncogene (2010) 29, 1773-1786; doi:10.1038/onc.2009.461; published online 21 December 2009	[Morawska-Onyszczuk, M.; Dobbelstein, M.] Univ Gottingen, Dept Mol Oncol, Gottingen Ctr Mol Biosci, D-37077 Gottingen, Germany; [Morawska-Onyszczuk, M.; Bienkowska-Szewczyk, K.] Univ Gdansk, Dept Mol Virol, Intercoll Fac Biotechnol, PL-80952 Gdansk, Poland; [Morawska-Onyszczuk, M.; Bienkowska-Szewczyk, K.] Med Univ Gdansk, Gdansk, Poland	University of Gottingen; Fahrenheit Universities; University of Gdansk; Fahrenheit Universities; Medical University Gdansk	Dobbelstein, M (corresponding author), Univ Gottingen, Dept Mol Oncol, Gottingen Ctr Mol Biosci, Ernst Caspari Haus,Justus Liebig Weg 11, D-37077 Gottingen, Germany.	mdobbel@uni-goettingen.de		Morawska, Magdalena/0000-0003-0449-5226; Bienkowska-szewczyk, Krystyna/0000-0003-3650-2902; Dobbelstein, Matthias/0000-0001-5052-3967	German Cancer Aid/Dr Mildred Scheel Stiftung; EU; German Research Foundation (DFG); Wilhelm Sander Stiftung; Statens Sundhedsvidenskabelige Forskningsrad of Denmark; Danish Cancer Society; Fonden til Laegevidenskabens Fremme; Novonordisk fonden; University of Gottingen; Gottingen Graduate School for Neurosciences and Molecular Biosciences (GGNB)	German Cancer Aid/Dr Mildred Scheel Stiftung(Deutsche Krebshilfe); EU(European Commission); German Research Foundation (DFG)(German Research Foundation (DFG)); Wilhelm Sander Stiftung; Statens Sundhedsvidenskabelige Forskningsrad of Denmark; Danish Cancer Society(Danish Cancer Society); Fonden til Laegevidenskabens Fremme; Novonordisk fonden(Novo Nordisk Foundation); University of Gottingen; Gottingen Graduate School for Neurosciences and Molecular Biosciences (GGNB)	We thank C Hippel and A Dickmanns for excellent technical assistance. We thank M Oren (Rehovot) and K Vousden (Glasgow) for plasmids and cells. Our work was supported by the German Cancer Aid/Dr Mildred Scheel Stiftung, the EU 6th Framework Program (Integrated Project Active p53), the German Research Foundation (DFG), the Wilhelm Sander Stiftung, the Statens Sundhedsvidenskabelige Forskningsrad of Denmark, the Danish Cancer Society, the Fonden til Laegevidenskabens Fremme, the Novonordisk fonden, the MSc/PhD Molecular Biology Program at the University of Gottingen, and The Gottingen Graduate School for Neurosciences and Molecular Biosciences (GGNB).	Araujo FD, 2005, J VIROL, V79, P11382, DOI 10.1128/JVI.79.17.11382-11391.2005; Baker A, 2007, J VIROL, V81, P7034, DOI 10.1128/JVI.00029-07; BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Dallaire F, 2009, J VIROL, V83, P5329, DOI 10.1128/JVI.00089-09; DAVIS AC, 1989, IMMUNOL TODAY, V10, P118, DOI 10.1016/0167-5699(89)90244-2; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; DISSANAYAKE S, 1977, IMMUNOLOGY, V32, P309; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Fleisig HB, 2007, ONCOGENE, V26, P4797, DOI 10.1038/sj.onc.1210281; Gonzalez RA, 2002, J VIROL, V76, P4507, DOI 10.1128/JVI.76.9.4507-4519.2002; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; GRAND RJA, 1995, VIROLOGY, V207, P255, DOI 10.1006/viro.1995.1074; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Horridge JJ, 1998, J VIROL, V72, P9374, DOI 10.1128/JVI.72.11.9374-9379.1998; Konig C, 1999, J VIROL, V73, P2253; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; Levine AJ, 2009, VIROLOGY, V384, P285, DOI 10.1016/j.virol.2008.09.034; Lilyestrom W, 2006, GENE DEV, V20, P2373, DOI 10.1101/gad.1456306; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu Y, 2005, J VIROL, V79, P14004, DOI 10.1128/JVI.79.22.14004-14016.2005; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Marshall LJ, 2008, J VIROL, V82, P6395, DOI 10.1128/JVI.00043-08; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Olivier M, 2009, CANCER GENE THER, V16, P1, DOI 10.1038/cgt.2008.69; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schwartz RA, 2008, J VIROL, V82, P9043, DOI 10.1128/JVI.00925-08; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; Singh RK, 2007, J BIOL CHEM, V282, P10901, DOI 10.1074/jbc.M610879200; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003	48	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1773	1786		10.1038/onc.2009.461	http://dx.doi.org/10.1038/onc.2009.461			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20023703				2022-12-17	WOS:000276022800007
J	Zhao, LJ; Subramanian, T; Chinnadurai, G				Zhao, L-J; Subramanian, T.; Chinnadurai, G.			Inhibition of transcriptional activation and cell proliferation activities of adenovirus E1A by the unique N-terminal domain of CtBP2	ONCOGENE			English	Article						E1A; CtBP; transcriptional repression; cell proliferation	NUCLEAR-LOCALIZATION; NEGATIVE MODULATION; MOLECULAR-CLONING; TRANSFORMATION; BINDING; PROTEIN; REGION; GENE; PHOSPHOPROTEIN; TUMORIGENESIS	The 243-residue E1A protein of adenovirus induces cellular proliferation, at least partly by regulating the transcription of cellular genes. This E1A function requires E1A N-terminal region and conserved regions 1 and 2 (CR1 and CR2), which interact with histone acetyl transferases, p400 chromatin-modifying complex and the Rb family proteins. A PLDLS motif at the E1A C-terminal (CR4) region, interacts with the C-terminal binding proteins (CtBP1 and CtBP2), and antagonizes some E1A functions. In this report, we discovered that the transcriptional activation function of E1A was specifically repressed by a short N-terminal domain unique to CtBP2. The CtBP2-mediated repression of E1A transcriptional activation activity is independent of histone deacetylases, which can be recruited by CtBP1/2 proteins to inhibit transcription. Fusion of the CtBP2 N-terminal 20 residues to the E1A C-terminal region rendered E1A to be inactive in transcriptional activation without interfering with E1A's ability to interact with major cofactors such as pRb, p400 and p300. Substitution of the N-terminal domain of CtBP1 for the CtBP2 domain in E1A-CtBP2 fusion partially restored the transactivation activity of E1A. In a cell-proliferation model utilizing primary baby rat kidney cells and retrovirally expressed E1A, the ability of E1A to induce cellular proliferation was strongly inhibited when the CtBP2 N-terminal region was fused to E1A. These results are consistent with a hypothesis that CtBP2 may inhibit E1A induced cell proliferation by antagonizing the transcriptional activation function controlled by the N-terminal region of E1A.	[Zhao, L-J; Subramanian, T.; Chinnadurai, G.] St Louis Univ, Sch Med, Doisy Res Ctr, Inst Mol Virol, St Louis, MO 63104 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Sch Med, Doisy Res Ctr, Inst Mol Virol, 1100 S Grand Blvd, St Louis, MO 63104 USA.	chinnag@slu.edu			 [CA-84941];  [CA-33616]; NATIONAL CANCER INSTITUTE [R01CA084941, R01CA033616] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank R Subramanian for technical assistance. This study was supported by research grants CA-84941 and CA-33616.	Bergman LM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-35; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; CHINNADURAI G, 2007, MOL BIOL INTELL UNIT, pR9; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Grignani F, 1998, CANCER RES, V58, P14; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Kuppuswamy M, 2008, MOL CELL BIOL, V28, P269, DOI 10.1128/MCB.01077-07; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Samuelson AV, 2005, J BIOL CHEM, V280, P21915, DOI 10.1074/jbc.M414564200; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schmitz F, 2000, NEURON, V28, P857, DOI 10.1016/S0896-6273(00)00159-8; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Verger A, 2006, MOL CELL BIOL, V26, P4882, DOI 10.1128/MCB.02402-05; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; Zhao LJ, 2007, ONCOGENE, V26, P7544, DOI 10.1038/sj.onc.1210569; Zhao LJ, 2006, J BIOL CHEM, V281, P36613, DOI 10.1074/jbc.M603550200; Zhao LJ, 2006, J BIOL CHEM, V281, P4183, DOI 10.1074/jbc.M509051200	26	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	39					5214	5222		10.1038/onc.2008.162	http://dx.doi.org/10.1038/onc.2008.162			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18490918	Green Accepted			2022-12-17	WOS:000258915100005
J	Perazzona, B; Lin, H; Sun, T; Wang, Y; Arlinghaus, R				Perazzona, B.; Lin, H.; Sun, T.; Wang, Y.; Arlinghaus, R.			Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects	ONCOGENE			English	Article						BCR-ABL; CML; BCR kinase-defective BCR	NEGATIVE REGULATOR; TYROSINE KINASE; GENE ENCODES; P160 BCR; C-ABL; ONCOPROTEIN; LEUKEMIA; TRANSFORMATION; EXPRESSION; PROTEIN	Bcr-Abl acquires its transforming ability through its upregulated Abl tyrosine kinase activity. Bcr is a phosphoprotein with a novel serine/threonine kinase activity encoded by its first exon. In chronic myelogenous leukemia (CML) cells, Bcr-Abl phosphorylates Bcr on tyrosine residues reducing its kinase activity. Overexpression of BCR in BCR-ABL + cells produces a phosphoserine form of Bcr, which inhibits the oncogenic effects of BCR-ABL. To investigate the inhibitory effects of Bcr on Bcr-Abl, we expressed BCR/GFP in TonB210 cells, which contain a tetracycline-inducible BCR-ABL. In nude mice injected with cell clones of TonB210/BCR/GFP, tumor formation was delayed, and tumors were 50% smaller compared with the TonB210/GFP. In addition, TonB210/BCR/GFP cells had little colony-forming ability in soft agar compared with TonB210/GFP cells. In contrast, a point mutant of BCR (Y360F), which disrupts its kinase activity, not only blocked Bcr's inhibitory effects but also enhanced the oncogenic effects of Bcr-Abl in a solid tumor model and in soft agar colony assays. Similar effects were observed with a second BCR kinase domain mutant, S354A. These results indicate that the inhibitory function of Bcr directed toward Bcr-Abl requires its kinase function.	[Perazzona, B.; Lin, H.; Sun, T.; Wang, Y.; Arlinghaus, R.] Univ Texas MD Anderson Canc Ctr, Unit 951, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Unit 951, Dept Mol Pathol, 7435 Fannin St, Houston, TX 77030 USA.	rarlingh@mdanderson.org			NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER; NCI NIH HHS [CA49639, P01 CA049639, P01 CA049639-150024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Arlinghaus RB, 2002, ONCOGENE, V21, P8560, DOI 10.1038/sj.onc.1206083; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; GUO JQ, 1994, BLOOD, V83, P3629; Hawk N, 2002, CANCER RES, V62, P386; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; LI WJ, 1989, ONCOGENE, V4, P127; Lin F, 2001, ONCOGENE, V20, P1873, DOI 10.1038/sj.onc.1204409; Ling XY, 2003, CANCER RES, V63, P298; LIU J, 1996, MOL CELL BIOL, V3, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; Mahon GM, 2003, CURR BIOL, V13, P437, DOI 10.1016/S0960-9822(03)00090-3; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Moravcova J, 2005, NEOPLASMA, V52, P119; Nagar B, 2006, MOL CELL, V21, P787, DOI 10.1016/j.molcel.2006.01.035; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Ress A, 2005, EMBO REP, V6, P1095, DOI 10.1038/sj.embor.7400536; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942	23	3	4	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2208	2214		10.1038/sj.onc.1210851	http://dx.doi.org/10.1038/sj.onc.1210851			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17934518	Green Accepted			2022-12-17	WOS:000254621300011
J	Brenner, C; Grimm, S				Brenner, C.; Grimm, S.			The permeability transition pore complex in cancer cell death (vol 25, pg 4744, 2006)	ONCOGENE			English	Correction																		Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609	1	3	3	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2006	25	50					6678	6678		10.1038/sj.onc.1210020	http://dx.doi.org/10.1038/sj.onc.1210020			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI		Bronze			2022-12-17	WOS:000241569700013
J	Yang, X; Chen, MW; Terry, S; Vacherot, F; Bemis, DL; Capodice, J; Kitajewski, J; de la Taille, A; Benson, MC; Guo, Y; Buttyan, R				Yang, X.; Chen, M-W; Terry, S.; Vacherot, F.; Bemis, D. L.; Capodice, J.; Kitajewski, J.; de la Taille, A.; Benson, M. C.; Guo, Y.; Buttyan, R.			Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells (vol 25, pg 3436, 2006)	ONCOGENE			English	Correction													Terry, Stephane/K-5351-2013; Vacherot, Francis/R-6588-2018; de la taille, Alex/ABE-8422-2021	Terry, Stephane/0000-0003-3089-7886; Vacherot, Francis/0000-0002-3677-1267; 				Yang X, 2006, ONCOGENE, V25, P3436, DOI 10.1038/sj.onc.1209366	1	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	30					4256	4256		10.1038/sj.onc.1209730	http://dx.doi.org/10.1038/sj.onc.1209730			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA		Bronze			2022-12-17	WOS:000239004800014
J	Henderson, CC; Zhang, ZQ; Manson, SR; Riehm, JJ; Kataoka, M; Flye, MW; Garbow, JR; You, M; Weintraub, SJ				Henderson, CC; Zhang, ZQ; Manson, SR; Riehm, JJ; Kataoka, M; Flye, MW; Garbow, JR; You, M; Weintraub, SJ			A moderate reduction of Bcl-X-L expression protects against tumorigenesis; however, it also increases susceptibility to tissue injury	ONCOGENE			English	Article						Bcl-X-L; lung cancer; tumorigenesis; carcinogen; apoptosis; tissue injury	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; INDUCED APOPTOSIS; HEPATOCYTE APOPTOSIS; MEDIATED APOPTOSIS; LIVER-INJURY; INDUCTION; ALCOHOL; DEATH; INTERLEUKIN-6	Little consideration has been given to the possibility that there could be variations in protein expression that alter susceptibility to tumorigenesis without causing other obvious phenotypic effects. Therefore, we sought to determine if haploinsufficiency for the antiapoptotic protein Bcl-x(L) would affect tumorigenesis. We chose to study Bcl-x(L) because although bcl-x(+/-) mice were thought to be phenotypically normal, we and others found that haploinsufficiency for Bcl-x(L) lowers fibroblast resistance to apoptosis in tissue culture. Since resistance to certain forms of apoptosis is required for tumor formation, this suggested that decreased Bcl-xL expression would afford protection against tumorigenesis. Indeed, we demonstrate here that bcl-x(+/-) mice are strikingly resistant to carcinogen-induced tumorigenesis. However, we found that they pay a price for their resistance in that they are more susceptible to clinically relevant forms of tissue injury - they suffer increased hepatic injury in a model of binge alcohol abuse and in response to TNF-alpha treatment. These findings are important because they suggest that even minor variations in Bcl-x(L) expression could affect susceptibility to cancer and other diseases. Additionally, they indicate that the potential for increased susceptibility to tissue injury must be considered in the design of chemopreventative and antineoplastic strategies that involve inhibition of Bcl-x(L) activity.	Washington Univ, Sch Med, Div Urol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Chem, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Weintraub, SJ (corresponding author), Washington Univ, Sch Med, Div Urol, Campus Box 8242, St Louis, MO 63110 USA.	weintraub@wustl.edu	Weintraub, Steve/GSE-3366-2022		NATIONAL CANCER INSTITUTE [R01CA098605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA098605-05] Funding Source: Medline; NIDDK NIH HHS [P30-DK52574] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amundson SA, 2000, CANCER RES, V60, P6101; Becker U, 1996, HEPATOLOGY, V23, P1025, DOI 10.1002/hep.510230513; Bergsland EK, 2001, SEMIN ONCOL, V28, P521, DOI 10.1053/sonc.2001.26955; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Colantoni A, 2003, ALCOHOL CLIN EXP RES, V27, P1184, DOI 10.1097/01.ALC.0000075834.52279.F9; Cossentino Mark J, 2003, Semin Gastrointest Dis, V14, P128; Day CP, 2001, J HEPATOL, V34, P330, DOI 10.1016/S0168-8278(00)00110-0; De la Coste A, 1999, AM J PHYSIOL-GASTR L, V277, pG702, DOI 10.1152/ajpgi.1999.277.3.G702; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Diehl AM, 2000, IMMUNOL REV, V174, P160, DOI 10.1034/j.1600-0528.2002.017411.x; Dvorakova K, 2004, CLIN CANCER RES, V10, P2020, DOI 10.1158/1078-0432.CCR-0437-03; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hatano E, 2001, AM J PHYSIOL-GASTR L, V281, pG1357, DOI 10.1152/ajpgi.2001.281.6.G1357; Hong F, 2002, ONCOGENE, V21, P32, DOI 10.1038/sj.onc.1205016; Karnauskas R, 2003, ONCOGENE, V22, P688, DOI 10.1038/sj.onc.1206159; LEIST M, 1994, J IMMUNOL, V153, P1778; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; McManus DT, 2004, CANCER RES, V64, P1561, DOI 10.1158/0008-5472.CAN-03-2438; MUTO Y, 1988, LANCET, V2, P72; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Natori S, 2001, J HEPATOL, V34, P248, DOI 10.1016/S0168-8278(00)00089-1; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Riegman PHJ, 2001, CANCER RES, V61, P3164; Sato N, 2001, ALCOHOL CLIN EXP RES, V25, p40S, DOI 10.1111/j.1530-0277.2001.tb02371.x; Shimkin M B, 1975, Adv Cancer Res, V21, P1, DOI 10.1016/S0065-230X(08)60970-7; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Tzung SP, 1997, AM J PATHOL, V150, P1985; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wetscher GJ, 1998, AM J SURG, V176, P569, DOI 10.1016/S0002-9610(98)00258-X; Yoon JH, 2002, J HEPATOL, V37, P400, DOI 10.1016/S0168-8278(02)00209-X; Zhang H, 2003, J PHARMACOL EXP THER, V307, P24, DOI 10.1124/jpet.103.050435; Ziol M, 2001, J HEPATOL, V34, P254, DOI 10.1016/S0168-8278(00)00047-7; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	40	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7120	7124		10.1038/sj.onc.1208887	http://dx.doi.org/10.1038/sj.onc.1208887			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007126				2022-12-17	WOS:000232833200014
J	Hanson, AJ; Nahreini, P; Andreatta, C; Yan, XD; Prasad, KN				Hanson, AJ; Nahreini, P; Andreatta, C; Yan, XD; Prasad, KN			Role of the adenosine 3 ',5 '-cyclic monophosphate (cAMP) in enhancing the efficacy of siRNA-mediated gene silencing in neuroblastoma cells	ONCOGENE			English	Article						cAMP; siRNA; neuroblastoma; phosphatidylinositol 3-kinase	INDUCED DIFFERENTIATION; RNA INTERFERENCE; MAMMALIAN-CELLS; EXPRESSION; GROWTH; APOPTOSIS; NEURONS; CULTURE; CANCER	Gene-silencing activity mediated by siRNA has been demonstrated in mammalian cells; however, the mechanism of its regulation is not well understood. Since downregulation of a number of genes occurs during adenosine 3',5'-cyclic monophosphate (cAMP)-induced differentiation of neuroblastoma ( NB) cells, it is possible that cAMP may play a role in regulating siRNA activity during differentiation. To study this, we utilized an NB cell line (NBP2-PN25) that expresses a short-lived green fluorescent protein (d2EGFP) under the CMV promoter. These cells were transfected with a retroviral plasmid that expresses U6 promoter-driven expression of siRNA targeted to d2EGFP and then were treated with cAMP-elevating agents ( 200 mu g/ml RO20- 1724, an inhibitor of cyclic nucleotide phosphodiesterase, and 1 mu g/ml prostaglandin A(1), a stimulator of adenylate cyclase) for 2 or 24 h. The siRNA activity was measured by determining the level of intensity of d2EGFP protein by flow cytometry, and the level of d2EGFP mRNA by real-time PCR. The results showed that cAMP-elevating agents enhanced U6-driven siRNA activity directed towards d2EGFP in NB cells 24 h after treatment. One of the mechanisms of action of cAMP is mediated via phosphatidylinositol 3-kinase (PI3K) inhibition; therefore, we have investigated the effect of a PI3K inhibitor on siRNA activity. This study showed that inhibition of PI3K also enhanced U6-driven siRNA activity towards d2EGFP. cAMP-stimulating agents increased U6 transcript levels, perhaps suggesting that increased siRNA activity may in part be due to an increase in transcriptional activity. When NB cells were transfected with a synthetic siRNA directed to d2EGFP, both cAMP elevation and PI3K inhibition similarly enhanced siRNA activity. Sodium butyrate, which inhibits the growth of NB cells similar to the effect produced by cAMP, did not affect U6-driven siRNA activity towards d2EGFP. Protein kinase C (PKC) activation or inhibition also failed to affect siRNA activity in NB cells. This study also showed that cAMP elevation and PI3K inhibition increases U6-driven siRNA activity directed towards an endogenous gene, p53. Our data suggest a role for the cAMP pathway in affecting the efficacy of siRNA system during differentiation of NB cells.	Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Radiol,Ctr Vitamins & Canc Res, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Prasad, KN (corresponding author), Premier Mironutr Corp, 14 Galli Dr,Suite 200, Navato, CA 94949 USA.	kedar@knprasad.com			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018285] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG18285] Funding Source: Medline; NINDS NIH HHS [R01 NS38647] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Castell X, 2003, NEUROCHEM RES, V28, P557, DOI 10.1023/A:1022829608540; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hanson AJ, 2003, J NEUROSCI RES, V74, P148, DOI 10.1002/jnr.10726; KHALED M, 2003, PIGM CELL RES, V16, P573; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Lee HT, 2003, INVEST OPHTH VIS SCI, V44, P3816, DOI 10.1167/iovs.03-0147; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Nahreini P, 2001, CELL MOL NEUROBIOL, V21, P509, DOI 10.1023/A:1013819423394; Nahreini P, 2001, CELL MOL NEUROBIOL, V21, P65, DOI 10.1023/A:1007173329237; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pickford AS, 2003, CELL MOL LIFE SCI, V60, P871, DOI 10.1007/s00018-003-2245-2; Poser S, 2003, J NEUROSCI, V23, P4420; PRASAD KN, 1980, LIFE SCI, V27, P1351, DOI 10.1016/0024-3205(80)90397-5; PRASAD KN, 1991, BIOL REV, V66, P431, DOI 10.1111/j.1469-185X.1991.tb01148.x; PRASAD KN, 1976, IN VITRO CELL DEV B, V12, P125; Takei Y, 2004, CANCER RES, V64, P3365, DOI 10.1158/0008-5472.CAN-03-2682; Tijsterman M, 2002, ANNU REV GENET, V36, P489, DOI 10.1146/annurev.genet.36.043002.091619; Yan XD, 2002, IN VITRO CELL DEV-AN, V38, P529	21	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4149	4154		10.1038/sj.onc.1208577	http://dx.doi.org/10.1038/sj.onc.1208577			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806165				2022-12-17	WOS:000229680300013
J	Vo, QN; Kim, WJ; Cvitanovic, L; Boudreau, DA; Ginzinger, DG; Brown, KD				Vo, QN; Kim, WJ; Cvitanovic, L; Boudreau, DA; Ginzinger, DG; Brown, KD			The ATM gene is a target for epigenetic silencing in locally advanced breast cancer (vol 24, pg 1964, 2005)	ONCOGENE			English	Correction																		Vo QN, 2005, ONCOGENE, V24, P1964, DOI 10.1038/sj.onc.1208629	1	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 10	2005	24	11					1964	1964		10.1038/sj.onc.1208629	http://dx.doi.org/10.1038/sj.onc.1208629			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH		Bronze			2022-12-17	WOS:000227542000016
J	Lechanteur, C; Jacobs, N; Greimers, R; Benoit, V; Deregowski, V; Chariot, A; Merville, MP; Bours, V				Lechanteur, C; Jacobs, N; Greimers, R; Benoit, V; Deregowski, V; Chariot, A; Merville, MP; Bours, V			Low daunomycin concentrations protect colorectal cancer cells from hypoxia-induced apoptosis	ONCOGENE			English	Article						hypoxia; apoptosis; daunomycin; colorectal cancer; Akt; Bad	LOW-OXYGEN CONDITIONS; SOLID TUMORS; DRUG-RESISTANCE; IN-VITRO; P53; AKT; THERAPY; GROWTH; DOXORUBICIN; INHIBITION	Hypoxia, a common feature of solid tumors, is a direct stress that triggers apoptosis in many cell types. Poor or irregular tumor vascularization also leads to a decreased drug diffusion and cancer cells distant from blood vessels ( hypoxic cells) are exposed to low drug concentrations. In this report, we show that low daunomycin concentrations protect HCT116 colorectal cancer cells from hypoxia-induced apoptosis. While hypoxia induced p53 accumulation without expression of its responsive genes (bax and p21), daunomycin treatment restored p53 transactivation activity and cell cycle progression. We also demonstrated a role for Akt activation in daunomycin-induced protection through phosphorylation and inactivation of the Bcl-2 family proapoptotic factor Bad. Our data therefore suggest that chemotherapy could possibly, because of low concentrations in poorly vascularized tumors, protect cancer cells from hypoxia-induced cytotoxicity.	Univ Liege, Lab Med Chem & Human Genet, CHU B35, Ctr Biomed Integrated Genoprote,Lab Med Chem & Hu, B-4000 Liege, Belgium; Univ Liege, Ctr Biomed Integrated Genoprote, Lab Anatomopathol, Liege, Belgium	University of Liege; University of Liege	Bours, V (corresponding author), Univ Liege, Lab Med Chem & Human Genet, CHU B35, Ctr Biomed Integrated Genoprote,Lab Med Chem & Hu, B-4000 Liege, Belgium.	vbours@ulg.ac.be		Chariot, Alain/0000-0002-1691-4347; BENOIT, Valerie/0000-0002-1098-9452; Jacobs, Nathalie/0000-0002-9895-8465				Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Brown JM, 1998, CANCER RES, V58, P1408; Chao W, 2003, J GENE MED, V5, P277, DOI 10.1002/jgm.347; Clark AS, 2002, MOL CANCER THER, V1, P707; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hirai K, 2004, MOL BRAIN RES, V124, P51, DOI 10.1016/j.molbrainres.2004.02.009; Kim CY, 1997, CANCER RES, V57, P4200; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Ogiso Y, 2000, CANCER RES, V60, P2429; Plo I, 1999, FEBS LETT, V452, P150, DOI 10.1016/S0014-5793(99)00631-6; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SANNA K, 1994, INT J CANCER, V58, P258, DOI 10.1002/ijc.2910580219; Tanaka M, 2003, GENE THER, V10, P1636, DOI 10.1038/sj.gt.3302056; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yu JL, 2002, DIFFERENTIATION, V70, P599, DOI 10.1046/j.1432-0436.2002.700913.x; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	28	3	3	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1788	1793		10.1038/sj.onc.1208436	http://dx.doi.org/10.1038/sj.onc.1208436			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15688011	Green Published			2022-12-17	WOS:000227345100014
J	Cao, C; Mu, Y; Hallahan, DE; Lu, B				Cao, C; Mu, Y; Hallahan, DE; Lu, B			XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer (vol 23, pg 7047, 2004)	ONCOGENE			English	Correction																		Cao C, 2004, ONCOGENE, V23, P7047, DOI 10.1038/sj.onc.1207929	1	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2004	23	58					9448	9448		10.1038/sj.onc.1208365	http://dx.doi.org/10.1038/sj.onc.1208365			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT		Bronze			2022-12-17	WOS:000225764100020
J	Elhasid, R; Sahar, D; Merling, A; Zivony, Y; Rotem, A; Ben-Arush, M; Izraeli, S; Bercovich, D; Larisch, S				Elhasid, R; Sahar, D; Merling, A; Zivony, Y; Rotem, A; Ben-Arush, M; Izraeli, S; Bercovich, D; Larisch, S			Mitochondrial proapoptotic ARTS protein is lost in the majority of acute lymphoblastic leukemia patients (vol 23, pg 5468, 2004)	ONCOGENE			English	Correction																		Elhasid R, 2004, ONCOGENE, V23, P5468, DOI 10.1038/sj.onc.1207725	1	3	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2004	23	58					9450	9450		10.1038/sj.onc.1208363	http://dx.doi.org/10.1038/sj.onc.1208363			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT		Bronze			2022-12-17	WOS:000225764100024
J	Zhou, AW; Scoggin, S; Gaynor, RB; Williams, NS				Zhou, AW; Scoggin, S; Gaynor, RB; Williams, NS			Identification of NF-kappa B-regulated genes induced by TNF alpha utilizing expression profiling and RNA interference (vol 22, pg 2054, 2003)	ONCOGENE			English	Correction																		Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	1	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2004	23	58					9447	9447		10.1038/sj.onc.1208322	http://dx.doi.org/10.1038/sj.onc.1208322			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT		Bronze			2022-12-17	WOS:000225764100017
J	Malavaud, B; Pedron, S; Sordello, S; Mazerolles, C; Billottet, C; Thiery, JP; Jouanneau, J; Plouet, J				Malavaud, B; Pedron, S; Sordello, S; Mazerolles, C; Billottet, C; Thiery, JP; Jouanneau, J; Plouet, J			Direct FGF receptor 1 activation through an anti-idiotypic strategy mimicks the biological activity of FGF-2 and inhibits the progression of the bladder carcinoma derived from NBT-II cells	ONCOGENE			English	Article						anti-idiotypic antibodies; fibroblast growth factor; angiogenesis; tumor proliferation	FIBROBLAST-GROWTH-FACTOR; ENDOTHELIAL-CELLS; FACTOR-2; SUFFICIENT; RELEASE	The hypothesis that tumor growth is angiogenesis-dependent has been documented by a considerable body of direct and indirect experimental data. Since the discovery of the vascular endothelial growth factor ( VEGF), most attention has been focused on the VEGF system. Although fibroblast growth factors 1 and 2 (FGF-1 and FGF-2) can exert a strong angiogenic activity when they are supplied as a single pharmacological agent, their role in pathological angiogenesis in preclinical models remains controversial. To decipher the contribution of FGF receptors in various models of angiogenesis, we took advantage of the anti-idiotypic strategy to obtain circulating agonists specific for FGFR-1 and FGFR-2 (AIdF-1 and AIdF-2). They mimicked FGF-1 and FGF-2 for receptor binding, signal transduction, proliferation of endothelial cells and differentiation of the bladder carcinoma cell NBT-II which expresses FGFR-2b but not FGFR-1. The constitutive expression of FGFR-1 allowed binding of FGF-2 and AIdF-2 and inhibition of the proliferation of NBT-II cells. AIdF-1 and AIdF-2 induced angiogenesis in the corneal pocket assay. Although FGFR-1 dimerization achieved by AIdF-2 injection led to highly differentiated and smaller NBT-II tumors, no sign of reduction of tumor angiogenesis was observed, thus suggesting that endothelial cells are resistant to FGF.	Inst Pharmacol & Biol Struct, CNRS, UMR 5089, F-31077 Toulouse, France; Univ Toulouse 3, CHU Toulouse Rangueil, Clin Univ Urol, F-31062 Toulouse, France; CHU Toulouse Purpan, Lab Anatomopathol, F-31059 Toulouse, France; Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite	Plouet, J (corresponding author), Hop Lariboisiere, Inst Vaisseaux & Sang, 8 Rue Guy Patin, F-75010 Paris, France.	jean.plouet@idf.inserm.fr	Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Billottet C, 2002, ONCOGENE, V21, P8128, DOI 10.1038/sj.onc.1205935; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; COURAUD PO, 1991, BIOCHEM SOC T, V19, P147, DOI 10.1042/bst0190147; GOSPODAROWICZ D, 1987, NUCL MED BIOL, V14, P421, DOI 10.1016/0883-2897(87)90019-5; Hutchings H, 2002, BIOCHEM BIOPH RES CO, V294, P764, DOI 10.1016/S0006-291X(02)00548-X; JERNE NK, 1982, EMBO J, V1, P243, DOI 10.1002/j.1460-2075.1982.tb01154.x; Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; Jouanneau J, 1999, ONCOGENE, V18, P327, DOI 10.1038/sj.onc.1202285; Kudla AJ, 1998, J CELL BIOL, V142, P241, DOI 10.1083/jcb.142.1.241; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; Okada-Ban M, 2000, INT J BIOCHEM CELL B, V32, P263, DOI 10.1016/S1357-2725(99)00133-8; Ortega N, 1997, AM J PATHOL, V151, P1215; Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2; PLOUET J, 1990, EXP EYE RES, V51, P519, DOI 10.1016/0014-4835(90)90082-6; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; QUARTO N, 1994, J CELL SCI, V107, P3201; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; SCHWEIGERER L, 1987, J CLIN INVEST, V80, P1516, DOI 10.1172/JCI113236; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Soulet F, 2001, BIOCHEM BIOPH RES CO, V289, P591, DOI 10.1006/bbrc.2001.5960; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6	30	3	3	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6769	6778		10.1038/sj.onc.1207135	http://dx.doi.org/10.1038/sj.onc.1207135			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273729				2022-12-17	WOS:000223653600008
J	Parghi, SS; Brandvold, KA; Bowers, SJ; Neiman, PE; Ruddell, A				Parghi, SS; Brandvold, KA; Bowers, SJ; Neiman, PE; Ruddell, A			Reduced Myc overexpression and normal B-cell differentiation mediate resistance to avian leukosis virus lymphomagenesis	ONCOGENE			English	Article						lymphoma resistance; c-Myc oncogene; avian leukosis virus	REPEAT-ENHANCED TRANSCRIPTION; PROVIRAL C-MYC; LYMPHOID LEUKOSIS; DNA INTEGRATION; EXPRESSION; CHICKENS; BURSA; FABRICIUS; INFECTION; ACTIVATION	Avian leukosis virus (ALV) induces bursal lymphoma in tumor-susceptible chicken strains after proviral integration within the c-myc gene, and subsequent expansion of Myc-overexpressing lymphocytes within transformed follicles. Line 63 strain chickens are resistant to ALV tumorigenesis, largely failing to develop Myc-transformed follicles, although they show similar levels of ALV infection and integration as lymphoma-susceptible strains. Immunohistochemical analysis determined that the transformed follicles that do arise in lymphoma-resistant birds show much lower and more variable Myc overexpression than those of susceptible birds. This reduced Myc overexpression fails to block B-cell differentiation in resistant birds, while high Myc consistently blocks development at a late embryo stage in susceptible birds. This failure of Myc to block differentiation results in a normal pattern of posthatching bursal emigration in resistant transformed follicles, while transformed follicles of susceptible birds grow rapidly due to blocked emigration. Forced Myc overexpression produces transformed follicles in resistant birds, indicating that resistant lymphocytes can tolerate high Myc expression. The coding sequence and expression of the endogenous c-myc gene is the same in resistant and susceptible birds, suggesting that genetic resistance is instead mediated by reduced ALV LTR enhancer-driven transcription in the target lymphocytes of resistant birds.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,POB 19024,MS C2-023, Seattle, WA 98109 USA.	aruddell@fhcrc.org		Ruddell, Alanna/0000-0002-0195-5576	NATIONAL CANCER INSTITUTE [R01CA068328, R01CA020068] Funding Source: NIH RePORTER; NCI NIH HHS [CA68328, CA20068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABA TW, 1984, J VIROL, V51, P123, DOI 10.1128/JVI.51.1.123-130.1984; BABA TW, 1985, P NATL ACAD SCI USA, V82, P213, DOI 10.1073/pnas.82.1.213; Bird KJ, 1999, ONCOGENE, V18, P201, DOI 10.1038/sj.onc.1202283; Bowers WJ, 1996, J VIROL, V70, P3051, DOI 10.1128/JVI.70.5.3051-3059.1996; Brandvold KA, 2000, ONCOGENE, V19, P2780, DOI 10.1038/sj.onc.1203589; Brandvold KA, 2001, ONCOGENE, V20, P3226, DOI 10.1038/sj.onc.1204431; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; COOPER MD, 1968, JNCI-J NATL CANCER I, V41, P373; Curristin SM, 1997, J VIROL, V71, P5972, DOI 10.1128/JVI.71.8.5972-5981.1997; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; EWERT DL, 1988, ADV VET SCI COMP MED, V32, P37; FADLY AM, 1986, INT J CANCER, V38, P139, DOI 10.1002/ijc.2910380122; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; FUNG YKT, 1982, VIROLOGY, V119, P411; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HENRIKSSON M, 1996, ADV CANCER RES, V68, P110; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; LEE LF, 1981, J NATL CANCER I, V66, P789; MAAS HJL, 1982, AVIAN PATHOL, V11, P309, DOI 10.1080/03079458208436103; MASTELLER EL, 1995, J IMMUNOL, V155, P5550; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; OLSON WC, 1990, HYBRIDOMA, V9, P331, DOI 10.1089/hyb.1990.9.331; PARAMITHIOTIS E, 1994, EUR J IMMUNOL, V24, P458, DOI 10.1002/eji.1830240229; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PURCHASE HG, 1977, NATURE, V270, P61, DOI 10.1038/270061a0; RUDDELL A, 1988, J VIROL, V62, P2728, DOI 10.1128/JVI.62.8.2728-2735.1988	33	3	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4413	4421		10.1038/sj.onc.1207577	http://dx.doi.org/10.1038/sj.onc.1207577			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15064748				2022-12-17	WOS:000221661300007
J	La Rocca, SA; Vannucchi, S; Pompili, M; Pinney, DF; Emerson, CP; Grossi, M; Tato, F				La Rocca, SA; Vannucchi, S; Pompili, M; Pinney, DF; Emerson, CP; Grossi, M; Tato, F			Selective repression of myoD transcription by v-Myc prevents terminal differentiation of quail embryo myoblasts transformed by the MC29 strain of avian myelocytomatosis virus	ONCOGENE			English	Article						Myc; qmyoD; myogenic differentiation; cell transformation	MUSCLE DIFFERENTIATION; MYOGENIC DIFFERENTIATION; NORMAL-CELLS; DNA-BINDING; MECHANISMS; EXPRESSION; GENE; ONCOGENES; PROMOTER; PROTEINS	We have investigated the mechanism by which expression of the v-myc oncogene interferes with the competence of primary quail myoblasts to undergo terminal differentiation. Previous studies have established that quail myoblasts transformed by myc oncogenes are severely impaired in the accumulation of mRNAs encoding the myogenic transcription factors Myf-5, MyoD and Myogenin. However, the mechanism responsible for such a repression remains largely unknown. Here we present evidence that v-Myc selectively interferes with quail myoD expression at the transcriptional level. Cis-regulatory elements involved in the auto-activation of qmyoD are specifically targeted in this unique example of transrepression by v-Myc, without the apparent participation of Myc-specific E-boxes or InR sequences. Transiently expressed v-Myc efficiently interfered with MyoD-dependent transactivation of the qmyoD regulatory elements, while the myogenin promoter was unaffected. Finally, we show that forced expression of MyoD in v-myc-transformed quail myoblasts restored myogenin expression and promoted extensive terminal differentiation. These data suggest that transcriptional repression of qmyoD is a major and rate-limiting step in the molecular pathway by which v-Myc severely inhibits terminal differentiation in myogenic cells.	Univ Roma La Sapienza, Sezione Sci Microbiol, Ist Pasteur,Dipartimento Biol Cellulare & Svilupp, Fdn Cenci Bolognetti, I-00185 Rome, Italy; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	Fondazione Cenci Bolognetti; Sapienza University Rome; University of Pennsylvania	Grossi, M (corresponding author), Dipartimento Biol Cellulare & Sviluppo, Sezione Microbiol, Via Sardi 70, I-00185 Rome, Italy.		la rocca, severina anna/D-8028-2011; Grossi, Milena/D-2955-2009					ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; CRESCENZI M, 1994, J CELL BIOL, V125, P1137, DOI 10.1083/jcb.125.5.1137; CROUCH DH, 1993, ONCOGENE, V8, P1849; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LI L, 1992, ADV CANCER RES, V58, P95, DOI 10.1016/S0065-230X(08)60292-4; MAIONE R, 1997, BIOCHIM BIOPHYS ACTA, V1332, P19; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MOLKENTIN JD, 1996, CURR OPIN GENE DEV, V6, P455; Murry CE, 1996, J CLIN INVEST, V98, P2209, DOI 10.1172/JCI119030; PINNEY DF, 1995, DEV BIOL, V170, P21, DOI 10.1006/dbio.1995.1192; POLLERBERG GE, 1995, J NEUROSCI RES, V41, P427, DOI 10.1002/jnr.490410402; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Russo S, 1997, ONCOGENE, V14, P63, DOI 10.1038/sj.onc.1200805; TAJBAKHSH S, 1994, P NATL ACAD SCI USA, V91, P747, DOI 10.1073/pnas.91.2.747; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	23	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4838	4842		10.1038/sj.onc.1205586	http://dx.doi.org/10.1038/sj.onc.1205586			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101422				2022-12-17	WOS:000176716300013
J	Sreedhar, AS; Pardhasaradhi, BVV; Khar, A; Srinivas, UK				Sreedhar, AS; Pardhasaradhi, BVV; Khar, A; Srinivas, UK			Effect of C-terminal deletion of P53 on heat induced CD95 expression and apoptosis in a rat histiocytoma	ONCOGENE			English	Article						deletion in p53; CD95; apoptosis; heat stress	FAS-INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; DEATH FACTOR; CELL-DEATH; GENES; SHOCK; INVOLVEMENT; GROWTH; SYSTEM; LIGAND	Tumor suppressor gene product p53 in its wild-type conformation, is an effector of apoptosis. A rat histiocytic tumor, AK-5 which has a rearranged and mutated p53 gene undergoes apoptosis upon heat shock through surface expression of CD95 receptor. DNA sequence analysis of p53 gene from tumor cells revealed a deletion of 'C' at nucleotide position 942 and an addition of 'A' at position 1055. Deletion of one nucleotide caused premature termination of p53 protein which resulted in shorter p53 protein with an altered sequence from amino acids 315 to 341. Altered p53 was unable to protect BC-8, a single cell clone of AK-5 cells from apoptosis upon heat shock. BC-8 cells transfected with a wild-type p53gene (3B4 cells) were resistant to heat induced apoptosis and did not show the expression CD95 death receptor. Inhibition of p53 expression by using antisense oligo induced apoptosis upon heat shock in 3134 cells. Similarly, inhibition of CD95 expression by antisense oligo inhibited heat induced apoptosis in BC-8 cells. In addition, cell cycle regulatory molecules, cdc2 and cdk2 are differentially regulated in a non-cell cycle dependent manner in these tumor cells. These results, in view of lack of heat shock response in BC-8 cells suggest a complex interaction between p53, CD95 and hsp70 which determines the fate of the cell. In the absence of functional p53, CD95 appears to be an effector of apoptosis in BC-8 cells.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Srinivas, UK (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.							Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBATIN KM, 1994, EUR J IMMUNOL, V24, P753, DOI 10.1002/eji.1830240339; DESHPANDE G, 1990, FEBS LETT, V271, P199, DOI 10.1016/0014-5793(90)80405-8; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; KHAR A, 1990, IN VITRO CELL DEV B, V26, P1024; Kim JM, 1999, ENDOCRINOLOGY, V140, P2307, DOI 10.1210/en.140.5.2307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murayama Y, 2000, HUM IMMUNOL, V61, P474, DOI 10.1016/S0198-8859(00)00100-2; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pardhasaradhi B. V. V., 1996, Indian Journal of Experimental Biology, V34, P945; RAFF M, 1992, NATURE, V343, P76; ROBINSON JP, 1988, CURRENT PROTOCOLS CY; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; Sreedhar AS, 1999, FEBS LETT, V456, P339, DOI 10.1016/S0014-5793(99)00970-9; Sreedhar AS, 2000, FEBS LETT, V472, P271, DOI 10.1016/S0014-5793(00)01467-8; Swamynathan SK, 1996, DNA CELL BIOL, V15, P897, DOI 10.1089/dna.1996.15.897; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUTH BC, 1989, SCIENCE, V245, P539; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785; Zhou M, 1998, LEUKEMIA, V12, P1756, DOI 10.1038/sj.leu.2401198	40	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					4042	4049		10.1038/sj.onc.1205504	http://dx.doi.org/10.1038/sj.onc.1205504			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037686				2022-12-17	WOS:000175869900010
J	Stubbs, MC; Hall, DJ				Stubbs, MC; Hall, DJ			The amino-terminus of the E2F-1 transcription factor inhibits DNA replication of autonomously replicating plasmids in mammalian cells	ONCOGENE			English	Article						S phase checkpoint; E2F-1; replication inhibition; elongation phase	ZINC-FINGER PROTEIN; S-PHASE; CORE ORIGIN; APOPTOSIS; INDUCTION; EXPRESSION; INITIATION; BINDING; DAMAGE; BRCA1	The E2F1 transcription factor plays a pivotal role in driving cells out of a quiescent state and into the S phase of the cell cycle, in part by transactivating genes needed for DNA replication including DHFR, thymidine kinase, and DNA Polymerase x. E2F1 has also been implicated in regulating an S phase checkpoint, however its role in this checkpoint is not well defined. To determine how E2F1 affects such a checkpoint, we utilized an in vivo replication assay employing a plasmid based SV40 origin of replication, transfected into cells expressing SV40 large T antigen. Here we show that expression of full length E2F1, or only its N terminus, represses replication from plasmids containing the SV40 origin, while N terminal deletions of E2F1 do not. E2F1 appears to inhibit the elongation phase of replication and not the initiation phase since it does not affect the replication of other cotransfected plasmids containing only the SV40 origin. Further, inhibition of replication is dependent on both the amino-terminus of the E2F1 protein and on a DNA sequence that is contained within the 3' end of the E2F1 cDNA. Additionally, both full-length E2F1, or just its N-terminus, form protein complexes with two portions of the 3' end of the E2F1 cDNA. These data provide a clue to the mechanism by which E2F1 regulates transit through the S phase checkpoint, by acting on a specific DNA sequence via its amino-terminal region, to inhibit elongation of DNA replication.	NIAMSD, Cartilage & Orthopaed Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Hall, DJ (corresponding author), NIAMSD, Cartilage & Orthopaed Branch, NIH, MSC 5755,9000 Rockville Pk, Bethesda, MD 20892 USA.	halld@ep.niams.nih.gov		, Matthew/0000-0003-3771-7083	NCI NIH HHS [CA67032] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; CHITTENDEN T, 1991, J VIROL, V65, P5944, DOI 10.1128/JVI.65.11.5944-5951.1991; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEB S, 1986, MOL CELL BIOL, V6, P1663, DOI 10.1128/MCB.6.5.1663; DEB S, 1987, J VIROL, V61, P2143, DOI 10.1128/JVI.61.7.2143-2149.1987; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Deng CX, 2000, BIOESSAYS, V22, P728; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; HARLOW F, 1988, ANTIBODIES LAB MANUA; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Izzo MW, 1999, J BIOL CHEM, V274, P19498, DOI 10.1074/jbc.274.27.19498; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOrdan KL, 1996, BIOCHEMISTRY-US, V35, P12320, DOI 10.1021/bi9611927; Jordan-Sciutto KL, 1998, BIOCHEM CELL BIOL, V76, P37; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; LOGAN TJ, 1995, CANCER RES, V55, P2883; LOGAN TJ, 1994, MOL BIOL CELL, V5, P667, DOI 10.1091/mbc.5.6.667; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Stubbs MC, 1999, BIOCHEM BIOPH RES CO, V258, P77, DOI 10.1006/bbrc.1999.0603; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	44	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3715	3726		10.1038/sj.onc.1205473	http://dx.doi.org/10.1038/sj.onc.1205473			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032840				2022-12-17	WOS:000175676000007
J	Ortiz-Vega, S; Khokhlatchev, A; Nedwidek, M; Zhang, XF; Dammann, R; Pfeifer, GP; Avruch, J				Ortiz-Vega, S; Khokhlatchev, A; Nedwidek, M; Zhang, XF; Dammann, R; Pfeifer, GP; Avruch, J			The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1 (vol 21, pg 1381, 2002)	ONCOGENE			English	Correction																		Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192	1	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1943	1943		10.1038/sj.onc.1205378	http://dx.doi.org/10.1038/sj.onc.1205378			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ		Bronze			2022-12-17	WOS:000174284500018
J	Sheard, MA; Vojtesek, B				Sheard, MA; Vojtesek, B			Simian virus-40 infection inhibits DNA damage-induced enhancement of CD95 expression and function	ONCOGENE			English	Article						CD95/Fas; SV40; p53/Trp53/TP53; apoptosis	LARGE T-ANTIGEN; MURINE RENAL-CANCER; WILD-TYPE P53; CELL-DEATH; MONOCLONAL-ANTIBODIES; GAMMA-IRRADIATION; INDUCED APOPTOSIS; TUMOR-ANTIGEN; UP-REGULATION; FAS RECEPTOR	Many viruses are known to disarm or suppress the cell death machinery of infected cells. Apoptotic cell death can be activated by aggregation of the CD95 cell surface death receptor in sensitive cells, and in most insensitive cells treated with sensitizing agents such as interferon-gamma or inhibitors of protein synthesis. We show that, subsequent to sequestration and inactivation of the p53 tumour suppressor protein, SV40 abrogates p53-dependent, DNA damage-inducible up-regulation of CD95 surface expression. Loss of surface up-regulation of CD95 after sub-lethal mitomycin C treatment resulted in an impaired enhancement of both caspase-8 cleavage and apoptotic cell death following CD95 aggregation. We conclude that infection of human cells with SV40 virus strongly inhibits DNA damage-induced enhancement of CD95-mediated apoptosis.	Masaryk Mem Canc Inst, Lab Apoptosis Res, Brno 65653, Czech Republic; Masaryk Mem Canc Inst, Dept Expt Oncol, Brno 65653, Czech Republic	Masaryk Memorial Cancer Institute; Masaryk Memorial Cancer Institute	Sheard, MA (corresponding author), Masaryk Mem Canc Inst, Lab Apoptosis Res, Zluty Kopec 7, Brno 65653, Czech Republic.	sheard@mou.cz	Sheard, Michael/J-1374-2019	Sheard, Michael/0000-0002-4960-7650				Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Broome HE, 1998, CELL DEATH DIFFER, V5, P200, DOI 10.1038/sj.cdd.4400329; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Carbone M, 1999, J CELL PHYSIOL, V180, P167, DOI 10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; del Arroyo AG, 2000, ONCOGENE, V19, P3647, DOI 10.1038/sj.onc.1203662; Dirks W, 1997, BRIT J HAEMATOL, V96, P584, DOI 10.1046/j.1365-2141.1997.d01-2048.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fulda S, 1998, INT J CANCER, V76, P105; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275; Hashimoto W, 1999, J IMMUNOL, V163, P583; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; JAATTELA M, 1995, ONCOGENE, V10, P2297; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kimura K, 2000, J BIOL CHEM, V275, P8610, DOI 10.1074/jbc.275.12.8610; Krammer P H, 1999, Adv Immunol, V71, P163; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lee JK, 2000, J IMMUNOL, V164, P231, DOI 10.4049/jimmunol.164.1.231; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Levresse V, 1998, ONCOGENE, V16, P1041, DOI 10.1038/sj.onc.1201627; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Maecker HL, 2000, CANCER RES, V60, P4638; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; METCALF RA, 1992, CANCER RES, V52, P2610; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Mor O, 1997, ONCOGENE, V15, P3113, DOI 10.1038/sj.onc.1201549; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nguyen PL, 1996, AM J PATHOL, V148, P847; O'Connor L, 2000, CANCER RES, V60, P1217; Okayasu R, 1999, CANCER RES, V59, P298; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; Rodier F, 2000, ONCOGENE, V19, P6261, DOI 10.1038/sj.onc.1204015; Rosen D, 2000, J IMMUNOL, V164, P3229, DOI 10.4049/jimmunol.164.6.3229; ROUQUET N, 1995, ONCOGENE, V11, P1061; Sayers TJ, 2000, J LEUKOCYTE BIOL, V68, P81; Sayers TJ, 1998, J IMMUNOL, V161, P3957; Screpanti V, 2001, J IMMUNOL, V167, P2068, DOI 10.4049/jimmunol.167.4.2068; Sheard MA, 1999, BRIT J CANCER, V80, P1689, DOI 10.1038/sj.bjc.6690585; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Topham DJ, 1997, J IMMUNOL, V159, P5197; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wigginton JM, 2001, J CLIN INVEST, V108, P51	58	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					190	197						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803462				2022-12-17	WOS:000173026200003
J	Park, JS; Qiao, L; Su, ZZ; Hinman, D; Willoughby, K; McKinstry, R; Yacoub, A; Duigou, GJ; Young, CSH; Grant, S; Hagan, MP; Elliss, E; Fisher, PB; Dent, P				Park, JS; Qiao, L; Su, ZZ; Hinman, D; Willoughby, K; McKinstry, R; Yacoub, A; Duigou, GJ; Young, CSH; Grant, S; Hagan, MP; Elliss, E; Fisher, PB; Dent, P			Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways (vol 20, pg 3266, 2001)	ONCOGENE			English	Correction																		Park JS, 2001, ONCOGENE, V20, P3266, DOI 10.1038/sj.onc.1204258	1	3	3	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7817	7817		10.1038/sj.onc.1204931	http://dx.doi.org/10.1038/sj.onc.1204931			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE		Bronze			2022-12-17	WOS:000172161700015
J	Ono, Y; De-Meyts, ER; Guellaen, G; Bulle, F				Ono, Y; De-Meyts, ER; Guellaen, G; Bulle, F			Sporadic testicular germ cell cancers do not exhibit specific alteration in CAG/CTG repeats containing genes expressed in human testis	ONCOGENE			English	Article						human testicular germ cell tumours; CAG/CTG repeat expansion; genetic anticipation	ANDROGEN RECEPTOR GENE; TRINUCLEOTIDE REPEAT; TRIPLET REPEAT; HUNTINGTON-DISEASE; PROSTATE-CANCER; HUMAN BRAIN; CAG REPEAT; EXPANSION; CARCINOMA; TUMORS	CAG/CTG repeat expansions in genomic DNA of testicular tumour cell lines, and germline DNA from members of families predisposed to this malignancy, have been previously described. In order to identify genes possibly concerned by this alteration, we attempted to clone all possible human testis cDNA containing at least five CAG/CTG repeats. Thirty-four different transcripts were identified. By using PCR and non denaturing gel electrophoresis, we determined the size of their repeats, as well as their polymorphisms in a collection of human testicular germ cell tumours and the normal surrounding tissues. For all tested genes, we detected the presence of several species of the same mRNA for each person. Nine genes exhibited specific patterns of expression among different groups of individuals, indicative of polymorphism. None of these polymorphisms was related to human testicular tumours.	Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France; Univ Copenhagen, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Rigshospitalet; University of Copenhagen	Bulle, F (corresponding author), Hop Henri Mondor, INSERM, U99, F-94010 Creteil, France.		Bulle-Thomas, Frederique/L-2528-2017					BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; Bulle F, 1997, GENOME RES, V7, P705, DOI 10.1101/gr.7.7.705; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Debrauwere H, 1997, BIOCHIMIE, V79, P577, DOI 10.1016/S0300-9084(97)82006-8; Dieckmann KP, 1999, INT J CANCER, V83, P815, DOI 10.1002/(SICI)1097-0215(19991210)83:6<815::AID-IJC21>3.3.CO;2-Q; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Han S, 2000, CANCER, V88, P2319, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2319::AID-CNCR16>3.0.CO;2-O; Holmes SE, 1999, NAT GENET, V23, P391, DOI 10.1038/70493; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; King BL, 1997, CANCER RES, V57, P209; Kinoshita M, 1997, MUSCLE NERVE, V20, P622, DOI 10.1002/(SICI)1097-4598(199705)20:5<622::AID-MUS16>3.0.CO;2-Y; LI SH, 1993, GENOMICS, V16, P572, DOI 10.1006/geno.1993.1232; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; Nataraj AJ, 1999, ELECTROPHORESIS, V20, P1177, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1177::AID-ELPS1177>3.0.CO;2-2; Panagopoulos I, 1999, HUM MUTAT, V13, P232, DOI 10.1002/(SICI)1098-1004(1999)13:3<232::AID-HUMU7>3.0.CO;2-N; Pawlak A, 1998, MAMM GENOME, V9, P745, DOI 10.1007/s003359900856; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; Rajpert-De Meyts E, 1998, APMIS, V106, P198; Sasaki M, 2000, MOL CARCINOGEN, V27, P237, DOI 10.1002/(SICI)1098-2744(200003)27:3<237::AID-MC11>3.3.CO;2-S; Schmutte C, 1999, ANTICANCER RES, V19, P4665; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Stanford JL, 1997, CANCER RES, V57, P1194; Teh BT, 1999, J MED GENET, V36, P348; TELENIUS H, 1995, HUM MOL GENET, V4, P189, DOI 10.1093/hmg/4.2.189; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	30	3	3	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5548	5553		10.1038/sj.onc.1204714	http://dx.doi.org/10.1038/sj.onc.1204714			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571654	Bronze			2022-12-17	WOS:000170781100017
J	Cobellis, G; Missero, C; Simionati, B; Valle, G; Di Lauro, R				Cobellis, G; Missero, C; Simionati, B; Valle, G; Di Lauro, R			Immediate early genes induced by H-Ras in thyroid cells	ONCOGENE			English	Article						thyroid; tumorigenicity; differentiation; subtraction library; adenovirus	ACTIN STRESS FIBERS; MAP KINASE KINASE; E2F FAMILY; EPITHELIAL-CELLS; TRANSFORMATION; DIFFERENTIATION; EXPRESSION; ACTIVATION; MEMBER; RHO	Expression of oncogenic v-H-Ras in the thyroid cell line FRTL-5 (FRTL-5(Ras)) results in uncontrolled proliferation, loss of thyroid-specific gene expression and tumorigenicity. Concomitant expression of constitutively activated MEK and pac, two major H-Ras downstream effecters, in FRTL-5 (FRTL-5(MEK/Rac)) recapitulates H-Ras effects on proliferation and morphology, In contrast to FRTL-5(Ras), however, FRTL-5(MEK/Rac) cells remain differentiated and are not tumorigenic, To find H-Ras induced genes potentially responsible for tumorigenicity and loss of differentiation, we have used subtractive suppression hybridization (SSH), a PCR-based cDNA subtraction technique, between de-differentiated and tumorigenic FRTL-5(Ras) cells and differentiated and nontumorigenic FRTL-5(MEK/Rac) cells. We examined 800 of the cDNA clones obtained after subtraction and verified their levels of expression in the two cell lines by reverse northern, identifying 337 H-Ras induced genes. By sequence analysis, we clustered 57 different genes. Among these, 39 were known genes (involved in diverse signal transduction processes regulating mitogenic activity, cell survival, cytoskeletal reorganization, stress response and invasion) while the remaining 18 clones were novel genes. Among the 57 H-Ras specific clones, we identified those genes whose expression is induced early by H-Ras, We suggest that these immediate-early genes may play a crucial role in H-Ras-mediated transformation in thyroid epithelial cells.	Staz Zool Anton Dohrn, Lab Biochim & Biol Mol, I-80121 Naples, Italy; Univ Padua, Dipartimento Biol, CRIBI Biotechnol Ctr, I-35121 Padua, Italy	Stazione Zoologica Anton Dohrn di Napoli; University of Padua	Di Lauro, R (corresponding author), Staz Zool Anton Dohrn, Lab Biochim & Biol Mol, Villa Comunale, I-80121 Naples, Italy.		Di Lauro, Roberto/A-2746-2012	Di Lauro, Roberto/0000-0001-9493-3036; VALLE, GIORGIO/0000-0003-4377-5685; simionati, barbara/0000-0002-0522-0737; Cobellis, Gilda/0000-0003-2687-2272; Missero, Caterina/0000-0003-0905-5123	Telethon [TGM06S01, D.067] Funding Source: Medline	Telethon(Fondazione Telethon)		AMBESIIMPIOMBAT.FS, 1982, COLD SPRING HARBOR C, V9, P483; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; BOS JL, 1989, CANCER RES, V49, P4682; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Ciccarelli FD, 2000, HUM MOL GENET, V9, P1001, DOI 10.1093/hmg/9.6.1001; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; FARID NR, 1994, ENDOCR REV, V15, P202, DOI 10.1210/er.15.2.202; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Langnaese K, 1997, J BIOL CHEM, V272, P821, DOI 10.1074/jbc.272.2.821; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sutton G.G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Uwabe K, 1997, NEUROSCIENCE, V80, P501, DOI 10.1016/S0306-4522(97)00112-7; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YOSHIMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P504, DOI 10.1016/0006-291X(91)91445-I; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	37	3	5	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2281	2290		10.1038/sj.onc.1204320	http://dx.doi.org/10.1038/sj.onc.1204320			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402323				2022-12-17	WOS:000168404500010
J	Yuen, PH; Ryan, EA; Devroe, E; Wong, PKY				Yuen, PH; Ryan, EA; Devroe, E; Wong, PKY			A single Glu(62)-to-Lys(62) mutation in the Mos residues of the R7 Delta 447Gag-tMos protein causes the mutant virus to induce brain lesions	ONCOGENE			English	Article						Mos mutation; MEK; ERK; brain lesions	MURINE LEUKEMIA-VIRUS; MYELOPROLIFERATIVE SARCOMA-VIRUS; TEMPERATURE-SENSITIVE MUTANTS; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; TRANSFORMING GENE; OOCYTE MATURATION; CYTOSTATIC FACTOR; KINASE CASCADE; C-MOS	We previously reported that R7 Delta 447, a 2954-base-pair (bp) laboratory-generated Moloney murine sarcoma virus, induced subcutaneous tumors in about 14% of infected mice but did not induce brain lesions. We now report that R7 Delta 447K, a spontaneous mutant of R7 Delta 447, induced brain lesions as well as subcutaneous tumors in all injected mice. The genomes of the two viruses differ in a single base pair: the deduced Glu(62) of the Mos residue of the R7 Delta 447 Gag-tMos protein is changed to Lys(62), More R7 Delta 447 than R7 Delta 447K focus-forming units were detected in both NIH3T3 and mouse cerebral vascular endothelial (MCVE) cells. However, R7 Delta 447K transformed NIH3T3 and MCVE: cells more acutely than did R7 Delta 447. A distinctive feature that distinguished the morphologic transformation of R7 Delta 447- and R7 Delta 447K-infected MCVE cells is the markedly prolonged spindle-shaped phase exhibited by R7 Delta 447-infected MCVE cells. In addition, R7 Delta 447K was more efficient in inducting the phosphorylation of ERK1/2 than R7 Delta 447 in both MCVE and NIH3T3 cells. Moreover morphologic transformation was inhibited, and levels of phosphorylated ERK1/2 were reduced when R7 Delta 447- or R7 Delta 447K-infected NIH3T3 or MCVE cells were grown in the presence of the MEK1/2-specific inhibitor PD98095. Thus, ne have identified a key residue in the Gag-tMos protein that profoundly affects activation of the Mos/MEK/ERK pathway, virus and cell replication, morphologic transformation in vitro and pathogenicity in vivo.	Univ Texas, MD Anderson Canc Ctr, Div Res, Dept Carcinogenesis, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Yuen, PH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Res, Dept Carcinogenesis, Sci Pk, Smithville, TX 78957 USA.				NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALROY J, 1987, HISTOCHEMISTRY, V86, P603, DOI 10.1007/BF00489554; BERMAN LD, 1969, INT J CANCER, V4, P820, DOI 10.1002/ijc.2910040611; BOUSSEKERDILES MCL, 1980, EUR J CANCER, V16, P43, DOI 10.1016/0014-2964(80)90106-1; BROW MAD, 1984, J VIROL, V49, P579, DOI 10.1128/JVI.49.2.579-582.1984; CHIRIGOS MA, 1968, INT J CANCER, V3, P223, DOI 10.1002/ijc.2910030207; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; GAZDAR AF, 1972, INT J CANCER, V9, P219; GONZALEZSCARANO F, 1995, RETROVIRIDAE, V4, P409; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HAYASHI Y, 1988, PATHOL RES PRACT, V183, P314, DOI 10.1016/S0344-0338(88)80128-6; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Lim KY, 2000, J NEUROVIROL, V6, P106, DOI 10.3109/13550280009013154; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; OKAZAKI K, 1995, ONCOGENE, V10, P1149; OSTERTAG W, 1980, J VIROL, V33, P573, DOI 10.1128/JVI.33.2.573-582.1980; PERK K, 1966, J NATL CANCER I, V37, P581; PHAM CD, 1995, ONCOGENE, V10, P1683; PROPST F, 1990, P NATL ACAD SCI USA, V87, P9703, DOI 10.1073/pnas.87.24.9703; PROPST F, 1992, J NEUROPATH EXP NEUR, V51, P499, DOI 10.1097/00005072-199209000-00004; PULS A, 1995, ONCOGENE, V10, P623; RIBACCHI RODOLFO, 1966, LAV IST ANAT ISTOL PATOL UNTV STUDI PERUGIA, V26, P149; Robertson SC, 1996, MOL CELL BIOL, V16, P3472; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SIMONS PJ, 1970, J NATL CANCER I, V44, P1289; STACEY A, 1984, J VIROL, V50, P725, DOI 10.1128/JVI.50.3.725-732.1984; STANTON MF, 1968, J NATL CANCER I, V40, P1113; STOICA G, 1990, AM J PATHOL, V136, P933; TOPOL LZ, 1995, CELL GROWTH DIFFER, V6, P1119; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WONG PKY, 1990, CURR TOP MICROBIOL, V160, P29; WONG PKY, 1981, VIROLOGY, V109, P366, DOI 10.1016/0042-6822(81)90507-9; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; Yuen PH, 1998, AM J PATHOL, V152, P1509; YUEN PH, 1989, J VIROL, V63, P471, DOI 10.1128/JVI.63.2.471-480.1989; YUEN PH, 1991, MOL CARCINOGEN, V4, P72, DOI 10.1002/mc.2940040111; Yuen PH, 1997, VIROLOGY, V236, P213, DOI 10.1006/viro.1997.8729; YUEN PH, 1985, J VIROL, V54, P178, DOI 10.1128/JVI.54.1.178-185.1985; Yuen PH, 2000, J NEUROVIROL, V6, P329, DOI 10.3109/13550280009030759	46	3	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					692	703		10.1038/sj.onc.1204150	http://dx.doi.org/10.1038/sj.onc.1204150			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314003				2022-12-17	WOS:000166806000005
J	Epinat, JC; Dvorin, EL; Gilmore, TD				Epinat, JC; Dvorin, EL; Gilmore, TD			Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells	ONCOGENE			English	Article						v-Rel; retroviral oncogene; transcription factor; malignant transformation; NF-kappa B; envelope sequences	VIRUS STRAIN-T; ONCOGENE; DOMAIN; ACTIVATION; SEQUENCES	The retroviral oncoprotein v-Rel is a chimeric protein that has 11 helper virus-derived Envelope (Env) amino acids (aa) at its N terminus. Within these N-terminal Env aa of v-Rel there are three aa substitutions compared to the Rev-A helper virus Env, These aa substitutions have previously been shown to impart a number of unique properties onto v-Rel, including increased transforming and transactivating ability. In this study, we have analysed the sequence requirements for the Env aa to influence several properties of v-Rel, Phe residues at aa 3 and 9 are critical for an N-terminal transactivation function of v-Rel, and the analysis of several Env mutants demonstrates that transactivation ability parallels the transforming ability of v-Rel, Substitutions of conservative aa, such as leucine and tyrosine, for Phe 3 and 9 are tolerated for transactivation in chicken embryo fibroblasts and for transformation of chicken spleen cells. In contrast, the substitution of 10 Phe residues at the N terminus of v-Rel does not enable transactivation, indicating that a distinct structure surrounding Phe-3 and Phe-9 is essential for v-Rel function. We also show that the addition of the v-Rel Env aa to the N terminus of human c-Rel can enable it to activate transcription. Taken together, these results indicate that Phe residues at positions 3 and 9 have been selected for their ability to enhance the oncogenicity of v-Rel by increasing its ability to activate transcription.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.			Dvorin, Evan/0000-0001-5037-2783	NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHAT GV, 1990, ONCOGENE, V5, P625; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chen CL, 1999, MOL CELL BIOL, V19, P307; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KEWALRAMANI VN, 1992, J VIROL, V66, P3026, DOI 10.1128/JVI.66.5.3026-3031.1992; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Sambrook J, 1989, MOL CLONING LAB MANU; SARKAR S, 1993, ONCOGENE, V8, P2245; SMARDOVA J, 1995, ONCOGENE, V10, P2017; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	16	3	3	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 29	2000	19	28					3131	3137		10.1038/sj.onc.1203651	http://dx.doi.org/10.1038/sj.onc.1203651			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918567				2022-12-17	WOS:000088019200001
J	DePinho, RA; Jacks, T				DePinho, RA; Jacks, T			Mouse models of cancer - Introductory comments	ONCOGENE			English	Editorial Material									MIT, Ctr Canc Res, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Genet, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Jacks, T (corresponding author), MIT, Ctr Canc Res, 77 Massachusetts Ave,Bldg E17-517, Cambridge, MA 02139 USA.								0	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5248	5248		10.1038/sj.onc.1203108	http://dx.doi.org/10.1038/sj.onc.1203108			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP					2022-12-17	WOS:000082808400001
J	Huang, JQ; Zhang, BT; Li, YQ; Mayer, B; Carraway, KL; Carraway, CAC				Huang, JQ; Zhang, BT; Li, YQ; Mayer, B; Carraway, KL; Carraway, CAC			c-Src association with and phosphorylation of p58(gag), a membrane- and microfilament-associated retroviral Gag-like protein in a xenotransplantable rat mammary tumor	ONCOGENE			English	Article						signal transduction; microfilaments; retroviral Gag protein; Src; SH3 domain; polyproline motif	SIGNAL-TRANSDUCTION PARTICLE; ACTIN-BINDING DOMAINS; ROUS-SARCOMA VIRUS; TYROSINE KINASE; SH3 DOMAINS; CELL MICROVILLI; ASCITES ADENOCARCINOMA; GLYCOPROTEIN COMPLEX; FOCAL ADHESIONS; IIB-IIIA	The retroviral Gag-like protein p58(gag) expressed in a highly metastatic ascites rat mammary adenocarcinoma has been implicated in cell surface changes contributing to xenotransplantability. p58(gag) is present in the cells in a plasma membrane- and microfilament-associated signal transduction particle containing Src and is phosphorylated on tyrosine. Overlay analyses and affinity chromatography with glutathione S-transferase (GST) fusion proteins of Src homology-3 (SH3) domains showed direct binding of the Src but not the Crk SH3 domain to p58(gag), This association was confirmed by coimmunoprecipitation of partially purified p58(gag) from ascites cell lysates with platelet Src, Further, a GST-p58(gag) fusion protein bound full length c-Src from either platelets or c-Src-expressing insect cells. The GST-p58(gag) fusion protein, but not GST, was phosphorylated by platelet or insect cell-expressed c-Src, but not by a kinase negative c-Src variant. The binding of GST-p58(gag) to c-Src was almost completely abolished by a 50-fold excess of the GST-SH3 domain of Src, and a parallel decrease in tyrosine phosphorylation of p58(gag) was observed. These results demonstrate that p58(gag) is tyrosine-phosphorylated as a consequence of its specific association with c-Src via its SH3 domain. These observations suggest a mechanism by which Gag proteins may contribute to retroviral maturation or pathogenesis through binding and relocalization of SH3 domain-containing proteins such as Src-like tyrosine kinases to sites of association of microfilaments with the plasma membrane.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Harvard Univ, Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA	University of Miami; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Carraway, CAC (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.				NATIONAL CANCER INSTITUTE [P30CA014395, R01CA072577] Funding Source: NIH RePORTER; NCI NIH HHS [CA72577-01A1, CA 14395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; BURRIDGE K, 1986, Cancer Reviews, V4, P18; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY CAC, 1985, EXP CELL RES, V161, P150, DOI 10.1016/0014-4827(85)90499-9; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1991, J BIOL CHEM, V266, P16238; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY CAC, 1996, ROLE CELL PHYSL, V2, P207; CARRAWAY CAC, 1999, IN PRESS J BIOL CHEM; CARRAWAY CAC, 1998, GUIDEBOOK CYTOSKELET; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; CARRAWAY KL, 1998, SIGNAL TRANSDUCTION; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DAMSKY CH, 1977, J CELL BIOL, V75, P593, DOI 10.1083/jcb.75.2.593; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; EDBAUER CA, 1984, VIROLOGY, V134, P389, DOI 10.1016/0042-6822(84)90306-4; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1994, ANN NY ACAD SCI, V714, P75, DOI 10.1111/j.1749-6632.1994.tb12032.x; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; Higley S, 1997, CURR OPIN CELL BIOL, V9, P62, DOI 10.1016/S0955-0674(97)80153-6; HOLME TC, 1990, EUR J SURG ONCOL, V16, P161; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; HUGGINS JW, 1980, BIOCHIM BIOPHYS ACTA, V127, P31; JUANG SH, 1994, J BIOL CHEM, V269, P15067; Juang SH, 1996, ONCOGENE, V12, P1033; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; LI Y, 1999, IN PRESS J BIOL CHEM; LIN D, 1997, TRENDS CELL BIOL, V8; LIU YC, 1989, J BIOL CHEM, V264, P1208; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORSE HC, 1992, AIDS, V6, P607, DOI 10.1097/00002030-199207000-00001; NICOLSON GL, 1976, BIOCHIM BIOPHYS ACTA, V458, P1, DOI 10.1016/0304-419X(76)90014-7; Nievers MG, 1997, J CELL SCI, V110, P389; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHERBLOM AP, 1980, EXP CELL RES, V126, P417, DOI 10.1016/0014-4827(80)90281-5; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	62	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4099	4107		10.1038/sj.onc.1202779	http://dx.doi.org/10.1038/sj.onc.1202779			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435591				2022-12-17	WOS:000081431000007
J	Felici, A; Giorgio, M; Krauzewicz, N; Della Rocca, C; Santoro, M; Rovere, P; Manni, I; Amati, P; Pozzi, L				Felici, A; Giorgio, M; Krauzewicz, N; Della Rocca, C; Santoro, M; Rovere, P; Manni, I; Amati, P; Pozzi, L			Medullary thyroid carcinomas in transgenic mice expressing a polyoma carboxyl-terminal truncated middle-T and wild type small-T antigens	ONCOGENE			English	Article						transgenic; oncogene; middle-T; medullary thyroid carcinoma	GROWTH-FACTOR RECEPTOR; TUMOR-ANTIGEN; VIRUS MUTANT; MONOCLONAL-ANTIBODIES; CELL-TRANSFORMATION; REGULATORY REGION; SARCOMA-VIRUSES; GENE; PROTEIN; ASSOCIATION	Medullary thyroid carcinoma (MTC) is a rare human tumor affecting the calcitonin-secreting c-cells of the thyroid. Here me report that two independent strains of transgenic mice expressing a Polyomavirus (Py) truncated middle-T antigen (Delta MT), consisting of the aminoterminal 304 amino acids, and the full length Py small-T antigen, developed multifocal bilateral MTCs with 100% penetrance, Occasionally one strain also developed mammary and bone tumors. Furthermore, offspring from both transgenic lines displayed pronounced waviness of the whiskers and fur, previously associated,vith defective epidermal growth factor receptor signaling, Transgene transcription, driven by the homologous early promoter/enhancer, and the corresponding translation products mere detected in tumors and in many other organs which did not develop pathologies. The subcellular distribution of Delta MT and its interactions with the adapter proteins of the SHC family have also been analysed. Our study describes a novel murine model of MTC and provides evidence that the N-terminal 304 amino acid fragment of Py middle-T antigen, possibly in co-operation with small-T antigen, acts as a potent oncogene in c-cells of the thyroid.	Ist Regina Elena, Ctr Ric Sperimentale, I-00158 Rome, Italy; Univ Rome La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, I-00161 Rome, Italy; Ist Dermopat Immacolata, Dept Patol Vasc, I-00167 Rome, Italy; Royal Postgrad Med Sch, Dept Virol, London W12 0NN, England; Univ Rome La Sapienza, Dipartimento Med Sperimentale, I-00161 Rome, Italy; Univ Naples, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, CNR,Ctr Endocrinol Oncol Sperimentale, I-80131 Naples, Italy; Ist Regina Elena, Lab Oncogenesi Mol, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Imperial College London; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Felici, A (corresponding author), Ist Regina Elena, Ctr Ric Sperimentale, I-00158 Rome, Italy.		Manni, Isabella/ABH-6460-2020; Giorgio, Marco/I-9425-2012	Manni, Isabella/0000-0003-4823-0596; Giorgio, Marco/0000-0002-5842-6042				ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; BAETSCHER M, 1991, ONCOGENE, V6, P1133; BAUTCH VL, 1989, MOL BIOL MED, V6, P309; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BOLEN JB, 1984, J BIOL CHEM, V259, P1686; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; Bronson R, 1997, P NATL ACAD SCI USA, V94, P7954, DOI 10.1073/pnas.94.15.7954; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CARSON EB, 1995, CANCER RES, V55, P2048; CHALIFOUR LE, 1992, MOL CARCINOGEN, V5, P178, DOI 10.1002/mc.2940050304; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5299; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Crew FAE, 1933, J GENET, V27, P95, DOI 10.1007/BF02984383; DAWE CJ, 1980, PHYLETIC APPROACHES; DESIMONE V, 1987, J VIROL, V61, P1615, DOI 10.1128/JVI.61.5.1615-1620.1987; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Elliott J, 1998, ONCOGENE, V17, P1797, DOI 10.1038/sj.onc.1202083; FIMIA GM, 1995, BIOCHEM BIOPH RES CO, V207, P339, DOI 10.1006/bbrc.1995.1193; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; FREUND R, 1992, AM J PATHOL, V141, P1409; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HARVEY M, 1995, CANCER RES, V55, P1146; HELSETH A, 1992, AM J PATHOL, V140, P1071; HOGAN B, 1986, MANIPULATING MOUSE E, P79; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; Johnston D, 1998, ONCOGENE, V16, P167, DOI 10.1038/sj.onc.1201478; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KRIPPL B, 1988, NUCLEIC ACIDS RES, V16, P8963, DOI 10.1093/nar/16.18.8963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEL M, 1995, CELL GROWTH DIFFER, V6, P1591; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MAIONE R, 1985, EMBO J, V4, P3215, DOI 10.1002/j.1460-2075.1985.tb04068.x; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MCLAREN A, 1969, NATURE, V224, P238, DOI 10.1038/224238a0; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAQUISFLUCKLINGER V, 1993, ONCOGENE, V8, P2087; RASSOULZADEGAN M, 1990, ONCOGENE, V5, P1507; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHULZ N, 1992, CANCER RES, V52, P450; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; Tehranian A, 1996, AM J PATHOL, V149, P1177; TEMPLETON D, 1982, J VIROL, V41, P1014, DOI 10.1128/JVI.41.3.1014-1024.1982; Tooze J, 1980, DNA TUMOR VIRUSES; TSUZUKI T, 1995, ONCOGENE, V10, P191; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	56	3	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2387	2395		10.1038/sj.onc.1202578	http://dx.doi.org/10.1038/sj.onc.1202578			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327060				2022-12-17	WOS:000079595500012
J	Bird, KJ; Semus, HL; Ruddell, A				Bird, KJ; Semus, HL; Ruddell, A			Resistance to avian leukosis virus lymphomagenesis occurs subsequent to proviral c-myc integration	ONCOGENE			English	Article						c-myc; c-erbB; lymphoma; tumor resistance; avian leukosis virus	REPEAT-ENHANCED TRANSCRIPTION; INDUCED ERYTHROBLASTOSIS; LYMPHOID LEUKOSIS; PROMOTER INSERTION; ERBB ACTIVATION; EGF-RECEPTOR; CELLS; INDUCTION; CHICKENS; MICE	Most chicken strains are highly susceptible to avian leukosis virus (ALV) induction of bursal lymphoma, involving proviral integration within the c-myc protoncogene, while certain strains are genetically resistant to lymphomagenesis, A nested PCR assay was developed to analyse the appearance of proviral c-myc integrations after ALV infection of lymphoma-susceptible birds, and to determine whether these integrations arise in lymphoma-resistant birds. Proviral c-myc integrations are detected in bursa and other tissues from 6 day-old lymphoma-susceptible birds infected as embryos, The abundance of bursal cells carrying these integrations increases roughly 40-fold by 35 days of age, indicating that these cells hyperproliferate within the bursal environment. Bursal cells with proviral c-myc integrations also arise soon after infection of lymphoma-resistant embryos. However, these cells expand much more slowly than cells from lymphoma-susceptible birds. Both strains show the same rate of viral infection, so that resistance to lymphomagenesis occurs at a step subsequent to proviral c-myc integration. Proviral c-erbB gene integrations arise at the same frequency in bursa and other tissues of both strains, and they do not increase in abundance during development. These findings indicate that the mechanism of resistance to lymphomagenesis involves specific inhibition of cells with proviral c-myc integrations within the bursa.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Univ Rochester, Dept Microbiol & Immunol, Rochester, NY USA	Fred Hutchinson Cancer Center; University of Rochester	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N,Mailstop C2-023,POB 19024, Seattle, WA 98104 USA.			Ruddell, Alanna/0000-0002-0195-5576	NCI NIH HHS [R01 CA68328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABA TW, 1984, J VIROL, V51, P123, DOI 10.1128/JVI.51.1.123-130.1984; BACON L, 1979, POULTRY SCI, V58, P1033; BACON LD, 1986, IMMUNOGENETICS, V23, P213, DOI 10.1007/BF00373015; BACON LD, 1981, POULTRY SCI, V60, P1132, DOI 10.3382/ps.0601132; BELLI B, 1995, J VIROL, V69, P5138, DOI 10.1128/JVI.69.8.5138-5141.1995; Bowers WJ, 1996, J VIROL, V70, P3051, DOI 10.1128/JVI.70.5.3051-3059.1996; BOWERS WJ, 1994, LEUKEMIA, V8, pS211; BURMESTER BR, 1960, J NATL CANCER I, V24, P1423; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CLURMAN BE, 1989, MOL CELL BIOL, V9, P2657, DOI 10.1128/MCB.9.6.2657; COOPER MD, 1968, JNCI-J NATL CANCER I, V41, P373; Curristin SM, 1997, J VIROL, V71, P5972, DOI 10.1128/JVI.71.8.5972-5981.1997; ESCOT C, 1993, ONCOGENE, V8, P969; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWERT DL, 1988, ADV VET SCI COMP MED, V32, P37; FLAMANT F, 1987, VIROLOGY, V160, P301, DOI 10.1016/0042-6822(87)90079-1; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; FUNG YKT, 1982, VIROLOGY, V119, P411; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HENRIKSSON M, 1996, ADV CANCER RES, V68, P110; HIHARA H, 1980, AVIAN DIS, V24, P971, DOI 10.2307/1589971; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; LINIAL M, 1985, P NATL ACAD SCI USA, V82, P53, DOI 10.1073/pnas.82.1.53; MAAS HJL, 1982, AVIAN PATHOL, V11, P309, DOI 10.1080/03079458208436103; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; Muller JR, 1996, CANCER RES, V56, P419; Muller JR, 1997, BLOOD, V89, P291, DOI 10.1182/blood.V89.1.291.291_291_296; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; Neiman P. E., 1980, Viruses in naturally occurring cancers. Book A, P519; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PELICCI PG, 1986, J EXP MED, V164, P2049, DOI 10.1084/jem.164.6.2049; PETERSON RD, 1966, JNCI-J NATL CANCER I, V36, P585, DOI 10.1093/jnci/36.4.585; PINK JRL, 1985, IMMUNOLOGICAL METHOD, V3, P385; PURCHASE HG, 1977, NATURE, V270, P61, DOI 10.1038/270061a0; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; ROBINSON HL, 1986, J VIROL, V57, P28, DOI 10.1128/JVI.57.1.28-36.1986; RUDDELL A, 1988, J VIROL, V62, P2728, DOI 10.1128/JVI.62.8.2728-2735.1988; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; SMITH CD, 1994, J VIROL, V68, P6232, DOI 10.1128/JVI.68.10.6232-6242.1994; SMITH EJ, 1979, AVIAN DIS, V23, P698, DOI 10.2307/1589746; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414	45	3	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					201	209		10.1038/sj.onc.1202283	http://dx.doi.org/10.1038/sj.onc.1202283			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926935				2022-12-17	WOS:000078166000022
J	Chan, SY; Lee, DCW				Chan, SY; Lee, DCW			Sex difference in immunostaining of RET in the adult mouse kidney	ONCOGENE			English	Article						c-ret; RET; kidney	EPIDERMAL GROWTH-FACTOR; MICE LACKING GDNF; TYROSINE KINASE; NUCLEAR TRANSLOCATION; FACTOR RECEPTOR; FACTOR EGF; PROTOONCOGENE; EXPRESSION; LOCALIZATION; TRAFFICKING	The c-ret proto-oncogene encodes a receptor tyrosine kinase which is important for the development of the kidney and the enteric nervous system. During nephrogenesis, c-ret is expressed in the ureteric bud epithelium and later in its derivative, the collecting duct. This takes place during 11-17.5 days post-coitum (d.p.c.) in the mouse and our immunohistochemical study showed that the RET protein co-localized with the transcript. At 18.5 d.p.c. the kidney is fully differentiated. At 18.5 d.p.c., 1 week and 10 weeks old, RET was found in the proximal convoluted tubules, which is formed from the condensed mesenchyme, This suggests that c-ret may also play a role in kidney function. For the 10 weeks old kidney, RET immunostaining in male was concentrated on the basolateral side while female had a stronger staining in the whole cell. Furthermore, cytoplasmic staining was observed in male whereas both cytoplasmic and nuclear staining was found in female. c-ret transcript was detected by RT-PCR, and in situ hybridization showed its expression throughout the kidney. The reason for the sex-specific staining and the role of RET in kidney function remain to be determined.	Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong	University of Hong Kong	Chan, SY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Paediat, Hong Kong, Hong Kong.			Chan, Siu Yuen/0000-0001-7262-1293				AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BACHINSKY DR, 1993, AM J PATHOL, V143, P598; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CURTIS BM, 1990, J IMMUNOL, V144, P1295; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; HARRIS RC, 1991, AM J KIDNEY DIS, V17, P627, DOI 10.1016/S0272-6386(12)80336-2; Hellmich HL, 1996, MECH DEVELOP, V54, P95, DOI 10.1016/0925-4773(95)00464-5; HOLT SJ, 1994, BIOCHEM PHARMACOL, V47, P117, DOI 10.1016/0006-2952(94)90444-8; Ivanchuk SM, 1997, ONCOGENE, V14, P1811, DOI 10.1038/sj.onc.1201016; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JIANG LW, 1990, J CELL BIOL, V110, P559, DOI 10.1083/jcb.110.3.559; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kilkenny DM, 1996, ENDOCRINOLOGY, V137, P5078, DOI 10.1210/en.137.11.5078; Lee DCW, 1998, J UROLOGY, V159, P291, DOI 10.1016/S0022-5347(01)64084-9; Maher PA, 1996, J CELL BIOL, V134, P529, DOI 10.1083/jcb.134.2.529; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PODLECKI DA, 1987, J BIOL CHEM, V262, P3362; PROCHIANTZ A, 1995, BIOESSAYS, V17, P39, DOI 10.1002/bies.950170109; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; RAKOWICZSZULCZYNSKA EM, 1989, ARCH BIOCHEM BIOPHYS, V268, P456, DOI 10.1016/0003-9861(89)90313-5; RUGH R, 1994, MOUSE ITS REPROD DEV; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368	35	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					661	666		10.1038/sj.onc.1201970	http://dx.doi.org/10.1038/sj.onc.1201970			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704933				2022-12-17	WOS:000075195300015
J	Kim, E; Albrechtsen, N; Deppert, W				Kim, E; Albrechtsen, N; Deppert, W			DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53 (vol 15, pg 857, 1997)	ONCOGENE			English	Correction, Addition													Holst, Jens/AAA-8022-2022					Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412	1	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2385	2385		10.1038/sj.onc.1201511	http://dx.doi.org/10.1038/sj.onc.1201511			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157		Bronze			2022-12-17	WOS:A1997YE15700013
J	Pan, BT; Zhang, Y; Brott, B; Chen, DH				Pan, BT; Zhang, Y; Brott, B; Chen, DH			The 96 kDa protein kinase activated by oncogenic Ras in Xenopus egg extracts is also activated by constitutively active Mek: Activation requires serine/threonine phosphorylation	ONCOGENE			English	Article						oncogenic Ras; Mek; Xenopus eggs; protein kinases and phosphatases; signal transduction; p96(h2bk)	SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; OOCYTE MATURATION; MEIOTIC MATURATION; EXTRACELLULAR SIGNALS; P34(CDC2) KINASE; CELL-CYCLE; IN-VITRO; M-PHASE; TYROSINE	In the Xenopus egg and oocyte system, oncogenic Ras protein can induce cell cycle arrest. The effect of oncogenic Ras on the cell cycle seems to be mediated by the Raf-Mek-Erk pathway of Ras signal transduction since constitutively active Raf, Mek, or Erk can mimic the effect of oncogenic Ras protein and since specific inhibition of these kinases can block the effect of oncogenic Ras. Using activated Xenopus egg extracts, we previously reported that the cell cycle arrest induced by oncogenic Ras correlates with the activation of a 96 kDa protein that phosphorylates histone h2b in vitro. This result raised the possibility that the 96 kDa kinase (designated as p96(h2bk)) is a potential target of the Raf-Mek-Erk pathway that links the pathway to the control of the cell cycle. We report here that constitutively active Mek1 could activate p96(h2bk) in the absence of oncogenic Ras. Moreover, inhibition of endogenous Mek by a specific inhibitor, PD 098059, suppressed the activation of p96(h2bk) by oncogenic Ras. These results are consistent with the concept that p96(h2bk) is a component or target of the Raf-Mek-Erk pathway. Furthermore, we have shown that activation of p96(h2bk) requires serine/threonine phosphorylation of p96(h2bk).	UNIV KENTUCKY,CHANDLER MED CTR,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; UNIV KENTUCKY,CHANDLER MED CTR,LUCILLE P MARKEY CANC CTR,LEXINGTON,KY 40536; HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	University of Kentucky; University of Kentucky; Harvard University	Pan, BT (corresponding author), UNIV KENTUCKY,DEPT SURG,DIV NEUROSURG,CHANDLER MED CTR,800 ROSE ST,LEXINGTON,KY 40536, USA.							ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHEN CT, 1994, J BIOL CHEM, V269, P28034; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Hung W., 1994, P NATL ACAD SCI USA, V91, P8960; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; MACNICOL AM, 1995, MOL CELL BIOL, V15, P6686; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, ONCOGENE, V8, P467; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAN BT, 1994, J BIOL CHEM, V269, P5968; PAN BT, 1990, MOL CELL BIOL, V10, P923, DOI 10.1128/MCB.10.3.923; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; ZHANG CF, 1994, EMBO J, V13, P1123	46	3	3	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1653	1660		10.1038/sj.onc.1201009	http://dx.doi.org/10.1038/sj.onc.1201009			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135066				2022-12-17	WOS:A1997WR89300003
J	CassarMalek, I; Marchal, S; Rochard, P; Wrutniak, C; Samarut, J; Cabello, G				CassarMalek, I; Marchal, S; Rochard, P; Wrutniak, C; Samarut, J; Cabello, G			Molecular basis of the cell-specific activity of v-erb A in quail myoblasts	ONCOGENE			English	Article						v-erb A; myoblast; RAR; RXR; T3R; AP1 activity	THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTORS; C-ERBA; DNA-BINDING; RESPONSE ELEMENT; DOMAIN; GENE; DIFFERENTIATION; REPRESSION; PROTEINS	We have previously shown that v-erb A expression strongly stimulates quail myoblast proliferation and differentiation without alteration of the triiodothyronine (T3) influence in this cell type, In order to understand the molecular basis of v-erb A action in myoblasts, we have studied the influence of this oncoprotein on c-erb A alpha 1 encoded T3 nuclear receptor (TRu) activity, In transfection experiments, v-erb A did not inhibit the T3-dependent c-erb A alpha 1 transcriptional activity in QM7 myoblasts in contrast to its action in HeLa cells. However, it repressed the retinoic acid receptor RAR alpha activity in both cell-types, indicating that v-erb A interactions with T3 or RA mediated transcription significantly differs, In EMSA experiments using a TRE(pal) probe. T3R alpha binds as three complexes in HeLa cells, We have previously identified the slow migrating complex, undetectable in QM7 myoblasts, as a T3R/RXR heterodimer. Interestingly, v-erb A inhibited binding of this complex in HeLa cells, but did not affect binding of the two other complexes in QM7 myoblasts. Expression of RXR (gamma isoform), the TR alpha dimerization partner absent in proliferating QM7 cells, restored inhibition of c-erb A alpha 1 transcriptional activity in these cells and abrogated the v-erb A myogenic influence, Lastly, v-erb A induced a T3-independent c-erb A alpha 1 activity in QM7 cells when cotransfected in equimolar ratio with the receptor, by inhibiting AP-1 activity and stimulating transcription of a reporter gene driven by a TRE sequence.	INRA,UNITE ENDOCRINOL CELLULAIRE,LAB DIFFERENCIAT CELLULAIRE & CROISSANCE,F-34060 MONTPELLIER 01,FRANCE; ECOLE NORMALE SUPER LYON,INRA,CNRS UMR 40,LAB BIOL MOL & CELLULAIRE,F-69364 LYON 07,FRANCE	INRAE; INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet			Samarut, Jacques/AAD-2587-2019; , Cassar-Malek/AAW-6386-2020	, Cassar-Malek/0000-0001-7407-1408				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; CassarMalek I, 1996, J BIOL CHEM, V271, P11392, DOI 10.1074/jbc.271.19.11392; CASSARMALEK I, 1994, ONCOGENE, V9, P2197; CASSARMALEK I, 1994, THESIS U MONTPELLIER; CHEN DJ, 1995, NATURE, V377, P454; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FORCE WR, 1994, J BIOL CHEM, V269, P8863; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HERMANN T, 1993, ONCOGENE, V8, P55; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HOROWITZ ZD, 1989, MOL ENDOCRINOL, V3, P148, DOI 10.1210/mend-3-1-148; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MARCHAL S, 1993, BIOL CELL, V78, P191, DOI 10.1016/0248-4900(93)90129-3; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; RASCLE A, 1994, ONCOGENE, V9, P2853; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P217; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARIF M, 1992, ONCOGENE, V7, P953; Snedecor G.W., 1961, STAT METHODS; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YN PM, 1994, J BIOL CHEM, V269, P903; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	46	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1099	1108		10.1038/sj.onc.1200928	http://dx.doi.org/10.1038/sj.onc.1200928			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070659				2022-12-17	WOS:A1997WM07000012
J	Gaben, AM; Saucier, C; Bedin, M; Barbu, V; Courilleau, D; BonHoa, DH; Mester, J				Gaben, AM; Saucier, C; Bedin, M; Barbu, V; Courilleau, D; BonHoa, DH; Mester, J			Activation of p21ras is not sufficient to ensure a complete G(1) phase of the cell division cycle in mouse fibroblasts	ONCOGENE			English	Article						p21ras; cell cycle; growth factor requirement; SRE-dependent transcription; insulin signalling	EPIDERMAL GROWTH-FACTOR; MITOGENIC SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE FACTOR; SERUM-RESPONSE ELEMENT; NIH 3T3 CELLS; FACTOR-I; C-FOS; TYPE-1 NEUROFIBROMATOSIS; GUANINE-NUCLEOTIDES; GENE-EXPRESSION	In the mouse BP-A31 fibroblasts, mRNAs coding the three isoforms (Ha, Ki, N) of ras are expressed, and there are no activating mutations in the codons 12, 13 or 61. We have produced a subline (Ras2) expressing an oestrogen-inducible v-Ha-ras gene. The contribution of v-Ha-ras to the overall p21ras-GTP content was evaluated by metabolic labelling with P-32. Surprisingly, p21ras-GTP complexes were predominant in the serum-deprived BP-A31 cells as well as in the Ras2 cells. The excess of p21ras-GTP was not due to the lack of the GTPase activating protein. In transient transfection experiments, the serum response element (SRE)-directed CAT was expressed in serum-deprived BP-A31 cells, and insulin caused a further two- to threefold increase in CAT activity. A dominant negative ras mutant (Ha-Ras Asn-17) cancelled both the basal and insulin-induced CAT expression in the BP-A31 but not in the Ras2 cells. Expression of v-Ha-ras in Ras2 cells did not relax their growth factor-dependence and oestradiol had only a minor mitogenic effect. We conclude that p21ras activation does not ensure a complete cell division cycle in these cells, and does not entirely account for the transduction of the mitogenic signal initiated by insulin.	UNIV PARIS 06,FAC MED,F-75012 PARIS,FRANCE	UDICE-French Research Universities; Sorbonne Universite	Gaben, AM (corresponding author), HOP ST ANTOINE,INSERM U55,184 RUE FAUBOURG ST ANTOINE,F-75012 PARIS,FRANCE.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BRUNET A, 1994, ONCOGENE, V9, P3379; BUCHOU T, 1989, EXP CELL RES, V182, P129, DOI 10.1016/0014-4827(89)90285-1; BUCHOU T, 1990, J CELL PHYSIOL, V142, P559, DOI 10.1002/jcp.1041420315; BuquetFagot C, 1996, J CELL PHYSIOL, V166, P631, DOI 10.1002/(SICI)1097-4652(199603)166:3<631::AID-JCP18>3.0.CO;2-9; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHAROLLAIS RH, 1990, J CELL PHYSIOL, V145, P46, DOI 10.1002/jcp.1041450108; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAGOT D, 1991, ENDOCRINOLOGY, V129, P1033, DOI 10.1210/endo-129-2-1033; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU KH, 1992, P NATL ACAD SCI USA, V89, P3889, DOI 10.1073/pnas.89.9.3889; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLAT P, 1992, BIO-TECHNOL, V10, P1151, DOI 10.1038/nbt1092-1151; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSTROWSKI MC, 1983, MOL CELL BIOL, V3, P2045, DOI 10.1128/MCB.3.11.2045; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SAMBROOK J, 1989, MOL CLONING LAB HDB; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; Yenush L, 1996, MOL CELL BIOL, V16, P2509	52	3	3	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2113	2120						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950978				2022-12-17	WOS:A1996VV14500008
J	Phinney, DG; Tseng, SW; Hall, B; Ryder, K				Phinney, DG; Tseng, SW; Hall, B; Ryder, K			Chromosomal integration dependent induction of junB by growth factors requires multiple flanking evolutionarily conserved sequences	ONCOGENE			English	Article						chromatin; regulation; evolutionary conservation	SERUM RESPONSE ELEMENT; C-FOS PROMOTER; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; GENE; BINDING; COMPLEX; PROTEINS; DIFFERENTIATION; IDENTIFICATION	The junB locus contains nine flanking evolutionarily conserved sequences (FECS) that share 72% to 91% sequence identity between human and mouse, These FECS encompass the same regions of flanking DNA necessary for maximal mitogenic induction of junB, Most of the cis elements reported to date that affect junB regulation also reside within FECS, These observations suggest that the persistence of FECS through evolution reflects a necessary role in junB transcriptional regulation, In this report, we identify specific regulatory cis elements within junB FECS II and III and provide a quantitative analysis of the contribution made by these sequences to junB induction, These cis elements include a Serum Response Element (SRE), two Ets sites previously unrecognized as contributing to junB expression, and two novel Ets-linked motifs (ELMs), In general, mutating any single element significantly impairs junB induction, Moreover, the same mutations alter the structure of junB 5' flanking DNA within chromatin, Collectively, these results suggest that multiple proteins bound within FECS confederate to form a functional promoter complex, the activity of which is dependent upon a specific chromatin architecture.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19007	Fox Chase Cancer Center			Phinney, Donald G/D-2155-2014	Phinney, Donald/0000-0002-8688-2619	NATIONAL CANCER INSTITUTE [R01CA052752, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927-31, CA-52752] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COFFER P, 1994, ONCOGENE, V9, P911; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NORDHEIM A, 1994, FOS JUN FAMILIES TRA, P97; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; PHINNEY DG, 1994, ONCOGENE, V9, P2353; PHINNEY DG, 1995, GENOMICS, V28, P228, DOI 10.1006/geno.1995.1135; RAO VN, 1994, ONCOGENE, V9, P1855; RIVERA FM, 1990, GENE DEV, V4, P225; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167	34	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1875	1883						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934533				2022-12-17	WOS:A1996VR79500006
J	VanHouten, JN; Natoli, F; Asch, BB				VanHouten, JN; Natoli, F; Asch, BB			Frequent ectopic expression of a placenta-specific gene at high levels in BALB/c mouse mammary carcinomas	ONCOGENE			English	Article						MIPP; retrotransposon; mammary tumorigenesis; intracisternal A-particle	INTRACISTERNAL-A-PARTICLES; HEMATOPOIETIC-CELLS; DNA REARRANGEMENT; INSERTION; SEQUENCES; RETROTRANSPOSONS; TRANSFORMATION; IDENTIFICATION; TRANSPOSITION; PLASMACYTOMA	A placenta-specific gene, MIPP, is transcriptionally regulated in BALB/c mice by a solo long terminal repeat (LTR) of an intracisternal A-particle (IAP), an endogenous retrotransposon, Expression of IAPs, which is also promoted by LTR sequences, is a frequent aberration in many mouse mammary tumors of BALB/c mice, Given that these retroelements and the placental gene have a common promoter, we hypothesized that the tumors also express the gene, Northern blot analysis and RT-PCR revealed high expression of the placenta-specific gene in BALB/c mouse mammary preneoplasias and carcinomas of diverse etiologies, but not in normal mammary gland from virgin, pregnant and lactating mice, The preneoplasias and tumors expressed two transcripts, one of which is apparently unique to the mammary lesions, The other transcript is the same as one expressed in placenta that is not promoted by the IAP LTR, Despite the parallel expression of the placental gene and IAPs in the mammary tissues, RT-PCR showed that LTR sequences are absent from tumor-associated MIPP transcripts, Southern analysis revealed no gross mutations of the MIPP gene in mammary preneoplasias and tumors, The ectopic expression of the placenta-specific gene in BALB/c mouse mammary preneoplasias and carcinomas raises the possibility that it acts as an oncogene.			VanHouten, JN (corresponding author), ROSWELL PK CANC INST, DEPT EXPTL PATHOL, BUFFALO, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA059906] Funding Source: NIH RePORTER; NCI NIH HHS [CA59906] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGATE PA, 1993, ONCOGENE, V8, P1221; ASCH BB, 1990, CANCER RES, V50, P2404; ASCH BB, 1993, INT J CANCER, V54, P813, DOI 10.1002/ijc.2910540516; BANVILLE D, 1989, J MOL BIOL, V207, P481, DOI 10.1016/0022-2836(89)90458-0; BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CARDIFF RD, 1988, ANTICANCER RES, V8, P925; CHANGYEH A, 1993, P NATL ACAD SCI USA, V90, P292, DOI 10.1073/pnas.90.1.292; CHANGYEH A, 1991, NUCLEIC ACIDS RES, V19, P3667, DOI 10.1093/nar/19.13.3667; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHRISTY RJ, 1985, NUCLEIC ACIDS RES, V13, P289, DOI 10.1093/nar/13.1.289; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; HAWLEY RG, 1984, MOL CELL BIOL, V4, P2565, DOI 10.1128/MCB.4.12.2565; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LUEDERS KK, 1977, CELL, V12, P963, DOI 10.1016/0092-8674(77)90161-1; MEDINA D, 1987, J NATL CANCER I, V79, P569; MEDINA D, 1970, J NATL CANCER I, V45, P353; MIYAMOTO S, 1990, MOL CELL BIOL, V10, P1593, DOI 10.1128/MCB.10.4.1593; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SLAGLE BL, 1987, CELLULAR MOL BIOL MA, P275; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TOHYAMA K, 1990, EMBO J, V9, P1823, DOI 10.1002/j.1460-2075.1990.tb08307.x; VARKEY JP, 1995, GENE DEV, V9, P1074, DOI 10.1101/gad.9.9.1074; VONBULOW M, 1995, EXP CELL RES, V219, P407, DOI 10.1006/excr.1995.1246; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WIVEL NA, 1971, INT J CANCER, V7, P167, DOI 10.1002/ijc.2910070119; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; WUJCIK KM, 1984, J VIROL, V52, P29, DOI 10.1128/JVI.52.1.29-36.1984; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	35	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	1996	12	10					2241	2245						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668351				2022-12-17	WOS:A1996UP28300024
J	Quignon, F; Renard, CA; Tiollais, P; Buendia, MA; Transy, C				Quignon, F; Renard, CA; Tiollais, P; Buendia, MA; Transy, C			A functional N-myc2 retroposon in ground squirrels: Implications for hepadnavirus-associated carcinogenesis	ONCOGENE			English	Article						N-myc; hepadnavirus; carcinogenesis; viral determinants; host determinants	HEPATITIS-B VIRUS; WOODCHUCK LIVER-TUMORS; FOCUS-FORMING VIRUSES; HEPATOCELLULAR-CARCINOMA; C-MYC; ACTIVATION; GENE; EXPRESSION; INFECTION; REGION	Three hepatitis B viruses infecting humans, woodchucks and ground squirrels increase the risk of hepatocellular carcinoma in their respective hosts. The woodchuck hepatitis B virus (WHV), unlike the two other viruses, induces a rapid carcinogenic process characterized by direct activation of myc proto-oncogenes by insertion of viral DNA. The highly preferred target of insertional mutagenesis in woodchucks is N-myc2, an intronless N-myc gene. Strikingly, N-myc2 has no human homolog and the homologous N-myc2 locus previously detected in the ground squirrel genome, remains silent during hepatocarcinogenesis. Therefore, N-myc2 may represent a critical host determinant in the evolution of the disease associated with hepadnavirus infection. To address this question, we performed a structural and functional analysis of the ground squirrel N-myc2 locus. We show that ground squirrel N-myc2 is highly homologous to its woodchuck counterpart and is a functional protooncogene, Existence of a functional N-myc2 gene as a potential target for insertional activation by viral DNA is therefore not restricted to the woodchuck species. This suggests that viral rather than host factors determine the higher oncogenic phenotype of WHV as compared to the two other mammalian hepadnaviruses.	INST PASTEUR,INSERM,UNITE RECOMBINAISON & EXPRESS GENET,U163,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Quignon, Frédérique/P-4249-2017					ATHAS GB, 1994, CRIT REV ONCOGENESIS, V5, P169, DOI 10.1615/CritRevOncog.v5.i2-3.40; BEASLEY RP, 1981, LANCET, V2, P1129; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; DAVIS BR, 1987, P NATL ACAD SCI USA, V84, P4875, DOI 10.1073/pnas.84.14.4875; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; FOUREL G, 1990, NUCLEIC ACIDS RES, V18, P4918, DOI 10.1093/nar/18.16.4918; HAGIWARA T, 1992, EUR J BIOCHEM, V209, P945, DOI 10.1111/j.1432-1033.1992.tb17367.x; HANSEN LJ, 1993, MOL CELL BIOL, V13, P659, DOI 10.1128/MCB.13.1.659; HOLLAND CA, 1989, J VIROL, V63, P1284, DOI 10.1128/JVI.63.3.1284-1292.1989; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; MORRISON HL, 1995, J VIROL, V69, P446, DOI 10.1128/JVI.69.1.446-455.1995; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SEEGER C, 1991, J VIROL, V65, P1673, DOI 10.1128/JVI.65.4.1673-1679.1991; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; TRANSY C, 1994, J VIROL, V68, P5291, DOI 10.1128/JVI.68.8.5291-5295.1994; TSICHLIS PN, 1991, P NATL ACAD SCI USA, V88, P4611, DOI 10.1073/pnas.88.11.4611; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992	28	3	5	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					2011	2017						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649862				2022-12-17	WOS:A1996UK49800020
J	Matsuda, S; Nakanishi, H; Sasaki, T; Takai, Y				Matsuda, S; Nakanishi, H; Sasaki, T; Takai, Y			A membrane-associated GDP/GTP exchange protein specific for Rho small GTP-binding protein - Partial purification and characterization from rat brain	ONCOGENE			English	Article						small G protein; Rho; mRho GEP; Rho GDI; dbl	SWISS 3T3 CELLS; ADP-RIBOSYLATION; CLOSTRIDIUM-BOTULINUM; REGULATORY PROTEIN; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; ONCOGENE PRODUCT; DBL ONCOGENE; SMG P21S; GDP	The Rho subfamily, consisting of three members (RhoA, -B and -C), belongs to the small GTP-binding protein superfamily. The Rho subfamily is implicated in regulation of various actin filament-dependent cell functions, such as cell aggregation, cell motility and cytokinesis. The Rho subfamily receives an upstream signal and is converted from the GDP-bound inactive form to the GTP-bound active form which transduces a signal to a downstream pathway. This conversion is regulated by GDP/GTP exchange proteins (GEPs) and several GEPs for the Rho subfamily have been identified. The GEPs thus far reported are mainly isolated from the cytosol fraction of various tissues and are not specific for the Rho subfamily. Here we have partially purified a membrane-associated GEP specific for the Rho subfamily (mRho GEP). mRho GEP was extracted from the crude synaptic membrane fraction of rat brain by a combination of detergent and NaCl, and partially purified by several column chromatographies. The partially purified mRho GEP was active on RhoA but was inactive on other small GTP-binding proteins including at least Rad, Ki-Ras and Rab3A. RhoA undergoes post-translational lipid modifications and mRho GEP required these lipid modifications for its GEP activity. mRho GEP was not active in the presence of Rho GDI, an inhibitory Rho GEP. These results indicate that there is a membrane-associated GEP specific for Rho and suggest that Rho is activated by this GEP on the membranes.	OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,SUITA,OSAKA 565,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)				Nakanishi, Hiroyuki/0000-0002-9765-0266				BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GRAZIANI G, 1989, ONCOGENE, V4, P823; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HORI Y, 1991, ONCOGENE, V6, P515; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; ISOMURA M, 1991, ONCOGENE, V6, P119; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KIKUCHI A, 1992, ONCOGENE, V7, P289; KIKUCHI A, 1995, METHOD ENZYMOL, V257, P57; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LANG P, 1992, J BIOL CHEM, V267, P11677; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIURA Y, 1993, J BIOL CHEM, V268, P510; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MORII N, 1992, J BIOL CHEM, V267, P20921; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NONAKA H, 1995, IN PRESS EMBO J; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SELF AJ, 1993, ONCOGENE, V8, P655; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKAISHI K, 1995, ONCOGENE, V11, P39; TANAKA K, 1995, METHOD ENZYMOL, V256, P41; TOKSOZ D, 1994, ONCOGENE, V9, P621; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	60	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					915	920						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632914				2022-12-17	WOS:A1996TW68600023
J	LANFRANCONE, L; PELICCI, G; BRIZZI, MF; ARONICA, MG; CASCIARI, C; GIULI, S; PEGORARO, L; PAWSON, T; PELICCI, PG				LANFRANCONE, L; PELICCI, G; BRIZZI, MF; ARONICA, MG; CASCIARI, C; GIULI, S; PEGORARO, L; PAWSON, T; PELICCI, PG			OVEREXPRESSION OF SHC PROTEINS POTENTIATES THE PROLIFERATIVE RESPONSE TO THE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AND RECRUITMENT OF GRB2/SOS AND GRB2/P140 COMPLEXES TO THE BETA-RECEPTOR SUBUNIT (VOL 10, PG 907, 1995)	ONCOGENE			English	Correction, Addition													Pelicci, Pier Giuseppe/AAL-6572-2020; Pelicci, Giuliana/AAA-8921-2022; Brizzi, Maria Felice/J-7882-2016; Lanfrancone, Luisa/AAC-8671-2019	Pelicci, Giuliana/0000-0003-0986-8255; Lanfrancone, Luisa/0000-0002-4523-3815; CASCIARI, CRISTINA/0000-0002-9170-370X				LANFRANCONE L, 1995, ONCOGENE, V10, P907	1	3	3	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					607	607						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530					2022-12-17	WOS:A1995RN53000024
J	SU, ZZ; YEMUL, S; STEIN, CA; FISHER, PB				SU, ZZ; YEMUL, S; STEIN, CA; FISHER, PB			C-FOS IS A POSITIVE REGULATOR OF CARCINOGEN ENHANCEMENT OF ADENOVIRUS TRANSFORMATION	ONCOGENE			English	Article						IMMEDIATE-EARLY RESPONSE GENES; INDUCIBLE EXPRESSION VECTORS; C-FOS ANTISENSE RNA; VIRAL TRANSFORMATION; AP-1 BINDING; NUCLEAR RUN-ON	EMBRYO FIBROBLAST CELLS; DNA-DAMAGING AGENTS; HOST-RANGE MUTANT; TYPE-5 ADENOVIRUS; METHYL METHANESULFONATE; GROWTH-ARREST; JUN-B; IONIZING-RADIATION; GENOTOXIC-STRESS; GENE-EXPRESSION	The early gene expression changes mediating carcinogen enhancement of viral transformation (GET) remain to be elucidated. A model cell culture system has been developed that is now permitting a molecular analysis of GET. Pretreatment of cloned rat embryo fibroblast (CREF) cells with methyl methanesulfonate (MMS) prior to infection with the cold-sensitive host-range type 5 adenovirus mutant, H5hr1, results in a dose-dependent increase in viral transformation, The present study investigates the role of immediate-early response genes, specifically c-fos, in the CET process, MMS pretreatment, alone or in combination with infection with H5hr1 temporally and differentially increases c-fos, c-jun, jun-B, jun-D and c-myc steady-state mRNA levels, Maximum induction occurs with c-fos and c-jun 8 to 12 h posttreatment and the magnitude of response is generally greatest in CREF cells pretreated with MMS and then infected with H5hr1. Enhancement in RNA levels is observed in the presence of cycloheximide indicating that ongoing protein synthesis is not required for induction of c-fos, c-jun, jun-B or c-myc expression, Nuclear run-on analysis indicates an enhancement in transcriptional rates for c-fos, c-jun, jun-B and c-myc in CREF cells treated with MMS or MMS plus infection with H5hr1. A requirement for elevated c-fos in the early stages of CET is indicated by the ability of c-fos antisense oligonucleotides to prevent the CET process, Direct evidence implicating early increases in c-fos as a mediator of the CET process is demonstrated by stably expressing mouse mammary tumor virus promoter-regulated human sense and antisense c-fos genes in CREF cells, Induction of c-fos sense expression by dexamethasone (DEX) in the absence of MMS treatment results in enhanced c-fos mRNA, Fos protein, AP-1 DNA-binding activity and H5hr1-induced transformation and GET. Induction of c-fos expression by DEX in stable c-fos-sense CREF constructs also results in elevated levels of c-jun, jun-B and c-myc mRNA and protein. Conversely, induction of c-fos antisense expression prevents the increase in c-fos mRNA, Fos protein and AP-I DNA-binding activity and eliminates GET. In the antisense-c-fos constructs, increases in c-jun, jun-B and c-myc mRNA and protein normally induced by MMS also are not apparent, Thus, induction or inhibition in c-fos expression affects the level of expression of additional immediate-early response genes, including c-jun, jun-B and c-myc. These results demonstrate a pivotal role for the early induction of c-fos and possibly c-fos responsive genes, in the CET process.	COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES, CTR COMPREHENS CANC,DEPT UROL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES, CTR COMPREHENS CANC,DEPT SURG, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES, CTR COMPREHENS CANC,DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG,INST CANC RES, CTR COMPREHENS CANC,DEPT PATHOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University					NATIONAL CANCER INSTITUTE [R01CA043208, R01CA035675, R29CA060639] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA43208, R29 CA60639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1983, P NATL ACAD SCI-BIOL, V80, P1352, DOI 10.1073/pnas.80.5.1352; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P2167, DOI 10.1073/pnas.83.7.2167; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN PH, 1993, ONCOGENE, V8, P877; Casto B C, 1973, Prog Med Virol, V16, P1; CATLING AD, 1993, ONCOGENE, V8, P1875; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CURRAN T, 1987, ONCOGENE, V2, P79; Curran T, 1988, ONCOGENE HDB, P307; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISHER PB, 1983, CANCER INVEST, V1, P495, DOI 10.3109/07357908309020275; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FISHER PB, 1984, MECHANISMS TUMOR PRO, V3, P57; FISHER PB, 1981, CARCINOGENS IND ENV, P113; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRITSCHE M, 1993, ONCOGENE, V8, P307; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HAUGEN A, 1990, HDB EXPT PHARM, V94, P249; HERMO H, 1987, CARCINOGENESIS, V8, P967, DOI 10.1093/carcin/8.7.967; HERMO H, 1988, CANCER RES, V48, P3050; HERMO H, 1985, MOL BASIS CANCER A, P489; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLANDER MC, 1989, CANCER RES, V49, P1687; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P197; JIANG HP, 1992, INT J ONCOL, V1, P227; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PRICE BD, 1994, CANCER RES, V54, P896; REDDY PG, 1993, METHODS MOL GENETICS, V1, P68; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHEN R, 1995, IN PRESS P NATL ACAD; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SU ZZ, 1989, MOL CARCINOGEN, V2, P252, DOI 10.1002/mc.2940020505; SU ZZ, 1993, ONCOGENE, V8, P1211; SU ZZ, 1990, MOL CARCINOGEN, V3, P141, DOI 10.1002/mc.2940030307; SU ZZ, 1994, ONCOGENE, V9, P1123; SU ZZ, 1991, MOL CARCINOGEN, V4, P328, DOI 10.1002/mc.2940040412; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; SU ZZ, 1993, MOL CARCINOGEN, V8, P155, DOI 10.1002/mc.2940080306; SU ZZ, 1993, CANCER RES, V53, P1929; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TISHLER RB, 1993, CANCER RES, V53, P2212; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WICK M, 1992, ONCOGENE, V7, P859; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; zur Hausen H, 1987, Appl Pathol, V5, P19; [No title captured]	86	3	4	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					2037	2049						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761104				2022-12-17	WOS:A1995QZ92600018
J	SHIRAISHI, M; SEKIYA, T				SHIRAISHI, M; SEKIYA, T			MUTATIONS IN AN ALU REPEATED SEQUENCE ASSOCIATED WITH THE DXS43 LOCUS IN HUMAN SMALL-CELL LUNG CANCERS	ONCOGENE			English	Note						HUMAN SMALL CELL LUNG CANCER; X CHROMOSOME; ALU REPEATED SEQUENCE; POINT MUTATION	CARCINOMAS; GENE; DNA	Point mutations in an Alu repeated sequence associated with the DXS43 locus were identified in two out of 10 human small cell lung cancers. Since these aberrations were identified in DNA from both metastatic lesions and primary lesions from the same patient, they would appear to have occurred at a relatively early stage. Although this sequence is not apparently associated with known genes, these tumor-specific mutations occurred at an early stage may play an important role in tumorigenesis.			SHIRAISHI, M (corresponding author), NATL CANC CTR, RES INST, DIV ONCOGENE, CHUO KU, 1-1 TSUKIJI 5 CHOME, TOKYO 104, JAPAN.							AUSTIN GE, 1993, LEUKEMIA, V7, P1445; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; IIZUKA M, 1995, INPRESS GENES CHROMO; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; SHIRAISHI M, 1989, CANCER RES, V49, P6474; SHIRAISHI M, 1989, JPN J CANCER RES, V80, P924, DOI 10.1111/j.1349-7006.1989.tb01627.x	8	3	3	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1453	1454						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731698				2022-12-17	WOS:A1995QR65100025
J	TILBROOK, PA; PATERSON, HF; MARSHALL, CJ				TILBROOK, PA; PATERSON, HF; MARSHALL, CJ			REVERSION OF A HUMAN TUMOR-CELL LINE CONTAINING ONCOGENIC P21(RAS) IS ASSOCIATED WITH A DEFECT IN THE POSTTRANSLATIONAL PROCESSING OF THE RAS PROTEIN	ONCOGENE			English	Note						RAS; ISOPRENYLATION; POSTTRANSLATIONAL MODIFICATIONS; REVERTANT	P21RAS ONCOPROTEIN; PLASMA-MEMBRANE; TRANSFORMATION; PRODUCT; SIGNAL; KINASE; MOTIF; ACID; CAAX	Correct post-translational modifications of the ras proteins are essential for their membrane localisation and functioning. The flat revertant cell lines 1aCB and 8b, derived from the human bladder carcinoma cell line EJ, contain the transforming gene V12Ha-ras and are resistant to retransformation by vas protein or DNA, but still do require the presence of ras for proliferation. Both revertant cell lines demonstrated reduced levels of membrane associated p21(ras) when compared to their parental EJ cell lines. This reduced level in 1aCB was reflected by an increase in nuclear associated p21(ras), as seen by immunofluorescence of endogenous and introduced ras. In addition, 1aCB had a reduced ratio of ras in the detergent to aqueous phases after triton X114 partitioning, suggesting a defect in Step I processing of the p21(ras) in the cell line. This was not however due to defects in the Step I enzymes farnesyltransferase or carboxymethyltransferase whose activities were not reduced.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOSS JL, 1988, MUTAT RES, V195, P255; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P1167; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, SCIENCE, V220, P1175, DOI 10.1126/science.6304875; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1986, J BIOL CHEM, V261, P963; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HUANG S, 1991, ONCOGENE, V6, P1211; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MORRIS JDH, 1989, ONCOGENE, V4, P27; PATERSON HF, 1989, CIBA F S, V142, P135; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHULZ TF, 1988, IMMUNOLOGY, V64, P581; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x	25	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					805	809						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862461				2022-12-17	WOS:A1995QH61200024
J	STONGE, L; BASTIN, M				STONGE, L; BASTIN, M			TRANSCRIPTION ACTIVATION MEDIATED BY CHROMOSOMAL INVERSION IN RAT-CELLS	ONCOGENE			English	Article							HOMOLOGOUS RECOMBINATION; INTRACHROMOSOMAL RECOMBINATION; GENE-AMPLIFICATION; DNA METHYLATION; MAMMALIAN-CELLS; STEM-CELLS; POLYOMAVIRUS; VIRUS; TRANSFORMATION; FIBROBLASTS	To investigate the relationship between the local configuration of a gene and its level of expression, we constructed a rat cell line, Hy5, carrying a mutant polyomavirus middle T oncogene (pmt) whose overexpression converted the cells to the transformed state. The structure of the transgene was such that pmt was able to undergo chromosomal inversion at a relatively high rate by a cross-over in flanking pBR322 sequences. Hy5 cells became spontaneously transformed at a rate of 10(-5) per cell generation and all of the transformants analysed had sustained pmt inversion. CpG sequences were partially methylated in the Hy5 insert but appeared demethylated in transformants. In two subclones derived from untransformed Hy5 cells, the pmt insert was densely methylated, transcriptionally inactive and unable to undergo homologous recombination. Our results suggest that DNA repair associated with recombinational events leads to a heritable hypomethylation of the locus which is responsible for its activation.	UNIV SHERBROOKE,DEPT BIOCHEM,SHERBROOKE J1H 5N4,PQ,CANADA	University of Sherbrooke								ALT FW, 1978, J BIOL CHEM, V253, P1357; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ASSELIN C, 1986, J VIROL, V57, P165, DOI 10.1128/JVI.57.1.165-172.1986; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird A.J., 1980, CATALYSIS ORGANIC SY, P61; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BOUCHARD L, 1987, J VIROL, V61, P2448, DOI 10.1128/JVI.61.8.2448-2453.1987; BOUCHARD L, 1987, ONCOGENE, V2, P379; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Croce C M, 1986, Horiz Biochem Biophys, V8, P545; CROCE CM, 1985, BLOOD, V65, P1; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMERMAN M, 1984, CELL, V39, P459, DOI 10.1016/0092-8674(84)90453-7; GELINAS C, 1985, VIROLOGY, V146, P233, DOI 10.1016/0042-6822(85)90007-8; GREEN AR, 1986, EMBO J, V5, P707, DOI 10.1002/j.1460-2075.1986.tb04271.x; Hatfull GF, 1988, GENETIC RECOMBINATIO, P357; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; JAT P, 1982, NUCLEIC ACIDS RES, V10, P871, DOI 10.1093/nar/10.3.871; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; KASTAN MB, 1982, CELL, V30, P509, DOI 10.1016/0092-8674(82)90248-3; KEIL RL, 1984, CELL, V39, P377, DOI 10.1016/0092-8674(84)90016-3; LAROSE A, 1990, VIROLOGY, V176, P98, DOI 10.1016/0042-6822(90)90234-I; Luria SE, 1943, GENETICS, V28, P491; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATHEYPREVOT B, 1984, J VIROL, V50, P325, DOI 10.1128/JVI.50.2.325-334.1984; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NICKOLOFF JA, 1990, MOL CELL BIOL, V10, P4837, DOI 10.1128/MCB.10.9.4837; NICKOLOFF JA, 1992, MOL CELL BIOL, V12, P5311, DOI 10.1128/MCB.12.12.5311; NOTTENBURG C, 1987, J VIROL, V61, P1828, DOI 10.1128/JVI.61.6.1828-1833.1987; PALL ML, 1981, P NATL ACAD SCI-BIOL, V78, P2465, DOI 10.1073/pnas.78.4.2465; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RENZO A, 1989, ONCOGENE, V4, P1469; ROGINSKI RS, 1983, CELL, V35, P149, DOI 10.1016/0092-8674(83)90217-9; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SHAD D, 1986, SCIENCE, V233, P478; SHENKAR R, 1991, MOL CELL BIOL, V11, P1813, DOI 10.1128/MCB.11.4.1813; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONGE L, 1990, J VIROL, V64, P2958, DOI 10.1128/JVI.64.6.2958-2966.1990; STONGE L, 1993, J VIROL, V67, P1788, DOI 10.1128/JVI.67.4.1788-1795.1993; STONGE L, 1991, NUCLEIC ACIDS RES, V19, P6619, DOI 10.1093/nar/19.23.6619; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; VARSHAVSKY A, 1981, CELL, V25, P561, DOI 10.1016/0092-8674(81)90074-X; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	47	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					781	789						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108120				2022-12-17	WOS:A1994MW55100013
J	BAIERBITTERLICH, G; RAPPAPORT, J; BAIER, G; LOONEY, D; WONGSTAAL, F				BAIERBITTERLICH, G; RAPPAPORT, J; BAIER, G; LOONEY, D; WONGSTAAL, F			TRANSCELLULAR ACTIVATION OF THE HTLV PROMOTER BY HUMAN HEMATOPOIETIC-CELLS	ONCOGENE			English	Note							LEUKEMIA-LYMPHOMA VIRUS; T-CELL; INTERLEUKIN-2; EXPRESSION; RETROVIRUS; GENE; LYMPHOCYTES; INFECTION; SEQUENCES; DISTINCT	We examined the ability of hematopoietic cells to transactivate the HTLV promoter by a transcellular mechanism. HeLa cells containing a CAT reporter gene driven by the HTLV-2 promoter were cocultivated with hematopoietic cells of the B-(Raji), T-(HuT78, Jurkat) and monocyte/promyelocytic (THP-1, U937 and HL60) lineages. Cocultivation with U937 and HuT78 cells constitutively and significantly transactivated the HTLV-2 promoter, while no effect was observed with the other lines. However, activation of other T-cell lines (CEM, Jurkat, Molt-3 and MT-4) with a combination of phorbolester and phytohemagglutinin also resulted in potent transactivation. Supernatant from HuT78 cells exhibited detectable transactivating activity, suggesting that the activation is mediated by a secreted factor(s). This factor also transactivates the HTLV-1 promoter. We used a panel of HTLV-1 LTR deletion mutants to map the responsive elements to this factor(s). Unlike the response element to the HTLV transactivator protein, Tax, which can be mapped to a small region in the enhancer, maximal transactivation by the cellular factor(s) required the complete U3 sequence. Transcellular activation of the HTLV promoter by activated T-cells may play a role in the development of leukemia in HTLV infected individuals.	UNIV CALIF SAN DIEGO,SAN DIEGO,CA; NIH,BETHESDA,MD; SAN DIEGO VA MED CTR,SAN DIEGO,CA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA	BAIERBITTERLICH, G (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL,LA JOLLA,CA, USA.		Baier, Gottfried/E-8755-2012	Baier, Gottfried/0000-0002-2085-8325				BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BOEHNLEIN E, 1988, CONTROL HUMAN RETROV, P191; CHEN ISY, 1982, J VIROL, V41, P183, DOI 10.1128/JVI.41.1.183-191.1982; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DAEFLER S, 1991, MOL F ONCOLOGY, P229; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; MANZARI V, 1983, P NATL ACAD SCI-BIOL, V80, P1574, DOI 10.1073/pnas.80.6.1574; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MERL S, 1984, BLOOD, V64, P967; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PAVLAKIS GN, 1988, CONTROL OF HUMAN RETROVIRUS GENE EXPRESSION, P281; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; ROSENBLATT JD, 1988, BLOOD, V71, P363; SAXON A, 1978, ANN INTERN MED, V88, P323, DOI 10.7326/0003-4819-88-3-323; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; TEMIN HM, 1974, J VIROL, V13, P291, DOI 10.1128/JVI.13.2.291-297.1974; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	28	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					319	322						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302596				2022-12-17	WOS:A1994MW24700039
J	ALI, IU; SAXENA, A; MEISSNER, S; BARRICK, J; LIDEREAU, R				ALI, IU; SAXENA, A; MEISSNER, S; BARRICK, J; LIDEREAU, R			CLOSE PROXIMITY OF C-ERBA2 AND C-ERBA-BETA GENES ON THE SHORT ARM OF CHROMOSOME-3	ONCOGENE			English	Note							THYROID-HORMONE RECEPTOR; RENAL-CELL CARCINOMA; HUMAN LUNG-CANCER; DELETION; LOCALIZATION; REGION; HETEROZYGOSITY; SEQUENCE; HOMOLOGS; PROTEIN	The common loss region on the short arm of chromosome 3 (3p) in human breast tumors harbors two members of the c-erbA receptor gene family, c-erbA2 and c-erbA-beta, both of which recognize a BamHI polymorphism in human genomic DNA. Analysis of lymphocyte DNAs from 50 normal individuals and lymphocyte and tumor DNAs from 116 breast cancer patients revealed identical genotypes (a/a, b/b or a/b) for both probes. Furthermore, deletion of the same allele (a/- or -/b) of c-erbA2 and c-erbA-beta was detected in 25% of the 66 breast tumors from patients with constitutionally heterozygous genotypes for both genes. No sequence homology was detected between the c-erbA2 and c-erbA-beta genes, suggesting a physical linkage between these two genes. Digestion of the genomic DNA with combinations of restriction enzymes and hybridization with c-erbA2, which is a genomic fragment, and c-erbA-beta, which is a cDNA clone, provide evidence that c-erbA2 and a region of the c-erbA-beta gene are physically contiguous on the short arm of chromosome 3 and are separated by no more than 1.8 kb of DNA sequences.	NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892; CTR RENE HUGUENIN,F-92211 ST CLOUD,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rene Huguenin Hospital	ALI, IU (corresponding author), NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892, USA.							ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DOBROVIC A, 1988, CANCER RES, V48, P682; DOUGLAS JB, 1991, GENOMICS, V9, P398, DOI 10.1016/0888-7543(91)90274-I; DRABKIN H, 1988, P NATL ACAD SCI USA, V85, P9258, DOI 10.1073/pnas.85.23.9258; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOSDEN JR, 1986, CYTOGENET CELL GENET, V43, P150, DOI 10.1159/000132313; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HIBI K, 1992, ONCOGENE, V7, P445; JANSSON M, 1983, EMBO J, V2, P561, DOI 10.1002/j.1460-2075.1983.tb01463.x; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LEDUC F, 1989, AM J HUM GENET, V44, P282; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; RIDER SH, 1987, ANN HUM GENET, V51, P153, DOI 10.1111/j.1469-1809.1987.tb01057.x; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SPURR NK, 1984, EMBO J, V3, P159, DOI 10.1002/j.1460-2075.1984.tb01777.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YAMAKAWA K, 1991, CANCER RES, V51, P4707; YOKOTA J, 1989, CANCER RES, V49, P3958; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	25	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2299	2301						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393165				2022-12-17	WOS:A1993LP17100033
J	GHOSN, CR; RAL, BBA; WINOKUR, ST; UNGER, TF; STEELE, RE				GHOSN, CR; RAL, BBA; WINOKUR, ST; UNGER, TF; STEELE, RE			STRUCTURAL ORGANIZATION OF A SRC GENE FROM XENOPUS-LAEVIS	ONCOGENE			English	Note							MURINE HCK GENE; C-SRC; NUCLEOTIDE-SEQUENCE; PROTO-ONCOGENE; CHLORAMPHENICOL ACETYLTRANSFERASE; EUKARYOTIC RIBOSOMES; SECONDARY STRUCTURE; MAMMALIAN-CELLS; MESSENGER-RNA; FYN GENES	By sequence analysis of genomic clones, the exon-intron structure of one of the two src genes from Xenopus laevis has been determined. The coding region of the gene is interrupted by 10 introns whose locations are identical to the introns in the coding regions of the src genes of human and chicken. The 5' untranslated region is contained on a separate exon with no sequence conservation relative to the corresponding region of the chicken gene. The 5' untranslated region of the Xenopus gene contains a G + C-rich stem-loop sequence and two ATG triplets. A 1.4-kb fragment containing the 5' untranslated region and sequences upstream of it acts as a promoter when introduced in the correct orientation into X. laevis cell lines. The DNA sequence of this fragment lacks the typical arrangement of TATA and CCAAT sequences but contains the ATGCAAAT octamer sequence and a (TA)39 sequence.	UNIV CALIF IRVINE,DEPT BIOL CHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717	University of California System; University of California Irvine; University of California System; University of California Irvine								ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CILIBERTO G, 1985, EMBO J, V4, P1537, DOI 10.1002/j.1460-2075.1985.tb03814.x; COLLETT JW, 1992, IN PRESS DEV BIOL; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREAVES DR, 1985, EMBO J, V4, P2617, DOI 10.1002/j.1460-2075.1985.tb03979.x; GREAVES DR, 1985, J MOL BIOL, V185, P461, DOI 10.1016/0022-2836(85)90064-6; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUTKIND JS, 1991, MOL CELL BIOL, V11, P1500, DOI 10.1128/MCB.11.3.1500; HANIFORD DB, 1985, NUCLEIC ACIDS RES, V13, P4343, DOI 10.1093/nar/13.12.4343; HANNIG G, 1991, ONCOGENE, V6, P361; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LOCK P, 1990, MOL CELL BIOL, V10, P4603, DOI 10.1128/MCB.10.9.4603; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MATSUZAWA Y, 1991, ONCOGENE, V6, P1561; MATTAJ IW, 1985, NATURE, V316, P163, DOI 10.1038/316163a0; MURPHY JT, 1982, CELL, V29, P265, DOI 10.1016/0092-8674(82)90111-8; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; PATEL M, 1990, ONCOGENE, V5, P201; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; RAFFERTY KA, 1969, BIOL AMPHIBIAN TUMOR, P52; RAULF F, 1989, J NEUROSCI RES, V24, P81, DOI 10.1002/jnr.490240112; SCHARTL M, 1989, ONCOGENE, V4, P1185; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIVE HL, 1986, MOL CELL BIOL, V6, P3329, DOI 10.1128/MCB.6.10.3329; STEELE RE, 1985, NUCLEIC ACIDS RES, V13, P1747, DOI 10.1093/nar/13.5.1747; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STEELE RE, 1989, ONCOGENE RES, V4, P223; STEELE RE, 1990, ONCOGENE, V5, P369; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; ZIEGLER SF, 1991, ONCOGENE, V6, P283	49	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2345	2350						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437158				2022-12-17	WOS:A1992JW66500030
J	MERZAK, A; SORET, J; MARTINERIE, C; SUREAU, A; CROCHET, J; PERBAL, B				MERZAK, A; SORET, J; MARTINERIE, C; SUREAU, A; CROCHET, J; PERBAL, B			TRANSFORMING POTENTIAL OF TRUNCATED V-MYB AND STIMULATION OF REPLICATION BY GAG-MYB FUSION PRODUCTS	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; CHICKEN-EMBRYO FIBROBLASTS; ONCOGENE PRODUCT; FUNCTIONAL DOMAINS; DNA-REPLICATION; GENE-EXPRESSION; SEQUENCES; PROTEIN; PROTOONCOGENE; PROLIFERATION	We have previously reported that truncated forms of the v-myb oncogene of avian myeloblastosis virus (AMV) are expressed in transformed chicken embryo fibroblasts (CEF). In this paper, we show that deletion mutants encoding v-myb products altered in either the DNA-binding or the negative regulatory domains are able to induce CEF transformation. In addition, we report that recombinant plasmids expressing gag-myb fusion proteins are maintained as extrachromosomal forms in transfected cells. This observation provides an important clue for a possible role of myb in the DNA replication processes.	CTR UNIV ORSAY,INST CURIE,BATIMENT 110,F-91405 ORSAY,FRANCE; UNIV PARIS 07,F-75221 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite			Sureau, Alain/M-1998-2017	Sureau, Alain/0000-0003-1523-0207; MERZAK, Abderrahim/0000-0002-7269-2224				BADING H, 1989, ONCOGENE, V4, P33; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BEARD JW, 1963, ADV CANCER RES, V7, P1, DOI 10.1016/S0065-230X(08)60982-3; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; DARLIX JL, 1982, J MOL BIOL, V160, P147, DOI 10.1016/0022-2836(82)90172-3; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLST A, 1988, CELL, V52, P355; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KRYCEVEMARTINER.C, 1987, NUCLEIC ACIDS RES, V15, P1329; KRYCEVEMARTINERIE C, 1987, FEBS LETT, V214, P81, DOI 10.1016/0014-5793(87)80017-0; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIPSICK JS, 1984, CANCER CELLS, V2, P143; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MELANI C, 1991, CANCER RES, V51, P2897; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI MG, 1983, P NATL ACAD SCI-BIOL, V80, P1421, DOI 10.1073/pnas.80.5.1421; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PERBAL B, 1985, J VIROL, V56, P240, DOI 10.1128/JVI.56.1.240-244.1985; PERBAL B, 1986, BIOCHIMIE, V68, P969, DOI 10.1016/S0300-9084(86)80040-2; PERBAL B, 1984, ADV VIRAL ONCOL, V4, P163; Perbal B., 1988, PRACTICAL GUIDE MOL; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SORET J, 1985, J VIROL, V55, P193, DOI 10.1128/JVI.55.1.193-205.1985; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; VALTIERI M, 1991, BLOOD, V77, P1181; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WASYLYK C, 1990, ONCOGENE, V5, P1055; ZASTROW G, 1989, NUCLEIC ACIDS RES, V17, P1867, DOI 10.1093/nar/17.5.1867	44	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					535	542						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549366				2022-12-17	WOS:A1992HK00500020
J	ESPINO, PC; CHOU, WY; SMITH, AE; CHENG, SH				ESPINO, PC; CHOU, WY; SMITH, AE; CHENG, SH			THE AMINO-TERMINAL HALF OF PP59C-FYN CONTAINS SEQUENCES NECESSARY FOR FORMATION OF A 75KDA FORM AND ALSO REPRESSIVE ELEMENTS ABSENT IN PP60C-SRC	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASES; MIDDLE-T-ANTIGEN; SIGNAL TRANSDUCTION; REGULATORY DOMAIN; COMPLEX-FORMATION; CARBOXY TERMINUS; PHOSPHOLIPASE-C; GENE-PRODUCT; SRC; PHOSPHORYLATION	Members of the src family of tyrosine kinases are composed of amino acid sequences which can be divided into three regions: the unique amino-terminal 80 residues; the next 180 residues of conserved but non-catalytic sequence; and the catalytic carboxy-terminal half of the molecule. To characterize the elements that regulate the catalytic and transforming activities of two members of this family, pp59c-fyn and pp60c-src, we generated six chimeric proteins by interchanging the three regions of the 531F mutant of pp59c-fyn and of the 527F mutant of pp60c-src. Our data indicate that substituting all or part of the amino-terminal 263 residues of pp59c-fyn for those of 527F inhibited the kinase and transforming activities of 527F. Conversely, substituting the amino-terminal half of pp60c-src for that of 531F resulted in an increase in the transforming potential of 531F. These results suggest that the amino-terminal half of pp59c-fyn contains elements which act to suppress the catalytic and transforming activities of the enzyme and that these suppressive elements are either absent or inactive in pp60c-src. These differences argue that the src family of tyrosine kinases are regulated differently in the cell. In vitro translation of some of the chimeras in rabbit reticulocyte lysates generated a 75kDa protein in addition to the expected 59kDa product. This 75kDa species is analogous to the p75 protein previously detected in wild-type pp59c-fyn translation products. Interestingly, formation of p75 required the presence of DNA sequences encoding the unique amino-terminal residues of pp59c-fyn.			ESPINO, PC (corresponding author), GENZYME CORP,CELLULAR REGULAT LAB,1 MT RD,FRAMINGHAM,MA 01701, USA.		Cheng, Seng H/AAC-6564-2022		NATIONAL CANCER INSTITUTE [P01CA050661, R01CA043186] Funding Source: NIH RePORTER; NCI NIH HHS [CA43186, CA50661] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; ESPINO PC, 1990, ONCOGENE, V5, P283; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; POTTER H, 1991, ALZHEIMERS DISEASE B, P276; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAMUELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0	33	3	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					317	322						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1372400				2022-12-17	WOS:A1992HG98200017
J	STETTER, G; BRAUN, MA; MONTENARH, M				STETTER, G; BRAUN, MA; MONTENARH, M			A NEW DNA-BINDING ASSAY TO STUDY SUBCLASSES OF SV40 LARGE T-ANTIGEN BINDING TO INDIVIDUAL BINDING-SITES ON THE SV40 DNA	ONCOGENE			English	Article							LARGE-TUMOR-ANTIGEN; SIMIAN-VIRUS 40; PRODUCTIVELY INFECTED-CELLS; ORIGIN DNA; SV40-TRANSFORMED CELLS; TRANSCRIPTION INVITRO; REPLICATION INVITRO; MUTATIONAL ANALYSIS; REGULATORY MUTANTS; CONTROL REGION	SV40 large T antigen interacts specifically with three different sequences, termed sites I, II or III, within the control region of the SV40 DNA to regulate transcription as well as the initiation and progress of SV40 DNA replication. We have biotinylated three different DNAs containing either site I, II or III and immobilized these constructs on a streptavidin agarose matrix. All three immobilized DNAs were shown to bind T antigen from a total cell extract of SV40 infected monkey cells although with different affinities. Pulse chase experiments revealed that newly synthesized T antigen bound efficiently to all three binding sites whereas mature T antigen bound only to site I and site III DNA. The analysis of non-binding and DNA-bound T antigen on sucrose density gradients showed that only low molecular weight forms of T antigen were bound to all three immobilized DNAs. However, incubation of T antigen in the total cell extract with site I DNA resulted in high molecular weight forms of T antigen, indicating that the presence of site I DNA influences the quaternary structure of T antigen which might result in a detachment from the DNA.	UNIV ULM,DEPT BIOCHEM,W-7900 ULM,GERMANY	Ulm University			Montenarh, Mathias/AAB-6689-2020					ARTHUR AK, 1988, J VIROL, V62, P1999, DOI 10.1128/JVI.62.6.1999-2006.1988; BRADLEY MK, 1984, P NATL ACAD SCI-BIOL, V81, P6574, DOI 10.1073/pnas.81.21.6574; BRADLEY MK, 1982, CELL, V28, P125, DOI 10.1016/0092-8674(82)90382-8; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, P99; DIMAIO D, 1980, J MOL BIOL, V140, P129, DOI 10.1016/0022-2836(80)90359-9; DIMAIO D, 1982, J MOL BIOL, V156, P531, DOI 10.1016/0022-2836(82)90265-0; DORN A, 1982, EUR J BIOCHEM, V128, P53; FANNING E, 1981, J VIROL, V37, P92, DOI 10.1128/JVI.37.1.92-102.1981; FANNING E, 1982, EMBO J, V1, P1023, DOI 10.1002/j.1460-2075.1982.tb01290.x; FIELDS BN, 1985, VIROLOGY; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIDONI D, 1982, J VIROL, V42, P456, DOI 10.1128/JVI.42.2.456-466.1982; GUO ZS, 1989, MOL CELL BIOL, V9, P3593, DOI 10.1128/MCB.9.9.3593; HANSEN U, 1981, CELL, V27, P603, DOI 10.1016/0092-8674(81)90402-5; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; JONES KA, 1984, EMBO J, V3, P3247, DOI 10.1002/j.1460-2075.1984.tb02286.x; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KLAUSING K, 1988, J VIROL, V62, P1258, DOI 10.1128/JVI.62.4.1258-1265.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEBLONDFRANCILLARD M, 1987, EUR J BIOCHEM, V166, P351, DOI 10.1111/j.1432-1033.1987.tb13522.x; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARGOLSKEE R, 1984, J VIROL, V49, P385; MASTRANGELO IA, 1985, P NATL ACAD SCI USA, V82, P3626, DOI 10.1073/pnas.82.11.3626; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MONTENARH M, 1983, J VIROL, V45, P531, DOI 10.1128/JVI.45.2.531-538.1983; MONTENARH M, 1986, FEBS LETT, V204, P51, DOI 10.1016/0014-5793(86)81386-2; MONTENARH M, 1980, FEBS LETT, V114, P107, DOI 10.1016/0014-5793(80)80870-2; MULLER D, 1987, VIROLOGY, V161, P81, DOI 10.1016/0042-6822(87)90173-5; Rigby P. W. J., 1983, ADV VIRAL ONCOL, V3, P31; RIO D, 1980, P NATL ACAD SCI-BIOL, V77, P5706, DOI 10.1073/pnas.77.10.5706; RUNZLER R, 1987, J VIROL, V61, P2076, DOI 10.1128/JVI.61.7.2076-2083.1987; SAWAI ET, 1989, J VIROL, V63, P3961, DOI 10.1128/JVI.63.9.3961-3973.1989; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1984, J VIROL, V50, P1; SCHELLER A, 1982, CELL, V29, P375, DOI 10.1016/0092-8674(82)90154-4; SCHIRMBECK R, 1988, VIROLOGY, V165, P527, DOI 10.1016/0042-6822(88)90597-1; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SCHURMANN C, 1985, VIROLOGY, V146, P1, DOI 10.1016/0042-6822(85)90047-9; SHALLOWAY D, 1980, CELL, V20, P411, DOI 10.1016/0092-8674(80)90627-3; SHORTLE DR, 1979, P NATL ACAD SCI USA, V76, P6128, DOI 10.1073/pnas.76.12.6128; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STETTER G, 1988, VIROLOGY, V164, P309, DOI 10.1016/0042-6822(88)90543-0; STETTER G, 1989, ONCOGENE, V4, P1353; TEGTMEYER P, 1983, J VIROL, V46, P151, DOI 10.1128/JVI.46.1.151-161.1983; TENEN DG, 1982, J MOL BIOL, V157, P473, DOI 10.1016/0022-2836(82)90472-7; TRAUT W, 1988, MOL CELL BIOL, V8, P903, DOI 10.1128/MCB.8.2.903; VOGT B, 1986, J VIROL, V58, P765, DOI 10.1128/JVI.58.3.765-772.1986; WACHTER M, 1985, J VIROL, V56, P520, DOI 10.1128/JVI.56.2.520-526.1985; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643	58	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					389	396						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1849245				2022-12-17	WOS:A1991FT34400006
J	HIRST, MC; PORTEOUS, DJ				HIRST, MC; PORTEOUS, DJ			MOLECULAR-CLONING OF A REARRANGED HRAS1 ONCOGENE IN CHROMOSOME MEDIATED GENE-TRANSFER ASSOCIATED WITH ELEVATED TUMORIGENICITY	ONCOGENE			English	Note							DNA-SEQUENCE ANALYSIS; TELOMERIC DNA; HAMSTER-CELLS; TUMOR DNAS; APRT LOCUS; BCR GENE; TRANSLOCATION; FRAGMENTS; REPEAT; UNIQUE	We describe the molecular cloning of the rearranged HRASI oncogene found in association with the increased tumorigenic potential of the chromosome mediated gene transfectant E65.5. The rearrangement occurs immediately 3' to the c-Ha-ras coding region, removing the variable numbered tandem repeat (VNTR) but not altering the HRASI transcription unit. The novel 3' DNA sequence contains a short open reading frame but shows no homology to any previously cloned elements. Sequence analysis identifies a number of short DNA motifs consistent with the activity of an aberrant recombinogenic mechanism.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			Porteous, David/AAA-3446-2021; Porteous, David J/C-7289-2013	Porteous, David/0000-0003-1249-6106; Porteous, David J/0000-0003-1249-6106; Hirst, Mark/0000-0003-3851-9740				ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BICKMORE W, 1988, NUCLEIC ACIDS RES, V16, P51, DOI 10.1093/nar/16.1.51; BISHOP JM, 1986, TRENDS GENET, V1, P245; BODRUG SE, 1987, SCIENCE, V237, P1620, DOI 10.1126/science.3629260; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; DEININGER PL, 1981, J MOL BIOL, V151, P17, DOI 10.1016/0022-2836(81)90219-9; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GOSDEN JR, 1987, CYTOGENET CELL GENET, V45, P44, DOI 10.1159/000132429; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HEISTERKAMP N, 1985, NATURE, V317, P559, DOI 10.1038/317559b0; HELMS C, 1985, DNA-J MOLEC CELL BIO, V4, P39, DOI 10.1089/dna.1985.4.39; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HOPE TJ, 1986, SCIENCE, V231, P1141, DOI 10.1126/science.3003919; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KRONTIRIS TG, 1981, P NATL ACAD SCI-BIOL, V78, P1181, DOI 10.1073/pnas.78.2.1181; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; LEHRMAN MA, 1985, SCIENCE, V227, P140, DOI 10.1126/science.3155573; Maniatis T., 1982, MOL CLONING; MORTEN JEN, 1987, ANTICANCER RES, V7, P573; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NALBANTOGLU J, 1988, J MOL BIOL, V200, P449, DOI 10.1016/0022-2836(88)90535-9; NALBANTOGLU J, 1987, MOL CELL BIOL, V7, P1445, DOI 10.1128/MCB.7.4.1445; PICOLLI SP, 1984, NATURE, V310, P327; PORTEOUS DJ, 1985, SOMAT CELL MOLEC GEN, V11, P445, DOI 10.1007/BF01534838; PORTEOUS DJ, 1986, INT J CANCER, V38, P603, DOI 10.1002/ijc.2910380422; PORTEOUS DJ, 1906, MOL CELL BIOL, V6, P2223; ROGERS J, 1985, NATURE, V317, P559, DOI 10.1038/317559a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHUANGYOUNG X, 1986, GENE ANAL TECH, V3, P90; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VANDERFELTZ MJM, 1989, NUCLEIC ACIDS RES, V17, P1, DOI 10.1093/nar/17.1.1; VANIN EF, 1983, CELL, V35, P701, DOI 10.1016/0092-8674(83)90103-4; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VIERA J, 1982, GENE, V19, P259; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WYMAN AR, 1985, P NATL ACAD SCI USA, V82, P2880, DOI 10.1073/pnas.82.9.2880	47	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					153	157						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1992442				2022-12-17	WOS:A1991EY03900022
J	MENEGUZZI, G; LATHE, R; KIENY, MP; VOGT, N				MENEGUZZI, G; LATHE, R; KIENY, MP; VOGT, N			THE E2 TRANS-ACTIVATING PROTEIN OF BOVINE PAPILLOMAVIRUS TYPE-1 (BPV1) IS SERINE-PHOSPHORYLATED INVIVO	ONCOGENE			English	Article									CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE; TRANSGENE SA,F-67000 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Transgene SA	MENEGUZZI, G (corresponding author), FAC SCI NICE,CTR BIOCHIM,INSERM,U273,F-06034 NICE,FRANCE.		Kieny, Marie-Paule/N-3914-2017; Kieny, Marie-Paule/Q-1238-2019	Kieny, Marie-Paule/0000-0002-5943-6488; Meneguzzi, Guerrino/0000-0002-1609-6540; Lathe, Richard/0000-0001-9698-9834				ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; BARBOSA MS, 1988, J VIROL, V62, P3242, DOI 10.1128/JVI.62.9.3242-3249.1988; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Dales S, 1981, Virol Monogr, V18, P1; DOSTATNI N, 1988, EMBO J, V7, P3807, DOI 10.1002/j.1460-2075.1988.tb03265.x; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; GUIZANI I, 1988, GENE, V73, P163, DOI 10.1016/0378-1119(88)90322-8; HAUGEN TH, 1988, EMBO J, V7, P4245, DOI 10.1002/j.1460-2075.1988.tb03322.x; HOWLEY PM, 1987, PAPOVAVIRIDAE, V2, P141; HOWLEYNELSON P, 1988, EMBO J, V7, P525; HUBBERT NL, 1988, P NATL ACAD SCI USA, V85, P5864, DOI 10.1073/pnas.85.16.5864; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; LAMBERT PF, 1989, GENE DEV, V3, P38, DOI 10.1101/gad.3.1.38; LATHE R, 1987, NATURE, V326, P878, DOI 10.1038/326878a0; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; MCBRIDE AA, 1988, EMBO J, V7, P533, DOI 10.1002/j.1460-2075.1988.tb02842.x; MCBRIDE AA, 1989, P NATL ACAD SCI USA, V86, P510, DOI 10.1073/pnas.86.2.510; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MOSKALUK C, 1987, P NATL ACAD SCI USA, V84, P1215, DOI 10.1073/pnas.84.5.1215; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; SMITH GL, 1984, BIOTECHNOL GENET ENG, V2, P383, DOI 10.1080/02648725.1984.10647806; SMOTKIN D, 1987, J VIROL, V61, P1686, DOI 10.1128/JVI.61.5.1686-1689.1987; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STAMATOS NM, 1987, J VIROL, V61, P516, DOI 10.1128/JVI.61.2.516-525.1987; STANWAY CA, 1989, NUCLEIC ACIDS RES, V17, P2187, DOI 10.1093/nar/17.6.2187; TUREK LP, 1987, PAPILLOMAVIRUSES HUM, P410; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030	34	3	3	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1285	1290						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2554235				2022-12-17	WOS:A1989AX65900003
J	SCHATZL, HM; VONDERHELM, K				SCHATZL, HM; VONDERHELM, K			V-SIS GENE (SSV) IS EXPRESSED TRANSIENTLY AND INDEPENDENTLY OF V-GAG (SSAV) AFTER INFECTION OF FIBROBLASTS WITH SSV SSAV	ONCOGENE			English	Article									UNIV MUNICH, MAX VONPETTENKOFER INST HYG & MED MICROBIOL, D-8000 MUNICH 2, GERMANY	University of Munich			Schatzl, Hermann/G-4958-2011	Schatzl, Hermann/0000-0003-4972-8740				ALITALO R, 1987, EMBO J, V6, P1213, DOI 10.1002/j.1460-2075.1987.tb02356.x; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BORN M, 1982, EMBO J, V1, P1029, DOI 10.1002/j.1460-2075.1982.tb01291.x; BOWENPOPE DF, 1984, P NATL ACAD SCI-BIOL, V81, P2396, DOI 10.1073/pnas.81.8.2396; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; CROCE CM, 1984, CANCER CELL, V2, P235; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DEINHARDT F, 1978, Z NATURFORSCH C, V33, P969; DEINHARDT F, 1980, VIRAL ONCOLOGY, P357; DELLAFAVERA R, 1981, NATURE, V292, P31; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FORSBERG K, 1988, J CELL PHYSIOL, V136, P266, DOI 10.1002/jcp.1041360208; GARRETT JS, 1984, P NATL ACAD SCI-BIOL, V81, P7466, DOI 10.1073/pnas.81.23.7466; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; JOHNSSON A, 1986, EMBO J, V5, P1535, DOI 10.1002/j.1460-2075.1986.tb04394.x; JOHNSSON A, 1985, P NATL ACAD SCI USA, V82, P1721, DOI 10.1073/pnas.82.6.1721; KELLY JM, 1985, EUR J BIOCHEM, V153, P367, DOI 10.1111/j.1432-1033.1985.tb09312.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRONKE M, 1987, P NATL ACAD SCI USA, V84, P469, DOI 10.1073/pnas.84.2.469; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MAKELA TP, 1987, MOL CELL BIOL, V7, P3656; Maniatis T., 1982, MOL CLONING; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER R, 1986, TRENDS BIOCHEM SCI, V11, P129, DOI 10.1016/0968-0004(86)90066-6; PANTAZIS P, 1986, P NATL ACAD SCI USA, V83, P6455, DOI 10.1073/pnas.83.17.6455; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; ROBBINS KC, 1981, P NATL ACAD SCI-BIOL, V78, P2918, DOI 10.1073/pnas.78.5.2918; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SELIGER B, 1987, J VIROL, V61, P2567, DOI 10.1128/JVI.61.8.2567-2572.1987; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WOLFE LG, 1971, JNCI-J NATL CANCER I, V47, P1115; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	52	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1989	4	9					1095	1101						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2550873				2022-12-17	WOS:A1989AM53100007
J	TALBOT, N; TAGLIAFERRI, P; YANAGIHARA, K; RHIM, JS; BASSIN, RH; BENADE, LE				TALBOT, N; TAGLIAFERRI, P; YANAGIHARA, K; RHIM, JS; BASSIN, RH; BENADE, LE			A PH-DEPENDENT DIFFERENTIAL CYTO-TOXICITY OF OUABAIN FOR HUMAN-CELLS TRANSFORMED BY CERTAIN ONCOGENES	ONCOGENE			English	Note									AMER TYPE CULTURE COLLECT,DEPT VIROL,ROCKVILLE,MD 20852; NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20205; NCI,TUMOR CELL BIOL LAB,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Tagliaferri, Pierosandro/K-9546-2016					BASSIN RH, 1984, CANCER CELL, V2, P463; BENADE LE, 1986, BIOCHEM BIOPH RES CO, V136, P807, DOI 10.1016/0006-291X(86)90512-7; CHANG KSS, 1976, CANCER RES, V36, P3294; CHO HY, 1978, INT J CANCER, V21, P22, DOI 10.1002/ijc.2910210106; CHO HY, 1976, SCIENCE, V194, P951, DOI 10.1126/science.62397; COOK DL, 1984, NATURE, V311, P269, DOI 10.1038/311269a0; GLYNN IM, 1964, PHARMACOL REV, V16, P381; HENDERSO.PJ, 1969, BIOCHEM J, V111, P521, DOI 10.1042/bj1110521; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LARKIN JM, 1985, J CELL PHYSIOL, V124, P372, DOI 10.1002/jcp.1041240303; LELIEVRE LG, 1985, EUR J BIOCHEM, V148, P13, DOI 10.1111/j.1432-1033.1985.tb08800.x; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MCALLISTER RM, 1971, CANCER-AM CANCER SOC, V27, P397, DOI 10.1002/1097-0142(197102)27:2<397::AID-CNCR2820270224>3.0.CO;2-X; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; PRESSMAN BC, 1967, P NATL ACAD SCI USA, V58, P1949, DOI 10.1073/pnas.58.5.1949; RACKER E, 1983, FED PROC, V42, P2899; RHIM JS, 1977, INT J CANCER, V19, P505, DOI 10.1002/ijc.2910190411; RHIM JS, 1975, INT J CANCER, V16, P840, DOI 10.1002/ijc.2910160516; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; RHIM JS, 1981, P SOC EXP BIOL MED, V167, P597; RHIM JS, 1982, P SOC EXP BIOL MED, V170, P350; ROSOFF PM, 1983, P NATL ACAD SCI-BIOL, V80, P7547, DOI 10.1073/pnas.80.24.7547; Rozengurt E, 1980, Ann N Y Acad Sci, V339, P175, DOI 10.1111/j.1749-6632.1980.tb15977.x; SCHULDINER S, 1982, P NATL ACAD SCI-BIOL, V79, P7778, DOI 10.1073/pnas.79.24.7778; SHEN SS, 1980, EXP CELL RES, V125, P55, DOI 10.1016/0014-4827(80)90188-3; SKOU JC, 1957, BIOCHIM BIOPHYS ACTA, V23, P394, DOI 10.1016/0006-3002(57)90343-8; SMITH RL, 1982, J BIOL CHEM, V257, P773; STEINHARDT RA, 1973, NATURE, V241, P400, DOI 10.1038/241400a0; TAGLIAFERRI P, IN PRESS INT J CANCE; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; ZACHOWSKI A, 1977, P NATL ACAD SCI USA, V74, P633, DOI 10.1073/pnas.74.2.633	33	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					23	26						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400004
J	BOUCHARD, L; MATHIEU, F; BASTIN, M				BOUCHARD, L; MATHIEU, F; BASTIN, M			POLYOMA LARGE T CAN ACTIVATE MIDDLE T EXPRESSION BY A HIT-AND-RUN MECHANISM	ONCOGENE			English	Article									UNIV SHERBROOKE, DEPT MICROBIOL, SHERBROOKE J1H 5N4, QUEBEC, CANADA	University of Sherbrooke								ALT FW, 1978, J BIOL CHEM, V253, P1357; ALWINE JC, 1985, MOL CELL BIOL, V5, P1034, DOI 10.1128/MCB.5.5.1034; ASSELIN C, 1986, J VIROL, V57, P165, DOI 10.1128/JVI.57.1.165-172.1986; ASSELIN C, 1984, MOL CELL BIOL, V4, P755, DOI 10.1128/MCB.4.4.755; ASSELIN C, 1983, MOL CELL BIOL, V3, P1451, DOI 10.1128/MCB.3.8.1451; BIRD AP, 1980, GENE REITERATION GEN, V3, P61; BOUCHARD L, 1986, VIROLOGY, V155, P1, DOI 10.1016/0042-6822(86)90162-5; BOUCHARD L, 1984, VIROLOGY, V135, P53, DOI 10.1016/0042-6822(84)90116-8; BOUCHARD L, 1987, J VIROL, V61, P2448, DOI 10.1128/JVI.61.8.2448-2453.1987; BRADY J, 1984, P NATL ACAD SCI-BIOL, V81, P2040, DOI 10.1073/pnas.81.7.2040; COLBY WW, 1982, P NATL ACAD SCI-BIOL, V79, P5189, DOI 10.1073/pnas.79.17.5189; CROCE CM, 1985, BLOOD, V65, P1; CUZIN F, 1984, BIOCHIM BIOPHYS ACTA, V781, P193, DOI 10.1016/0167-4781(84)90084-8; FRIED M, 1965, VIROLOGY, V25, P669, DOI 10.1016/0042-6822(65)90098-X; GELINAS C, 1985, VIROLOGY, V146, P233, DOI 10.1016/0042-6822(85)90007-8; GREEN AR, 1986, EMBO J, V5, P707, DOI 10.1002/j.1460-2075.1986.tb04271.x; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; GRIFFIN BE, 1983, ADV CANCER RES, V39, P183, DOI 10.1016/S0065-230X(08)61036-2; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; IMPERIALE MJ, 1983, CELL, V35, P127, DOI 10.1016/0092-8674(83)90215-5; ITO Y, 1977, P NATL ACAD SCI USA, V74, P1259, DOI 10.1073/pnas.74.3.1259; KAMEN R, 1979, COLD SPRING HARB SYM, V44, P63, DOI 10.1101/SQB.1980.044.01.009; KELLER JM, 1984, CELL, V36, P381, DOI 10.1016/0092-8674(84)90231-9; KIMURA G, 1975, NATURE, V253, P639, DOI 10.1038/253639b0; KINGSTON RE, 1985, CELL, V41, P3, DOI 10.1016/0092-8674(85)90049-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; NOTTENBURG C, 1987, J VIROL, V61, P1828, DOI 10.1128/JVI.61.6.1828-1833.1987; PICHE A, 1987, J VIROL, V61, P845; RABBITTS TH, 1983, NATURE, V306, P806, DOI 10.1038/306806a0; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; RASSOULZADEGAN M, 1978, J VIROL, V28, P421, DOI 10.1128/JVI.28.2.421-426.1978; RASSOULZADEGAN M, 1981, VIROLOGY, V114, P489, DOI 10.1016/0042-6822(81)90228-2; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RULEY HE, 1982, NUCLEIC ACIDS RES, V10, P4515, DOI 10.1093/nar/10.15.4515; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SMOLAR N, 1981, J VIROL, V38, P958, DOI 10.1128/JVI.38.3.958-967.1981; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOW ND, 1976, J GEN VIROL, V33, P447, DOI 10.1099/0022-1317-33-3-447; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; WAHL GM, 1979, J BIOL CHEM, V254, P8679; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	45	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1988	2	4					379	386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3362552				2022-12-17	WOS:A1988M947200010
J	Hu, XS; Liu, RC; Hou, JB; Peng, W; Wan, SC; Xu, MH; Li, YS; Zhang, GH; Zhai, X; Liang, P; Cui, HJ				Hu, Xiaosong; Liu, Ruochen; Hou, Jianbing; Peng, Wen; Wan, Sicheng; Xu, Minghao; Li, Yongsen; Zhang, Guanghui; Zhai, Xuan; Liang, Ping; Cui, Hongjuan			SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation	ONCOGENE			English	Article							N-MYC; THERAPEUTIC TARGET; DNA-BINDING; GENE; EXPRESSION; COMPLEX; PROTEIN; STABILIZATION; PROLIFERATION; AMPLIFICATION	SMARCE1 gene, encoding a core subunit of SWI/SNF chromatin remodeling complex, is situated on chromosome 17q21-ter region that is frequently gained in neuroblastoma. However, its role in the tumorigenesis remains unknown. Here, we showed that high expression of SMARCE1 was associated with poor prognosis of patients with neuroblastoma, especially those with MYCN amplification. Knockdown of SMARCE1 reduced proliferation, colony formation, and tumorigenicity of neuroblastoma cells. Mechanistically, SMARCE1 directly interacted with MYCN, which was necessary for MYCN-mediated transcriptional activation of downstream target genes including PLK1, ODC1, and E2F2. Overexpression of PLK1, ODC1 or E2F2 significantly reversed the inhibiting effect of SMARCE1 knockdown on the proliferation, colony formation, and tumorigenicity of MYCN-amplified neuroblastoma cells. Moreover, we revealed that MYCN directly regulated SMARCE1 transcription through binding to a non-canonical E-box of SMARCE1 promoter, thus enhancing SMARCE1-MYCN cooperativity. These findings establish SMARCE1 is a critical oncogenic factor in neuroblastoma and provide a new potential target for treatment of neuroblastoma with 17q21-ter gain and MYCN amplification.	[Hu, Xiaosong; Liu, Ruochen; Hou, Jianbing; Peng, Wen; Wan, Sicheng; Xu, Minghao; Li, Yongsen; Zhang, Guanghui; Cui, Hongjuan] Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China; [Hu, Xiaosong; Liu, Ruochen; Hou, Jianbing; Peng, Wen; Wan, Sicheng; Xu, Minghao; Li, Yongsen; Zhang, Guanghui; Cui, Hongjuan] Southwest Univ, Canc Ctr, Med Res Inst, Chongqing 400716, Peoples R China; [Zhai, Xuan; Liang, Ping] Chongqing Med Univ, Childrens Hosp, Dept Neurosurg, Chongqing 400014, Peoples R China; [Zhai, Xuan; Liang, Ping] Chongqing Key Lab Pediat, Chongqing 400010, Peoples R China	Southwest University - China; Southwest University - China; Chongqing Medical University	Cui, HJ (corresponding author), Southwest Univ, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China.; Cui, HJ (corresponding author), Southwest Univ, Canc Ctr, Med Res Inst, Chongqing 400716, Peoples R China.; Liang, P (corresponding author), Chongqing Med Univ, Childrens Hosp, Dept Neurosurg, Chongqing 400014, Peoples R China.; Liang, P (corresponding author), Chongqing Key Lab Pediat, Chongqing 400010, Peoples R China.	pingliangnet@163.com; hcui@swu.edu.cn		Xu, Minghao/0000-0003-0535-8231	Natural Science Foundation of Chongqing [cstc2019jcyj-zdxmX0033, cstc2022ycjh-bgzxm0145]; pilot program of Southwest University [SWU-XDZD22006]	Natural Science Foundation of Chongqing(Natural Science Foundation of Chongqing); pilot program of Southwest University	This research was supported by the Natural Science Foundation of Chongqing (cstc2019jcyj-zdxmX0033, cstc2022ycjh-bgzxm0145), the pilot program of Southwest University (SWU-XDZD22006).	Albihn A, 2010, ADV CANCER RES, V107, P163, DOI 10.1016/S0065-230X(10)07006-5; Amente S, 2015, ONCOTARGET, V6, P14572, DOI 10.18632/oncotarget.3990; Amente S, 2011, NUCLEIC ACIDS RES, V39, P9498, DOI 10.1093/nar/gkr638; Baluapuri A, 2020, NAT REV MOL CELL BIO, V21, P255, DOI 10.1038/s41580-020-0215-2; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bell E, 2010, CANCER LETT, V293, P144, DOI 10.1016/j.canlet.2010.01.015; Bell JL, 2015, J CLIN ONCOL, V33, P1285, DOI 10.1200/JCO.2014.55.9880; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bourdeaut F, 2009, J PATHOL, V219, P463, DOI 10.1002/path.2614; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Burkhart CA, 2003, J NATL CANCER I, V95, P1394, DOI 10.1093/jnci/djg045; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Clapier CR, 2017, NAT REV MOL CELL BIO, V18, P407, DOI 10.1038/nrm.2017.26; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; Davis CA, 2018, NUCLEIC ACIDS RES, V46, pD794, DOI 10.1093/nar/gkx1081; DIAS P, 1990, INT J CANCER, V45, P593, DOI 10.1002/ijc.2910450403; Duffy DJ, 2018, GENE REP, V12, P187, DOI 10.1016/j.genrep.2018.06.018; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Fetahu IS, 2021, CANCER METAST REV, V40, P173, DOI 10.1007/s10555-020-09946-y; Gryder BE, 2017, CANCER DISCOV, V7, P884, DOI 10.1158/2159-8290.CD-16-1297; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Heo Y, 2020, BIOCHEM BIOPH RES CO, V533, P919, DOI 10.1016/j.bbrc.2020.09.094; Hogarty MD, 2008, CANCER RES, V68, P9735, DOI 10.1158/0008-5472.CAN-07-6866; Hou J, 2017, ONCOGENE, V36, P1134, DOI 10.1038/onc.2016.280; Hu XS, 2022, BIOCHEM BIOPH RES CO, V599, P148, DOI 10.1016/j.bbrc.2022.01.124; Huang M, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014415; Hui ABY, 2001, LAB INVEST, V81, P717, DOI 10.1038/labinvest.3780280; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Krstic A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.612518; Kumar P, 2020, SEMIN CANCER BIOL, V67, P105, DOI 10.1016/j.semcancer.2019.06.016; Lee TH, 2009, NAT CELL BIOL, V11, P97, DOI 10.1038/ncb1818; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; Li YS, 2021, MEDCOMM, V2, P467, DOI 10.1002/mco2.73; Mao L, 2011, CANCER RES, V71, P4314, DOI 10.1158/0008-5472.CAN-11-0051; Mastronikolis N, 2019, J BUON, V24, P2242; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Monclair T, 2009, J CLIN ONCOL, V27, P298, DOI 10.1200/JCO.2008.16.6876; Nagy Z, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22143-x; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Nakayama RT, 2017, NAT GENET, V49, P1613, DOI 10.1038/ng.3958; NISEN PD, 1986, CANCER RES, V46, P6217; O'Neill S, 2001, GENE CHROMOSOME CANC, V30, P87, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1055>3.0.CO;2-J; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Peng W, 2022, ONCOGENE, V41, P3051, DOI 10.1038/s41388-022-02296-9; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Rust K, 2018, EMBO J, V37, DOI 10.15252/embj.201798659; Sethuraman A, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0738-9; Sokol ES, 2017, P NATL ACAD SCI USA, V114, P4153, DOI 10.1073/pnas.1703931114; Sun JR, 2018, J INVEST DERMATOL, V138, P1795, DOI 10.1016/j.jid.2018.02.028; Tonelli R, 2005, MOL CANCER THER, V4, P779, DOI 10.1158/1535-7163.MCT-04-0213; Tsukiyama T, 2002, NAT REV MOL CELL BIO, V3, P422, DOI 10.1038/nrm828; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wan M, 2009, EUR J IMMUNOL, V39, P580, DOI 10.1002/eji.200838909; Wattler F, 1999, GENOMICS, V60, P172, DOI 10.1006/geno.1999.5913; Wei JC, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00176; WENZEL A, 1995, EUR J CANCER, V31A, P516, DOI 10.1016/0959-8049(95)00060-V; Wong M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11132-w; Wong M, 2017, CANCER RES, V77, P2522, DOI 10.1158/0008-5472.CAN-16-1663; Xiao DB, 2016, MOL CELL, V64, P493, DOI 10.1016/j.molcel.2016.09.016; Yang R, 2020, ONCOGENE, V39, P2975, DOI 10.1038/s41388-020-1199-2; Zafar AT, 2021, MED RES REV, V41, P961, DOI 10.1002/med.21750; Zeid R, 2018, NAT GENET, V50, P515, DOI 10.1038/s41588-018-0044-9; Zhang K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1086-8; Zhang WW, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0581-9	74	2	2	9	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4295	4306		10.1038/s41388-022-02428-1	http://dx.doi.org/10.1038/s41388-022-02428-1		AUG 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35978151				2022-12-17	WOS:000843817400001
J	Li, ZW; Li, BH; Yu, HY; Wang, PF; Wang, WW; Hou, PF; Li, ML; Chu, SF; Zheng, JN; Mao, LJ; Bai, J				Li, Zhongwei; Li, Bingheng; Yu, Haiyuan; Wang, Pengfei; Wang, Wenwen; Hou, Pingfu; Li, Minle; Chu, Sufang; Zheng, Junnian; Mao, Lijun; Bai, Jin			DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability	ONCOGENE			English	Article							METHYLATION; DEGRADATION	A plethora of studies have shown that both DNMT1 and EZH2 have great effects on the progression of a variety of cancers. However, it remains unclear whether the expression profiles of these two epigenetic enzymes are molecularly intertwined in prostate cancer (PC), especially in castration-resistant prostate cancer (CRPC). Here, we found that DNMT1 is highly expressed and facilitates PC cell proliferation and migration. Importantly, we demonstrate that the abrogation of DNMT1 expression can induce the decreased expression of EZH2, resulting in the less aggressive capacity of PC cells. Mechanistically, we discovered that DNMT1 promotes PC tumorigenesis and metastasis by inhibiting TRAF6 transcriptional expression and subsequent TRAF6-mediated EZH2 ubiquitination. Finally, we confirmed that there is a negative correlation between DNMT1 and TRAF6 expression and a positive correlation between DNMT1 and EZH2 expression in PC patients. In this study, we first disclose that there is a direct crosstalk between DNA methyltransferase DNMT1 expression and histone methyltransferase EZH2 expression in tumorigenesis and cancer metastasis in vitro and in vivo. Our results also show that targeting DNMT1 with its inhibitor decitabine (an FDA-approved drug) is an appealing treatment strategy for CRPC patients through epigenetic suppression of both DNMT1-mediated DNA methylation and EZH2-modulated histone methylation.	[Li, Zhongwei; Li, Bingheng; Yu, Haiyuan; Wang, Pengfei; Wang, Wenwen; Hou, Pingfu; Li, Minle; Chu, Sufang; Zheng, Junnian; Mao, Lijun; Bai, Jin] Xuzhou Med Univ, Canc Inst, Xuzhou, Jiangsu, Peoples R China; [Li, Zhongwei; Hou, Pingfu; Li, Minle; Zheng, Junnian; Bai, Jin] Xuzhou Med Univ, Affiliated Hosp, Ctr Clin Oncol, Xuzhou, Jiangsu, Peoples R China; [Li, Zhongwei; Hou, Pingfu; Li, Minle; Zheng, Junnian; Bai, Jin] Xuzhou Med Univ, Canc Inst, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Xuzhou, Jiangsu, Peoples R China; [Mao, Lijun] Xuzhou Med Univ, Affiliated Hosp, Dept Urinary Surg, Xuzhou, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University; Xuzhou Medical University; Xuzhou Medical University	Zheng, JN; Mao, LJ; Bai, J (corresponding author), Xuzhou Med Univ, Canc Inst, Xuzhou, Jiangsu, Peoples R China.; Zheng, JN; Bai, J (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Ctr Clin Oncol, Xuzhou, Jiangsu, Peoples R China.; Zheng, JN; Bai, J (corresponding author), Xuzhou Med Univ, Canc Inst, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Xuzhou, Jiangsu, Peoples R China.; Mao, LJ (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Dept Urinary Surg, Xuzhou, Jiangsu, Peoples R China.	jnzheng@xzhmu.edu.cn; mljmlj05@126.com; bj@xzhmu.edu.cn		Li, Zhongwei/0000-0003-1014-4238; Zheng, Junnian/0000-0003-0208-6410	National Natural Science Foundation of China [82173060, 82072649]; Outstanding Youth Foundation of Jiangsu Province [BK20200046]; National Postdoctoral Research Funds of China [2019M651971, 2021T140577]; Postgraduate Research & Practice Innovation Program of Jiangsu [KYCX21_2689]; Jiangsu Provincial Key Medical Discipline; Project of Invigorating Health Care through Science, Technology and Education [ZDXKA2016014]; Qinglan Project of Jiangsu	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Outstanding Youth Foundation of Jiangsu Province; National Postdoctoral Research Funds of China; Postgraduate Research & Practice Innovation Program of Jiangsu; Jiangsu Provincial Key Medical Discipline; Project of Invigorating Health Care through Science, Technology and Education; Qinglan Project of Jiangsu	This work was supported by grants from the National Natural Science Foundation of China (82173060 and 82072649), the Outstanding Youth Foundation of Jiangsu Province (BK20200046), the National Postdoctoral Research Funds of China (2019M651971 and 2021T140577), the Postgraduate Research & Practice Innovation Program of Jiangsu (KYCX21_2689), the Jiangsu Provincial Key Medical Discipline, the Project of Invigorating Health Care through Science, Technology and Education (NO. ZDXKA2016014) and the Qinglan Project of Jiangsu.	Agarwal S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-99; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Bai J, 2019, P NATL ACAD SCI USA, V116, P11754, DOI 10.1073/pnas.1820990116; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Chen XT, 2021, CANCER LETT, V508, P115, DOI 10.1016/j.canlet.2021.03.023; Dhillon S, 2020, DRUGS, V80, P1373, DOI 10.1007/s40265-020-01389-7; DiNardo CD, 2019, BLOOD, V133, P7, DOI 10.1182/blood-2018-08-868752; Garcia-Manero G, 2020, BLOOD, V136, P674, DOI 10.1182/blood.2019004143; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Klutstein M, 2016, CANCER RES, V76, P3446, DOI 10.1158/0008-5472.CAN-15-3278; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li Z, 2016, CELL DEATH DIFFER, V23, P583, DOI 10.1038/cdd.2015.125; Li ZW, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04381-5; Li ZW, 2020, BIOCHEM BIOPH RES CO, V533, P679, DOI 10.1016/j.bbrc.2020.10.037; Li ZW, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00505-0; Li ZW, 2020, CELL DEATH DIFFER, V27, P3226, DOI 10.1038/s41418-020-00615-9; Li ZW, 2017, ONCOTARGET, V8, P67329, DOI 10.18632/oncotarget.18622; Liu H, 2020, CELL DEATH DIFFER, V27, P966, DOI 10.1038/s41418-019-0389-3; Lyko F, 2018, NAT REV GENET, V19, P81, DOI 10.1038/nrg.2017.80; Mao LJ, 2021, J CANCER, V12, P1846, DOI 10.7150/jca.46868; Montesinos P, 2021, LEUKEMIA, V35, P62, DOI 10.1038/s41375-020-0773-5; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Teo MY, 2019, ANNU REV MED, V70, P479, DOI 10.1146/annurev-med-051517-011947; Tzelepi V, 2020, PATHOLOGY, V52, P218, DOI 10.1016/j.pathol.2019.10.006; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wong KK, 2021, SEMIN CANCER BIOL, V72, P198, DOI 10.1016/j.semcancer.2020.05.010; Yu J, 2018, J CLIN INVEST, V128, P2376, DOI 10.1172/JCI97924; Zhu AP, 2021, CARCINOGENESIS, V42, P220, DOI 10.1093/carcin/bgaa088	28	2	2	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2022	41	33					3991	4002		10.1038/s41388-022-02404-9	http://dx.doi.org/10.1038/s41388-022-02404-9		JUL 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T2HP	35804015				2022-12-17	WOS:000824972000001
J	Thirusangu, P; Ray, U; Bhattacharya, SS; Oien, DB; Jin, L; Staub, J; Kannan, N; Molina, JR; Shridhar, V				Thirusangu, Prabhu; Ray, Upasana; Bhattacharya, Sayantani Sarkar; Oien, Derek B.; Jin, Ling; Staub, Julie; Kannan, Nagarajan; Molina, Julian R.; Shridhar, Viji			PFKFB3 regulates cancer stemness through the hippo pathway in small cell lung carcinoma	ONCOGENE			English	Article							RESISTANCE PROTEIN BCRP/ABCG2; EXPRESSION	PFKFB3 (6-phosphofructo-2-kinase) is the rate-limiting enzyme of glycolysis and is overexpressed in several human cancers that are associated with poor prognosis. High PFKFB3 expression in cancer stem cells promotes glycolysis and survival in the tumor microenvironment. Inhibition of PFKFB3 by the glycolytic inhibitor PFK158 and by shRNA stable knockdown in small cell lung carcinoma (SCLC) cell lines inhibited glycolysis, proliferation, spheroid formation, and the expression of cancer stem cell markers CD133, Aldh1, CD44, Sox2, and ABCG2. These factors are also associated with chemotherapy resistance. We found that PFK158 treatment and PFKFB3 knockdown enhanced the ABCG2-interacting drugs doxorubicin, etoposide, and 5-fluorouracil in reducing cell viability under conditions of enriched cancer stem cells (CSC). Additionally, PFKFB3 inhibition attenuated the invasion/migration of SCLC cells by downregulating YAP/TAZ signaling while increasing pLATS1 via activation of pMST1 and NF2 and by reducing the mesenchymal protein expression. PFKFB3 knockdown and PFK158 treatment in a H1048 SCLC cancer stem cell-enriched mouse xenograft model showed significant reduction in tumor growth and weight with reduced expression of cancer stem cell markers, ABCG2, and YAP/TAZ. Our findings identify that PFKFB3 is a novel target to regulate cancer stem cells and its associated therapeutic resistance markers YAP/TAZ and ABCG2 in SCLC models.	[Thirusangu, Prabhu; Ray, Upasana; Bhattacharya, Sayantani Sarkar; Oien, Derek B.; Jin, Ling; Staub, Julie; Shridhar, Viji] Mayo Clin, Dept Expt Pathol & Med, Rochester, MN 55905 USA; [Kannan, Nagarajan] Mayo Clin, Ctr Regenerat Med, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN USA; [Molina, Julian R.] Mayo Clin, Dept Med Oncol, Rochester, MN USA; [Oien, Derek B.] AstraZeneca, Oncol R&D, Boston, MA USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; AstraZeneca	Shridhar, V (corresponding author), Mayo Clin, Dept Expt Pathol & Med, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Oien, Derek B/ABF-3114-2021; Sarkar Bhattacharya, Sayantani/AAG-6222-2020	Oien, Derek B/0000-0002-0730-5654; Sarkar Bhattacharya, Sayantani/0000-0001-8971-7566; Ray, Upasana/0000-0002-9804-6888	Department of Defense (DOD) [W81XWH-18-1-0504]; Department of Experimental Pathology and Laboratory, Mayo Clinic, United States	Department of Defense (DOD)(United States Department of Defense); Department of Experimental Pathology and Laboratory, Mayo Clinic, United States	This work was supported by grant from the Department of Defense (DOD) (W81XWH-18-1-0504) to V.S., Department of Experimental Pathology and Laboratory, Mayo Clinic, United States.	Altan M, 2015, CANCER J, V21, P425, DOI 10.1097/PPO.0000000000000148; Ashrafian H, 2006, LANCET, V367, P618, DOI 10.1016/S0140-6736(06)68228-7; Atsumi T, 2002, CANCER RES, V62, P5881; Avin BRV, 2014, EUR J MED CHEM, V75, P211, DOI 10.1016/j.ejmech.2014.01.050; Begicevic RR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112362; Bhattacharya SS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1916-3; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; Codony-Servat J, 2016, TRANSL LUNG CANCER R, V5, P16, DOI 10.3978/j.issn.2218-6751.2016.01.01; Dai YY, 2017, ONCOTARGET, V8, P4096, DOI 10.18632/oncotarget.13686; Fan FQ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2304; Gatti L, 2009, MINI-REV MED CHEM, V9, P1102, DOI 10.2174/138955709788922656; Gong J, 2018, J ONCOL PRACT, V14, P359, DOI 10.1200/JOP.18.00204; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Jung D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20531-w; Klameth L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05562-z; LeBlanc L, 2021, CELL MOL LIFE SCI, V78, P4201, DOI 10.1007/s00018-021-03781-2; Li HM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0481-1; Lu L, 2017, ONCOTARGET, V8, P62793, DOI 10.18632/oncotarget.19513; MacDonagh L, 2016, CANCER LETT, V372, P147, DOI [10.1016/j.canlet.2016,01.012, 10.1016/j.canlet.2016.01.012]; Mao QC, 2015, AAPS J, V17, P65, DOI 10.1208/s12248-014-9668-6; Matak D, 2017, CYTOTECHNOLOGY, V69, P565, DOI 10.1007/s10616-016-0063-2; Minchenko OH, 2014, WORLD J GASTROENTERO, V20, P13705, DOI 10.3748/wjg.v20.i38.13705; Mondal S, 2019, INT J CANCER, V144, P178, DOI 10.1002/ijc.31868; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nakanishi T, 2012, CHIN J CANCER, V31, P73, DOI 10.5732/cjc.011.10320; Natarajan K, 2012, BIOCHEM PHARMACOL, V83, P1084, DOI 10.1016/j.bcp.2012.01.002; Noguchi K, 2009, ADV DRUG DELIVER REV, V61, P26, DOI 10.1016/j.addr.2008.07.003; Park JH, 2018, MOL CELLS, V41, P83, DOI 10.14348/molcells.2018.2242; Plouffe SW, 2016, MOL CELL, V64, P993, DOI 10.1016/j.molcel.2016.10.034; Qin A, 2018, J ONCOL PRACT, V14, P369, DOI 10.1200/JOP.18.00278; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Shi LL, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.44; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Song J, 2018, ONCOL LETT, V16, P3949, DOI 10.3892/ol.2018.9141; Thirusangu P, 2020, CHRONIC LUNG DIS PAT, P129; Thirusangu P, 2021, CANCERS, V13, DOI 10.3390/cancers13092004; Thirusangu P, 2017, ANGIOGENESIS, V20, P55, DOI 10.1007/s10456-016-9528-3; Thirusangu P, 2017, BIOCHEM PHARMACOL, V125, P26, DOI 10.1016/j.bcp.2016.11.009; Verma S, 2019, P NATL ACAD SCI USA, V116, P7363, DOI 10.1073/pnas.1822155116; Vinci M, 2015, JOVE-J VIS EXP, DOI 10.3791/52686; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warren JSA, 2018, CANCERS, V10, DOI 10.3390/cancers10040115; Xiao YN, 2021, ONCOGENE, V40, P1409, DOI 10.1038/s41388-020-01621-4; Yadav UP, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01010; Yamaguchi H, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00928; Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025; Yuan JH, 2009, CANCER CHEMOTH PHARM, V63, P1103, DOI 10.1007/s00280-008-0838-z; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhu X, 2020, WORLD J STEM CELLS, V12, P448, DOI 10.4252/wjsc.v12.i6.448	50	2	2	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2022	41	33					4003	4017		10.1038/s41388-022-02391-x	http://dx.doi.org/10.1038/s41388-022-02391-x		JUL 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T2HP	35804016	hybrid, Green Published			2022-12-17	WOS:000824972000002
J	Zhang, MX; Wang, JL; Mo, CQ; Mao, XP; Feng, ZH; Li, JY; Lin, HS; Song, HD; Xu, QH; Wang, YH; Lu, J; Wei, JH; Han, H; Chen, W; Mao, HP; Luo, JH; Chen, ZH				Zhang, Ming-xiao; Wang, Jia-li; Mo, Cheng-qiang; Mao, Xiao-peng; Feng, Zi-hao; Li, Jia-ying; Lin, Hai-shan; Song, Hong-de; Xu, Quan-hui; Wang, Ying-han; Lu, Jun; Wei, Jin-huan; Han, Hui; Chen, Wei; Mao, Hai-ping; Luo, Jun-hang; Chen, Zhen-hua			CircME1 promotes aerobic glycolysis and sunitinib resistance of clear cell renal cell carcinoma through cis-regulation of ME1	ONCOGENE			English	Article							CANCER PROGRESSION; CONTRIBUTES; METASTASIS; MYC	Circular RNAs (circRNAs) play critical roles in clear cell renal cell carcinoma (ccRCC). However, their involvement in sunitinib resistance remains largely unknown. Herein, we identified a novel circRNA, named circME1, which contributes to sunitinib resistance development in ccRCC. CircME1 also promoted proliferation, migration, and invasion of ccRCC cells. Further mechanism analysis showed that circME1 interacted with U1 snRNP at the promoter of its parental gene ME1, thereby upregulating the expression of ME1, enhancing aerobic glycolysis of ccRCC, and promoting its malignant phenotype. Furthermore, ME1 specific inhibitor could effectively repress the oncogenic functions of circME1. Taken together, our study demonstrates that the circME1/ME1 pathway is involved in ccRCC progression and sunitinib resistance development, which may be exploited for anticancer therapy.	[Zhang, Ming-xiao; Mo, Cheng-qiang; Mao, Xiao-peng; Feng, Zi-hao; Li, Jia-ying; Lin, Hai-shan; Song, Hong-de; Xu, Quan-hui; Wang, Ying-han; Lu, Jun; Wei, Jin-huan; Chen, Wei; Luo, Jun-hang; Chen, Zhen-hua] Sun Yat sen Univ, Affiliated Hosp 1, Dept Urol, 58 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China; [Wang, Jia-li; Mao, Hai-ping] Sun Yat sen Univ, Affiliated Hosp 1, Dept Nephrol, 58 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China; [Han, Hui] Sun Yat sen Univ, Ctr Canc, Dept Urol, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China; [Luo, Jun-hang] Sun Yat sen Univ, Affiliated Hosp 1, Inst Precis Med, 58 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Luo, JH; Chen, ZH (corresponding author), Sun Yat sen Univ, Affiliated Hosp 1, Dept Urol, 58 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China.; Mao, HP (corresponding author), Sun Yat sen Univ, Affiliated Hosp 1, Dept Nephrol, 58 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China.; Luo, JH (corresponding author), Sun Yat sen Univ, Affiliated Hosp 1, Inst Precis Med, 58 Zhongshan 2nd Rd, Guangzhou 510080, Peoples R China.	maohp@mail.sysu.edu.cn; luojunh@mail.sysu.edu.cn; chenzhh75@mail.sysu.edu.cn			National Natural Science Foundation of China [81902576, 81725016, 81872094, 82002684]; Natural Science Foundation of Guangdong Province, China [2017B020227004, 2017A030313538]; China Postdoctoral Science Foundation [2020M683082]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (Nos. 81902576, 81725016, 81872094 and 82002684), the Natural Science Foundation of Guangdong Province, China (2017B020227004 and 2017A030313538), and China Postdoctoral Science Foundation Funded Project (No. 2020M683082).	Adelaiye-Ogala R, 2017, CANCER RES, V77, P6651, DOI 10.1158/0008-5472.CAN-17-0899; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Cao SB, 2019, ONCOGENE, V38, P7060, DOI 10.1038/s41388-019-0947-7; Chen Q, 2020, CANCER LETT, V469, P68, DOI 10.1016/j.canlet.2019.10.017; Chen RX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12651-2; Chen X, 2018, CLIN CANCER RES, V24, P6319, DOI 10.1158/1078-0432.CCR-18-1270; Chow LQM, 2007, J CLIN ONCOL, V25, P884, DOI 10.1200/JCO.2006.06.3602; Conn VM, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.53; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Escudier B, 2007, DRUGS, V67, P1257, DOI 10.2165/00003495-200767090-00002; Frank I, 2003, J UROLOGY, V170, P2225, DOI 10.1097/01.ju.0000095541.10333.a7; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; He JH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1120-1; He RF, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0614-1; Li JF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01225-2; Li Q, 2019, HEPATOLOGY, V70, P1298, DOI 10.1002/hep.30671; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liang WC, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1685-4; Liang YK, 2021, MOL THER-NUCL ACIDS, V23, P355, DOI 10.1016/j.omtn.2020.11.012; Liao RC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35106-y; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Ljungberg B, 2019, EUR UROL, V75, P799, DOI 10.1016/j.eururo.2019.02.011; Lu YX, 2018, CANCER RES, V78, P1972, DOI 10.1158/0008-5472.CAN-17-3155; Molina AM, 2014, EUR J CANCER, V50, P351, DOI 10.1016/j.ejca.2013.08.021; Nakashima C, 2018, CANCER SCI, V109, P2036, DOI 10.1111/cas.13594; Oudard S, 2007, ANN ONCOL, V18, P25, DOI 10.1093/annonc/mdm411; Pascale RM, 2020, CANCERS, V12, DOI 10.3390/cancers12102819; Patop IL, 2018, CURR OPIN GENET DEV, V48, P121, DOI 10.1016/j.gde.2017.11.007; Pisarsky L, 2016, CELL REP, V15, P1161, DOI 10.1016/j.celrep.2016.04.028; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Ruan HL, 2020, ONCOGENE, V39, P6113, DOI 10.1038/s41388-020-01409-6; Wang XH, 2021, MOL THER-NUCL ACIDS, V26, P122, DOI 10.1016/j.omtn.2021.07.003; Weng HQ, 2021, MOL THER-NUCL ACIDS, V23, P811, DOI 10.1016/j.omtn.2020.12.019; Will CL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003707; Yang Z, 2019, ONCOGENE, V38, P2516, DOI 10.1038/s41388-018-0602-8; Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012; Yu T, 2021, MOL THER-NUCL ACIDS, V26, P649, DOI 10.1016/j.omtn.2021.08.029; Zhang ML, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06862-2; Zhu YH, 2020, MOL CELL, V77, P138, DOI 10.1016/j.molcel.2019.10.015	39	2	2	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2022	41	33					3979	3990		10.1038/s41388-022-02386-8	http://dx.doi.org/10.1038/s41388-022-02386-8		JUL 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T2HP	35798876	Green Published			2022-12-17	WOS:000821721300001
J	Cheng, Y; Sun, FM; Thornton, K; Jing, XF; Dong, J; Yun, G; Pisano, M; Zhan, FH; Kim, SH; Katzenellenbogen, JA; Katzenellenbogen, BS; Hari, P; Janz, S				Cheng, Yan; Sun, Fumou; Thornton, Krista; Jing, Xuefang; Dong, Jing; Yun, Grant; Pisano, Michael; Zhan, Fenghuang; Kim, Sung Hoon; Katzenellenbogen, John A.; Katzenellenbogen, Benita S.; Hari, Parameswaran; Janz, Siegfried			FOXM1 regulates glycolysis and energy production in multiple myeloma	ONCOGENE			English	Article							TRANSCRIPTION FACTOR FOXM1; CONNECTIVITY MAP; PROGRESSION; PROMOTES; TARGET; PLASTICITY; HSP90; CELLS	The transcription factor, forkhead box M1 (FOXM1), has been implicated in the natural history and outcome of newly diagnosed high-risk myeloma (HRMM) and relapsed/refractory myeloma (RRMM), but the mechanism with which FOXM1 promotes the growth of neoplastic plasma cells is poorly understood. Here we show that FOXM1 is a positive regulator of myeloma metabolism that greatly impacts the bioenergetic pathways of glycolysis and oxidative phosphorylation (OxPhos). Using FOXM1-deficient myeloma cells as principal experimental model system, we find that FOXM1 increases glucose uptake, lactate output, and oxygen consumption in myeloma. We demonstrate that the novel 1,1-diarylethylene small-compound FOXM1 inhibitor, NB73, suppresses myeloma in cell culture and human-in-mouse xenografts using a mechanism that includes enhanced proteasomal FOXM1 degradation. Consistent with the FOXM1-stabilizing chaperone function of heat shock protein 90 (HSP90), the HSP90 inhibitor, geldanamycin, collaborates with NB73 in slowing down myeloma. These findings define FOXM1 as a key driver of myeloma metabolism and underscore the feasibility of targeting FOXM1 for new approaches to myeloma therapy and prevention.	[Cheng, Yan; Dong, Jing; Yun, Grant; Pisano, Michael; Hari, Parameswaran; Janz, Siegfried] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA; [Thornton, Krista] Univ Iowa, Dept Pathol, Master Sci Grad Program, Iowa City, IA 52242 USA; [Jing, Xuefang] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; [Pisano, Michael] Univ Iowa, Interdisciplinary Grad Program Immunol, Iowa City, IA USA; [Zhan, Fenghuang] Univ Arkansas Med Sci, Myeloma Ctr, Div Hematol & Oncol, Dept Med, Little Rock, AR 72205 USA; [Zhan, Fenghuang] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, Little Rock, AR 72205 USA; [Kim, Sung Hoon; Katzenellenbogen, John A.] Univ Illinois, Dept Chem, Urbana, IL 61801 USA; [Katzenellenbogen, Benita S.] Univ Illinois, Mol & Integrat Physiol & Canc Ctr, Urbana, IL 61801 USA; [Hari, Parameswaran; Janz, Siegfried] Med Coll Wisconsin, Ctr Canc, Milwaukee, WI 53226 USA	Medical College of Wisconsin; University of Iowa; University of Iowa; University of Iowa; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Medical College of Wisconsin	Janz, S (corresponding author), Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI 53226 USA.; Janz, S (corresponding author), Med Coll Wisconsin, Ctr Canc, Milwaukee, WI 53226 USA.	sjanz@mcw.edu		Zhan, Fenghuang/0000-0001-5417-2973; Jing, Xuefang/0000-0002-8670-4505; Dong, Jing/0000-0001-9856-5963; Sun, Fumou/0000-0003-2034-3492	Breast Cancer Research Foundation [083, 084]; NCI [R01CA151354, R01CA236814]; DoD [CA180190]; Riney Family Multiple Myeloma Research Program award; MCW Milwaukee William G. Schuett, Jr., Multiple Myeloma Research Endowment; Myeloma Crowd Research Initiative award	Breast Cancer Research Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DoD(United States Department of Defense); Riney Family Multiple Myeloma Research Program award; MCW Milwaukee William G. Schuett, Jr., Multiple Myeloma Research Endowment; Myeloma Crowd Research Initiative award	We wish to acknowledge expert technical assistance from MCW Cancer Center core facility staff, especially Monika Zielonka, Redox and Bioenergetics Shared Resource (CCRBSR); Galina Petrova, Flow Cytometry Shared Resource; and Donna McAllister, Biomedical Imaging Shared Resource. This work was supported by Breast Cancer Research Foundation grants 083 (to BSK) and 084 (to JAK); by NCI R01CA236814, DoD CA180190, Myeloma Crowd Research Initiative and Riney Family Multiple Myeloma Research Program awards (to FZ); and by NCI R01CA151354 (to SJ). Additional support was provided by the MCW Milwaukee William G. Schuett, Jr., Multiple Myeloma Research Endowment.	Abdollahi P, 2021, FASEB J, V35, DOI 10.1096/fj.202001920RR; Bajpai R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15051-z; Barger CJ, 2019, CANCERS, V11, DOI 10.3390/cancers11020251; Bergamaschi A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0436-4; Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005592; Black M, 2020, MOL BIOL CELL, V31, P1411, DOI 10.1091/mbc.E19-07-0413; Bloedjes TA, 2021, CANCERS, V13, DOI 10.3390/cancers13030396; Boreel DF, 2021, CLIN CANCER RES, V27, P2970, DOI 10.1158/1078-0432.CCR-20-3913; Borhani S, 2020, EXPERT OPIN THER TAR, V24, P205, DOI 10.1080/14728222.2020.1727888; Buchner M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7471; Caillot M, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00253-3; Cui JJ, 2014, CLIN CANCER RES, V20, P2595, DOI 10.1158/1078-0432.CCR-13-2407; Dalva-Aydemir S, 2015, CLIN CANCER RES, V21, P1161, DOI 10.1158/1078-0432.CCR-14-1088; Deribe YL, 2018, NAT MED, V24, P1047, DOI 10.1038/s41591-018-0019-5; Dey P, 2020, CANCERS, V12, DOI 10.3390/cancers12092677; Duncan K, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.61; El Arfani C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041200; Fujiwara S, 2015, EXP HEMATOL ONCOL, V4, DOI 10.1186/s40164-015-0008-z; Gormally MV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6165; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Gu C, 2016, LEUKEMIA, V30, P873, DOI 10.1038/leu.2015.334; Gu CY, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5015-0; Gu CY, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0060-0; Gu ZM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0392-4; Hajek R, 2013, BRIT J HAEMATOL, V163, P551, DOI 10.1111/bjh.12563; Halasi M, 2016, J BIOL CHEM, V291, P142, DOI 10.1074/jbc.M115.678227; Hassanzadeh A, 2019, ANTI-CANCER AGENT ME, V19, P1523, DOI 10.2174/1871520619666190729150442; He YH, 2015, LEUKEMIA RES, V39, P1428, DOI 10.1016/j.leukres.2015.09.019; Hegde NS, 2011, NAT CHEM, V3, P725, DOI [10.1038/nchem.1114, 10.1038/NCHEM.1114]; Hoang PH, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-0315-4; Hou Y, 2015, NAT IMMUNOL, V16, P810, DOI 10.1038/ni.3204; Jang JS, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-018-0160-x; Kalathil D, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.626836; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Lagana A, 2018, LEUKEMIA, V32, P120, DOI 10.1038/leu.2017.197; Lam WY, 2016, IMMUNITY, V45, P60, DOI 10.1016/j.immuni.2016.06.011; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lis P, 2016, MOLECULES, V21, DOI 10.3390/molecules21121730; Maiso P, 2015, CANCER RES, V75, P2071, DOI 10.1158/0008-5472.CAN-14-3400; Marlein CR, 2019, CANCER RES, V79, P2285, DOI 10.1158/0008-5472.CAN-18-0773; Misund K, 2020, LEUKEMIA, V34, P322, DOI 10.1038/s41375-019-0543-4; Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood-2005-03-1158; Nakano A, 2012, J BIOENERG BIOMEMBR, V44, P31, DOI 10.1007/s10863-012-9412-9; Pracht K, 2021, EUR J IMMUNOL, V51, P1089, DOI 10.1002/eji.202048993; Qin XD, 2017, SCI REP-UK, V7, DOI 10.1038/srep45305; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Ray A, 2020, ONCOGENE, V39, P2786, DOI 10.1038/s41388-020-1172-0; Ryu D, 2020, CLIN CANCER RES, V26, P935, DOI 10.1158/1078-0432.CCR-19-0694; Sanchez J, 2020, CURR CANCER DRUG TAR, V20, P253, DOI 10.2174/1568009619666191202101330; Sanchez WY, 2013, BRIT J CANCER, V108, P1624, DOI 10.1038/bjc.2013.120; Shukla S, 2019, MOL CANCER THER, V18, P1217, DOI 10.1158/1535-7163.MCT-18-0709; Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049; Trasanidis N, 2022, BLOOD, V139, P1939, DOI 10.1182/blood.2021014391; Waldschmidt JM, 2021, CLIN CANCER RES, V27, P6432, DOI 10.1158/1078-0432.CCR-21-2040; Wang HS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18028-z; Wang Y, 2016, ONCOTARGET, V7, P47985, DOI 10.18632/oncotarget.10103; Xiang Y, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117971; Xu SL, 2019, CANCER RES, V79, P2748, DOI 10.1158/0008-5472.CAN-18-2799; Zhan X, 2017, ONCOTARGET, V8, P111213, DOI 10.18632/oncotarget.22740; Zhang HY, 2018, MOL ONCOL, V12, P1579, DOI 10.1002/1878-0261.12363; Zhang W, 2021, MOL ONCOL, V15, P1466, DOI 10.1002/1878-0261.12879; Ziegler Y, 2019, NPJ BREAST CANCER, V5, DOI 10.1038/s41523-019-0141-7	62	2	2	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2022	41	32					3899	3911		10.1038/s41388-022-02398-4	http://dx.doi.org/10.1038/s41388-022-02398-4		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3O2GY	35794249	hybrid, Green Published			2022-12-17	WOS:000823188300001
J	Chand, V; Liao, XB; Guzman, G; Benevolenskaya, E; Raychaudhuri, P				Chand, Vaibhav; Liao, Xiubei; Guzman, Grace; Benevolenskaya, Elizaveta; Raychaudhuri, Pradip			Hepatocellular carcinoma evades RB1-induced senescence by activating the FOXM1-FOXO1 axis	ONCOGENE			English	Article							RETINOBLASTOMA TUMOR-SUPPRESSOR; TRANSCRIPTIONAL PROGRAM; FOXM1; PHOSPHORYLATION; PROTEIN; GENES; RB; PROGRESSION; BINDING; PRB	Hepatocellular carcinoma (HCC) is one of the deadliest cancers. The retinoblastoma protein (RB1), a regulator of cell proliferation, is functionally inactivated in HCC by CYCLIN D/E-mediated phosphorylation. However, the mechanism of RB1-inactivation is unclear because only small percentages of HCCs exhibit amplification of CYCLIN D/E or mutations in the CDK-inhibitory genes. We show that FOXM1, which is overexpressed and critical for HCC, plays essential roles in inactivating RB1 and suppressing RB1-induced senescence of the HCC cells. Mechanistically, FOXM1 binds RB1 and DNMT3B to repress the expression of FOXO1, leading to a decrease in the levels of the CDK-inhibitors, creating an environment for phosphorylation and inactivation of RB1. Consistent with that, inhibition of FOXM1 causes increased expression of FOXO1 with consequent activation of RB1, leading to senescence of the HCC cells, in vitro and in vivo. Also, repression-deficient mutants of FOXM1 induce senescence that is blocked by depletion of RB1 or FOXO1. We provide evidence that human HCCs rely upon this FOXM1-FOXO1 axis for phosphorylation and inactivation of RB1. The observations demonstrate the existence of a new autoregulatory loop of RB1-inactivation in HCC involving a FOXM1-FOXO1 axis that is required for phosphorylation of RB1 and for aggressive progression of HCC.	[Chand, Vaibhav; Liao, Xiubei; Benevolenskaya, Elizaveta; Raychaudhuri, Pradip] Univ Illinois, Coll Med, Dept Biochem & Mol Genet MC 669, 900S Ashland Ave, Chicago, IL 60607 USA; [Guzman, Grace] Univ Illinois, Coll Med, Dept Pathol, Chicago, IL 60612 USA; [Raychaudhuri, Pradip] Jesse Brown VA Med Ctr, 820S Damen Ave, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Raychaudhuri, P (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet MC 669, 900S Ashland Ave, Chicago, IL 60607 USA.; Raychaudhuri, P (corresponding author), Jesse Brown VA Med Ctr, 820S Damen Ave, Chicago, IL 60612 USA.	pradip@uic.edu		Benevolenskaya, Elizaveta/0000-0003-3573-1754; raychaudhuri, pradip/0000-0003-2968-4701	Department of Veterans Affair (Biomedical Laboratory Research Development Service) [I01 BX000131]; NIH [5 RO1 CA243247, RO1 CA211095]	Department of Veterans Affair (Biomedical Laboratory Research Development Service); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a grant (I01 BX000131) from the Department of Veterans Affair (Biomedical Laboratory Research Development Service), and a grant from the NIH (5 RO1 CA243247) to PR. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. EB acknowledges support from NIH grant (RO1 CA211095).	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055; Baker GL, 2005, CELL CYCLE, V4, P330; Barsotti AM, 2009, ONCOGENE, V28, P4295, DOI 10.1038/onc.2009.282; Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012; Berman SD, 2008, MOL CANCER RES, V6, P1440, DOI 10.1158/1541-7786.MCR-08-0176; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; Carr JR, 2012, CELL REP, V1, P715, DOI 10.1016/j.celrep.2012.05.005; Chand V, 2019, MOL CANCER RES, V17, P1063, DOI 10.1158/1541-7786.MCR-18-0968; Chen YJ, 2009, J BIOL CHEM, V284, P30695, DOI 10.1074/jbc.M109.007997; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Diep CH, 2013, CELL CYCLE, V12, P1433, DOI 10.4161/cc.24550; Dimri GP, 1996, BIOL SIGNAL, V5, P154; Dimri GP, 1996, MOL BIOL CELL, V7, P3102; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Jiao W, 2006, J BIOL CHEM, V281, P38098, DOI 10.1074/jbc.M605271200; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Knudsen ES, 2019, TRENDS CANCER, V5, P308, DOI 10.1016/j.trecan.2019.03.005; Kopanja D, 2015, J HEPATOL, V63, P429, DOI 10.1016/j.jhep.2015.03.023; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Liu JK, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12660; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Marceau AH, 2019, ELIFE, V8, DOI 10.7554/eLife.46131; Midorikawa Y, 2020, CANCER RES, V80, P3810, DOI 10.1158/0008-5472.CAN-20-0225; Mukhopadhyay NK, 2017, SCI REP-UK, V7, DOI 10.1038/srep46017; Narasimha AM, 2014, ELIFE, V3, DOI 10.7554/eLife.02872; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nowak K, 2007, BBA-GENE STRUCT EXPR, V1769, P244, DOI 10.1016/j.bbaexp.2007.04.001; Park HJ, 2008, ONCOGENE, V27, P1696, DOI 10.1038/sj.onc.1210814; Park HJ, 2011, EMBO MOL MED, V3, P21, DOI 10.1002/emmm.201000107; Park JW, 2019, J HEPATOL, V70, P684, DOI 10.1016/j.jhep.2018.11.029; Pozo OJ, 2007, ANAL BIOANAL CHEM, V389, P1765, DOI 10.1007/s00216-007-1407-8; Reed CA, 2009, ONCOGENE, V28, P4434, DOI 10.1038/onc.2009.303; Rubin SM, 2020, MOL CELL, V80, P183, DOI 10.1016/j.molcel.2020.08.020; Ruscetti M, 2020, CELL, V181, P424, DOI 10.1016/j.cell.2020.03.008; Shang YK, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010892; Siegel R., 2015, CA-CANCER J CLIN, V65, P29, DOI [10.3322/caac.21254, DOI 10.3322/CAAC.21254, DOI 10.3322/caac.21208]; Song BN, 2018, EXP MOL MED, V50, DOI 10.1038/emm.2017.159; Topacio BR, 2019, MOL CELL, V74, P758, DOI 10.1016/j.molcel.2019.03.020; Viatour P, 2011, J EXP MED, V208, P1963, DOI 10.1084/jem.20110198; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Zappia MP, 2019, CELL REP, V26, P702, DOI 10.1016/j.celrep.2018.12.080; Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061	46	2	2	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2022	41	30					3778	3790		10.1038/s41388-022-02394-8	http://dx.doi.org/10.1038/s41388-022-02394-8		JUN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D1SP	35761036				2022-12-17	WOS:000817034400002
J	Strocchi, S; Reggiani, F; Gobbi, G; Ciarrocchi, A; Sancisi, V				Strocchi, Silvia; Reggiani, Francesca; Gobbi, Giulia; Ciarrocchi, Alessia; Sancisi, Valentina			The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation	ONCOGENE			English	Review							RNA-POLYMERASE-II; PROLINE-HYDROXYLATION; NITRIC-OXIDE; TRANSCRIPTIONAL ACTIVITY; BREAST TUMORIGENESIS; PROTEIN STABILITY; DOMAIN PROTEIN-2; DIRECT BINDING; LARGE SUBUNIT; GROWTH-FACTOR	EGLN1, EGLN2 and EGLN3 are proline hydroxylase whose main function is the regulation of the HIF factors. They work as oxygen sensors and are the main responsible of HIF alpha subunits degradation in normoxia. Being their activity strictly oxygen-dependent, when oxygen tension lowers, their control on HIF alpha is released, leading to activation of systemic and cellular response to hypoxia. However, EGLN family members activity is not limited to HIF modulation, but it includes the regulation of essential mechanisms for cell survival, cell cycle metabolism, proliferation and transcription. This is due to their reported hydroxylase activity on a number of non-HIF targets and sometimes to hydroxylase-independent functions. For these reasons, EGLN enzymes appear fundamental for development and progression of different cancer types, playing either a tumor-suppressive or a tumor-promoting role, according to EGLN isoform and to tumor context. Notably, EGLN1, the most studied isoform, has been shown to have also a central role in tumor micro-environment modulation, mediating CAF activation and impairing HIF1 alpha -related angiogenesis, thus covering an important function in cancer metastasis promotion. Considering the recent knowledge acquired on EGLNs, the possibility to target these enzymes for cancer treatment is emerging. However, due to their multifaceted and controversial roles in different cancer types, the use of EGLN inhibitors as anti-cancer drugs should be carefully evaluated in each context.	[Strocchi, Silvia; Reggiani, Francesca; Gobbi, Giulia; Ciarrocchi, Alessia; Sancisi, Valentina] Azienda USL IRCCS Reggio Emilia, Lab Translat Res, Reggio Emilia, Italy		Sancisi, V (corresponding author), Azienda USL IRCCS Reggio Emilia, Lab Translat Res, Reggio Emilia, Italy.	valentina.sancisi@ausl.re.it	REGGIANI, FRANCESCA/K-1082-2018; Sancisi, Valentina/H-6701-2018	REGGIANI, FRANCESCA/0000-0002-4090-8908; Sancisi, Valentina/0000-0003-4357-1228	AIRC under IG 2021 [26377]; Italian Ministry of Health through Bando per la Valorizzazione della Ricerca in ambito oncologico 2020 - Fondi 5 per Mille 2018; Italian Ministry of Health through Bando per la Valorizzazione della Ricerca in ambito oncologico 2019 - Fondi 5 per Mille 2017; Fondazione Umberto Veronesi (FUV); Italian Ministry of Health - Ricerca Corrente Annual Program 2023	AIRC under IG 2021(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health through Bando per la Valorizzazione della Ricerca in ambito oncologico 2020 - Fondi 5 per Mille 2018; Italian Ministry of Health through Bando per la Valorizzazione della Ricerca in ambito oncologico 2019 - Fondi 5 per Mille 2017; Fondazione Umberto Veronesi (FUV)(Fondazione Umberto Veronesi); Italian Ministry of Health - Ricerca Corrente Annual Program 2023	The research leading to this work has received funding from AIRC under IG 2021 - ID. 26377 project - P.I. Sancisi Valentina. Valentina Sancisi is funded by the Italian Ministry of Health through Bando per la Valorizzazione della Ricerca in ambito oncologico 2020 - Fondi 5 per Mille 2018. Giulia Gobbi is funded by the Italian Ministry of Health through Bando per la Valorizzazione della Ricerca in ambito oncologico 2019 - Fondi 5 per Mille 2017. Francesca Reggiani is supported by Fondazione Umberto Veronesi (FUV). This study was partially supported by Italian Ministry of Health - Ricerca Corrente Annual Program 2023.	Akizawa T, 2019, AM J NEPHROL, V49, P271, DOI 10.1159/000499111; Andersen S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023847; Apanovich N, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.615787; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Barratt J, 2021, NEPHROL DIAL TRANSPL, V36, P1616, DOI 10.1093/ndt/gfab191; Berchner-Pfannschmidt U, 2007, J BIOL CHEM, V282, P1788, DOI 10.1074/jbc.M607065200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bordoli MR, 2011, ONCOGENE, V30, P548, DOI 10.1038/onc.2010.433; Briggs KJ, 2016, CELL, V166, P126, DOI 10.1016/j.cell.2016.05.042; Bryant JD, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00647-17; Bur H, 2018, ANTICANCER RES, V38, P329, DOI 10.21873/anticanres.12226; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; Chan MC, 2016, J BIOL CHEM, V291, P20661, DOI 10.1074/jbc.M116.749291; Chen F, 2019, NAT CELL BIOL, V21, P498, DOI 10.1038/s41556-019-0299-0; Chen N, 2011, CELL RES, V21, P983, DOI 10.1038/cr.2011.66; Chen SF, 2011, MOL CELL BIOCHEM, V358, P257, DOI 10.1007/s11010-011-0976-1; Choueiri TK, 2020, NAT MED, V26, P1519, DOI 10.1038/s41591-020-1093-z; Chowdhury R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12673; Cockmann ME, 2019, ELIFE, V8, DOI 10.7554/eLife.46490; Couvelard A, 2008, CLIN CANCER RES, V14, P6634, DOI 10.1158/1078-0432.CCR-07-5258; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; D'Hulst G, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13889-6; de Oliveira RL, 2012, CANCER CELL, V22, P263, DOI 10.1016/j.ccr.2012.06.028; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; Deschoemaeker S, 2015, EMBO MOL MED, V7, P1350, DOI 10.15252/emmm.201505492; Dey A, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz8534; Di Conza G, 2017, CELL REP, V18, P2836, DOI 10.1016/j.celrep.2017.02.081; Di Conza G, 2017, CELL REP, V18, P1699, DOI 10.1016/j.celrep.2017.01.051; Dopeso H, 2018, CANCER RES, V78, P1805, DOI 10.1158/0008-5472.CAN-17-1346; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Erber L, 2019, MOL CELL PROTEOMICS, V18, P1772, DOI 10.1074/mcp.RA119.001535; Erez N, 2003, CANCER RES, V63, P8777; Fitzpatrick SF, 2016, BIOCHEM BIOPH RES CO, V474, P579, DOI 10.1016/j.bbrc.2016.04.085; Foxler DE, 2012, NAT CELL BIOL, V14, P201, DOI 10.1038/ncb2424; Fujimoto TN, 2019, CANCER RES, V79, P2327, DOI 10.1158/0008-5472.CAN-18-1785; Garvalov BK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6577; German NJ, 2016, MOL CELL, V63, P1006, DOI 10.1016/j.molcel.2016.08.014; Giatromanolaki A, 2008, CANCER LETT, V262, P87, DOI 10.1016/j.canlet.2007.11.041; Guan D, 2021, J INORG BIOCHEM, V218, DOI 10.1016/j.jinorgbio.2021.111413; Guo JP, 2016, SCIENCE, V353, P929, DOI 10.1126/science.aad5755; Guo JQ, 2020, ARTIF CELL NANOMED B, V48, P37, DOI 10.1080/21691401.2019.1699806; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Heindryckx F, 2012, J HEPATOL, V57, P61, DOI 10.1016/j.jhep.2012.02.021; Hogel H, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0410-5; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2017, MOL CELL, V66, P772, DOI 10.1016/j.molcel.2017.06.002; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jokilehto T, 2006, CLIN CANCER RES, V12, P1080, DOI 10.1158/1078-0432.CCR-05-2022; Jokilehto T, 2010, J CELL MOL MED, V14, P758, DOI 10.1111/j.1582-4934.2010.01030.x; Jokilehto T, 2010, EXP CELL RES, V316, P1169, DOI 10.1016/j.yexcr.2010.02.012; Jubb AM, 2004, J CLIN PATHOL, V57, P504, DOI 10.1136/jcp.2003.012963; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Klotzsche-von Ameln A, 2012, CANCER BIOL THER, V13, DOI 10.4161/cbt.13.4.18830; Klotzsche-von Ameln A, 2011, CANCER RES, V71, P3306, DOI 10.1158/0008-5472.CAN-10-3838; Koivunen P, 2007, J BIOL CHEM, V282, P30544, DOI 10.1074/jbc.M704988200; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Koren A, 2021, CANCERS, V13, DOI 10.3390/cancers13102309; Kozlova N, 2019, CANCER RES, V79, P4042, DOI 10.1158/0008-5472.CAN-18-3852; Kozlova N, 2017, ONCOTARGET, V8, P9885, DOI 10.18632/oncotarget.14241; Kuchnio A, 2015, CELL REP, V12, P992, DOI 10.1016/j.celrep.2015.07.010; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lee G, 2016, SCI REP-UK, V6, DOI 10.1038/srep18928; Lee SH, 2014, ONCOGENE, V33, P1458, DOI 10.1038/onc.2013.76; Lee SB, 2020, MOL CELL, V79, P376, DOI 10.1016/j.molcel.2020.06.021; Leinonen H, 2019, NEUROPHARMACOLOGY, V153, P63, DOI 10.1016/j.neuropharm.2019.04.023; Leinonen H, 2016, HUM MOL GENET, V25, P3810, DOI 10.1093/hmg/ddw228; Li Z, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000179; Li ZQ, 2019, CLIN CANCER RES, V25, P5947, DOI 10.1158/1078-0432.CCR-18-4145; Lieb ME, 2002, BIOCHEM CELL BIOL, V80, P421, DOI 10.1139/O02-115; Liu XJ, 2020, MOL CELL, V77, P1294, DOI 10.1016/j.molcel.2020.01.009; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Luukkaa M, 2009, INT J RADIAT BIOL, V85, P900, DOI [10.3109/09553000903074104, 10.1080/09553000903074104]; Ma MY, 2017, ONCOTARGET, V8, P12983, DOI 10.18632/oncotarget.14677; Madsen CD, 2015, EMBO REP, V16, P1394, DOI 10.15252/embr.201540107; Maher ER, 2013, SEMIN CANCER BIOL, V23, P10, DOI 10.1016/j.semcancer.2012.06.003; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.E02-12-0791; Miikkulainen P, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0167-y; Mikhaylova O, 2008, MOL CELL BIOL, V28, P2701, DOI 10.1128/MCB.01231-07; Moser SC, 2013, DEV CELL, V26, P381, DOI 10.1016/j.devcel.2013.06.014; Naba A, 2014, ELIFE, V3, DOI 10.7554/eLife.01308; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Nunez-O'Mara A, 2015, J CELL SCI, V128, P40, DOI 10.1242/jcs.151514; Oh ET, 2016, SCI REP-UK, V6, DOI 10.1038/srep27382; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ortmann B, 2016, J CELL SCI, V129, P191, DOI 10.1242/jcs.179911; Oughtred R, 2021, PROTEIN SCI, V30, P187, DOI 10.1002/pro.3978; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; Peurala E, 2012, BREAST CANCER RES TR, V133, P179, DOI 10.1007/s10549-011-1750-5; Price C, 2019, CANCER RES, V79, P2564, DOI 10.1158/0008-5472.CAN-18-2674; Ramani MKV, 2021, J MOL BIOL, V433, DOI 10.1016/j.jmb.2021.166912; Rawluszko AA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-526; Reggiani F, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01357-z; Rodriguez J, 2018, CELL REP, V24, P1316, DOI 10.1016/j.celrep.2018.06.108; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shi M, 2021, CANCER LETT, V496, P144, DOI 10.1016/j.canlet.2020.10.011; Song DS, 2013, J BIOL CHEM, V288, P9662, DOI 10.1074/jbc.M112.440552; Steinhoff A, 2009, BIOCHEM BIOPH RES CO, V387, P705, DOI 10.1016/j.bbrc.2009.07.090; Su Y, 2010, BRIT J CANCER, V103, P1571, DOI 10.1038/sj.bjc.6605936; Su Y, 2012, CANCER-AM CANCER SOC, V118, P960, DOI 10.1002/cncr.26344; Takada M, 2017, ONCOTARGET, V8, P6787, DOI 10.18632/oncotarget.14290; Takeda K, 2007, CIRCULATION, V116, P774, DOI 10.1161/CIRCULATIONAHA.107.701516; Takeda K, 2006, MOL CELL BIOL, V26, P8336, DOI 10.1128/MCB.00425-06; Tanaka T, 2015, J GASTROENTEROL, V50, P975, DOI 10.1007/s00535-014-1030-3; Tanaka T, 2014, J CANCER RES CLIN, V140, P503, DOI 10.1007/s00432-014-1593-7; Tennant DA, 2009, ONCOGENE, V28, P4009, DOI 10.1038/onc.2009.250; To KKW, 2005, J BIOL CHEM, V280, P38102, DOI 10.1074/jbc.M504342200; Tseng CW, 2018, CANCER RES, V78, P2799, DOI 10.1158/0008-5472.CAN-17-2906; Ullah K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17376-0; Vidimar V, 2019, CANCER LETT, V440, P145, DOI 10.1016/j.canlet.2018.09.029; Wang L, 2020, LIFE SCI, V242, DOI 10.1016/j.lfs.2019.117167; Xiang JF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0367-6; Xie GF, 2012, EXP BIOL MED, V237, P860, DOI 10.1258/ebm.2012.011331; Xie X, 2014, CANCER GENET-NY, V207, P188, DOI 10.1016/j.cancergen.2014.04.008; Xu YM, 2019, J BIOL CHEM, V294, P9949, DOI 10.1074/jbc.RA118.007181; Yi Y, 2010, CLIN CANCER RES, V16, P5142, DOI 10.1158/1078-0432.CCR-09-3416; Zacharias NM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062849; Zhang J, 2015, EMBO J, V34, P2953, DOI 10.15252/embj.201591437; Zhang LL, 2017, CANCER LETT, V390, P11, DOI 10.1016/j.canlet.2017.01.003; Zhang Q, 2009, CANCER CELL, V16, P413, DOI 10.1016/j.ccr.2009.09.029; Zheng F, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21535-3; Zheng XN, 2014, GENE DEV, V28, P1429, DOI 10.1101/gad.242131.114; Zurlo G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13168-4	127	2	2	10	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2022	41	29					3665	3679		10.1038/s41388-022-02378-8	http://dx.doi.org/10.1038/s41388-022-02378-8		JUN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y6YE	35705735				2022-12-17	WOS:000811468900001
J	Hang, XH; Zhao, L; Wu, BH; Li, SJ; Liu, PP; Xu, J; Wang, XY; Chi, PL; Chen, C; Niu, T; Dai, LZ; Liu, Y				Hang, Xiaohang; Zhao, Lei; Wu, Baohong; Li, Shujun; Liu, Pengpeng; Xu, Jing; Wang, Xinyuan; Chi, Pengliang; Chen, Chong; Niu, Ting; Dai, Lunzhi; Liu, Yu			BCL-2 isoform beta promotes angiogenesis by TRiC-mediated upregulation of VEGF-A in lymphoma	ONCOGENE			English	Article							EXPRESSION; INHIBITION; CELLS; OVEREXPRESSION; DISCOVERIES; INDUCTION; VEGF(165); SURVIVAL	Bcl-2 (B-cell lymphoma 2), the first identified anti-apoptosis factor, encodes two transcripts, the long isoform alpha and the short isoform beta. The current understanding of the Bcl-2 function mainly focuses on Bcl-2 alpha, while little is known about the function of Bcl-2 beta, which lacks the transmembrane domain and contains 10 unique amino acids at the C-terminus instead. Here, we analyzed the expressions of BCL-2 two isoforms in diffused large B-cell lymphoma (DLBCL) and found a significant positive correlation between them. Then, with the CRISPR/Cas9-based transcriptional activator (CRISPRa), we generated mouse B-cell lymphomas with Bcl-2 upregulation from the endogenous locus, in which both Bcl-2 alpha and Bcl-2 beta levels were increased. Bcl-2 beta itself promoted angiogenesis both in vitro and in vivo through increased vascular endothelial growth factor A (VEGF-A). Inhibiting VEGF receptors with Axitinib reduced angiogenesis induced by Bcl-2 beta overexpression. Co-immunoprecipitation and mass spectrometry analysis revealed that Bcl-2 beta interacted with the T-complex protein ring complex (TRiC). Disruption of TRiC significantly impaired the angiogenesis-promoting activity of Bcl-2 beta, indicated by reduced VEGF-A protein level and HUVEC tube formation. Thus, our study suggests that Bcl-2 isoform beta plays a role in promoting tumor angiogenesis through the Bcl-2 beta-TRiC-VEGF-A axis.	[Hang, Xiaohang; Zhao, Lei; Wu, Baohong; Li, Shujun; Liu, Pengpeng; Xu, Jing; Chi, Pengliang; Chen, Chong; Niu, Ting; Liu, Yu] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Hematol, Chengdu, Sichuan, Peoples R China; [Hang, Xiaohang; Zhao, Lei; Wu, Baohong; Li, Shujun; Liu, Pengpeng; Xu, Jing; Chi, Pengliang; Chen, Chong; Niu, Ting; Liu, Yu] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Sichuan, Peoples R China; [Wang, Xinyuan; Dai, Lunzhi] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Gen Practice, Chengdu, Sichuan, Peoples R China; [Wang, Xinyuan; Dai, Lunzhi] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Natl Clin Res Ctr Geriatr, Chengdu, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan University	Liu, Y (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Hematol, Chengdu, Sichuan, Peoples R China.; Liu, Y (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Sichuan, Peoples R China.; Dai, LZ (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Gen Practice, Chengdu, Sichuan, Peoples R China.; Dai, LZ (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Natl Clin Res Ctr Geriatr, Chengdu, Sichuan, Peoples R China.	lunzhi.dai@scu.edu.cn; yuliuscu@scu.edu.cn	wang, xinyuan/HHM-2418-2022	Chen, Chong/0000-0002-6787-0495; Dai, Lunzhi/0000-0002-3003-8910	National Natural Science Foundation of China [82130007, 81670182, 82073221]; National Key R&D Program of China [2017YFA0505600, 2018YFC2000305]; Sichuan Science and Technology Program [2018JZ0077]; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYJC21009, ZYYC20007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Sichuan Science and Technology Program; 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University	We thank Dr. Yuquan Wei for his generous support. We thank Dr. Ruizhan Tong and Dr. Yinglan Zhao for their technical assistance. We thank Dr. Jianjun Li for his clinical assistance. We thank all the lab members in the Chen and Liu laboratory for their insightful advice and kindly support. The results published here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.This work was supported by the National Natural Science Foundation of China (grants 82130007, 81670182, and 82073221), the National Key R&D Program of China (grants 2017YFA0505600 and 2018YFC2000305), the Sichuan Science and Technology Program (grants 2018JZ0077), and the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (grants ZYJC21009 and ZYYC20007).	[Anonymous], 2014, GENOME BIOL, DOI DOI 10.1186/S13059-014-0550-8; Ashkenazi A, 2017, NAT REV DRUG DISCOV, V16, P273, DOI 10.1038/nrd.2016.253; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Bohonowych JE, 2010, J ONCOL, V2010, DOI 10.1155/2010/412985; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Chavez A, 2015, NAT METHODS, V12, P326, DOI [10.1038/NMETH.3312, 10.1038/nmeth.3312]; Chen M, 2021, CANCER DISCOV, V11, P194, DOI 10.1158/2159-8290.CD-20-0336; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; DeCicco-Skinner KL, 2014, JOVE-J VIS EXP, DOI 10.3791/51312; Delbridge ARD, 2016, NAT REV CANCER, V16, P99, DOI 10.1038/nrc.2015.17; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; FUKUHARA S, 1978, INT J CANCER, V22, P14, DOI 10.1002/ijc.2910220105; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Guillem V, 2015, LEUKEMIA RES, V39, P1278, DOI 10.1016/j.leukres.2015.08.014; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095; Kawatani M, 2003, EXP CELL RES, V286, P57, DOI 10.1016/S0014-4827(03)00098-3; Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; Massaad CA, 2004, J BIOL CHEM, V279, P54470, DOI 10.1074/jbc.M407659200; Merino D, 2018, CANCER CELL, V34, P879, DOI 10.1016/j.ccell.2018.11.004; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Ozawa K, 2001, J CLIN INVEST, V108, P41, DOI 10.1172/JCI11772; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; Riedell PA, 2018, CANCER-AM CANCER SOC, V124, P4622, DOI 10.1002/cncr.31646; Singh R, 2019, NAT REV MOL CELL BIO, V20, P175, DOI 10.1038/s41580-018-0089-8; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Warren CFA, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1407-6; Wei T., 2021, R PACKAGE CORRPLOT V; Zhang Q, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.153768	36	2	2	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2022	41	28					3655	3663		10.1038/s41388-022-02372-0	http://dx.doi.org/10.1038/s41388-022-02372-0		JUN 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y2ND	35701534				2022-12-17	WOS:000810849500003
J	Alfaro-Arnedo, E; Lopez, IP; Pineiro-Hermida, S; Canalejo, M; Gotera, C; Sola, JJ; Roncero, A; Peces-Barba, G; Ruiz-Martinez, C; Pichel, JG				Alfaro-Arnedo, Elvira; Lopez, Iciar P.; Pineiro-Hermida, Sergio; Canalejo, Marta; Gotera, Carolina; Javier Sola, Jesus; Roncero, Alejandra; Peces-Barba, German; Ruiz-Martinez, Carlos; Pichel, Jose G.			IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression	ONCOGENE			English	Article							FACTOR 1 RECEPTOR; PROGNOSTIC-FACTOR; DENDRITIC CELLS; GROWTH-FACTORS; UP-REGULATION; T-CELLS; EXPRESSION; ACTIVATION; BLOCKADE; PATHWAY	Given the long-term ineffectiveness of current therapies and late-stage diagnoses, lung cancer is a leading cause of malignant diseases. Tumor progression is influenced by cancer cell interactions with the tumor microenvironment (TME). Insulin-like growth factor 1 receptor (IGF1R) was reported to affect the TME; however, the role of IGF1R in lung TME has not been investigated. First, we assessed IGF1R genomic alterations and expression in NSCLC patient tissue samples, as well as IGF1R serum levels. Next, we performed tumor heterotopic transplantation and pulmonary metastases in IGF1R-deficient mice using melanoma and Lewis lung carcinoma (LLC) cells. Herein we report increased amplification and mRNA expression, as well as increased protein expression (IGF1R/p-IGF1R) and IGF1R levels in tumor samples and serum from NSCLC patients, respectively. Moreover, IGF1R deficiency in mice reduced tumor growth, proliferation, inflammation and vascularization, and increased apoptosis after tumor heterotopic transplantation. Following induction of lung metastasis, IGF1R-deficient lungs also demonstrated a reduced tumor burden, and decreased expression of tumor progression markers, p-IGF1R and p-ERK1/2. Additionally, IGF1R-deficient lungs showed increased apoptosis and diminished proliferation, vascularization, EMT and fibrosis, along with attenuated inflammation and immunosuppression. Accordingly, IGF1R deficiency decreased expression of p-IGF1R in blood vessels, fibroblasts, tumor-associated macrophages and FOXP3(+) tumor-infiltrating lymphocytes. Our results demonstrate that IGF1R promotes( )metastatic tumor initiation and progression in lung TME. Furthermore, our research indicates that IGF1R could be a potential biomarker for early prediction of drug response and clinical evolution in NSCLC patients.	[Alfaro-Arnedo, Elvira; Lopez, Iciar P.; Canalejo, Marta; Pichel, Jose G.] Fdn Rioja Salud, Ctr Biomed Res La Rioja CIBIR, Lung Canc & Resp Dis Unit, Logrono, Spain; [Pineiro-Hermida, Sergio] Spanish Natl Canc Ctr CNIO, Mol Oncol Program, Telomeres & Telomerase Grp, Madrid, Spain; [Gotera, Carolina; Peces-Barba, German] IIS Fdn Jimenez Diaz, Madrid, Spain; [Gotera, Carolina; Peces-Barba, German; Pichel, Jose G.] CIBERES, Spanish Biomed Res Networking Ctr, Madrid, Spain; [Javier Sola, Jesus] Rioja Salud, Pathol Anat Serv, Hosp Univ San Pedro, Logrono, Spain; [Roncero, Alejandra; Ruiz-Martinez, Carlos] Rioja Salud, Hosp Univ San Pedro, Pneumol Serv, Logrono, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Fundacion Jimenez Diaz; CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Pichel, JG (corresponding author), Fdn Rioja Salud, Ctr Biomed Res La Rioja CIBIR, Lung Canc & Resp Dis Unit, Logrono, Spain.; Pichel, JG (corresponding author), CIBERES, Spanish Biomed Res Networking Ctr, Madrid, Spain.	jgpichel@riojasalud.es	Pichel, Jose G/AAF-2255-2019; Sola Gallego, Jesus Javier/Q-3991-2017	Pichel, Jose G/0000-0001-8580-0952; Sola Gallego, Jesus Javier/0000-0002-3177-168X	Spanish MCIN/AEI [PGC2018-097397-B-I00]; Fundacion Rioja Salud (Gobierno de La Rioja, Spain) [6.FRS-ABC.006]; European Regional Development and European Social Funds; European Union	Spanish MCIN/AEI; Fundacion Rioja Salud (Gobierno de La Rioja, Spain); European Regional Development and European Social Funds; European Union(European Commission)	This work was supported by the Spanish MCIN/AEI/https://doi.org/10.13039/501100011033 (Project PGC2018-097397-B-I00), the Fundacion Rioja Salud (Gobierno de La Rioja, Spain) (Project 6.FRS-ABC.006), and the European Regional Development and European Social Funds (ERDF/ESF by the European Union) to JGP.	Ahamed K, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-31; Ajona D, 2020, NAT CANCER, V1, P75, DOI 10.1038/s43018-019-0007-9; Alami N, 2008, GROWTH HORM IGF RES, V18, P487, DOI 10.1016/j.ghir.2008.04.002; Alfaro-Arnedo E, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9080912; Bacic I, 2018, ONCOL LETT, V15, P2335, DOI 10.3892/ol.2017.7576; Baxter RC, 2014, NAT REV CANCER, V14, P329, DOI 10.1038/nrc3720; Bertrand F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02358-7; Bertrand F, 2015, CANCER RES, V75, P2619, DOI 10.1158/0008-5472.CAN-14-2524; Bilbao D, 2014, EMBO MOL MED, V6, P1423, DOI 10.15252/emmm.201303376; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Calon A, 2014, SEMIN CANCER BIOL, V25, P15, DOI 10.1016/j.semcancer.2013.12.008; Chen B, 2013, CANCER INVEST, V31, P454, DOI 10.3109/07357907.2013.820315; Chen YB, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0568-z; Chou CH, 2012, ONCOGENE, V31, P458, DOI 10.1038/onc.2011.240; Cox G, 2000, CLIN CANCER RES, V6, P2349; DiToro D, 2020, IMMUNITY, V52, P650, DOI 10.1016/j.immuni.2020.03.013; El-Badrawy MK, 2014, J BRONCHOL INTERN PU, V21, P327, DOI 10.1097/LBR.0000000000000094; Fraser Douglas D, 2020, Crit Care Explor, V2, pe0189, DOI 10.1097/CCE.0000000000000189; Gerull WD, 2021, J THORAC DIS, V13, P2585, DOI 10.21037/jtd.2020.04.28; Girnita L, 2014, CELL MOL LIFE SCI, V71, P2403, DOI 10.1007/s00018-013-1514-y; Goc J, 2014, CANCER RES, V74, P705, DOI 10.1158/0008-5472.CAN-13-1342; Griffiths CD, 2020, NATURE, V583, P615, DOI 10.1038/s41586-020-2369-7; Han SW, 2006, CANCER RES, V66, P315, DOI 10.1158/0008-5472.CAN-05-2367; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He M, 2014, LAB CHIP, V14, P3773, DOI 10.1039/c4lc00662c; Hiraoka K, 2006, BRIT J CANCER, V94, P275, DOI 10.1038/sj.bjc.6602934; Hou PF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173048; Huang JQ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1895-2; Iams WT, 2015, CLIN CANCER RES, V21, P4270, DOI 10.1158/1078-0432.CCR-14-2518; Ireland L, 2018, ONCOGENE, V37, P2022, DOI 10.1038/s41388-017-0115-x; Ireland L, 2016, CANCER RES, V76, P6851, DOI 10.1158/0008-5472.CAN-16-1201; Jackson HW, 2017, NAT REV CANCER, V17, P38, DOI 10.1038/nrc.2016.115; Kasi, 2021, LUNG METASTASIS; Kellar A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/621324; Kim BN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67325-7; Le HT, 2021, CANCERS, V13, DOI 10.3390/cancers13051041; Li Z, 2018, LUNG CANCER, V123, P127, DOI 10.1016/j.lungcan.2018.07.015; Lin HH, 2015, CANCER SCI, V106, P299, DOI 10.1111/cas.12604; Lopez IP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166388; Maru Y, 2015, J MOL MED, V93, P1185, DOI 10.1007/s00109-015-1355-2; Mojic M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010089; Moody G, 2014, J ENDOCRINOL, V221, P145, DOI 10.1530/JOE-13-0306; Neeve SC, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1076; Nurwidya F, 2016, MALAYS J MED SCI, V23, P9; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Orlow I, 2008, J CLIN ONCOL, V26, P3560, DOI 10.1200/JCO.2007.13.2654; Osher E, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080895; Passlick B, 2000, CLIN CANCER RES, V6, P3944; Lopez IP, 2015, TRANSGENIC RES, V24, P279, DOI 10.1007/s11248-014-9837-5; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Perrot I, 2007, J IMMUNOL, V178, P2763, DOI 10.4049/jimmunol.178.5.2763; Pineiro-Hermida S, 2017, ALLERGY, V72, P1317, DOI 10.1111/all.13142; Pineiro-Hermida S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190159; Pineiro-Hermida S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04561-4; Rangachari D, 2013, CURR TREAT OPTION ON, V14, P580, DOI 10.1007/s11864-013-0250-8; Schulze AB, 2020, THORAC CANCER, V11, P120, DOI 10.1111/1759-7714.13248; Shang GS, 2017, ONCOL LETT, V13, P4657, DOI 10.3892/ol.2017.6048; Siegel RL., CANC STAT CA CANC J, V2021, P7; Spadaro O, 2017, CELL REP, V19, P225, DOI 10.1016/j.celrep.2017.03.046; Sumitomo R, 2019, EXP THER MED, V18, P4490, DOI 10.3892/etm.2019.8068; Sung WW, 2013, CLIN CANCER RES, V19, P4092, DOI 10.1158/1078-0432.CCR-12-3439; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Tsai Jong-Rung, 2012, Cell Oncol (Dordr), V35, P461, DOI 10.1007/s13402-012-0105-5; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644; Lopez-Malpartida AV, 2009, LUNG CANCER, V65, P25, DOI 10.1016/j.lungcan.2008.10.009; Wang JY, 2015, ONCOTARGET, V6, P20636, DOI 10.18632/oncotarget.4114; Wang YA, 2017, MOL CANCER RES, V15, P896, DOI 10.1158/1541-7786.MCR-16-0390; Wang Z, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6057589; Xiao Y, 2017, ONCOL LETT, V14, P6876, DOI 10.3892/ol.2017.7014; Yamaguchi T, 2015, INT J CARDIOL, V178, P239, DOI 10.1016/j.ijcard.2014.10.144; Yang CH, 2015, BBA-MOL BASIS DIS, V1852, P1540, DOI 10.1016/j.bbadis.2015.04.020; Yang SC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0700-1; Yang YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099763; Yao MJ, 2020, CELL, V180, P502, DOI 10.1016/j.cell.2019.12.024; Yohena T, 2009, J THORAC ONCOL, V4, P284, DOI 10.1097/JTO.0b013e31819852d5; Yuan JS, 2018, ONCOL LETT, V15, P41, DOI 10.3892/ol.2017.7276; Zaidi MR, 2019, J INTERF CYTOK RES, V39, P30, DOI 10.1089/jir.2018.0087; Zhao YY, 2012, J THORAC ONCOL, V7, P71, DOI 10.1097/JTO.0b013e31823085f4; Zheng X, 2020, CANCER RES, V80, P4414, DOI 10.1158/0008-5472.CAN-20-0069; Zuazo M, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910293	81	2	2	7	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2022	41	28					3625	3639		10.1038/s41388-022-02376-w	http://dx.doi.org/10.1038/s41388-022-02376-w		JUN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y2ND	35688943	hybrid, Green Published			2022-12-17	WOS:000809307500002
J	Liu, YT; Ouyang, LL; Mao, C; Chen, YB; Li, TS; Liu, N; Wang, ZL; Lai, WW; Zhou, YL; Cao, Y; Liu, S; Liang, YM; Wang, M; Liu, SP; Chen, L; Shi, Y; Xiao, DS; Tao, YG				Liu, Yating; Ouyang, Lianlian; Mao, Chao; Chen, Yuanbing; Li, Tiansheng; Liu, Na; Wang, Zuli; Lai, Weiwei; Zhou, Yanling; Cao, Ya; Liu, Shuang; Liang, Yinming; Wang, Min; Liu, Shouping; Chen, Ling; Shi, Ying; Xiao, Desheng; Tao, Yongguang			PCDHB14 promotes ferroptosis and is a novel tumor suppressor in hepatocellular carcinoma	ONCOGENE			English	Article							METHYLATION	Liver cancer, a result of multifactorial interplay between heredity and the environment, is one of the leading causes of cancer-related death worldwide. Hepatocellular carcinoma (HCC) is the most common histologic type of primary liver cancer. Here, we reported that deficiency in PCDHB14, a member of the cadherin superfamily, participates in the progression of HCC. We found that PCDHB14 is inactivated by aberrant methylation of its promoter in HCC patients and that PCDHB14 functions as a tumor suppressor to promote cell cycle arrest, inhibit cell proliferation, and induce ferroptosis. Furthermore, PCDHB14 ablation dramatically enhanced diethylenenitrite-induced HCC development. Mechanistically, PCDHB14 is induced by p53, and increased PCDHB14 downregulates the expression of SLC7A11, which is critical for ferroptosis. This effect is mediated by accelerated p65 protein degradation resulting from PCDHB14 promoting E3 ubiquitin ligase RNF182-mediated ubiquitination of p65 to block p65 binding to the promoter of SLC7A11. This study reports the new discovery that PCDHB14 serves as a potential prognostic marker for HCC.	[Liu, Yating] Cent South Univ, Xiangya Hosp 3, Postdoctoral Res Stn Clin Med, Changsha 410000, Peoples R China; [Liu, Yating] Cent South Univ, Xiangya Hosp 3, Dept Hematol & Crit Care Med, Changsha 410000, Peoples R China; [Liu, Yating; Ouyang, Lianlian; Mao, Chao; Chen, Yuanbing; Li, Tiansheng; Liu, Na; Wang, Zuli; Lai, Weiwei; Zhou, Yanling; Cao, Ya; Wang, Min; Liu, Shouping; Chen, Ling; Shi, Ying; Xiao, Desheng; Tao, Yongguang] Cent South Univ, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Dept Pathol,Xiangya Hosp, Changsha 410078, Hunan, Peoples R China; [Liu, Yating; Ouyang, Lianlian; Mao, Chao; Chen, Yuanbing; Li, Tiansheng; Liu, Na; Wang, Zuli; Lai, Weiwei; Zhou, Yanling; Wang, Min; Liu, Shouping; Chen, Ling; Shi, Ying; Xiao, Desheng; Tao, Yongguang] Cent South Univ, NHC Key Lab Carcinogenesis, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Liu, Yating; Ouyang, Lianlian; Mao, Chao; Chen, Yuanbing; Li, Tiansheng; Liu, Na; Wang, Zuli; Lai, Weiwei; Zhou, Yanling; Wang, Min; Liu, Shouping; Chen, Ling; Shi, Ying; Xiao, Desheng; Tao, Yongguang] Cent South Univ, Sch Basic Med, Changsha 410078, Hunan, Peoples R China; [Liu, Shuang] Cent South Univ, Xiangya Hosp, Ctr Geriatr Disorders, Inst Med Sci,Dept Oncol,Natl Clin Res, Changsha 410008, Hunan, Peoples R China; [Liang, Yinming] Xinxiang Med Univ, Sch Lab Med, Xinxiang 453003, Henan, Peoples R China; [Tao, Yongguang] Cent South Univ, Xiangya Hosp 2, Hunan Key Lab Early Diag & Precis Therapy Lung Ca, Changsha 410011, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Xinxiang Medical University; Central South University	Shi, Y; Xiao, DS; Tao, YG (corresponding author), Cent South Univ, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Dept Pathol,Xiangya Hosp, Changsha 410078, Hunan, Peoples R China.; Shi, Y; Xiao, DS; Tao, YG (corresponding author), Cent South Univ, NHC Key Lab Carcinogenesis, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.; Shi, Y; Xiao, DS; Tao, YG (corresponding author), Cent South Univ, Sch Basic Med, Changsha 410078, Hunan, Peoples R China.; Tao, YG (corresponding author), Cent South Univ, Xiangya Hosp 2, Hunan Key Lab Early Diag & Precis Therapy Lung Ca, Changsha 410011, Peoples R China.	yingshi@csu.edu.cn; xdsh96@csu.edu.cn; taoyong@csu.edu.cn			National Natural Science Foundation of China [81872285, 81874139, 82073097, 82072594, 82073136]; Natural Science Foundation of Hunan Province [2021JJ30907, 2020JJ5790, 2021JJ40937]; China Postdoctoral Science Foundation [2021M700173]; Hunan Provincial Key Area RD Program [2021SK2013]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Hunan Provincial Key Area RD Program	This work is supported by National Natural Science Foundation of China [81872285 (YS), 81874139 and 82073097 (SL), 82072594 (YT), 82073136 (DX)], Natural Science Foundation of Hunan Province [2021JJ30907 (YS)], [2020JJ5790 (CM)], [2021JJ40937 (YLiu)], China Postdoctoral Science Foundation [2021M700173 (YLiu)] and the Hunan Provincial Key Area R&D Program [2021SK2013 (YT)].	Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055; Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586-019-1705-2; Cao LYL, 2016, NATURE, V539, P575, DOI 10.1038/nature20170; Cao Y, 2019, FEBS LETT, V593, P3210, DOI 10.1002/1873-3468.13583; Chen L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0196-9; Chen L, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0302-9; Chen XY, 2022, BRIT J CANCER, V126, P165, DOI 10.1038/s41416-021-01543-2; Danese E, 2013, BRIT J CANCER, V109, P807, DOI 10.1038/bjc.2013.351; Fujiwara N, 2018, J HEPATOL, V68, P526, DOI 10.1016/j.jhep.2017.09.016; Gao RZ, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202114351; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Jiang YQ, 2017, THERANOSTICS, V7, P3293, DOI 10.7150/thno.19988; Koppula P, 2021, PROTEIN CELL, V12, P599, DOI 10.1007/s13238-020-00789-5; Li SJ, 2020, MEDCOMM, V1, P178, DOI 10.1002/mco2.15; Liang C, 2019, ADV MATER, V31, DOI 10.1002/adma.201904197; Liu QY, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-4; Liu YT, 2020, ONCOGENE, V39, P2358, DOI 10.1038/s41388-019-1151-5; Mao C, 2018, CANCER RES, V78, P3484, DOI 10.1158/0008-5472.CAN-17-3454; Mazzaferro V, 2020, LANCET ONCOL, V21, P947, DOI 10.1016/S1470-2045(20)30224-2; Morris LGT, 2013, NAT GENET, V45, P253, DOI 10.1038/ng.2538; Pastushenko I, 2021, NATURE, V589, P448, DOI 10.1038/s41586-020-03046-1; Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251; Voisinne G, 2019, NAT IMMUNOL, V20, P1530, DOI 10.1038/s41590-019-0489-8; Wang LQ, 2018, CELL, V173, P1413, DOI 10.1016/j.cell.2018.04.012; Wang M, 2019, CELL DEATH DIFFER, V26, P2329, DOI 10.1038/s41418-019-0304-y; Wang ZL, 2021, MOL THER, V29, P263, DOI 10.1016/j.ymthe.2020.09.024; Ye W, 2018, J PATHOL, V245, P222, DOI 10.1002/path.5073; Yu JS, 2008, ONCOGENE, V27, P4657, DOI 10.1038/onc.2008.101; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zhang T, 2021, MEDCOMM, V2, P618, DOI 10.1002/mco2.104; Zhang YL, 2018, NAT CELL BIOL, V20, P1181, DOI 10.1038/s41556-018-0178-0; Zhang YC, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0610-5; Zhao Y, 2014, CANCER RES, V74, P5103, DOI 10.1158/0008-5472.CAN-14-0427; Zhou XR, 2017, CANCER RES, V77, P187, DOI 10.1158/0008-5472.CAN-16-1267-T	34	2	2	11	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2022	41	27					3570	3583		10.1038/s41388-022-02370-2	http://dx.doi.org/10.1038/s41388-022-02370-2		JUN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2P6AJ	35688944				2022-12-17	WOS:000809307500001
J	Zheng, XC; Liu, ZF; Zhong, JL; Zhou, LW; Chen, JW; Zheng, LS; Li, ZY; Zhang, RH; Pan, JX; Wu, YZ; Liu, ZW; Kang, TB				Zheng, Xianchong; Liu, Zefu; Zhong, Jianliang; Zhou, Liwen; Chen, Jiawei; Zheng, Lisi; Li, Zhiyong; Zhang, Ruhua; Pan, Jingxuan; Wu, Yuanzhong; Liu, Zhuowei; Kang, Tiebang			Downregulation of HINFP induces senescence-associated secretory phenotype to promote metastasis in a non-cell-autonomous manner in bladder cancer	ONCOGENE			English	Article							C-MYC; EXPRESSION; IDENTIFICATION; CISPLATIN	Transcription dysregulation is a salient characteristic of bladder cancer (BC), but no appropriate therapeutic target for it has been established. Here, we found that heterogeneous downregulation of histone H4 transcription factor (HINFP) was associated with senescence in BC tissues and that lower HINFP expression could predict an unfavorable outcome in BC patients. Knockout of HINFP transcriptionally inhibited H1F0 and H1FX to trigger DNA damage, consequently inducing cell senescence to repress the proliferation and growth of BC cells. However, the senescence-associated secretory phenotype, characterized by increases in MMP1/3, enhances the invasion and metastasis of non-senescent BC cells. Histone deacetylase inhibitors (HDACis) could efficiently eliminate the senescent cells induced by HINFP knockout to suppress the invasion and metastasis of BC cells. Our study suggests that HDACis, widely used in multiple cancer types in a clinical context, may also benefit BC patients with metastases induced by cell senescence.	[Zheng, Xianchong; Liu, Zefu; Zhong, Jianliang; Zhou, Liwen; Chen, Jiawei; Zheng, Lisi; Zhang, Ruhua; Wu, Yuanzhong; Liu, Zhuowei; Kang, Tiebang] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China; [Zheng, Xianchong; Liu, Zefu; Chen, Jiawei; Li, Zhiyong; Liu, Zhuowei] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Peoples R China; [Pan, Jingxuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Wu, YZ; Liu, ZW; Kang, TB (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China.; Liu, ZW (corresponding author), Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Peoples R China.	wuyzh@sysucc.org.cn; liuzhw@sysucc.org.cn; kangtb@sysucc.org.cn		Wu, Yuanzhong/0000-0002-3577-7069	National Key Research and Development Program of China [2021YFA1300601, 2020YFA0509400]; National Nature Science Foundation of China (NSFC) [82030090, 82073103, 82103264, 82172939, 82002917]; Science and Technology Program of Guangzhou [202002020092]	National Key Research and Development Program of China; National Nature Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangzhou	We thank Dr. Meisongzhu Yang from SYSUCC for her help in constructing the animal models and Dr. Jietian Jin from SYSUCC for help with pathological diagnosis. This work was supported by grants from the National Key Research and Development Program of China (2021YFA1300601 to TK, 2020YFA0509400 to JP), the National Nature Science Foundation of China (NSFC) (82030090 to TK, 82073103 to ZWL, 82103264 to XCZ, 82172939 to YW, 82002917 to LWZ), and the Science and Technology Program of Guangzhou (202002020092).	Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Brooks TA, 2009, NAT REV CANCER, V9, P849, DOI 10.1038/nrc2733; Cai YS, 2020, CELL RES, V30, P574, DOI 10.1038/s41422-020-0314-9; Chan KS, 2009, P NATL ACAD SCI USA, V106, P14016, DOI 10.1073/pnas.0906549106; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Faget DV, 2019, NAT REV CANCER, V19, P439, DOI 10.1038/s41568-019-0156-2; Fane M, 2020, NAT REV CANCER, V20, P89, DOI 10.1038/s41568-019-0222-9; Funayama R, 2006, J CELL BIOL, V175, P869, DOI 10.1083/jcb.200604005; Ghule PN, 2016, DEV BIOL, V419, P311, DOI 10.1016/j.ydbio.2016.09.003; Guccini I, 2021, CANCER CELL, V39, P68, DOI 10.1016/j.ccell.2020.10.012; Guo YX, 2020, CELL DEATH DIFFER, V27, P1862, DOI 10.1038/s41418-019-0466-7; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hayden A, 2014, UROL ONCOL-SEMIN ORI, V32, P806, DOI 10.1016/j.urolonc.2014.02.006; Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8; Kim YH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15208; Koike-Yusa H, 2014, NAT BIOTECHNOL, V32, P267, DOI 10.1038/nbt.2800; Li C, 2002, J AM COLL CARDIOL, V39, P1852, DOI 10.1016/S0735-1097(02)01873-9; Liu LJ, 2011, GENE, V483, P1, DOI 10.1016/j.gene.2011.05.002; Milanovic M, 2018, TRENDS CELL BIOL, V28, P1049, DOI 10.1016/j.tcb.2018.09.001; Sardi I, 1998, EUR UROL, V33, P424, DOI 10.1159/000019629; SchmitzDrager BJ, 1997, UROL RES, V25, pS45, DOI 10.1007/BF00942047; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Sieben CJ, 2018, TRENDS CELL BIOL, V28, P723, DOI 10.1016/j.tcb.2018.04.006; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stein JP, 2006, WORLD J UROL, V24, P296, DOI 10.1007/s00345-006-0061-7; Sulli G, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3344; Sun Y, 2018, TRENDS MOL MED, V24, P871, DOI 10.1016/j.molmed.2018.08.002; Valencia AM, 2019, NAT CELL BIOL, V21, P152, DOI 10.1038/s41556-018-0258-1; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757; Wang LQ, 2018, CELL, V173, P1413, DOI 10.1016/j.cell.2018.04.012; Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Watanabe S, 2017, CANCER SCI, V108, P563, DOI 10.1111/cas.13184; Xie RL, 2009, P NATL ACAD SCI USA, V106, P12359, DOI 10.1073/pnas.0905651106; Xu Y, 2017, DRUG TODAY, V53, P167, DOI 10.1358/dot.2017.53.3.2595452; Zhang Z, 2007, HUM PATHOL, V38, P598, DOI 10.1016/j.humpath.2006.10.004; Zhou YX, 2014, NATURE, V509, P487, DOI 10.1038/nature13166	38	2	2	8	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2022	41	28					3587	3598		10.1038/s41388-022-02371-1	http://dx.doi.org/10.1038/s41388-022-02371-1		JUN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y2ND	35668172				2022-12-17	WOS:000806674700001
J	Meijer, TG; Nguyen, L; Van Hoeck, A; Sieuwerts, AM; Verkaik, NS; Ladan, MM; Ruigrok-Ritstier, K; van Deurzen, CHM; van de Werken, HJG; Lips, EH; Linn, SC; Memari, Y; Davies, H; Nik-Zainal, S; Kanaar, R; Martens, JWM; Cuppen, E; Jager, A; van Gent, DC				Meijer, Titia G.; Nguyen, Luan; Van Hoeck, Arne; Sieuwerts, Anieta M.; Verkaik, Nicole S.; Ladan, Marjolijn M.; Ruigrok-Ritstier, Kirsten; van Deurzen, Carolien H. M.; van de Werken, Harmen J. G.; Lips, Esther H.; Linn, Sabine C.; Memari, Yasin; Davies, Helen; Nik-Zainal, Serena; Kanaar, Roland; Martens, John W. M.; Cuppen, Edwin; Jager, Agnes; van Gent, Dik C.			Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests	ONCOGENE			English	Article							BREAST-CANCER; OLAPARIB; CHEMOTHERAPY; ASSOCIATION; LANDSCAPE; BENEFIT	Germline BRCA1/2 mutation status is predictive for response to Poly-[ADP-Ribose]-Polymerase (PARP) inhibitors in breast cancer (BC) patients. However, non-germline BRCA1/2 mutated and homologous recombination repair deficient (HRD) tumors are likely also PARP-inhibitor sensitive. Clinical validity and utility of various HRD biomarkers are under investigation. The REpair CAPacity (RECAP) test is a functional method to select HRD tumors based on their inability to form RAD51 foci. We investigated whether this functional test defines a similar group of HRD tumors as DNA-based tests. An HRD enriched cohort (n = 71; 52 primary and 19 metastatic BCs) selected based on the RECAP test (26 RECAP-HRD; 37%), was subjected to DNA-based HRD tests (i.e., Classifier of HOmologous Recombination Deficiency (CHORD) and BRCA1/2-like classifier). Whole genome sequencing (WGS) was carried out for 38 primary and 19 metastatic BCs. The RECAP test identified all bi-allelic BRCA deficient samples (n = 15) in this cohort. RECAP status partially correlated with DNA-based HRD test outcomes (70% concordance for both RECAP-CHORD and RECAP-BRCA1/2-like classifier). RECAP selected additional samples unable to form RAD51 foci, suggesting that this functional assay identified deficiencies in other DNA repair genes, which could also result in PARP-inhibitor sensitivity. Direct comparison of these HRD tests in clinical trials will be required to evaluate the optimal predictive test for clinical decision making.	[Meijer, Titia G.; Verkaik, Nicole S.; Ladan, Marjolijn M.; Kanaar, Roland; van Gent, Dik C.] Erasmus MC, Erasmus MC Canc Inst, Dept Mol Genet, Rotterdam, Netherlands; [Meijer, Titia G.; van Deurzen, Carolien H. M.; Kanaar, Roland; van Gent, Dik C.] Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands; [Meijer, Titia G.; Nguyen, Luan; Van Hoeck, Arne; Verkaik, Nicole S.; Ladan, Marjolijn M.; Cuppen, Edwin] Oncode Inst, Utrecht, Netherlands; [Nguyen, Luan; Van Hoeck, Arne; Cuppen, Edwin] Univ Med Ctr Utrecht, Dept Mol Genet, Utrecht, Netherlands; [Sieuwerts, Anieta M.; Ruigrok-Ritstier, Kirsten; Martens, John W. M.; Jager, Agnes] Erasmus MC, Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands; [van de Werken, Harmen J. G.] Erasmus MC, Canc Computat Biol Ctr, Erasmus MC Canc Inst, Rotterdam, Netherlands; [van de Werken, Harmen J. G.] Erasmus MC, Erasmus MC Canc Inst, Dept Urol, Rotterdam, Netherlands; [van de Werken, Harmen J. G.] Erasmus MC, Erasmus MC Canc Inst, Dept Immunol, Rotterdam, Netherlands; [Lips, Esther H.; Linn, Sabine C.] Netherlands Canc Inst, Dept Mol Pathol, Amsterdam, Netherlands; [Linn, Sabine C.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands; [Linn, Sabine C.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Memari, Yasin; Davies, Helen; Nik-Zainal, Serena] Univ Cambridge, Acad Dept Med Genet, Cambridge Biomed Campus, Cambridge, England; [Memari, Yasin; Davies, Helen; Nik-Zainal, Serena] Univ Cambridge, MRC Canc Unit, Cambridge Biomed Campus, Cambridge, England; [Cuppen, Edwin] Hartwig Med Fdn, Sci Pk, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Utrecht University; Utrecht University Medical Center; University of Cambridge; University of Cambridge	Meijer, TG (corresponding author), Erasmus MC, Erasmus MC Canc Inst, Dept Mol Genet, Rotterdam, Netherlands.; Meijer, TG (corresponding author), Erasmus MC, Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands.; Meijer, TG (corresponding author), Oncode Inst, Utrecht, Netherlands.	t.meijer@erasmusmc.nl	Werken, Harmen van de/G-8979-2013; Nguyen, Luan/GYA-2927-2022	Werken, Harmen van de/0000-0002-9794-1477; Lips, Esther/0000-0003-3488-4935; van Gent, Dik C./0000-0003-1473-8148	Dutch Cancer Society [EMCR 2014-7048, EMCR 2008-4045]; Dutch Cancer Society; Netherlands Organization for Scientific Research (NWO)	Dutch Cancer Society(KWF Kankerbestrijding); Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	DCvG, AJ, and RK have received funding from the Dutch Cancer Society (Alpe d'Huzes grant number EMCR 2014-7048 and grant number EMCR 2008-4045). This work is part of the Oncode Institute which is partly financed by the Dutch Cancer Society and was funded by the gravitation program CancerGenomiCs.nl from the Netherlands Organization for Scientific Research (NWO).	Angus L, 2019, NAT GENET, V51, P1450, DOI 10.1038/s41588-019-0507-7; [Anonymous], BIORXIV, DOI 10.1101/781013; Chopra N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16142-7; Davies H, 2017, NAT MED, V23, P517, DOI 10.1038/nm.4292; Eikesdal HP, 2021, ANN ONCOL, V32, P240, DOI 10.1016/j.annonc.2020.11.009; Ettl J, 2018, ANN ONCOL, V29, P1939, DOI 10.1093/annonc/mdy257; Goncalves A, 2020, CANCERS, V12, DOI 10.3390/cancers12061378; Joosse SA, 2012, BREAST CANCER RES TR, V132, P379, DOI 10.1007/s10549-010-1016-7; Joosse SA, 2009, BREAST CANCER RES TR, V116, P479, DOI 10.1007/s10549-008-0117-z; Knijnenburg TA, 2018, CELL REP, V23, P239, DOI 10.1016/j.celrep.2018.03.076; Ladan MM, 2021, CANCERS, V13, DOI 10.3390/cancers13051004; LI A, 2019, NPJ BREAST CANCER, V5; Lips EH, 2011, ANN ONCOL, V22, P870, DOI 10.1093/annonc/mdq468; Litton JK, 2018, NEW ENGL J MED, V379, P753, DOI 10.1056/NEJMoa1802905; LITTON JK, 2020, J CLIN ONCOL, V38; Llop-Guevara A, 2021, ANN ONCOL, V32, P1590, DOI 10.1016/j.annonc.2021.09.003; Loibl S, 2018, ANN ONCOL, V29, P2341, DOI 10.1093/annonc/mdy460; Mayer EL, 2020, ANN ONCOL, V31, P1518, DOI 10.1016/j.annonc.2020.08.2064; Meijer TG, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00268; Meijer TG, 2018, CLIN CANCER RES, V24, P6277, DOI 10.1158/1078-0432.CCR-18-0063; Naipal KAT, 2014, CLIN CANCER RES, V20, P4816, DOI 10.1158/1078-0432.CCR-14-0571; Nguyen L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19406-4; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Nones K, 2019, ANN ONCOL, V30, P1071, DOI 10.1093/annonc/mdz132; Pilie PG, 2019, CLIN CANCER RES, V25, P3759, DOI 10.1158/1078-0432.CCR-18-0968; Priestley P, 2019, NATURE, V575, P210, DOI 10.1038/s41586-019-1689-y; Robson ME, 2019, ANN ONCOL, V30, P558, DOI 10.1093/annonc/mdz012; Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450; Schouten PC, 2016, INT J CANCER, V139, P882, DOI 10.1002/ijc.30078; Schouten PC, 2015, MOL ONCOL, V9, P1274, DOI 10.1016/j.molonc.2015.03.002; Schouten PC, 2013, BREAST CANCER RES TR, V139, P317, DOI 10.1007/s10549-013-2558-2; Schwartz LH, 2016, EUR J CANCER, V62, P132, DOI 10.1016/j.ejca.2016.03.081; Severson TM, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0861-2; Sharma P, 2018, ANN ONCOL, V29, P654, DOI 10.1093/annonc/mdx821; Shimelis H, 2017, CANCER RES, V77, P2789, DOI 10.1158/0008-5472.CAN-16-2568; Staaf J, 2019, NAT MED, V25, P1526, DOI 10.1038/s41591-019-0582-4; Stronach EA, 2018, MOL CANCER RES, V16, P1103, DOI 10.1158/1541-7786.MCR-18-0034; Tudini E, 2018, BREAST CANCER RES TR, V172, P497, DOI 10.1007/s10549-018-4903-y; Tutt A, 2018, NAT MED, V24, P628, DOI 10.1038/s41591-018-0009-7; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Vollebergh MA, 2011, ANN ONCOL, V22, P1561, DOI 10.1093/annonc/mdq624	41	2	2	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2022	41	26					3498	3506		10.1038/s41388-022-02363-1	http://dx.doi.org/10.1038/s41388-022-02363-1		JUN 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2J2QW	35662281	hybrid, Green Published, Green Submitted			2022-12-17	WOS:000805724700002
J	Puccini, A; Poorman, K; Catalano, F; Seeber, A; Goldberg, RM; Salem, ME; Shields, AF; Berger, MD; Battaglin, F; Tokunaga, R; Naseem, M; Zhang, W; Philip, PA; Marshall, JL; Korn, WM; Lenz, HJ				Puccini, Alberto; Poorman, Kelsey; Catalano, Fabio; Seeber, Andreas; Goldberg, Richard M.; Salem, Mohamed E.; Shields, Anthony F.; Berger, Martin D.; Battaglin, Francesca; Tokunaga, Ryuma; Naseem, Madiha; Zhang, Wu; Philip, Philip A.; Marshall, John L.; Korn, W. Michael; Lenz, Heinz-Josef			Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets	ONCOGENE			English	Article							PROGNOSTIC-SIGNIFICANCE; COLORECTAL-CANCER; HISTOLOGY; FEATURES; OUTCOMES	Signet ring cell carcinoma (SRCC) is rare: about 10% of gastric cancer (GC) and 1% of colorectal cancer (CRC). SRCC is associated with poor prognosis, however the underlying molecular characteristics are unknown. SRCCs were analyzed using NGS, immunohistochemistry, and in situ hybridization. Tumor mutational burden (TMB) was calculated based on somatic nonsynonymous missense mutations, and microsatellite instability (MSI) was evaluated by NGS of known MSI loci. A total of 8500 CRC and 1100 GC were screened. Seventy-six SRCC were identified from the CRC cohort (<1%) and 98 from the GC cohort (9%). The most frequently mutated genes in CRC-SRCC were TP53 (47%), ARID1A (26%), APC (25%); in GC-SRCC were TP53 (42%), ARID1A (27%), CDH1 (11%). When compared to non-SRCC histology (N = 3522), CRC-SRCC (N = 37) more frequently had mutations in BRCA1 (11% vs 1%, P < 0.001) and less frequently mutations in APC (19% vs 78%, P < 0.001), KRAS (22% vs 51%, P = 0.001) and TP53 (47% vs 73%, P = 0.001). Among the GC cohort, SRCC (N = 54) had a higher frequency of mutations in CDH1, BAP1, and ERBB2, compared to non-SRCC (N = 540). Our data suggest that SRCCs harbor a similar molecular profile, regardless of the tumor location. Tailored therapy may become available for these patients.	[Puccini, Alberto; Berger, Martin D.; Battaglin, Francesca; Tokunaga, Ryuma; Naseem, Madiha; Zhang, Wu; Lenz, Heinz-Josef] Univ Southern Calif, Norris Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90007 USA; [Puccini, Alberto; Catalano, Fabio] Univ Genoa, Osped Policlin San Martino IRCCS, Genoa, Italy; [Poorman, Kelsey; Korn, W. Michael] Caris Life Sci, Phoenix, AZ USA; [Seeber, Andreas] Innsbruck Med Univ, Comprehens Canc Ctr Innsbruck, Dept Hematol & Oncol, Innsbruck, Austria; [Goldberg, Richard M.] West Virginia Univ, Canc Inst, Morgantown, WV 26506 USA; [Salem, Mohamed E.] Levine Canc Inst, Charlotte, NC USA; [Shields, Anthony F.; Philip, Philip A.] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA; [Marshall, John L.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Med Ctr, Washington, DC USA	University of Southern California; University of Genoa; Medical University of Innsbruck; West Virginia University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Georgetown University	Lenz, HJ (corresponding author), Univ Southern Calif, Norris Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90007 USA.	lenz@med.usc.edu	Battaglin, Francesca/C-2746-2017	Battaglin, Francesca/0000-0002-9869-0163; Puccini, Alberto/0000-0002-2492-4043	National Cancer Institute [P30CA014089]; Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Gene Gregg Pancreas Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler Research Fund; Victoria and Philip Wilson Research Fund; Fong research project; Ming Hsieh research fund	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Gene Gregg Pancreas Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler Research Fund; Victoria and Philip Wilson Research Fund; Fong research project; Ming Hsieh research fund	This work was partly supported by National Cancer Institute (grant number P30CA014089), Gloria Borges WunderGlo Foundation, Dhont Family Foundation, Gene Gregg Pancreas Research Fund, San Pedro Peninsula Cancer Guild, Daniel Butler Research Fund, Victoria and Philip Wilson Research Fund, Fong research project and Ming Hsieh research fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute of the National Institutes of Health.	Alvi MA, 2017, BRIT J CANCER, V117, P203, DOI 10.1038/bjc.2017.168; Andre T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699; Bamboat ZM, 2014, ANN SURG ONCOL, V21, P1678, DOI 10.1245/s10434-013-3466-8; Barresi V, 2020, FUTURE ONCOL, V16, P1161, DOI 10.2217/fon-2020-0242; Benesch MGK, 2020, CANCERS, V12, DOI 10.3390/cancers12061544; Bosman FT, 2010, WHO CLASSIFICATION T; Bosman FT, 2010, WHO CLASSIFICATION T; Caravagna G, 2018, NAT METHODS, V15, P707, DOI 10.1038/s41592-018-0108-x; Catalano F, 2022, CANCERS, V14, DOI 10.3390/cancers14061388; Chen L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176637; Chon HJ, 2017, ANN SURG, V265, P946, DOI 10.1097/SLA.0000000000001793; Gong HY, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033820960746; Henson DE, 2004, ARCH PATHOL LAB MED, V128, P765; Hugen N, 2015, INT J CANCER, V136, P333, DOI 10.1002/ijc.28981; Hyngstrom JR, 2012, ANN SURG ONCOL, V19, P2814, DOI 10.1245/s10434-012-2321-7; Inamura K, 2015, ANN SURG ONCOL, V22, P1226, DOI 10.1245/s10434-014-4159-7; Jin SY, 2017, ONCOTARGET, V8, P38850, DOI 10.18632/oncotarget.16407; Kim S, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0148-y; Kong PF, 2016, SCI REP-UK, V6, DOI 10.1038/srep26313; Korphaisarn K, 2019, BRIT J CANCER, V121, P505, DOI 10.1038/s41416-019-0548-9; Kwon KJ, 2014, GASTRIC CANCER, V17, P43, DOI 10.1007/s10120-013-0234-1; Lee WS, 2007, AM J SURG, V194, P294, DOI 10.1016/j.amjsurg.2006.12.041; Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105; Mariette C, 2019, GASTRIC CANCER, V22, P1, DOI 10.1007/s10120-018-0868-0; Mauri G, 2020, ANN ONCOL, V31, P1135, DOI 10.1016/j.annonc.2020.05.027; Mengardo V, 2018, UPDATES SURG, V70, P167, DOI 10.1007/s13304-018-0550-4; Nagtegaal ID, 2020, HISTOPATHOLOGY, V76, P182, DOI 10.1111/his.13975; Nitsche U, 2016, J CANCER RES CLIN, V142, P2357, DOI 10.1007/s00432-016-2224-2; Nitsche U, 2013, ANN SURG, V258, P775, DOI 10.1097/SLA.0b013e3182a69f7e; Noh MG, 2021, EXP MOL MED, V53, P223, DOI 10.1038/s12276-021-00559-1; Pande R, 2008, DIS COLON RECTUM, V51, P50, DOI 10.1007/s10350-007-9073-7; Pernot S, 2015, WORLD J GASTROENTERO, V21, P11428, DOI 10.3748/wjg.v21.i40.11428; Piessen G, 2009, ANN SURG, V250, P878, DOI 10.1097/SLA.0b013e3181b21c7b; Puccini A, 2019, ONCOLOGIST, V24, P319, DOI 10.1634/theoncologist.2018-0117; Taghavi S, 2012, J CLIN ONCOL, V30, P3493, DOI 10.1200/JCO.2012.42.6635; Tajiri K, 2017, ANTICANCER RES, V37, P3817, DOI 10.21873/anticanres.11760; Tung SY, 1996, AM J GASTROENTEROL, V91, P2195; Warner JN, 2010, MAYO CLIN PROC, V85, P1130, DOI 10.4065/mcp.2010.0463; World Health Organization, 2019, DIG SYST TUM, V5th, DOI DOI 10.1111/HIS.13975; Wu XF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162088; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Zhao Z, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70985-0; Zimmer K, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.662055	43	2	2	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2022	41	26					3455	3460		10.1038/s41388-022-02350-6	http://dx.doi.org/10.1038/s41388-022-02350-6		MAY 2022	6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2J2QW	35618879	Green Accepted			2022-12-17	WOS:000805545200001
J	Li, DX; Yu, XF; Kottur, J; Gong, WD; Zhang, Z; Storey, AJ; Tsai, YH; Uryu, H; Shen, YD; Byrum, SD; Edmondson, RD; Mackintosh, SG; Cai, L; Liu, ZJ; Aggarwal, AK; Tackett, AJ; Liu, J; Jin, J; Wang, GG				Li, Dongxu; Yu, Xufen; Kottur, Jithesh; Gong, Weida; Zhang, Zhao; Storey, Aaron J.; Tsai, Yi-Hsuan; Uryu, Hidetaka; Shen, Yudao; Byrum, Stephanie D.; Edmondson, Rick D.; Mackintosh, Samuel G.; Cai, Ling; Liu, Zhijie; Aggarwal, Aneel K.; Tackett, Alan J.; Liu, Jing; Jin, Jian; Wang, Gang Greg			Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic	ONCOGENE			English	Article							PROTEIN 5 WDR5; ENZYMATIC-ACTIVITY; STRUCTURAL BASIS; HIGH-AFFINITY; MLL1; DEGRADATION; COMPLEX; RECOGNITION; EXPRESSION; CANCER	WD repeat domain 5 (WDR5), an integral component of the MLL/KMT2A lysine methyltransferase complex, is critically involved in oncogenesis and represents an attractive onco-target. Inhibitors targeting protein-protein interactions (PPIs) between WDR5 and its binding partners, however, do not inhibit all of WDR5-mediated oncogenic functions and exert rather limited antitumor effects. Here, we report a cereblon (CRBN)-recruiting proteolysis targeting chimera (PROTAC) of WDR5, MS40, which selectively degrades WDR5 and the well-established neo-substrates of immunomodulatory drugs (IMiDs):CRBN, the Ikaros zinc finger (IKZF) transcription factors IKZF1 and IKZF3. MS40-induced WDR5 degradation caused disassociation of the MLL/KMT2A complex off chromatin, resulting in decreased H3K4me2. Transcriptomic profiling revealed that targets of both WDR5 and IMiDs:CRBN were significantly repressed by treatment of MS40. In MLL-rearranged leukemias, which exhibit IKZF1 high expression and dependency, co-suppression of WDR5 and Ikaros by MS40 is superior in suppressing oncogenesis to the WDR5 PPI inhibitor, to MS40's non-PROTAC analog controls (MS40N1 and MS40N2, which do not bind CRBN and WDR5, respectively), and to a matched VHL-based WDR5 PROTAC (MS169, which degrades WDR5 but not Ikaros). MS40 suppressed the growth of primary leukemia patient cells in vitro and patient-derived xenografts in vivo. Thus, dual degradation of WDR5 and Ikaros is a promising anti-cancer strategy.	[Li, Dongxu; Gong, Weida; Tsai, Yi-Hsuan; Uryu, Hidetaka; Cai, Ling; Wang, Gang Greg] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Li, Dongxu; Uryu, Hidetaka; Wang, Gang Greg] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27515 USA; [Yu, Xufen; Kottur, Jithesh; Shen, Yudao; Liu, Jing; Jin, Jian] Icahn Sch Med Mt Sinai, Mt Sinai Ctr Therapeut Discovery, New York, NY 10029 USA; [Yu, Xufen; Kottur, Jithesh; Shen, Yudao; Aggarwal, Aneel K.; Liu, Jing; Jin, Jian] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pharmacol Sci, New York, NY 10029 USA; [Yu, Xufen; Kottur, Jithesh; Shen, Yudao; Aggarwal, Aneel K.; Liu, Jing; Jin, Jian] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA; [Zhang, Zhao; Liu, Zhijie] Univ Texas Hlth Sci Ctr San Antonio, Mays Canc Ctr, Dept Mol Med, San Antonio, TX USA; [Storey, Aaron J.; Byrum, Stephanie D.; Edmondson, Rick D.; Mackintosh, Samuel G.; Tackett, Alan J.] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR USA; [Cai, Ling] Univ N Carolina, Dept Genet, Chapel Hill, NC USA; [Wang, Gang Greg] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Health San Antonio; University of Arkansas System; University of Arkansas Medical Sciences; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wang, GG (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.; Wang, GG (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27515 USA.; Jin, J (corresponding author), Icahn Sch Med Mt Sinai, Mt Sinai Ctr Therapeut Discovery, New York, NY 10029 USA.; Jin, J (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Pharmacol Sci, New York, NY 10029 USA.; Jin, J (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA.; Wang, GG (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA.	jian.jin@mssm.edu; greg_wang@med.unc.edu	; Wang, G Greg/L-6666-2014	Kottur, Jithesh/0000-0002-8075-3883; YU, XUFEN/0000-0001-7794-7890; Wang, G Greg/0000-0002-7210-9940	US National Institutes of Health [R01GM122749, P30CA196521, R01CA211336, R01CA215284, R01CA268384, R35GM131780, R24GM137786, P20GM121293, R01CA236209, P20GM103429]; NIH/Office of the Director Grant [S10OD018445, R01GM137009, U54 CA217297/PRJ001]; Icahn School of Medicine at Mount Sinai; Gabrielle's Angel Foundation for Cancer Research; When Everyone Survives (WES) Leukemia Research Foundation; UNC Lineberger Cancer Center UCRF Stimulus Initiative Grants; National Institutes of Health SIG grants [1S10OD025132, 1S10OD028504]; UNC Lineberger Comprehensive Cancer Center Core Support Grant [P30CA016086]	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/Office of the Director Grant; Icahn School of Medicine at Mount Sinai; Gabrielle's Angel Foundation for Cancer Research; When Everyone Survives (WES) Leukemia Research Foundation; UNC Lineberger Cancer Center UCRF Stimulus Initiative Grants; National Institutes of Health SIG grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UNC Lineberger Comprehensive Cancer Center Core Support Grant	We graciously thank Drs. J Bradner, W Kaelin, Y Dou, H Wen, X Shi, and H Jiang for providing reagents and cells used in the study and the Wang and Jin Laboratory members for helpful discussion and technical support. This work was supported in part by the US National Institutes of Health grants R01GM122749 (to JJ), P30CA196521 (to JJ), R01CA211336 (to GGW), R01CA215284 (to GGW), R01CA268384 (to JJ and GGW), R35GM131780 (to AKA), R24GM137786 (to AJT), P20GM121293 (to AJT), R01CA236209 (to AJT), P20GM103429 (to AJT), an NIH/Office of the Director Grant S10OD018445 (to SGM), R01GM137009 (to ZL), U54 CA217297/PRJ001 (to ZL), endowed professorships from the Icahn School of Medicine at Mount Sinai (to JJ and AKA), and grants/awards from Gabrielle's Angel Foundation for Cancer Research (to GGW), When Everyone Survives (WES) Leukemia Research Foundation (to GGW) and UNC Lineberger Cancer Center UCRF Stimulus Initiative Grants (to GGW and LC). G.G.W. is an American Cancer Society Research Scholar, a Leukemia and Lymphoma Society Scholar, and an American Society of Hematology Scholar in Basic Science. This work utilized the NMR Spectrometer Systems at Mount Sinai acquired with funding from National Institutes of Health SIG grants 1S10OD025132 and 1S10OD028504. We thank UNC's facilities, including Highthroughput Sequencing Facility (HTSF), Bioinformatics Core, Tissue Culture Facility, Animal Studies Core, and UNC Tissue Procurement Facility, for their professional assistance in this work. The cores affiliated with the UNC Cancer Center are supported in part by the UNC Lineberger Comprehensive Cancer Center Core Support Grant P30CA016086.	Ahn JH, 2021, NATURE, V595, P591, DOI 10.1038/s41586-021-03662-5; Aho ER, 2019, CELL REP, V26, P2916, DOI 10.1016/j.celrep.2019.02.047; Akuffo AA, 2018, J BIOL CHEM, V293, P6187, DOI 10.1074/jbc.M117.816868; Alicea-Velazquez NL, 2016, J BIOL CHEM, V291, P22357, DOI 10.1074/jbc.M116.752626; An J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15398; Bolshan Y, 2013, ACS MED CHEM LETT, V4, P353, DOI 10.1021/ml300467n; Cai L, 2018, MOL CELL, V72, P341, DOI 10.1016/j.molcel.2018.08.029; Cao F, 2014, MOL CELL, V53, P247, DOI 10.1016/j.molcel.2013.12.001; Carugo A, 2016, CELL REP, V16, P133, DOI 10.1016/j.celrep.2016.05.063; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Ciceri P, 2014, NAT CHEM BIOL, V10, P305, DOI 10.1038/nchembio.1471; Dale B, 2021, NAT REV CANCER, V21, P638, DOI 10.1038/s41568-021-00365-x; Dawson MA, 2017, SCIENCE, V355, P1147, DOI 10.1126/science.aam7304; Dharmarajan V, 2012, J BIOL CHEM, V287, P27275, DOI 10.1074/jbc.M112.364125; Dobrovolsky D, 2019, BLOOD, V133, P952, DOI 10.1182/blood-2018-07-862953; Dolle A, 2021, J MED CHEM, V64, P10682, DOI 10.1021/acs.jmedchem.1c00146; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Egan B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166438; Fan HT, 2020, NAT GENET, V52, P1384, DOI 10.1038/s41588-020-00729-3; Gadd MS, 2017, NAT CHEM BIOL, V13, P514, DOI [10.1038/NCHEMBIO.2329, 10.1038/nchembio.2329]; Ge Z, 2016, ONCOTARGET, V7, P37740, DOI 10.18632/oncotarget.9312; Getlik M, 2016, J MED CHEM, V59, P2478, DOI 10.1021/acs.jmedchem.5b01630; Grebien F, 2015, NAT CHEM BIOL, V11, P571, DOI [10.1038/NCHEMBIO.1859, 10.1038/nchembio.1859]; Guarnaccia AD, 2018, J CLIN MED, V7, DOI 10.3390/jcm7020021; Ishoey M, 2018, ACS CHEM BIOL, V13, P553, DOI 10.1021/acschembio.7b00969; Jin J, 2019, WD40 REPEAT DOMAIN PROTEIN 5 (WDR5) DEGRADATION/DISRUPTION COMPOUNDS AND METHODS OF USE, Patent No. [WO2019246570, 2019246570]; Karatas H, 2017, J MED CHEM, V60, P4818, DOI 10.1021/acs.jmedchem.6b01796; Karatas H, 2013, J AM CHEM SOC, V135, P669, DOI 10.1021/ja306028q; Kronke J, 2015, NATURE, V523, P183, DOI 10.1038/nature14610; Lai AC, 2017, NAT REV DRUG DISCOV, V16, P101, DOI 10.1038/nrd.2016.211; Li DD, 2016, EUR J MED CHEM, V124, P480, DOI 10.1016/j.ejmech.2016.08.036; Li JX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21293-2; Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Lu R, 2016, CANCER CELL, V30, P92, DOI 10.1016/j.ccell.2016.05.008; Macdonald JD, 2019, J MED CHEM, V62, P11232, DOI 10.1021/acs.jmedchem.9b01411; Matyskiela ME, 2016, NATURE, V535, P252, DOI 10.1038/nature18611; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; MORI T, 2018, SCI REP-UK, V8; Odho Z, 2010, J BIOL CHEM, V285, P32967, DOI 10.1074/jbc.M110.159921; Park I, 2021, CANCERS, V13, DOI 10.3390/cancers13205084; Patel A, 2008, J BIOL CHEM, V283, P32162, DOI 10.1074/jbc.M806317200; Patel A, 2008, J BIOL CHEM, V283, P32158, DOI 10.1074/jbc.C800164200; Patel A, 2011, J BIOL CHEM, V286, P3359, DOI 10.1074/jbc.M110.174524; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Ren ZH, 2019, BLOOD, V134, P1176, DOI 10.1182/blood.2019000578; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Romanelli A, 2020, ACS MED CHEM LETT, V11, P977, DOI 10.1021/acsmedchemlett.0c00014; Schapira M, 2019, NAT REV DRUG DISCOV, V18, P949, DOI 10.1038/s41573-019-0047-y; Senisterra G, 2013, BIOCHEM J, V449, P151, DOI 10.1042/BJ20121280; Simon SC, 2020, J MED CHEM, V63, P4315, DOI 10.1021/acs.jmedchem.0c00224; Steward MM, 2006, NAT STRUCT MOL BIOL, V13, P852, DOI 10.1038/nsmb1131; Sun YT, 2015, CANCER RES, V75, P5143, DOI 10.1158/0008-5472.CAN-15-0423; Thomas LR, 2015, MOL CELL, V58, P440, DOI 10.1016/j.molcel.2015.02.028; Tian J, 2020, J MED CHEM, V63, P656, DOI 10.1021/acs.jmedchem.9b01608; Townsend EC, 2016, CANCER CELL, V29, P574, DOI 10.1016/j.ccell.2016.03.008; Trievel RC, 2009, NAT STRUCT MOL BIOL, V16, P678, DOI 10.1038/nsmb0709-678; Wang F, 2018, J MED CHEM, V61, P5623, DOI 10.1021/acs.jmedchem.8b00375; Xia RL, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.788440; Xu BW, 2015, BLOOD, V125, P346, DOI 10.1182/blood-2014-06-581082; Xu J, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.8; YU X, 2021, SCI TRANSL MED, V13; Zhao S, 2021, NAT REV CANCER, V21, P413, DOI 10.1038/s41568-021-00357-x; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	64	2	2	14	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3328	3340		10.1038/s41388-022-02340-8	http://dx.doi.org/10.1038/s41388-022-02340-8		MAY 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35525905	Green Accepted			2022-12-17	WOS:000791911500001
J	Iida, T; Mizutani, Y; Esaki, N; Ponik, SM; Burkel, BM; Weng, L; Kuwata, K; Masamune, A; Ishihara, S; Haga, H; Kataoka, K; Mii, S; Shiraki, Y; Ishikawa, T; Ohno, E; Kawashima, H; Hirooka, Y; Fujishiro, M; Takahashi, M; Enomoto, A				Iida, Tadashi; Mizutani, Yasuyuki; Esaki, Nobutoshi; Ponik, Suzanne M.; Burkel, Brian M.; Weng, Liang; Kuwata, Keiko; Masamune, Atsushi; Ishihara, Seiichiro; Haga, Hisashi; Kataoka, Kunio; Mii, Shinji; Shiraki, Yukihiro; Ishikawa, Takuya; Ohno, Eizaburo; Kawashima, Hiroki; Hirooka, Yoshiki; Fujishiro, Mitsuhiro; Takahashi, Masahide; Enomoto, Atsushi			Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics (Apr, 10.1038/s41388-022-02288-9, 2022)	ONCOGENE			English	Correction									[Fujishiro, Mitsuhiro] Nagoya Univ, Dept Gastroenterol & Hepatol, Grad Sch Med, Nagoya, Aichi, Japan; [Takahashi, Masahide] Fujita Hlth Univ, Int Ctr Cell & Gene Therapy, Toyoake, Aichi, Japan; [Fujishiro, Mitsuhiro] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan	Nagoya University; Fujita Health University; University of Tokyo		enomoto@iar.nagoya-u.ac.jp	Mii, Shinji/I-7480-2014	Mii, Shinji/0000-0001-8266-3235				LIDA T, 2022, ONCOGENE, DOI DOI 10.1038/S41388-022-02288-9	1	2	2	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3302	3302		10.1038/s41388-022-02336-4	http://dx.doi.org/10.1038/s41388-022-02336-4		MAY 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35508544	Bronze			2022-12-17	WOS:000790621800001
J	Kim, JY; Cho, TM; Park, JM; Park, S; Park, M; Dal Nam, K; Ko, D; Seo, J; Kim, S; Jung, E; Farrand, L; Nguyen, CT; Hoang, VH; La, MT; Ann, J; Nam, G; Park, HJ; Lee, J; Kim, YJ; Seo, JH				Kim, Ji Young; Cho, Tae-Min; Park, Jung Min; Park, Soeun; Park, Minsu; Dal Nam, Kee; Ko, Dongmi; Seo, Juyeon; Kim, Seongjae; Jung, Eunsun; Farrand, Lee; Nguyen, Cong-Truong; Hoang, Van-Hai; La, Minh Thanh; Ann, Jihyae; Nam, Gibeom; Park, Hyun-Ju; Lee, Jeewoo; Kim, Yoon-Jae; Seo, Jae Hong			A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response	ONCOGENE			English	Article							MATRIX METALLOPROTEINASE-2; STEM-CELLS; PROTEINS; EXPRESSION; HSP90-ALPHA; CHAPERONES; INVASION; GROWTH; PHASE; ALDH1	Despite recent advances, there remains a significant unmet need for the development of new targeted therapies for triple-negative breast cancer (TNBC). Although the heat shock protein HSP90 is a promising target, previous inhibitors have had issues during development including undesirable induction of the heat shock response (HSR) and off-target effects leading to toxicity. SL-145 is a novel, rationally-designed C-terminal HSP90 inhibitor that induces apoptosis in TNBC cells via the suppression of oncogenic AKT, MEK/ERK, and JAK2/STAT3 signaling and does not trigger the HSR, in contrast to other inhibitors. In an orthotopic allograft model incorporating breast cancer stem cell-enriched TNBC tumors, SL-145 potently suppressed tumor growth, angiogenesis, and metastases concomitant with dysregulation of the JAK2/STAT3 signaling pathway. Our findings highlight the potential of SL-145 in suppressing metastatic TNBC independent of the HSR.	[Kim, Ji Young; Cho, Tae-Min; Park, Jung Min; Park, Soeun; Park, Minsu; Dal Nam, Kee; Ko, Dongmi; Seo, Juyeon; Kim, Seongjae; Jung, Eunsun; Kim, Yoon-Jae; Seo, Jae Hong] Korea Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul 02841, South Korea; [Kim, Ji Young; Cho, Tae-Min; Dal Nam, Kee; Jung, Eunsun; Kim, Yoon-Jae; Seo, Jae Hong] Korea Univ, Guro Hosp, Dept Biomed Res Ctr, Seoul 08308, South Korea; [Cho, Tae-Min; Park, Jung Min; Park, Soeun; Park, Minsu; Ko, Dongmi; Seo, Juyeon; Kim, Seongjae; Jung, Eunsun; Kim, Yoon-Jae; Seo, Jae Hong] Korea Univ, Coll Med, Brain Korea 21 Program Biomed Sci, Seoul 02841, South Korea; [Farrand, Lee] Univ Adelaide, Fac Hlth & Med Sci, Adelaide Med Sch, Adelaide, SA 5000, Australia; [Nguyen, Cong-Truong; Hoang, Van-Hai; La, Minh Thanh; Ann, Jihyae; Lee, Jeewoo] Seoul Natl Univ, Coll Pharm, Lab Med Chem, Seoul 08826, South Korea; [Nam, Gibeom; Park, Hyun-Ju] Sungkyunkwan Univ, Sch Pharm, Suwon 16419, Gyeonggi Do, South Korea	Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine); Korea University; Korea University Medicine (KU Medicine); University of Adelaide; Seoul National University (SNU); Sungkyunkwan University (SKKU)	Kim, YJ; Seo, JH (corresponding author), Korea Univ, Coll Med, Dept Internal Med, Div Med Oncol, Seoul 02841, South Korea.; Kim, YJ; Seo, JH (corresponding author), Korea Univ, Guro Hosp, Dept Biomed Res Ctr, Seoul 08308, South Korea.; Kim, YJ; Seo, JH (corresponding author), Korea Univ, Coll Med, Brain Korea 21 Program Biomed Sci, Seoul 02841, South Korea.; Lee, J (corresponding author), Seoul Natl Univ, Coll Pharm, Lab Med Chem, Seoul 08826, South Korea.	jeewoo@snu.ac.kr; natureyj@nate.com; cancer@korea.ac.kr		jeong, eunseon/0000-0002-5900-6138; Nguyen, Cong Truong/0000-0001-8142-4187	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HA17C0053, HR20C0021]; National Research Foundation (NRF) - Korean government (MSIT) [2019M3E5D1A01068998, 2021R1A2C2009723, 2021R1I1A1A01045588]; Brain Korea (BK) 21 Plus Program	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea; National Research Foundation (NRF) - Korean government (MSIT)(National Research Foundation of Korea); Brain Korea (BK) 21 Plus Program	This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: HA17C0053, HR20C0021), the National Research Foundation (NRF) funded by the Korean government (MSIT) (Grant number: 2019M3E5D1A01068998, 2021R1A2C2009723, 2021R1I1A1A01045588), and was supported by the Brain Korea (BK) 21 Plus Program.	Ayub A, 2015, BIOMED PHARMACOTHER, V75, P40, DOI 10.1016/j.biopha.2015.08.031; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Bocchini Claire E, 2014, JAKSTAT, V3, pe970459, DOI 10.4161/21623988.2014.970459; Bradley E, 2012, STEM CELLS, V30, P1624, DOI 10.1002/stem.1143; Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006; Cho TM, 2019, CANCER LETT, V447, P141, DOI 10.1016/j.canlet.2019.01.029; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Frezzato F, 2019, INT J CANCER, V145, P3089, DOI 10.1002/ijc.32383; Garcia-Carbonero R, 2013, LANCET ONCOL, V14, pE358, DOI 10.1016/S1470-2045(13)70169-4; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Jhaveri K, 2012, BBA-MOL CELL RES, V1823, P742, DOI 10.1016/j.bbamcr.2011.10.008; Kalimutho M, 2015, TRENDS PHARMACOL SCI, V36, P822, DOI 10.1016/j.tips.2015.08.009; Khan MA, 2019, DRUG DISCOV TODAY, V24, P2181, DOI 10.1016/j.drudis.2019.09.001; Kummar S, 2010, EUR J CANCER, V46, P340, DOI 10.1016/j.ejca.2009.10.026; Lambert AW, 2021, NAT REV CANCER, V21, P325, DOI 10.1038/s41568-021-00332-6; Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; Merdad A, 2014, ANTICANCER RES, V34, P1355; Metz JT, 2010, CURR OPIN CHEM BIOL, V14, P498, DOI 10.1016/j.cbpa.2010.06.166; Neckers L, 2018, CELL STRESS CHAPERON, V23, P467, DOI 10.1007/s12192-018-0877-2; Oh E, 2018, INT J CANCER, V143, P1978, DOI 10.1002/ijc.31585; Pacey S, 2011, CLIN CANCER RES, V17, P1561, DOI 10.1158/1078-0432.CCR-10-1927; Park JM, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01283-6; Park SY, 2019, CANCERS, V11, DOI 10.3390/cancers11070965; Peon A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04264-w; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Qin JJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1206-z; Rao MS, 2019, FRONT BIG DATA, V2, DOI 10.3389/fdata.2019.00025; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Sauvage F, 2017, J CONTROL RELEASE, V248, P133, DOI 10.1016/j.jconrel.2017.01.013; Schopf FH, 2017, NAT REV MOL CELL BIO, V18, P345, DOI 10.1038/nrm.2017.20; Solit DB, 2007, CLIN CANCER RES, V13, P1775, DOI 10.1158/1078-0432.CCR-06-1863; Song XM, 2010, J BIOL CHEM, V285, P40039, DOI 10.1074/jbc.M110.181941; Subramanian C, 2020, MOL ONCOL, V14, P2058, DOI 10.1002/1878-0261.12686; Thakur R, 2015, SCI REP-UK, V5, DOI 10.1038/srep10194; Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887; Wagner AJ, 2016, EUR J CANCER, V61, P94, DOI 10.1016/j.ejca.2016.03.076; Wang XX, 2014, INT J ONCOL, V45, P18, DOI 10.3892/ijo.2014.2399; Wang Y, 2015, CHEM COMMUN, V51, P1410, DOI 10.1039/c4cc07284g; Wu JM, 2017, TRENDS PHARMACOL SCI, V38, P226, DOI 10.1016/j.tips.2016.11.009; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383	45	2	2	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3289	3297		10.1038/s41388-022-02269-y	http://dx.doi.org/10.1038/s41388-022-02269-y		MAY 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35501463	Green Published, hybrid			2022-12-17	WOS:000789736500002
J	Kim, Y; Ko, JY; Lee, SB; Oh, S; Park, JW; Kang, HG; Kim, DH; Chung, D; Lim, S; Kong, H; Kim, J; Yoo, KH; Han, W; Chun, KH; Park, JH				Kim, Yesol; Ko, Je Yeong; Lee, Soo-Been; Oh, Sumin; Park, Jee Won; Kang, Hyeok-Gu; Kim, Da-Hyun; Chung, Daeun; Lim, Sera; Kong, Hyunkyung; Kim, Jongmin; Yoo, Kyung Hyun; Han, Wonshik; Chun, Kyung-Hee; Park, Jong Hoon			Reduced miR-371b-5p expression drives tumor progression via CSDE1/RAC1 regulation in triple-negative breast cancer	ONCOGENE			English	Article							RNA-BINDING PROTEIN; COLD-SHOCK DOMAINS; NEOADJUVANT CHEMOTHERAPY; CELL-MIGRATION; MICRORNAS; SURVIVAL; UNR	Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer; however, specific prognostic biomarkers have not yet been developed. In this study, we identified dysregulated microRNAs (miRNAs) in TNBC by profiling miRNA and mRNA expression. In patients with TNBC, miR-371b-5p expression was reduced, and miR-371b-5p overexpression significantly mitigated TNBC cell growth, migration, and invasion. In addition, we found that expression of cold shock domain-containing protein E1 (CSDE1), a direct target gene of miR-371b-5p, was upregulated in TNBC cells, and inhibition of CSDE1 expression alleviated TNBC cell growth by regulating RAC1 transcription. Mechanistically, CSDE1, phosphorylated C-terminal domain (p-CTD) of RNA polymerase II (RNAPII), and CDK7 form a complex, and downregulation of CSDE1 leads to weak interaction between RNAPII p-CTD and CDK7, resulting in a decrease in RNAPII p-CTD expression to reduce RAC1 transcript levels in CSDE1-deficient TNBC cells. Our data demonstrate that miR-371b-5p is a tumor-suppressive miRNA that regulates the CSDE1/Rac1 axis and could be a potential prognostic biomarker for TNBC.	[Kim, Yesol; Ko, Je Yeong; Lee, Soo-Been; Oh, Sumin; Park, Jee Won; Chung, Daeun; Lim, Sera; Kong, Hyunkyung; Kim, Jongmin; Yoo, Kyung Hyun; Park, Jong Hoon] Sookmyung Womens Univ, Dept Biol Sci, Seoul, South Korea; [Kang, Hyeok-Gu; Kim, Da-Hyun; Chun, Kyung-Hee] Yonsei Univ, Grad Sch Med Sci, Dept Biochem & Mol Biol, Brain Korea 21 Project,Coll Med, Seoul, South Korea; [Han, Wonshik] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea; [Han, Wonshik] Seoul Natl Univ, Dept Surg, Coll Med, Seoul, South Korea; [Park, Jong Hoon] Sookmyung Womens Univ, Res Inst Womens Hlth, Seoul, South Korea	Sookmyung Women's University; Yonsei University; Yonsei University Health System; Seoul National University (SNU); Seoul National University (SNU); Sookmyung Women's University	Park, JH (corresponding author), Sookmyung Womens Univ, Dept Biol Sci, Seoul, South Korea.; Chun, KH (corresponding author), Yonsei Univ, Grad Sch Med Sci, Dept Biochem & Mol Biol, Brain Korea 21 Project,Coll Med, Seoul, South Korea.	KHCHUN@yuhs.ac; parkjh@sookmyung.ac.kr		Chun, Kyung-Hee/0000-0002-9867-7321	National Research Foundation of Korea (NRF) - Korean government (MSIT) [2019R1A2B5B03069738, 2016R1A5A1011974]	National Research Foundation of Korea (NRF) - Korean government (MSIT)(National Research Foundation of Korea)	This study was supported by grant from the National Research Foundation of Korea (NRF) funded by the Korean government (MSIT) (2019R1A2B5B03069738 and 2016R1A5A1011974).	Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043; Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Berrada N, 2010, ANN ONCOL, V21, P30, DOI 10.1093/annonc/mdq279; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Blows FM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000279; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Dormoy-Raclet V, 2007, ONCOGENE, V26, P2595, DOI 10.1038/sj.onc.1210068; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Goroncy Alexander K., 2010, Journal of Structural and Functional Genomics, V11, P181, DOI 10.1007/s10969-010-9081-z; Guo AX, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-019-0496-2; Huang CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076421; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Khoshnaw SM, 2009, J CLIN PATHOL, V62, P422, DOI 10.1136/jcp.2008.060681; King CE, 2011, CANCER RES, V71, P4260, DOI 10.1158/0008-5472.CAN-10-4637; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Li CH, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1210-4; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Martinez-Useros J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040560; Masuda H, 2013, CLIN CANCER RES, V19, P5533, DOI 10.1158/1078-0432.CCR-13-0799; Mishra PJ, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-19; Mitchell SF, 2014, MOL CELL, V54, P547, DOI 10.1016/j.molcel.2014.04.033; Moore KS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20518-7; Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184; Steffen A, 2013, J CELL SCI, V126, P4572, DOI 10.1242/jcs.118232; Svoronos AA, 2016, CANCER RES, V76, P3666, DOI 10.1158/0008-5472.CAN-16-0359; Vo DT, 2012, AM J PATHOL, V181, P1762, DOI 10.1016/j.ajpath.2012.07.031; Wang YB, 2015, CELL, V163, P174, DOI 10.1016/j.cell.2015.08.063; Wurth L, 2016, CANCER CELL, V30, P694, DOI 10.1016/j.ccell.2016.10.004; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhou Q, 2012, ANNU REV BIOCHEM, V81, P119, DOI 10.1146/annurev-biochem-052610-095910	37	2	2	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3151	3161		10.1038/s41388-022-02326-6	http://dx.doi.org/10.1038/s41388-022-02326-6		APR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35490208	hybrid, Green Published			2022-12-17	WOS:000789076800001
J	Tyagi, A; Wu, SY; Sharma, S; Wu, KR; Zhao, D; Deshpande, R; Singh, R; Li, WC; Topaloglu, U; Ruiz, J; Watabe, K				Tyagi, Abhishek; Wu, Shih-Ying; Sharma, Sambad; Wu, Kerui; Zhao, Dan; Deshpande, Ravindra; Singh, Ravi; Li, Wencheng; Topaloglu, Umit; Ruiz, Jimmy; Watabe, Kounosuke			Exosomal miR-4466 from nicotine-activated neutrophils promotes tumor cell stemness and metabolism in lung cancer metastasis	ONCOGENE			English	Article							CIGARETTE-SMOKING; LYMPHOCYTE RATIO; BRAIN METASTASES; SERUM COTININE; SURVIVAL; PROTEIN; GLIOBLASTOMA; PROLIFERATION; COLONIZATION; INFLAMMATION	Smoking is associated with lung cancer and has a profound impact on tumor immunity. Nicotine, the addictive and non-carcinogenic smoke component, influences various brain cells and the immune system. However, how long-term use of nicotine affects brain metastases is poorly understood. We, therefore, examined the mechanism by which nicotine promotes lung cancer brain metastasis. In this study, we conducted a retrospective analysis of 810 lung cancer patients with smoking history and assessed brain metastasis. We found that current smoker's lung cancer patients have significantly higher brain metastatic incidence compared to the never smokers. We also found that chronic nicotine exposure recruited STAT3-activated N2-neutrophils within the brain pre-metastatic niche and secreted exosomal miR-4466 which promoted stemness and metabolic switching via SKI/SOX2/CPT1A axis in the tumor cells in the brain thereby enabling metastasis. Importantly, exosomal miR-4466 levels were found to be elevated in serum/urine of cancer-free subjects with a smoking history and promote tumor growth in vivo, suggesting that exosomal miR-4466 may serve as a promising prognostic biomarker for predicting increased risk of metastatic disease among smoker(s). Our findings suggest a novel pro-metastatic role of nicotine-induced N2-neutrophils in the progression of brain metastasis. We also demonstrated that inhibiting nicotine-induced STAT3-mediated neutrophil polarization effectively abrogated brain metastasis in vivo. Our results revealed a novel mechanistic insight on how chronic nicotine exposure contributes to worse clinical outcome of metastatic lung cancer and implicated the risk of using nicotine gateway for smoking cessation in cancer patients.	[Tyagi, Abhishek; Wu, Shih-Ying; Sharma, Sambad; Wu, Kerui; Zhao, Dan; Deshpande, Ravindra; Singh, Ravi; Li, Wencheng; Topaloglu, Umit; Ruiz, Jimmy; Watabe, Kounosuke] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Watabe, K (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	kwatabe@wakehealth.edu	Zhao, Dan/Y-8065-2019; Tyagi, Abhishek/CAF-1274-2022; Tyagi, Abhishek/AFZ-6213-2022; Singh, Ravi/A-5740-2011	Zhao, Dan/0000-0002-5120-6725; Tyagi, Abhishek/0000-0002-0155-2099; Tyagi, Abhishek/0000-0002-0155-2099; Singh, Ravi/0000-0003-0750-1804	NIH [R01CA173499, R01CA185650, R01CA205067]; Comprehensive Cancer Center of Wake Forest University, National Institutes of Health [P30CA012197]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Comprehensive Cancer Center of Wake Forest University, National Institutes of Health	This work was supported by NIH grant R01CA173499, R01CA185650 and R01CA205067 (to KW). This study used various Shared Resources including Tumor Tissue and Pathology, Cancer Genomics, Flow Cytometry, Biostatistics and Cell Engineering that are supported by the Comprehensive Cancer Center of Wake Forest University, National Institutes of Health Grant (P30CA012197).	Ali A, 2013, CURR ONCOL, V20, pE300, DOI 10.3747/co.20.1481; Aoshiba K, 1996, J LAB CLIN MED, V127, P186, DOI 10.1016/S0022-2143(96)90077-3; Asakura K, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0863-y; Bambury RM, 2013, J NEURO-ONCOL, V114, P149, DOI 10.1007/s11060-013-1164-9; Benhammou K, 2000, NEUROPHARMACOLOGY, V39, P2818, DOI 10.1016/S0028-3908(00)00153-2; Bleesing JJH, 2003, CYTOM PART B-CLIN CY, V51B, P1, DOI 10.1002/cyto.b.10007; Boire A, 2017, CELL, V168, P1101, DOI 10.1016/j.cell.2017.02.025; Caraballo RS, 1998, JAMA-J AM MED ASSOC, V280, P135, DOI 10.1001/jama.280.2.135; Caraballo RS, 2004, NICOTINE TOB RES, V6, P19, DOI 10.1080/14622200310001656821; Souto JC, 2011, MED RES REV, V31, P311, DOI 10.1002/med.20185; Ceccarelli SM, 2011, J MED CHEM, V54, P3109, DOI 10.1021/jm100809g; Chawla K, 2013, BIOINFORMATICS, V29, P2519, DOI 10.1093/bioinformatics/btt432; Cheng L, 2019, IMMUNOBIOLOGY, V224, P388, DOI 10.1016/j.imbio.2019.02.009; Chou YT, 2013, STEM CELLS, V31, P2607, DOI 10.1002/stem.1518; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; Cui P, 2020, CELL SIGNAL, V71, DOI 10.1016/j.cellsig.2020.109598; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; DeJarnette JB, 1998, P NATL ACAD SCI USA, V95, P14909, DOI 10.1073/pnas.95.25.14909; Deng C, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016875; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Doi H, 2019, IN VIVO, V33, P195, DOI 10.21873/invivo.11459; Dong Y, 2018, ANN NEUROL, V83, P387, DOI 10.1002/ana.25159; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Fuchs J, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0253601; Gong JN, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00941; Haftchenary S, 2013, ACS MED CHEM LETT, V4, P1102, DOI 10.1021/ml4003138; Han SJ, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01201; Hawkins BT, 2004, BRAIN RES, V1027, P48, DOI 10.1016/j.brainres.2004.08.043; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Hsiao SH, 2013, LUNG CANCER, V82, P319, DOI 10.1016/j.lungcan.2013.08.004; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Karachaliou N, 2013, TRANSL LUNG CANCER R, V2, P172, DOI 10.3978/j.issn.2218-6751.2013.01.01; Kazuyori TTN., 2017, J CANC SCI RES, V3, P1; Kim S, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121236; Kobayashi H, 2018, ONCOL LETT, V16, P4243, DOI 10.3892/ol.2018.9225; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kudo Y, 2019, ANN ONCOL, V30, P1521, DOI 10.1093/annonc/mdz207; Laughney AM, 2020, NAT MED, V26, P259, DOI 10.1038/s41591-019-0750-6; Lauterstein DE, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13040417; Lee W, 2019, J EXP MED, V216, P176, DOI 10.1084/jem.20181170; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Li YPD, 2019, J NEURO-ONCOL, V143, P337, DOI 10.1007/s11060-019-03169-0; Lin H, 2017, NEURO-ONCOLOGY, V19, P43, DOI 10.1093/neuonc/now128; Liu Y, 2013, NEURO-ONCOLOGY, V15, P891, DOI 10.1093/neuonc/not031; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Loeffler JS, 2020, EPIDEMIOLOGY CLIN MA; Luke Florian, 2018, Oncotarget, V9, P18844, DOI 10.18632/oncotarget.24787; Mansouri Sheila, 2016, CNS Oncol, V5, P159, DOI 10.2217/cns-2016-0001; Maru Y, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a036897; Mashimo T, 2014, CELL, V159, P1603, DOI 10.1016/j.cell.2014.11.025; Mitsuya K, 2017, J NEUROSURG, V127, P433, DOI 10.3171/2016.8.JNS16899; Morad G, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1627164; O'Keeffe LM, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021611; O'Loughlin J, 2008, NICOTINE TOB RES, V10, P525, DOI 10.1080/14622200801901997; Ohsawa K, 2004, J NEUROCHEM, V88, P844, DOI 10.1046/j.1471-4159.2003.02213.x; Panopoulos AD, 2006, BLOOD, V108, P3682, DOI 10.1182/blood-2006-02-003012; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Piccard H, 2012, CRIT REV ONCOL HEMAT, V82, P296, DOI 10.1016/j.critrevonc.2011.06.004; Rodrigues G, 2019, NAT CELL BIOL, V21, P1403, DOI 10.1038/s41556-019-0404-4; Rottiers V, 2012, NAT REV MOL CELL BIO, V13, P239, DOI 10.1038/nrm3313; Sacks P, 2020, NEUROSURG CLIN N AM, V31, P481, DOI 10.1016/j.nec.2020.06.001; Schaal CM, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0901-2; Shaul ME, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1232221; Shenker RF, 2017, CANCER MED-US, V6, P944, DOI 10.1002/cam4.1058; Shigdar S, 2014, CANCER LETT, V345, P271, DOI 10.1016/j.canlet.2013.07.031; Sifat AE, 2018, J NEUROCHEM, V147, P204, DOI 10.1111/jnc.14561; Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73; Singh SP, 2000, TOXICOL APPL PHARM, V164, P65, DOI 10.1006/taap.2000.8897; Sodja E, 2016, RADIOL ONCOL, V50, P188, DOI 10.1515/raon-2015-0027; Stapleton JM, 2003, NEUROPSYCHOPHARMACOL, V28, P765, DOI 10.1038/sj.npp.1300106; Szczerba BM, 2019, NATURE, V566, P553, DOI 10.1038/s41586-019-0915-y; TOTTI N, 1984, SCIENCE, V223, P169, DOI 10.1126/science.6318317; Tyagi A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20733-9; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang TY, 2018, CELL METAB, V27, P1357, DOI 10.1016/j.cmet.2018.04.018; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wingrove E, 2019, CELL REP, V27, P1277, DOI 10.1016/j.celrep.2019.03.085; Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150; Zhang HY, 2010, BLOOD, V116, P2462, DOI 10.1182/blood-2009-12-259630; Zhang L, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz5387	82	2	2	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3079	3092		10.1038/s41388-022-02322-w	http://dx.doi.org/10.1038/s41388-022-02322-w		APR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35461327	Green Published, hybrid			2022-12-17	WOS:000785962300001
J	Odeniyide, P; Yohe, ME; Pollard, K; Vaseva, AV; Calizo, A; Zhang, L; Rodriguez, FJ; Gross, JM; Allen, AN; Wan, XL; Somwar, R; Schreck, KC; Kessler, L; Wang, JW; Pratilas, CA				Odeniyide, Patience; Yohe, Marielle E.; Pollard, Kai; Vaseva, Angelina V.; Calizo, Ana; Zhang, Lindy; Rodriguez, Fausto J.; Gross, John M.; Allen, Amy N.; Wan, Xiaolin; Somwar, Romel; Schreck, Karisa C.; Kessler, Linda; Wang, Jiawan; Pratilas, Christine A.			Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma	ONCOGENE			English	Article							PHASE-II TRIAL; FARNESYLTRANSFERASE INHIBITOR TIPIFARNIB; ACUTE MYELOGENOUS LEUKEMIA; METASTATIC BREAST-CANCER; TRANSFERASE INHIBITOR; MEMBRANE ASSOCIATION; ONCOLOGY-GROUP; SOLID TUMORS; RAS; CHILDREN	Activating RAS mutations are found in a subset of fusion-negative rhabdomyosarcoma (RMS), and therapeutic strategies to directly target RAS in these tumors have been investigated, without clinical success to date. A potential strategy to inhibit oncogenic RAS activity is the disruption of RAS prenylation, an obligate step for RAS membrane localization and effector pathway signaling, through inhibition of farnesyltransferase (FTase). Of the major RAS family members, HRAS is uniquely dependent on FTase for prenylation, whereas NRAS and KRAS can utilize geranylgeranyl transferase as a bypass prenylation mechanism. Tumors driven by oncogenic HRAS may therefore be uniquely sensitive to FTase inhibition. To investigate the mutation-specific effects of FTase inhibition in RMS we utilized tipifarnib, a potent and selective FTase inhibitor, in in vitro and in vivo models of RMS genomically characterized for RAS mutation status. Tipifarnib reduced HRAS processing, and plasma membrane localization leading to decreased GTP-bound HRAS and decreased signaling through RAS effector pathways. In HRAS-mutant cell lines, tipifarnib reduced two-dimensional and three-dimensional cell growth, and in vivo treatment with tipifarnib resulted in tumor growth inhibition exclusively in HRAS-mutant RMS xenografts. Our data suggest that small molecule inhibition of FTase is active in HRAS-driven RMS and may represent an effective therapeutic strategy for a genomically-defined subset of RMS patients.	[Odeniyide, Patience; Pollard, Kai; Calizo, Ana; Zhang, Lindy; Allen, Amy N.; Wang, Jiawan; Pratilas, Christine A.] Johns Hopkins Univ, Sch Med, Dept Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA; [Yohe, Marielle E.; Wan, Xiaolin] NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; [Vaseva, Angelina V.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Rodriguez, Fausto J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Lab Med & Pathol, Los Angeles, CA 90095 USA; [Rodriguez, Fausto J.; Gross, John M.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Somwar, Romel] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Schreck, Karisa C.; Pratilas, Christine A.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Schreck, Karisa C.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Kessler, Linda] Kura Oncol, San Diego, CA USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Health San Antonio; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Johns Hopkins University; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Pratilas, CA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA.; Pratilas, CA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA.	cpratil1@jhmi.edu		Rodriguez, Fausto/0000-0001-8662-1219; Calizo, Ana/0000-0002-2581-6378; Odeniyide, Patience/0000-0002-9783-1657; Wang, Jiawan/0000-0002-2137-1826	Kura Oncology [NIH T32CA060441]; SKCCC Cancer Center Core Support [NIH P30 CA006973]; Memorial Sloan Kettering Cancer Center Support Grant [P30 CA008748]; Childhood Solid Tumor Network	Kura Oncology; SKCCC Cancer Center Core Support; Memorial Sloan Kettering Cancer Center Support Grant; Childhood Solid Tumor Network	This work has been funded by a grant from Kura Oncology (to CAP), the NIH T32CA060441 Pediatric Oncology Fellowship Training grant (to PO), the SKCCC Cancer Center Core Support (NIH P30 CA006973) and the Memorial Sloan Kettering Cancer Center Support Grant (P30 CA008748, RS). Cell line SJRHB000026_X1 was graciously provided by the Childhood Solid Tumor Network. Immunostaining was performed at the Oncology Tissue Services Core of Johns Hopkins University.	Alonso-Alonso R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63434-5; [Anonymous], 2021, CANCER DISCOV, V11; Arndt CAS, 2009, J CLIN ONCOL, V27, P5182, DOI 10.1200/JCO.2009.22.3768; Baba TT, 2008, J MUSCLE RES CELL M, V29, P127, DOI 10.1007/s10974-008-9146-9; Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151; Berzat AC, 2006, METHOD ENZYMOL, V407, P575, DOI 10.1016/S0076-6879(05)07046-1; BOS JL, 1989, CANCER RES, V49, P4682; Burnett AK, 2012, BRIT J HAEMATOL, V158, P519, DOI 10.1111/j.1365-2141.2012.09165.x; Case M, 2008, CANCER RES, V68, P6803, DOI 10.1158/0008-5472.CAN-08-0101; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Cloughesy TF, 2006, J CLIN ONCOL, V24, P3651, DOI 10.1200/JCO.2006.06.2323; Contente Sara, 2011, Genes Cancer, V2, P166, DOI 10.1177/1947601911405042; Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dalin MG, 2016, CLIN CANCER RES, V22, P4623, DOI 10.1158/1078-0432.CCR-16-0637; DER CJ, 1991, CANCER CELL-MON REV, V3, P331; Ding HS, 2014, HAEMATOLOGICA, V99, P60, DOI 10.3324/haematol.2013.087734; Ding HS, 2011, BLOOD, V118, DOI 10.1182/blood-2011-02-334870; End DW, 2001, CANCER RES, V61, P131; Fedele C, 2018, CANCER DISCOV, V8, P1237, DOI 10.1158/2159-8290.CD-18-0444; Gervais R, 2005, ANN ONCOL, V16, P90, DOI 10.1093/annonc/mdi018; Gilardi M, 2020, MOL CANCER THER, V19, P1784, DOI 10.1158/1535-7163.MCT-19-0958; Haas-Kogan DA, 2011, NEURO-ONCOLOGY, V13, P298, DOI 10.1093/neuonc/noq202; Hanna GJ, 2020, CANCER-AM CANCER SOC, V126, P3972, DOI 10.1002/cncr.33036; Harousseau JL, 2009, BLOOD, V114, P1166, DOI 10.1182/blood-2009-01-198093; Hillig RC, 2019, P NATL ACAD SCI USA, V116, P2551, DOI 10.1073/pnas.1812963116; Ho A, 2018, MOL CANCER THER, V17, DOI 10.1158/1535-7163.TARG-17-LB-A10; Ho A, 2019, MOL CANCER THER, V18, DOI 10.1158/1535-7163.TARG-19-PR08; Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Karp JE, 2008, CLIN CANCER RES, V14, P3077, DOI 10.1158/1078-0432.CCR-07-4743; Kazi A, 2019, CLIN CANCER RES, V25, P5984, DOI 10.1158/1078-0432.CCR-18-3399; Kurzrock R, 2003, BLOOD, V102, P4527, DOI 10.1182/blood-2002-11-3359; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lee HW, 2020, CLIN CANCER RES, V26, P5113, DOI 10.1158/1078-0432.CCR-20-1246; Lee HW, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00741-6; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Li T, 2009, ANN ONCOL, V20, P642, DOI 10.1093/annonc/mdn689; Li TH, 2012, BREAST CANCER RES TR, V134, P345, DOI 10.1007/s10549-012-2071-z; Liu ZH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16135-6; Pratilas CA, 2008, CANCER RES, V68, P9375, DOI 10.1158/0008-5472.CAN-08-2223; Rao S, 2004, J CLIN ONCOL, V22, P3950, DOI 10.1200/JCO.2004.10.037; Raponi M, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-56; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Sasaki AT, 2009, METHODS MOL BIOL, V571, P333, DOI 10.1007/978-1-60761-198-1_23; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Shern JF, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.10515; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Sparano JA, 2009, CLIN CANCER RES, V15, P2942, DOI 10.1158/1078-0432.CCR-08-2658; Stalnecker CA, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay6013; Stewart E, 2017, NATURE, V549, P96, DOI 10.1038/nature23647; Stieglitz E, 2015, PEDIATR BLOOD CANCER, V62, P629, DOI 10.1002/pbc.25342; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Tanaka T, 2017, J CELL PHYSIOL, V232, P192, DOI 10.1002/jcp.25411; Untch BR, 2018, CANCER RES, V78, P4642, DOI 10.1158/0008-5472.CAN-17-1925; Van Cutsem E, 2004, J CLIN ONCOL, V22, P1430, DOI 10.1200/JCO.2004.10.112; Wang JY, 2017, MEDCHEMCOMM, V8, P841, DOI 10.1039/c7md00030h; Weigel BJ, 2016, J CLIN ONCOL, V34, P117, DOI 10.1200/JCO.2015.63.4048; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Widemann BC, 2006, J CLIN ONCOL, V24, P507, DOI 10.1200/JCO.2005.03.8638; Widemann BC, 2014, NEURO-ONCOLOGY, V16, P707, DOI 10.1093/neuonc/nou004; Widemann BC, 2011, PEDIATR BLOOD CANCER, V56, P226, DOI 10.1002/pbc.22775; Wong GS, 2018, NAT MED, V24, P968, DOI 10.1038/s41591-018-0022-x; Wurzer G, 2001, J CELL BIOCHEM, P1; Zujewski J, 2000, J CLIN ONCOL, V18, P927, DOI 10.1200/JCO.2000.18.4.927	69	2	2	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2973	2983		10.1038/s41388-022-02305-x	http://dx.doi.org/10.1038/s41388-022-02305-x		APR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35459782	Green Published, hybrid			2022-12-17	WOS:000787474100004
J	Ratze, MAK; Koorman, T; Sijnesael, T; Bassey-Archibong, B; van de Ven, R; Enserink, L; Visser, D; Jaksani, S; Viciano, I; Bakker, ERM; Richard, F; Tutt, A; O'Leary, L; Fitzpatrick, A; Roca-Cusachs, P; van Diest, PJ; Desmedt, C; Daniel, JM; Isacke, CM; Derksen, PWB				Ratze, Max A. K.; Koorman, Thijs; Sijnesael, Thijmen; Bassey-Archibong, Blessing; van de Ven, Robert; Enserink, Lotte; Visser, Daan; Jaksani, Sridevi; Viciano, Ignacio; Bakker, Elvira R. M.; Richard, Francois; Tutt, Andrew; O'Leary, Lynda; Fitzpatrick, Amanda; Roca-Cusachs, Pere; van Diest, Paul J.; Desmedt, Christine; Daniel, Juliet M.; Isacke, Clare M.; Derksen, Patrick W. B.			Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer	ONCOGENE			English	Article							MAMMARY EPITHELIAL-CELLS; ANOIKIS RESISTANCE; GENE-EXPRESSION; CARCINOMA; ID2; GROWTH; D1; PROLIFERATION; DIFFERENTIATION; REPRESSION	Invasive lobular breast carcinoma (ILC) is characterized by proliferative indolence and long-term latency relapses. This study aimed to identify how disseminating ILC cells control the balance between quiescence and cell cycle re-entry. In the absence of anchorage, ILC cells undergo a sustained cell cycle arrest in G0/G1 while maintaining viability. From the genes that are upregulated in anchorage independent ILC cells, we selected Inhibitor of DNA binding 2 (Id2), a mediator of cell cycle progression. Using loss-of-function experiments, we demonstrate that Id2 is essential for anchorage independent survival (anoikis resistance) in vitro and lung colonization in mice. Importantly, we find that under anchorage independent conditions, E-cadherin loss promotes expression of Id2 in multiple mouse and (organotypic) human models of ILC, an event that is caused by a direct p120-catenin/Kaiso-dependent transcriptional de-repression of the canonical Kaiso binding sequence TCCTGCNA. Conversely, stable inducible restoration of E-cadherin expression in the ILC cell line SUM44PE inhibits Id2 expression and anoikis resistance. We show evidence that Id2 accumulates in the cytosol, where it induces a sustained and CDK4/6-dependent G0/G1 cell cycle arrest through interaction with hypo-phosphorylated Rb. Finally, we find that Id2 is indeed enriched in ILC when compared to other breast cancers, and confirm cytosolic Id2 protein expression in primary ILC samples. In sum, we have linked mutational inactivation of E-cadherin to direct inhibition of cell cycle progression. Our work indicates that loss of E-cadherin and subsequent expression of Id2 drive indolence and dissemination of ILC. As such, E-cadherin and Id2 are promising candidates to stratify low and intermediate grade invasive breast cancers for the use of clinical cell cycle intervention drugs.	[Ratze, Max A. K.; Koorman, Thijs; Sijnesael, Thijmen; van de Ven, Robert; Enserink, Lotte; Visser, Daan; Jaksani, Sridevi; Bakker, Elvira R. M.; van Diest, Paul J.; Derksen, Patrick W. B.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Bassey-Archibong, Blessing; Daniel, Juliet M.] McMaster Univ, Dept Biol, Hamilton, ON, Canada; [Viciano, Ignacio; Roca-Cusachs, Pere] Barcelona Inst Technol BIST, Inst Bioengn Catalonia IBEC, Barcelona, Spain; [Richard, Francois; Desmedt, Christine] Katholieke Univ Leuven, Lab Translat Breast Canc Res, Leuven, Belgium; [Tutt, Andrew] Kings Coll London, Breast Canc Now Res Unit, London, England; [Tutt, Andrew; O'Leary, Lynda; Fitzpatrick, Amanda; Isacke, Clare M.] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England	Utrecht University; Utrecht University Medical Center; McMaster University; Barcelona Institute of Science & Technology; Institut de Bioenginyeria de Catalunya; University of Barcelona; KU Leuven; University of London; King's College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Derksen, PWB (corresponding author), Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands.	p.w.b.derksen@umcutrecht.nl	; Derksen, Patrick/C-6643-2008; Desmedt, Christine/P-7438-2017	Koorman, Thijs/0000-0002-6064-3353; Derksen, Patrick/0000-0003-0732-7762; Desmedt, Christine/0000-0002-5223-5579; Isacke, Clare/0000-0002-9222-3345; Sijnesael, Thijmen/0000-0003-2248-9786; Tutt, Andrew/0000-0001-8715-2901	NHS; St Thomas' NHS Foundation Trust and King's College London; Royal Marsden NHS Foundation Trust; Canadian Breast Cancer Foundation; Juravinski Hospital and Cancer Center Foundation; Schlumberger Faculty for the Future Fellowship; Breast Cancer Now [2018NovPCC1297]; NC3Rs [NC/P001262/1]; Medical Research Council Clinical Research Training Fellowship; Netherlands Organization for Scientific Research [NWO/ZonMW-VIDI 016.096.318]; Dutch Cancer Society [KWF-UU-2011-5230, KWF-UU-2014-7201, KWF-UU-2016-10456]; Pfizer; European Union [731957, CA19138]; COST (European Cooperation in Science and Technology)	NHS; St Thomas' NHS Foundation Trust and King's College London; Royal Marsden NHS Foundation Trust(Royal Society of New ZealandMarsden Fund (NZ)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); Juravinski Hospital and Cancer Center Foundation; Schlumberger Faculty for the Future Fellowship(Schlumberger); Breast Cancer Now; NC3Rs(UK Research & Innovation (UKRI)National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs)); Medical Research Council Clinical Research Training Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Dutch Cancer Society(KWF Kankerbestrijding); Pfizer(Pfizer); European Union(European Commission); COST (European Cooperation in Science and Technology)(European Cooperation in Science and Technology (COST))	We thank Jonathan R. Keller (National Cancer Institute, Frederick, MA, USA) for the Id2 reporter, and Livio Kleij and Nikki Kolsters for technical support. Members from the De Bruin and Daniel laboratories are acknowledged for input and fruitful discussions. We thank the UMC Utrecht Cell Microscopy Center for imaging support. Rebecca Marlow and Eleanor Knight (BCN Organoid Facility) for their advice on the ILC PDO generation and Angela Clifford (KCL) in her role as BTBC trial coordinator. We acknowledge NHS funding to the NIHR Biomedical Research Centres at both Guy's and St Thomas' NHS Foundation Trust and King's College London, and the Royal Marsden NHS Foundation Trust and the Canadian Breast Cancer Foundation, the Juravinski Hospital and Cancer Center Foundation (JHCCF). BIB-A was partly supported by a Schlumberger Faculty for the Future Fellowship. We received financial support by Breast Cancer Now (CTR-Q4-Y3), NC3Rs (NC/P001262/1) (CMI/AT) and a Medical Research Council Clinical Research Training Fellowship (AF), grants from the Netherlands Organization for Scientific Research (NWO/ZonMW-VIDI 016.096.318), the Dutch Cancer Society (KWF-UU-2011-5230, KWF-UU-2014-7201 and KWF-UU-2016-10456), Breast Cancer Now (2018NovPCC1297) which is supported by funding from Pfizer, and the European Union's Horizon 2020 FET Proactive program under the grant agreement No. 731957 (MECHANO-CONTROL). This publication is based upon work from COST action LOBSTERPOT (CA19138), supported by COST (European Cooperation in Science and Technology).	Annunziato S, 2016, GENE DEV, V30, P1470, DOI 10.1101/gad.279190.116; Arpino G, 2004, BREAST CANCER RES, V6, pR149, DOI 10.1186/bcr767; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Boelens MC, 2016, CELL REP, V16, P2087, DOI 10.1016/j.celrep.2016.07.059; Booij TH, 2016, J BIOMOL SCREEN, V21, P912, DOI 10.1177/1087057116657269; Bruner HC, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029330; Christgen M, 2021, CANCERS, V13, DOI 10.3390/cancers13153695; Christgen M, 2016, PATHOL RES PRACT, V212, P583, DOI 10.1016/j.prp.2016.05.002; Coma S, 2010, CANCER RES, V70, P3823, DOI 10.1158/0008-5472.CAN-09-3048; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Derksen PWB, 2011, DIS MODEL MECH, V4, P347, DOI 10.1242/dmm.006395; Desmedt C, 2017, SEMIN CANCER BIOL, V44, P98, DOI 10.1016/j.semcancer.2017.03.007; Di Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109688; Engel J, 2003, EUR J CANCER, V39, P1794, DOI 10.1016/S0959-8049(03)00422-2; Engelstaedter Verena, 2011, Arch Gynecol Obstet, V283 Suppl 1, P93, DOI 10.1007/s00404-011-1843-8; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gainer SM, 2012, J SURG RES, V177, P93, DOI 10.1016/j.jss.2012.03.014; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gray MJ, 2008, ONCOGENE, V27, P7192, DOI 10.1038/onc.2008.356; Guiu S, 2014, CRIT REV ONCOL HEMAT, V92, P235, DOI 10.1016/j.critrevonc.2014.07.003; Herold MJ, 2008, P NATL ACAD SCI USA, V105, P18507, DOI 10.1073/pnas.0806213105; Hornsveld M, 2016, CELL DEATH DIFFER, V23, P1483, DOI 10.1038/cdd.2016.33; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Jares P, 1997, J PATHOL, V182, P160; Johnson J, 2016, ONCOGENE, V35, P4829, DOI 10.1038/onc.2016.32; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kijewska M, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-018-1093-9; Kim NS, 2011, MOL CELL BIOL, V31, P4775, DOI 10.1128/MCB.05646-11; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korhonen T, 2013, BREAST, V22, P1119, DOI 10.1016/j.breast.2013.06.001; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Li HJ, 2010, BLOOD, V116, P1060, DOI 10.1182/blood-2009-11-255075; Liu Y, 2019, BREAST CANCER RES TR, V175, P77, DOI 10.1007/s10549-018-05126-3; Mandoli A, 2014, GENOM DATA, V2, P170, DOI 10.1016/j.gdata.2014.06.014; Manning AL, 2012, NAT REV CANCER, V12, P220, DOI 10.1038/nrc3216; Mathieu MC, 2004, EUR J CANCER, V40, P342, DOI 10.1016/j.ejca.2003.08.015; Meng WX, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002899; Meng YG, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-75; Metzger O, 2013, ANN ONCOL, V24, P377, DOI 10.1093/annonc/mds280; Michaut M, 2016, SCI REP-UK, V6, DOI 10.1038/srep18517; NEWSTEAD GM, 1992, RADIOLOGY, V184, P623, DOI 10.1148/radiology.184.3.1324506; O'Brien N, 2018, MOL CANCER THER, V17, P897, DOI 10.1158/1535-7163.MCT-17-0290; Oyama T, 1998, CANCER RES, V58, P2876; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Pestalozzi BC, 2008, J CLIN ONCOL, V26, P3006, DOI 10.1200/JCO.2007.14.9336; Pierre CC, 2015, BBA-GENE REGUL MECH, V1849, P1432, DOI 10.1016/j.bbagrm.2015.10.018; Pinto Proenca Rita, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2017-223542; Rollin J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004158; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Sandercock AM, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0415-0; Schackmann RCJ, 2013, CANCER RES, V73, P4937, DOI 10.1158/0008-5472.CAN-13-0180; Schackmann RCJ, 2011, J CLIN INVEST, V121, P3176, DOI 10.1172/JCI41695; Shapiro GI, 2000, CELL BIOCHEM BIOPHYS, V33, P189, DOI 10.1385/CBB:33:2:189; Suzuki Keiko, 2010, BMC Res Notes, V3, P294, DOI 10.1186/1756-0500-3-294; Teo K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33525-5; Tobin NP, 2012, HUM PATHOL, V43, P2053, DOI 10.1016/j.humpath.2012.02.015; Troyanovsky RB, 2003, MOL CELL BIOL, V23, P7965, DOI 10.1128/MCB.23.22.7965-7972.2003; van de Ven RAH, 2015, DIS MODEL MECH, V8, P373, DOI 10.1242/dmm.018648; vanDiest PJ, 1997, AM J PATHOL, V150, P705; Vlug EJ, 2013, CELL ONCOL, V36, P375, DOI 10.1007/s13402-013-0143-7; Wazir U, 2013, ANTICANCER RES, V33, P2179; Zhou JD, 2017, ONCOTARGET, V8, P91979, DOI 10.18632/oncotarget.20559	67	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2932	2944		10.1038/s41388-022-02314-w	http://dx.doi.org/10.1038/s41388-022-02314-w		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35437308	Green Published, hybrid			2022-12-17	WOS:000784068300002
J	Bramhecha, YM; Guerard, KP; Audet-Walsh, E; Rouzbeh, S; Kassem, O; Pernet, E; Scarlata, E; Hamel, L; Brimo, F; Divangahi, M; Aprikian, AG; Chevalier, S; Giguere, V; Lapointe, J				Bramhecha, Yogesh M.; Guerard, Karl-Philippe; Audet-Walsh, Etienne; Rouzbeh, Shaghayegh; Kassem, Ola; Pernet, Erwan; Scarlata, Eleonora; Hamel, Lucie; Brimo, Fadi; Divangahi, Maziar; Aprikian, Armen G.; Chevalier, Simone; Giguere, Vincent; Lapointe, Jacques			Fatty acid oxidation enzyme Delta 3, Delta 2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients	ONCOGENE			English	Article							BETA-OXIDATION; METABOLISM; PATHWAY; COA	Prostate cancer (PCa) metastases are highly enriched with genomic alterations including a gain at the 16p13.3 locus, recently shown to be associated with disease progression and poor clinical outcome. ECI1, residing at the 16p13.3 gain region, encodes Delta 3, Delta 2-Enoyl-CoA Delta Isomerase 1 (ECI1), a key mitochondrial fatty acid beta-oxidation enzyme. Although deregulated mitochondrial fatty acid beta-oxidation is known to drive PCa pathogenesis, the role of ECI1 in PCa is still unknown. We investigated the impacts of ECI1 on PCa phenotype in vitro and in vivo by modulating its expression in cell lines and assessed the clinical implications of its expression in human prostate tissue samples. In vitro, ECI1 overexpression increased PCa cell growth while ECI1 deficiency reduced its growth. ECI1 also enhanced colony formation, cell motility, and maximal mitochondrial respiratory capacity. In vivo, PCa cells stably overexpressing ECI1 injected orthotopically in nude mice formed larger prostate tumors with higher number of metastases. Immunohistochemistry analysis of the human tissue microarray representing 332 radical prostatectomy cases revealed a stronger ECI1 staining in prostate tumors compared to corresponding benign tissues. ECI1 expression varied amongst tumors and was higher in cases with 16p13.3 gain, high Gleason grade, and advanced tumor stage. ECI1 overexpression was a strong independent predictor of biochemical recurrence after adjusting for known clinicopathologic parameters (hazard ratio: 3.65, P < 0.001) or the established CAPRA-S score (hazard ratio: 3.95, P < 0.001). ECI1 overexpression was also associated with significant increased risk of distant metastasis and reduced overall survival. Overall, this study demonstrates the functional capacity of ECI1 in PCa progression and highlights the clinical implication of ECI1 as a potential target for the management of PCa.	[Bramhecha, Yogesh M.; Guerard, Karl-Philippe; Rouzbeh, Shaghayegh; Kassem, Ola; Scarlata, Eleonora; Hamel, Lucie; Aprikian, Armen G.; Chevalier, Simone; Lapointe, Jacques] McGill Univ, Div Urol, Dept Surg, Montreal, PQ, Canada; [Bramhecha, Yogesh M.; Guerard, Karl-Philippe; Audet-Walsh, Etienne; Rouzbeh, Shaghayegh; Kassem, Ola; Pernet, Erwan; Scarlata, Eleonora; Hamel, Lucie; Brimo, Fadi; Divangahi, Maziar; Aprikian, Armen G.; Chevalier, Simone; Giguere, Vincent; Lapointe, Jacques] McGill Univ, Hlth Ctr, Res Inst, Montreal, PQ, Canada; [Bramhecha, Yogesh M.; Kassem, Ola; Chevalier, Simone; Lapointe, Jacques] McGill Univ, Div Expt Med, Montreal, PQ, Canada; [Audet-Walsh, Etienne; Giguere, Vincent] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada; [Pernet, Erwan; Divangahi, Maziar] McGill Univ, Dept Med, Meakins Christie Labs, Montreal, PQ, Canada; [Bramhecha, Yogesh M.] IMV Inc, Dartmouth, NS, Canada; [Audet-Walsh, Etienne] Univ Laval, Ctr Rech, CHU Quebec, Quebec City, PQ, Canada	McGill University; McGill University; McGill University; McGill University; McGill University; Laval University	Lapointe, J (corresponding author), McGill Univ, Div Urol, Dept Surg, Montreal, PQ, Canada.; Lapointe, J (corresponding author), McGill Univ, Hlth Ctr, Res Inst, Montreal, PQ, Canada.; Lapointe, J (corresponding author), McGill Univ, Div Expt Med, Montreal, PQ, Canada.	Jacques.lapointe@mcgill.ca			US Department of Defense (DoD) [W81XWH-11-1-0638]; Prostate Cancer Canada [D2019-2192]; Fonds de Recherche du Quebec-Sante (FRQS, Chercheur boursier); Canadian Institutes of Health Research (CIHR) Foundation; CIHR System Biology and McGill Division of Urology studentships; 100 Days Across Canada Urology Studentship Program on Prostate Cancer	US Department of Defense (DoD)(United States Department of Defense); Prostate Cancer Canada; Fonds de Recherche du Quebec-Sante (FRQS, Chercheur boursier); Canadian Institutes of Health Research (CIHR) Foundation(Canadian Institutes of Health Research (CIHR)); CIHR System Biology and McGill Division of Urology studentships(Canadian Institutes of Health Research (CIHR)); 100 Days Across Canada Urology Studentship Program on Prostate Cancer	US Department of Defense (DoD, W81XWH-11-1-0638), Prostate Cancer Canada (D2019-2192), the Fonds de Recherche du Quebec-Sante (FRQS, Chercheur boursier) to JL. Canadian Institutes of Health Research (CIHR) Foundation Grant to VG, CIHR System Biology and McGill Division of Urology studentships to YB, and 100 Days Across Canada Urology Studentship Program on Prostate Cancer to OK.	AASMUNDSTAD TA, 1992, J CLIN PATHOL, V45, P125, DOI 10.1136/jcp.45.2.125; Audet-Walsh E, 2017, GENE DEV, V31, P1228, DOI 10.1101/gad.299958.117; Audet-Walsh E, 2017, CANCER RES, V77, P378, DOI 10.1158/0008-5472.CAN-16-1204; Bramhecha YM, 2019, MODERN PATHOL, V32, P128, DOI 10.1038/s41379-018-0107-6; Bramhecha YM, 2018, MOL CANCER RES, V16, P115, DOI 10.1158/1541-7786.MCR-17-0270; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Cai QY, 2013, PROSTATE, V73, P842, DOI 10.1002/pros.22630; Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483; Choucair K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-543; Choucair KA, 2012, TRANSL ONCOL, V5, P453, DOI 10.1593/tlo.12286; De Schrijver E, 2003, CANCER RES, V63, P3799; Deep G, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071061; Dueregger A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135704; Flaig TW, 2017, ONCOTARGET, V8, P56051, DOI 10.18632/oncotarget.17359; Gurvitz A, 1999, BIOCHEM J, V344, P903, DOI 10.1042/0264-6021:3440903; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Higgins LH, 2009, BBA-BIOENERGETICS, V1787, P1433, DOI 10.1016/j.bbabio.2009.06.003; Houten SM, 2010, J INHERIT METAB DIS, V33, P469, DOI 10.1007/s10545-010-9061-2; Itkonen HM, 2017, ONCOTARGET, V8, P38264, DOI 10.18632/oncotarget.16123; Janssen U, 2002, J BIOL CHEM, V277, P19579, DOI 10.1074/jbc.M110993200; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Joshi M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101115; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lapointe J, 2008, AM J SURG PATHOL, V32, P205, DOI 10.1097/PAS.0b013e318124a865; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Lee SH, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/854502; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; McDonnell E, 2016, CELL REP, V17, P1463, DOI 10.1016/j.celrep.2016.10.012; McShane LM, 2005, NAT CLIN PRACT ONCOL, V2, P416, DOI 10.1038/ncponc0252; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Oliva CR, 2010, J BIOL CHEM, V285, P39759, DOI 10.1074/jbc.M110.147504; Park JH, 2016, CELL REP, V14, P2154, DOI 10.1016/j.celrep.2016.02.004; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pfleger J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.202; Poluri RTK, 2021, ENDOCR-RELAT CANCER, V28, P257, DOI 10.1530/ERC-20-0504; Poluri RTK, 2019, DATA BRIEF, V25, DOI 10.1016/j.dib.2019.104372; Pougovkina O, 2014, HUM MOL GENET, V23, P3513, DOI 10.1093/hmg/ddu059; Punnen S, 2014, EUR UROL, V65, P1171, DOI 10.1016/j.eururo.2013.03.058; Qian J, 2015, P NATL ACAD SCI USA, V112, P3469, DOI 10.1073/pnas.1421975112; Qu Q, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.132; Rasmussen AL, 2011, J VIROL, V85, P11646, DOI 10.1128/JVI.05605-11; Rogers GW., 2014, CURR PROTOC TOXICOL, V60, p25 3 1, DOI 10.1002/0471140856.tx2503s60; Schlaepfer IR, 2014, MOL CANCER THER, V13, P2361, DOI 10.1158/1535-7163.MCT-14-0183; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Teh JT, 2019, MOL CANCER THER, V18, P693, DOI 10.1158/1535-7163.MCT-18-0766; Tuomela JM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-81; van Weeghel M, 2012, FASEB J, V26, P4316, DOI 10.1096/fj.12-206326; Wang SY, 2018, J BIOL CHEM, V293, P6544, DOI 10.1074/jbc.RA117.001323; WARBURG O, 1956, SCIENCE, V124, P269; Wong BW, 2017, NATURE, V542, P49, DOI 10.1038/nature21028; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Zadra G, 2019, P NATL ACAD SCI USA, V116, P631, DOI 10.1073/pnas.1808834116; Zadra G, 2013, BBA-MOL CELL BIOL L, V1831, P1518, DOI 10.1016/j.bbalip.2013.03.010; Zhang DY, 2002, J BIOL CHEM, V277, P9127, DOI 10.1074/jbc.M112228200	55	2	2	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2798	2810		10.1038/s41388-022-02276-z	http://dx.doi.org/10.1038/s41388-022-02276-z		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35411033				2022-12-17	WOS:000780668900004
J	Chadet, S; Allard, J; Brisson, L; Lopez-Charcas, O; Lemoine, R; Heraud, A; Lerondel, S; Guibon, R; Fromont, G; Le Pape, A; Angoulvant, D; Jiang, LH; Murrell-Lagnado, R; Roger, S				Chadet, Stephanie; Allard, Jordan; Brisson, Lucie; Lopez-Charcas, Osbaldo; Lemoine, Roxane; Heraud, Audrey; Lerondel, Stephanie; Guibon, Roseline; Fromont, Gaelle; Le Pape, Alain; Angoulvant, Denis; Jiang, Lin-Hua; Murrell-Lagnado, Ruth; Roger, Sebastien			P2x4 receptor promotes mammary cancer progression by sustaining autophagy and associated mesenchymal transition	ONCOGENE			English	Article							P2X(4) RECEPTORS; CELLS; RELEASE; INHIBITION; LYSOSOMES; CHANNELS; ROLES; EMT	Metastatic progression is a major burden for breast cancer patients and is associated with the ability of cancer cells to overcome stressful conditions, such as nutrients deprivation and hypoxia, and to gain invasive properties. Autophagy and epithelial-to-mesenchymal transition are critical contributors to these processes. Here, we show that the P2X4 purinergic receptor is upregulated in breast cancer biopsies from patients and it is primarily localised in endolysosomes. We demonstrate that P2X4 enhanced invasion in vitro, as well as mammary tumour growth and metastasis in vivo. The pro-malignant role of P2X4 was mediated by the regulation of lysosome acidity, the promotion of autophagy and cell survival. Furthermore, the autophagic activity was associated with epithelial-to-mesenchymal transition (EMT), and this role of P2X4 was even more pronounced under metabolic challenges. Pharmacological and gene silencing of P2X4 inhibited both autophagy and EMT, whereas its rescue in knocked-down cells led to the restoration of the aggressive phenotype. Together, our results demonstrate a previously unappreciated role for P2X4 in regulating lysosomal functions and fate, promoting breast cancer progression and aggressiveness.	[Chadet, Stephanie; Allard, Jordan; Lopez-Charcas, Osbaldo; Lemoine, Roxane; Heraud, Audrey; Angoulvant, Denis; Roger, Sebastien] Univ Tours, EA4245 Transplantat Immunol Inflammat, Tours, France; [Brisson, Lucie; Guibon, Roseline; Fromont, Gaelle] Univ Tours, Nutr Growth & Canc, Inserm UMR1069, Tours, France; [Lerondel, Stephanie; Le Pape, Alain] Ctr Imagerie Petit Anim, CNRS UPS44 TAAM, Orleans, France; [Jiang, Lin-Hua] Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; [Jiang, Lin-Hua] Xinxiang Med Univ, Sino UK Joint Lab Brain Funct & Injury, Xinxiang 453003, Henan, Peoples R China; [Jiang, Lin-Hua] Xinxiang Med Univ, Dept Physiol & Pathophysiol, Xinxiang 453003, Henan, Peoples R China; [Murrell-Lagnado, Ruth] Univ Sussex, Sch Life Sci, Brighton, E Sussex, England; [Roger, Sebastien] Inst Univ France, Paris, France	Universite de Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; University of Leeds; Xinxiang Medical University; Xinxiang Medical University; University of Sussex; Institut Universitaire de France	Chadet, S (corresponding author), Univ Tours, EA4245 Transplantat Immunol Inflammat, Tours, France.	stephanie.chadet@univ-tours.fr	Brisson, Lucie/R-1179-2016	Brisson, Lucie/0000-0001-7811-1382; Murrell-Lagnado, Ruth/0000-0003-2743-7977	Ministere de la Recherche et des Technologies; Region Centre-Val de Loire (grant "CanalEx"); Institut National du Cancer [INCA_16110]; School of Life Science, University of Sussex (UK); AURCIL Association in Tours (France); Ligue Nationale Contre le Cancer -Interregion Grand-Ouest	Ministere de la Recherche et des Technologies; Region Centre-Val de Loire (grant "CanalEx"); Institut National du Cancer(Institut National du Cancer (INCA) France); School of Life Science, University of Sussex (UK); AURCIL Association in Tours (France); Ligue Nationale Contre le Cancer -Interregion Grand-Ouest	This work was supported by the "Ministere de la Recherche et des Technologies", the "Ligue Nationale Contre le Cancer -Interregion Grand-Ouest" to SR, the Region CentreVal de Loire (grant "CanalEx" to SR), the Institut National du Cancer (grant INCA_16110 "PURIN4EXO" to SR). SR was recipient of a prize "Prix Ruban Rose Avenir 2017" from the Charity "le Cancer du sein: parlons-en!". SC was recipient of a post-doctoral grant from the School of Life Science, University of Sussex (UK) and from the AURCIL Association in Tours (France). We thank Mrs Carole Desplanches for secretary and administrative assistance. We thank Mrs Stephanie Retif, Mrs Marilyne Le Mee and M. Julien Sobilo for the assistance with in vivo experiments performed at CNRS UPS44 CIPA, Orleans. Our microscopy data were obtained with the assistance of the IBiSA Electron Microscopy Facility of the University of Tours, and we are grateful to M. Julien Burlaud-Gaillard for his help with electronic and confocal microscopy. We thank Dr Vinh Ta Phuoc for the insightful discussions on lysosomal distribution analyses. This work was supported by the "Ministere de la Recherche et des Technologies", the "Ligue Nationale Contre le Cancer -Interregion Grand-Ouest" to SR, the Region Centre-Val de Loire (grant "CanalEx" to SR), the Institut National du Cancer (grant INCA_16110 "PURIN4EXO" to SR). SR was recipient of a prize "Prix Ruban Rose Avenir 2017" from the Charity "le Cancer du sein: parlons-en!". SC was recipient of a post-doctoral grant from the School of Life Science, University of Sussex (UK) and from the AURCIL Association in Tours (France).	Adinolfi E, 2015, CURR MED CHEM, V22, P878, DOI 10.2174/0929867321666141012172913; Biskou O, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209665; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Brisson L, 2016, CANCER CELL, V30, P418, DOI 10.1016/j.ccell.2016.08.005; Brix DM, 2019, ONCOGENE, V38, P3170, DOI 10.1038/s41388-018-0653-x; Burnstock G, 2013, PURINERG SIGNAL, V9, P541, DOI 10.1007/s11302-013-9381-4; Cao Q, 2015, J CELL BIOL, V209, P879, DOI 10.1083/jcb.201409071; Carnero Corrales MA, 2021, CELL CHEM BIOL; Caviston JP, 2011, MOL BIOL CELL, V22, P478, DOI 10.1091/mbc.E10-03-0233; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen HT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1030-2; Chittaranjan S, 2014, CLIN CANCER RES, V20, P3159, DOI 10.1158/1078-0432.CCR-13-2060; Cogli L, 2013, BBA-MOL CELL RES, V1833, P1283, DOI 10.1016/j.bbamcr.2013.02.024; Di Virgilio F, 2009, PURINERG SIGNAL, V5, P251, DOI 10.1007/s11302-009-9145-3; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Gouirand V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00117; Groth-Pedersen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045381; Gugnoni M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.415; Hamalisto S, 2016, CURR OPIN CELL BIOL, V39, P69, DOI 10.1016/j.ceb.2016.02.009; Huang P, 2014, J BIOL CHEM, V289, P17658, DOI 10.1074/jbc.M114.552158; Ivaska Johanna, 2011, Small GTPases, V2, P51; Izuishi K, 2000, CANCER RES, V60, P6201; Janda E, 2006, ONCOGENE, V25, P7117, DOI 10.1038/sj.onc.1209701; Jelassi B, 2011, ONCOGENE, V30, P2108, DOI 10.1038/onc.2010.593; Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292; Ketterer S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18935-2; Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004; Kundu ST, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05013-x; Lahiri V, 2019, CELL METAB, V29, P803, DOI 10.1016/j.cmet.2019.03.003; Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282; Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a; Li S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09634-8; Liang DH, 2016, CANCER LETT, V376, P249, DOI 10.1016/j.canlet.2016.04.002; Majora M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam7510; Martin FT, 2010, BREAST CANCER RES TR, V124, P317, DOI 10.1007/s10549-010-0734-1; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019; Miklavc P, 2011, P NATL ACAD SCI USA, V108, P14503, DOI 10.1073/pnas.1101039108; Morgan MJ, 2018, P NATL ACAD SCI USA, V115, pE8479, DOI 10.1073/pnas.1706526115; Murrell-Lagnado RD, 2019, CURR OPIN PHARMACOL, V47, P126, DOI 10.1016/j.coph.2019.03.002; Murrell-Lagnado RD, 2018, J GEN PHYSIOL, V150, P185, DOI 10.1085/jgp.201711963; Olson OC, 2015, NAT REV CANCER, V15, P712, DOI 10.1038/nrc4027; Roger S, 2015, BBA-BIOMEMBRANES, V1848, P2584, DOI 10.1016/j.bbamem.2014.10.029; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; Tan SL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910492; Toulme E, 2010, J GEN PHYSIOL, V135, P333, DOI 10.1085/jgp.200910336; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Westley BR, 1996, EUR J CANCER, V32A, P15, DOI 10.1016/0959-8049(95)00530-7; Zhitomirsky B, 2017, ONCOTARGET, V8, P45117, DOI 10.18632/oncotarget.15155	51	2	2	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2920	2931		10.1038/s41388-022-02297-8	http://dx.doi.org/10.1038/s41388-022-02297-8		APR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35411034				2022-12-17	WOS:000780668900002
J	Fujita, H; Ikeda, M; Ui, A; Ouchi, Y; Mikami, Y; Kanno, S; Yasui, A; Tanaka, K				Fujita, Hiroki; Ikeda, Masanori; Ui, Ayako; Ouchi, Yunosuke; Mikami, Yoshiko; Kanno, Shin-ichiro; Yasui, Akira; Tanaka, Kozo			CHAMP1-POGZ counteracts the inhibitory effect of 53BP1 on homologous recombination and affects PARP inhibitor resistance	ONCOGENE			English	Article							STRAND BREAK REPAIR; DNA-END RESECTION; EPIGENETIC HISTONE MARKS; INTELLECTUAL DISABILITY; PATHWAY CHOICE; DAMAGE; PROTEIN; POGZ; MAD2L2; BRCA1	DNA double-strand break (DSB) repair-pathway choice regulated by 53BP1 and BRCA1 contributes to genome stability. 53BP1 cooperates with the REV7-Shieldin complex and inhibits DNA end resection to block homologous recombination (HR) and affects the sensitivity to inhibitors for poly (ADP-ribose) polymerases (PARPs) in BRCA1-deficient cells. Here, we show that a REV7 binding protein, CHAMP1 (chromosome alignment-maintaining phosphoprotein 1), has an opposite function of REV7 in DSB repair and promotes HR through DNA end resection together with POGZ (POGO transposable element with ZNF domain). CHAMP1 was recruited to laser-micro-irradiation-induced DSB sites and promotes HR, but not NHEJ. CHAMP1 depletion suppressed the recruitment of BRCA1, but not the recruitment of 53BP1, suggesting that CHAMP1 regulates DSB repair pathway in favor of HR. Depletion of either CHAMP1 or POGZ impaired the recruitment of phosphorylated RPA2 and CtIP (CtBP-interacting protein) at DSB sites, implying that CHAMP1, in complex with POGZ, promotes DNA end resection for HR. Furthermore, loss of CHAMP1 and POGZ restored the sensitivity to a PARP inhibitor in cells depleted of 53BP1 together with BRCA1. These data suggest that CHAMP1and POGZ counteract the inhibitory effect of 53BP1 on HR by promoting DNA end resection and affect the resistance to PARP inhibitors.	[Fujita, Hiroki; Ikeda, Masanori; Ui, Ayako; Ouchi, Yunosuke; Mikami, Yoshiko; Tanaka, Kozo] Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Oncol, 4-1 Seiryo Machi,Aoba Ku, Sendai, Miyagi 9808575, Japan; [Ui, Ayako; Kanno, Shin-ichiro; Yasui, Akira] Tohoku Univ, Inst Dev Aging & Canc, IDAC Lab, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University	Tanaka, K (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Oncol, 4-1 Seiryo Machi,Aoba Ku, Sendai, Miyagi 9808575, Japan.	kozo.tanaka.d2@tohoku.ac.jp	Ui, Ayako/GON-4666-2022; Tanaka, Kozo/Y-6566-2018	Ui, Ayako/0000-0001-6698-7168; Tanaka, Kozo/0000-0001-6086-2858	JSPS KAKENHI [24370078, 24650616, 15H04368, 18H02434, 17K19615]; MEXT KAKENHI [26116501, 16H01296, 18H04896]; Takeda Science Foundation; Princess Takamatsu Cancer Research Fund [10-24210]; Naito Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); MEXT KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Princess Takamatsu Cancer Research Fund; Naito Foundation(Naito Memorial Foundation)	The authors thank Dr. H. Kurumizaka (The University of Tokyo) for an antibody against Rad51, Dr. M. Takata (Kyoto University) for U2OS cells stably expressing GFP-tagged CtIP, and Dr. T. Hirota (The Cancer Institute of Japanese Foundation for Cancer Research) for HeLa Kyoto cells. The authors also thank members of the K.T. laboratory for discussions, Y. Yoshizaki for his critical reading of the manuscript, and A. Harata for technical assistance. This work was supported by JSPS KAKENHI Grant Numbers 24370078, 24650616, 15H04368, 18H02434 and 17K19615; MEXT KAKENHI Grant Numbers 26116501, 16H01296, and 18H04896; and grants from the Takeda Science Foundation, Princess Takamatsu Cancer Research Fund (10-24210), and the Naito Foundation to K.T.	Abe Y, 2016, DEV CELL, V36, P487, DOI 10.1016/j.devcel.2016.02.008; Adachi N, 2004, J BIOL CHEM, V279, P37343, DOI 10.1074/jbc.M313910200; Baude A, 2016, NUCLEIC ACIDS RES, V44, P2214, DOI 10.1093/nar/gkv1526; Bluhm A, 2016, PROTEOMICS, V16, P427, DOI 10.1002/pmic.201500217; Bochum Sylvia, 2018, Recent Results Cancer Res, V211, P217, DOI 10.1007/978-3-319-91442-8_15; Boersma V, 2015, NATURE, V521, P537, DOI 10.1038/nature14216; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Caron MC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10741-9; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029; Chen H, 2013, MOL CELL, V50, P589, DOI 10.1016/j.molcel.2013.04.032; Chen J, 2001, GENE DEV, V15, P1765, DOI 10.1101/gad.898701; Clairmont CS, 2020, NAT CELL BIOL, V22, P87, DOI 10.1038/s41556-019-0442-y; Cruz-Garcia A, 2014, CELL REP, V9, P451, DOI 10.1016/j.celrep.2014.08.076; Daugaard M, 2012, NAT STRUCT MOL BIOL, V19, P803, DOI 10.1038/nsmb.2314; Dev H, 2018, NAT CELL BIOL, V20, P954, DOI 10.1038/s41556-018-0140-1; Escribano-Diaz C, 2013, MOL CELL, V49, P872, DOI 10.1016/j.molcel.2013.01.001; Fanti L, 2008, CURR OPIN GENET DEV, V18, P169, DOI 10.1016/j.gde.2008.01.009; Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318; Garrity M, 2021, CSH MOL CASE STUD, V7, DOI 10.1101/mcs.a006092; Ghezraoui H, 2018, NATURE, V560, P122, DOI 10.1038/s41586-018-0362-1; Gudmundsdottir B, 2018, CELL REP, V23, P3236, DOI 10.1016/j.celrep.2018.05.043; Gupta R, 2018, CELL, V173, P972, DOI 10.1016/j.cell.2018.03.050; Hara K, 2017, J BIOL CHEM, V292, P17658, DOI 10.1074/jbc.M117.804237; Hein MY, 2015, CELL, V163, P712, DOI 10.1016/j.cell.2015.09.053; Hempel M, 2015, AM J HUM GENET, V97, P493, DOI 10.1016/j.ajhg.2015.08.003; Hino M, 2021, CANCER SCI, V112, P3711, DOI 10.1111/cas.15018; Ikeda M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09114-3; Isidor B, 2016, HUM MUTAT, V37, P354, DOI 10.1002/humu.22952; Itoh G, 2011, EMBO J, V30, P130, DOI 10.1038/emboj.2010.276; Kowalczykowski SC, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016410; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lan L, 2010, MOL CELL, V40, P976, DOI 10.1016/j.molcel.2010.12.003; Lee YJ, 2006, CARCINOGENESIS, V27, P446, DOI 10.1093/carcin/bgi254; Marechal A, 2015, CELL RES, V25, P9, DOI 10.1038/cr.2014.147; Mcrae JF, 2017, NATURE, V542, P433, DOI 10.1038/nature21062; Mirman Z, 2018, NATURE, V560, P112, DOI 10.1038/s41586-018-0324-7; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Nakajima S, 2006, J BIOL CHEM, V281, P34687, DOI 10.1074/jbc.M605545200; Noordermeer SM, 2018, NATURE, V560, P117, DOI 10.1038/s41586-018-0340-7; Nozawa RS, 2010, NAT CELL BIOL, V12, P719, DOI 10.1038/ncb2075; Ogiwara H, 2011, ONCOGENE, V30, P2135, DOI [10.1038/onc.2010.592, 10.1038/onc.2010.592;]; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rose M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.564601; Rulten SL, 2013, DNA REPAIR, V12, P558, DOI 10.1016/j.dnarep.2013.04.008; Sack LM, 2018, CELL, V173, P499, DOI 10.1016/j.cell.2018.02.037; Sale JE, 2015, EMBO J, V34, P1609, DOI 10.15252/embj.201591697; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Sharma S, 2012, NUCLEIC ACIDS RES, V40, P682, DOI 10.1093/nar/gkr769; Silverman J, 2004, GENE DEV, V18, P2108, DOI 10.1101/gad.1216004; Simonetta M, 2018, CELL CYCLE, V17, P124, DOI 10.1080/15384101.2017.1404210; Stessman HAF, 2016, AM J HUM GENET, V98, P541, DOI 10.1016/j.ajhg.2016.02.004; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Tan B, 2016, J HUM GENET, V61, P357, DOI 10.1038/jhg.2015.156; Tanaka AJ, 2016, CSH MOL CASE STUD, V2, DOI 10.1101/mcs.a000661; Tomida J, 2018, EMBO J, V37, DOI 10.15252/embj.201899543; Unno J, 2014, CELL REP, V7, P1039, DOI 10.1016/j.celrep.2014.04.005; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; White J, 2016, GENOME MED, V8, DOI 10.1186/s13073-015-0253-0; Willmore E, 2004, BLOOD, V103, P4659, DOI 10.1182/blood-2003-07-2527; Xu GT, 2015, NATURE, V521, P541, DOI 10.1038/nature14328; Ye Y, 2015, CSH MOL CASE STUD, V1, DOI 10.1101/mcs.a000455; Yearim A, 2015, CELL REP, V10, P1122, DOI 10.1016/j.celrep.2015.01.038; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; You ZS, 2009, MOL CELL, V36, P954, DOI 10.1016/j.molcel.2009.12.002; Zeng W, 2010, EPIGENETICS-US, V5, P287, DOI 10.4161/epi.5.4.11683; Zhu Z, 2008, CELL, V134, P981, DOI 10.1016/j.cell.2008.08.037	69	2	2	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2706	2718		10.1038/s41388-022-02299-6	http://dx.doi.org/10.1038/s41388-022-02299-6		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35393543				2022-12-17	WOS:000779227700004
J	Peng, L; Zhou, N; Zhang, CY; Li, GC; Yuan, XQ				Peng, Li; Zhou, Nan; Zhang, Chao-Yang; Li, Guan-Cheng; Yuan, Xiao-Qing			eccDNAdb: a database of extrachromosomal circular DNA profiles in human cancers	ONCOGENE			English	Article							REPEATED GENOMIC SEQUENCES; CHROMATIN; STATISTICS; CIRCLES; ATLAS	Extrachromosomal circular DNA (eccDNA) elements are circular DNA molecules that are derived from but are independent of chromosomal DNA. EccDNA is emerging as a rising star because of its ubiquitous existence in cancers and its crucial role in oncogene amplification and tumor progression. In the present study, whole-genome sequencing (WGS) data of cancer samples were downloaded from public repositories. Afterwards, eccDNAs were identified from WGS data via bioinformatic analyses. To leverage database coverage, eccDNAs were also collected by manual curation of literatures. Gene expression and clinical data were downloaded from TCGA and CCLE and then used to investigate the roles of eccDNAs in cancers. Finally, the first integrated database of eccDNAs, eccDNAdb, was developed. eccDNAdb currently includes 1270 eccDNAs, which were identified in 480 samples (of 42 cancers) after analyzing a total number of 3395 tumor samples (of 57 cancers) including patient tissues, patient-derived xenografts, and cancer cell lines. A total number of 54,901 eccDNA genes were annotated and included in the database as well. With the integration of gene expression, clinical information and chromatin accessibility data, eccDNAdb enables users to easily determine the biological function and clinical relevance of eccDNAs in human cancers. In conclusion, eccDNAdb is freely accessible at http://www.eccdnadb.org. To our knowledge, eccDNAdb is the first database in the eccDNA research field. It is expected to provide insight for novel cancer therapies.	[Peng, Li; Yuan, Xiao-Qing] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangdong Hong Kong Joint Lab RNA Med, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China; [Peng, Li] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangzhou, Peoples R China; [Zhou, Nan] Guangzhou Med Univ, Dept Res, Affiliated Brain Hosp, Guangzhou, Peoples R China; [Zhou, Nan] Guangdong Engn Technol Res Ctr Translat Med Menta, Guangzhou, Peoples R China; [Zhang, Chao-Yang] German Canc Res Ctr, Div Funct Genome Anal, Heidelberg, Germany; [Li, Guan-Cheng] Cent South Univ, Key Lab Carcinogenesis, Chinese Minist Hlth, Changsha, Peoples R China; [Li, Guan-Cheng] Cent South Univ, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, Canc Res Inst, Changsha, Peoples R China; [Yuan, Xiao-Qing] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; Helmholtz Association; German Cancer Research Center (DKFZ); Central South University; Central South University; Sun Yat Sen University	Peng, L; Yuan, XQ (corresponding author), Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangdong Hong Kong Joint Lab RNA Med, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China.; Peng, L (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangzhou, Peoples R China.; Yuan, XQ (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Peoples R China.	pengli9@mail.sysu.edu.cn; yuanxq7@mail.sysu.edu.cn		Peng, Li/0000-0001-5358-6736; Zhou, Nan/0000-0002-0393-316X; Zhang, Chaoyang/0000-0001-6816-3840	National Natural Science Foundation of China [81972658, 81802812, 81803636]; Guangdong Basic and Applied Basic Research Foundation [2019A1515012114, 2018A030313129, 2018A0303130329]; National Postdoctoral Program for Innovation Talents [BX20190395]; China Postdoctoral Science Foundation [2019M663254]; Fundamental Research Funds for the Central Universities [20ykpy105]; Basic and Applied Basic Research of Guangzhou Municipal Basic Research Plan [202102020742]; Science and Technology Plan Project of Guangdong Province [2019B030316001]; Guangzhou Municipal Key Discipline in Medicine	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; National Postdoctoral Program for Innovation Talents; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Basic and Applied Basic Research of Guangzhou Municipal Basic Research Plan; Science and Technology Plan Project of Guangdong Province; Guangzhou Municipal Key Discipline in Medicine	This work was supported in part by the National Natural Science Foundation of China (grant no. 81972658 and 81802812 to LP, grant no. 81803636 to XQY), Guangdong Basic and Applied Basic Research Foundation (grant no. 2019A1515012114 and 2018A030313129 to LP, grant no. 2018A0303130329 to XQY), National Postdoctoral Program for Innovation Talents (grant no. BX20190395 to LP), China Postdoctoral Science Foundation (grant no. 2019M663254 to LP), and the Fundamental Research Funds for the Central Universities (grant no. 20ykpy105 to LP). Also, this work was supported in part by Basic and Applied Basic Research of Guangzhou Municipal Basic Research Plan (No. 202102020742); Science and Technology Plan Project of Guangdong Province (No. 2019B030316001); Guangzhou Municipal Key Discipline in Medicine (2021-2023).	Adam RC, 2020, NAT CELL BIOL, V22, P640, DOI 10.1038/s41556-020-0513-0; Alsford NS, 2003, MOL MICROBIOL, V47, P277, DOI 10.1046/j.1365-2958.2003.03266.x; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cohen S, 2003, GENOME RES, V13, P1133, DOI 10.1101/gr.907603; Cohen S, 2002, EMBO REP, V3, P1168, DOI 10.1093/embo-reports/kvf240; Cohen S, 1999, MOL CELL BIOL, V19, P6682; Cohen S, 2008, PLANT J, V53, P1027, DOI 10.1111/j.1365-313X.2007.03394.x; Corces MR, 2018, SCIENCE, V362, P420, DOI 10.1126/science.aav1898; COX D, 1965, LANCET, V2, P55; Deshpande V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08200-y; Ding YY, 2021, BLOOD, V137, P190, DOI 10.1182/blood.2020005219; Gorkin DU, 2020, NATURE, V583, P744, DOI 10.1038/s41586-020-2093-3; HOTTA Y, 1965, P NATL ACAD SCI USA, V53, P356, DOI 10.1073/pnas.53.2.356; Hull RM, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000471; Kamburov A, 2013, NUCLEIC ACIDS RES, V41, pD793, DOI 10.1093/nar/gks1055; Kim H, 2020, NAT GENET, V52, P891, DOI 10.1038/s41588-020-0678-2; Koche RP, 2020, NAT GENET, V52, P29, DOI 10.1038/s41588-019-0547-z; Kumar P, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba2489; Lanciano S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006630; Lazzarotto CR, 2018, NAT PROTOC, V13, P2615, DOI 10.1038/s41596-018-0055-0; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Link JC, 2020, J CLIN INVEST, V130, P5688, DOI 10.1172/JCI140223; Markenscoff-Papadimitriou E, 2020, CELL, V182, P754, DOI 10.1016/j.cell.2020.06.002; Mehta D, 2020, NAT PROTOC, V15, P1673, DOI 10.1038/s41596-020-0301-0; Miller CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016327; Moller Henrik D, 2015, G3 (Bethesda), V6, P453, DOI 10.1534/g3.115.025858; Moller HD, 2015, P NATL ACAD SCI USA, V112, pE3114, DOI 10.1073/pnas.1508825112; Morton AR, 2019, CELL, V179, P1330, DOI 10.1016/j.cell.2019.10.039; Nathanson DA, 2014, SCIENCE, V343, P72, DOI 10.1126/science.1241328; Navratilova A, 2008, BMC PLANT BIOL, V8, DOI 10.1186/1471-2229-8-90; Prada-Luengo I, 2020, NUCLEIC ACIDS RES, V48, P7883, DOI 10.1093/nar/gkaa545; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tsai SQ, 2017, NAT METHODS, V14, P607, DOI [10.1038/nmeth.4278, 10.1038/NMETH.4278]; TSUDA T, 1983, PLASMID, V10, P235, DOI 10.1016/0147-619X(83)90037-9; Turner KM, 2017, NATURE, V543, P122, DOI 10.1038/nature21356; Verhaak RGW, 2019, NAT REV CANCER, V19, P283, DOI 10.1038/s41568-019-0128-6; Wu SH, 2019, NATURE, V575, P699, DOI 10.1038/s41586-019-1763-5; Yerlici VT, 2019, NUCLEIC ACIDS RES, V47, P9741, DOI 10.1093/nar/gkz725; Zhu J, 2018, MOL DIAGN THER, V22, P515, DOI 10.1007/s40291-018-0348-6	42	2	2	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2696	2705		10.1038/s41388-022-02286-x	http://dx.doi.org/10.1038/s41388-022-02286-x		APR 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35388171	hybrid, Green Published			2022-12-17	WOS:000779712500001
J	Wang, L; Wang, JY; Yin, XL; Guan, X; Li, Y; Xin, CQ; Liu, J				Wang, Liang; Wang, Jiayi; Yin, Xiaolin; Guan, Xin; Li, Ying; Xin, Chenqi; Liu, Jing			GIPC2 interacts with Fzd7 to promote prostate cancer metastasis by activating WNT signaling	ONCOGENE			English	Article							INHIBITION; STATISTICS; EXOSOMES; PROTEIN; CELLS	Prostate cancer (PCa) causes significant mortality and morbidity, with advanced metastasis. WNT signaling is a promising therapeutic target for metastatic PCa. GIPC2 is a GIPC1 paralog involved in WNT signaling pathways associated with tumor progression, but its role in PCa metastasis remains unclear. Herein, we demonstrated that high GIPC2 expression in PCa tissues was significantly associated with distant metastasis and poor prognosis. Functional studies demonstrated that high GIPC2 expression due to CpG-island demethylation promoted increased metastatic capabilities of PCa cells. Conversely, silencing GIPC2 expression significantly inhibited PCa metastasis in vitro and in vivo. Furthermore, GIPC2 directly bound the WNT co-receptor Fzd7 through its PDZ domain, which enabled activation of WNT-beta-catenin cascades, thereby stimulating PCa metastasis. Interestingly, GIPC2 protein was also identified as a component of exosomes and that it robustly stimulated PCa adhesion, invasion, and migration. The presence of GIPC2 in tumor-derived exosomes and ability to impact the behavior of tumor cells suggest that GIPC2 is a novel epigenetic oncogene involved in PCa metastasis. Our findings identified GIPC2 as a novel exosomal molecule associated with WNT signaling and may represent a potential therapeutic target and biomarker for metastatic PCa.	[Wang, Liang; Wang, Jiayi; Yin, Xiaolin; Guan, Xin; Li, Ying; Xin, Chenqi; Liu, Jing] Dalian Med Univ, Affiliated Hosp 1, Regenerat Med Ctr, Stem Cell Clin Res Ctr,Natl Joint Engn Lab, 193 Lianhe Rd, Dalian 116011, Liaoning, Peoples R China; [Wang, Liang; Wang, Jiayi; Yin, Xiaolin; Guan, Xin; Li, Ying; Xin, Chenqi; Liu, Jing] Dalian Innovat Inst Stem Cell & Precis Med, 57 Xinda St,Dalian High Tech Pk, Dalian 116023, Liaoning, Peoples R China	Dalian Medical University	Liu, J (corresponding author), Dalian Med Univ, Affiliated Hosp 1, Regenerat Med Ctr, Stem Cell Clin Res Ctr,Natl Joint Engn Lab, 193 Lianhe Rd, Dalian 116011, Liaoning, Peoples R China.; Liu, J (corresponding author), Dalian Innovat Inst Stem Cell & Precis Med, 57 Xinda St,Dalian High Tech Pk, Dalian 116023, Liaoning, Peoples R China.	liujing@dmu.edu.cn		Wang, Liang/0000-0003-2244-7535	National Nature Science Foundation of China [31600614, 82072953]; Innovative leading talents of Liaoning Province [XLYC1902031]; Young top talents of Liaoning Province [XLYC1907009]; Dalian outstanding young scientific and technological talents [2021RJ12]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovative leading talents of Liaoning Province; Young top talents of Liaoning Province; Dalian outstanding young scientific and technological talents	We would like to acknowledge the patients for the tissue samples. This work was supported by the National Nature Science Foundation of China (Grant Nos. 31600614, 82072953), the Innovative leading talents of Liaoning Province (Grant No. XLYC1902031), Young top talents of Liaoning Province (Grant No. XLYC1907009), and Dalian outstanding young scientific and technological talents (Grant No. 2021RJ12).	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Atala Anthony, 2017, J Urol, V197, P701, DOI 10.1016/j.juro.2016.12.032; Bersini S, 2014, BIOMATERIALS, V35, P2454, DOI 10.1016/j.biomaterials.2013.11.050; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Cooperberg MR, 2015, EUR UROL, V67, P326, DOI 10.1016/j.eururo.2014.05.039; Culp MB, 2020, EUR UROL, V77, P38, DOI 10.1016/j.eururo.2019.08.005; Dong Y., CELL DEATH DIS, V2021; Francis JC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003180; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; Ito K, 2014, NAT REV UROL, V11, P197, DOI 10.1038/nrurol.2014.42; Katoh M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.49; Kirikoshi H, 2002, INT J ONCOL, V20, P571; Kong J, 2016, ONCOTARGET, V7, P78421, DOI 10.18632/oncotarget.9382; Kuang SQ, 2008, LEUKEMIA, V22, P1529, DOI 10.1038/leu.2008.130; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Kypta RM, 2012, NAT REV UROL, V9, P418, DOI 10.1038/nrurol.2012.116; Li J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150247; Li Y, 2017, ONCOGENE, V36, P6293, DOI 10.1038/onc.2017.223; Liu TJ, 2009, ELECTROPHORESIS, V30, P4285, DOI 10.1002/elps.200900289; Ma F, 2016, J CLIN INVEST, V126, P1745, DOI 10.1172/JCI78815; Mao XY, 2010, CANCER RES, V70, P5207, DOI 10.1158/0008-5472.CAN-09-4074; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151; Muders MH, 2009, CLIN CANCER RES, V15, P4095, DOI 10.1158/1078-0432.CCR-08-2837; Murillo-Garzon V, 2017, NAT REV UROL, V14, P683, DOI 10.1038/nrurol.2017.144; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Nilsson J, 2009, BRIT J CANCER, V100, P1603, DOI 10.1038/sj.bjc.6605058; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Pernar CH, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a030361; Phesse T, 2016, CANCERS, V8, DOI 10.3390/cancers8050050; Shang GJ, 2017, ELIFE, V6, P1, DOI 10.7554/eLife.27322; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Song JW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005756; Tan C, 2001, DEVELOPMENT, V128, P3665; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thiele S, 2011, J CELL BIOCHEM, V112, P1593, DOI 10.1002/jcb.23070; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; van Amerongen R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007914; Yang YH, 2013, MOL BIOL REP, V40, P4241, DOI 10.1007/s11033-013-2506-6; Yavelsky V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-247; You SY, 2016, CANCER RES, V76, P4948, DOI 10.1158/0008-5472.CAN-16-0902; Zong Y, 2012, P NATL ACAD SCI USA, V109, pE3395, DOI 10.1073/pnas.1217982109	45	2	2	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2609	2623		10.1038/s41388-022-02255-4	http://dx.doi.org/10.1038/s41388-022-02255-4		MAR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35347223	Green Published, hybrid			2022-12-17	WOS:000773837500001
J	Song, HJ; Wang, JQ; Wang, XJ; Yuan, BL; Li, D; Hu, AP; Guo, YH; Cai, S; Jin, SK; Zhou, Y; Li, QL; Chen, G; Gao, HY; Zheng, LD; Tong, QS				Song, Huajie; Wang, Jianqun; Wang, Xiaojing; Yuan, Boling; Li, Dan; Hu, Anpei; Guo, Yanhua; Cai, Shuang; Jin, Shikai; Zhou, Yi; Li, Qilan; Chen, Guo; Gao, Haiyang; Zheng, Liduan; Tong, Qiangsong			HNF4A-AS1-encoded small peptide promotes self-renewal and aggressiveness of neuroblastoma stem cells via eEF1A1-repressed SMAD4 transactivation	ONCOGENE			English	Article							SENESCENCE; PROGRESSION; ACTIVATION; PROTEIN; CLASSIFICATION; IDENTIFICATION; STRATEGIES	Cancer stem cells play crucial roles in tumorigenesis and aggressiveness, while regulatory mechanisms in neuroblastoma (NB), a pediatric extracranial malignancy with highest incidence, are still unknown. Herein, a small 51-amino acid peptide (sPEP1) encoded by hepatocyte nuclear factor 4 alpha antisense RNA 1 (HNF4A-AS1) was identified in tumor tissues and cells, which facilitated self-renewal and aggressiveness of NB stem cells. MiRNA-409-5p interacted with HNF4A-AS1 to facilitate sPEP1 translation via recruiting eukaryotic translation initiation factor 3 subunit G, while sPEP1 repressed serum deprivation-induced senescence and promoted sphere formation, growth, or metastasis of NB stem cells. Mechanistically, sPEP1 directly interacted with eukaryotic translation elongation factor 1 alpha 1 (eEF1A1) to facilitate its binding to SMAD family member 4 (SMAD4), resulting in repression of SMAD4 transactivation and transcriptional upregulation of stem cell genes associated with tumor progression. Rescue experiments revealed that sPEP1 exerted oncogenic roles via facilitating physical interaction between eEF1A1 and SMAD4. Notably, knockdown of sPEP1 significantly repressed the self-renewal and metastasis of NB stem cells in vivo. High sPEP1 or eEF1A1 levels in clinical NB tissues were linked to poor patients' survival. These findings suggest that HNF4A-AS1-encoded sPEP1 promotes self-renewal and aggressive features of NB stem cells by eEF1A1-repressed SMAD4 transactivation.	[Song, Huajie; Wang, Jianqun; Yuan, Boling; Li, Dan; Hu, Anpei; Guo, Yanhua; Jin, Shikai; Li, Qilan; Chen, Guo; Tong, Qiangsong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pediat Surg, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China; [Wang, Xiaojing] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Geriatr, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China; [Cai, Shuang; Zhou, Yi; Zheng, Liduan] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China; [Gao, Haiyang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China; [Zheng, Liduan; Tong, Qiangsong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Clin Ctr Human Genom Res, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Tong, QS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pediat Surg, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.; Zheng, LD (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pathol, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.; Zheng, LD; Tong, QS (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Clin Ctr Human Genom Res, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.	ld_zheng@hotmail.com; qs_tong@hotmail.com			National Natural Science Foundation of China [81773094, 81772967, 81874085, 81874066, 81802925, 81903011, 81903008, 82072801, 82173316]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We are grateful for Dr. Ralf Janknecht for providing vectors. This work was granted by the National Natural Science Foundation of China (81773094, 81772967, 81874085, 81874066, 81802925, 81903011, 81903008, 82072801, 82173316).	Abbas W, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00075; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Balko JM, 2013, CANCER RES, V73, P6346, DOI 10.1158/0008-5472.CAN-13-1385; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Chiba T, 2010, HEPATOLOGY, V52, P1111, DOI 10.1002/hep.23793; Choi, 2019, SCI REP-UK, V9; Choi SW, 2019, BRIEF BIOINFORM, V20, P1853, DOI 10.1093/bib/bby055; Edmonds BT, 1996, J CELL SCI, V109, P2705; Fang EH, 2020, THERANOSTICS, V10, P1555, DOI 10.7150/thno.37383; Fang EH, 2019, ADV SCI, V6, DOI 10.1002/advs.201900581; Fujimaki K, 2019, P NATL ACAD SCI USA, V116, P22624, DOI 10.1073/pnas.1915905116; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hansford LM, 2007, CANCER RES, V67, P11234, DOI 10.1158/0008-5472.CAN-07-0718; Hernandez AL, 2019, MOL CARCINOGEN, V58, P1648, DOI 10.1002/mc.23049; Huang JZ, 2017, MOL CELL, V68, P171, DOI 10.1016/j.molcel.2017.09.015; Johnsson A, 2000, BRIT J CANCER, V83, P1047, DOI 10.1054/bjoc.2000.1420; Kojima K, 2007, CANCER RES, V67, P8121, DOI 10.1158/0008-5472.CAN-06-4167; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Li, 2018, NAT COMMUN, V9; Li D, 2018, CANCER RES, V78, P1169, DOI 10.1158/0008-5472.CAN-17-2295; Li HH, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910835; Li XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15909; Lindemann C, 2017, BIOL CHEM, V398, P687, DOI 10.1515/hsz-2017-0104; Magny EG, 2013, SCIENCE, V341, P1116, DOI 10.1126/science.1238802; Matsumoto A, 2017, NATURE, V541, P228, DOI 10.1038/nature21034; Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167; Mishra AK, 2007, P NATL ACAD SCI USA, V104, P13930, DOI 10.1073/pnas.0704915104; Nottrott S, 2006, NAT STRUCT MOL BIOL, V13, P1108, DOI 10.1038/nsmb1173; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Pandian V, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0002-8; Pauli A, 2014, SCIENCE, V343, P746, DOI 10.1126/science.1248636; Pinto NR, 2015, J CLIN ONCOL, V33, P3008, DOI 10.1200/JCO.2014.59.4648; Pringle Eric S, 2019, Curr Protoc Mol Biol, V125, pe79, DOI 10.1002/cpmb.79; Rennie W, 2014, NUCLEIC ACIDS RES, V42, pW114, DOI 10.1093/nar/gku376; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Slavoff SA, 2013, NAT CHEM BIOL, V9, P59, DOI [10.1038/NCHEMBIO.1120, 10.1038/nchembio.1120]; Song HJ, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00857-7; Takenobu H, 2011, ONCOGENE, V30, P97, DOI 10.1038/onc.2010.383; Tan H, 2019, EBIOMEDICINE, V43, P82, DOI 10.1016/j.ebiom.2019.03.082; Thomas SK, 2004, J BIOL CHEM, V279, P27994, DOI 10.1074/jbc.M312663200; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Vera M, 2014, ELIFE, V3, DOI 10.7554/eLife.03164; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wang, 2020, J EXP MED, V217, pe20190950; Wu P, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1147-3; Yang G, 2010, INT J BIOL SCI, V6, P1; Yu CC, 2011, J ONCOL, V2011, DOI 10.1155/2011/609259; Zhao X, 2016, ONCOGENE, V35, P3565, DOI 10.1038/onc.2015.422; Zhao X, 2020, MOL THER, V28, P946, DOI 10.1016/j.ymthe.2019.12.013; Zhao X, 2018, MOL THER, V26, P755, DOI 10.1016/j.ymthe.2017.12.017	50	2	2	5	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2505	2519		10.1038/s41388-022-02271-4	http://dx.doi.org/10.1038/s41388-022-02271-4		MAR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35318442				2022-12-17	WOS:000771890400002
J	Georgiou, M; Ntavelou, P; Stokes, W; Roy, R; Maher, GJ; Stoilova, T; Rakhit, CP; Martins, M; Ajuh, P; Horowitz, N; Berkowitz, RS; Elias, K; Seckl, MJ; Pardo, OE				Georgiou, Marina; Ntavelou, Panagiota; Stokes, William; Roy, Rajat; Maher, Geoffrey J.; Stoilova, Tsvetana; Rakhit, Callum P.; Martins, Miguel; Ajuh, Paul; Horowitz, Neil; Berkowitz, Ross S.; Elias, Kevin; Seckl, Michael J.; Pardo, Olivier E.			ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma	ONCOGENE			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; DIHYDROFOLATE-REDUCTASE; WEE1 KINASE; TROPHOBLASTIC-DISEASE; MOLECULAR-MECHANISMS; BREAST-CANCER; DNA; EXPRESSION; THERAPY; P53	Low-risk gestational trophoblastic neoplasia including choriocarcinoma is often effectively treated with Methotrexate (MTX) as a first line therapy. However, MTX resistance (MTX-R) occurs in at least approximate to 33% of cases. This can sometimes be salvaged with actinomycin-D but often requires more toxic combination chemotherapy. Moreover, additional therapy may be needed and, for high-risk patients, 5% still die from the multidrug-resistant disease. Consequently, new treatments that are less toxic and could reverse MTX-R are needed. Here, we compared the proteome/phosphoproteome of MTX-resistant and sensitive choriocarcinoma cells using quantitative mass-spectrometry to identify therapeutically actionable molecular changes associated with MTX-R. Bioinformatics analysis of the proteomic data identified cell cycle and DNA damage repair as major pathways associated with MTX-R. MTX-R choriocarcinoma cells undergo cell cycle delay in G1 phase that enables them to repair DNA damage more efficiently through non-homologous end joining in an ATR-dependent manner. Increased expression of cyclin-dependent kinase 4 (CDK4) and loss of p16(Ink4a) in resistant cells suggested that CDK4 inhibition may be a strategy to treat MTX-R choriocarcinoma. Indeed, inhibition of CDK4/6 using genetic silencing or the clinically relevant inhibitor, Palbociclib, induced growth inhibition both in vitro and in an orthotopic in vivo mouse model. Finally, targeting the ATR pathway, genetically or pharmacologically, re-sensitised resistant cells to MTX in vitro and potently prevented the growth of MTX-R tumours in vivo. In short, we identified two novel therapeutic strategies to tackle MTX-R choriocarcinoma that could rapidly be translated into the clinic.	[Georgiou, Marina; Ntavelou, Panagiota; Stokes, William; Roy, Rajat; Maher, Geoffrey J.; Stoilova, Tsvetana; Seckl, Michael J.; Pardo, Olivier E.] Imperial Coll, Dept Surg & Canc, Div Canc, London, England; [Rakhit, Callum P.; Martins, Miguel] Univ Cambridge, MRC Toxicol Unit, Cambridge, England; [Ajuh, Paul] Gemini Biosci, Liverpool, Merseyside, England; [Horowitz, Neil; Berkowitz, Ross S.; Elias, Kevin] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Obstet & Gynecol,Div Gynecol Oncol, Boston, MA USA	Imperial College London; University of Cambridge; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	Seckl, MJ; Pardo, OE (corresponding author), Imperial Coll, Dept Surg & Canc, Div Canc, London, England.	m.seckl@imperial.ac.uk; o.pardo@imperial.ac.uk	Pardo, Oliver/AEM-2071-2022	Pardo, Oliver/0000-0003-2223-1435	MRC [MR/K016776/1]; Cancer Treatment and Research Trust; UK Medical Research Council [MC_UU_00025/3 (RG94521)]	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Treatment and Research Trust; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank the MRC for funding the work of MG (MR/K016776/1), The Cancer Treatment and Research Trust for funding WS and RR. The authors gratefully acknowledge infrastructure support from the Cancer Research UK Imperial Centre, the Imperial Experimental Cancer Medicine Centre and the National Institute for Health Research Imperial Biomedical Research Centre. We also acknowledge the Donald P Goldstein, MD Trophoblastic Tumour Registry Endowment and the Dyett Family Trophoblastic Disease Research and Registry Endowment. LMM and CR are funded by the UK Medical Research Council, intramural project MC_UU_00025/3 (RG94521). In addition, we would like to acknowledge the kind help of Drs Lorenzo Ferrando and Gabriele Zoppoli from the Universita di Genova in reformatting our Ion Torrent sequencing data prior to deposition.	Alifrangis C, 2010, FUTURE ONCOL, V6, P1915, DOI 10.2217/FON.10.153; Araki T, 2016, ENDOCR-RELAT CANCER, V23, P857, DOI 10.1530/ERC-16-0206; Assaraf YG, 2006, DRUG RESIST UPDATE, V9, P227, DOI 10.1016/j.drup.2006.09.001; Banerjee D, 1995, ACTA BIOCHIM POL, V42, P457; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; Bertino JR, 2009, BEST PRACT RES CL HA, V22, P577, DOI 10.1016/j.beha.2009.09.004; Bolze PA, 2020, GYNECOL ONCOL, V158, P785, DOI 10.1016/j.ygyno.2020.05.042; Caretti V, 2013, MOL CANCER THER, V12, P141, DOI 10.1158/1535-7163.MCT-12-0735; Castrogiovanni C, 2018, CELL DEATH DIFFER, V25, P190, DOI 10.1038/cdd.2017.143; Chu J, 2012, MOL BIOL CELL, V23, P59, DOI 10.1091/mbc.E11-06-0487; Corrales L, 2017, CELL RES, V27, P96, DOI 10.1038/cr.2016.149; Do K, 2015, J CLIN ONCOL, V33, P3409, DOI 10.1200/JCO.2014.60.4009; Elias KM, 2017, AM J REPROD IMMUNOL, V77, DOI 10.1111/aji.12666; Engelke CG, 2013, CLIN CANCER RES, V19, P4412, DOI 10.1158/1078-0432.CCR-12-3748; Feng X, 2020, EMBO J, V39, DOI 10.15252/embj.2019104036; Fokas E, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.181; Froeling FE., 2014, CURR ONCOL REP, V16; Galletti G, 2017, CANCER TREAT REV, V57, P16, DOI 10.1016/j.ctrv.2017.04.008; Ghorani E, 2017, LANCET, V390, P2343, DOI 10.1016/S0140-6736(17)32894-5; Goldstein M, 2015, ANNU REV MED, V66, P129, DOI 10.1146/annurev-med-081313-121208; Gu GW, 2016, CURR OPIN PHARMACOL, V31, P97, DOI 10.1016/j.coph.2016.11.005; Hamilton E, 2016, CANCER TREAT REV, V45, P129, DOI 10.1016/j.ctrv.2016.03.002; Han B, 2010, INT J GYNECOL CANCER, V20, P1259, DOI 10.1111/IGC.0b013e3181f05128; Hilton BA, 2015, MOL CELL, V60, P35, DOI 10.1016/j.molcel.2015.08.008; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Hochhaus A, 2007, SEMIN HEMATOL, V44, pS15, DOI 10.1053/j.seminhematol.2006.12.002; Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216; Joukov V, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar4195; Kapke Jonathan T, 2019, Hematol Oncol Stem Cell Ther, V12, P189, DOI 10.1016/j.hemonc.2019.08.008; King C, 2014, INVEST NEW DRUG, V32, P213, DOI 10.1007/s10637-013-0036-7; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; Kori S, 2020, J MOL BIOL, V432, P4061, DOI 10.1016/j.jmb.2020.05.006; Krajewska M, 2015, ONCOGENE, V34, P3474, DOI 10.1038/onc.2014.276; Kuhne C, 2003, NUCLEIC ACIDS RES, V31, P7227, DOI 10.1093/nar/gkg937; LaPak KM, 2014, MOL CANCER RES, V12, P167, DOI 10.1158/1541-7786.MCR-13-0350; Laquente B, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3131-x; Lecona E, 2014, EXP CELL RES, V329, P26, DOI 10.1016/j.yexcr.2014.09.019; Lee EK, 2019, TRENDS CANCER, V5, P524, DOI 10.1016/j.trecan.2019.06.004; Li HD, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.31; Li QY, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-474; Lin LH, 2021, AM J OBSTET GYNECOL, V224, DOI 10.1016/j.ajog.2020.09.048; Liskovykh M, 2019, GENOME RES, V29, P1719, DOI 10.1101/gr.254276.119; Liu MH, 2018, ONCOL REP, V39, P901, DOI 10.3892/or.2018.6221; Liu WJ, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107438; Lurain JR, 2010, AM J OBSTET GYNECOL, V203, P531, DOI 10.1016/j.ajog.2010.06.073; Ma HH, 2012, P NATL ACAD SCI USA, V109, P4828, DOI 10.1073/pnas.1116349109; Mangili G, 2014, INT J GYNECOL CANCER, V24, pS109, DOI 10.1097/IGC.0000000000000294; Meazza C, 2021, EXPERT OPIN PHARMACO, V22, P1995, DOI 10.1080/14656566.2021.1936499; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Meng XN, 2015, J MED GENET, V52, P135, DOI 10.1136/jmedgenet-2014-102703; Menolfi D, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-0376-x; Mishra PJ, 2007, P NATL ACAD SCI USA, V104, P13513, DOI 10.1073/pnas.0706217104; Mishra SK, 2004, ONCOGENE, V23, P4422, DOI 10.1038/sj.onc.1207569; Muller IB, 2021, RHEUMATOLOGY, V60, P1273, DOI 10.1093/rheumatology/keaa428; Nagel ZD, 2014, P NATL ACAD SCI USA, V111, pE1823, DOI 10.1073/pnas.1401182111; Olsen JV, 2004, P NATL ACAD SCI USA, V101, P13417, DOI 10.1073/pnas.0405549101; Ovejero S, 2012, MOL BIOL CELL, V23, P4515, DOI 10.1091/mbc.E12-04-0260; Pereira AL, 2006, MOL BIOL CELL, V17, P4526, DOI 10.1091/mbc.E06-07-0579; Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z; Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580; Roskoski R, 2019, PHARMACOL RES, V139, P471, DOI 10.1016/j.phrs.2018.11.035; Rots MG, 2000, LEUKEMIA, V14, P2166, DOI 10.1038/sj.leu.2401943; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Schnittger A, 2018, TRENDS PLANT SCI, V23, P475, DOI 10.1016/j.tplants.2018.03.015; Seckl MJ, 2010, LANCET, V376, P717, DOI 10.1016/S0140-6736(10)60280-2; Serra M, 2004, ANN ONCOL, V15, P151, DOI 10.1093/annonc/mdh004; Shah MA, 2001, CLIN CANCER RES, V7, P2168; Shamash J, 2020, BJU INT, V125, P843, DOI 10.1111/bju.14947; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422; Spring LM, 2020, LANCET, V395, P817, DOI 10.1016/S0140-6736(20)30165-3; SRIMATKANDADA S, 1983, BIOCHEMISTRY-US, V22, P5774, DOI 10.1021/bi00294a015; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Thingholm TE, 2006, NAT PROTOC, V1, P1929, DOI 10.1038/nprot.2006.185; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Wang BD, 2018, CANCERS, V10, DOI 10.3390/cancers10110458; Whittle JR, 2020, CLIN CANCER RES, V26, P4120, DOI 10.1158/1078-0432.CCR-19-1872; Wisniewski JR, 2009, J PROTEOME RES, V8, P5674, DOI 10.1021/pr900748n; Wojtuszkiewicz A, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0158-9; Wolf J, 2005, ANN RHEUM DIS, V64, P564, DOI 10.1136/ard.2003.014985; Wu Guanming, 2014, F1000Res, V3, P146, DOI 10.12688/f1000research.4431.1; Yap TA, 2020, J CLIN ONCOL, V38, P3195, DOI 10.1200/JCO.19.02404; Zhang W., 2017, J MED CASE REP, V11; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60	87	2	2	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2540	2554		10.1038/s41388-022-02251-8	http://dx.doi.org/10.1038/s41388-022-02251-8		MAR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35301407	hybrid, Green Published			2022-12-17	WOS:000770216400001
J	Ma, SJ; Dong, ZZ; Huang, YF; Liu, JY; Zhang, JT				Ma, Shijie; Dong, Zizheng; Huang, Yanfei; Liu, Jing-Yuan; Zhang, Jian-Ting			eIF3a regulation of mTOR signaling and translational control via HuR in cellular response to DNA damage	ONCOGENE			English	Article							RIBONUCLEOTIDE REDUCTASE M2; SMALL-MOLECULE INHIBITORS; INITIATION-FACTOR 3; BIOCHEMICAL-CHARACTERIZATION; PROTEIN-SYNTHESIS; MAMMALIAN TARGET; OVARIAN-CANCER; RAPAMYCIN TOR; ENTRY SITE; COMPLEX 1	eIF3a (eukaryotic translation initiation factor 3a), a subunit of the eIF3 complex, has been suggested to play a regulatory role in protein synthesis and in cellular response to DNA-damaging treatments. S6K1 is an effector and a mediator of mTOR complex 1 (mTORC1) in regulating protein synthesis and integrating diverse signals into control of cell growth and response to stress. Here, we show that eIF3a regulates S6K1 activity by inhibiting mTORC1 kinase via regulating Raptor synthesis. The regulation of Raptor synthesis is via eIF3a interaction with HuR (human antigen R) and binding of the eIF3a-HuR complex to the 5MODIFIER LETTER PRIME-UTR of Raptor mRNA. Furthermore, mTORC1 may mediate eIF3a function in cellular response to cisplatin by regulating synthesis of NER proteins and NER activity. Taken together, we conclude that the mTOR signaling pathway may also be regulated by translational control and mediate eIF3a regulation of cancer cell response to cisplatin by regulating NER protein synthesis.	[Ma, Shijie; Dong, Zizheng; Zhang, Jian-Ting] Univ Toledo, Coll Med & Life Sci, Dept Cell & Canc Biol, 2801 W Bancroft St, Toledo, OH 43606 USA; [Huang, Yanfei; Liu, Jing-Yuan] Univ Toledo, Coll Med & Life Sci, Dept Med, 2801 W Bancroft St, Toledo, OH 43606 USA	University System of Ohio; University of Toledo; University System of Ohio; University of Toledo	Zhang, JT (corresponding author), Univ Toledo, Coll Med & Life Sci, Dept Cell & Canc Biol, 2801 W Bancroft St, Toledo, OH 43606 USA.	jianting.zhang@utoledo.edu	huang, yan/GWM-4747-2022		NIH [R01 CA211904]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by the NIH grant R01 CA211904.	Ahn B, 2004, MOL CELLS, V18, P249; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Babichev Y, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0814-z; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078; Carriere A, 2011, J BIOL CHEM, V286, P567, DOI 10.1074/jbc.M110.159046; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chen J, 2021, BIOCHEM PHARMACOL, V190, DOI 10.1016/j.bcp.2021.114616; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Dong ZZ, 2006, CRIT REV ONCOL HEMAT, V59, P169, DOI 10.1016/j.critrevonc.2006.03.005; Dong ZZ, 2020, BIOCHEM J, V477, P1939, DOI 10.1042/BCJ20200025; Dong ZZ, 2013, J BIOL CHEM, V288, P27951, DOI 10.1074/jbc.M113.483164; Dong ZZ, 2005, NUCLEIC ACIDS RES, V33, P2715, DOI 10.1093/nar/gki569; Dong ZZ, 2004, ONCOGENE, V23, P3790, DOI 10.1038/sj.onc.1207465; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; Dunlop EA, 2009, CELL SIGNAL, V21, P827, DOI 10.1016/j.cellsig.2009.01.012; Espeillac C, 2011, J CLIN INVEST, V121, P2821, DOI 10.1172/JCI44203; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Foster KG, 2010, J BIOL CHEM, V285, P80, DOI 10.1074/jbc.M109.029637; Grunwald V, 2002, CANCER RES, V62, P6141; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Gwinn DM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009197; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Huang W, 2016, ONCOGENE, V35, P783, DOI 10.1038/onc.2015.215; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kocalis HE, 2014, MOL METAB, V3, P394, DOI 10.1016/j.molmet.2014.01.014; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Kwak D, 2012, J BIOL CHEM, V287, P18398, DOI 10.1074/jbc.M111.326538; Liu RY, 2011, ONCOGENE, V30, P4814, DOI 10.1038/onc.2011.189; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892; Nassim R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065257; Neher TM, 2010, ACS CHEM BIOL, V5, P953, DOI 10.1021/cb1000444; Neher TM, 2010, BIOCHEMISTRY-US, V49, P669, DOI 10.1021/bi901575h; Nouspikel T, 2009, CELL MOL LIFE SCI, V66, P994, DOI 10.1007/s00018-009-8737-y; Peery R, 2020, J MED CHEM, V63, P7243, DOI 10.1021/acs.jmedchem.0c00475; Peng DJ, 2010, BIOCHEM BIOPH RES CO, V394, P600, DOI 10.1016/j.bbrc.2010.03.029; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Qi J, 2014, ONCOGENE, V33, P4156, DOI 10.1038/onc.2013.397; Qiao YW, 2002, MUTAT RES-FUND MOL M, V509, P165, DOI 10.1016/S0027-5107(02)00219-1; Ramirez-Valle F, 2010, MOL CELL BIOL, V30, P3151, DOI 10.1128/MCB.00322-09; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Stronach EA, 2011, NEOPLASIA, V13, P1069, DOI 10.1593/neo.111032; Su B, 2011, CRIT REV BIOCHEM MOL, V46, P527, DOI 10.3109/10409238.2011.618113; Tumia R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00753; Vandamme T, 2016, BRIT J CANCER, V114, P650, DOI 10.1038/bjc.2016.25; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wagner S, 2016, NUCLEIC ACIDS RES, V44, P10772, DOI 10.1093/nar/gkw972; Wagner S, 2014, MOL CELL BIOL, V34, P3041, DOI 10.1128/MCB.00663-14; Wei F, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-81; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yin JY, 2018, CANCER LETT, V412, P81, DOI 10.1016/j.canlet.2017.09.055; Yin JY, 2013, CARCINOGENESIS, V34, P1224, DOI 10.1093/carcin/bgt052; Yin JY, 2011, CLIN CANCER RES, V17, P4600, DOI 10.1158/1078-0432.CCR-10-2591; Yin JY, 2011, BIOSCIENCE REP, V31, P1, DOI 10.1042/BSR20100077; Yuan HX, 2016, CELL RES, V26, P267, DOI 10.1038/cr.2016.10; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	63	2	2	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2431	2443		10.1038/s41388-022-02262-5	http://dx.doi.org/10.1038/s41388-022-02262-5		MAR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35279705	Green Accepted			2022-12-17	WOS:000767909000003
J	Rong, ZX; Zhang, L; Li, Z; Xiao, Z; Duan, YM; Ren, XX; Zi, YY; Gao, J; Mu, Y; Guan, YD; Cao, Z; Wang, XT; Pei, Q; Zeng, Y; Fan, Q; Zeng, ZM; Ou, DM; He, J; Nie, YJ; Tan, R; Weng, L; Li, YH; Xiang, R; Deng, YZ; Sun, LQ				Rong, Zhuoxian; Zhang, Lu; Li, Zhi; Xiao, Zhi; Duan, Yumei; Ren, Xinxin; Zi, Yuyuan; Gao, Jie; Mu, Yun; Guan, Yidi; Cao, Zhen; Wang, Xitao; Pei, Qian; Zeng, Yu; Fan, Qi; Zeng, Zimei; Ou, Danmin; He, Jiang; Nie, Yingjie; Tan, Rong; Weng, Liang; Li, Yuhao; Xiang, Rong; Deng, Yuezhen; Sun, Lunquan			SIK2 maintains breast cancer stemness by phosphorylating LRP6 and activating Wnt/beta-catenin signaling	ONCOGENE			English	Article							INDUCIBLE KINASE 2; WNT; HETEROGENEITY; CELLS; TUMORIGENESIS; EXPRESSION; ROLES	Breast cancer stem cells (BCSCs) are the main drivers of recurrence and metastasis. However, commonly used drugs rarely target BCSCs. Via screenings, we found that Salt-inducible kinase 2 (SIK2) participated in breast cancer (BC) stemness maintenance and zebrafish embryos development. SIK2 was upregulated in recurrence samples. Knockdown of SIK2 expression reduced the proportion of BCSCs and the tumor initiation of BC cells. Mechanistically, SIK2, phosphorylated by CK1 alpha, directly phosphorylated LRP6 in a SIK2 kinase activity-dependent manner, leading to Wnt/beta-catenin signaling pathway activation. ARN-3236 and HG-9-91-01, inhibitors of SIK2, inhibited LRP6 phosphorylation and beta-catenin accumulation and disturbed stemness maintenance. In addition, the SIK2-activated Wnt/beta-catenin signaling led to induction of IDH1 expression, causing metabolic reprogramming in BC cells. These findings demonstrate a novel mechanism whereby Wnt/beta-catenin signaling pathway is regulated by different kinases in response to metabolic requirement of CSCs, and suggest that SIK2 inhibition may potentially be a strategy for eliminating BCSCs.	[Rong, Zhuoxian; Zhang, Lu; Li, Zhi; Ren, Xinxin; Zi, Yuyuan; Gao, Jie; Mu, Yun; Guan, Yidi; Cao, Zhen; Wang, Xitao; Pei, Qian; Zeng, Yu; Fan, Qi; Zeng, Zimei; Ou, Danmin; He, Jiang; Tan, Rong; Weng, Liang; Deng, Yuezhen; Sun, Lunquan] Cent South Univ, Xiangya Hosp, Xiangya Canc Ctr, Changsha 410008, Peoples R China; [Rong, Zhuoxian; Zhang, Lu; Li, Zhi; Ren, Xinxin; Zi, Yuyuan; Gao, Jie; Mu, Yun; Guan, Yidi; Cao, Zhen; Wang, Xitao; Pei, Qian; Zeng, Yu; Fan, Qi; Zeng, Zimei; Ou, Danmin; He, Jiang; Tan, Rong; Weng, Liang; Deng, Yuezhen; Sun, Lunquan] Lab Mol Radiat Oncol Hunan Prov, Changsha 410008, Peoples R China; [Rong, Zhuoxian; Li, Zhi; He, Jiang; Tan, Rong; Weng, Liang; Deng, Yuezhen; Sun, Lunquan] Natl Clin Res Ctr Gerontol, Inst Gerontol Canc Res, Changsha 410008, Peoples R China; [Rong, Zhuoxian; Li, Zhi; Tan, Rong; Weng, Liang; Deng, Yuezhen; Sun, Lunquan] Hunan Int Sci & Technol Collaborat Base Precis Me, Changsha 410008, Peoples R China; [Rong, Zhuoxian; Li, Zhi; Tan, Rong; Weng, Liang; Deng, Yuezhen; Sun, Lunquan] Cent South Univ, Xiangya Hosp, Ctr Mol Imaging, Changsha 410008, Peoples R China; [Xiao, Zhi] Cent South Univ, Xiangya Hosp, Dept Breast Surg, Changsha 410008, Peoples R China; [Duan, Yumei] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Peoples R China; [Nie, Yingjie] Guizhou Prov Peoples Hosp, NHC Key Lab Pulm Immune Related Dis, Guiyang 550000, Peoples R China; [Li, Yuhao; Xiang, Rong] Nankai Univ, Coll Med, 94 Weijin Rd, Tianjin 300071, Peoples R China	Central South University; Central South University; Central South University; Central South University; Nankai University	Deng, YZ; Sun, LQ (corresponding author), Cent South Univ, Xiangya Hosp, Xiangya Canc Ctr, Changsha 410008, Peoples R China.; Deng, YZ; Sun, LQ (corresponding author), Lab Mol Radiat Oncol Hunan Prov, Changsha 410008, Peoples R China.; Deng, YZ; Sun, LQ (corresponding author), Natl Clin Res Ctr Gerontol, Inst Gerontol Canc Res, Changsha 410008, Peoples R China.; Deng, YZ; Sun, LQ (corresponding author), Hunan Int Sci & Technol Collaborat Base Precis Me, Changsha 410008, Peoples R China.; Deng, YZ; Sun, LQ (corresponding author), Cent South Univ, Xiangya Hosp, Ctr Mol Imaging, Changsha 410008, Peoples R China.	yuezhendeng@csu.edu.cn; lunquansun@csu.edu.cn			National Natural Science Foundation of China [81874200, 82030087, 82103675, 82172980, 82060308]; Hunan Provincial Science and Technology Department [2018RS3028, 2021JJ0039]; Guizhou Science and Technology Immunology and infection Platform [2018-5706, 2017-5724]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Science and Technology Department; Guizhou Science and Technology Immunology and infection Platform	This work was supported partly by National Natural Science Foundation of China (81874200, 82030087, 82103675, 82172980, and 82060308), Fund 2018RS3028, and 2021JJ0039 from Hunan Provincial Science and Technology Department and Guizhou Science and Technology Immunology and infection Platform (2018-5706 and 2017-5724).	Acebron SP, 2016, TRENDS CELL BIOL, V26, P956, DOI 10.1016/j.tcb.2016.07.009; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Almeida LL, 2018, STEM CELL REP, V11, P1040, DOI 10.1016/j.stemcr.2018.09.008; Angeloni V, 2015, SEMIN CANCER BIOL, V31, P43, DOI 10.1016/j.semcancer.2014.08.004; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Cai SJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0337-z; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen JX, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1076-1; Cheng R, 2016, DIABETES, V65, P3730, DOI 10.2337/db16-0426; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Dittmer J, 2018, SEMIN CANCER BIOL, V53, P59, DOI 10.1016/j.semcancer.2018.07.007; El-Sahli S, 2019, CANCERS, V11, DOI 10.3390/cancers11070904; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hiraga T, 2016, INT J CANCER, V138, P1698, DOI 10.1002/ijc.29921; Jackson HW, 2020, NATURE, V578, P615, DOI 10.1038/s41586-019-1876-x; Jalalirad M, 2021, ONCOGENE, V40, P2509, DOI 10.1038/s41388-021-01711-x; Kim SE, 2013, SCIENCE, V340, P867, DOI 10.1126/science.1232389; Krug K, 2020, CELL, V183, P1436, DOI 10.1016/j.cell.2020.10.036; Lanczky A, 2021, J MED INTERNET RES, V23, DOI 10.2196/27633; Liu B., 2021, J TRANSL MED, V19, P1; Liu CC, 2010, P NATL ACAD SCI USA, V107, P5136, DOI 10.1073/pnas.0911220107; Liu W, 2006, EMBO J, V25, P1646, DOI 10.1038/sj.emboj.7601057; Maxfield KE, 2016, MOL CELL BIOL, V36, P3048, DOI 10.1128/MCB.00380-16; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Miller-Kleinhenz J, 2018, BIOMATERIALS, V152, P47, DOI 10.1016/j.biomaterials.2017.10.035; Miranda F, 2016, CANCER CELL, V30, P273, DOI 10.1016/j.ccell.2016.06.020; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Ou DM, 2020, CANCER BIOL MED, V17, P328, DOI 10.20892/j.issn.2095-3941.2019.0229; Raisch J, 2019, CANCERS, V11, DOI 10.3390/cancers11081162; Ren XX, 2022, CANCER RES, V82, P60, DOI 10.1158/0008-5472.CAN-21-1020; Sakamoto K, 2018, TRENDS ENDOCRIN MET, V29, P828, DOI 10.1016/j.tem.2018.09.007; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Vitale I, 2021, NAT MED, V27, P212, DOI 10.1038/s41591-021-01233-9; Waitkus MS, 2018, CANCER CELL, V34, P186, DOI 10.1016/j.ccell.2018.04.011; Xie JR, 2022, CANCER RES, V82, P872, DOI 10.1158/0008-5472.CAN-21-2187; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang ZN, 2016, SCI REP-UK, V6, DOI 10.1038/srep23317; Zhou JH, 2017, CLIN CANCER RES, V23, P1945, DOI 10.1158/1078-0432.CCR-16-1562; Zohrap Neslihan, 2018, Oncotarget, V9, P21876, DOI 10.18632/oncotarget.25082	43	2	2	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2390	2403		10.1038/s41388-022-02259-0	http://dx.doi.org/10.1038/s41388-022-02259-0		MAR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35277657				2022-12-17	WOS:000767708400001
J	Wu, WR; Shi, XD; Zhang, FP; Zhu, K; Zhang, R; Yu, XH; Qin, YF; He, SP; Fu, HW; Zhang, L; Zeng, H; Zhu, MS; Xu, LB; Wong, PP; Liu, C				Wu, Wen-Rui; Shi, Xiang-De; Zhang, Fa-Peng; Zhu, Ke; Zhang, Rui; Yu, Xian-Huan; Qin, Yu-Fei; He, Shun-Peng; Fu, Hou-Wei; Zhang, Lei; Zeng, Hong; Zhu, Man-Sheng; Xu, Lei-Bo; Wong, Ping-Pui; Liu, Chao			Activation of the Notch1-c-myc-VCAM1 signalling axis initiates liver progenitor cell-driven hepatocarcinogenesis and pulmonary metastasis	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; POTENTIAL THERAPEUTIC TARGET; NEOPLASTIC TRANSFORMATION; BREAST-CANCER; STEM-CELLS; VCAM-1; NOTCH1; MACROPHAGES; HEPATOCYTES; EXPRESSION	The cellular origin of hepatocellular carcinomas (HCC) and the role of Notch1 signalling in HCC initiation are controversial. Herein, we establish Notch1 as a regulator of HCC development and progression. Clinically, high Notch1 expression correlates with enhanced cancer progression, elevated lung metastasis, increased cancer stem cell (CSC)-like cells' gene signature expression, and poor overall survival in HCC patients. Notch1 intracellular domain (N1ICD) overexpression spontaneously transforms rat liver progenitor cells (LPC) into CSC-like cells (WBN1ICD C5) under a selective growth environment, while orthotopic injection of these cells generates liver tumors and spontaneous pulmonary metastasis in an isogenic rat model. Mechanistically, the elevated Notch1 activity increases c-myc expression, which then transcriptionally upregulates VCAM1 expression to activate macrophage dependent HCC transendothelial migration. In vivo, silencing c-myc prohibits the tumorigenicity of WBN1ICD C5 cells, while depletion of VCAM1 reduces spontaneous lung metastasis without affecting primary WBN1ICD C5 orthotopic liver tumor growth. Importantly, depletion of macrophage or blockade of macrophage VCAM1 binding receptor alpha 4 beta 1-integrin reduces the number of WBN1ICD C5 lung nodules in an experimental metastasis model. Overall, our work discovers that the Notch1-c-myc-VCAM1 signaling axis initiates LPC-driven hepatocarcinogenesis and metastasis, providing a preclinical model for HCC study and therapeutic targets for an improved HCC treatment.	[Wu, Wen-Rui; Shi, Xiang-De; Zhang, Fa-Peng; Zhu, Ke; Zhang, Rui; Yu, Xian-Huan; Qin, Yu-Fei; He, Shun-Peng; Fu, Hou-Wei; Zhang, Lei; Zeng, Hong; Zhu, Man-Sheng; Xu, Lei-Bo; Liu, Chao] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Biliary Pancreat Surg, Guangzhou 510120, Peoples R China; [Wu, Wen-Rui; Shi, Xiang-De; Zhang, Fa-Peng; Zhu, Ke; Zhang, Rui; Yu, Xian-Huan; Qin, Yu-Fei; He, Shun-Peng; Fu, Hou-Wei; Zhang, Lei; Zeng, Hong; Zhu, Man-Sheng; Xu, Lei-Bo; Wong, Ping-Pui; Liu, Chao] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangdong Hong Kong Joint Lab RNA Med, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China; [Wong, Ping-Pui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangzhou 510120, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Xu, LB; Liu, C (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Biliary Pancreat Surg, Guangzhou 510120, Peoples R China.; Xu, LB; Wong, PP; Liu, C (corresponding author), Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangdong Hong Kong Joint Lab RNA Med, Sun Yat Sen Mem Hosp, Guangzhou 510120, Peoples R China.; Wong, PP (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Guangzhou 510120, Peoples R China.	xuleibo3@mail.sysu.edu.cn; huangbp3@mail.sysu.edu.cn; liuchao3@mail.sysu.edu.cn		Wong, Ping Pui/0000-0003-1592-4823; He, Shun-peng/0000-0001-6307-9690	National Natural Science Foundation of China [81972255, 82173195, 81920108028, 81872142, 81772597, 82173229, 81702904, 81972262]; Guangdong Natural Science Foundation [2021A1515010095, 712055485047]; Guangzhou Science and Technology Program Key Project [201904020008]; Sun Yat-sen University Clinical Research 5010 Program [2018008]; Science and Technology Program of Guangzhou [202102010326]; Sun Yat-sen University Fundamental Research Funds [19ykpy113]; Key Training Program for Young Scholars of Sun Yat-sen University [18ykzd07]; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology [[2013]163]; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes [KLB09001]; Guangdong Science and Technology Department [2020A0505100029, 2020B1212060018, 2020B1212030004]; Guangdong Translational Medicine Public Platform of Guangdong Province [4202037]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Program Key Project; Sun Yat-sen University Clinical Research 5010 Program; Science and Technology Program of Guangzhou; Sun Yat-sen University Fundamental Research Funds; Key Training Program for Young Scholars of Sun Yat-sen University; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes; Guangdong Science and Technology Department; Guangdong Translational Medicine Public Platform of Guangdong Province	Some of the illustrations were created using Biorender.com. This work was supported by grants from the National Natural Science Foundation of China (81972255, 82173195, 81920108028, 81872142, 81772597, 82173229, 81702904, 81972262), Guangdong Natural Science Foundation (2021A1515010095, 712055485047), Guangzhou Science and Technology Program Key Project (201904020008), Sun Yat-sen University Clinical Research 5010 Program (2018008), Science and Technology Program of Guangzhou (202102010326), Sun Yat-sen University Fundamental Research Funds (19ykpy113), the Key Training Program for Young Scholars of Sun Yat-sen University (18ykzd07), grant from the Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology ([2013]163), the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes (KLB09001), Guangdong Science and Technology Department (2020A0505100029, 2020B1212060018, 2020B1212030004), the Guangdong Translational Medicine Public Platform of Guangdong Province (4202037).	Ahn S, 2013, HEPATOB PANCREAT DIS, V12, P286, DOI 10.1016/S1499-3872(13)60046-6; Benhamouche S, 2010, GENE DEV, V24, P1718, DOI 10.1101/gad.1938710; Byrne GJ, 2000, J NATL CANCER I, V92, P1329, DOI 10.1093/jnci/92.16.1329; Cardoso AP, 2014, ONCOGENE, V33, P2123, DOI 10.1038/onc.2013.154; Chan LH, 2015, MOL CELLS, V38, P202, DOI 10.14348/molcells.2015.2356; Chen Q, 2012, CLIN CANCER RES, V18, P5520, DOI 10.1158/1078-0432.CCR-11-2904; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Cook J, 2013, CURR OPIN PHARMACOL, V13, P595, DOI 10.1016/j.coph.2013.05.017; Ding L, 2014, EXP TOXICOL PATHOL, V66, P139, DOI 10.1016/j.etp.2013.11.007; Fan B, 2012, J CLIN INVEST, V122, P2911, DOI 10.1172/JCI63212; Font-Burgada J, 2015, CELL, V162, P766, DOI 10.1016/j.cell.2015.07.026; Gurzu S, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2962580; Harney AS, 2015, CANCER DISCOV, V5, P932, DOI 10.1158/2159-8290.CD-15-0012; Hooth MJ, 1998, AM J PATHOL, V153, P1913, DOI 10.1016/S0002-9440(10)65705-7; Hussain SP, 2007, ONCOGENE, V26, P2166, DOI 10.1038/sj.onc.1210279; Jin H, 2006, CANCER RES, V66, P2146, DOI 10.1158/0008-5472.CAN-05-2704; Kim MJ, 2018, DEV CELL, V44, P582, DOI 10.1016/j.devcel.2018.02.010; Lai GH, 2005, GASTROENTEROLOGY, V129, P2047, DOI 10.1053/j.gastro.2005.10.010; Lai YS, 2019, J CELL MOL MED, V23, P1257, DOI 10.1111/jcmm.14027; Li XF, 2010, CANCER SCI, V101, P1099, DOI 10.1111/j.1349-7006.2010.01513.x; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Luo ZY, 2020, J MOL CELL BIOL, V12, P345, DOI 10.1093/jmcb/mjz088; Mishra A, 2016, J IMMUNOL, V197, P2828, DOI 10.4049/jimmunol.1501041; Mishra L, 2009, HEPATOLOGY, V49, P318, DOI 10.1002/hep.22704; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Ntziachristos P, 2014, CANCER CELL, V25, P318, DOI 10.1016/j.ccr.2014.02.018; Padilla-Nash HM, 2012, GENE CHROMOSOME CANC, V51, P353, DOI 10.1002/gcc.21921; Qi RZ, 2003, CANCER RES, V63, P8323; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Sell S, 2008, J CLIN ONCOL, V26, P2800, DOI 10.1200/JCO.2007.15.5945; Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413; Strazzabosco M, 2012, GASTROENTEROLOGY, V143, P1430, DOI 10.1053/j.gastro.2012.10.025; Sun Q, 2014, ONCOL REP, V31, P933, DOI 10.3892/or.2013.2917; Vandereyken M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185786; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Verginelli F, 2015, ONCOTARGET, V6, P43216, DOI 10.18632/oncotarget.6456; Viatour P, 2011, J EXP MED, V208, P1963, DOI 10.1084/jem.20110198; Villanueva A, 2012, GASTROENTEROLOGY, V143, P1660, DOI 10.1053/j.gastro.2012.09.002; Wei C, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0976-4; Wieland E, 2017, CANCER CELL, V31, P355, DOI 10.1016/j.ccell.2017.01.007; Wu K, 2012, HEPATOLOGY, V56, P2255, DOI 10.1002/hep.26007; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Zhang HL, 2019, ONCOL LETT, V17, P4487, DOI 10.3892/ol.2019.10081; Zhang R, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.6; Zhang RL, 2013, NATURE, V498, P497, DOI 10.1038/nature12322; Zhang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08863-5; Zhu WJ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2005-1	48	2	2	5	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2340	2356		10.1038/s41388-022-02246-5	http://dx.doi.org/10.1038/s41388-022-02246-5		MAR 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	36490380				2022-12-17	WOS:000765674100003
J	Turdo, A; Gaggianesi, M; Di Franco, S; Veschi, V; D'Accardo, C; Porcelli, G; Lo Iacono, M; Pillitteri, I; Verona, F; Militello, G; Zippo, A; Poli, V; Fagnocchi, L; Beyes, S; Stella, S; Lattanzio, R; Faldetta, N; Lentini, VL; Porcasi, R; Pistone, G; Bongiorno, MR; Stassi, G; De Maria, R; Todaro, M				Turdo, Alice; Gaggianesi, Miriam; Di Franco, Simone; Veschi, Veronica; D'Accardo, Caterina; Porcelli, Gaetana; Lo Iacono, Melania; Pillitteri, Irene; Verona, Francesco; Militello, Gabriella; Zippo, Alessio; Poli, Vittoria; Fagnocchi, Luca; Beyes, Sven; Stella, Stefania; Lattanzio, Rossano; Faldetta, Naida; Lentini, Vincenzo L.; Porcasi, Rossana; Pistone, Giuseppe; Bongiorno, Maria Rita; Stassi, Giorgio; De Maria, Ruggero; Todaro, Matilde			Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51	ONCOGENE			English	Article							RESISTANCE; COMBINATION; PROGNOSIS; DYNAMICS; MARKER; GENES	Breast cancer (BC) is the second cause of cancer-related deceases in the worldwide female population. Despite the successful treatment advances, 25% of BC develops resistance to current therapeutic regimens, thereby remaining a major hurdle for patient management. Current therapies, targeting the molecular events underpinning the adaptive resistance, still require effort to improve BC treatment. Using BC sphere cells (BCSphCs) as a model, here we showed that BC stem-like cells express high levels of Myc, which requires the presence of the multifunctional DNA/RNA binding protein Sam68 for the DNA-damage repair. Analysis of a cohort of BC patients displayed that Sam68 is an independent negative factor correlated with the progression of the disease. Genetic inhibition of Sam68 caused a defect in PARP-induced PAR chain synthesis upon DNA-damaging insults, resulting in cell death of TNBC cells. In contrast, BC stem-like cells were able to survive due to an upregulation of Rad51. Importantly, the inhibition of Rad51 showed synthetic lethal effect with the silencing of Sam68, hampering the cell viability of patient-derived BCSphCs and stabilizing the growth of tumor xenografts, including those TNBC carrying BRCA mutation. Moreover, the analysis of Myc, Sam68 and Rad51 expression demarcated a signature of a poor outcome in a large cohort of BC patients. Thus, our findings suggest the importance of targeting Sam68-PARP1 axis and Rad51 as potential therapeutic candidates to counteract the expansion of BC cells with an aggressive phenotype.	[Turdo, Alice; D'Accardo, Caterina; Porcelli, Gaetana; Lo Iacono, Melania; Pillitteri, Irene; Verona, Francesco; Porcasi, Rossana; Pistone, Giuseppe; Bongiorno, Maria Rita; Todaro, Matilde] Univ Palermo, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties PROMISE, Palermo, Italy; [Gaggianesi, Miriam; Di Franco, Simone; Veschi, Veronica; Militello, Gabriella; Stassi, Giorgio] Univ Palermo, Dept Surg Oncol & Stomatol Sci DICHIRONS, Palermo, Italy; [Zippo, Alessio; Poli, Vittoria; Fagnocchi, Luca; Beyes, Sven] Univ Trento, Dept Cellular Computat & Integrat Biol, Trento, Italy; [Stella, Stefania] Univ Catania, Ctr Expt Oncol & Hematol, Dept Clin & Expt Med, AOU Policlin Vittorio Emanuele, Catania, Italy; [Lattanzio, Rossano] G dAnnunzio Univ Chieti Pescara, Ctr Adv Studies & Technol Cast, Dept Innovat Technol Med & Dent, Chieti, Italy; [Faldetta, Naida; Lentini, Vincenzo L.] Villa Sofia Cervello Hosp, Palermo, Italy; [De Maria, Ruggero] Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Dipartimento Med & Chirurg Traslaz, Rome, Italy; [De Maria, Ruggero] Fdn Policlin A Gemelli IRCCS, Rome, Lazio, Italy	University of Palermo; University of Palermo; University of Trento; Azienda Ospedaliera Universitaria Policlinico Vittorio Emanuele Presidio Ferraotto; University of Catania; G d'Annunzio University of Chieti-Pescara; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Todaro, M (corresponding author), Univ Palermo, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties PROMISE, Palermo, Italy.; De Maria, R (corresponding author), Univ Cattolica Sacro Cuore, Fac Med & Chirurg, Dipartimento Med & Chirurg Traslaz, Rome, Italy.; De Maria, R (corresponding author), Fdn Policlin A Gemelli IRCCS, Rome, Lazio, Italy.	ruggero.demaria@unicatt.it; matilde.todaro@unipa.it	di franco, simone/M-3714-2019; Turdo, Alice/ABB-8063-2022; Fagnocchi, Luca/M-2715-2017; Turdo, Alice/AIA-6591-2022	di franco, simone/0000-0002-6217-2161; Turdo, Alice/0000-0002-6152-4903; Fagnocchi, Luca/0000-0002-9551-5474; Turdo, Alice/0000-0002-6152-4903; GAGGIANESI, Miriam/0000-0002-7810-856X; Veschi, Veronica/0000-0002-6379-7366	European Union-FESR FSE, PON Ricerca e Innovazione 2014-2020 (AIM line 1); AIRC fellowship; AIRC [2018-ID. 22911, 2018-ID. 21492]; PSN2015, 6.2 project [CUP176J17000470001]	European Union-FESR FSE, PON Ricerca e Innovazione 2014-2020 (AIM line 1); AIRC fellowship(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); PSN2015, 6.2 project	The authors thank Giorgia Scalici and Antonella Loggia for their contribution to patient data management, and Francesco Cal and Dario Cricchio for statistical analysis and image editing. AT and VV are research fellows funded by European Union-FESR FSE, PON Ricerca e Innovazione 2014-2020 (AIM line 1). G.P., C.D. and F.V. are PhD students in the Molecular and Clinical Medicine program. VP is recipient of an AIRC fellowship. AZ received funding from AIRC under IG 2018-ID. 22911 project. MT received funding from AIRC under IG 2018-ID. 21492 project and from PSN2015, 6.2, CUP176J17000470001 project.	Akashi-Tanaka S, 2015, CLIN BREAST CANCER, V15, P80, DOI 10.1016/j.clbc.2014.08.003; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Benoit YD, 2017, CELL CHEM BIOL, V24, P833, DOI 10.1016/j.chembiol.2017.05.026; Bielli P, 2011, ENDOCR-RELAT CANCER, V18, pR91, DOI 10.1530/ERC-11-0041; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Busa R, 2010, NUCLEIC ACIDS RES, V38, P3005, DOI 10.1093/nar/gkq004; Byrum AK, 2019, TRENDS CELL BIOL, V29, P740, DOI 10.1016/j.tcb.2019.06.005; Caggiano C, 2019, NUCLEIC ACIDS RES, V47, P6160, DOI 10.1093/nar/gkz344; Carey JPW, 2018, CANCER RES, V78, P742, DOI 10.1158/0008-5472.CAN-17-1494; Cerrato A, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0456-2; Cheng CH, 2006, GENE DEV, V20, P1715, DOI 10.1101/gad.1430906; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cruz C, 2018, ANN ONCOL, V29, P1203, DOI 10.1093/annonc/mdy099; Di Franco S, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102664; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Fagnocchi L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11903; Fu K, 2016, ELIFE, V5, DOI 10.7554/eLife.21957; Fu K, 2016, ELIFE, V5, DOI 10.7554/eLife.15018; Gaggianesi M, 2017, CANCER RES, V77, P3268, DOI 10.1158/0008-5472.CAN-16-3126; Gaytan-Cervantes J, 2017, J BIOL CHEM, V292, P13745, DOI 10.1074/jbc.M117.800318; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Golan H, 2018, STEM CELL REP, V11, P795, DOI 10.1016/j.stemcr.2018.07.010; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]; Heijink AM, 2019, CELL REP, V28, P2345, DOI 10.1016/j.celrep.2019.07.070; Huang RX, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0150-x; Johnson SF, 2016, CELL REP, V17, P2367, DOI 10.1016/j.celrep.2016.10.077; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kollareddy M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8389; Lee JH, 2020, BLOOD ADV, V4, P2032, DOI 10.1182/bloodadvances.2019000757; Leroy B, 2014, HUM MUTAT, V35, P756, DOI 10.1002/humu.22556; Liston DR, 2017, CLIN CANCER RES, V23, P3489, DOI 10.1158/1078-0432.CCR-16-3083; Liu YJ, 2017, CLIN CANCER RES, V23, P514, DOI 10.1158/1078-0432.CCR-15-1348; Mangiapane LR, 2022, GUT, V71, P119, DOI 10.1136/gutjnl-2020-323553; Manic G, 2018, GUT, V67, P903, DOI 10.1136/gutjnl-2016-312623; McGill G, 1999, J CLIN INVEST, V104, P223, DOI 10.1172/JCI7861; Misenko SM, 2018, CELL CYCLE, V17, P881, DOI 10.1080/15384101.2018.1456295; Mitri Z, 2015, INVEST NEW DRUG, V33, P890, DOI 10.1007/s10637-015-0244-4; Pak S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1342-5; Paronetto MP, 2010, CANCER RES, V70, P229, DOI 10.1158/0008-5472.CAN-09-2788; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Piggott L, 2018, CLIN CANCER RES, V24, P2452, DOI 10.1158/1078-0432.CCR-17-1381; Poli V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03264-2; Polyak Kornelia, 2012, Cancer Cell, V22, P562, DOI 10.1016/j.ccr.2012.06.021; Rottenberg S, 2007, P NATL ACAD SCI USA, V104, P12117, DOI 10.1073/pnas.0702955104; Sachs N, 2018, CELL, V172, P373, DOI 10.1016/j.cell.2017.11.010; Schnitt SJ, 2010, MODERN PATHOL, V23, pS60, DOI 10.1038/modpathol.2010.33; Siegel RL., 2020, CA-CANCER J CLIN, V70; Sniadecki M, 2020, GENES-BASEL, V11, DOI 10.3390/genes11111251; Song LB, 2010, J PATHOL, V222, P227, DOI 10.1002/path.2751; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Turdo A, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00016; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Wu M, 2019, INT J CLIN EXP PATHO, V12, P1; Zhang JF, 2020, BREAST CANCER RES TR, V182, P719, DOI 10.1007/s10549-020-05730-2; Zhang SP, 2019, P NATL ACAD SCI USA, V116, P1370, DOI 10.1073/pnas.1816262116; Zhu YH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03951-0	59	2	2	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2196	2209		10.1038/s41388-022-02239-4	http://dx.doi.org/10.1038/s41388-022-02239-4		FEB 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35217791	Green Published, hybrid			2022-12-17	WOS:000761867900001
J	Zhang, YJ; Dho, SE; Othman, K; Simpson, CD; Lapierre, J; Bondoc, A; McGlade, CJ				Zhang, Yangjing; Dho, Sascha E.; Othman, Kamal; Simpson, Craig D.; Lapierre, Jessica; Bondoc, Andrew; McGlade, C. Jane			Numb exon 9 inclusion regulates Integrin beta 5 surface expression and promotes breast cancer metastasis	ONCOGENE			English	Article							FATE DETERMINANT NUMB; CELL FATE; ISOFORMS; DIFFERENTIATION; IDENTIFICATION; INVOLVEMENT; ENDOCYTOSIS; PROGRESSION; ATTACHMENT; SUPPRESSOR	The endocytic adaptor protein Numb acts as a tumor suppressor through downregulation of oncogenic pathways in multiple cancer types. The identification of splicing alterations giving rise to changes in Numb protein isoform expression indicate that Numb also has tumor promoting activity, though the underlying mechanisms are unknown. Here we report that NUMB exon 9 inclusion, which results in production of a protein isoform with an additional 49 amino acids, is a feature of multiple cancer types including all subtypes of breast cancer and correlates with worse progression-free survival. Specific deletion of exon 9-included Numb isoforms (Exon9in) from breast cancer cells reduced cell growth and prevents spontaneous lung metastasis in a mouse model. Quantitative proteome profiling showed that loss of Exon9in causes downregulation of membrane receptors and adhesion molecules, as well as proteins involved in extracellular matrix organization and the epithelial-mesenchymal transition (EMT) state. In addition, exon 9 deletion caused remodeling of the endocytic network, decreased ITG beta 5 surface localization, cell spreading on vitronectin and downstream signaling to ERK and SRC. Together these observations suggest that Exon9in isoform expression disrupts the endocytic trafficking functions of Numb, resulting in increased surface expression of ITG beta 5 as well as other plasma membrane proteins to promote cell adhesion, EMT, and tumor metastasis.	[Zhang, Yangjing; Othman, Kamal; McGlade, C. Jane] Univ Toronto, Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada; [Zhang, Yangjing; Dho, Sascha E.; Othman, Kamal; Lapierre, Jessica; Bondoc, Andrew; McGlade, C. Jane] Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; [Dho, Sascha E.; Lapierre, Jessica; Bondoc, Andrew; McGlade, C. Jane] Program Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; [Simpson, Craig D.] Hosp Sick Children, SPARC BioCtr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	McGlade, CJ (corresponding author), Univ Toronto, Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.; McGlade, CJ (corresponding author), Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.; McGlade, CJ (corresponding author), Program Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jmcglade@sickkids.ca		Zhang, Yangjing/0000-0003-3762-0767	Canadian Institutes of Health Research [FRN 106507]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The authors thank the following: Michael Reedijk and Qiang Shen for assistance with mouse xenograft experiments, SPARC Molecular Analysis for TMT mass spectrometry, Amanda Luck for mouse colony maintenance and caliper measurements, Nesrin Sabha for help with IHC staining, and Kim Lau and Paul Paroutis (The Imaging Facility, The Hospital for Sick Children) for their assistance with TIRF microscopy and imaging analysis. This work was supported with funds from the Canadian Institutes of Health Research to CJM (FRN 106507).	Bani-Yaghoub M, 2007, DEV DYNAM, V236, P696, DOI 10.1002/dvdy.21072; Baschieri F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06367-y; Bechara EG, 2013, MOL CELL, V52, P720, DOI 10.1016/j.molcel.2013.11.010; Bianchi-Smiraglia A, 2013, ONCOGENE, V32, P3049, DOI 10.1038/onc.2012.320; Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66; Calderwood DA, 2003, P NATL ACAD SCI USA, V100, P2272, DOI 10.1073/pnas.262791999; Chaudhuri O, 2014, NAT MATER, V13, P970, DOI [10.1038/nmat4009, 10.1038/NMAT4009]; Chen HZ, 2009, PATHOBIOLOGY, V76, P149, DOI 10.1159/000209393; Cheng C, 2020, AM J PHYSIOL-GASTR L, V318, pG841, DOI 10.1152/ajpgi.00178.2019; Colaluca IN, 2008, NATURE, V451, P76, DOI 10.1038/nature06412; Colaluca IN, 2018, J CELL BIOL, V217, P745, DOI 10.1083/jcb.201709092; Cullen PJ, 2018, NAT REV MOL CELL BIO, V19, P679, DOI 10.1038/s41580-018-0053-7; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Dooley CM, 2003, J NEUROBIOL, V54, P313, DOI 10.1002/neu.10176; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568-018-0038-z; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Ke H, 2018, P NATL ACAD SCI USA, V115, pE3426, DOI 10.1073/pnas.1714573115; Khan I, 2021, BRIT J CANCER, V124, P66, DOI 10.1038/s41416-020-01179-8; Kim KK, 2013, J CELL BIOL, V200, P443, DOI 10.1083/jcb.201206146; Koike S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09617-9; Krieger JR, 2019, J PROTEOME RES, V18, P2346, DOI 10.1021/acs.jproteome.9b00082; Krieger JR, 2015, PROTEOMICS, V15, P434, DOI 10.1002/pmic.201400232; Krieger JR, 2013, MOL CELL PROTEOMICS, V12, P499, DOI 10.1074/mcp.M112.020768; Lajoie P, 2010, INT REV CEL MOL BIO, V282, P135, DOI 10.1016/S1937-6448(10)82003-9; Lamaze C, 2015, BIOMED J, V38, P367, DOI 10.4103/2319-4170.164229; Lau KM, 2011, EXP CELL RES, V317, P539, DOI 10.1016/j.yexcr.2010.12.005; Leyton-Puig D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16068; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Lock JG, 2018, NAT CELL BIOL, V20, P1290, DOI 10.1038/s41556-018-0220-2; Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116; Lu YY, 2015, HEPATOLOGY, V62, P1122, DOI 10.1002/hep.27923; McGill MA, 2009, J BIOL CHEM, V284, P26427, DOI 10.1074/jbc.M109.014845; Misquitta-Ali CM, 2011, MOL CELL BIOL, V31, P138, DOI 10.1128/MCB.00709-10; Moran TB, 2011, MOL ENDOCRINOL, V25, P117, DOI 10.1210/me.2010-0248; Moreno-Layseca P, 2019, NAT CELL BIOL, V21, P122, DOI 10.1038/s41556-018-0223-z; Nishimura T, 2007, DEV CELL, V13, P15, DOI 10.1016/j.devcel.2007.05.003; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Peden AA, 2004, J CELL BIOL, V164, P1065, DOI 10.1083/jcb.200311064; Rajendran D, 2016, ONCOGENE, V35, P5202, DOI 10.1038/onc.2016.69; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596-018-0103-9; Ricono JM, 2009, CANCER RES, V69, P1383, DOI 10.1158/0008-5472.CAN-08-3612; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; Sanchez E, 2019, J BIOL CHEM, V294, P3012, DOI 10.1074/jbc.RA118.005532; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Smith CA, 2004, MOL BIOL CELL, V15, P3698, DOI 10.1091/mbc.E04-01-0026; Song W, 2017, ONCOGENE, V36, P5620, DOI 10.1038/onc.2017.170; Sun LX, 2018, ONCOGENE, V37, P3698, DOI 10.1038/s41388-018-0202-7; TAFTAF R, NAT COMMUN, V2021, P12; Toriya M, 2006, DEV NEUROSCI-BASEL, V28, P142, DOI 10.1159/000090760; Tosoni D, 2015, J CELL BIOL, V211, P845, DOI 10.1083/jcb.201505037; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; Verdi JM, 1999, P NATL ACAD SCI USA, V96, P10472, DOI 10.1073/pnas.96.18.10472; Wang ZZ, 2009, EMBO J, V28, P2360, DOI 10.1038/emboj.2009.190; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; Wei R, 2019, J MOL CELL BIOL, V11, P994, DOI 10.1093/jmcb/mjz003; Welinder C, 2011, J PROTEOME RES, V10, P1416, DOI 10.1021/pr1011476; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106; Yamaguchi H, 2009, CANCER RES, V69, P8594, DOI 10.1158/0008-5472.CAN-09-2305; Zecchini S, 2011, EMBO MOL MED, V3, P480, DOI 10.1002/emmm.201100152; Zhang SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094974; Zhang Y, 2016, FASEB J, V30, P3474, DOI 10.1096/fj.201600387R; Zheng KL, 2015, INT J CLIN EXP PATHO, V8, P6181; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289; Zuidema A, 2018, J CELL SCI, V131, DOI 10.1242/jcs.221317	68	2	2	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2079	2094		10.1038/s41388-022-02225-w	http://dx.doi.org/10.1038/s41388-022-02225-w		FEB 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35181737				2022-12-17	WOS:000757709600001
J	Zhao, D; Zheng, SL; Wang, XW; Liu, H; Zhao, KM; Li, L; Hu, Y				Zhao, Dong; Zheng, Shanliang; Wang, Xingwen; Liu, Hao; Zhao, Kunming; Li, Li; Hu, Ying			iASPP is essential for HIF-1 alpha stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; HYPOXIA-INDUCIBLE FACTORS; UP-REGULATION; EXPRESSION; RESISTANCE; CELLS; HIF-1; P53; REPRESSION; HIF1-ALPHA	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) plays central roles in the hypoxia response. It is highly expressed in multiple cancers, but not always correlated with hypoxia. Mutation of the von Hippel-Lindau (VHL) gene, which encodes an E3 ligase, contributes to the constructive activation of HIF-1 alpha in specific tumor types, as exemplified by renal cell carcinoma; but how VHL wild-type tumors acquire this ability is not completely understood. Here, we found that the oncogene iASPP (inhibitor of apoptosis-simulating protein of p53) plays essential roles in such a context. Genetic inhibition of iASPP reduced tumor growth, accompanied by impaired angiogenesis, increased areas of tumor necrosis, and reduced glycolysis that was HIF-1 alpha-dependent. These abilities of iASPP were validated by in vitro assays. Mechanistically, iASPP directly binds VHL at its beta domain, a region also involved in HIF-1 alpha binding, therefore blocking VHL's binding and the subsequent degradation of HIF-1 alpha protein under normoxia. iASPP levels correlate with HIF-1 alpha protein and vascular endothelial growth factor (VEGF) and the glucose transporter protein type 1(GLUT1), representative HIF-1 alpha target genes, in human colon cancer tissues. Furthermore, inhibition of iASPP expression synergizes with low toxic dose of the HIF-1 alpha inhibitor YC-1 to inhibit HIF-1 alpha expression and tumor growth. Our findings suggest that iASPP contributes to HIF-1 alpha activation in cancers, and that iASPP-mediated HIF-1 alpha stabilization has potential as a therapeutic approach against cancer.	[Zhao, Dong; Zheng, Shanliang; Wang, Xingwen; Liu, Hao; Zhao, Kunming; Hu, Ying] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Heilongjiang, Peoples R China; [Li, Li] Harbin Med Univ, Affiliated Hosp 3, Harbin 150040, Heilongjiang, Peoples R China	Harbin Institute of Technology; Harbin Medical University	Hu, Y (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Heilongjiang, Peoples R China.	huying@hit.edu.cn		Zhao, Dong/0000-0001-7214-6947	National Natural Science Foundation of China [82025027, 31871389, 31741084, 32000517]; China Postdoctoral Science Foundation [2020M680045, 2021T140161]; Nature Science Foundation of Heilongjiang Province [YQ2021C024]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Nature Science Foundation of Heilongjiang Province(Natural Science Foundation of Heilongjiang Province)	This work was funded by the National Natural Science Foundation of China (No. 82025027, 31871389, 31741084, 32000517), China Postdoctoral Science Foundation (No. 2020M680045 and 2021T140161), and the Nature Science Foundation of Heilongjiang Province (No. YQ2021C024).	Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029; Buckley DL, 2012, J AM CHEM SOC, V134, P4465, DOI 10.1021/ja209924v; Cai Y, 2012, APOPTOSIS, V17, P777, DOI 10.1007/s10495-012-0728-z; de Heer EC, 2020, J CLIN INVEST, V130, P5074, DOI 10.1172/JCI137552; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; De Saedeleer CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046571; Domene C, 2012, PROTEINS, V80, P733, DOI 10.1002/prot.23230; Du SC., 2019, CANCER CELL INT, V19; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Gao K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0561-6; Ge WJ, 2017, CANCER CELL, V32, P561, DOI 10.1016/j.ccell.2017.09.008; Geng H, 2011, J BIOL CHEM, V286, P38095, DOI 10.1074/jbc.M111.257055; Ghosh AK, 2009, BLOOD, V113, P5568, DOI 10.1182/blood-2008-10-185686; Hoefflin R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17873-3; Hu Y, 2015, ONCOTARGET, V6, P42478, DOI 10.18632/oncotarget.6478; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jia YJ, 2014, FASEB J, V28, P2816, DOI 10.1096/fj.13-244632; Jiang LL, 2011, CLIN CANCER RES, V17, P6924, DOI 10.1158/1078-0432.CCR-11-0588; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kim JW, 2015, ANN SURG ONCOL, V22, P662, DOI 10.1245/s10434-014-4003-0; Kim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10347; Krzywinska E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01599-w; Kuczynski EA, 2019, NAT REV CLIN ONCOL, V16, P469, DOI 10.1038/s41571-019-0181-9; Kwon SJ, 2005, CLIN CANCER RES, V11, P7607, DOI 10.1158/1078-0432.CCR-05-0981; LaGory EL, 2016, NAT CELL BIOL, V18, P356, DOI 10.1038/ncb3330; Lang JY, 2019, ACS NANO, V13, P2176, DOI 10.1021/acsnano.8b08823; Lee P, 2020, NAT REV MOL CELL BIO, V21, P268, DOI 10.1038/s41580-020-0227-y; Lee YH, 2015, CLIN CANCER RES, V21, P1438, DOI 10.1158/1078-0432.CCR-14-1979; Li HY, 2020, J BIOL CHEM, V295, P4049, DOI 10.1074/jbc.RA119.011411; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Lu B, 2010, GASTROENTEROLOGY, V139, P2183, DOI 10.1053/j.gastro.2010.06.049; Lu M, 2016, CANCER CELL, V30, P822, DOI 10.1016/j.ccell.2016.09.019; Lu M, 2013, CANCER CELL, V23, P618, DOI 10.1016/j.ccr.2013.03.013; Luu VD, 2009, CLIN CANCER RES, V15, P3297, DOI 10.1158/1078-0432.CCR-08-2779; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Martinez-Reyes I, 2021, NAT REV CANCER, V21, P669, DOI 10.1038/s41568-021-00378-6; Mastrogiannaki M, 2009, J CLIN INVEST, V119, P1159, DOI 10.1172/JCI38499; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Merlo A, 2017, ONCOTARGET, V8, P1, DOI 10.18632/oncotarget.14265; Pandolfi S, 2015, CELL DEATH DIFFER, V22, P2006, DOI 10.1038/cdd.2015.56; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tosetti F, 2002, FASEB J, V16, P2, DOI 10.1096/fj.01-0300rev; Trigiante G, 2006, NAT REV CANCER, V6, P217, DOI 10.1038/nrc1818; Triner D, 2016, J CLIN INVEST, V126, P3689, DOI 10.1172/JCI84430; Xiong Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0520-6; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhao WH, 2013, INT J MOL MED, V32, P101, DOI 10.3892/ijmm.2013.1365; Zhong H, 1999, CANCER RES, V59, P5830	55	2	2	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1944	1958		10.1038/s41388-022-02234-9	http://dx.doi.org/10.1038/s41388-022-02234-9		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35169254				2022-12-17	WOS:000755405100001
J	Chen, B; Xu, F; Gao, Y; Hu, GS; Zhu, KL; Lu, HY; Xu, A; Chen, SP; Wu, LJ; Zhao, GP				Chen, Bin; Xu, Feng; Gao, Yang; Hu, Guanshuo; Zhu, Kaili; Lu, Huayi; Xu, An; Chen, Shaopeng; Wu, Lijun; Zhao, Guoping			DNA damage-induced translocation of mitochondrial factor HIGD1A into the nucleus regulates homologous recombination and radio/chemo-sensitivity	ONCOGENE			English	Article							STRAND BREAK REPAIR; PROTEIN-A RPA; REPLICATION; RAD51; IDENTIFICATION; INHIBITORS; DYNAMICS; SITES; SSDNA	HIGD1A is an important mitochondrial protein recently shown to have a novel nuclear localization under severe stress. However, whether this protein is also associated with the DNA damage response has rarely been studied. Here, we reported that DSBs-induced the translocation of mitochondrial HIGD1A to the nucleus is dependent on nuclear pore complex (NPCs), which finally promotes HR and radio/chemo-resistance. Importantly, NUP93 and HIGD1A physically interact and the interaction domain with NUP93 is located at residues 46-60 of HIGD1A. Chromatin-enriched HIGD1A can then directly interact with RPA. During the early stages of HR, HIGD1A promotes the loading of RPA to DSBs and activates the DNA damage-dependent chromatin association of RAD9-RAD1-HUS1 complex (9-1-1), which stimulates the ATR-Chk1-dependent G2/M DNA damage checkpoint. After facilitating RPA-ssDNA binding, HIGD1A in turn inhibits abnormal persistence of RPA1 foci by promoting ubiquitination of RPA1 and inducing its eventual proteasomal degradation. In addition, we have identified clinical drug Preveon associated with the HIGD1A-NUP93 interaction domain using a virtual screening approach. This compound directly interacted with HIGD1A, which was verified by NMR, and then inhibited HIGD1A translocation. Collectively, we demonstrate a novel role for HIGD1A in DSBs and provide rationale for using HIGD1A inhibitors as cancer therapeutics.	[Chen, Bin; Xu, Feng; Gao, Yang; Hu, Guanshuo; Zhu, Kaili; Xu, An; Chen, Shaopeng; Wu, Lijun; Zhao, Guoping] Chinese Acad Sci, High Magnet Field Lab, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Anhui, Peoples R China; [Chen, Bin; Xu, Feng; Gao, Yang; Hu, Guanshuo; Zhu, Kaili; Xu, An; Chen, Shaopeng; Wu, Lijun; Zhao, Guoping] Chinese Acad Sci, Hefei Inst Phys Sci, Anhui Prov Key Lab Environm Toxicol & Pollut Cont, Hefei 230031, Anhui, Peoples R China; [Chen, Bin; Xu, Feng; Gao, Yang; Hu, Guanshuo; Zhu, Kaili] Univ Sci & Technol China, Hefei 230026, Anhui, Peoples R China; [Lu, Huayi] Univ Sci & Technol China, Affiliated Hosp 1, Div Life Sci & Med, USTC, Hefei 230001, Anhui, Peoples R China; [Wu, Lijun] Anhui Univ, Inst Phys Sci, Informat Mat & Intelligent Sensing Lab Anhui Prov, Hefei 230601, Anhui, Peoples R China	Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui University; Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS	Zhao, GP (corresponding author), Chinese Acad Sci, High Magnet Field Lab, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Anhui, Peoples R China.	gpz@ipp.ac.cn		Zhao, Guoping/0000-0002-4691-3257	National Science Fund for Excellent Young Scholars [12122510]; National Natural Science Foundation of China [32171240, 11835014, 31870845]; HFIPS Director's Fund [YZJJZX202014]; CAS Pioneer Hundred Talents Program	National Science Fund for Excellent Young Scholars; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); HFIPS Director's Fund; CAS Pioneer Hundred Talents Program	This work was supported by the National Science Fund for Excellent Young Scholars (12122510), the National Natural Science Foundation of China (32171240, 11835014, and 31870845), the HFIPS Director's Fund (Grant No. YZJJZX202014) and the CAS Pioneer Hundred Talents Program (GZ).	Ameri K, 2015, CELL REP, V10, P891, DOI 10.1016/j.celrep.2015.01.020; Ameri K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062758; An HJ, 2013, P NATL ACAD SCI USA, V110, P13014, DOI 10.1073/pnas.1307170110; Basu A, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/201367; Brandsma Inger, 2012, Genome Integr, V3, P9, DOI 10.1186/2041-9414-3-9; Cheng ZH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02823-0; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Chuderland D, 2008, MOL CELL, V31, P850, DOI 10.1016/j.molcel.2008.08.007; Ci SS, 2020, FASEB J, V34, P10443, DOI 10.1096/fj.201902904RR; Damasceno JD, 2016, MOL MICROBIOL, V101, P1054, DOI 10.1111/mmi.13441; Dudas A, 2004, MUTAT RES-REV MUTAT, V566, P131, DOI 10.1016/j.mrrev.2003.07.001; Dueva Rositsa, 2020, NAR Cancer, V2, pzcaa022, DOI 10.1093/narcan/zcaa022; Hayashi H, 2012, FASEB J, V26, P2306, DOI 10.1096/fj.11-196063; Hayashi T, 2015, P NATL ACAD SCI USA, V112, P1553, DOI 10.1073/pnas.1419767112; Hsu DW, 2011, J CELL SCI, V124, P1655, DOI 10.1242/jcs.081471; Inano S, 2017, MOL CELL, V66, P622, DOI 10.1016/j.molcel.2017.04.022; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Klammt C, 2012, NAT METHODS, V9, P834, DOI [10.1038/NMETH.2033, 10.1038/nmeth.2033]; Kosova AA, 2017, BIOCHEMISTRY-MOSCOW+, V82, P643, DOI 10.1134/S0006297917060013; Lans H, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-4; Li T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6051262; Liu C, 2013, INT J MOL SCI, V14, P14225, DOI 10.3390/ijms140714225; Ma CJ, 2017, NUCLEIC ACIDS RES, V45, P749, DOI 10.1093/nar/gkw1125; Mohr D, 2009, EMBO J, V28, P2541, DOI 10.1038/emboj.2009.200; Nagao T, 2020, FASEB J, V34, P1859, DOI 10.1096/fj.201800389R; Nuss JE, 2005, BIOCHEMISTRY-US, V44, P8428, DOI 10.1021/bi0480584; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Pantano C, 2006, ANTIOXID REDOX SIGN, V8, P1791, DOI 10.1089/ars.2006.8.1791; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Pokhrel N, 2017, NUCLEIC ACIDS RES, V45, P9413, DOI 10.1093/nar/gkx598; Qian W, 2012, J CELL SCI, V125, P5745, DOI 10.1242/jcs.109769; Raynard S, 2008, GENE DEV, V22, P2903, DOI 10.1101/gad.1742408; Saldivar JC, 2017, NAT REV MOL CELL BIO, V18, P783, DOI 10.1038/nrm.2017.116; Shaughnessy DT, 2014, ENVIRON HEALTH PERSP, V122, P1271, DOI 10.1289/ehp.1408418; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Tang JB, 2010, MOL CANCER RES, V8, P67, DOI 10.1158/1541-7786.MCR-09-0411; Timon-Gomez A, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107607; Wassing IE, 2021, SEMIN CELL DEV BIOL, V113, P38, DOI 10.1016/j.semcdb.2020.08.010; WOZNIAK AJ, 1984, CANCER RES, V44, P626; Xu LM, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101604; Yang QY, 2017, P NATL ACAD SCI USA, V114, pE6054, DOI 10.1073/pnas.1700694114; Ying WH, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/691251; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; Zou Y, 2006, J CELL PHYSIOL, V208, P267, DOI 10.1002/jcp.20622	45	2	2	44	91	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1918	1930		10.1038/s41388-022-02226-9	http://dx.doi.org/10.1038/s41388-022-02226-9		FEB 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35152263				2022-12-17	WOS:000754368500002
J	Hong, SY; Lu, YC; Hsiao, SH; Kao, YR; Lee, MH; Lin, YP; Wang, CY; Wu, CW				Hong, Shiao-Ya; Lu, Yi-Chun; Hsiao, Shih-Hsin; Kao, Yu-Rung; Lee, Meng-Hsuan; Lin, Yi-Ping; Wang, Cheng-Yi; Wu, Cheng-Wen			Stabilization of AURKA by the E3 ubiquitin ligase CBLC in lung adenocarcinoma	ONCOGENE			English	Article							AURORA-A KINASE; FAMILY; GROWTH	CBL family proteins (CBL, CBLB and CBLC in mammals) are E3 ubiquitin ligases of protein tyrosine kinases. CBL mediates the lysosomal degradation of activated EGFR through K63-linked ubiquitination, while CBLC has an oncogenic function by positively regulating EGFR activation through K6 and K11-linked ubiquitination in EGFR mutant lung adenocarcinoma (LAD). Here, we used immunoprecipitation and mass spectrometry to study the CBLC interactome, and found that CBLC is also involved in cell cycle regulation by stabilizing Aurora kinase A (AURKA). CBLC interacted with the kinase domain of AURKA and positively regulated the stability of AURKA by conjugating monoubiquitination and K11/K63-linked polyubiquitination, which are protective from degrading K11/K48 polyubiquitination. CBLC depletion markedly decreased the half-life of AURKA in cycloheximide-treated LAD cells. When LAD cells were synchronized with double thymidine block at the G1/S boundary and then released into mitotic arrest, CBLC depletion delayed the accumulation and activation of AURKA and prevented cancer cells from entering mitosis. CBLC deficiency significantly delayed cell cycle progression, reduced the mitotic population, and increased apoptosis of LAD cells. Targeting CBLC inhibited tumor growth of LAD cells and enhanced their sensitivity to paclitaxel in xenograft models. Immunohistochemical staining of the tissue microarray also revealed a positive correlation between the expression of CBLC and AURKA in normal and LAD tissues, further supporting the positive regulation of AURKA expression by CBLC. In summary, these findings indicate that the oncogenic E3 ligase CBLC plays a role in mitotic entry by stabilizing AURKA via ubiquitination in LAD. This work demonstrates that targeting CBLC combined with paclitaxel might be a potential option for the treatment of LAD patients who have no available targeted therapies.	[Hong, Shiao-Ya; Lu, Yi-Chun] Cardinal Tien Hosp, Med Res Ctr, New Taipei, Taiwan; [Hong, Shiao-Ya; Kao, Yu-Rung; Wu, Cheng-Wen] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Hsiao, Shih-Hsin] Taipei Med Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Lee, Meng-Hsuan; Lin, Yi-Ping] Natl Yang Ming Chiao Tung Univ, Inst Microbiol & Immunol, Taipei, Taiwan; [Wang, Cheng-Yi] Cardinal Tien Hosp, Dept Internal Med, New Taipei, Taiwan; [Wang, Cheng-Yi] Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan; [Wu, Cheng-Wen] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan	Academia Sinica - Taiwan; Taipei Medical University; Taipei Medical University Hospital; National Yang Ming Chiao Tung University; Fu Jen Catholic University; National Yang Ming Chiao Tung University	Wu, CW (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.; Wang, CY (corresponding author), Cardinal Tien Hosp, Dept Internal Med, New Taipei, Taiwan.; Wang, CY (corresponding author), Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan.; Wu, CW (corresponding author), Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan.	cywang@mospital.com; chengwenwu@nycu.edu.tw		Hong, Shiao-Ya/0000-0003-4302-1509; Wang, Cheng-Yi/0000-0001-7426-0743	Ministry of Science and Technology of Taiwan [MOST 109-2314-B-567-001-MY2, MOST 110-2314-B-567-004, MOST 109-2320-B-A49-001]; Cardinal Tien Hospital [CTH 110A-2207, CTH 110A-NDMC-2227]; Academia Sinica [AS-CFII-108-115, AS-CFII-108-113]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Cardinal Tien Hospital; Academia Sinica(Academia Sinica - Taiwan)	This work was supported by the Ministry of Science and Technology of Taiwan (MOST 109-2314-B-567-001-MY2 and MOST 110-2314-B-567-004 to SYH, MOST 109-2320-B-A49-001 to CWW) and Cardinal Tien Hospital (CTH 110A-2207 to SYH and CTH 110A-NDMC-2227 to CYW). We also thank the core facilities of IBMS, funded by Academia Sinica Core Facility and Innovative Instrument Projects (AS-CFII-108-115, AS-CFII-108-113).	Abdelbaki A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.243071; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bassermann F, 2014, BBA-MOL CELL RES, V1843, P150, DOI 10.1016/j.bbamcr.2013.02.028; Bertolin G, 2020, CELL MOL LIFE SCI, V77, P1031, DOI 10.1007/s00018-019-03310-2; Caracciolo D, 2020, INT J CANCER, V147, P2658, DOI 10.1002/ijc.33038; Cowley DO, 2009, MOL CELL BIOL, V29, P1059, DOI 10.1128/MCB.01062-08; Du RJ, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01305-3; Frankum J, 2015, ONCOTARGET, V6, P10746, DOI 10.18632/oncotarget.3628; Galetta D, 2020, CANCERS, P12; Genova C, 2020, EXPERT REV RESP MED, V14, P367, DOI 10.1080/17476348.2020.1714441; Gilberto S, 2017, J CELL BIOL, V216, P2259, DOI 10.1083/jcb.201703170; Griffiths EK, 2003, MOL CELL BIOL, V23, P7708, DOI 10.1128/MCB.23.21.7708-7718.2003; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hirst J, 2017, AGING-US, V9, P1945, DOI 10.18632/aging.101291; Hong SY, 2018, CANCER RES, V78, P4984, DOI 10.1158/0008-5472.CAN-17-3858; Hsu FF, 2017, ONCOGENE, V36, P6805, DOI 10.1038/onc.2017.294; Ke YW, 2003, CELL RES, V13, P69, DOI 10.1038/sj.cr.7290152; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; Kim B, 2007, CANCER RES, V67, P7431, DOI 10.1158/0008-5472.CAN-07-0003; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Lee WY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138789; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin XR, 2020, AM J CANCER RES, V10, P2705; Lindon C, 2016, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00307; Lu LY, 2008, J BIOL CHEM, V283, P31785, DOI 10.1074/jbc.M805880200; Moghe S, 2012, BIOL OPEN, V1, P82, DOI 10.1242/bio.2011018; Mou PK, 2021, EXP MOL MED, V53, P835, DOI 10.1038/s12276-021-00635-6; Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7; Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Reiter R, 2006, CLIN CANCER RES, V12, P5136, DOI 10.1158/1078-0432.CCR-05-1650; Sadowski M, 2012, IUBMB LIFE, V64, P136, DOI 10.1002/iub.589; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105; Teixeira LK, 2013, ANNU REV BIOCHEM, V82, P387, DOI 10.1146/annurev-biochem-060410-105307; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Do TV, 2017, ONCOTARGET, V8, P50376, DOI 10.18632/oncotarget.18970; Willems E, 2018, CELL DIV, V13, DOI 10.1186/s13008-018-0040-6; Yan M, 2016, MED RES REV, V36, P1036, DOI 10.1002/med.21399; Yau R, 2016, NAT CELL BIOL, V18, P579, DOI 10.1038/ncb3358	42	2	2	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1907	1917		10.1038/s41388-022-02180-6	http://dx.doi.org/10.1038/s41388-022-02180-6		FEB 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35149839				2022-12-17	WOS:000754149000001
J	Li, BS; Kang, HY; Xiao, YF; Du, YX; Xiao, YH; Song, GJ; Zhang, Y; Guo, Y; Yang, F; He, FT; Yang, SM				Li, Bosheng; Kang, Houyi; Xiao, Yufeng; Du, Yexiang; Xiao, Yunhua; Song, Guojing; Zhang, Yan; Guo, Yu; Yang, Fan; He, Fengtian; Yang, Shiming			LncRNA GAL promotes colorectal cancer liver metastasis through stabilizing GLUT1	ONCOGENE			English	Article							GLUCOSE; SUMOYLATION; INTERACTS	Colorectal cancer liver metastasis (CRLM) is the leading cause of colorectal cancer-related deaths and remains a clinical challenge. Enhancement of glucose uptake is involved in CRLM; however, whether long noncoding RNAs (lncRNAs) participate in these molecular events remains largely unclear. Here, we report an lncRNA, GAL (glucose transporter 1 (GLUT1) associated lncRNA), that was upregulated in CRLM tissues compared with primary colorectal cancer (CRC) tissues or matched normal tissues and was associated with the overall survival rates of CRLM patients. Functionally, GAL served as an oncogene because it promoted CRC cell migration and invasion in vitro and enhanced the ability of CRC cells to metastasize from the intestine to the liver in vivo. Mechanistically, GAL interacted with the GLUT1 protein to increase GLUT1 SUMOylation, inhibiting the effect of the ubiquitin-proteasome system on the GLUT1 protein. GLUT1-knockout (-/+) repressed the GAL-mediated increase in CRC cell uptake of glucose, migrate, and invade in vitro, as well as metastasis from the intestine to the liver in vivo, and enforced expression of GLUT1 rescued GAL knockout-induced biological functions in CRC cells. Taken together, our findings demonstrated that GAL promotes CRLM by stabilizing GLUT1, suggesting that the GAL-GLUT1 complex may act as a potential therapeutic target for CRLM.	[Li, Bosheng; Zhang, Yan; Yang, Fan; He, Fengtian] Army Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China; [Li, Bosheng; Xiao, Yufeng; Du, Yexiang; Yang, Shiming] Army Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing 400037, Peoples R China; [Kang, Houyi; Guo, Yu] Army Med Univ, Daping Hosp, Dept Radiol, Chongqing 400042, Peoples R China; [Xiao, Yunhua] Army Med Univ, Southwest Hosp, Dept Radiol, Chongqing 400038, Peoples R China; [Song, Guojing] Army Med Univ, Southwest Hosp, Dept Urol, Chongqing 400038, Peoples R China	Army Medical University; Army Medical University; Army Medical University; Army Medical University; Army Medical University	He, FT (corresponding author), Army Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China.; Yang, SM (corresponding author), Army Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing 400037, Peoples R China.	hefengtian06@aliyun.com; yangshiming@tmmu.edu.cn		Xiao, Yu-Feng/0000-0002-4410-4448; Xiao, Yunhua/0000-0002-2898-7180	Natural Science Foundation of China [81773037]; Chongqing Science and Technology Commission Fund [cstc2019jcyj-msxmX0378, cstc2019jcyj-bshX0040]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chongqing Science and Technology Commission Fund	This work was supported by grants from the Natural Science Foundation of China (81773037) and the Chongqing Science and Technology Commission Fund (cstc2019jcyj-msxmX0378 and cstc2019jcyj-bshX0040).	Actis Dato V, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84090-3; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; Bu PC, 2018, CELL METAB, V27, P1249, DOI 10.1016/j.cmet.2018.04.003; Bu PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7879; Burger AM, 2004, EUR J CANCER, V40, P2217, DOI 10.1016/j.ejca.2004.07.006; Chen HR, 2021, GASTROENTEROLOGY, V160, P1284, DOI 10.1053/j.gastro.2020.11.013; Deng D, 2014, NATURE, V510, P121, DOI 10.1038/nature13306; Fang YW, 2016, GENOM PROTEOM BIOINF, V14, P42, DOI 10.1016/j.gpb.2015.09.006; Fernandes R, 2004, MOL VIS, V10, P618; Ferre F, 2016, BRIEF BIOINFORM, V17, P106, DOI 10.1093/bib/bbv031; Gil N, 2020, NAT REV GENET, V21, P102, DOI 10.1038/s41576-019-0184-5; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Gras D, 2014, REV NEUROL-FRANCE, V170, P91, DOI 10.1016/j.neurol.2013.09.005; Graziano F, 2017, PHARMACOGENOMICS J, V17, P258, DOI 10.1038/tpj.2016.13; Gu J, 2006, DIGEST DIS SCI, V51, P2198, DOI 10.1007/s10620-006-9428-2; Haber RS, 1998, CANCER, V83, P34, DOI 10.1002/(SICI)1097-0142(19980701)83:1<34::AID-CNCR5>3.0.CO;2-E; Han X, 2015, GRAEF ARCH CLIN EXP, V253, P1279, DOI 10.1007/s00417-015-2999-x; Huang HJ, 2015, AM J CANCER RES, V5, P309; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Lee MH, 2006, NAT CELL BIOL, V8, P1424, DOI 10.1038/ncb1512; Li SJ, 2020, CELL SIGNAL, V73, DOI 10.1016/j.cellsig.2020.109686; Liao ZM, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.641343; McHugh CA, 2015, NATURE, V521, P232, DOI 10.1038/nature14443; Mueckler M, 2013, MOL ASPECTS MED, V34, P121, DOI 10.1016/j.mam.2012.07.001; Nickels KC, 2016, NAT REV NEUROL, V12, P465, DOI 10.1038/nrneurol.2016.98; Salvi AM, 2021, NAT CELL BIOL, V23, P457, DOI 10.1038/s41556-021-00677-y; Sarropoulos I, 2019, NATURE, V571, P510, DOI 10.1038/s41586-019-1341-x; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Shen CQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01190-w; Tang JY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11447-8; Tsoi LC, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0570-4; Zambrano A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133374; Zhang MY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36238-x; Zhang YC, 2020, ACTA PHARMACOL SIN B, V10, P79, DOI 10.1016/j.apsb.2019.12.005	34	2	2	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1882	1894		10.1038/s41388-022-02230-z	http://dx.doi.org/10.1038/s41388-022-02230-z		FEB 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35149838				2022-12-17	WOS:000754149100001
J	Han, L; Lin, X; Yan, Q; Gu, CC; Li, MS; Pan, L; Meng, Y; Zhao, XM; Liu, SD; Li, AM				Han, Lu; Lin, Xin; Yan, Qun; Gu, Chuncai; Li, Mengshu; Pan, Lei; Meng, Yan; Zhao, Xinmei; Liu, Side; Li, Aimin			PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; SORAFENIB; PROTEIN; VEGF; EXPRESSION; MIGRATION; PATHWAY; DISEASE; GROWTH	Sustained anti-angiogenesis therapy increases the level of tumor hypoxia, leading to increased expression of HIF-1a, thereby contributing to the resistance to anti-angiogenesis therapy in hepatocellular carcinoma (HCC). Here, we report that phenazine biosynthesis-like domain-containing protein (PBLD) inhibits hypoxia-induced angiogenesis via ERK/HIF-1a/VEGF axis in HCC cells. Bioinformatic analysis of the TCGA database and clinical samples validation also identify a negative correlation between PBLD and angiogenesis-related genes expression including HIF-1a. Apart from the downregulation of HIF-1a/VEGF expression in HCC cells, PBLD also blocks VEGF receptor 2 (VEGFR2) on endothelial cells via HCC-derived exosomal miR-940. PBLD also activates TCF4 transcriptional promotion effects on miR-940 by directly interacting with it. Together, PBLD exerts an inhibitory effect on angiogenesis not only via blocking the VEGFR2 expression in endothelial cells, but also through downregulating HIF-1a-induced VEGF expression and secretion in HCC cells. These explorations may provide a theoretical basis for exploring new targets and strategies to overcome resistance to anti-angiogenesis therapy.	[Han, Lu; Lin, Xin; Yan, Qun; Gu, Chuncai; Li, Mengshu; Pan, Lei; Meng, Yan; Zhao, Xinmei; Liu, Side; Li, Aimin] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China; [Han, Lu] Guangzhou Univ Tradit Chinese Med, Affiliated Hosp 2, Dept Gastroenterol, Guangzhou 510120, Guangdong, Peoples R China	Southern Medical University - China; Guangzhou University of Chinese Medicine	Zhao, XM; Liu, SD; Li, AM (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China.	xmzhao914@163.com; liuside2011@163.com; lam0725@163.com	Meng, Yan/HGC-0394-2022	zhao, Xinmei/0000-0003-3940-788X	National Natural Science Foundation of China [81402028, 82072758, 12026605]; Guangdong Science and Technology Project [2017A020215046]; Guangdong Gastrointestinal Disease Research Center [2017B020209003, 2017B030314037]; Major National Science and Technology Special Fund Projects [2020ZX09201017]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Science and Technology Project; Guangdong Gastrointestinal Disease Research Center; Major National Science and Technology Special Fund Projects	This work was supported by grants from the National Natural Science Foundation of China (grant numbers 81402028, 82072758, 12026605), Guangdong Science and Technology Project (grant numbers 2017A020215046), Guangdong Gastrointestinal Disease Research Center (grant numbers 2017B020209003 and 2017B030314037), and the Major National Science and Technology Special Fund Projects (grant numbers 2020ZX09201017).	Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021; Arderiu G, 2019, CIRC RES, V125, P74, DOI 10.1161/CIRCRESAHA.118.314290; Bayly R, 2004, J BIOL CHEM, V279, P55362, DOI 10.1074/jbc.M408654200; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9; Caunt CJ, 2013, FEBS J, V280, P489, DOI 10.1111/j.1742-4658.2012.08716.x; Chappell JC, 2019, J CLIN INVEST, V129, P442, DOI 10.1172/JCI120855; Chen HF, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112668; Chen X, 2017, ONCOL REP, V38, P522, DOI 10.3892/or.2017.5697; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Choudhry H, 2018, CELL METAB, V27, P281, DOI 10.1016/j.cmet.2017.10.005; Conigliaro A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0426-x; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; Dittmer J, 2015, SEMIN CANCER BIOL, V35, P20, DOI 10.1016/j.semcancer.2015.09.010; Forrest MP, 2014, TRENDS MOL MED, V20, P322, DOI 10.1016/j.molmed.2014.01.010; Gu CC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1962-x; Hannafon BN, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0400-7; Huang AX, 2015, INT J BIOL SCI, V11, P961, DOI 10.7150/ijbs.11943; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jayson GC, 2016, LANCET, V388, P518, DOI 10.1016/S0140-6736(15)01088-0; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kaelin WG, 2010, NATURE, V465, P562, DOI 10.1038/465562a; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Kurokawa Y, 2004, J EXP CLIN CANC RES, V23, P135; Li AM, 2016, ONCOTARGET, V7, P524, DOI 10.18632/oncotarget.6358; Li P, 2019, J CELL MOL MED, V23, P2475, DOI 10.1111/jcmm.14121; Li QY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1330-9; Liang YJ, 2013, HEPATOLOGY, V57, P1847, DOI 10.1002/hep.26224; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Long JA, 2010, HEPATOB PANCREAT DIS, V9, P296; Lonne GK, 2009, J BIOL CHEM, V284, P33456, DOI 10.1074/jbc.M109.036186; Martin MJ, 2012, CANCER DISCOV, V2, P344, DOI 10.1158/2159-8290.CD-11-0280; Mashouri L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0991-5; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; Meurette O, 2018, CANCER CELL, V34, P536, DOI 10.1016/j.ccell.2018.07.009; Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200; Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87; Tang WM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08225-3; Wirgenes KV, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.39; Yen C, 2017, LIVER CANCER, V6, P313, DOI 10.1159/000480441; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937; Zhao J, 2020, ONCOGENE, V39, P1724, DOI 10.1038/s41388-019-1093-y; Zhao Shaorong, 2019, Cell Physiol Biochem, V53, P19, DOI 10.33594/000000118	43	2	2	7	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1851	1865		10.1038/s41388-022-02197-x	http://dx.doi.org/10.1038/s41388-022-02197-x		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35140333	Green Published, hybrid			2022-12-17	WOS:000753256400001
J	Zhang, T; Wang, Y; Li, Q; Lin, LY; Xu, CL; Xue, YQ; Hu, MY; Shi, YF; Wang, Y				Zhang, Tao; Wang, Yu; Li, Qing; Lin, Liangyu; Xu, Chunliang; Xue, Yueqing; Hu, Mingyuan; Shi, Yufang; Wang, Ying			Mesenchymal stromal cells equipped by IFN alpha empower T cells with potent anti-tumor immunity	ONCOGENE			English	Article							I INTERFERON; DENDRITIC CELLS; TUMOR-METASTASIS; PD-1 BLOCKADE; RESPONSES; MELANOMA; CXCR3; EXPRESSION; INSIGHTS; GENES	Cancer treatments have been revolutionized by the emergence of immune checkpoint blockade therapies. However, only a minority of patients with various tumor types have benefited from such treatments. New strategies focusing on the immune contexture of the tumor tissue microenvironment hold great promises. Here, we created IFN alpha-overexpressing mesenchymal stromal cells (IFN alpha-MSCs). Upon direct injection into tumors, we found that these cells are powerful in eliminating several types of tumors. Interestingly, the intra-tumoral injection of IFN alpha-MSCs could also induce specific anti-tumor effects on distant tumors. These IFN alpha-MSCs promoted tumor cells to produce CXCL10, which in turn potentiates the infiltration of CD8(+) T cells in the tumor site. Furthermore, IFN alpha-MSCs enhanced the expression of granzyme B (GZMB) in CD8(+) T cells and invigorated their cytotoxicity in a Stat3-dependent manner. Genetic ablation of Stat3 in CD8(+) T cells impaired the effect of IFN alpha-MSCs on GZMB expression. Importantly, the combination of IFN alpha-MSCs and PD-L1 blockade induced an even stronger anti-tumor immunity. Therefore, IFN alpha-MSCs represent a novel tumor immunotherapy strategy, especially when combined with PD-L1 blockade.	[Zhang, Tao; Wang, Yu; Li, Qing; Lin, Liangyu; Xu, Chunliang; Xue, Yueqing; Hu, Mingyuan; Shi, Yufang; Wang, Ying] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai 200031, Peoples R China; [Shi, Yufang] Soochow Univ, Inst Translat Med, State Key Lab Radiat Med & Protect, Soochow Univ Med Coll,Affiliated Hosp 3, Suzhou 215123, Jiangsu, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; University of Chinese Academy of Sciences, CAS; Soochow University - China	Shi, YF; Wang, Y (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Nutr & Hlth, CAS Key Lab Tissue Microenvironm & Tumor, Shanghai 200031, Peoples R China.; Shi, YF (corresponding author), Soochow Univ, Inst Translat Med, State Key Lab Radiat Med & Protect, Soochow Univ Med Coll,Affiliated Hosp 3, Suzhou 215123, Jiangsu, Peoples R China.	yufangshi@sibs.ac.cn; yingwang@sibs.ac.cn	Shi, Yufang/AAE-4431-2020	Shi, Yufang/0000-0001-8964-319X; wang, ying/0000-0002-2571-9367; shi, yu fang/0000-0001-9716-2126; Xu, Chunliang/0000-0002-4514-8477; Liangyu, Lin/0000-0003-4312-8955; Wang, Yu/0000-0002-7309-7304	National Key R&D Program of China [2018YFA0107500]; Scientific Innovation Project of the Chinese Academy of Sciences [XDA16020403]; National Natural Science Foundation of China [32070872, 31961133024, 31771641, 81571612, 31771581, 81861138015]; Soochow University; Department of Science and Technology of Jiangsu Province research fund [BE2016671]	National Key R&D Program of China; Scientific Innovation Project of the Chinese Academy of Sciences; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Soochow University; Department of Science and Technology of Jiangsu Province research fund	The study was supported by grants from the National Key R&D Program of China (2018YFA0107500), the Scientific Innovation Project of the Chinese Academy of Sciences (XDA16020403), the National Natural Science Foundation of China (32070872, 31961133024, 31771641, 81571612, 31771581 and 81861138015), a start-up fund from Soochow University, and the Department of Science and Technology of Jiangsu Province research fund (BE2016671).	Aref S, 2020, MOL THER, V28, P1043, DOI 10.1016/j.ymthe.2020.01.027; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bald T, 2014, CANCER DISCOV, V4, P674, DOI 10.1158/2159-8290.CD-13-0458; Bazhin AV, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02129; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bracarda S, 2010, EUR J CANCER, V46, P284, DOI 10.1016/j.ejca.2009.10.013; Burnette BC, 2011, CANCER RES, V71, P2488, DOI 10.1158/0008-5472.CAN-10-2820; Cauwels A, 2018, CANCER RES, V78, P463, DOI 10.1158/0008-5472.CAN-17-1980; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Chheda ZS, 2016, J IMMUNOL, V197, P2016, DOI 10.4049/jimmunol.1502376; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Delaunay T, 2020, J THORAC ONCOL, V15, P827, DOI 10.1016/j.jtho.2019.12.128; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; Doron H, 2019, CELL REP, V28, P1785, DOI 10.1016/j.celrep.2019.07.033; Fend L, 2017, CANCER RES, V77, P4146, DOI 10.1158/0008-5472.CAN-16-2165; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Guo J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219829; Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Ji RR, 2012, CANCER IMMUNOL IMMUN, V61, P1019, DOI 10.1007/s00262-011-1172-6; Kather JN, 2018, ELIFE, V7, DOI 10.7554/eLife.36967; Kawada K, 2004, CANCER RES, V64, P4010, DOI 10.1158/0008-5472.CAN-03-1757; Liang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06890-y; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Mohty M, 2003, J IMMUNOL, V171, P3385, DOI 10.4049/jimmunol.171.7.3385; Montoya M, 2002, BLOOD, V99, P3263, DOI 10.1182/blood.V99.9.3263; Muller E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02520; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]; Paolini R, 2015, CYTOKINE GROWTH F R, V26, P113, DOI 10.1016/j.cytogfr.2014.11.003; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pestka S, 2007, J BIOL CHEM, V282, P20047, DOI 10.1074/jbc.R700004200; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Robb RJ, 2011, BLOOD, V118, P3399, DOI 10.1182/blood-2010-12-325746; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193; Shou P, 2016, ONCOGENE, V35, P5953, DOI 10.1038/onc.2016.128; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tecchio C, 2004, BLOOD, V103, P3837, DOI 10.1182/blood-2003-08-2806; Tsuchiya N, 2019, CELL REP, V29, P162, DOI 10.1016/j.celrep.2019.08.086; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wightman SC, 2015, BRIT J CANCER, V113, P327, DOI 10.1038/bjc.2015.193; Xu C, 2014, ONCOGENE, V33, P5047, DOI 10.1038/onc.2013.458; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004; Yeruva S, 2008, INT J COLORECTAL DIS, V23, P305, DOI 10.1007/s00384-007-0396-6; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845	57	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1866	1881		10.1038/s41388-022-02201-4	http://dx.doi.org/10.1038/s41388-022-02201-4		FEB 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35145233	hybrid, Green Published			2022-12-17	WOS:000754012300002
J	Xu, LM; Zhang, J; Ma, Y; Yuan, YJ; Yu, H; Wang, J; Cao, XC; Zhu, L; Wang, P				Xu, Li-Ming; Zhang, Jiao; Ma, Yue; Yuan, Ya-Jing; Yu, Hao; Wang, Jun; Cao, Xu-Chen; Zhu, Li; Wang, Ping			MicroRNA-135 inhibits initiation of epithelial-mesenchymal transition in breast cancer by targeting ZNF217 and promoting m6A modification of NANOG	ONCOGENE			English	Article							CELL-PROLIFERATION; STEM-CELLS; TRANSCRIPTION; BIOMARKER; ONCOGENE	MicroRNAs play significant roles in various malignancies, with breast cancer (BC) being no exception. Consequently, we explored the functional mechanism of miR-135 in the progression of BC. In total, 55 pairs of BC and matched adjacent normal tissues were clinically collected from patients, followed by quantification of miR-135 and zinc finger protein 217 (ZNF217) expression patterns in BC tissues and cells. Accordingly, high ZNF217 expression and low miR-135 expression levels were identified in BC tissues and cells. Subsequently, the expressions of miR-135 and ZNF217 were altered to evaluate their effects on BC cell migration, invasion and EMT initiation. It was found that when ZNF217 was silenced or miR-135 was elevated, BC cell malignant behaviors were significantly inhibited, which was reproduced in nude mice for in vivo evidence. Furthermore, dual-luciferase reporter gene assay revealed the presence of direct binding between miR-135 and ZNF217. Subsequent co-immunoprecipitation, methylated-RNA binding protein immunoprecipitation and photoactivatable ribonucleoside enhanced-crosslinking and immunoprecipitation assays further revealed that ZNF217 could upregulate NANOG by reducing N6-methyladenosine levels via methyltransferase-like 13 (METTL3). Collectively, our findings highlighted the role of the miR-135/ZNF217/METTL3/NANOG axis in the progression of BC, emphasizing potential therapeutic targets ZNF217 silencing and miR-135 upregulation in preventing or treating BC.	[Xu, Li-Ming; Yu, Hao; Wang, Jun; Zhu, Li; Wang, Ping] Tianjin Med Univ, Minist Educ,Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc,Key Lab Breast Canc Preven, Dept Radiotherapy,Tianjins Clin Res Ctr Canc,Key, Tianjin 300060, Peoples R China; [Xu, Li-Ming; Wang, Jun] Tianjin Med Univ, Dept Radiotherapy, Canc Hosp, Airport Hosp, Tianjin 300308, Peoples R China; [Zhang, Jiao; Ma, Yue; Cao, Xu-Chen] Tianjin Med Univ, Minist Educ,Tianjins Clin Res Ctr Canc,Key Lab Br, Dept Breast Canc 1,Key Lab Canc Prevent & Therapy, Tianjin Med Univ Canc Inst & Hosp,Natl Clin Res C, Tianjin 300060, Peoples R China; [Zhang, Jiao] Zhengzhou Univ, Henan Breast Canc Ctr, Dept Breast Dis, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China; [Zhang, Jiao] Henan Canc Hosp, Zhengzhou 450008, Peoples R China; [Yuan, Ya-Jing] Tianjin Med Univ Canc Inst & Hosp, Dept Anesthesia, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Tianjins Clin Res, Tianjin 300060, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Zhengzhou University; Zhengzhou University; Tianjin Medical University	Zhu, L; Wang, P (corresponding author), Tianjin Med Univ, Minist Educ,Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc,Key Lab Breast Canc Preven, Dept Radiotherapy,Tianjins Clin Res Ctr Canc,Key, Tianjin 300060, Peoples R China.; Cao, XC (corresponding author), Tianjin Med Univ, Minist Educ,Tianjins Clin Res Ctr Canc,Key Lab Br, Dept Breast Canc 1,Key Lab Canc Prevent & Therapy, Tianjin Med Univ Canc Inst & Hosp,Natl Clin Res C, Tianjin 300060, Peoples R China.	xlm19821223@126.com; zhuli@tjmuch.com; wangping@tjmuch.com			National Natural Science Foundation of China [81502656, 81501140]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (No. 81502656 and No. 81501140).	Aguilo F, 2015, CELL STEM CELL, V17, P689, DOI 10.1016/j.stem.2015.09.005; Akram M, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0140-9; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P1; Ayuk SM, 2016, J PHOTOCH PHOTOBIO B, V161, P368, DOI 10.1016/j.jphotobiol.2016.05.027; Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019; Bellanger A, 2017, J PATHOL, V242, P73, DOI 10.1002/path.4882; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cohen PA, 2015, ONCOTARGET, V6, P41566, DOI 10.18632/oncotarget.5893; Gibadulinova A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124299; Goh JN, 2016, BIOL REV, V91, P409, DOI 10.1111/brv.12176; Hamam R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.440; Horne HN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23733-4; Hu C, 2016, J DRUG TARGET, V24, P422, DOI 10.3109/1061186X.2015.1082567; Jiang DQ, 2019, INT J MOL MED, V43, P1623, DOI 10.3892/ijmm.2019.4081; Jiang XK, 2016, ONCOTARGET, V7, P84893, DOI 10.18632/oncotarget.12753; Suarez-Sanchez FJ, 2021, CANCERS, V13, DOI 10.3390/cancers13030395; Kocak A, 2020, AM J PATHOL, V190, P1643, DOI 10.1016/j.ajpath.2020.04.015; Li F, 2020, MOL THER-NUCL ACIDS, V22, P456, DOI 10.1016/j.omtn.2020.09.008; Li ZW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116170; Lin CH, 2018, ONCOTARGETS THER, V11, P5419, DOI 10.2147/OTT.S164575; Littlepage LE, 2012, CANCER DISCOV, V2, P638, DOI 10.1158/2159-8290.CD-12-0093; McGuire A, 2015, CANCER METAST REV, V34, P145, DOI 10.1007/s10555-015-9551-7; Qin S, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160247; Qiu Y, 2018, ONCOL REP, V39, P138, DOI 10.3892/or.2017.6081; Rezaei M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3367; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1; Smith BN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104987; Sun YS, 2017, INT J BIOL SCI, V13, P1387, DOI 10.7150/ijbs.21635; Taipaleenmaki H, 2015, CANCER RES, V75, P1433, DOI 10.1158/0008-5472.CAN-14-1026; Vendrell JA, 2012, CANCER RES, V72, P3593, DOI 10.1158/0008-5472.CAN-11-3095; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang L, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10030457; Wang XW, 2020, BREAST CANCER-TOKYO, V27, P765, DOI 10.1007/s12282-020-01075-2; Yamada Y, 2013, CANCER SCI, V104, P304, DOI 10.1111/cas.12072; Yang DD, 2018, NUCLEIC ACIDS RES, V46, P3906, DOI 10.1093/nar/gky130; Yang Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08759-0; Yeung KT, 2017, MOL ONCOL, V11, P28, DOI 10.1002/1878-0261.12017; Zhang CZ, 2016, ONCOTARGET, V7, P64527, DOI 10.18632/oncotarget.11743; Zhao M, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317691682	40	2	2	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1742	1751		10.1038/s41388-022-02211-2	http://dx.doi.org/10.1038/s41388-022-02211-2		FEB 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35121826				2022-12-17	WOS:000751251500002
J	Biondini, M; Kiepas, A; El-Houjeiri, L; Nis, MGA; Hsu, BE; Fortier, AM; Morin, G; Martina, JA; Sirois, I; Aguilar-Mahecha, A; Gruosso, T; McGuirk, S; Rose, AAN; Tokat, UM; Johnson, RM; Sahin, O; Bareke, E; St-Pierre, J; Park, M; Basik, M; Majewski, J; Puertollano, R; Pause, A; Huang, SD; Keler, T; Siegel, PM				Biondini, Marco; Kiepas, Alex; El-Houjeiri, Leeanna; Nis, Matthew G. An; Hsu, Brian E.; Fortier, Anne-Marie; Morin, Genevieve; Martina, Jose A.; Sirois, Isabelle; Aguilar-Mahecha, Adriana; Gruosso, Tina; McGuirk, Shawn; Rose, April A. N.; Tokat, Unal M.; Johnson, Radia M.; Sahin, Ozgur; Bareke, Eric; St-Pierre, Julie; Park, Morag; Basik, Mark; Majewski, Jacek; Puertollano, Rosa; Pause, Arnim; Huang, Sidong; Keler, Tibor; Siegel, Peter M.			HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin	ONCOGENE			English	Article							ANTIBODY-DRUG CONJUGATE; GLYCOPROTEIN NONMETASTATIC B; PHASE-II; TFEB; AUTOPHAGY; MELANOMA; PATHWAY; FLCN; RECRUITMENT; MECHANISMS	Transmembrane glycoprotein NMB (GPNMB) is a prognostic marker of poor outcome in patients with triple-negative breast cancer (TNBC). Glembatumumab Vedotin, an antibody drug conjugate targeting GPNMB, exhibits variable efficacy against GPNMB-positive metastatic TNBC as a single agent. We show that GPNMB levels increase in response to standard-of-care and experimental therapies for multiple breast cancer subtypes. While these therapeutic stressors induce GPNMB expression through differential engagement of the MiTF family of transcription factors, not all are capable of increasing GPNMB cell-surface localization required for Glembatumumab Vedotin inhibition. Using a FACS-based genetic screen, we discovered that suppression of heat shock protein 90 (HSP90) concomitantly increases GPNMB expression and cell-surface localization. Mechanistically, HSP90 inhibition resulted in lysosomal dispersion towards the cell periphery and fusion with the plasma membrane, which delivers GPNMB to the cell surface. Finally, treatment with HSP90 inhibitors sensitizes breast cancers to Glembatumumab Vedotin in vivo, suggesting that combination of HSP90 inhibitors and Glembatumumab Vedotin may be a viable treatment strategy for patients with metastatic TNBC.	[Biondini, Marco; Kiepas, Alex; El-Houjeiri, Leeanna; Nis, Matthew G. An; Hsu, Brian E.; Fortier, Anne-Marie; Morin, Genevieve; Gruosso, Tina; McGuirk, Shawn; Park, Morag; Pause, Arnim; Huang, Sidong; Siegel, Peter M.] McGill Univ, Goodman Canc Res Inst, Montreal, PQ, Canada; [Biondini, Marco; Nis, Matthew G. An; Hsu, Brian E.; Park, Morag; Pause, Arnim; Siegel, Peter M.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Kiepas, Alex; McGuirk, Shawn] McGill Univ, Dept Physiol, Montreal, PQ, Canada; [El-Houjeiri, Leeanna; Fortier, Anne-Marie; Morin, Genevieve; Gruosso, Tina; Park, Morag; Huang, Sidong; Siegel, Peter M.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Martina, Jose A.; Puertollano, Rosa] NHLBI, Cell & Dev Biol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA; [Sirois, Isabelle; Aguilar-Mahecha, Adriana; Basik, Mark] Sir Mortimer B Davis Jewish Hosp, Segal Canc Ctr, Lady Davis Inst Med Res, Montreal, PQ, Canada; [Rose, April A. N.; Basik, Mark] McGill Univ, Dept Oncol & Surg, Montreal, PQ, Canada; [Tokat, Unal M.] Bilkent Univ, Dept Mol Biol & Genet, Ankara, Turkey; [Johnson, Radia M.] Genentech Inc, 1 DNA Way South, San Francisco, CA USA; [Sahin, Ozgur] Univ South Carolina, Dept Drug Discovery & Biomed Sci, Columbia, SC 29208 USA; [Bareke, Eric; Majewski, Jacek] McGill Univ, Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Bareke, Eric; Majewski, Jacek] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [St-Pierre, Julie] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [St-Pierre, Julie] Univ Ottawa, Ottawa Inst Syst Biol, Ottawa, ON, Canada; [Keler, Tibor] Celldex Therapeut, Hampton, NJ USA	McGill University; McGill University; McGill University; McGill University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Lady Davis Institute; McGill University; McGill University; Ihsan Dogramaci Bilkent University; Roche Holding; Genentech; University of South Carolina System; University of South Carolina Columbia; McGill University; McGill University; University of Ottawa; University of Ottawa	Siegel, PM (corresponding author), McGill Univ, Goodman Canc Res Inst, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Siegel, PM (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ, Canada.	peter.siegel@mcgill.ca	Johnson, Radia/GYV-4663-2022; St-Pierre, Julie/AGB-3651-2022; Aguilar, Adriana/GRF-2369-2022; Kiepas, Alex/GVS-8491-2022; Tokat, Ünal Metin/ABA-6061-2020	Johnson, Radia/0000-0002-9755-9307; St-Pierre, Julie/0000-0002-2815-7099; Tokat, Ünal Metin/0000-0003-0026-368X; Kiepas, Alexander/0000-0001-8169-3897	Fonds de recherche du Quebec-Sante (FRQS) post-doctoral fellowship; Canadian Institutes of Health Research [PJT-153327]	Fonds de recherche du Quebec-Sante (FRQS) post-doctoral fellowship; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We acknowledge technical assistance from the McGill GCRC Histology core facility for routine histological services. We acknowledge McGill Life Science Complex Advanced BioImaging Facility (ABIF) for technical assistance in acquisition/analysis of images. We acknowledge McGill Platform for Cellular Perturbation (MPCP) for providing the shRNAs libraries and technical assistance with screnning process and analysis. We acknowledge McGill Life Science Complex Cell Vision Core for technical assistance in acquisition/analysis of flow cytometry data. We acknowledge Genome Quebec and McGill University for support of the Q-CROC-03 trial. We acknowledge Dr. Alana Welm for providing us with HCI-010 PDX tumor model. We thank members of the Siegel laboratory, all collaborators and Dr. Ursini-Siegel for thoughtful discussions and critical reading of the paper. MB was the recipient of a Fonds de recherche du Quebec-Sante (FRQS) post-doctoral fellowship. PMS is a William Dawson Scholar of McGill University. This work was supported by an operating grant from the Canadian Institutes of Health Research to PMS (PJT-153327).	Agarraberes FA, 2001, J CELL SCI, V114, P2491; Bandyopadhyay U, 2008, MOL CELL BIOL, V28, P5747, DOI 10.1128/MCB.02070-07; Bekki H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1830-8; Bendell J, 2014, J CLIN ONCOL, V32, P3619, DOI 10.1200/JCO.2013.52.5683; Bergin Alice R T, 2019, F1000Res, V8, DOI 10.12688/f1000research.18888.1; Boshuizen J, 2020, MOL CELL, V78, P1002, DOI 10.1016/j.molcel.2020.05.031; Butler LM, 2015, MOL CANCER RES, V13, P1445, DOI 10.1158/1541-7786.MCR-15-0234; Chen C, 2018, CANCER RES, V78, P6424, DOI 10.1158/0008-5472.CAN-18-0599; Cheng Y, 2017, MOLECULES, V22, DOI 10.3390/molecules22101551; Dai CK, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0525; Damaskos C, 2019, ANTICANCER RES, V39, P5285, DOI 10.21873/anticanres.13722; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; El-Houjeiri L, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI144871; El-Houjeiri L, 2019, CELL REP, V26, P3613, DOI 10.1016/j.celrep.2019.02.102; Giulino-Roth L, 2017, MOL CANCER THER, V16, P1779, DOI 10.1158/1535-7163.MCT-16-0848; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hoffmann RM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1395127; Hong SB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015793; Jansson KH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35417-0; Jing JP, 2012, MOL CANCER THER, V11, P720, DOI 10.1158/1535-7163.MCT-11-0505; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Jongsma MLM, 2016, CELL, V166, P152, DOI 10.1016/j.cell.2016.05.078; Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292; Kong T, 2020, CANCER RES, V80, P444, DOI 10.1158/0008-5472.CAN-19-1108; Kopp LM, 2019, EUR J CANCER, V121, P177, DOI 10.1016/j.ejca.2019.08.015; Lauwers E, 2018, MOL CELL, V71, P689, DOI 10.1016/j.molcel.2018.07.016; Le Borgne R, 2001, J CELL SCI, V114, P2831; Li B, 2010, FASEB J, V24, P4767, DOI 10.1096/fj.10-154757; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Liu H, 2018, CANCER DISCOV, V8, P354, DOI 10.1158/2159-8290.CD-17-0679; Martina JA, 2017, TRANSCR-AUSTIN, V8, P48, DOI 10.1080/21541264.2016.1264353; Martina JA, 2016, EMBO J, V35, P479, DOI 10.15252/embj.201593428; Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754; Martina JA, 2013, J CELL BIOL, V200, P475, DOI 10.1083/jcb.201209135; Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653; McGuirk Shawn, 2021, Elife, V10, DOI 10.7554/eLife.65150; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Noda Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11828-3; Nytko KJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69619-2; Ott PA, 2019, CANCER-AM CANCER SOC, V125, P1113, DOI 10.1002/cncr.31892; Park S, 2019, BIOMOL THER, V27, P423, DOI 10.4062/biomolther.2019.051; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Petit CS, 2013, J CELL BIOL, V202, P1107, DOI 10.1083/jcb.201307084; Pick E, 2007, CANCER RES, V67, P2932, DOI 10.1158/0008-5472.CAN-06-4511; Pogenberg V, 2012, GENE DEV, V26, P2647, DOI 10.1101/gad.198192.112; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Pu J, 2016, J CELL SCI, V129, P4329, DOI 10.1242/jcs.196287; Puertollano R, 2018, EMBO J, V37, DOI 10.15252/embj.201798804; Qian XZ, 2008, MOL ONCOL, V2, P81, DOI 10.1016/j.molonc.2008.02.002; Raben N, 2016, ANNU REV CELL DEV BI, V32, P255, DOI 10.1146/annurev-cellbio-111315-125407; Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790; Rose AAN, 2017, PHARMACOL THERAPEUT, V179, P127, DOI 10.1016/j.pharmthera.2017.05.010; Rose AAN, 2016, CLIN CANCER RES, V22, P6088, DOI 10.1158/1078-0432.CCR-16-1192; Rose AAN, 2010, CLIN CANCER RES, V16, P2147, DOI 10.1158/1078-0432.CCR-09-1611; Schmidt LS, 2018, GENE, V640, P28, DOI 10.1016/j.gene.2017.09.044; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Sirois I, 2019, MOL CANCER RES, V17, P2492, DOI 10.1158/1541-7786.MCR-19-0264; Slade L, 2017, MOL CANCER RES, V15, P1637, DOI 10.1158/1541-7786.MCR-17-0320; Starling GP, 2016, EMBO REP, V17, P823, DOI 10.15252/embr.201541382; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Tanaka M, 2017, CANCER RES, V77, P897, DOI 10.1158/0008-5472.CAN-16-2486; Tse KF, 2006, CLIN CANCER RES, V12, P1373, DOI 10.1158/1078-0432.CCR-05-2018; Vahdat LT, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-P6-20-01; van der Lienden MJC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010066; Vega-Rubin-de-Celis S, 2017, AUTOPHAGY, V13, P464, DOI 10.1080/15548627.2016.1271514; Wada S, 2016, GENE DEV, V30, P2551, DOI 10.1101/gad.287953.116; Wang H, 2016, MOL CLIN ONCOL, V5, P326, DOI 10.3892/mco.2016.963; Wang Y, 2015, CHEM COMMUN, V51, P1410, DOI 10.1039/c4cc07284g; Woodford MR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12037; Yang ZJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09181-2; Yardley DA, 2015, J CLIN ONCOL, V33, P1609, DOI 10.1200/JCO.2014.56.2959; Zhitomirsky B, 2015, ONCOTARGET, V6, P1143, DOI 10.18632/oncotarget.2732	76	2	2	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1701	1717		10.1038/s41388-022-02206-z	http://dx.doi.org/10.1038/s41388-022-02206-z		FEB 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35110681				2022-12-17	WOS:000749991500001
J	Ma, GZ; Deng, YF; Qian, LX; Vallega, KA; Zhang, GJ; Deng, XM; Owonikoko, TK; Ramalingam, SS; Fang, DD; Zhai, YF; Sun, SY				Ma, Guangzhi; Deng, Yunfu; Qian, Luxi; Vallega, Karin A.; Zhang, Guojing; Deng, Xingming; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Fang, Douglas D.; Zhai, Yifan; Sun, Shi-Yong			Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both	ONCOGENE			English	Article							LUNG-CANCER; MODULATION	Treatment of EGFR-mutant non-small cell lung cancer (NSCLC) with mutation-selective third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib has achieved remarkable success in the clinic. However, the immediate challenge is the emergence of acquired resistance, limiting the long-term remission of patients. This study suggests a novel strategy to overcome acquired resistance to osimertinib and other third-generation EGFR-TKIs through directly targeting the intrinsic apoptotic pathway. We found that osimertinib, when combined with Mcl-1 inhibition or Bax activation, synergistically decreased the survival of different osimertinib-resistant cell lines, enhanced the induction of intrinsic apoptosis, and inhibited the growth of osimertinib-resistant tumor in vivo. Interestingly, the triple-combination of osimertinib with Mcl-1 inhibition and Bax activation exhibited the most potent activity in decreasing the survival and inducing apoptosis of osimertinib-resistant cells and in suppressing the growth of osimertinib-resistant tumors. These effects were associated with increased activation of the intrinsic apoptotic pathway evidenced by augmented mitochondrial cytochrome C and Smac release. Hence, this study convincingly demonstrates a novel strategy for overcoming acquired resistance to osimertinib and other 3rd generation EGFR-TKIs by targeting activation of the intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation or both, warranting further clinical validation of this strategy.	[Ma, Guangzhi] Sichuan Univ, West China Hosp, Dept Thorac Surg, Chengdu, Sichuan, Peoples R China; [Ma, Guangzhi; Deng, Yunfu; Qian, Luxi; Vallega, Karin A.; Zhang, Guojing; Ramalingam, Suresh S.; Sun, Shi-Yong] Emory Univ, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA; [Ma, Guangzhi; Deng, Yunfu; Qian, Luxi; Vallega, Karin A.; Zhang, Guojing; Deng, Xingming; Ramalingam, Suresh S.; Sun, Shi-Yong] Winship Canc Inst, Atlanta, GA 30322 USA; [Deng, Yunfu] Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Sichuan, Peoples R China; [Qian, Luxi] Nanjing Med Univ, Dept Radiat Oncol, Jiangsu Canc Hosp, Jiangsu Inst Canc Res, Nanjing, Jiangsu, Peoples R China; [Qian, Luxi] Nanjing Med Univ, Affiliated Canc Hosp, Nanjing, Jiangsu, Peoples R China; [Deng, Xingming] Emory Univ, Dept Radiat Oncol, Sch Med, Atlanta, GA 30322 USA; [Owonikoko, Taofeek K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; [Owonikoko, Taofeek K.] Hillman Canc Ctr, Pittsburgh, PA USA; [Fang, Douglas D.; Zhai, Yifan] Ascentage Pharma Suzhou Co Ltd, Suzhou, Jiangsu, Peoples R China	Sichuan University; Emory University; Sichuan University; Nanjing Medical University; Nanjing Medical University; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sun, SY (corresponding author), Emory Univ, Dept Hematol & Med Oncol, Sch Med, Atlanta, GA 30322 USA.; Sun, SY (corresponding author), Winship Canc Inst, Atlanta, GA 30322 USA.	ssun@emory.edu	Owonikoko, Taofeek/C-3012-2011	Owonikoko, Taofeek/0000-0002-7724-7728	Emory University Winship Cancer Institute lung cancer pilot fund; NIH/NCI [SPORE P50 CA217691]; Ascentage Pharma	Emory University Winship Cancer Institute lung cancer pilot fund; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ascentage Pharma(Dexcel Pharma)	We thank Dr. A. Hammond in our department for editing the manuscript. This work was supported by Emory University Winship Cancer Institute lung cancer pilot fund (to SYS), NIH/NCI SPORE P50 CA217691 (to XD) and a research fund from Ascentage Pharma (to SYS). TKO, SSR and SYS are Georgia Research Alliance Distinguished Cancer Scientists.	Carlisle JW, 2019, FUTURE ONCOL, V15, P805, DOI 10.2217/fon-2018-0626; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Fulda S, 2009, J CELL MOL MED, V13, P1221, DOI 10.1111/j.1582-4934.2009.00748.x; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Li R, 2017, CANCER RES, V77, P3001, DOI 10.1158/0008-5472.CAN-16-2356; Negi A, 2021, EUR J MED CHEM, V210, DOI 10.1016/j.ejmech.2020.113038; Penn L Z, 2001, Curr Opin Investig Drugs, V2, P684; Piper-Vallillo AJ, 2020, J CLIN ONCOL, V38, P2926, DOI 10.1200/JCO.19.03123; Pogmore JP, 2021, J MED CHEM, V64, P5276, DOI 10.1021/acs.jmedchem.0c02200; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Rowinsky EK, 2005, J CLIN ONCOL, V23, P9394, DOI 10.1200/JCO.2005.02.2889; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Shah R, 2020, CLIN LUNG CANCER, V21, pE216, DOI 10.1016/j.cllc.2019.12.003; Shi PY, 2017, CLIN CANCER RES, V23, P6567, DOI 10.1158/1078-0432.CCR-17-1574; Shi PY, 2016, CANCER LETT, V380, P494, DOI 10.1016/j.canlet.2016.07.021; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Sun SY, 2004, JNCI-J NATL CANCER I, V96, P662, DOI 10.1093/jnci/djh123; Sun SY, 1997, CANCER RES, V57, P4931; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Walensky LD, 2019, NAT CHEM BIOL, V15, P657, DOI 10.1038/s41589-019-0306-6; Wang HL, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01079-1; Xin MG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5935; Zang HJ, 2020, CANCER-AM CANCER SOC, V126, P2024, DOI 10.1002/cncr.32744; Zhang LL, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188569; Zimmermann KC, 2001, J ALLERGY CLIN IMMUN, V108, pS99, DOI 10.1067/mai.2001.117819; Zong D, 2020, CANCER RES, V80, P2380, DOI 10.1158/0008-5472.CAN-19-3674	28	2	2	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1691	1700		10.1038/s41388-022-02200-5	http://dx.doi.org/10.1038/s41388-022-02200-5		JAN 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35102249				2022-12-17	WOS:000750409400002
J	Fidyt, K; Pastorczak, A; Cyran, J; Crump, NT; Goral, A; Madzio, J; Muchowicz, A; Poprzeczko, M; Domka, K; Komorowski, L; Winiarska, M; Harman, JR; Siudakowska, K; Graczyk-Jarzynka, A; Patkowska, E; Lech-Maranda, E; Mlynarski, W; Golab, J; Milne, TA; Firczuk, M				Fidyt, Klaudyna; Pastorczak, Agata; Cyran, Julia; Crump, Nicholas T.; Goral, Agnieszka; Madzio, Joanna; Muchowicz, Angelika; Poprzeczko, Martyna; Domka, Krzysztof; Komorowski, Lukasz; Winiarska, Magdalena; Harman, Joe R.; Siudakowska, Karolina; Graczyk-Jarzynka, Agnieszka; Patkowska, Elzbieta; Lech-Maranda, Ewa; Mlynarski, Wojciech; Golab, Jakub; Milne, Thomas A.; Firczuk, Malgorzata			Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax	ONCOGENE			English	Article							H3K79 METHYLATION; FUSION PROTEINS; BCL-2; INHIBITOR; AURANOFIN; APOPTOSIS; MCL-1; THIOREDOXIN; UBIQUITINATION; TRANSCRIPTION	The prognosis for B-cell precursor acute lymphoblastic leukemia patients with Mixed-Lineage Leukemia (MLL) gene rearrangements (MLLr BCP-ALL) is still extremely poor. Inhibition of anti-apoptotic protein BCL-2 with venetoclax emerged as a promising strategy for this subtype of BCP-ALL, however, lack of sufficient responses in preclinical models and the possibility of developing resistance exclude using venetoclax as monotherapy. Herein, we aimed to uncover potential mechanisms responsible for limited venetoclax activity in MLLr BCP-ALL and to identify drugs that could be used in combination therapy. Using RNA-seq, we observed that long-term exposure to venetoclax in vivo in a patient-derived xenograft model leads to downregulation of several tumor protein 53 (TP53)-related genes. Interestingly, auranofin, a thioredoxin reductase inhibitor, sensitized MLLr BCP-ALL to venetoclax in various in vitro and in vivo models, independently of the p53 pathway functionality. Synergistic activity of these drugs resulted from auranofin-mediated upregulation of NOXA pro-apoptotic protein and potent induction of apoptotic cell death. More specifically, we observed that auranofin orchestrates upregulation of the NOXA-encoding gene Phorbol-12-Myristate-13-Acetate-Induced Protein 1 (PMAIP1) associated with chromatin remodeling and increased transcriptional accessibility. Altogether, these results present an efficacious drug combination that could be considered for the treatment of MLLr BCP-ALL patients, including those with TP53 mutations.	[Fidyt, Klaudyna; Cyran, Julia; Goral, Agnieszka; Muchowicz, Angelika; Poprzeczko, Martyna; Domka, Krzysztof; Komorowski, Lukasz; Winiarska, Magdalena; Siudakowska, Karolina; Graczyk-Jarzynka, Agnieszka; Golab, Jakub; Firczuk, Malgorzata] Med Univ Warsaw, Dept Immunol, Warsaw, Poland; [Fidyt, Klaudyna; Komorowski, Lukasz] Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland; [Pastorczak, Agata; Madzio, Joanna; Mlynarski, Wojciech] Med Univ Lodz, Dept Pediat Oncol & Hematol, Lodz, Poland; [Crump, Nicholas T.; Harman, Joe R.; Milne, Thomas A.] Univ Oxford, Med Res Council Mol Haematol Unit, Oxford, England; [Poprzeczko, Martyna; Domka, Krzysztof; Winiarska, Magdalena; Graczyk-Jarzynka, Agnieszka] Polish Acad Sci, Mossakowski Med Res Inst, Warsaw, Poland; [Patkowska, Elzbieta; Lech-Maranda, Ewa] Inst Hematol & Transfus Med, Dept Hematol, Warsaw, Poland	Medical University of Warsaw; Medical University of Warsaw; Medical University Lodz; University of Oxford; Polish Academy of Sciences; Mossakowski Medical Research Institute of the Polish Academy of Sciences	Firczuk, M (corresponding author), Med Univ Warsaw, Dept Immunol, Warsaw, Poland.	mfirczuk@wum.edu.pl	Patkowska, Elżbieta/AAD-3938-2020; Madzio, Joanna/ABC-5122-2020; Golab, Jakub/K-6974-2013; Muchowicz, Angelika/J-7494-2012	Patkowska, Elżbieta/0000-0001-8691-4310; Madzio, Joanna/0000-0003-0766-0194; Fidyt, Klaudyna/0000-0003-0568-4950; Golab, Jakub/0000-0002-2830-5100; Muchowicz, Angelika/0000-0003-4707-1722; Goral, Agnieszka/0000-0002-7324-9718; Komorowski, Lukasz Wit/0000-0002-7646-1968; Crump, Nicholas/0000-0001-9610-6763; Pastorczak, Agata/0000-0003-3089-6947; Janowska (Poprzeczko), Martyna/0000-0002-8703-5614; Winiarska, Magdalena/0000-0001-5605-3329; Mlynarski, Wojciech/0000-0003-2714-5851	National Science Centre (Poland) [2015/18/E/NZ5/00723, 2018/31/N/NZ5/01438, 2019/32/T/NZ5/00241]; Ministry of Education and Science (Poland) [013/RID/2018/19]; Medical Research Council (MRC, UK) Molecular Haematology Unit (MHU) grant [MC_UU_00016/6]; Engineering and Physical Sciences Research Council (EPSRC) [2119788, EP/R513295/1]	National Science Centre (Poland)(National Science Centre, Poland); Ministry of Education and Science (Poland)(Ministry of Science and Higher Education, Poland); Medical Research Council (MRC, UK) Molecular Haematology Unit (MHU) grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council (EPSRC)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by the National Science Centre (Poland) grants: 2015/18/E/NZ5/00723 (MF), 2018/31/N/NZ5/01438 (KF), 2019/32/T/NZ5/00241 (KF), and by the Ministry of Education and Science (Poland) within "Regional Initiative of Excellence" program 013/RID/2018/19 (JG), project budget 12 000 000 PLN. TAM, NTC, and JRH are supported by Medical Research Council (MRC, UK) Molecular Haematology Unit (MHU) grant MC_UU_00016/6 and Engineering and Physical Sciences Research Council (EPSRC) Doctoral Training Program grant project reference 2119788 and EP/R513295/1. We gratefully acknowledge Prof Meinrad Busslinger who kindly provided GFP+ OP9 cells for the co-culture studies. We would also like to acknowledge methodological support in co-culture studies and PDXs generation provided by the researchers from Newcastle University, Prof Olaf Heidenreich (currently Princess Maxima Center, Utrecht, the Netherlands), Dr Deepali Pal, and Dr Helen Blair. We thank for the technical support provided by Elzbieta Gutkowska, Ewa Chmiel, Ewa Pieta, Magdalena Dlugolecka from the Department of Immunology at Medical University of Warsaw. We would also like to thank all patients, their parents and staff from Central Clinical Hospital of the Medical University of Lodz, and from the Institute of Hematology and Transfusion Medicine in Warsaw. We also acknowledge Dr Maksymilian Bielecki from SWPS University of Social Sciences and Humanities for advising in statistical analyses.	Agirre X, 2003, MOL CARCINOGEN, V38, P201, DOI 10.1002/mc.10159; Alford SE, 2015, CANCER RES, V75, P1366, DOI 10.1158/0008-5472.CAN-14-1849; Anderson MA, 2016, BLOOD, V127, P3215, DOI 10.1182/blood-2016-01-688796; Benito JM, 2015, CELL REP, V13, P2715, DOI 10.1016/j.celrep.2015.12.003; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bhatt S, 2020, CANCER CELL, V38, P872, DOI 10.1016/j.ccell.2020.10.010; Biswas D, 2011, P NATL ACAD SCI USA, V108, P15751, DOI 10.1073/pnas.1111498108; Bohler S, 2021, HAEMATOLOGICA, V106, P3136, DOI 10.3324/haematol.2020.252130; Chen HC, 2015, NAT CELL BIOL, V17, P1270, DOI 10.1038/ncb3236; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cox AG, 2008, BIOCHEM PHARMACOL, V76, P1097, DOI 10.1016/j.bcp.2008.08.021; Czabotar PE, 2007, P NATL ACAD SCI USA, V104, P6217, DOI 10.1073/pnas.0701297104; Deregowska A, 2020, GENES-BASEL, V11, DOI 10.3390/genes11101145; Diaz-Flores E, 2019, CANCER RES, V79, P2339, DOI 10.1158/0008-5472.CAN-18-0236; Fidyt K, 2019, MOL ONCOL, V13, P1180, DOI 10.1002/1878-0261.12476; Fischer U, 2015, NAT GENET, V47, P1020, DOI 10.1038/ng.3362; Frismantas V, 2017, BLOOD, V129, pE26, DOI 10.1182/blood-2016-09-738070; Gibson CJ, 2015, CLIN CANCER RES, V21, P5021, DOI 10.1158/1078-0432.CCR-15-0364; Gomez-Bougie P, 2011, BIOCHEM BIOPH RES CO, V413, P460, DOI 10.1016/j.bbrc.2011.08.118; Herling CD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03170-7; Jain P, 2020, AM J HEMATOL, V95, P623, DOI 10.1002/ajh.25796; Jin S, 2020, CLIN CANCER RES, V26, P3371, DOI 10.1158/1078-0432.CCR-19-1900; Khaw SL, 2016, BLOOD, V128, P1382, DOI 10.1182/blood-2016-03-707414; Leonard JT, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1583.1583; Li BS, 2020, BLOOD, V135, P41, DOI 10.1182/blood.2019002220; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Liu NN, 2014, ONCOTARGET, V5, P5453, DOI 10.18632/oncotarget.2113; Lukashchuk N, 2007, MOL CELL BIOL, V27, P8284, DOI 10.1128/MCB.00050-07; Maji S, 2018, ADV CANCER RES, V137, P37, DOI 10.1016/bs.acr.2017.11.001; Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213; Milne TA, 2005, CANCER RES, V65, P11367, DOI 10.1158/0008-5472.CAN-05-1041; MIYASHITA T, 1992, CANCER RES, V52, P5407; Moujalled DM, 2020, BLOOD ADV, V4, P2762, DOI 10.1182/bloodadvances.2019001416; Moujalled DM, 2019, LEUKEMIA, V33, P905, DOI 10.1038/s41375-018-0261-3; Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514; Nechiporuk T, 2019, CANCER DISCOV, V9, P910, DOI 10.1158/2159-8290.CD-19-0125; Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Pal D, 2016, LEUKEMIA, V30, P1691, DOI 10.1038/leu.2016.79; Pang XM, 2014, J BIOL CHEM, V289, P17802, DOI 10.1074/jbc.M114.548172; Pollyea DA, 2021, AM J HEMATOL, V96, P208, DOI 10.1002/ajh.26039; Radenkovic F, 2017, BIOCHEM PHARMACOL, V146, P42, DOI 10.1016/j.bcp.2017.09.009; Ramsey HE, 2018, CANCER DISCOV, V8, P1566, DOI 10.1158/2159-8290.CD-18-0140; Richmond J, 2015, CLIN CANCER RES, V21, P1395, DOI 10.1158/1078-0432.CCR-14-2300; Rigobello MP, 2005, FREE RADICAL RES, V39, P687, DOI 10.1080/10715760500135391; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Scherr M, 2019, LEUKEMIA, V33, P1313, DOI 10.1038/s41375-018-0315-6; Seyfried F, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1801-0; Seyfried F, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1081.1081; Stengel A, 2014, BLOOD, V124, P251, DOI 10.1182/blood-2014-02-558833; Thijssen R, 2021, BLOOD, V137, P2721, DOI 10.1182/blood.2020010167; Trino S, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00491; Wang J, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0259-8; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Yokoyama A, 2010, CANCER CELL, V17, P198, DOI 10.1016/j.ccr.2009.12.040; Zeisig DT, 2005, ONCOGENE, V24, P5525, DOI 10.1038/sj.onc.1208699	58	2	2	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1600	1609		10.1038/s41388-022-02196-y	http://dx.doi.org/10.1038/s41388-022-02196-y		JAN 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35091682	hybrid, Green Published			2022-12-17	WOS:000749073300001
J	Li, J; Zheng, CM; Wang, MS; Umano, AD; Dai, QY; Zhang, CY; Huang, H; Yang, Q; Yang, XZ; Lu, JY; Pan, WF; Li, B; Yao, SZ; Pan, CY				Li, Jie; Zheng, Cuimiao; Wang, Mingshuo; Umano, Anna D.; Dai, Qingyuan; Zhang, Chunyu; Huang, Hua; Yang, Qing; Yang, Xianzhi; Lu, Jingyi; Pan, Wenfeng; Li, Bo; Yao, Shuzhong; Pan, Chaoyun			ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer	ONCOGENE			English	Article							KINASE-II; ACTIVATION; PROTEIN	Platinum resistance accounts for much of the high mortality and morbidity associated with ovarian cancer. Identification of targets with significant clinical translational potential remains an unmet challenge. Through a high-throughput synthetical lethal screening for clinically relevant targets using 290 kinase inhibitors, we identify calcium/calmodulin-dependent protein kinase II gamma (CAMK2G) as a critical vulnerability in cisplatin-resistant ovarian cancer cells. Pharmacologic inhibition of CAMK2G significantly sensitizes ovarian cancer cells to cisplatin treatment in vitro and in vivo. Mechanistically, CAMK2G directly senses ROS, both basal and cisplatin-induced, to control the phosphorylation of ITPKB at serine 174, which directly regulates ITPKB activity to modulate cisplatin-induced ROS stress. Thereby, CAMK2G facilitates the adaptive redox homeostasis upon cisplatin treatment and drives cisplatin resistance. Clinically, upregulation of CAMK2G activity and ITPKB pS174 correlates with cisplatin resistance in human ovarian cancers. This study reveals a key kinase network consisting of CAMK2G and ITPKB for ROS sense and scavenging in ovarian cancer cells to maintain redox homeostasis, offering a potential strategy for cisplatin resistance treatment.	[Li, Jie; Zhang, Chunyu; Huang, Hua; Yao, Shuzhong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Guangzhou 510080, Peoples R China; [Zheng, Cuimiao; Wang, Mingshuo; Dai, Qingyuan; Yang, Qing; Yang, Xianzhi; Lu, Jingyi; Pan, Wenfeng; Li, Bo; Pan, Chaoyun] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem & Mol Biol, Guangzhou 510080, Peoples R China; [Zheng, Cuimiao; Li, Bo; Pan, Chaoyun] Sun Yat Sen Univ, Affiliated Hosp 1, Adv Med Technol Ctr, Zhongshan Sch Med, Guangzhou 510080, Peoples R China; [Umano, Anna D.] Duke Univ, Dept Microbiol & Mol Genet, Sch Med, Durham, NC 27708 USA	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Duke University	Pan, CY (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem & Mol Biol, Guangzhou 510080, Peoples R China.; Pan, CY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Adv Med Technol Ctr, Zhongshan Sch Med, Guangzhou 510080, Peoples R China.	panchy27@mail.sysu.edu.cn	Yang, Xian/GVU-9087-2022; Zhang, Chun-yu/HDP-5776-2022	Zheng, Cuimiao/0000-0002-1177-0575; Yao, Shuzhong/0000-0002-5145-5705	National Natural Science Foundation of China [82003194, 82073074]; Guangdong Basic and Applied Basic Research Foundation [2021A1515012446]; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation [2020B1212060018]; 2019 AACR Anna D. Barker Basic Cancer Research Fellowship	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation; 2019 AACR Anna D. Barker Basic Cancer Research Fellowship	This work was supported by the grants from the National Natural Science Foundation of China 82003194 (CP) and 82073074 (BL), Guangdong Basic and Applied Basic Research Foundation 2021A1515012446 (CP), Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation 2020B1212060018 (CP), and 2019 AACR Anna D. Barker Basic Cancer Research Fellowship (CP).	Bhullar KS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0804-2; Chen D, 2019, CANCER DISCOV, V9, P756, DOI 10.1158/2159-8290.CD-18-1040; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gu Y, 2017, CANCER CELL, V32, P115, DOI 10.1016/j.ccell.2017.06.001; He YJ, 2018, NATURE, V563, P522, DOI 10.1038/s41586-018-0670-5; Hegyi B, 2021, CIRC RES, V129, P98, DOI 10.1161/CIRCRESAHA.120.318402; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Holmes D, 2015, NATURE, V527, pS217, DOI 10.1038/527S217a; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Ishida S, 2010, CANCER CELL, V17, P574, DOI 10.1016/j.ccr.2010.04.011; Jemal A., 2019, CA-CANCER J CLIN, V69, P7, DOI [DOI 10.3322/caac.21551, DOI 10.3322/CAAC.21551]; Jin LT, 2018, CANCER CELL, V34, P315, DOI 10.1016/j.ccell.2018.06.012; Li J, 2020, CLIN CANCER RES, V26, P3843, DOI 10.1158/1078-0432.CCR-19-3790; Liu D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03590-5; Liu XJ, 2021, CIRCULATION, V143, P1894, DOI 10.1161/CIRCULATIONAHA.120.048698; Marechal Y, 2011, IMMUNOBIOLOGY, V216, P103, DOI 10.1016/j.imbio.2010.03.012; Miller AT, 2009, J IMMUNOL, V182, P4696, DOI 10.4049/jimmunol.0802850; Nassal D, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00035; Pan CY, 2019, J CLIN INVEST, V129, P2431, DOI 10.1172/JCI124550; Pellicena P, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00021; Pouillon V, 2003, NAT IMMUNOL, V4, P1136, DOI 10.1038/ni980; Sanij E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16393-4; Schroyer AL, 2018, ONCOGENE, V37, P1031, DOI 10.1038/onc.2017.396; Wen CY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2035-x; Wojtaszek JL, 2019, CELL, V178, P152, DOI 10.1016/j.cell.2019.05.028; Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013	28	2	2	4	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1114	1128		10.1038/s41388-021-02149-x	http://dx.doi.org/10.1038/s41388-021-02149-x		JAN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35039634				2022-12-17	WOS:000743422300001
J	Chiavarina, B; Ronca, R; Otaka, Y; Sutton, RB; Rezzola, S; Yokobori, T; Chiodelli, P; Souche, R; Pourquier, D; Maraver, A; Faa, G; Khellaf, L; Turtoi, E; Oyama, T; Gofflot, S; Bellahcene, A; Detry, O; Delvenne, P; Castronovo, V; Nishiyama, M; Turtoi, A				Chiavarina, Barbara; Ronca, Roberto; Otaka, Yukihiro; Sutton, Roger Bryan; Rezzola, Sara; Yokobori, Takehiko; Chiodelli, Paola; Souche, Regis; Pourquier, Didier; Maraver, Antonio; Faa, Gavino; Khellaf, Lakhdar; Turtoi, Evgenia; Oyama, Tetsunari; Gofflot, Stephanie; Bellahcene, Akeila; Detry, Olivier; Delvenne, Philippe; Castronovo, Vincent; Nishiyama, Masahiko; Turtoi, Andrei			Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma	ONCOGENE			English	Article							CANCER-ASSOCIATED FIBROBLASTS; SARCOMA-VIRUS; CELLS; HETEROGENEITY; EXPRESSION; SORAFENIB; INHIBITOR; TARGETS; PROTEIN; VEGF	Cancer-associated fibroblasts (CAF) are important constituents of the tumor microenvironment (TME) and are major drivers of tumorigenesis. Yet, therapies aiming at eliminating CAF have failed to cure patients. This setback has raised questions regarding whether CAF exclusively favour cancer progression, or if they may also assume tumor-suppressor functions. In the present study, we used proteomics and single cell RNA-sequencing analysis to examine the CAF landscape in hepatocellular carcinoma (HCC). We thereby unveil three major CAF populations in HCC, one of which specifically expressing the prolargin protein. This CAF subpopulation (further termed as CAF_Port) shared a strong transcriptomic signature with portal liver fibroblasts. We further show that CAF_Port deposit prolargin in the TME and that its levels are lower in tumors as compared to the peritumoral region. Mechanistically, aggressive cancer cells degraded prolargin using matrix metalloprotease activity. Survival analysis of 188 patients revealed that high prolargin protein levels correlate with good patient outcome (HR = 0.37; p = 0.01). In vivo, co-injection of cancer cells with fibroblasts silenced for prolargin, led to faster tumor development (5-fold; p = 0.01), mainly due to stronger angiogenesis. Using protein-protein interaction study and structural modelling, we further demonstrate that prolargin binds and inhibits the activity of several pro-agiogenic proteins, including hepatocyte and fibroblast growth factors. In conclusion, prolargin is angiogenesis modulator and CAF-derived tumor suppressor in HCC. Stabilizing prolargin levels in the CAF_Port subpopulation may revert their tumor-antagonizing properties, warranting exploration in further pre-clinical studies.	[Chiavarina, Barbara; Souche, Regis; Pourquier, Didier; Turtoi, Evgenia; Turtoi, Andrei] INSERM, Tumor Microenvironm & Resistance Treatment Lab, Inst Rech Cancerol Montpellier, U1194, Montpellier, France; [Chiavarina, Barbara; Souche, Regis; Maraver, Antonio; Turtoi, Evgenia; Turtoi, Andrei] Univ Montpellier, Montpellier, France; [Chiavarina, Barbara; Souche, Regis; Pourquier, Didier; Maraver, Antonio; Khellaf, Lakhdar; Turtoi, Evgenia; Turtoi, Andrei] Inst Reg Canc Montpellier ICM Val dAurelle, Montpellier, France; [Ronca, Roberto; Rezzola, Sara; Chiodelli, Paola] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Otaka, Yukihiro; Nishiyama, Masahiko] Gunma Univ, Dept Mol Pharmacol & Oncol, Grad Sch Med, Gunma, Japan; [Otaka, Yukihiro; Yokobori, Takehiko; Nishiyama, Masahiko; Turtoi, Andrei] Gunma Univ Initiat Adv Res GIAR, Gunma, Japan; [Sutton, Roger Bryan] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Physiol & Mol Biophys, Lubbock, TX 79430 USA; [Yokobori, Takehiko] Gunma Univ Maebashi, Grad Sch Med, Dept Gen Surg Sci, Gunma, Japan; [Maraver, Antonio] INSERM, Oncogen Pathways Lung Canc Lab, Inst Rech Cancerol Montpellier, U1194, Montpellier, France; [Faa, Gavino] Univ Cagliari, Univ Hosp San Giovanni Dio AOU Cagliari, Dept Pathol, Cagliari, Italy; [Oyama, Tetsunari] Gunma Univ, Grad Sch Med, Dept Diagnost Pathol, Maebashi, Gumma, Japan; [Gofflot, Stephanie] Univ Liege, BIOTHEQUE, Liege, Belgium; [Bellahcene, Akeila; Castronovo, Vincent] Univ Liege, Metastasis Res Lab, GIGA Canc, Liege, Belgium; [Detry, Olivier] Univ Liege, Univ Hosp, Dept Abdominal Surg, Liege, Belgium; [Delvenne, Philippe] Univ Liege, Univ Hosp, Dept Pathol, Liege, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); University of Brescia; Gunma University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Cagliari; Gunma University; University of Liege; University of Liege; University of Liege; University of Liege	Chiavarina, B; Turtoi, A (corresponding author), INSERM, Tumor Microenvironm & Resistance Treatment Lab, Inst Rech Cancerol Montpellier, U1194, Montpellier, France.; Chiavarina, B; Turtoi, A (corresponding author), Univ Montpellier, Montpellier, France.; Chiavarina, B; Turtoi, A (corresponding author), Inst Reg Canc Montpellier ICM Val dAurelle, Montpellier, France.; Turtoi, A (corresponding author), Gunma Univ Initiat Adv Res GIAR, Gunma, Japan.	barbara.chiavarina@inserm.fr; andrei.turtoi@inserm.fr	Detry, Olivier/I-9333-2019; Ronca, Roberto/AAC-6470-2022	Detry, Olivier/0000-0002-9436-6673; Ronca, Roberto/0000-0001-8979-7068; Otaka, Yukihiro/0000-0002-9162-7188; Chiavarina, Barbara/0000-0003-1444-174X; Turtoi, Andrei/0000-0003-3813-6635; Maraver, Antonio/0000-0002-5527-5680	University of Liege; National Fund for Scientific Research (FNRS); Gunma University (GIAR Research Program for Omics-Based Medical Science); Fondation de France grant [00078461]; Associazione Italiana per la Ricerca sul Cancro (AIRC) [MFAG 18459, 23151]; Fondazione Umberto Veronesi fellowship; LabEx MabImprove Starting Grant; Fondation Contre le Cancer	University of Liege(University of Liege); National Fund for Scientific Research (FNRS)(Fonds de la Recherche Scientifique - FNRS); Gunma University (GIAR Research Program for Omics-Based Medical Science); Fondation de France grant; Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Umberto Veronesi fellowship(Fondazione Umberto Veronesi); LabEx MabImprove Starting Grant; Fondation Contre le Cancer	The authors acknowledge the experimental support of Naima Maloujahmoum (Metastasis Research Laboratory, University of Liege), Susumu Rokudai (Department of Molecular Pharmacology and Oncology, Gunma University), and Tadashi Handa (Pathology Dept. Gunma University). The authors are particularly thankful to Arnaud Blomme (Metastasis Research Laboratory, University of Liege) and Touko Hirano (Laboratory for Analytical Instruments, Gunma University Graduate School of Medicine) for the help concerning the MS analysis of patient material. The authors thank the Small Animal Imaging Platform of Montpellier (IPAM, http://www.ipam.cnrs.fr/) for the help with animal experiments. AT is thankful to Jacques Colinge (Bioinformatics and Systems Biology group, IRCM, Montpellier) for his R teachings and to Peter Friedl (The University of Texas MD Anderson Cancer Center, Houston, Texas, USA) for the helpful discussions. This work was supported with grants from the University of Liege, National Fund for Scientific Research (FNRS), Gunma University (GIAR Research Program for Omics-Based Medical Science). BC is supported by a Fondation de France grant (No. 00078461). RR is supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), grant number MFAG 18459 and IG 2019 -ID. 23151; SR is supported by Fondazione Umberto Veronesi fellowship. AT is a senior research fellow of the French National Institute of Health and Medical Research (INSERM) and is supported by LabEx MabImprove Starting Grant. OD is supported by a grant from the "Fondation Contre le Cancer". No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the paper.	Adnane L, 2006, METHOD ENZYMOL, V407, P597, DOI 10.1016/S0076-6879(05)07047-3; Altekruse SF, 2009, J CLIN ONCOL, V27, P1485, DOI 10.1200/JCO.2008.20.7753; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Cabello-Aguilar S, 2020, NUCLEIC ACIDS RES, V48, DOI 10.1093/nar/gkaa183; Catenacci DVT, 2015, J CLIN ONCOL, V33, P4284, DOI 10.1200/JCO.2015.62.8719; Chang PH, 2012, CANCER RES, V72, P4652, DOI 10.1158/0008-5472.CAN-12-0877; Chiavarina B, 2017, CURR MED CHEM, V24, P2846, DOI 10.2174/0929867324666170428104311; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; DeFilippis RA, 2012, CANCER DISCOV, V2, P826, DOI 10.1158/2159-8290.CD-12-0107; Dobie R, 2019, CELL REP, V29, P1832, DOI 10.1016/j.celrep.2019.10.024; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fields GB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01278; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Guo DJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03032-0; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Li HP, 2017, NAT GENET, V49, P708, DOI 10.1038/ng.3818; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Ma LC, 2019, CANCER CELL, V36, P418, DOI 10.1016/j.ccell.2019.08.007; Maris P, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001871; Morse MA, 2019, CLIN CANCER RES, V25, P912, DOI 10.1158/1078-0432.CCR-18-1254; Neill T, 2012, AM J PATHOL, V181, P380, DOI 10.1016/j.ajpath.2012.04.029; Nwosu ZC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0872-6; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Orimo A, 2007, CANCER BIOL THER, V6, P618, DOI 10.4161/cbt.6.4.4255; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ramisch S, 2014, P NATL ACAD SCI USA, V111, P17875, DOI 10.1073/pnas.1413638111; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Ronca R, 2018, CURR OPIN ONCOL, V30, P45, DOI 10.1097/CCO.0000000000000420; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Turtoi A, 2011, J PROTEOME RES, V10, P3160, DOI 10.1021/pr200212r; Turtoi A, 2011, AM J PATHOL, V178, P12, DOI 10.1016/j.ajpath.2010.08.004; Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559; Waltregny D, 1998, J NATL CANCER I, V90, P1000, DOI 10.1093/jnci/90.13.1000; Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013; Winer A, 2018, MOL CANCER THER, V17, P1147, DOI 10.1158/1535-7163.MCT-17-0646	45	2	2	5	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1410	1420		10.1038/s41388-021-02171-z	http://dx.doi.org/10.1038/s41388-021-02171-z		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35031773				2022-12-17	WOS:000742613600003
J	Aponte, E; Lafitte, M; Sirvent, A; Simon, V; Barbery, M; Fourgous, E; Maffei, M; Armand, F; Hamelin, R; Pannequin, J; Fort, P; Pons, M; Roche, S; Boublik, Y				Aponte, Emilie; Lafitte, Marie; Sirvent, Audrey; Simon, Valerie; Barbery, Maud; Fourgous, Elise; Maffei, Mariano; Armand, Florence; Hamelin, Romain; Pannequin, Julie; Fort, Philippe; Pons, Miquel; Roche, Serge; Boublik, Yvan			Regulation of Src tumor activity by its N-terminal intrinsically disordered region	ONCOGENE			English	Article							TYROSINE KINASES; UNIQUE DOMAIN; FAMILY; CELL; PHOSPHORYLATION; DIMERIZATION; REQUIREMENT; SEQUENCE; REVEALS; BINDING	The membrane-anchored Src tyrosine kinase is involved in numerous pathways and its deregulation is involved in human cancer. Our knowledge on Src regulation relies on crystallography, which revealed intramolecular interactions to control active Src conformations. However, Src contains a N-terminal intrinsically disordered unique domain (UD) whose function remains unclear. Using NMR, we reported that UD forms an intramolecular fuzzy complex involving a conserved region with lipid-binding capacity named Unique Lipid-Binding Region (ULBR), which could modulate Src membrane anchoring. Here we show that the ULBR is essential for Src's oncogenic capacity. ULBR inactive mutations inhibited Src transforming activity in NIH3T3 cells and in human colon cancer cells. It also reduced Src-induced tumor development in nude mice. An intact ULBR was required for MAPK signaling without affecting Src kinase activity nor sub-cellular localization. Phospho-proteomic analyses revealed that, while not impacting on the global tyrosine phospho-proteome in colon cancer cells, this region modulates phosphorylation of specific membrane-localized tyrosine kinases needed for Src oncogenic signaling, including EPHA2 and Fyn. Collectively, this study reveals an important role of this intrinsically disordered region in malignant cell transformation and suggests a novel layer of Src regulation by this unique region via membrane substrate phosphorylation.	[Aponte, Emilie; Lafitte, Marie; Sirvent, Audrey; Simon, Valerie; Barbery, Maud; Fourgous, Elise; Fort, Philippe; Roche, Serge; Boublik, Yvan] Univ Montpellier, CNRS, CRBM, F-34000 Montpellier, France; [Aponte, Emilie; Lafitte, Marie; Sirvent, Audrey; Simon, Valerie; Barbery, Maud; Fourgous, Elise; Roche, Serge; Boublik, Yvan] Univ Montpellier, CNRS, CRBM, Equipe Labellisee Ligue Canc, F-34000 Montpellier, France; [Maffei, Mariano; Pons, Miquel] Univ Barcelona, Dept Inorgan & Organ Chem, Biomol NMR Lab, Baldiri Reixac 10-12, Barcelona 08028, Spain; [Maffei, Mariano] Evvivax Srl, Via Castel Romano 100, I-00128 Rome, Italy; [Armand, Florence; Hamelin, Romain] Ecole Polytech Fed Lausanne EPFL, Sch Life Sci, Prote Core Facil, CH-1015 Lausanne, Switzerland; [Pannequin, Julie; Roche, Serge] Univ Montpellier, CNRS, IGF, F-34000 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Barcelona; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Roche, S (corresponding author), Univ Montpellier, CNRS, CRBM, F-34000 Montpellier, France.; Roche, S (corresponding author), Univ Montpellier, CNRS, CRBM, Equipe Labellisee Ligue Canc, F-34000 Montpellier, France.; Pons, M (corresponding author), Univ Barcelona, Dept Inorgan & Organ Chem, Biomol NMR Lab, Baldiri Reixac 10-12, Barcelona 08028, Spain.; Roche, S (corresponding author), Univ Montpellier, CNRS, IGF, F-34000 Montpellier, France.	mpons@ub.edu; serge.roche@crbm.cnrs.fr	Maffei, Mariano/AAD-3508-2021	roche, serge/0000-0003-3413-3859; Maffei, Mariano/0000-0003-0909-4886	Fundacio Marato de TV3; Spanish Ministry of Science and Innovation [PID2019-104914RB-I00]; La Ligue Nationale Contre le Cancer (LNCC); Montpellier SIRIC Grant [INCa-DGOS-Inserm 6045]; ANR; CNRS; University of Montpellier; SIRIC Montpellier Cancer Grant [INCa_Inserm_DGOS_12553]; Fondation pour la Recherche Medicale (FRM); Fondation de France; european regional development foundation; occitanian region (FEDER-FSE 2014-2020 Languedoc Roussillon)	Fundacio Marato de TV3; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); La Ligue Nationale Contre le Cancer (LNCC); Montpellier SIRIC Grant; ANR(French National Research Agency (ANR)); CNRS(Centre National de la Recherche Scientifique (CNRS)); University of Montpellier; SIRIC Montpellier Cancer Grant; Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Fondation de France(Fondation de France); european regional development foundation; occitanian region (FEDER-FSE 2014-2020 Languedoc Roussillon)	We thank the Montpellier RIO Imaging and RHEM platforms for imaging and immunohistochemistry analyses, and the Proteomic Core Platform of EPFL for proteomic analyses. This work was supported by Fundacio Marato de TV3, Spanish Ministry of Science and Innovation (project PID2019-104914RB-I00), La Ligue Nationale Contre le Cancer (LNCC), Montpellier SIRIC Grant "INCa-DGOS-Inserm 6045", ANR, CNRS, and the University of Montpellier. RHEM facility supported by SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553, the european regional development foundation and the occitanian region (FEDER-FSE 2014-2020 Languedoc Roussillon), IBiSA and Ligue contre le cancer for processing our animal tissues and histology technics. ML is supported by the Fondation pour la Recherche Medicale (FRM) and the Fondation de France. SR is an INSERM investigator.	Amata I, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00181; Amata I, 2013, CHEMBIOCHEM, V14, P1820, DOI 10.1002/cbic.201300139; Arbesu M, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00039; Arbesu M, 2017, STRUCTURE, V25, P630, DOI 10.1016/j.str.2017.02.011; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; Eide CA, 2019, CANCER CELL, V36, P431, DOI 10.1016/j.ccell.2019.08.004; Fuxreiter M, 2012, MOL BIOSYST, V8, P168, DOI 10.1039/c1mb05234a; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Jeitany M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201707918; Kashiwagi K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16872-7; Kato G, 2019, ENEURO, V6, DOI 10.1523/ENEURO.0418-18.2019; Katoh Kazutaka, 2013, Mol Biol Evol, V30, P772, DOI 10.1093/molbev/mst010; Kerjouan A, 2021, J CELL SCI, V134, DOI 10.1242/jcs.254599; Kim PW, 2003, SCIENCE, V301, P1725, DOI 10.1126/science.1085643; Le Roux AL, 2019, ISCIENCE, V12, P194, DOI 10.1016/j.isci.2019.01.010; Le Roux AL, 2016, CHEMISTRYSELECT, V1, P642, DOI 10.1002/slct.201600117; Le Roux AL, 2016, COLLOID SURFACE B, V138, P17, DOI 10.1016/j.colsurfb.2015.11.013; Lecointre C, 2018, STRUCTURE, V26, P545, DOI 10.1016/j.str.2018.01.017; Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354; Maffei M, 2015, STRUCTURE, V23, P893, DOI 10.1016/j.str.2015.03.009; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Naudin C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4159; Perez Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep01295; Perez Y, 2009, J MOL BIOL, V391, P136, DOI 10.1016/j.jmb.2009.06.018; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Sirvent A, 2010, ONCOGENE, V29, P1303, DOI 10.1038/onc.2009.450; Sirvent A, 2020, CANCERS, V12, DOI 10.3390/cancers12082014; Sirvent A, 2012, MOL CELL PROTEOMICS, V11, P1937, DOI 10.1074/mcp.M112.018168; Sirvent A, 2012, AM J CANCER RES, V2, P357; Spassov DS, 2018, CELL REP, V25, P449, DOI 10.1016/j.celrep.2018.09.035; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Teixeira JMC, 2018, MOLECULES, V23, DOI 10.3390/molecules23112731; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Veracini L, 2006, J CELL SCI, V119, P2921, DOI 10.1242/jcs.03015; Wright PE, 2015, NAT REV MOL CELL BIO, V16, P18, DOI 10.1038/nrm3920; Yang ZH, 2007, MOL BIOL EVOL, V24, P1586, DOI 10.1093/molbev/msm088; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	42	2	2	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					960	970		10.1038/s41388-021-02092-x	http://dx.doi.org/10.1038/s41388-021-02092-x		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34999732	Green Published, hybrid, Green Submitted			2022-12-17	WOS:000740423400002
J	Cho, HC; Huang, YL; Hung, JT; Hung, TH; Cheng, KC; Liu, YH; Kuo, MW; Wang, SH; Yu, AL; Yu, J				Cho, Huan-Chieh; Huang, Yenlin; Hung, Jung-Tung; Hung, Tsai-Hsien; Cheng, Kai-Chun; Liu, Yun-Hen; Kuo, Ming-Wei; Wang, Sheng-Hung; Yu, Alice L.; Yu, John			Puf-A promotes cancer progression by interacting with nucleophosmin in nucleolus	ONCOGENE			English	Article							CELL-CYCLE; TRANSCRIPTION FACTOR; RIBOSOME BIOGENESIS; BINDING-SITE; LUNG-CANCER; P53; TARGET; EXPRESSION; PROLIFERATION; RECOGNITION	Previously, we identified Puf-A as a novel member of Puf-family RNA-binding proteins; however, its biological functions remain obscure. Analysis of tumor samples of non-small cell lung cancer (NSCLC) showed that high Puf-A expression correlated with high histology grade and abnormal p53 status. Kaplan-Meier curve for overall survival revealed high expression of Puf-A to predict poor prognosis in stage I NSCLC. Among patients with colorectal cancer, high Puf-A expression also showed an adverse impact on overall survival. In lung cancer cell lines, downregulation of p53 increased Puf-A expression, and upregulation of p53 dampened its expression. However, luciferase reporter assays indicated that PUF-A locus harbored the p53-response element, but regulated Puf-A transcription indirectly. In vivo suppression of p53 in CCSP-rtTA/TetO-Cre/LSL-Kras(G12D)/p53(flox/flox) conditional mutant mice accelerated the progression of the Kras(G12D)-driven lung cancer, along with enhanced expression of Puf-A. Importantly, intranasal delivery of shPuf-A to the inducible Kras(G12D)/p53(flox/flox) mice suppressed tumor progression. Puf-A silencing led to marked decreases in the 80S ribosomes, along with decrease in S6 and L5 in the cytoplasm and accumulation in the nucleolus. Based on immunofluorescence staining and immunoprecipitation studies, Puf-A interacted with NPM1 in nucleolus. Puf-A silencing resulted in NPM1 translocation from nucleolus to nucleoplasm and this disruption of NPM1 localization was reversed by a rescue experiment. Mechanistically, Puf-A silencing altered NPM1 localization, leading to the retention of ribosomal proteins in nucleolus and diminished ribosome biogenesis, followed by cell-cycle arrest/cell death. Puf-A is a potential theranostic target for cancer therapy and an important player in cancer progression.	[Cho, Huan-Chieh; Huang, Yenlin; Hung, Jung-Tung; Hung, Tsai-Hsien; Cheng, Kai-Chun; Kuo, Ming-Wei; Wang, Sheng-Hung; Yu, Alice L.; Yu, John] Chang Gung Mem Hosp Linkou, Inst Stem Cell & Translat Canc Res, Taoyuan, Taiwan; [Huang, Yenlin] Chang Gung Mem Hosp Linkou, Dept Anat Pathol, Taoyuan, Taiwan; [Liu, Yun-Hen] Chang Gung Mem Hosp Linkou, Dept Surg, Taoyuan, Taiwan; [Yu, Alice L.] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Yu, Alice L.] Univ Calif San Diego, Med Ctr, Dept Pediat, San Diego, CA 92103 USA; [Yu, John] Acad Sinica, Inst Cellular & Organism Biol, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Academia Sinica - Taiwan; University of California System; University of California San Diego; Academia Sinica - Taiwan	Yu, J (corresponding author), Chang Gung Mem Hosp Linkou, Inst Stem Cell & Translat Canc Res, Taoyuan, Taiwan.	johnyu@gate.sinica.edu.tw		Yu, John/0000-0002-3237-4272	Ministry of Science and Technology of Taiwan [MOST 106-3114-B-182A-001, MOST 107-2321-B-182A-005, MOST 108-2321-B-182A-004, MOST 109-2321-B-182A-005]; CGMH at Linkou of Taiwan [CMRPG3H1342, OMRPG3C0047-OMRPG3C0048, CMRPG3J0311-CMRPG3J0313]; CGMH fellowship	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); CGMH at Linkou of Taiwan; CGMH fellowship	This work was supported by Ministry of Science and Technology of Taiwan (MOST 106-3114-B-182A-001, MOST 107-2321-B-182A-005, MOST 108-2321-B-182A-004, and MOST 109-2321-B-182A-005); and CGMH at Linkou of Taiwan (CMRPG3H1342, OMRPG3C0047-OMRPG3C0048 to JY and CMRPG3J0311-CMRPG3J0313 to JTH). HCC is a recipient of CGMH fellowship.	Ando K, 2017, J CELL BIOL, V216, P1795, DOI 10.1083/jcb.201608095; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Bursac S, 2014, BBA-MOL BASIS DIS, V1842, P817, DOI 10.1016/j.bbadis.2013.08.014; Chang HY, 2011, CANCER RES, V71, P1126, DOI 10.1158/0008-5472.CAN-10-1831; Chen SY, 2018, J DRUG TARGET, V26, P27, DOI 10.1080/1061186X.2017.1332066; Cho HC, 2011, CANCER RES, V71, P7250, DOI 10.1158/0008-5472.CAN-11-0903; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Dez C, 2004, CURR OPIN MICROBIOL, V7, P631, DOI 10.1016/j.mib.2004.10.007; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fan CC, 2013, TUMOR BIOL, V34, P2557, DOI 10.1007/s13277-013-0801-4; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Fischer M, 2016, CELL CYCLE, V15, P2852, DOI 10.1080/15384101.2016.1205393; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P164, DOI 10.1093/nar/gkv927; Fischer M, 2015, ONCOTARGET, V6, P41402, DOI 10.18632/oncotarget.6356; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Golomb L, 2014, FEBS LETT, V588, P2571, DOI 10.1016/j.febslet.2014.04.014; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; Iqbal Nida, 2014, Mol Biol Int, V2014, P852748, DOI 10.1155/2014/852748; Ishibashi H, 2003, J CLIN ENDOCR METAB, V88, P2309, DOI 10.1210/jc.2002-021353; Jordan JJ, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000104; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kiankhooy A, 2014, ANN THORAC SURG, V98, P1175, DOI 10.1016/j.athoracsur.2014.05.061; Kreft L, 2017, NUCLEIC ACIDS RES, V45, pW490, DOI 10.1093/nar/gkx376; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuo MW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004980; Li SH, 2017, J ORAL PATHOL MED, V46, P175, DOI 10.1111/jop.12482; Li ZL, 2008, P NATL ACAD SCI USA, V105, P18794, DOI 10.1073/pnas.0806879105; Li ZH, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000213; Lindstrom MS, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/195209; Liu GY, 2017, J CELL BIOCHEM, V118, P4697, DOI 10.1002/jcb.26135; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Mitrea DM, 2016, ELIFE, V5, DOI 10.7554/eLife.13571; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Ponkratova D., 2020, BIOL B REV, V10, P266; Qiu C, 2014, P NATL ACAD SCI USA, V111, P18554, DOI 10.1073/pnas.1407634112; Rosorius O, 2000, J BIOL CHEM, V275, P12061, DOI 10.1074/jbc.275.16.12061; Sawazaki H, 2017, WORLD J UROL, V35, P1081, DOI 10.1007/s00345-016-1977-1; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; Sinn HP, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3111-1; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stepinski D, 2018, HISTOCHEM CELL BIOL, V150, P607, DOI 10.1007/s00418-018-1706-5; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang XQ, 2002, CELL, V110, P501, DOI 10.1016/S0092-8674(02)00873-5; Xie DY, 2014, ONCOL REP, V32, P2517, DOI 10.3892/or.2014.3538; Xie M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13280; Zhu CQ, 2014, TRANSL LUNG CANCER R, V3, P149, DOI 10.3978/j.issn.2218-6751.2014.06.09	51	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1155	1165		10.1038/s41388-021-02138-0	http://dx.doi.org/10.1038/s41388-021-02138-0		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	34999733	hybrid, Green Published			2022-12-17	WOS:000740423400001
J	Kwon, OJ; Zhang, BY; Jia, DY; Zhang, L; Wei, X; Zhou, ZC; Liu, DL; Huynh, KT; Zhang, K; Zhang, YQ; Labhart, P; Sboner, A; Barbieri, C; Haffner, MC; Creighton, CJ; Xin, L				Kwon, Oh-Joon; Zhang, Boyu; Jia, Deyong; Zhang, Li; Wei, Xing; Zhou, Zhicheng; Liu, Deli; Khoi Trung Huynh; Zhang, Kai; Zhang, Yiqun; Labhart, Paul; Sboner, Andrea; Barbieri, Chris; Haffner, Michael C.; Creighton, Chad J.; Xin, Li			Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130	ONCOGENE			English	Article							TO-LUMINAL DIFFERENTIATION; ANDROGEN-RECEPTOR; ACCELERATES INITIATION; CHRONIC INFLAMMATION; GENE-EXPRESSION; MOUSE MODEL; CANCER; HYPERPLASIA; TISSUE; PROGRESSION	Macrophages are increased in human benign prostatic hyperplasia and prostate cancer. We generate a Pb-Csf1 mouse model with prostate-specific overexpression of macrophage colony-stimulating factor (M-Csf/Csf1). Csf1 overexpression promotes immune cell infiltration into the prostate, modulates the macrophage polarity in a lobe-specific manner, and induces senescence and low-grade prostatic intraepithelial neoplasia (PIN). The Pb-Csf1 prostate luminal cells exhibit increased stem cell features and undergo an epithelial-to-mesenchymal transition. Human prostate cancer patients with high CSF-1 expression display similar transcriptional alterations with the Pb-Csf1 model. P53 knockout alleviates senescence but fails to progress PIN lesions. Ablating epithelial Gp130 but not Il1r1 substantially blocks PIN lesion formation. The androgen receptor (AR) is downregulated in Pb-Csf1 mice. ChIP-Seq analysis reveals altered AR binding in 2482 genes although there is no significant widespread change in global AR transcriptional activity. Collectively, our study demonstrates that increased macrophage infiltration causes PIN formation but fails to transform prostate cells.	[Kwon, Oh-Joon; Jia, Deyong; Zhang, Li; Wei, Xing; Zhou, Zhicheng; Zhang, Kai; Xin, Li] Univ Washington, Dept Urol, Seattle, WA 98109 USA; [Zhang, Boyu] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Liu, Deli; Sboner, Andrea; Barbieri, Chris] Weill Cornell Med, Sandra & Edward Meyer Canc Ctr, New York, NY USA; [Liu, Deli; Sboner, Andrea; Barbieri, Chris] Weill Cornell Med, Dept Urol, New York, NY USA; [Khoi Trung Huynh] Univ Washington, Dept Biol, Seattle, WA 98109 USA; [Zhang, Yiqun; Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Labhart, Paul] Act Motif, San Diego, CA USA; [Haffner, Michael C.] Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98109 USA; [Xin, Li] Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Baylor College of Medicine; Cornell University; Cornell University; University of Washington; University of Washington Seattle; Baylor College of Medicine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Xin, L (corresponding author), Univ Washington, Dept Urol, Seattle, WA 98109 USA.; Xin, L (corresponding author), Univ Washington, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA.	xin18@uw.edu	Jia, Deyong/GSJ-0327-2022; Jia, Deyong/GQP-9611-2022; Zhang, YiQun/HCI-2427-2022	Jia, Deyong/0000-0003-2034-0363; Kwon, Oh-Joon/0000-0001-9067-0240; Zhang, Yiqun/0000-0001-5058-5623	 [R01CA190378];  [R01DK092202];  [R01DK107436]	; ; 	We thank Dr. Fen Wang for the ARR2PB-Cre mice, Dr. Rodger McEver for the Gp130fl/fl mice, and Dr. Richard Stanley for the mouse Csf-1 cDNA. This work is supported by R01CA190378, R01DK092202 and R01DK107436 (L.X.).	Barron DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013751; Becerra-Diaz M, 2018, J IMMUNOL, V201, P2923, DOI 10.4049/jimmunol.1800352; Birbach A, 2011, NEOPLASIA, V13, P692, DOI 10.1593/neo.11524; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chen TS, 2000, CANCER RES, V60, P2132; Cioni B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18313-y; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Debelec-Butuner B, 2014, MOL CARCINOGEN, V53, P85, DOI 10.1002/mc.21948; Dennis LK, 2002, UROLOGY, V60, P78, DOI 10.1016/S0090-4295(02)01637-0; Elkahwaji JE, 2007, PROSTATE, V67, P14, DOI 10.1002/pros.20445; Endo Y, 2007, ONCOGENE, V26, P5587, DOI 10.1038/sj.onc.1210344; Fong L, 1997, J IMMUNOL, V159, P3113; Graham TR, 2010, BREAST CANCER RES TR, V123, P139, DOI 10.1007/s10549-009-0623-7; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gurel B, 2014, CANCER EPIDEM BIOMAR, V23, P847, DOI 10.1158/1055-9965.EPI-13-1126; Haverkamp JM, 2011, PROSTATE, V71, P1139, DOI 10.1002/pros.21327; Hewitt SC, 2012, MOL ENDOCRINOL, V26, P887, DOI 10.1210/me.2011-1311; Hmadcha A, 1999, J EXP MED, V190, P1595, DOI 10.1084/jem.190.11.1595; Husaini Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043833; Ide H, 2002, P NATL ACAD SCI USA, V99, P14404, DOI 10.1073/pnas.222537099; Jin RJ, 2008, CANCER RES, V68, P6762, DOI 10.1158/0008-5472.CAN-08-0107; Kazma R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051680; Khalili M, 2010, AM J PATHOL, V176, P2259, DOI 10.2353/ajpath.2010.080747; Kirma N, 2004, CANCER RES, V64, P4162, DOI 10.1158/0008-5472.CAN-03-2971; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Kumar V, 2017, CANCER CELL, V32, P654, DOI 10.1016/j.ccell.2017.10.005; Kwon OJ, 2016, STEM CELL RES, V16, P682, DOI 10.1016/j.scr.2016.04.009; Kwon OJ, 2014, P NATL ACAD SCI USA, V111, pE592, DOI 10.1073/pnas.1318157111; Leach DA, 2017, MOL CELL ENDOCRINOL, V439, P261, DOI 10.1016/j.mce.2016.09.010; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lissbrant IF, 2000, INT J ONCOL, V17, P445; Liu G, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0386-7; Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656; Maggio M, 2005, J Endocrinol Invest, V28, P116; Maggio M, 2006, J ANDROL, V27, P725, DOI 10.2164/jandrol.106.000141; Malinen M, 2017, NUCLEIC ACIDS RES, V45, P619, DOI 10.1093/nar/gkw855; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; ORMANDY CJ, 1992, INT J CANCER, V50, P777, DOI 10.1002/ijc.2910500519; Park JH, 2002, AM J PATHOL, V161, P727, DOI 10.1016/S0002-9440(10)64228-9; Platz EA, 2017, CANCER EPIDEM BIOMAR, V26, P1549, DOI 10.1158/1055-9965.EPI-17-0503; Schlomm T, 2016, EUR UROL, V69, P1157, DOI 10.1016/j.eururo.2016.02.024; Shinohara DB, 2013, PROSTATE, V73, P1007, DOI 10.1002/pros.22648; Simons BW, 2015, J PATHOL, V235, P478, DOI 10.1002/path.4472; Sorrentino C, 2011, CLIN CANCER RES, V17, P1571, DOI 10.1158/1078-0432.CCR-10-2804; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Stanley ER, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a021857; Strobel O, 2007, GASTROENTEROLOGY, V133, P1999, DOI 10.1053/j.gastro.2007.09.009; Traish A, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120549; Valdez JM, 2012, CELL STEM CELL, V11, P676, DOI 10.1016/j.stem.2012.07.003; Vignozzi L, 2012, J ENDOCRINOL, V214, P31, DOI 10.1530/JOE-12-0142; Vignozzi L, 2012, J ENDOCRINOL, V212, P71, DOI 10.1530/JOE-11-0289; Wang XH, 2012, J BIOL CHEM, V287, P18376, DOI 10.1074/jbc.M112.355164; Wang ZW, 2017, J PATHOL, V243, P457, DOI 10.1002/path.4985; Zhang BY, 2016, MOL CELL, V63, P976, DOI 10.1016/j.molcel.2016.07.025; Zhang LY, 2009, AM J PATHOL, V175, P489, DOI 10.2353/ajpath.2009.080727; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	60	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1309	1323		10.1038/s41388-021-02169-7	http://dx.doi.org/10.1038/s41388-021-02169-7		JAN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	34999736	Green Accepted			2022-12-17	WOS:000740423700001
J	Williams, R; Jobling, S; Sims, AH; Mou, CY; Wilkinson, L; Collu, GM; Streuli, CH; Gilmore, AP; Headon, DJ; Brennan, K				Williams, Rebecca; Jobling, Stephanie; Sims, Andrew H.; Mou, Chunyan; Wilkinson, Lorna; Collu, Giovanna M.; Streuli, Charles H.; Gilmore, Andrew P.; Headon, Denis J.; Brennan, Keith			Elevated EDAR signalling promotes mammary gland tumourigenesis with squamous metaplasia	ONCOGENE			English	Article							HYPOHIDROTIC ECTODERMAL DYSPLASIA; BREAST-CANCER; KAPPA-B; ANTI-ECTODYSPLASIN; BILATERAL AMASTIA; TRANSGENIC MICE; HAIR; ACTIVATION; GENE; DIFFERENTIATION	Ectodysplasin A receptor (EDAR) is a death receptor in the Tumour Necrosis Factor Receptor (TNFR) superfamily with roles in the development of hair follicles, teeth and cutaneous glands. Here we report that human Oestrogen Receptor (ER) negative breast carcinomas which display squamous differentiation express EDAR strongly. Using a mouse model with a high Edar copy number, we show that elevated EDAR signalling results in a high incidence of mammary tumours in breeding female mice. These tumours resemble the EDAR-high human tumours in that they are characterised by a lack of oestrogen receptor expression, contain extensive squamous metaplasia, and display strong beta-catenin transcriptional activity. In the mouse model, all of the tumours carry somatic deletions of the third exon of the CTNNB1 gene that encodes beta-catenin. Deletion of this exon yields unconstrained beta-catenin signalling activity. We also demonstrate that beta-catenin activity is required for transformed cell growth, showing that increased EDAR signalling creates an environment in which beta-catenin activity can readily promote tumourigenesis. Together, this work identifies a novel death receptor oncogene in breast cancer, whose mechanism of transformation is based on the interaction between the WNT and Ectodysplasin A (EDA) pathways.	[Williams, Rebecca; Jobling, Stephanie; Wilkinson, Lorna; Collu, Giovanna M.; Streuli, Charles H.; Gilmore, Andrew P.; Brennan, Keith] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Manchester, Lancs, England; [Sims, Andrew H.] Edinburgh Canc Res Ctr, Inst Genet & Mol Med, Edinburgh Breakthrough Unit, Appl Bioinformat Canc, Edinburgh, Midlothian, Scotland; [Mou, Chunyan; Headon, Denis J.] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland; [Mou, Chunyan; Headon, Denis J.] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland	University of Manchester; University of Edinburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Edinburgh	Brennan, K (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Manchester, Lancs, England.; Headon, DJ (corresponding author), Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.; Headon, DJ (corresponding author), Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland.	denis.headon@roslin.ed.ac.uk; keith.brennan@manchester.ac.uk	Collu, Giovanna/AAS-5593-2020; Sims, Andrew/E-4819-2012	Collu, Giovanna/0000-0002-7437-4000; Brennan, Keith/0000-0002-9384-125X; Sims, Andrew/0000-0001-9082-3665	Breast Cancer Campaign [2010NovPR63, 2011MayPR33]; Wellcome Trust [085073]; Breakthrough Breast Cancer; BBSRC	Breast Cancer Campaign; Wellcome Trust(Wellcome TrustEuropean Commission); Breakthrough Breast Cancer; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We would like to thank Rebecca Rock for her help establishing the qRT-PCR assays, and Julia Cheung for training SJ in histology techniques. The work was supported by a BBSRC Ph.D. studentship to SJ and RW, and by grants from the Breast Cancer Campaign (KB, grant numbers 2010NovPR63 and 2011MayPR33), Wellcome Trust (KB, grant number 085073), Breakthrough Breast Cancer (AHS) and BBSRC (DJH).	Al Marzouqi F, 2014, BRIT J DERMATOL, V171, P671, DOI 10.1111/bjd.13023; Ashkenazi A, 2014, ANNU REV CELL DEV BI, V30, P337, DOI 10.1146/annurev-cellbio-100913-013226; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33; Brisken C, 2002, DEV CELL, V3, P877, DOI 10.1016/S1534-5807(02)00365-9; Bryk J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002209; Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936; Calza S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1517; Chang SH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007591; CLARKE A, 1987, ARCH DIS CHILD, V62, P989, DOI 10.1136/adc.62.10.989; Collu GM, 2012, DEVELOPMENT, V139, P4405, DOI 10.1242/dev.081885; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fernandez-Valdivia R, 2009, DEV BIOL, V328, P127, DOI 10.1016/j.ydbio.2009.01.019; Fliniaux I, 2008, DEV BIOL, V320, P60, DOI 10.1016/j.ydbio.2008.04.023; Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495; Haghighi A, 2013, BRIT J DERMATOL, V168, P1353, DOI 10.1111/bjd.12151; Hayes MJ, 2008, CLIN CANCER RES, V14, P4038, DOI 10.1158/1078-0432.CCR-07-4379; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Headon DJ, 2001, NATURE, V414, P913, DOI 10.1038/414913a; Huttner K, 2014, AM J MED GENET A, V164, P2433, DOI 10.1002/ajmg.a.36499; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Kendellen MF, 2014, ONCOGENE, V33, P1297, DOI 10.1038/onc.2013.64; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Kowalczyk C, 2011, J BIOL CHEM, V286, P30769, DOI 10.1074/jbc.M111.267997; Kowalczyk-Quintas C, 2014, J BIOL CHEM, V289, P4273, DOI 10.1074/jbc.M113.535740; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; Majumder K, 1998, MAMM GENOME, V9, P863, DOI 10.1007/s003359900884; Meurette O, 2009, CANCER RES, V69, P5015, DOI 10.1158/0008-5472.CAN-08-3478; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Mikkola ML, 2007, SEMIN CELL DEV BIOL, V18, P225, DOI 10.1016/j.semcdb.2007.01.007; Mikkola ML, 2011, ADV EXP MED BIOL, V691, P23, DOI 10.1007/978-1-4419-6612-4_3; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Mou C, 2006, P NATL ACAD SCI USA, V103, P9075, DOI 10.1073/pnas.0600825103; Mou C, 2008, HUM MUTAT, V29, P1405, DOI 10.1002/humu.20795; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pummila M, 2007, DEVELOPMENT, V134, P117, DOI 10.1242/dev.02708; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; Schmidt-Ullrich R, 2006, DEVELOPMENT, V133, P1045, DOI 10.1242/dev.02278; Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387; Shehata M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3334; Shostak K, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2886; Sims AH, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-42; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Voutilainen M, 2012, P NATL ACAD SCI USA, V109, P5744, DOI 10.1073/pnas.1110627109; Weigelt B, 2008, J PATHOL, V216, P141, DOI 10.1002/path.2407; Weigelt B, 2010, MOL ONCOL, V4, P192, DOI 10.1016/j.molonc.2010.04.004; Weigelt B, 2009, BREAST CANCER RES TR, V117, P273, DOI 10.1007/s10549-008-0197-9; Zhang YH, 2009, DEV CELL, V17, P49, DOI 10.1016/j.devcel.2009.05.011	52	2	2	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					1040	1049		10.1038/s41388-021-01902-6	http://dx.doi.org/10.1038/s41388-021-01902-6		DEC 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34916592	Green Published, hybrid			2022-12-17	WOS:000730901200001
J	Alhayyani, S; McLeod, L; West, AC; Balic, JJ; Hodges, C; Yu, L; Smith, JA; Prodanovic, Z; Bozinovski, S; Kumar, B; Ruwanpura, SM; Saad, MI; Jenkins, BJ				Alhayyani, Sultan; McLeod, Louise; West, Alison C.; Balic, Jesse J.; Hodges, Christopher; Yu, Liang; Smith, Julian A.; Prodanovic, Zdenka; Bozinovski, Steven; Kumar, Beena; Ruwanpura, Saleela M.; Saad, Mohamed I.; Jenkins, Brendan J.			Oncogenic dependency on STAT3 serine phosphorylation in KRAS mutant lung cancer	ONCOGENE			English	Article							K-RAS MUTATIONS; MITOCHONDRIAL STAT3; SIGNAL TRANSDUCER; EPITHELIAL-CELLS; ACTIVATION; EXPRESSION; MYC; TRANSCRIPTION; RECEPTOR; TYROSINE	The oncogenic potential of the latent transcription factor signal transducer and activator of transcription (STAT)3 in many human cancers, including lung cancer, has been largely attributed to its nuclear activity as a tyrosine-phosphorylated (pY(705) site) transcription factor. By contrast, an alternate mitochondrial pool of serine phosphorylated (pS(727) site) STAT3 has been shown to promote tumourigenesis by regulating metabolic processes, although this has been reported in only a restricted number of mutant RAS-addicted neoplasms. Therefore, the involvement of STAT3 serine phosphorylation in the pathogenesis of most cancer types, including mutant KRAS lung adenocarcinoma (LAC), is unknown. Here, we demonstrate that LAC is suppressed in oncogenic Kras(G12D)-driven mouse models engineered for pS(727)-STAT3 deficiency. The proliferative potential of the transformed Kras(G12D) lung epithelium, and mutant KRAS human LAC cells, was significantly reduced upon pS(727)-STAT3 deficiency. Notably, we uncover the multifaceted capacity of constitutive pS(727)-STAT3 to metabolically reprogramme LAC cells towards a hyper-proliferative state by regulating nuclear and mitochondrial (mt) gene transcription, the latter via the mtDNA transcription factor, TFAM. Collectively, our findings reveal an obligate requirement for the transcriptional activity of pS(727)-STAT3 in mutant KRAS-driven LAC with potential to guide future therapeutic targeting approaches.	[Alhayyani, Sultan; McLeod, Louise; West, Alison C.; Balic, Jesse J.; Hodges, Christopher; Yu, Liang; Ruwanpura, Saleela M.; Saad, Mohamed I.; Jenkins, Brendan J.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic 3168, Australia; [Alhayyani, Sultan; McLeod, Louise; West, Alison C.; Balic, Jesse J.; Hodges, Christopher; Yu, Liang; Ruwanpura, Saleela M.; Saad, Mohamed I.; Jenkins, Brendan J.] Monash Univ, Sch Clin Sci, Dept Mol & Translat Sci, Clayton, Vic 3168, Australia; [Alhayyani, Sultan] King Abdulaziz Univ, Coll Arts & Sci, Dept Chem, Rabigh, Saudi Arabia; [Smith, Julian A.] Monash Univ, Sch Clin Sci, Dept Surg, Monash Hlth, Clayton, Vic 3168, Australia; [Smith, Julian A.] Monash Hlth, Dept Cardiothorac Surg, Clayton, Vic 3168, Australia; [Prodanovic, Zdenka] Monash Hlth, Monash Biobank, Clayton, Vic 3168, Australia; [Bozinovski, Steven] RMIT Univ, Sch Hlth & Biomed Sci, Bundoora, Vic 3082, Australia; [Kumar, Beena] Monash Hlth, Dept Anat Pathol, Clayton, Vic 3168, Australia	Hudson Institute of Medical Research; Monash University; King Abdulaziz University; Monash University; Royal Melbourne Institute of Technology (RMIT)	Jenkins, BJ (corresponding author), Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic 3168, Australia.; Jenkins, BJ (corresponding author), Monash Univ, Sch Clin Sci, Dept Mol & Translat Sci, Clayton, Vic 3168, Australia.	brendan.jenkins@hudson.org.au	Alhayyani/AAR-7025-2020	Saad, Mohamed I./0000-0002-4855-2360; Bozinovski, Steven/0000-0001-6533-8641; McLeod, Louise/0000-0002-7595-6432	National Health and Medical Research Council (NHMRC) of Australia; Cancer Council Victoria Postdoctoral Fellowship by the Victorian Government of Australia; Department of Chemistry, College of Sciences and Arts, King Abdulaziz University, Rabigh, Saudi Arabia; NHMRC Senior Medical Research Fellowship; Cancer Council Victoria Postdoctoral Fellowship	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria Postdoctoral Fellowship by the Victorian Government of Australia; Department of Chemistry, College of Sciences and Arts, King Abdulaziz University, Rabigh, Saudi Arabia; NHMRC Senior Medical Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria Postdoctoral Fellowship(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria)	We are deeply grateful to D. Gough and S. Fernando (Hudson Institute of Medical Research, Melbourne, Australia) for expert technical assistance and proofreading of the manuscript, as well as A. Vais (Monash Histology Platform, Melbourne, Australia) for immunofluorescence expertise. This work was supported by a research grant awarded by the National Health and Medical Research Council (NHMRC) of Australia to BJJ, as well as the Operational Infrastructure Support Programme by the Victorian Government of Australia. MIS is supported by a Cancer Council Victoria Postdoctoral Fellowship. SA was sponsored by the Department of Chemistry, College of Sciences and Arts, King Abdulaziz University, Rabigh, Saudi Arabia. BJJ is supported by a NHMRC Senior Medical Research Fellowship.	Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Balic JJ, 2019, CANCER RES, V79, P5272, DOI 10.1158/0008-5472.CAN-19-0974; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Brooks GD, 2016, CANCER RES, V76, P866, DOI 10.1158/0008-5472.CAN-15-2388; Caetano MS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07042-y; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; D'Amico S, 2018, GENE DEV, V32, P1175, DOI 10.1101/gad.311852.118; Dragoj M, 2015, TUMOR BIOL, V36, P8773, DOI 10.1007/s13277-015-3620-y; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Dutta P, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6649-2; Garama DJ, 2016, CYTOKINE, V87, P20, DOI 10.1016/j.cyto.2016.05.019; Garassino MC, 2011, ANN ONCOL, V22, P235, DOI 10.1093/annonc/mdq680; Gough DJ, 2014, BLOOD, V124, P2252, DOI 10.1182/blood-2013-02-484196; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Grabner B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7285; Han YH, 2008, ONCOL REP, V20, P689, DOI 10.3892/or_00000061; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirahara K, 2015, IMMUNITY, V42, P877, DOI 10.1016/j.immuni.2015.04.014; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Ji H, 2006, ONCOGENE, V25, P2105, DOI 10.1038/sj.onc.1209237; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kim HS, 2010, CANCER-AM CANCER SOC, V116, P676, DOI 10.1002/cncr.24748; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li Y, 2007, CANCER RES, V67, P8494, DOI 10.1158/0008-5472.CAN-07-0647; Liou GY, 2016, CELL REP, V14, P2325, DOI 10.1016/j.celrep.2016.02.029; Liu YD, 2019, INT J CANCER, V144, P3056, DOI 10.1002/ijc.32060; Macias E, 2014, J INVEST DERMATOL, V134, P1971, DOI 10.1038/jid.2014.68; Mao YQ, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00058; Marson VJ, 2004, HISTOPATHOLOGY, V45, P125, DOI 10.1111/j.1365-2559.2004.01893.x; McClelland MR, 2007, AM J RESP CELL MOL, V36, P343, DOI 10.1165/rcmb.2006-0311OC; Meissl K, 2017, CYTOKINE, V89, P12, DOI 10.1016/j.cyto.2015.11.011; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Nagao A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020238; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; Noonan KL, 2015, J THORAC ONCOL, V10, P1523, DOI 10.1097/JTO.0000000000000667; Oft M, 2014, CANCER IMMUNOL RES, V2, P194, DOI 10.1158/2326-6066.CIR-13-0214; Poli V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00121; Roman M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0789-x; Ruwanpura SM, 2011, AM J RESP CELL MOL, V45, P720, DOI 10.1165/rcmb.2010-0462OC; Saad MI, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809976; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Shen YH, 2004, MOL CELL BIOL, V24, P407, DOI 10.1128/MCB.24.1.407-419.2004; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tong MT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182282; Tran PT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002125; Walser Tonya, 2008, Proc Am Thorac Soc, V5, P811, DOI 10.1513/pats.200809-100TH; Wang XC, 2016, ONCOTARGETS THER, V9, P5461, DOI 10.2147/OTT.S94745; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Weng MT, 2013, PROTEIN CELL, V4, P807, DOI 10.1007/s13238-013-3056-3; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; Wong MCS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14513-7; Yang Q, 2012, EXP MOL PATHOL, V93, P227, DOI 10.1016/j.yexmp.2012.04.009; Yu CH, 2015, AM J PHYSIOL-GASTR L, V309, pG146, DOI 10.1152/ajpgi.00462.2014; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yu L, 2018, CLIN CANCER RES, V24, P1459, DOI 10.1158/1078-0432.CCR-17-2485; Zhou J, 2015, ONCOGENE, V34, P3804, DOI 10.1038/onc.2014.318; Zhu SG, 2014, BLOOD, V124, P403, DOI 10.1182/blood-2013-05-499707; Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646; Zouein FA, 2013, HYPERTENS RES, V36, P496, DOI 10.1038/hr.2012.223	71	2	2	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					809	823		10.1038/s41388-021-02134-4	http://dx.doi.org/10.1038/s41388-021-02134-4		DEC 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34857889				2022-12-17	WOS:000725388800002
J	Han, FY; Zhang, L; Liao, SX; Zhang, YM; Qian, LL; Hou, FJ; Gong, JW; Lai, MD; Zhang, HH				Han, Fengyan; Zhang, Lei; Liao, Shaoxia; Zhang, Yanmin; Qian, Lili; Hou, Feijun; Gong, Jingwen; Lai, Maode; Zhang, Honghe			The interaction between S100A2 and KPNA2 mediates NFYA nuclear import and is a novel therapeutic target for colorectal cancer metastasis	ONCOGENE			English	Article							ALPHA-2 KPNA2; PROTEIN; TRANSPORT; MARKER; EXPRESSION; MECHANISM; SUBUNIT; P53	Nucleocytoplasmic transport of proteins is disrupted and dysregulated in cancer cells. Nuclear pore complexes and cargo proteins are two main transportation regulators. However, the mechanism regulating nucleocytoplasmic transport in cancer remains elusive. Here, we identified a S100A2/KPNA2 cotransport complex that transports the tumor-associated transcription factor NFYA in colorectal cancer (CRC). Through the S100A2/KNPA2 complex, depending on its interaction with S100A2, NFYA is transported to the nucleus and inhibits the transcriptional activity of E-cadherin, which in turn promotes CRC metastasis. Targeting the S100A2/KPNA2 binding sites with the specific inhibitor delanzomib is a potential therapeutic approach for CRC.	[Han, Fengyan; Liao, Shaoxia; Qian, Lili; Hou, Feijun; Zhang, Honghe] Zhejiang Univ, Dept Pathol, Chinese Acad Med Sci,Sch Med, Res Unit Intelligence Classificat Tumor Pathol &, 2019RU042, Hangzhou 310058, Zhejiang, Peoples R China; [Han, Fengyan; Liao, Shaoxia; Qian, Lili; Hou, Feijun; Zhang, Honghe] Zhejiang Univ, Womens Hosp, Chinese Acad Med Sci,Sch Med, Res Unit Intelligence Classificat Tumor Pathol &, 2019RU042, Hangzhou 310058, Zhejiang, Peoples R China; [Zhang, Lei; Gong, Jingwen; Lai, Maode; Zhang, Honghe] Key Lab Dis Prote Zhejiang Prov, Hangzhou 310058, Zhejiang, Peoples R China; [Zhang, Lei; Gong, Jingwen; Lai, Maode; Zhang, Honghe] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Zhejiang, Peoples R China; [Zhang, Lei; Lai, Maode] China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Peoples R China; [Zhang, Yanmin] China Pharmaceut Univ, Sch Sci, Lab Mol Design & Drug Discovery, 639 Longmian Ave, Nanjing 211198, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Zhejiang University; Chinese Academy of Medical Sciences - Peking Union Medical College; Zhejiang University; Zhejiang University; China Pharmaceutical University; China Pharmaceutical University	Zhang, HH (corresponding author), Zhejiang Univ, Dept Pathol, Chinese Acad Med Sci,Sch Med, Res Unit Intelligence Classificat Tumor Pathol &, 2019RU042, Hangzhou 310058, Zhejiang, Peoples R China.; Zhang, HH (corresponding author), Zhejiang Univ, Womens Hosp, Chinese Acad Med Sci,Sch Med, Res Unit Intelligence Classificat Tumor Pathol &, 2019RU042, Hangzhou 310058, Zhejiang, Peoples R China.; Lai, MD; Zhang, HH (corresponding author), Key Lab Dis Prote Zhejiang Prov, Hangzhou 310058, Zhejiang, Peoples R China.; Lai, MD; Zhang, HH (corresponding author), Zhejiang Univ, Canc Ctr, Hangzhou 310058, Zhejiang, Peoples R China.; Lai, MD (corresponding author), China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Peoples R China.	lmp@zju.edu.cn; honghezhang@zju.edu.cn	钱, 钱丽丽/GWV-8162-2022		National Natural Science Foundation of China [81871937, 82001586, 91859204, 82072629, 82072811]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2019-I2M-5-044]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS)	This work is supported by the National Natural Science Foundation of China (81871937, 82001586, 91859204, 82072629, 82072811) and CAMS Innovation Fund for Medical Sciences (CIFMS, 2019-I2M-5-044).	Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Bulk E, 2009, CLIN CANCER RES, V15, P22, DOI 10.1158/1078-0432.CCR-08-0953; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Christiansen A, 2013, CANCER LETT, V331, P18, DOI 10.1016/j.canlet.2012.12.013; Dummer R, 1997, DERMATOLOGY, V194, P208, DOI 10.1159/000246103; Gravina GL, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0085-1; Jamieson C, 2014, SEMIN CANCER BIOL, V27, P20, DOI 10.1016/j.semcancer.2014.04.012; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Kelley JB, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-63; Kirschner RD, 2008, NUCLEIC ACIDS RES, V36, P2969, DOI 10.1093/nar/gkn132; Kumar M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0369-9; Li C, 2020, FASEB J, V34, P13333, DOI 10.1096/fj.202000555R; Li J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0861-9; Li XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-232; Masuda T, 2016, INT J ONCOL, V48, P975, DOI 10.3892/ijo.2016.3329; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mueller A, 2005, J BIOL CHEM, V280, P29186, DOI 10.1074/jbc.M505000200; Narayanan S, 2020, DRUG RESIST UPDATE, V48, DOI 10.1016/j.drup.2019.100663; Naz S, 2014, CARCINOGENESIS, V35, P14, DOI 10.1093/carcin/bgt287; Ohuchida K, 2007, J PATHOL, V213, P275, DOI 10.1002/path.2250; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Sato Y, 2013, J GASTROEN HEPATOL, V28, P1422, DOI 10.1111/jgh.12247; Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114; Strom AC, 2001, GENOME BIOL, V2; Takata M, 2010, FEBS LETT, V584, P4517, DOI 10.1016/j.febslet.2010.09.052; van Bon L, 2014, ANN RHEUM DIS, V73, P1585, DOI 10.1136/annrheumdis-2013-205013; van Dieck J, 2010, ONCOGENE, V29, P2024, DOI 10.1038/onc.2009.490; Wang CI, 2012, MOL CELL PROTEOMICS, V11, P1105, DOI 10.1074/mcp.M111.016592; Wang HJ, 2005, INT J CANCER, V116, P285, DOI 10.1002/ijc.21035; Xiang SS, 2019, ONCOGENE, V38, P1269, DOI 10.1038/s41388-018-0494-7	31	2	2	7	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					657	670		10.1038/s41388-021-02116-6	http://dx.doi.org/10.1038/s41388-021-02116-6		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34802034				2022-12-17	WOS:000720700200002
J	Chen, Y; Zhao, H; Liang, WL; Jiang, E; Zhou, XC; Shao, Z; Liu, K; Shang, ZJ				Chen, Yang; Zhao, Hui; Liang, Weilian; Jiang, Erhui; Zhou, Xiaocheng; Shao, Zhe; Liu, Ke; Shang, Zhengjun			Autophagy regulates the cancer stem cell phenotype of head and neck squamous cell carcinoma through the noncanonical FOXO3/SOX2 axis	ONCOGENE			English	Article							EXPRESSION; TUMOR; BMI1	Autophagy is an essential catabolic process that orchestrates cellular homeostasis and plays dual roles in tumor promotion and suppression. However, the mechanism by which autophagy affects the self-renewal of cancer stem cells (CSCs) remains unclear. In this study, we investigated whether autophagy activation contributes to CSC properties of head and neck squamous cell carcinoma (HNSCC). The results showed that the autophagy level and CSC properties of HNSCC cells were elevated in response to several adverse conditions, including treatment with cisplatin, starvation, and hypoxia. Pretreatment with autophagy inhibitors, such as 3-MA and chloroquine, diminished the CSC properties acquired under adverse conditions. In addition, the isolated CSCs were endowed with stronger autophagic activity than non-CSCs, and the CSC properties were dampened when autophagy was inhibited either by 3-MA, chloroquine, or Beclin1 knockdown. Notably, the tumor-initiating activity of CSCs was decreased upon knocking down Beclin1. Further study revealed that FOXO3, a substrate for autophagy, was enriched in the nucleus of cells with lower autophagy levels. Nuclear FOXO3 directly bound to the promoter region of SOX2 and negatively regulated its transcriptional activity. Overexpression of FOXO3 decreased the expression of SOX2 and thereby impaired the CSC phenotype both in vitro and in vivo. Taken together, our findings suggest that the activation of autophagy is essential for the acquisition of CSC properties in adverse conditions and the self-renewal of CSCs. We clarify the role of autophagy in regulating the CSC phenotype and demonstrate that the noncanonical FOXO3/SOX2 axis is the intrinsic regulatory mechanism.	[Chen, Yang; Zhao, Hui; Liang, Weilian; Jiang, Erhui; Zhou, Xiaocheng; Shao, Zhe; Liu, Ke; Shang, Zhengjun] Wuhan Univ, Hubei Prov & Key Lab Oral Biomed, State Key Lab Breeding Base Basic Sci Stomatol, Hubei MOST KLOS & KLOBM, Wuhan, Peoples R China; [Jiang, Erhui; Zhou, Xiaocheng; Shao, Zhe; Liu, Ke; Shang, Zhengjun] Wuhan Univ, Sch & Hosp Stomatol, Dept Oral & Maxillofacial Head & Neck Oncol, Wuhan, Peoples R China	Wuhan University; Wuhan University	Shang, ZJ (corresponding author), Wuhan Univ, Hubei Prov & Key Lab Oral Biomed, State Key Lab Breeding Base Basic Sci Stomatol, Hubei MOST KLOS & KLOBM, Wuhan, Peoples R China.	shangzhengjun@whu.edu.cn		Chen, Yang/0000-0002-9838-0843; shang, zhengjun/0000-0002-4884-8129	National Natural Science Foundation of China [81972547]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (Grant no. 81972547 to Z Shang). In addition, YC wants to thank, in particular, Ying Tang (Wuhan University) for her invaluable support over the past years.	Abbaszadegan MR, 2017, J CELL PHYSIOL, V232, P2008, DOI 10.1002/jcp.25759; Agro L, 2015, Bio Protoc, V5, P1; Alemohammad H, 2020, LIFE SCI, V260, DOI 10.1016/j.lfs.2020.118337; An YF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2308-4; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Buccarelli M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0864-7; Camuzard O, 2020, CANCER LETT, V490, P143, DOI 10.1016/j.canlet.2020.06.015; Chaurasia M, 2019, AUTOPHAGY, V15, P1391, DOI 10.1080/15548627.2019.1582973; Chen Y, 2020, J CELL PHYSIOL, V235, P5995, DOI 10.1002/jcp.29525; Chow LQM, 2020, NEW ENGL J MED, V382, P60, DOI 10.1056/NEJMra1715715; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507; Fitzwalter BE, 2018, DEV CELL, V44, P555, DOI 10.1016/j.devcel.2018.02.014; Folkerts H, 2019, MED RES REV, V39, P517, DOI 10.1002/med.21531; Gasch C, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0601-3; Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252; Hao CC, 2019, THER ADV RESPIR DIS, V13, DOI 10.1177/1753466619866097; Hornsveld M, 2018, SEMIN CANCER BIOL, V50, P90, DOI 10.1016/j.semcancer.2017.11.017; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jia LF, 2020, CELL STEM CELL, V27, P238, DOI 10.1016/j.stem.2020.06.022; Jiramongkol Y, 2020, CANCER METAST REV, V39, P681, DOI 10.1007/s10555-020-09883-w; Khammanivong A, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-260; Kumazoe M, 2017, ONCOGENE, V36, P2643, DOI 10.1038/onc.2016.426; Kumazoe M, 2017, J BIOL CHEM, V292, P10813, DOI 10.1074/jbc.M116.772111; Li K, 2019, EBIOMEDICINE, V48, P70, DOI 10.1016/j.ebiom.2019.09.027; Liu H, 2020, CELL DEATH DIFFER, V27, P966, DOI 10.1038/s41418-019-0389-3; Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131; Liu YQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0751-3; Marie-Egyptienne DT, 2013, CANCER LETT, V341, P63, DOI 10.1016/j.canlet.2012.11.019; Muhammad N, 2017, CLIN CANCER RES, V23, P3120, DOI 10.1158/1078-0432.CCR-16-2811; Nakano T, 2021, J DENT RES, V100, P377, DOI 10.1177/0022034520965141; Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y; Peng QH, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0644-8; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Siegel RL., 2020, CA-CANCER J CLIN, V70; Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6; Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222; Sun XY, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110623; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Yang LQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0110-5; Yang MC, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0449-3; Yang WY, 2019, CANCER LETT, V451, P34, DOI 10.1016/j.canlet.2019.02.052; Yeo SK, 2016, CANCER RES, V76, P3397, DOI 10.1158/0008-5472.CAN-15-2946; Yu SS, 2020, J CELL PHYSIOL, V235, P65, DOI 10.1002/jcp.28963	46	2	2	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					634	646		10.1038/s41388-021-02115-7	http://dx.doi.org/10.1038/s41388-021-02115-7		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34795388	Green Published, hybrid			2022-12-17	WOS:000720257200001
J	Seo, SU; Woo, SM; Kim, S; Park, JW; Lee, HS; Bae, YS; Kim, SH; Im, SS; Seo, JH; Min, KJ; Kwon, TK				Seo, Seung Un; Woo, Seon Min; Kim, Shin; Park, Jong-Wook; Lee, Hyun-Shik; Bae, Young-Seuk; Kim, Sang Hyun; Im, Seung-Soon; Seo, Ji Hae; Min, Kyoung-Jin; Kwon, Taeg Kyu			Inhibition of cathepsin K sensitizes oxaliplatin-induced apoptotic cell death by Bax upregulation through OTUB1-mediated p53 stabilization in vitro and in vivo	ONCOGENE			English	Article							TUMOR-SUPPRESSOR P53; MEMBRANE PERMEABILIZATION; EXPRESSION; BCL-2	Cathepsin K is highly expressed in various types of cancers. However, the effect of cathepsin K inhibition in cancer cells is not well characterized. Here, cathepsin K inhibitor (odanacatib; ODN) and knockdown of cathepsin K (siRNA) enhanced oxaliplatin-induced apoptosis in multiple cancer cells through Bax upregulation. Bax knockdown significantly inhibited the combined ODN and oxaliplatin treatment-induced apoptotic cell death. Stabilization of p53 by ODN played a critical role in upregulating Bax expression at the transcriptional level. Casein kinase 2 (CK2)-dependent phosphorylation of OTUB1 at Ser16 played a critical role in ODN- and cathepsin K siRNA-mediated p53 stabilization. Interestingly, ODN-induced p53 and Bax upregulation were modulated by the production of mitochondrial reactive oxygen species (ROS). Mitochondrial ROS scavengers prevented OTUB1-mediated p53 stabilization and Bax upregulation by ODN. These in vitro results were confirmed by in mouse xenograft model, combined treatment with ODN and oxaliplatin significantly reduced tumor size and induced Bax upregulation. Furthermore, human renal clear carcinoma (RCC) tissues revealed a strong correlation between phosphorylation of OTUB1(Ser16) and p53/Bax expression. Our results demonstrate that cathepsin K inhibition enhances oxaliplatin-induced apoptosis by increasing OTUB1 phosphorylation via CK2 activation, thereby promoting p53 stabilization, and hence upregulating Bax.	[Seo, Seung Un; Woo, Seon Min; Kim, Shin; Park, Jong-Wook; Kwon, Taeg Kyu] Keimyung Univ, Sch Med, Dept Immunol, Daegu 42601, South Korea; [Lee, Hyun-Shik; Bae, Young-Seuk] Kyungpook Natl Univ, Coll Nat Sci, Sch Life Sci, BK21 Plus KNU Creat BioRes Grp, Daegu 41566, South Korea; [Kim, Sang Hyun] Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Daegu 41944, South Korea; [Im, Seung-Soon] Keimyung Univ, Sch Med, Dept Physiol, Daegu 42601, South Korea; [Seo, Ji Hae] Keimyung Univ, Sch Med, Dept Biochem, Daegu 42601, South Korea; [Min, Kyoung-Jin] Daegu Gyeongbuk Med Innovat Fdn DGMIF, New Drug Dev Ctr, Daegu 41061, South Korea; [Kwon, Taeg Kyu] Keimyung Univ, Ctr Forens Pharmaceut Sci, Daegu 42601, South Korea	Keimyung University; Kyungpook National University; Kyungpook National University; Keimyung University; Keimyung University; Keimyung University	Kwon, TK (corresponding author), Keimyung Univ, Sch Med, Dept Immunol, Daegu 42601, South Korea.; Kwon, TK (corresponding author), Keimyung Univ, Ctr Forens Pharmaceut Sci, Daegu 42601, South Korea.	kwontk@dsmc.or.kr						Ashton TM, 2018, CLIN CANCER RES, V24, P2482, DOI 10.1158/1078-0432.CCR-17-3070; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Brooks CL, 2004, CELL CYCLE, V3, P895; Dai R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00433; Grabowska UB, 2005, CURR OPIN DRUG DISC, V8, P619; Gu XY, 2019, EUR J PHARMACOL, V858, DOI 10.1016/j.ejphar.2019.05.011; Herhaus L, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa0441; Hock AK, 2014, BBA-MOL CELL RES, V1843, P137, DOI 10.1016/j.bbamcr.2013.05.022; Kim S, 2019, CANCERS, V11, DOI 10.3390/cancers11030344; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Leusink FK, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4315-8; Liang WP, 2019, J CANCER RES CLIN, V145, P1999, DOI 10.1007/s00432-019-02950-y; Mauri G, 2020, CANCER TREAT REV, V91, DOI 10.1016/j.ctrv.2020.102112; Min KJ, 2020, TOXICOL RES-GER, V36, P167, DOI 10.1007/s43188-019-00025-1; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Petermann I, 2006, FASEB J, V20, P1266, DOI 10.1096/fj.05-5517fje; Saldana M, 2019, ENDOCR-RELAT CANCER, V26, pR1, DOI 10.1530/ERC-18-0264; Seo BR, 2017, ANTIOXID REDOX SIGN, V27, P215, DOI 10.1089/ars.2016.6749; Seo J, 2018, ONCOGENE, V37, P4994, DOI 10.1038/s41388-018-0323-z; Seo SU, 2020, REDOX BIOL, V30, DOI 10.1016/j.redox.2019.101422; Seo SU, 2018, ONCOGENE, V37, P5205, DOI 10.1038/s41388-018-0345-6; Simpson D, 2003, DRUGS, V63, P2127, DOI 10.2165/00003495-200363190-00013; Sun XX, 2012, EMBO J, V31, P576, DOI 10.1038/emboj.2011.434; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Tsukuba T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082415; Verbovsek U, 2015, SEMIN CANCER BIOL, V35, P71, DOI 10.1016/j.semcancer.2015.08.010; Wiener R, 2013, NAT STRUCT MOL BIOL, V20, P1033, DOI 10.1038/nsmb.2655; Wiener R, 2012, NATURE, V483, P618, DOI 10.1038/nature10911; Yang H, 2020, MOLECULES, V25, DOI 10.3390/molecules25184136; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; ZHAN QM, 1994, ONCOGENE, V9, P3743	32	2	2	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					550	559		10.1038/s41388-021-02088-7	http://dx.doi.org/10.1038/s41388-021-02088-7		NOV 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34785775	hybrid, Green Published			2022-12-17	WOS:000719277200002
J	Bui, T; Gu, Y; Ancot, F; Sanguin-Gendreau, V; Zuo, DM; Muller, WJ				Bui, Tung; Gu, Yu; Ancot, Frederic; Sanguin-Gendreau, Virginie; Zuo, Dongmei; Muller, William J.			Emergence of beta 1 integrin-deficient breast tumours from dormancy involves both inactivation of p53 and generation of a permissive tumour microenvironment	ONCOGENE			English	Article							EXTRACELLULAR-MATRIX; MOUSE MODEL; PROGRESSION; DISRUPTION; KINASE	The molecular and cellular mechanisms underlying mammary tumour dormancy and cancer recurrence are unclear and remain to be elucidated. Here, we report that mammary epithelial-specific disruption of beta 1 integrin in a murine model of Luminal B human breast cancer drastically impairs tumour growth with proliferation block, apoptosis induction and cellular senescence. beta 1 integrin-deficient dormant lesions show activation of the tumour suppressor p53, and tumours that circumvent dormancy possess p53 mutation analogous to those in human disease. We further demonstrate that mammary epithelial deletion of p53 in beta 1 integrin-deficient mice fully rescues tumour dormancy and bypasses cellular senescence. Additionally, recurrent beta 1 integrin-deficient tumours exhibit fibrosis with increased cancer-associated fibroblast infiltration and extracellular matrix deposition, absent in fast-growing beta 1 integrin/p53-deficient lesions. Taken together, these observations argue that beta 1 integrin modulates p53-dependent cellular senescence resulting in tumour dormancy and that pro-tumourigenic stromal cues and intrinsic genetic mutation are required for dormancy exit.	[Bui, Tung; Gu, Yu; Ancot, Frederic; Sanguin-Gendreau, Virginie; Zuo, Dongmei; Muller, William J.] McGill Univ, Rosalind & Morris Goodman Canc Inst, Montreal, PQ H3A 1A3, Canada; [Bui, Tung; Gu, Yu; Muller, William J.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Muller, William J.] McGill Univ, Fac Med, Montreal, PQ H3G 2M1, Canada	McGill University; McGill University; McGill University	Muller, WJ (corresponding author), McGill Univ, Rosalind & Morris Goodman Canc Inst, Montreal, PQ H3A 1A3, Canada.; Muller, WJ (corresponding author), McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.; Muller, WJ (corresponding author), McGill Univ, Fac Med, Montreal, PQ H3G 2M1, Canada.	william.muller@mcgill.ca			Cedars Cancer Institute Fellowship; McGill Integrated Cancer Research Training Programme award; CURE Foundation Fellowship in Breast Cancer Research; Canderel Graduate Studentship Award; Canada Research Chair in Molecular Oncology; CIHR Foundation; CCSRI innovation programmes	Cedars Cancer Institute Fellowship; McGill Integrated Cancer Research Training Programme award; CURE Foundation Fellowship in Breast Cancer Research; Canderel Graduate Studentship Award; Canada Research Chair in Molecular Oncology(Canada Research Chairs); CIHR Foundation(Canadian Institutes of Health Research (CIHR)); CCSRI innovation programmes	We thank Alain Sarabia Pacis, Goodman Cancer Institute Bionformatics Core, Canadian Tumour for Computational Genomics (C3G), McGill University for bioinformatic analyses of RNA-seq and scRNA-seq data, Dr. Erika Wee and the Advanced BioImaging Facility, McGill University for analysis using Imaris software, Cleber Silveira Moraes from GCI Histology Core, Cynthia Lavoie for monitoring mouse cohort and Mitra Cowen from GCI Transgenic Core. We are also grateful to Dr. Stephen Dilworth for supplying PyV mT antibodies. TB is supported by the Cedars Cancer Institute Fellowship and McGill Integrated Cancer Research Training Programme award. YG is supported by the CURE Foundation Fellowship in Breast Cancer Research and the Canderel Graduate Studentship Award. WJM is supported by Canada Research Chair in Molecular Oncology and grants from CIHR Foundation and CCSRI innovation programmes.	Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h; Barkan D, 2010, EUR J CANCER, V46, P1181, DOI 10.1016/j.ejca.2010.02.027; Bartoschek M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07582-3; Bui T, 2019, CELL REP, V29, P589, DOI 10.1016/j.celrep.2019.09.004; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Faget DV, 2019, NAT REV CANCER, V19, P439, DOI 10.1038/s41568-019-0156-2; Graus-Porta D, 2001, NEURON, V31, P367, DOI 10.1016/S0896-6273(01)00374-9; Grochova D, 2008, ONCOGENE, V27, P1243, DOI 10.1038/sj.onc.1210748; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Hamidi H, 2019, NAT REV CANCER, V19, P179, DOI 10.1038/s41568-019-0112-1; Ilic D, 1998, J CELL BIOL, V143, P547; Jones LM, 2016, CANCER RES, V76, P1416, DOI 10.1158/0008-5472.CAN-15-2770; Jones MC, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0227; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kren A, 2007, EMBO J, V26, P2832, DOI 10.1038/sj.emboj.7601738; Lahlou H, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3131; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108; Marino S, 2000, GENE DEV, V14, P994; Martin MD, 2008, CANCER RES, V68, P6251, DOI 10.1158/0008-5472.CAN-08-0537; McConnell JC, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0664-2; Moreno-Layseca P, 2014, MATRIX BIOL, V34, P144, DOI 10.1016/j.matbio.2013.10.011; Murnyak B, 2016, ONCOTARGET, V7, P64910, DOI 10.18632/oncotarget.11912; Pelaez R, 2019, CANCERS, V11, DOI 10.3390/cancers11050615; Phan TG, 2020, NAT REV CANCER, V20, P398, DOI 10.1038/s41568-020-0263-0; Pontier SM, 2010, ONCOGENE, V29, P3374, DOI 10.1038/onc.2010.86; Pontier SM, 2008, APMIS, V116, P677, DOI 10.1111/j.1600-0463.2008.01026.x; Rao T, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3603; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Smith HW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10681-4; Triana-Martinez F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020346; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Winkler J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18794-x; Zerdoumi Y, 2017, HUM MOL GENET, V26, P2591, DOI 10.1093/hmg/ddx106	35	2	2	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					527	537		10.1038/s41388-021-02107-7	http://dx.doi.org/10.1038/s41388-021-02107-7		NOV 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34782719	hybrid, Green Published			2022-12-17	WOS:000718778400004
J	Wu, D; Tan, H; Su, WJ; Cheng, DM; Wang, GW; Wang, J; Ma, DA; Dong, GM; Sun, PQ				Wu, Dan; Tan, Hua; Su, Weijun; Cheng, Dongmei; Wang, Guanwen; Wang, Juan; Ma, Ding A.; Dong, George M.; Sun, Peiqing			MZF1 mediates oncogene-induced senescence by promoting the transcription of p16(INK4A)	ONCOGENE			English	Article							CELLULAR SENESCENCE; TUMOR-SUPPRESSOR; CANCER; EXPRESSION; RAS; CHROMATIN; CHD7; P53; OVEREXPRESSION; RETINOBLASTOMA	Oncogene induced senescence is a tumor suppressing defense mechanism, in which the cell cycle-dependent protein kinase (CDK) inhibitor p16(INK4A) (encoded by the CDKN2A gene) plays a key role. We previously reported that a transcriptional co-activator chromodomain helicase DNA binding protein 7 (CHD7) mediates oncogenic ras-induced senescence by inducing transcription of the p16(INK4A) gene. In the current study, we identified myeloid zinc finger 1 (MZF1) as the transcriptional factor that recruits CHD7 to the p16(INK4A) promoter, where it mediates oncogenic ras-induced p16(INK4A) transcription and senescence through CHD7, in primary human cells from multiple origins. Moreover, the expression of MZF1 is induced by oncogenic ras in senescent cells through the c-Jun and Ets1 transcriptional factors upon their activation by the Ras-Raf-1-MEK-ERK signaling pathway. In non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma (PAAD) where activating ras mutations occur frequently, reduced MZF1 expression is observed in tumors, as compared to corresponding normal tissues, and correlates with poor patient survival. Analysis of single cell RNA-sequencing data from PAAD patients revealed that among the tumor cells with normal RB expression levels, those with reduced levels of MZF1 are more likely to express lower p16(INK4A) levels. These findings have identified novel signaling components in the pathway that mediates induction of the p16(INK4A) tumor suppressor and the senescence response, and suggested that MZF1 is a potential tumor suppressor in at least some cancer types, the loss of which contributes to the inactivation of the p16(INK4A)/RB pathway and disruption of senescence in tumor cells with intact RB.	[Wu, Dan; Cheng, Dongmei; Wang, Guanwen; Wang, Juan; Ma, Ding A.; Dong, George M.; Sun, Peiqing] Wake Forest Baptist Med Ctr, Comprehens Canc Ctr, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA; [Tan, Hua] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA; [Su, Weijun; Wang, Guanwen; Wang, Juan] Nankai Univ Sch Med, Tianjin, Peoples R China	Wake Forest University; Wake Forest Baptist Medical Center; University of Texas System; University of Texas Health Science Center Houston	Sun, PQ (corresponding author), Wake Forest Baptist Med Ctr, Comprehens Canc Ctr, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	psun@wakehealth.edu		Sun, Peiqing/0000-0003-2255-6504	NIH/NCI [CA131231, CA172115, P30CA012197]; Anderson Oncology Research Professorship	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Anderson Oncology Research Professorship	We thank the Cell Engineering and Cellular Imaging Shared Resources of WFBCCC. This study was supported by NIH/NCI grants CA131231, CA172115 and P30CA012197 (PS). PS is supported by the Anderson Oncology Research Professorship.	Bajpai R, 2010, NATURE, V463, P958, DOI 10.1038/nature08733; Bastide K, 2009, LUNG CANCER, V63, P348, DOI 10.1016/j.lungcan.2008.06.007; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brix DM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010223; Brix DM, 2019, ONCOGENE, V38, P3170, DOI 10.1038/s41388-018-0653-x; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen Y, 2015, ONCOGENE, V34, P3839, DOI 10.1038/onc.2014.310; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Coppe JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Deng Y, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/868131; di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071; Dublin EA, 1998, INT J CANCER, V79, P71, DOI 10.1002/(SICI)1097-0215(19980220)79:1<71::AID-IJC14>3.0.CO;2-K; Eguchi T, 2015, J CELL BIOCHEM, V116, P2146, DOI 10.1002/jcb.25203; Eguchi T, 2019, CANCERS, V11, DOI 10.3390/cancers11060792; Engelen E, 2011, NAT GENET, V43, P607, DOI 10.1038/ng.825; Feng WJ, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00309; Feng WJ, 2013, CELL STEM CELL, V13, P62, DOI 10.1016/j.stem.2013.05.002; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005; Gorgoulis VG, 1998, AM J PATHOL, V153, P1749, DOI 10.1016/S0002-9440(10)65690-8; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hellmich C, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00230; Hernandez-Segura A, 2017, CURR BIOL, V27, P2652, DOI 10.1016/j.cub.2017.07.033; Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142; Hsieh YH, 2006, BIOCHEM BIOPH RES CO, V339, P217, DOI 10.1016/j.bbrc.2005.11.015; Hsieh YH, 2007, CHINESE J PHYSIOL, V50, P9; Iwasaki O, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13604-5; Kagey MH, 2010, NATURE, V467, P430, DOI 10.1038/nature09380; Kanojia D, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax2879; Kotake Y, 2015, ANTICANCER RES, V35, P4397; Krizhanovsky V, 2008, COLD SH Q B, V73, P513, DOI 10.1101/sqb.2008.73.048; Kwong J, 2013, MOL CELL BIOL, V33, P3780, DOI 10.1128/MCB.00784-13; LaPak KM, 2014, MOL CANCER RES, V12, P167, DOI 10.1158/1541-7786.MCR-13-0350; Lee JH, 2017, INT J ONCOL, V50, P272, DOI 10.3892/ijo.2016.3793; Lee S, 2019, BMB REP, V52, P35, DOI 10.5483/BMBRep.2019.52.1.294; Lee S, 2019, NAT CELL BIOL, V21, P94, DOI 10.1038/s41556-018-0249-2; Li GQ, 2017, CELL PHYSIOL BIOCHEM, V44, P1242, DOI 10.1159/000485454; Li JJ, 2021, CANCER RES, V81, P114, DOI 10.1158/0008-5472.CAN-20-2270; Li WB, 2015, MOL CELL, V59, P188, DOI 10.1016/j.molcel.2015.06.002; Liu XP, 2015, ONCOTARGET, V6, P7930, DOI 10.18632/oncotarget.3181; Liu XL, 2018, ACTA PHARMACOL SIN, V39, P1553, DOI 10.1038/aps.2017.198; Murai K, 1997, GENES CELLS, V2, P581, DOI 10.1046/j.1365-2443.1997.1430341.x; Ohtani N, 2012, EXP DERMATOL, V21, P1, DOI 10.1111/j.1600-0625.2012.01493.x; Ouyang XS, 2002, CARCINOGENESIS, V23, P721, DOI 10.1093/carcin/23.5.721; Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422-019-0195-y; Peterson MJ, 2000, GENE, V254, P105, DOI 10.1016/S0378-1119(00)00281-X; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; Roman M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0789-x; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Scaglioni PP, 2012, EMBO MOL MED, V4, P594, DOI 10.1002/emmm.201200233; Schnetz MP, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001023; Schnetz MP, 2009, GENOME RES, V19, P590, DOI 10.1101/gr.086983.108; Schosserer M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00278; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Su WJ, 2018, ONCOGENE, V37, P5618, DOI 10.1038/s41388-018-0358-1; Sun LY, 2018, GENES-BASEL, V9, DOI 10.3390/genes9040211; Tsai LH, 2015, ONCOGENE, V34, P1641, DOI 10.1038/onc.2014.118; Tsai SJ, 2012, BIOCHEM BIOPH RES CO, V425, P462, DOI 10.1016/j.bbrc.2012.07.125; Tvingsholm SA, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0014-6; Ulianov SV, 2016, GENOME RES, V26, P70, DOI 10.1101/gr.196006.115; Vishwamitra D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0324-2; Waters AM, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031435; Yokoyama Y, 2015, CELL CYCLE, V14, P2160, DOI 10.1080/15384101.2015.1049778; Zhang SL, 2019, J BIOL CHEM, V294, P16756, DOI 10.1074/jbc.RA119.009779; Zhang Y, 2014, BIOCHEM BIOPH RES CO, V453, P172, DOI 10.1016/j.bbrc.2014.09.092; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	71	2	2	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					414	426		10.1038/s41388-021-02110-y	http://dx.doi.org/10.1038/s41388-021-02110-y		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34773072	Green Accepted			2022-12-17	WOS:000717915200001
J	Raab, M; Matthess, Y; Raab, CA; Gutfreund, N; Dotsch, V; Becker, S; Sanhaji, M; Strebhardt, K				Raab, Monika; Matthess, Yves; Raab, Christopher A.; Gutfreund, Niklas; Doetsch, Volker; Becker, Sven; Sanhaji, Mourad; Strebhardt, Klaus			A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1	ONCOGENE			English	Article							POLO-LIKE KINASE-1; AURORA-A; STRUCTURAL BASIS; CANCER; PHOSPHORYLATION; EXPRESSION; CELLS; DEGRADATION; CHECKPOINT; VOLASERTIB	Polo-like kinase 1 (PLK1) is a crucial regulator of cell cycle progression. It is established that the activation of PLK1 depends on the coordinated action of Aurora-A and Bora. Nevertheless, very little is known about the spatiotemporal regulation of PLK1 during G2, specifically, the mechanisms that keep cytoplasmic PLK1 inactive until shortly before mitosis onset. Here, we describe PLK1 dimerization as a new mechanism that controls PLK1 activation. During the early G2 phase, Bora supports transient PLK1 dimerization, thus fine-tuning the timely regulated activation of PLK1 and modulating its nuclear entry. At late G2, the phosphorylation of T210 by Aurora-A triggers dimer dissociation and generates active PLK1 monomers that support entry into mitosis. Interfering with this critical PLK1 dimer/monomer switch prevents the association of PLK1 with importins, limiting its nuclear shuttling, and causes nuclear PLK1 mislocalization during the G2-M transition. Our results suggest a novel conformational space for the design of a new generation of PLK1 inhibitors.	[Raab, Monika; Matthess, Yves; Raab, Christopher A.; Becker, Sven; Sanhaji, Mourad; Strebhardt, Klaus] Goethe Univ, Med Sch, Dept Gynecol, Frankfurt, Germany; [Gutfreund, Niklas; Doetsch, Volker] Goethe Univ, Inst Viophys Chem, Max von Laue Str 9, D-60438 Frankfurt, Germany; [Gutfreund, Niklas; Doetsch, Volker] Goethe Univ, Ctr Biomol Magnet Resonance, Max von Laue Str 9, D-60438 Frankfurt, Germany; [Strebhardt, Klaus] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ)	Sanhaji, M; Strebhardt, K (corresponding author), Goethe Univ, Med Sch, Dept Gynecol, Frankfurt, Germany.; Strebhardt, K (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.	mourad.sanhaji@kgu.de; strebhardt@em.uni-frankfurt.de		Sanhaji, Mourad/0000-0001-8202-0694; Strebhardt, Klaus/0000-0003-2173-9763	Deutsche Forschungsgemeinschaft; Messer Stiftung; Deutsche Krebshilfe; German Cancer Consortium (DKTK), Heidelberg; Verein zur Forderung der Wissenschaft; Pravention and Therapie von Kehlkopfkrebs e.V; Projekt DEAL	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Messer Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); German Cancer Consortium (DKTK), Heidelberg; Verein zur Forderung der Wissenschaft; Pravention and Therapie von Kehlkopfkrebs e.V; Projekt DEAL	This work was supported by grants from the Deutsche Forschungsgemeinschaft (M. Raab), Messer Stiftung, Deutsche Krebshilfe, German Cancer Consortium (DKTK), Heidelberg and Verein zur Forderung der Wissenschaft, Pravention and Therapie von Kehlkopfkrebs e.V. Open Access funding enabled and organized by Projekt DEAL.	Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Asteriti IA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00283; Barbosa J, 2020, EMBO J, V39, DOI 10.15252/embj.2018100789; Baxter M, 2020, CHEMMEDCHEM, V15, P1058, DOI 10.1002/cmdc.202000137; Bruinsma W, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00132; Bruinsma W, 2012, TRENDS BIOCHEM SCI, V37, P534, DOI 10.1016/j.tibs.2012.09.005; Byrne DP, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aax2713; Chan EHY, 2008, CHROMOSOMA, V117, P457, DOI 10.1007/s00412-008-0165-5; de Carcer G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05429-5; Dohner H, 2014, BLOOD, V124, P1426, DOI 10.1182/blood-2014-03-560557; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Gheghiani L, 2017, CELL REP, V19, P2060, DOI 10.1016/j.celrep.2017.05.031; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Gutteridge REA, 2016, MOL CANCER THER, V15, P1427, DOI 10.1158/1535-7163.MCT-15-0897; Joukov V, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar4195; Joukov V, 2014, MOL CELL, V55, P578, DOI 10.1016/j.molcel.2014.06.016; Kachaner D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01876-8; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lee MS, 2009, BBA-MOL CELL RES, V1793, P1571, DOI 10.1016/j.bbamcr.2009.07.005; Li HC, 2010, EMBO J, V29, P2953, DOI 10.1038/emboj.2010.174; Lim DC, 2020, MOL CELL ONCOL, V7, DOI 10.1080/23723556.2020.1832419; Lossl P, 2016, ACS CENTRAL SCI, V2, P445, DOI 10.1021/acscentsci.6b00053; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Macville M, 1999, CANCER RES, V59, P141; Matthess Y, 2010, MOL CELL BIOL, V30, P5726, DOI 10.1128/MCB.00731-10; Meng L, 2015, MOL CELL BIOL, V35, P2626, DOI 10.1128/MCB.00068-15; Meunier S, 2016, TRENDS CELL BIOL, V26, P80, DOI 10.1016/j.tcb.2015.09.001; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Park CH, 2015, J BIOL CHEM, V290, P8569, DOI 10.1074/jbc.M114.623546; Pitzius S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1936-z; Pujade-Lauraine E, 2016, J CLIN ONCOL, V34, P706, DOI 10.1200/JCO.2015.62.1474; Qi FF, 2018, CELL REP, V24, P546, DOI 10.1016/j.celrep.2018.06.087; Raab M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45627-9; Raab M, 2018, ACS CHEM BIOL, V13, P1921, DOI 10.1021/acschembio.7b01078; Rapley J, 2005, MOL CELL BIOL, V25, P1309, DOI 10.1128/MCB.25.4.1309-1324.2005; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Seki A, 2008, J CELL BIOL, V181, P65, DOI 10.1083/jcb.200712027; Sells TB, 2015, ACS MED CHEM LETT, V6, P630, DOI 10.1021/ml500409n; Seo YH, 2009, P NATL ACAD SCI USA, V106, P16163, DOI 10.1073/pnas.0903015106; Singh P, 2021, MOL CELL, V81, P67, DOI 10.1016/j.molcel.2020.10.040; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Song XH, 2020, FASEB J, V34, P4348, DOI 10.1096/fj.201902007R; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Strebhardt K, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1485539; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Taniguchi E, 2002, J BIOL CHEM, V277, P48884, DOI 10.1074/jbc.M206307200; Tsuchiya Y, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101318; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Wilhelm T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11584-0; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Xu J, 2013, NAT STRUCT MOL BIOL, V20, P1047, DOI 10.1038/nsmb.2623; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhu K, 2016, STRUCTURE, V24, P1110, DOI 10.1016/j.str.2016.04.012; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	62	2	2	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					372	386		10.1038/s41388-021-02094-9	http://dx.doi.org/10.1038/s41388-021-02094-9		NOV 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34759346	Green Published, hybrid			2022-12-17	WOS:000716867900001
J	Zhang, Z; Liu, RY; Wang, YF; Wang, Y; Shuai, YJ; Ke, CW; Jin, R; Wang, XD; Luo, JT				Zhang, Ze; Liu, Ruoyan; Wang, Yafei; Wang, Yun; Shuai, Yanjie; Ke, Chuangwu; Jin, Rui; Wang, Xudong; Luo, Jingtao			Phosphorylation of MICAL2 by ARG promotes head and neck cancer tumorigenesis by regulating skeletal rearrangement	ONCOGENE			English	Article							CELL-MIGRATION; ACTIN; INVASION; KINASES; METASTASIS; TRANSITION; CCG-1423; FAMILY; GROWTH	The actin cytoskeletal architecture provides the structural underpinnings for crucial cellular behaviors. In cancer cells, changes in the actin cytoskeleton may serve as prerequisites for proliferation, invasion, and metastatic dissemination. However, the underlying mechanisms remain largely unknown. Here, we show that MICAL2, which is increased in head and neck squamous cell carcinoma (HNSCC) and inversely associated with patient survival, promotes HNSCC growth, invasion, and migration. MICAL2 serves as a flavoprotein monooxygenase and directly induces actin filament depolymerization by specifically oxidizing the methionine 44 and 47 residues of F-actin. The kinase ARG interacts with MICAL2 and augments MICAL2-mediated actin disassembly. Direct phosphorylation assay and mass spectrometry confirmed that ARG phosphorylates MICAL2 at Tyr445, Tyr463, and Tyr488. Substitution of the Tyr445 or Tyr463 residue of purified recombinant MICAL2-redox with phenylalanine (generating a non-phosphorylatable mutant) abolishes the enhanced MICAL2-mediated F-actin disassembly induced by ARG. Consistently, ectopic expression of non-phosphorylatable MICAL2 mutants (MICAL2(Y445F) and MICAL2(Y463F), not MICAL2(Y488F)) failed to ameliorate HNSCC cell growth, whereas expression of wild-type MICAL2 or MICAL2(Y488F) rescued the impaired proliferation induced by MICAL2 knockdown. Moreover, CCG-1423, an inhibitor of MICAL2, was shown to inhibit HNSCC cell proliferation, invasion, and migration. Taken together, our findings indicate that phosphorylation of MICAL2 at Tyr445 and Tyr463 by ARG mediates F-actin disassembly and promotes HNSCC progression.	[Zhang, Ze; Wang, Yafei; Wang, Yun; Shuai, Yanjie; Ke, Chuangwu; Jin, Rui; Wang, Xudong; Luo, Jingtao] Tianjin Med Univ Canc Inst & Hosp, Dept Maxillofacial & Otorhinolaryngol Oncol, Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Zhang, Ze; Wang, Yafei; Wang, Yun; Shuai, Yanjie; Ke, Chuangwu; Jin, Rui; Wang, Xudong; Luo, Jingtao] Tianjin Med Univ Canc Inst & Hosp, Dept Head & Neck Oncol, Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Zhang, Ze; Liu, Ruoyan; Wang, Yafei; Wang, Yun; Shuai, Yanjie; Ke, Chuangwu; Jin, Rui; Wang, Xudong; Luo, Jingtao] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Zhang, Ze; Liu, Ruoyan; Wang, Yafei; Wang, Yun; Shuai, Yanjie; Ke, Chuangwu; Jin, Rui; Wang, Xudong; Luo, Jingtao] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China; [Liu, Ruoyan] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Gynecol Oncol, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Luo, JT (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Dept Maxillofacial & Otorhinolaryngol Oncol, Natl Clin Res Ctr Canc, Tianjin, Peoples R China.; Luo, JT (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Dept Head & Neck Oncol, Natl Clin Res Ctr Canc, Tianjin, Peoples R China.; Luo, JT (corresponding author), Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.; Luo, JT (corresponding author), Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.	jluo@tmu.edu.cn			Natural Science Foundation of China [81902757, 82073006, 82002757]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Our sincere appreciation goes out to Professor Ren and Dr. Zhu of the State Key Laboratory of Plant Physiology and Biochemistry of China Agricultural University, for providing technical guidance. We thank the TCGA project for its valuable contributions to HNSCC research. This study was supported by the Natural Science Foundation of China (nos. 81902757, 82073006, and 82002757).	Alto LT, 2018, CURR BIOL, V28, pR538, DOI 10.1016/j.cub.2018.01.025; [Anonymous], 2020, Nat Rev Dis Primers, V6, P93, DOI 10.1038/s41572-020-00233-2; Ashida S, 2006, CLIN CANCER RES, V12, P2767, DOI 10.1158/1078-0432.CCR-05-1995; Barravecchia I, 2019, BBA-MOL BASIS DIS, V1865, P2111, DOI 10.1016/j.bbadis.2019.04.008; Beuchle D, 2007, MECH DEVELOP, V124, P390, DOI 10.1016/j.mod.2007.01.006; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Brandt DT, 2009, NAT CELL BIOL, V11, P557, DOI 10.1038/ncb1862; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Colicelli J, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3139re6; Evelyn CR, 2007, MOL CANCER THER, V6, P2249, DOI 10.1158/1535-7163.MCT-06-0782; Fremont S, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms14528; Gau D, 2017, ANGIOGENESIS, V20, P663, DOI 10.1007/s10456-017-9560-y; Giridharan SSP, 2012, J CELL SCI, V125, P614, DOI 10.1242/jcs.089367; Greuber EK, 2013, NAT REV CANCER, V13, P559, DOI 10.1038/nrc3563; Grintsevich EE, 2016, NAT CELL BIOL, V18, P876, DOI 10.1038/ncb3390; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayes KE, 2013, ONCOGENE, V32, P4766, DOI 10.1038/onc.2012.513; Hellweg R, 2018, HORM CANCER-US, V9, P326, DOI 10.1007/s12672-018-0337-6; Hung RJ, 2011, SCIENCE, V334, P1710, DOI 10.1126/science.1211956; Hung RJ, 2010, NATURE, V463, P823, DOI 10.1038/nature08724; IKKAI T, 1966, SCIENCE, V152, P1756, DOI 10.1126/science.152.3730.1756; Kobayashi M, 2019, INVEST OPHTH VIS SCI, V60, P528, DOI 10.1167/iovs.18-25678; Kunda P, 2009, TRENDS CELL BIOL, V19, P174, DOI 10.1016/j.tcb.2009.01.006; Li CF, 2019, NAT CELL BIOL, V21, P251, DOI 10.1038/s41556-018-0268-z; Liu L, 2018, BBA-MOL BASIS DIS, V1864, P3109, DOI 10.1016/j.bbadis.2018.05.026; Lundquist MR, 2014, CELL, V156, P563, DOI 10.1016/j.cell.2013.12.035; Mariotti S, 2016, ONCOTARGET, V7, P1808, DOI 10.18632/oncotarget.6577; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Mouneimne G, 2012, CANCER CELL, V22, P615, DOI 10.1016/j.ccr.2012.09.027; Orr BO, 2017, NATURE, V550, P109, DOI 10.1038/nature24017; Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; Shaul YD, 2014, CELL, V158, P1094, DOI 10.1016/j.cell.2014.07.032; Sutherland JD, 1999, CURR OPIN CELL BIOL, V11, P142, DOI 10.1016/S0955-0674(99)80018-0; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Wang J, 2015, TRENDS CANCER, V1, P110, DOI 10.1016/j.trecan.2015.07.004; Wang Y, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12920; Wu H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17943-5; Wu H, 2016, PROTEIN EXPRES PURIF, V127, P116, DOI 10.1016/j.pep.2016.05.008; Ye GT, 2017, THERANOSTICS, V7, P3338, DOI 10.7150/thno.20512; Yoon J, 2017, DEV CELL, V42, P117, DOI 10.1016/j.devcel.2017.06.007; Zhang Z, 2020, BRIT J CANCER, V122, P82, DOI 10.1038/s41416-019-0637-9; Zhang Z, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00434; Zhou WL, 2020, CANCER LETT, V483, P75, DOI 10.1016/j.canlet.2020.04.019	47	2	2	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					334	346		10.1038/s41388-021-02101-z	http://dx.doi.org/10.1038/s41388-021-02101-z		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34750518				2022-12-17	WOS:000715670800001
J	Boudhraa, Z; Zaoui, K; Fleury, H; Cahuzac, M; Gilbert, S; Tchakarska, G; Kendall-Dupont, J; Carmona, E; Provencher, D; Mes-Masson, AM				Boudhraa, Zied; Zaoui, Kossay; Fleury, Hubert; Cahuzac, Maxime; Gilbert, Sophie; Tchakarska, Guergana; Kendall-Dupont, Jennifer; Carmona, Euridice; Provencher, Diane; Mes-Masson, Anne-Marie			NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer	ONCOGENE			English	Article							DNA-DAMAGE; CELL-CYCLE; ACTIVATION; METABOLISM; EXPRESSION; SURVIVIN; GRADE	While aneuploidy is a main enabling characteristic of cancers, it also creates specific vulnerabilities. Here we demonstrate that Ran inhibition targets epithelial ovarian cancer (EOC) survival through its characteristic aneuploidy. We show that induction of aneuploidy in rare diploid EOC cell lines or normal cells renders them highly dependent on Ran. We also establish an inverse correlation between Ran and the tumor suppressor NR1D1 and reveal the critical role of Ran/NR1D1 axis in aneuploidy-associated endogenous DNA damage repair. Mechanistically, we show that Ran, through the maturation of miR4472, destabilizes the mRNA of NR1D1 impacting several DNA repair pathways. We showed that NR1D1 interacts with both PARP1 and BRCA1 leading to the inhibition of DNA repair. Concordantly, loss of Ran was associated with NR1D1 induction, accumulation of DNA damages, and lethality of aneuploid EOC cells. Our findings suggest a synthetic lethal strategy targeting aneuploid cells based on their dependency to Ran.	[Boudhraa, Zied; Zaoui, Kossay; Fleury, Hubert; Cahuzac, Maxime; Gilbert, Sophie; Tchakarska, Guergana; Kendall-Dupont, Jennifer; Carmona, Euridice; Provencher, Diane; Mes-Masson, Anne-Marie] Univ Montreal CRCHUM, Ctr Hosp, Ctr Rech, Montreal, PQ, Canada; [Boudhraa, Zied; Zaoui, Kossay; Fleury, Hubert; Cahuzac, Maxime; Gilbert, Sophie; Tchakarska, Guergana; Kendall-Dupont, Jennifer; Carmona, Euridice; Provencher, Diane; Mes-Masson, Anne-Marie] Inst Canc Montreal ICM, Montreal, PQ, Canada; [Provencher, Diane] Univ Montreal, Div Gynecol Oncol, Montreal, PQ, Canada; [Mes-Masson, Anne-Marie] Univ Montreal, Dept Med, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal	Mes-Masson, AM (corresponding author), Univ Montreal CRCHUM, Ctr Hosp, Ctr Rech, Montreal, PQ, Canada.; Mes-Masson, AM (corresponding author), Inst Canc Montreal ICM, Montreal, PQ, Canada.; Mes-Masson, AM (corresponding author), Univ Montreal, Dept Med, Montreal, PQ, Canada.	anne-marie.mes-masson@umontreal.ca			Canadian Institute for Health Research (CIHR) [MOP142724, PJT148642]; ICM (Fonds Defi Spyder and Anne-Marie Chagnon); Ovarian Cancer Canada (OCC); Banque de tissus et de donnees of the Reseau de recherche sur le cancer of the FRQS; Canadian Tumor Repository Network (CTRNet)	Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); ICM (Fonds Defi Spyder and Anne-Marie Chagnon); Ovarian Cancer Canada (OCC); Banque de tissus et de donnees of the Reseau de recherche sur le cancer of the FRQS; Canadian Tumor Repository Network (CTRNet)	This work was supported by the Canadian Institute for Health Research (CIHR MOP142724 and PJT148642) and the ICM (Fonds Defi Spyder and Anne-Marie Chagnon). Cell lines used in this study were provided by the CRCHUM ovarian tumor bank, which is supported by Ovarian Cancer Canada (OCC) and by the Banque de tissus et de donnees of the Reseau de recherche sur le cancer of the FRQS affiliated with the Canadian Tumor Repository Network (CTRNet).	Altman BJ, 2015, CELL METAB, V22, P1009, DOI 10.1016/j.cmet.2015.09.003; Barres V, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-272; Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230; Boudhraa Z, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00345; Brodeur MN, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-97434-w; Bugge A, 2012, GENE DEV, V26, P657, DOI 10.1101/gad.186858.112; Caceres-Gorriti KY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091000; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Cekan P, 2016, MOL BIOL CELL, V27, P1346, DOI 10.1091/mbc.E16-01-0025; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Deng L, 2013, BIOCHEM BIOPH RES CO, V440, P322, DOI 10.1016/j.bbrc.2013.09.079; Fleury H, 2017, ONCOTARGET, V8, P40152, DOI 10.18632/oncotarget.10308; Fleury Hubert, 2015, Genes Cancer, V6, P378; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hasegawa K, 2013, J CELL BIOL, V200, P151, DOI 10.1083/jcb.201206142; Ka NL, 2017, MOL CELL ENDOCRINOL, V454, P87, DOI 10.1016/j.mce.2017.06.004; Ka NL, 2017, CANCER RES, V77, P2453, DOI 10.1158/0008-5472.CAN-16-2099; Kim G, 2015, CLIN CANCER RES, V21, P4257, DOI 10.1158/1078-0432.CCR-15-0887; Krietsch J, 2012, NUCLEIC ACIDS RES, V40, P10287, DOI 10.1093/nar/gks798; Letourneau IJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-379; Levine MS, 2017, DEV CELL, V40, P313, DOI 10.1016/j.devcel.2016.12.022; Mocellin S, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1010-1; Ouellet V, 2005, ONCOGENE, V24, P4672, DOI 10.1038/sj.onc.1208214; Ouellet V, 2006, INT J CANCER, V119, P599, DOI 10.1002/ijc.21902; Ouellet V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-152; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Renault L, 2001, CELL, V105, P245, DOI 10.1016/S0092-8674(01)00315-4; Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030; Sulli G, 2018, NATURE, V553, P351, DOI 10.1038/nature25170; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Wang YJ, 2015, BIOCHEM PHARMACOL, V96, P315, DOI 10.1016/j.bcp.2015.06.010; Woldt E, 2013, NAT MED, V19, P1039, DOI 10.1038/nm.3213; Xia F, 2008, MOL CELL BIOL, V28, P5299, DOI 10.1128/MCB.02039-07; Zhu J, 2018, DEV CELL, V44, P420, DOI 10.1016/j.devcel.2018.02.002	38	2	2	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					309	320		10.1038/s41388-021-02082-z	http://dx.doi.org/10.1038/s41388-021-02082-z		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34743206	hybrid, Green Published			2022-12-17	WOS:000715015000003
J	Yi, BZ; Wang, SB; Wang, XR; Liu, ZC; Zhang, C; Li, M; Gao, S; Wei, S; Bae, S; Stringer-Reasor, E; Wang, LZ; Liu, RH				Yi, Baozhu; Wang, Shuaibin; Wang, Xinran; Liu, Zhichao; Zhang, Chao; Li, Ming; Gao, Song; Wei, Shi; Bae, Sejong; Stringer-Reasor, Erica; Wang, Lizhong; Liu, Runhua			CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer	ONCOGENE			English	Article							TRANSCRIPTIONAL REPRESSOR HBP1; BETA-CATENIN; INVASION; PATHWAY; FOXP3; EXPRESSION; MICRORNAS; MIR-3662; THERAPY; COMPLEX	MicroRNA-3662 (miR-3662) is minimally expressed in normal human tissues but is highly expressed in all types of cancers, including breast cancer. As determined with The Cancer Genome Atlas dataset, miR-3662 expression is higher in triple-negative breast cancers (TNBCs) and African American breast cancers than in other breast cancer types. However, the functional role of miR-3662 remains a topic of debate. Here, we found that inhibition or knockout of endogenous, mature miR-3662 in TNBC cells suppresses proliferation and migration in vitro and tumor growth and metastasis in vivo. Functional analysis revealed that, for TNBC cells, knockout of miR-3662 reduces the activation of Wnt/beta-catenin signaling. Furthermore, using CRISPR-mediated miR-3662 activation and repression, dual-luciferase assays, and miRNA/mRNA immunoprecipitation assays, we established that HMG-box transcription factor 1 (HBP-1), a Wnt/beta-catenin signaling inhibitor, is a target of miR-3662 and is most likely responsible for miR-3662-mediated TNBC cell proliferation. Our results suggest that miR-3662 has an oncogenic function in tumor progression and metastasis via an miR-3662-HBP1 axis, regulating the Wnt /beta-catenin signaling pathway in TNBC cells. Since miR-3662 expression occurs a tumor-specific manner, it is a promising biomarker and therapeutic target for patients who have TNBCs with dysregulation of miR-3662, especially African Americans.	[Yi, Baozhu; Wang, Shuaibin; Wang, Xinran; Liu, Zhichao; Zhang, Chao; Li, Ming; Gao, Song; Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA; [Wei, Shi; Bae, Sejong; Stringer-Reasor, Erica; Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA; [Wei, Shi] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Bae, Sejong; Stringer-Reasor, Erica] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Wang, LZ; Liu, RH (corresponding author), Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA.; Wang, LZ; Liu, RH (corresponding author), Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35294 USA.	lwang12@uab.edu; runhua@uab.edu		LI, Ming/0000-0002-4198-8807; bae, sejong/0000-0001-9982-3223	National Cancer Institute [CA223077, CA238273, CA242917]; Breast Cancer Research Foundation of Alabama	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation of Alabama	We thank Dr. Donald Hill for editorial assistance in preparing this manuscript. This work was supported by grants from the National Cancer Institute (CA223077, CA238273 and CA242917 for R. Liu) and the Breast Cancer Research Foundation of Alabama (L. Wang). Results are based, in part, upon data generated by TCGA Research Network: http://cancergenome.nih.gov/.	Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048; Berasi SP, 2004, MOL CELL BIOL, V24, P3011, DOI 10.1128/MCB.24.7.3011-3024.2004; Bertoli G, 2015, THERANOSTICS, V5, P1122, DOI 10.7150/thno.11543; Bollaert E, 2019, CELL MOL LIFE SCI, V76, P1529, DOI 10.1007/s00018-019-03012-9; Caparica R, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2019-000504; Chen ZQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0616-8; Cicekdal MB, 2021, BRIT J NUTR, V125, P1, DOI 10.1017/S0007114519002757; Cittelly DM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-317; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Gao S, 2017, ONCOTARGET, V8, P41451, DOI 10.18632/oncotarget.17816; Gao YC, 2016, NAT METHODS, V13, P1043, DOI [10.1038/nmeth.4042, 10.1038/NMETH.4042]; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Hansen TB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010961; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu RH, 2015, CANCER RES, V75, P1714, DOI 10.1158/0008-5472.CAN-14-2109; Liu RH, 2015, CANCER RES, V75, P1703, DOI 10.1158/0008-5472.CAN-14-2108; Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maharry SE, 2016, CANCER DISCOV, V6, P1036, DOI 10.1158/2159-8290.CD-16-0023; O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402; Powrozek T, 2017, J CANCER RES CLIN, V143, P1941, DOI 10.1007/s00432-017-2444-0; Powrozek T, 2015, TRANSL RES, V166, P315, DOI 10.1016/j.trsl.2015.05.009; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Shi YX, 2017, MED SCI MONITOR, V23, P2042, DOI 10.12659/MSM.901191; Shih HH, 2001, MOL CELL BIOL, V21, P5723, DOI 10.1128/MCB.21.17.5723-5732.2001; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tang J, 2012, INT J MOL SCI, V13, P13414, DOI 10.3390/ijms131013414; van Schooneveld E, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0526-y; Wang LZ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6909; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Wang M, 2020, MOL CANCER RES, V18, P943, DOI 10.1158/1541-7786.MCR-19-1033; Wang YC, 2019, ONCOGENE, V38, P4820, DOI 10.1038/s41388-019-0760-3; Xiu M, 2003, MOL CELL BIOL, V23, P8890, DOI 10.1128/MCB.23.23.8890-8901.2003; Xu JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117097; Xu SH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11406; Ye J, 2020, NEOPLASMA, V67, P773, DOI 10.4149/neo_2020_190730N689; Yee AS, 2004, GENE, V336, P1, DOI 10.1016/j.gene.2004.04.004; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang GX, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0858-x; Zhang W, 2016, CLIN CANCER RES, V22, P2545, DOI 10.1158/1078-0432.CCR-15-1927; Zhu L, 2019, CANCER MANAG RES, V11, P5845, DOI 10.2147/CMAR.S200540	48	2	2	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					268	279		10.1038/s41388-021-02089-6	http://dx.doi.org/10.1038/s41388-021-02089-6		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34728806	Green Accepted			2022-12-17	WOS:000713936100001
J	Jiang, XJ; Deng, XY; Wang, J; Mo, YZ; Shi, L; Wei, F; Zhang, SS; Gong, ZJ; He, Y; Xiong, F; Wang, YM; Guo, C; Xiang, B; Zhou, M; Liao, QJ; Li, XL; Li, Y; Li, GY; Xiong, W; Zeng, ZY				Jiang, Xianjie; Deng, Xiangying; Wang, Jie; Mo, Yongzhen; Shi, Lei; Wei, Fang; Zhang, Shanshan; Gong, Zhaojian; He, Yi; Xiong, Fang; Wang, Yumin; Guo, Can; Xiang, Bo; Zhou, Ming; Liao, Qianjin; Li, Xiaoling; Li, Yong; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang			BPIFB1 inhibits vasculogenic mimicry via downregulation of GLUT1-mediated H3K27 acetylation in nasopharyngeal carcinoma	ONCOGENE			English	Article							VIRUS-ENCODED MICRORNAS; TUMOR ANGIOGENESIS; HISTONE ACETYLATION; CELL-PROLIFERATION; EXPRESSION; METABOLISM; LPLUNC1; DIFFERENTIATION; SUPPRESSES; MECHANISMS	Nasopharyngeal carcinoma (NPC) demonstrates significant regional differences and a high incidence in Southeast Asia and Southern China. Bactericidal/permeability-increasing-fold- containing family B member 1 (BPIFB1) is a relatively specific and highly expressed protein in the nasopharyngeal epithelium. BPIFB1 expression is substantially downregulated in NPC and is significantly associated with poor prognosis in patients with NPC. However, the specific molecular mechanism by which BPIFB1 regulates NPC is not well understood. In this study, we found that BPIFB1 inhibits vasculogenic mimicry by regulating the metabolic reprogramming of NPC. BPIFB1 decreases GLUT1 transcription by downregulating the JNK/AP1 signaling pathway. Altered glycolysis reduces the acetylation level of histone and decreases the expression of vasculogenic mimicry-related genes, VEGFA, VE-cadherin, and MMP2, ultimately leading to the inhibition of vasculogenic mimicry. To our knowledge, this is the first report on the role and specific mechanism of BPIFB1 as a tumor suppressor gene involved in regulating glycolysis and vasculogenic mimicry in NPC. Overall, these results provide a new therapeutic target for NPC diagnosis and treatment.	[Jiang, Xianjie; He, Yi; Xiang, Bo; Zhou, Ming; Liao, Qianjin; Li, Xiaoling; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang] Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China; [Jiang, Xianjie; He, Yi; Xiang, Bo; Zhou, Ming; Liao, Qianjin; Li, Xiaoling; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang] Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, Hunan Key Lab Canc Metab, Changsha, Hunan, Peoples R China; [Jiang, Xianjie; He, Yi; Xiang, Bo; Zhou, Ming; Liao, Qianjin; Li, Xiaoling; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang] Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, Affiliated Canc Hosp, Changsha, Hunan, Peoples R China; [Jiang, Xianjie; Deng, Xiangying; Wang, Jie; Mo, Yongzhen; Shi, Lei; Wei, Fang; Wang, Yumin; Guo, Can; Xiang, Bo; Zhou, Ming; Li, Xiaoling; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang] Cent South Univ, Canc Res Inst, Chinese Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China; [Shi, Lei; Gong, Zhaojian] Cent South Univ, Xiangya Hosp 2, Dept Oral & Maxillofacial Surg, Changsha, Hunan, Peoples R China; [Zhang, Shanshan; Xiong, Fang] Cent South Univ, Xiangya Hosp, Dept Stomatol, Changsha, Hunan, Peoples R China; [Li, Yong] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Dept Med, Houston, TX 77030 USA	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Baylor College of Medicine	Zeng, ZY (corresponding author), Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China.; Zeng, ZY (corresponding author), Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, Hunan Key Lab Canc Metab, Changsha, Hunan, Peoples R China.; Zeng, ZY (corresponding author), Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, Affiliated Canc Hosp, Changsha, Hunan, Peoples R China.; Zeng, ZY (corresponding author), Cent South Univ, Canc Res Inst, Chinese Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China.	zengzhaoyang@csu.edu.cn	li, xiao/GSN-6181-2022; li, xiaofeng/GXF-9442-2022		National Natural Science Foundation of China [81903138, 81972776, U20A20367]; Overseas Expertize Introduction Project for Discipline Innovation (111 Project) [111-2-12]; Natural Science Foundation of Hunan Province [2019JJ50778, 2019JJ50872, 2020JJ4766]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Overseas Expertize Introduction Project for Discipline Innovation (111 Project); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province)	This study was supported by grants from the National Natural Science Foundation of China (81903138, 81972776, U20A20367), the Overseas Expertize Introduction Project for Discipline Innovation (111 Project, No. 111-2-12), the Natural Science Foundation of Hunan Province (2019JJ50778, 2019JJ50872, 2020JJ4766).	Audia JE, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019521; Bao LL, 2018, ONCOGENE, V37, P2873, DOI 10.1038/s41388-018-0183-6; Barnes CE, 2019, ESSAYS BIOCHEM, V63, P97, DOI 10.1042/EBC20180061; Bo H, 2015, ONCOTARGET, V6, P20404, DOI 10.18632/oncotarget.4057; Chen Q, 2019, CANCER LETT, V463, P37, DOI 10.1016/j.canlet.2019.07.019; Chen SQ, 2020, J CELL PHYSIOL, V235, P7757, DOI 10.1002/jcp.29382; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Dong HY, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0931-9; Fan CM, 2021, CANCER LETT, V496, P41, DOI 10.1016/j.canlet.2020.09.006; Fan CM, 2018, J CANCER, V9, P2852, DOI 10.7150/jca.25460; FOLKMAN J, 1974, CANCER RES, V34, P2109; Ge JS, 2021, CANCER RES, V81, P5074, DOI 10.1158/0008-5472.CAN-20-4321; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jiang XJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01709-5; Ju SW, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01285-4; Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004; Krug B, 2019, CANCER CELL, V35, P782, DOI [10.1016/j.ccell.2019.04.004, 10.1016/j.ccell.2019.08.012]; Liao Q, 2014, ONCOGENE, V33, P2098, DOI 10.1038/onc.2013.161; Liu DS, 2020, J CELL BIOCHEM, V121, P1923, DOI 10.1002/jcb.29427; Loges Sonja, 2010, Genes Cancer, V1, P12, DOI 10.1177/1947601909356574; Lu JC, 2016, CANCER LETT, V380, P191, DOI 10.1016/j.canlet.2016.05.032; Lugano R, 2020, CELL MOL LIFE SCI, V77, P1745, DOI 10.1007/s00018-019-03351-7; Lyu XM, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007484; Ma WL, 2018, CANCER SCI, V109, P1710, DOI 10.1111/cas.13584; Mahfouz N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179202; Moussaieff A, 2015, CELL METAB, V21, P392, DOI 10.1016/j.cmet.2015.02.002; Peleg S, 2016, TRENDS BIOCHEM SCI, V41, P700, DOI 10.1016/j.tibs.2016.05.008; Peng M, 2016, SCIENCE, V354, P481, DOI 10.1126/science.aaf6284; Priya SK, 2016, INT J CANCER, V139, P729, DOI 10.1002/ijc.30067; Rosenbloom KR, 2010, NUCLEIC ACIDS RES, V38, pD620, DOI 10.1093/nar/gkp961; Sabari BR, 2017, NAT REV MOL CELL BIO, V18, P90, DOI 10.1038/nrm.2016.140; Shi L, 2015, CURR OPIN CELL BIOL, V33, P125, DOI 10.1016/j.ceb.2015.02.003; Tang L, 2021, ONCOGENE, V40, P307, DOI 10.1038/s41388-020-01531-5; Tang L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0758-7; Tu CF, 2018, CARCINOGENESIS, V39, P1517, DOI 10.1093/carcin/bgy108; Wang HF, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12600; Wang HR, 2019, ONCOGENE, V38, P5062, DOI 10.1038/s41388-019-0778-6; Wei F, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0409-0; Wei F, 2018, BRIT J CANCER, V118, P233, DOI 10.1038/bjc.2017.385; Wei F, 2017, SCI CHINA LIFE SCI, V60, P1271, DOI 10.1007/s11427-017-9172-6; Wei XX, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01288-1; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wu CC, 2019, SCI CHINA LIFE SCI, V62, P640, DOI 10.1007/s11427-018-9461-5; Wu YF, 2020, FASEB J, V34, P16205, DOI 10.1096/fj.202001508R; Xiang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07308-5; Xiong F, 2019, CHINESE MED J-PEKING, V132, P749, DOI 10.1097/CM9.0000000000000132; Xu S, 2018, ONCOL REP, V40, P377, DOI 10.3892/or.2018.6414; Zarrin B, 2017, J RES MED SCI, V22, DOI 10.4103/jrms.JRMS_182_17; Zeng ZY, 2014, SCI CHINA LIFE SCI, V57, P315, DOI 10.1007/s11427-013-4577-y; Zeng ZY, 2011, SCI CHINA LIFE SCI, V54, P966, DOI 10.1007/s11427-011-4223-5; Zhang BC, 2003, GENE CHROMOSOME CANC, V38, P80, DOI 10.1002/gcc.10247; Zhang EB, 2017, NUCLEIC ACIDS RES, V45, P3086, DOI 10.1093/nar/gkw1247; Zhao J, 2020, CANCER LETT, V477, P131, DOI 10.1016/j.canlet.2020.02.010; Zhao J, 2018, ONCOGENE, V37, P4094, DOI 10.1038/s41388-018-0250-z; Zhou YJ, 2016, J CANCER, V7, P367, DOI 10.7150/jca.13695; Zhu YJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00025	58	2	2	8	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					233	245		10.1038/s41388-021-02079-8	http://dx.doi.org/10.1038/s41388-021-02079-8		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34725462	Green Submitted			2022-12-17	WOS:000713567000002
J	Wang, F; Zhang, JY; Tang, HY; Pang, Y; Ke, XX; Peng, W; Chen, ST; Abbas, MN; Dong, Z; Cui, ZB; Cui, HJ				Wang, Feng; Zhang, Jiayi; Tang, Houyi; Pang, Yi; Ke, Xiaoxue; Peng, Wen; Chen, Shitong; Abbas, Muhammad Nadeem; Dong, Zhen; Cui, Zhaobo; Cui, Hongjuan			Nup54-induced CARM1 nuclear importation promotes gastric cancer cell proliferation and tumorigenesis through transcriptional activation and methylation of Notch2	ONCOGENE			English	Article							ARGININE METHYLATION; GLYCOSYLATION; PHOSPHORYLATION; COACTIVATOR; METABOLISM; MASTERMIND; REGULATOR; GROWTH; P63	Gastric cancer (GC) has the fifth highest incidence globally, but its molecular mechanisms are not well understood. Here, we report that coactivator-associated arginine methyltransferase 1 (CARM1) is specifically highly expressed in gastric cancer and that its overexpression correlates with poor prognosis in patients with gastric cancer. Nucleoporin 54 (Nup54) was identified as a CARM1-interacting protein that promoted CARM1 nuclear importation. In the nucleus, CARM1 cooperates with transcriptional factor EB (TFEB) to activate Notch2 transcription by inducing H3R17me2 of the Notch2 promoter but not H3R26me2. Additionally, the Notch2 intracellular domain (N2ICD) was identified as a CARM1 substrate. Methylation of N2ICD at R1786, R1838, and R2047 by CARM1 enhanced the binding between N2ICD and mastermind-like protein 1 (MAML1) and increased gastric cancer cell proliferation in vitro and tumor formation in vivo. Our findings reveal a molecular mechanism linking CARM1-mediated transcriptional activation of the Notch2 signaling pathway to Notch2 methylation in gastric cancer progression.	[Wang, Feng; Zhang, Jiayi; Tang, Houyi; Ke, Xiaoxue; Peng, Wen; Chen, Shitong; Abbas, Muhammad Nadeem; Dong, Zhen; Cui, Hongjuan] Southwest Univ, Inst Sericulture & Syst Biol, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China; [Wang, Feng; Zhang, Jiayi; Tang, Houyi; Ke, Xiaoxue; Peng, Wen; Chen, Shitong; Abbas, Muhammad Nadeem; Dong, Zhen; Cui, Hongjuan] Southwest Univ, Canc Ctr, Med Res Inst, Chongqing 400716, Peoples R China; [Pang, Yi] Chongqing Three Gorges Med Coll, Chongqing Engn Res Ctr Antitumor Nat Drugs, Chongqing 404120, Peoples R China; [Cui, Zhaobo] Harrison Int Peace Hosp, Dept Intens Care Unit, Hengshui 053000, Hebei, Peoples R China	Southwest University - China; Southwest University - China	Cui, HJ (corresponding author), Southwest Univ, Inst Sericulture & Syst Biol, State Key Lab Silkworm Genome Biol, Chongqing 400716, Peoples R China.; Cui, HJ (corresponding author), Southwest Univ, Canc Ctr, Med Res Inst, Chongqing 400716, Peoples R China.; Cui, ZB (corresponding author), Harrison Int Peace Hosp, Dept Intens Care Unit, Hengshui 053000, Hebei, Peoples R China.	zhaobocui2014@sina.com; hcui@swu.edu.cn		Dong, Zhen/0000-0003-3108-0245	China Postdoctoral Science Foundation [2021M692679]; Chongqing Postdoctoral Research Institute [7820100607]; National Key Research, and Development Program of China [2016YFC1302204, 2017YFC308600]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Chongqing Postdoctoral Research Institute; National Key Research, and Development Program of China	This study was supported by the fellowship of China Postdoctoral Science Foundation (2021M692679), the special support from Chongqing Postdoctoral Research Institute (7820100607), the National Key Research, and Development Program of China (No.2016YFC1302204 and 2017YFC308600). We thank GEPIA 2 database (http://gepia2.cancer-pku.cn/#survival), TIMER 2.0 database (http://timer.cistrome.org/), Oncomine database (https://www.oncomine.org/resource/login.html) for initial data analysis. We are grateful to PMeS (http://bioinfo.ncu.edu.cn/inquiries_PMeS.aspx) for the prediction of protein methylation sites. Technical support of confocal microscopy from Lei Zhang is greatly appreciated.	Al-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426; Andersen P, 2012, TRENDS CELL BIOL, V22, P257, DOI 10.1016/j.tcb.2012.02.003; Asakawa H, 2018, METHODS MOL BIOL, V1721, P105, DOI 10.1007/978-1-4939-7546-4_10; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; Blanc RS, 2017, MOL CELL, V65, P8, DOI 10.1016/j.molcel.2016.11.003; Borlido J, 2018, EMBO REP, V19, P3, DOI 10.15252/embr.201745497; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cheng DH, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800117; Chug H, 2015, SCIENCE, V350, P106, DOI 10.1126/science.aac7420; Demitrack ES, 2017, CELL MOL GASTROENTER, V3, P323, DOI 10.1016/j.jcmgh.2017.01.012; Deng Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1082-z; El Messaoudi S, 2006, P NATL ACAD SCI USA, V103, P13351, DOI 10.1073/pnas.0605692103; Frietze S, 2008, CANCER RES, V68, P301, DOI 10.1158/0008-5472.CAN-07-1983; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Gao WW, 2018, MOL CELL, V70, P340, DOI 10.1016/j.molcel.2018.03.006; Haines N, 2003, NAT REV MOL CELL BIO, V4, P786, DOI 10.1038/nrm1228; Hazawa M, 2018, EMBO REP, V19, P73, DOI 10.15252/embr.201744523; Hunter GL, 2020, ADV EXP MED BIOL, V1227, P51, DOI 10.1007/978-3-030-36422-9_4; Jeong GY, 2021, CANCER RES, V81, P77, DOI 10.1158/0008-5472.CAN-20-0360; Karakashev S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03031-3; Kawabe YI, 2012, CELL STEM CELL, V11, P333, DOI 10.1016/j.stem.2012.07.001; Kim YR, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-197; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kunnimalaiyaan S, 2015, HPB, V17, P770, DOI 10.1111/hpb.12442; Larsen SC, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf7329; Lim R, 2019, SCIENCE, V364, P188, DOI 10.1126/science.aat0778; Liu FB, 2017, NAT CELL BIOL, V19, P1358, DOI 10.1038/ncb3630; Liu JW, 2020, EMBO REP, V21, DOI 10.15252/embr.201948597; Penton AL, 2012, SEMIN CELL DEV BIOL, V23, P450, DOI 10.1016/j.semcdb.2012.01.010; Rodriguez-Bravo V, 2018, CELL, V174, P1200, DOI 10.1016/j.cell.2018.07.015; Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014; Shishkova E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15571; Takeuchi H, 2014, BIOCHEM BIOPH RES CO, V453, P235, DOI 10.1016/j.bbrc.2014.05.115; Takeuchi H, 2010, SEMIN CELL DEV BIOL, V21, P638, DOI 10.1016/j.semcdb.2010.03.003; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Thandapani P, 2013, MOL CELL, V50, P613, DOI 10.1016/j.molcel.2013.05.021; Torres-Padilla ME, 2007, NATURE, V445, P214, DOI 10.1038/nature05458; Wang F, 2017, ONCOTARGET, V8, P57187, DOI 10.18632/oncotarget.19231; Wang L, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500463; Wang L, 2016, CANCER CELL, V30, P179, DOI 10.1016/j.ccell.2016.06.013; Wang L, 2014, CANCER CELL, V25, P21, DOI 10.1016/j.ccr.2013.12.007; Wang XM, 2014, AM J PHYSIOL-RENAL, V306, pF205, DOI 10.1152/ajprenal.90005.2013; Wang YP, 2016, MOL CELL, V64, P673, DOI 10.1016/j.molcel.2016.09.028; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu Q, 2009, STEM CELLS, V27, P2637, DOI 10.1002/stem.131; Xiu MX, 2019, AM J CANCER RES, V9, P837; Yadav N, 2008, EMBO REP, V9, P193, DOI 10.1038/sj.embor.7401151; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Zhang DK, 2017, ONCOTARGET, V8, P80956, DOI 10.18632/oncotarget.20898; Zhong XY, 2018, CELL REP, V24, P3207, DOI 10.1016/j.celrep.2018.08.066; Zhou MH, 2014, ONCOL LETT, V8, P959, DOI 10.3892/ol.2014.2263	52	2	2	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					246	259		10.1038/s41388-021-02078-9	http://dx.doi.org/10.1038/s41388-021-02078-9		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34725461				2022-12-17	WOS:000713567000001
J	Cicek, E; Circir, A; Oyken, M; Caliskan, OA; Dioken, DN; Ergun, SG; Cetin-Atalay, R; Sapmaz, A; Ovaa, H; Sahin, O; Erson-Bensan, AE				Cicek, Esra; Circir, Ayca; Oyken, Merve; Caliskan, Ozge Akbulut; Dioken, Didem Naz; Ergun, Sezen Guntekin; Cetin-Atalay, Rengul; Sapmaz, Aysegul; Ovaa, Huib; Sahin, Ozgur; Erson-Bensan, Ayse Elif			EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; UP-REGULATION; RETROGRADE TRANSPORT; DEGRADATION; RETROMER; EGFR; TRAFFICKING; EXPRESSION; INHIBITOR; EFFICACY	Epidermal growth factor receptor (EGFR) has critical roles in epithelial cell physiology. Over-expression and over-activation of EGFR have been implicated in diverse cancers, including triple-negative breast cancers (TNBCs), prompting anti-EGFR therapies. Therefore, developing potent therapies and addressing the inevitable drug resistance mechanisms necessitates deciphering of EGFR related networks. Here, we describe Sorting Nexin 3 (SNX3), a member of the recycling retromer complex, as a critical player in the epidermal growth factor (EGF) stimulated EGFR network in TNBCs. We show that SNX3 is an immediate and sustained target of EGF stimulation initially at the protein level and later at the transcriptional level, causing increased SNX3 abundance. Using a proximity labeling approach, we observed increased interaction of SNX3 and EGFR upon EGF stimulation. We also detected colocalization of SNX3 with early endosomes and endocytosed EGF. Moreover, we show that EGFR protein levels are sensitive to SNX3 loss. Transient RNAi models of SNX3 downregulation have a temporary reduction in EGFR levels. In contrast, long-term silencing forces cells to recover and overexpress EGFR mRNA and protein, resulting in increased proliferation, colony formation, migration, invasion in TNBC cells, and increased tumor growth and metastasis in syngeneic models. Consistent with these results, low SNX3 and high EGFR mRNA levels correlate with poor relapse-free survival in breast cancer patients. Overall, our results suggest that SNX3 is a critical player in the EGFR network in TNBCs with implications for other cancers dependent on EGFR activity.	[Cicek, Esra; Circir, Ayca; Oyken, Merve; Dioken, Didem Naz; Erson-Bensan, Ayse Elif] Middle East Tech Univ METU, Dept Biol Sci, Dumlupinar Blv 1,Universiteler Mah, TR-06800 Ankara, Turkey; [Oyken, Merve; Sapmaz, Aysegul; Ovaa, Huib] Leiden Univ, Oncode Inst, Med Ctr, Einthovenweg 20, NL-2333 ZC Leiden, Netherlands; [Oyken, Merve; Sapmaz, Aysegul; Ovaa, Huib] Leiden Univ, Dept Cell & Chem Biol, Med Ctr, Einthovenweg 20, NL-2333 ZC Leiden, Netherlands; [Caliskan, Ozge Akbulut] Bilkent Univ, Dept Mol Biol & Genet, TR-06800 Ankara, Turkey; [Ergun, Sezen Guntekin; Cetin-Atalay, Rengul; Erson-Bensan, Ayse Elif] Middle East Tech Univ, Grad Sch Informat, Canc Syst Biol Lab, CanSyL, TR-06800 Ankara, Turkey; [Sahin, Ozgur] Univ South Carolina, Coll Pharm, Drug Discovery & Biomed Sci, Columbia, SC 29208 USA	Middle East Technical University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Ihsan Dogramaci Bilkent University; Middle East Technical University; University of South Carolina System; University of South Carolina Columbia	Erson-Bensan, AE (corresponding author), Middle East Tech Univ METU, Dept Biol Sci, Dumlupinar Blv 1,Universiteler Mah, TR-06800 Ankara, Turkey.	erson@metu.edu.tr	Akbulut Çalışkan, Özge/Q-8134-2018; DIOKEN, Didem Naz/AAE-7962-2022; Erson-Bensan, AYSE ELIF/L-7229-2018; Sahin, Ozgur/F-4403-2014	Akbulut Çalışkan, Özge/0000-0002-3647-1969; Erson-Bensan, AYSE ELIF/0000-0001-7398-9313; Sapmaz, Aysegul/0000-0003-3942-7602; Sahin, Ozgur/0000-0002-8033-7089; DIOKEN, Didem Naz/0000-0001-8285-8147	TUBITAK [116Z257, 119Z672]; EMBO short term fellowship; National Institutes of Health [2P20GM109091-06, 1R01CA251374-01A1]; Turkish Ministry of Development project [KanSil 2016K121540]	TUBITAK(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); EMBO short term fellowship(European Molecular Biology Organization (EMBO)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Turkish Ministry of Development project	We thank current and past members of the laboratory for critical reading of the manuscript and discussions. We thank METABRIC Consortium for sharing the breast cancer data. TUBITAK 116Z257 (AEEB), and 119Z672 (EC). EMBO short term fellowship (MO). National Institutes of Health Grant 2P20GM109091-06 (OS), 1R01CA251374-01A1 (OS). The Turkish Ministry of Development project #KanSil 2016K121540 (CanSyL).	Akhavantabasi S, 2012, CELL STRUCT FUNCT, V37, P27; Akman BH, 2012, NUCLEIC ACIDS RES, V40, P10679, DOI 10.1093/nar/gks855; Akman HB, 2015, HUM MOL GENET, V24, P6910, DOI 10.1093/hmg/ddv391; Ali R, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2016.42; Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Arighi CN, 2004, J CELL BIOL, V165, P123, DOI 10.1083/jcb.200312055; Bag N, 2015, BIOPHYS J, V109, P1925, DOI 10.1016/j.bpj.2015.09.007; Bakker J, 2017, J CELL SCI, V130, P4087, DOI 10.1242/jcs.209197; Brzozowska B, 2019, RADIAT ENVIRON BIOPH, V58, P109, DOI 10.1007/s00411-018-00772-z; Burd C, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016774; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Cavet ME, 2008, FASEB J, V22, P3607, DOI 10.1096/fj.07-094086; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD-2010-0307; Chiow KH, 2012, CELL MOL LIFE SCI, V69, P1505, DOI 10.1007/s00018-011-0887-z; Choi JH, 2004, J CELL SCI, V117, P4209, DOI 10.1242/jcs.01233; Ciuffreda L, 2009, NEOPLASIA, V11, P720, DOI 10.1593/neo.09398; Crowley Lisa C, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot087171; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dickler MN, 2009, BREAST CANCER RES TR, V115, P115, DOI 10.1007/s10549-008-0055-9; Erfani P, 2015, EPIGENETICS-US, V10, P496, DOI 10.1080/15592294.2015.1042645; Fleige Simone, 2006, Molecular Aspects of Medicine, V27, P126, DOI 10.1016/j.mam.2005.12.003; Franovic A, 2007, P NATL ACAD SCI USA, V104, P13092, DOI 10.1073/pnas.0702387104; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Golan-Lavi R, 2017, CELL REP, V18, P3129, DOI 10.1016/j.celrep.2017.03.014; Gullapalli A, 2004, MOL BIOL CELL, V15, P2143, DOI 10.1091/mbc.E03-09-0711; Harterink M, 2011, NAT CELL BIOL, V13, P914, DOI 10.1038/ncb2281; Heesom, 2013, NAT CELL BIOL, V15, P821; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Horibe T, 2014, LUMINESCENCE, V29, P96, DOI 10.1002/bio.2508; Huang YL, 2018, CANCER MANAG RES, V10, P545, DOI 10.2147/CMAR.S142650; Hwang SG, 2005, J BIOL CHEM, V280, P12758, DOI 10.1074/jbc.M413367200; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01854-0; Liu H, 2006, BIOCHEM BIOPH RES CO, V342, P537, DOI 10.1016/j.bbrc.2006.01.179; Lu J, 2021, CELL DEATH DIFFER, V28, P2871, DOI 10.1038/s41418-021-00789-w; Lucas M, 2016, CELL, V167, P1623, DOI 10.1016/j.cell.2016.10.056; Lurje G, 2009, ONCOLOGY-BASEL, V77, P400, DOI 10.1159/000279388; Masuda Hiroko, 2012, Breast Cancer Res Treat, V136, P331, DOI 10.1007/s10549-012-2289-9; McGough IJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06114-3; Miller HE, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007005; Nishi H, 2002, CANCER RES, V62, P827; Pan BR, 2019, ONCOL LETT, V18, P5332, DOI 10.3892/ol.2019.10860; Park HS, 2014, MODERN PATHOL, V27, P1212, DOI 10.1038/modpathol.2013.251; Pons V, 2008, PLOS BIOL, V6, P1942, DOI 10.1371/journal.pbio.0060214; Priya A, 2017, J CELL SCI, V130, P2707, DOI 10.1242/jcs.201905; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; Rimawi MF, 2010, CANCER-AM CANCER SOC, V116, P1234, DOI 10.1002/cncr.24816; SAINSBURY JRC, 1987, LANCET, V1, P1398; Sapmaz A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09437-x; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Seaman MNJ, 2004, J CELL BIOL, V165, P111, DOI 10.1083/jcb.200312034; Shinde SR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10689; Singh Bhuminder, 2016, F1000Res, V5, DOI 10.12688/f1000research.9025.1; Strochlic TI, 2007, J CELL BIOL, V177, P115, DOI 10.1083/jcb.200609161; Temkin P, 2011, NAT CELL BIOL, V13, P715, DOI 10.1038/ncb2252; van Weering JRT, 2012, EMBO J, V31, P4466, DOI 10.1038/emboj.2012.283; Vardarajan BN, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2012.04.020; Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018-008-7440-8; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zeisel A, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.62; Zhang P, 2011, CELL RES, V21, P1677, DOI 10.1038/cr.2011.167	65	2	2	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					220	232		10.1038/s41388-021-02086-9	http://dx.doi.org/10.1038/s41388-021-02086-9		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34718348	Green Accepted, Green Published			2022-12-17	WOS:000712941800003
J	Cherif, C; Nguyen, DT; Paris, C; Le, TK; Sefiane, T; Carbuccia, N; Finetti, P; Chaffanet, M; El Kaoutari, A; Vernerey, J; Fazli, L; Gleave, M; Manai, M; Barthelemy, P; Birnbaum, D; Bertucci, F; Taieb, D; Rocchi, P				Cherif, Chaima; Nguyen, Dang Tan; Paris, Clement; Le, Thi Khanh; Sefiane, Thibaud; Carbuccia, Nadine; Finetti, Pascal; Chaffanet, Max; El Kaoutari, Abdessamad; Vernerey, Julien; Fazli, Ladan; Gleave, Martin; Manai, Mohamed; Barthelemy, Philippe; Birnbaum, Daniel; Bertucci, Francois; Taieb, David; Rocchi, Palma			Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; ANDROGEN ABLATION; PROTEIN; GENE; APOPTOSIS; SIGNAL; CELLS; HSP27; OPPORTUNITIES; CHEMOTHERAPY	Disease progression and therapeutic resistance of prostate cancer (PC) are linked to multiple molecular events that promote survival and plasticity. We previously showed that heat shock protein 27 (HSP27) acted as a driver of castration-resistant phenotype (CRPC) and developed an oligonucleotides antisense (ASO) against HSP27 with evidence of anti-cancer activity in men with CRPC. Here, we show that the tumor suppressor Menin (MEN1) is highly regulated by HSP27. Menin is overexpressed in high-grade PC and CRPC. High MEN1 mRNA expression is associated with decreased biochemical relapse-free and overall survival. Silencing Menin with ASO technology inhibits CRPC cell proliferation, tumor growth, and restores chemotherapeutic sensitivity. ChIP-seq analysis revealed differential DNA binding sites of Menin in various prostatic cells, suggesting a switch from tumor suppressor to oncogenic functions in CRPC. These data support the evaluation of ASO against Menin for CRPC.	[Cherif, Chaima; Nguyen, Dang Tan; Paris, Clement; Le, Thi Khanh; Sefiane, Thibaud; Carbuccia, Nadine; Finetti, Pascal; Chaffanet, Max; El Kaoutari, Abdessamad; Vernerey, Julien; Birnbaum, Daniel; Bertucci, Francois; Taieb, David; Rocchi, Palma] Aix Marseille Univ, Inst Paoli Calmettes, CNRS UMR 7258, Inserm UMR 1068,Ctr Rech Cancerol Marseille,Predi, 27 Bd Lei Roure, F-13009 Marseille, France; [Cherif, Chaima; Manai, Mohamed] Sci Univ Tunis, Lab Biochem & Mol Biol, Tunis 2092, Tunisia; [Fazli, Ladan; Gleave, Martin] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Barthelemy, Philippe] Univ Bordeaux, ARNA Lab, INSERM U1212, CNRS UMR 5320, F-33076 Bordeaux, France; [Taieb, David] Aix Marseille Univ, La Timone Univ Hosp, European Ctr Res Med Imaging, Biophys & Nucl Med Dept, F-13005 Marseille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Universite de Tunis-El-Manar; University of British Columbia; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Rocchi, P (corresponding author), Aix Marseille Univ, Inst Paoli Calmettes, CNRS UMR 7258, Inserm UMR 1068,Ctr Rech Cancerol Marseille,Predi, 27 Bd Lei Roure, F-13009 Marseille, France.	palma.rocchi@inserm.fr	CHAFFANET, Max/AAU-5743-2020; EL KAOUTARI, Abdessamad/AAR-8318-2021; Taieb, Pr. David/M-5219-2017; Finetti, Pascal/O-8669-2017; Rocchi, Palma/P-5455-2014	EL KAOUTARI, Abdessamad/0000-0003-2334-3121; Finetti, Pascal/0000-0002-2674-3123; Rocchi, Palma/0000-0002-4383-4684; Le, Thi Khanh/0000-0003-1883-0371; CHAFFANET, Max/0000-0002-2344-1488; Bertucci, Francois/0000-0002-0157-0959; CHERIF, Chaima/0000-0002-5689-0327; vernerey, Julien/0000-0002-5413-4210	Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)	Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)	We would like to thank Jose Adelaide (IPC) for his help with PCR experiments, the platform ICEP for help for Ki67 experiment, Daniel Islardon (CRCM) for his help in confocal microscopy, Sebastien Benizri for antisense oligonucleotides synthesis, Estelle Duprez team and Eddy Pasquier for their help in ChIP-seq experiment, Stephane Audebert for his help with Mass spectrometry analysis for Menin interactome and Association pour la Recherche sur les Tumeurs de la Prostate (ARTP) for CC funding.	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Andrieu C, 2010, ONCOGENE, V29, P1883, DOI 10.1038/onc.2009.479; Baylot V, 2012, MOL THER, V20, P2244, DOI 10.1038/mt.2012.155; Bazzi W, 2008, GASTROENTEROLOGY, V135, P1698, DOI 10.1053/j.gastro.2008.07.031; Bello-DeOcampo D, 2003, CURR DRUG TARGETS, V4, P197, DOI 10.2174/1389450033491118; Bonnavion R, 2017, J PATHOL, V242, P90, DOI 10.1002/path.4885; Borkin D, 2018, J MED CHEM, V61, P4832, DOI 10.1021/acs.jmedchem.8b00071; Borkin D, 2016, J MED CHEM, V59, P892, DOI 10.1021/acs.jmedchem.5b01305; Borkin D, 2015, CANCER CELL, V27, P589, DOI 10.1016/j.ccell.2015.02.016; Boukarabila H, 2009, GENE DEV, V23, P1195, DOI 10.1101/gad.512009; Cao YA, 2009, MOL CELL BIOL, V29, P5477, DOI 10.1128/MCB.00335-09; Cao Z, 2015, ASIAN J UROL, V2, P11, DOI 10.1016/j.ajur.2015.04.011; Cierpicki T, 2014, FUTURE MED CHEM, V6, P447, DOI 10.4155/fmc.13.214; Crumbaker M, 2017, CANCERS, V9, DOI 10.3390/cancers9040034; Nguyen DT, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070795; Dong QC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010147; Dreijerink KMA, 2017, ENDOCR-RELAT CANCER, V24, pT135, DOI 10.1530/ERC-17-0281; Falchetti A., 2017, F1000RESEARCH, V6, pF1000, DOI [10.12688/f1000research.7230.1, DOI 10.12688/F1000RESEARCH.7230.1]; Fusi A, 2004, TUMORI J, V90, P535, DOI 10.1177/030089160409000601; Gherardi S, 2017, BBA-GENE REGUL MECH, V1860, P427, DOI 10.1016/j.bbagrm.2017.02.003; Grembecka J, 2012, NAT CHEM BIOL, V8, P277, DOI [10.1038/NCHEMBIO.773, 10.1038/nchembio.773]; Gumulec J, 2014, INT J ONCOL, V44, P923, DOI 10.3892/ijo.2013.2223; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222; Kao CJ, 2014, ONCOGENE, V33, P2495, DOI 10.1038/onc.2013.200; Katsogiannou M, 2014, MOL CELL PROTEOMICS, V13, P3585, DOI 10.1074/mcp.M114.041228; Kim H, 2003, CANCER RES, V63, P6135; Ko B, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.09; Kosaka T, 2011, J UROLOGY, V185, P2376, DOI 10.1016/j.juro.2011.02.016; Kuhn MWM, 2016, CANCER DISCOV, V6, P1166, DOI 10.1158/2159-8290.CD-16-0237; La P, 2006, ONCOGENE, V25, P3537, DOI 10.1038/sj.onc.1209400; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lemos MC, 2008, HUM MUTAT, V29, P22, DOI 10.1002/humu.20605; Lu J, 2012, ONCOGENE, V31, P3647, DOI 10.1038/onc.2011.538; Malik R, 2015, NAT MED, V21, P344, DOI 10.1038/nm.3830; Matkar S, 2013, TRENDS BIOCHEM SCI, V38, P394, DOI [10.1016/j.tibs.2013.0S.005, 10.1016/j.tibs.2013.05.005]; Menin-ASO, 2017, [No title captured], Patent No. 2017134252; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; Pang K, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5423-9; Peng DJ, 2010, BIOCHEM BIOPH RES CO, V394, P600, DOI 10.1016/j.bbrc.2010.03.029; Qian DZ, 2010, PROSTATE, V70, P433, DOI 10.1002/pros.21077; Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; Rocchi P, 2006, BJU INT, V98, P1082, DOI 10.1111/j.1464-410X.2006.06425.x; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Sehrawat A, 2018, P NATL ACAD SCI USA, V115, pE4179, DOI 10.1073/pnas.1719168115; Stein CA, 2017, MOL THER, V25, P1069, DOI 10.1016/j.ymthe.2017.03.023; Wu GW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15278; Xiong HY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073295; Yu EY, 2018, INVEST NEW DRUG, V36, P278, DOI 10.1007/s10637-017-0553-x	50	2	2	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					125	137		10.1038/s41388-021-02039-2	http://dx.doi.org/10.1038/s41388-021-02039-2		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34711954	Green Published, hybrid			2022-12-17	WOS:000712340800001
J	Kuiken, HJ; Dhakal, S; Selfors, LM; Friend, CM; Zhang, T; Callari, M; Schackmann, RCJ; Gray, GK; Crowdis, J; Bhang, HEC; Baslan, T; Stegmeier, F; Gygi, SP; Caldas, C; Brugge, JS				Kuiken, Hendrik J.; Dhakal, Sabin; Selfors, Laura M.; Friend, Chandler M.; Zhang, Tian; Callari, Maurizio; Schackmann, Ron C. J.; Gray, G. Kenneth; Crowdis, Jett; Bhang, Hyo-Eun C.; Baslan, Timour; Stegmeier, Frank; Gygi, Steven P.; Caldas, Carlos; Brugge, Joan S.			Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts	ONCOGENE			English	Article							TUMOR HETEROGENEITY; CANCER; EVOLUTION; CELLS; METASTASIS; XENOGRAFTS; MEDICINE; METAGENE; ACID	Intratumoral heterogeneity has been described for various tumor types and models of human cancer, and can have profound effects on tumor progression and drug resistance. This study describes an in-depth analysis of molecular and functional heterogeneity among subclonal populations (SCPs) derived from a single triple-negative breast cancer cell line, including copy number analysis, whole-exome and RNA sequencing, proteome analysis, and barcode analysis of clonal dynamics, as well as functional assays. The SCPs were found to have multiple unique genetic alterations and displayed significant variation in anchorage independent growth and tumor forming ability. Analyses of clonal dynamics in SCP mixtures using DNA barcode technology revealed selection for distinct clonal populations in different in vitro and in vivo environmental contexts, demonstrating that in vitro propagation of cancer cell lines using different culture conditions can contribute to the establishment of unique strains. These analyses also revealed strong enrichment of a single SCP during the development of xenograft tumors in immune-compromised mice. This SCP displayed attenuated interferon signaling in vivo and reduced sensitivity to the antiproliferative effects of type I interferons. Reduction in interferon signaling was found to provide a selective advantage within the xenograft microenvironment specifically. In concordance with the previously described role of interferon signaling as tumor suppressor, these findings suggest that similar selective pressures may be operative in human cancer and patient-derived xenograft models.	[Kuiken, Hendrik J.; Dhakal, Sabin; Selfors, Laura M.; Friend, Chandler M.; Zhang, Tian; Schackmann, Ron C. J.; Gray, G. Kenneth; Crowdis, Jett; Gygi, Steven P.; Brugge, Joan S.] Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA; [Kuiken, Hendrik J.; Dhakal, Sabin; Selfors, Laura M.; Friend, Chandler M.; Schackmann, Ron C. J.; Gray, G. Kenneth; Crowdis, Jett; Brugge, Joan S.] Ludwig Ctr Harvard, Boston, MA 02115 USA; [Callari, Maurizio; Caldas, Carlos] Univ Cambridge, Li Ka Shing Ctr, Canc Res UK Cambridge Inst, Robinson Way, Cambridge CB2 0RE, England; [Bhang, Hyo-Eun C.; Stegmeier, Frank] Novartis Inst Biomed Res, Dept Oncol, Cambridge, MA 02139 USA; [Baslan, Timour] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Kuiken, Hendrik J.] Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; [Dhakal, Sabin] Inzen Therapeut, Cambridge, MA 02142 USA; [Schackmann, Ron C. J.] Merus, NL-3584 CM Utrecht, Netherlands; [Crowdis, Jett] Broad Inst, Cambridge, MA 02142 USA; [Bhang, Hyo-Eun C.] Civetta Therapeut, Cambridge, MA 02142 USA; [Stegmeier, Frank] KSQ Therapeut Inc, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Novartis; Memorial Sloan Kettering Cancer Center; Netherlands Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Brugge, JS (corresponding author), Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA.; Brugge, JS (corresponding author), Ludwig Ctr Harvard, Boston, MA 02115 USA.	Joan_Brugge@hms.harvard.edu		SELFORS, LAURA/0000-0002-1317-7353	NIH [PPG P01CA080111]; Breast Cancer Research Foundation [BCRF-19-021]; Ludwig Center at Harvard	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; Ludwig Center at Harvard	We are grateful to Angie Martinez-Gakidis for scientific editing, the ICCB-Longwood Screening Facility at Harvard Medical School for providing support and access to instruments, and the BioPolymers Facility at Harvard Medical School and Bauer Core Facility at Harvard University for providing support with next-generation sequencing. This work was supported by grants from the NIH (PPG P01CA080111), the Breast Cancer Research Foundation (BCRF-19-021), and the Ludwig Center at Harvard.	Agelopoulos K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-78; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bakhoum SF, 2018, CELL, V174, P1347, DOI 10.1016/j.cell.2018.08.027; Baslan T, 2020, ELIFE, V9, DOI 10.7554/eLife.51480; Baslan T, 2017, NAT REV CANCER, V17, P557, DOI 10.1038/nrc.2017.58; Ben-David U, 2018, NATURE, V560, P325, DOI 10.1038/s41586-018-0409-3; Ben-David U, 2017, NAT GENET, V49, P1567, DOI 10.1038/ng.3967; Bhang HEC, 2015, NAT MED, V21, P440, DOI 10.1038/nm.3841; Bruna A, 2016, CELL, V167, P260, DOI 10.1016/j.cell.2016.08.041; Byrne AT, 2017, NAT REV CANCER, V17, P254, DOI 10.1038/nrc.2016.140; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; Callari M, 2016, CLIN CANCER RES, V22, P337, DOI 10.1158/1078-0432.CCR-15-0757; Callari M, 2014, MOL ONCOL, V8, P1278, DOI 10.1016/j.molonc.2014.04.010; Cantor JR, 2017, CELL, V169, P258, DOI 10.1016/j.cell.2017.03.023; Cassidy JW, 2015, CANCER RES, V75, P2963, DOI 10.1158/0008-5472.CAN-15-0727; Chung W, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15081; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Echeverria GV, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07406-4; Eirew P, 2015, NATURE, V518, P422, DOI 10.1038/nature13952; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; Gao RL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00244-w; Gao RL, 2016, NAT GENET, V48, P1119, DOI 10.1038/ng.3641; Georgopoulou D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22303-z; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grigoriadis A, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-619; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003; Karaayvaz M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06052-0; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Laks E, 2019, CELL, V179, P1207, DOI 10.1016/j.cell.2019.10.026; Li WZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14364-2; Lim B, 2020, CANCER CELL, V37, P456, DOI 10.1016/j.ccell.2020.03.008; Liu YS, 2019, NAT BIOTECHNOL, V37, P314, DOI 10.1038/s41587-019-0037-y; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marusyk A, 2020, CANCER CELL, V37, P471, DOI 10.1016/j.ccell.2020.03.007; Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Merino D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08595-2; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Meyer M, 2015, P NATL ACAD SCI USA, V112, P851, DOI 10.1073/pnas.1320611111; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Naffar-Abu Amara S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19584-1; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; Nolan-Stevaux O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067316; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Olive JF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198790; Paludan SR, 2019, NAT REV IMMUNOL, V19, P141, DOI 10.1038/s41577-018-0117-0; Post AEM, 2018, CLIN CANCER RES, V24, P3397, DOI 10.1158/1078-0432.CCR-17-2551; Reis-Filho JS, 2008, HISTOPATHOLOGY, V52, P108, DOI 10.1111/j.1365-2559.2007.02889.x; Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27; Saleiro D, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.101299; Sato K, 2019, CANCER GENOM PROTEOM, V16, P21, DOI 10.21873/cgp.20109; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Sondka Z, 2018, NAT REV CANCER, V18, P696, DOI 10.1038/s41568-018-0060-1; Tabassum DP, 2015, NAT REV CANCER, V15, P473, DOI 10.1038/nrc3971; Waclaw B, 2015, NATURE, V525, P261, DOI 10.1038/nature14971; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600; WEBER H, 1987, EMBO J, V6, P591, DOI 10.1002/j.1460-2075.1987.tb04795.x; Woo XY, 2021, NAT GENET, V53, DOI 10.1038/s41588-020-00750-6; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Zardavas D, 2015, NAT REV CLIN ONCOL, V12, P381, DOI 10.1038/nrclinonc.2015.73; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845	71	2	2	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					112	124		10.1038/s41388-021-02075-y	http://dx.doi.org/10.1038/s41388-021-02075-y		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34703030	Green Accepted			2022-12-17	WOS:000711362100001
J	Ingram, K; Samson, SC; Zewdu, R; Zitnay, RG; Snyder, EL; Mendoza, MC				Ingram, Kelley; Samson, Shiela C.; Zewdu, Rediet; Zitnay, Rebecca G.; Snyder, Eric L.; Mendoza, Michelle C.			NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity	ONCOGENE			English	Article							KINASE PHOSPHATASES; ADENOCARCINOMA; EXPRESSION; CLASSIFICATION; SUPPRESSION; ACTIVATION; INITIATION; KRAS(G12D); COOPERATE; DRIVEN	The RAS -> RAF -> MEK -> ERK pathway is hyperactivated in the majority of human lung adenocarcinoma (LUAD). However, the initial activating mutations induce homeostatic feedback mechanisms that limit ERK activity. How ERK activation reaches the tumor-promoting levels that overcome the feedback and drive malignant progression is unclear. We show here that the lung lineage transcription factor NKX2-1 suppresses ERK activity. In human tissue samples and cell lines, xenografts, and genetic mouse models, NKX2-1 induces the ERK phosphatase DUSP6, which inactivates ERK. In tumor cells from late-stage LUAD with silenced NKX2-1, re-introduction of NKX2-1 induces DUSP6 and inhibits tumor growth and metastasis. We show that DUSP6 is necessary for NKX2-1-mediated inhibition of tumor progression in vivo and that DUSP6 expression is sufficient to inhibit RAS-driven LUAD. Our results indicate that NKX2-1 silencing, and thereby DUSP6 downregulation, is a mechanism by which early LUAD can unleash ERK hyperactivation for tumor progression.	[Ingram, Kelley; Samson, Shiela C.; Snyder, Eric L.; Mendoza, Michelle C.] Univ Utah, Dept Ontol Sci, Salt Lake City, UT 84112 USA; [Ingram, Kelley; Samson, Shiela C.; Zewdu, Rediet; Zitnay, Rebecca G.; Snyder, Eric L.; Mendoza, Michelle C.] Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Zewdu, Rediet; Snyder, Eric L.] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; [Zitnay, Rebecca G.; Mendoza, Michelle C.] Univ Utah, Dept Biomed Engn, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Mendoza, MC (corresponding author), Univ Utah, Dept Ontol Sci, Salt Lake City, UT 84112 USA.; Mendoza, MC (corresponding author), Huntsman Canc Inst, Salt Lake City, UT 84112 USA.; Mendoza, MC (corresponding author), Univ Utah, Dept Biomed Engn, Salt Lake City, UT 84112 USA.	Michelle.Mendoza@hci.utah.edu		Mendoza, Michelle/0000-0002-6490-1794; Snyder, Eric/0000-0003-3591-3195	University of Utah Flow Cytometry Facility; American Cancer Society [RSG CSM130435]; V Scholar Award; Burroughs Wellcome Fund; American Lung Association Research Grant;  [K01CA168850];  [R21CA215891];  [5P30CA042014-24];  [1S10RR026802-01];  [R01CA212415];  [R01CA240317]	University of Utah Flow Cytometry Facility; American Cancer Society(American Cancer Society); V Scholar Award; Burroughs Wellcome Fund(Burroughs Wellcome Fund); American Lung Association Research Grant; ; ; ; ; ; 	Thanks to Dr. Stephen Keyse for the gift of the DUSP6 promoter constructs and Dr. Doug Mackay for H2B-mCherry-N2. Thanks to Keith Carney for the development of software for automated cell migration tracking. Flow cytometry was supported by the University of Utah Flow Cytometry Facility and funding from 5P30CA042014-24 and 1S10RR026802-01. Thanks to the University of Utah Cell Imaging Core and the Huntsman Cancer Institute Preclinical Research Resource. M.C.M was supported by K01CA168850, R21CA215891, an American Lung Association Research Grant, American Cancer Society RSG CSM130435, and V Scholar Award. E.L.S. was supported by a Career Award for Medical Scientists from the Burroughs Wellcome Fund, a V Scholar Award, and R01CA212415 and R01CA240317.	Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Camolotto SA, 2018, ELIFE, V7, DOI 10.7554/eLife.38579; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096; Cicchini M, 2017, CELL REP, V18, P1958, DOI 10.1016/j.celrep.2017.01.069; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Davies AE, 2020, CELL SYST, V11, P161, DOI 10.1016/j.cels.2020.07.004; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ding W, 2003, GENE, V322, P175, DOI 10.1016/j.gene.2003.09.004; Ekerot M, 2008, BIOCHEM J, V412, P287, DOI 10.1042/BJ20071512; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Gilbert-Ross M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90487; Gillies TE, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20209518; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hrustanovic G, 2015, NAT MED, V21, P1038, DOI 10.1038/nm.3930; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kong XJ, 2017, NATURE, V550, P270, DOI 10.1038/nature24037; Li CMC, 2015, GENE DEV, V29, P1850, DOI 10.1101/gad.267393.115; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; Marjanovic ND, 2020, CANCER CELL, V38, P229, DOI 10.1016/j.ccell.2020.06.012; Minoo P, 2007, MOL CELL BIOL, V27, P2155, DOI 10.1128/MCB.01133-06; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Nieto P, 2017, NATURE, V548, P239, DOI 10.1038/nature23297; Noguchi M, 2010, CANCER METAST REV, V29, P15, DOI 10.1007/s10555-010-9210-y; Nunes-Xavier C, 2011, ANTI-CANCER AGENT ME, V11, P109, DOI 10.2174/187152011794941190; Okudela K, 2009, AM J PATHOL, V175, P867, DOI 10.2353/ajpath.2009.080489; Premsrirut PK, 2011, CELL, V145, P145, DOI 10.1016/j.cell.2011.03.012; Russell PA, 2011, J THORAC ONCOL, V6, P1496, DOI 10.1097/JTO.0b013e318221f701; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224; Trejo CL, 2012, CANCER RES, V72, P3048, DOI 10.1158/0008-5472.CAN-11-3649; Unni AM, 2018, ELIFE, V7, DOI 10.7554/eLife.33718; Vicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644; Watanabe H, 2013, GENE DEV, V27, P197, DOI 10.1101/gad.203208.112; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Xu X, 2012, P NATL ACAD SCI USA, V109, P4910, DOI 10.1073/pnas.1112499109; Yatabe Y, 2005, AM J SURG PATHOL, V29, P633, DOI 10.1097/01.pas.0000157935.28066.35; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232; Zewdu R, 2021, ELIFE, V10, DOI 10.7554/eLife.66788	43	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					293	300		10.1038/s41388-021-02076-x	http://dx.doi.org/10.1038/s41388-021-02076-x		OCT 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34689179	Green Accepted, Green Submitted			2022-12-17	WOS:000710613600002
J	Alam, SK; Zhang, YC; Wang, L; Zhu, Z; Hernandez, CE; Zhou, YL; Yang, N; Lei, J; Chen, XY; Zeng, L; Klein, MA; Hoeppner, LH				Alam, Sk. Kayum; Zhang, Yongchang; Wang, Li; Zhu, Zhu; Hernandez, Christina E.; Zhou, Yuling; Yang, Nong; Lei, Jian; Chen, Xiaoyan; Zeng, Liang; Klein, Mark A.; Hoeppner, Luke H.			DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; MEDIATES TRASTUZUMAB RESISTANCE; TYROSINE KINASE INHIBITORS; T-DARPP; ACQUIRED-RESISTANCE; CANCER CELLS; GEFITINIB; MUTATIONS; MEHD7945A; DOPAMINE	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-refractory lung adenocarcinoma (LUAD) progression is a major clinical problem. New approaches to predict and prevent acquired resistance to EGFR TKIs are urgently needed. Here, we show that dopamine and cyclic AMP-regulated phosphoprotein, Mr 32000 (DARPP-32) physically recruits ERBB3 (HER3) to EGFR to mediate switching from EGFR homodimers to EGFR:ERBB3 heterodimers to bypass EGFR TKI-mediated inhibition by potentiating ERBB3-dependent activation of oncogenic signaling. In paired LUAD patient-derived specimens before and after EGFR TKI-refractory disease progression, we reveal that DARPP-32 and kinase-activated EGFR and ERBB3 proteins are overexpressed upon acquired resistance. In mice, DARPP-32 ablation sensitizes gefitinib-resistant xenografts to EGFR TKIs, while DARPP-32 overexpression increases gefitinib-refractory LUAD progression in gefitinib-sensitive lung tumors. We introduce a DARPP-32-mediated, ERBB3-dependent mechanism the LUAD cells use to evade EGFR TKI-induced cell death, potentially paving the way for the development of therapies to better combat therapy-refractory LUAD progression.	[Alam, Sk. Kayum; Wang, Li; Zhu, Zhu; Hernandez, Christina E.; Hoeppner, Luke H.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Zhang, Yongchang; Zhou, Yuling; Yang, Nong; Zeng, Liang] Cent South Univ, Affiliated Canc Hosp, Hunan Canc Hosp,Dept Med Oncol, Lung Canc & Gastrointestinal Unit,Xiangya Sch Med, Changsha, Peoples R China; [Lei, Jian; Chen, Xiaoyan] Cent South Univ, Affiliated Canc Hosp, Hunan Canc Hosp, Dept Pathol,Xiangya Sch Med, Changsha, Peoples R China; [Klein, Mark A.] Minneapolis Vet Affairs Healthcare Syst, Hematol Oncol Sect, Minneapolis, MN USA; [Klein, Mark A.] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA; [Klein, Mark A.; Hoeppner, Luke H.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA	University of Minnesota System; Central South University; Central South University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Alam, SK; Hoeppner, LH (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.; Hoeppner, LH (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.	skalam@umn.edu; hoepp005@umn.edu	Wang, Li/AAM-2454-2021; ALAM, SK KAYUM/ABA-3659-2020	Wang, Li/0000-0002-8969-7427; ALAM, SK KAYUM/0000-0001-5342-4542; Zhang, Yongchang/0000-0002-6829-7176; Hoeppner, Luke/0000-0003-3948-4244	Elsa U. Pardee Foundation; American Cancer Society [129819-IRG-16-189-58-IRG81]; Hormel Foundation; Fifth District Eagles Cancer Telethon Postdoctoral Fellowship Award; Department of Veterans Affairs (Veterans Health Administration)	Elsa U. Pardee Foundation; American Cancer Society(American Cancer Society); Hormel Foundation; Fifth District Eagles Cancer Telethon Postdoctoral Fellowship Award; Department of Veterans Affairs (Veterans Health Administration)(US Department of Veterans Affairs)	This work was supported by The Elsa U. Pardee Foundation, Institutional Research Grant #129819-IRG-16-189-58-IRG81 from the American Cancer Society, and The Hormel Foundation (to L.H.H.) as well as the Fifth District Eagles Cancer Telethon Postdoctoral Fellowship Award (to S.K.A.). This material is based partially upon work supported by the Department of Veterans Affairs (specifically, the Veterans Health Administration). M.A.K. is an employee of the Minneapolis VA Healthcare System.	Alam SK, 2020, BRIT J CANCER, V123, P819, DOI 10.1038/s41416-020-0923-6; Alam SK, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0050-6; [Anonymous], 2021, Cancer Discov, V11, pOF6, DOI 10.1158/2159-8290.CD-NB2021-0340; Avanes A, 2019, BIOCHEM PHARMACOL, V160, P71, DOI 10.1016/j.bcp.2018.12.008; Balz LM, 2012, J PATHOL, V227, P234, DOI 10.1002/path.3991; Beckler A, 2003, CANCER, V98, P1547, DOI 10.1002/cncr.11654; Belkhiri A, 2005, CANCER RES, V65, P6583, DOI 10.1158/0008-5472.CAN-05-1433; Belkhiri A, 2008, CLIN CANCER RES, V14, P4564, DOI 10.1158/1078-0432.CCR-08-0121; Belkhiri A, 2008, CANCER RES, V68, P395, DOI 10.1158/0008-5472.CAN-07-1580; Belkhiri A, 2016, ONCOTARGET, V7, P17631, DOI 10.18632/oncotarget.7268; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Chen Z, 2016, GUT, V65, P925, DOI 10.1136/gutjnl-2014-308416; Christenson JL, 2015, ONCOTARGET, V6, P33134, DOI 10.18632/oncotarget.5311; Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794; Cortot AB, 2014, EUR RESPIR REV, V23, P356, DOI 10.1183/09059180.00004614; El-Rifai W, 2002, CANCER RES, V62, P4061; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Fayette J, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00232; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; Hamel S, 2010, BREAST CANCER RES TR, V120, P47, DOI 10.1007/s10549-009-0364-7; Han SW, 2005, INT J CANCER, V113, P109, DOI 10.1002/ijc.20550; Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; Hoeppner LH, 2015, MOL ONCOL, V9, P270, DOI 10.1016/j.molonc.2014.08.008; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hong J, 2012, CANCER RES, V72, P4504, DOI 10.1158/0008-5472.CAN-12-1119; Huang S, 2013, CANCER RES, V73, P824, DOI 10.1158/0008-5472.CAN-12-1611; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Juchum M, 2015, DRUG RESIST UPDATE, V20, P12, DOI 10.1016/j.drup.2015.05.002; Jura N, 2009, P NATL ACAD SCI USA, V106, P21608, DOI 10.1073/pnas.0912101106; Juric D, 2015, CLIN CANCER RES, V21, P2462, DOI 10.1158/1078-0432.CCR-14-2412; Kumagai Shogo, 2021, Nat Rev Cancer, V21, P181, DOI 10.1038/s41568-020-00322-0; Lee CK, 2015, J CLIN ONCOL, V33, P1958, DOI 10.1200/JCO.2014.58.1736; Lemmon MA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020768; Lenz G, 2018, CLIN CANCER RES, V24, P1216, DOI 10.1158/1078-0432.CCR-17-0824; Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8; Li CR, 2015, MOL CANCER THER, V14, P2049, DOI 10.1158/1535-7163.MCT-15-0155; Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6; Liu Q, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0793-1; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; McKnight BN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27454-6; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Momand J, 2017, FEBS OPEN BIO, V7, P1328, DOI 10.1002/2211-5463.12269; Mukherjee K, 2010, SURGERY, V148, P354, DOI 10.1016/j.surg.2010.05.011; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Offin M, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00126; Ono M, 2004, MOL CANCER THER, V3, P465; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Reck M, 2017, NEW ENGL J MED, V377, P849, DOI 10.1056/NEJMra1703413; Roberts TC, 2020, NAT REV DRUG DISCOV, V19, P673, DOI 10.1038/s41573-020-0075-7; Roper N, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100007; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Saba NF, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00031; Salvesen GS, 2002, CELL DEATH DIFFER, V9, P3, DOI 10.1038/sj.cdd.4400963; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shih Andrew J, 2011, Cancers (Basel), V3, P1195, DOI 10.3390/cancers3011195; Sidaway P, 2020, NAT REV CLIN ONCOL, V17, P336, DOI 10.1038/s41571-020-0366-2; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Skoulidis F, 2019, NAT REV CANCER, V19, P495, DOI 10.1038/s41568-019-0179-8; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Song XL, 2015, CANCER RES, V75, P1035, DOI 10.1158/0008-5472.CAN-13-1625; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; Tiwari A, 2020, GASTROENTEROLOGY, V159, P1882, DOI 10.1053/j.gastro.2020.07.046; Tomasello C, 2018, CRIT REV ONCOL HEMAT, V123, P149, DOI 10.1016/j.critrevonc.2018.01.013; Tumbrink HL, 2021, ONCOGENE, V40, P1, DOI 10.1038/s41388-020-01510-w; Vangamudi B, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-32; Vangamudi B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-240; WALAAS SI, 1983, J NEUROSCI, V3, P291; Wang DD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128360; Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2; Wang MSJ, 2005, INT J CLIN PRACT, V59, P58, DOI 10.1111/j.1742-1241.2004.00305.x; Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018-008-7440-8; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xia WL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3480; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980; Zhang X, 2021, CANCER RES, V81, P3051, DOI 10.1158/0008-5472.CAN-20-2435; Zhou Q, 2012, BRIT J PHARMACOL, V166, P1756, DOI 10.1111/j.1476-5381.2012.01875.x; Zhu SM, 2020, CANCER LETT, V491, P87, DOI 10.1016/j.canlet.2020.07.014; Zhu SM, 2019, ONCOGENE, V38, P5805, DOI 10.1038/s41388-019-0843-1; Zhu SM, 2017, GUT, V66, P802, DOI 10.1136/gutjnl-2016-312141; Zhu SM, 2011, GASTROENTEROLOGY, V141, P1738, DOI 10.1053/j.gastro.2011.06.070	94	2	2	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					83	98		10.1038/s41388-021-02028-5	http://dx.doi.org/10.1038/s41388-021-02028-5		OCT 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34675407	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000709687900003
J	Chen, J; Guanizo, A; Luong, Q; Jayasekara, WSN; Jayasinghe, D; Inampudi, C; Szczepny, A; Garama, DJ; Russell, PA; Ganju, V; Cain, JE; Watkins, DN; Gough, DJ				Chen, Jasmine; Guanizo, Aleks; Luong, Quinton; Jayasekara, W. Samantha N.; Jayasinghe, Dhilshan; Inampudi, Chaitanya; Szczepny, Anette; Garama, Daniel J.; Russell, Prudence A.; Ganju, Vinod; Cain, Jason E.; Watkins, D. Neil; Gough, Daniel J.			Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium	ONCOGENE			English	Article							C-MYC; CLARA CELLS; MICE; AMPLIFICATION; PROGRESSION; NUMBER; NFIB	Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer characterized by loss of function TP53 and RB1 mutations in addition to mutations in other oncogenes including MYC. Overexpression of MYC together with Trp53 and Rb1 loss in pulmonary neuroendocrine cells of the mouse lung drives an aggressive neuroendocrine low variant subtype of SCLC. However, the transforming potential of MYC amplification alone on airway epithelium is unclear. Therefore, we selectively and conditionally overexpressed MYC stochastically throughout the airway or specifically in neuroendocrine, club, or alveolar type II cells in the adult mouse lung. We observed that MYC overexpression induced carcinoma in situ which did not progress to invasive disease. The formation of adenoma or SCLC carcinoma in situ was dependent on the cell of origin. In contrast, MYC overexpression combined with conditional deletion of both Trp53 and Rb1 exclusively gave rise to SCLC, irrespective of the cell lineage of origin. However, cell of origin influenced disease latency, metastatic potential, and the transcriptional profile of the SCLC phenotype. Together this reveals that MYC overexpression alone provides a proliferative advantage but when combined with deletion of Trp53 and Rb1 it facilitates the formation of aggressive SCLC from multiple cell lineages.	[Chen, Jasmine; Guanizo, Aleks; Luong, Quinton; Jayasekara, W. Samantha N.; Jayasinghe, Dhilshan; Inampudi, Chaitanya; Szczepny, Anette; Garama, Daniel J.; Ganju, Vinod; Cain, Jason E.; Gough, Daniel J.] Hudson Inst Med Res, Ctr Canc Res, 27-31 Wright St, Clayton, Vic 3168, Australia; [Chen, Jasmine; Guanizo, Aleks; Luong, Quinton; Jayasekara, W. Samantha N.; Jayasinghe, Dhilshan; Inampudi, Chaitanya; Szczepny, Anette; Garama, Daniel J.; Ganju, Vinod; Cain, Jason E.; Gough, Daniel J.] Monash Univ, Dept Mol & Translat Sci, 27-31 Wright St, Clayton, Vic 3168, Australia; [Russell, Prudence A.] St Vincents Hosp, Dept Anat Pathol, Melbourne, Vic, Australia; [Watkins, D. Neil] Res Inst Oncol & Hematol, Canc Care Manitoba, Winnipeg, MB R3E 0V9, Canada; [Watkins, D. Neil] Univ Manitoba, Rady Fac Hlth Sci, Dept Internal Med, Winnipeg, MB R3T 2N2, Canada	Hudson Institute of Medical Research; Monash University; St Vincent's Hospital Melbourne; University of Manitoba	Gough, DJ (corresponding author), Hudson Inst Med Res, Ctr Canc Res, 27-31 Wright St, Clayton, Vic 3168, Australia.; Gough, DJ (corresponding author), Monash Univ, Dept Mol & Translat Sci, 27-31 Wright St, Clayton, Vic 3168, Australia.	Daniel.gough@hudson.org.au		Gough, Daniel/0000-0001-6479-1735	Operational Infrastructure Support Program by the Victorian Government of Australia; Victorian Cancer Agency Mid-Career Fellowship [MCRF19033]; Cancer Council of Victoria [GNT1140528]	Operational Infrastructure Support Program by the Victorian Government of Australia; Victorian Cancer Agency Mid-Career Fellowship; Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria)	This work was supported by the Operational Infrastructure Support Program by the Victorian Government of Australia. D.J. Gough is supported by a Victorian Cancer Agency Mid-Career Fellowship (MCRF19033) and a grant in aid from the Cancer Council of Victoria (GNT1140528).	Alves RDS, 2014, J CANCER RES CLIN, V140, P2021, DOI 10.1007/s00432-014-1769-1; Boers JE, 1999, AM J RESP CRIT CARE, V159, P1585, DOI 10.1164/ajrccm.159.5.9806044; Burr ML, 2019, CANCER CELL, V36, P385, DOI 10.1016/j.ccell.2019.08.008; Calado DP, 2012, NAT IMMUNOL, V13, P1092, DOI 10.1038/ni.2418; CRAPO JD, 1982, AM REV RESPIR DIS, V126, P332; Denny SK, 2016, CELL, V166, P328, DOI 10.1016/j.cell.2016.05.052; Ehrhardt A, 2001, BRIT J CANCER, V84, P813, DOI 10.1054/bjoc.2000.1676; Farago AF, 2018, TRANSL LUNG CANCER R, V7, P69, DOI 10.21037/tlcr.2018.01.16; Foroutan M, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2435-4; Geick A, 2001, TRANSGENIC RES, V10, P501, DOI 10.1023/A:1013085228119; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Grunblatt E, 2020, GENE DEV, V34, P1210, DOI 10.1101/gad.340133.120; Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064; Huang YH, 2018, GENE DEV, V32, P915, DOI 10.1101/gad.314815.118; Ireland AS, 2020, CANCER CELL, V38, P60, DOI 10.1016/j.ccell.2020.05.001; Johnson BE, 1996, J CELL BIOCHEM, P210; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Mollaoglu G, 2017, CANCER CELL, V31, P270, DOI 10.1016/j.ccell.2016.12.005; Morton JP, 2013, MOL ONCOL, V7, P248, DOI 10.1016/j.molonc.2013.02.015; Olsen RR, 2021, GENE DEV, V35, P847, DOI 10.1101/gad.348295.121; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Plasschaert LW, 2018, NATURE, V560, P377, DOI 10.1038/s41586-018-0394-6; Rotinen M, 2018, NAT MED, V24, P1887, DOI 10.1038/s41591-018-0241-1; Semenova EA, 2016, CELL REP, V16, P631, DOI 10.1016/j.celrep.2016.06.020; Simpson DS, 2009, CANCER RES, V69, P8733, DOI 10.1158/0008-5472.CAN-09-1359; Sutherland KD, 2011, CANCER CELL, V19, P754, DOI 10.1016/j.ccr.2011.04.019; Voortman J, 2010, P NATL ACAD SCI USA, V107, P13040, DOI 10.1073/pnas.1008132107; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Yang D, 2018, CANCER DISCOV, V8, P1316, DOI 10.1158/2159-8290.CD-17-0987; Zhang W, 2018, TRANSL LUNG CANCER R, V7, P32, DOI 10.21037/tlcr.2018.02.02	32	2	2	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					138	145		10.1038/s41388-021-02070-3	http://dx.doi.org/10.1038/s41388-021-02070-3		OCT 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34675406				2022-12-17	WOS:000709687900004
J	Liu, WL; Li, HZ; Aerbajinai, W; Botos, I; Rodgers, GP				Liu, Wenli; Li, Hongzhen; Aerbajinai, Wulin; Botos, Istvan; Rodgers, Griffin P.			OLFM4-RET fusion is an oncogenic driver in small intestine adenocarcinoma	ONCOGENE			English	Article							TYROSINE KINASE; AUTOPHOSPHORYLATION SITES; PAPILLARY CARCINOMAS; RET PROTOONCOGENE; RET/PTC1 ONCOGENE; EXPRESSION; IDENTIFICATION; HGC-1; ACTIVATION; APOPTOSIS	Small intestine adenocarcinoma is a rare intestinal malignancy with distinct clinical, pathological, and molecular characteristics. Recently, a fusion of the intestinal stem-cell marker olfactomedin 4 (OLFM4) and the proto-oncogene RET has been identified in a small intestine adenocarcinoma patient. Here we investigated the biological effects of OLFM4-RET fusion and whether it can initiate tumorigenesis in small intestine. OLFM4 expression was found to be frequently lost or reduced in human small intestine adenocarcinoma, and its downregulation correlated with high tumor grade and advanced tumor stage. Expression of OLFM4-RET fusion-induced cellular transformation in HEK293 cells and blocked RET-induced inhibition of colony growth in HuTu 80 small intestine adenocarcinoma cells. Further, expression of OLFM4-RET activated the RAS-RAF-MAPK and STAT3 cell signaling pathways in both HEK293 cells and HuTu 80 cells. OLFM4-RET expression in HEK293 cells upregulated multiple families of genes related to carcinogenesis, cancer progression, and metastasis. Targeted expression of OLFM4-RET in the small intestine led to the development of hyperplasia, adenoma, or adenocarcinoma in transgenic mice. Our study suggests that OLFM4-RET is an oncogenic driver of small intestine tumorigenesis. Therefore, the small intestine adenocarcinoma patients with OLFM4-RET fusion may benefit from treatment with RET kinase inhibitor.	[Liu, Wenli; Li, Hongzhen; Aerbajinai, Wulin; Rodgers, Griffin P.] NHLBI, Mol & Clin Hematol Branch, Bldg 10, Bethesda, MD 20892 USA; [Botos, Istvan] NIDDK, Lab Mol Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Rodgers, GP (corresponding author), NHLBI, Mol & Clin Hematol Branch, Bldg 10, Bethesda, MD 20892 USA.	griffinr@extra.niddk.nih.gov		Rodgers, Griffin/0000-0002-4710-0012				Ballerini P, 2012, LEUKEMIA, V26, P2384, DOI 10.1038/leu.2012.109; Blaker H, 2004, SCAND J GASTROENTERO, V39, P748, DOI 10.1080/00365520410005847; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Canibano C, 2007, EMBO J, V26, P2015, DOI 10.1038/sj.emboj.7601636; Eblen ST, 2018, ADV CANCER RES, V138, P99, DOI 10.1016/bs.acr.2018.02.004; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hwang JH, 2003, MOL ENDOCRINOL, V17, P1155, DOI 10.1210/me.2002-0401; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Ju YS, 2012, GENOME RES, V22, P436, DOI 10.1101/gr.133645.111; Kawamoto Y, 2004, J BIOL CHEM, V279, P14213, DOI 10.1074/jbc.M312600200; Keshet Y, 2010, METHODS MOL BIOL, V661, P3, DOI 10.1007/978-1-60761-795-2_1; Knowles PP, 2006, J BIOL CHEM, V281, P33577, DOI 10.1074/jbc.M605604200; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Kollara A, 2001, BREAST CANCER RES TR, V67, P245, DOI 10.1023/A:1017938608460; Le Rolle AF, 2015, ONCOTARGET, V6, P28929, DOI 10.18632/oncotarget.4325; Leone V, 2010, ONCOGENE, V29, P4341, DOI 10.1038/onc.2010.179; Levy DE, 2006, P NATL ACAD SCI USA, V103, P10151, DOI 10.1073/pnas.0604042103; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Liu W, 2007, HISTOPATHOLOGY, V51, P157, DOI 10.1111/j.1365-2559.2007.02763.x; Liu W, 2016, ONCOGENE, V35, P5237, DOI 10.1038/onc.2016.58; Liu WL, 2008, CLIN CANCER RES, V14, P1041, DOI 10.1158/1078-0432.CCR-07-4125; Liu WL, 2006, EXP CELL RES, V312, P1785, DOI 10.1016/j.yexcr.2006.02.011; Liu WL, 2016, CANCER METAST REV, V35, P201, DOI 10.1007/s10555-016-9624-2; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Luo Y, 2013, ONCOGENE, V32, P2037, DOI 10.1038/onc.2012.225; Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680; Nikiforov YE, 2011, NAT REV ENDOCRINOL, V7, P569, DOI 10.1038/nrendo.2011.142; Perea D, 2017, EMBO J, V36, P3029, DOI 10.15252/embj.201696247; Powell DJ, 1998, CANCER RES, V58, P5523; Raghav K, 2013, NAT REV CLIN ONCOL, V10, P534, DOI 10.1038/nrclinonc.2013.132; Reeser JW, 2017, J MOL DIAGN, V19, P682, DOI 10.1016/j.jmoldx.2017.05.006; Resemann HK, 2014, MOL CELL ENDOCRINOL, V382, P603, DOI 10.1016/j.mce.2013.06.029; Santoro M, 1996, ONCOGENE, V12, P1821; Santoro Massimo, 2013, Cold Spring Harb Perspect Biol, V5, pa009233, DOI 10.1101/cshperspect.a009233; Sariola H, 2003, J CELL SCI, V116, P3855, DOI 10.1242/jcs.00786; Sasselli V, 2012, DEV BIOL, V366, P64, DOI 10.1016/j.ydbio.2012.01.012; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; Tallini G, 2001, ADV ANAT PATHOL, V8, P345, DOI 10.1097/00125480-200111000-00005; Van der Flier LG, 2009, GASTROENTEROLOGY, V137, P15, DOI 10.1053/j.gastro.2009.05.035; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Zhang JC, 2002, GENE, V283, P83, DOI 10.1016/S0378-1119(01)00763-6	43	2	2	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					72	82		10.1038/s41388-021-02072-1	http://dx.doi.org/10.1038/s41388-021-02072-1		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34675408				2022-12-17	WOS:000709687900001
J	Vaziri, C; Rogozin, IB; Gu, QS; Wu, D; Day, TA				Vaziri, Cyrus; Rogozin, Igor B.; Gu, Qisheng; Wu, Di; Day, Tovah A.			Unravelling roles of error-prone DNA polymerases in shaping cancer genomes	ONCOGENE			English	Review							FRAGILE SITE STABILITY; MUTATIONAL SIGNATURES; SOMATIC HYPERMUTATION; GERMLINE MUTATIONS; COLORECTAL ADENOMAS; EXCISION-REPAIR; POLE MUTATIONS; A-T; ETA; REPLICATION	Mutagenesis is a key hallmark and enabling characteristic of cancer cells, yet the diverse underlying mutagenic mechanisms that shape cancer genomes are not understood. This review will consider the emerging challenge of determining how DNA damage response pathways-both tolerance and repair-act upon specific forms of DNA damage to generate mutations characteristic of tumors. DNA polymerases are typically the ultimate mutagenic effectors of DNA repair pathways. Therefore, understanding the contributions of DNA polymerases is critical to develop a more comprehensive picture of mutagenic mechanisms in tumors. Selection of an appropriate DNA polymerase-whether error-free or error-prone-for a particular DNA template is critical to the maintenance of genome stability. We review different modes of DNA polymerase dysregulation including mutation, polymorphism, and over-expression of the polymerases themselves or their associated activators. Based upon recent findings connecting DNA polymerases with specific mechanisms of mutagenesis, we propose that compensation for DNA repair defects by error-prone polymerases may be a general paradigm molding the mutational landscape of cancer cells. Notably, we demonstrate that correlation of error-prone polymerase expression with mutation burden in a subset of patient tumors from The Cancer Genome Atlas can identify mechanistic hypotheses for further testing. We contrast experimental approaches from broad, genome-wide strategies to approaches with a narrower focus on a few hundred base pairs of DNA. In addition, we consider recent developments in computational annotation of patient tumor data to identify patterns of mutagenesis. Finally, we discuss the innovations and future experiments that will develop a more comprehensive portrait of mutagenic mechanisms in human tumors.	[Vaziri, Cyrus] Univ N Carolina, Dept Pathol & Lab Med, 614 Brinkhous Bullitt Bldg, Chapel Hill, NC 27599 USA; [Rogozin, Igor B.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA; [Gu, Qisheng; Wu, Di] Univ N Carolina, Dept Biostat, 135 Dauer Dr,3101 McGavran Greenberg Hall, Chapel Hill, NC 27599 USA; [Day, Tovah A.] Northeastern Univ, Dept Biol, Boston, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); University of North Carolina; University of North Carolina Chapel Hill; Northeastern University	Day, TA (corresponding author), Northeastern Univ, Dept Biol, Boston, MA 02115 USA.	t.day@northeastern.edu		Day, Tovah/0000-0003-3894-1407; Gu, Qisheng/0000-0001-7294-042X	Intramural Research Program of the National Library of Medicine at the National Institutes of Health; National Institute of Health [R01CA215347, R01ES029079, R01CA229530, K01AG056554]	Intramural Research Program of the National Library of Medicine at the National Institutes of Health; National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the Intramural Research Program of the National Library of Medicine at the National Institutes of Health (IBR), and National Institute of Health grants R01CA215347, R01ES029079, R01CA229530 (CV), and K01AG056554 (TAD).	Adar S, 2016, P NATL ACAD SCI USA, V113, pE2124, DOI 10.1073/pnas.1603388113; Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Allen F, 2019, NAT BIOTECHNOL, V37, P64, DOI 10.1038/nbt.4317; Aoude LG, 2015, FAM CANCER, V14, P621, DOI 10.1007/s10689-015-9826-8; Arana ME, 2008, NUCLEIC ACIDS RES, V36, P3847, DOI 10.1093/nar/gkn310; Bacolla A, 2021, NUCLEIC ACIDS RES, V49, P221, DOI 10.1093/nar/gkaa1120; Barnes RP, 2017, DNA REPAIR, V57, P1, DOI 10.1016/j.dnarep.2017.05.006; Bavoux C, 2005, CANCER RES, V65, P325; Bellido F, 2016, GENET MED, V18, P325, DOI 10.1038/gim.2015.75; Bergoglio V, 2013, J CELL BIOL, V201, P395, DOI 10.1083/jcb.201207066; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Bhattacharya P, 2008, EUR J IMMUNOL, V38, P227, DOI 10.1002/eji.200737664; Brinkman EK, 2018, MOL CELL, V70, P801, DOI 10.1016/j.molcel.2018.04.016; Brown AJ, 2018, METHOD ENZYMOL, V601, P111, DOI 10.1016/bs.mie.2017.11.028; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Carvajal-Garcia J, 2020, P NATL ACAD SCI USA, V117, P8476, DOI 10.1073/pnas.1921791117; Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184; Chakrabarti AM, 2019, MOL CELL, V73, P699, DOI 10.1016/j.molcel.2018.11.031; Chan K, 2015, NAT GENET, V47, P1067, DOI 10.1038/ng.3378; Charpentier M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03475-7; Chroma K, 2017, ONCOGENE, V36, P2405, DOI 10.1038/onc.2016.392; Church DN, 2013, HUM MOL GENET, V22, P2820, DOI 10.1093/hmg/ddt131; Cipolla L, 2019, NUCLEIC ACIDS RES, V47, P11268, DOI 10.1093/nar/gkz824; Clarke R, 2018, MOL CELL, V71, P42, DOI 10.1016/j.molcel.2018.06.005; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Dai ZM, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002826; Durando M, 2013, NUCLEIC ACIDS RES, V41, P3079, DOI 10.1093/nar/gkt016; Erson-Omay EZ, 2015, NEURO-ONCOLOGY, V17, P1356, DOI 10.1093/neuonc/nov027; Feng WJ, 2021, NUCLEIC ACIDS RES, V49, P5095, DOI 10.1093/nar/gkab299; Fouquerel E, 2019, MOL CELL, V75, P117, DOI 10.1016/j.molcel.2019.04.024; Gadgil RY, 2020, J BIOL CHEM, V295, P15378, DOI 10.1074/jbc.RA120.013495; Gao YZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12105; Ghezraoui H, 2014, MOL CELL, V55, P829, DOI 10.1016/j.molcel.2014.08.002; Gisler S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09551-w; Goncearenco A, 2017, NUCLEIC ACIDS RES, V45, pW514, DOI 10.1093/nar/gkx367; Hansen MF, 2015, FAM CANCER, V14, P437, DOI 10.1007/s10689-015-9803-2; Heng YJ, 2020, CANCER EPIDEM BIOMAR, V29, P599, DOI 10.1158/1055-9965.EPI-19-1087; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hile SE, 2008, NUCLEIC ACIDS RES, V36, P688, DOI 10.1093/nar/gkm1089; Hino H, 2019, CANCER MED-US, V8, P4587, DOI 10.1002/cam4.2344; Hollstein M, 2017, ONCOGENE, V36, P158, DOI 10.1038/onc.2016.192; House NCM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237759; Hu JC, 2016, P NATL ACAD SCI USA, V113, P11507, DOI 10.1073/pnas.1614430113; Hu JC, 2015, GENE DEV, V29, P948, DOI 10.1101/gad.261271.115; Hu X., 2020, NAR CANC, V2, pZCAA026; Hwang Taejoo, 2020, NAR Cancer, V2, pzcaa017, DOI 10.1093/narcan/zcaa017; Ingram SP, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008476; Jung YS, 2012, DNA REPAIR, V11, P177, DOI 10.1016/j.dnarep.2011.10.017; Khodaverdian VY, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx1056; Koole W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4216; Kosicki M, 2018, NAT BIOTECHNOL, V36, P765, DOI 10.1038/nbt.4192; Kryklyva V, 2020, PANCREAS, V49, P999, DOI 10.1097/MPA.0000000000001588; Kumari N, 2019, ISCIENCE, V21, P288, DOI 10.1016/j.isci.2019.10.033; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Kurashima K, 2018, J CELL SCI, V131, DOI 10.1242/jcs.212183; Layer JV, 2020, P NATL ACAD SCI USA, V117, P27566, DOI 10.1073/pnas.2014176117; Lee DH, 2003, J BIOL CHEM, V278, P10314, DOI 10.1074/jbc.M212696200; Lemmens B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9909; Lemos BR, 2018, P NATL ACAD SCI USA, V115, pE2040, DOI 10.1073/pnas.1716855115; Li HD, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138829; Li HD, 2018, J CLIN INVEST, V128, P4179, DOI 10.1172/JCI122095; Lin JR, 2011, MOL CELL, V42, P237, DOI 10.1016/j.molcel.2011.02.026; Lindsay H, 2019, CSH MOL CASE STUD, V5, DOI 10.1101/mcs.a004499; Listovsky T, 2013, J CELL BIOL, V203, P87, DOI 10.1083/jcb.201302060; Loeillet S, 2020, P NATL ACAD SCI USA, V117, P24947, DOI 10.1073/pnas.2011332117; Lou, 2021, NAR CANC, V3, pZCAA037; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; Martomo SA, 2008, DNA REPAIR, V7, P1603, DOI 10.1016/j.dnarep.2008.04.002; Masuda K, 2005, P NATL ACAD SCI USA, V102, P13986, DOI 10.1073/pnas.0505636102; McCulloch SD, 2008, CELL RES, V18, P148, DOI 10.1038/cr.2008.4; McVey M, 2016, ANNU REV GENET, V50, P393, DOI 10.1146/annurev-genet-120215-035243; MILLER JH, 1983, ANNU REV GENET, V17, P215, DOI 10.1146/annurev.ge.17.120183.001243; Moreno NC, 2020, NUCLEIC ACIDS RES, V48, P1941, DOI 10.1093/nar/gkz1182; Mosbach V, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008924; Nayak S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz7808; Nguyen L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19406-4; Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503; Park J, 2017, BIOINFORMATICS, V33, P286, DOI 10.1093/bioinformatics/btw561; Pinello L, 2016, NAT BIOTECHNOL, V34, P695, DOI 10.1038/nbt.3583; Prodhomme MK, 2021, CANCER RES, V81, P1595, DOI 10.1158/0008-5472.CAN-20-2626; Ray S, 2018, NUCLEIC ACIDS RES, V46, P242, DOI 10.1093/nar/gkx1147; Rey L, 2009, MOL CELL BIOL, V29, P3344, DOI 10.1128/MCB.00115-09; Richardson CD, 2016, NAT BIOTECHNOL, V34, P339, DOI 10.1038/nbt.3481; Richardson RR, 2020, CAS9 FUSIONS PRECISI, DOI 10.1101/2020.07.15.199620; Roerink SF, 2014, GENOME RES, V24, P954, DOI 10.1101/gr.170431.113; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Rogozin IB, 2003, MUTAT RES-REV MUTAT, V544, P65, DOI 10.1016/S1383-5742(03)00032-2; Rogozin IB, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.671866; Rogozin IB, 2019, CANCERS, V11, DOI 10.3390/cancers11020211; Rogozin IB, 2018, CELL CYCLE, V17, P348, DOI 10.1080/15384101.2017.1404208; Rogozin IB, 2018, BRIEF BIOINFORM, V19, P1085, DOI 10.1093/bib/bbx049; Rohlin A, 2014, INT J ONCOL, V45, P77, DOI 10.3892/ijo.2014.2410; Rosner G, 2018, DIS COLON RECTUM, V61, P1073, DOI 10.1097/DCR.0000000000001150; Sakiyama T, 2005, INT J CANCER, V114, P730, DOI 10.1002/ijc.20790; Sasatani M, 2017, CARCINOGENESIS, V38, P570, DOI 10.1093/carcin/bgw208; Schep R, 2021, MOL CELL, V81, P2216, DOI 10.1016/j.molcel.2021.03.032; Schimmel J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25154-w; Shachar S, 2009, EMBO J, V28, P383, DOI 10.1038/emboj.2008.281; Shen MW, 2018, NATURE, V563, P646, DOI 10.1038/s41586-018-0686-x; Shou J, 2018, MOL CELL, V71, P498, DOI 10.1016/j.molcel.2018.06.021; Siraj AK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1058-9; Soong CP, 2015, DNA REPAIR, V26, P44, DOI 10.1016/j.dnarep.2014.12.002; Spier I, 2015, INT J CANCER, V137, P320, DOI 10.1002/ijc.29396; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; Stewart GS, 2009, CELL CYCLE, V8, P1532, DOI 10.4161/cc.8.10.8351; Supek F, 2017, CELL, V170, P534, DOI 10.1016/j.cell.2017.07.003; Taheri-Ghahfarokhi A, 2018, NUCLEIC ACIDS RES, V46, P8417, DOI 10.1093/nar/gky653; Temiz NA, 2015, HUM GENET, V134, P851, DOI 10.1007/s00439-015-1566-1; Temko D, 2018, J PATHOL, V245, P283, DOI 10.1002/path.5081; Tonzi P, 2018, ELIFE, V7, DOI 10.7554/eLife.41426; Tsao WC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103255; Tubbs A, 2018, CELL, V174, P1127, DOI 10.1016/j.cell.2018.07.011; Valle L, 2014, HUM MOL GENET, V23, P3506, DOI 10.1093/hmg/ddu058; van Bostelen I, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008759; van Overbeek M, 2016, MOL CELL, V63, P633, DOI 10.1016/j.molcel.2016.06.037; van Schendel R, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006368; van Schendel R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8394; Volkova NV, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15912-7; Walsh E, 2013, J MOL BIOL, V425, P232, DOI 10.1016/j.jmb.2012.11.016; Wang AS, 2020, MOL CELL, V79, P221, DOI 10.1016/j.molcel.2020.06.014; Wang HB, 2010, NEURO-ONCOLOGY, V12, P679, DOI 10.1093/neuonc/nop074; Wang R, 2020, P NATL ACAD SCI USA, V117, P33436, DOI 10.1073/pnas.2008821117; Wang Y, 2007, CANCER RES, V67, P3018, DOI 10.1158/0008-5472.CAN-06-3073; Willis NA, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007486; Wimmer K, 2017, FAM CANCER, V16, P67, DOI 10.1007/s10689-016-9925-1; Wong A, 2016, GYNECOL ONCOL, V141, P113, DOI 10.1016/j.ygyno.2015.12.031; Wyatt DW, 2016, MOL CELL, V63, P662, DOI 10.1016/j.molcel.2016.06.020; Xu HL, 2013, CANCER EPIDEMIOL, V37, P917, DOI 10.1016/j.canep.2013.08.003; Yang J, 2004, CANCER RES, V64, P5597, DOI 10.1158/0008-5472.CAN-04-0603; Yang Y, 2017, J CELL BIOL, V216, P3097, DOI 10.1083/jcb.201702006; Yeom M, 2016, CHEM RES TOXICOL, V29, P367, DOI 10.1021/acs.chemrestox.5b00513; Yuan F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069317; Zammataro L, 2019, P NATL ACAD SCI USA, V116, P22730, DOI 10.1073/pnas.1911385116; Zan H, 2005, EMBO J, V24, P3757, DOI 10.1038/sj.emboj.7600833; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740; Zhang JJ, 2019, NAT BIOTECHNOL, V37, P367, DOI 10.1038/s41587-019-0055-9; ZHANG Y, 2021, PLOS GENET, V17; Ziv O, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6437; Ziv O, 2009, P NATL ACAD SCI USA, V106, P11552, DOI 10.1073/pnas.0812548106; Zou XQ, 2021, NAT CANCER, V2, DOI 10.1038/s43018-021-00200-0	144	2	2	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6549	6565		10.1038/s41388-021-02032-9	http://dx.doi.org/10.1038/s41388-021-02032-9		OCT 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34663880	hybrid, Green Published			2022-12-17	WOS:000708355700002
J	Gill, T; Wang, HC; Bandaru, R; Lawlor, M; Lu, CY; Nieman, LT; Tao, JN; Zhang, YX; Anderson, DG; Ting, DVT; Chen, X; Bradner, JE; Ott, CJ				Gill, Taylor; Wang, Haichuan; Bandaru, Raj; Lawlor, Matthew; Lu, Chenyue; Nieman, Linda T.; Tao, Junyan; Zhang, Yixian; Anderson, Daniel G.; Ting, David T.; Chen, Xin; Bradner, James E.; Ott, Christopher J.			Selective targeting of MYC mRNA by stabilized antisense oligonucleotides	ONCOGENE			English	Article							LOCKED NUCLEIC-ACIDS; C-MYC; CELL-CYCLE; IN-VITRO; EXPRESSION; INHIBITION; ACTIVATION; GROWTH; OLIGODEOXYNUCLEOTIDE; PROLIFERATION	MYC is a prolific proto-oncogene driving the malignant behaviors of numerous common cancers, yet potent and selective cell-permeable inhibitors of MYC remain elusive. In order to ultimately realize the goal of therapeutic MYC inhibition in cancer, we have initiated discovery chemistry efforts aimed at inhibiting MYC translation. Here we describe a series of conformationally stabilized synthetic antisense oligonucleotides designed to target MYC mRNA (MYCASOs). To support bioactivity, we designed and synthesized this focused library of MYCASOs incorporating locked nucleic acid (LNA) bases at the 5MODIFIER LETTER PRIME- and 3MODIFIER LETTER PRIME-ends, a phosphorothioate backbone, and internal DNA bases. Treatment of MYC-expressing cancer cells with MYCASOs leads to a potent decrease in MYC mRNA and protein levels. Cleaved MYC mRNA in MYCASO-treated cells is detected with a sensitive 5MODIFIER LETTER PRIME Rapid Amplification of cDNA Ends (RACE) assay. MYCASO treatment of cancer cell lines leads to significant inhibition of cellular proliferation while specifically perturbing MYC-driven gene expression signatures. In a MYC-induced model of hepatocellular carcinoma, MYCASO treatment decreases MYC protein levels within tumors, decreases tumor burden, and improves overall survival. MYCASOs represent a new chemical tool for in vitro and in vivo modulation of MYC activity, and promising therapeutic agents for MYC-addicted tumors.	[Gill, Taylor; Anderson, Daniel G.] MIT, Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Gill, Taylor; Bradner, James E.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Gill, Taylor; Ott, Christopher J.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Wang, Haichuan; Tao, Junyan; Chen, Xin] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Bandaru, Raj; Zhang, Yixian] ENZON Pharmaceut, Cranford, NJ 07016 USA; [Lawlor, Matthew; Lu, Chenyue; Nieman, Linda T.; Ting, David T.; Ott, Christopher J.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA; [Anderson, Daniel G.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02142 USA; [Anderson, Daniel G.] MIT, Dept Chem Engn, Cambridge, MA 02142 USA; [Anderson, Daniel G.] MIT, Inst Med Engn & Sci, Cambridge, MA 02142 USA; [Ting, David T.; Bradner, James E.; Ott, Christopher J.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Bradner, James E.] Novartis Inst BioMed Res, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Novartis	Bradner, JE (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.; Ott, CJ (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Ott, CJ (corresponding author), Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA.; Bradner, JE; Ott, CJ (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.; Bradner, JE (corresponding author), Novartis Inst BioMed Res, Cambridge, MA 02139 USA.	james.bradner@novartis.com; christopher.ott@mgh.harvard.edu	Wang, Haichuan/AAA-3997-2019; Ting, David/F-4389-2017	Wang, Haichuan/0000-0002-6886-5698; Gill, Taylor/0000-0002-7400-2354; Ting, David/0000-0002-3261-2322; Lawlor, Matthew/0000-0003-0700-5763	US National Cancer Institute (NCI) Pathway to Independence Award [K99/R00CA190861]; DFCI; MGH; Broad Institute; Koch Institute Support (core) Grant from the National Cancer Institute [P30-CA14051]	US National Cancer Institute (NCI) Pathway to Independence Award; DFCI; MGH; Broad Institute; Koch Institute Support (core) Grant from the National Cancer Institute	We thank M. Gabay and D. Felsher (Stanford University), S. He, T. Look, E. Dhimolea, C. Mitsiades, and members of the Lurie Family Imaging Center (Dana-Farber Cancer Institute) for assistance with animal studies. This work was supported by a US National Cancer Institute (NCI) Pathway to Independence Award (K99/R00CA190861) (C.J.O), and institutional funding from DFCI, MGH, and the Broad Institute (J.E.B, C.J.O, T.G.), and the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer Institute (D.G.A.).	Adey A, 2013, NATURE, V500, P207, DOI 10.1038/nature12064; Beaulieu ME, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar5012; Bennett CF, 2010, ANNU REV PHARMACOL, V50, P259, DOI 10.1146/annurev.pharmtox.010909.105654; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Browne EP, 2001, J VIROL, V75, P12319, DOI 10.1128/JVI.75.24.12319-12330.2001; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; Casey SC, 2017, TRENDS IMMUNOL, V38, P298, DOI 10.1016/j.it.2017.01.002; Castanotto D, 2015, NUCLEIC ACIDS RES, V43, P9350, DOI 10.1093/nar/gkv964; Chan JHP, 2006, CLIN EXP PHARMACOL P, V33, P533, DOI 10.1111/j.1440-1681.2006.04403.x; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Chery J, 2018, NUCLEIC ACID THER, V28, P273, DOI 10.1089/nat.2018.0722; Chow EKH, 2012, HEPATOLOGY, V56, P1331, DOI 10.1002/hep.25776; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Clausen DM, 2010, J PHARMACOL EXP THER, V335, P715, DOI 10.1124/jpet.110.170555; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; Coulis CM, 2000, MOL PHARMACOL, V57, P485, DOI 10.1124/mol.57.3.485; Cowley GS, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.35; Croce C M, 1986, Adv Immunol, V38, P245, DOI 10.1016/S0065-2776(08)60008-5; Crooke S.T., 2007, ANTISENSE DRUG TECHN, VSecond, P519; Crooke ST, 2017, NAT BIOTECHNOL, V35, P230, DOI 10.1038/nbt.3779; Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dowling JJ, 2016, NAT REV NEUROL, V12, P675, DOI 10.1038/nrneurol.2016.180; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Han HY, 2019, CANCER CELL, V36, P483, DOI 10.1016/j.ccell.2019.10.001; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; Hong D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5272; Hoy SM, 2017, DRUGS, V77, P473, DOI 10.1007/s40265-017-0711-7; Iwamoto N, 2017, NAT BIOTECHNOL, V35, P845, DOI 10.1038/nbt.3948; Kalkat M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060151; Khvorova A, 2017, NAT BIOTECHNOL, V35, P238, DOI 10.1038/nbt.3765; Kiessling A, 2007, CHEMMEDCHEM, V2, P627, DOI 10.1002/cmdc.200600294; Klar R, 2020, CANCER IMMUNOL IMMUN, V69, P57, DOI 10.1007/s00262-019-02438-1; Koehler AN, 2010, CURR OPIN CHEM BIOL, V14, P331, DOI 10.1016/j.cbpa.2010.03.022; Koshkin AA, 1998, TETRAHEDRON, V54, P3607, DOI 10.1016/S0040-4020(98)00094-5; Le BT, 2017, MOL THER-NUCL ACIDS, V9, P155, DOI 10.1016/j.omtn.2017.09.002; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Mondala PK, 2021, CELL STEM CELL, V28, P623, DOI 10.1016/j.stem.2020.12.017; Mui B, 2001, J PHARMACOL EXP THER, V298, P1185; Palomero T, 2006, LEUKEMIA, V20, P1279, DOI 10.1038/sj.leu.2404258; Parham JS, 2019, EXPERT OPIN PHARMACO, V20, P127, DOI 10.1080/14656566.2018.1550071; Ross SJ, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5253; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Schlee M, 2007, ADV CANCER RES, V97, P167, DOI 10.1016/S0065-230X(06)97007-9; Schlee M, 2007, INT J CANCER, V120, P1387, DOI 10.1002/ijc.22372; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Shang RZ, 2021, GUT, V70, P1746, DOI 10.1136/gutjnl-2020-320716; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Singh SK, 1998, CHEM COMMUN, P455, DOI 10.1039/a708608c; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Struntz NB, 2019, CELL CHEM BIOL, V26, P711, DOI 10.1016/j.chembiol.2019.02.009; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wang HB, 2007, MOL CANCER THER, V6, P2399, DOI 10.1158/1535-7163.MCT-07-0005; Wang HB, 2013, ONCOTARGET, V4, P936, DOI 10.18632/oncotarget.1108; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; Wu HJ, 2004, J BIOL CHEM, V279, P17181, DOI 10.1074/jbc.M311683200; Xu Y, 2006, BIOORGAN MED CHEM, V14, P2660, DOI 10.1016/j.bmc.2005.11.052; Yashiro-Ohtani Y, 2014, P NATL ACAD SCI USA, V111, pE4946, DOI 10.1073/pnas.1407079111; Zhang WD, 2005, NAT MED, V11, P56, DOI 10.1038/nm1174; Zhang Y, 2011, GENE THER, V18, P326, DOI 10.1038/gt.2010.133; Zhang YX, 2011, MOL CANCER THER, V10, P2309, DOI 10.1158/1535-7163.MCT-11-0329	68	2	2	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6527	6539		10.1038/s41388-021-02053-4	http://dx.doi.org/10.1038/s41388-021-02053-4		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34650218	Green Accepted, Green Submitted			2022-12-17	WOS:000707295500002
J	Liu, R; Gou, DM; Xiang, J; Pan, XM; Gao, QZ; Zhou, P; Liu, Y; Hu, J; Wang, K; Tang, N				Liu, Rui; Gou, Dongmei; Xiang, Jin; Pan, Xuanming; Gao, Qingzhu; Zhou, Peng; Liu, Yi; Hu, Jie; Wang, Kai; Tang, Ni			O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis	ONCOGENE			English	Article							CYTOSOLIC PHOSPHOENOLPYRUVATE CARBOXYKINASE; TIP60 HISTONE ACETYLTRANSFERASE; GROWTH-FACTOR; CANCER; ACETYLATION; EXPRESSION; LINKS; MYC; GLYCOSYLATION; TUMORIGENESIS	Aberrant glucose metabolism and elevated O-linked beta-N-acetylglucosamine modification (O-GlcNAcylation) are hallmarks of hepatocellular carcinoma (HCC). Loss of phosphoenolpyruvate carboxykinase 1 (PCK1), the major rate-limiting enzyme of hepatic gluconeogenesis, increases hexosamine biosynthetic pathway (HBP)-mediated protein O-GlcNAcylation in hepatoma cell and promotes cell growth and proliferation. However, whether PCK1 deficiency and hyper O-GlcNAcylation can induce HCC metastasis is largely unknown. Here, gain- and loss-of-function studies demonstrate that PCK1 suppresses HCC metastasis in vitro and in vivo. Specifically, lysine acetyltransferase 5 (KAT5), belonging to the MYST family of histone acetyltransferases (HAT), is highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells. Mechanistically, PCK1 depletion suppressed KAT5 ubiquitination by increasing its O-GlcNAcylation, thereby stabilizing KAT5. KAT5 O-GlcNAcylation epigenetically activates TWIST1 expression via histone H4 acetylation, and enhances MMP9 and MMP14 expression via c-Myc acetylation, thus promoting epithelial-mesenchymal transition (EMT) in HCC. In addition, targeting HBP-mediated O-GlcNAcylation of KAT5 inhibits lung metastasis of HCC in hepatospecific Pck1-deletion mice. Collectively, our findings demonstrate that PCK1 depletion increases O-GlcNAcylation of KAT5, epigenetically induces TWIST1 expression and promotes HCC metastasis, and link metabolic enzyme, post-translational modification (PTM) with epigenetic regulation.	[Liu, Rui; Gou, Dongmei; Xiang, Jin; Pan, Xuanming; Gao, Qingzhu; Zhou, Peng; Liu, Yi; Hu, Jie; Wang, Kai; Tang, Ni] Chongqing Med Univ, Affiliated Hosp 2, Key Lab Mol Biol Infect Dis, Minist Educ,Inst Viral Hepatitis,Dept Infect Dis, Chongqing 400010, Peoples R China	Chongqing Medical University	Wang, K; Tang, N (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Key Lab Mol Biol Infect Dis, Minist Educ,Inst Viral Hepatitis,Dept Infect Dis, Chongqing 400010, Peoples R China.	wangkai@cqmu.edu.cn; nitang@cqmu.edu.cn	Wang, Kai/U-3552-2019	Wang, Kai/0000-0002-0137-1247; Xiang, Jin/0000-0002-3890-5556	National Natural Science Foundation of China [82073251, 82072286, 81872270]; Natural Science Foundation Project of Chongqing [cstc2018jcyjAX0254, cstc2019jscx-dxwtBX0019, cstc2019jcyj-msxmX0587]; Talent Development Program of CQMU for Postgraduate [BJRC201913]; Kuanren talents program of the second affiliated hospital of Chongqing Medical University; Science and Technology Research Program of Chongqing Municipal Education Commission [KJZD-M202000401, KJQN201900429]; Scientific Research Innovation Project for Postgraduate in Chongqing [CYB21196]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation Project of Chongqing(Natural Science Foundation of Chongqing); Talent Development Program of CQMU for Postgraduate; Kuanren talents program of the second affiliated hospital of Chongqing Medical University; Science and Technology Research Program of Chongqing Municipal Education Commission; Scientific Research Innovation Project for Postgraduate in Chongqing	We would like to thank Dr. T.-C He (University of Chicago, USA) for providing the pAdEasy system. We are grateful to Prof. Ding Xue (Tsinghua University, China) for supplying the CRISPR/Cas9 system. We also thank Prof. Bing Sun (Shanghai Institute of Biochemistry and Cell Biology, China) for providing the pLL3.7 vector. This work was supported by the National Natural Science Foundation of China [grant no. 82073251, 82072286, and 81872270]; the Natural Science Foundation Project of Chongqing [cstc2018jcyjAX0254, cstc2019jscx-dxwtBX0019, and cstc2019jcyj-msxmX0587]; the Talent Development Program of CQMU for Postgraduate [grant no. BJRC201913], the Kuanren talents program of the second affiliated hospital of Chongqing Medical University, the Science and Technology Research Program of Chongqing Municipal Education Commission (KJZD-M202000401, KJQN201900429), and the Scientific Research Innovation Project for Postgraduate in Chongqing (grant no. CYB21196).	Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bian XL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14420; Brauns-Schubert P, 2018, EMBO REP, V19, P244, DOI 10.15252/embr.201744311; Charvet C, 2011, MOL CELL, V42, P584, DOI 10.1016/j.molcel.2011.03.033; Col E, 2005, EMBO J, V24, P2634, DOI 10.1038/sj.emboj.7600734; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Ezponda T, 2013, ONCOGENE, V32, P2882, DOI 10.1038/onc.2012.297; Feng J, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01629-4; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Gao SS, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba7822; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Ghobashi AH, 2018, J APPL GENET, V59, P161, DOI 10.1007/s13353-018-0432-y; Grasmann G, 2019, BBA-REV CANCER, V1872, P24, DOI 10.1016/j.bbcan.2019.05.006; Halkidou K, 2004, NUCLEIC ACIDS RES, V32, P1654, DOI 10.1093/nar/gkh296; Han CF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01654-6; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hirata H, 2016, CANCER RES, V76, P3265, DOI 10.1158/0008-5472.CAN-15-2601; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Jiang MZ, 2019, THERANOSTICS, V9, P5359, DOI 10.7150/thno.34024; Jiang MZ, 2019, ONCOGENE, V38, P301, DOI 10.1038/s41388-018-0435-5; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kwan SY, 2020, HEPATOLOGY, V71, P275, DOI 10.1002/hep.30807; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Lemercier C, 2003, J BIOL CHEM, V278, P4713, DOI 10.1074/jbc.M211811200; Li B, 2007, P NATL ACAD SCI USA, V104, P4571, DOI 10.1073/pnas.0700298104; Li Y, 2015, CANCER RES, V75, P1191, DOI 10.1158/0008-5472.CAN-14-2615; Liang YJ, 2015, CANCER RES, V75, P3672, DOI 10.1158/0008-5472.CAN-15-0930; Lin SY, 2012, SCIENCE, V336, P477, DOI 10.1126/science.1217032; Liu GM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1165-x; Liu MX, 2018, ONCOGENE, V37, P1637, DOI 10.1038/s41388-017-0070-6; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Ma RH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3508; Montal ED, 2015, MOL CELL, V60, P571, DOI 10.1016/j.molcel.2015.09.025; Nagel AK, 2015, ADV CANCER RES, V126, P137, DOI 10.1016/bs.acr.2014.12.003; Park SY, 2010, EMBO J, V29, P3787, DOI 10.1038/emboj.2010.254; Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x; Shay G, 2015, MATRIX BIOL, V44-46, P200, DOI 10.1016/j.matbio.2015.01.019; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Song ZM, 2020, P NATL ACAD SCI USA, V117, P21568, DOI 10.1073/pnas.1922330117; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tan M, 2019, MOL ONCOL, V13, P757, DOI 10.1002/1878-0261.12425; Tuo L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1029-y; Vieira P, 2017, MOL GENET METAB, V120, P337, DOI 10.1016/j.ymgme.2017.02.003; Wang LT, 2019, ONCOGENE, V38, P518, DOI 10.1038/s41388-018-0457-z; Wei X, 2019, ENDOCR-RELAT CANCER, V26, P141, DOI 10.1530/ERC-18-0193; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Xiang J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI144703; Yamaguchi N, 2019, ELIFE, V8, DOI 10.7554/eLife.52135; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yoshiji H, 2004, HEPATOLOGY, V39, P1517, DOI 10.1002/hep.20218; Zachara NE, 2004, BBA-GEN SUBJECTS, V1673, P13, DOI 10.1016/j.bbagen.2004.03.016; Zhu GZ, 2016, GLYCOBIOLOGY, V26, P820, DOI 10.1093/glycob/cww025; Zhu QQ, 2012, MED ONCOL, V29, P985, DOI 10.1007/s12032-011-9912-1; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	59	2	2	5	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2021	40	50					6707	6719		10.1038/s41388-021-02058-z	http://dx.doi.org/10.1038/s41388-021-02058-z		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP7IH	34650217	Green Published, hybrid			2022-12-17	WOS:000707295500001
J	Ren, SW; Zhang, N; Shen, LP; Lu, YY; Chang, YX; Lin, ZN; Sun, N; Zhang, YM; Xu, JH; Huang, HS; Jin, HL				Ren, Shuwei; Zhang, Ning; Shen, Liping; Lu, Yongyong; Chang, Yixin; Lin, Zhenni; Sun, Ning; Zhang, Yuanmei; Xu, Jiheng; Huang, Haishan; Jin, Honglei			Lnc00892 competes with c-Jun to block NCL transcription, reducing the stability of RhoA/RhoC mRNA and impairing bladder cancer invasion	ONCOGENE			English	Article							LONG NONCODING RNA; RHO-GTPASES; LNCRNA; EXPRESSION; LOCALIZATION	Metastasis of bladder cancer is a complex process and has been associated with poor clinical outcomes. However, the mechanisms of bladder cancer metastasis remain largely unknown. The present study found that the long noncoding RNA lnc00892 was significantly downregulated in bladder cancer tissues, with low lnc00892 expression associated with poor prognosis of bladder cancer patients. Lnc00892 significantly inhibited the migration, invasion, and metastasis of bladder cancer cells in vitro and in vivo. In-depth analysis showed that RhoA/C acted downstream of lnc00892 to inhibit bladder cancer metastasis. Mechanistically, lnc00892 reduces nucleolin gene transcription by competitively binding the promoter of nucleolin with c-Jun, thereby inhibiting nucleolin-mediated stabilization of RhoA/RhoC mRNA. Taken together, these findings provide novel insights into understanding the mechanisms of bladder cancer metastasis and suggest that lnc00892 can serve as a potential therapeutic target in patients with invasive bladder cancer.	[Ren, Shuwei; Zhang, Ning; Shen, Liping; Chang, Yixin; Lin, Zhenni; Sun, Ning; Zhang, Yuanmei; Xu, Jiheng; Huang, Haishan; Jin, Honglei] Wenzhou Med Univ, Sch Lab Med & Life Sci, Minist Educ, Zhejiang Prov Key Lab Med Genet,Key Lab Lab Med, Wenzhou, Zhejiang, Peoples R China; [Ren, Shuwei] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Clin Lab, Guangzhou, Guangdong, Peoples R China; [Lu, Yongyong] Wenzhou Med Univ, Affiliated Hosp 1, Dept Urol, Wenzhou, Zhejiang, Peoples R China	Wenzhou Medical University; Sun Yat Sen University; Wenzhou Medical University	Jin, HL (corresponding author), Wenzhou Med Univ, Sch Lab Med & Life Sci, Minist Educ, Zhejiang Prov Key Lab Med Genet,Key Lab Lab Med, Wenzhou, Zhejiang, Peoples R China.	jinhonglei@wmu.edu.cn	Xu, Jiheng/AAV-5732-2020	Xu, Jiheng/0000-0002-3538-3174	Natural Science Foundation of China [NSFC81702530]; Wenzhou Science and Technology Bureau [Y20190065]; Key Discipline of Zhejiang Province in Medical Technology	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wenzhou Science and Technology Bureau; Key Discipline of Zhejiang Province in Medical Technology	This work was partially supported by the Natural Science Foundation of China NSFC81702530, and Wenzhou Science and Technology Bureau (Y20190065), Key Discipline of Zhejiang Province in Medical Technology (First Class, Category A).	Abdelmohsen K, 2010, WIRES RNA, V1, P214, DOI 10.1002/wrna.4; Amodio N, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0606-4; Berger CM, 2015, BIOCHIMIE, V113, P78, DOI 10.1016/j.biochi.2015.03.023; Caswell PT, 2009, NAT REV MOL CELL BIO, V10, P843, DOI 10.1038/nrm2799; Chen CH, 2020, J CLIN INVEST, V130, P404, DOI 10.1172/JCI130892; Chen CH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06152-x; Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Diring J, 2019, NAT CELL BIOL, V21, P845, DOI 10.1038/s41556-019-0337-y; Evans JR, 2016, J CLIN INVEST, V126, P2775, DOI 10.1172/JCI84421; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Gongadze E, 2011, INT J NANOMED, V6, P1801, DOI [10.2147/IJN.S21755, 10.2147/IJN.S16982]; He W, 2018, J CLIN INVEST, V128, P861, DOI 10.1172/JCI96218; Hua XH, 2020, CELL DEATH DIFFER, V27, P632, DOI 10.1038/s41418-019-0377-7; Huang JG, 2016, NUCLEIC ACIDS RES, V44, P3059, DOI 10.1093/nar/gkv1353; Jia WY, 2017, LIFE SCI, V186, P1, DOI 10.1016/j.lfs.2017.07.025; Jin HL, 2021, AUTOPHAGY, V17, P840, DOI 10.1080/15548627.2020.1733262; Jordan B, 2019, NAT REV UROL, V16, P23, DOI 10.1038/s41585-018-0105-y; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim JG, 2018, J CELL PHYSIOL, V233, P6381, DOI 10.1002/jcp.26487; Kim J, 2016, NUCLEIC ACIDS RES, V44, P2378, DOI 10.1093/nar/gkw017; Kim J, 2018, NAT GENET, V50, P1705, DOI 10.1038/s41588-018-0252-3; Kramer S, 2011, TRENDS PARASITOL, V27, P23, DOI 10.1016/j.pt.2010.06.011; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Li Y, 2020, CANCER LETT, V485, P38, DOI 10.1016/j.canlet.2020.04.023; Lin GT, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.567200; Liu GH, 2017, AM J CANCER RES, V7, P2515; Liu H, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0950-9; Marin-Bejar O, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1331-y; Martens-Uzunova ES, 2014, EUR UROL, V65, P1140, DOI 10.1016/j.eururo.2013.12.003; Meeks JJ, 2012, EUR UROL, V62, P523, DOI 10.1016/j.eururo.2012.05.048; Ni W, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0449-4; Nomikou E, 2018, CELL MOL LIFE SCI, V75, P2111, DOI 10.1007/s00018-018-2787-y; Peng MG, 2019, AUTOPHAGY, V15, P1523, DOI 10.1080/15548627.2019.1586254; Peng WX, 2017, ONCOGENE, V36, P5661, DOI 10.1038/onc.2017.184; Pittayapruek P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060868; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Salviano-Silva Amanda, 2018, Non-Coding RNA, V4, P3, DOI 10.3390/ncrna4010003; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Soundararajan S, 2008, CANCER RES, V68, P2358, DOI 10.1158/0008-5472.CAN-07-5723; Sun J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000110; Sun TT, 2016, CANCER DISCOV, V6, P784, DOI 10.1158/2159-8290.CD-15-0921; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tan X, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03413-4; Tang Y, 2008, FRONT BIOSCI-LANDMRK, V13, P759, DOI 10.2741/2718; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Wang X, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0860-7; Wu YC, 2020, AGING-US, V12, P23306, DOI 10.18632/aging.104115; Yan C, 2014, NATURE, V515, P443, DOI 10.1038/nature13713; Yoon JH, 2013, J MOL BIOL, V425, P3723, DOI 10.1016/j.jmb.2012.11.024; Yoshino H, 2013, NAT REV UROL, V10, P396, DOI 10.1038/nrurol.2013.113; Yu YH, 2018, INT J CANCER, V142, P2040, DOI 10.1002/ijc.31223; Zhan Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0893-y; Zhan YH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1143-7; Zhang XN, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0182-7; Zuiverloon TCM, 2018, BLADDER CANCER, V4, P169, DOI 10.3233/BLC-180167	60	2	2	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6579	6589		10.1038/s41388-021-02033-8	http://dx.doi.org/10.1038/s41388-021-02033-8		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34615995				2022-12-17	WOS:000705759400001
J	Hu, LL; Chen, X; Narwade, N; Lim, MGL; Chen, ZK; Tennakoon, C; Guan, PY; Chan, UI; Zhao, ZXL; Deng, MK; Xu, XL; Sung, WK; Cheung, E				Hu, Lingling; Chen, Xin; Narwade, Nitin; Lim, Michelle Gek Liang; Chen, Zikai; Tennakoon, Chandana; Guan, Peiyong; Chan, Un In; Zhao, Zuxianglan; Deng, Mokan; Xu, Xiaoling; Sung, Wing-Kin; Cheung, Edwin			Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression	ONCOGENE			English	Article							GENE-EXPRESSION; AUTOPHAGY; DEGRADATION; RECRUITMENT; POPULATIONS; APOPTOSIS; NETWORKS; PROGRAM; GROWTH	Androgen receptor (AR) plays a central role in driving prostate cancer (PCa) progression. How AR promotes this process is still not completely clear. Herein, we used single-cell transcriptome analysis to reconstruct the transcriptional network of AR in PCa. Our work shows AR directly regulates a set of signature genes in the ER-to-Golgi protein vesicle-mediated transport pathway. The expression of these genes is required for maximum androgen-dependent ER-to-Golgi trafficking, cell growth, and survival. Our analyses also reveal the signature genes are associated with PCa progression and prognosis. Moreover, we find inhibition of the ER-to-Golgi transport process with a small molecule enhanced antiandrogen-mediated tumor suppression of hormone-sensitive and insensitive PCa. Finally, we demonstrate AR collaborates with CREB3L2 in mediating ER-to-Golgi trafficking in PCa. In summary, our findings uncover a critical role for dysregulation of ER-to-Golgi trafficking expression and function in PCa progression, provide detailed mechanistic insights for how AR tightly controls this process, and highlight the prospect of targeting the ER-to-Golgi pathway as a therapeutic strategy for advanced PCa.	[Hu, Lingling; Narwade, Nitin; Chan, Un In; Zhao, Zuxianglan; Deng, Mokan; Xu, Xiaoling; Cheung, Edwin] Univ Macau, Canc Ctr, Taipa, Macao, Peoples R China; [Hu, Lingling; Narwade, Nitin; Chan, Un In; Zhao, Zuxianglan; Deng, Mokan; Xu, Xiaoling; Cheung, Edwin] Univ Macau, Ctr Precis Med Res & Training, Taipa, Macao, Peoples R China; [Hu, Lingling; Narwade, Nitin; Chan, Un In; Deng, Mokan; Xu, Xiaoling; Cheung, Edwin] Univ Macau, Frontier Sci Ctr Precis Oncol, Minist Educ, Taipa, Macao, Peoples R China; [Hu, Lingling; Chen, Xin; Narwade, Nitin; Chen, Zikai; Chan, Un In; Zhao, Zuxianglan; Deng, Mokan; Xu, Xiaoling; Cheung, Edwin] Univ Macau, Fac Hlth Sci, Taipa, Macao, Peoples R China; [Chen, Xin] Guangdong Univ Technol, Sch Automat, Guangdong Key Lab LoT Informat Technol, Guangzhou 510006, Guangdong, Peoples R China; [Lim, Michelle Gek Liang; Tennakoon, Chandana; Guan, Peiyong; Sung, Wing-Kin] Genome Inst Singapore, Singapore 138672, Singapore; [Sung, Wing-Kin] Natl Univ Singapore, Sch Comp, Singapore 117417, Singapore; [Chen, Zikai] Hanshan Normal Univ, Chaozhou 521041, Guangdong, Peoples R China	University of Macau; University of Macau; University of Macau; University of Macau; Guangdong University of Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; Hanshan Normal University	Cheung, E (corresponding author), Univ Macau, Canc Ctr, Taipa, Macao, Peoples R China.; Cheung, E (corresponding author), Univ Macau, Ctr Precis Med Res & Training, Taipa, Macao, Peoples R China.; Cheung, E (corresponding author), Univ Macau, Frontier Sci Ctr Precis Oncol, Minist Educ, Taipa, Macao, Peoples R China.; Cheung, E (corresponding author), Univ Macau, Fac Hlth Sci, Taipa, Macao, Peoples R China.; Sung, WK (corresponding author), Genome Inst Singapore, Singapore 138672, Singapore.; Sung, WK (corresponding author), Natl Univ Singapore, Sch Comp, Singapore 117417, Singapore.	ksung@gis.a-star.edu.sg; echeung@um.edu.mo	hu, ling/GWC-1104-2022; Guan, Peiyong/A-3715-2015	Guan, Peiyong/0000-0001-9958-0137; NARWADE, NITIN/0000-0002-1368-307X	National Science Foundation of China [62003094]; University of Macau [MYRG2018-00033-FHS, MYRG2020-00100-FHS]; Macau Science and Technology Development Fund [102/2015/A3, 0137/2020/A3, 0011/2019/AKP]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); University of Macau; Macau Science and Technology Development Fund	We are grateful for financial support from the National Science Foundation of China (Grant No. 62003094) to X.C., the University of Macau (MYRG2018-00033-FHS and MYRG2020-00100-FHS) and the Macau Science and Technology Development Fund (102/2015/A3, 0137/2020/A3, and 0011/2019/AKP) to E.C.	Alberts B, 2002, MOL BIOL CELL, V4th; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Arakel EC, 2018, J CELL SCI, V131, DOI 10.1242/jcs.209890; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Blessing AM, 2017, AUTOPHAGY, V13, P506, DOI 10.1080/15548627.2016.1268300; Boncompain G, 2012, NAT METHODS, V9, P493, DOI [10.1038/NMETH.1928, 10.1038/nmeth.1928]; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Cha JH, 2018, MOL CELL, V71, P606, DOI 10.1016/j.molcel.2018.07.030; Chapman JR, 1999, BJU INT, V83, P703; Chng KR, 2013, CANCER LETT, V340, P254, DOI 10.1016/j.canlet.2012.11.009; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Cho U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162623; David JM, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030022; Davis JE, 2016, ONCOTARGET, V7, P39834, DOI 10.18632/oncotarget.9405; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Der E, 2019, NAT IMMUNOL, V20, P915, DOI 10.1038/s41590-019-0386-1; Enge M, 2017, CELL, V171, P321, DOI 10.1016/j.cell.2017.09.004; Feng Q, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00858; Fong KW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07475-5; Gao S, 2016, CELL REP, V17, P966, DOI 10.1016/j.celrep.2016.09.064; Gomez-Navarro N, 2016, CURR BIOL, V26, pR54, DOI 10.1016/j.cub.2015.12.017; Gonthier K, 2019, J STEROID BIOCHEM, V191, DOI 10.1016/j.jsbmb.2019.04.016; Guan Y, 2020, J HEPATOL, V72, P746, DOI 10.1016/j.jhep.2019.11.007; He YD, 2018, NUCLEIC ACIDS RES, V46, P1895, DOI 10.1093/nar/gkx1306; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Howley BV, 2018, ONCOGENE, V37, P1308, DOI 10.1038/s41388-017-0023-0; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Ishikawa T, 2017, J CELL BIOL, V216, P1761, DOI 10.1083/jcb.201609100; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Iwamoto H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125982; Jensen D, 2011, J CELL SCI, V124, P1, DOI 10.1242/jcs.069773; Jeong YT, 2018, ELIFE, V7, DOI 10.7554/eLife.42253; Jing JC, 2019, INT J BIOL SCI, V15, P2419, DOI 10.7150/ijbs.37008; Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim TH, 2017, SCI REP-UK, V7, DOI 10.1038/srep45300; Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008-5472.CAN-05-1809; La Manno G, 2016, CELL, V167, P566, DOI 10.1016/j.cell.2016.09.027; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee JH, 2017, CELL, V170, P1149, DOI 10.1016/j.cell.2017.07.028; Linja MJ, 2001, CANCER RES, V61, P3550; Lonergan Peter E, 2011, J Carcinog, V10, P20, DOI 10.4103/1477-3163.83937; Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mediavilla-Varela M, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-68; Mills IG, 2014, NAT REV CANCER, V14, P187, DOI 10.1038/nrc3678; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Mordente JA, 1998, J UROLOGY, V159, P275, DOI 10.1016/S0022-5347(01)64081-3; Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310206200; Nauseef JT, 2011, NAT REV UROL, V8, P428, DOI 10.1038/nrurol.2011.85; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Niu TK, 2005, MOL BIOL CELL, V16, P1213, DOI 10.1091/mbc.E04-07-0599; Paek SM, 2018, MAR DRUGS, V16, DOI 10.3390/md16040133; Parolia A, 2019, NATURE, V571, P413, DOI 10.1038/s41586-019-1347-4; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Rajamahanty S, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-5; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Reck-Peterson SL, 2018, NAT REV MOL CELL BIO, V19, P382, DOI 10.1038/s41580-018-0004-3; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; Saito A, 2009, NAT CELL BIOL, V11, P1197, DOI 10.1038/ncb1962; Sampieri L, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00123; Scharaw S, 2016, J CELL BIOL, V215, P543, DOI 10.1083/jcb.201601090; Sheng X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08152-3; Sheng X, 2015, EMBO MOL MED, V7, P788, DOI 10.15252/emmm.201404509; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sung YY, 2014, ENDOCR-RELAT CANCER, V21, pR1, DOI 10.1530/ERC-13-0326; Swinnen JV, 2004, J STEROID BIOCHEM, V92, P273, DOI 10.1016/j.jsbmb.2004.10.013; Sztul E, 2009, FEBS LETT, V583, P3770, DOI 10.1016/j.febslet.2009.10.083; Takeda DY, 2018, CELL, V174, P422, DOI 10.1016/j.cell.2018.05.037; Tan PY, 2012, MOL CELL BIOL, V32, P399, DOI 10.1128/MCB.05958-11; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Tomoishi S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08703-6; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Webber MM, 1995, CLIN CANCER RES, V1, P1089; Wise GJ, 2000, J UROLOGY, V164, P722, DOI 10.1016/S0022-5347(05)67289-8; Wu DY, 2014, NUCLEIC ACIDS RES, V42, P3607, DOI 10.1093/nar/gkt1382; Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zeisel A, 2018, CELL, V174, P999, DOI 10.1016/j.cell.2018.06.021; Zhang JB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0571-4; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhang Z, 2018, MED SCI MONITOR, V24, P8190, DOI 10.12659/MSM.912643; Zhao SG, 2019, JNCI-J NATL CANCER I, V111, P301, DOI 10.1093/jnci/djy141; Zhou Y, 2019, NAT COMMUN, V10, DOI [DOI 10.1038/S41467-019-09234-6, 10.1038/s41467-019-09234-6]; Zhu DT, 2018, CELL REP, V25, P2285, DOI 10.1016/j.celrep.2018.10.093; Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237	93	2	2	9	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6479	6493		10.1038/s41388-021-02026-7	http://dx.doi.org/10.1038/s41388-021-02026-7		OCT 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34611310				2022-12-17	WOS:000703836100003
J	Xu, H; Wong, CC; Li, WL; Zhou, YF; Li, Y; Wang, LF; Liu, L; Yu, J				Xu, Hui; Wong, Chi Chun; Li, Weilin; Zhou, Yunfei; Li, Yan; Wang, Lifu; Liu, Lei; Yu, Jun			RING-finger protein 6 promotes colorectal tumorigenesis by transcriptionally activating SF3B2	ONCOGENE			English	Article							SOMATIC MUTATIONS; PHASE-I; CANCER; GENE; RNF6; TARGET; E7107	RNF6 is a RING finger protein with oncogenic potential. In this study, we established colon-specific RNF6 transgenic (tg) mice, and demonstrated that RNF6 overexpression accelerated colorectal carcinogenesis compared to wild-type littermates in a chemically induced colorectal cancer (CRC) model. To understand whether transcriptional activity of RNF6 underlies its oncogenic effect, we performed integrated chromatin immunoprecipitation (ChIP)-sequencing and RNA-sequencing analysis to identify splicing factor 3b subunit 2 (SF3B2) as a potential downstream target of RNF6. RNF6 binds to the SF3B2 promoter and the overexpression of RNF6 activates SF3B2 expression in CRC cells, primary CRC organoids, and RNF6 tg mice. SF3B2 knockout abrogated the tumor promoting effect of RNF6 overexpression, whereas the reexpression of SF3B2 recused cell growth and migration/invasion in RNF6 knockout cells, indicating that SF3B2 is a functional downstream target of RNF6 in CRC. Targeting of RNF6-SF3B2 axis with SF3B2 inhibitor with pladienolide B suppressed the growth of CRC cells with RNF6 overexpression in vitro and in vivo. Moreover, the combination of 5-fluorouracil (5-FU) plus pladienolide B exerted synergistic effects in CRC with high RNF6 expression, leading to tumor regression in xenograft models. These findings indicate that tumor promoting effect of RNF6 is achieved mainly via transcriptional upregulation of SF3B2, and that RNF6-SF3B2 axis is a promising target for CRC therapy.	[Xu, Hui; Wang, Lifu; Liu, Lei] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China; [Xu, Hui; Wong, Chi Chun; Zhou, Yunfei; Li, Yan; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Xu, Hui; Wong, Chi Chun; Zhou, Yunfei; Li, Yan; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Li, Weilin] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Genet, Boston, MA 02115 USA	Shanghai Jiao Tong University; Chinese University of Hong Kong; Chinese University of Hong Kong; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Wang, LF; Liu, L (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, State Key Lab Digest Dis, Hong Kong, Peoples R China.	lifuwang@sjtu.edu.cn; ll11860@rjh.com.cn; junyu@cuhk.edu.hk	Li, Weilin/ABG-9032-2021; Jun, Yu/D-8569-2015	Wong, Chi Chun/0000-0003-1362-3541; Jun, Yu/0000-0001-5008-2153	Natural Science Foundation of China [81802331]; National Key R&D Program of China [2018YFC1315000, 2018YFC1315004, 2017YFE0190700]; National Natural Science Foundation of China (NSFC) [81972576]; Science and Technology Program Grant Shenzhen [JCYJ20170413161534162, JCYJ20180307151253271]; RGC-GRF Hong Kong [14111216, 14163817, 14101917, 14108718, 24100520]; RGC-CRF [C4039-19G]; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Science and Technology Program Grant Shenzhen; RGC-GRF Hong Kong(Hong Kong Research Grants Council); RGC-CRF; Vice-Chancellor's Discretionary Fund CUHK; Shenzhen Virtual University Park Support Scheme	This project was supported by Natural Science Foundation of China (81802331), National Key R&D Program of China (No. 2018YFC1315000, 2018YFC1315004, and 2017YFE0190700), National Natural Science Foundation of China (NSFC; 81972576), Science and Technology Program Grant Shenzhen (JCYJ20170413161534162 and JCYJ20180307151253271), RGC-GRF Hong Kong (14111216, 14163817, 14101917, and 14108718, 24100520), RGC-CRF (C4039-19G), Vice-Chancellor's Discretionary Fund CUHK, Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.	Cai J, 2019, EXP CELL RES, V374, P152, DOI 10.1016/j.yexcr.2018.11.019; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cretu C, 2016, MOL CELL, V64, P307, DOI 10.1016/j.molcel.2016.08.036; Dehm SM, 2013, CLIN CANCER RES, V19, P6064, DOI 10.1158/1078-0432.CCR-13-2461; Dong YJ, 2019, THERANOSTICS, V9, P6517, DOI 10.7150/thno.34989; Eskens FALM, 2013, CLIN CANCER RES, V19, P6296, DOI 10.1158/1078-0432.CCR-13-0485; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Hong DS, 2014, INVEST NEW DRUG, V32, P436, DOI 10.1007/s10637-013-0046-5; Kawamura N, 2019, CANCER RES, V79, P5204, DOI 10.1158/0008-5472.CAN-18-3965; Kotake Y, 2007, NAT CHEM BIOL, V3, P570, DOI 10.1038/nchembio.2007.16; Liang Q, 2018, CLIN CANCER RES, V24, P1473, DOI 10.1158/1078-0432.CCR-17-2133; Liu L, 2018, CANCER RES, V78, P1958, DOI 10.1158/0008-5472.CAN-17-2683; Lo HS, 2002, CANCER RES, V62, P4191; Lopez P, 2002, MOL CELL BIOL, V22, P3488, DOI 10.1128/MCB.22.10.3488-3496.2002; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Rai K, 2015, CANCER DISCOV, V5, P1314, DOI 10.1158/2159-8290.CD-15-0493; Ren Y, 2020, ACTA PHARMACOL SIN, V41, P394, DOI 10.1038/s41401-019-0309-6; Sato M, 2014, CANCER SCI, V105, P110, DOI 10.1111/cas.12317; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021; Xu LX, 2016, GUT, V65, P635, DOI 10.1136/gutjnl-2014-308257; Xu X, 2016, J BIOL CHEM, V291, P9617, DOI 10.1074/jbc.M115.701979	24	2	2	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6513	6526		10.1038/s41388-021-01872-9	http://dx.doi.org/10.1038/s41388-021-01872-9		OCT 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34611311	Green Published, hybrid			2022-12-17	WOS:000703836100001
J	Wilhelm, A; Marschalek, R				Wilhelm, Alexander; Marschalek, Rolf			The role of reciprocal fusions in MLL-r acute leukemia: studying the chromosomal translocation t(4;11)	ONCOGENE			English	Article							COMPLEX; MUTATIONS; PROTEIN; INFANT; ELONGATION; ACTIVATION; TARGET; MODEL	Leukemia patients bearing the t(4;11)(q21;q23) translocations can be divided into two subgroups: those expressing both reciprocal fusion genes, and those that have only the MLL-AF4 fusion gene. Moreover, a recent study has demonstrated that patients expressing both fusion genes have a better outcome than patients that are expressing the MLL-AF4 fusion protein alone. All this may point to a clonal process where the reciprocal fusion gene AF4-MLL could be lost during disease progression, as this loss may select for a more aggressive type of leukemia. Therefore, we were interested in unraveling the decisive role of the AF4-MLL fusion protein at an early timepoint of disease development. We designed an experimental model system where the MLL-AF4 fusion protein was constitutively expressed, while an inducible AF4-MLL fusion gene was induced for only 48 h. Subsequently, we investigated genome-wide changes by RNA- and ATAC-Seq experiments at distinct timepoints. These analyses revealed that the expression of AF4-MLL for only 48 h was sufficient to significantly change the genomic landscape (transcription and chromatin) even on a longer time scale. Thus, we have to conclude that the AF4-MLL fusion protein works through a hit-and-run mechanism, probably necessary to set up pre-leukemic conditions, but being dispensable for later disease progression.	[Wilhelm, Alexander; Marschalek, Rolf] Goethe Univ Frankfurt, Inst Pharmaceut Biol DCAL, Frankfurt, Germany	Goethe University Frankfurt	Marschalek, R (corresponding author), Goethe Univ Frankfurt, Inst Pharmaceut Biol DCAL, Frankfurt, Germany.	Rolf.Marschalek@em.uni-frankfurt.de		Wilhelm, Alexander/0000-0003-0904-3376; Marschalek, Rolf/0000-0003-4870-3445	DFG [Ma 1876/12-1, Ma 1876/13-1]; Wilhelm Sander Foundation [2018.070.1, 2018.070.2]; Projekt DEAL	DFG(German Research Foundation (DFG)); Wilhelm Sander Foundation; Projekt DEAL	This work is funded by DFG grants Ma 1876/12-1 and Ma 1876/13-1, and grant 2018.070.1 and 2018.070.2 from the Wilhelm Sander Foundation. Open Access funding enabled and organized by Projekt DEAL.	Agraz-Doblas A, 2019, HAEMATOLOGICA, V104, P1176, DOI 10.3324/haematol.2018.206375; Andersson AK, 2015, NAT GENET, V47, P330, DOI 10.1038/ng.3230; Bardini M, 2010, LEUKEMIA, V24, P169, DOI 10.1038/leu.2009.203; Benedikt A, 2011, LEUKEMIA, V25, P135, DOI 10.1038/leu.2010.249; Bitoun E, 2007, HUM MOL GENET, V16, P92, DOI 10.1093/hmg/ddl444; Bursen A, 2010, BLOOD, V115, P3570, DOI 10.1182/blood-2009-06-229542; Cho S, 2010, CELL CYCLE, V9, P1697, DOI 10.4161/cc.9.9.11346; Chu SH, 2018, BLOOD ADV, V2, P2478, DOI 10.1182/bloodadvances.2018021592; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Kowarz E, 2007, LEUKEMIA, V21, P1232, DOI 10.1038/sj.leu.2404686; Kowarz E, 2015, BIOTECHNOL J, V10, P647, DOI 10.1002/biot.201400821; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Lin S, 2016, CANCER CELL, V30, P737, DOI 10.1016/j.ccell.2016.10.008; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo ZJ, 2012, NAT REV MOL CELL BIO, V13, P543, DOI 10.1038/nrm3417; Mansur MB, 2017, BBA-REV CANCER, V1868, P521, DOI 10.1016/j.bbcan.2017.10.005; Marschalek R, 2020, BBA-GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2020.194547; Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213; Milne TA, 2005, P NATL ACAD SCI USA, V102, P14765, DOI 10.1073/pnas.0503630102; Prelle C, 2013, LEUKEMIA, V27, P1425, DOI 10.1038/leu.2012.365; Rossler T, 2013, PHARMAZIE, V68, P601, DOI 10.1691/ph.2013.6514; Secker KA, 2020, CANCERS, V12, DOI 10.3390/cancers12061487; Sharaf-Eldein M, 2018, CLIN LAB, V64, P1429, DOI 10.7754/Clin.Lab.2018.180308; Tyagi A, 2019, INT J HEMATOL, V110, P205, DOI 10.1007/s12185-019-02666-2; Wang AY, 2021, CANCER GENOM PROTEOM, V18, P43, DOI 10.21873/cgp.20240; Wilkinson AC, 2013, CELL REP, V3, P116, DOI 10.1016/j.celrep.2012.12.016; Wu Sharon, 2019, Metabol Open, V2, P100009, DOI 10.1016/j.metop.2019.100009; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004	29	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6093	6102		10.1038/s41388-021-02001-2	http://dx.doi.org/10.1038/s41388-021-02001-2		SEP 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34489550	Green Published, hybrid			2022-12-17	WOS:000692963000001
J	Tong, K; Kothari, OA; Haro, KS; Panda, A; Bandari, MM; Carrick, JN; Hur, JJ; Zhang, LJ; Chan, CS; Xing, JC; Gatza, ML; Ganesan, S; Verzi, MP				Tong, Kevin; Kothari, Om A.; Haro, Katherine S.; Panda, Anshuman; Bandari, Manisha M.; Carrick, Jillian N.; Hur, Joseph J.; Zhang, Lanjing; Chan, Chang S.; Xing, Jinchuan; Gatza, Michael L.; Ganesan, Shridar; Verzi, Michael P.			SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis	ONCOGENE			English	Article							ISLAND METHYLATOR PHENOTYPE; SPORADIC MICROSATELLITE INSTABILITY; BRAF MUTATION STATUS; COLORECTAL-CANCER; BETA-CATENIN; MOUSE MODELS; STEM-CELLS; REPEAT MARKERS; POOR SURVIVAL; COLON	BRAF-driven colorectal cancer is among the poorest prognosis subtypes of colon cancer. Previous studies suggest that BRAF-mutant serrated cancers frequently exhibit Microsatellite Instability (MSI) and elevated levels of WNT signaling. The loss of tumor-suppressor Smad4 in oncogenic BRAF-V600E mouse models promotes rapid serrated tumor development and progression, and SMAD4 mutations co-occur in human patient tumors with BRAF-V600E mutations. This study assesses the role of SMAD4 in early-stage serrated tumorigenesis. SMAD4 loss promotes microsatellite stable (MSS) serrated tumors in an oncogenic BRAF-V600E context, providing a model for MSS serrated cancers. Inactivation of Msh2 in these mice accelerated tumor formation, and whole-exome sequencing of both MSS and MSI serrated tumors derived from these mouse models revealed that all serrated tumors developed oncogenic WNT mutations, predominantly in the WNT-effector gene Ctnnb1 (beta-catenin). Mouse models mimicking the oncogenic beta-catenin mutation show that the combination of three oncogenic mutations (Ctnnb1, Braf, and Smad4) are critical to drive rapid serrated dysplasia formation. Re-analysis of human tumor data reveals BRAF-V600E mutations co-occur with oncogenic mutations in both WNT and SMAD4/TGF beta pathways. These findings identify SMAD4 as a critical factor in early-stage serrated cancers and helps broaden the knowledge of this rare but aggressive subset of colorectal cancer.	[Tong, Kevin; Kothari, Om A.; Haro, Katherine S.; Bandari, Manisha M.; Carrick, Jillian N.; Hur, Joseph J.; Xing, Jinchuan; Verzi, Michael P.] Rutgers State Univ, Human Genet Inst New Jersey HGINJ, Dept Genet, Piscataway, NJ 08854 USA; [Panda, Anshuman; Zhang, Lanjing; Gatza, Michael L.; Ganesan, Shridar; Verzi, Michael P.] Rutgers Canc Inst New Jersey CINJ, New Brunswick, NJ 08901 USA; [Zhang, Lanjing] Penn Med Princeton Med Ctr, Dept Pathol, Plainsboro, NJ USA; [Chan, Chang S.] Rutgers Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ USA; [Gatza, Michael L.] Univ Med & Dent New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Verzi, MP (corresponding author), Rutgers State Univ, Human Genet Inst New Jersey HGINJ, Dept Genet, Piscataway, NJ 08854 USA.; Verzi, MP (corresponding author), Rutgers Canc Inst New Jersey CINJ, New Brunswick, NJ 08901 USA.	verzi@biology.rutgers.edu	Zhang, Lanjing/AGY-7838-2022; Zhang, Lanjing/GZB-0260-2022; Panda, Anshuman/T-5101-2018	Zhang, Lanjing/0000-0001-5436-887X; Panda, Anshuman/0000-0001-7917-0317; Chan, Chang/0000-0001-9897-4759	NCI [5P30CA072720, 1R01CA243547, 1F32CA235829, 5K99CA245123, 5R01CA190558]; Rutgers Undergraduate Research Fellowships; Douglass Project STEM; ARESTY Summer Research Fellowships; NIDDK [1R01DK121915]; Rutgers Human Genetics Institute of New Jersey; Cancer Institute of New Jersey [5P30CA072720]; US Department of Defense; American Association for Cancer Research	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Rutgers Undergraduate Research Fellowships; Douglass Project STEM; ARESTY Summer Research Fellowships; NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Rutgers Human Genetics Institute of New Jersey; Cancer Institute of New Jersey; US Department of Defense(United States Department of Defense); American Association for Cancer Research	KT is funded by NCI (1F32CA235829, 5K99CA245123). OAK, KSH, MMB, and JNC were funded by Rutgers Undergraduate Research Fellowships, Douglass Project STEM, and ARESTY Summer Research Fellowships. MPV is funded by NCI (5R01CA190558), NIDDK (1R01DK121915), and supported by the Rutgers Human Genetics Institute of New Jersey and the Cancer Institute of New Jersey (5P30CA072720). SG is funded by NCI (5P30CA072720, 1R01CA243547) and the US Department of Defense. Authors also thank members of Verzi Lab, Rutgers Epigenetic Group, and Rutgers High Performance Computing for constructive input and expertise in Whole Exome Sequencing processing and analysis. Msh2KO mouse model was provided as a gift from Jiehui Deng and the Wong Lab. The authors would like to acknowledge the American Association for Cancer Research and its financial and material support in the development of the AACR Project GENIE registry, as well as members of the consortium for their commitment to data sharing. Interpretations are the responsibility of study authors.	AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Afgan E, 2016, NUCLEIC ACIDS RES, V44, pW3, DOI 10.1093/nar/gkw343; Alberici P, 2006, ONCOGENE, V25, P1841, DOI 10.1038/sj.onc.1209226; Alberici Paola, 2008, Pathogenetics, V1, P2, DOI 10.1186/1755-8417-1-2; Ando Y, 2020, CLIN J GASTROENTEROL, V13, P867, DOI 10.1007/s12328-020-01099-3; Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Andre T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699; Ang PW, 2009, CANCER LETT, V273, P221, DOI 10.1016/j.canlet.2008.08.001; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Bacher JW, 2005, MOL CARCINOGEN, V44, P285, DOI 10.1002/mc.20146; Barata P, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001065; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Basu Sayon, 2016, F1000Res, V5, DOI 10.12688/f1000research.7579.1; Biswas S, 2008, GENE CHROMOSOME CANC, V47, P95, DOI 10.1002/gcc.20511; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakravarty D, 2017, JCO PRECIS ONCOL, V1; Chang LS, 2018, APPL IMMUNOHISTO M M, V26, pE15, DOI 10.1097/PAI.0000000000000575; Chapnick DA, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-42; Chen XY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00301-9; Chouhan H, 2019, ASIA-PAC J CLIN ONCO, V15, P69, DOI 10.1111/ajco.13096; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Das S, 2020, CLIN COLORECTAL CANC, V19, P137, DOI 10.1016/j.clcc.2020.02.006; de Sousa EMF, 2011, CLIN CANCER RES, V17, P647, DOI 10.1158/1078-0432.CCR-10-1204; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Eto T, 2018, J PATHOL, V245, P445, DOI 10.1002/path.5098; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fernando WC, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/374926; Fodde R, 2002, EUR J CANCER, V38, P867, DOI 10.1016/S0959-8049(02)00040-0; Freeman TJ, 2012, GASTROENTEROLOGY, V142, P562, DOI 10.1053/j.gastro.2011.11.026; Fumagalli A, 2017, P NATL ACAD SCI USA, V114, pE2357, DOI 10.1073/pnas.1701219114; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Gotovac JR, 2018, DISCOV MED, V26, P103; Guo TA, 2019, INT J CANCER, V145, P1625, DOI 10.1002/ijc.32489; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Hinoue T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008357; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; JENG MH, 1991, MOL ENDOCRINOL, V5, P1120, DOI 10.1210/mend-5-8-1120; Kabbarah O, 2003, MOL CARCINOGEN, V38, P155, DOI 10.1002/mc.10157; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kane AM, 2020, NEOPLASIA, V22, P120, DOI 10.1016/j.neo.2019.12.002; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kucherlapati MH, 2010, GASTROENTEROLOGY, V138, P993, DOI 10.1053/j.gastro.2009.11.009; Lange S, 2020, NAT PROTOC, V15, P266, DOI 10.1038/s41596-019-0234-7; Lannagan TRM, 2019, GUT, V68, P684, DOI 10.1136/gutjnl-2017-315920; Leggett B, 2010, GASTROENTEROLOGY, V138, P2088, DOI 10.1053/j.gastro.2009.12.066; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu Q, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00799; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Mizuno T, 2018, EJSO-EUR J SURG ONC, V44, P684, DOI 10.1016/j.ejso.2018.02.247; O'Rourke KP, 2017, NAT BIOTECHNOL, V35, P577, DOI 10.1038/nbt.3837; Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473; Panarelli NC, 2015, AM J SURG PATHOL, V39, P313, DOI 10.1097/PAS.0000000000000380; Panda A, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00146; Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269; Perekatt AO, 2018, CANCER RES, V78, P4878, DOI 10.1158/0008-5472.CAN-18-0043; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Provost E, 2003, J BIOL CHEM, V278, P31781, DOI 10.1074/jbc.M304953200; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Rex DK, 2012, AM J GASTROENTEROL, V107, P1315, DOI 10.1038/ajg.2012.161; Riemer P, 2015, ONCOGENE, V34, P3164, DOI 10.1038/onc.2014.247; Robinson JT, 2017, CANCER RES, V77, pE31, DOI 10.1158/0008-5472.CAN-17-0337; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Roper J, 2017, NAT BIOTECHNOL, V35, P569, DOI 10.1038/nbt.3836; Sakai E, 2018, CANCER RES, V78, P1334, DOI 10.1158/0008-5472.CAN-17-3303; Sakamoto N, 2017, ELIFE, V6, DOI 10.7554/eLife.20331; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schatoff EM, 2017, CURR COLORECT CANC R, V13, P101, DOI 10.1007/s11888-017-0354-9; Seppala TT, 2015, BRIT J CANCER, V112, P1966, DOI 10.1038/bjc.2015.160; Sinicrope FA, 2019, CLIN GASTROENTEROL H, V17, P391, DOI 10.1016/j.cgh.2018.06.038; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]; Taieb J, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw272; Taketo MM, 2009, GASTROENTEROLOGY, V136, P780, DOI 10.1053/j.gastro.2008.12.049; Tanaka H, 2006, INT J CANCER, V118, P2765, DOI 10.1002/ijc.21701; Tao Y, 2019, CANCER CELL, V35, P315, DOI 10.1016/j.ccell.2019.01.005; The Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI [DOI 10.1038/NATURE11252, 10.1038/nature11252]; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tian XX, 2009, BIOCHEM BIOPH RES CO, V380, P478, DOI 10.1016/j.bbrc.2009.01.124; Tong K, 2017, CELL REP, V21, P3833, DOI 10.1016/j.celrep.2017.11.104; Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Xia JX, 2006, J DERMATOL SCI, V41, P67, DOI 10.1016/j.jdermsci.2005.09.005; Xue X, 2013, JOVE-J VIS EXP, DOI 10.3791/50210; Yagyu R, 2004, INT J ONCOL, V25, P1343; Yamane L, 2014, WORLD J GASTROENTERO, V20, P2634, DOI 10.3748/wjg.v20.i10.2634; Yan P, 2016, CLIN CANCER RES, V22, P3037, DOI 10.1158/1078-0432.CCR-15-0939; Yang G, 2010, INT J BIOL SCI, V6, P1; Yang X, 2002, GENESIS, V32, P80, DOI 10.1002/gene.10029; Yang YC, 2018, CANCER MANAG RES, V10, P3911, DOI 10.2147/CMAR.S169649; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhao PF, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0738-1	101	2	2	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					6034	6048		10.1038/s41388-021-01997-x	http://dx.doi.org/10.1038/s41388-021-01997-x		AUG 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34453124	Green Accepted			2022-12-17	WOS:000690353500001
J	Mu, ML; Niu, WX; Zhang, XM; Hu, SS; Niu, CS				Mu, Maolin; Niu, Wanxiang; Zhang, Xiaoming; Hu, Shanshan; Niu, Chaoshi			LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway (vol 39, 6879, 2021)	ONCOGENE			English	Correction												hss923@ustc.edu.cn; niuchaoshi@ustc.edu.cn						Mu ML, 2020, ONCOGENE, V39, P6879, DOI 10.1038/s41388-020-01466-x	1	2	2	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5972	5973		10.1038/s41388-021-01990-4	http://dx.doi.org/10.1038/s41388-021-01990-4		AUG 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34400767	Green Published, hybrid			2022-12-17	WOS:000685396300001
J	He, SN; Zimmerman, MW; Layden, HM; Berezovskaya, A; Etchin, J; Martel, MW; Thurston, G; Jing, CB; van Rooijen, E; Kaufman, CK; Rodig, SJ; Zon, LI; Patton, EE; Mansour, MR; Look, AT				He, Shuning; Zimmerman, Mark W.; Layden, Hillary M.; Berezovskaya, Alla; Etchin, Julia; Martel, Megan W.; Thurston, Grace; Jing, Chang-Bin; van Rooijen, Ellen; Kaufman, Charles K.; Rodig, Scott J.; Zon, Leonard I.; Patton, E. Elizabeth; Mansour, Marc R.; Look, A. Thomas			Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss	ONCOGENE			English	Article							MUTATIONS; AUTOPHAGY; NF1; GENES; TUMORIGENESIS; TEMSIROLIMUS; SENSITIVITY; CHLOROQUINE; RESISTANCE; SCREEN	Melanomas driven by loss of the NF1 tumor suppressor have a high risk of treatment failure and effective therapies have not been developed. Here we show that loss-of-function mutations of nf1 and pten result in aggressive melanomas in zebrafish, representing the first animal model of NF1-mutant melanomas harboring PTEN loss. MEK or PI3K inhibitors show little activity when given alone due to cross-talk between the pathways, and high toxicity when given together. The mTOR inhibitors, sirolimus, everolimus, and temsirolimus, were the most active single agents tested, potently induced tumor-suppressive autophagy, but not apoptosis. Because addition of the BCL2 inhibitor venetoclax resulted in compensatory upregulation of MCL1, we established a three-drug combination composed of sirolimus, venetoclax, and the MCL1 inhibitor S63845. This well-tolerated drug combination potently and synergistically induces apoptosis in both zebrafish and human NF1/PTEN-deficient melanoma cells, providing preclinical evidence justifying an early-stage clinical trial in patients with NF1/PTEN-deficient melanoma.	[He, Shuning; Zimmerman, Mark W.; Layden, Hillary M.; Berezovskaya, Alla; Etchin, Julia; Martel, Megan W.; Thurston, Grace; Jing, Chang-Bin; Mansour, Marc R.; Look, A. Thomas] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [van Rooijen, Ellen; Kaufman, Charles K.; Zon, Leonard I.] Howard Hughes Med Inst, Childrens Hosp Boston, Stem Cell Program, Boston, MA 02115 USA; [van Rooijen, Ellen; Kaufman, Charles K.] Howard Hughes Med Inst, Childrens Hosp Boston, Div Hematol Oncol, Boston, MA 02115 USA; [Rodig, Scott J.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Patton, E. Elizabeth] Univ Edinburgh, MRC Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh, Midlothian, Scotland; [Mansour, Marc R.] UCL, UCL Canc Inst, Dept Hematol, London, England	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; University of Edinburgh; University of London; University College London	He, SN; Mansour, MR; Look, AT (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.; Mansour, MR (corresponding author), UCL, UCL Canc Inst, Dept Hematol, London, England.	shuning_he@dfci.harvard.edu; m.mansour@ucl.ac.uk; Thomas_Look@dfci.harvard.edu		Layden, Hillary/0000-0001-8583-620X; Zimmerman, Mark/0000-0003-2489-3889	Melanoma Research Alliance award [509233]	Melanoma Research Alliance award	We would like to thank John Gilbert for critical review of the manuscript and editorial suggestions; Kassandra Bacon and Daniel Debiasi for zebrafish husbandry; Jeoren den Hertog, Alejandro Gutierrez and David M. Langenau for providing zebrafish lines; Yi Zhou and Andrew Hong for stimulating suggestions; Christine L. Unitt, Benjamin Ferland and Dana-Farber/Harvard Cancer Center Research Pathology Core for technical support. This study was funded by Melanoma Research Alliance award #509233.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; Avniel-Polak S, 2016, NEUROENDOCRINOLOGY, V103, P724, DOI 10.1159/000442589; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Chen KG, 2009, JNCI-J NATL CANCER I, V101, P1259, DOI 10.1093/jnci/djp259; Cirenajwis H, 2017, MOL ONCOL, V11, P438, DOI 10.1002/1878-0261.12050; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; Dovey M, 2009, ZEBRAFISH, V6, P397, DOI 10.1089/zeb.2009.0606; Faucherre A, 2008, ONCOGENE, V27, P1079, DOI 10.1038/sj.onc.1210730; Garman B, 2017, CELL REP, V21, P1936, DOI 10.1016/j.celrep.2017.10.052; Gutierrez A, 2011, J EXP MED, V208, P1595, DOI 10.1084/jem.20101691; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; He SN, 2012, J PATHOL, V227, P431, DOI 10.1002/path.4013; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; Kaneko M, 2014, J CANCER RES CLIN, V140, P769, DOI 10.1007/s00432-014-1628-0; Kaufman CK, 2016, ADV EXP MED BIOL, V916, P439, DOI 10.1007/978-3-319-30654-4_19; Kaufman CK, 2016, SCIENCE, V351, DOI 10.1126/science.aad2197; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Kuzu OF, 2015, CANCER GROWTH METAST, P81, DOI 10.4137/CGM.S21214; Lam LT, 2010, MOL CANCER THER, V9, P2943, DOI 10.1158/1535-7163.MCT-10-0427; Leverson JD, 2017, CANCER DISCOV, V7, P1376, DOI 10.1158/2159-8290.CD-17-0797; Li ZD, 2019, LEUKEMIA, V33, P262, DOI 10.1038/s41375-018-0201-2; Lister JA, 2014, J INVEST DERMATOL, V134, P133, DOI 10.1038/jid.2013.293; Macintosh RL, 2013, SEMIN CANCER BIOL, V23, P344, DOI 10.1016/j.semcancer.2013.05.006; Maertens Ophelia, 2014, Advances in Biological Regulation, V55, P1, DOI 10.1016/j.jbior.2014.04.002; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313; Mar VJ, 2013, CLIN CANCER RES, V19, P4589, DOI 10.1158/1078-0432.CCR-13-0398; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Mohana-Kumaran N, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12242; Mukherjee N, 2015, J INVEST DERMATOL, V135, P2155, DOI 10.1038/jid.2015.145; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Potter DS, 2016, COLD SH Q B, V81, P131, DOI 10.1101/sqb.2016.81.030841; Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119; Sharma K, 2014, INT J MOL SCI, V15, P10034, DOI 10.3390/ijms150610034; Shin J, 2012, DIS MODEL MECH, V5, P881, DOI 10.1242/dmm.009779; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tang Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10358; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Yang SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026343	45	2	2	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5718	5729		10.1038/s41388-021-01926-y	http://dx.doi.org/10.1038/s41388-021-01926-y		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34331013	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000679620500002
J	Zhang, SY; Guo, XM; Liu, XF; Zhong, ZX; Yang, SL; Wang, HH				Zhang, Shaoyang; Guo, Xueming; Liu, Xiufeng; Zhong, Zhixiong; Yang, Shulan; Wang, Haihe			Adaptor SH3BGRL promotes breast cancer metastasis through PFN1 degradation by translational STUB1 upregulation	ONCOGENE			English	Article							KAPPA-B; CELL MOTILITY; PROFILIN; PROTEIN; PROLIFERATION; SUPPRESSION; INHIBITION; BIOMARKER	Metastatic recurrence is still a major challenge in breast cancer treatment, but the underlying mechanisms remain unclear. Here, we report that a small adaptor protein, SH3BGRL, is upregulated in the majority of breast cancer patients, especially elevated in those with metastatic relapse, indicating it as a marker for the poor prognosis of breast cancer. Physiologically, SH3BGRL can multifunctionally promote breast cancer cell tumorigenicity, migration, invasiveness, and efficient lung colonization in nude mice. Mechanistically, SH3BGRL downregulates the acting-binding protein profilin 1 (PFN1) by accelerating the translation of the PFN1 E3 ligase, STUB1 via SH3BGRL interaction with ribosomal proteins, or/and enhancing the interaction of PFN1 with STUB1 to accelerate PFN1 degradation. Loss of PFN1 consequently contributes to downstream multiple activations of AKT, NF-B-k, and WNT signaling pathways. In contrast, the forced expression of compensatory PFN1 in SH3BGRL-high cells efficiently neutralizes SH3BGRL-induced metastasis and tumorigenesis with PTEN upregulation and PI3K-AKT signaling inactivation. Clinical analysis validates that SH3BGRL expression is negatively correlated with PFN1 and PTEN levels, but positively to the activations of AKT, NF-B-k, and WNT signaling pathways in breast patient tissues. Our results thus suggest that SH3BGRL is a valuable prognostic factor and a potential therapeutic target for preventing breast cancer progression and metastasis.	[Zhang, Shaoyang; Liu, Xiufeng; Yang, Shulan] Sun Yat Sen Univ, Affiliated Hosp 1, Translat Med Ctr, Guangzhou, Peoples R China; [Zhang, Shaoyang; Wang, Haihe] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Peoples R China; [Guo, Xueming; Zhong, Zhixiong] Meizhou City Peoples Hosp, Ctr Hlth Examinat, Guangzhou, Guangdong, Peoples R China; [Guo, Xueming; Zhong, Zhixiong] Guangdong Prov Key Lab Precis Med & Clin Translat, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Yang, SL (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Translat Med Ctr, Guangzhou, Peoples R China.; Wang, HH (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Peoples R China.	yangshl3@mail.sysu.edu.cn; wanghaih@mail.sysu.edu.cn		Yang, Shu-Lan/0000-0002-6864-2195; Zhong, Zhixiong/0000-0002-3200-3105; , Haihe/0000-0002-9302-2334; Guo, Xuemin/0000-0003-2929-7461	National Science Foundation of China [81672704]; Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translation Research of Hakka Population [2018B030322003KF02]; Natural Science Foundation of Guangdong Province [2021A1515010999]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translation Research of Hakka Population; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This work was supported by National Science Foundation of China (No. 81672704), the Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translation Research of Hakka Population (2018B030322003KF02), and Natural Science Foundation of Guangdong Province (No. 2021A1515010999) to WH.	Abba MC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-37; Bae YH, 2010, P NATL ACAD SCI USA, V107, P21547, DOI 10.1073/pnas.1002309107; Bae YH, 2009, J CELL PHYSIOL, V219, P354, DOI 10.1002/jcp.21677; Birbach A, 2008, BIOESSAYS, V30, P994, DOI 10.1002/bies.20822; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; Choi YN, 2014, BIOCHEM BIOPH RES CO, V446, P1060, DOI 10.1016/j.bbrc.2014.03.061; Das T, 2009, J CELL PHYSIOL, V218, P436, DOI 10.1002/jcp.21618; Ding Z, 2014, ONCOGENE, V33, P2065, DOI 10.1038/onc.2013.166; Egeo A, 1998, BIOCHEM BIOPH RES CO, V247, P302, DOI 10.1006/bbrc.1998.8763; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gronborg M, 2006, MOL CELL PROTEOMICS, V5, P157, DOI 10.1074/mcp.M500178-MCP200; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hohenester E, 2013, CELL ADHES MIGR, V7, P56, DOI 10.4161/cam.21831; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Jockusch BM, 2007, REV PHYSIOL BIOCH P, V159, P131, DOI 10.1007/112_2007_704; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Li H, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01577-z; Loibl S, 2021, LANCET, V397, P1750, DOI 10.1016/S0140-6736(20)32381-3; Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036; Majid SM, 2006, ONCOGENE, V25, P756, DOI 10.1038/sj.onc.1209107; Mouneimne G, 2012, CANCER CELL, V22, P615, DOI 10.1016/j.ccr.2012.09.027; Lino MAM, 2014, J PROTEOMICS, V111, P198, DOI 10.1016/j.jprot.2014.04.019; Nagaraj N, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.81; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tong F, 2016, DEV GENES EVOL, V226, P287, DOI 10.1007/s00427-016-0552-5; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Waks Adrienne G, 2019, JAMA, V321, P288, DOI 10.1001/jama.2018.19323; Wang H, 2016, ONCOGENE, V35, P3303, DOI 10.1038/onc.2015.391; Werner CJ, 2008, PROTEOME SCI, V6, DOI 10.1186/1477-5956-6-8; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003; Wu N, 2006, PROTEOMICS, V6, P6095, DOI 10.1002/pmic.200500321; Xu LM, 2018, LEUKEMIA LYMPHOMA, V59, P918, DOI 10.1080/10428194.2017.1344843; Yarmola EG, 2006, TRENDS BIOCHEM SCI, V31, P197, DOI 10.1016/j.tibs.2006.02.006; Yin L, 2005, PROTEINS, V61, P213, DOI 10.1002/prot.20523; Zoidakis J, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.009449; Zou L, 2010, J CELL PHYSIOL, V223, P623, DOI 10.1002/jcp.22058	41	2	2	4	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5677	5690		10.1038/s41388-021-01970-8	http://dx.doi.org/10.1038/s41388-021-01970-8		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34331014				2022-12-17	WOS:000679620500003
J	Whately, KM; Voronkova, MA; Maskey, A; Gandhi, J; Loskutov, J; Choi, H; Yanardag, S; Chen, DQ; Wen, SJ; Margaryan, NV; Smolkin, MB; Purazo, ML; Hu, GQ; Pugacheva, EN				Whately, Kristina M.; Voronkova, Maria A.; Maskey, Abha; Gandhi, Jasleen; Loskutov, Juergen; Choi, Hyeran; Yanardag, Sila; Chen, Dongquan; Wen, Sijin; Margaryan, Naira, V; Smolkin, Matthew B.; Purazo, Marc L.; Hu, Gangqing; Pugacheva, Elena N.			Nuclear Aurora-A kinase-induced hypoxia signaling drives early dissemination and metastasis in breast cancer: implications for detection of metastatic tumors	ONCOGENE			English	Article							INDUCIBLE FACTOR-1-ALPHA; MESENCHYMAL TRANSITION; DOWN-REGULATION; EXPRESSION; SURVIVAL; ACTIVATION; PROGNOSIS; CARCINOMA; THERAPY	Metastatic breast cancer causes most breast cancer-associated deaths, especially in triple negative breast cancers (TNBC). The metastatic drivers of TNBCs are still poorly understood, and effective treatment non-existent. Here we reveal that the presence of Aurora-A Kinase (AURKA) in the nucleus and metastatic dissemination are molecularly connected through HIF1 (Hypoxia-Inducible Factor-1) signaling. Nuclear AURKA activates transcription of "hypoxia-induced genes" under normoxic conditions (pseudohypoxia) and without upregulation of oxygen-sensitive HIF1A subunit. We uncover that AURKA preferentially binds to HIF1B and co-localizes with the HIF complex on DNA. The mass-spectrometry analysis of the AURKA complex further confirmed the presence of CBP and p300 along with other TFIIB/RNApol II components. Importantly, the expression of multiple HIF-dependent genes induced by nuclear AURKA (N-AURKA), including migration/invasion, survival/death, and stemness, promote early cancer dissemination. These results indicate that nuclear, but not cytoplasmic, AURKA is a novel driver of early metastasis. Analysis of clinical tumor specimens revealed a correlation between N-AURKA presence and decreased patient survival. Our results establish a mechanistic link between two critical pathways in cancer metastasis, identifying nuclear AURKA as a crucial upstream regulator of the HIF1 transcription complex and a target for anti-metastatic therapy.	[Whately, Kristina M.; Voronkova, Maria A.; Maskey, Abha; Loskutov, Juergen; Choi, Hyeran; Yanardag, Sila; Margaryan, Naira, V; Purazo, Marc L.; Pugacheva, Elena N.] West Virginia Univ, Dept Biochem, Morgantown, WV 26506 USA; [Whately, Kristina M.; Voronkova, Maria A.; Maskey, Abha; Loskutov, Juergen; Yanardag, Sila; Wen, Sijin; Purazo, Marc L.; Hu, Gangqing; Pugacheva, Elena N.] West Virginia Univ, WVU Canc Inst, Sch Med, Morgantown, WV 26506 USA; [Gandhi, Jasleen; Hu, Gangqing] West Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; [Chen, Dongquan] UAB Comprehens Canc Ctr, Dept Med, Div Prevent Med, Birmingham, AL USA; [Wen, Sijin] West Virginia Univ, Sch Publ Hlth, Dept Biostat, Morgantown, WV 26506 USA; [Smolkin, Matthew B.] West Virginia Univ, Dept Pathol, Morgantown, WV 26506 USA	West Virginia University; West Virginia University; West Virginia University; University of Alabama System; University of Alabama Birmingham; West Virginia University; West Virginia University	Pugacheva, EN (corresponding author), West Virginia Univ, Dept Biochem, Morgantown, WV 26506 USA.; Pugacheva, EN (corresponding author), West Virginia Univ, WVU Canc Inst, Sch Med, Morgantown, WV 26506 USA.	epugacheva@hsc.wvu.edu		Whately, Kristina/0000-0002-5908-8145; Maskey, Abha/0000-0003-3688-5376; Gandhi, Jasleen/0000-0001-5724-4194; Yanardag, Sila/0000-0002-0658-3978; Voronkova, Maria/0000-0001-9778-5032	WVUCI; NIH [P20 RR016440, P30 RR032138/GM103488, P30GM103488, P30RR032138, RCP1101809, P20RR016440, U54GM104942, S10RR026378, GM104942, GM103434, OD016165, GM121322, P20GM103434, U54 GM-104942]; NIH-NCI [CA148671]; National Cancer Institute of the National Institutes of Health [CA148671]	WVUCI; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank WVU HSC Office of Graduate Research and Education for outstanding administrative support, WVU Tissue Bank, Genetic Tumor Modeling Core, and Animal Models & Imaging Facilities, supported by the WVUCI and NIH grants P20 RR016440, P30 RR032138/GM103488, and S10RR026378. Flow Cytometry Facility was supported by NIH grants P30GM103488, P30RR032138, and RCP1101809. Bioinformatics Core by NIH grants P20GM103434 and U54 GM-104942. This work was supported by a grant from NIH-NCI CA148671 to ENP. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number CA148671 (to ENP). Small animal imaging and cell image analysis were performed in the West Virginia University Animal Models & Imaging Facility, supported by NIH grants P20RR016440, P30GM103488, U54GM104942, P20GM103434, and S10RR026378. The flow cytometry analysis was done in WVU Flow Cytometry & Single Cell Core Facility, supported by NIH grants GM121322, GM104942, GM103434, and OD016165. The genetic tumor modeling (GTM) core facility provided animal models supported by NIH grant GM121322. The WVU Bioinformatics Core Facility supported by NIH grants P20GM103434 and U54 GM-104942 assisted with RNA-Seq data analysis and interpretation.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Andrzejewski S, 2017, CELL METAB, V26, P778, DOI 10.1016/j.cmet.2017.09.006; Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood-2011-09-380410; Baba Y, 2009, NEOPLASIA, V11, P418, DOI 10.1593/neo.09154; Bierie B, 2017, P NATL ACAD SCI USA, V114, pE2337, DOI 10.1073/pnas.1618298114; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Briassouli P, 2007, CANCER RES, V67, P1689, DOI 10.1158/0008-5472.CAN-06-2272; Brooks DLP, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0510-x; Chen A, 2018, ONCOGENE, V37, P4214, DOI 10.1038/s41388-018-0259-3; D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628; De Bock K, 2011, NAT REV CLIN ONCOL, V8, P393, DOI 10.1038/nrclinonc.2011.83; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Friedl P, 2011, CURR OPIN CELL BIOL, V23, P55, DOI 10.1016/j.ceb.2010.10.015; Generali D, 2006, CLIN CANCER RES, V12, P4562, DOI 10.1158/1078-0432.CCR-05-2690; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Gruber G, 2004, BREAST CANCER RES, V6, pR191, DOI 10.1186/bcr775; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hayashi Y, 2019, CANCER SCI, V110, P1510, DOI 10.1111/cas.13990; Ice RJ, 2013, CANCER RES, V73, P3168, DOI 10.1158/0008-5472.CAN-12-4008; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jones BC, 2017, MOL CANCER RES, V15, P670, DOI 10.1158/1541-7786.MCR-16-0411; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kozyreva VK, 2016, MOL CANCER THER, V15, P1809, DOI 10.1158/1535-7163.MCT-15-0688; Mao JH, 2007, CANCER CELL, V11, P161, DOI 10.1016/j.ccr.2006.11.025; Melchionna R, 2010, CARDIOVASC RES, V86, P293, DOI 10.1093/cvr/cvp393; Nadler Y, 2008, CLIN CANCER RES, V14, P4455, DOI 10.1158/1078-0432.CCR-07-5268; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Orlando IMC, 2020, HAEMATOLOGICA, V105, P2774, DOI 10.3324/haematol.2019.236406; Pankova K, 2010, CELL MOL LIFE SCI, V67, P63, DOI 10.1007/s00018-009-0132-1; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; SEMENZA GL, 2016, BBA-MOL CELL RES, V1863, P382, DOI DOI 10.1016/J.BBAMCR.2015.05.036; Tanaka E, 2005, CLIN CANCER RES, V11, P1827, DOI 10.1158/1078-0432.CCR-04-1627; Tatsuka M, 2009, MOL CARCINOGEN, V48, P810, DOI 10.1002/mc.20525; Wang LH, 2010, CANCER RES, V70, P9118, DOI 10.1158/0008-5472.CAN-10-1246; Wang W, 2014, CLIN CHIM ACTA, V428, P32, DOI 10.1016/j.cca.2013.10.018; Xu HT, 2006, PATHOL INT, V56, P375, DOI 10.1111/j.1440-1827.2006.01974.x; Xu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056919; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; Yang N, 2017, ONCOGENE, V36, P3428, DOI 10.1038/onc.2016.490; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365; Zheng FM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10180	44	2	2	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5651	5664		10.1038/s41388-021-01969-1	http://dx.doi.org/10.1038/s41388-021-01969-1		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34326467	Green Accepted			2022-12-17	WOS:000679262900002
J	Sahu, B; Pihlajamaa, P; Zhang, KY; Palin, K; Ahonen, S; Cervera, A; Ristimaki, A; Aaltonen, LA; Hautaniemi, S; Taipale, J				Sahu, Biswajyoti; Pihlajamaa, Paivi; Zhang, Kaiyang; Palin, Kimmo; Ahonen, Saija; Cervera, Alejandra; Ristimaki, Ari; Aaltonen, Lauri A.; Hautaniemi, Sampsa; Taipale, Jussi			Human cell transformation by combined lineage conversion and oncogene expression	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; HUMAN FIBROBLASTS; RAS ONCOGENES; CANCER; TUMOR; GENES; MYC; METHYLATION; INDUCTION; TUMORIGENESIS	Cancer is the most complex genetic disease known, with mutations implicated in more than 250 genes. However, it is still elusive which specific mutations found in human patients lead to tumorigenesis. Here we show that a combination of oncogenes that is characteristic of liver cancer (CTNNB1, TERT, MYC) induces senescence in human fibroblasts and primary hepatocytes. However, reprogramming fibroblasts to a liver progenitor fate, induced hepatocytes (iHeps), makes them sensitive to transformation by the same oncogenes. The transformed iHeps are highly proliferative, tumorigenic in nude mice, and bear gene expression signatures of liver cancer. These results show that tumorigenesis is triggered by a combination of three elements: the set of driver mutations, the cellular lineage, and the state of differentiation of the cells along the lineage. Our results provide direct support for the role of cell identity as a key determinant in transformation and establish a paradigm for studying the dynamic role of oncogenic drivers in human tumorigenesis.	[Sahu, Biswajyoti; Pihlajamaa, Paivi; Palin, Kimmo; Ahonen, Saija; Ristimaki, Ari; Aaltonen, Lauri A.; Taipale, Jussi] Univ Helsinki, Fac Med, Res Programs Unit, Appl Tumor Genom Res Program, Helsinki, Finland; [Sahu, Biswajyoti; Ristimaki, Ari] Univ Helsinki, Fac Med, Med, Helsinki, Finland; [Sahu, Biswajyoti; Pihlajamaa, Paivi; Taipale, Jussi] Univ Cambridge, Dept Biochem, Cambridge, England; [Sahu, Biswajyoti; Palin, Kimmo; Aaltonen, Lauri A.] iCAN Digital Precis Canc Med Flagship, Helsinki, Finland; [Zhang, Kaiyang; Cervera, Alejandra; Hautaniemi, Sampsa] Univ Helsinki, Fac Med, Res Programs Unit, Res Program Syst Oncol, Helsinki, Finland; [Palin, Kimmo; Aaltonen, Lauri A.] Univ Helsinki, Dept Med & Clin Genet, Helsinki, Finland; [Cervera, Alejandra] Inst Nacl Med Gen6m, Mexico City, DF, Mexico; [Ristimaki, Ari] Univ Helsinki, HUSLAB, Dept Pathol, Helsinki, Finland; [Ristimaki, Ari] Univ Helsinki, HUS Diagnost Ctr, Helsinki, Finland; [Ristimaki, Ari] Helsinki Univ Hosp, Helsinki, Finland; [Taipale, Jussi] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden	University of Helsinki; University of Helsinki; University of Cambridge; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Karolinska Institutet	Taipale, J (corresponding author), Univ Helsinki, Fac Med, Res Programs Unit, Appl Tumor Genom Res Program, Helsinki, Finland.; Taipale, J (corresponding author), Univ Cambridge, Dept Biochem, Cambridge, England.; Taipale, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden.	ajt208@cam.ac.uk	Pihlajamaa, Paivi/AAY-2063-2021; Hautaniemi, Sampsa/A-3122-2009; Aaltonen, Lauri/A-5375-2010; Cervera, Alejandra/ABD-8200-2020; Hautaniemi, Sampsa/CAG-0362-2022; Pihlajamaa, Paivi/AAD-8065-2020; Sahu, Biswajyoti/U-6724-2017	Pihlajamaa, Paivi/0000-0001-9725-6907; Hautaniemi, Sampsa/0000-0002-7749-2694; Aaltonen, Lauri/0000-0001-6839-4286; Cervera, Alejandra/0000-0002-6274-1168; Hautaniemi, Sampsa/0000-0002-7749-2694; Pihlajamaa, Paivi/0000-0001-9725-6907; Sahu, Biswajyoti/0000-0001-6576-5440; Palin, Kimmo/0000-0002-4621-6128; Zhang, Kaiyang/0000-0002-0470-9581; Ahonen, Saija/0000-0003-3313-784X	Academy of Finland (Finnish Center of Excellence in Tumor Genetics Research) [312042, 250345]; Finnish Cancer Foundation; Cancer Research UK [RG99643]; Academy of Finland [250345, 312041, 335823, 319083, 320149, 288836, 274555, 317807]; Sigrid Juselius Foundation; Jane and Aatos Erkko Foundation; Finska Lakaresallskapet; iCAN Digital Precision Cancer Medicine Flagship [320185]; European Union's Horizon 2020 research and innovation program [667403]; University of Helsinki; Helsinki University Central Hospital Research Funds; Helsinki University Central Hospital; iCAN Digital Precision Cancer Medicine Flagship	Academy of Finland (Finnish Center of Excellence in Tumor Genetics Research); Finnish Cancer Foundation; Cancer Research UK(Cancer Research UK); Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Jane and Aatos Erkko Foundation; Finska Lakaresallskapet; iCAN Digital Precision Cancer Medicine Flagship; European Union's Horizon 2020 research and innovation program; University of Helsinki; Helsinki University Central Hospital Research Funds; Helsinki University Central Hospital; iCAN Digital Precision Cancer Medicine Flagship	JT was supported by grants from Academy of Finland (Finnish Center of Excellence in Tumor Genetics Research 2018-2025, grant number 312042 and 2012-2017; 250345), Finnish Cancer Foundation, and Cancer Research UK (grant number RG99643). BS was supported by the Academy of Finland (post-doctoral fellowship, 274555; research fellowship, 317807), Finnish Cancer Foundation, Sigrid Juselius Foundation, Jane and Aatos Erkko Foundation and iCAN Digital Precision Cancer Medicine Flagship. PP was supported by the post-doctoral fellowship 288836 from Academy of Finland. AR was supported by Finska Lakaresallskapet, Helsinki University Central Hospital Research Funds, and Sigrid Juselius Foundation. LA was supported by Academy of Finland (grant numbers 312041, 335823, 250345, 319083, 320149), iCAN Digital Precision Cancer Medicine Flagship (grant number 320185), Finnish Cancer Foundation, Sigrid Juselius Foundation and Jane and Aatos Erkko Foundation. SH was supported by the European Union's Horizon 2020 research and innovDation program under Grant Agreement No. 667403 for HERCULES. Open access funding provided by University of Helsinki including Helsinki University Central Hospital.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; [Anonymous], 2019, WHO CLASSIFICATION T; [Anonymous], 2014, GENOME BIOL, DOI DOI 10.1186/S13059-014-0550-8; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; Beer S, 2004, PLOS BIOL, V2, P1785, DOI 10.1371/journal.pbio.0020332; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Borggrefe T, 2009, CELL MOL LIFE SCI, V66, P1631, DOI 10.1007/s00018-009-8668-7; Bou-Nader M, 2020, GUT, V69, P355, DOI 10.1136/gutjnl-2018-318021; Broutier L, 2017, NAT MED, V23, P1424, DOI 10.1038/nm.4438; Cai SH, 2017, THER ADV GASTROENTER, V10, P761, DOI 10.1177/1756283X17725998; Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002; Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu, 2017, Cell, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Chaffer CL, 2015, CANCER DISCOV, V5, P22, DOI 10.1158/2159-8290.CD-14-0788; Chen HJ, 2019, J EXP MED, V216, P674, DOI 10.1084/jem.20181155; Corces MR, 2017, NAT METHODS, V14, P959, DOI [10.1038/NMETH.4396, 10.1038/nmeth.4396]; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Diamond L, 1980, Adv Cancer Res, V32, P1, DOI 10.1016/S0065-230X(08)60360-7; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; Du YY, 2014, CELL STEM CELL, V14, P394, DOI 10.1016/j.stem.2014.01.008; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Farrell JA, 2018, SCIENCE, V360, P979, DOI 10.1126/science.aar3131; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Haigis KM, 2019, SCIENCE, V363, P1150, DOI 10.1126/science.aaw3472; Hooks KB, 2018, HEPATOLOGY, V68, P89, DOI 10.1002/hep.29672; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Huang PY, 2014, CELL STEM CELL, V14, P370, DOI 10.1016/j.stem.2014.01.003; Icay K, 2016, BIODATA MIN, V9, DOI 10.1186/s13040-016-0099-z; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kalkat M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060151; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kasper M, 2011, P NATL ACAD SCI USA, V108, P4099, DOI 10.1073/pnas.1014489108; Kelly TK, 2012, GENOME RES, V22, P2497, DOI 10.1101/gr.143008.112; Korotkevich G, 2019, FAST GENE SET ENRICH, DOI 10.1101/060012; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Ladewig J, 2012, NAT METHODS, V9, P575, DOI [10.1038/NMETH.1972, 10.1038/nmeth.1972]; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee I, 2020, NAT METHODS, V17, P1191, DOI 10.1038/s41592-020-01000-7; Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191; Liu ML, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3183; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Marthandan S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154531; Martincorena I, 2018, SCIENCE, V362, P911, DOI 10.1126/science.aau3879; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Moinzadeh P, 2005, BRIT J CANCER, V92, P935, DOI 10.1038/sj.bjc.6602448; Moore PS, 2010, NAT REV CANCER, V10, P878, DOI 10.1038/nrc2961; Morris SA, 2014, CELL, V158, P889, DOI 10.1016/j.cell.2014.07.021; Ning BF, 2010, CANCER RES, V70, P7640, DOI 10.1158/0008-5472.CAN-10-0824; Ovaska K, 2010, GENOME MED, V2, DOI 10.1186/gm186; Palin K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06132-1; Pang ZPP, 2011, NATURE, V476, P220, DOI 10.1038/nature10202; Park JW, 2018, SCIENCE, V362, P91, DOI 10.1126/science.aat5749; Rackham OJL, 2016, NAT GENET, V48, P331, DOI 10.1038/ng.3487; Rahman M, 2015, BIOINFORMATICS, V31, P3666, DOI 10.1093/bioinformatics/btv377; RANGANATHAN S, 2016, SCI REP-UK, V6; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Roadmap Epigenomics Consortium, 2015, Nature, V518, P317, DOI 10.1038/nature14248; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Sekiya S, 2011, NATURE, V475, P390, DOI 10.1038/nature10263; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; Shin S, 2016, HEPATOLOGY, V64, P1163, DOI 10.1002/hep.28602; Shipony Z, 2020, NAT METHODS, V17, P319, DOI 10.1038/s41592-019-0730-2; Simpson JT, 2017, NAT METHODS, V14, P407, DOI 10.1038/nmeth.4184; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Soneson Charlotte, 2015, F1000Res, V4, P1521, DOI 10.12688/f1000research.7563.1; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun R, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.591507; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Taylor AM, 2018, CANCER CELL, V33, P676, DOI 10.1016/j.ccell.2018.03.007; Timek DT, 2012, AM J CLIN PATHOL, V138, P203, DOI 10.1309/AJCPK1ZC9WNHCCMU; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Villanueva A, 2012, GASTROENTEROLOGY, V143, P1660, DOI 10.1053/j.gastro.2012.09.002; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; YAMAGIWA K, 1977, CA-CANCER J CLIN, V27, P172, DOI 10.3322/canjclin.27.3.174; Zerbino DR, 2018, NUCLEIC ACIDS RES, V46, pD754, DOI 10.1093/nar/gkx1098; Zhu B, 2017, ONCOTARGET, V8, P23289, DOI 10.18632/oncotarget.15576	87	2	2	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5533	5547		10.1038/s41388-021-01940-0	http://dx.doi.org/10.1038/s41388-021-01940-0		JUL 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34302118	Green Published, hybrid, Green Submitted			2022-12-17	WOS:000676064800002
J	Xu, GQ; Yang, ZJ; Ding, YZ; Liu, Y; Zhang, L; Wang, BS; Tang, M; Jing, TT; Jiao, K; Xu, XL; Chen, ZH; Xiang, L; Xu, C; Fu, YJ; Zhao, XJ; Jin, WL; Liu, YZ				Xu, Guiqin; Yang, Zhaojuan; Ding, Yizong; Liu, Yun; Zhang, Li; Wang, Boshi; Tang, Ming; Jing, Tiantian; Jiao, Kun; Xu, Xiaoli; Chen, Zehong; Xiang, Lvzhu; Xu, Chen; Fu, Yujie; Zhao, Xiaojing; Jin, Weilin; Liu, Yongzhong			The deubiquitinase USP16 functions as an oncogenic factor in K-RAS-driven lung tumorigenesis	ONCOGENE			English	Article							P38-ALPHA MAP KINASE; P38 MAPK; OXIDATIVE STRESS; GENE-EXPRESSION; ACTIVATION; STEM; STAT3; PHOSPHORYLATION; STABILIZATION; PROGRESSION	K-RAS mutation and molecular alterations of its surrogates function essentially in lung tumorigenesis and malignant progression. However, it remains elusive how tumor-promoting and deleterious events downstream of K-RAS signaling are coordinated in lung tumorigenesis. Here, we show that USP16, a deubiquitinase involved in various biological processes, functions as a promoter for the development of K-RAS-driven lung tumor. Usp16 deletion significantly attenuates K-ras(G12D)-mutation-induced lung tumorigenesis in mice. USP16 upregulation upon RAS activation averts reactive oxygen species (ROS)-induced p38 activation that would otherwise detrimentally influence the survival and proliferation of tumor cells. In addition, USP16 interacts with and deubiquitinates JAK1, and thereby promoting lung tumor growth by augmenting JAK1 signaling. Therefore, our results reveal that USP16 functions critically in the K-RAS-driven lung tumorigenesis through modulating the strength of p38 and JAK1 signaling.	[Xu, Guiqin; Yang, Zhaojuan; Liu, Yun; Zhang, Li; Wang, Boshi; Tang, Ming; Jing, Tiantian; Chen, Zehong; Xiang, Lvzhu; Xu, Chen; Liu, Yongzhong] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China; [Ding, Yizong; Fu, Yujie; Zhao, Xiaojing] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Thorac Surg, Shanghai, Peoples R China; [Jiao, Kun; Xu, Xiaoli] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China; [Jin, Weilin] Lanzhou Univ, Clin Med Coll 1, Hosp 1, Inst Canc Neurosci,Med Frontier Innovat Res Ctr, Lanzhou, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Lanzhou University	Liu, YZ (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China.	liuyzg@shsci.org	Jin, Wei-Lin/A-8355-2013	Jin, Wei-Lin/0000-0001-8011-2405; Liu, Yongzhong/0000-0002-1477-116X	National Natural Science Foundation of China [81802746, 81572694, 81972579]; Natural Science Foundation of Shanghai [20ZR1454100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai)	This work was supported by the National Natural Science Foundation of China (81802746, 81572694, and 81972579), and the Natural Science Foundation of Shanghai (20ZR1454100).	Adachi Y, 2008, ONCOGENE, V27, P4921, DOI 10.1038/onc.2008.133; Adorno M, 2013, NATURE, V501, P380, DOI 10.1038/nature12530; Ali SA, 2016, CANCER CELL, V29, P367, DOI 10.1016/j.ccell.2016.02.012; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Brooks GD, 2016, CANCER RES, V76, P866, DOI 10.1158/0008-5472.CAN-15-2388; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Cai SY, 1999, P NATL ACAD SCI USA, V96, P2828, DOI 10.1073/pnas.96.6.2828; Chen X, 2019, CANCER LETT, V456, P49, DOI 10.1016/j.canlet.2019.04.020; Chuang CH, 2017, NAT MED, V23, P291, DOI 10.1038/nm.4285; D'Amico S, 2018, GENE DEV, V32, P1175, DOI 10.1101/gad.311852.118; Deng KY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0126-x; Deng L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0107-0; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Fasbender A, 1998, J CLIN INVEST, V102, P184, DOI 10.1172/JCI2732; Grabner B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7285; Gu Y, 2016, P NATL ACAD SCI USA, V113, pE51, DOI 10.1073/pnas.1517041113; Gwinn DM, 2018, CANCER CELL, V33, P91, DOI 10.1016/j.ccell.2017.12.003; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Hill KS, 2014, ONCOGENE, V33, P2134, DOI 10.1038/onc.2013.147; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Kennedy NJ, 2007, CANCER CELL, V11, P101, DOI 10.1016/j.ccr.2007.01.009; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Lim JKM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2192-y; Liu CM, 2020, AGING-US, V12, P8680, DOI 10.18632/aging.103191; Liu D, 2017, ONCOL LETT, V14, P3959, DOI 10.3892/ol.2017.6690; Lu L, 2018, ONCOGENE, V37, P5292, DOI 10.1038/s41388-018-0340-y; McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775; Metz HE, 2016, P NATL ACAD SCI USA, V113, P8795, DOI 10.1073/pnas.1601989113; Miotto B, 2018, NUCLEIC ACIDS RES, V46, P4392, DOI 10.1093/nar/gky149; Nicke B, 2005, MOL CELL, V20, P673, DOI 10.1016/j.molcel.2005.10.038; Obana M, 2012, AM J PHYSIOL-HEART C, V303, pH569, DOI 10.1152/ajpheart.00060.2012; Pan J, 2015, ONCOGENE, V34, P3957, DOI 10.1038/onc.2014.327; Qi XM, 2004, J BIOL CHEM, V279, P22138, DOI 10.1074/jbc.M313964200; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Song LX, 2011, MOL CANCER THER, V10, P481, DOI 10.1158/1535-7163.MCT-10-0502; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Taverna JA, 2020, CANCER RES, V80, P1551, DOI 10.1158/0008-5472.CAN-19-3183; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Xu Jianming, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2801s70; Xu Y, 2013, CELL CYCLE, V12, P3219, DOI 10.4161/cc.26278; Yan MX, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1479-2; Yang W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4818; Zhang JG, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920917558; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Zhang Y, 2019, J CLIN INVEST, V129, P2856, DOI 10.1172/JCI123801; Zhou J, 2015, ONCOGENE, V34, P3804, DOI 10.1038/onc.2014.318; Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646; Zhuo XL, 2015, J CELL BIOL, V210, P727, DOI 10.1083/jcb.201502044	50	2	2	7	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5482	5494		10.1038/s41388-021-01964-6	http://dx.doi.org/10.1038/s41388-021-01964-6		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34294846				2022-12-17	WOS:000678017100001
J	Vanoli, F; Meskauskaite, B; Herviou, L; Mallen, W; Sung, YS; Fujisawa, Y; Zhang, L; Simon, S; Huangfu, DW; Jasin, M; Antonescu, CR				Vanoli, Fabio; Meskauskaite, Brigita; Herviou, Laurie; Mallen, William; Sung, Yun-Shao; Fujisawa, Yumi; Zhang, Lei; Simon, Steven; Huangfu, Danwei; Jasin, Maria; Antonescu, Cristina R.			Generation of human embryonic stem cell models to exploit the EWSR1-CREB fusion promiscuity as a common pathway of transformation in human tumors	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; SOFT-TISSUE; CHROMOSOMAL TRANSLOCATIONS; CHIMERIC TRANSCRIPTS; PROTEIN EXPRESSION; MOLECULAR ANALYSIS; EWSR1-ATF1 FUSION; GENE FUSION; SARCOMA; DIFFERENTIATION	Chromosomal translocations constitute driver mutations in solid tumors and leukemias. The mechanisms of how related or even identical gene fusions drive the pathogenesis of various tumor types remain elusive. One remarkable example is the presence of EWSR1 fusions with CREB1 and ATF1, members of the CREB family of transcription factors, in a variety of sarcomas, carcinomas and mesotheliomas. To address this, we have developed in vitro models of oncogenic fusions, in particular, EWSR1-CREB1 and EWSR1-ATF1, in human embryonic stem (hES) cells, which are capable of multipotent differentiation, using CRISPR-Cas9 technology and HDR together with conditional fusion gene expression that allows investigation into the early steps of cellular transformation. We show that expression of EWSR1-CREB1/ATF1 fusion in hES cells recapitulates the core gene signatures, respectively, of angiomatoid fibrous histiocytoma (AFH) and gastrointestinal clear cell sarcoma (GI-CCS), although both fusions lead to cell lethality. Conversely, expression of the fusions in hES cells differentiated to mesenchymal progenitors is compatible with prolonged viability while maintaining the core gene signatures. Moreover, in the context of a mesenchymal lineage, the proliferation of cells expressing the EWSR1-CREB1 fusion is further extended by deletion of the tumor suppressor TP53. We expect the generation of isogenic lines carrying oncogenic fusions in various cell lineages to expand our general understanding of how those single genetic events drive tumorigenesis while providing valuable resources for drug discovery.	[Vanoli, Fabio; Meskauskaite, Brigita; Herviou, Laurie; Mallen, William; Sung, Yun-Shao; Fujisawa, Yumi; Zhang, Lei; Simon, Steven; Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Huangfu, Danwei; Jasin, Maria] Mem Sloan Kettering Canc Ctr, Dev Biol Program, 1275 York Ave, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Antonescu, CR (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.; Jasin, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dev Biol Program, 1275 York Ave, New York, NY 10021 USA.	m-jasin@ski.mskcc.org; antonesc@mskcc.org	Zhang, Lei/GYQ-7446-2022	Vanoli, Fabio/0000-0002-1260-8078; Herviou, Laurie/0000-0002-8607-8380; Jasin, Maria/0000-0002-7976-2379; Huangfu, Danwei/0000-0002-1145-6199	Cycle for Survival; Kristin Ann Carr Foundation; St Baldrick Foundation; Cancer Center Support Grant [NIH P30 CA008748];  [R35 CA253174];  [P50 CA140146];  [P50 CA217694]	Cycle for Survival; Kristin Ann Carr Foundation; St Baldrick Foundation; Cancer Center Support Grant; ; ; 	We thank Chew-Li Soh and Xian Zhang for technical assistance and reagents; members of the Jasin Laboratory for discussions and suggestions; and Rohit Prakash, Travis White and Pei Xin Lim for critical reading of the manuscript. This work was supported in part by: R35 CA253174 (MJ), P50 CA140146 (CRA), P50 CA217694 (CRA), Cycle for Survival (CRA), Kristin Ann Carr Foundation (CRA), St Baldrick Foundation (CRA). Core facilities at MSK are supported by the Cancer Center Support Grant (NIH P30 CA008748).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Antonescu CR, 2002, J MOL DIAGN, V4, P44, DOI 10.1016/S1525-1578(10)60679-4; Antonescu CR, 2007, GENE CHROMOSOME CANC, V46, P1051, DOI 10.1002/gcc.20491; Antonescu CR, 2006, CLIN CANCER RES, V12, P5356, DOI 10.1158/1078-0432.CCR-05-2811; Antonescu CR, 2013, GENE CHROMOSOME CANC, V52, P775, DOI 10.1002/gcc.22073; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Antonescu CR, 2009, CANCER RES, V69, P7175, DOI 10.1158/0008-5472.CAN-09-2068; Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629; Braunreiter CL, 2006, CELL CYCLE, V5, P2753, DOI 10.4161/cc.5.23.3505; Brunet E, 2018, ADV EXP MED BIOL, V1044, P15, DOI 10.1007/978-981-13-0593-1_2; Desmeules P, 2017, AM J SURG PATHOL, V41, P980, DOI 10.1097/PAS.0000000000000864; Feng WR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00634-0; Filion TM, 2009, J CELL PHYSIOL, V220, P586, DOI 10.1002/jcp.21735; Gartel AL, 2002, MOL CANCER THER, V1, P639; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; Hajdu M, 2010, J PATHOL, V221, P300, DOI 10.1002/path.2715; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Hisaoka M, 2008, AM J SURG PATHOL, V32, P452, DOI 10.1097/PAS.0b013e31814b18fb; Jakubauskas A, 2011, EXP MOL PATHOL, V90, P194, DOI 10.1016/j.yexmp.2010.12.005; Kao Yu-Chien, 2017, Am J Surg Pathol, V41, P482, DOI 10.1097/PAS.0000000000000788; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; Komura S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11745-1; Lee SB, 1997, NAT GENET, V17, P309, DOI 10.1038/ng1197-309; Liang Q, 2018, NATURE, V563, P701, DOI 10.1038/s41586-018-0733-7; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Mertens F, 2016, GENE CHROMOSOME CANC, V55, P291, DOI 10.1002/gcc.22335; Panagopoulos I, 2002, INT J CANCER, V99, P560, DOI 10.1002/ijc.10404; Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Qin H, 2007, J BIOL CHEM, V282, P5842, DOI 10.1074/jbc.M610464200; Rossi S, 2007, CLIN CANCER RES, V13, P7322, DOI 10.1158/1078-0432.CCR-07-1744; Stockman DL, 2012, AM J SURG PATHOL, V36, P857, DOI 10.1097/PAS.0b013e31824644ac; Straessler KM, 2013, CANCER CELL, V23, P215, DOI 10.1016/j.ccr.2012.12.019; Thway K, 2011, AM J SURG PATHOL, V35, P1722, DOI 10.1097/PAS.0b013e318227e4d2; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; Vanoli F, 2017, METHODS, V121, P138, DOI 10.1016/j.ymeth.2017.05.006; Vanoli F, 2017, P NATL ACAD SCI USA, V114, P3696, DOI 10.1073/pnas.1700622114; Vriend LEM, 2016, NUCLEIC ACIDS RES, V44, P5204, DOI 10.1093/nar/gkw179; Wang WL, 2009, MODERN PATHOL, V22, P1201, DOI 10.1038/modpathol.2009.85; Zhang Y, 2014, METHODS, V69, P171, DOI 10.1016/j.ymeth.2014.05.003; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	43	2	2	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2021	40	32					5095	5104		10.1038/s41388-021-01843-0	http://dx.doi.org/10.1038/s41388-021-01843-0		JUN 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA7OD	34193943	Green Accepted			2022-12-17	WOS:000668403200001
J	Bauer, J; Cuvelier, N; Ragab, N; Simon-Keller, K; Nitzki, F; Geyer, N; Botermann, DS; Elmer, DP; Rosenberger, A; Rando, TA; Biressi, S; Fagin, JA; Saur, D; Dullin, C; Schildhaus, HU; Schulz-Schaeffer, W; Aberger, F; Uhmann, A; Hahn, H				Bauer, Julia; Cuvelier, Nicole; Ragab, Nada; Simon-Keller, Katja; Nitzki, Frauke; Geyer, Natalie; Botermann, Dominik S.; Elmer, Dominik P.; Rosenberger, Albert; Rando, Thomas A.; Biressi, Stefano; Fagin, James A.; Saur, Dieter; Dullin, Christian; Schildhaus, Hans-Ulrich; Schulz-Schaeffer, Walter; Aberger, Fritz; Uhmann, Anja; Hahn, Heidi			Context-dependent modulation of aggressiveness of pediatric tumors by individual oncogenic RAS isoforms	ONCOGENE			English	Article							EMBRYONAL RHABDOMYOSARCOMA; K-RAS; SIGNALING PATHWAY; CELL-SURVIVAL; N-RAS; CANCER; HEDGEHOG; ACTIVATION; GENE; EXPRESSION	A prototypic pediatric cancer that frequently shows activation of RAS signaling is embryonal rhabdomyosarcoma (ERMS). ERMS also show aberrant Hedgehog (HH)/GLI signaling activity and can be driven by germline mutations in this pathway. We show, that in ERMS cell lines derived from sporadic tumors i.e. from tumors not caused by an inherited genetic variant, HH/GLI signaling plays a subordinate role, because oncogenic mutations in HRAS, KRAS, or NRAS (collectively named oncRAS) inhibit the main HH target GLI1 via the MEK/ERK-axis, but simultaneously increase proliferation and tumorigenicity. oncRAS also modulate expression of stem cell markers in an isoform- and context-dependent manner. In Hh-driven murine ERMS that are caused by a Patched mutation, oncHRAS and mainly oncKRAS accelerate tumor development, whereas oncNRAS induces a more differentiated phenotype. These features occur when the oncRAS mutations are induced at the ERMS precursor stage, but not when induced in already established tumors. Moreover, in contrast to what is seen in human cell lines, oncRAS mutations do not alter Hh signaling activity and marginally affect expression of stem cell markers. Together, all three oncRAS mutations seem to be advantageous for ERMS cell lines despite inhibition of HH signaling and isoform-specific modulation of stem cell markers. In contrast, oncRAS mutations do not inhibit Hh-signaling in Hh-driven ERMS. In this model, oncRAS mutations seem to be advantageous for specific ERMS populations that occur within a specific time window during ERMS development. In addition, this window may be different for individual oncRAS isoforms, at least in the mouse.	[Bauer, Julia; Cuvelier, Nicole; Ragab, Nada; Nitzki, Frauke; Geyer, Natalie; Botermann, Dominik S.; Uhmann, Anja; Hahn, Heidi] Univ Med Ctr Goettingen, Dept Human Genet, Gottingen, Germany; [Simon-Keller, Katja] Heidelberg Univ, Univ Med Ctr Mannheim, Inst Pathol, Mannheim, Germany; [Elmer, Dominik P.; Aberger, Fritz] Paris Lodron Univ Salzburg, Dept Biosci, Canc Cluster Salzburg, Salzburg, Austria; [Rosenberger, Albert] Univ Med Ctr Goettingen, Dept Genet Epidemiol, Gottingen, Germany; [Rando, Thomas A.; Biressi, Stefano] Stanford Univ, Paul Glenn Ctr Biol Aging, Sch Med, Stanford, CA USA; [Rando, Thomas A.; Biressi, Stefano] Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA USA; [Biressi, Stefano] Vet Affairs Palo Alto Hlth Care Syst, Neurol Serv, Palo Alto, CA USA; [Biressi, Stefano] Univ Trento, Dept Cellular Computat & Integrat Biol CIBIO, Povo, Italy; [Biressi, Stefano] Univ Trento, Dulbecco Telethon Inst, Povo, Italy; [Fagin, James A.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Saur, Dieter] Klin & Poliklin Innere Med II, Klinikum Rechts Isar TUM, Munich, Germany; [Dullin, Christian] Univ Med Ctr Goettingen, Inst Diagnost & Intervent Radiol, Gottingen, Germany; [Schildhaus, Hans-Ulrich] Univ Med Ctr Essen, Inst Pathol, Essen, Germany; [Schulz-Schaeffer, Walter] Saarland Univ, Dept Neuropathol, Med Ctr, Homburg, Germany	University of Gottingen; Ruprecht Karls University Heidelberg; Salzburg University; University of Gottingen; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Trento; Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Trento; Memorial Sloan Kettering Cancer Center; Technical University of Munich; University of Gottingen; University of Duisburg Essen; Universitatsklinikum des Saarlandes	Hahn, H (corresponding author), Univ Med Ctr Goettingen, Dept Human Genet, Gottingen, Germany.	hhahn@gwdg.de	Saur, Dieter/O-8355-2015	Saur, Dieter/0000-0001-5874-0210; Bauer, Julia/0000-0001-5390-1855; Botermann, Dominik Simon/0000-0001-7747-7147; Biressi, Stefano Augusto Maria/0000-0001-8631-3419; Rosenberger, Albert/0000-0001-7848-1332; Aberger, Fritz/0000-0003-2009-6305; Dullin, Christian/0000-0003-4297-8077	German Research Foundation [HA 2197/9-1, HA 2197/9-2]; Wilhelm Sander foundation [2017.110.1]; Austrian Science Fund (FWF) [P25629, W1213]; Projekt DEAL	German Research Foundation(German Research Foundation (DFG)); Wilhelm Sander foundation; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Projekt DEAL	This work was supported by grants HA 2197/9-1 and HA 2197/9-2 from the German Research Foundation to HH, by grant 2017.110.1 of the Wilhelm Sander foundation to HH. and KSK. and by grants P25629 and W1213 of the Austrian Science Fund (FWF) to FA. Open Access funding enabled and organized by Projekt DEAL.	Aberger F, 2012, VITAM HORM, V88, P25, DOI 10.1016/B978-0-12-394622-5.00002-X; Almazan-Moga A, 2017, BRIT J CANCER, V117, P1314, DOI 10.1038/bjc.2017.305; Ashford AL, 2016, CELL MOL LIFE SCI, V73, P883, DOI 10.1007/s00018-015-2032-x; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Biressi S, 2013, DEV BIOL, V379, P195, DOI 10.1016/j.ydbio.2013.04.021; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; Chen L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005075; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Chen X, 2009, P NATL ACAD SCI USA, V106, P7979, DOI 10.1073/pnas.0900343106; Dasgupta R, 2016, SEMIN PEDIATR SURG, V25, P276, DOI 10.1053/j.sempedsurg.2016.09.011; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Genadry KC, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00475; Geyer N, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00396; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Hettmer S, 2015, J PEDIAT HEMATOL ONC, V37, P147, DOI 10.1097/MPH.0000000000000115; Ignatius MS, 2012, CANCER CELL, V21, P680, DOI 10.1016/j.ccr.2012.03.043; Jongmans MCJ, 2010, GENE CHROMOSOME CANC, V49, P635, DOI 10.1002/gcc.20773; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kratz CP, 2011, AM J MED GENET C, V157C, P83, DOI 10.1002/ajmg.c.30300; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Lauth M, 2010, NAT STRUCT MOL BIOL, V17, P718, DOI 10.1038/nsmb.1833; Martinez-Cruzado L, 2016, SCI REP-UK, V6, DOI 10.1038/srep27878; Mercer SE, 2006, CANCER RES, V66, P5143, DOI 10.1158/0008-5472.CAN-05-1539; MOON B, 2014, JNCI-J NATL CANCER I, V106; Nakahata K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125454; Nitzki F, 2011, ONCOGENE, V30, P4428, DOI 10.1038/onc.2011.157; Paulson V, 2011, GENE CHROMOSOME CANC, V50, P397, DOI 10.1002/gcc.20864; Pietrobono S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00556; Pressey JG, 2011, PEDIATR BLOOD CANCER, V57, P930, DOI 10.1002/pbc.23174; Ridzewski R, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00130; Robbins KM, 2016, AM J MED GENET A, V170, P3197, DOI 10.1002/ajmg.a.37949; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Sesillo FB, 2019, CELL REP, V26, P689, DOI 10.1016/j.celrep.2018.12.089; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Sieber OM, 2005, NAT REV CANCER, V5, P649, DOI 10.1038/nrc1674; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Soleimani VD, 2011, CANCER CELL, V19, P157, DOI 10.1016/j.ccr.2011.01.044; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052; Tostar Ulrica, 2010, Genes Cancer, V1, P941, DOI 10.1177/1947601910385449; Tsumura H, 2006, ONCOGENE, V25, P7673, DOI 10.1038/sj.onc.1209749; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Wang JY, 2011, BLOOD, V118, P368, DOI 10.1182/blood-2010-12-326058; Yohe ME, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan4470; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; Zhao XS, 2015, CANCER RES, V75, P3623, DOI 10.1158/0008-5472.CAN-14-2999-T; Zibat A, 2010, ONCOGENE, V29, P6323, DOI 10.1038/onc.2010.368; Zibat A, 2009, CARCINOGENESIS, V30, P918, DOI 10.1093/carcin/bgp068	54	2	2	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					4955	4966		10.1038/s41388-021-01904-4	http://dx.doi.org/10.1038/s41388-021-01904-4		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34172934	hybrid, Green Published			2022-12-17	WOS:000667016100003
J	Ottina, E; Panova, V; Doglio, L; Kazachenka, A; Cornish, G; Kirkpatrick, J; Attig, J; Young, GR; Litchfield, K; Lesluyes, T; Van Loo, P; Swanton, C; MacRae, J; Tuting, T; Kassiotis, G				Ottina, Eleonora; Panova, Veera; Doglio, Laura; Kazachenka, Anastasiya; Cornish, Georgina; Kirkpatrick, Joanna; Attig, Jan; Young, George R.; Litchfield, Kevin; Lesluyes, Tom; Van Loo, Peter; Swanton, Charles; MacRae, James; Tuting, Thomas; Kassiotis, George			E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion	ONCOGENE			English	Article							CANCER; CELLS; CHECKPOINTS; PROMOTES; THERAPY; INNATE; IMPACT; GENES	The ubiquitin-proteasome system maintains protein homoeostasis, underpins the cell cycle, and is dysregulated in cancer. However, the role of individual E3 ubiquitin ligases, which mediate the final step in ubiquitin-mediated proteolysis, remains incompletely understood. Identified through screening for cancer-specific endogenous retroviral transcripts, we show that the little-studied E3 ubiquitin ligase HECTD2 exerts dominant control of tumour progression in melanoma. HECTD2 cell autonomously drives the proliferation of human and murine melanoma cells by accelerating the cell cycle. HECTD2 additionally regulates cancer cell production of immune mediators, initiating multiple immune suppressive pathways, which include the cyclooxygenase 2 (COX2) pathway. Accordingly, higher HECTD2 expression is associated with weaker anti-tumour immunity and unfavourable outcome of PD-1 blockade in human melanoma and counteracts immunity against a model tumour antigen in murine melanoma. This central, multifaceted role of HECTD2 in cancer cell-autonomous proliferation and in immune evasion may provide a single target for a multipronged therapy of melanoma.	[Ottina, Eleonora; Panova, Veera; Doglio, Laura; Kazachenka, Anastasiya; Cornish, Georgina; Attig, Jan; Kassiotis, George] Francis Crick Inst, Retroviral Immunol Lab, London, England; [Kirkpatrick, Joanna; MacRae, James] Francis Crick Inst, Prote STP, London, England; [Young, George R.] Francis Crick Inst, Retrovirus Host Interact Lab, London, England; [Litchfield, Kevin; Swanton, Charles] Francis Crick Inst, Canc Evolut & Genome Instabil Lab, London, England; [Lesluyes, Tom; Van Loo, Peter] Francis Crick Inst, Canc Genom Lab, London, England; [Tuting, Thomas] Univ Magdeburg, Dept Dermatol, Lab Expt Dermatol, Magdeburg, Germany; [Kassiotis, George] Imperial Coll London, Dept Infect Dis, Fac Med, London, England	Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Otto von Guericke University; Imperial College London	Kassiotis, G (corresponding author), Francis Crick Inst, Retroviral Immunol Lab, London, England.; Kassiotis, G (corresponding author), Imperial Coll London, Dept Infect Dis, Fac Med, London, England.	george.kassiotis@crick.ac.uk	Young, George/C-6733-2009; Lesluyes, Tom/AAB-6229-2019; Lesluyes, Tom/GSD-4621-2022	Young, George/0000-0002-1203-588X; Lesluyes, Tom/0000-0003-2251-5884; Lesluyes, Tom/0000-0003-2251-5884; Swanton, Charles/0000-0002-4299-3018; Attig, Jan/0000-0002-2159-2880; Ottina, Eleonora/0000-0002-9630-496X; Litchfield, Kevin/0000-0002-3725-0914; Panova, Veera/0000-0001-8433-6430	Francis Crick Institute [FC001099, FC001169, FC001202]; Cancer Research UK (CRUK); UK Medical Research Council (MRC); Wellcome Trust; Wellcome Trust [FC001099, FC001169, FC001202, 102898/B/13/Z]; CRUK [C55533/A22158]	Francis Crick Institute; Cancer Research UK (CRUK)(Cancer Research UK); UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Wellcome Trust(Wellcome TrustEuropean Commission); CRUK(Cancer Research UK)	We are grateful for assistance from the Advanced Light Microscopy, Biological Research Facility, Cell Services, Flow Cytometry and Scientific Computing facilities at the Francis Crick Institute. The results shown here are in whole or part based upon data generated by the TCGA Research Network (http://cancergenome.nih.gov).This work benefited from data assembled by the CCLE consortium. This work was supported by the Francis Crick Institute (FC001099, FC001169, FC001202), which receives its core funding from Cancer Research UK (CRUK), the UK Medical Research Council (MRC), and the Wellcome Trust; and by the Wellcome Trust (102898/B/13/Z to GK) and CRUK (C55533/A22158 to GK). This research was funded in whole, or in part, by the Wellcome Trust (102898/B/13/Z; FC001099, FC001169, FC001202). For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Attig J, 2019, GENOME RES, V29, P1578, DOI 10.1101/gr.248922.119; Bald T, 2014, NATURE, V507, P109, DOI 10.1038/nature13111; Barclay AN, 2014, ANNU REV IMMUNOL, V32, P25, DOI 10.1146/annurev-immunol-032713-120142; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bedognetti D, 2016, CURR OPIN IMMUNOL, V39, P150, DOI 10.1016/j.coi.2016.02.001; Coon TA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3881; Danelli L, 2021, CELL MOL IMMUNOL, V18, P1809, DOI 10.1038/s41423-020-0415-x; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Garofalo M, 2012, CURR MOL MED, V12, P27, DOI 10.2174/156652412798376170; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Ishak CA, 2020, ANNU REV CANC BIOL, V4, P159, DOI 10.1146/annurev-cancerbio-030419-033525; Kassiotis G, 2016, NAT REV IMMUNOL, V16, P207, DOI 10.1038/nri.2016.27; Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538; Lau AN, 2020, ANNU REV CANC BIOL, V4, P17, DOI 10.1146/annurev-cancerbio-030419-033333; Lloyd SE, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-90; Lloyd SE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000383; MacKie RM, 2009, ANN ONCOL, V20, P1, DOI 10.1093/annonc/mdp252; Ottina E, 2018, CANCER IMMUNOL RES, V6, P1292, DOI 10.1158/2326-6066.CIR-18-0038; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pelechano V, 2013, NAT REV GENET, V14, P880, DOI 10.1038/nrg3594; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rossi M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09754-1; Schumacher TN, 2019, ANNU REV IMMUNOL, V37, P173, DOI 10.1146/annurev-immunol-042617-053402; Sperka T, 2012, NAT REV MOL CELL BIO, V13, P579, DOI 10.1038/nrm3420; Spranger S, 2018, NAT REV CANCER, V18, P139, DOI 10.1038/nrc.2017.117; Sun T, 2014, ONCOGENE, V33, P2790, DOI 10.1038/onc.2013.230; Suo C, 2018, BIOL DIRECT, V13, DOI 10.1186/s13062-018-0218-5; Takimoto CH, 2019, ANN ONCOL, V30, P486, DOI 10.1093/annonc/mdz006; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Wang YY, 2020, J CELL SCI, V133, DOI 10.1242/jcs.228072; Wellenstein MD, 2018, IMMUNITY, V48, P399, DOI 10.1016/j.immuni.2018.03.004; Wu S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05467-z; Zapparoli E, 2020, NUCLEIC ACIDS RES, V48, P9053, DOI 10.1093/nar/gkaa628; Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015	42	2	2	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5567	5578		10.1038/s41388-021-01885-4	http://dx.doi.org/10.1038/s41388-021-01885-4		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34145398	Green Published, hybrid			2022-12-17	WOS:000663295300001
J	Sherman, J; Verstandig, G; Brumer, Y				Sherman, Jeff; Verstandig, Grant; Brumer, Yisroel			Application of machine learning to large in-vitro databases to identify cancer cell characteristics: telomerase reverse transcriptase (TERT) expression	ONCOGENE			English	Article								Advances in biotechnology and machine learning have created an enhanced environment for unearthing and exploiting previously unrecognized relationships between genomic and epigenetic data with potential therapeutic implications. We applied advanced algorithms to data from the Cancer Dependency Map to uncover increasingly complex relationships. Specifically, we investigate characteristics of tumor cell lines with varying levels of telomerase reverse transcriptase (TERT) expression in liver cancer. The findings indicate that the effect of CRISPR knockout of Histone Deacetylase 1 (HDAC1) and numerous individual respiratory complex I genes is strongly related to the level of TERT expression, with knockout being particularly efficacious at killing or inhibiting growth of tumor cells with low levels of TERT expression for HDAC1 and high levels for Complex I genes. These findings suggest key biomarkers for therapeutic efficacy and yield novel potential pathways for drug development and provide further proof of principle for the potential of artificial intelligence in oncology.	[Sherman, Jeff; Verstandig, Grant; Brumer, Yisroel] Zephyr AI, Washington, DC 20006 USA; [Sherman, Jeff; Verstandig, Grant; Brumer, Yisroel] Red Cell Partners, Washington, DC 20011 USA		Sherman, J (corresponding author), Zephyr AI, Washington, DC 20006 USA.; Sherman, J (corresponding author), Red Cell Partners, Washington, DC 20011 USA.	sherman@redcellpartners.com		Sherman, Jeff/0000-0003-1377-0357; Brumer, Yisroel/0000-0002-7046-0198				Amisaki M, 2019, CANCER SCI, V110, P550, DOI 10.1111/cas.13884; Bazaga A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67846-1; DepMap Broad, 2020, DEPMAP 21Q1 PUBL FIG, DOI [10.6084/m9.figshare.13681534.v1, DOI 10.6084/M9.FIGSHARE.13681534.V1]; Dezso Z, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-3442-9; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Indran IR, 2011, CANCER RES, V71, P266, DOI 10.1158/0008-5472.CAN-10-1588; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Koh CM, 2015, J CLIN INVEST, V125, P2109, DOI 10.1172/JCI79134; Liu TT, 2016, GENES-BASEL, V7, DOI 10.3390/genes7070038; Madhukar NS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12928-6; Rosen J, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101543; Saretzki G, 2014, CURR PHARM DESIGN, V20, P6386, DOI 10.2174/1381612820666140630095606; Seynnaeve B, 2017, SCI REP-UK, V7, DOI 10.1038/srep45704; Sherman J, 2021, ONCOGENE, V40, P3766, DOI 10.1038/s41388-021-01807-4; Shimada K, 2019, TOOL BROWSING CANC D, DOI 10.1101/2019.12.13.874776v1; Travis J, 2015, SCIENCE, V350, P1456, DOI 10.1126/science.350.6267.1456; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Urra FA, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00118; Yuan XT, 2019, ONCOGENE, V38, P6172, DOI 10.1038/s41388-019-0872-9; Yuan XT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133338	20	2	2	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					5038	5041		10.1038/s41388-021-01894-3	http://dx.doi.org/10.1038/s41388-021-01894-3		JUN 2021	4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34135463				2022-12-17	WOS:000662140500001
J	Wang, XL; Zhang, L; Song, YF; Jiang, Y; Zhang, D; Wang, R; Hu, TH; Han, S				Wang, Xiaoliang; Zhang, Li; Song, Yifu; Jiang, Yang; Zhang, Di; Wang, Run; Hu, Tianhao; Han, Sheng			MCM8 is regulated by EGFR signaling and promotes the growth of glioma stem cells through its interaction with DNA-replication-initiating factors	ONCOGENE			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; FUNCTIONAL-CHARACTERIZATION; COMPLEX; EXPRESSION; CANCER; ACTIVATION; PROGNOSIS; FAMILY; CDC6	Mini-chromosome maintenance (MCM) proteins are critical components of DNA-replication-licensing factors. MCM8 is an MCM protein that exhibits oncogenic functions in several human malignancies. However, the role of MCM8 in glioblastomas (GBMs) has remained unclear. In the present study, we investigated the biological functions and mechanisms of MCM8 in glioma stem cells (GSCs). The clinical relevance of MCM8 mRNA expression was explored via TCGA and REMBRANDT datasets. The effects of MCM8 on the self-renewal and tumorigenicity of GSCs were examined both in vitro and in vivo. The regulation of MCM8 expression and its interacting proteins were also evaluated. We found that the expression of MCM8 was elevated in high-grade gliomas and classical molecular subtypes and was inversely correlated with patient prognosis. GSCs had a significantly higher expression of MCM8 compared with that in normal glioma cells. Silencing of MCM8 induced G0/G1 arrest and apoptosis, as well as inhibited the proliferation and self-renewal of GSCs. Forced expression of MCM8 enhanced clonogenicity of GSCs both in vitro and in vivo. MCM8 expression was regulated by EGFR signaling, which was mediated by NF-kappa B (p65). MCM8 interacted with DNA-replication-initiating factors-including EZH2, CDC6, and CDCA2-and influenced these factors to associate with chromatin. In addition, MCM8 knockdown increased the sensitivity of GSCs to radiation and TMZ treatments. Our findings suggest that MCM8, regulated by the EGFR pathway, maintains the clonogenic and tumorigenic potential of GSCs through interaction with DNA-replication-initiating factors; hence, MCM8 may represent a novel therapeutic target in GBMs.	[Wang, Xiaoliang; Zhang, Li; Song, Yifu; Jiang, Yang; Wang, Run; Hu, Tianhao; Han, Sheng] China Med Univ, Hosp 1, Dept Neurosurg, Shenyang, Peoples R China; [Jiang, Yang] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Neurosurg, Sch Med, Shanghai, Peoples R China; [Zhang, Di] China Med Univ, Dept Pathol, Shenyang, Peoples R China	China Medical University; Shanghai Jiao Tong University; China Medical University	Han, S (corresponding author), China Med Univ, Hosp 1, Dept Neurosurg, Shenyang, Peoples R China.	hansheng2001_x@aliyun.com		Han, Sheng/0000-0001-6991-0529; song, yi fu/0000-0002-5096-5949	LiaoNing Revitalization Talents Program [XLYC1807253]; National Natural Science Foundation of China [81772653, 81402045]	LiaoNing Revitalization Talents Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Qingchang Li from the Department of Pathology at China Medical University for technological support and assistance with statistical analyses. This work was supported by the LiaoNing Revitalization Talents Program (No. XLYC1807253) and the National Natural Science Foundation of China (No. 81772653 and 81402045)	Azzarelli R, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.162693; Bowman RL, 2017, NEURO-ONCOLOGY, V19, P139, DOI 10.1093/neuonc/now247; Cai HQ, 2018, HUM PATHOL, V78, P182, DOI 10.1016/j.humpath.2018.04.024; Cai LL, 2015, INT J CLIN EXP PATHO, V8, P14180; De Ruysscher D, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0064-5; Erkan EP, 2014, ONCOGENE, V33, P4778, DOI 10.1038/onc.2013.423; Freeman A, 1999, CLIN CANCER RES, V5, P2121; Friedman HS, 2000, CLIN CANCER RES, V6, P2585; Gozuacik D, 2003, NUCLEIC ACIDS RES, V31, P570, DOI 10.1093/nar/gkg136; Greenall SA, 2019, NEURO-ONCOLOGY, V21, P1016, DOI 10.1093/neuonc/noz073; Guo SY, 2021, THERANOSTICS, V11, P4316, DOI 10.7150/thno.51745; Han S, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0552-y; Han S, 2015, J NEURO-ONCOL, V124, P45, DOI 10.1007/s11060-015-1818-x; He DM, 2017, ONCOGENE, V36, P3629, DOI 10.1038/onc.2017.123; Honeycutt KA, 2006, ONCOGENE, V25, P4027, DOI 10.1038/sj.onc.1209435; Hua C, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-526; Im JS, 2009, P NATL ACAD SCI USA, V106, P15628, DOI 10.1073/pnas.0908039106; Ishimi Y, 2018, GENES GENET SYST, V93, P125, DOI 10.1266/ggs.18-00026; Jiang Y, 2019, CANCER RES, V79, P2593, DOI 10.1158/0008-5472.CAN-18-3297; Jin X, 2017, NAT MED, V23, P1352, DOI 10.1038/nm.4415; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Lee KY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8744; Li XJ, 2018, MOL CELL, V72, P650, DOI 10.1016/j.molcel.2018.09.007; Liu YQ, 2017, J MOL CELL BIOL, V9, P178, DOI 10.1093/jmcb/mjx013; Liu ZK, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4056-8; Matson JP, 2017, ELIFE, V6, DOI 10.7554/eLife.30473; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mukherjee S, 2018, CELL REP, V23, P1651, DOI 10.1016/j.celrep.2018.04.016; Nishimura K, 2012, MOL CELL, V47, P511, DOI 10.1016/j.molcel.2012.05.047; Park J, 2013, MOL CELL BIOL, V33, P1632, DOI 10.1128/MCB.01503-12; Peng YP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164150; Song YF, 2019, THERANOSTICS, V9, P6019, DOI 10.7150/thno.35747; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Volkening M, 2005, MOL CELL BIOL, V25, P1560, DOI 10.1128/MCB.25.4.1560-1568.2005; Wang QY, 2018, CLIN CANCER RES, V24, P950, DOI 10.1158/1078-0432.CCR-17-1475; Wang YF, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188415; Weller M, 2017, LANCET ONCOL, V18, pE315, DOI 10.1016/S1470-2045(17)30194-8; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Zhang X, 2014, MOL CANCER RES, V12, P1535, DOI 10.1158/1541-7786.MCR-13-0641	41	2	2	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4615	4624		10.1038/s41388-021-01888-1	http://dx.doi.org/10.1038/s41388-021-01888-1		JUN 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34131285				2022-12-17	WOS:000661812800002
J	Zhang, Z; Min, L; Li, HC; Chen, L; Zhao, Y; Liu, S; Guo, QD; Zhu, ST; Li, P; Zhang, ST				Zhang, Zheng; Min, Li; Li, Hengcun; Chen, Lei; Zhao, Yu; Liu, Si; Guo, Qingdong; Zhu, Shengtao; Li, Peng; Zhang, Shutian			Asporin represses gastric cancer apoptosis via activating LEF1-mediated gene transcription independent of beta-catenin	ONCOGENE			English	Article							TUMOR MICROENVIRONMENT; BORRMANN TYPE; WNT; SUSCEPTIBILITY; COACTIVATOR; PROTEINS; PROTECTS; INVASION; PATHWAY; TARGET	Asporin (ASPN) presents in the tumor microenvironment and exhibits a cancer-promoting effect as a stroma protein. Even though ASPN has already been observed inside cancer cells, the functions of intracellular ASPN and its underlying mechanisms remain unknown. Here we reported that ASPN was upregulated in different stages of gastric cancer (GC), and associated with a poor prognosis. Moreover, we found that ASPN markedly inhibited GC cell apoptosis and promoted cell growth in vitro and in vivo. Further mechanism investigations revealed that ASPN directly binding to lymphoid enhancer-binding factor 1 (LEF1) and promoted LEF1-mediated gene transcription independent of beta-catenin, the classic co-factor in the Wnt/LEF1 pathway. We also demonstrated that ASPN selectively facilitated LEF1 binding to and activating the promoters of PTGS2, IL6, and WISP1 to promote their transcription. The suppression of cell apoptosis by ASPN overexpression could be attenuated by LEF1 knockdown or 100 mu M aspirin (PTGS2 inhibitor), and siASPN mediated apoptosis could be rescued by LEF1 ectopic expression or adding recombinant IL6. Therefore, we concluded that ASPN repressed GC cell apoptosis via activating LEF1-mediated gene transcription independent of beta-catenin, which could serve as a potential prognostic biomarker in GC patients.	[Zhang, Zheng; Min, Li; Li, Hengcun; Chen, Lei; Zhao, Yu; Liu, Si; Guo, Qingdong; Zhu, Shengtao; Li, Peng; Zhang, Shutian] Capital Med Univ, Beijing Key Lab Precancerous Lesion Digest Dis, Natl Clin Res Ctr Digest Dis, Dept Gastroenterol,Beijing Friendship Hosp,Beijin, Beijing, Peoples R China	Capital Medical University	Li, P; Zhang, ST (corresponding author), Capital Med Univ, Beijing Key Lab Precancerous Lesion Digest Dis, Natl Clin Res Ctr Digest Dis, Dept Gastroenterol,Beijing Friendship Hosp,Beijin, Beijing, Peoples R China.	lipeng@ccmu.edu.cn; zhangshutian@ccmu.edu.cn	Min, Li/T-8107-2018	Min, Li/0000-0001-9595-5536; Zhang, Zheng/0000-0002-0822-7985; Li, Peng/0000-0003-2927-2758	National Natural Science Foundation of China [81570507, 81702314]; National Key Research and Development Program of China [2017YFC0113600]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China	This study was supported by National Natural Science Foundation of China (81570507, 81702314) and National Key Research and Development Program of China (2017YFC0113600).	Acebron SP, 2016, TRENDS CELL BIOL, V26, P956, DOI 10.1016/j.tcb.2016.07.009; An JY, 2008, J GASTROINTEST SURG, V12, P1364, DOI 10.1007/s11605-008-0516-9; Badgwell B, 2016, LANCET ONCOL, V17, P1628, DOI 10.1016/S1470-2045(16)30521-6; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Castellana B, 2012, J CANCER, V3, P175, DOI 10.7150/jca.4120; Chiurillo MA, 2015, WORLD J EXP MED, V5, P84, DOI [DOI 10.5493/WJEM.V5.I2.84, 10.5493/wjem.v5.i2.84]; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; Cottini F, 2014, NAT MED, V20, P599, DOI 10.1038/nm.3562; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960; D'Errico M, 2009, EUR J CANCER, V45, P461, DOI 10.1016/j.ejca.2008.10.032; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Hrckulak D, 2016, CANCERS, V8, DOI 10.3390/cancers8070070; Hughes RM, 2019, CANCER RES, V79, P3636, DOI 10.1158/0008-5472.CAN-18-2931; Hurley PJ, 2016, CLIN CANCER RES, V22, P448, DOI 10.1158/1078-0432.CCR-15-0256; Ikegawa S, 2008, CURR MED CHEM, V15, P724, DOI 10.2174/092986708783885237; Ikeguchi M, 2004, IN VIVO, V18, P577; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kessler M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9989; Kim HK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016694; Kizawa H, 2005, NAT GENET, V37, P138, DOI 10.1038/ng1496; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; Lee HH, 2018, ANN SURG ONCOL, V25, P778, DOI 10.1245/s10434-018-7051-z; Li C, 2009, ONCOLOGY-BASEL, V77, P197, DOI 10.1159/000236018; Li HC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1376-9; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Lordick F, 2014, CANCER TREAT REV, V40, P692, DOI 10.1016/j.ctrv.2014.03.002; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Luehders K, 2015, DEVELOPMENT, V142, P3351, DOI 10.1242/dev.124438; Luo JW, 2019, TRANSL ONCOL, V12, P475, DOI 10.1016/j.tranon.2018.11.010; Maris P, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001871; Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Packham S, 2015, ONCOGENE, V34, P2227, DOI 10.1038/onc.2014.165; Park JH, 2018, MOL CELLS, V41, P290, DOI 10.14348/molcells.2018.2167; Perez-Garijo A, 2015, DEVELOPMENT, V142, P3253, DOI 10.1242/dev.127878; Pinto M, 2003, J PATHOL, V200, P32, DOI 10.1002/path.1327; Rodriguez-Lopez J, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1920; Santiago L, 2017, AM J CANCER RES, V7, P1389; Satoyoshi R, 2015, ONCOGENE, V34, P650, DOI 10.1038/onc.2013.584; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Simkova D, 2016, BIOMED PAP, V160, P467, DOI 10.5507/bp.2016.037; Song YJ, 2017, BRIT J CANCER, V116, P973, DOI 10.1038/bjc.2017.54; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; STEWART D, 2014, JNCI-J NATL CANCER I, V106; Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902; Uhlen M, 2016, NAT METHODS, V13, P823, DOI [10.1038/NMETH.3995, 10.1038/nmeth.3995]; Uka R, 2020, ONCOGENE, V39, P4132, DOI 10.1038/s41388-020-1267-7; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wang L, 2018, ANN ONCOL, V29, P352, DOI 10.1093/annonc/mdx689; Wang LL, 2017, CANCER LETT, V398, P24, DOI 10.1016/j.canlet.2017.04.001; Warsito D, 2012, EMBO REP, V13, P244, DOI 10.1038/embor.2011.251; Wenzel J, 2020, ONCOGENE, V39, P3893, DOI 10.1038/s41388-020-1259-7; Wu H, 2016, ONCOTARGET, V7, P73402, DOI 10.18632/oncotarget.12336	55	2	2	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4552	4566		10.1038/s41388-021-01858-7	http://dx.doi.org/10.1038/s41388-021-01858-7		JUN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34127813				2022-12-17	WOS:000661408100001
J	Malkomes, P; Lunger, I; Oppermann, E; Abou-El-Ardat, K; Oellerich, T; Gunther, S; Canbulat, C; Bothur, S; Schnutgen, F; Yu, WJ; Wingert, S; Haetscher, N; Catapano, C; Dietz, MS; Heilemann, M; Kvasnicka, HM; Holzer, K; Serve, H; Bechstein, WO; Rieger, MA				Malkomes, Patrizia; Lunger, Ilaria; Oppermann, Elsie; Abou-El-Ardat, Khalil; Oellerich, Thomas; Guenther, Stefan; Canbulat, Can; Bothur, Sabrina; Schnuetgen, Frank; Yu, Weijia; Wingert, Susanne; Haetscher, Nadine; Catapano, Claudia; Dietz, Marina S.; Heilemann, Mike; Kvasnicka, Hans-Michael; Holzer, Katharina; Serve, Hubert; Bechstein, Wolf Otto; Rieger, Michael A.			Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53	ONCOGENE			English	Article							TISSUE TRANSGLUTAMINASE; TP53 MUTATION; STEM-CELLS; INHIBITION; EXPRESSION; SURVIVAL; TG2; ADJUVANT; INVASION; DISEASE	Despite a high clinical need for the treatment of colorectal carcinoma (CRC) as the second leading cause of cancer-related deaths, targeted therapies are still limited. The multifunctional enzyme Transglutaminase 2 (TGM2), which harbors transamidation and GTPase activity, has been implicated in the development and progression of different types of human cancers. However, the mechanism and role of TGM2 in colorectal cancer are poorly understood. Here, we present TGM2 as a promising drug target. In primary patient material of CRC patients, we detected an increased expression and enzymatic activity of TGM2 in colon cancer tissue in comparison to matched normal colon mucosa cells. The genetic ablation of TGM2 in CRC cell lines using shRNAs or CRISPR/Cas9 inhibited cell expansion and tumorsphere formation. In vivo, tumor initiation and growth were reduced upon genetic knockdown of TGM2 in xenotransplantations. TGM2 ablation led to the induction of Caspase-3-driven apoptosis in CRC cells. Functional rescue experiments with TGM2 variants revealed that the transamidation activity is critical for the pro-survival function of TGM2. Transcriptomic and protein-protein interaction analyses applying various methods including super-resolution and time-lapse microscopy showed that TGM2 directly binds to the tumor suppressor p53, leading to its inactivation and escape of apoptosis induction. We demonstrate here that TGM2 is an essential survival factor in CRC, highlighting the therapeutic potential of TGM2 inhibitors in CRC patients with high TGM2 expression. The inactivation of p53 by TGM2 binding indicates a general anti-apoptotic function, which may be relevant in cancers beyond CRC.	[Malkomes, Patrizia; Oppermann, Elsie; Canbulat, Can; Holzer, Katharina; Bechstein, Wolf Otto] Goethe Univ Hosp Frankfurt, Dept Gen Visceral & Transplant Surg, Frankfurt, Germany; [Lunger, Ilaria; Abou-El-Ardat, Khalil; Oellerich, Thomas; Bothur, Sabrina; Schnuetgen, Frank; Yu, Weijia; Wingert, Susanne; Haetscher, Nadine; Serve, Hubert; Rieger, Michael A.] Goethe Univ Hosp Frankfurt, Dept Med, Hematol Oncol, Frankfurt, Germany; [Abou-El-Ardat, Khalil; Oellerich, Thomas; Schnuetgen, Frank; Serve, Hubert; Rieger, Michael A.] German Canc Consortium & German Canc Res Ctr DKFZ, Heidelberg, Germany; [Oellerich, Thomas; Schnuetgen, Frank; Serve, Hubert; Rieger, Michael A.] Frankfurt Canc Inst, Frankfurt, Germany; [Guenther, Stefan] Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodelling 1, Bad Nauheim, Germany; [Catapano, Claudia; Dietz, Marina S.; Heilemann, Mike] Goethe Univ Frankfurt, Inst Phys & Theoret Chem, Single Mol Biophys, Frankfurt, Germany; [Kvasnicka, Hans-Michael] Goethe Univ Frankfurt, Senckenberg Inst Pathol, Frankfurt, Germany; [Rieger, Michael A.] Cardio Pulm Inst, Frankfurt, Germany; [Holzer, Katharina] Philipps Univ Marburg, Dept Visceral Thorac & Vasc Surg, Marburg, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Max Planck Society; Goethe University Frankfurt; Goethe University Frankfurt; Philipps University Marburg	Rieger, MA (corresponding author), Goethe Univ Hosp Frankfurt, Dept Med, Hematol Oncol, Frankfurt, Germany.; Rieger, MA (corresponding author), German Canc Consortium & German Canc Res Ctr DKFZ, Heidelberg, Germany.; Rieger, MA (corresponding author), Frankfurt Canc Inst, Frankfurt, Germany.; Rieger, MA (corresponding author), Cardio Pulm Inst, Frankfurt, Germany.	m.rieger@em.uni-frankfurt.de	Schnütgen, Frank/ABD-8637-2020; Malkomes, Patrizia/AAV-3314-2021; Kvasnicka, Hans Michael/E-7993-2011	Schnütgen, Frank/0000-0002-2426-6685; Kvasnicka, Hans Michael/0000-0002-3081-1395; Heilemann, Mike/0000-0002-9821-3578; Yu, Weijia/0000-0001-8471-3048	Else Kroner Fresenius-Stiftung; Deutsche Krebshilfe; LOEWE Centers Cell and Gene Therapy Frankfurt (Hessen State Ministry for Higher Education, Research and the Arts) [III L 4-518/17.004 [2014]]; Frankfurt Cancer Institute (Hessen State Ministry for Higher Education, Research and the Arts) [III L 5 - 519/03/03.001 - [0015]]; Projekt DEAL	Else Kroner Fresenius-Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); LOEWE Centers Cell and Gene Therapy Frankfurt (Hessen State Ministry for Higher Education, Research and the Arts); Frankfurt Cancer Institute (Hessen State Ministry for Higher Education, Research and the Arts); Projekt DEAL	The study was supported in part by the Else Kroner Fresenius-Stiftung, the Deutsche Krebshilfe (both to P.M.) and by the LOEWE Centers Cell and Gene Therapy Frankfurt (Hessen State Ministry for Higher Education, Research and the Arts, III L 4-518/17.004 [2014]) and Frankfurt Cancer Institute (Hessen State Ministry for Higher Education, Research and the Arts, III L 5 - 519/03/03.001 - [0015]). Open Access funding enabled and organized by Projekt DEAL.	Advani S, 2019, J SURG ONCOL, V119, P642, DOI 10.1002/jso.25441; Ahvazi B, 2002, EMBO J, V21, P2055, DOI 10.1093/emboj/21.9.2055; Antonyak MA, 2006, P NATL ACAD SCI USA, V103, P18609, DOI 10.1073/pnas.0604844103; Ashour AA, 2014, J CELL MOL MED, V18, P2235, DOI 10.1111/jcmm.12361; Ayinde O, 2017, ONCOTARGET, V8, P20025, DOI 10.18632/oncotarget.15370; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Barrier A, 2006, J CLIN ONCOL, V24, P4685, DOI 10.1200/JCO.2005.05.0229; Begg GE, 2006, P NATL ACAD SCI USA, V103, P19683, DOI 10.1073/pnas.0609283103; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cellura D, 2015, MOL CANCER RES, V13, P1095, DOI 10.1158/1541-7786.MCR-14-0466; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chhabra A, 2009, ANTICANCER RES, V29, P1909; Condello S, 2018, CANCER RES, V78, P2990, DOI 10.1158/0008-5472.CAN-17-2319; Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126; Dietz P., 2020, METHODS, VS1046-2023, P30024; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fisher ML, 2016, CANCER RES, V76, P7265, DOI 10.1158/0008-5472.CAN-16-2032; FOLK JE, 1966, J BIOL CHEM, V241, P3238; Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784; Nguyen HT, 2018, ONCOL LETT, V16, P9, DOI 10.3892/ol.2018.8679; Harwardt MLIE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082803; Hilsenbeck O, 2016, NAT BIOTECHNOL, V34, P703, DOI 10.1038/nbt.3626; Hwang JY, 2008, CANCER RES, V68, P5849, DOI 10.1158/0008-5472.CAN-07-6130; Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175; Fernandez-Acenero M, 2016, VIRCHOWS ARCH, V469, P611, DOI 10.1007/s00428-016-2020-z; Kang JH, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.14; Klock C, 2012, SEMIN IMMUNOPATHOL, V34, P513, DOI 10.1007/s00281-012-0305-0; Kosa K, 1997, BIOCHEM BIOPH RES CO, V232, P737, DOI 10.1006/bbrc.1997.6363; Kotsakis P, 2011, AMINO ACIDS, V41, P909, DOI 10.1007/s00726-010-0790-1; Ku BM, 2013, FASEB J, V27, P3487, DOI 10.1096/fj.12-224220; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1202, P1, DOI 10.1016/0167-4838(93)90055-V; LORAND L, 1992, P NATL ACAD SCI USA, V89, P11161, DOI 10.1073/pnas.89.23.11161; Malkomes P, 2016, ANN SURG ONCOL, V23, P2849, DOI 10.1245/s10434-016-5218-z; Mangala LS, 2007, ONCOGENE, V26, P2459, DOI 10.1038/sj.onc.1210035; Mehta Kapil, 2011, Cancers (Basel), V3, P897, DOI 10.3390/cancers3010897; MICANOVIC R, 1994, J BIOL CHEM, V269, P9190; Mishra S, 2006, BIOCHEM BIOPH RES CO, V339, P726, DOI 10.1016/j.bbrc.2005.11.071; Miyoshi N, 2010, ANN SURG ONCOL, V17, P967, DOI 10.1245/s10434-009-0865-y; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3; O'Connor ES, 2011, J CLIN ONCOL, V29, P3381, DOI 10.1200/JCO.2010.34.3426; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Oono M, 2014, J NEUROCHEM, V128, P403, DOI 10.1111/jnc.12441; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; Pinkas DM, 2007, PLOS BIOL, V5, P2788, DOI 10.1371/journal.pbio.0050327; Rieger MA, 2009, SCIENCE, V325, P217, DOI 10.1126/science.1171461; SARKAR NK, 1957, BIOCHIM BIOPHYS ACTA, V25, P451, DOI 10.1016/0006-3002(57)90512-7; Sauer M, 2017, CHEM REV, V117, P7478, DOI 10.1021/acs.chemrev.6b00667; Shah MA, 2016, J CLIN ONCOL, V34, P843, DOI 10.1200/JCO.2015.63.0558; Shao MH, 2009, CANCER RES, V69, P9192, DOI 10.1158/0008-5472.CAN-09-1257; Soussi T, 2005, HUM MUTAT, V25, P6, DOI 10.1002/humu.20114; Tatsukawa H, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-4; Telci D, 2006, FRONT BIOSCI-LANDMRK, V11, P867, DOI 10.2741/1843; Thalheimer FB, 2014, STEM CELL REP, V3, DOI 10.1016/j.stemcr.2014.05.010; Varga J, 2017, NAT CELL BIOL, V19, P1133, DOI 10.1038/ncb3611; Verma A, 2008, CLIN CANCER RES, V14, P1997, DOI 10.1158/1078-0432.CCR-07-1533; Verma A, 2008, CLIN CANCER RES, V14, P2476, DOI 10.1158/1078-0432.CCR-07-4529; Yeo SY, 2016, ELIFE, V5, DOI 10.7554/eLife.07101; Yin J, 2017, CANCER RES, V77, P4973, DOI 10.1158/0008-5472.CAN-17-0388; Zhang H, 2016, CANCER RES, V76, P6410, DOI 10.1158/0008-5472.CAN-16-0595	60	2	2	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4352	4367		10.1038/s41388-021-01847-w	http://dx.doi.org/10.1038/s41388-021-01847-w		JUN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103685	Green Published, hybrid			2022-12-17	WOS:000659032900003
J	Lindzen, M; Ghosh, S; Noronha, A; Drago, D; Nataraj, NB; Leitner, O; Carvalho, S; Zmora, E; Sapoznik, S; Shany, KB; Levanon, K; Aderka, D; Ramirez, BS; Dahlhoff, M; McNeish, I; Yarden, Y				Lindzen, Moshit; Ghosh, Soma; Noronha, Ashish; Drago, Diana; Nataraj, Nishanth Belugali; Leitner, Orith; Carvalho, Silvia; Zmora, Einav; Sapoznik, Stav; Shany, Keren Bahar; Levanon, Keren; Aderka, Dan; Ramirez, Belinda Sanchez; Dahlhoff, Maik; McNeish, Iain; Yarden, Yosef			Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53	ONCOGENE			English	Article							GRADE SEROUS CARCINOMA; GROWTH-FACTOR RECEPTOR; TUMOR INVASION; PROLIFERATION; CELLS; CXCL1; EGF; CHEMOTHERAPY; PHENOTYPE; LIGAND	Ovarian cancer (OvCA) remains one of the most devastating malignancies, but treatment options are still limited. We report that amphiregulin (AREG) can serve as an effective and safe pharmacological target in a syngeneic murine model. AREG is highly abundant in abdominal fluids of patients with advanced OvCa. In immunocompetent animals, depletion or overexpression of AREG respectively prolonged or shortened animal survival. A new antibody we generated in AREG-knockout mice recognized murine AREG and reproducibly prolonged animal survival in the syngeneic model. The underlying mechanism likely involves binding of wildtype p53 to AREG's promoter and autocrine activation of the epidermal growth factor receptor (EGFR), a step blocked by the antibody. Accordingly, depletion of p53 downregulated AREG secretion and conferred tolerance, whereas blocking an adaptive process involving CXCL1, which transactivates EGFR, might increase therapeutic efficacy. Consistent with these observations, analysis of OvCa patients revealed that high AREG correlates with poor prognosis of patients expressing wildtype TP53. In conclusion, clinical tests of the novel antibody are warranted; high AREG, normal TP53, and reduced CXCL1 activity might identify patients with OvCa who may derive therapeutic benefit.	[Lindzen, Moshit; Ghosh, Soma; Noronha, Ashish; Drago, Diana; Nataraj, Nishanth Belugali; Zmora, Einav; Yarden, Yosef] Weizmann Inst Sci, Dept Biol Regulat, Rehovot, Israel; [Leitner, Orith; Carvalho, Silvia] Weizmann Inst Sci, Biol Serv, Rehovot, Israel; [Sapoznik, Stav; Shany, Keren Bahar; Levanon, Keren; Aderka, Dan] Tel Aviv Univ, Chaim Sheba Med Ctr, Sheba Canc Res Ctr, Ramat Aviv, Israel; [Sapoznik, Stav; Shany, Keren Bahar; Levanon, Keren; Aderka, Dan] Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel; [Ramirez, Belinda Sanchez] Ctr Mol Immunol, Direct Immunol & Immunotherapy, Havana, Cuba; [Dahlhoff, Maik] Univ Vet Med Vienna, Inst Vivo & In Vitro Models, Vienna, Austria; [McNeish, Iain] Imperial Coll, London, England; [McNeish, Iain] Hammersmith Hosp, London, England	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; University of Veterinary Medicine Vienna; Imperial College London; Imperial College London	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Noronha, Ashish/GPG-0252-2022; Nataraj, Nishanth Belugali/AAB-9317-2021; Dahlhoff, Maik/AGH-1182-2022; Ghosh, Soma/HFZ-9279-2022; Noronha, Ashish/GPX-4834-2022	Noronha, Ashish/0000-0002-3415-6113; Nataraj, Nishanth Belugali/0000-0003-2970-6739; Ghosh, Soma/0000-0002-9133-8538; Noronha, Ashish/0000-0002-3415-6113; Carvalho, Silvia/0000-0003-2102-7723; McNeish, Iain/0000-0002-9387-7586; Drago-Garcia, Diana/0000-0001-6397-3123	Israel Cancer Research Fund (ICRF); Israel Science Foundation (ISF); European Research Council (ERC); Dr. Miriam and Sheldon G. Adelson Medical Research Foundation	Israel Cancer Research Fund (ICRF); Israel Science Foundation (ISF)(Israel Science Foundation); European Research Council (ERC)(European Research Council (ERC)European Commission); Dr. Miriam and Sheldon G. Adelson Medical Research Foundation	We thank all members of our laboratory for their kind help and insightful comments. This work was performed in the Marvin Tanner Laboratory for Research on Cancer. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair in Molecular Cell Biology. Our studies have been supported by the Israel Cancer Research Fund (ICRF), the Israel Science Foundation (ISF), the European Research Council (ERC; Oncombine Project), and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation.	Berasain C, 2014, SEMIN CELL DEV BIOL, V28, P31, DOI 10.1016/j.semcdb.2014.01.005; Bolitho C, 2010, ENDOCR-RELAT CANCER, V17, P929, DOI 10.1677/ERC-10-0107; Borriello F, 1997, IMMUNITY, V6, P303, DOI 10.1016/S1074-7613(00)80333-7; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Carvalho S, 2016, ONCOGENE, V35, P438, DOI 10.1038/onc.2015.93; Castillo J, 2006, CANCER RES, V66, P6129, DOI 10.1158/0008-5472.CAN-06-0404; Cheng WL, 2011, ANN ONCOL, V22, P2267, DOI 10.1093/annonc/mdq739; Garrido G, 2004, HYBRIDOMA HYBRIDOM, V23, P168, DOI 10.1089/1536859041224280; Hosur V, 2018, FEBS OPEN BIO, V8, P702, DOI 10.1002/2211-5463.12407; Hsu D, 2010, LAB INVEST, V90, P1295, DOI 10.1038/labinvest.2010.100; Jamieson AM, 2013, SCIENCE, V340, P1230, DOI 10.1126/science.1233632; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jones S, 2012, J PATHOL, V226, P413, DOI 10.1002/path.3967; Kawanishi H, 2008, CLIN CANCER RES, V14, P2579, DOI 10.1158/1078-0432.CCR-07-1922; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kochupurakkal BS, 2005, J BIOL CHEM, V280, P8503, DOI 10.1074/jbc.M413919200; Lee CH, 2015, ONCOTARGET, V6, P38866, DOI 10.18632/oncotarget.5640; Lieber S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1424672; Lindzen M, 2012, ONCOGENE, V31, P3505, DOI 10.1038/onc.2011.518; Lindzen M, 2010, P NATL ACAD SCI USA, V107, P12559, DOI 10.1073/pnas.1006218107; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Luppi F, 2007, LUNG CANCER, V56, P25, DOI 10.1016/j.lungcan.2006.11.014; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Pujade-Lauraine E, 2014, J CLIN ONCOL, V32, P1302, DOI 10.1200/JCO.2013.51.4489; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Taira N, 2014, P NATL ACAD SCI USA, V111, P717, DOI 10.1073/pnas.1313675111; Togashi Y, 2017, CURR TOP MICROBIOL, V410, P3, DOI 10.1007/82_2017_58; Vang R, 2016, INT J GYNECOL PATHOL, V35, P48, DOI 10.1097/PGP.0000000000000207; Walton J, 2016, CANCER RES, V76, P6118, DOI 10.1158/0008-5472.CAN-16-1272; Walton JB, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17119-1; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; Zaiss DM, 2006, SCIENCE, V314, P1746, DOI 10.1126/science.1133715; Zaiss DMW, 2015, IMMUNITY, V42, P216, DOI 10.1016/j.immuni.2015.01.020	36	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3665	3679		10.1038/s41388-021-01784-8	http://dx.doi.org/10.1038/s41388-021-01784-8		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33941851	Green Published, hybrid			2022-12-17	WOS:000646512100001
J	Rangel, DF; Dubeau, L; Park, R; Chan, PC; Ha, DP; Pulido, MA; Mullen, DJ; Vorobyova, I; Zhou, BY; Borok, Z; Offringa, IA; Lee, AS				Rangel, Daisy Flores; Dubeau, Louis; Park, Ryan; Chan, Priscilla; Ha, Dat P.; Pulido, Mario A.; Mullen, Daniel J.; Vorobyova, Ivetta; Zhou, Beiyun; Borok, Zea; Offringa, Ite A.; Lee, Amy S.			Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis	ONCOGENE			English	Article							CANCER-CELLS; PROTEINS; KNOCKOUT; SURVIVAL	Lung cancer is the leading cause of cancer mortality worldwide and KRAS is the most commonly mutated gene in lung adenocarcinoma (LUAD). The 78-kDa glucose-regulated protein GRP78/BiP is a key endoplasmic reticulum chaperone protein and a major pro-survival effector of the unfolded protein response (UPR). Analysis of the Cancer Genome Atlas database and immunostain of patient tissues revealed that compared to normal lung, GRP78 expression is generally elevated in human lung cancers, including tumors bearing the KRAS(G12D) mutation. To test the requirement of GRP78 in human lung oncogenesis, we generated mouse models containing floxed Grp78 and Kras Lox-Stop-Lox G12D (Kras(LSL-G12D)) alleles. Simultaneous activation of the Kras(G12D) allele and knockout of the Grp78 alleles were achieved in the whole lung or selectively in lung alveolar epithelial type 2 cells known to be precursors for adenomas that progress to LUAD. Here we report that GRP78 haploinsufficiency is sufficient to suppress Kras(G12D)-mediated lung tumor progression and prolong survival. Furthermore, GRP78 knockdown in human lung cancer cell line A427 (Kras(G12D/+)) leads to activation of UPR and apoptotic markers and loss of cell viability. Our studies provide evidence that targeting GRP78 represents a novel therapeutic approach to suppress mutant KRAS-mediated lung tumorigenesis.	[Rangel, Daisy Flores; Chan, Priscilla; Ha, Dat P.; Borok, Zea; Offringa, Ite A.; Lee, Amy S.] Univ Southern Calif, Keck Sch Med, Dept Biochem & Mol Med, Los Angeles, CA 90007 USA; [Rangel, Daisy Flores; Dubeau, Louis; Chan, Priscilla; Ha, Dat P.; Pulido, Mario A.; Mullen, Daniel J.; Offringa, Ite A.; Lee, Amy S.] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA; [Dubeau, Louis] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90007 USA; [Park, Ryan; Vorobyova, Ivetta] Univ Southern Calif, Keck Sch Med, Dept Radiol, Los Angeles, CA 90007 USA; [Pulido, Mario A.; Mullen, Daniel J.; Offringa, Ite A.] Univ Southern Calif, Keck Sch Med, Dept Surg, Los Angeles, CA 90007 USA; [Zhou, Beiyun; Borok, Zea] Univ Southern Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90007 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Lee, AS (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Biochem & Mol Med, Los Angeles, CA 90007 USA.; Lee, AS (corresponding author), Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA.	amylee@usc.edu	Ha, Dat/AFS-3983-2022	Ha, Dat/0000-0002-2592-1223; Borok, Zea/0000-0001-8673-8177; Chan, Priscilla/0000-0003-1338-363X	NIH [R01 CA027607, R35 HL135747]; Judy and Larry Freeman Chair; NIH Diversity Supplements; Hastings Foundation; Ralph Edgington Chair;  [P30 CA014089];  [1S10OD012371];  [1S10OD18500]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Judy and Larry Freeman Chair; NIH Diversity Supplements(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hastings Foundation; Ralph Edgington Chair; ; ; 	We thank Hal Chapman for the SPC-Cre mice, Peter Conti and Jennifer Choi for assistance with PET/CT, and Jorge Nieva and Robert Hsu for tumor samples. The work was supported by NIH grants R01 CA027607 and the Judy and Larry Freeman Chair (ASL), NIH Diversity Supplements (DFR), the Hastings Foundation (BZ, ZB), and NIH grant R35 HL135747 and Ralph Edgington Chair (ZB). We thank the USC Norris Comprehensive Cancer Translational Pathology Core and the USC Molecular Imaging Center (supported by P30 CA014089, 1S10OD012371 and 1S10OD18500) for technical assistance.	Bakewell Suzanne J, 2018, Oncotarget, V9, P29698, DOI 10.18632/oncotarget.25679; Burris HA, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000154; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Cerezo M, 2016, CANCER CELL, V29, P805, DOI 10.1016/j.ccell.2016.04.013; Chae YC, 2012, CANCER CELL, V22, P331, DOI 10.1016/j.ccr.2012.07.015; Chapman HA, 2011, J CLIN INVEST, V121, P2855, DOI 10.1172/JCI57673; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; De Raedt T, 2011, CANCER CELL, V20, P400, DOI 10.1016/j.ccr.2011.08.014; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Desai TJ, 2014, NATURE, V507, P190, DOI 10.1038/nature12930; Du TD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10824-7; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Gifford JB, 2016, MOL CANCER THER, V15, P1043, DOI 10.1158/1535-7163.MCT-15-0774; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Imai H, 2017, THORAC CANCER, V8, P379, DOI 10.1111/1759-7714.12463; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kwon D, 2018, LUNG CANCER, V122, P131, DOI 10.1016/j.lungcan.2018.06.005; Lee AS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40919; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Lizardo MM, 2016, NEOPLASIA, V18, P699, DOI 10.1016/j.neo.2016.09.001; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Ma X, 2015, DIS MARKERS, V2015, P1, DOI 10.1155/2015/814670; Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pobre KFR, 2019, J BIOL CHEM, V294, P2098, DOI 10.1074/jbc.REV118.002804; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374; Shen JL, 2017, P NATL ACAD SCI USA, V114, pE4020, DOI 10.1073/pnas.1616060114; Uramoto H, 2007, ANTICANCER RES, V27, P2297; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wey S, 2012, BLOOD, V119, P817, DOI 10.1182/blood-2011-06-357384; Ye RS, 2010, DIABETES, V59, P6, DOI 10.2337/db09-0755; Zhang XY, 2019, DRUG DES DEV THER, V13, P1357, DOI 10.2147/DDDT.S198400; Zhang Y, 2010, J BIOL CHEM, V285, P15065, DOI 10.1074/jbc.M109.087445	37	2	2	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3624	3632		10.1038/s41388-021-01791-9	http://dx.doi.org/10.1038/s41388-021-01791-9		APR 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33931739	Green Accepted			2022-12-17	WOS:000645887000001
J	Chen, SS; Du, YY; Xu, B; Li, Q; Yang, L; Jiang, Z; Zeng, ZX; Chen, LF				Chen, Sisi; Du, Yunyan; Xu, Bin; Li, Qing; Yang, Le; Jiang, Zi; Zeng, Zhaoxia; Chen, Leifeng			Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance	ONCOGENE			English	Article							CANCER; VRK2; PHOSPHORYLATION; RESISTANCE; MECHANISMS; EXPRESSION; CROSSTALK; STABILITY; CELLS	Hepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options. Sorafenib is the only Food and Drug Administration (FDA)-approved first-line targeted drug for the treatment of advanced HCC. However, its effect on patient survival is limited. Recently, studies have demonstrated that the imbalance between apoptosis and autophagy plays a critical role in chemoresistance, and it is hypothesised that restoring the balance between these processes is a potential treatment strategy for improving chemoresistance in cancer. However, there is currently no evidence supporting this hypothesis. We aimed to investigate if vaccinia-related kinase 2 (VRK2), a serine/threonine protein kinase, confers sorafenib resistance in HCC cells. Here, we found that VRK2 was enriched in sorafenib-resistant HCC cells and patient-derived xenografts. Both in vivo and in vitro evidences showed that VRK2 blunts the efficacy of sorafenib against hepatocellular carcinoma by disturbing the balance between apoptosis and autophagy. Mechanistically, VRK2 promotes the phosphorylation of Bcl-2 by activating JNK1/MAPK8, thereby enhancing the dissociation of Bcl-2 from Beclin-1 and promoting the formation of the Beclin-1-Atg14-Vps34 complex, which facilitates autophagy. Furthermore, VRK2-induced phosphorylation of Bcl-2 promotes the interaction of Bcl-2 with BAX, thereby inhibiting apoptosis. In conclusion, targeting VRK2 for modulation of the balance between autophagy and apoptosis may be a novel strategy for overcoming sorafenib resistance in HCC.	[Chen, Sisi; Chen, Leifeng] Nanchang Univ, Affiliated Hosp 2, Dept Gen Surg, Nanchang, Jiangxi, Peoples R China; [Du, Yunyan] Nanchang Univ, Jiangxi Prov Peoples Hosp, Dept Med, Nanchang, Jiangxi, Peoples R China; [Xu, Bin] Nanchang Univ, Dept Burns, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China; [Li, Qing] Nanchang Univ, Affiliated Hosp 2, Dept Pathol, Nanchang, Jiangxi, Peoples R China; [Yang, Le; Jiang, Zi] Nanchang Univ, Affiliated Hosp 2, Dept Pharm, Nanchang, Jiangxi, Peoples R China; [Zeng, Zhaoxia] Nanchang Univ, Affiliated Hosp 2, Dept Radiol, Nanchang, Jiangxi, Peoples R China	Nanchang University; Nanchang University; Nanchang University; Nanchang University; Nanchang University; Nanchang University	Chen, LF (corresponding author), Nanchang Univ, Affiliated Hosp 2, Dept Gen Surg, Nanchang, Jiangxi, Peoples R China.	18770099029@126.com		Chen, Sisi/0000-0002-1908-5054; chen, Leifeng/0000-0001-8305-1900	National Natural Science Foundation of China [81760523]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (81760523).	Almarzooq S, 2020, MOL BIOL REP, V47, P5127, DOI 10.1007/s11033-020-05584-3; Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Birendra KC, 2017, MOL BIOL CELL, V28, P2241, DOI 10.1091/mbc.E17-03-0138; Blanco S, 2006, FEBS J, V273, P2487, DOI 10.1111/j.1742-4658.2006.05256.x; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cabral LKD, 2020, CANCERS, V12, DOI 10.3390/cancers12061576; Choo SP, 2016, CANCER-AM CANCER SOC, V122, P3430, DOI 10.1002/cncr.30237; Fernandez IF, 2010, MOL CELL BIOL, V30, P4687, DOI 10.1128/MCB.01581-09; Gao LX, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0478-9; Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x; Goyal L, 2019, CLIN CANCER RES, V25, P80, DOI 10.1158/1078-0432.CCR-18-0847; Ho CJ, 2019, CANCERS, V11, DOI 10.3390/cancers11111775; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Keating GM, 2017, TARGET ONCOL, V12, P243, DOI 10.1007/s11523-017-0484-7; Kfir-Erenfeld S, 2010, LEUKEMIA LYMPHOMA, V51, P1968, DOI 10.3109/10428194.2010.506570; Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280-002-0522-7; Kim S, 2015, MOL CELL BIOL, V35, P1754, DOI 10.1128/MCB.01325-14; Kulik L, 2019, GASTROENTEROLOGY, V156, P477, DOI 10.1053/j.gastro.2018.08.065; Lazarou M, 2015, NATURE, V524, P309, DOI 10.1038/nature14893; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Li Ming, 2018, Mol Neuropsychiatry, V4, P119, DOI 10.1159/000493941; Li Y, 2015, BASIC CLIN PHARMACOL, V116, P216, DOI 10.1111/bcpt.12365; Liu J, 2019, ACS CHEM NEUROSCI, V10, P792, DOI 10.1021/acschemneuro.8b00356; Liu J, 2018, AUTOPHAGY, V14, P845, DOI 10.1080/15548627.2017.1390636; Lu S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0681-z; Maejima Y, 2013, NAT MED, V19, P1478, DOI 10.1038/nm.3322; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Meyer T, 2017, LANCET GASTROENTEROL, V2, P565, DOI 10.1016/S2468-1253(17)30156-5; Mokdad AA, 2017, CHIN CLIN ONCOL, V6, DOI 10.21037/cco.2017.04.04; Monsalve DM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.40; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Ou JJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08902-x; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Perez-Hernandez M, 2019, CANCERS, V11, DOI 10.3390/cancers11101599; Rubinstein AD, 2012, J CELL SCI, V125, P5259, DOI 10.1242/jcs.115865; Sisinni L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040857; Tong M, 2018, J HEPATOL, V69, P826, DOI 10.1016/j.jhep.2018.05.034; Vasilevskaya IA, 2016, MOL CANCER RES, V14, P753, DOI 10.1158/1541-7786.MCR-16-0035; Vazquez-Cedeira M, 2012, J BIOL CHEM, V287, P42739, DOI 10.1074/jbc.M112.404285; Vega FM, 2003, FEBS LETT, V544, P176, DOI 10.1016/S0014-5793(03)00501-5; Wang KW, 2015, CELL CYCLE, V14, P1631, DOI 10.1080/15384101.2015.1038685; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Yang XW, 2015, INT J CLIN PHARM-NET, V37, P1047, DOI 10.1007/s11096-015-0151-y; Zhao XL, 2013, CANCER INVEST, V31, P555, DOI 10.3109/07357907.2013.834925; Zhu YJ, 2017, ACTA PHARMACOL SIN, V38, P614, DOI 10.1038/aps.2017.5	48	2	2	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3378	3393		10.1038/s41388-021-01780-y	http://dx.doi.org/10.1038/s41388-021-01780-y		APR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33875785	hybrid			2022-12-17	WOS:000641218600003
J	Hao, TS; Zhang, CX; Wang, ZQ; Buck, A; Vonderfecht, SL; Ermel, R; Kim, Y; Chen, WY				Hao, Taisen; Zhang, Chunxiao; Wang, Zhiqiang; Buck, Alison; Vonderfecht, Steven L.; Ermel, Richard; Kim, Young; Chen, WenYong			An aging mouse model of human chronic myeloid leukemia	ONCOGENE			English	Article								Chronic myeloid leukemia (CML) is an age-dependent blood malignancy. Like many other age-dependent human diseases, laboratory animal research of CML uses young mice that do not factor in the influence of aging. To understand how aging may impact animal modeling of human age-dependent diseases, we established the first aging mouse model of human CML in BALB/c mice in the advanced age defined by 75% survival. This model was developed by noncytotoxic depletion of bone marrow lineage-positive cells followed by BCR-ABL retroviral transduction and transplantation. CML developed in aging mice shared many similarities to that in young mice, but had increased incidence of anemia that is often seen in human CML. Importantly, we showed that aging of both donor hematopoietic stem cells and recipient bone marrow niche impacted BCR-ABL mediated leukemogenesis and leukemia spectrum. Optimal CML induction relied on age-matching for donors and recipients, and cross-transplantation between young and old mice produced a mixture of different leukemia. Therefore, our model provides initial evidence of the feasibility and merit of CML modeling in aging mice and offers a new tool for future studies of CML stem cell drug resistance and therapeutic intervention in which aging would be taken into consideration as an influencing factor.	[Hao, Taisen; Zhang, Chunxiao; Wang, Zhiqiang; Chen, WenYong] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA; [Buck, Alison] City Hope Natl Med Ctr, Eugene & Ruth Roberts Summer Student Acad, Duarte, CA USA; [Vonderfecht, Steven L.] Vet Pathol, Reno, NV USA; [Ermel, Richard] City Hope Natl Med Ctr, Beckman Res Inst, Ctr Comparat Med, Duarte, CA USA; [Kim, Young] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope	Chen, WY (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA.	wechen@coh.org		Zhang, Chunxiao/0000-0001-5543-4509; Chen, WenYong/0000-0001-6913-5729	NIH National Cancer Institute and National Institute of Aging [UH2/3 CA213385]; NIH Office of the Director [3UH3CA213385-05S1]; City of Hope Center for Cancer and Aging; Norton Basic Research Fund; National Cancer Institute [P30CA33572]	NIH National Cancer Institute and National Institute of Aging; NIH Office of the Director(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); City of Hope Center for Cancer and Aging; Norton Basic Research Fund; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the grants UH2/3 CA213385 (co-sponsored by NIH National Cancer Institute and National Institute of Aging) and 3UH3CA213385-05S1 (sponsored by NIH Office of the Director), as well as institutional grants from the City of Hope Center for Cancer and Aging, and Norton Basic Research Fund to WYC. Research reported in this publication included work performed in the Animal Resources Center and Flow Cytometry Core supported by the National Cancer Institute under the award P30CA33572. The content is solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	Alexander TB, 2018, NATURE, V562, P373, DOI 10.1038/s41586-018-0436-0; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Brubaker AL, 2013, J IMMUNOL, V190, P1746, DOI 10.4049/jimmunol.1201213; Butcher SK, 2001, J LEUKOCYTE BIOL, V70, P881; Chomel JC, 2011, BLOOD, V118, P3657, DOI 10.1182/blood-2011-02-335497; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; de Haan G, 2018, BLOOD, V131, P479, DOI 10.1182/blood-2017-06-746412; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Dell Ralph B, 2002, ILAR J, V43, P207; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Duarte D, 2018, BLOOD, V131, P1507, DOI 10.1182/blood-2017-12-784132; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Florian MC, 2012, CELL STEM CELL, V10, P520, DOI 10.1016/j.stem.2012.04.007; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hamamyh T, 2020, PHARMACOLOGY, V105, P630, DOI 10.1159/000507295; Hao T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48445-1; Hehlmann R, 2007, LANCET, V370, P342, DOI 10.1016/S0140-6736(07)61165-9; Helbling PM, 2019, CELL REP, V29, P3313, DOI 10.1016/j.celrep.2019.11.004; Ho YH, 2020, HAEMATOLOGICA, V105, P38, DOI 10.3324/haematol.2018.211334; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; Hsieh MY, 2014, BLOOD, V123, P2401, DOI 10.1182/blood-2014-01-547943; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; Ko PS, 2017, CURR MED RES OPIN, V33, P1737, DOI 10.1080/03007995.2017.1356708; Koptyra M, 2006, BLOOD, V108, P319, DOI 10.1182/blood-2005-07-2815; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Liu ZY, 2020, HEMATOLOGY, V25, P181, DOI 10.1080/16078454.2020.1765563; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Moura MS, 2019, HEMATOL TRANSF CELL, V41, P329, DOI 10.1016/j.htct.2019.03.006; Nowell PC, 2007, J CLIN INVEST, V117, P2033, DOI 10.1172/JCI31771; Oyekunle AA, 2016, CLIN MED INSIGHTS-BL, V9, P9, DOI 10.4137/CMBD.S31562; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Perrotti D, 2010, J CLIN INVEST, V120, P2254, DOI 10.1172/JCI41246; Pophali PA, 2016, CANCER J, V22, P40, DOI 10.1097/PPO.0000000000000165; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; ROWLEY JD, 1980, CLIN HAEMATOL, V9, P55; Smith, 2007, MOUSE BIOMEDICAL RES, P623, DOI [10.1016/B978-012369454-6/50053-4, DOI 10.1016/B978-012369454-6/50053-4)]; Van Etten RA, 2002, ONCOGENE, V21, P8643, DOI 10.1038/sj.onc.1206091; Walz C, 2012, BLOOD, V119, P3550, DOI 10.1182/blood-2011-12-397554; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wang XF, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0574-7; Wang ZQ, 2015, STEM CELLS, V33, P3437, DOI 10.1002/stem.2218; Wendel HG, 2006, P NATL ACAD SCI USA, V103, P7444, DOI 10.1073/pnas.0602402103; Wolach O, 2015, BLOOD, V125, P2477, DOI 10.1182/blood-2014-10-551465; Wolff NC, 2005, BLOOD, V105, P3995, DOI 10.1182/blood-2004-09-3534; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Ye D, 2006, BLOOD, V107, P4917, DOI 10.1182/blood-2005-10-4110; Yuan HF, 2012, BLOOD, V119, P1904, DOI 10.1182/blood-2011-06-361691; Yuan R, 2009, AGING CELL, V8, P277, DOI 10.1111/j.1474-9726.2009.00478.x; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	56	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3152	3163		10.1038/s41388-021-01770-0	http://dx.doi.org/10.1038/s41388-021-01770-0		APR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33824471	Green Accepted			2022-12-17	WOS:000637478800002
J	Mantilla-Rojas, C; Yu, M; Rinella, ES; Lynch, RM; Perry, A; Jaimes-Alvarado, J; Anderson, KR; Barba, E; Bourgeois, EJ; Konganti, K; Threadgill, DW				Mantilla-Rojas, Carolina; Yu, Ming; Rinella, Erica S.; Lynch, Rachel M.; Perry, Amie; Jaimes-Alvarado, Jorge; Anderson, Kathryn R.; Barba, Estefania; Bourgeois, Evann J.; Konganti, Kranti; Threadgill, David W.			A molecular subtype of colorectal cancers initiates independently of epidermal growth factor receptor and has an accelerated growth rate mediated by IL10-dependent anergy	ONCOGENE			English	Article							CELL LUNG-CANCER; MOUSE MODELS; COLON; MUTATIONS; CETUXIMAB; MICE; CARCINOMAS; INHIBITOR; GEFITINIB; ADENOMAS	Although epidermal growth factor receptor (EGFR)-targeted therapies are approved for colorectal cancer (CRC) treatment, only 15% of CRC patients respond to EGFR inhibition. Here, we show that colorectal cancers (CRC) can initiate and grow faster through an EGFR-independent mechanism, irrespective of the presence of EGFR, in two different mouse models using tissue-specific ablation of Egfr. The growth benefit in the absence of EGFR is also independent of Kras status. An EGFR-independent gene expression signature, also observed in human CRCs, revealed that anergy-inducing genes are overexpressed in EGFR-independent polyps, suggesting increased infiltration of anergic lymphocytes promotes an accelerated growth rate that is partially caused by escape from cell-mediated immune responses. Many genes in the EGFR-independent gene expression signature are downstream targets of interleukin 10 receptor alpha (IL10RA). We further show that IL10 is detectable in serum from mice with EGFR-independent colon polyps. Using organoids in vitro and Src ablation in vivo, we show that IL10 contributes to growth of EGFR-independent CRCs, potentially mediated by the well-documented role of SRC in IL10 signaling. Based on these data, we show that the combination of an EGFR inhibitor with an anti-IL10 neutralizing antibody results in decreased cell proliferation in organoids and in decreased polyp size in pre-clinical models harboring EGFR-independent CRCs, providing a new therapeutic intervention for CRCs resistant to EGFR inhibitor therapies.	[Mantilla-Rojas, Carolina; Threadgill, David W.] Texas A&M Univ, Interdisciplinary Program Genet, College Stn, TX 77843 USA; [Mantilla-Rojas, Carolina; Lynch, Rachel M.; Perry, Amie; Jaimes-Alvarado, Jorge; Anderson, Kathryn R.; Barba, Estefania; Bourgeois, Evann J.; Threadgill, David W.] Texas A&M Univ, Dept Mol & Cellular Med, College Stn, TX 77843 USA; [Yu, Ming; Rinella, Erica S.; Lynch, Rachel M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27515 USA; [Yu, Ming] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA; [Rinella, Erica S.] GeneDx, Gaithersburg, MD USA; [Perry, Amie] Thompson Bishop Sparks State Diagnost Lab, Auburn, AL USA; [Konganti, Kranti; Threadgill, David W.] Texas A&M Univ, Texas A&M Inst Genome Sci & Soc, College Stn, TX 77843 USA; [Threadgill, David W.] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; [Threadgill, David W.] Texas A&M Univ, Dept Nutr, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of North Carolina; University of North Carolina Chapel Hill; Fred Hutchinson Cancer Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Threadgill, DW (corresponding author), Texas A&M Univ, Interdisciplinary Program Genet, College Stn, TX 77843 USA.; Threadgill, DW (corresponding author), Texas A&M Univ, Dept Mol & Cellular Med, College Stn, TX 77843 USA.; Threadgill, DW (corresponding author), Texas A&M Univ, Texas A&M Inst Genome Sci & Soc, College Stn, TX 77843 USA.; Threadgill, DW (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.; Threadgill, DW (corresponding author), Texas A&M Univ, Dept Nutr, College Stn, TX 77843 USA.	dwt@tamu.edu		Mantilla Rojas, Carolina/0000-0002-3320-2122; Lynch, Rachel/0000-0001-8164-0744	NIH [R01 CA092479]; NIEHS [P30 ES029067]; Tom and Jean McMullin Chair of Genetics;  [F31 AT002835];  [F32 CA168301];  [T32 OD011083]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Tom and Jean McMullin Chair of Genetics; ; ; 	This work was supported by fellowships F31 AT002835 (ESR), F32 CA168301 (RML), T32 OD011083 (AP), and by NIH grants R01 CA092479 (DWT), NIEHS P30 ES029067, and the Tom and Jean McMullin Chair of Genetics (DWT). We thank members of the Threadgill lab for constructive criticism on manuscript drafts; Dr. Andrew Hillhouse and the Texas A&M Institute for Genome Sciences and Society's (TIGSS) Molecular Genomics Core for RNAseq data generation; and Kristen Hanneman for mouse husbandry. The results published here are in whole or part based upon data generated by The Cancer Genome Atlas managed by the NCI and NHGRI. Information about TCGA can be found at http://ca ncergenome.nih.gov..	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Becker C, 2005, GUT, V54, P950, DOI 10.1136/gut.2004.061283; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Chen L, 2019, ONCOL REP, V42, P595, DOI 10.3892/or.2019.7206; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Edin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047045; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Golas JM, 2005, CANCER RES, V65, P5358, DOI 10.1158/0008-5472.CAN-04-2484; Herbeuval JP, 2004, J IMMUNOL, V172, P4630, DOI 10.4049/jimmunol.172.7.4630; Hsu TI, 2016, ONCOTARGET, V7, P20840, DOI 10.18632/oncotarget.7894; Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jackstadt R, 2016, J PATHOL, V238, P141, DOI 10.1002/path.4645; Jackute J, 2018, BMC IMMUNOL, V19, DOI 10.1186/s12865-018-0241-4; Kamizato M, 2009, J GASTROENTEROL, V44, P1172, DOI 10.1007/s00535-009-0119-6; Karapetis CS, 2014, CLIN CANCER RES, V20, P744, DOI 10.1158/1078-0432.CCR-13-0606; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kuraguchi M, 2006, PLOS GENET, V2, P1362, DOI 10.1371/journal.pgen.0020146; Lee TC, 2009, GENESIS, V47, P85, DOI 10.1002/dvg.20464; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mager LF, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00096; Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x; Martins M, 2018, ADV EXP MED BIOL, V1110, P113, DOI 10.1007/978-3-030-02771-1_8; MASUI H, 1984, CANCER RES, V44, P1002; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Moran AE, 2004, J BIOL CHEM, V279, P43261, DOI 10.1074/jbc.M404276200; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Mounir M, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006701; Olson TJP, 2014, CANCER PREV RES, V7, P105, DOI 10.1158/1940-6207.CAPR-13-0163; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, JNCI-J NATL CANCER I, V96, P1117, DOI 10.1093/jnci/djh244; Parseghian CM, 2019, CLIN CANCER RES, V25, P6899, DOI 10.1158/1078-0432.CCR-19-0823; Pizarro TT, 2000, AM J PHYSIOL-GASTR L, V278, pG665, DOI 10.1152/ajpgi.2000.278.5.G665; Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017; Ren JZ, 2019, J CANCER RES CLIN, V145, P1111, DOI 10.1007/s00432-019-02883-6; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Saqib Uzma, 2018, Oncotarget, V9, P17937, DOI 10.18632/oncotarget.24788; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schumacher D, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008076; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Troiani T, 2013, CLIN CANCER RES, V19, P6751, DOI 10.1158/1078-0432.CCR-13-0423; Warmuth M, 2003, CURR PHARM DESIGN, V9, P2043, DOI 10.2174/1381612033454126; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Yang YH, 2014, J CANCER RES CLIN, V140, P1927, DOI 10.1007/s00432-014-1741-0; Zhao S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139598	51	2	2	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3047	3059		10.1038/s41388-021-01752-2	http://dx.doi.org/10.1038/s41388-021-01752-2		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33767440	Green Accepted			2022-12-17	WOS:000632820300005
J	Blokzijl-Franke, S; Ponsioen, B; Schulte-Merker, S; Herbomel, P; Kissa, K; Choorapoikayil, S; den Hertog, J				Blokzijl-Franke, Sasja; Ponsioen, Bas; Schulte-Merker, Stefan; Herbomel, Philippe; Kissa, Karima; Choorapoikayil, Suma; den Hertog, Jeroen			Phosphatidylinositol-3 kinase signaling controls survival and stemness of hematopoietic stem and progenitor cells	ONCOGENE			English	Article								Hematopoietic stem and progenitor cells (HSPCs) are multipotent cells giving rise to all blood lineages during life. HSPCs emerge from the ventral wall of the dorsal aorta (VDA) during a specific timespan in embryonic development through endothelial hematopoietic transition (EHT). We investigated the ontogeny of HSPCs in mutant zebrafish embryos lacking functional pten, an important tumor suppressor with a central role in cell signaling. Through in vivo live imaging, we discovered that in pten mutant embryos a proportion of the HSPCs died upon emergence from the VDA, an effect rescued by inhibition of phosphatidylinositol-3 kinase (PI3K). Surprisingly, inhibition of PI3K in wild-type embryos also induced HSPC death. Surviving HSPCs colonized the caudal hematopoietic tissue (CHT) normally and committed to all blood lineages. Single-cell RNA sequencing indicated that inhibition of PI3K enhanced survival of multipotent progenitors, whereas the number of HSPCs with more stem-like properties was reduced. At the end of the definitive wave, loss of Pten caused a shift to more restricted progenitors at the expense of HSPCs. We conclude that PI3K signaling tightly controls HSPCs survival and both up- and downregulation of PI3K signaling reduces stemness of HSPCs.	[Blokzijl-Franke, Sasja; Ponsioen, Bas; Schulte-Merker, Stefan; Choorapoikayil, Suma; den Hertog, Jeroen] Hubrecht Inst KNAW, Utrecht, Netherlands; [Blokzijl-Franke, Sasja; Ponsioen, Bas; Schulte-Merker, Stefan; Choorapoikayil, Suma; den Hertog, Jeroen] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Ponsioen, Bas] Univ Utrecht, Univ Med Ctr Utrecht, Ctr Mol Med, Mol Canc Res, Utrecht, Netherlands; [Schulte-Merker, Stefan] WWU Munster, Inst Cardiovasc Organogenesis & Regenerat, Med Fac, Munster, Germany; [Herbomel, Philippe; Kissa, Karima] Inst Pasteur, Dept Dev & Stem Cell Biol, Paris, France; [Herbomel, Philippe; Kissa, Karima] CNRS, UMR 3738, Paris, France; [Kissa, Karima; Choorapoikayil, Suma] Univ Montpellier, CNRS, Lab Pathogen Host Interact, INSERM, Montpellier, France; [den Hertog, Jeroen] Leiden Univ, Inst Biol, Leiden, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Munster; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Leiden University; Leiden University - Excl LUMC	den Hertog, J (corresponding author), Hubrecht Inst KNAW, Utrecht, Netherlands.; den Hertog, J (corresponding author), Univ Med Ctr Utrecht, Utrecht, Netherlands.; den Hertog, J (corresponding author), Leiden Univ, Inst Biol, Leiden, Netherlands.	j.denhertog@hubrecht.eu	Kissa, Karima/N-6801-2018	Kissa, Karima/0000-0002-7683-3661	EU (FP7) grant, ZF-CANCER [HEALTH-F2-2008-201439]	EU (FP7) grant, ZF-CANCER	The authors would like to thank Mark Reijnen and animal caretakers for excellent management of the fish facility. Microscopy was done in the Hubrecht Imaging Centre. The authors would like to thank Stefan van der Elst and Reinier van der Linden for FACS-sorting. The authors would like to thank Jeroen Paardekooper Overman for statistical analysis, Laila Ritsma, Sylvain de Rossi, and Miriam Stumpf for technical support and Bas Castelijns for help with scRNA data analysis. This work was supported in part by an EU (FP7) grant, ZF-CANCER (HEALTH-F2-2008-201439).	Alestrom P, 2020, LAB ANIM-UK, V54, P213, DOI 10.1177/0023677219869037; Athanasiadis EI, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02305-6; Baron CS, 2019, CELL, V179, P527, DOI 10.1016/j.cell.2019.08.006; Baron CS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04893-3; Beis D, 2005, DEVELOPMENT, V132, P4193, DOI 10.1242/dev.01970; Bertrand JY, 2010, NATURE, V464, P108, DOI 10.1038/nature08738; Bertrand JY, 2005, P NATL ACAD SCI USA, V102, P134, DOI 10.1073/pnas.0402270102; Blackburn JS, 2014, CANCER CELL, V25, P366, DOI 10.1016/j.ccr.2014.01.032; Boisset JC, 2010, NATURE, V464, P116, DOI 10.1038/nature08764; Bolli N, 2011, BLOOD, V117, P3996, DOI 10.1182/blood-2010-08-304030; Buenrostro JD, 2018, CELL, V173, P1535, DOI 10.1016/j.cell.2018.03.074; Challen GA, 2009, CYTOM PART A, V75A, P14, DOI 10.1002/cyto.a.20674; Chen MJ, 2009, NATURE, V457, P887, DOI 10.1038/nature07619; Choorapoikayil S, 2014, BLOOD, V123, P184, DOI 10.1182/blood-2013-05-501544; Choorapoikayil S, 2013, DIS MODEL MECH, V6, P1159, DOI 10.1242/dmm.012377; Choorapoikayil S, 2012, DIS MODEL MECH, V5, P241, DOI 10.1242/dmm.008326; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Davidson AJ, 2004, ONCOGENE, V23, P7233, DOI 10.1038/sj.onc.1207943; Dixon Giles, 2012, ISRN Hematol, V2012, P915868, DOI 10.5402/2012/915868; Faucherre A, 2008, ONCOGENE, V27, P1079, DOI 10.1038/sj.onc.1210730; Gering M, 2005, DEV CELL, V8, P389, DOI 10.1016/j.devcel.2005.01.010; Godin I, 2002, NAT REV IMMUNOL, V2, P593, DOI 10.1038/nri857; Grun D, 2014, NAT METHODS, V11, P637, DOI [10.1038/NMETH.2930, 10.1038/nmeth.2930]; Gurskaya NG, 2006, NAT BIOTECHNOL, V24, P461, DOI 10.1038/nbt1191; Hashimshony T, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0938-8; Herman JS, 2018, NAT METHODS, V15, P379, DOI 10.1038/nmeth.4662; Hogan BM, 2009, NAT GENET, V41, P396, DOI 10.1038/ng.321; Kartalaei PS, 2015, J EXP MED, V212, P93, DOI 10.1084/jem.20140767; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kissa K, 2008, BLOOD, V111, P1147, DOI 10.1182/blood-2007-07-099499; Kissa K, 2010, NATURE, V464, P112, DOI 10.1038/nature08761; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kowalczyk MS, 2015, GENOME RES, V25, P1860, DOI 10.1101/gr.192237.115; Lai SJ, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0038-x; Lin HF, 2005, BLOOD, V106, P3803, DOI 10.1182/blood-2005-01-0179; Lin HT, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2011.0334; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Muraro MJ, 2016, CELL SYST, V3, P385, DOI 10.1016/j.cels.2016.09.002; Murayama E, 2006, IMMUNITY, V25, P963, DOI 10.1016/j.immuni.2006.10.015; Nestorowa S, 2016, BLOOD, V128, pE20, DOI 10.1182/blood-2016-05-716480; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Renaud O, 2011, NAT PROTOC, V6, P1897, DOI 10.1038/nprot.2011.408; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Signer RAJ, 2014, NATURE, V509, P49, DOI 10.1038/nature13035; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stachura DL, 2011, METHOD CELL BIOL, V101, P75, DOI 10.1016/B978-0-12-387036-0.00004-9; Stumpf M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154771; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Svoboda O, 2014, BLOOD, V124, P220, DOI 10.1182/blood-2014-03-564682; Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514; Tian Y, 2017, J EXP MED, V214, P3347, DOI 10.1084/jem.20170488; Urasaki A, 2006, GENETICS, V174, P639, DOI 10.1534/genetics.106.060244; van den Brink SC, 2017, NAT METHODS, V14, P935, DOI 10.1038/nmeth.4437; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE; Xue YY, 2019, CELL REP, V27, P1567, DOI 10.1016/j.celrep.2019.04.030; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zovein AC, 2008, CELL STEM CELL, V3, P625, DOI 10.1016/j.stem.2008.09.018	61	2	2	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2741	2755		10.1038/s41388-021-01733-5	http://dx.doi.org/10.1038/s41388-021-01733-5		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33714985	hybrid, Green Submitted, Green Published			2022-12-17	WOS:000628485300003
J	Leon, LM; Gautier, M; Allan, R; Ilie, M; Nottet, N; Pons, N; Paquet, A; Lebrigand, K; Truchi, M; Fassy, J; Magnone, V; Kinnebrew, G; Radovich, M; Cheok, MHC; Barbry, P; Vassaux, G; Marquette, CH; Ponzio, G; Ivan, M; Pottier, N; Hofman, P; Mari, B; Rezzonico, R				Leon, Laura Moreno; Gautier, Marine; Allan, Richard; Ilie, Marius; Nottet, Nicolas; Pons, Nicolas; Paquet, Agnes; Lebrigand, Kevin; Truchi, Marin; Fassy, Julien; Magnone, Virginie; Kinnebrew, Garrett; Radovich, Milan; Cheok, Meyling Hua-Chen; Barbry, Pascal; Vassaux, Georges; Marquette, Charles-Hugo; Ponzio, Gilles; Ivan, Mircea; Pottier, Nicolas; Hofman, Paul; Mari, Bernard; Rezzonico, Roger			The nuclear hypoxia-regulated NLUCAT1 long noncoding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress (vol 38, pg 7146, 2019)	ONCOGENE			English	Correction												mari@unice.fr; rezzonico@ipmc.cnrs.fr	REZZONICO, Roger/N-9626-2016; Moreno Leon, Laura/AGP-7137-2022; Mari, Bernard P/GVS-3100-2022; Vassaux, Georges/N-9724-2016; Mari, Bernard/Q-5832-2019; Cheok, Meyling/AFS-4025-2022; Cheok, Meyling h/C-3822-2014; Barbry, Pascal/O-5021-2016	REZZONICO, Roger/0000-0002-8460-1641; Moreno Leon, Laura/0000-0002-5560-1765; Mari, Bernard P/0000-0002-0422-9182; Vassaux, Georges/0000-0002-1149-7716; Mari, Bernard/0000-0002-0422-9182; Cheok, Meyling/0000-0002-7820-8026; Cheok, Meyling h/0000-0002-7820-8026; Barbry, Pascal/0000-0001-9632-6483				Leon LM, 2019, ONCOGENE, V38, P7146, DOI 10.1038/s41388-019-0935-y	1	2	2	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2621	2621		10.1038/s41388-021-01670-3	http://dx.doi.org/10.1038/s41388-021-01670-3		MAR 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33686243	Bronze			2022-12-17	WOS:000626396000004
J	Ahmed, SF; Buetow, L; Gabrielsen, M; Lilla, S; Sibbet, GJ; Sumpton, D; Zanivan, S; Hedley, A; Clark, W; Huang, DT				Ahmed, Syed Feroj; Buetow, Lori; Gabrielsen, Mads; Lilla, Sergio; Sibbet, Gary J.; Sumpton, David; Zanivan, Sara; Hedley, Ann; Clark, William; Huang, Danny T.			E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis	ONCOGENE			English	Article							GAIN-OF-FUNCTION; C-CBL; DOWN-REGULATION; TYROSINE PHOSPHORYLATION; NEGATIVE REGULATION; MYELOID-LEUKEMIA; STRUCTURAL BASIS; ADAPTER PROTEIN; EGF RECEPTOR; CIN85	Casitas B-lineage lymphoma (CBL) is a ubiquitin ligase (E3) that becomes activated upon Tyr371-phosphorylation and targets receptor protein tyrosine kinases for ubiquitin-mediated degradation. Deregulation of CBL and its E3 activity is observed in myeloproliferative neoplasms and other cancers, including breast, colon, and prostate cancer. Here, we explore the oncogenic mechanism of E3-inactive CBL mutants identified in myeloproliferative neoplasms. We show that these mutants bind strongly to CIN85 under normal growth conditions and alter the CBL interactome. Lack of E3 activity deregulates CIN85 endosomal trafficking, leading to an altered transcriptome that amplifies signaling events to promote oncogenesis. Disruption of CBL mutant interactions with EGFR or CIN85 reduces oncogenic transformation. Given the importance of the CBL-CIN85 interaction in breast cancers, we examined the expression levels of CIN85, CBL, and the status of Tyr371-phosphorylated CBL (pCBL) in human breast cancer tissue microarrays. Interestingly, pCBL shows an inverse correlation with both CIN85 and CBL, suggesting that high expression of inactivated CBL could coordinate with CIN85 for breast cancer progression. Inhibition of the CBL-CIN85 interaction with a proline-rich peptide of CBL that binds CIN85 reduced the proliferation of MDA-MB-231 cells. Together, these results provide a rationale for exploring the potential of targeting the EGFR-CBL-CIN85 axis in CBL-inactivated mutant cancers.	[Ahmed, Syed Feroj; Buetow, Lori; Gabrielsen, Mads; Lilla, Sergio; Sibbet, Gary J.; Sumpton, David; Zanivan, Sara; Hedley, Ann; Clark, William; Huang, Danny T.] Canc Res UK Beatson Inst, Glasgow, Lanark, Scotland; [Zanivan, Sara; Huang, Danny T.] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland	Beatson Institute; University of Glasgow	Huang, DT (corresponding author), Canc Res UK Beatson Inst, Glasgow, Lanark, Scotland.; Huang, DT (corresponding author), Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland.	d.huang@beatson.gla.ac.uk	Zanivan, Sara/GOV-5505-2022; Huang, Danny/AAM-3631-2021	Huang, Danny/0000-0002-6192-259X; Ahmed, Syed Feroj/0000-0003-1033-2538; Gabrielsen, Mads/0000-0002-9848-2276; Sumpton, David/0000-0002-9004-4079	Beatson Institute's Cancer Research UK core funding [A17196]; Cancer Research UK [A23278/A29256, C596/A12935]; European Research Council (ERC) under the European Union [647849]	Beatson Institute's Cancer Research UK core funding; Cancer Research UK(Cancer Research UK); European Research Council (ERC) under the European Union(European Research Council (ERC))	This work was supported by the Beatson Institute's Cancer Research UK core funding (A17196), Cancer Research UK (A23278/A29256) to DTH and (C596/A12935) to SZ, and European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement no. 647849) to DTH. We thank Catherine Winchester for her assistance in critically reviewing this manuscript and Core Services and Advanced Technologies at the Cancer Research UK Beatson Institute (C596/A17196), with particular thanks to Proteomics, Histology, and Molecular Technologies services.	Ahmad G, 2014, INT J BIOCHEM CELL B, V57, P123, DOI 10.1016/j.biocel.2014.10.019; Ahmed SF, 2015, MOL THER, V23, P255, DOI 10.1038/mt.2014.202; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Bandi SR, 2009, BLOOD, V114, P4197, DOI 10.1182/blood-2008-12-190934; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; Buetow L, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0298-6; Caligiuri MA, 2007, BLOOD, V110, P1022, DOI 10.1182/blood-2006-12-061176; Cascio S, 2015, CANCERS, V7, P342, DOI 10.3390/cancers7010342; Cascio S, 2013, ONCOTARGET, V4, P1700, DOI 10.18632/oncotarget.1265; Clara JA, 2016, CANCER BIOL MED, V13, P360, DOI 10.20892/j.issn.2095-3941.2016.0043; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dou H, 2013, NAT STRUCT MOL BIOL, V20, P982, DOI 10.1038/nsmb.2621; Dou H, 2012, NAT STRUCT MOL BIOL, V19, P184, DOI 10.1038/nsmb.2231; Dufour C, 2008, BONE, V42, P1032, DOI 10.1016/j.bone.2008.02.009; Fernandes MS, 2010, J BIOL CHEM, V285, P32596, DOI 10.1074/jbc.M110.106161; Grand FH, 2009, BLOOD, V113, P6182, DOI 10.1182/blood-2008-12-194548; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Jozic D, 2005, NAT STRUCT MOL BIOL, V12, P972, DOI 10.1038/nsmb1000; Kales SC, 2010, CANCER RES, V70, P4789, DOI 10.1158/0008-5472.CAN-10-0610; Kang JM, 2012, ONCOGENE, V31, P5123, DOI 10.1038/onc.2012.18; Kassenbrock CK, 2004, J BIOL CHEM, V279, P28017, DOI 10.1074/jbc.M404114200; Knight JF, 2008, BRIT J CANCER, V99, P1849, DOI 10.1038/sj.bjc.6604774; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Miura-Shimura Y, 2003, J BIOL CHEM, V278, P38495, DOI 10.1074/jbc.M305656200; Nadeau S, 2012, BIOCH ANAL BIOCH, P7921, DOI DOI 10.4172/2161-1009.S6-001; Nadeau SA, 2017, J BIOL CHEM, V292, P3666, DOI 10.1074/jbc.M116.772723; Nakata Y, 2017, BLOOD, V129, P2148, DOI 10.1182/blood-2016-06-724658; Nam JM, 2007, EMBO J, V26, P647, DOI 10.1038/sj.emboj.7601534; Ng C, 2008, EMBO J, V27, P804, DOI 10.1038/emboj.2008.18; Niemeyer CM, 2010, NAT GENET, V42, P794, DOI 10.1038/ng.641; Nihal M, 2016, ONCOTARGET, V7, P53869, DOI 10.18632/oncotarget.10861; Paul Manash K, 2004, Int J Med Sci, V1, P101; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Rathinam C, 2010, CANCER CELL, V18, P341, DOI 10.1016/j.ccr.2010.09.008; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ronning SB, 2011, EXP CELL RES, V317, P1804, DOI 10.1016/j.yexcr.2011.05.016; Samoylenko A, 2012, CARCINOGENESIS, V33, P1976, DOI 10.1093/carcin/bgs228; Sanada M, 2009, NATURE, V460, P904, DOI 10.1038/nature08240; Sargin B, 2007, BLOOD, V110, P1004, DOI 10.1182/blood-2007-01-066076; Schroeder B, 2012, MOL BIOL CELL, V23, P3602, DOI 10.1091/mbc.E11-08-0666; Schroeder B, 2010, EMBO J, V29, P3039, DOI 10.1038/emboj.2010.190; Smit GDV, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000217; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	54	2	2	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2149	2164		10.1038/s41388-021-01684-x	http://dx.doi.org/10.1038/s41388-021-01684-x		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33627783	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000621289100005
J	Solan, JL; Hingorani, SR; Lampe, PD				Solan, Joell L.; Hingorani, Sunil R.; Lampe, Paul D.			Cx43 phosphorylation sites regulate pancreatic cancer metastasis	ONCOGENE			English	Article								Pancreatic ductal adenocarcinoma (PDA) is aggressive, highly metastatic and characterized by a robust desmoplasia. Connexin proteins that form gap junctions have been implicated in tumor suppression for over 30 years. Cx43, the most widely expressed connexin, regulates cell behaviors, including migration and proliferation. Thus, we hypothesized that Cx43 could regulate PDA progression. Phosphorylation of Cx43 by Casein Kinase 1 (CK1) regulates gap junction assembly. We interbred the well-established Kras(LSL-G12D/+;p48Cre/+) (KC) mouse model of PDA with homozygous "knock-in" mutant Cx43 mice bearing amino acid substitution at CK1 sites (Cx43(CK1A)) and found profound and surprising effects on cancer progression. Crossing the Cx43(CK1A) mouse onto the KC background (termed KC;Cx(CK1A)) led to significant extension of lifespan, from a median of 370 to 486 days (p = 0.03) and a decreased incidence of metastasis (p = 0.045). However, when we examined early stages of disease, we found more rapid onset of tissue remodeling in the KC;Cx(CK1A) mouse followed by divergence to a cystic phenotype. During tumorigenesis, gap junctions are increasingly present in stromal cells of the KC mice but are absent from the KC;Cx43(CK1A) mice. Tail vein metastasis assays with cells derived from KC or KC;Cx(CK1A) tumors showed that KC;Cx(CK1A) cells could efficiently colonize the lung and downregulate Cx43 expression, arguing that inhibition of metastasis was not occurring at the distal site. Instead, stromal gap junctions, their associated signaling events or other unknown Cx43-dependent events facilitate metastatic capacity in the primary tumor.	[Solan, Joell L.; Hingorani, Sunil R.; Lampe, Paul D.] Publ Hlth Sci Div, Translat Res Program, Seattle, WA 98109 USA; [Solan, Joell L.; Lampe, Paul D.] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA; [Hingorani, Sunil R.] Fred Hutchinson Canc Res Ctr, Clin Div, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Lampe, PD (corresponding author), Publ Hlth Sci Div, Translat Res Program, Seattle, WA 98109 USA.; Lampe, PD (corresponding author), Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA.	plampe@fredhutch.org		Lampe, Paul/0000-0002-1399-2761; Hingorani, Sunil/0000-0002-3869-8729	National Institutes of Health [R21CA149554, GM55632]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	H & E pathology analysis was performed by Sue Knoblaugh, DVM, Diplomate ACVP. Yutaka Yasui, PhD performed power calculations and aided in the experimental design of the mouse experiments. This work was supported by grants R21CA149554 and GM55632 from the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Aasen T, 2016, NAT REV CANCER, V16, P775, DOI 10.1038/nrc.2016.105; Angst E, 2006, BRIT J CANCER, V95, P307, DOI 10.1038/sj.bjc.6603256; Barrett R, 2020, CURR OPIN IMMUNOL, V64, P80, DOI 10.1016/j.coi.2020.03.004; Best SA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12164-y; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Cen G, 2017, ONCOL REP, V37, P1189, DOI 10.3892/or.2017.5355; Chen XM, 2019, NAT REV DRUG DISCOV, V18, P99, DOI 10.1038/s41573-018-0004-1; Chu GC, 2007, J CELL BIOCHEM, V101, P887, DOI 10.1002/jcb.21209; Cigliola V, 2015, PANCREAS, V44, P1234, DOI 10.1097/MPA.0000000000000378; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; Daley D, 2017, J EXP MED, V214, P1711, DOI 10.1084/jem.20161707; Dvorak HF, 2015, CANCER IMMUNOL RES, V3, P1, DOI 10.1158/2326-6066.CIR-14-0209; Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215; Garcia-Rodriguez L, 2011, MOL CANCER THER, V10, P505, DOI 10.1158/1535-7163.MCT-10-0693; Gomez D, 2012, CARDIOVASC RES, V95, P156, DOI 10.1093/cvr/cvs115; Grek CL, 2015, WOUND REPAIR REGEN, V23, P203, DOI 10.1111/wrr.12275; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Helms E, 2020, CANCER DISCOV, V10, P648, DOI 10.1158/2159-8290.CD-19-1353; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Huang Guo-Ying, 2011, J Cardiovasc Dis Res, V2, P206, DOI 10.4103/0975-3583.89804; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; King TJ, 2005, BBA-BIOMEMBRANES, V1719, P24, DOI 10.1016/j.bbamem.2005.07.010; King TJ, 2004, CARCINOGENESIS, V25, P669, DOI 10.1093/carcin/bgh071; King TJ, 2005, ONCOGENE, V24, P1718, DOI 10.1038/sj.onc.1208355; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Kyo N, 2008, ONCOL REP, V19, P627; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; Lampe PD, 2006, J CELL SCI, V119, P3435, DOI 10.1242/jcs.03089; Lastwika KJ, 2019, J CELL SCI, V132, DOI 10.1242/jcs.234633; Lo A, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92232; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; Maitra A, 2005, ADV ANAT PATHOL, V12, P81, DOI 10.1097/01.pap.0000155055.14238.25; Mann KM, 2016, PHARMACOL THERAPEUT, V168, P29, DOI 10.1016/j.pharmthera.2016.09.003; Masamune A, 2013, PANCREAS, V42, P308, DOI 10.1097/MPA.0b013e31825c51d6; Mazur PK, 2010, P NATL ACAD SCI USA, V107, P13438, DOI 10.1073/pnas.1002423107; Mugisho OO, 2018, BBA-GEN SUBJECTS, V1862, P385, DOI 10.1016/j.bbagen.2017.11.015; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Remo BF, 2011, CIRC RES, V108, P1459, DOI 10.1161/CIRCRESAHA.111.244046; Richards TS, 2004, J CELL BIOL, V167, P555, DOI 10.1083/jcb.200404142; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Salameh A, 2013, BBA-BIOMEMBRANES, V1828, P147, DOI 10.1016/j.bbamem.2011.12.030; Schofield HK, 2018, CELL MOL GASTROENTER, V5, P169, DOI 10.1016/j.jcmgh.2017.10.008; Sin WC, 2016, ONCOGENE, V35, P1504, DOI 10.1038/onc.2015.210; Solan JL, 2019, J BIOL CHEM, V294, P11762, DOI 10.1074/jbc.RA119.009162; Solan JL, 2016, SEMIN CELL DEV BIOL, V50, P40, DOI 10.1016/j.semcdb.2015.12.010; Solan JL, 2014, FEBS LETT, V588, P1423, DOI 10.1016/j.febslet.2014.01.049; Solan JL, 2012, J MEMBRANE BIOL, V245, P255, DOI 10.1007/s00232-012-9446-2; Solan JL, 2009, BIOCHEM J, V419, P261, DOI 10.1042/BJ20082319; Song MB, 2009, EXP BIOL MED, V234, P1192, DOI 10.3181/0902-RM-80; TROSKO JE, 1990, PATHOBIOLOGY, V58, P265, DOI 10.1159/000163596; Vickman Renee E, 2020, Oncotarget, V11, P3621, DOI 10.18632/oncotarget.27736; Whittle MC, 2019, GASTROENTEROLOGY, V156, P2085, DOI 10.1053/j.gastro.2018.12.044; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yang WD, 2019, ISCIENCE, V19, P450, DOI 10.1016/j.isci.2019.07.033; Yen TNF, 2002, SURGERY, V131, P129, DOI 10.1067/msy.2002.119192; Zhang XH, 2015, LEUKEMIA LYMPHOMA, V56, P211, DOI 10.3109/10428194.2014.913289; Zhang ZQ, 2016, CELL PHYSIOL BIOCHEM, V39, P423, DOI 10.1159/000445636	59	2	3	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1909	1920		10.1038/s41388-021-01668-x	http://dx.doi.org/10.1038/s41388-021-01668-x		FEB 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33603164	Green Accepted			2022-12-17	WOS:000619433100006
J	Westendorp, F; Karpus, ON; Koelink, PJ; Vermeulen, JLM; Meisner, S; Koster, J; Buller, NVJA; Wildenberg, ME; Muncan, V; van den Brink, GR				Westendorp, Florien; Karpus, Olga N.; Koelink, Pim J.; Vermeulen, Jacqueline L. M.; Meisner, Sander; Koster, Jan; Buller, Nike V. J. A.; Wildenberg, Manon E.; Muncan, Vanesa; van den Brink, Gijs R.			Epithelium-derived Indian Hedgehog restricts stromal expression of ErbB family members that drive colonic tumor cell proliferation	ONCOGENE			English	Article							INTESTINAL EPITHELIUM; HOMEOSTASIS; GROWTH; ACTIVATION; RECEPTORS; POLYPOSIS; ADENOMA; GENE	Indian Hedgehog (Ihh) is a morphogen expressed by epithelial cells in the small intestine and colon that signals in a paracrine manner to gp38+ stromal cells. The loss of Ihh signaling results in increased epithelial proliferation, lengthening and multiplication of intestinal crypts and the activation of a stromal cell immune response. How Ihh controls epithelial proliferation through the stroma and how it affects colorectal cancer development remains poorly defined. To study the influence of Ihh signaling on the earliest stage of colorectal carcinogenesis, we used a well characterized mouse model in which both alleles of the Adenoma Polyposis Coli (Apc) gene could be inducibly deleted, leading to instant transformation of the colonic epithelium to an adenomatous phenotype. Concurrent deletion of Ihh from the adenomatous colonic epithelium of Apc inducible double mutant mice resulted in a remarkable increase in the hyperproliferative epithelial phenotype and increased accumulation of Lgr5+ stem cells. Transcriptional profiling of sorted colonic gp38+ fibroblasts showed upregulation of three ErbB pathway ligands (EREG, BTC, and NRG1) in Apc(-/-)Ihh(-/-) double mutant mice. We found that recombinant EREG, BTC, and NRG1 but not Lgr5 ligand R-Spondin promoted growth and proliferation of Apc double mutant colonic organoids. Thus, the loss of Ihh enhances Apc-driven colonic adenomagenesis via upregulation of ErbB pathway family members in colonic stromal cells. Our findings highlight the critical role of epithelium-derived Indian Hedgehog as a stromal tumor suppressor in the intestine.	[Westendorp, Florien; Karpus, Olga N.; Koelink, Pim J.; Vermeulen, Jacqueline L. M.; Meisner, Sander; Buller, Nike V. J. A.; Wildenberg, Manon E.; Muncan, Vanesa; van den Brink, Gijs R.] Univ Amsterdam, Tytgat Inst Liver & Intestinal Res, Amsterdam Gastroenterol & Metab, Amsterdam UMC, Amsterdam, Netherlands; [Westendorp, Florien; Karpus, Olga N.; Koelink, Pim J.; Vermeulen, Jacqueline L. M.; Meisner, Sander; Buller, Nike V. J. A.; Wildenberg, Manon E.; Muncan, Vanesa; van den Brink, Gijs R.] Univ Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam Gastroenterol & Metab, Amsterdam UMC, Amsterdam, Netherlands; [Koster, Jan] Univ Amsterdam, Dept Oncogen, Amsterdam UMC, Amsterdam, Netherlands; [van den Brink, Gijs R.] F Hoffmann La Roche & Cie AG, Roche Innovat Ctr Basel, Basel, Switzerland	University of Amsterdam; University of Amsterdam; University of Amsterdam; Roche Holding	Westendorp, F (corresponding author), Univ Amsterdam, Tytgat Inst Liver & Intestinal Res, Amsterdam Gastroenterol & Metab, Amsterdam UMC, Amsterdam, Netherlands.; Westendorp, F (corresponding author), Univ Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam Gastroenterol & Metab, Amsterdam UMC, Amsterdam, Netherlands.	b.f.westendorp@amsterdamumc.nl		Wildenberg, Manon Elisabeth/0000-0003-0671-818X; Koster, Jan/0000-0002-0890-7585	Netherlands Organization for Scientific Research (NWO) [016140605]	Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	We thank our colleagues Berend Hooibrink and Toni van Capel from the Department of Experimental Immunology at the Amsterdam UMC, location AMC, for support with cell sorting, and the AMC Animal Research Facility (ARIA) for help with mouse experiments. We thank S.M. van Neerven and prof. dr. L. Vermeulen for providing Lgr5-EGFR-IRES-cre<SUP>ERT2</SUP>-Apc<SUP>fl/fl</SUP> colon organoids. This work was financially supported by a VICI grant (016140605) from the Netherlands Organization for Scientific Research (NWO) to GRB.	Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Berlin J, 2013, CLIN CANCER RES, V19, P258, DOI 10.1158/1078-0432.CCR-12-1800; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Buller NVJA, 2015, GASTROENTEROLOGY, V148, P170, DOI 10.1053/j.gastro.2014.10.006; Buller NVJA, 2012, PHYSIOLOGY, V27, P148, DOI 10.1152/physiol.00003.2012; Cai XY, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S71034; Dunker N, 2002, GASTROENTEROLOGY, V122, P1364, DOI 10.1053/gast.2002.32991; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frampton JE, 2018, DRUGS, V78, P1145, DOI 10.1007/s40265-018-0948-9; Gerling M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12321; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Hanna A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0509-3; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; International Agency for Research on Cancer, GLOBAL CANC OBSERVAT; Jackstadt R, 2016, J PATHOL, V238, P141, DOI 10.1002/path.4645; Karpus ON, 2019, CELL REP, V26, P3698, DOI 10.1016/j.celrep.2019.02.101; Kolterud A, 2009, GASTROENTEROLOGY, V137, P618, DOI 10.1053/j.gastro.2009.05.002; Mazumdar T, 2011, CANCER RES, V71, P1092, DOI 10.1158/0008-5472.CAN-10-2315; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; NAKAMURA Y, 1992, TOHOKU J EXP MED, V168, P141, DOI 10.1620/tjem.168.141; Preston SL, 2003, CANCER RES, V63, P3819; Razzaque MS, 2005, J PATHOL, V207, P453, DOI 10.1002/path.1870; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Shi T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013054; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559; van den Brink GR, 2007, PHYSIOL REV, V87, P1343, DOI 10.1152/physrev.00054.2006; van den Brink GR, 2007, CANCER CELL, V11, P109, DOI 10.1016/j.ccr.2007.01.003; van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304; van Dop WA, 2010, GASTROENTEROLOGY, V139, P1665, DOI 10.1053/j.gastro.2010.07.045; van Dop WA, 2009, GASTROENTEROLOGY, V136, P2195, DOI 10.1053/j.gastro.2009.02.068; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Warren CM, 2006, CELL SIGNAL, V18, P923, DOI 10.1016/j.cellsig.2005.12.007; Westendorp BF, 2018, CELL MOL GASTROENTER, V5, P67, DOI 10.1016/j.jcmgh.2017.08.004; Xie H, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050394; Xie PX, 2018, J AM ACAD DERMATOL, V79, P1089, DOI 10.1016/j.jaad.2018.07.004; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; You SH, 2010, UPSALA J MED SCI, V115, P169, DOI 10.3109/03009731003668316; Zacharias WJ, 2011, DEV BIOL, V355, P152, DOI 10.1016/j.ydbio.2011.04.025	47	2	2	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1628	1643		10.1038/s41388-020-01633-0	http://dx.doi.org/10.1038/s41388-020-01633-0		JAN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33479497				2022-12-17	WOS:000609352300003
J	Goss, KL; Koppenhafer, SL; Waters, T; Terry, WW; Wen, KK; Wu, M; Ostergaard, J; Gordon, PM; Gordon, DJ				Goss, Kelli L.; Koppenhafer, Stacia L.; Waters, Torin; Terry, William W.; Wen, Kuo-Kuang; Wu, Meng; Ostergaard, Jason; Gordon, Peter M.; Gordon, David J.			The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors	ONCOGENE			English	Article							TARGETED PROTEIN-DEGRADATION; RIBONUCLEOTIDE REDUCTASE R2; REPLICATION STRESS; KINASE INHIBITOR; PHASE-I; CANCER; WEE1; HOMOHARRINGTONINE; GEMCITABINE; ACTIVATION	Ribonucleotide reductase (RNR), which is a heterodimeric tetramer composed of RRM1 and RRM2 subunits, is the rate-limiting enzyme in the synthesis of deoxyribonucleoside triphosphates (dNTPs) and essential for both DNA replication and the repair of DNA damage. The activity of RNR is coordinated with the cell cycle and regulated by fluctuations in the level of the RRM2 subunit. Multiple cancer types, including Ewing sarcoma tumors, are sensitive to inhibitors of RNR or a reduction in the levels of either the RRM1 or RRM2 subunits of RNR. Here, we show that the expression of the RRM2 protein is dependent on active protein synthesis and that 4E-BP1, a repressor of cap-dependent protein translation, specifically regulates the level of the RRM2 protein. Furthermore, inhibition of mTORC1/2, but not mTORC1, activates 4E-BP1, inhibits protein synthesis, and reduces the level of the RRM2 protein in multiple sarcoma cell lines. This effect of mTORC1/2 inhibitors on protein synthesis and RRM2 levels was rescued in cell lines with the CRISPR/Cas9-mediated knockout of 4E-BP1. In addition, the inducible expression of a mutant 4E-BP1 protein that cannot be phosphorylated by mTOR blocked protein synthesis and inhibited the growth of Ewing sarcoma cells in vitro and in vivo in a xenograft. Overall, these results provide insight into the multifaceted regulation of RRM2 protein levels and identify a regulatory link between protein translation and DNA replication.	[Goss, Kelli L.; Koppenhafer, Stacia L.; Waters, Torin; Terry, William W.; Gordon, David J.] Univ Iowa, Dept Pediat, Div Pediat Hematol Oncol, Iowa City, IA 52242 USA; [Wen, Kuo-Kuang; Wu, Meng] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; [Ostergaard, Jason; Gordon, Peter M.] Univ Minnesota, Dept Pediat, Div Pediat Hematol Oncol, Minneapolis, MN 55455 USA	University of Iowa; University of Iowa; University of Minnesota System; University of Minnesota Twin Cities	Gordon, DJ (corresponding author), Univ Iowa, Dept Pediat, Div Pediat Hematol Oncol, Iowa City, IA 52242 USA.	david-j-gordon@uiowa.edu		Gordon, David/0000-0003-1830-4371; Wu, Meng/0000-0003-2222-0736	University of Iowa Dance Marathon Award; Holden Comprehensive Cancer Center Sarcoma Multidisciplinary Oncology Group Seed Grant; University of Iowa Oberley Seed Grant; St. Baldrick's Research Foundation; Aiming for a Cure Foundation; Matt Morrell and Natalie Sanchez Pediatric Cancer Research Foundation; NIH [R37-CA217910]; University of Iowa [NIH/NCI P30CA086862]; RPPA Core Facility at MD Anderson Cancer Center (NCI) [CA16672]	University of Iowa Dance Marathon Award; Holden Comprehensive Cancer Center Sarcoma Multidisciplinary Oncology Group Seed Grant; University of Iowa Oberley Seed Grant; St. Baldrick's Research Foundation; Aiming for a Cure Foundation; Matt Morrell and Natalie Sanchez Pediatric Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Iowa; RPPA Core Facility at MD Anderson Cancer Center (NCI)	DJG is supported by a University of Iowa Dance Marathon Award, a Holden Comprehensive Cancer Center Sarcoma Multidisciplinary Oncology Group Seed Grant, a University of Iowa Oberley Seed Grant, St. Baldrick's Research Foundation, Aiming for a Cure Foundation, The Matt Morrell and Natalie Sanchez Pediatric Cancer Research Foundation, and NIH Grant R37-CA217910. We would also like to acknowledge the use of the University of Iowa Flow Cytometry and High Throughput Screening Core Facilities (NIH/NCI P30CA086862), as well as the RPPA Core Facility at MD Anderson Cancer Center (NCI #CA16672).	Aye Y, 2015, ONCOGENE, V34, P2011, DOI 10.1038/onc.2014.155; Ayuso MI, 2010, J BIOL CHEM, V285, P34355, DOI 10.1074/jbc.M110.135103; Burslem GM, 2018, CELL CHEM BIOL, V25, P67, DOI 10.1016/j.chembiol.2017.09.009; Cerqueira NMFSA, 2005, CURR MED CHEM, V12, P1283, DOI 10.2174/0929867054020981; Cerqueira NMFSA, 2007, RECENT PAT ANTI-CANC, V2, P11; Chabes AL, 2004, J BIOL CHEM, V279, P10796, DOI 10.1074/jbc.M312482200; Chang LS, 2020, MOL CANCER THER, V19, P731, DOI 10.1158/1535-7163.MCT-19-0809; Chen R, 2011, BLOOD, V117, P156, DOI 10.1182/blood-2010-01-262808; Choi SH, 2019, GENE DEV, V33, P418, DOI 10.1101/gad.322339.118; Clark NA, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3689-3; De Gassart A, 2016, EMBO REP, V17, P1471, DOI 10.15252/embr.201642194; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Do K, 2015, J CLIN ONCOL, V33, P3409, DOI 10.1200/JCO.2014.60.4009; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Goss KL, 2017, ONCOTARGET, V8, P87016, DOI 10.18632/oncotarget.18776; Goss KL, 2016, ONCOTARGET, V7, P63003, DOI 10.18632/oncotarget.11416; Gurel G, 2009, J MOL BIOL, V389, P146, DOI 10.1016/j.jmb.2009.04.005; Guo XE, 2014, CURR DRUG TARGETS, V15, P2, DOI 10.2174/1389450114666140106095151; Hafner M, 2016, NAT METHODS, V13, P521, DOI [10.1038/NMETH.3853, 10.1038/nmeth.3853]; Hai J, 2017, CLIN CANCER RES, V23, P6993, DOI 10.1158/1078-0432.CCR-17-1098; He ZF, 2017, ONCOTARGET, V8, P41422, DOI 10.18632/oncotarget.17440; Hill SJ, 2018, CANCER DISCOV, V8, P1404, DOI 10.1158/2159-8290.CD-18-0474; Hinnebusch AG, 2016, SCIENCE, V352, P1413, DOI 10.1126/science.aad9868; Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162; Iyer DR, 2017, GENES-BASEL, V8, DOI 10.3390/genes8020074; Jones SE, 2017, CANCER RES, V77, P7014, DOI 10.1158/0008-5472.CAN-17-2056; Ki DH, 2019, ONCOGENE, V38, P6585, DOI 10.1038/s41388-019-0965-5; Kim JR, 2018, INT J MOL SCI, V19, pE674, DOI [10.3390/ijms19030674, DOI 10.1186/s12881-018-0722-6]; Knott MML, 2019, CANCER METAST REV, V38, P625, DOI 10.1007/s10555-019-09839-9; Koppenhafer SL, 2020, MOL CANCER RES, V18, P91, DOI 10.1158/1541-7786.MCR-19-0585; Koppenhafer SL, 2018, MOL CANCER THER, V17, P2676, DOI 10.1158/1535-7163.MCT-18-0260; Kotova I, 2003, EUR J BIOCHEM, V270, P1791, DOI 10.1046/j.1432-1033.2003.03541.x; Lai AC, 2017, NAT REV DRUG DISCOV, V16, P101, DOI 10.1038/nrd.2016.211; Lam SSY, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf3735; Laroche-Clary A, 2018, ANN ONCOL, V29, P1023, DOI 10.1093/annonc/mdy039; Larsson KM, 2004, NAT STRUCT MOL BIOL, V11, P1142, DOI 10.1038/nsmb838; Lecona E, 2014, EXP CELL RES, V329, P26, DOI 10.1016/j.yexcr.2014.09.019; Lee EYHP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003236; Lee JA, 2016, PEDIATR BLOOD CANCER, V63, P1552, DOI 10.1002/pbc.26058; Leijen S, 2016, J CLIN ONCOL, V34, P4371, DOI 10.1200/JCO.2016.67.5991; Li X., 2020, HAEMATOLOGICA, DOI [10.3324/haematol.2019.233445, DOI 10.3324/HAEMAT0L.2019.233445]; Li XY, 2019, HAEMATOLOGICA, V104, P2225, DOI 10.3324/haematol.2018.201343; Liu Y, 2017, CANCER RES, V77, P5068, DOI 10.1158/0008-5472.CAN-17-0567; Lowery CD, 2019, CLIN CANCER RES, V25, P2278, DOI 10.1158/1078-0432.CCR-18-2728; Lowery CD, 2017, CLIN CANCER RES, V23, P4354, DOI 10.1158/1078-0432.CCR-16-2876; Moorthy NSHN, 2013, MINI-REV MED CHEM, V13, P1862, DOI 10.2174/13895575113136660090; Muller D, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.121951; Murai J, 2019, PHARMACOL THERAPEUT, V201, P94, DOI 10.1016/j.pharmthera.2019.05.009; Musa J, 2016, ONCOGENE, V35, P4675, DOI 10.1038/onc.2015.515; Neklesa TK, 2017, PHARMACOL THERAPEUT, V174, P138, DOI 10.1016/j.pharmthera.2017.02.027; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Okimoto RA, 2019, J CLIN INVEST, V129, P3401, DOI 10.1172/JCI126366; Paiva SL, 2019, CURR OPIN CHEM BIOL, V50, P111, DOI 10.1016/j.cbpa.2019.02.022; Pettersson Mariell, 2019, Drug Discov Today Technol, V31, P15, DOI 10.1016/j.ddtec.2019.01.002; Pfister SX, 2015, CANCER CELL, V28, P557, DOI 10.1016/j.ccell.2015.09.015; Qin XY, 2016, CELL CYCLE, V15, P781, DOI 10.1080/15384101.2016.1151581; Rundle S, 2017, CANCERS, V9, DOI 10.3390/cancers9050041; Saini P, 2015, ONCOTARGET, V6, P13072, DOI 10.18632/oncotarget.3865; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Slotkin EK, 2015, MOL CANCER THER, V14, P395, DOI 10.1158/1535-7163.MCT-14-0711; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Stewart E, 2018, CANCER CELL, V34, P411, DOI 10.1016/j.ccell.2018.07.012; Stewart E, 2017, NATURE, V549, P96, DOI 10.1038/nature23647; Tang RP, 2006, MOL CANCER THER, V5, P723, DOI 10.1158/1535-7163.MCT-05-0164; Tang SW, 2015, CLIN CANCER RES, V21, P4184, DOI 10.1158/1078-0432.CCR-14-2112; Truman AW, 2015, J PROTEOMICS, V112, P285, DOI 10.1016/j.jprot.2014.09.028; van der Donk WA, 1998, BIOCHEMISTRY-US, V37, P6419, DOI 10.1021/bi9729357; Wallez Y, 2018, MOL CANCER THER, V17, P1670, DOI 10.1158/1535-7163.MCT-18-0010; Wang H, 2006, SEMIN ONCOL, V33, P513, DOI 10.1053/j.seminoncol.2006.04.013; Wang XH, 2014, MOL CELL ENDOCRINOL, V382, P8, DOI 10.1016/j.mce.2013.09.003; Wang ZY, 2019, CANCER RES, V79, P1438, DOI 10.1158/0008-5472.CAN-18-1220; Zhang YW, 2009, J BIOL CHEM, V284, P18085, DOI 10.1074/jbc.M109.003020; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhao JY, 2017, ONCOTARGET, V8, P6319, DOI 10.18632/oncotarget.14062; Zhou BS, 2013, CANCER RES, V73, P6484, DOI 10.1158/0008-5472.CAN-13-1094; Zoppoli G, 2012, P NATL ACAD SCI USA, V109, P15030, DOI 10.1073/pnas.1205943109	77	2	2	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					564	577		10.1038/s41388-020-01552-0	http://dx.doi.org/10.1038/s41388-020-01552-0		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33191406	Green Accepted			2022-12-17	WOS:000589571100002
J	Qian, KY; Wang, G; Ju, LG; Liu, JY; Luo, YW; Wang, YP; Peng, TC; Chen, FJ; Zhang, Y; Xiao, Y; Wang, XH				Qian, Kaiyu; Wang, Gang; Ju, Lingao; Liu, Jiyan; Luo, Yongwen; Wang, Yejinpeng; Peng, Tianchen; Chen, Fangjin; Zhang, Yi; Xiao, Yu; Wang, Xinghuan			A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype	ONCOGENE			English	Article							MUTATION	5-10% of total prostate cancer (PCa) cases are hereditary. Particularly, immune checkpoint inhibitor-sensitive tandem duplicator phenotype (TDP) accounts for 6.9% of PCa cases, whereas genetic susceptibility genes remain completely unknown. We identified a Chinese family with two PCa patients, in which the PCa phenotype co-segregated with a rare germline variant EGFR(R831H). Patient-derived conditionally reprogrammed cells (CRC) exhibited increased EGFR and AKT phosphorylation, and a sensitivity to EGFR antagonist Afatinib in migration assays, suggesting the EGFR allele was constitutively active. Both EGFR(R831H)-mutant tumours contained biallelic CDK12 inactivation, together with prominent tandem duplication across the genome. These somatic mutations could be detected in urine before surgery. Analysis of public databases showed a significant correlation between the mutation status of EGFR and CDK12. Taken together, our genetic and functional analyses identified a previously undescribed link between EGFR and PCa.	[Qian, Kaiyu; Luo, Yongwen; Wang, Yejinpeng; Peng, Tianchen; Xiao, Yu; Wang, Xinghuan] Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China; [Qian, Kaiyu; Wang, Gang; Ju, Lingao; Xiao, Yu] Wuhan Univ, Zhongnan Hosp, Dept Biol Repositories, Wuhan, Peoples R China; [Qian, Kaiyu; Wang, Gang; Ju, Lingao; Xiao, Yu] Human Genet Resources Preservat Ctr Hubei Prov, Wuhan, Peoples R China; [Wang, Gang; Ju, Lingao; Xiao, Yu] Wuhan Univ, Zhongnan Hosp, Lab Precis Med, Wuhan, Peoples R China; [Liu, Jiyan] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Peoples R China; [Chen, Fangjin; Zhang, Yi] Peking Univ, Ctr Life Sci, Beijing, Peoples R China; [Zhang, Yi] Euler Technol, Beijing, Peoples R China; [Wang, Xinghuan] Wuhan Univ, Med Res Inst, Wuhan, Peoples R China	Wuhan University; Wuhan University; Wuhan University; Sichuan University; Peking University; Wuhan University	Wang, XH (corresponding author), Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan, Peoples R China.; Zhang, Y (corresponding author), Peking Univ, Ctr Life Sci, Beijing, Peoples R China.; Zhang, Y (corresponding author), Euler Technol, Beijing, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Med Res Inst, Wuhan, Peoples R China.	zy@eulertechnology.com; wangxinghuan@whu.edu.cn	Wang, Xinghuan/AAB-3192-2021; Xiao, Yu/AGA-4786-2022; Ju, Lingao/ADP-8482-2022	Wang, Xinghuan/0000-0003-3497-0024; Xiao, Yu/0000-0003-1377-9685; Ju, Lingao/0000-0003-0813-3628; Qian, Kaiyu/0000-0003-4153-1265; Zhang, Yi/0000-0001-5388-1276	Health commission of Hubei Province scientific research project [WJ2019H080]; Chinese Central Special Fund for Local Science and Technology Development of Hubei Province [2018ZYYD023]; Science and Technology Department of Hubei Province Key Project [2018ACA159]; Wuhan Science and Technology Bureau Key Project [2018061005132294]	Health commission of Hubei Province scientific research project; Chinese Central Special Fund for Local Science and Technology Development of Hubei Province; Science and Technology Department of Hubei Province Key Project; Wuhan Science and Technology Bureau Key Project	This study was supported in part by grants from the Health commission of Hubei Province scientific research project (WJ2019H080), Chinese Central Special Fund for Local Science and Technology Development of Hubei Province (2018ZYYD023), Science and Technology Department of Hubei Province Key Project (2018ACA159), and Wuhan Science and Technology Bureau Key Project (2018061005132294). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armenia J, 2018, NAT GENET, V50, P645, DOI 10.1038/s41588-018-0078-z; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Frank C, 2017, EUR UROL, V71, P162, DOI 10.1016/j.eururo.2016.07.031; Giri VN, 2019, PROSTATE, V79, P333, DOI 10.1002/pros.23739; Giri VN, 2016, SEMIN ONCOL, V43, P560, DOI 10.1053/j.seminoncol.2016.08.001; Liu W, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.95; Liu XF, 2017, NAT PROTOC, V12, P439, DOI 10.1038/nprot.2016.174; Lu S, 2019, J THORAC ONCOL, V14, P732, DOI 10.1016/j.jtho.2018.12.006; Luo YW, 2020, CLIN TRANSL MED, V10, P294, DOI 10.1002/ctm2.36; Lynch HT, 2016, INT J CANCER, V138, P2579, DOI 10.1002/ijc.29949; Matsushima S, 2014, J THORAC ONCOL, V9, P1377, DOI 10.1097/JTO.0000000000000241; Menghi F, 2018, CANCER CELL, V34, P197, DOI 10.1016/j.ccell.2018.06.008; Pilie PG, 2017, CANCER-AM CANCER SOC, V123, P3925, DOI 10.1002/cncr.30817; Tonon L, 2019, EUR UROL, V75, P11, DOI 10.1016/j.eururo.2018.08.026; Wagner A, 2018, JCO PRECIS ONCOL, V2, P1; Wu YM, 2018, CELL, V173, P1770, DOI 10.1016/j.cell.2018.04.034; Yu HA, 2014, J THORAC ONCOL, V9, P554, DOI 10.1097/JTO.0000000000000052; Yuan YQ, 2020, J CANCER, V11, P3762, DOI 10.7150/jca.42314	18	2	2	3	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6871	6878		10.1038/s41388-020-01476-9	http://dx.doi.org/10.1038/s41388-020-01476-9		SEP 2020	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32978518	Green Submitted			2022-12-17	WOS:000572714000005
J	Wang, KX; Ji, WX; Yu, YF; Li, ZM; Niu, XM; Xia, WL; Lu, S				Wang, Kaixuan; Ji, Wenxiang; Yu, Yongfeng; Li, Ziming; Niu, Xiaomin; Xia, Weiliang; Lu, Shun			FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer (vol 15, pg 732, 2020)	ONCOGENE			English	Correction												wlxia@sjtu.edu.cn; shunlu@sjtu.edu.cn	Lu, Shun/ABF-8341-2021; XIA, WEILIANG/AEA-0835-2022	XIA, WEILIANG/0000-0002-0256-4219	National Natural Science Foundation of China (National Science Foundation of China) [81672272, 81773115] Funding Source: Medline; Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission) [17431906103] Funding Source: Medline	National Natural Science Foundation of China (National Science Foundation of China)(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission)		Wang KX, 2018, ONCOGENE, V37, P5340, DOI 10.1038/s41388-018-0311-3	1	2	2	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6619	6620		10.1038/s41388-020-01441-6	http://dx.doi.org/10.1038/s41388-020-01441-6		SEP 2020	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32895480	Bronze			2022-12-17	WOS:000566854200002
J	Su, Y; Wang, XY; Guo, Z; Wang, J				Su, Yao; Wang, Xueying; Guo, Zhen; Wang, Jun			Aberrant JmjC domain-containing protein 8 (JMJD8) expression promotes activation of AKT and tumor epithelial-mesenchymal transition	ONCOGENE			English	Article							BETA-CATENIN; CELL-MIGRATION; KINASE; PHOSPHORYLATION; EPIGENOMICS; METHYLATION; METASTASIS; INHIBITION; PATHWAY; FAMILY	Posttranslational modifications of histone and nonhistone proteins greatly influence numerous molecular events in multiple diseases. Jumonji domain-containing proteins are a family functioning as histone demethylase. Jumonji domain-containing protein 8 (JMJD8) is Jumonji C (JmjC) domain-only member of this family, and its physiological functions remain largely unknown. In this study, we investigated the mechanism by which aberrant JMJD8 stimulates phosphorylation of AKT and activate AKT/GSK3 beta/beta-catenin signaling pathway thereby promotes tumor cell epithelial-mesenchymal transition (EMT). We demonstrated that knockdown of JMJD8 increased the interaction of SETDB1 and phosphoinositide-dependent kinase 1 (PDK1) with AKT1 and resulted in enhanced trimethylation of AKT1 at lysine 142 (K142), which is crucial for cell membrane recruitment, phosphorylation, and activation of AKT. Moreover, the mutation of histidine 200 of JMJD8 (JMJD8-H200Q) disrupted its binding with AKT1 and increased interaction of SETDB1 and PDK1 with AKT1. Furthermore, histone demethylase jumonji domain-containing protein 2B functioned as an adapter to recruit beta-catenin to the methylated AKT1 upon JMJD8 depression, which facilitated the phosphorylation of beta-catenin at Ser552 and its accumulation in cell nucleus where the activated beta-catenin transcriptionally stimulated the expression of genes involved in EMT. In conclusion, our data unraveled a novel role of JMJD8 in regulating the migration and invasion of tumor via modulating AKT methylation and activation. In addition, this study showed that JMJD8 is a potential biomarker and drug design target for tumor EMT.	[Su, Yao; Wang, Jun] Chinese Acad Sci, HFIPS, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Peoples R China; [Wang, Xueying; Guo, Zhen] Univ Sci & Technol China, Sch Life Sci, Anhui Key Lab Cellular Dynam & Chem Biol, Hefei 230027, Peoples R China	Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wang, J (corresponding author), Chinese Acad Sci, HFIPS, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Peoples R China.; Guo, Z (corresponding author), Univ Sci & Technol China, Sch Life Sci, Anhui Key Lab Cellular Dynam & Chem Biol, Hefei 230027, Peoples R China.	zhenguo@ustc.edu.cn; wangjun0457@ipp.ac.cn			National Natural Science Foundation [11575232, 31471268]; National Key Research and Development Program of China (Stem Cell and Translational Research) [2016YFA0101202]; International Partnership Program of Chinese Academy of Sciences [116134KYSB20160084]; Innovative Program of Development Foundation of Hefei Center for Physical Science and Technology [2016FXCX005]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China (Stem Cell and Translational Research); International Partnership Program of Chinese Academy of Sciences; Innovative Program of Development Foundation of Hefei Center for Physical Science and Technology	This study was supported by the National Natural Science Foundation (11575232, 31471268), the National Key Research and Development Program of China (Stem Cell and Translational Research) 2016YFA0101202, the International Partnership Program of Chinese Academy of Sciences (116134KYSB20160084), and the Innovative Program of Development Foundation of Hefei Center for Physical Science and Technology (2016FXCX005).	Alam H, 2015, CELL MOL LIFE SCI, V72, P4577, DOI 10.1007/s00018-015-2023-y; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Boeckel JN, 2016, ARTERIOSCL THROM VAS, V36, P1425, DOI 10.1161/ATVBAHA.116.307695; Chu N, 2018, CELL, V174, P897, DOI 10.1016/j.cell.2018.07.003; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; De Santis MC, 2019, BBA-REV CANCER, V1871, P361, DOI 10.1016/j.bbcan.2019.03.003; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Gao CX, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-13; Ghahhari NM, 2015, EUR J CANCER, V51, P1638, DOI 10.1016/j.ejca.2015.04.021; Guo JP, 2019, CELL CYCLE, V18, P917, DOI 10.1080/15384101.2019.1609832; Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6; Hamamoto R, 2015, NAT REV CANCER, V15, P110, DOI 10.1038/nrc3884; Henderson V, 2015, CELL ADHES MIGR, V9, P255, DOI 10.1080/19336918.2015.1013383; Hermida Miguel A., 2017, Advances in Biological Regulation, V65, P5, DOI 10.1016/j.jbior.2017.06.003; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Jamieson C, 2012, INT J BIOCHEM CELL B, V44, P847, DOI 10.1016/j.biocel.2012.03.001; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kelly AD, 2017, CURR OPIN GENET DEV, V42, P68, DOI 10.1016/j.gde.2017.03.015; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li Q, 2015, INT J CLIN EXP PATHO, V8, P6334; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343; Oh S, 2019, BBA-REV CANCER, V1871, P406, DOI 10.1016/j.bbcan.2019.04.002; Revathidevi S, 2019, SEMIN CANCER BIOL, V59, P80, DOI 10.1016/j.semcancer.2019.06.002; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sechler M, 2017, ONCOGENE, V36, P4150, DOI 10.1038/onc.2017.44; Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x; Shin S, 2007, BIOCHEM BIOPH RES CO, V353, P973, DOI 10.1016/j.bbrc.2006.12.147; Skrypek N, 2017, TRENDS GENET, V33, P943, DOI 10.1016/j.tig.2017.08.004; Song Y, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317712617; Su Y, 2019, BBA-MOL CELL RES, V1866, DOI 10.1016/j.bbamcr.2019.118541; Sun LD, 2016, CELL MOL LIFE SCI, V73, P4493, DOI 10.1007/s00018-016-2303-1; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Tang B, 2016, CANCER RES, V76, P6520, DOI 10.1158/0008-5472.CAN-15-3029; Tang B, 2015, ONCOTARGET, V6, P12723, DOI 10.18632/oncotarget.3713; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Wang GH, 2019, NAT CELL BIOL, V21, P214, DOI 10.1038/s41556-018-0266-1; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Yang F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09289-5; Yang Q, 2019, SEMIN CANCER BIOL, V59, P112, DOI 10.1016/j.semcancer.2019.04.001; Yeo KS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15676-z; Yeo KS, 2016, SCI REP-UK, V6, DOI 10.1038/srep34125; Zhang HH, 2006, MOL CELL, V24, P185, DOI 10.1016/j.molcel.2006.09.019; Zhang J, 2019, MOL MED REP, V19, P3963, DOI 10.3892/mmr.2019.10111; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254	47	2	3	2	32	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6451	6467		10.1038/s41388-020-01446-1	http://dx.doi.org/10.1038/s41388-020-01446-1		SEP 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32879443				2022-12-17	WOS:000565482600004
J	Wang, SX; Somisetty, VS; Bai, BY; Chernukhin, I; Niskanen, H; Kaikkonen, MU; Bellet, M; Carroll, JS; Hurtado, A				Wang, Shixiong; Somisetty, Venkata S.; Bai, Baoyan; Chernukhin, Igor; Niskanen, Henri; Kaikkonen, Minna U.; Bellet, Meritxell; Carroll, Jason S.; Hurtado, Antoni			The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen	ONCOGENE			English	Article							BREAST-CANCER; EXPRESSION; PAX2; ACETYLATION	Tamoxifen is the most prescribed selective estrogen receptor (ER) modulator in patients with ER-positive breast cancers. Tamoxifen requires the transcription factor paired box 2 protein (PAX2) to repress the transcription of ERBB2/HER2. Now, we identified that PAX2 inhibits cell growth of ER+/HER2- tumor cells in a dose-dependent manner. Moreover, we have identified that cell growth inhibition can be achieved by expressing moderate levels of PAX2 in combination with tamoxifen treatment. Global run-on sequencing of cells overexpressing PAX2, when coupled with PAX2 ChIP-seq, identified common targets regulated by both PAX2 and tamoxifen. The data revealed that PAX2 can inhibit estrogen-induced gene transcription and this effect is enhanced by tamoxifen, suggesting that they converge on repression of the same targets. Moreover, PAX2 and tamoxifen have an additive effect and both induce coding genes and enhancer RNAs (eRNAs). PAX2-tamoxifen upregulated genes are also enriched with PAX2 eRNAs. The enrichment of eRNAs is associated with the highest expression of genes that positivity regulate apoptotic processes. In luminal tumors, the expression of a subset of these proapoptotic genes predicts good outcome and their expression are significantly reduced in tumors of patients with relapse to tamoxifen treatment. Mechanistically, PAX2 and tamoxifen coexert an antitumoral effect by maintaining high levels of transcription of tumor suppressors that promote cell death. The apoptotic effect is mediated in large part by the gene interferon regulatory factor 1. Altogether, we conclude that PAX2 contributes to better clinical outcome in tamoxifen treated ER-positive breast cancer patients by repressing estrogen signaling and inducing cell death related pathways.	[Wang, Shixiong; Somisetty, Venkata S.; Bai, Baoyan] Univ Oslo, Ctr Mol Med Norway NCMM, Cell Cycle Regulat Grp, Nord EMBL Partnership, PO 1137, N-0318 Oslo, Norway; [Chernukhin, Igor; Carroll, Jason S.] Univ Cambridge, Canc Res UK Cambridge Inst, Robinson Way, Cambridge CB2 0RE, England; [Niskanen, Henri; Kaikkonen, Minna U.] Univ Eastern Finland, AI Virtanen Inst Mol Sci, POB 1627, Kuopio 70211, Finland; [Bellet, Meritxell] Vall Hebron Inst Oncol, Barcelona, Spain; [Bellet, Meritxell] Vall Hebron Univ Hosp, Barcelona, Spain; [Hurtado, Antoni] Univ Barcelona, Dept Biomed Sci, Canc Genom & Prote Grp, Casanova,143, Barcelona 08014, Spain; [Hurtado, Antoni] August Pi & Sunyer Res Ctr IDIBAPS, C Rossello 149-153, Barcelona 08036, Spain	University of Oslo; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Eastern Finland; Vall d'Hebron Institut d'Oncologia (VHIO); Hospital Universitari Vall d'Hebron; University of Barcelona	Hurtado, A (corresponding author), Univ Barcelona, Dept Biomed Sci, Canc Genom & Prote Grp, Casanova,143, Barcelona 08014, Spain.; Hurtado, A (corresponding author), August Pi & Sunyer Res Ctr IDIBAPS, C Rossello 149-153, Barcelona 08036, Spain.	toni.hurtado@ub.edu		Carroll, Jason/0000-0003-3643-0080; Kaikkonen, Minna/0000-0001-6294-0979; Hurtado, Antoni/0000-0002-0145-4763				Beauchemin D, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-148; Cai Y, 2003, EMBO J, V22, P5522, DOI 10.1093/emboj/cdg536; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Daniel JA, 2010, SCIENCE, V329, P917, DOI 10.1126/science.1187942; Dornan D, 2004, MOL CELL BIOL, V24, P10083, DOI 10.1128/MCB.24.22.10083-10098.2004; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jahangiri R, 2018, TISSUE CELL, V52, P135, DOI 10.1016/j.tice.2018.05.005; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Martinez-Outschoorn UE, 2012, CELL CYCLE, V11, P3964, DOI 10.4161/cc.22137; Patel SR, 2007, DEV CELL, V13, P580, DOI 10.1016/j.devcel.2007.09.004; Pistelli M, 2018, CURR ONCOL, V25, pE168, DOI 10.3747/co.25.3735; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ramirez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Sane S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020442; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Schwartz JL, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/912102; Sharma R, 2015, SEMIN CELL DEV BIOL, V44, P97, DOI 10.1016/j.semcdb.2015.09.016; Silberstein GB, 2002, ONCOGENE, V21, P1009, DOI 10.1038/sj.onc.1205172; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	29	2	2	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6300	6312		10.1038/s41388-020-01435-4	http://dx.doi.org/10.1038/s41388-020-01435-4		AUG 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32843722	Green Published, hybrid			2022-12-17	WOS:000562669100001
J	Anderson, KJ; Osvaldsdottir, AB; Atzinger, B; Traustadottir, GA; Jensen, KN; Larusdottir, AE; Bergthorsson, JT; Hardardottir, I; Magnusdottir, E				Anderson, Kimberley Jade; Osvaldsdottir, Arny Bjorg; Atzinger, Birgit; Traustadottir, Gunnhildur Asta; Jensen, Kirstine Nolling; Larusdottir, Adalheidur Elin; Bergthorsson, Jon Thor; Hardardottir, Ingibjorg; Magnusdottir, Erna			The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma	ONCOGENE			English	Article							PLASMA-CELL DIFFERENTIATION; CLASS-II TRANSACTIVATOR; WALDENSTROM MACROGLOBULINEMIA; B-CELLS; TRANSCRIPTIONAL REPRESSION; METHYLTRANSFERASE ACTIVITY; SOMATIC MUTATIONS; MYD88 L265P; BLIMP-1; EXPRESSION	Waldenstrom's macroglobulinemia (WM) is a non-Hodgkin lymphoma, resulting in antibody-secreting lymphoplasmacytic cells in the bone marrow and pathologies resulting from high levels of monoclonal immunoglobulin M (IgM) in the blood. Despite the key role for BLIMP1 in plasma cell maturation and antibody secretion, its potential effect on WM cell biology has not yet been explored. Here we provide evidence of a crucial role for BLIMP1 in the survival of cells from WM cell line models and further demonstrate that BLIMP1 is necessary for the expression of the histone methyltransferase EZH2 in both WM and multiple myeloma cell lines. The effect of BLIMP1 on EZH2 levels is post-translational, at least partially through the regulation of proteasomal targeting of EZH2. Chromatin immunoprecipitation analysis and transcriptome profiling suggest that the two factors co-operate in regulating genes involved in cancer cell immune evasion. Co-cultures of natural killer cells and cells from a WM cell line further suggest that both factors participate in immune evasion by promoting escape from natural killer cell-mediated cytotoxicity. Together, the interplay of BLIMP1 and EZH2 plays a vital role in promoting the survival of WM cell lines, suggesting a role for the two factors in Waldenstrom's macroglobulinaemia.	[Anderson, Kimberley Jade; Osvaldsdottir, Arny Bjorg; Atzinger, Birgit; Traustadottir, Gunnhildur Asta; Larusdottir, Adalheidur Elin; Magnusdottir, Erna] Univ Iceland, Fac Med, Dept Anat, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland; [Anderson, Kimberley Jade; Osvaldsdottir, Arny Bjorg; Atzinger, Birgit; Larusdottir, Adalheidur Elin; Bergthorsson, Jon Thor; Magnusdottir, Erna] Univ Iceland, Fac Med, Dept Biomed Sci, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland; [Anderson, Kimberley Jade; Osvaldsdottir, Arny Bjorg; Atzinger, Birgit; Traustadottir, Gunnhildur Asta; Jensen, Kirstine Nolling; Larusdottir, Adalheidur Elin; Bergthorsson, Jon Thor; Hardardottir, Ingibjorg; Magnusdottir, Erna] Univ Iceland, Biomed Ctr, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland; [Jensen, Kirstine Nolling; Hardardottir, Ingibjorg] Univ Iceland, Fac Med, Dept Biochem & Mol Biol, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland; [Jensen, Kirstine Nolling; Hardardottir, Ingibjorg] Landspitali Natl Univ Hosp Iceland, Dept Immunol, IS-101 Reykjavik, Iceland; [Bergthorsson, Jon Thor] Landspitali Natl Univ Hosp Iceland, Dept Lab Haematol, IS-101 Reykjavik, Iceland	University of Iceland; University of Iceland; University of Iceland; University of Iceland	Magnusdottir, E (corresponding author), Univ Iceland, Fac Med, Dept Anat, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland.; Magnusdottir, E (corresponding author), Univ Iceland, Fac Med, Dept Biomed Sci, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland.; Magnusdottir, E (corresponding author), Univ Iceland, Biomed Ctr, Vatnsmyrarvegur 16, IS-101 Reykjavik, Iceland.	erna@hi.is	Magnusdottir, Erna/H-5181-2013	Magnusdottir, Erna/0000-0002-3369-4390; Hardardottir, Ingibjorg/0000-0003-0178-7047; Anderson, Kimberley/0000-0003-0629-6343; Nolling Jensen, Kirstine/0000-0002-7625-7529; Traustadottir, Gunnhildur Asta/0000-0001-6044-0989; Bergthorsson, Jon Thor/0000-0002-0560-2639				Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Barakat FH, 2011, AM J CLIN PATHOL, V135, P365, DOI 10.1309/AJCP15YFULCZHZVH; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Calado DP, 2010, CANCER CELL, V18, P580, DOI 10.1016/j.ccr.2010.11.024; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; Chen H, 2007, MOL IMMUNOL, V44, P1461, DOI 10.1016/j.molimm.2006.04.026; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; de Charette M, 2018, HAEMATOLOGICA, V103, P1256, DOI 10.3324/haematol.2017.184192; de Tute RM, 2013, CL LYMPH MYELOM LEUK, V13, P211, DOI 10.1016/j.clml.2013.02.018; Doody GM, 2007, J IMMUNOL, V179, P7614, DOI 10.4049/jimmunol.179.11.7614; El-Ayoubi A, 2017, PATHOLOGY, V49, P337, DOI 10.1016/j.pathol.2017.02.004; Elias S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18652-9; Garcia JF, 2006, HAEMATOLOGICA, V91, P467; Gavriatopoulou M, 2018, LEUKEMIA, V32, P1883, DOI 10.1038/s41375-018-0209-7; Ghobrial IM, 2004, CANCER-AM CANCER SOC, V101, P2593, DOI 10.1002/cncr.20658; Guo M, 2018, J IMMUNOL, V200, P1039, DOI 10.4049/jimmunol.1701470; Gyory I, 2004, NAT IMMUNOL, V5, P299, DOI 10.1038/ni1046; Hackett JA, 2013, SCIENCE, V339, P448, DOI 10.1126/science.1229277; Hernando H, 2016, MOL CANCER THER, V15, P287, DOI 10.1158/1535-7163.MCT-15-0486; Herviou L, 2019, LEUKEMIA, V33, P2047, DOI 10.1038/s41375-019-0392-1; Hung KH, 2016, CELL DEATH DIFFER, V23, P1175, DOI 10.1038/cdd.2015.167; Hunter ZR, 2016, BLOOD, V128, P827, DOI 10.1182/blood-2016-03-708263; Iwanaga M, 2014, INT J CANCER, V134, P174, DOI 10.1002/ijc.28343; Jalali S, 2018, BLOOD ADV, V2, P1985, DOI 10.1182/bloodadvances.2018021113; Kallies A, 2004, J EXP MED, V200, P967, DOI 10.1084/jem.20040973; Kallies A, 2007, IMMUNITY, V26, P555, DOI 10.1016/j.immuni.2007.04.007; Kriangkum J, 2004, BLOOD, V104, P2134, DOI 10.1182/blood-2003-11-4024; Kuo TC, 2004, J IMMUNOL, V173, P5556, DOI 10.4049/jimmunol.173.9.5556; Kurimoto K, 2015, CELL STEM CELL, V16, P517, DOI 10.1016/j.stem.2015.03.002; Kyle RA, 2018, MAYO CLIN PROC, V93, P739, DOI 10.1016/j.mayocp.2018.02.011; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin FR, 2007, CANCER RES, V67, P11914, DOI 10.1158/0008-5472.CAN-07-1868; Lin KI, 2002, MOL CELL BIOL, V22, P4771, DOI 10.1128/MCB.22.13.4771-4780.2002; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lozano E, 2018, J IMMUNOL, V200, P2581, DOI 10.4049/jimmunol.1701622; Magnusdottir E, 2007, P NATL ACAD SCI USA, V104, P14988, DOI 10.1073/pnas.0707323104; Magnusdottir E, 2013, NAT CELL BIOL, V15, P905, DOI 10.1038/ncb2798; Mandelbaum J, 2010, CANCER CELL, V18, P568, DOI 10.1016/j.ccr.2010.10.030; Minnich M, 2016, NAT IMMUNOL, V17, P331, DOI 10.1038/ni.3349; Morgan MAJ, 2009, MOL CELL BIOL, V29, P5813, DOI 10.1128/MCB.00670-09; Morice WG, 2009, MODERN PATHOL, V22, P807, DOI 10.1038/modpathol.2009.34; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mould AW, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005375; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Murakami K, 2016, NATURE, V529, P403, DOI 10.1038/nature16480; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267; Pasqualucci L, 2006, J EXP MED, V203, P311, DOI 10.1084/jem.20052204; Pasricha SR, 2011, J CLIN PATHOL, V64, P520, DOI 10.1136/jcp.2010.088591; Paulus A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122338; Pawlyn C, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.27; Petermann F, 2019, MOL CELL, V75, P1229, DOI 10.1016/j.molcel.2019.06.025; Piskurich JF, 2000, NAT IMMUNOL, V1, P526, DOI 10.1038/82788; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roberts MJ, 2013, AM J CLIN PATHOL, V139, P210, DOI 10.1309/AJCP0YGM8BLFYHJY; Roccaro AM, 2010, BLOOD; Savitsky D, 2006, J EXP MED, V203, P2305, DOI 10.1084/jem.20060411; Schop RFJ, 2002, BLOOD, V100, P2996, DOI 10.1182/blood.V100.8.2996; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Steinberg MW, 2011, IMMUNOL REV, V244, P169, DOI 10.1111/j.1600-065X.2011.01064.x; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tellier J, 2016, NAT IMMUNOL, V17, P323, DOI 10.1038/ni.3348; Tooze RM, 2006, J IMMUNOL, V177, P4584, DOI 10.4049/jimmunol.177.7.4584; Treon SP, 2014, BLOOD, V123, P2791, DOI 10.1182/blood-2014-01-550905; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; Treon SP, 2009, BLOOD, V114, P2375, DOI 10.1182/blood-2009-05-174359; Varghese AM, 2009, CLIN LYMPHOMA MYELOM, V9, P53, DOI 10.3816/CLM.2009.n.013; Vijay A, 2007, BLOOD, V109, P5096, DOI 10.1182/blood-2006-11-055012; Wang HJ, 2012, CANCER-AM CANCER SOC, V118, P3793, DOI 10.1002/cncr.26627; Xu L, 2014, LEUKEMIA, V28, P1698, DOI 10.1038/leu.2014.65; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000; Yu XF, 2018, CANCER RES, V78, P2457, DOI 10.1158/0008-5472.CAN-18-0215; Zhou YS, 2014, BRIT J HAEMATOL, V166, P677, DOI 10.1111/bjh.12936; Zingg D, 2017, CELL REP, V20, P854, DOI 10.1016/j.celrep.2017.07.007	77	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2020	39	28					5138	5151		10.1038/s41388-020-1347-8	http://dx.doi.org/10.1038/s41388-020-1347-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MH4RK	32533097	Green Submitted, Green Published			2022-12-17	WOS:000546718100005
J	Boissinot, M; King, H; Adams, M; Higgins, J; Shaw, G; Ward, TA; Steele, LP; Tams, D; Morton, R; Polson, E; da Silva, B; Droop, A; Hayes, JL; Martin, H; Laslo, P; Morrison, E; Tomlinson, DC; Wurdak, H; Bond, J; Lawler, SE; Short, SC				Boissinot, M.; King, H.; Adams, M.; Higgins, J.; Shaw, G.; Ward, T. A.; Steele, L. P.; Tams, D.; Morton, R.; Polson, E.; da Silva, B.; Droop, A.; Hayes, J. L.; Martin, H.; Laslo, P.; Morrison, E.; Tomlinson, D. C.; Wurdak, H.; Bond, J.; Lawler, S. E.; Short, S. C.			Profiling cytotoxic microRNAs in pediatric and adult glioblastoma cells by high-content screening, identification, and validation of miR-1300	ONCOGENE			English	Article							CLEAVAGE FURROW FORMATION; EXCHANGE FACTORS; ECT2; TARGETS; POLYPLOIDIZATION; PATHWAYS; MIRBASE; MEDIATE; TRIO	MicroRNAs play an important role in the regulation of mRNA translation and have therapeutic potential in cancer and other diseases. To profile the landscape of microRNAs with significant cytotoxicity in the context of glioblastoma (GBM), we performed a high-throughput screen in adult and pediatric GBM cells using a synthetic oligonucleotide library representing all known human microRNAs. Bioinformatics analysis was used to refine this list and the top seven microRNAs were validated in a larger panel of GBM cells using state-of-the-art in vitro assays. The cytotoxic effect of our most relevant candidate was assessed in a preclinical model. Our screen identified similar to 100 significantly cytotoxic microRNAs with 70% concordance between cell lines. MicroRNA-1300 (miR-1300) was the most potent and robust candidate. We observed a striking binucleated phenotype in miR-1300 transfected cells due to cytokinesis failure followed by apoptosis. This was also observed in two stem-like patient-derived cultures. We identified the physiological role of miR-1300 as a regulator of endomitosis in megakaryocyte differentiation where blockade of cytokinesis is an essential step. In GBM cells, where miR-1300 is normally not expressed, the oncogene Epithelial Cell Transforming 2 (ECT2) was validated as a direct key target. ECT2 siRNA phenocopied the effects of miR-1300, and ECT2 overexpression led to rescue of miR-1300 induced binucleation. We showed that ectopic expression of miR-1300 led to decreased tumor growth in an orthotopic GBM model. Our screen provides a resource for the neuro-oncology community and identified miR-1300 as a novel regulator of endomitosis with translatable potential for therapeutic application.	[Boissinot, M.; Higgins, J.; Shaw, G.; Ward, T. A.; Steele, L. P.; Tams, D.; Hayes, J. L.; Lawler, S. E.; Short, S. C.] Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Radiat Biol & Therapy Grp, Leeds LS9 7TF, W Yorkshire, England; [King, H.; Adams, M.; Tomlinson, D. C.; Bond, J.] Univ Leeds, St Jamess Hosp, BioScreening Technol Grp, Leeds LS9 7TF, W Yorkshire, England; [Tams, D.] Babraham, Roslin Cell Sci, Cambridge CB22 3AT, England; [Morton, R.; Polson, E.; da Silva, B.; Wurdak, H.] Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Stem Cells & Brain Tumour Res Grp, Leeds LS9 7TF, W Yorkshire, England; [Droop, A.] Univ Leeds, MRC Med Bioinformat Ctr, Clarendon Way, Leeds LS2 9NL, W Yorkshire, England; [Hayes, J. L.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Martin, H.; Tomlinson, D. C.] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England; [Laslo, P.] Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Myeloid Differentiat Grp, Leeds LS9 7TF, W Yorkshire, England; [Morrison, E.] Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Cell Biol Res Grp, Leeds LS9 7TF, W Yorkshire, England; [Bond, J.] Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Microcephaly & Neurogenesis Res Grp, Leeds LS9 7TF, W Yorkshire, England; [Lawler, S. E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Harvey Cushing Neurooncol Labs, Boston, MA 02115 USA; [Short, S. C.] Univ Leeds, St Jamess Hosp, St Jamess Inst Oncol, Leeds LS9 7TF, W Yorkshire, England; [Short, S. C.] Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Saint James's University Hospital; University of Leeds; University of Leeds; University of California System; University of California Berkeley; University of Leeds; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds	Lawler, SE; Short, SC (corresponding author), Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Radiat Biol & Therapy Grp, Leeds LS9 7TF, W Yorkshire, England.; Lawler, SE (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Harvey Cushing Neurooncol Labs, Boston, MA 02115 USA.; Short, SC (corresponding author), Univ Leeds, St Jamess Hosp, St Jamess Inst Oncol, Leeds LS9 7TF, W Yorkshire, England.; Short, SC (corresponding author), Univ Leeds, St Jamess Hosp, Leeds Inst Med Res, Leeds LS9 7TF, W Yorkshire, England.	SLAWLER@bwh.harvard.edu; S.C.Short@leeds.ac.uk		Ward, Thomas/0000-0003-0937-4554; Boissinot, Marjorie/0000-0002-5241-2520; Wurdak, Heiko/0000-0003-4385-4324; Martin, Heather/0000-0002-5455-4434; Short, Susan/0000-0003-4423-7256	UK-based charities Yorkshire Cancer Research [L369]; Brain Tumor Charity [13/192]; Brain Tumor Research and Support Yorkshire; Candle-lighters; MRC [MR/J001171/1] Funding Source: UKRI	UK-based charities Yorkshire Cancer Research; Brain Tumor Charity; Brain Tumor Research and Support Yorkshire; Candle-lighters; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This project was supported by the UK-based charities Yorkshire Cancer Research (award L369 SEL, DCT), The Brain Tumor Charity (Program reference number 13/192 SCS), Candle-lighters and Brain Tumor Research and Support Yorkshire (SEL).	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Ahir BK, 2017, CRIT REV ONCOL HEMAT, V120, P22, DOI 10.1016/j.critrevonc.2017.10.003; Alexander BM, 2017, J CLIN ONCOL, V35, P2402, DOI 10.1200/JCO.2017.73.0119; Banelli B, 2017, INT J GENOMICS, V2017, DOI 10.1155/2017/7639084; Bastos RN, 2012, J CELL BIOL, V198, P865, DOI 10.1083/jcb.201204107; Bhaskaran V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08390-z; Brower JV, 2014, NEUROCHEM INT, V77, P68, DOI 10.1016/j.neuint.2014.06.002; Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615; Castoreno AB, 2010, NAT CHEM BIOL, V6, P457, DOI 10.1038/nchembio.363; Chalamalasetty RB, 2006, J CELL SCI, V119, P3008, DOI 10.1242/jcs.03032; Chen LY, 2015, ONCOTARGET, V6, P38628, DOI 10.18632/oncotarget.5926; Eulalio A, 2015, J BIOMOL SCREEN, V20, P1003, DOI 10.1177/1087057115578837; Fields AP, 2010, ADV ENZYME REGUL, V50, P190, DOI 10.1016/j.advenzreg.2009.10.010; Fortin SP, 2012, MOL CANCER RES, V10, P958, DOI 10.1158/1541-7786.MCR-11-0616; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gao Y, 2012, DEV CELL, V22, P573, DOI 10.1016/j.devcel.2011.12.019; Garcia DM, 2011, NAT STRUCT MOL BIOL, V18, P1139, DOI 10.1038/nsmb.2115; Godlewski J, 2010, CELL DEATH DIFFER, V17, P221, DOI 10.1038/cdd.2009.71; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005; Katsushima K, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00014; King HO, 2017, STEM CELL REP, V8, P125, DOI 10.1016/j.stemcr.2016.12.005; Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181; Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027; Krichevsky AM, 2019, NEUROTHERAPEUTICS, V16, P319, DOI 10.1007/s13311-018-00702-3; Lannutti BJ, 2005, BLOOD, V105, P3875, DOI 10.1182/blood-2004-10-3934; LeBlanc VC, 2015, J CLIN MED, V4, P1612, DOI 10.3390/jcm4081612; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Mercatelli N, 2017, INT REV CEL MOL BIO, V333, P269, DOI 10.1016/bs.ircmb.2017.03.002; Moskwa P, 2014, MOL CANCER RES, V12, P1767, DOI 10.1158/1541-7786.MCR-14-0268; Nagalla S, 2011, BLOOD, V117, P5189, DOI 10.1182/blood-2010-09-299719; Nam JW, 2014, MOL CELL, V53, P1031, DOI 10.1016/j.molcel.2014.02.013; Normand G, 2010, ADV EXP MED BIOL, V676, P27; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Polson ES, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar2718; Salhia B, 2008, AM J PATHOL, V173, P1828, DOI 10.2353/ajpath.2008.080043; Sana J, 2011, J CELL MOL MED, V15, P1636, DOI 10.1111/j.1582-4934.2011.01317.x; Sano M, 2006, ONCOL REP, V16, P1093; Shin C, 2010, MOL CELL, V38, P789, DOI 10.1016/j.molcel.2010.06.005; Su KC, 2011, DEV CELL, V21, P1104, DOI 10.1016/j.devcel.2011.11.003; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Wen Q, 2012, CELL, V150, P575, DOI 10.1016/j.cell.2012.06.032; Westphal M, 2015, NAT REV NEUROL, V11, P556, DOI 10.1038/nrneurol.2015.171; Wurdak H, 2010, CELL STEM CELL, V6, P37, DOI 10.1016/j.stem.2009.11.002	48	2	2	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	2020	39	30					5292	5306		10.1038/s41388-020-1360-y	http://dx.doi.org/10.1038/s41388-020-1360-y		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MO5BV	32555332	Green Published, hybrid			2022-12-17	WOS:000545371000004
J	Hyslop, SR; Alexander, M; Thai, AA; Kersbergen, A; Kueh, AJ; Herold, MJ; Corbin, J; Gangatirkar, P; Ng, AP; Solomon, BJ; Alexander, WS; Sutherland, KD; Josefsson, EC				Hyslop, Stephanie R.; Alexander, Marliese; Thai, Alesha A.; Kersbergen, Ariena; Kueh, Andrew J.; Herold, Marco J.; Corbin, Jason; Gangatirkar, Pradnya; Ng, Ashley P.; Solomon, Benjamin J.; Alexander, Warren S.; Sutherland, Kate D.; Josefsson, Emma C.			Targeting platelets for improved outcome inKRAS-driven lung adenocarcinoma	ONCOGENE			English	Article							CANCER; METASTASIS; THROMBOCYTOSIS; SUPPRESSION; PROGRESSION; TUMORS; CELLS	Elevated platelet count is associated with poor survival in certain solid cancers, including lung cancer. In addition, experimental transplantation of cancer cell lines has uncovered a role for platelets in blood-borne metastasis. These studies, however, do not account for heterogeneity between lung cancer subtypes. Subsequently, the role of platelets in the major subtypes of non-small cell lung cancer (adenocarcinoma (ADC) and squamous cell carcinoma (SqCC)) is not fully understood. We utilised an autochthonousKras(LSL-G12D/+);p53(flox/flox)mouse model of lung ADC together with genetic models of thrombocytopenia to interrogate the role of platelets in lung cancer growth and progression. While thrombocytopenia failed to impact primary tumour growth, in experimental metastatic models however, thrombocytopenic mice displayed significantly extended survival. Utilising a novel thrombocytopenic immunocompromised mouse, the importance of platelets in metastatic dissemination was confirmed with humanKRAS-mutant ADC cell lines. Finally, retrospective analysis of a NSCLC patient cohort revealed thrombocytosis was predictive of poor survival in ADC patients with metastatic disease. Interestingly, this association was not apparent in SqCC patients. Overall, these data highlight the possibility of patient stratification using thrombocytosis as a biomarker, and indicates opportunities for potential novel treatment strategies that combine anti-platelet and lung cancer therapies.	[Hyslop, Stephanie R.; Kersbergen, Ariena; Corbin, Jason; Gangatirkar, Pradnya; Sutherland, Kate D.; Josefsson, Emma C.] Walter & Eliza Hall Inst Med Res, ACRF Canc Biol & Stem Cells Div, Melbourne, Vic, Australia; [Hyslop, Stephanie R.; Kueh, Andrew J.; Herold, Marco J.; Ng, Ashley P.; Alexander, Warren S.; Josefsson, Emma C.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Alexander, Marliese] Univ Melbourne, Peter MacCallum Canc Ctr, Pharm Dept, Parkville, Vic, Australia; [Alexander, Marliese; Solomon, Benjamin J.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia; [Thai, Alesha A.; Solomon, Benjamin J.] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia; [Kueh, Andrew J.; Herold, Marco J.; Ng, Ashley P.; Alexander, Warren S.] Walter & Eliza Hall Inst Med Res, Blood Cells & Blood Canc Div, Melbourne, Vic, Australia	University of Melbourne; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center	Josefsson, EC (corresponding author), Walter & Eliza Hall Inst Med Res, ACRF Canc Biol & Stem Cells Div, Melbourne, Vic, Australia.; Josefsson, EC (corresponding author), Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia.	josefsson@wehi.edu.au	Ng, Ashley/D-3842-2011; Josefsson, Emma/CAF-4970-2022; Herold, Marco J/C-8039-2013	Ng, Ashley/0000-0001-9690-0879; Herold, Marco J/0000-0001-7539-7581; Alexander, Marliese/0000-0001-5782-7912; Solomon, Benjamin/0000-0003-3059-5730; Hyslop, Stephanie Rose/0000-0001-5006-1627; Josefsson, Emma/0000-0001-6478-5204	Australian National Health and Medical Research Council [1079250, 1113577, 1122783, 1159658, 1058344, 1156095]; Independent Research Institutes Infrastructure Support Scheme Grant [9000220]; Victorian State Government Operational Infrastructure Support Grant; Lorenzo and Pamela Galli Charitable Trust; Australian Postgraduate Award from the University of Melbourne; Victorian Cancer Agency Mid-Career Fellowship [MCRF18003]; Peter and Julie Alston Centenary Fellowship; Australian Phenomics Network; Leukemia and Lymphoma Society [LLS SCOR 7001-13 MJH]; Australian Government through the National Collaborative Research Infrastructure Strategy program	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Independent Research Institutes Infrastructure Support Scheme Grant; Victorian State Government Operational Infrastructure Support Grant; Lorenzo and Pamela Galli Charitable Trust; Australian Postgraduate Award from the University of Melbourne; Victorian Cancer Agency Mid-Career Fellowship; Peter and Julie Alston Centenary Fellowship; Australian Phenomics Network; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Australian Government through the National Collaborative Research Infrastructure Strategy program(Australian GovernmentDepartment of Industry, Innovation and Science)	We thank Prof Benjamin Kile for generously providing Bcl-x<SUP>Plt20</SUP> mice and A/Prof Marie-Liesse Asselin-Labat for kindly sharing cell lines. We thank Janelle Lochland, Dr Amanda Au, Nicole Lynch, Stephanie Bound, Keti Stoev, Rebekah Meeny and Shannon Oliver for outstanding assistance and Prof Doug Hilton for helpful discussions. Ann Officer facilitated data collection for the Thoracic Malignancies Cohort Study and Him Ahmad assisted with patient pathology data collation. This work was supported by Australian National Health and Medical Research Council Project, Ideas, and Program Grants (1079250 ECJ, 1113577, 1122783 APN, 1186575 MJH, 1159658 MJH), Fellowships (1058344 WSA, 1156095 MJH), an Independent Research Institutes Infrastructure Support Scheme Grant (9000220), and a Victorian State Government Operational Infrastructure Support Grant. ECJ is the recipient of a fellowship from the Lorenzo and Pamela Galli Charitable Trust. SRH is the recipient of an Australian Postgraduate Award from the University of Melbourne. KDS is supported by a Victorian Cancer Agency Mid-Career Fellowship (MCRF18003) and the Peter and Julie Alston Centenary Fellowship. The generation of the NSG Mpl-/-mice was supported by the Australian Phenomics Network, the Leukemia and Lymphoma Society (LLS SCOR 7001-13 MJH), and the Australian Government through the National Collaborative Research Infrastructure Strategy program.	Alexander WS, 1996, BLOOD, V87, P2162, DOI 10.1182/blood.V87.6.2162.bloodjournal8762162; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Cho MS, 2012, BLOOD, V120, P4869, DOI 10.1182/blood-2012-06-438598; Coenen DM, 2017, BLOOD, V130, P2819, DOI 10.1182/blood-2017-04-780825; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Gay LJ, 2011, CANCER CELL, V20, P553, DOI 10.1016/j.ccr.2011.11.001; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Han R, 2020, MOL ONCOL, V14, P1152, DOI 10.1002/1878-0261.12682; Hu X, 2018, ONCOL LETT, V16, P2715, DOI 10.3892/ol.2018.8956; Hyslop SR, 2017, TRENDS CANCER, V3, P235, DOI 10.1016/j.trecan.2017.01.006; Izaguirre-Avila R, 2002, CLIN APPL THROMB-HEM, V8, P169, DOI 10.1177/107602960200800214; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; JAIN R, 1983, SOUTHERN MED J, V76, P1380, DOI 10.1097/00007611-198311000-00013; Kopp HG, 2009, CANCER RES, V69, P7775, DOI 10.1158/0008-5472.CAN-09-2123; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Lebois M, 2016, J THROMB HAEMOST, V14, P1882, DOI 10.1111/jth.13397; LEVIN J, 1964, ARCH INTERN MED, V114, P497, DOI 10.1001/archinte.1964.03860100079008; Lucotti S, 2019, J CLIN INVEST, V129, P1845, DOI 10.1172/JCI121985; Malhotra J, 2017, TRANSL LUNG CANCER R, V6, P196, DOI 10.21037/tlcr.2017.03.01; Mammadova-Bach E, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88245; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; McNeil JJ, 2018, NEW ENGL J MED, V379, P1519, DOI 10.1056/NEJMoa1803955; Michael JV, 2017, BLOOD, V130, P567, DOI 10.1182/blood-2016-11-751099; Miyata K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04324-1; Niki M, 2017, LUNG CANCER-TARGETS, V8, P91, DOI 10.2147/LCTT.S138887; Osmani L, 2018, SEMIN CANCER BIOL, V52, P103, DOI 10.1016/j.semcancer.2017.11.019; Pedersen LM, 1996, EUR RESPIR J, V9, P1826; Plantureux L, 2020, CANCER RES, V80, P291, DOI 10.1158/0008-5472.CAN-19-1181; Pucci F, 2016, CELL REP, V17, P1764, DOI 10.1016/j.celrep.2016.10.031; Rachidi S, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aai7911; Riesenberg BP, 2019, J IMMUNOL, V203, P1105, DOI 10.4049/jimmunol.1900594; Roselli M, 2004, CLIN CANCER RES, V10, P610, DOI 10.1158/1078-0432.CCR-0348-03; Roselli M, 2002, INT J BIOL MARKER, V17, P56, DOI 10.1177/172460080201700107; Rothwell PM, 2011, LANCET, V377, P31, DOI 10.1016/S0140-6736(10)62110-1; Schumacher D, 2013, CANCER CELL, V24, P130, DOI 10.1016/j.ccr.2013.05.008; Spiro SG, 2005, CURR OPIN PULM MED, V11, P287, DOI 10.1097/01.mcp.0000166590.03042.56; Takagi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073609; Tomita Masaki, 2008, Interact Cardiovasc Thorac Surg, V7, P613, DOI 10.1510/icvts.2007.174391; Wang JJ, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819837261; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Yu LX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6256; Zhang H, 2015, AM J SURG, V210, P526, DOI 10.1016/j.amjsurg.2015.03.022; Zhang X, 2015, INT J CLIN EXP MED, V8, P5379	44	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2020	39	29					5177	5186		10.1038/s41388-020-1357-6	http://dx.doi.org/10.1038/s41388-020-1357-6		JUN 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ML6WO	32535617				2022-12-17	WOS:000539953300001
J	Richart, L; Felipe, I; Delgado, P; de Andres, MP; Prieto, J; del Pozo, N; Garcia, JF; Piris, MA; Ramiro, A; Real, FX				Richart, Laia; Felipe, Irene; Delgado, Pilar; de Andres, Monica P.; Prieto, Jaime; del Pozo, Natalia; Garcia, Juan F.; Piris, Miguel A.; Ramiro, Almudena; Real, Francisco X.			Bptf determines oncogenic addiction in aggressive B-cell lymphomas	ONCOGENE			English	Article							BURKITTS-LYMPHOMA; DISTINCT TYPES; MYC; CANCER; MODEL; PATHWAY; DRIVEN; GENES; MOUSE	Chromatin remodeling factors contribute to establish aberrant gene expression programs in cancer cells and therefore represent valuable targets for therapeutic intervention. BPTF (Bromodomain PhD Transcription Factor), a core subunit of the nucleosome remodeling factor (NURF), modulates c-MYC oncogenic activity in pancreatic cancer. Here, we analyze the role of BPTF in c-MYC-driven B-cell lymphomagenesis using the E mu-Myc transgenic mouse model of aggressive B-cell lymphoma. We find that BPTF is required for normal B-cell differentiation without evidence of haploinsufficiency. In contrast, deletion of one Bptf allele is sufficient to delay lymphomagenesis in E mu-Myc mice. Tumors arising in a Bptf heterozygous background display decreased c-MYC levels and pathway activity, together with increased activation of the NF-kappa B pathway, a molecular signature characteristic of human diffuse large B-cell lymphoma (DLBCL). In human B-cell lymphoma samples, we find a strong correlation between BPTF and c-MYC mRNA and protein levels, together with an anti-correlation between BPTF and NF-kappa B pathway activity. Our results indicate that BPTF is a relevant therapeutic target in B-cell lymphomas and that, upon its inhibition, cells acquire distinct oncogenic dependencies.	[Richart, Laia; Felipe, Irene; de Andres, Monica P.; Prieto, Jaime; del Pozo, Natalia; Real, Francisco X.] CNIO, Spanish Natl Canc Res Ctr, Mol Oncol Programme, Epithelial Carcinogenesis Grp, Madrid 28029, Spain; [Delgado, Pilar; Ramiro, Almudena] CNIC, B Lymphocyte Biol Lab, Madrid 28029, Spain; [del Pozo, Natalia; Piris, Miguel A.; Real, Francisco X.] Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain; [Garcia, Juan F.] MD Anderson Canc Ctr, Dept Pathol, Madrid 28033, Spain; [Piris, Miguel A.] Fdn Jimenez Diaz, Dept Pathol, Madrid 28040, Spain; [Piris, Miguel A.] Hosp Univ Marques de Valdecilla, Dept Pathol, Santander 39008, Spain; [Real, Francisco X.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona 08003, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Cardiovasculares (CNIC); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Texas System; UTMD Anderson Cancer Center; Hospital Universitario Marques de Valdecilla (HUMV); Pompeu Fabra University	Real, FX (corresponding author), CNIO, Spanish Natl Canc Res Ctr, Mol Oncol Programme, Epithelial Carcinogenesis Grp, Madrid 28029, Spain.; Real, FX (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Madrid 28029, Spain.; Real, FX (corresponding author), Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona 08003, Spain.	preal@cnio.es	FELIPE, IRENE/ABF-9743-2021; Arribas, Francisco X Real/H-5275-2015; Delgado, Pilar/F-3365-2016; Ramiro, Almudena R/H-6037-2015	FELIPE, IRENE/0000-0001-7781-1459; Arribas, Francisco X Real/0000-0001-9501-498X; Delgado, Pilar/0000-0002-8431-8002; Ramiro, Almudena R/0000-0002-7539-3844	(Ministerio de Ciencia, Innovacion y Universidades, Madrid, Spain) (ERDF-EU) [SAF2011-29530, SAF2015-70553-R, RTI2018-101071-B-I00]; RTICC [RD12/0036/0034, RD12/0036/0050]; ERC [StG BCLYM-207844, SAF2013-42767-R, SAF2016-75511-R]; Fondo Europeo de Desarrollo Regional (FEDER); Ministerio de Ciencia, Innovacion y Universidades as a Centro de Excelencia Severo Ochoa [SEV-2015-0510]; Ministerio de Ciencia, Innovacion y Universidades (MCNU); Pro CNIC Foundation; Asociacion Espanola Contra el Cancer; Amigos del CNIO/Juegaterapia; Ministerio de Ciencia, Innovacion y Universidades, Spain	(Ministerio de Ciencia, Innovacion y Universidades, Madrid, Spain) (ERDF-EU); RTICC(Instituto de Salud Carlos III); ERC(European Research Council (ERC)European Commission); Fondo Europeo de Desarrollo Regional (FEDER)(European CommissionSpanish Government); Ministerio de Ciencia, Innovacion y Universidades as a Centro de Excelencia Severo Ochoa; Ministerio de Ciencia, Innovacion y Universidades (MCNU)(Spanish Government); Pro CNIC Foundation; Asociacion Espanola Contra el Cancer; Amigos del CNIO/Juegaterapia; Ministerio de Ciencia, Innovacion y Universidades, Spain(Spanish Government)	We thank the CNIO Core facilities and ECG members for support, V. J. Sanchez-Arevalo for valuable discussions, E. Carrillo-de-Santa Pau for discussion on bioinformatics analyses, and V. de Yebenes for critical comments to a previous version of the manuscript. We thank M. Reth and C. Blanco for providing Mb1-Cre and E mu-Myc mice, respectively. FXR was supported, in part, by grants SAF2011-29530, SAF2015-70553-R, RTI2018-101071-B-I00, and RTI2018-101071-B-I00 (Ministerio de Ciencia, Innovacion y Universidades, Madrid, Spain) (co-funded by the ERDF-EU) and RTICC (RD12/0036/0034, RD12/0036/0050, Instituto de Salud Carlos III). AR was supported by ERC StG BCLYM-207844, SAF2013-42767-R, and SAF2016-75511-R grants and co-funding by Fondo Europeo de Desarrollo Regional (FEDER). CNIO is supported by Ministerio de Ciencia, Innovacion y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510. The CNIC is supported by the Ministerio de Ciencia, Innovacion y Universidades (MCNU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505). Personal grants: PD and JP, Asociacion Espanola Contra el Cancer; IF, Amigos del CNIO/Juegaterapia; MPA, Ministerio de Ciencia, Innovacion y Universidades, Spain. FXR acknowledges the support of Asociacion Espanola Contra el Cancer.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Balbas-Martinez C, 2013, NAT GENET, V45, P1464, DOI 10.1038/ng.2799; Bishop PC, 2000, CANCER INVEST, V18, P574, DOI 10.3109/07357900009012197; Dar AA, 2016, P NATL ACAD SCI USA, V113, P6254, DOI 10.1073/pnas.1606027113; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Frey WD, 2017, STEM CELL REP, V9, P23, DOI 10.1016/j.stemcr.2017.04.031; Gonzalez-Perez A., 2013, GENOME BIOL, V14, pr106; Grana O, 2018, CURR BIOINFORM, V13, P583, DOI 10.2174/1574893612666170810153850; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hobeika E, 2006, P NATL ACAD SCI USA, V103, P13789, DOI 10.1073/pnas.0605944103; Hummel M, 2006, NEW ENGL J MED, V354, P2419, DOI 10.1056/NEJMoa055351; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Keller U, 2005, ONCOGENE, V24, P6231, DOI 10.1038/sj.onc.1208779; Klapper W, 2008, BLOOD, V112, P1374, DOI 10.1182/blood-2008-01-136465; Klapproth K, 2009, BLOOD, V114, P2448, DOI 10.1182/blood-2008-09-181008; Landry J, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000241; Landry JW, 2011, GENE DEV, V25, P275, DOI 10.1101/gad.2007311; Lee SCW, 2013, BLOOD, V122, P2654, DOI 10.1182/blood-2013-02-484055; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; Lunning MA, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.89; Malysheva V, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0310-3; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Mori S, 2008, CANCER RES, V68, P8525, DOI 10.1158/0008-5472.CAN-08-1329; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Pasqualucci L, 2008, NAT GENET, V40, P108, DOI 10.1038/ng.2007.35; Pfister SX, 2017, NAT REV DRUG DISCOV, V16, P241, DOI 10.1038/nrd.2016.256; Pujana MA, 2007, NAT GENET, V39, P1338, DOI 10.1038/ng.2007.2; Rempel RE, 2014, MOL CANCER THER, V13, P3219, DOI 10.1158/1535-7163.MCT-13-0044; Richart L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10153; Ruthenburg AJ, 2011, CELL, V145, P692, DOI 10.1016/j.cell.2011.03.053; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Xu BW, 2018, STEM CELL REP, V10, P675, DOI 10.1016/j.stemcr.2018.01.020; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Yang ZH, 2018, J CLIN INVEST, V128, P3605, DOI 10.1172/JCI97072; Yu DN, 2005, ANN NY ACAD SCI, V1059, P145, DOI 10.1196/annals.1339.047	42	2	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4884	4895		10.1038/s41388-020-1331-3	http://dx.doi.org/10.1038/s41388-020-1331-3		MAY 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32451433				2022-12-17	WOS:000535403900001
J	Shoumariyeh, K; Schneider, N; Poggio, T; Veratti, P; Ehrenfeld, S; Redhaber, DM; Khan, R; Pfeifer, D; Klingeberg, C; Kreutmair, S; Rudelius, M; Quintanilla-Martinez, L; Fend, F; Illert, AL; Duyster, J; Miething, C				Shoumariyeh, Khalid; Schneider, Nicolas; Poggio, Teresa; Veratti, Pia; Ehrenfeld, Sophia; Redhaber, Desiree M.; Khan, Robin; Pfeifer, Dietmar; Klingeberg, Cathrin; Kreutmair, Stefanie; Rudelius, Martina; Quintanilla-Martinez, Leticia; Fend, Falko; Illert, Anna L.; Duyster, Justus; Miething, Cornelius			A novel conditional NPM-ALK-driven model of CD30+T-cell lymphoma mediated by a translational stop cassette	ONCOGENE			English	Article							LARGE-CELL LYMPHOMA; T-CELLS; GENE; EXPRESSION; MACROPHAGES; MECHANISMS; DISEASE	Targeted expression of transgenes is essential for the accurate representation of human disease in in vivo models. Current approaches to generate conditional transgenic mouse models are cumbersome and not amenable to high-throughput analysis since they require de novo generation and characterization of genetically modified mice. Here we describe a new system for lineage-restricted expression of transgenes based on a retroviral vector incorporating a translational stop cassette flanked by loxP recombination sites. Conditional transgene expression in chimeric mice is achieved by retroviral infection and transplantation of hematopoietic stem cells (HSC) derived from transgenic mice expressing Cre-recombinase from a lineage-specific promoter. For validation, we directed expression of NPM-ALK, the fusion oncogene driving a subset of anaplastic large cell lymphoma (ALCL), to T-cells by infecting hematopoietic stem cells from Lck-Cre-transgenic mice with a retroviral construct containing the NPM-ALK cDNA preceded by a translational stop cassette. These mice developed T-cell lymphomas within 12-16 weeks, featuring increased expression of the ALCL hallmark antigen CD30 as well as other cytotoxic T-cell markers, similar to the human disease. The new model represents a versatile tool for the rapid analysis of gene function in a defined lineage or in a developmental stage in vivo.	[Shoumariyeh, Khalid; Poggio, Teresa; Veratti, Pia; Ehrenfeld, Sophia; Redhaber, Desiree M.; Khan, Robin; Pfeifer, Dietmar; Klingeberg, Cathrin; Kreutmair, Stefanie; Illert, Anna L.; Duyster, Justus; Miething, Cornelius] Univ Freiburg, Fac Med, Med Ctr, Dept Hematol Oncol & Stem Cell Transplantat, D-79106 Freiburg, Germany; [Shoumariyeh, Khalid; Veratti, Pia; Ehrenfeld, Sophia; Redhaber, Desiree M.; Kreutmair, Stefanie; Illert, Anna L.; Duyster, Justus; Miething, Cornelius] German Canc Consortium DKTK, Partner Site Freiburg, D-79106 Freiburg, Germany; [Schneider, Nicolas] Tech Univ Munich, Klinikum Rechts Isar, Dept Hematol Oncol & Stem Cell Transplantat, D-81675 Munich, Germany; [Poggio, Teresa; Ehrenfeld, Sophia; Redhaber, Desiree M.] Albert Ludwigs Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany; [Veratti, Pia; Ehrenfeld, Sophia; Redhaber, Desiree M.; Illert, Anna L.; Duyster, Justus; Miething, Cornelius] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Rudelius, Martina] Ludwig Maximilians Univ Munchen, Inst Pathol, D-81377 Munich, Germany; [Quintanilla-Martinez, Leticia; Fend, Falko] Univ Hosp Tubingen, Dept Pathol, D-72076 Tubingen, Germany	University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Technical University of Munich; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Miething, C (corresponding author), Univ Freiburg, Fac Med, Med Ctr, Dept Hematol Oncol & Stem Cell Transplantat, D-79106 Freiburg, Germany.; Miething, C (corresponding author), German Canc Consortium DKTK, Partner Site Freiburg, D-79106 Freiburg, Germany.; Miething, C (corresponding author), German Canc Res Ctr, D-69120 Heidelberg, Germany.	cornelius.miething@uniklinik-freiburg.de	Kreutmair, Stefanie/GOK-2757-2022; Shoumariyeh, Khalid/AAB-8421-2021; Kreutmair, Stefanie/AAE-6952-2022	Kreutmair, Stefanie/0000-0001-8466-6675; Poggio, Teresa/0000-0003-2560-8488; Schneider, Nicolas/0000-0002-9044-446X	European Union [675712]; German Research Council (DFG) [TRR54, 34712712]	European Union(European Commission); German Research Council (DFG)(German Research Foundation (DFG))	This work was in part funded by the European Union Horizon 2020 Marie Sklodowska-Curie Innovative Training Network Grant No 675712 (ALI and TP) and by the German Research Council (DFG) TRR54 grant No 34712712 (JD).	Babendure JR, 2006, RNA, V12, P851, DOI 10.1261/rna.2309906; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Brierley I, 2007, NAT REV MICROBIOL, V5, P598, DOI 10.1038/nrmicro1704; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Dow LE, 2015, TRENDS MOL MED, V21, P609, DOI 10.1016/j.molmed.2015.07.006; Frese KK, 2007, NAT REV CANCER, V7, P645, DOI 10.1038/nrc2192; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; HANNA Z, 1994, MOL CELL BIOL, V14, P1084, DOI 10.1128/MCB.14.2.1084; Hanson G, 2018, NAT REV MOL CELL BIO, V19, P20, DOI 10.1038/nrm.2017.91; Hemann Michael, 2015, Cold Spring Harb Protoc, V2015, P725, DOI 10.1101/pdb.top069872; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; Heyer J, 2010, NAT REV CANCER, V10, P470, DOI 10.1038/nrc2877; Jacob J, 1999, NATURE, V399, P593, DOI 10.1038/21208; Jager R, 2005, ANTICANCER RES, V25, P3191; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Maresch R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10770; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Miething C, 2003, ONCOGENE, V22, P4642, DOI 10.1038/sj.onc.1206575; Mou HW, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0178-7; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pfleger BF, 2005, BIOTECHNOL BIOENG, V92, P553, DOI 10.1002/bit.20630; Roth TL, 2018, NATURE, V559, P405, DOI 10.1038/s41586-018-0326-5; Sperschneider J, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq021; Stein H, 2000, BLOOD, V96, P3681; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Turner SD, 2003, ONCOGENE, V22, P7750, DOI 10.1038/sj.onc.1207048; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	31	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1904	1913		10.1038/s41388-019-1058-1	http://dx.doi.org/10.1038/s41388-019-1058-1			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31754210				2022-12-17	WOS:000516579800006
J	Martin-Padron, J; Boyero, L; Rodriguez, MI; Andrades, A; Diaz-Cano, I; Peinado, P; Balinas-Gavira, C; Alvarez-Perez, JC; Coira, IF; Farez-Vidal, ME; Medina, PP				Martin-Padron, Joel; Boyero, Laura; Isabel Rodriguez, Maria; Andrades, Alvaro; Diaz-Cano, Ines; Peinado, Paola; Balinas-Gavira, Carlos; Carlos Alvarez-Perez, Juan; Coira, Isabel F.; Esther Farez-Vidal, Maria; Medina, Pedro P.			Plakophilin 1 enhances MYC translation, promoting squamous cell lung cancer (vol 54, pg 982, 2019)	ONCOGENE			English	Correction								An amendment to this paper has been published and can be accessed via a link at the top of the paper.				efarez@ugr.es	Perez, Juan Carlos Alvarez/AAE-4518-2021; Andrades, Álvaro/A-6890-2017; Coira, Isabel F./N-4002-2014; Lara, María Isabel Rodríguez/A-1961-2017	Perez, Juan Carlos Alvarez/0000-0001-6396-311X; Andrades, Álvaro/0000-0001-9042-8964; Coira, Isabel F./0000-0003-3368-4691; Lara, María Isabel Rodríguez/0000-0002-2270-0070	Fundacion Anticancer San Francisco Javier y Santa Candida/UGR; PhD FPU fellowship [FPU17/00067]; La Caixa Foundation [LCF/BQ/DE15/10360019]; PhD FPI-fellowship [BES-2013-064596]; Marie Sklodowska Curie action (H2020-MSCA-IF-2018); Consejeria de Sanidad de la Junta de Andalucia [Pl-0245-2017]; PAIDI program; Group BIO309; Ministry of Economy of Spain [SAF2015-67919-R]; Junta de Andalucia [P12-BIO-1655, PAIDI CTS-993]; Francisco Cobos Foundation; FERO foundation; International Association for the study of lung cancer (IASLC); Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (Lab AECC-2018); Instituto de Salud Carlos III-Fondo de Investigacion Sanitaria [PI10/00198]	Fundacion Anticancer San Francisco Javier y Santa Candida/UGR; PhD FPU fellowship; La Caixa Foundation(La Caixa Foundation); PhD FPI-fellowship; Marie Sklodowska Curie action (H2020-MSCA-IF-2018); Consejeria de Sanidad de la Junta de Andalucia(Junta de Andalucia); PAIDI program; Group BIO309; Ministry of Economy of Spain(Spanish Government); Junta de Andalucia(Junta de Andalucia); Francisco Cobos Foundation; FERO foundation; International Association for the study of lung cancer (IASLC); Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (Lab AECC-2018); Instituto de Salud Carlos III-Fondo de Investigacion Sanitaria(Instituto de Salud Carlos IIIEuropean Commission)	JM-P and LB were supported by fellowships from Fundacion Anticancer San Francisco Javier y Santa Candida/UGR. AA was supported by a PhD FPU fellowship (FPU17/00067). PP was supported by a PhD "La Caixa Foundation" LCF/BQ/DE15/10360019 Fellowship. IFC was supported by a PhD FPI-fellowship (BES-2013-064596). JCA-P is supported by a Marie Sklodowska Curie action (H2020-MSCA-IF-2018). CB and MIR were supported by Consejeria de Sanidad de la Junta de Andalucia (Pl-0245-2017). MEF-V was supported by PAIDI program. Group BIO309. Junta de Andalucia, and Instituto de Salud Carlos III-Fondo de Investigacion Sanitaria PI10/00198. PPM laboratory is funded by the Ministry of Economy of Spain (SAF2015-67919-R), Junta de Andalucia (P12-BIO-1655, PAIDI CTS-993), Francisco Cobos Foundation, FERO foundation, International Association for the study of lung cancer (IASLC) and Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (Lab AECC-2018). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Martin-Padron J, 2020, ONCOGENE, V39, P5479, DOI 10.1038/s41388-019-1129-3	1	2	2	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5494	5494		10.1038/s41388-019-1147-1	http://dx.doi.org/10.1038/s41388-019-1147-1		JAN 2020	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	31937909	Bronze			2022-12-17	WOS:000508950500001
J	Chen, CJ; Yang, CJ; Yang, SF; Huang, MS; Liu, YP				Chen, Chao-Ju; Yang, Chih-Jen; Yang, Sheau-Fang; Huang, Ming-Shyang; Liu, Yu-Peng			The MyoD family inhibitor domain-containing protein enhances the chemoresistance of cancer stem cells in the epithelial state by increasing beta-catenin activity	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; LUNG ADENOCARCINOMA; TUMOR-CELLS; MECHANISM; RESPONSES; INTERACT; SELECTS	Cancer cells with mesenchymal attributes potentially display chemoresistance. Cancer stem cells (CSCs), which are intrinsically resistant to most chemotherapy agents, exhibit considerable phenotypic heterogeneity in their epithelial versus mesenchymal states. However, the drug response of CSCs in the epithelial and mesenchymal states has not been completely investigated. In this study, we found that epithelial-type (E-cadherin(high)/CD133(high)) CSCs displayed a higher sphere formation ability and chemoresistance than mesenchymal-type (E-cadherin(low)CD133(high)) CSCs. Gene expression profiling of the CSC and non-CSC subpopulations with distinct epithelial-to-mesenchymal transition (EMT) states showed that MyoD family inhibitor domain-containing (MDFIC) was selectively upregulated in epithelial-type CSCs. Knockdown of MDFIC sensitized epithelial-type CSCs to chemotherapy agents. Ectopic expression of MDFIC increased the chemoresistance of mesenchymal-type CSCs. In a tissue microarray, high MDFIC expression was associated with poor prognosis of non-small cell lung cancer (NSCLC) patients. A mechanistic study showed that the MDFIC p32 isoform, which is located in the cytoplasm, interacted with the destruction complex, Axin/GSK-3/beta-catenin. This interaction stabilized beta-catenin by inhibiting beta-catenin phosphorylation at S33/37 and increased the nuclear translocation and transcriptional activity of beta-catenin. Knockdown of beta-catenin decreased MDFIC-enhanced chemoresistance. These results suggested that the upregulation of MDFIC enhanced the chemoresistance of epithelial-type CSCs by elevating beta-catenin activity. Thus, targeting MDFIC-regulated beta-catenin signaling of epithelial-type CSCs may be a potential strategy to overcome chemoresistance in NSCLC.	[Chen, Chao-Ju] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan; [Chen, Chao-Ju] Kaohsiung Med Univ Hosp, Dept Lab Med, Kaohsiung, Taiwan; [Yang, Chih-Jen] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Internal Med, Kaohsiung, Taiwan; [Yang, Chih-Jen] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Kaohsiung, Taiwan; [Yang, Sheau-Fang] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Pathol, Kaohsiung, Taiwan; [Huang, Ming-Shyang] E DA Canc Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Kaohsiung, Taiwan; [Huang, Ming-Shyang] I Shou Univ, Coll Med, Sch Med, Kaohsiung, Taiwan; [Liu, Yu-Peng] Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Kaohsiung, Taiwan; [Liu, Yu-Peng] Kaohsiung Med Univ, Res Ctr Environm Med, Kaohsiung, Taiwan; [Liu, Yu-Peng] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; E-Da Hospital; I Shou University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Liu, YP (corresponding author), Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Kaohsiung, Taiwan.; Liu, YP (corresponding author), Kaohsiung Med Univ, Res Ctr Environm Med, Kaohsiung, Taiwan.; Liu, YP (corresponding author), Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan.	ypliu@kmu.edu.tw		Liu, Yu-Peng/0000-0002-2716-0050	Ministry of Science and Technology of Taiwan [MOST 107-2320-B-037-025-]; Kaohsiung Medical University Hospital [KMUH106-6M63]; Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project, Ministry of Education (MOE) in Taiwan	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Kaohsiung Medical University Hospital; Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project, Ministry of Education (MOE) in Taiwan	This study was financially supported by the Ministry of Science and Technology of Taiwan (MOST 107-2320-B-037-025-) and Kaohsiung Medical University Hospital (KMUH106-6M63). This work was also financially supported by the Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. We thank Dr Michael Hsiao for providing the tissue microarray chips. We thank the assistance of the Department of Pathology and the Biobank in Kaohsiung Medical University Hospital, Kaohsiung, Taiwan for the clinical sample collection. We thank the Center for Research Resources and Development in Kaohsiung Medical University for the instrumental support for the confocal microscope and TissueFAX system. The authors thank the Immunobiology core facility of Clinical Medicine Research Center in National Cheng Kung University Hospital for assisting with the fluorescence-activated cell sorting.	Beck TN, 2016, CELL REP, V16, P657, DOI 10.1016/j.celrep.2016.06.043; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chang YW, 2015, CANCER RES, V75, P3398, DOI 10.1158/0008-5472.CAN-14-3265; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gupta PB, 2019, CELL STEM CELL, V24, P65, DOI 10.1016/j.stem.2018.11.011; Huang XJ, 2018, J BIOL CHEM, V293, P6693, DOI 10.1074/jbc.RA118.001689; Kusano S, 2002, MOL CELL BIOL, V22, P6393, DOI 10.1128/MCB.22.18.6393-6405.2002; Li GM, 2018, INT J BIOL SCI, V14, P280, DOI 10.7150/ijbs.23756; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu YP, 2013, CANCER RES, V73, P406, DOI 10.1158/0008-5472.CAN-12-1733; Luo M, 2018, CELL METAB, V28, P69, DOI 10.1016/j.cmet.2018.06.006; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mittal V, 2016, ADV EXP MED BIOL, V890, P37, DOI 10.1007/978-3-319-24932-2_3; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Oakley RH, 2017, J BIOL CHEM, V292, P5825, DOI 10.1074/jbc.M116.758888; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Pore M, 2016, CLIN LUNG CANCER, V17, P535, DOI 10.1016/j.cllc.2016.05.015; Reck M, 2017, NEW ENGL J MED, V377, P849, DOI 10.1056/NEJMra1703413; Sculier JP, 2008, J THORAC ONCOL, V3, P457, DOI 10.1097/JTO.0b013e31816de2b8; Sen Heng W, 2019, BIOCHEM PHARMACOL, V160, P121, DOI 10.1016/j.bcp.2018.12.010; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Snider L, 2001, MOL CELL BIOL, V21, P1866, DOI 10.1128/MCB.21.5.1866-1873.2001; Song C, 2009, BIOL CHEM, V390, P215, DOI 10.1515/BC.2009.028; Sullivan JP, 2010, CANCER RES, V70, P9937, DOI 10.1158/0008-5472.CAN-10-0881; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Thebault S, 2001, CURR PROTEIN PEPT SC, V2, P155, DOI 10.2174/1389203013381143; Thebault S, 2000, J BIOL CHEM, V275, P4848, DOI 10.1074/jbc.275.7.4848; Thu Kelsie L, 2014, Oncoscience, V1, P326; Tiran V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09929-0; Tsoukalas N, 2017, ANTICANCER RES, V37, P1773, DOI 10.21873/anticanres.11510; Vijay GV, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1125-0; Wang D, 2018, CANCER BIOMARK, V22, P385, DOI 10.3233/CBM-170835; Wang Q, 2007, J MOL BIOL, V367, P630, DOI 10.1016/j.jmb.2007.01.020; Wu DM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1591-4; Xu YR, 2017, SEMIN CELL DEV BIOL, V63, P23, DOI 10.1016/j.semcdb.2016.07.028; Yadav AK, 2019, STEM CELL REV REP, V15, P331, DOI 10.1007/s12015-019-09887-2; Yakisich JS, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694310; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zhang M, 2019, CURR MOL MED, V19, P349, DOI 10.2174/1566524019666190405121139	44	2	2	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2377	2390		10.1038/s41388-019-1152-4	http://dx.doi.org/10.1038/s41388-019-1152-4		JAN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31911618				2022-12-17	WOS:000508154600002
J	Das, S; Nair, RS; Mishra, R; Sondarva, G; Viswakarma, N; Abdelkarim, H; Gaponenko, V; Sathyanarayana, P; Rana, B; Rana, A				Das, Subhasis; Nair, Rakesh Sathish; Mishra, Rajakishore; Sondarva, Gautam; Viswakarma, Navin; Abdelkarim, Hazem; Gaponenko, Vadim; Sathyanarayana, Pradeep; Rana, Basabi; Rana, Ajay			Mixed lineage kinase 3 promotes breast tumorigenesis via phosphorylation and activation of p21-activated kinase 1 (vol 73, pg 812, 2019)	ONCOGENE			English	Correction									[Das, Subhasis; Nair, Rakesh Sathish; Sondarva, Gautam; Viswakarma, Navin; Rana, Basabi; Rana, Ajay] Univ Illinois, Dept Surg, Div Surg Oncol, Chicago, IL 60612 USA; [Mishra, Rajakishore] Cent Univ Jharkhand, Ctr Life Sci, Sch Nat Sci, Ranchi 835205, Jharkhand, India; [Abdelkarim, Hazem; Gaponenko, Vadim] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; [Sathyanarayana, Pradeep] Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME USA; [Rana, Basabi; Rana, Ajay] Univ Illinois Hosp, Chicago, IL 60612 USA; [Rana, Basabi; Rana, Ajay] Univ Illinois, Hlth Sci Syst Canc Ctr, Chicago, IL 60612 USA; [Rana, Basabi; Rana, Ajay] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Central University of Jharkhand; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Maine Medical Center; University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Rana, A (corresponding author), Univ Illinois, Dept Surg, Div Surg Oncol, Chicago, IL 60612 USA.; Rana, A (corresponding author), Univ Illinois Hosp, Chicago, IL 60612 USA.; Rana, A (corresponding author), Univ Illinois, Hlth Sci Syst Canc Ctr, Chicago, IL 60612 USA.; Rana, A (corresponding author), Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.	arana@uic.edu	Rana, Ajay/ABE-3739-2020; Mishra, Rajakishore/ABC-3550-2020	Rana, Ajay/0000-0003-0951-2566; 				Das S, 2019, ONCOGENE, V38, P3569, DOI 10.1038/s41388-019-0690-0	1	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					722	722		10.1038/s41388-019-1011-3	http://dx.doi.org/10.1038/s41388-019-1011-3			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31530933	Bronze			2022-12-17	WOS:000509718300019
J	Yang, TT; Ren, CN; Qiao, PY; Han, X; Wang, L; Lv, SJ; Sun, YH; Liu, ZJ; Du, Y; Yu, ZH				Yang, Tingting; Ren, Chune; Qiao, Pengyun; Han, Xue; Wang, Li; Lv, Shijun; Sun, Yonghong; Liu, Zhijun; Du, Yu; Yu, Zhenhai			PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer (vol 37, pg 5997, 2019)	ONCOGENE			English	Correction									[Yang, Tingting; Ren, Chune; Qiao, Pengyun; Han, Xue; Wang, Li; Yu, Zhenhai] Weifang Med Univ, Affiliated Hosp, Dept Reprod Med, Weifang, Shandong, Peoples R China; [Lv, Shijun; Sun, Yonghong] Weifang Med Univ, Affiliated Hosp, Dept Pathol, Weifang, Shandong, Peoples R China; [Liu, Zhijun; Du, Yu] Weifang Med Univ, Dept Med Microbiol, Weifang, Shandong, Peoples R China	Weifang Medical University; Weifang Medical University; Weifang Medical University	Yu, ZH (corresponding author), Weifang Med Univ, Affiliated Hosp, Dept Reprod Med, Weifang, Shandong, Peoples R China.	tomsyu@163.com	Liu, Zhijun/AAV-9805-2021					Yang TT, 2018, ONCOGENE, V37, P5997, DOI 10.1038/s41388-018-0386-x	1	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					720	721		10.1038/s41388-019-0982-4	http://dx.doi.org/10.1038/s41388-019-0982-4			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31511646	hybrid, Green Published			2022-12-17	WOS:000509718300018
J	Gregory, PA				Gregory, Philip A.			The miR-200-Quaking axis functions in tumour angiogenesis	ONCOGENE			English	Editorial Material							RNA-BINDING PROTEINS; MIR-200 FAMILY; QUAKING; METASTASIS; PROMOTES; CANCER; ZEB1; REPRESSION; INVASION; EMT		[Gregory, Philip A.] Univ South Australia, Ctr Canc Biol, Adelaide, SA 5000, Australia; [Gregory, Philip A.] SA Pathol, Adelaide, SA 5000, Australia; [Gregory, Philip A.] Univ Adelaide, Discipline Med, Adelaide, SA 5005, Australia	Centre for Cancer Biology; University of South Australia; SA Pathology; University of Adelaide	Gregory, PA (corresponding author), Univ South Australia, Ctr Canc Biol, Adelaide, SA 5000, Australia.; Gregory, PA (corresponding author), SA Pathol, Adelaide, SA 5000, Australia.; Gregory, PA (corresponding author), Univ Adelaide, Discipline Med, Adelaide, SA 5005, Australia.	philip.gregory@unisa.edu.au			Cancer Council's Beat Cancer Project; State Government through the Department of Health	Cancer Council's Beat Cancer Project; State Government through the Department of Health	This work was undertaken with the financial support of Cancer Council's Beat Cancer Project on behalf of its donors and the State Government through the Department of Health.	Azam SH, 2019, ONCOGENE, V38, P5191, DOI 10.1038/s41388-019-0786-6; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Bracken CP, 2014, EMBO J, V33, P2040, DOI 10.15252/embj.201488641; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chan YC, 2012, ARTERIOSCL THROM VAS, V32, P1372, DOI 10.1161/ATVBAHA.112.248583; Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790; Chen AJ, 2012, GENE DEV, V26, P1459, DOI 10.1101/gad.189001.112; Cochrane A, 2017, STEM CELLS, V35, P952, DOI 10.1002/stem.2594; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Darbelli L, 2016, WIRES RNA, V7, P399, DOI 10.1002/wrna.1344; de Bruin RG, 2016, SCI REP-UK, V6, DOI 10.1038/srep21643; Ding YZ, 2017, LIFE SCI, V191, P245, DOI 10.1016/j.lfs.2017.09.001; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gill JG, 2012, STEM CELLS DEV, V21, P167, DOI 10.1089/scd.2011.0194; Goel S, 2018, TRENDS CELL BIOL, V28, P911, DOI 10.1016/j.tcb.2018.07.002; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Harrison EB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00307; Hoefert JE, 2018, J CELL BIOL, V217, P2185, DOI 10.1083/jcb.201708173; Kim EJ, 2019, INT J CANCER, V145, P1585, DOI 10.1002/ijc.32372; Larocque D, 2005, NAT NEUROSCI, V8, P27, DOI 10.1038/nn1359; Liu TZ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13923; Lupo G, 2017, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00519; Magenta A, 2011, CELL DEATH DIFFER, V18, P1628, DOI 10.1038/cdd.2011.42; Noveroske JK, 2002, GENESIS, V32, P218, DOI 10.1002/gene.10060; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Pillman KA, 2018, EMBO J, V37, DOI 10.15252/embj.201899016; Schettini F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00608; van Mil A, 2012, CARDIOVASC RES, V93, P655, DOI 10.1093/cvr/cvs003; Zhou X, 2017, ONCOTARGET, V8, P82174, DOI 10.18632/oncotarget.19066; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289	33	2	2	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6767	6769		10.1038/s41388-019-0916-1	http://dx.doi.org/10.1038/s41388-019-0916-1			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31406253				2022-12-17	WOS:000489552900004
J	Jiang, MZ; Xu, B; Li, XW; Shang, YL; Chu, Y; Wang, WJ; Chen, D; Wu, N; Hu, SJ; Zhang, S; Li, MB; Wu, KC; Yang, XY; Liang, J; Nie, Y; Fan, DM				Jiang, Mingzuo; Xu, Bing; Li, Xiaowei; Shang, Yulong; Chu, Yi; Wang, Weijie; Chen, Di; Wu, Nan; Hu, Sijun; Zhang, Song; Li, Mengbin; Wu, Kaichun; Yang, Xiaoyong; Liang, Jie; Nie, Yongzhan; Fan, Daiming			O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit (vol 38, pg 301, 2019)	ONCOGENE			English	Correction									[Jiang, Mingzuo; Xu, Bing; Li, Xiaowei; Shang, Yulong; Chu, Yi; Wang, Weijie; Chen, Di; Wu, Nan; Hu, Sijun; Zhang, Song; Li, Mengbin; Wu, Kaichun; Liang, Jie; Nie, Yongzhan; Fan, Daiming] Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Jiang, Mingzuo; Xu, Bing; Li, Xiaowei; Shang, Yulong; Chu, Yi; Wang, Weijie; Chen, Di; Wu, Nan; Hu, Sijun; Zhang, Song; Li, Mengbin; Wu, Kaichun; Liang, Jie; Nie, Yongzhan; Fan, Daiming] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China; [Xu, Bing] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Gastroenterol, Xian 710004, Shaanxi, Peoples R China; [Wu, Nan] Northwest Univ, Fac Life Sci, Lab Tissue Engn, Xian, Shaanxi, Peoples R China; [Yang, Xiaoyong] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA	Air Force Military Medical University; Air Force Military Medical University; Xi'an Jiaotong University; Northwest University Xi'an; Yale University	Nie, Y; Fan, DM (corresponding author), Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China.; Nie, Y; Fan, DM (corresponding author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China.	yongznie@fmmu.edu.cn; daimingfan@fmmu.edu.cn						Jiang MZ, 2019, ONCOGENE, V38, P301, DOI 10.1038/s41388-018-0435-5	1	2	2	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5744	5745		10.1038/s41388-019-0834-2	http://dx.doi.org/10.1038/s41388-019-0834-2			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31160652	Bronze, Green Published			2022-12-17	WOS:000474845100016
J	Song, ZY; Wang, F; Cui, SX; Gao, ZH; Qu, XJ				Song, Zhi-Yu; Wang, Feng; Cui, Shu-Xiang; Gao, Zu-Hua; Qu, Xian-Jun			CXCR7/CXCR4 heterodimer-induced histone demethylation: a new mechanism of colorectal tumorigenesis (vol 38, pg 1560, 2019)	ONCOGENE			English	Correction									[Song, Zhi-Yu; Qu, Xian-Jun] Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China; [Wang, Feng; Gao, Zu-Hua] McGill Univ, Dept Pathol, Montreal, PQ, Canada; [Cui, Shu-Xiang] Capital Med Univ, Sch Publ Hlth, Toxicol & Sanit Chem, Beijing, Peoples R China; [Song, Zhi-Yu] Henan Prov Peoples Hosp, Dept Pharm, Zhengzhou, Henan, Peoples R China	Capital Medical University; McGill University; Capital Medical University; Zhengzhou University	Qu, XJ (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China.; Gao, ZH (corresponding author), McGill Univ, Dept Pathol, Montreal, PQ, Canada.	zu-hua.gao@mcgill.ca; quxj@ccmu.edu.cn						Song ZY, 2019, ONCOGENE, V38, P1560, DOI 10.1038/s41388-018-0519-2	1	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5747	5747		10.1038/s41388-019-0836-0	http://dx.doi.org/10.1038/s41388-019-0836-0			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31182792	Bronze			2022-12-17	WOS:000474845100018
J	Soria-Valles, C; Gutierrez-Fernandez, A; Guiu, M; Mari, B; Fueyo, A; Gomis, RR; Lopez-Otin, C				Soria-Valles, C.; Gutierrez-Fernandez, A.; Guiu, M.; Mari, B.; Fueyo, A.; Gomis, R. R.; Lopez-Otin, C.			The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21 (vol 33, pg 3054, 2014)	ONCOGENE			English	Correction									[Soria-Valles, C.; Gutierrez-Fernandez, A.; Lopez-Otin, C.] Univ Oviedo, Inst Univ Oncol IUOPA, Fac Med, Dept Bioquim & Biol Mol,193 Rea Fisiol, Oviedo, Spain; [Guiu, M.; Gomis, R. R.] Inst Res Biomed IRB Barcelona, Oncol Programme, Barcelona, Spain; [Mari, B.] CNRS, Valbonne Sophia Antipoll, France; [Mari, B.] Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, Valbonne Sophia Antipoll, France; [Fueyo, A.] Univ Oviedo, Inst Univ Oncol IUOPA, Fac Med, Dept Biol Func, Oviedo, Spain	University of Oviedo; Instituto Universitario de Oncologia de Asturias; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Oviedo; Instituto Universitario de Oncologia de Asturias	Lopez-Otin, C (corresponding author), Univ Oviedo, Inst Univ Oncol IUOPA, Fac Med, Dept Bioquim & Biol Mol,193 Rea Fisiol, Oviedo, Spain.	clo@uniovi.es	Mari, Bernard P/GVS-3100-2022; Fueyo, Antonio/ABH-3243-2020; Mari, Bernard/Q-5832-2019; Lopez-Otin, Carlos/AAB-2106-2020	Mari, Bernard P/0000-0002-0422-9182; Fueyo, Antonio/0000-0002-7121-9398; Mari, Bernard/0000-0002-0422-9182; Lopez-Otin, Carlos/0000-0001-6964-1904				Soria-Valles C, 2014, ONCOGENE, V33, P3054, DOI 10.1038/onc.2013.267	1	2	2	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5739	5739		10.1038/s41388-019-0825-3	http://dx.doi.org/10.1038/s41388-019-0825-3			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31053808	Bronze			2022-12-17	WOS:000474845100013
J	Hepburn, AC; Steele, RE; Veeratterapillay, R; Wilson, L; Kounatidou, EE; Barnard, A; Berry, P; Cassidy, JR; Moad, M; El-Sherif, A; Gaughan, L; Mills, IG; Robson, CN; Heer, R				Hepburn, A. C.; Steele, R. E.; Veeratterapillay, R.; Wilson, L.; Kounatidou, E. E.; Barnard, A.; Berry, P.; Cassidy, J. R.; Moad, M.; El-Sherif, A.; Gaughan, L.; Mills, I. G.; Robson, C. N.; Heer, R.			The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance (vol 38, pg 4412, 2019)	ONCOGENE			English	Correction									[Hepburn, A. C.; Wilson, L.; Kounatidou, E. E.; Barnard, A.; Berry, P.; Cassidy, J. R.; Moad, M.; Gaughan, L.; Robson, C. N.; Heer, R.] Newcastle Univ, Northern Inst Canc Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Steele, R. E.; Mills, I. G.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Prostate Canc UK Movember Ctr Excellence Prostate, Belfast BT9 7AE, Antrim, North Ireland; [Veeratterapillay, R.; Heer, R.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Dept Urol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; [El-Sherif, A.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Mills, I. G.] Univ Oxford, Nuffield Dept Surg Sci, Oxford OX3 9DU, England	Newcastle University - UK; Queens University Belfast; Newcastle Freeman Hospital; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Oxford	Hepburn, AC; Robson, CN; Heer, R (corresponding author), Newcastle Univ, Northern Inst Canc Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.; Heer, R (corresponding author), Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Dept Urol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.	anastasia.hepburn@newcastle.ac.uk; c.n.robson@newcastle.ac.uk; rakesh.heer@newcastle.ac.uk	Mills, Ian/AAK-9292-2020	Mills, Ian/0000-0001-5347-5083				Hepburn AC, 2019, ONCOGENE, V38, P4412, DOI 10.1038/s41388-019-0712-y	1	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4425	4425		10.1038/s41388-019-0826-2	http://dx.doi.org/10.1038/s41388-019-0826-2			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	31068666	Green Published, hybrid			2022-12-17	WOS:000469339100016
J	Jing, Y; Zhang, Y; Zhu, H; Zhang, K; Cai, MC; Ma, PF; Shen, PY; Zhang, ZF; Shao, MH; Wang, J; Yu, MH; Yin, X; Zhang, MY; Hu, Y; Chen, DN; Di, W; Wang, XJ; Zhuang, GL				Jing, Ying; Zhang, Yi; Zhu, Hui; Zhang, Ke; Cai, Mei-Chun; Ma, Pengfei; Shen, Peiye; Zhang, Zhenfeng; Shao, Minghui; Wang, Jing; Yu, Minhua; Yin, Xia; Zhang, Meiying; Hu, Yuan; Chen, Danni; Di, Wen; Wang, Xiaojie; Zhuang, Guanglei			Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer	ONCOGENE			English	Article							UPDATED RESOURCE; ALIGNMENT; QUANTIFICATION; HETEROGENEITY; CARBOPLATIN; MECHANISMS; BORTEZOMIB; LANDSCAPE; CARCINOMA; ONCOLOGY	Comprehensive molecular characterization of myriad somatic alterations and aberrant gene expressions at personal level is key to precision cancer therapy, yet limited by current short-read sequencing technology, individualized catalog of complete genomic and transcriptomic features is thus far elusive. Here, we integrated second- and third-generation sequencing platforms to generate a multidimensional dataset on a patient affected by metastatic epithelial ovarian cancer. Whole-genome and hybrid transcriptome dissection captured global genetic and transcriptional variants at previously unparalleled resolution. Particularly, single-molecule mRNA sequencing identified a vast array of unannotated transcripts, novel long noncoding RNAs and gene chimeras, permitting accurate determination of transcription start, splice, polyadenylation and fusion sites. Phylogenetic and enrichment inference of isoform-level measurements implicated early functional divergence and cytosolic proteostatic stress in shaping ovarian tumorigenesis. A complementary imaging-based high-throughput drug screen was performed and subsequently validated, which consistently pinpointed proteasome inhibitors as an effective therapeutic regime by inducing protein aggregates in ovarian cancer cells. Therefore, our study suggests that clinical application of the emerging long-read full-length analysis for improving molecular diagnostics is feasible and informative. An in-depth understanding of the tumor transcriptome complexity allowed by leveraging the hybrid sequencing approach lays the basis to reveal novel and valid therapeutic vulnerabilities in advanced ovarian malignancies.	[Jing, Ying; Zhang, Yi; Ma, Pengfei; Shen, Peiye; Yu, Minhua; Yin, Xia; Zhang, Meiying; Hu, Yuan; Di, Wen; Zhuang, Guanglei] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Dept Obstet & Gynecol, Ren Ji Hosp,Sch Med, Shanghai, Peoples R China; [Jing, Ying; Zhang, Yi; Yu, Minhua; Yin, Xia; Zhang, Meiying; Hu, Yuan; Di, Wen; Zhuang, Guanglei] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Shanghai Key Lab Gynecol Oncol, Shanghai, Peoples R China; [Zhu, Hui] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China; [Zhang, Ke] Rizhao Peoples Hosp, Dept Oncol, Rizhao, Shandong, Peoples R China; [Cai, Mei-Chun; Zhang, Zhenfeng] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Ren Ji Hosp,Sch Med, Shanghai, Peoples R China; [Shao, Minghui; Wang, Jing] Novogene Bioinformat Technol Co Ltd, Beijing, Peoples R China; [Chen, Danni; Wang, Xiaojie] Shanghai Jiao Tong Univ, Tongren Hosp, Dept Obstet & Gynecol, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhuang, GL (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Dept Obstet & Gynecol, Ren Ji Hosp,Sch Med, Shanghai, Peoples R China.; Zhuang, GL (corresponding author), Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Shanghai Key Lab Gynecol Oncol, Shanghai, Peoples R China.; Wang, XJ (corresponding author), Shanghai Jiao Tong Univ, Tongren Hosp, Dept Obstet & Gynecol, Sch Med, Shanghai, Peoples R China.	wangxiaojie2008@hotmail.com; zhuangguanglei@gmail.com	Zhang, Yi/ABE-2574-2020	Zhuang, Guanglei/0000-0001-8141-5096	National Natural Science Foundation of China [81472537, 81672714, 81502597, 81472426]; State Key Laboratory of Oncogenes and Related Genes [SB17-06]; Shanghai Jiao Tong University School of Medicine [DLY201505, YG2016MS51]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20161313]; Shanghai Institutions of Higher Learning (Eastern Scholar); Shanghai Rising-Star Program [16QA1403600]; Shanghai Municipal Commission of Health and Family Planning [2013ZYJB0202, 15GWZK0701, 20174Y0189, 20174Y0043]; Shanghai Key Laboratory of Gynecologic Oncology [FKZL-2017-01]; Science and Technology Commission of Shanghai Municipality [16140904401]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Oncogenes and Related Genes; Shanghai Jiao Tong University School of Medicine; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Shanghai Institutions of Higher Learning (Eastern Scholar); Shanghai Rising-Star Program; Shanghai Municipal Commission of Health and Family Planning; Shanghai Key Laboratory of Gynecologic Oncology; Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by the National Natural Science Foundation of China (81472537 and 81672714 to GZ; 81502597 to YJ; 81472426 to WD), the Grants from the State Key Laboratory of Oncogenes and Related Genes (SB17-06 to M-CC), the grants from Shanghai Jiao Tong University School of Medicine (DLY201505 to WD; YG2016MS51 to XY), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20161313 to GZ), the Shanghai Institutions of Higher Learning (Eastern Scholar to GZ), Shanghai Rising-Star Program (16QA1403600 to GZ), Shanghai Municipal Commission of Health and Family Planning (2013ZYJB0202 and 15GWZK0701 to WD; 20174Y0189 to YJ; 20174Y0043 to M-CC), the grant from Shanghai Key Laboratory of Gynecologic Oncology (FKZL-2017-01 to YJ), and the grant from Science and Technology Commission of Shanghai Municipality (16140904401 to XY).	Abdel-Ghany SE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11706; Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76; Alkan C, 2011, NAT METHODS, V8, P61, DOI 10.1038/NMETH.1527; Au KF, 2013, P NATL ACAD SCI USA, V110, pE4821, DOI 10.1073/pnas.1320101110; Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230; Bazzaro M, 2006, CANCER RES, V66, P3754, DOI 10.1158/0008-5472.CAN-05-2321; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Boeva V, 2012, BIOINFORMATICS, V28, P423, DOI 10.1093/bioinformatics/btr670; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chatterjee S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091978; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/nmeth.1363, 10.1038/NMETH.1363]; Choi YJ, 2017, J PATHOL, V241, P57, DOI 10.1002/path.4819; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cieslik M, 2018, NAT REV GENET, V19, P93, DOI 10.1038/nrg.2017.96; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Cui TY, 2018, NUCLEIC ACIDS RES, V46, pD371, DOI 10.1093/nar/gkx1025; de Klerk E, 2015, TRENDS GENET, V31, P128, DOI 10.1016/j.tig.2015.01.001; Eid J, 2009, SCIENCE, V323, P133, DOI 10.1126/science.1162986; Engstrom PG, 2013, NAT METHODS, V10, P1185, DOI [10.1038/NMETH.2722, 10.1038/nmeth.2722]; Faoro R, 2018, P NATL ACAD SCI USA, V115, P1204, DOI 10.1073/pnas.1717282115; Finn RD, 2016, NUCLEIC ACIDS RES, V44, pD279, DOI 10.1093/nar/gkv1344; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Fulda S, 2012, EMBO MOL MED, V4, P545, DOI 10.1002/emmm.201100707; Hackl T, 2014, BIOINFORMATICS, V30, P3004, DOI 10.1093/bioinformatics/btu392; Hoogstraat M, 2014, GENOME RES, V24, P200, DOI 10.1101/gr.161026.113; Jandial DA, 2017, GYNECOL ONCOL, V145, P236, DOI 10.1016/j.ygyno.2017.03.013; Jia WL, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-2-r12; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kong L, 2007, NUCLEIC ACIDS RES, V35, pW345, DOI 10.1093/nar/gkm391; Koren S, 2012, NAT BIOTECHNOL, V30, P692, DOI 10.1038/nbt.2280; Kornblihtt AR, 2013, NAT REV MOL CELL BIO, V14, P153, DOI 10.1038/nrm3525; Kuang Z, 2017, GENOME RES, V27, P145, DOI 10.1101/gr.208041.116; Kumar SK, 2017, J NATL COMPR CANC NE, V15, P709, DOI 10.6004/jnccn.2017.0080; Kumar-Sinha C, 2018, NAT BIOTECHNOL, V36, P46, DOI 10.1038/nbt.4017; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Li AM, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-311; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li S, 2016, DEV CELL, V39, P508, DOI 10.1016/j.devcel.2016.10.012; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Manasanch EE, 2017, NAT REV CLIN ONCOL, V14, P417, DOI [10.1038/nrclinonc.2016.206, 10.1007/s12079-011-0121-7]; Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; McPherson A, 2016, NAT GENET, V48, P758, DOI 10.1038/ng.3573; Mertens F, 2015, NAT REV CANCER, V15, P371, DOI 10.1038/nrc3947; Miller CA, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003665; Mills Kathryn, 2017, F1000Res, V6, P84, DOI 10.12688/f1000research.9977.1; Nandi D, 2006, J BIOSCIENCES, V31, P137, DOI 10.1007/BF02705243; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Niu BF, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-187; Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Ramirez PT, 2008, GYNECOL ONCOL, V108, P68, DOI 10.1016/j.ygyno.2007.08.071; Rhoads A, 2015, GENOM PROTEOM BIOINF, V13, P278, DOI 10.1016/j.gpb.2015.08.002; Roberts RJ, 2013, GENOME BIOL, V14, DOI [10.1186/gb-2013-14-6-405, 10.1186/gb-2013-14-7-405]; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/NMETH.2883, 10.1038/nmeth.2883]; Rubio-Perez C, 2015, CANCER CELL, V27, P382, DOI 10.1016/j.ccell.2015.02.007; Schram AM, 2017, NAT REV CLIN ONCOL, V14, P735, DOI 10.1038/nrclinonc.2017.127; Sharon D, 2013, NAT BIOTECHNOL, V31, P1009, DOI 10.1038/nbt.2705; Steijger T, 2013, NAT METHODS, V10, P1177, DOI [10.1038/nmeth.2714, 10.1038/NMETH.2714]; Sun L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt646; Tang ZJ, 2015, CELL, V160, P729, DOI 10.1016/j.cell.2015.01.028; Tian B, 2017, NAT REV MOL CELL BIO, V18, P18, DOI 10.1038/nrm.2016.116; Tilgner H, 2014, P NATL ACAD SCI USA, V111, P9869, DOI 10.1073/pnas.1400447111; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Travers KJ, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq543; Trincado JL, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1417-1; Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784; Vilasi S, 2018, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00099; Wang B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11708; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang YK, 2017, NAT GENET, V49, P856, DOI 10.1038/ng.3849; Weirather JL, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv562; Wu TD, 2016, METHODS MOL BIOL, V1418, P283, DOI 10.1007/978-1-4939-3578-9_15; Xia Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6274; Yi Y, 2017, NUCLEIC ACIDS RES, V45, pD115, DOI 10.1093/nar/gkw1052; Yin X, 2017, CANCER RES, V77, P6551, DOI 10.1158/0008-5472.CAN-17-1461; Zhang T, 2017, NUCLEIC ACIDS RES, V45, pD135, DOI 10.1093/nar/gkw728; Zhang ZF, 2017, MOL CANCER THER, V16, P1739, DOI 10.1158/1535-7163.MCT-17-0078; Zhang ZF, 2016, THERANOSTICS, V6, P219, DOI 10.7150/thno.13178	83	2	3	4	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3047	3060		10.1038/s41388-018-0644-y	http://dx.doi.org/10.1038/s41388-018-0644-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30617306				2022-12-17	WOS:000465167600013
J	Liu, XJ; Bao, YH; Meng, W; Yang, P; An, Y; Ma, J; Tang, YJ; Liu, ZG; Lu, Y; Zhou, JF; Zhang, Y; Feng, JF; Gao, XF; Su, ZD; Pu, YY; He, C				Liu, Xiujie; Bao, Yinghui; Meng, Wei; Yang, Ping; An, Yi; Ma, Jie; Tang, Yujie; Liu, Zhigang; Lu, Yan; Zhou, Jianfeng; Zhang, Yong; Feng, Jifeng; Gao, Xiaofei; Su, Zhida; Pu, Yingyan; He, Cheng			TROY interacts with RKIP to promote glioma development	ONCOGENE			English	Article							NF-KAPPA-B; KINASE INHIBITOR PROTEIN; RECEPTOR FAMILY-MEMBER; GENOME-WIDE ASSOCIATION; THERAPEUTIC TARGET; TYROSINE KINASES; EXPRESSION; GLIOBLASTOMA; CANCER; TNF	TROY is a component of the Nogo receptor complex and plays the key role in neuronal survival, migration, and differentiation. Here, we show the up-regulation of TROY in human glioma tissues and cells. Inhibition of TROY expression slowed glioma development in vivo and in vitro. Raf kinase inhibitor (RKIP) was found to interact with TROY. The physical interaction of TROY/RKIP was confirmed via co-immunoprecipitation (co-IP) assays. Furthermore, we found that the TROY/RKIP interaction was enhanced by fetal bovine serum (FBS) exposure, and TROY knockdown also led to down-regulation of NF-kappa B. Finally, disruption of the TROY/RKIP interaction using the TAT-TROY (234-371 aa) protein reduced the glioma development in xenografted mice. This suggests the TROY/RKIP interaction is a potential target for therapy of gliomas.	[Liu, Xiujie; Lu, Yan; Zhou, Jianfeng; Zhang, Yong; Feng, Jifeng; Gao, Xiaofei; Su, Zhida; Pu, Yingyan; He, Cheng] Second Mil Med Univ, Minist Educ, Key Lab Mol Neurobiol, Inst Neurosci, Shanghai 200433, Peoples R China; [Liu, Xiujie; Lu, Yan; Zhou, Jianfeng; Zhang, Yong; Feng, Jifeng; Gao, Xiaofei; Su, Zhida; Pu, Yingyan; He, Cheng] Second Mil Med Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200433, Peoples R China; [Bao, Yinghui] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Neurosurg, Shanghai 200127, Peoples R China; [Meng, Wei; Ma, Jie] Shanghai Jiao Tong Univ, Sch Med, Xin Hua Hosp, Dept Pediat Neurosurg, Shanghai 200092, Peoples R China; [Yang, Ping] Fudan Univ, Sch Pharm, Instrumental Anal Ctr, Shanghai 201203, Peoples R China; [An, Yi] Yale Univ, Sch Med, Dept Therapeut Oncol, New Haven, CT USA; [Tang, Yujie] Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis, Natl Minist Educ,Dept Pathophysiol, 280 South Chongqing Rd, Shanghai 200025, Peoples R China; [Liu, Zhigang] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiat Oncol, Zhuhai 519001, Guangdong, Peoples R China; [Liu, Zhigang] Sun Yat Sen Univ, Affiliated Hosp 5, Phase Clin Trial Ward 1, Zhuhai 519001, Guangdong, Peoples R China	Naval Medical University; Naval Medical University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan University; Yale University; Shanghai Jiao Tong University; Sun Yat Sen University; Sun Yat Sen University	Liu, XJ; He, C (corresponding author), Second Mil Med Univ, Minist Educ, Key Lab Mol Neurobiol, Inst Neurosci, Shanghai 200433, Peoples R China.; Liu, XJ; He, C (corresponding author), Second Mil Med Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200433, Peoples R China.	LXJ186517@126.com; chenghe@smmu.edu.cn	Su, Zhida/G-6094-2015		National Key Basic Research Program [2011CB504401]; National Natural Science Foundation of China [81572500]; Natural Science Foundation of Shanghai City [13ZR1448500]; Hunan Young Talents [2016RS3036]	National Key Basic Research Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai City(Natural Science Foundation of Shanghai); Hunan Young Talents	This work was supported by the National Key Basic Research Program (2011CB504401), the National Natural Science Foundation of China (31070922; 31130024; 81471224) and the Natural Science Foundation of Shanghai City (13ZR1448500). This work was partially supported by National Natural Science Foundation of China (NO. 81572500); Hunan Young Talents (NO. 2016RS3036).	Al-Mulla F, 2006, J CLIN ONCOL, V24, P5672, DOI 10.1200/JCO.2006.07.5499; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Bei JX, 2010, NAT GENET, V42, P599, DOI 10.1038/ng.601; Bossen C, 2006, J BIOL CHEM, V281, P13964, DOI 10.1074/jbc.M601553200; Carrasco-Garcia E, 2014, CELLS-BASEL, V3, P199, DOI 10.3390/cells3020199; Chumbalkar VC, 2005, PROTEOMICS, V5, P1167, DOI 10.1002/pmic.200401202; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Ding X, 2010, JNCI-J NATL CANCER I, V102, P1052, DOI 10.1093/jnci/djq217; Eby MT, 2000, J BIOL CHEM, V275, P15336, DOI 10.1074/jbc.275.20.15336; Fafilek B, 2013, GASTROENTEROLOGY, V144, P381, DOI 10.1053/j.gastro.2012.10.048; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Granovsky AE, 2008, CELL RES, V18, P452, DOI 10.1038/cr.2008.43; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hashimoto T, 2008, CELL CYCLE, V7, P106, DOI 10.4161/cc.7.1.5135; He SQ, 2011, NEURON, V69, P120, DOI 10.1016/j.neuron.2010.12.001; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hisaoka T, 2006, BRAIN RES, V1110, P81, DOI 10.1016/j.brainres.2006.06.068; Hu ZB, 2011, NAT GENET, V43, P792, DOI 10.1038/ng.875; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Kojima T, 2000, J BIOL CHEM, V275, P20742, DOI 10.1074/jbc.M002691200; Lee HC, 2006, GASTROENTEROLOGY, V131, P1208, DOI 10.1053/j.gastro.2006.07.012; Loftus JC, 2013, MOL CANCER RES, V11, P865, DOI 10.1158/1541-7786.MCR-13-0008; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu Y, 2013, J BIOL CHEM, V288, P34276, DOI 10.1074/jbc.M113.519744; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maresch J, 2011, CANCER-AM CANCER SOC, V117, P2499, DOI 10.1002/cncr.25799; Mi S, 2008, CYTOKINE GROWTH F R, V19, P245, DOI 10.1016/j.cytogfr.2008.04.007; Nogueira L, 2011, ONCOTARGET, V2, P646, DOI 10.18632/oncotarget.322; Ohazama A, 2004, DEV DYNAM, V229, P131, DOI 10.1002/dvdy.10400; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Paulino VM, 2010, MOL CANCER RES, V8, P1558, DOI 10.1158/1541-7786.MCR-10-0334; Pispa J, 2008, HUM MOL GENET, V17, P3380, DOI 10.1093/hmg/ddn232; Purow B, 2009, NAT REV NEUROL, V5, P419, DOI 10.1038/nrneurol.2009.96; Reyes SB, 2013, MOL BIOL CELL, V24, P474, DOI 10.1091/mbc.E12-07-0521; Satoh J, 2007, NEUROPATH APPL NEURO, V33, P99, DOI 10.1111/j.1365-2990.2006.00787.x; Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Shin SY, 2009, J CELL SCI, V122, P425, DOI 10.1242/jcs.036319; Spanjaard RA, 2007, INT J CANCER, V120, P1304, DOI 10.1002/ijc.22367; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tam SJ, 2012, DEV CELL, V22, P403, DOI 10.1016/j.devcel.2011.11.018; Trakul N, 2005, CELL RES, V15, P19, DOI 10.1038/sj.cr.7290258; Trakul N, 2005, J BIOL CHEM, V280, P24931, DOI 10.1074/jbc.M413929200; Wan JH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0556-3; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Yu ZW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009956; Ziegler DS, 2008, J CLIN INVEST, V118, P3109, DOI 10.1172/JCI34120; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	54	2	3	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1544	1559		10.1038/s41388-018-0503-x	http://dx.doi.org/10.1038/s41388-018-0503-x			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30337686	hybrid, Green Published			2022-12-17	WOS:000459945800013
J	Patel, Y; Soni, M; Awgulewitsch, A; Kern, MJ; Liu, S; Shah, N; Singh, UP; Chen, H				Patel, Y.; Soni, M.; Awgulewitsch, A.; Kern, M. J.; Liu, S.; Shah, N.; Singh, U. P.; Chen, H.			Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis (vol 38, pg 445, 2018)	ONCOGENE			English	Correction									[Patel, Y.; Soni, M.; Liu, S.; Shah, N.; Chen, H.] Univ South Carolina, Dept Biol Sci, Columbia, SC 29208 USA; [Patel, Y.; Soni, M.; Liu, S.; Shah, N.; Chen, H.] Univ South Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA; [Awgulewitsch, A.] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA; [Awgulewitsch, A.] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Transgen & Genome Editing Core, Charleston, SC 29425 USA; [Kern, M. J.] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Gene Funct Core, Charleston, SC 29425 USA; [Singh, U. P.] Univ South Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA	University of South Carolina System; University of South Carolina Columbia; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Chen, H (corresponding author), Univ South Carolina, Dept Biol Sci, Columbia, SC 29208 USA.; Chen, H (corresponding author), Univ South Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA.	hchen@biol.sc.edu	chen, hexin/F-1714-2011	Chen, Hexin/0000-0001-9300-0859; Singh, Udai/0000-0002-7048-4325	U.S. Department of Health &amp; Human Services | NIH | National Institute of General Medical Sciences (NIGMS) [4P30 GM103342-05] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI) [4R01 CA178386-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA178386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103342] Funding Source: NIH RePORTER	U.S. Department of Health &amp; Human Services | NIH | National Institute of General Medical Sciences (NIGMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Patel Y, 2019, ONCOGENE, V38, P445, DOI 10.1038/s41388-018-0439-1	1	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2019	38	3					454	454		10.1038/s41388-018-0559-7	http://dx.doi.org/10.1038/s41388-018-0559-7			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HH6OP	30375491	Bronze			2022-12-17	WOS:000455851200011
J	Tan, ZY; Song, LB; Wu, WJ; Zhou, YQ; Zhu, JR; Wu, GY; Cao, LX; Song, JW; Li, J; Zhang, W				Tan, Zhanyao; Song, Libing; Wu, Wenjiao; Zhou, Yanqing; Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Song, Junwei; Li, Jun; Zhang, Wei			TRIM14 promotes chemoresistance in gliomas by activating Wnt/beta-catenin signaling via stabilizing Dvl2 (vol 37, pg 5403, 2018)	ONCOGENE			English	Correction									[Tan, Zhanyao; Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Song, Junwei; Li, Jun] Sun Yat Sen Univ, Affiliated Hosp 3, Key Lab Liver Dis Guangdong Prov, Guangzhou, Guangdong, Peoples R China; [Tan, Zhanyao; Zhu, Jinrong; Wu, Geyan; Cao, Lixue; Song, Junwei; Li, Jun] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangdong Prov Key Lab Brain Funct & Dis, Guangzhou, Guangdong, Peoples R China; [Song, Libing] Sun Yat Sen Univ, Dept Expt Res, Canc Ctr, State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China; [Song, Libing] Guangzhou Med Univ, Sch Basic Med Sci, Affiliated Canc Hosp & Inst, Key Lab Prot Modificat & Degradat, Guangzhou, Guangdong, Peoples R China; [Wu, Wenjiao] Jinan Univ, Dept Neurosurg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Zhou, Yanqing; Zhang, Wei] Guangdong Pharmaceut Univ, Neurosurg Res Inst, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Guangzhou Medical University; Jinan University; Guangdong Pharmaceutical University	Li, J (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Key Lab Liver Dis Guangdong Prov, Guangzhou, Guangdong, Peoples R China.; Li, J (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangdong Prov Key Lab Brain Funct & Dis, Guangzhou, Guangdong, Peoples R China.; Zhang, W (corresponding author), Guangdong Pharmaceut Univ, Neurosurg Res Inst, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.	lijun37@mail.sysu.edu.cn; 18666003902@163.com	Cao, Lixue/AAM-9316-2020; wu, ge/ABE-3285-2020	Cao, Lixue/0000-0002-0486-6587; 				Tan ZY, 2018, ONCOGENE, V37, P5403, DOI 10.1038/s41388-018-0344-7	1	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5476	5476	476	10.1038/s41388-018-0467-x	http://dx.doi.org/10.1038/s41388-018-0467-x			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	30158671	Bronze			2022-12-17	WOS:000446312900008
J	Zhou, X; Li, GH; An, SQ; Li, WX; Yang, HH; Guo, YC; Dai, Z; Dai, SX; Zheng, JJ; Huang, JF; Iavarone, A; Zhao, XD				Zhou, Xia; Li, Gonghua; An, Sanqi; Li, Wen-Xing; Yang, Huihui; Guo, Yicheng; Dai, Zhi; Dai, Shaoxing; Zheng, Junjuan; Huang, Jingfei; Iavarone, Antonio; Zhao, Xudong			A new method of identifying glioblastoma subtypes and creation of corresponding animal models	ONCOGENE			English	Article							ONCOGENE ACTIVATION; CO-DELETION; MUTATIONS; GENE; GLIOMAS; IDH1; CANCER; DEFINE; 1P/19Q	Glioblastoma (GBM) accounts for up to 50% of brain parenchymal tumors. It is the most malignant type of brain cancer with very poor survival and limited remedies. Cancer subtyping is important for cancer research and therapy. Here, we report a new subtyping method for GBM based on the genetic alterations of CDKN2A and TP53 genes. CDKN2A and TP53 are the most frequently mutated genes with mutation rates of 60 and 30%, respectively. We found that patients with deletion of CDKN2A possess worse survival than those with TP53 mutation. Interestingly, survival of patients with both TP53 mutation and CDKN2A deletion is no worse than for those with only one of these genetic alterations, but similar to those with TP53 mutation alone. Next, we investigated differences in the gene expression profile between TP53 and CDKN2A samples. Consistent with the survival data, the samples with both TP53 mutation and CDKN2A deletion showed a gene expression profile similar to those samples with TP53 mutation alone. Finally, we found that activation of RAS pathway plus Cdkn2a/b silencing can induce GBM, in a similar way to tumor induction by RAS activation plus TP53 silencing. In conclusion, we show that the genetic alterations of CDKN2A and TP53 may be used to stratify GBM, and the new animal models matching this stratification method were generated.	[Zhou, Xia; An, Sanqi; Yang, Huihui; Dai, Zhi; Zhao, Xudong] Chinese Acad Sci, Kunming Inst Zool, Key Lab Bioact Peptides Yunnan Prov, Key Lab Anim Models & Human Dis Mech, Kunming 650223, Yunnan, Peoples R China; [Zhou, Xia; An, Sanqi; Yang, Huihui; Guo, Yicheng; Dai, Zhi; Dai, Shaoxing; Zheng, Junjuan; Huang, Jingfei; Zhao, Xudong] Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming 650204, Yunnan, Peoples R China; [Li, Gonghua; An, Sanqi; Li, Wen-Xing; Guo, Yicheng; Dai, Shaoxing; Zheng, Junjuan; Huang, Jingfei] Chinese Acad Sci, Kunming Inst Zool, Lab Evolutionary & Funct Genom, State Key Lab Genet Resources & Evolut, Kunming 650223, Yunnan, Peoples R China; [Li, Wen-Xing] Anhui Univ, Inst Hlth Sci, Hefei 230601, Anhui, Peoples R China; [Iavarone, Antonio] Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; [Zhao, Xudong] Chinese Acad Sci, Kunming Primate Res Ctr, Kunming 650223, Yunnan, Peoples R China; [Zhao, Xudong] Soochow Univ, Coll Pharmaceut Sci, KIZ SU Joint Lab Anim Model & Drug Dev, Suzhou 215000, Jiangsu, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Kunming Institute of Zoology; Anhui University; Columbia University; Chinese Academy of Sciences; Soochow University - China	Zhao, XD (corresponding author), Chinese Acad Sci, Kunming Inst Zool, Key Lab Bioact Peptides Yunnan Prov, Key Lab Anim Models & Human Dis Mech, Kunming 650223, Yunnan, Peoples R China.; Huang, JF; Zhao, XD (corresponding author), Univ Chinese Acad Sci, Kunming Coll Life Sci, Kunming 650204, Yunnan, Peoples R China.; Huang, JF (corresponding author), Chinese Acad Sci, Kunming Inst Zool, Lab Evolutionary & Funct Genom, State Key Lab Genet Resources & Evolut, Kunming 650223, Yunnan, Peoples R China.; Iavarone, A (corresponding author), Columbia Univ, Inst Canc Genet, New York, NY 10032 USA.; Zhao, XD (corresponding author), Chinese Acad Sci, Kunming Primate Res Ctr, Kunming 650223, Yunnan, Peoples R China.; Zhao, XD (corresponding author), Soochow Univ, Coll Pharmaceut Sci, KIZ SU Joint Lab Anim Model & Drug Dev, Suzhou 215000, Jiangsu, Peoples R China.	huangjf@mail.kiz.ac.cn; ai2102@cumc.columbia.edu; zhaoxudong@mail.kiz.ac.cn	Dai, shaoxing/ABA-8699-2020	zhao, zhao xu dong/0000-0001-9126-7365; Iavarone, Antonio/0000-0002-0683-4634; Li, Gong-Hua/0000-0002-9311-6613; Guo, Yicheng/0000-0001-5357-660X; Li, Wen-Xing/0000-0001-9984-8439	Strategic Priority Research Program of the Chinese Academy of Sciences [XDA 01040403]; National Natural Science Foundation of China (NSFC) [81171960]; Top Talents Program of Yunnan Province China [2012HA014]; Yunnan Applied Basic Research Projects [2013FA020]	Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Top Talents Program of Yunnan Province China; Yunnan Applied Basic Research Projects	We thank Dr. Dong Yang and Qiu Tu for the useful advice. We also thank Yujie Xia for technical assistance with the histological analysis. This work was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA 01040403), the National Natural Science Foundation of China (NSFC, 81171960), the Top Talents Program of Yunnan Province China (2012HA014) to XZ, and Yunnan Applied Basic Research Projects (2013FA020).	Arvold ND, 2014, CLIN INTERV AGING, V9, P357, DOI 10.2147/CIA.S44259; Bhowmick DA, 2004, CANCER RES, V64, P1220, DOI 10.1158/0008-5472.CAN-03-3137; Boots-Sprenger SHE, 2013, MODERN PATHOL, V26, P922, DOI 10.1038/modpathol.2012.166; Brennan CW, 2014, CELL, V157, P753, DOI 10.1016/j.cell.2014.04.004; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Costa BM, 2010, CANCER RES, V70, P453, DOI 10.1158/0008-5472.CAN-09-2189; Dong SM, 2005, J NEUROPATH EXP NEUR, V64, P948, DOI 10.1097/01.jnen.0000186940.14779.90; Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279; Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Gallardo T, 2007, GENESIS, V45, P413, DOI 10.1002/dvg.20310; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Geraerts M, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-34; Goel Manish Kumar, 2010, Int J Ayurveda Res, V1, P274, DOI 10.4103/0974-7788.76794; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Helseth R, 2010, ACTA NEUROL SCAND, V122, P159, DOI 10.1111/j.1600-0404.2010.01350.x; Huang W, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-1; Ichimura K, 1996, ONCOGENE, V13, P1065; Ichimura K, 2009, NEURO-ONCOLOGY, V11, P341, DOI 10.1215/15228517-2009-025; Kato H, 2000, CLIN CANCER RES, V6, P3937; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Langmead Ben, 2010, Curr Protoc Bioinformatics, VChapter 11, DOI 10.1002/0471250953.bi1107s32; Lee JC, 2011, J CLIN INVEST, V121, P4170, DOI 10.1172/JCI59255; Liu YC, 2013, IEEE T CYBERNETICS, V43, P982, DOI 10.1109/TSMCB.2012.2220543; Marumoto T, 2009, NAT MED, V15, P110, DOI 10.1038/nm.1863; Marusyk Andriy, 2010, Biochim Biophys Acta, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002; Mischel PS, 2003, J NEUROPATH EXP NEUR, V62, P542; Mistry M, 2015, J CLIN ONCOL, V33, P1015, DOI 10.1200/JCO.2014.58.3922; Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487; Murtagh F, 2014, J CLASSIF, V31, P274, DOI 10.1007/s00357-014-9161-z; Niola F, 2013, J CLIN INVEST, V123, P405, DOI 10.1172/JCI63811; Noushmehr Houtan, 2010, Cancer Cell, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Popova SN, 2014, HISTOPATHOLOGY, V64, P365, DOI 10.1111/his.12252; Qian WF, 2010, TRENDS GENET, V26, P425, DOI 10.1016/j.tig.2010.07.002; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rothschild G, 2006, MOL CELL BIOL, V26, P4351, DOI 10.1128/MCB.01743-05; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stancheva G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/654727; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Tu Q, 2018, ONCOGENE, V37, P128, DOI 10.1038/onc.2017.316; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vogazianou AP, 2010, NEURO-ONCOLOGY, V12, P664, DOI 10.1093/neuonc/nop075; Wiedemeyer R, 2008, CANCER CELL, V13, P355, DOI 10.1016/j.ccr.2008.02.010	50	2	2	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4781	4791		10.1038/s41388-018-0305-1	http://dx.doi.org/10.1038/s41388-018-0305-1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29769617				2022-12-17	WOS:000443146000002
J	Pinato, DJ				Pinato, David J.			Circulating-free tumour DNA and the promise of disease phenotyping in hepatocellular carcinoma	ONCOGENE			English	Editorial Material							INTRATUMOR HETEROGENEITY; EVOLUTION; TARGETS		[Pinato, David J.] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London W12 0NN, England	Imperial College London	Pinato, DJ (corresponding author), Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Du Cane Rd, London W12 0NN, England.	david.pinato@imperial.ac.uk	Pinato, David James/ABB-3719-2020	Pinato, David James/0000-0002-3529-0103	National Institute for Health Research (NIHR); Academy of Medical Sciences (AMS); Cancer Research UK (CRUK)	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Academy of Medical Sciences (AMS)(Academy of Medical Sciences (AMS)); Cancer Research UK (CRUK)(Cancer Research UK)	DJP is supported by grant funding from the National Institute for Health Research (NIHR), the Academy of Medical Sciences (AMS) and Cancer Research UK (CRUK).	Bruix J, 2016, GASTROENTEROLOGY, V150, P835, DOI 10.1053/j.gastro.2015.12.041; Buccisano F, 2018, EXPERT REV HEMATOL, V11, P307, DOI 10.1080/17474086.2018.1447378; Burrell RA, 2014, MOL ONCOL, V8, P1095, DOI 10.1016/j.molonc.2014.06.005; Cleary SP, 2013, HEPATOLOGY, V58, P1693, DOI 10.1002/hep.26540; Friemel J, 2015, CLIN CANCER RES, V21, P1951, DOI 10.1158/1078-0432.CCR-14-0122; Gerbes A, 2018, GUT, V67, P380, DOI 10.1136/gutjnl-2017-315068; Hoshida Y, 2010, SEMIN LIVER DIS, V30, P35, DOI 10.1055/s-0030-1247131; Howell JA, 2017, TRANSL RES, V183, P137, DOI 10.1016/j.trsl.2016.12.006; Ikeda S, 2018, MOL CANCER THER, V17, P1114, DOI 10.1158/1535-7163.MCT-17-0604; Kancherla V, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00002; Karlas T, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1208-6; Khagi Y, 2017, CLIN CANCER RES, V23, P5729, DOI 10.1158/1078-0432.CCR-17-1439; Labgaa I, 2018, ONCOGENE, V37, P3740, DOI 10.1038/s41388-018-0206-3; Llovet JM, 2016, HEPATOLOGY AASLD M S, V64, P601; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Maida M, 2015, WORLD J HEPATOL, V7, P2053, DOI 10.4254/wjh.v7.i17.2053; Nault JC, 2018, J HEPATOL, V69, P237, DOI 10.1016/j.jhep.2018.02.016; Oxnard GR, 2016, J CLIN ONCOL, V34, P3375, DOI 10.1200/JCO.2016.66.7162; Piciocchi M, 2013, HEPATOL INT, V7, P1050, DOI 10.1007/s12072-013-9481-9; Pinato DJ, 2018, HEPATOLOGY, V67, P1663, DOI 10.1002/hep.29714; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Sherman M, 2008, NEW ENGL J MED, V359, P2045, DOI 10.1056/NEJMe0807581; Shibata T, 2014, NAT REV GASTRO HEPAT, V11, DOI 10.1038/nrgastro.2014.6; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Tabernero J, 2015, LANCET ONCOL, V16, P937, DOI 10.1016/S1470-2045(15)00138-2; Yeung CCS, 2016, EXPERT REV MOL DIAGN, V16, P1083, DOI 10.1080/14737159.2016.1227243; Zhai WW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14565	27	2	2	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4635	4638		10.1038/s41388-018-0262-8	http://dx.doi.org/10.1038/s41388-018-0262-8			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29755128	Green Submitted, hybrid			2022-12-17	WOS:000442514400001
J	Stebbing, J; Sanders, DA				Stebbing, J.; Sanders, D. A.			The importance of being earnest in post-publication review: scientific fraud and the scourges of anonymity and excuses	ONCOGENE			English	Editorial Material									[Stebbing, J.] Charing Cross Hosp, Imperial Healthcare NHS Trust, Imperial Coll, Dept Canc Med & Med Oncol, London, England; [Sanders, D. A.] Purdue Univ, Dept Biol Sci, Markey Ctr Struct Biol, W Lafayette, IN 47907 USA	Imperial College London; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Stebbing, J (corresponding author), Charing Cross Hosp, Imperial Healthcare NHS Trust, Imperial Coll, Dept Canc Med & Med Oncol, London, England.	j.stebbing@imperial.ac.uk		Stebbing, Justin/0000-0002-1117-6947	National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish; Department of Health [NIHR-RP-011-053] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Department of Health			0	2	2	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					695	696		10.1038/onc.2017.390	http://dx.doi.org/10.1038/onc.2017.390			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29035386	Green Submitted, Bronze			2022-12-17	WOS:000424628100001
J	Youn, H; Lee, HK; Sohn, HR; Park, UH; Kim, EJ; Youn, B; Um, SJ				Youn, H.; Lee, H-K; Sohn, H-R; Park, U-H; Kim, E-J; Youn, B.; Um, S-J			RaRF confers RA resistance by sequestering RAR to the nucleolus and regulating MCL1 in leukemia cells	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; EMBRYONAL CARCINOMA-CELLS; BCL-2 RELATED GENE; RETINOIC ACID; DIFFERENTIATION; CANCER; EXPRESSION; RECEPTORS; APOPTOSIS; GROWTH	Retinoic acid (RA) has broad clinical applications for the treatment of various cancers, particularly acute promyelocytic leukemia. However, RA-based therapy is limited by relapse in patients associated with RA resistance, the mechanism of which is poorly understood. Here, we suggest a new molecular mechanism of RA resistance by a repressor, named RA resistance factor (RaRF). RaRF suppressed transcriptional activity of the RA receptor (RAR) by directly interacting with and sequestering RAR to the nucleolus in response to RA. RaRF was highly expressed in RA-resistant leukemia cells and its expression was strongly correlated with RA sensitivity. MCL1 was upregulated by RA treatment upon RaRF depletion, accompanying leukemic myeloblast differentiation, which is negatively regulated by ectopic RaRF expression. Collectively, we propose that RaRF may be a factor in the resistance mechanism and thus a potential target for leukemia therapy using RA.	[Youn, H.; Lee, H-K; Sohn, H-R; Park, U-H; Um, S-J] Sejong Univ, Dept Integrat Biosci & Biotechnol, 209 Neungdong Ro, Seoul 05006, South Korea; [Kim, E-J] Dankook Univ, Dept Mol Biol, Cheonan Si, Chungnam, South Korea; [Youn, B.] Pusan Natl Univ, Dept Biol Sci, Busan 46241, South Korea	Sejong University; Dankook University; Pusan National University	Kim, EJ; Um, SJ (corresponding author), Sejong Univ, Dept Integrat Biosci & Biotechnol, 209 Neungdong Ro, Seoul 05006, South Korea.	nbrejk@dankook.ac.kr; umsj@sejong.ac.kr		LEE, HYE KYUNG/0000-0002-7785-5942	Korea Food Research Institute; Basic Science Research Program through NRF grant, Republic of Korea [2014R1A2A1A11052685, 2016R1D1A1B03931405]	Korea Food Research Institute; Basic Science Research Program through NRF grant, Republic of Korea	We would like to thank Dr Masahiro Kizaki (Division of Hematology and Clinical Laboratories, Keio University School of Medicine, Japan) and Dr Chi-Dug Kang (Pusan National University School of Medicine, Korea) for providing UF-1 and NB4 cells, respectively. This study was supported in part by a grant from the Korea Food Research Institute (to SJU) and a grant of the Basic Science Research Program through NRF grant (2014R1A2A1A11052685 to SJU and 2016R1D1A1B03931405 to HY), Republic of Korea.	Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Berghofer-Hochheimer Y, 1998, J CELL BIOCHEM, V69, P1, DOI 10.1002/(SICI)1097-4644(19980401)69:1<1::AID-JCB1>3.0.CO;2-X; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Bushue N, 2010, ADV DRUG DELIVER REV, V62, P1285, DOI 10.1016/j.addr.2010.07.003; CHAMBON P, 1995, RECENT PROG HORM RES, V50, P317; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; DE LUCA LM, 1991, FASEB J, V5, P2924; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Gerbi SA, 2003, CURR OPIN CELL BIOL, V15, P318, DOI 10.1016/S0955-0674(03)00049-8; GRIGNANI F, 1994, BLOOD, V83, P10; Gurevich I, 2007, TOXICOL APPL PHARM, V223, P288, DOI 10.1016/j.taap.2007.05.019; Gushima M, 2010, MOL CELL ENDOCRINOL, V319, P14, DOI 10.1016/j.mce.2010.01.006; Han HS, 2004, INT J CANCER, V109, P58, DOI 10.1002/ijc.11643; Hasina R, 2006, ONCOGENE, V25, P588, DOI 10.1038/sj.onc.1209070; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lall R, 2009, CELL BIOL INT, V33, P447, DOI 10.1016/j.cellbi.2009.01.015; Lee HK, 2007, EMBO J, V26, P3545, DOI 10.1038/sj.emboj.7601797; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; Lindstrom MS, 2009, BIOCHEM BIOPH RES CO, V379, P167, DOI 10.1016/j.bbrc.2008.12.083; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Martindill DMJ, 2008, CELL CYCLE, V7, P17, DOI 10.4161/cc.7.1.5228; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; O'Malley B, 2008, MOL ENDOCRINOL, V22, P2751, DOI 10.1210/me.2008-0297; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Okita H, 1998, BBA-GENE STRUCT EXPR, V1398, P335, DOI 10.1016/S0167-4781(98)00059-1; Okuno M, 2004, CURR CANCER DRUG TAR, V4, P285, DOI 10.2174/1568009043333023; Olson Mark O J, 2004, Sci STKE, V2004, ppe10; Oren T, 2003, LEUKEMIA LYMPHOMA, V44, P1881, DOI 10.1080/1042819031000116661; Pederson T, 2009, J CELL BIOL, V184, P771, DOI 10.1083/jcb.200812014; Sanz MA, 2011, J CLIN ONCOL, V29, P495, DOI 10.1200/JCO.2010.32.1067; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Schlenk RF, 2005, LEUKEMIA, V19, P978, DOI 10.1038/sj.leu.2403766; Schulz M, 2001, BIOCHEM BIOPH RES CO, V280, P476, DOI 10.1006/bbrc.2000.4141; Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303; Um SJ, 2003, INT J CANCER, V107, P1038, DOI 10.1002/ijc.11489; Um SJ, 2014, BIOCHEM BIOPH RES CO, V444, P605, DOI 10.1016/j.bbrc.2014.01.105; Um SJ, 2012, BIOCHEM BIOPH RES CO, V418, P290, DOI 10.1016/j.bbrc.2012.01.013; Umezawa A, 1996, CELL STRUCT FUNCT, V21, P143, DOI 10.1247/csf.21.143; Wang R, 2016, CLIN CANCER RES, V22, P1211, DOI 10.1158/1078-0432.CCR-15-0663; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Yang J, 2013, APOPTOSIS, V18, P1403, DOI 10.1007/s10495-013-0872-0; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; Zhuang J, 2006, CELL DEATH DIFFER, V13, P1263, DOI 10.1038/sj.cdd.4401952	50	2	3	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					352	362		10.1038/onc.2017.329	http://dx.doi.org/10.1038/onc.2017.329			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28945224				2022-12-17	WOS:000422753900008
J	Ding, D; Huang, H; Jiang, W; Yu, W; Zhu, H; Liu, J; Saiyin, H; Wu, J; Huang, H; Jiang, S; Yu, L				Ding, D.; Huang, H.; Jiang, W.; Yu, W.; Zhu, H.; Liu, J.; Saiyin, H.; Wu, J.; Huang, H.; Jiang, S.; Yu, L.			Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway (vol 36, pg 6691, 2017)	ONCOGENE			English	Correction																		Ding D, 2017, ONCOGENE, V36, P6691, DOI 10.1038/onc.2017.230	1	2	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6747	6748		10.1038/onc.2017.366	http://dx.doi.org/10.1038/onc.2017.366			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	29188822	Bronze			2022-12-17	WOS:000416780800009
J	Sizemore, GM; Balakrishnan, S; Hammer, AM; Thies, KA; Trimboli, AJ; Wallace, JA; Sizemore, ST; Kladney, RD; Woelke, SA; Yu, L; Fernandez, SA; Chakravarti, A; Leone, G; Ostrowski, MC				Sizemore, G. M.; Balakrishnan, S.; Hammer, A. M.; Thies, K. A.; Trimboli, A. J.; Wallace, J. A.; Sizemore, S. T.; Kladney, R. D.; Woelke, S. A.; Yu, L.; Fernandez, S. A.; Chakravarti, A.; Leone, G.; Ostrowski, M. C.			Stromal PTEN inhibits the expansion of mammary epithelial stem cells through Jagged-1 (vol 36, pg 2297, 2017)	ONCOGENE			English	Correction													Sizemore, Gina/ABI-7542-2020					Sizemore GM, 2017, ONCOGENE, V36, P2297, DOI 10.1038/onc.2016.383	1	2	3	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6658	6658		10.1038/onc.2017.347	http://dx.doi.org/10.1038/onc.2017.347			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	29035387	Bronze			2022-12-17	WOS:000416049200014
J	Su, CM; Wang, MY; Hong, CC; Chen, HA; Su, YH; Wu, CH; Huang, MT; Chang, YW; Jiang, SS; Sung, SY; Chang, JY; Chen, LT; Chen, PS; Su, JL				Su, C-M; Wang, M-Y; Hong, C-C; Chen, H-A; Su, Y-H; Wu, C-H; Huang, M-T; Chang, Y-W; Jiang, S-S; Sung, S-Y; Chang, J-Y; Chen, L-T; Chen, P-S; Su, J-L			miR-520h is crucial for DAPK2 regulation and breast cancer progression (vol 35, pg 1134, 2016)	ONCOGENE			English	Correction																		Su CM, 2016, ONCOGENE, V35, P1134, DOI 10.1038/onc.2015.168	1	2	2	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5770	5770		10.1038/onc.2017.231	http://dx.doi.org/10.1038/onc.2017.231			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28825723	Bronze			2022-12-17	WOS:000412843900011
J	Tonks, ID; Mukhopadhyay, P; Schroder, WA; Sorolla, A; Mould, AW; Handoko, HY; Ferguson, B; Muller, HK; Keith, P; Hayward, NK; Walker, GJ; Kay, GF				Tonks, I. D.; Mukhopadhyay, P.; Schroder, W. A.; Sorolla, A.; Mould, A. W.; Handoko, H. Y.; Ferguson, B.; Muller, H. K.; Keith, P.; Hayward, N. K.; Walker, G. J.; Kay, G. F.			Melanocyte transformation requires complete loss of all pocket protein function via a mechanism that mitigates the need for MAPK pathway activation	ONCOGENE			English	Article							RETINOBLASTOMA PROTEIN; TARGETED DISRUPTION; CDK INHIBITORS; IN-VIVO; P107; RB; PHOSPHORYLATION; P130; PRB; P53	Deregulation of p16INK4A is a critical event in melanoma susceptibility and progression. It is generally assumed that the major effect of loss of p16 function is mediated through the CDK-cyclin pathway via its influence on the pocket protein (PP) pRb. However, there are also two other PPs, p107 and p130, which, when phosphorylated by CDK-cyclin complexes, play a role in permitting cell progression. Cohorts of mice carrying melanocyte-specific knockouts (KOs) of various combinations of the three PPs were generated. Mice null for pRb, p107, p130 or any combination of double mutants did not develop melanoma. Surprisingly, melanocyte-specific loss of all three PPs facilitated melanoma development (median age of onset 308 days, penetrance 40% at 1 year). Tumorigenesis was exacerbated by Trp53 co-deletion (median age of onset 275 days, penetrance 82% at 1 year), with cell culture studies indicating that this difference may result from the apoptotic role of Trp53. Melanomas in PP; Trp53-deficient mice lacked either Ras or Braf mutations, and hence developed in the absence of constitutive MAPK pathway activation. The lag period between induction of total PP or PP/Trp53 KO and melanoma development indicates that additional genetic or epigenetic alterations may account for neoplastic progression. However, exome sequencing of PP; Trp53 KO melanomas failed to reveal any additional recurrent driver mutations. Analysis of the putative mutation signature of the PP; Trp53 KO melanomas suggests that melanocytes are primed for transformation via a mutagenic mechanism involving an excess of T>G substitutions, but not involving a preponderance of C>T substitutions at CpG sites, which is the case for most spontaneous cancers not driven by a specific carcinogen. In sum, deregulation of all three PPs appears central to neoplastic progression for melanoma, and the customary reference to the p16(INKA)/CDK4/pRB pathway may no longer be accurate; all PPs are potentially critical targets of CDK-cyclins in melanoma.	[Tonks, I. D.; Mukhopadhyay, P.; Schroder, W. A.; Mould, A. W.; Handoko, H. Y.; Ferguson, B.; Keith, P.; Hayward, N. K.; Walker, G. J.; Kay, G. F.] QIMR Berghofer Med Res Inst, Cell & Mol Biol Dept, Herston, Qld, Australia; [Sorolla, A.] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley, WA, Australia; [Mould, A. W.] Univ Oxford, Sir William Dunn Sch Pathol, South Parks Rd, Oxford, England; [Muller, H. K.] Univ Tasmania, Sch Med, Dept Pathol, Hobart, Tas, Australia; [Keith, P.] Univ Queensland, Diamantina Inst Canc Immunol & Metab Med, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Western Australia; University of Oxford; University of Tasmania; University of Queensland	Walker, GJ (corresponding author), QIMR Berghofer Med Res Inst, 300 Herston Rd, Herston, Qld 4006, Australia.	Graeme.Walker@qimrberghofer.edu.au	Sorolla, Anabel/E-2546-2012; hayward, nick/AAV-8802-2020; hayward, nicholas/C-1367-2015; , Herlina/F-4193-2015	Sorolla, Anabel/0000-0001-8238-8763; Ferguson, Blake/0000-0002-5643-6976; hayward, nicholas/0000-0003-4760-1033; Mould, Arne/0000-0002-2004-4348; , Herlina/0000-0003-3153-2248	Cancer Council of Queensland; National Health and Medical Research Council Fellowship	Cancer Council of Queensland(Cancer Council Queensland); National Health and Medical Research Council Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by research grants and fellowships to GFK and GW from the Cancer Council of Queensland. NKH is supported by a National Health and Medical Research Council Fellowship. We are grateful to Linda Chin and Marcus Bosenberg for the gift of the Tyr::CreERT2 mice.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Bosenberg M, 2006, GENESIS, V44, P262, DOI 10.1002/dvg.20205; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Damsky WE, 2010, PIGM CELL MELANOMA R, V23, P853, DOI 10.1111/j.1755-148X.2010.00777.x; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; Epe B, 2012, PHOTOCH PHOTOBIO SCI, V11, P98, DOI 10.1039/c1pp05190c; Ferguson Blake, 2015, Methods Mol Biol, V1267, P251, DOI 10.1007/978-1-4939-2297-0_11; Ferguson B, 2010, PIGM CELL MELANOMA R, V23, P771, DOI 10.1111/j.1755-148X.2010.00752.x; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; Huang PH, 2015, MOL CELL ONCOL, V3; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee JH, 2011, BRIT J DERMATOL, V164, P776, DOI 10.1111/j.1365-2133.2010.10185.x; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; MINTZ B, 1993, P NATL ACAD SCI USA, V90, P8817, DOI 10.1073/pnas.90.19.8817; Mukhopadhyay P, 2016, ONCOGENE, V35, P3342, DOI 10.1038/onc.2015.386; Ruiz S, 2003, DEVELOPMENT, V130, P2341, DOI 10.1242/dev.00453; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Tonks ID, 2006, PIGM CELL RES, V19, P260, DOI 10.1111/j.1600-0749.2006.00321.x; Tonks ID, 2010, PIGM CELL MELANOMA R, V23, P564, DOI 10.1111/j.1755-148X.2010.00722.x; Tonks ID, 2005, PIGM CELL RES, V18, P252, DOI 10.1111/j.1600-0749.2005.00245.x; Walker GJ, 2011, PIGM CELL MELANOMA R, V24, P1158, DOI 10.1111/j.1755-148X.2011.00923.x; Yang GA, 2005, J INVEST DERMATOL, V125, P1242, DOI 10.1111/j.0022-202X.2005.23931.x; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	36	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3789	3795		10.1038/onc.2016.511	http://dx.doi.org/10.1038/onc.2016.511			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192409				2022-12-17	WOS:000404349700014
J	Patrick, BA; Gong, X; Jaiswal, AK				Patrick, B. A.; Gong, X.; Jaiswal, A. K.			RETRACTION: Disruption of NAD(P)H: quinone oxidoreductase 1 gene in mice leads to 20S proteasomal degradation of p63 resulting in thinning of epithelium and chemical-induced skin cancer (Retraction of Vol 30, Pg 1098, 2011)	ONCOGENE			English	Retraction																		Patrick BA, 2011, ONCOGENE, V30, P1098, DOI 10.1038/onc.2010.491	1	2	2	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2919	2919		10.1038/onc.2016.475	http://dx.doi.org/10.1038/onc.2016.475			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	28263975	Green Accepted, Bronze			2022-12-17	WOS:000401697800014
J	Patrick, BA; Jaiswal, AK				Patrick, B. A.; Jaiswal, A. K.			RETRACTION: Stress-induced NQO1 controls stability of C/EBP alpha against 20S proteasomal degradation to regulate p63 expression with implications in protection against chemical-induced skin cancer (Retraction of Vol 31, Pg 4361, 2012)	ONCOGENE			English	Retraction																		Patrick BA, 2012, ONCOGENE, V31, P4362, DOI 10.1038/onc.2011.600	1	2	2	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2920	2920		10.1038/onc.2016.476	http://dx.doi.org/10.1038/onc.2016.476			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	28263979	Green Accepted, Bronze			2022-12-17	WOS:000401697800015
J	Das, CM; Taylor, P; Gireud, M; Singh, A; Lee, D; Fuller, G; Ji, L; Fangusaro, J; Rajaram, V; Goldman, S; Eberhart, C; Gopalakrishnan, V				Das, C. M.; Taylor, P.; Gireud, M.; Singh, A.; Lee, D.; Fuller, G.; Ji, L.; Fangusaro, J.; Rajaram, V.; Goldman, S.; Eberhart, C.; Gopalakrishnan, V.			The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation (vol 32, pg 1691, 2012)	ONCOGENE			English	Correction														Fuller, Gregory/0000-0001-9447-2647				DAS CM, 2012, ONCOGENE, V32, P1691	1	2	3	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6153	6154		10.1038/onc.2016.141	http://dx.doi.org/10.1038/onc.2016.141			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27425592	Bronze			2022-12-17	WOS:000388509800011
J	De Martino, I; Visone, R; Fedele, M; Petrocca, F; Palmieri, D; Hoyos, JM; Forzati, F; Croce, CM; Fusco, A				De Martino, I.; Visone, R.; Fedele, M.; Petrocca, F.; Palmieri, D.; Hoyos, J. M.; Forzati, F.; Croce, C. M.; Fusco, A.			Regulation of microRNA expression by HMGA1 proteins (vol 28, pg 1432, 2009)	ONCOGENE			English	Correction															NCI NIH HHS [R35 CA197706] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA197706] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		IDEMARTINO, 2009, ONCOGENE, V28, P1432, DOI DOI 10.1038/ONC.2008.495	1	2	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5817	5818		10.1038/onc.2016.136	http://dx.doi.org/10.1038/onc.2016.136			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27399337	Bronze			2022-12-17	WOS:000386998400012
J	Suzuki, E; Umezawa, K; Bonavida, B				Suzuki, E.; Umezawa, K.; Bonavida, B.			RETRACTION: Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis (Retraction of vol 26, pg 6184, 2016)	ONCOGENE			English	Retraction																		SUZUKI E, 2016, ONCOGENE, V26, P6184, DOI DOI 10.1038/SJ.0NC.1210448	1	2	2	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5576	5576		10.1038/onc.2016.207	http://dx.doi.org/10.1038/onc.2016.207			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27345401	Bronze			2022-12-17	WOS:000386998200012
J	Dong, J; Zhao, W; Shi, A; Toneff, M; Lydon, J; So, D; Li, Y				Dong, J.; Zhao, W.; Shi, A.; Toneff, M.; Lydon, J.; So, D.; Li, Y.			The PR status of the originating cell of ER/PR-negative mouse mammary tumors	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER; IN-VIVO; EXPRESSION; GLAND; MODEL; IMMUNOHISTOCHEMISTRY; PROLIFERATION; TUMORIGENESIS; ONCOPROTEIN	Progesterone receptor (PR) is usually co-localized with estrogen receptor (ER) in normal mammary cells. It is not known whether ER/PR-negative human breast cancer arises from an ER/PR-negative cell or from an ER/PR-positive cell that later lost ER/PR. Using intraductal injection of a lentivirus to deliver both an oncogene (ErbB2) and a floxed green fluorescent protein (GFP) in PRCre/+ mice, whose Cre gene is under the control of the PR promoter, we were able to trace the PR status of the infected cells as they progressed to cancer. We found that the resulting early lesions stained negative for PR in most of the cells and usually retained GFP. The resulting tumors lacked ER and PR, and 75% (15/20) of them retained the GFP signal in all tumor cells, suggesting PR was never expressed throughout the evolution of a majority of these tumors. In conclusion, our data demonstrate that ErbB2-initiated ER/PR-negative mammary tumors primarily originate from the subset of the mammary epithelium that is negative for PR and probably ER as well. These findings also provide an explanation for why antihormonal therapy fails to prevent ER-negative breast cancers.	[Dong, J.; Zhao, W.; Shi, A.; Toneff, M.; So, D.; Li, Y.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Dong, J.; Toneff, M.; Lydon, J.; Li, Y.] Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA; [Shi, A.] Jilin Univ, Hosp 1, Dept Breast Surg, Changchun, Peoples R China; [Li, Y.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Jilin University; Baylor College of Medicine	Li, Y (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza MS600, Houston, TX 77030 USA.	liyi@bcm.edu	; Li, Yi/A-7635-2009	shi, aiping/0000-0002-7272-453X; Li, Yi/0000-0002-9976-518X	NIH [CA124820, U54CA149196]; CDMRP [BC060332, BC085050, BC073703]; Mary Kay Foundation [TMKF042-14]; Dan L. Duncan Cancer Center [P30CA125123]; BCM SPORE career development award [P50-CA058183]; NATIONAL CANCER INSTITUTE [R01CA124820, P50CA186784, U54CA149196] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CDMRP(United States Department of Defense); Mary Kay Foundation; Dan L. Duncan Cancer Center; BCM SPORE career development award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Vidya Sinha and Sarah Hein for stimulating discussion. This work was supported in part by funds from NIH CA124820 (to YL) and U54CA149196 (to YL; PI: Stephan Wong); from CDMRP BC060332 (to YL), BC085050 (to YL) and BC073703 (to YL) and from Mary Kay Foundation (TMKF042-14 (to YL) as well as by the resources from the Lester & Sue Smith Breast Center (P50 CA186784), the Dan L. Duncan Cancer Center (P30CA125123). JD was supported by BCM SPORE career development award (P50-CA058183).	Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047; Allred DC, 2004, BREAST CANCER RES, V6, P240, DOI 10.1186/bcr938; Aubele M, 2002, ANAL CELL PATHOL, V24, P69, DOI 10.1155/2002/371680; Bu W, 2011, ONCOGENE, V30, P4399, DOI 10.1038/onc.2011.147; Bu W, 2009, J MAMMARY GLAND BIOL, V14, P401, DOI 10.1007/s10911-009-9154-4; Clarke RB, 1997, CANCER RES, V57, P4987; Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011; Du ZJ, 2007, CELL CYCLE, V6, P823, DOI 10.4161/cc.6.7.4074; Du ZJ, 2006, P NATL ACAD SCI USA, V103, P17396, DOI 10.1073/pnas.0608607103; Edorh A, 1999, CELL MOL BIOL, V45, P831; Fendrick JL, 1998, J MAMMARY GLAND BIOL, V3, P7, DOI 10.1023/A:1018766000275; GUSTERSON BA, 1988, BRIT J CANCER, V58, P453, DOI 10.1038/bjc.1988.239; Haricharan S, 2014, ONCOGENE, V33, P5729, DOI 10.1038/onc.2013.521; Haricharan S, 2013, ELIFE, V2, DOI 10.7554/eLife.00996; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Heffelfinger SC, 2000, PATHOBIOLOGY, V68, P129, DOI 10.1159/000055913; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Mukherjee A, 2006, GENESIS, V44, P601, DOI 10.1002/dvg.20257; Reddy JP, 2010, P NATL ACAD SCI USA, V107, P3728, DOI 10.1073/pnas.0910665107; Reddy JP, 2009, J MAMMARY GLAND BIOL, V14, P405, DOI 10.1007/s10911-009-9157-1; Shoker BS, 1999, AM J PATHOL, V155, P1811, DOI 10.1016/S0002-9440(10)65498-3; Siwko SK, 2008, NEOPLASIA, V10, P653, DOI 10.1593/neo.08266; Toneff MJ, 2010, NEOPLASIA, V12, P718, DOI 10.1593/neo.10516; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x	27	2	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4149	4154		10.1038/onc.2015.465	http://dx.doi.org/10.1038/onc.2015.465			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26640140	Green Accepted			2022-12-17	WOS:000381020900013
J	Yan, H; Tang, G; Wang, H; Hao, L; He, T; Sun, X; Ting, AH; Deng, A; Sun, S				Yan, H.; Tang, G.; Wang, H.; Hao, L.; He, T.; Sun, X.; Ting, A. H.; Deng, A.; Sun, S.			DNA methylation reactivates GAD1 expression in cancer by preventing CTCF-mediated polycomb repressive complex 2 recruitment (vol 35, pg 3995, 2016)	ONCOGENE			English	Correction																		Yan H, 2016, ONCOGENE, V35, P3995, DOI 10.1038/onc.2015.423	1	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					4020	4020		10.1038/onc.2016.28	http://dx.doi.org/10.1038/onc.2016.28			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	27345404	Bronze			2022-12-17	WOS:000381013100014
J	Garcia, I; Crowther, AJ; Gama, V; Miller, CR; Deshmukh, M; Gershon, TR				Garcia, I.; Crowther, A. J.; Gama, V.; Miller, C. Ryan; Deshmukh, M.; Gershon, T. R.			Bax deficiency prolongs cerebellar neurogenesis, accelerates medulloblastoma formation and paradoxically increases both malignancy and differentiation (vol 32, pg 2304, 2013)	ONCOGENE			English	Correction													Gershon, Timothy/H-5398-2019; Miller, Ryan/B-9365-2008	Gershon, Timothy/0000-0001-7034-6400; Miller, Ryan/0000-0002-0096-8762; Gama, Vivian/0000-0002-1201-1394				Garcia I, 2013, ONCOGENE, V32, P2304, DOI 10.1038/onc.2012.248	1	2	3	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3881	3881		10.1038/onc.2015.204	http://dx.doi.org/10.1038/onc.2015.204			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	26179456	Bronze			2022-12-17	WOS:000358001600013
J	Thomas, A; Perry, T; Berhane, S; Oldreive, C; Zlatanou, A; Williams, LR; Weston, VJ; Stankovic, T; Kearns, P; Pors, K; Grand, RJ; Stewart, GS				Thomas, A.; Perry, T.; Berhane, S.; Oldreive, C.; Zlatanou, A.; Williams, L. R.; Weston, V. J.; Stankovic, T.; Kearns, P.; Pors, K.; Grand, R. J.; Stewart, G. S.			The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; INDUCED REPLICATION STRESS; DEPENDENT PROTEIN-KINASE; RESISTANT OVARIAN-CANCER; DNA TOPOISOMERASE-II; GENE; REPAIR; INACTIVATION; DEFICIENCY; MECHANISMS	Topoisomerase inhibitors are in common use as chemotherapeutic agents although they can display reduced efficacy in chemotherapy-resistant tumours, which have inactivated DNA damage response (DDR) genes, such as ATM and TP53. Here, we characterise the cellular response to the dual-acting agent, Alchemix (ALX), which is a modified anthraquinone that functions as a topoisomerase inhibitor as well as an alkylating agent. We show that ALX induces a robust DDR at nano-molar concentrations and this is mediated primarily through ATR- and DNA-PK- but not ATM-dependent pathways, despite DNA double strand breaks being generated after prolonged exposure to the drug. Interestingly, exposure of epithelial tumour cell lines to ALX in vitro resulted in potent activation of the G2/M checkpoint, which after a prolonged arrest, was bypassed allowing cells to progress into mitosis where they ultimately died by mitotic catastrophe. We also observed effective killing of lymphoid tumour cell lines in vitro following exposure to ALX, although, in contrast, this tended to occur via activation of a p53-independent apoptotic pathway. Lastly, we validate the effectiveness of ALX as a chemotherapeutic agent in vivo by demonstrating its ability to cause a significant reduction in tumour cell growth, irrespective of TP53 status, using a mouse leukaemia xenograft model. Taken together, these data demonstrate that ALX, through its dual action as an alkylating agent and topoisomerase inhibitor, represents a novel anti-cancer agent that could be potentially used clinically to treat refractory or relapsed tumours, particularly those harbouring mutations in DDR genes.	[Thomas, A.; Perry, T.; Berhane, S.; Oldreive, C.; Zlatanou, A.; Williams, L. R.; Weston, V. J.; Stankovic, T.; Kearns, P.; Grand, R. J.; Stewart, G. S.] Univ Birmingham, Coll Med & Dent, Sch Canc Sci, IBR West Extens, Birmingham B15 2TT, W Midlands, England; [Pors, K.] Univ Bradford, Sch Life Sci, Inst Canc Therapeut, Bradford BD7 1DP, W Yorkshire, England	University of Birmingham; University of Bradford	Stewart, GS (corresponding author), Univ Birmingham, Coll Med & Dent, Sch Canc Sci, IBR West Extens, Vincent Dr, Birmingham B15 2TT, W Midlands, England.	k.pors1@bradford.ac.uk; R.J.A.Grand@bham.ac.uk; G.S.Stewart@bham.ac.uk	Kearns, Pamela/AAD-6011-2021	Kearns, Pamela/0000-0003-2756-5813; Stewart, Grant/0000-0002-0960-3241; Berhane, Sarah/0000-0002-1437-0411; Stankovic, Tatjana/0000-0002-3780-274X; Pors, Klaus/0000-0002-0837-5208	University of Birmingham; MRC [G0900088]; Cancer Research UK [C17183/A13030]; Leukaemia Lymphoma Research [11045]; Lister Institute; Yorkshire Cancer Research; Cancer Research UK [13030] Funding Source: researchfish; Medical Research Council [G0900088] Funding Source: researchfish	University of Birmingham; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Leukaemia Lymphoma Research; Lister Institute; Yorkshire Cancer Research; Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are most grateful to Fred Bunz, Alan D'Andrea, Eva Petermann, Panagiotis Kotsantis and Jiri Lukas for the gift of cell lines, and Philip Byrd, Arnold Levine and David Lane for antibodies. We would especially like to thank Cyrus Vaziri for providing cell lines and a recombinant adenovirus expressing Cyclin E, Rebbeca Jones for helping us with PFGE and Malcolm Taylor for helpful discussions. Last, we would also thank the University of Birmingham (AT-PhD studentship), MRC (GSS, RJG-Project grant: G0900088), the Cancer Research UK (GSS-Senior Fellowship: C17183/A13030), the Leukaemia Lymphoma Research (TS, GSS-Programme grant: 11045), the Lister Institute (GSS, AZ-Research Prize) and the Yorkshire Cancer Research (KP) for funding this study.	Abdallah QMA, 2012, BIOCHEM PHARMACOL, V83, P1514, DOI 10.1016/j.bcp.2012.02.017; Al-Ejeh F, 2010, ONCOGENE, V29, P6085, DOI 10.1038/onc.2010.407; Beeharry N, 2013, CELL CYCLE, V12, P1588, DOI 10.4161/cc.24740; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Bhojwani D, 2013, LANCET ONCOL, V14, pE205, DOI 10.1016/S1470-2045(12)70580-6; CALDECOTT K, 1990, CANCER RES, V50, P5778; Chan EYW, 2007, J BIOL CHEM, V282, P25464, DOI 10.1074/jbc.M703663200; Forrest RA, 2013, CANCER CHEMOTH PHARM, V71, P809, DOI 10.1007/s00280-012-2049-x; Greaves M, 2013, BRIT J CANCER, V109, P1391, DOI 10.1038/bjc.2013.490; Hof J, 2011, J CLIN ONCOL, V29, P3185, DOI 10.1200/JCO.2011.34.8144; Holmfeldt L, 2013, NAT GENET, V45, P242, DOI 10.1038/ng.2532; Inaba H, 2013, LANCET, V381, P1943, DOI 10.1016/S0140-6736(12)62187-4; Jones RM, 2013, ONCOGENE, V32, P3744, DOI 10.1038/onc.2012.387; Larsen AK, 2003, PHARMACOL THERAPEUT, V99, P167, DOI 10.1016/S0163-7258(03)00058-5; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; McNeely S, 2010, CELL CYCLE, V9, P995, DOI 10.4161/cc.9.5.10935; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Nitiss JL, 2009, NAT REV CANCER, V9, P327, DOI 10.1038/nrc2608; Orth JD, 2012, MOL BIOL CELL, V23, P567, DOI 10.1091/mbc.E11-09-0781; Pabla N, 2011, J BIOL CHEM, V286, P10411, DOI 10.1074/jbc.M110.210989; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pommier Y, 2013, ACS CHEM BIOL, V8, P82, DOI 10.1021/cb300648v; Pors K, 2005, J MED CHEM, V48, P6690, DOI 10.1021/jm050438f; Pors K, 2004, J MED CHEM, V47, P1856, DOI 10.1021/jm031070u; Pors K, 2003, MOL CANCER THER, V2, P607; Pors K, 2005, CURR TOP MED CHEM, V5, P1133, DOI 10.2174/156802605774370883; Redmond KM, 2008, FRONT BIOSCI-LANDMRK, V13, P5138, DOI 10.2741/3070; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Sy SMH, 2011, J BIOL CHEM, V286, P22355, DOI 10.1074/jbc.M111.232041; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Yajima H, 2006, MOL CELL BIOL, V26, P7520, DOI 10.1128/MCB.00048-06; Yajima H, 2009, J MOL BIOL, V385, P800, DOI 10.1016/j.jmb.2008.11.036	37	2	2	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3336	3348		10.1038/onc.2014.266	http://dx.doi.org/10.1038/onc.2014.266			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25132271	Green Accepted			2022-12-17	WOS:000356592300012
J	Macha, MA; Rachagani, S; Pai, P; Gupta, S; Lydiatt, WM; Smith, RB; Johansson, SL; Lele, SM; Kakar, SS; Farghaly, H; Lee, JH; Meza, J; Ganti, AK; Jain, M; Batra, SK				Macha, M. A.; Rachagani, S.; Pai, P.; Gupta, S.; Lydiatt, W. M.; Smith, R. B.; Johansson, S. L.; Lele, S. M.; Kakar, S. S.; Farghaly, H.; Lee, J. H.; Meza, J.; Ganti, A. K.; Jain, M.; Batra, S. K.			MUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway (vol 34, pg 1698, 2015)	ONCOGENE			English	Correction									[Macha, M. A.; Rachagani, S.; Pai, P.; Gupta, S.; Jain, M.; Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Lydiatt, W. M.; Smith, R. B.] Univ Nebraska Med Ctr, Dept Otolaryngol, Omaha, NE USA; [Johansson, S. L.; Lele, S. M.] Univ Nebraska Med Ctr, Dept Pathol, Omaha, NE USA; [Kakar, S. S.; Farghaly, H.] Univ Louisville, Dept Physiol & Biophys, Louisville, KY 40292 USA; [Lee, J. H.] Sanford Canc Res Ctr, Sanford ENT Head & Neck Surg, Sioux Falls, SD USA; [Meza, J.] Univ Nebraska Med Ctr, Dept Biostat, Coll Publ Hlth, Omaha, NE USA; [Ganti, A. K.] VA Nebraska Western Iowa Hlth Care Syst, Dept Internal Med, Omaha, NE USA; [Ganti, A. K.] Univ Nebraska Med Ctr, Omaha, NE USA; [Batra, S. K.] Univ Nebraska Med Ctr, Buffett Canc Ctr, Omaha, NE USA; [Batra, S. K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Louisville; Sanford Health; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Macha, MA (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.		Ganti, Apar Kishor/D-5498-2015; MACHA, MUZAFAR AHMAD/AAN-5735-2020	Ganti, Apar Kishor/0000-0003-3724-2671; MACHA, MUZAFAR AHMAD/0000-0003-4468-4435				Macha MA, 2015, ONCOGENE, V34, P1698, DOI 10.1038/onc.2014.102	1	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2814	2814		10.1038/onc.2015.116	http://dx.doi.org/10.1038/onc.2015.116			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25994150	Bronze			2022-12-17	WOS:000354979500014
J	Zhang, C; Casas-Tinto, S; Li, G; Lin, N; Chung, M; Moreno, E; Moberg, KH; Zhou, L				Zhang, C.; Casas-Tinto, S.; Li, G.; Lin, N.; Chung, M.; Moreno, E.; Moberg, K. H.; Zhou, L.			An intergenic regulatory region mediates Drosophila Myc-induced apoptosis and blocks tissue hyperplasia (vol 34, pg 2385, 2015)	ONCOGENE			English	Correction													Casas-Tinto, Sergio/G-8220-2015; Li, Guangyao/I-8241-2015	Casas-Tinto, Sergio/0000-0002-9589-9981; Li, Guangyao/0000-0003-0029-3854; moreno, eduardo/0000-0001-5040-452X				Zhang C, 2015, ONCOGENE, V34, P2385, DOI 10.1038/onc.2014.160	1	2	2	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2412	2412		10.1038/onc.2014.463	http://dx.doi.org/10.1038/onc.2014.463			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	25924716	Bronze			2022-12-17	WOS:000353824800015
J	Lai, WL; Hung, WY; Ching, YP				Lai, W. L.; Hung, W. Y.; Ching, Y. P.			The tumor suppressor, TAX1BP2, is a novel substrate of ATM kinase	ONCOGENE			English	Article						ATM; TAX1BP2; HCC and phosphorylation	DNA-DAMAGE; HEPATOCELLULAR-CARCINOMA; PROTEIN; P53; PHOSPHORYLATION; ACTIVATION; CANCER; IDENTIFICATION	DNA damage repair response is a crucial process for cancer prevention. One of the key regulators of this process is ataxia telangiectasia mutated (ATM) kinase, which modulates the p53 level by direct and indirect phosphorylation. Recent data showed that ATM also localizes at the centrosome, but the function remains elusive. TAX1BP2 was initially identified as a novel centrosomal protein that interacts directly with the human T-cell leukemia virus type 1 (HTLV-1)-encoded oncoprotein, Tax, and inhibits centrosome overduplication. Subsequently, TAX1BP2 was found to be a tumor suppressor in hepatocellular carcinoma, and accumulation of TAX1BP2 was observed upon chemotherapeutic drug treatment. Here, we provide evidence that TAX1BP2 is a direct phosphorylation substrate of ATM. The protein level of TAX1BP2 is significantly upregulated in response to DNA damaging agents. Serine-922 of TAX1BP2 is the phosphorylation site of ATM, and such phosphorylation modulates the protein stability, ubiquitination and tumor suppressor activity of TAX1BP2. Taken together, we demonstrate for the first time that TAX1BP2 is a novel effector of ATM in DNA damage response and delineated a new mechanism by which ATM stabilizes the tumor suppressor TAX1BP2.	[Lai, W. L.; Hung, W. Y.; Ching, Y. P.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Pokfulam, Hong Kong, Peoples R China; [Ching, Y. P.] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Hong Kong, Peoples R China; [Ching, Y. P.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Ching, YP (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Room L1-43,Fac Med Bldg, Pokfulam, Hong Kong, Peoples R China.	ypching@hku.hk		CHING, Yick Pang/0000-0002-6461-8358	Hong Kong Health and Medical Research Fund [12110872]; Hong Kong Research Grant Council (HKU) [763509, 7/CRF/09]; SK Yee Medical Research Fund; University of Hong Kong [201209176008]	Hong Kong Health and Medical Research Fund; Hong Kong Research Grant Council (HKU)(University of Hong KongHong Kong Research Grants Council); SK Yee Medical Research Fund; University of Hong Kong(University of Hong Kong)	We are very grateful to Prof Jin DY for providing the HA-p38-expressing plasmid, Prof SW Tsao for providing the anti-Chk1 and anti-Chk2 antibodies and Dr MS Huen for providing the FLAG-ubiquitin-expressing plasmid. Financial support was received from the Hong Kong Health and Medical Research Fund (No. 12110872), the Hong Kong Research Grant Council (HKU 763509 and 7/CRF/09), the SK Yee Medical Research Fund 2011 (to YPC) and The University of Hong Kong (Small Project Funding 201209176008 to WLL).	Asghar U, 2012, J HEPATOL, V56, P686, DOI 10.1016/j.jhep.2011.07.031; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Ching YP, 2007, CANCER RES, V67, P3601, DOI 10.1158/0008-5472.CAN-06-3994; Ching YP, 2006, NAT CELL BIOL, V8, P717, DOI 10.1038/ncb1432; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Ikeda F, 2010, CELL, V143, P677, DOI 10.1016/j.cell.2010.10.026; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lai WL, 2012, HEPATOLOGY, V56, P1770, DOI 10.1002/hep.25851; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Nigg EA, 2011, NAT CELL BIOL, V13, P1154, DOI 10.1038/ncb2345; Teoh N, 2010, GASTROENTEROLOGY, V138, P1155, DOI 10.1053/j.gastro.2009.11.008; Wysocki PJ, 2010, EXPERT OPIN INV DRUG, V19, P265, DOI 10.1517/13543780903514110; Zhang SS, 2007, J CELL BIOCHEM, V101, P451, DOI 10.1002/jcb.21195	16	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5303	5309		10.1038/onc.2013.481	http://dx.doi.org/10.1038/onc.2013.481			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24240686				2022-12-17	WOS:000345120400008
J	Blanchard, JM				Blanchard, J. M.			To be or not to be a proliferation marker?	ONCOGENE			English	Editorial Material							CYCLIN-A; CANCER; MYC	Whether it is nobler in the mind to suffer the slings and arrows of outrageous proliferation, or to take arms against stroma, and favor metastasis... This pastiche of Hamlet's famous monologue illustrates recent reports on the paradoxical functions of well-established proliferation markers such as c-Myc or cyclin A2 that have revealed their ambiguous roles in the control of proliferation and metastasis. On the one hand, overexpression of c-Myc, while stimulating local proliferation, inhibits invasiveness of cancer cells, whereas on the other, downregulation of cyclin A2 leads to increased motility of transformed cells.	[Blanchard, J. M.] Inst Genet Mol Montpellier, CNRS, F-34293 Montpellier, France; [Blanchard, J. M.] Univ Montpellier 2, Montpellier, France; [Blanchard, J. M.] Univ Montpellier I, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; Universite de Montpellier	Blanchard, JM (corresponding author), Inst Genet Mol Montpellier, CNRS, 1919 Route Mende, F-34293 Montpellier, France.	jean-marie.blanchard@igmm.cnrs.fr						Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Arsic N, 2012, J CELL BIOL, V196, P147, DOI 10.1083/jcb.201102085; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Kalaszczynska I, 2009, CELL, V138, P352, DOI 10.1016/j.cell.2009.04.062; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Liu H, 2012, NAT CELL BIOL, V14, P567, DOI 10.1038/ncb2491; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Ohtoshi A, 2000, BIOCHEM BIOPH RES CO, V267, P947, DOI 10.1006/bbrc.1999.2007; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796	13	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					954	955		10.1038/onc.2013.19	http://dx.doi.org/10.1038/onc.2013.19			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23396366				2022-12-17	WOS:000331933200002
J	Ashman, LK				Ashman, L. K.			Renal disease as a potential compounding factor in carcinogenesis experiments with Cd151-null mice	ONCOGENE			English	Letter							LACKING		Univ Newcastle, Hunter Med Res Inst, Sch Biomed Sci & Pharm, Newcastle, NSW 2300, Australia	Hunter Medical Research Institute; University of Newcastle	Ashman, LK (corresponding author), Univ Newcastle, Hunter Med Res Inst, Sch Biomed Sci & Pharm, Newcastle, NSW 2300, Australia.	leonie.ashman@newcastle.edu.au						Baleato RM, 2008, AM J PATHOL, V173, P927, DOI 10.2353/ajpath.2008.071149; Li Q, 2013, ONCOGENE, V32, P1772, DOI 10.1038/onc.2012.205; Sachs N, 2006, J CELL BIOL, V175, P33, DOI 10.1083/jcb.200603073; Wright MD, 2004, MOL CELL BIOL, V24, P5978, DOI 10.1128/MCB.24.13.5978-5988.2004	4	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4457	4457		10.1038/onc.2013.73	http://dx.doi.org/10.1038/onc.2013.73			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23474759				2022-12-17	WOS:000324404200014
J	Chen, Y; Yang, D; Li, S; Gao, Y; Jiang, R; Deng, L; Frankel, FR; Sun, B				Chen, Y.; Yang, D.; Li, S.; Gao, Y.; Jiang, R.; Deng, L.; Frankel, F. R.; Sun, B.			Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma (vol 31, pg 2140, 2012)	ONCOGENE			English	Correction																		Chen Y, 2012, ONCOGENE, V31, P2140, DOI 10.1038/onc.2011.395	1	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	45					4810	4810		10.1038/onc.2012.430	http://dx.doi.org/10.1038/onc.2012.430			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF		Bronze			2022-12-17	WOS:000311033000010
J	Kang, J; Qian, PX; Pandey, V; Perry, JK; Miller, LD; Liu, ET; Zhu, T; Liu, DX; Lobie, PE				Kang, J.; Qian, P. X.; Pandey, V.; Perry, J. K.; Miller, L. D.; Liu, E. T.; Zhu, T.; Liu, D. X.; Lobie, P. E.			Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma (vol 29, pg 3228, 2010)	ONCOGENE			English	Correction													Pandey, Vijay/P-2767-2016	Miller, Lance/0000-0003-3799-2528				Kang J, 2010, ONCOGENE, V29, P3228, DOI 10.1038/onc.2010.71	1	2	2	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	3					402	402		10.1038/onc.2011.553	http://dx.doi.org/10.1038/onc.2011.553			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ		Bronze			2022-12-17	WOS:000299542100012
J	Ponnusamy, MP; Lakshmanan, I; Jain, M; Das, S; Chakraborty, S; Dey, P; Batra, SK				Ponnusamy, M. P.; Lakshmanan, I.; Jain, M.; Das, S.; Chakraborty, S.; Dey, P.; Batra, S. K.			MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells (vol 29, pg 6084, 2010)	ONCOGENE			English	Correction														Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X; lakshmanan, Imayavaramban/0000-0003-1733-2223				Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309	1	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	45					6084	6084		10.1038/onc.2010.472	http://dx.doi.org/10.1038/onc.2010.472			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA		Bronze			2022-12-17	WOS:000284108700010
J	Lara, E; Mai, A; Calvanese, V; Altucci, L; Lopez-Nieva, P; Martinez-Chantar, ML; Varela-Rey, M; Rotili, D; Nebbioso, A; Ropero, S; Montoya, G; Oyarzabal, J; Velasco, S; Serrano, M; Witt, M; Villar-Garea, A; Imhof, A; Mato, JM; Esteller, M; Fraga, MF				Lara, E.; Mai, A.; Calvanese, V.; Altucci, L.; Lopez-Nieva, P.; Martinez-Chantar, M. L.; Varela-Rey, M.; Rotili, D.; Nebbioso, A.; Ropero, S.; Montoya, G.; Oyarzabal, J.; Velasco, S.; Serrano, M.; Witt, M.; Villar-Garea, A.; Imhof, A.; Mato, J. M.; Esteller, M.; Fraga, M. F.			Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect (vol 28, pg 781, 2009)	ONCOGENE			English	Correction													Nieva, Pilar López/R-9516-2019; Chantar, Maria Luz Martinez/F-5190-2011; Imhof, Axel/AAU-5313-2021; MATO, JOSE/A-5187-2011; Calvanese, Vincenzo/E-1145-2016; Fraga, Mario F/H-7824-2017; Varela-Rey, Marta/C-5460-2019; Mai, Antonello/AAC-2144-2019; Oyarzabal, Julen/K-7393-2017; Rotili, Dante/J-9157-2016; Calvanese, Vincenzo/AAO-4311-2020; NEBBIOSO, ANGELA/GVS-1294-2022; Altucci, Lucia/S-8031-2019; Esteller, Manel/L-5956-2014; NEBBIOSO, Angela/C-3566-2016	Nieva, Pilar López/0000-0001-6369-2444; Chantar, Maria Luz Martinez/0000-0002-6446-9911; Imhof, Axel/0000-0003-2993-8249; MATO, JOSE/0000-0003-1264-3153; Calvanese, Vincenzo/0000-0002-7937-1511; Fraga, Mario F/0000-0001-8450-2603; Oyarzabal, Julen/0000-0003-1941-7255; Calvanese, Vincenzo/0000-0002-7937-1511; Esteller, Manel/0000-0003-4490-6093; NEBBIOSO, Angela/0000-0001-5374-3527; Mai, Antonello/0000-0001-9176-2382; altucci, lucia/0000-0002-7312-5387; Rotili, Dante/0000-0002-8428-8763				Lara E, 2009, ONCOGENE, V28, P781, DOI 10.1038/onc.2008.436	1	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2009	28	8					1168	1168		10.1038/onc.2009.1	http://dx.doi.org/10.1038/onc.2009.1			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE		Bronze			2022-12-17	WOS:000263722900012
J	Reed, JC				Reed, J. C.			Foreword	ONCOGENE			English	Editorial Material									Burnham Inst Med Res, La Jolla, CA USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst Med Res, La Jolla, CA USA.								0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	48					6192	+		10.1038/onc.2008.296	http://dx.doi.org/10.1038/onc.2008.296			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	361YB	18931686				2022-12-17	WOS:000260162800001
J	Moniz, S; Verissimo, F; Matos, P; Brazao, R; Silva, E; Kotelevets, L; Chastre, E; Gespach, C; Jordan, P				Moniz, S.; Verissimo, F.; Matos, P.; Brazao, R.; Silva, E.; Kotelevets, L.; Chastre, E.; Gespach, C.; Jordan, P.			Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2 (vol 26, pg 6071, 2007)	ONCOGENE			English	Correction													CHASTRE, Eric/L-8446-2018; Matos, Paulo/P-3012-2019	CHASTRE, Eric/0000-0002-8993-1228; Matos, Paulo/0000-0002-9379-9696				Moniz S, 2007, ONCOGENE, V26, P6071, DOI 10.1038/sj.onc.1210706	1	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					155	155		10.1038/sj.onc.1210931	http://dx.doi.org/10.1038/sj.onc.1210931			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO		Bronze			2022-12-17	WOS:000252118700016
J	Hunter, T; Simon, J				Hunter, T.; Simon, J.			A not so brief history of the Oncogene Meeting and its Cartoons	ONCOGENE			English	Article									Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Hunter, T (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hunter@salk.edu							0	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2007	26	9					1260	1267		10.1038/sj.onc.1210262	http://dx.doi.org/10.1038/sj.onc.1210262			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322910				2022-12-17	WOS:000244558700002
J	Sawada, M; Nakashima, S; Banno, Y; Yamakura, H; Takenaka, K; Shinoda, J; Nishimura, Y; Sakai, N; Nozawa, Y				Sawada, M.; Nakashima, S.; Banno, Y.; Yamakura, H.; Takenaka, K.; Shinoda, J.; Nishimura, Y.; Sakai, N.; Nozawa, Y.			Influence of Bax or Bcl-2 overexpression on the ceramide-dependent apoptosis pathway in glioma cells (vol 19, pg 3508, 2000)	ONCOGENE			English	Correction																		Sawada M, 2006, ONCOGENE, V25, P7440, DOI 10.1038/sj.onc.1210105	1	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7440	7440		10.1038/sj.onc.1210105	http://dx.doi.org/10.1038/sj.onc.1210105			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE		Bronze			2022-12-17	WOS:000242419100013
J	Proud, CG				Proud, C. G.			Introduction	ONCOGENE			English	Editorial Material									Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada	University of British Columbia	Proud, CG (corresponding author), Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada.			Proud, Christopher/0000-0003-0704-6442					0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2006	25	48					6346	6346		10.1038/sj.onc.1209904	http://dx.doi.org/10.1038/sj.onc.1209904			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH					2022-12-17	WOS:000241380700001
J	Muerkoster, SS; Lust, J; Arlt, A; Hasler, R; Witt, M; Sebens, T; Schreiber, S; Folsch, UR; Schafer, H				Muerkoster, S. Sebens; Lust, J.; Arlt, A.; Hasler, R.; Witt, M.; Sebens, T.; Schreiber, S.; Folsch, U. R.; Schafer, H.			Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1 beta and NO lead to inactivation of caspases (vol 25, pg 4628, 2006)	ONCOGENE			English	Correction													Arlt, Alexander/G-7308-2019; Häsler, Robert/A-4908-2009; Sebens, Susanne/C-1222-2010	Arlt, Alexander/0000-0002-6160-1059; Häsler, Robert/0000-0003-4174-8229; 				Muerkoster SS, 2006, ONCOGENE, V25, P4628, DOI 10.1038/sj.onc.1209806	1	2	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4628	4628		10.1038/sj.onc.1209806	http://dx.doi.org/10.1038/sj.onc.1209806			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG		Bronze			2022-12-17	WOS:000239457500013
J	Ayrault, O; Karayan, L; Riou, JF; Larsen, CJ; Seite, P				Ayrault, O; Karayan, L; Riou, JF; Larsen, CJ; Seite, P			Delineation of the domains required for physical and functional interaction of p14(ARF) with human topoisomerase I (vol 22, pg 1945, 2003)	ONCOGENE			English	Correction														riou, jean-francois/0000-0002-0055-6506				Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214	1	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19								10.1038/sj.onc.1209539	http://dx.doi.org/10.1038/sj.onc.1209539			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW		Bronze			2022-12-17	WOS:000237272900015
J	Rodriguez-Viciana, P; Collins, CH; Moule, MG; Fried, M				Rodriguez-Viciana, P; Collins, CH; Moule, MG; Fried, M			Chromosomal instability at a mutational hotspot in polyoma middle T-antigen affects its ability to activate the ARF-p53 tumor suppressor pathway	ONCOGENE			English	Article						ARF; p53; polyoma virus middle T-antigen; REF52 cells; chromosomal instability; hot spot mutations	FRAMESHIFT MUTATION; REF52 CELLS; P53; TRANSFORMATION; ONCOGENES; GROWTH; MECHANISMS; PROTEINS; MUTANTS; ARREST	We have isolated spontaneous mutants of polyoma virus middle T-antigen (PyMT) that do not activate the ARF-p53 pathway based on their inability to block REF52 cell division. The REF52 cells containing these mutants have a. at untransformed morphological phenotype and do not express the ARF protein. The PyMT mutations in the different cell isolates so far analysed occur at a mutational hotspot in the PyMT sequence between nucleotides 1241 and 1249, which contains nine consecutive cytosines. In one set of mutants a single cytosine was deleted, while in another mutant set an additional cytosine was inserted. Both these mutations result in frameshifts, generating altered PyMT proteins containing amino-acid sequences derived from each of the two other alternative reading frames of the polyoma virus early region. Both types of mutations result in the loss of the C-terminal PyMT region containing the membrane-binding hydrophobic region and result is mislocalization of the PyMT mutant proteins. Revertant wild-type PyMT ( containing nine cytosines) was easily detected in transformants generated after infection of REF52 cells expressing high amounts of dominant negative p53 with retroviruses containing either mutation. We demonstrate that wild-type PyMT revertants are derived from mutations in the hotspot sequence of the integrated mutant PyMT sequences.	Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Fried, M (corresponding author), Univ Calif San Francisco, Inst Canc Res, 2340 Sutter St, San Francisco, CA 94115 USA.	fried@cc.ucsf.edu		Moule, Madeleine/0000-0002-9612-4563	NCI NIH HHS [CA92454, CA101967] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101967, R01CA092454] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN B, 1985, EMBO J, V4, P351, DOI 10.1002/j.1460-2075.1985.tb03636.x; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Gottlieb KA, 2001, MICROBIOL MOL BIOL R, V65, P288, DOI 10.1128/MMBR.65.2.288-318.2001; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; KOHL NE, 1987, ONCOGENE, V2, P41; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; Lomax M, 2001, ONCOGENE, V20, P4951, DOI 10.1038/sj.onc.1204717; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MCCLURE DB, 1984, EFFECT SY40 TRANSFOR; Mor O, 1997, ONCOGENE, V15, P3113, DOI 10.1038/sj.onc.1201549; Moule MG, 2004, P NATL ACAD SCI USA, V101, P14063, DOI 10.1073/pnas.0405533101; O'Shea CC, 2005, CELL CYCLE, V4, P449, DOI 10.4161/cc.4.3.1555; Prives C, 1999, J PATHOL, V187, P112; QUELLE DE, 1995, CELL, V83, P993; RAGOZZINO MM, 1991, ENVIRON HEALTH PERSP, V93, P97, DOI 10.1289/ehp.919397; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Steele RJC, 1998, BRIT J SURG, V85, P1460; Strauss BS, 1999, MUTAT RES-REV MUTAT, V437, P195, DOI 10.1016/S1383-5742(99)00066-6; STREISINGER G, 1985, GENETICS, V109, P633; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; WILSON JB, 1986, CELL, V44, P477, DOI 10.1016/0092-8674(86)90469-1	30	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1454	1462		10.1038/sj.onc.1209197	http://dx.doi.org/10.1038/sj.onc.1209197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261156				2022-12-17	WOS:000235890400003
J	Dominguez, PL; Kolodney, MS				Dominguez, PL; Kolodney, MS			Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens (vol 25, pg 656, 2006)	ONCOGENE			English	Correction														kolodney, Michael/0000-0003-1931-8644				Dominguez PL, 2006, ONCOGENE, V25, P656, DOI 10.1038/sj.onc.1209332	1	2	2	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2006	25	4					656	656		10.1038/sj.onc.1209332	http://dx.doi.org/10.1038/sj.onc.1209332			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW		Bronze			2022-12-17	WOS:000234897400017
J	Zhang, QP; Xiong, J; Jin, YX; Wu, Q; Ju, W; Liu, C; Wang, J; Liu, Y; Hu, CS; Yang, MZ; Gao, QP; Li, Q; Zhang, KJ; Sun, ZM; Liu, JY; Tan, JQ				Zhang, QP; Xiong, J; Jin, YX; Wu, Q; Ju, W; Liu, C; Wang, J; Liu, Y; Hu, CS; Yang, MZ; Gao, QP; Li, Q; Zhang, KJ; Sun, ZM; Liu, JY; Tan, JQ			RETRACTED: Selectively frequent expression of CXCR5 enhances resistance to apoptosis in CD8(+)CD34(+) T cells from patients with T-cell-lineage acute lymphocytic leukemia (Retracted article. See vol. 30, pg. 2798, 2011)	ONCOGENE			English	Article; Retracted Publication						leukemia; T cells; chemokine receptor; apoptosis; chemotaxis	NECROSIS-FACTOR FAMILY; RECEPTOR 9/TECK INTERACTION; B-CELL; CHEMOKINE RECEPTOR; DENDRITIC CELLS; LYMPH-NODES; STRUCTURAL BASIS; PROTEIN FAMILY; ML-IAP; APRIL	We investigated CD4(+)CD34(+), CD8(+)CD34(+), CD4(+)CD34(-), and CD8(+)CD34(-) T cells from cord blood and from typical patients with T-cell-lineage acute lymphocytic leukemia and T-cell-lineage chronic lymphocytic leukemia in terms of expression and functions of CXCR5/CXCL13. We found that CXCR5 was selectively frequently expressed on T-cell-lineage acute (chronic) lymphocytic leukemia (T-ALL) CD8(+)CD34(+) T cells, but not on T-ALL CD4(+)CD34(+), CD4(+)CD34(-), and CD8(+)CD34(-) T cells. CXCR5 was rarely expressed on all types of CD34(+) and CD34(-) CB or T-CLL T cells. CXCL13/B cells attracting chemokine 1 induced significant resistance to TNF-alpha-mediated apoptosis in T-ALL CD8(+)CD34(-) T cells, instead of induction of chemotactic and adhesive responsiveness. A proliferation-inducing ligand expression in T-ALL CD8(+)CD34(+) T cells was upregulated by CXCL13/BCA-1 (B-cell attracting chemokine 1). The CXCR5/CXCL13 pair by means of activation of APRIL ( A proliferation-inducinglig and) induced resistance to apoptosis in T-ALL CD8(+)CD34(+) T cells in livin-dependent manner. In this process, cell - cell contact in culture was necessary. Based on our findings, we suggested that there were differential functions of CXCR5/CXCL13 in distinct types of cells. Normal lymphocytes, especially naive B and T cells, utilized CXCR5/CXCL13 for migration, homing, maturation, and cell homeostasis, as well as secondary lymphoid tissue organogenesis. Meanwhile, certain malignant cells took advantages of CXCR5/CXCL13 for infiltration, resistance to apoptosis, and inappropriate proliferation.	Wuhan Univ, Sch Med, Med Res Ctr,Inst Allergy & Immune Related Dis, Dept Immunol,Lab Allergy & Clin Immunol, Wuhan 430071, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai, Peoples R China; Anhui med Univ, Coll Basic Med Sci, Dept Immunol, Hefei 230032, Peoples R China; Anhui Med Univ, Affiliated Univ Hosp, Dept Hematol, Hefei 230031, Peoples R China; Wuhan Univ, Affiliated Univ Hosp 1, Dept Hematol, Wuhan 430071, Peoples R China; Wuhan Univ, Affiliated Univ Hosp 2, Dept Hematol, Wuhan 430071, Peoples R China; Prov Hosp Anhui, Dept Hematol, Hefei 230020, Peoples R China	Wuhan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Anhui Medical University; Anhui Medical University; Wuhan University; Wuhan University	Tan, JQ (corresponding author), Wuhan Univ, Sch Med, Med Res Ctr,Inst Allergy & Immune Related Dis, Dept Immunol,Lab Allergy & Clin Immunol, Dong Hu Rd 115, Wuhan 430071, Peoples R China.	jinquan_tan@hotmail.com						Algeciras-Schimnich A, 2002, AIDS, V16, P1467, DOI 10.1097/00002030-200207260-00003; Ansel KM, 2000, NATURE, V406, P309, DOI 10.1038/35018581; BENNETT JM, 1981, BRIT J HAEMATOL, V47, P553, DOI 10.1111/j.1365-2141.1981.tb02684.x; Berndt C, 1998, P NATL ACAD SCI USA, V95, P12556, DOI 10.1073/pnas.95.21.12556; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Finke D, 2002, IMMUNITY, V17, P363, DOI 10.1016/S1074-7613(02)00395-3; FORSTER R, 1994, BLOOD, V84, P830; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Han ZC, 1997, BLOOD, V89, P2328, DOI 10.1182/blood.V89.7.2328; Hargreaves DC, 2001, J EXP MED, V194, P45, DOI 10.1084/jem.194.1.45; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Kanbe K, 1999, VIROLOGY, V265, P264, DOI 10.1006/viro.1999.0036; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kelly K, 2000, CANCER RES, V60, P1021; Kern C, 2004, BLOOD, V103, P679, DOI 10.1182/blood-2003-02-0540; Kim CH, 2001, J EXP MED, V193, P1373, DOI 10.1084/jem.193.12.1373; Kruse N, 1997, J IMMUNOL METHODS, V210, P195, DOI 10.1016/S0022-1759(97)00188-9; Lin JH, 2000, BIOCHEM BIOPH RES CO, V279, P820, DOI 10.1006/bbrc.2000.4027; Lopez-Fraga M, 2001, EMBO REP, V2, P945, DOI 10.1093/embo-reports/kve198; Luther SA, 2000, IMMUNITY, V12, P471, DOI 10.1016/S1074-7613(00)80199-5; Massari P, 2000, P NATL ACAD SCI USA, V97, P9070, DOI 10.1073/pnas.97.16.9070; Mazzucchelli L, 1999, J CLIN INVEST, V104, pR49, DOI 10.1172/JCI7830; Medema JP, 2003, CELL DEATH DIFFER, V10, P1121, DOI 10.1038/sj.cdd.4401291; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Muller G, 2003, IMMUNOL REV, V195, P117, DOI 10.1034/j.1600-065X.2003.00073.x; Ohl L, 2003, J EXP MED, V197, P1199, DOI 10.1084/jem.20030169; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; Pradet-Balade B, 2002, EMBO J, V21, P5711, DOI 10.1093/emboj/cdf565; Reif K, 2002, NATURE, V416, P94, DOI 10.1038/416094a; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(01)00274-4; Roth W, 2001, CELL DEATH DIFFER, V8, P403, DOI 10.1038/sj.cdd.4400827; Saeki H, 2000, EUR J IMMUNOL, V30, P2808, DOI 10.1002/1521-4141(200010)30:10<2808::AID-IMMU2808>3.0.CO;2-K; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Scheuerer B, 2000, BLOOD, V95, P1158, DOI 10.1182/blood.V95.4.1158.004k31_1158_1166; Schmollinger JC, 2003, P NATL ACAD SCI USA, V100, P3398, DOI 10.1073/pnas.0530311100; Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969; Siegel RM, 2001, NAT IMMUNOL, V2, P577, DOI 10.1038/89715; Smith JR, 2003, BLOOD, V101, P815, DOI 10.1182/blood-2002-05-1576; Stein JV, 2002, J CLIN INVEST, V109, P1587, DOI 10.1172/JCI200215034; Tan JQ, 2000, BLOOD, V96, P1230, DOI 10.1182/blood.V96.4.1230.h8001230_1230_1238; Tan JQ, 2003, J IMMUNOL, V171, P1722, DOI 10.4049/jimmunol.171.4.1722; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Till KJ, 2002, BLOOD, V99, P2977, DOI 10.1182/blood.V99.8.2977; Voigt I, 2000, EUR J IMMUNOL, V30, P560, DOI 10.1002/1521-4141(200002)30:2<560::AID-IMMU560>3.0.CO;2-T; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wu MT, 2002, J IMMUNOL, V168, P5096, DOI 10.4049/jimmunol.168.10.5096; Youn BS, 2001, BLOOD, V98, P925, DOI 10.1182/blood.V98.4.925; Youn BS, 2002, APOPTOSIS, V7, P271, DOI 10.1023/A:1015320321511; Yu G, 2000, NAT IMMUNOL, V1, P252, DOI 10.1038/79802; Yu P, 2002, J IMMUNOL, V168, P5117, DOI 10.4049/jimmunol.168.10.5117; Zhang QP, 2003, CANCER RES, V63, P6469	58	2	9	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					573	584		10.1038/sj.onc.1208184	http://dx.doi.org/10.1038/sj.onc.1208184			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF					2022-12-17	WOS:000226420400005
J	Li, L; Hooi, D; Chhabra, SR; Pritchard, D; Shaw, PE				Li, L; Hooi, D; Chhabra, SR; Pritchard, D; Shaw, PE			Bacterial N-acylhomoserine lactone-induced apoptosis in breast carcinoma cells correlated with downmodulation of STAT3 (vol 23, pg 4894, 2004)	ONCOGENE			English	Correction														SHAW, Peter/0000-0002-2598-4283				Li L, 2004, ONCOGENE, V23, P4894, DOI 10.1038/sj.onc.1207612	1	2	2	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2004	23	58					9450	9450		10.1038/sj.onc.1208361	http://dx.doi.org/10.1038/sj.onc.1208361			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT					2022-12-17	WOS:000225764100023
J	Kim, M; Tezuka, T; Tanaka, K; Yamamoto, T				Kim, M; Tezuka, T; Tanaka, K; Yamamoto, T			Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent protein degradation (vol 23, pg 1645, 2003)	ONCOGENE			English	Correction														Kim, Minsoo/0000-0001-8536-8653				Kim M, 2004, ONCOGENE, V23, P1645, DOI 10.1038/sj.onc.1207298	1	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7903	7904		10.1038/sj.onc.1207736	http://dx.doi.org/10.1038/sj.onc.1207736			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX		Bronze			2022-12-17	WOS:000224331600017
J	Pupa, SM; Argraves, SW; Forti, S; Casalini, P; Berno, V; Agresti, R; Aiello, P; Invernizzi, A; Baldassari, P; Otwal, W; Mortarini, R; Anichini, A; Menard, S				Pupa, SM; Argraves, SW; Forti, S; Casalini, P; Berno, V; Agresti, R; Aiello, P; Invernizzi, A; Baldassari, P; Otwal, W; Mortarini, R; Anichini, A; Menard, S			Immunological and pathobiological roles of fibulin-1 in breast cancer (vol 23, pg 2153, 2004)	ONCOGENE			English	Correction													Berno, Valeria/AAN-3997-2020; Pupa, Serenella/K-6388-2016; Mortarini, Roberta/C-9483-2017; Anichini, Andrea/K-1434-2016; Agresti, Roberto/AAB-6062-2019	Berno, Valeria/0000-0001-5848-494X; Pupa, Serenella/0000-0002-4592-6830; Mortarini, Roberta/0000-0001-7732-0561; Anichini, Andrea/0000-0001-5096-5538; Agresti, Roberto/0000-0003-4700-1951				Pupa SM, 2004, ONCOGENE, V23, P2153, DOI 10.1038/sj.onc.1207323	1	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	2004	23	37					6325	6325		10.1038/sj.onc.1207746	http://dx.doi.org/10.1038/sj.onc.1207746			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC		Bronze			2022-12-17	WOS:000223399000018
J	Eason, DD; LeBron, C; Coppola, D; Moscinski, LC; Livingston, S; Sutton, ET; Blanck, G				Eason, DD; LeBron, C; Coppola, D; Moscinski, LC; Livingston, S; Sutton, ET; Blanck, G			Development of CD30+ lymphoproliferative disease in mice lacking interferon regulatory factor-1	ONCOGENE			English	Article						CD30; lymphoma; interferon regulatory factor-1	LARGE-CELL LYMPHOMA; TRANSCRIPTION FACTOR IRF-1; REED-STERNBERG CELLS; KAPPA-B ACTIVATION; HUMAN-IMMUNODEFICIENCY-VIRUS; CDKN2 MTS1/P16(INK4A) GENE; NITRIC-OXIDE SYNTHASE; NATURAL-KILLER-CELLS; CD4(+) T-CELLS; FACTOR-I IRF-1	Human lymphomas continue to represent a major challenge in oncology, and in particular occur at very high frequencies in AIDS patients. We report here the development of a CD30+ lymphoproliferative disease in mice lacking the proapoptotic transcription factor, interferon regulatory factor-1. These mice most closely represent a model of human anaplastic large-cell lymphoma (ALCL). This mouse model of lymphoma will likely be useful in understanding the development of ALCL and in understanding the development of other closely related CD30+ forms of lymphoma, such as CD30+ Hodgkin's disease and CD30+ cutaneous T-cell lymphoma. This mouse model will also be useful in testing therapies for different forms of CD30+ lymphoma, in particular anti-CD30-based therapies.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Physiol & Biophys, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Publ Hlth, Dept Environm & Occupat Hlth, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Blanck, G (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Bd MDC7, Tampa, FL 33612 USA.		Blanck, George/A-5365-2012		NCI NIH HHS [R01-CA81497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aizawa S, 1997, J BIOL CHEM, V272, P2042; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; ANAGNOSTOPOULOS I, 1990, AM J PATHOL, V137, P1317; ANDREESEN R, 1984, BLOOD, V63, P1299; Annunziata CM, 2000, BLOOD, V96, P2841; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; BARTETT M, 1996, ONCOGENE, V12, P1873; BASHIR MS, 1992, CLIN EXP IMMUNOL, V88, P543; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CARBONE A, 1991, CANCER, V68, P842, DOI 10.1002/1097-0142(19910815)68:4<842::AID-CNCR2820680429>3.0.CO;2-E; CHADBURN A, 1993, CANCER, V72, P3078, DOI 10.1002/1097-0142(19931115)72:10<3078::AID-CNCR2820721033>3.0.CO;2-F; Chan WC, 2001, HEMATOL ONCOL, V19, P1; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; DELPRETE G, 1995, IMMUNOL TODAY, V16, P76, DOI 10.1016/0167-5699(95)80092-1; DELPRETE G, 1995, FASEB J, V9, P81, DOI 10.1096/fasebj.9.1.7821763; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; Eason DD, 2001, J IMMUNOL, V166, P1041, DOI 10.4049/jimmunol.166.2.1041; Foss HD, 1996, BLOOD, V88, P4005, DOI 10.1182/blood.V88.10.4005.bloodjournal88104005; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; Galon J, 1999, J IMMUNOL, V162, P7256; Gardner LJ, 2001, ARCH PATHOL LAB MED, V125, P1036; GONZALEZCLEMENTE JM, 1991, AIDS, V5, P751, DOI 10.1097/00002030-199106000-00017; GRUSS HJ, 1994, BLOOD, V83, P2045; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HERBST H, 1989, LEUKEMIA RES, V13, P103, DOI 10.1016/0145-2126(89)90134-3; Heyman M, 1996, LEUKEMIA, V10, P909; Hobart M, 1997, J IMMUNOL, V158, P4260; Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj.onc.1205337; HSU PL, 1990, CANCER RES, V50, P350; Hsu PL, 2000, LAB INVEST, V80, P1111, DOI 10.1038/labinvest.3780117; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Kumanishi T, 1996, JPN J CANCER RES, V87, P691, DOI 10.1111/j.1349-7006.1996.tb00279.x; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Marafioti T, 2000, BLOOD, V95, P1443, DOI 10.1182/blood.V95.4.1443.004k55_1443_1450; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; McElligott DL, 1997, J IMMUNOL, V159, P4180; Mir SS, 2000, BLOOD, V96, P4307; MIURA I, 1992, CANCER RES, V52, P1322; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Moller MB, 2000, LEUKEMIA, V14, P898, DOI 10.1038/sj.leu.2401761; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Nosari A, 1996, BRIT J HAEMATOL, V95, P508, DOI 10.1046/j.1365-2141.1996.d01-1940.x; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Ogasawara S, 1996, GASTROENTEROLOGY, V110, P52, DOI 10.1053/gast.1996.v110.pm8536888; OGAWA S, 1995, BLOOD, V86, P1548, DOI 10.1182/blood.V86.4.1548.bloodjournal8641548; OHMORI Y, 1995, J IMMUNOL, V154, P5235; Ohteki T, 1998, J EXP MED, V187, P967, DOI 10.1084/jem.187.6.967; Penninger JM, 1997, IMMUNITY, V7, P243, DOI 10.1016/S1074-7613(00)80527-0; Pinyol M, 1997, BLOOD, V89, P272, DOI 10.1182/blood.V89.1.272.272_272_280; Ransom DT, 1996, HEAD NECK-J SCI SPEC, V18, P248; Salkowski CA, 1996, J IMMUNOL, V156, P3107; SIEBERT R, 1995, BRIT J HAEMATOL, V91, P350, DOI 10.1111/j.1365-2141.1995.tb05302.x; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; Spink J, 1997, J BIOL CHEM, V272, P24417, DOI 10.1074/jbc.272.39.24417; Sugimura J, 1997, PATHOL INT, V47, P79; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Telford WG, 1997, CELL IMMUNOL, V182, P125, DOI 10.1006/cimm.1997.1228; Uchida T, 1998, LEUKEMIA LYMPHOMA, V29, P27, DOI 10.3109/10428199809058379; UCHIDA T, 1995, BLOOD, V86, P2724, DOI 10.1182/blood.V86.7.2724.bloodjournal8672724; UDAYACHANDER M, 1983, BRIT J CANCER, V48, P717, DOI 10.1038/bjc.1983.255; WENDTNER CM, 1995, CANCER RES, V55, P4157; WIDGREN S, 1985, PATHOL RES PRACT, V180, P563, DOI 10.1016/S0344-0338(85)80025-X; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Zhao ND, 1997, P NATL ACAD SCI USA, V94, P6948, DOI 10.1073/pnas.94.13.6948	77	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6166	6176		10.1038/sj.onc.1206563	http://dx.doi.org/10.1038/sj.onc.1206563			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679855				2022-12-17	WOS:000185506200006
J	Gearhart, PJ				Gearhart, PJ			B cells pay a price	ONCOGENE			English	Editorial Material							CYTIDINE DEAMINASE AID; SOMATIC HYPERMUTATION; DNA DEAMINATION; GENES		NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Gearhart, PJ (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	gearhartp@grc.nia.nih.gov	Gearhart, Patricia/Y-7227-2019		NATIONAL INSTITUTE ON AGING [ZIAAG000732, Z01AG000732] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; Gordon MS, 2003, P NATL ACAD SCI USA, V100, P4126, DOI 10.1073/pnas.0735266100; Greagg MA, 1999, P NATL ACAD SCI USA, V96, P9045, DOI 10.1073/pnas.96.16.9045; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nilsen H, 2003, ONCOGENE, V22, P5381, DOI 10.1038/sj.onc.1206860; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740	17	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5379	5380		10.1038/sj.onc.1206874	http://dx.doi.org/10.1038/sj.onc.1206874			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934096				2022-12-17	WOS:000184735000001
J	Satoh, T; Toyoda, M; Hoshino, H; Monden, T; Yamada, M; Shimizu, H; Miyamoto, K; Mori, M				Satoh, T; Toyoda, M; Hoshino, H; Monden, T; Yamada, M; Shimizu, H; Miyamoto, K; Mori, M			Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells (vol 21, pg 2171, 2002)	ONCOGENE			English	Correction																		Satoh T, 2002, ONCOGENE, V21, P2171, DOI 10.1038/sj.onc.1205279	1	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8220	8220		10.1038/sj.onc.1205568	http://dx.doi.org/10.1038/sj.onc.1205568			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW		Bronze			2022-12-17	WOS:000179231400017
J	Crish, JF; Bone, F; Banks, EB; Eckert, RL				Crish, JF; Bone, F; Banks, EB; Eckert, RL			The human involucrin gene contains spatially distinct regulatory elements that regulate expression during early versus late epidermal differentiation (vol 21, pg 738, 2002)	ONCOGENE			English	Correction																		Crish JF, 2002, ONCOGENE, V21, P738, DOI 10.1038/sj.onc.1205038	1	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3826	3826		10.1038/sj.onc.1205456	http://dx.doi.org/10.1038/sj.onc.1205456			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE		Bronze			2022-12-17	WOS:000175676000018
J	La Vieira, H; Boya, P; Cohen, I; El Hamel, C; Haouzi, D; Druillenec, S; Belzacq, AS; Brenner, C; Roques, B; Kroemer, G				La Vieira, H; Boya, P; Cohen, I; El Hamel, C; Haouzi, D; Druillenec, S; Belzacq, AS; Brenner, C; Roques, B; Kroemer, G			Cell permeable BH3-peptides overcome the cytoprotective effect of Bcl-2 and BCI-X-L	ONCOGENE			English	Article						apoptosis; adenine nucleotide translocator; Bax; cell death; mitochondria	DEPENDENT ANION CHANNEL; ADENINE-NUCLEOTIDE TRANSLOCASE; CYTOCHROME-C; FAMILY-MEMBERS; INDUCE APOPTOSIS; TRANSITION PORE; CYCLOPHILIN-D; BH3 DOMAIN; BAX; MITOCHONDRIA	Peptides corresponding to the BH3 domains of Bax (BaxBH3) or Bcl-2 (Bcl2BH3) are potent inducers of apoptosis when fused to the Atennapedia plasma membrane translocation domain (Ant). BaxBH3Ant and Bcl2BH3Ant caused a mitochondrial membrane permeabilization (MNIP) and apoptosis, via a mechanism that was not inhibited by overexpressed Bcl-2 or Bcl-X-L, yet partially inhibited by cyclosporin A (CsA), an inhibitor of the mitochondrial permeability transition pore. When added to isolated mitochondria, BaxBH3 and Bcl2BH3 induced MMP, which was inhibited by CsA. However, Bcl-2 or Bcl-X-L failed to inhibit MMP induced by BaxBH3 and Bc2BH3 in vitro, while they efficiently suppressed the induction of MMP by the Vpr protein (from human immunodeficiency virus-1), a ligand of the adenine nucleotide translocator (ANT). BaxBH3 but not Bcl2BH3 was found to interact with ANT, and only BaxBH3 (not Bcl2BH3) permeabilized ANT proteoliposomes and induced ANT to form non-specific channels in electrophysiological experiments. In contrast, both BaxBH3 and Bcl2BH3 were able to stimulate channel formation by recombinant Bax protein. Thus, BaxBH3 might induce MMP via an action on at least two targets, ANT and Bax-like proteins. In contrast, Bcl2BH3 would elicit MMIP in an ANT-independent fashion. In purified mitochondria, two ligands of ANT, bongkrekic acid and the protein vMLA from cytomegalovirus, failed to prevent MMP induced by BaxBH3 or Bcl2BH3. In conclusion, BaxBH3 and Bcl2BH3 induce MMP and apoptosis through a mechanism which overcomes cytoprotection by Bcl-2 and Bcl-X-L.	Inst Gustave Roussy, CNRS, UMR1599, F-94805 Villejuif, France; Univ Paris 05, CNRS, Unite Pharmacol Mol & Struct, INSERM U266,UMR860, F-75005 Paris, France; Univ Technol Compiegne, CNRS, UMR6022, F-60205 Compiegne, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR1599, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; DRUILLENNEC, Sabine/B-2572-2019; Boya, Patricia/P-8345-2019; brenner, catherine/AAE-8632-2020; Boya, Patricia/K-2911-2014	KROEMER, Guido/0000-0002-9334-4405; DRUILLENNEC, Sabine/0000-0003-0237-1465; Boya, Patricia/0000-0003-3045-951X; Boya, Patricia/0000-0003-3045-951X				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cornille F, 1999, J PEPT RES, V54, P427, DOI 10.1034/j.1399-3011.1999.00129.x; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Pena JC, 1998, CANCER RES, V58, P2111; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Susin SA, 2000, METHOD ENZYMOL, V322, P205; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zheng TS, 2001, NAT CELL BIOL, V3, pE43, DOI 10.1038/35055145; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	44	2	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					1963	1977		10.1038/sj/onc/1205270	http://dx.doi.org/10.1038/sj/onc/1205270			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR					2022-12-17	WOS:000174827000003
J	Tulin, EE; Onoda, N; Hasegawa, M; Nomura, H; Kitamura, T				Tulin, EE; Onoda, N; Hasegawa, M; Nomura, H; Kitamura, T			Inhibition of human endothelial cell proliferation by ShIF, a vacuolar H+-ATPase-like protein	ONCOGENE			English	Article						ShIF; V-ATPase; endothelial cell proliferation; HUVEC	POLYPEPTIDE; SYNTHASE	ShIF is a bone marrow stroma cell-derived factor originally identified to support proliferation of bone marrow cells in vitro. This protein shares high sequence homology to the yeast vacuolar H+-ATPase subunit, Vph1p, and the 116 kDa proton pump of the rat and bovine synaptic vesicle, Vpp1. We examined the function of ShIF in the proliferation of human umbilical vein endothelial cells (HUVEC). ShIF inhibited HUVEC proliferation in a dose-dependent manner. Recombinant ShIF added at 10 and 20 ng/ml inhibited HUVEC proliferation by 21.6 and 44.3%, respectively and increasing the concentration of ShIF to 100 ng/ml inhibited proliferation by as much as 55.5%. When HUVEC cells were cultured at various concentrations of ShIF in the presence of anti-ShIF antibody, the inhibitory effects of ShIF to HUVEC proliferation were abrogated by 89-91% indicating that the activity of ShIF to HUVEC was specific. HUVEC cultured in the presence of ShIF and bafilomycin, a specific inhibitor of ATPase, resulted to a 90% growth inhibition. Thus, ShIF may act as an antagonist to the ATPase complex by disrupting the production of cellular ATP thereby decreasing the ability of HUVEC to proliferate.	Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan; Mol Med Inc, Chugai Res Inst, Niihari, Ibaraki 3004101, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy,Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo	Tulin, EE (corresponding author), Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Kitamura, Toshio/AAA-2071-2021					BODIN P, 1995, EXPERIENTIA, V51, P256, DOI 10.1007/BF01931108; Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; KANE PM, 1992, J EXP BIOL, V172, P93; KANE PM, 1989, J BIOL CHEM, V264, P19236; Kawamura Y, 2001, EUR J BIOCHEM, V268, P2801, DOI 10.1046/j.1432-1327.2001.02139.x; LEE CK, 1990, MOL IMMUNOL, V27, P1137; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Parra KJ, 2000, J BIOL CHEM, V275, P21761, DOI 10.1074/jbc.M002305200; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROZENGURT E, 1977, J BIOL CHEM, V252, P4584; Tulin EE, 2001, J BIOL CHEM, V276, P27519, DOI 10.1074/jbc.M101781200; Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397; Zheng JB, 1999, BIOCHEM BIOPH RES CO, V261, P499, DOI 10.1006/bbrc.1999.1063	18	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2002	21	5					844	848		10.1038/sj.onc.1205114	http://dx.doi.org/10.1038/sj.onc.1205114			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FB	11850812				2022-12-17	WOS:000173427000015
J	Brem, R; Certa, U; Neeb, M; Nair, APK; Moroni, C				Brem, R; Certa, U; Neeb, M; Nair, APK; Moroni, C			Global analysis of differential gene expression after transformation with the v-H-ras oncogene in a murine tumor model (vol 20, pg 2854, 2001)	ONCOGENE			English	Correction																		Brem R, 2001, ONCOGENE, V20, P2854, DOI 10.1038/sj.onc.1204403	1	2	2	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4916	4916		10.1038/sj.onc.1204737	http://dx.doi.org/10.1038/sj.onc.1204737			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH		Bronze			2022-12-17	WOS:000170271800018
J	Watson, DK; Seth, A; Mavrothalassitis, G; Maroulakou, IG; Hsu, T; Spyropoulos, DD; Reddy, EP				Watson, DK; Seth, A; Mavrothalassitis, G; Maroulakou, IG; Hsu, T; Spyropoulos, DD; Reddy, EP			Remembering Takis S Papas: A pioneer in Ets research	ONCOGENE			English	Biographical-Item								This review issue of ONCOGENE is unique in that it has two important functions: To remember Takis S Papas, a year after his unexpected and sudden death, and to provide a comprehensive analysis of the current status of Ets biology. As exemplified by the review articles in this issue of ONCOGENE, the Ets field has come a long way since the discovery of Ets1 as a virally transduced oncogene over 15 years ago. We have moved from studies directed towards understanding a limited number of family members to a more complex network of nearly 30 mammalian Ets transcription factors. Animal model systems from C. elegans, Drosophila, Xenopus, Birds and mice are rapidly being generated to allow for a more mechanistic understanding of the family, Already, functions predicted from expression analysis of specific Ets genes are beginning to be validated by elegant gain and loss of function studies. Dysregulated Ets function is associated with human disease. In addition to affording diagnostic tools, Ets factors and the genes they control provide unique therapeutic tools. Furthermore, novel therapeutic approaches are likely to be developed, as we better define mechanisms that modulate Ets function. We now wish to highlight Takis' accomplishments and offer some personal remembrances.	Med Univ S Carolina, Ctr Mol & Struct Biol, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Univ Toronto, Dept Lab Med & Patholbiol, Toronto, ON M5S 1B2, Canada	Medical University of South Carolina; University of Toronto	Watson, DK (corresponding author), Med Univ S Carolina, Ctr Mol & Struct Biol, Dept Pathol & Lab Med, 86 Jonathan Lucas St, Charleston, SC 29425 USA.		Reddy, E. Premkumar/F-6233-2011					PAPAS TS, PUBLICATION LIST	1	2	2	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2000	19	55					6394	6399		10.1038/sj.onc.1204070	http://dx.doi.org/10.1038/sj.onc.1204070			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395RL					2022-12-17	WOS:000166595000001
J	Challier, C; Cocault, L; Flon, M; Pauchard, M; Porteu, F; Gisselbrecht, S; Souyri, M				Challier, C; Cocault, L; Flon, M; Pauchard, M; Porteu, F; Gisselbrecht, S; Souyri, M			A new feature of Mpl receptor: ligand-induced transforming activity in FRE rat fibroblasts	ONCOGENE			English	Article						Mpl; transformation; fibroblasts; MAPK; Shc	PROTEIN-TYROSINE PHOSPHORYLATION; HUMAN BLOOD-PLATELETS; C-MPL; MEGAKARYOCYTIC DIFFERENTIATION; CYTOPLASMIC DOMAIN; CYTOKINE RECEPTOR; SHC PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PRIMARY REGULATOR	Mpl is the receptor for thrombopoietin, the primary regulator of platelet production by megakaryocytes. Upon stimulation by its ligand, Mpl receptor induces proliferation and differentiation of hematopoietic cell lines of various origins. In this paper, we show that Mpl is also able to transform FRE rat fibroblasts in the presence of MGDF (pegylated Megakaryocyte Growth and Development Factor), a modified form of its ligand. We also demonstrate that upon MGDF stimulation Mpl receptor activates the classical transduction pathways described for hematopoietic cell lines in FRE cells. Introduction of Mpl deletion mutants in FRE cells allowed us to demonstrate that the C-terminal region of the Mpl intracytoplasmic domain, which is involved in hematopoietic differentiation, is necessary for the transformation process. Within that region, site-directed mutagenesis showed that the Y112 residue, which is required for She phosphorylation, is essential for rat fibroblast transformation by Mpl/MGDF, suggesting the involvement of She in Mpl-mediated transformation. Interestingly, we showed that transformation correlated with strong and sustained MAPK activation. Neither Jak2 Stat3 nor Stat5 phosphorylation was sufficient to induce the transformation process. Taken altogether, our results suggest the oncogenicity of Mpl in fibroblastic cells in the presence of its ligand.	Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France; Hop Cochin, Inst Cochin Genet Mol, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Souyri, M (corresponding author), Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France.		Souyri, Michele/L-5845-2017; PORTEU, Françoise/I-8445-2016	PORTEU, Françoise/0000-0002-2403-4163; PETIT, Laurence/0000-0002-2475-9367				Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; ARECES LB, 1993, P NATL ACAD SCI USA, V90, P3963, DOI 10.1073/pnas.90.9.3963; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Cocault L, 1996, BLOOD, V88, P1656; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eaton DL, 1997, EXP HEMATOL, V25, P1; Fichelson S, 1999, BLOOD, V94, P1601, DOI 10.1182/blood.V94.5.1601.417k19_1601_1613; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HAWLEY RG, 1994, GENE THER, V1, P136; Hill RJ, 1996, CELL GROWTH DIFFER, V7, P1125; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; Kimura S, 1998, P NATL ACAD SCI USA, V95, P1195, DOI 10.1073/pnas.95.3.1195; Ljungdahl S, 1998, CELL GROWTH DIFFER, V9, P565; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Matsumura I, 1998, MOL CELL BIOL, V18, P4282, DOI 10.1128/MCB.18.7.4282; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; OLIFF AI, 1980, J VIROL, V33, P475, DOI 10.1128/JVI.33.1.475-486.1980; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Porteu F, 1996, MOL CELL BIOL, V16, P2473; Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04_1273_1282; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SATTLER M, 1995, EXP HEMATOL, V23, P1040; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SOUYRI M, 1987, VIROLOGY, V158, P69, DOI 10.1016/0042-6822(87)90239-X; Takatoku M, 1997, J BIOL CHEM, V272, P7259, DOI 10.1074/jbc.272.11.7259; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947	44	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2000	19	16					2033	2042		10.1038/sj.onc.1203472	http://dx.doi.org/10.1038/sj.onc.1203472			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803464				2022-12-17	WOS:000086613200007
J	Burr, PD; Argyle, DJ; Reid, SWJ; Nasir, L				Burr, PD; Argyle, DJ; Reid, SWJ; Nasir, L			Nucleotide sequence of the porcine p53 cDNA, and the detection of recombinant porcine p53 expressed in vitro with a variety of anti-p53 antibodies	ONCOGENE			English	Article						porcine; pig; p53; protein; gene; sequence	TUMOR-SUPPRESSOR GENE; STRUCTURAL ASPECTS; GROWTH ARREST; CELL-LINES; PROTEIN; MUTATIONS; XENOTRANSPLANTATION; APOPTOSIS; EVOLUTION; CANCER	The cDNA of porcine p53 was cloned and sequenced by a reverse transcriptase polymerase chain reaction (RT-PCR) approach with primers based on regions of homology between all known p53 sequences. The p53 cDNA was found to be 87% conserved to human p53 and 86% conserved to bovine p53 at the nucleotide level. The porcine p53 sequence was inserted into an expression vector and recombinant protein expressed in vitro. An approximately 50 kDa protein was detected by Western blotting using both polyclonal and monoclonal anti-p53 antibodies. The sequence data of porcine p53 and the ability to detect expressed protein with various anti-p53 antibodies will allow the p53 status of the pig population, and the role of p53 in porcine tumours, to be assessed. An understanding of tumour development in the pig may be important if pig cells, tissues or organs are to be used in the treatment of humans.	Univ Glasgow, Dept Vet Clin Studies, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Dept Vet Pathol, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow; University of Glasgow	Burr, PD (corresponding author), Univ Glasgow, Dept Vet Clin Studies, Glasgow G61 1QH, Lanark, Scotland.			Reid, Stuart/0000-0002-6872-9071				Bach FH, 1998, ANNU REV MED, V49, P301; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Holistein M., 1991, SCIENCE, V253, P49; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komori H, 1996, VET IMMUNOL IMMUNOP, V52, P53, DOI 10.1016/0165-2427(95)05538-X; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Nasir L, 1995, DNA Seq, V6, P61, DOI 10.3109/10425179509074702; OKUDA M, 1994, INT J CANCER, V58, P602, DOI 10.1002/ijc.2910580425; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pazzi KA, 1996, CANCER LETT, V107, P125, DOI 10.1016/0304-3835(96)04359-5; RETTENBERGER G, 1993, ANIM GENET, V24, P307, DOI 10.1111/j.1365-2052.1993.tb00318.x; Rogers NJ, 1998, IMMUNOL TODAY, V19, P206, DOI 10.1016/S0167-5699(98)01254-7; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1990, ONCOGENE, V5, P945; Veldhoen N, 1998, ONCOGENE, V16, P1077, DOI 10.1038/sj.onc.1201863; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	24	2	3	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					5005	5009		10.1038/sj.onc.1202870	http://dx.doi.org/10.1038/sj.onc.1202870			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490836				2022-12-17	WOS:000082321700014
J	Liebermann, DA				Liebermann, DA			Apoptosis - Preface	ONCOGENE			English	Editorial Material						apoptosis; growth suppression			Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Dept Biochem, Philadelphia, PA 19140 USA		Liebermann, DA (corresponding author), Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.							ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33	2	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3203	3205		10.1038/sj.onc.1202594	http://dx.doi.org/10.1038/sj.onc.1202594			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW		Bronze			2022-12-17	WOS:000078048200001
J	Chretien, S; Duprez, V; Maouche, L; Gisselbrecht, S; Mayeux, P; Lacombe, C				Chretien, S; Duprez, V; Maouche, L; Gisselbrecht, S; Mayeux, P; Lacombe, C			Abnormal erythropoietin (Epo) gene expression in the murine erythroleukemia IW32 cells results from a rearrangement between the G-protein beta 2 subunit gene and the Epo gene	ONCOGENE			English	Article						friend erythroleukemia; Epo rearrangement; G-protein beta 2 subunit	TRANSGENIC MICE; STAT5 ACTIVATION; LEUKEMIA-VIRUS; PYRUVATE-KINASE; RECEPTOR; IDENTIFICATION; SITE; DIFFERENTIATION; TUMORIGENICITY; TRANSCRIPTION	Abnormal production of erythropoietin (Epo) has been described in several human and murine erythroleukemia, The murine IW32 cell line is derived from an F-MuLV-induced erythroleukemia. An autocrine Epo production due to the rearrangement of one Epo allele has been previously described (Beru ed al., 1989), However, the exact mechanism leading to the transcriptional activation of the abnormal Epo gene was unknown, In this study, we show that this deregulated expression results from a deletion within chromosome 5, The Epo gene in the abnormal allele is under the control of the G-protein beta 2 subunit gene promoter and the expressed mRNA results from the fusion of the non coding exon 1 of the G-protein beta 2 subunit gene to a truncated Epo exon I gene, This resulting abnormal cDNA allows the expression of a normal Epo protein.	INST NATL TRANSFUS SANGUINE,F-75015 PARIS,FRANCE; HOP HENRI MONDOR,INSERM U91,F-94000 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Chretien, S (corresponding author), UNIV PARIS 05,HOP COCHIN,IGGM,INSERM U363,27 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE.		maouche, leila/E-3887-2017; Chretien, Stany/M-5166-2018					BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BERU N, 1989, DNA-J MOLEC CELL BIO, V8, P253, DOI 10.1089/dna.1.1989.8.253; CHIREUX MA, 1995, J NEUROSCI RES, V40, P427, DOI 10.1002/jnr.490400402; CHOPPIN J, 1984, BLOOD, V64, P341; CHOPPIN J, 1985, EXP HEMATOL, V13, P610; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; DREYFUS F, 1990, LEUKEMIA, V4, P590; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; HANKINS WD, 1986, BLOOD, V68, P263; HERMINE O, 1991, BLOOD, V78, P2253; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; Howard JC, 1996, ONCOGENE, V12, P1405; Kozak CA, 1996, MAMM GENOME, V6, pS97; LACOMBE C, 1988, BLOOD, V72, P1440; LACOMBE C, 1987, MOL CELLULAR ASPECTS, P61; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MAXWELL PH, 1993, KIDNEY INT, V44, P1149, DOI 10.1038/ki.1993.362; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MITJAVILA MT, 1991, J CLIN INVEST, V77, P461; MOREAUGACHELIN F, 1988, NATURE, V331, P227; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; SELS FT, 1992, ONCOGENE, V7, P643; SEMENZA GL, 1990, MOL CELL BIOL, V10, P930, DOI 10.1128/MCB.10.3.930; SEMENZA GL, 1989, P NATL ACAD SCI USA, V86, P2301, DOI 10.1073/pnas.86.7.2301; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; SHIBUYA T, 1982, CELL, V31, P483, DOI 10.1016/0092-8674(82)90141-6; StageMarroquin B, 1996, EXP HEMATOL, V24, P1322; TAMBOURIN P, 1983, P NATL ACAD SCI-BIOL, V80, P6269, DOI 10.1073/pnas.80.20.6269; VILLEVAL JL, 1992, LEUKEMIA, V6, P107; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	40	2	3	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1995	1999		10.1038/sj.onc.1201364	http://dx.doi.org/10.1038/sj.onc.1201364			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365246				2022-12-17	WOS:A1997YA87200014
J	Shinagawa, T; Ishiguro, N; Horiuchi, M; Matsui, T; Okada, K; Shinagawa, M				Shinagawa, T; Ishiguro, N; Horiuchi, M; Matsui, T; Okada, K; Shinagawa, M			Deletion of c-myb exon 9 induced by insertion of repeats	ONCOGENE			English	Article						12-nucleotide repeat; c-myb; exon skipping; transcription; T lymphoma	DNA-BINDING DOMAIN; T-LYMPHOMA-CELLS; V-MYB; TRANSCRIPTIONAL ACTIVATION; PROVIRAL INTEGRATION; CELLULAR PROGENITOR; ONCOGENE PRODUCT; GENE-EXPRESSION; LEUKEMIA-VIRUS; PROTEIN	A simple repeat was found to be inserted into exon 9 of the c-myb gene in three out of 20 bovine T lymphomas. The repeat was composed of multiple copies of a 12-nucleotide motif and had no significant homology to the sequences reported so far. Tumor cells containing the repeat expressed two kinds of c-myb mRNA: (1) are that included the repetitive sequence in exon 9, and (2) are that lacked the whole sequence of exon 9. Transfection of an expression vector containing exon and intron sequences and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the mRNA demonstrated that the insertion of the repeat enhanced exon skipping of the transfected minigene. These observations imply that the insertion of the repeat may enhance exon skipping of the c-myb pre-mRNA. Although the transcription-activating activity by the c-Myb with the repeat was low, that by the c-Myb without exon 9 was three- to eightfold higher than the wild-type c-Myb. These data suggest that insertion of the 12-nucleotide repeat in codon 359 may result in c-Myb proteins having high- and low-transcription-activating activity.	OBIHIRO UNIV AGR & VET MED,DEPT VET PUBL HLTH,OBIHIRO,HOKKAIDO 080,JAPAN; OBIHIRO UNIV AGR & VET MED,DEPT VET PATHOL,OBIHIRO,HOKKAIDO 080,JAPAN; IWATE UNIV,DEPT VET PATHOL,MORIOKA,IWATE 020,JAPAN	Obihiro University of Agriculture & Veterinary Medicine; Obihiro University of Agriculture & Veterinary Medicine; Iwate University								BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; ESS KC, 1995, MOL CELL BIOL, V15, P5707; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FAVIER D, 1994, ONCOGENE, V9, P305; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; ISHIGURO N, 1994, J BIOL CHEM, V269, P26822; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KU DH, 1993, J BIOL CHEM, V268, P2255; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1995, ONCOGENE, V11, P2113; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J, 1989, MOL CLONING LAB MANU; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHINAGAWA T, 1994, J VET MED SCI, V56, P957, DOI 10.1292/jvms.56.957; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; ZOBEL A, 1991, ONCOGENE, V6, P1397	47	2	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2775	2783		10.1038/sj.onc.1201130	http://dx.doi.org/10.1038/sj.onc.1201130			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190893				2022-12-17	WOS:A1997XD64300005
J	Chung, SW; Chen, H; Wong, PMC				Chung, SW; Chen, H; Wong, PMC			Activation of quiescent ABL-transduced hemopoietic stem cells	ONCOGENE			English	Article						ABL; hematopoietic stem cells	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; PRIMITIVE HEMATOPOIETIC PROGENITORS; CHRONIC MYELOCYTIC-LEUKEMIA; TYROSINE KINASE-ACTIVITY; BCR-ABL; ABELSON VIRUS; V-ABL; PHILADELPHIA-CHROMOSOME; AUTOCRINE MECHANISM	Chronic myelogenous leukemia (CML) is a hemopoietic stem cell disorder in which an activated ABL oncogene is expressed and has been shown to play an important role in disease pathogenesis. A mouse model has been established in which hemopoietic stem cells (HSCs) transduced with a retrovirus vector carrying an activated ABL oncogene can be analysed. Using this model, we now report that abl-transduced HSCs can be quiescent without causing a disease for an extended period of time. Recipient mice were able to survive more than one treatment of 5-fluorouracil (5-FU) at a dose that normally eliminates cycling hemopoietic progenitor cells; subsequently, transduced HSCs could become activated and undergo clonal expansion, resulting in abl-induced leukemic development. The disease developed in these mice was transplantable. Upon engraftment into secondary mice, previously unidentified abl-transduced HSC clones appeared. These data suggest the presence of an abl-suppressive mechanism in HSCs and have important implications to the pathogenesis of stem cell diseases and leukemic clonal evolution.	TEMPLE UNIV,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Chung, SW (corresponding author), TEMPLE UNIV,SCH MED,DEPT BIOCHEM,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140, USA.				NHLBI NIH HHS [HL46547] Funding Source: Medline; NIDDK NIH HHS [DK41298] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041298] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEDI A, 1993, BLOOD, V81, P2898; BRECHER G, 1993, P NATL ACAD SCI USA, V90, P6028, DOI 10.1073/pnas.90.13.6028; BRETCHER G, 1988, EXP HEMATOL, V16, P627; CHUNG SW, 1988, BLOOD, V71, P973; CHUNG SW, 1986, BLOOD, V68, P1074; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; CHUNG SW, 1995, ONCOGENE, V10, P1261; CHUNG SW, 1994, ONCOGENE, V9, P3527; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COULOMBEL L, 1983, NEW ENGL J MED, V308, P1493, DOI 10.1056/NEJM198306233082502; CRONKITE EP, 1987, EXP HEMATOL, V16, P627; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DUBE ID, 1984, BLOOD, V63, P1172; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FIORETOS T, 1994, BLOOD, V83, P3441; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; HADGSON GS, 1979, NATURE, V281, P381; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; Hariharan I K, 1988, Oncogene Res, V3, P387; HUMPHRIES RK, 1988, EXP HEMATOL, V16, P774; KEATING A, 1994, BLOOD, V83, P1744, DOI 10.1182/blood.V83.7.1744.bloodjournal8371744; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LANEUVILLE P, 1992, BLOOD, V80, P1788; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LEBIEN TW, 1979, NEW ENGL J MED, V301, P144, DOI 10.1056/NEJM197907193010307; LERNER C, 1990, EXP HEMATOL, V18, P114; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; NOWELL PC, 1960, SCIENCE, V132, P1497; OLIFF A, 1985, P NATL ACAD SCI USA, V82, P3306, DOI 10.1073/pnas.82.10.3306; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; POIRIER Y, 1989, J VIROL, V63, P2088, DOI 10.1128/JVI.63.5.2088-2098.1989; ROVERA G, 1987, ONCOGENE, V1, P29; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SCOTT M, 1991, P NATL ACAD SCI USA, V88, P6505; SIRARD C, 1994, BLOOD, V83, P1575; SOKAL JE, 1980, BLOOD, V56, P1072; SPOONCER E, 1994, LEUKEMIA, V8, P620; VANZANT G, 1984, J EXP MED, V159, P679, DOI 10.1084/jem.159.3.679; VERFAILLIE CM, 1992, BLOOD, V79, P1003; VOGT M, 1987, ONCOGENE RES, V2, P49; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; WONG PMC, 1987, GENE DEV, V1, P358, DOI 10.1101/gad.1.4.358; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P851	53	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2397	2405						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957081				2022-12-17	WOS:A1996VX10800012
J	BirchenallRoberts, MC; Kim, SJ; Bertolette, DC; Turley, JM; Fu, T; Bang, OS; Kasper, JJ; Yoo, YD; Ruscetti, FW				BirchenallRoberts, MC; Kim, SJ; Bertolette, DC; Turley, JM; Fu, T; Bang, OS; Kasper, JJ; Yoo, YD; Ruscetti, FW			P120-v-Abl expression overcomes TGF-beta 1 negative regulation of c-myc transcription but not cell growth	ONCOGENE			English	Article						v-Abl; E2F-1; RB; c-myc; TGF-beta 1	RETINOBLASTOMA GENE-PRODUCT; MURINE LEUKEMIA-VIRUS; TUMOR-SUPPRESSOR PROTEIN; FACTOR-BETA; MOLECULAR-CLONING; TRANS-ACTIVATION; EPITHELIAL-CELLS; KINASE-ACTIVITY; E2F SITE; ABL	Transformation of interleukin-3 dependent (IL-3) 32D-123 myeloid cells by p120-v-Abl produced the factor-independent 32D-abl cell Line, In 32D-abl cells, myc expression was found to be significantly higher than in the parental cells and was correlated with increased E2F-1 protein expression and DNA binding ability, Surprisingly, in 32D-abl cells, TGF-beta 1, a potent G(1)/S inhibitor of 32D-123 and 32D-abl cell growth, increased E2F transactivation as shown by increased c-myc promoter-CAT and GAL4-E2F-1 activity, In addition, TGF-beta 1 was also found to increase E2F-1 protein levels but had no effect on steady-state retinoblastoma (RE) protein levels or phosphorylation state, In the absence of TGF-beta 1, transient expression of RE in v-Abl expressing cells resulted in decreased c-myc transcription, inhibition of GAL4-E2F-1 driven transactivation and inhibition of cellular proliferation, RE and v-Abl were found to physically asssociate in vivo and in vitro via v-Abl's ATP binding region, In summary, these studies established that in myeloid cells: (1) v-Abl binds RE resulting in increased E2F-1-driven c-myc transcription, and (2) an alternative pathway exists for TGF-beta 1-mediated growth inhibition of v-Abl-transformed cells, in which increased rather than decreased E2F-mediated c-myc transcription is observed.	NCI, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA; NCI, DIV BASIC SCI, CHEMOPREVENT LAB, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, LAB LEUKOCYTE BIOL, DIV BASIC SCI, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	BirchenallRoberts, MC (corresponding author), SAIC FREDERICK, INTRAMURAL RES SUPPORT PROGRAM, FREDERICK, MD 21702 USA.							ABELSON HT, 1970, CANCER RES, V30, P2213; ARCINAS M, 1994, J BIOL CHEM, V269, P21919; Bang OS, 1996, J BIOL CHEM, V271, P7811, DOI 10.1074/jbc.271.13.7811; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BIRCHENALLROBERTS MC, 1991, J BIOL CHEM, V266, P9617; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FALTYNEK CR, 1988, J BIOL CHEM, V263, P7112; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GREENBERGER JS, 1984, LEUKEMIA RES, V8, P363, DOI 10.1016/0145-2126(84)90076-6; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KELLER J, 1988, BLOOD, V75, P506; KELLER JR, 1990, ONCOGENE, V5, P549; KELLER JR, 1990, TRANSFORMING GROWTH; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM TA, 1994, J CELL PHYSIOL, V160, P1, DOI 10.1002/jcp.1041600102; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEOF EB, 1986, J CELL PHYSIOL, V127, P83, DOI 10.1002/jcp.1041270111; LONGSTREET M, 1992, ONCOGENE, V7, P1549; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MILLER TL, 1993, MOL CELL ENDOCRINOL, V91, P83, DOI 10.1016/0303-7207(93)90258-L; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOSES HL, 1985, CANCER CELL, V3, P65; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NEVINS JR, 1992, SCIENCE, V258, P424; OSWALD F, 1994, ONCOGENE, V9, P2029; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SING GK, 1988, BLOOD, V72, P1504; SMELAND EB, 1987, EXP CELL RES, V171, P213, DOI 10.1016/0014-4827(87)90264-3; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WANG JYJ, 1984, CELL, V36, P349; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WONG KK, 1995, MOL CELL BIOL, V15, P6535; YAN ZF, 1992, ONCOGENE, V7, P801; ZAMMANIAN M, 1992, EMBO J, V11, P2603; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	63	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1499	1509						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875988				2022-12-17	WOS:A1996VL38400015
J	Raj, GV; Ansari, SA; Khalili, K				Raj, GV; Ansari, SA; Khalili, K			Evidence for GEAPs, novel glial E2F1-associated proteins in hamster glioma cells induced by the human neurotropic polyomavirus, JCV	ONCOGENE			English	Article						cell cycle regulation; JCV; glioma; E2F family	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR; GROWTH-REGULATION; BRAIN TUMORS; E2F; BINDING; VIRUS; DNA; PROMOTER; CYCLE	Injection of the human neurotropic polyomavirus, JCV, into neonatal hamsters causes tumors of glial origin. Previously, a rapidly proliferating cell line, HJC-15, which expresses high levels of the viral T-antigen, had been established from JCV-induced hamster glial tumors. In our analyses of the mechanisms involved in the control of glial cell proliferation in these tumor cells, we have focused our attention on E2F1, a DNA-binding transcription factor which modulates the activity of genes involved in the S-phase of the cell cycle. Here, we report the identification of a novel nucleo-protein complex that forms between select E2F1-binding sites and nuclear proteins from HJC-15 and normal hamster glial cells. In comparison to the previously characterized E2F1 complexes, this complex exhibited distinct mobility, binding, and biochemical characteristics. This slower migrating complex also contained several unique Glial E2F1-associated proteins, (GEAPs), which have a distinct molecular mass. Of particular, unlike the classical E2F1 whose DNA binding activity is increased during S-phase, the level of GEAPs remained constant throughout the cell cycle. GEAPs appeared to confer an increased basal transcriptional activity of promoters containing select E2F1 sites in HJC-15 cells. Interestingly, the increased transcriptional activity modulated by GEAPs in HJC-15 cells was overcome by overexpression of E2F1 in these cells. These data point to the presence of novel members of the E2F family in hamster glial cells with the potential to regulate expression of S-phase specific genes in glial tumors obtained upon intracerebral injection of JCV. The importance of these findings in the pathogenesis of viral-induced tumors and the role of cell cycle regulatory proteins in brain tumor formation is discussed.	THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,MOL NEUROVIROL SECT,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; DOU QP, 1994, J BIOL CHEM, V269, P1306; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FOSTER LM, 1993, DEV NEUROSCI-BASEL, V15, P100, DOI 10.1159/000111322; FRISQUE RJ, 1980, J VIROL, V35, P265, DOI 10.1128/JVI.35.1.265-269.1980; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KUNDU M, 1995, J VIROL, V69, P6940, DOI 10.1128/JVI.69.11.6940-6946.1995; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NEVINS JR, 1992, SCIENCE, V258, P424; PADGETT BL, 1971, LANCET, V1, P1257; QIN XQ, 1995, MOL CELL BIOL, V15, P742; RAJ GV, 1995, INT J ONCOL, V7, P801; RAJ GV, 1994, MOL CELL BIOL, V14, P7770, DOI 10.1128/MCB.14.12.7770; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; SALA A, 1994, CANCER RES, V54, P1402; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Schilling Lynda J., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P19; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WOOD WSM, 1980, J VIROL, V33, P1225; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357	44	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1279	1288						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649830				2022-12-17	WOS:A1996UC06700013
J	Lovric, J; Radziwill, G; Moelling, K				Lovric, J; Radziwill, G; Moelling, K			Specific association of Mil/Raf proteins with a 34 kDa phosphoprotein	ONCOGENE			English	Article						Mil/Raf kinase; phosphorylation; associated proteins; cell cycle; stimulation; cellular transformation	RAF-1 PROTEIN; MAP KINASE; PHOSPHORYLATION	Mil/Raf protein kinases are intermediates in signaling pathways leading to differentiation, mitogenesis and cellular transformation. To gain insight into the activity of Mil/Raf kinases at the molecular level we aimed to identify proteins specifically interacting with Mil/Raf proteins. A phosphoprotein of 34 kDa (pp34) was found to be associated with c-Raf as well as with viral and activated forms of Mil/Raf proteins in exponentially growing interphase cells. pp34 association was not detectable in mitotic cells. Serum stimulation or coexpression of activated Ras led to decreased electrophoretic mobility of pp34 complexed to Mil/Raf proteins while serum starvation rendered pp34 undetectable. Moreover, the association with pp34 became undetectable in parallel with the onset of morphological cellular transformation caused by overexpression of a constitutively activated mutant of c-Raf in an inducible expression system. Thus, the association of Mil/Raf proteins with pp34 is altered in the course of cell cycle progression, serum stimulation and cellular transformation. These events represent hallmarks of cellular Mil/Raf functions, rendering pp34 a candidate protein involved in Mil/Raf function.	UNIV ZURICH,INST MED VIROL,CH-8028 ZURICH,SWITZERLAND	University of Zurich				Lovric, Josip/0000-0002-0338-6581				BEIMLING P, 1994, BIOCHEM BIOPH RES CO, V204, P841, DOI 10.1006/bbrc.1994.2536; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1995, MOL CELL BIOL, V15, P4125; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; JAMAL S, 1995, ONCOGENE, V10, P2095; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LOVRIC J, 1994, FEBS LETT, V343, P15, DOI 10.1016/0014-5793(94)80598-9; LOVRIC J, 1996, IN PRESS ONCOGENE; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGREW BR, 1992, ONCOGENE, V7, P33; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; Rommel C, 1996, ONCOGENE, V12, P609; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SIGAL CT, 1993, MOL CELL BIOL, V13, P3084, DOI 10.1128/MCB.13.5.3084; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421	30	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1145	1151						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649807				2022-12-17	WOS:A1996UA88400024
J	Liu				Liu			CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines (vol 10, pg 1061, 1995)	ONCOGENE			English	Correction, Addition																		LIU Q, 1995, ONCOGENE, V10, P1061	1	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2455	2455						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702					2022-12-17	WOS:A1995TK70200033
J	FINCHAM				FINCHAM			V-SRC-INDUCED DEGRADATION OF FOCAL ADHESION KINASE DURING MORPHOLOGICAL TRANSFORMATION OF CHICKEN-EMBRYO FIBROBLASTS (VOL 10, PG 2247, 1995)	ONCOGENE			English	Correction, Addition																		FINCHAM, 1995, ONCOGENE, V10, P2247	1	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2185	2185						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297					2022-12-17	WOS:A1995TF29700032
J	FORSTER, A; RABBITTS, TH				FORSTER, A; RABBITTS, TH			A METHOD FOR IDENTIFYING GENES WITHIN YEAST ARTIFICIAL CHROMOSOMES - APPLICATION TO ISOLATION OF MLL FUSION CDNAS FROM ACUTE-LEUKEMIA TRANSLOCATIONS	ONCOGENE			English	Article							HUMAN ACUTE-LEUKEMIA; DROSOPHILA-TRITHORAX; SELECTION; 11Q23; REARRANGEMENT; REGIONS; PROBES	The majority of chromosomal translocations breakpoints are within regions of the genome where few DNA probes are available. The use of yeast artificial chromosomes (YACs) containing long stretches of human DNA allows dispersed DNA markers to be used to identify the position of breakpoints but does not readily allow subcloning of the precise breakpoint within the YAC DNA nor the cDNAs containing the affected genes. We describe a procedure allowing rapid isolation of cDNAs corresponding to genes within a YAC clone. Random cDNA is hybridised to PCR-generated biotinylated fragments of total DNA from a yeast strain harbouring a YAC clone. The hybrids can be recovered to facilitate subsequent cloning of the cDNA molecules. The application of this method to the cloning of cDNA molecules carrying sequences involved in the translocation t(4;11)(q21;q23) is illustrated.	MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology			Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; BARR FG, 1993, NAT GENET, V3, P133; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; ELVIN P, 1990, NUCLEIC ACIDS RES, V18, P3913, DOI 10.1093/nar/18.13.3913; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RABBITTS TH, 1993, IN PRESS NATURE; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	22	2	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3157	3160						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414518				2022-12-17	WOS:A1993MC09300033
J	NICKLIN, MJH; ZECHNER, D; KISLYAKOVA, T				NICKLIN, MJH; ZECHNER, D; KISLYAKOVA, T			ACCUMULATED HELIX-DESTABILIZING MUTATIONS IN THE LEUCINE-ZIPPER OF C-FOS LEADS TO ATTENUATION AND TEMPERATURE SENSITIVITY OF FUNCTION	ONCOGENE			English	Article							DNA-BINDING DOMAIN; CELLULAR-TRANSFORMATION; GROWTH-FACTOR; JUN; PROTEIN; GENE; EXPRESSION; THERMOSTABILITY; TRANSCRIPTION; FIBROBLASTS	Fos protein heterodimerizes through one surface of an alpha-helical domain called the leucine zipper. We have investigated the effect of destabilizing this domain by multiply substituting small residues of its non-interacting surface with glycine. Ternary complex formation between mutated Fos, Jun and DNA was determined in vitro in the presence of denaturant. We also tested the ability of constitutively expressed, mutated Fos proteins to support anchorage independent growth of the cell line Rat1A. Combinations of two substitutions are tolerated in both assays of Fos function, while four substitutions resulted in attenuation in both functions. Rat1A expressing one of the quadruple mutants also showed temperature sensitivity in anchorage independent growth. In dense monolayers of these cells, stromelysin (a Fos-responsive gene product) decreased in abundance as a function of temperature and was less abundant even at 34-degrees-C than in cells that overexpressed the wild-type c-fos mRNA. However the mutant transgene itself appeared to show temperature sensitive expression. We suggest that creating a range of glycine substitutions for small residues in the non-interacting face of a leucine zipper might be of general use as a strategy to produce attenuated mutants of other transcription factors.	FORSCH INST MOLEK PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Nicklin, Martin/0000-0002-0127-1131				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BOHMANN D, 1989, SCIENCE, V246, P911; BUSSLINGER M, 1981, CELL, V27, P289, DOI 10.1016/0092-8674(81)90412-8; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARAI SI, 1989, NEW BIOL, V1, P181; HECHT M H, 1986, Proteins Structure Function and Genetics, V1, P43, DOI 10.1002/prot.340010108; IMANAKA T, 1986, NATURE, V324, P695, DOI 10.1038/324695a0; JOOSS K, 1992, ONCOGENE, V7, P1933; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LOVELLBADGE RH, 1987, TERATOCARCINOMAS EMB, P132; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MILLER AD, 1984, CELL, V36, P51; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NEMETHY G, 1966, J PHYS CHEM-US, V70, P998, DOI 10.1021/j100876a008; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NICKLIN MJH, 1991, ONCOGENE, V6, P173; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PREVELIGE P, 1988, PREDICTION PROTEIN S, P391; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; SHORTLE D, 1985, GENETICS, V110, P539; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	47	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1737	1749						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510920				2022-12-17	WOS:A1993LG68200004
J	GILARDIHEBENSTREIT				GILARDIHEBENSTREIT			AN EPH-RELATED RECEPTOR PROTEIN TYROSINE KINASE SEGMENTALLY EXPRESSED IN THE DEVELOPING MOUSE HINDBRAIN (VOL 7, PG 2499, 1992)	ONCOGENE			English	Correction, Addition																		GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499	1	2	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1103	1103						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220					2022-12-17	WOS:A1993KT22000038
J	MAHADEVAN, LC				MAHADEVAN, LC			COMPLEXED AND CHROMATIN-ASSOCIATED PP33 AND THE PHOSPHOPROTEIN-S6 (VOL 4, PG 699, 1989)	ONCOGENE			English	Correction, Addition							PHOSPHORYLATION; PROTEIN; S6				MAHADEVAN, LC (corresponding author), UNIV LONDON KINGS COLL,DEV BIOL RES CTR,NUCL SIGNALLING LAB,26-29 DRURY LANE,LONDON WC2B 5RL,ENGLAND.							CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; FRANCO R, 1990, J BIOL CHEM, V265, P4321; MACFARLANE DE, 1990, CANCER RES, V50, P2895; MAHADEVAN LC, 1989, ONCOGENE, V4, P699; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; WETTENHALL REH, 1988, BIOCHEMISTRY-US, V27, P170, DOI 10.1021/bi00401a026	8	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1105	1105						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220					2022-12-17	WOS:A1993KT22000039
J	WANG, SM; NISHIGORI, C; MIYAKOSHI, J; TSUKADA, T; SHUNG, BS; YAGI, T; TAKEBE, H				WANG, SM; NISHIGORI, C; MIYAKOSHI, J; TSUKADA, T; SHUNG, BS; YAGI, T; TAKEBE, H			ACTIVATION OF C-MOS ONCOGENE BY INTEGRATION OF AN ENDOGENOUS LONG TERMINAL REPEAT ELEMENT DURING TRANSFECTION OF GENOMIC DNA FROM MOUSE SKIN TUMOR-CELLS	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; NUCLEOTIDE-SEQUENCE; TRANSFORMING GENE; PROTO-ONCOGENE; CELLULAR ONCOGENE; EXPRESSION; LTR; REARRANGEMENT; TRANSCRIPTS; JUNCTIONS	An activated c-mos oncogene was identified in a transformed clone of golden hamster embryo cells transfected with DNA extracted from cells cultured from a UV-induced mouse skin tumor. Southern blot hybridization with a v-mos oncogene probe showed that the mos oncogene was amplified in the primary and secondary transformed cells but not in the original tumor cells. Expression of the mos oncogene was very high in the primary and secondary transformants, but mos mRNA was undetectable in the original tumor cells. A genomic DNA fragment containing the activated mos oncogene was cloned and sequenced. The upstream mouse sequence of the mos oncogene, which functions as the transcription terminator, was lost and replaced by a mouse endogenous long terminal repeat (LTR) element that provides the promoter sequence, resulting in high expression of the gene. The rearrangement apparently occurred during transfection, since the polymerase chain reaction (PCR) product encompassing the junction region was present in the primary and secondary transformants but not in the original tumor cells. The LTR element is likely to have been amplified during the skin tumor development caused by UV irradiation. Southern blot hybridization showed that the copy number of LTR in the tumor cells was significantly higher than that in normal skin cells. The amplification of the LTR in the cells may have increased the chance of recombination between the LTR and c-mos gene during the DNA transfection.	KYOTO UNIV,FAC MED,DEPT DERMATOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	WANG, SM (corresponding author), KYOTO UNIV,FAC MED,DEPT EXPTL RADIOL,SAKYO KU,KYOTO 606,JAPAN.							BARDWELL L, 1989, MUTAGENESIS, V4, P245, DOI 10.1093/mutage/4.4.245; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coffin J.M., 1984, RNA TUMOR VIRUSES, P1109; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; DHAR R, 1980, P NATL ACAD SCI-BIOL, V77, P3937, DOI 10.1073/pnas.77.7.3937; DONOGHUE DJ, 1983, J VIROL, V45, P607, DOI 10.1128/JVI.45.2.607-617.1983; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FUJIMOTO S, 1985, P NATL ACAD SCI USA, V82, P2072, DOI 10.1073/pnas.82.7.2072; GAO CL, 1988, ONCOGENE, V3, P267; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; HOROWITZ M, 1984, EMBO J, V3, P2937, DOI 10.1002/j.1460-2075.1984.tb02235.x; HOUSEY GM, 1985, BIOCHEM BIOPH RES CO, V127, P391, DOI 10.1016/S0006-291X(85)80172-8; KIRSCHMEIER P, 1982, P NATL ACAD SCI-BIOL, V79, P2773, DOI 10.1073/pnas.79.9.2773; KUFF EL, 1983, NATURE, V302, P547, DOI 10.1038/302547a0; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; OHUCHI T, 1992, ONCOGENE, V7, P331; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PERUCHO M, 1980, CELL, V22, P309, DOI 10.1016/0092-8674(80)90178-6; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; TATSUKA M, 1988, EXP CELL RES, V178, P154, DOI 10.1016/0014-4827(88)90386-2; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; VANDERHOORN FA, 1982, EMBO J, V1, P1313, DOI 10.1002/j.1460-2075.1982.tb01316.x; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WILSON JH, 1982, MOL CELL BIOL, V2, P1258, DOI 10.1128/MCB.2.10.1258; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817	37	2	2	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1009	1016						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455928				2022-12-17	WOS:A1993KT22000024
J	STICKLAND, JE; TOMLINSON, IPM; RAMSHAW, AL; BROMLEY, L; POTTER, CG; MCGEE, JO				STICKLAND, JE; TOMLINSON, IPM; RAMSHAW, AL; BROMLEY, L; POTTER, CG; MCGEE, JO			QUANTIFICATION OF ONCOGENE DOSAGE IN TUMORS BY SIMULTANEOUS DUAL-LABEL HYBRIDIZATION	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; HUMAN-BREAST CANCER; PROTO-ONCOGENE; MESSENGER-RNA; AMPLIFICATION; QUANTITATION; INT-2; DNA	Gene amplification and allele loss occur in a variety of human tumours and some have prognostic value. Therefore, techniques which facilitate detection and quantification of gene dosage could have wide applicability in cancer research. Using the INT-2 gene as a model system, a quantitative procedure has been developed for measuring gene copy number using dual-label hybridization to DNA dot blots. A probe specific for the INT-2 gene was labelled with [alpha-P-32]dCTP and a probe to beta-actin, the control locus, was labelled with [alpha-S-35]dATP. Flat-bed scintillation counting was used to detect and separate the emissions resulting from each bound probe, and gene dosage was calculated from the ratio of INT-2 to the beta-actin probe compared with the ratio derived from constitutional DNA. Calculated ratios of greater than 1.22 and less than 0.78 indicated gene amplification and allelic loss respectively, at the 99% confidence limit derived from the population of 35 constitutional DNAs. The results were validated by RFLP analysis. It is expected that this technique will permit precise gene dosage quantification in many areas.	UNIV OXFORD,NUFFIELD DEPT PATHOL & BACTERIOL,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford								ADNANE J, 1989, ONCOGENE, V4, P1389; BLOCH W, 1991, BIOCHEMISTRY-US, V30, P2735, DOI 10.1021/bi00225a001; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CALLAHAN R, 1989, BREAST CANCER RES TR, V13, P191, DOI 10.1007/BF02106570; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; DONOVANPELUSO M, 1991, AM J PATHOL, V138, P835; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; LASKEY RA, 1990, RADIOISOTOPES BIOL; MACHOTKA SV, 1989, CLIN CHIM ACTA, V184, P207, DOI 10.1016/0009-8981(89)90053-3; NEUBAUER A, 1992, ONCOGENE, V7, P1019; Sambrook J., 1989, MOL CLONING LAB MANU; TSUDA H, 1989, CANCER RES, V49, P3104; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717	15	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					223	227						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8093811				2022-12-17	WOS:A1993KN00500029
J	ZHU, W; KRIAJEVSKAIA, M; CHOU, WG				ZHU, W; KRIAJEVSKAIA, M; CHOU, WG			A RETROVIRAL SEQUENCE OF THE CHINESE-HAMSTER OVARY CELL-LINE	ONCOGENE			English	Note							MURINE LEUKEMIA-VIRUS; EMBRYONAL CARCINOMA-CELLS; LONG TERMINAL REPEAT; EXPRESSION; GENOMES	A partial cDNA (B52) molecule with the characteristics of retroviral sequences was isolated from the Chinese hamster ovary (CHO) K1 cell line. The B52 cDNA contains 1184 nucleotides. The first 452 nucleotides (nt) are 71% homologous to the env gene of Moloney murine leukemia virus (MMLV) and murine endogenous retroviruses. The 139 amino acids predicted from the 452 nt have 82% homology with the carboxy-terminal amino acids of the env protein of MMLV. The remaining 732 nt have several features of a typical retroviral long terminal repeat (LTR). For example, the first 14 nt are identical to the 5' inverted repeat of the retroviral LTRs. The 41-nt sequence at the 3' end is common to the R region of retroviral LTRs. The 732-nt sequence was shown to have promoter activity. The activity is approximately twofold higher than that of the Rous sarcoma virus LTR, and 1.5-fold lower than that of the early promoter of SV40 virus. Two species of mRNA of 5.2 and 2.7 kb in size were readily detected by B52 cDNA in the CHO K1 cells.	UNIV ROCHESTER,MED CTR,DEPT RADIAT ONCOL,CTR CANC,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [R01CA051064] Funding Source: NIH RePORTER; NCI NIH HHS [CA51064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKLIS E, 1986, CELL, V47, P391, DOI 10.1016/0092-8674(86)90596-9; BOSZE Z, 1986, EMBO J, V5, P1615, DOI 10.1002/j.1460-2075.1986.tb04404.x; CELANDER D, 1984, NATURE, V312, P159, DOI 10.1038/312159a0; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; CULLEN BR, 1983, P NATL ACAD SCI-BIOL, V80, P2946, DOI 10.1073/pnas.80.10.2946; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; LENZ J, 1984, NATURE, V308, P467, DOI 10.1038/308467a0; LINNEY E, 1984, NATURE, V308, P470, DOI 10.1038/308470a0; LOH TP, 1990, MOL CELL BIOL, V10, P4045, DOI 10.1128/MCB.10.8.4045; LOSARDO JE, 1989, J VIROL, V63, P1087, DOI 10.1128/JVI.63.3.1087-1094.1989; NICOLAS JF, 1976, CANCER RES, V36, P4224; PRINCE VE, 1991, J VIROL, V65, P1803, DOI 10.1128/JVI.65.4.1803-1811.1991; ROBINSON HL, 1982, P NATL ACAD SCI-BIOL, V79, P1225, DOI 10.1073/pnas.79.4.1225; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SILVER JE, 1983, J EXP MED, V158, P1693, DOI 10.1084/jem.158.5.1693; WEBER F, 1985, EMBO J, V4, P946; ZHU W, 1992, IN PRESS MUTATION RE	18	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2081	2083						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408151				2022-12-17	WOS:A1992JP42400026
J	DAVIDPFEUTY, T; NOUVIANDOOGHE, Y				DAVIDPFEUTY, T; NOUVIANDOOGHE, Y			SLOW TIME-DEPENDENT CELLULAR-TRANSFORMATION INDUCED AT RESTRICTIVE TEMPERATURE BY TS-SRC MUTANTS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PROTEIN-KINASE ACTIVITY; ATP-BINDING SITE; GENE-PRODUCT; MONOCLONAL-ANTIBODIES; CELLS; PP60SRC; PP60V-SRC; LOCALIZATION; PARAMETERS	Cell lines infected with a temperature-sensitive Rous sarcoma virus have been widely used to study the temporal dynamics of various transformation parameters following downshift from the non-permissive temperature to the permissive temperature as it is considered that, at the non-permissive temperature, the infected cells exhibit the morphological and growth characteristics of normal cell whereas, at the permissive temperature, they exhibit characteristics of the transformed state. We show here that the apparently normal state in which tsPA1-infected FR3T3 cells are directed at the restrictive temperature is not a stationary stable state, but rather a transient one which continuously drifts as the cells are grown and passaged at this temperature and which eventually ends up as a new transformed state (T2) with morphological and growth properties definitely different from those belonging to the transformed state (T1) at the permissive temperature. The establishment of the transformed T2 state at the restrictive temperature occurs concomitantly with a steady accumulation of an intracellular pool of pp60v-src in the vicinity of the nucleus, whose traffic towards the plasma membrane is released following downshift to the permissive temperature, leading to the reappearance of transformation parameters characteristic of the transformed T1 state. Our finding raises the possibility that the v-src protein encoded by the tsPA1 mutant of Rous sarcoma virus may induce cellular transformation via two different pathways, leading to two different transformation states, depending on at which temperature the infected cells are grown. Various possible mechanisms that could be involved in the time-dependent establishment of a transformed state by ts-src mutants at the restrictive temperature are discussed.			DAVIDPFEUTY, T (corresponding author), CTR UNIV ORSAY, INST CURIE BIOL, BATIMENT 110, F-91405 ORSAY, FRANCE.							BARAK LS, 1980, P NATL ACAD SCI-BIOL, V77, P980, DOI 10.1073/pnas.77.2.980; BIQUARD J-M, 1970, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences Serie D Sciences Naturelles, V271, P2430; BIQUARD JM, 1972, VIROLOGY, V47, P444, DOI 10.1016/0042-6822(72)90280-2; BRE MH, 1987, J CELL BIOL, V105, P1283, DOI 10.1083/jcb.105.3.1283; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CALOTHY G, 1978, VIROLOGY, V89, P75, DOI 10.1016/0042-6822(78)90041-7; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GARBER EA, 1982, VIROLOGY, V118, P419, DOI 10.1016/0042-6822(82)90361-0; GIONTI E, 1980, VIROLOGY, V100, P219, DOI 10.1016/0042-6822(80)90515-2; HANAFUSA H, 1977, COMPREHENSIVE VIROLO, V10, P401; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; LEVINSON AD, 1981, P NATL ACAD SCI-BIOL, V78, P1624, DOI 10.1073/pnas.78.3.1624; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHLIWA M, 1986, CYTOSKELETON INTRO S, P47; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; WEBER MJ, 1979, CELL, V16, P25, DOI 10.1016/0092-8674(79)90184-3	41	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1611	1623						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1321405				2022-12-17	WOS:A1992JE81300018
J	THORN, JT				THORN, JT			CORRECTION	ONCOGENE			English	Correction, Addition								Overexpression of ras proto-oncogenes has been implicated in cancer development. We therefore initiated a study of the human N-ras promoter to determine the regions that control N-ras expression and their potential for interaction with DNA-binding proteins. N-ras CAT constructs were stably integrated into K562 cells by electric field-mediated gene transfer in order to determine functional regions within the human N-ras promoter. A significant proportion of promoter activity was found to lie within a 439 bp fragment comprising an untranslated exon (exon 1) with the adjacent 5' sequence and a small CpG island. A 109 bp fragment at the 5' end of exon 1 was essential for promoter activity, while a 45 bp deletion from within this region decreased promoter activity by two-thirds. Unlike the human H-ras and mouse K-ras promoters, the N-ras promoter did not exhibit bidirectional activity. DNAase footprinting of the 439 bp fragment revealed seven protected regions, many of which contain sequences homologous to known DNA-binding protein sites (MLTF/myc, CREB/ATF, AP-1, AP-2, myb and E4TF1). In contrast, four putative Sp1 sites did not footprint. Using purified MLTF and appropriate competitors in gel shift and DNAase footprinting assays, we demonstrated binding of MLTF to the MLTF consensus sequence within exon 1.										THORN JT, 1991, ONCOGENE, V6, P1843	1	2	2	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1047	1047						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570152				2022-12-17	WOS:A1992HP64200030
J	BECHADE, C; CALOTHY, G				BECHADE, C; CALOTHY, G			CELL-DIVISION IS REQUIRED FOR EXPRESSION OF V-MYC TRANSFORMING PROPERTIES IN CHICKEN EMBRYONIC NEURORETINA CELLS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; AVIAN MYELOCYTOMATOSIS VIRUS; NUCLEAR-LOCALIZATION; AUTOCRINE GROWTH; DNA-BINDING; SRC GENE; ONCOGENES; PROLIFERATION; MIL; PROTEINS	We previously reported that avian retrosiruses carrying the v-myc oncogene alone fail to induce sustained proliferation and transformation of non-dividing chicken neuroretina (CNR) cells from 7-day-old embryos. However, v-myc is capable of transforming CNR cells which have been induced to multiply by the v-mil oncogene. These results suggest that entry into the cell cycle is required for the transformation of CNR cells by v-myc. To further assess the role of cell division, we investigated the transforming properties of v-myc in CNR cells conditionally induced to divide by the v-src gene or by modified culture conditions. We show that v-myc transforms CNR cells infected with Rous sarcoma virus mutants which induce cell proliferation in the absence of transformation. Expression of these transforming properties in CNR cells infected with temperature-sensitive v-src mutants depends on the continuous mitogenic activity of p60v-src. We also report that v-myc is able to transform CNR cells and to increase their growth potential under culture conditions which allow transient multiplication of uninfected cells. However, these v-myc-transformed cells rapidly cease to divide when returned to culture conditions that restrict the growth of normal cells. Taken together, these results indicate that transformation of CNR cells by the v-myc oncogene continuously depends on their ability to enter the cell Cycle.	CTR UNIV ORSAY,INST CURIE BIOL,BAT 110,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			Bechade, Catherine/K-5528-2017	Bechade, Catherine/0000-0003-2070-2993				ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BECHADE C, 1988, J VIROL, V88, P1211; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BUNTE T, 1983, EMBO J, V2, P1087, DOI 10.1002/j.1460-2075.1983.tb01550.x; CALOTHY G, 1978, VIROLOGY, V89, P75, DOI 10.1016/0042-6822(78)90041-7; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CALOTHY G, 1987, J VIROL, V61, P1678, DOI 10.1128/JVI.61.5.1678-1681.1987; CASALBORE P, 1987, NATURE, V316, P188; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; CRISANTICOMBES P, 1977, CELL TISSUE RES, V185, P159; CROSS FR, 1985, MOL CELL BIOL, V5, P2789, DOI 10.1128/MCB.5.10.2789; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; EYCHENE A, 1990, J VIROL, V64, P231; FERRE F, 1986, CR ACAD SCI III-VIE, V303, P633; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MARX M, 1988, J VIROL, V62, P4627, DOI 10.1128/JVI.62.12.4627-4633.1988; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x	38	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2311	2317						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1662792				2022-12-17	WOS:A1991GX73500020
J	YIU, KC; HUANG, DP; CHAN, MKM; FOO, W				YIU, KC; HUANG, DP; CHAN, MKM; FOO, W			THE PHYSICAL STATE OF HUMAN PAPILLOMAVIRUS TYPE-16 DNA IN CERVICAL CARCINOMAS OF HONG-KONG CHINESE	ONCOGENE			English	Article							GENITAL TUMORS; CELL-LINES; MOLECULAR ANALYSIS; INTEGRATION SITES; SEQUENCES; GENE; P53; TRANSFORMATION; E6; IDENTIFICATION	The presence of human papillomavirus (HPV) in 15 cervical carcinoma specimens obtained from Hong Kong Chinese patients was analyzed by Southern blot hybridization studies. In nine (60%) of them, HPV 16 genomes were detected, while two others (13.3%) were found to harbor HPV DNA of unknown type closely related to HPV 16. All of them were classified as squamous cell carcinomas according to WHO guidelines. In addition, the presence of HPV 18 was shown in another two (13.3%) squamous cell carcinoma samples. Among the nine tumors harboring HPV 16, four specimens (44.4%) have HPV in integrated forms, while four others (44.4%) have HPV in episomal forms. The simultaneous presence of both episomal and integrated forms was demonstrated in the remaining tissue sample (11.2%). The result obtained here indicates a strong association between HPV infection and cervical carcinogenesis in Hong Kong Chinese, with HPV 16 prevalent in squamous cell carcinoma. Moreover, the persistence of HPV 16 episomes in some of the tumor specimens suggests that extrachromosomal HPV DNA, possibly acting synergistically with other oncogenic factors, is also capable of inducing cervical cancer.	CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT ANAT & CELLULAR PATHOL, SHA TIN, HONG KONG; QUEEN ELIZABETH HOSP, INST RADIOL & ONCOL, KOWLOON, HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital								ANDERSON MC, 1987, HAINES TAYLOR OBSTET, P255; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; CHOO KB, 1989, J VIROL, V63, P782, DOI 10.1128/JVI.63.2.782-789.1989; CHOO KB, 1987, J MED VIROL, V21, P101, DOI 10.1002/jmv.1890210202; DANOS O, 1984, J INVEST DERMATOL, V83, pS7, DOI 10.1111/1523-1747.ep12281115; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DILUCA D, 1986, J GEN VIROL, V67, P583, DOI 10.1099/0022-1317-67-3-583; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; FERENCZY A, 1987, BLAUSTEINS PATHOLOGY, P177; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUKUSHIMA M, 1985, CANCER RES, V45, P3252; GISSMANN L, 1984, J INVEST DERMATOL, V83, pS26, DOI 10.1111/1523-1747.ep12281143; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HOWLEY PM, 1988, AM J MED, V85, P155; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KOSS L G, 1987, Applied Pathology, V5, P7; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCCANCE DJ, 1983, BRIT MED J, V287, P784, DOI 10.1136/bmj.287.6395.784; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SCHNEIDERMAUNOURY S, 1987, J VIROL, V61, P3295, DOI 10.1128/JVI.61.10.3295-3298.1987; SMITH PP, 1989, INT J CANCER, V44, P1124, DOI 10.1002/ijc.2910440631; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WATTS SL, 1984, SCIENCE, V225, P634, DOI 10.1126/science.6330900; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YIU KC, 1990, ANTICANCER RES, V10, P917	33	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1339	1342						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1653409				2022-12-17	WOS:A1991GX27200007
J	ANDREWS, DF; TOMPKINS, CK; HENDRICKSON, SL; SINGER, JW				ANDREWS, DF; TOMPKINS, CK; HENDRICKSON, SL; SINGER, JW			CLONING AND SEQUENCING OF THE HUMAN C-ABL 3' UNTRANSLATED REGION	ONCOGENE			English	Note									UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	ANDREWS, DF (corresponding author), VET ADM MED CTR,DEPT MED 111,1660 S COLUMBIAN WAY,SEATTLE,WA 98108, USA.			Singer, Jack/0000-0003-4001-4549	NCI NIH HHS [CA18028, CA01333, CA16448] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA016448, K08CA001333, R01CA016448] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS DF, 1989, P NATL ACAD SCI USA, V86, P6788, DOI 10.1073/pnas.86.17.6788; ANDREWS DF, 1987, LEUKEMIA, V1, P718; ANDREWS DF, 1989, MOL CELL BIOL, V9, P2748, DOI 10.1128/MCB.9.6.2748; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; HOFFMANFALK H, 1983, CELL, V32, P589, DOI 10.1016/0092-8674(83)90478-6; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; MANIATIS T, 1983, MOL CLONING LABORATO, P387; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MUELLER R, 1982, NATURE, V299, P640; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PUSTELL J, 1982, NUCLEIC ACIDS RES, V10, P51, DOI 10.1093/nar/10.1.51; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SHTIVELMAN E, 1986, CELL, V47, P227; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WANG JYJ, 1984, CELL, V36, P349; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	25	2	2	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					441	444						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2179820				2022-12-17	WOS:A1990CW41500026
J	ISHIZAKA, Y				ISHIZAKA, Y			CORRECTION	ONCOGENE			English	Correction, Addition																		ISHIZAKA Y, 1989, ONCOGENE, V4, P789	1	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1415	1415						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659					2022-12-17	WOS:A1989AX65900021
J	HALL, BS; HOFFBRAND, AV; WICKREMASINGHE, RG				HALL, BS; HOFFBRAND, AV; WICKREMASINGHE, RG			AN ENDOGENOUS INHIBITOR OF THE PROTEIN TYROSINE KINASE-ACTIVITY OF NORMAL AND MALIGNANT HUMAN LYMPHOID-CELLS	ONCOGENE			English	Article									ROYAL FREE HOSP,DEPT HAEMATOL,POND ST,LONDON NW3 2QG,ENGLAND; UNIV LONDON,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London			Hall, Belinda/AGU-6214-2022	Hall, Belinda/0000-0002-3753-1978				AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; CHENG YSE, 1981, P NATL ACAD SCI-BIOL, V78, P2388, DOI 10.1073/pnas.78.4.2388; DEMAILLE JG, 1977, BIOCHEMISTRY-US, V16, P3080, DOI 10.1021/bi00633a006; ENDO T, 1981, J BIOL CHEM, V256, P2485; HAGIWARA M, 1988, J BIOL CHEM, V263, P6438; HALL BS, 1987, FEBS LETT, V223, P6, DOI 10.1016/0014-5793(87)80499-4; HARDIE G, 1988, NATURE, V335, P592, DOI 10.1038/335592a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KANAMORI M, 1982, BIOCHEM BIOPH RES CO, V108, P1447, DOI 10.1016/S0006-291X(82)80069-7; KATAN M, 1988, NATURE, V332, P203, DOI 10.1038/332203a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MIRE AR, 1986, FEBS LETT, V206, P53, DOI 10.1016/0014-5793(86)81339-4; PATEL MD, 1987, J BIOL CHEM, V262, P5831; PIGA A, 1985, EXP CELL RES, V159, P103, DOI 10.1016/S0014-4827(85)80041-0; SWARUP G, 1981, J BIOL CHEM, V256, P8197; THOMPSON ST, 1975, P NATL ACAD SCI USA, V72, P669, DOI 10.1073/pnas.72.2.669; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WICKREMASINGHE RG, 1985, LEUKEMIA RES, V9, P1443, DOI 10.1016/0145-2126(85)90034-7	23	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1225	1231						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2529467				2022-12-17	WOS:A1989AU50800010
J	WALSER, A; DEPPERT, W				WALSER, A; DEPPERT, W			A NOVEL MECHANISM FOR COVALENT ATTACHMENT OF FATTY-ACID TO SV40 LARGE T-ANTIGEN	ONCOGENE			English	Note									UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,D-2000 HAMBURG 20,FED REP GER	Heinrich Pette Institute; University of Hamburg								BERGER M, 1984, EMBO J, V3, P713, DOI 10.1002/j.1460-2075.1984.tb01874.x; BERGER M, 1984, J BIOL CHEM, V259, P7245; BRADLEY MK, 1984, P NATL ACAD SCI-BIOL, V81, P6574, DOI 10.1073/pnas.81.21.6574; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; CAROLL RB, 1988, ONCOGENE, V2, P437; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; Flint S. J, 1981, DNA TUMOR VIRUSES; FOLCH J, 1957, J BIOL CHEM, V226, P497; GOLDMAN N, 1981, CELL, V24, P567, DOI 10.1016/0092-8674(81)90347-0; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; JANATOVA J, 1981, BIOCHEMISTRY-US, V20, P2394, DOI 10.1021/bi00512a005; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KIT S, 1969, INT J CANCER, V4, P384, DOI 10.1002/ijc.2910040403; KLOCKMANN U, 1983, FEBS LETT, V151, P257, DOI 10.1016/0014-5793(83)80081-7; KLOCKMANN U, 1984, MOL CELL BIOL, V4, P1542, DOI 10.1128/MCB.4.8.1542; KLOCKMANN U, 1983, EMBO J, V2, P1151, DOI 10.1002/j.1460-2075.1983.tb01560.x; MACK D, 1987, J BIOL CHEM, V262, P4297; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MAGEE AI, 1982, BIOCHIM BIOPHYS ACTA, V694, P279, DOI 10.1016/0304-4157(82)90008-9; OLSON EN, 1986, PROTEIN COMPARTMENTA, P87; OMARY MB, 1981, J BIOL CHEM, V256, P2888; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; THOMAS ML, 1982, P NATL ACAD SCI-BIOL, V79, P1054, DOI 10.1073/pnas.79.4.1054; WOLD F, 1986, TRENDS BIOCHEM SCI, V11, P58, DOI 10.1016/0968-0004(86)90254-9	26	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					249	252						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2927946				2022-12-17	WOS:A1989U567500018
J	OHLSSON, RI; SCHWARZE, P; RUUD, E; PFEIFEROHLSSON, S				OHLSSON, RI; SCHWARZE, P; RUUD, E; PFEIFEROHLSSON, S			POTENTIAL MULTIPLE FUNCTIONS OF THE V-MYC ONCOGENE WITHIN A SINGLE CELL CLONE OF OK10 RETROVIRUS-TRANSFORMED QUAIL FIBROBLASTS	ONCOGENE			English	Article									NORWEGIAN RADIUMHOSP,DEPT TISSUE CULTURE,N-0310 OSLO 3,NORWAY; NORWEGIAN RADIUMHOSP,IMMUNOL LAB,N-0310 OSLO 3,NORWAY	University of Oslo; University of Oslo	OHLSSON, RI (corresponding author), KAROLINSKA INST,HUDDINGE HOSP,CTR BIOTECHNOL,F82,S-14186 HUDDINGE,SWEDEN.		Schwarze, Per/I-2080-2016					ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BISHOP JM, 1983, ANNU REV BIOCHEM, V47, P310; BROOME S, 1985, CELL, V40, P537, DOI 10.1016/0092-8674(85)90202-8; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CONNAN G, 1985, NATURE, V314, P277, DOI 10.1038/314277a0; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CRISSMAN HA, 1974, SCIENCE, V184, P1297, DOI 10.1126/science.184.4143.1297; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREENBERG ME, 1984, NATURE, V290, P475; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; JOHNSON BE, 1986, J CLIN INVEST, V78, P525, DOI 10.1172/JCI112604; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NISHIKURA K, 1984, SCIENCE, V224, P399, DOI 10.1126/science.6424234; OHLSSON RI, 1987, EXP CELL RES, V173, P1, DOI 10.1016/0014-4827(87)90327-2; OKERBLOM N, 1978, J GEN VIROL, V40, P623, DOI 10.1099/0022-1317-40-3-623; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PFEIFER S, 1983, J VIROL, V46, P347, DOI 10.1128/JVI.46.2.347-354.1983; PFEIFEROHLSSON S, 1984, INTERVIROLOGY, V21, P121, DOI 10.1159/000149510; PFEIFEROHLSSON S, 1984, CELL, V38, P585, DOI 10.1016/0092-8674(84)90513-0; PFEIFEROHLSSON S, 1985, P NATL ACAD SCI USA, V82, P5050, DOI 10.1073/pnas.82.15.5050; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SAGER R, 1984, CANCER SURV, V3, P321; SMELAND E, 1985, P NATL ACAD SCI USA, V82, P6255, DOI 10.1073/pnas.82.18.6255; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448	38	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					457	461						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078953				2022-12-17	WOS:A1988Q773900015
J	SEGEV, O; KIMCHIE, Z; LEV, Z				SEGEV, O; KIMCHIE, Z; LEV, Z			ISOLATION OF THE PROMOTER REGION OF THE DROSOPHILA ABL PROTO-ONCOGENE HOMOLOG	ONCOGENE			English	Article									TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Technion Israel Institute of Technology								ANDERSON KV, 1981, DEV BIOL, V82, P127, DOI 10.1016/0012-1606(81)90434-6; BENBERIA Y, 1986, CELL, V44, P577; BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Davidson E. H., 1986, GENE ACTIVITY EARLY; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Elgin S.C.R., 1978, P112; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANFALK H, 1983, CELL, V32, P589, DOI 10.1016/0092-8674(83)90478-6; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; HU MCT, 1986, GENE, V42, P21; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KUO CH, 1978, DEV BIOL, V67, P237, DOI 10.1016/0012-1606(78)90313-5; LEV Z, 1985, MOL CELL BIOL, V5, P1540, DOI 10.1128/MCB.5.6.1540; LEV Z, 1984, MOL CELL BIOL, V4, P982, DOI 10.1128/MCB.4.5.982; LEV Z, 1987, ANAL BIOCHEM, V160, P332, DOI 10.1016/0003-2697(87)90055-8; LEV Z, 1985, DEV BIOL, V110, P499, DOI 10.1016/0012-1606(85)90107-1; LEV Z, 1986, BIOCHIM BIOPHYS ACTA, V867, P144, DOI 10.1016/0167-4781(86)90074-6; LIN HC, 1985, ANAL BIOCHEM, V147, P114, DOI 10.1016/0003-2697(85)90016-8; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MANIATIS T, 1982, LABORATORY MANUAL; MARTIN P, 1986, DEV BIOL, V117, P574, DOI 10.1016/0012-1606(86)90326-X; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MERMOD JJ, 1978, DEV BIOL, V66, P586, DOI 10.1016/0012-1606(78)90264-6; MEYEROWITZ EM, 1987, TRENDS GENET, V3, P288, DOI 10.1016/0168-9525(87)90270-8; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOTHIGER R, 1980, DROS INFOR SERVICE, V55, P162; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGEV O, 1987, THESIS TECHNION ISRA; SHILO BZ, 1987, TRENDS GENET, V3, P69, DOI 10.1016/0168-9525(87)90178-8; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SNYDER M, 1982, CELL, V29, P1027, DOI 10.1016/0092-8674(82)90466-4; SPRADLING AC, 1982, SCIENCE, V218, P241; STELLER H, 1984, EMBO J, V3, P165, DOI 10.1002/j.1460-2075.1984.tb01778.x; TELFORD J, 1985, EMBO J, V4, P2609, DOI 10.1002/j.1460-2075.1985.tb03978.x; WADSWORTH SC, 1985, NUCLEIC ACIDS RES, V13, P2153, DOI 10.1093/nar/13.6.2153; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WANG JYJ, 1984, CELL, V36, P349; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	49	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					33	41						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400006
J	SHIOZAWA, M; OCHIYA, T; HATADA, I; IMAMURA, T; OKUDAIRA, Y; HIRAOKA, H; MATSUBARA, K				SHIOZAWA, M; OCHIYA, T; HATADA, I; IMAMURA, T; OKUDAIRA, Y; HIRAOKA, H; MATSUBARA, K			THE LCA AS AN ONCO-FETAL GENE - ITS EXPRESSION IN HUMAN-FETAL LIVER	ONCOGENE			English	Article									OSAKA UNIV,INST MOLEC & CELLULAR BIOL,YAMADA OKA,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,HOSP ATTACHED RES INST MICROBIAL DIS,SUITA,OSAKA 565,JAPAN; HANWA HOSP,DEPT GYNECOL & OBSTET,SUMIYOSHI,OSAKA 558,JAPAN	Osaka University; Osaka University			Ochiya, Takahiro/AAH-7585-2019					AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; GITLIN D, 1970, NATURE, V228, P995, DOI 10.1038/228995a0; HAN JH, 1986, P NATL ACAD SCI USA, V83, P110, DOI 10.1073/pnas.83.1.110; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LEFFERT H, 1978, P NATL ACAD SCI USA, V75, P1834, DOI 10.1073/pnas.75.4.1834; LEFFERT HL, 1972, J CELL BIOL, V52, P559, DOI 10.1083/jcb.52.3.559; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MANIATIS T, 1982, MOL CLONING LABORATO; MATSUBARA K, 1987, ONCOGENES CANCER; MOORE KL, 1977, DEV HUMAN; MORINAGA T, 1983, P NATL ACAD SCI-BIOL, V80, P4604, DOI 10.1073/pnas.80.15.4604; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SLAMON DJ, 1984, P NATL ACAD SCI-BIOL, V81, P7141, DOI 10.1073/pnas.81.22.7141; Van Furth R, 1969, Nature, V222, P1296, DOI 10.1038/2221296a0; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WIDDOWSON EM, 1972, ARCH DIS CHILD, V47, P652, DOI 10.1136/adc.47.254.652; ZHANG XK, 1987, BIOCHEM BIOPH RES CO, V142, P932, DOI 10.1016/0006-291X(87)91503-8	27	2	2	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					523	526						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	2836781				2022-12-17	WOS:A1988N434800015
J	COLOMBO, MP; FERRARI, G; PARMIANI, G; WETTSTEIN, PJ				COLOMBO, MP; FERRARI, G; PARMIANI, G; WETTSTEIN, PJ			RETROVIRAL HETEROGENEITY IN MOUSE LYMPHOMAS	ONCOGENE			English	Article									WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute	COLOMBO, MP (corresponding author), IST NAZL STUDIO & CURA TUMORI,VIA VENEZIAN 1,I-20133 MILAN,ITALY.		Colombo, Mario P./V-7166-2017; Ferrari, Giuliana/AAB-5546-2019	Colombo, Mario P./0000-0003-0042-7955; Ferrari, Giuliana/0000-0003-0790-3133	NCI NIH HHS [CA-10815] Funding Source: Medline; PHS HHS [A1-16052] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACH FH, 1982, POTENTIAL ROLE T CEL, P7; BUCKLER CE, 1982, J VIROL, V41, P228, DOI 10.1128/JVI.41.1.228-236.1982; CARBONE G, 1983, INT J CANCER, V31, P483, DOI 10.1002/ijc.2910310414; CLARKE MF, 1983, NATURE, V305, P60, DOI 10.1038/305060a0; COLOMBO MP, 1987, P NATL ACAD SCI USA, V84, P189, DOI 10.1073/pnas.84.1.189; COLOMBO MP, 1983, IMMUNOBIOLOGY, V165, P186, DOI 10.1016/S0171-2985(83)80059-X; COLOMBO MP, 1987, IMMUNOGENETICS, V26, P99, DOI 10.1007/BF00345461; CUYPERS HT, 1984, CELL, V37, P141; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DUDLEY J, 1984, J VIROL, V49, P92, DOI 10.1128/JVI.49.1.92-101.1984; DUDLEY JP, 1986, J VIROL, V57, P385, DOI 10.1128/JVI.57.1.385-388.1986; GOODENOW RS, 1985, SCIENCE, V230, P777, DOI 10.1126/science.2997918; JAHN CL, 1980, CELL, V21, P159, DOI 10.1016/0092-8674(80)90123-3; JENKINS NA, 1981, NATURE, V293, P370, DOI 10.1038/293370a0; KING W, 1985, SCIENCE, V228, P554, DOI 10.1126/science.3838595; MAJORS JE, 1981, NATURE, V289, P253, DOI 10.1038/289253a0; MANN DL, 1983, NATURE, V305, P58, DOI 10.1038/305058a0; MCCOY JL, 1967, CANCER RES, V27, P1743; MERUELO D, 1984, P NATL ACAD SCI-BIOL, V81, P1804, DOI 10.1073/pnas.81.6.1804; MERUELO D, 1983, P NATL ACAD SCI-BIOL, V80, P5032, DOI 10.1073/pnas.80.16.5032; MICHALIDES R, 1985, MOL CELL BIOL, V5, P823, DOI 10.1128/MCB.5.4.823; MICHALIDES R, 1982, J VIROL, V43, P819, DOI 10.1128/JVI.43.3.819-829.1982; PAMPENO CL, 1986, J VIROL, V58, P296, DOI 10.1128/JVI.58.2.296-306.1986; PARMIANI G, 1979, IMMUNOGENETICS, V9, P1, DOI 10.1007/BF01570389; PARMIANI G, 1982, INT J CANCER, V29, P323, DOI 10.1002/ijc.2910290316; ROSSOMANDO A, 1986, IMMUNOGENETICS, V23, P233, DOI 10.1007/BF00373018; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; SCHWARTZBERG P, 1983, J VIROL, V46, P538, DOI 10.1128/JVI.46.2.538-546.1983; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAYLOR BA, 1984, MOL GEN GENET, V195, P491, DOI 10.1007/BF00341452; TSICHLIS PN, 1983, NATURE, V302, P445, DOI 10.1038/302445a0; VARMUS HE, 1983, MOBILE GENETIC ELEME, P411; WEJMAN JC, 1984, J VIROL, V50, P237, DOI 10.1128/JVI.50.1.237-247.1984; WETTSTEIN PJ, 1986, IMMUNOGENETICS, V23, P156, DOI 10.1007/BF00373816; WIRSCHUBSKY Z, 1986, INT J CANCER, V38, P739, DOI 10.1002/ijc.2910380518	36	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1988	2	4					395	398						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	2896330				2022-12-17	WOS:A1988M947200012
J	OLSZEWSKA, E; HAY, DE; JONES, KW; CHETTY, U				OLSZEWSKA, E; HAY, DE; JONES, KW; CHETTY, U			SOMATIC DNA VARIABILITY IN HUMAN-BREAST CARCINOMA	ONCOGENE			English	Article									UNIV EDINBURGH,ROYAL INFIRM,DEPT CLIN SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh	OLSZEWSKA, E (corresponding author), UNIV EDINBURGH,DEPT GENET,KINGS BLDG,W MAINS RD,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND.							ALI S, 1986, HUM GENET, V74, P239; AYRAUD N, 1986, 9TH INT CHROM C MARS, P17; BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DELHANTY JDA, 1987, J MED GENET, V24, P188, DOI 10.1136/jmg.24.3.188; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GEBHART E, 1986, 9TH INT CHROM C MARS, P62; GOODBOURN SEY, 1983, P NATL ACAD SCI-BIOL, V80, P5022, DOI 10.1073/pnas.80.16.5022; HIGGS DR, 1981, NUCLEIC ACIDS RES, V9, P4213, DOI 10.1093/nar/9.17.4213; HU NT, 1982, GENE, V17, P271; JEFFREYS AJ, 1985, NATURE, V314, P63; JONES KW, 1986, CHROMOSOMES TODAY, V9, P22; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOZBOR D, 1984, CANCER RES, V44, P438; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEBO RV, 1983, P NATL ACAD SCI-BIOL, V80, P4808, DOI 10.1073/pnas.80.15.4808; MANIATIS T, 1982, MOL CLONING LABORATO; MATTEI MG, 1986, 9TH INT CHROM C MARS, P123; MITELMAN F, 1984, NATURE, V310, P325, DOI 10.1038/310325a0; PATHAK S, 1986, CANCER GENET CYTOGEN, V19, P29, DOI 10.1016/0165-4608(86)90368-7; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; ROWLEY JD, 1983, NATURE, V301, P290, DOI 10.1038/301290a0; SINGH L, 1986, HUM GENET, V73, P304, DOI 10.1007/BF00279091; SINGH L, 1982, CELL, V28, P205, DOI 10.1016/0092-8674(82)90338-5; SINGH L, 1984, CELL, V36, P111, DOI 10.1016/0092-8674(84)90079-5; STOKER NG, 1985, NUCLEIC ACIDS RES, V13, P4613, DOI 10.1093/nar/13.13.4613; THEIN SL, 1987, BRIT J CANCER, V55, P353, DOI 10.1038/bjc.1987.71; TRAUT W, 1987, GENETICS, V115, P493; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VASSART G, 1987, SCIENCE, V235, P683, DOI 10.1126/science.2880398; WYMAN AR, 1980, P NATL ACAD SCI-BIOL, V77, P6754, DOI 10.1073/pnas.77.11.6754; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	36	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					403	408						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	2898746				2022-12-17	WOS:A1987K748300009
J	Semba, S; Trapasso, F; Fabbri, M; McCorkell, KA; Volinia, S; Druck, T; Iliopoulos, D; Pekarsky, Y; Ishii, H; Garrison, PN; Barnes, LD; Croce, CM; Huebner, K				Semba, S.; Trapasso, F.; Fabbri, M.; McCorkell, K. A.; Volinia, S.; Druck, T.; Iliopoulos, D.; Pekarsky, Y.; Ishii, H.; Garrison, P. N.; Barnes, L. D.; Croce, C. M.; Huebner, K.			Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential (Jun, 10.1038/s41388-022-02472-x, 2022)	ONCOGENE			English	Correction												kay.huebner@osumc.edu						Semba S, 2022, ONCOGENE, V41, P5317, DOI 10.1038/s41388-022-02472-x	1	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2022	41	49					5317	5318		10.1038/s41388-022-02472-x	http://dx.doi.org/10.1038/s41388-022-02472-x		OCT 2022	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6R9BX	36266332	Bronze			2022-12-17	WOS:000870590600001
J	Saha, G; Sarkar, S; Mohanta, PS; Kumar, K; Chakrabarti, S; Basu, M; Ghosh, MK				Saha, Gouranga; Sarkar, Sibani; Mohanta, Partha S.; Kumar, Krishna; Chakrabarti, Saikat; Basu, Malini; Ghosh, Mrinal K.			USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITORS; APOPTOSIS PROTEIN XIAP; X-LINKED INHIBITOR; CELL-DEATH; EXPRESSION; RESISTANCE; FAMILY; HAUSP; OVEREXPRESSION; CARCINOMA	Ubiquitin specific peptidase 7 (USP7) is a deubiquitinating enzyme (DUB) that removes ubiquitin tags from specific target protein substrates in order to alter their degradation rate, sub-cellular localization, interaction, and activity. The induction of apoptosis upon USP7 inhibition is well established in cancer containing wild type p53, which operates through the 'USP7-Mdm2-p53' axis. However, in cancers without functional p53, USP7-dependent apoptosis is induced through many other alternative pathways. Here, we have identified another critical p53 independent path active under USP7 to regulate apoptosis. Proteomics analysis identifies XIAP as a potential target of USP7-dependent deubiquitination. GSEA analysis revealed up-regulation of apoptosis signalling upon USP7 inhibition associated with XIAP down-regulation. Modulation of USP7 expression and activity in multiple cancer cell lines showed that USP7 deubiquitinates XIAP to inhibit apoptosis in a caspase-dependent pathway, and the combinatorial inhibition of USP7 and XIAP induces apoptosis in vitro and in vivo. Immunohistochemical staining revealed that grade-wise accumulation of USP7 correlated with an elevated level of XIAP in glioma tissue. This is the first report on the identification and validation of XIAP as a novel substrate of USP7 and together, they involve in the empowerment of the tumorigenic potential of cancer cells by inhibiting apoptosis.	[Saha, Gouranga; Sarkar, Sibani; Mohanta, Partha S.; Ghosh, Mrinal K.] Council Sci & Ind Res Indian Inst Chem Biol CSIR, Canc Biol & Inflammatory Disorder Div, TRUE Campus,CN-6,Sect 5, Kolkata 700091, India; [Saha, Gouranga; Sarkar, Sibani; Mohanta, Partha S.; Ghosh, Mrinal K.] Council Sci & Ind Res Indian Inst Chem Biol CSIR, Canc Biol & Inflammatory Disorder Div, 4 Raja SC Mullick Rd, Kolkata 700032, India; [Kumar, Krishna; Chakrabarti, Saikat] CSIR IICB, Struct Biol & Bioinformat Div, TRUE Campus,CN-6,Sect 5, Kolkata 700091, India; [Basu, Malini] Dhruba Chand Halder Coll, Dept Microbiol, South 24 Paraganas, Dakshin Barasat 743372, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Ghosh, MK (corresponding author), Council Sci & Ind Res Indian Inst Chem Biol CSIR, Canc Biol & Inflammatory Disorder Div, TRUE Campus,CN-6,Sect 5, Kolkata 700091, India.; Ghosh, MK (corresponding author), Council Sci & Ind Res Indian Inst Chem Biol CSIR, Canc Biol & Inflammatory Disorder Div, 4 Raja SC Mullick Rd, Kolkata 700032, India.	mrinal.res@gmail.com			Department of Science and Technology [DST/NM/NT/2018/105(G), EMR/2017/000992]; Focused Basic Research, CSIR, Govt. of India [FBR #31-2(274)2020-21/Bud-II]	Department of Science and Technology(Department of Science & Technology (India)); Focused Basic Research, CSIR, Govt. of India	This work is jointly supported by the Department of Science and Technology (NanoMission: DST/NM/NT/2018/105(G); SERB: EMR/2017/000992) and Focused Basic Research (FBR #31-2(274)2020-21/Bud-II), HCT & HCP-40, CSIR, Govt. of India.	Agathanggelou A, 2017, BLOOD, V130, P156, DOI 10.1182/blood-2016-12-758219; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bhattacharya S, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0012-y; Bhattacharya S, 2014, FEBS J, V281, P3061, DOI 10.1111/febs.12843; Bhowmik A, ANTISSTR2 PEPTIDE BA; Bijnsdorp IV, 2011, METHODS MOL BIOL, V731, P421, DOI 10.1007/978-1-61779-080-5_34; Carra G, 2017, ONCOTARGET, V8, P35508, DOI 10.18632/oncotarget.16348; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Cheng CD, 2013, ONCOL REP, V29, P1730, DOI 10.3892/or.2013.2342; Choi H, 2011, NAT METHODS, V8, P70, DOI [10.1038/nmeth.1541, 10.1038/NMETH.1541]; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Clague MJ, 2013, PHYSIOL REV, V93, P1289, DOI 10.1152/physrev.00002.2013; Dar A, 2013, MOL CELL BIOL, V33, P3309, DOI 10.1128/MCB.00358-13; Datta N, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1889-2; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Emery IF, 2017, J NEURO-ONCOL, V133, P47, DOI 10.1007/s11060-017-2422-z; Engel K, 2016, EMBO MOL MED, V8, P851, DOI 10.15252/emmm.201506047; Fan YH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.400; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; HE J, 1994, GENE CHROMOSOME CANC, V11, P91, DOI 10.1002/gcc.2870110205; Huang X, 2013, EMBO J, V32, P2204, DOI 10.1038/emboj.2013.133; Kategaya L, 2017, NATURE, V550, P534, DOI 10.1038/nature24006; Khare V, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1304-y; Kojima K, 2006, BLOOD, V108, P993, DOI 10.1182/blood-2005-12-5148; Krepela E, 2009, INT J ONCOL, V35, P1449, DOI 10.3892/ijo_00000464; Lee G, 2016, BIOCHEM BIOPH RES CO, V470, P181, DOI 10.1016/j.bbrc.2016.01.021; Lee YJ, 2017, ENVIRON TOXICOL, V32, P2371, DOI 10.1002/tox.22450; Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120; Lopes RB, 2007, INT J CANCER, V120, P2344, DOI 10.1002/ijc.22554; Mansouri A, 2003, ONCOL RES, V13, P399; Mellacheruvu D, 2013, NAT METHODS, V10, P730, DOI 10.1038/nmeth.2557; Min DJ, 2019, CANCER CHEMOTH PHARM, V84, P771, DOI 10.1007/s00280-019-03898-z; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Oberoi-Khanuja TK, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.311; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Qi SM, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00233; Sampath D, 2017, BLOOD, V130, P100, DOI 10.1182/blood-2017-06-786236; Sarkar M, 2017, ONCOGENE, V36, P3080, DOI 10.1038/onc.2016.449; Sarkar M, 2015, ONCOGENE, V34, P5843, DOI 10.1038/onc.2015.42; Schauer NJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62076-x; Skaar JR, 2014, NAT REV DRUG DISCOV, V13, P889, DOI 10.1038/nrd4432; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Su DX, 2018, J CLIN INVEST, V128, P4280, DOI 10.1172/JCI120518; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sung KW, 2009, J KOREAN MED SCI, V24, P605, DOI 10.3346/jkms.2009.24.4.605; Suzuki Y, 2001, J BIOL CHEM, V276, P27058, DOI 10.1074/jbc.M102415200; Tamm I, 2004, HEMATOL J, V5, P489, DOI 10.1038/sj.thj.6200549; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; WANG LB, 2021, CANCER RES, V81; Wang Q, 2016, J CLIN INVEST, V126, P2205, DOI 10.1172/JCI85747; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhang Y, 2018, CANCERS, V10, DOI 10.3390/cancers10090297; Zhou Z, 2017, EBIOMEDICINE, V15, P48, DOI 10.1016/j.ebiom.2016.12.014	57	1	1	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2022	41	47					5061	5075		10.1038/s41388-022-02486-5	http://dx.doi.org/10.1038/s41388-022-02486-5		OCT 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	6H3BD	36243803	Bronze			2022-12-17	WOS:000869205700002
J	Ligumsky, H; Merenbakh-Lamin, K; Keren-Khadmy, N; Wolf, I; Rubinek, T				Ligumsky, Hagai; Merenbakh-Lamin, Keren; Keren-Khadmy, Noa; Wolf, Ido; Rubinek, Tami			The role of alpha-klotho in human cancer: molecular and clinical aspects	ONCOGENE			English	Review							NF-KAPPA-B; CELL LUNG-CANCER; TUMOR-SUPPRESSOR; OVARIAN-CANCER; BREAST-CANCER; EXPRESSION; GROWTH; INFLAMMATION; GENE; IDENTIFICATION	Klotho is a well-established longevity hormone. Its most prominent function is the regulation of phosphate homeostasis. However, klotho possesses multiple pleiotropic activities, including inhibition of major signaling pathways, reducing oxidative stress and suppressing inflammation. These activities are tightly associated with cancer, and klotho was discovered as a universal tumor suppressor. We review here novel molecular aspects of klotho activity in cancer, focusing on its structure-function relationships and clinical aspects regarding its expression, blood levels, clinical risk, and prognostic value in the clinical setting. In addition, the potential benefit of klotho treatment combined with chemotherapy, biological therapy, or immunotherapy, are discussed. Finally, as klotho was shown in preclinical models to inhibit cancer development and growth, we discuss various approaches to developing klotho-based therapies.	[Ligumsky, Hagai; Merenbakh-Lamin, Keren; Keren-Khadmy, Noa; Wolf, Ido; Rubinek, Tami] Tel Aviv Sourasky Med Ctr, Oncol Div, Tel Aviv, Israel; [Ligumsky, Hagai; Wolf, Ido; Rubinek, Tami] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Rubinek, T (corresponding author), Tel Aviv Sourasky Med Ctr, Oncol Div, Tel Aviv, Israel.; Rubinek, T (corresponding author), Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.	tamarru@tlvmc.gov.il			Tova and Sami Sagol Foundation	Tova and Sami Sagol Foundation	The research leading to this work has received funding supported by Tova and Sami Sagol Foundation.	Abramovitz L, 2011, CLIN CANCER RES, V17, P4254, DOI 10.1158/1078-0432.CCR-10-2749; Allaoui R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13050; Rubinstein TA, 2021, CANCERS, V13, DOI 10.3390/cancers13246297; Arbour KC, 2018, J CLIN ONCOL, V36, P2872, DOI 10.1200/JCO.2018.79.0006; Brownstein CA, 2008, P NATL ACAD SCI USA, V105, P3455, DOI 10.1073/pnas.0712361105; Camilli TC, 2011, PIGM CELL MELANOMA R, V24, P175, DOI 10.1111/j.1755-148X.2010.00792.x; Cha SK, 2008, P NATL ACAD SCI USA, V105, P9805, DOI 10.1073/pnas.0803223105; Chakravarthy A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06654-8; Chang B, 2012, ONCOL REP, V28, P1022, DOI 10.3892/or.2012.1865; Chen B, 2018, J CANCER, V9, P1248, DOI 10.7150/jca.23967; Chen B, 2012, CANCER BIOL THER, V13, P1221, DOI 10.4161/cbt.21420; Chen B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-99; Chen CD, 2007, P NATL ACAD SCI USA, V104, P19796, DOI 10.1073/pnas.0709805104; Chen CD, 2020, FASEB J, V34, P7234, DOI 10.1096/fj.202000171R; Chen CD, 2018, J MOL NEUROSCI, V64, P175, DOI 10.1007/s12031-017-1011-0; Chen GZ, 2018, NATURE, V553, P461, DOI 10.1038/nature25451; Chen JL, 2018, HYPERTENSION, V71, P877, DOI 10.1161/HYPERTENSIONAHA.117.10560; Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005; Dalton GD, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00323; Delcroix V, 2018, CANCERS, V10, DOI 10.3390/cancers10110439; Doi S, 2011, J BIOL CHEM, V286, P8655, DOI 10.1074/jbc.M110.174037; Drakaki A, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1824645; Fakhar M, 2022, ARCH BIOCHEM BIOPHYS, V719, DOI 10.1016/j.abb.2022.109171; Gigante M, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001917; Guo Y, 2018, BBA-MOL BASIS DIS, V1864, P238, DOI 10.1016/j.bbadis.2017.09.029; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heijboer AC, 2013, NEPHROL DIAL TRANSPL, V28, P2283, DOI 10.1093/ndt/gft236; Hui HP, 2017, ONCOTARGET, V8, P15663, DOI 10.18632/oncotarget.14933; Imura A, 2007, SCIENCE, V316, P1615, DOI 10.1126/science.1135901; Jiang B, 2014, CANCER INVEST, V32, P218, DOI 10.3109/07357907.2014.905586; Jorge LB, 2019, AM J PHYSIOL-RENAL, V316, pF438, DOI 10.1152/ajprenal.00625.2017; Kartolo A, 2021, J IMMUNOTHER, V44, P167, DOI 10.1097/CJI.0000000000000360; King GD, 2012, AGE, V34, P1405, DOI 10.1007/s11357-011-9315-4; King GD, 2012, BIOCHEM J, V441, P453, DOI 10.1042/BJ20101909; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lee J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-109; Li QG, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0241-2; Li XX, 2014, INT J ONCOL, V45, P611, DOI 10.3892/ijo.2014.2430; Ligumsky H, 2015, MOL CANCER RES, V13, P1398, DOI 10.1158/1541-7786.MCR-15-0141; Liu C, 2015, INT J CLIN EXP PATHO, V8, P7446; Liu F, 2011, NAT CELL BIOL, V13, P254, DOI 10.1038/ncb2167; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; Lojkin I, 2015, CANCER LETT, V362, P149, DOI 10.1016/j.canlet.2015.03.035; Lu L, 2008, CANCER INVEST, V26, P185, DOI 10.1080/07357900701638343; Madathil SV, 2014, AM J PATHOL, V184, P827, DOI 10.1016/j.ajpath.2013.11.016; Mao XQ, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01428-1; Masso A, 2018, MOL PSYCHIATR, V23, DOI 10.1038/mp.2017.211; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; Mazzotta C, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1233-0; Okada S, 2000, INT IMMUNOL, V12, P861, DOI 10.1093/intimm/12.6.861; Pako J, 2020, PATHOL ONCOL RES, V26, P233, DOI 10.1007/s12253-018-0441-5; Pan J, 2011, TUMOR BIOL, V32, P729, DOI 10.1007/s13277-011-0174-5; Pawlikowski M, 2019, ENDOKRYNOL POL, V70, P237, DOI 10.5603/EP.a2019.0004; Peshes-Yeloz N, 2019, WORLD NEUROSURG, V130, pE324, DOI 10.1016/j.wneu.2019.06.082; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rassy E, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920907504; Rubinek T, 2016, VITAM HORM, V101, P197, DOI 10.1016/bs.vh.2016.03.001; Rubinek T, 2012, BREAST CANCER RES TR, V133, P649, DOI 10.1007/s10549-011-1824-4; Rubinstein TA, 2019, ONCOGENE, V38, P794, DOI 10.1038/s41388-018-0489-4; Scott SC, 2018, J THORAC ONCOL, V13, P1771, DOI 10.1016/j.jtho.2018.06.004; Shimada T, 2004, CIRCULATION, V110, P1148, DOI 10.1161/01.CIR.0000139854.74847.99; Shmulevich R, 2020, ONCOGENE, V39, P4636, DOI 10.1038/s41388-020-1313-5; Shu GS, 2013, CELL ONCOL, V36, P121, DOI 10.1007/s13402-012-0118-0; Sun HD, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0717-0; Suvannasankha A, 2015, ONCOTARGET, V6, P19647, DOI 10.18632/oncotarget.3794; Takegahara K, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12679; Tang X, 2016, DIS ESOPHAGUS, V29, P207, DOI 10.1111/dote.12289; Tang XW, 2016, LAB INVEST, V96, P197, DOI 10.1038/labinvest.2015.86; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Tohyama O, 2004, J BIOL CHEM, V279, P9777, DOI 10.1074/jbc.M312392200; Usuda J, 2011, LUNG CANCER, V74, P332, DOI 10.1016/j.lungcan.2011.03.004; Usuda J, 2011, LUNG CANCER, V72, P355, DOI 10.1016/j.lungcan.2010.10.008; Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5; Wang LJ, 2011, AM J CANCER RES, V1, P111; Wang XL, 2011, ONCOL REP, V25, P1465, DOI 10.3892/or.2011.1178; Witkowski JM, 2007, J IMMUNOL, V178, P771, DOI 10.4049/jimmunol.178.2.771; Wolf I, 2010, ONCOGENE, V29, P26, DOI 10.1038/onc.2009.301; Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292; Wu Q, 2021, CANCER MANAG RES, V13, P4791, DOI 10.2147/CMAR.S295086; Wu XL, 2008, J BIOL CHEM, V283, P33304, DOI 10.1074/jbc.M803319200; Xie BA, 2016, ONCOTARGET, V7, P80765, DOI 10.18632/oncotarget.12623; Xie BA, 2013, HUM PATHOL, V44, P795, DOI 10.1016/j.humpath.2012.07.023; Xie B, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-18; Yan YL, 2017, MOL MED REP, V15, P1777, DOI 10.3892/mmr.2017.6172; Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963; Yuan Q, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28096-z; Zhou XX, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0391-5; Zhou YM, 2017, PHARMAZIE, V72, P227, DOI 10.1691/ph.2017.6867; Zhu WS, 2019, AGING-US, V11, P5246, DOI 10.18632/aging.102121; Zhu Y, 2013, CANCER SCI, V104, P663, DOI 10.1111/cas.12134; Zhu Y, 2019, CANCER MANAG RES, V11, P1383, DOI 10.2147/CMAR.S188415	93	1	1	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2022	41	40					4487	4497		10.1038/s41388-022-02440-5	http://dx.doi.org/10.1038/s41388-022-02440-5		AUG 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4Z8CT	36038662				2022-12-17	WOS:000847262000003
J	Du, QY; Huo, FC; Du, WQ; Sun, XL; Jiang, X; Zhang, LS; Pei, DS				Du, Qiu-Ying; Huo, Fu-Chun; Du, Wen-Qi; Sun, Xiao-Lin; Jiang, Xin; Zhang, Lan-Sheng; Pei, Dong-Sheng			METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM; DISULFIDE-ISOMERASE; LUNG-CANCER; EXPRESSION; APOPTOSIS; PROTEIN; CARCINOMA; ETS-1; TRANSCRIPTION; INVOLVEMENT	N6-methyladenosine (m6A) is the most abundant chemical modification on mRNA and plays significant roles in many bioprocesses. However, the functions of m6A on cervical cancer (CC) tumorigenesis remain unclear. Here we found methyltransferase-like 3 (METTL3), a core member of the m6A methyltransferase family, was greatly upregulated as an independent prognostic factor in CC. Mechanistically, the transcription factor ETS1 recruited P300 and WDR5 which separately mediated H3K27ac and H3K4me3 histone modification in the promoter of METTL3 and induced METTL3 transcription activation. Furthermore, we identified TXNDC5 as a target of METTL3-mediated m6A modification through MeRIP-seq, and revealed that METTL3-mediated TXNDC5 expression relied on the m6A reader-dependent manner. Functionally, we verified that METTL3 promoted proliferation and metastasis of CC cells by regulating of TXNDC5 expression through in vitro and in vivo experiments. In addition, our study verified the effect of METTL3/TXNDC5 axis on ER stress. Taken together, METTL3 facilitates the malignant progression of CC, suggesting that METTL3 might be a potential prognostic biomarker and therapeutic target for CC.	[Du, Qiu-Ying; Huo, Fu-Chun; Du, Wen-Qi; Sun, Xiao-Lin; Jiang, Xin; Pei, Dong-Sheng] Xuzhou Med Univ, Dept Pathol, 209 Tong Shan Rd, Xuzhou 221004, Jiangsu, Peoples R China; [Zhang, Lan-Sheng] Xuzhou Med Univ, Affiliated Hosp 2, Dept Oncol Radiotherapy, Xuzhou, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University	Pei, DS (corresponding author), Xuzhou Med Univ, Dept Pathol, 209 Tong Shan Rd, Xuzhou 221004, Jiangsu, Peoples R China.; Zhang, LS (corresponding author), Xuzhou Med Univ, Affiliated Hosp 2, Dept Oncol Radiotherapy, Xuzhou, Jiangsu, Peoples R China.	lanshengyan@163.com; dspei@xzhmu.edu.cn			National Natural Science Foundation of China [81872080]; Jiangsu Provincial Medical Talent [ZDRCA2016055]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Medical Talent	This work was supported by the National Natural Science Foundation of China (No.81872080), Jiangsu Provincial Medical Talent (ZDRCA2016055).	Beacon TH, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01126-1; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Biancotto C, 2010, ADV GENET, V70, P341, DOI [10.1016/B978-0-12-380866-0.60013-7, 10.1016/S0065-2660(10)70013-4]; Chawsheen HA, 2019, J BIOL CHEM, V294, P8991, DOI 10.1074/jbc.RA118.005804; Chen X, 2021, INT IMMUNOPHARMACOL, V95, DOI 10.1016/j.intimp.2021.107519; Datan E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.409; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Du QY, 2021, INVEST NEW DRUG, V39, P1682, DOI 10.1007/s10637-021-01148-9; Froimchuk E, 2017, GENE, V627, P337, DOI 10.1016/j.gene.2017.06.056; Funkner A, 2013, J MOL BIOL, V425, P1340, DOI 10.1016/j.jmb.2013.01.029; Hasanain M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.219; Horna-Terron E, 2014, INT J MOL SCI, V15, P23501, DOI 10.3390/ijms151223501; Jorgensen MM, 2003, APMIS, V111, P86; Kojima R, 2014, STRUCTURE, V22, P431, DOI 10.1016/j.str.2013.12.013; Kumar P, 2009, HYPERTENSION, V54, P172, DOI 10.1161/HYPERTENSIONAHA.109.133033; Lee CG, 2012, J IMMUNOL, V188, P2244, DOI 10.4049/jimmunol.1101614; Li Jian, 2017, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V34, P448, DOI 10.3760/cma.j.issn.1003-9406.2017.03.031; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Li X, 2017, ONCOTARGET, V8, P96103, DOI 10.18632/oncotarget.21726; Lin Y, 2020, CANCER MED-US, V9, P2859, DOI 10.1002/cam4.2918; Liu JY, 2020, ONCOTARGETS THER, V13, P11957, DOI 10.2147/OTT.S276559; Liu K, 2016, CURR PROTEIN PEPT SC, V17, P306, DOI 10.2174/1389203716666150901113553; Liu SP, 2020, AM J CANCER RES, V10, P1631; Liu SP, 2020, AM J CANCER RES, V10, P1068; Lu MJ, 2020, NAT MICROBIOL, V5, P584, DOI 10.1038/s41564-019-0653-9; Luo GY, 2020, J CELL PHYSIOL, V235, P7107, DOI 10.1002/jcp.29608; Lopez AM, 2021, GENES-BASEL, V12, DOI 10.3390/genes12071019; Matsusaki M, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2019.04.003; Park MS, 2013, ANTICANCER RES, V33, P3983; Pecoraro A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197334; Peng FS, 2018, MOL MED REP, V17, P4767, DOI 10.3892/mmr.2018.8376; Ren Tao-wen, 2009, Zhonghua Zhong Liu Za Zhi, V31, P674; Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002; Shen CQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01190-w; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Song SL, 2017, J CELL PHYSIOL, V232, P2977, DOI 10.1002/jcp.25785; Sullivan DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200; Sun T, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108613; Tan FB, 2018, INT J MOL MED, V42, P935, DOI 10.3892/ijmm.2018.3664; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; Tong JY, 2018, FRONT MED-PRC, V12, P481, DOI 10.1007/s11684-018-0654-8; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang L, 2015, ONCOGENE, V34, P4735, DOI 10.1038/onc.2014.401; Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl-2019-319639; Wang QQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03071-y; Wang TY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01204-7; Wang XL, 2017, ONCOTARGET, V8, P98918, DOI 10.18632/oncotarget.22041; Wei WW, 2019, CANCER MANAG RES, V11, P1177, DOI 10.2147/CMAR.S181058; Xu B, 2017, ONCOTARGET, V8, P91009, DOI 10.18632/oncotarget.18857; Xu J, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009530; Xu Y, 2015, MOL MED REP, V11, P189, DOI 10.3892/mmr.2014.2683; Yan JJ, 2020, BIOCHEM BIOPH RES CO, V521, P887, DOI 10.1016/j.bbrc.2019.11.016; Yang YX, 2020, J CELL MOL MED, V24, P2772, DOI 10.1111/jcmm.15030; Yue B, 2021, MOL THER-NUCL ACIDS, V26, P458, DOI 10.1016/j.omtn.2021.08.019; Zeng CW, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00951-w; Zhao W, 2020, MOL THER-NUCL ACIDS, V20, P1, DOI 10.1016/j.omtn.2020.01.033; Zhu LY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1585-2; Zou DL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1045-1	58	1	1	13	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2022	41	39					4420	4432		10.1038/s41388-022-02435-2	http://dx.doi.org/10.1038/s41388-022-02435-2		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4S3XC	35987795				2022-12-17	WOS:000843263800001
J	Peng, HY; Nerreter, T; Mestermann, K; Wachter, J; Chang, J; Hudecek, M; Rader, C				Peng, Haiyong; Nerreter, Thomas; Mestermann, Katrin; Wachter, Jakob; Chang, Jing; Hudecek, Michael; Rader, Christoph			ROR1-targeting switchable CAR-T cells for cancer therapy	ONCOGENE			English	Article							ANTIBODY-LIKE IMMUNORECEPTORS; CHIMERIC ANTIGEN RECEPTORS; AFFINITY; ROR1; TARGET; ACTIVATION; EXPRESSION; DESIGN; DOMAIN; RECRUITMENT	The success of chimeric antigen receptor T cell (CAR-T) therapy in the treatment of hematologic malignancies has prompted the development of numerous CAR-T technologies, including switchable CAR-T (sCAR-T) systems that combine a universal CAR-T with bispecific adapter proteins. Owing to their controllability and versatility, sCAR-Ts have received considerable attention. To explore the therapeutic utility of sCAR-Ts targeting the receptor tyrosine kinase ROR1, which is expressed in hematologic and solid malignancies, and to identify bispecific adaptor proteins that efficiently mediate universal CAR-T engagement, a panel of switches based on ROR1-targeting Fabs with different epitopes and affinities was compared in in vitro and in vivo models of ROR1-expressing cancers. For switches targeting overlapping or identical epitopes, potency correlated with affinity. Surprisingly, however, we identified a switch targeting a unique epitope with low affinity but mediating potent and selective antitumor activity in vitro and in vivo. Converted to a conventional CAR-T, the same anti-ROR1 mAb (324) outperformed a clinically investigated conventional CAR-T that is based on an anti-ROR1 mAb (R12) with similar to 200-fold higher affinity. Thus, demonstrating therapeutic utility on their own, sCAR-Ts also facilitate higher throughput screening for the identification of conventional CAR-T candidates for preclinical and clinical studies.	[Peng, Haiyong; Chang, Jing; Rader, Christoph] Univ Florida, Dept Immunol & Microbiol, UF Scripps Biomed Res, Jupiter, FL 33458 USA; [Nerreter, Thomas; Mestermann, Katrin; Wachter, Jakob; Hudecek, Michael] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Oberclurrbacher Str 6, D-97080 Wurzburg, Germany	State University System of Florida; University of Florida; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg	Peng, HY; Rader, C (corresponding author), Univ Florida, Dept Immunol & Microbiol, UF Scripps Biomed Res, Jupiter, FL 33458 USA.	h.peng@ufl.edu; c.rader@ufl.edu		peng, haiyong/0000-0003-0312-1337; Rader, Christoph/0000-0001-9955-3454	National Institutes of Health (NIH) [R01 CA174844, R01 CA181258, R01 CA204484, R21 CA229961, R21 CA263240]; Klorfine Foundation	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Klorfine Foundation	CR acknowledges support by National Institutes of Health (NIH) grants R01 CA174844, R01 CA181258, R01 CA204484, R21 CA229961, and R21 CA263240, and by the Klorfine Foundation.	Acevedo-Rocha CG, 2015, SCI REP-UK, V5, DOI 10.1038/srep10654; Arndt C, 2020, CANCERS, V12, DOI 10.3390/cancers12051302; Balakrishnan A, 2017, CLIN CANCER RES, V23, P3061, DOI 10.1158/1078-0432.CCR-16-2083; Baskar S, 2008, CLIN CANCER RES, V14, P396, DOI 10.1158/1078-0432.CCR-07-1823; Benmebarek MR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061283; Berger C, 2015, CANCER IMMUNOL RES, V3, P206, DOI 10.1158/2326-6066.CIR-14-0163; Cao Y, 2016, ANGEW CHEM INT EDIT, V55, P7520, DOI 10.1002/anie.201601902; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Chmielewski M, 2004, J IMMUNOL, V173, P7647, DOI 10.4049/jimmunol.173.12.7647; Cho JH, 2018, CELL, V173, P1426, DOI 10.1016/j.cell.2018.03.038; Choi MY, 2018, CELL STEM CELL, V22, P951, DOI 10.1016/j.stem.2018.05.018; Dana H, 2021, ACTA PHARM SIN B, V11, P1129, DOI 10.1016/j.apsb.2020.10.020; Darowski D, 2019, MABS-AUSTIN, V11, P621, DOI 10.1080/19420862.2019.1596511; Dave H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052655; Depil S, 2020, NAT REV DRUG DISCOV, V19, P185, DOI 10.1038/s41573-019-0051-2; Feins S, 2019, AM J HEMATOL, V94, pS3, DOI 10.1002/ajh.25418; Ghorashian S, 2019, NAT MED, V25, P1408, DOI 10.1038/s41591-019-0549-5; Goydel RS, 2020, J BIOL CHEM, V295, P5995, DOI 10.1074/jbc.RA120.012791; Greenman R, 2021, MOL CANCER THER, V20, P872, DOI 10.1158/1535-7163.MCT-19-1109; Hojjat-Farsangi M, 2014, SEMIN CANCER BIOL, V29, P21, DOI 10.1016/j.semcancer.2014.07.005; Hombach AA, 2007, J IMMUNOL, V178, P4650, DOI 10.4049/jimmunol.178.7.4650; Hong MH, 2020, CANCER CELL, V38, P473, DOI 10.1016/j.ccell.2020.07.005; Hoyos V, 2010, LEUKEMIA, V24, P1160, DOI 10.1038/leu.2010.75; Hudecek M, 2015, CANCER IMMUNOL RES, V3, P125, DOI 10.1158/2326-6066.CIR-14-0127; Hudecek M, 2013, CLIN CANCER RES, V19, P3153, DOI 10.1158/1078-0432.CCR-13-0330; Hudecek M, 2010, BLOOD, V116, P4532, DOI 10.1182/blood-2010-05-283309; Jayaraman J, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102931; Jensen MC, 2015, CURR OPIN IMMUNOL, V33, P9, DOI 10.1016/j.coi.2015.01.002; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kamrani A, 2019, EXPERT OPIN THER TAR, V23, P447, DOI 10.1080/14728222.2019.1602608; Labanieh L, 2022, CELL, V185, P1745, DOI 10.1016/j.cell.2022.03.041; Larson RC, 2021, NAT REV CANCER, V21, P145, DOI 10.1038/s41568-020-00323-z; Lee YG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10565-7; Lindner SE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz3223; Liu XJ, 2015, CANCER RES, V75, P3596, DOI 10.1158/0008-5472.CAN-15-0159; Menck K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010142; Minutolo NG, 2020, J AM CHEM SOC, V142, P6554, DOI 10.1021/jacs.9b11622; Minutolo NG, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00176; Nerreter T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10948-w; Peng Haiyong, 2021, Antib Ther, V4, P222, DOI 10.1093/abt/tbab023; Peng H, 2017, J MOL BIOL, V429, P2954, DOI 10.1016/j.jmb.2017.08.003; Picanco-Castro V, 2020, METHODS MOL BIOL, V2086, P1, DOI 10.1007/978-1-0716-0146-4_1; Qi JP, 2020, ANGEW CHEM INT EDIT, V59, P12178, DOI 10.1002/anie.202005432; Qi JP, 2018, P NATL ACAD SCI USA, V115, pE5467, DOI 10.1073/pnas.1719905115; Raj D, 2019, GUT, V68, P1052, DOI 10.1136/gutjnl-2018-316595; Rennert P, 2019, BLOOD, V134, DOI 10.1182/blood-2019-130654; Rodgers DT, 2016, P NATL ACAD SCI USA, V113, pE459, DOI 10.1073/pnas.1524155113; Sahillioglu AC, 2022, CURR OPIN IMMUNOL, V74, P190, DOI 10.1016/j.coi.2021.07.002; Schmid DA, 2010, J IMMUNOL, V184, P4936, DOI 10.4049/jimmunol.1000173; Shabani M, 2015, EXPERT OPIN THER TAR, V19, P941, DOI 10.1517/14728222.2015.1025753; Srivastava S, 2021, CANCER CELL, V39, P193, DOI 10.1016/j.ccell.2020.11.005; Srivastava S, 2019, CANCER CELL, V35, P489, DOI 10.1016/j.ccell.2019.02.003; Townsend MH, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0817-0; Viaud S, 2018, P NATL ACAD SCI USA, V115, pE10898, DOI 10.1073/pnas.1810060115; Wang ML., 2022, N ENGL J MED EVID, V1, P1; Wang XL, 2011, BLOOD, V118, P1255, DOI 10.1182/blood-2011-02-337360; Wu CY, 2015, SCIENCE, V350, DOI 10.1126/science.aab4077; Yam PY, 2002, MOL THER, V5, P479, DOI 10.1006/mthe.2002.0558; Yang JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021018; Zahnd C, 2004, J BIOL CHEM, V279, P18870, DOI 10.1074/jbc.M309169200; Zhao YM, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.680834	63	1	1	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2022	41	34					4104	4114		10.1038/s41388-022-02416-5	http://dx.doi.org/10.1038/s41388-022-02416-5			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3W0LE	35859167				2022-12-17	WOS:000842046700005
J	Wei, LY; Wang, WT; Yao, JX; Cui, ZY; Xu, ZH; Ding, HQ; Wu, XJ; Wang, DH; Luo, J; Ke, ZJ				Wei, Luyao; Wang, Wantao; Yao, Junxia; Cui, Zhengyu; Xu, Zihang; Ding, Hanqing; Wu, Xiaojun; Wang, Deheng; Luo, Jia; Ke, Zun-Ji			PACT promotes the metastasis of basal-like breast cancer through Rac1 SUMOylation and activation	ONCOGENE			English	Article							RNA-BINDING PROTEIN; MOLECULAR PORTRAITS; THERAPEUTIC TARGET; EXPRESSION; KINASE; UBC9; GENE; PKR; GTPASES; SUMO	Most basal-like breast cancers (BLBCs) are triple-negative breast cancers (TNBCs), which is associated with high malignancy, high rate of recurrence and distant metastasis, and poor prognosis among all types of breast cancer. However, there are currently no effective therapies for BLBC. Furthermore, chemoresistance limits the therapeutic options for BLBC treatment. In this study, we screen out protein activator of the interferon-induced protein kinase (PACT) as an essential gene in BLBC metastasis. We find that high PACT expression level was associated with poor prognosis among BLBC patients. In vivo and in vitro investigations indicated that PACT could regulate BLBC metastasis by interacting with SUMO-conjugating enzyme Ubc9 to stimulate the SUMOylation and thus consequently the activation of Rac1. BLBC patients receiving chemotherapy presents poorer prognosis with PACT high expression, and PACT disruption sensitizes experimental mammary tumor metastases to chemotherapy, thus providing insights to consider PACT as a potential therapeutic target to overcome acquired chemoresistance in BLBC.	[Wei, Luyao; Wang, Wantao; Ding, Hanqing; Wang, Deheng; Ke, Zun-Ji] Shanghai Univ Tradit Chinese Med, Acad Integrat Med, Dept Biochem, Shanghai Key Lab Hlth Identificat & Assessment, 1200 Cailun Rd, Shanghai 201203, Peoples R China; [Yao, Junxia] Fudan Univ, Dept Pathol, Qingpu Branch, Zhongshan Hosp, 1158 Gongyuan Rd, Shanghai 201700, Peoples R China; [Cui, Zhengyu] Tongji Univ, Shanghai East Hosp, Dept Internal Med Tradit Chinese Med, Sch Med, Shanghai 200120, PR, Peoples R China; [Xu, Zihang] Shanghai Univ Tradit Chinese Med, Sch Basic Med Sci, Dept Internal Class Med, 1200 Cailun Rd, Shanghai 201203, Peoples R China; [Wu, Xiaojun] Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, Shanghai Key Lab Compound Chinese Med, 1200 Cailun Rd, Shanghai 201203, PR, Peoples R China; [Luo, Jia] Univ Iowa, Dept Pathol, Carver Coll Med, 51 Newton Rd, Iowa City, IA 52242 USA	Shanghai University of Traditional Chinese Medicine; Fudan University; Tongji University; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; University of Iowa	Ke, ZJ (corresponding author), Shanghai Univ Tradit Chinese Med, Acad Integrat Med, Dept Biochem, Shanghai Key Lab Hlth Identificat & Assessment, 1200 Cailun Rd, Shanghai 201203, Peoples R China.	kezunji@shutcm.edu.cn	Ke, Zun-Ji/E-4822-2010	Ke, Zun-Ji/0000-0003-4038-2456	National Natural Science Foundation of China [31701217, 31570921]; Shanghai Key Laboratory of Health Identification and Assessment [13DZ2261000]; Shanghai Municipal Commission of Health and Family Planning [201540206]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Key Laboratory of Health Identification and Assessment; Shanghai Municipal Commission of Health and Family Planning	This research was supported by the National Natural Science Foundation of China (31701217 to LW, and 31570921 to ZJK), Shanghai Key Laboratory of Health Identification and Assessment (13DZ2261000), Shanghai Municipal Commission of Health and Family Planning (201540206 to ZJK).	Garcia MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023887; Bennett RL, 2008, MECH DEVELOP, V125, P777, DOI 10.1016/j.mod.2008.06.009; Bennett RL, 2006, BLOOD, V108, P821, DOI 10.1182/blood-2005-11-006817; Bennett RL, 2012, CELL CYCLE, V11, P407, DOI 10.4161/cc.11.2.18999; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bristow JM, 2009, J CELL SCI, V122, P4535, DOI 10.1242/jcs.053728; Cannon AC, 2020, TRENDS CANCER, V6, P478, DOI 10.1016/j.trecan.2020.02.021; Castillo-Lluva S, 2010, NAT CELL BIOL, V12, P1078, DOI 10.1038/ncb2112; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Chiosea S, 2008, BIOMARK INSIGHTS, V3, P253; DepMap Broad, 2021, DEPMAP 21Q3 PUBL FIG; Dickerman BK, 2015, FEBS J, V282, P4766, DOI 10.1111/febs.13533; Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437; Dokmanovic M, 2009, MOL CANCER THER, V8, P1557, DOI 10.1158/1535-7163.MCT-09-0140; Dunnebier T, 2010, BREAST CANCER RES TR, V121, P185, DOI 10.1007/s10549-009-0530-y; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hisamatsu T, 2019, MOL CANCER THER, V18, P162, DOI 10.1158/1535-7163.MCT-17-1050; Ho CW, 2011, J BIOL CHEM, V286, P21826, DOI 10.1074/jbc.M111.234914; Huang X, 2002, BIOCHEM J, V366, P175, DOI 10.1042/BJ20020204; Jiang YZ, 2019, CANCER CELL, V35, P428, DOI 10.1016/j.ccell.2019.02.001; Jin X, 2020, NATURE, V588, P331, DOI 10.1038/s41586-020-2969-2; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Li H, 2013, ONCOL REP, V29, P1588, DOI 10.3892/or.2013.2268; Li QJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15308-7; Liu Y, 2017, MOL THER, V25, P666, DOI 10.1016/j.ymthe.2016.12.021; Lorente M, 2019, J CELL SCI, V132, DOI 10.1242/jcs.234120; Mack NA, 2011, CELL CYCLE, V10, P1571, DOI 10.4161/cc.10.10.15612; Marei Hadir, 2017, Small GTPases, V8, P139, DOI 10.1080/21541248.2016.1211398; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Mullany LE, 2016, BMC MED GENOMICS, V9, DOI 10.1186/s12920-016-0181-x; Pan YL, 2004, BIOCHEM BIOPH RES CO, V315, P686, DOI 10.1016/j.bbrc.2004.01.108; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Peidis P, 2011, CELL DEATH DIFFER, V18, P145, DOI 10.1038/cdd.2010.76; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Peters GA, 2009, P NATL ACAD SCI USA, V106, P10696, DOI 10.1073/pnas.0900735106; Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Reijnders MRF, 2017, AM J HUM GENET, V101, P466, DOI 10.1016/j.ajhg.2017.08.007; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rios AC, 2019, CANCER CELL, V35, P618, DOI 10.1016/j.ccell.2019.02.010; Rowe TM, 2006, P NATL ACAD SCI USA, V103, P5823, DOI 10.1073/pnas.0601287103; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Schwartz S, 2016, GENETICS, V203, P1249, DOI 10.1534/genetics.115.183194; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Su YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034250; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Svensmark JH, 2019, ONCOGENE, V38, P7447, DOI 10.1038/s41388-019-0963-7; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; Xu J, 2016, Int J Chronic Dis Ther, V2, P31; YONG Y, 2015, SCI REP-UK, V5; Yoon C, 2017, MOL CANCER RES, V15, P1106, DOI 10.1158/1541-7786.MCR-17-0053; Yoon CH, 2009, P NATL ACAD SCI USA, V106, P7852, DOI 10.1073/pnas.0812148106	60	1	1	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4282	4294		10.1038/s41388-022-02431-6	http://dx.doi.org/10.1038/s41388-022-02431-6		AUG 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35974143				2022-12-17	WOS:000841092200001
J	Goodsell, DS; Dutta, S; Voigt, M; Zardecki, C; Burley, SK				Goodsell, David S.; Dutta, Shuchismita; Voigt, Maria; Zardecki, Christine; Burley, Stephen K.			Molecular explorations of cancer biology and therapeutics at PDB-101	ONCOGENE			English	Editorial Material							PROTEIN DATA-BANK; MACROMOLECULES; TOOLS; HER2		[Goodsell, David S.; Dutta, Shuchismita; Voigt, Maria; Zardecki, Christine; Burley, Stephen K.] Rutgers State Univ, Res Collaboratory Struct Bioinformat Prot Data Ba, Piscataway, NJ 08854 USA; [Goodsell, David S.; Dutta, Shuchismita; Voigt, Maria; Zardecki, Christine; Burley, Stephen K.] Rutgers State Univ, Inst Quantitat Biomed, Piscataway, NJ 08854 USA; [Goodsell, David S.; Dutta, Shuchismita; Burley, Stephen K.] Rutgers State Univ, Canc Inst New Jersey, New Brunswick, NJ 08901 USA; [Goodsell, David S.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA; [Burley, Stephen K.] Univ Calif, Res Collaboratory Struct Bioinformat Prot Data Ba, San Diego Supercomp Ctr, La Jolla, CA 92093 USA; [Burley, Stephen K.] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Scripps Research Institute; University of California System; University of California San Diego; Rutgers State University New Brunswick	Zardecki, C (corresponding author), Rutgers State Univ, Res Collaboratory Struct Bioinformat Prot Data Ba, Piscataway, NJ 08854 USA.; Zardecki, C (corresponding author), Rutgers State Univ, Inst Quantitat Biomed, Piscataway, NJ 08854 USA.	christine.zardecki@rcsb.org		zardecki, christine/0000-0002-4149-1745	National Science Foundation [DBI-1832184]; US Department of Energy [DE-SC0019749]; National Cancer Institute of the National Institutes of Health [R01GM133198]; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01GM133198]; National Institute of General Medical Sciences of the National Institutes of Health [R01GM133198]	National Science Foundation(National Science Foundation (NSF)); US Department of Energy(United States Department of Energy (DOE)); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the students who participated in the 9th Annual IQB Winter Boot Camp and the 2022 PDB101 Video Challenge. RCSB PDB core operations are jointly funded by the National Science Foundation (DBI-1832184, PI: SKB), the US Department of Energy (DE-SC0019749, PI: SKB), and the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Institute of General Medical Sciences of the National Institutes of Health (R01GM133198, PI: SKB).	Aertgeerts K, 2011, J BIOL CHEM, V286, P18756, DOI 10.1074/jbc.M110.206193; Ahmed F., 2022, RCSB PDB MOL MONTH, DOI [10.2210/rcsb_pdb/mom_2022_6, DOI 10.2210/RCSB_PDB/MOM_2022_6]; Bank P. D., 1971, NATURE-NEW BIOL, V233, P223, DOI [DOI 10.1038/NEWBIO233223B0, 10.1038/newbio233223a0, DOI 10.1038/NEWBIO233223A0]; Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Brooks L., 2022, RCSB PDB MOL MONTH, DOI [10.2210/rcsb_pdb/mom_2022_8, DOI 10.2210/RCSB_PDB/MOM_2022_8]; Burley SK, 2022, PROTEIN SCI, V31, P187, DOI 10.1002/pro.4213; Burley SK, 2021, NUCLEIC ACIDS RES, V49, pD437, DOI 10.1093/nar/gkaa1038; Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD520, DOI 10.1093/nar/gky949; Cartagena E., 2022, RCSB PDB MOL MONTH, DOI [10.2210/rcsb_pdb/mom_2022_3, DOI 10.2210/RCSB_PDB/MOM_2022_3]; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Choudhry K., 2022, RCSB PDB MOL MONTH, DOI [10.2210/rcsb_pdb/mom_2022_5, DOI 10.2210/RCSB_PDB/MOM_2022_5]; De Leon Cruz S, 2022, HER2 NEU TRASTUZUMAB, DOI [10.2210/rcsb_pdb/mom_2022_4, DOI 10.2210/RCSB_PDB/MOM_2022_4]; Diaz-Figueroa G., 2022, RCSB PDB MOL MONTH, DOI [10.2210/rcsb_pdb/mom_2022_7, DOI 10.2210/RCSB_PDB/MOM_2022_7]; Mineev KS, 2010, J MOL BIOL, V400, P231, DOI 10.1016/j.jmb.2010.05.016; Westbrook JD, 2020, DRUG DISCOV TODAY, V25, P837, DOI 10.1016/j.drudis.2020.02.002; Zardecki C, 2022, PROTEIN SCI, V31, P129, DOI 10.1002/pro.4200	17	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2022	41	38					4333	4335		10.1038/s41388-022-02424-5	http://dx.doi.org/10.1038/s41388-022-02424-5		AUG 2022	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4O3TC	35948649	hybrid, Green Published			2022-12-17	WOS:000838482900001
J	Wang, XH; Brea, L; Lu, XD; Gritsina, G; Park, SH; Xie, WQ; Zhao, JC; Yu, JD				Wang, Xiaohai; Brea, Lourdes; Lu, Xiaodong; Gritsina, Galina; Park, Su H.; Xie, Wanqing; Zhao, Jonathan C.; Yu, Jindan			FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A	ONCOGENE			English	Article							RESISTANT PROSTATE-CANCER; BIOCHEMICAL FAILURE; TUMOR HYPOXIA; RADIOTHERAPY; PROGRESSION; CCL2	Intratumoral hypoxia is associated with castration-resistant prostate cancer (CRPC), a lethal disease. FOXA1 is an epithelial transcription factor that is down-regulated in CRPC. We have previously reported that FOXA1 loss induces epithelial-mesenchymal transition (EMT) and cell motility through elevated TGF beta signaling. However, whether FOXA1 directly regulates hypoxia pathways of CRPC tumors has not been previously studied. Here we report that FOXA1 down-regulation induces hypoxia transcriptional programs, and FOXA1 level is negatively correlated with hypoxia markers in clinical prostate cancer (PCa) samples. Mechanistically, FOXA1 directly binds to an intragenic enhancer of HIF1A to inhibit its expression, and HIF1A, in turn, is critical in mediating FOXA1 loss-induced hypoxia gene expression. Further, we identify CCL2, a chemokine ligand that modulates tumor microenvironment and promotes cancer progression, as a crucial target of the FOXA1-HIF1A axis. We found that FOXA1 loss leads to immunosuppressive macrophage infiltration and increased cell invasion, dependent on HIF1A expression. Critically, therapeutic targeting of HIF1A-CCL2 using pharmacological inhibitors abolishes FOXA1 loss-induced macrophage infiltration and PCa cell invasion. In summary, our study reveals an essential role of FOXA1 in controlling the hypoxic tumor microenvironment and establishes the HIF1A-CCL2 axis as one mechanism of FOXA1 loss-induced CRPC progression.	[Wang, Xiaohai; Brea, Lourdes; Lu, Xiaodong; Gritsina, Galina; Park, Su H.; Xie, Wanqing; Zhao, Jonathan C.; Yu, Jindan] Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA; [Wang, Xiaohai] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Shanghai, Peoples R China; [Yu, Jindan] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Yu, Jindan] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Shanghai Jiao Tong University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine	Yu, JD (corresponding author), Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA.; Yu, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.; Yu, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu		Brea, Lourdes/0000-0001-9727-7185; Gritsina, Galina/0000-0002-3404-7961; Lu, xiaodong/0000-0003-4731-0762	NIH [P50CA180995, R50CA211271]; Prostate Cancer Foundation [2017CHAL2008]; NIH/NCI [T32 CA009560]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Prostate Cancer Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the NIH prostate SPORE P50CA180995 (to JY), NIH R50CA211271 (to JCZ), and Prostate Cancer Foundation 2017CHAL2008 (to JY, JCZ). LB, SHP, and GG were supported in part by NIH/NCI training grant T32 CA009560.	Brahimi-Horn MC, 2005, INT REV CYTOL, V242, P157; Fraga A, 2015, CLIN GENITOURIN CANC, V13, P295, DOI 10.1016/j.clgc.2015.03.006; Fumagalli D, 2016, ANN ONCOL, V27, P1860, DOI 10.1093/annonc/mdw286; Geng H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07411-7; Guo HY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08133-6; Gupta K, 2017, TRANSL CANCER RES, V6, pS104, DOI 10.21037/tcr.2017.01.20; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He YD, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI147025; Henze AT, 2016, J CLIN INVEST, V126, P3672, DOI 10.1172/JCI84427; Jin HJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4972; Jin HJ, 2013, CANCER RES, V73, P3725, DOI 10.1158/0008-5472.CAN-12-3468; Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206; Kim J, 2017, ONCOGENE, V36, P4072, DOI 10.1038/onc.2017.50; Korbecki J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165647; Kupelian PA, 2006, UROLOGY, V68, P593, DOI 10.1016/j.urology.2006.03.075; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lee GT, 2018, BRIT J CANCER, V118, P670, DOI 10.1038/bjc.2017.451; Li N, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060799; Lim SY, 2016, ONCOTARGET, V7, P28697, DOI 10.18632/oncotarget.7376; Lin YX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0760-3; Litwin MS, 2017, JAMA-J AM MED ASSOC, V317, P2532, DOI 10.1001/jama.2017.7248; Liu YW, 2014, NAT MED, V20, P272, DOI 10.1038/nm.3485; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Liu YQ, 2001, PROSTATE CANCER P D, V4, P81, DOI 10.1038/sj.pcan.4500506; Lo CH, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00247; Loberg RD, 2007, NEOPLASIA, V9, P556, DOI 10.1593/neo.07307; Milosevic M, 2012, CLIN CANCER RES, V18, P2108, DOI 10.1158/1078-0432.CCR-11-2711; Mimeault M, 2013, J CELL MOL MED, V17, P30, DOI 10.1111/jcmm.12004; Narita T, 2009, NEURO-ONCOLOGY, V11, P946; Nguyen HM, 2017, PROSTATE, V77, P654, DOI 10.1002/pros.23313; Noman MZ, 2015, AM J PHYSIOL-CELL PH, V309, pC569, DOI 10.1152/ajpcell.00207.2015; Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008; Phatnani HP, 2006, GENE DEV, V20, P2922, DOI 10.1101/gad.1477006; Ranasinghe WKB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054251; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551; Song B, 2019, J CLIN INVEST, V129, P569, DOI 10.1172/JCI122367; Su WJ, 2019, CANCER CELL, V36, P139, DOI 10.1016/j.ccell.2019.06.009; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tran MGB, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06890-6; Tsai YC, 2018, BBA-MOL BASIS DIS, V1864, P1717, DOI 10.1016/j.bbadis.2018.02.016; Tucci M, 2018, ONCOTARGETS THER, V11, P7353, DOI 10.2147/OTT.S153764; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; Vergis R, 2008, LANCET ONCOL, V9, P342, DOI 10.1016/S1470-2045(08)70076-7; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang KL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15396-5; Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009; Zhong H, 2004, CANCER DETECT PREV, V28, P88, DOI 10.1016/j.cdp.2003.12.009	50	1	1	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2022	41	37					4259	4270		10.1038/s41388-022-02423-6	http://dx.doi.org/10.1038/s41388-022-02423-6		AUG 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4L2AN	35931888				2022-12-17	WOS:000836492100001
J	Zhao, LY; Zhang, X; Zhou, YF; Fu, KL; Lau, HCH; Chun, TWY; Cheung, AHK; Coker, OO; Wei, H; Wu, WKK; Wong, SH; Sung, JJY; To, KF; Yu, J				Zhao, Liuyang; Zhang, Xiang; Zhou, Yunfei; Fu, Kaili; Lau, Harry Cheuk-Hay; Chun, Tommy Wai-Yiu; Cheung, Alvin Ho-Kwan; Coker, Olabisi Oluwabukola; Wei, Hong; Wu, William Ka-Kei; Wong, Sunny Hei; Sung, Joseph Jao-Yiu; To, Ka Fai; Yu, Jun			Parvimonas micra promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients	ONCOGENE			English	Article							GUT MICROBIOTA; CELLS	Large-scale fecal shotgun metagenomic sequencing revealed the high abundance of Parvimonas micra in colorectal cancer (CRC) patients. We investigated the role and clinical significance of P. micra in colorectal tumorigenesis. The abundance of P. micra was examined in 309 fecal samples and 165 colon biopsy tissues of CRC patients and healthy subjects. P. micra was significantly enriched in fecal samples from 128 CRC patients compared to 181 healthy subjects (P < 0.0001); and in colon tissue biopsies from 52 CRC patients compared to 61 healthy subjects (P < 0.0001). Multivariate analysis showed that P. micra is an independent risk factor of poor survival in CRC patients (Hazard Ratio: 1.93). P. micra strain was isolated from feces of a CRC patient. Apc(min/+) mice gavaged with P. micra showed significantly higher tumor burden and tumor load (both P < 0.01). Consistently, gavage of P. micra significantly promoted colonocyte proliferation in conventional mice, which was further confirmed by germ-free mice. P. micra colonization up-regulated genes involved in cell proliferation, stemness, angiogenesis and invasiveness/metastasis; and enhanced Th17 cells infiltration and expression of Th17 cells-secreted cytokines (Il-17, Il-22, and Il-23) in the colon of Apc(min/+), conventional and germ-free mice. P. micra-conditioned medium significantly promoted the differentiation of CD4(+) T cells to Th17 cells (IL-17(+)CD4(+) phenotype) and enhanced the oncogenic Wnt signaling pathway. In conclusion, P. micra promoted colorectal tumorigenesis in mice by inducing colonocyte proliferation and altering Th17 immune response. P. micra may act as a prognostic biomarker for poor survival of CRC patients.	[Zhao, Liuyang; Zhang, Xiang; Zhou, Yunfei; Fu, Kaili; Lau, Harry Cheuk-Hay; Chun, Tommy Wai-Yiu; Coker, Olabisi Oluwabukola; Wu, William Ka-Kei; Wong, Sunny Hei; Sung, Joseph Jao-Yiu; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,Inst Digest Dis,State Key La, Hong Kong, Peoples R China; [Zhao, Liuyang; Cheung, Alvin Ho-Kwan; To, Ka Fai] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China; [Wei, Hong] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Precis Med, Guangzhou, Peoples R China; [Wu, William Ka-Kei] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Sun Yat Sen University; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,Inst Digest Dis,State Key La, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Wu, William K.K./A-3277-2009; Lau, Harry Cheuk Hay/X-3413-2019	Wu, William K.K./0000-0002-5662-5240; Lau, Harry Cheuk Hay/0000-0003-3581-2909	National Key R&D Program of China [2020YFA0509200/2020YFA0509203]; RGC-Research Impact Fund Hong Kong [R4032-21F]; RGC-GRF Hong Kong [14163817]; Vice-Chancellor's Discretionary Fund CUHK; CUHK direct grant	National Key R&D Program of China; RGC-Research Impact Fund Hong Kong; RGC-GRF Hong Kong(Hong Kong Research Grants Council); Vice-Chancellor's Discretionary Fund CUHK; CUHK direct grant(Chinese University of Hong Kong)	This project was supported by National Key R&D Program of China (2020YFA0509200/2020YFA0509203); RGC-Research Impact Fund Hong Kong (R4032-21F); RGC-GRF Hong Kong (14163817); Vice-Chancellor's Discretionary Fund CUHK and CUHK direct grant.	Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Dai ZW, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0451-2; Flemer B, 2018, GUT, V67, P1454, DOI 10.1136/gutjnl-2017-314814; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535; Irrazabal T, 2014, MOL CELL, V54, P309, DOI 10.1016/j.molcel.2014.03.039; Koeth LM, 2004, J ANTIMICROB CHEMOTH, V53, P1039, DOI 10.1093/jac/dkh248; Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007; La Vecchia S, 2020, SEMIN CELL DEV BIOL, V98, P63, DOI 10.1016/j.semcdb.2019.05.018; Li BL, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368-018-0043-9; Li Q, 2021, GASTROENTEROLOGY, V160, P1179, DOI 10.1053/j.gastro.2020.09.003; Loftus M, 2021, BMC MICROBIOL, V21, DOI 10.1186/s12866-021-02153-x; Long XH, 2019, NAT MICROBIOL, V4, P2319, DOI 10.1038/s41564-019-0541-3; Louis P, 2014, NAT REV MICROBIOL, V12, P661, DOI 10.1038/nrmicro3344; Nakatsu G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9727; Park SY, 2021, CANCERS, V13, DOI 10.3390/cancers13092124; Purcell RV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11237-6; Segata N, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r42; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sillanpaa J, 2008, FEMS MICROBIOL LETT, V289, P104, DOI 10.1111/j.1574-6968.2008.01378.x; Tsoi H, 2017, GASTROENTEROLOGY, V152, P1419, DOI 10.1053/j.gastro.2017.01.009; VANDALEN PJ, 1993, INT J SYST BACTERIOL, V43, P787, DOI 10.1099/00207713-43-4-787; Wagner A, 2021, CELL, V184, P4168, DOI 10.1016/j.cell.2021.05.045; Wong SH, 2019, NAT REV GASTRO HEPAT, V16, P690, DOI 10.1038/s41575-019-0209-8; Wong SH, 2017, GASTROENTEROLOGY, V153, P1621, DOI 10.1053/j.gastro.2017.08.022; Wong SH, 2017, GUT, V66, P1441, DOI 10.1136/gutjnl-2016-312766; Xu J, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.11967; Yachida S, 2019, NAT MED, V25, P968, DOI 10.1038/s41591-019-0458-7; Yu J, 2017, GUT, V66, P70, DOI 10.1136/gutjnl-2015-309800; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Zheng DP, 2020, CELL RES, V30, P492, DOI 10.1038/s41422-020-0332-7	31	1	1	7	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2022	41	36					4200	4210		10.1038/s41388-022-02395-7	http://dx.doi.org/10.1038/s41388-022-02395-7		JUL 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4G5OH	35882981	Green Published, hybrid			2022-12-17	WOS:000830346600001
J	More, A; Ito, I; Haridas, V; Chowdhury, S; Gu, Y; Dickson, P; Fowlkes, N; Shen, JP				More, Aditya; Ito, Ichiaki; Haridas, Valsala; Chowdhury, Saikat; Gu, Yue; Dickson, Princess; Fowlkes, Natalie; Shen, John Paul			Oncogene addiction to GNAS in GNAS(R201) mutant tumors	ONCOGENE			English	Article							BETA-CATENIN; G-PROTEIN; ACTIVATING MUTATION; SIGNALING PATHWAY; FREQUENT EVENT; WNT; PHOSPHORYLATION; EXPRESSION; LOCUS	The GNAS(R201) gain-of-function mutation is the single most frequent cancer-causing mutation across all heterotrimeric G proteins, driving oncogenesis in various low-grade/benign gastrointestinal and pancreatic tumors. In this study, we investigated the role of GNAS and its product G alpha s in tumor progression using peritoneal models of colorectal cancer (CRC). GNAS was knocked out in multiple CRC cell lines harboring GNAS(R201C/H) mutations (KM12, SNU175, SKCO1), leading to decreased cell-growth in 2D and 3D organoid models. Nude mice were peritoneally injected with GNAS-knockout KM12 cells, leading to a decrease in tumor growth and drastically improved survival at 7 weeks. Supporting these findings, GNAS overexpression in LS174T cells led to increased cell-growth in 2D and 3D organoid models, and increased tumor growth in PDX mouse models. GNAS knockout decreased levels of cyclic AMP in KM12 cells, and molecular profiling identified phosphorylation of beta-catenin and activation of its targets as critical downstream effects of mutant GNAS signaling. Supporting these findings, chemical inhibition of both PKA and beta-catenin reduced growth of GNAS mutant organoids. Our findings demonstrate oncogene addiction to GNAS in peritoneal models of GNAS(R201C/H) tumors, which signal through the cAMP/PKA and Wnt/beta-catenin pathways. Thus, GNAS and its downstream mediators are promising therapeutic targets for GNAS mutant tumors.	[More, Aditya; Ito, Ichiaki; Haridas, Valsala; Chowdhury, Saikat; Gu, Yue; Dickson, Princess; Shen, John Paul] MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA; [Fowlkes, Natalie] MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Shen, JP (corresponding author), MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA.	jshen8@mdanderson.org		Gu, Yue/0000-0002-9642-0338; More, Aditya/0000-0003-4511-4733; Shen, John Paul/0000-0003-4588-2775	National Cancer Institute [L30 CA171000, K22 CA234406]; Cancer Center Support Grant [CA16672]; Cancer Prevention & Research Institute of Texas [RR180035]; Col. Daniel Connelly Memorial Fund; NCI [CA16672, CA016672, R50CA221675]; Khalifa Bin Zayed Al Nahyan Foundation	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support Grant; Cancer Prevention & Research Institute of Texas; Col. Daniel Connelly Memorial Fund; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Khalifa Bin Zayed Al Nahyan Foundation	This work was supported by the National Cancer Institute (L30 CA171000 and K22 CA234406 to JPS, and the Cancer Center Support Grant (P30 CA016672), the Cancer Prevention & Research Institute of Texas (RR180035 to JPS, JPS is a CPRIT Scholar in Cancer Research), and the Col. Daniel Connelly Memorial Fund. We thank the following core facilities at MD Anderson Cancer Center for their services used in this study: Reverse Phase Protein Array Core (Supported by NCI grant #CA16672 and #R50CA221675), Advanced Technology Genomics Core (Supported by NCI Grant CA016672(ATGC)), Biospecimen Extraction Facility for sample processing and DNA/RNA/protein extraction, and Small Animal Imaging Facility (Supported by the Cancer Center Support Grant CA16672) for in vivo live imaging. In addition, data generated by TCGA Research Network: https://www.cancer.gov/tcga was used in this publication. We also acknowledge Dr Kenna Shaw and data integration and clinical team members from the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, supported by the Khalifa Bin Zayed Al Nahyan Foundation, for building and maintaining the MOCLIP database.	Almeida MQ, 2011, MOL CELL ENDOCRINOL, V336, P162, DOI 10.1016/j.mce.2010.11.018; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Ang CSP, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.17.00302; Arang N, 2020, FEBS LETT, V594, P4201, DOI 10.1002/1873-3468.14017; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Coles GL, 2020, CANCER CELL, V38, P129, DOI 10.1016/j.ccell.2020.05.003; Conway T, 2012, BIOINFORMATICS, V28, pI172, DOI 10.1093/bioinformatics/bts236; Dai SA, 2020, BIORXIV; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Faias S, 2020, WORLD J GASTRO ONCOL, V12, P1056, DOI 10.4251/wjgo.v12.i9.1056; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garcia-Murillas I, 2014, ONCOGENE, V33, P2478, DOI 10.1038/onc.2013.202; Goh G, 2014, NAT GENET, V46, P613, DOI 10.1038/ng.2956; Gueorguiev M, 2009, PITUITARY, V12, P245, DOI 10.1007/s11102-008-0147-x; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Hosoda W, 2015, VIRCHOWS ARCH, V466, P665, DOI 10.1007/s00428-015-1751-6; Hu Q, 2018, CELL, V173, P1254, DOI 10.1016/j.cell.2018.03.018; Ideno N, 2018, GASTROENTEROLOGY, V155, P1593, DOI 10.1053/j.gastro.2018.08.006; Innamorati G, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4133-z; Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276-020-0380-6; Khan M, 2018, CLIN COLORECTAL CANC, V17, pE699, DOI 10.1016/j.clcc.2018.07.005; Khan SK, 2018, P NATL ACAD SCI USA, V115, pE418, DOI 10.1073/pnas.1714313114; Kimbrel EA, 2009, MOL IMAGING, V8, P140, DOI 10.2310/7290.2009.00007; Komatsu H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087875; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lin YL, 2020, J CANCER RES CLIN, V146, P2179, DOI 10.1007/s00432-020-03321-8; Lochner A, 2006, CARDIOVASC DRUG REV, V24, P261, DOI 10.1111/j.1527-3466.2006.00261.x; Nishikawa G, 2013, BRIT J CANCER, V108, P951, DOI 10.1038/bjc.2013.47; Nomura R, 2014, HUM PATHOL, V45, P2488, DOI 10.1016/j.humpath.2014.08.016; O'Hayre M, 2014, CURR OPIN CELL BIOL, V27, P126, DOI 10.1016/j.ceb.2014.01.005; Onken MD, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100403; Parsons MJ, 2021, CANCER DISCOV, V11, P2413, DOI 10.1158/2159-8290.CD-21-0190; Patel A, 2015, J CLIN ONCOL, V33; Patra KC, 2018, NAT CELL BIOL, V20, P811, DOI 10.1038/s41556-018-0122-3; Raghav K, 2020, BRIT J CANCER, V123, P1262, DOI 10.1038/s41416-020-1015-3; Regard JB, 2011, P NATL ACAD SCI USA, V108, P20101, DOI 10.1073/pnas.1114656108; Ritterhouse LL, 2017, MODERN PATHOL, V30, P1720, DOI 10.1038/modpathol.2017.88; Rosciglione S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5556; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Sassone-Corsi P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011148; Sastre-Perona Ana, 2012, Front Endocrinol (Lausanne), V3, P31, DOI 10.3389/fendo.2012.00031; Schatoff EM, 2017, CURR COLORECT CANC R, V13, P101, DOI 10.1007/s11888-017-0354-9; Stein MK, 2020, J SURG ONCOL, V121, P1320, DOI 10.1002/jso.25899; Stein MK, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.498; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Tischler G, 2014, SOURCE CODE BIOL MED, V9, DOI 10.1186/1751-0473-9-13; Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06464-y; Weinstein LS, 2004, ENDOCRINOLOGY, V145, P5459, DOI 10.1210/en.2004-0865; Wilson CH, 2010, ONCOGENE, V29, P4567, DOI 10.1038/onc.2010.202; Yang IS, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2852-6; Zhang HY, 2020, EXP HEMATOL ONCOL, V9, DOI 10.1186/s40164-020-00191-1	59	1	1	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2022	41	35					4159	4168		10.1038/s41388-022-02388-6	http://dx.doi.org/10.1038/s41388-022-02388-6		JUL 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	4A3US	35879396				2022-12-17	WOS:000829736900001
J	Peng, HY; Nerreter, T; Mestermann, K; Wachter, J; Chang, J; Hudecek, M; Rader, C				Peng, Haiyong; Nerreter, Thomas; Mestermann, Katrin; Wachter, Jakob; Chang, Jing; Hudecek, Michael; Rader, Christoph			ROR1-targeting switchable CAR-T cells for cancer therapy	ONCOGENE			English	Article; Early Access							ANTIBODY-LIKE IMMUNORECEPTORS; CHIMERIC ANTIGEN RECEPTORS; AFFINITY; ROR1; TARGET; ACTIVATION; EXPRESSION; DESIGN; DOMAIN; RECRUITMENT	The success of chimeric antigen receptor T cell (CAR-T) therapy in the treatment of hematologic malignancies has prompted the development of numerous CAR-T technologies, including switchable CAR-T (sCAR-T) systems that combine a universal CAR-T with bispecific adapter proteins. Owing to their controllability and versatility, sCAR-Ts have received considerable attention. To explore the therapeutic utility of sCAR-Ts targeting the receptor tyrosine kinase ROR1, which is expressed in hematologic and solid malignancies, and to identify bispecific adaptor proteins that efficiently mediate universal CAR-T engagement, a panel of switches based on ROR1-targeting Fabs with different epitopes and affinities was compared in in vitro and in vivo models of ROR1-expressing cancers. For switches targeting overlapping or identical epitopes, potency correlated with affinity. Surprisingly, however, we identified a switch targeting a unique epitope with low affinity but mediating potent and selective antitumor activity in vitro and in vivo. Converted to a conventional CAR-T, the same anti-ROR1 mAb (324) outperformed a clinically investigated conventional CAR-T that is based on an anti-ROR1 mAb (R12) with similar to 200-fold higher affinity. Thus, demonstrating therapeutic utility on their own, sCAR-Ts also facilitate higher throughput screening for the identification of conventional CAR-T candidates for preclinical and clinical studies.	[Peng, Haiyong; Chang, Jing; Rader, Christoph] Univ Florida, Dept Immunol & Microbiol, Scripps Biomed Res, Jupiter, FL 33458 USA; [Nerreter, Thomas; Mestermann, Katrin; Wachter, Jakob; Hudecek, Michael] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany	State University System of Florida; University of Florida; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg	Peng, HY; Rader, C (corresponding author), Univ Florida, Dept Immunol & Microbiol, Scripps Biomed Res, Jupiter, FL 33458 USA.	h.peng@ufl.edu; c.rader@ufl.edu		peng, haiyong/0000-0003-0312-1337; Rader, Christoph/0000-0001-9955-3454	National Institutes of Health (NIH) [R01 CA174844, R01 CA181258, R01 CA204484, R21 CA229961, R21 CA263240]; Klorfine Foundation	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Klorfine Foundation	CR acknowledges support by National Institutes of Health (NIH) grants R01 CA174844, R01 CA181258, R01 CA204484, R21 CA229961, and R21 CA263240, and by the Klorfine Foundation.	Acevedo-Rocha CG, 2015, SCI REP-UK, V5, DOI 10.1038/srep10654; Arndt C, 2020, CANCERS, V12, DOI 10.3390/cancers12051302; Balakrishnan A, 2017, CLIN CANCER RES, V23, P3061, DOI 10.1158/1078-0432.CCR-16-2083; Baskar S, 2008, CLIN CANCER RES, V14, P396, DOI 10.1158/1078-0432.CCR-07-1823; Benmebarek MR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061283; Berger C, 2015, CANCER IMMUNOL RES, V3, P206, DOI 10.1158/2326-6066.CIR-14-0163; Cao Y, 2016, ANGEW CHEM INT EDIT, V55, P7520, DOI 10.1002/anie.201601902; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Chmielewski M, 2004, J IMMUNOL, V173, P7647, DOI 10.4049/jimmunol.173.12.7647; Cho JH, 2018, CELL, V173, P1426, DOI 10.1016/j.cell.2018.03.038; Choi MY, 2018, CELL STEM CELL, V22, P951, DOI 10.1016/j.stem.2018.05.018; Dana H, 2021, ACTA PHARM SIN B, V11, P1129, DOI 10.1016/j.apsb.2020.10.020; Darowski D, 2019, MABS-AUSTIN, V11, P621, DOI 10.1080/19420862.2019.1596511; Dave H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052655; Depil S, 2020, NAT REV DRUG DISCOV, V19, P185, DOI 10.1038/s41573-019-0051-2; Feins S, 2019, AM J HEMATOL, V94, pS3, DOI 10.1002/ajh.25418; Ghorashian S, 2019, NAT MED, V25, P1408, DOI 10.1038/s41591-019-0549-5; Goydel RS, 2020, J BIOL CHEM, V295, P5995, DOI 10.1074/jbc.RA120.012791; Greenman R, 2021, MOL CANCER THER, V20, P872, DOI 10.1158/1535-7163.MCT-19-1109; Hojjat-Farsangi M, 2014, SEMIN CANCER BIOL, V29, P21, DOI 10.1016/j.semcancer.2014.07.005; Hombach AA, 2007, J IMMUNOL, V178, P4650, DOI 10.4049/jimmunol.178.7.4650; Hong MH, 2020, CANCER CELL, V38, P473, DOI 10.1016/j.ccell.2020.07.005; Hoyos V, 2010, LEUKEMIA, V24, P1160, DOI 10.1038/leu.2010.75; Hudecek M, 2015, CANCER IMMUNOL RES, V3, P125, DOI 10.1158/2326-6066.CIR-14-0127; Hudecek M, 2013, CLIN CANCER RES, V19, P3153, DOI 10.1158/1078-0432.CCR-13-0330; Hudecek M, 2010, BLOOD, V116, P4532, DOI 10.1182/blood-2010-05-283309; Jayaraman J, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102931; Jensen MC, 2015, CURR OPIN IMMUNOL, V33, P9, DOI 10.1016/j.coi.2015.01.002; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Kamrani A, 2019, EXPERT OPIN THER TAR, V23, P447, DOI 10.1080/14728222.2019.1602608; Labanieh L, 2022, CELL, V185, P1745, DOI 10.1016/j.cell.2022.03.041; Larson RC, 2021, NAT REV CANCER, V21, P145, DOI 10.1038/s41568-020-00323-z; Lee YG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10565-7; Lindner SE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz3223; Liu XJ, 2015, CANCER RES, V75, P3596, DOI 10.1158/0008-5472.CAN-15-0159; Menck K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010142; Minutolo NG, 2020, J AM CHEM SOC, V142, P6554, DOI 10.1021/jacs.9b11622; Minutolo NG, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00176; Nerreter T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10948-w; Peng Haiyong, 2021, Antib Ther, V4, P222, DOI 10.1093/abt/tbab023; Peng H, 2017, J MOL BIOL, V429, P2954, DOI 10.1016/j.jmb.2017.08.003; Picanco-Castro V, 2020, METHODS MOL BIOL, V2086, P1, DOI 10.1007/978-1-0716-0146-4_1; Qi JP, 2020, ANGEW CHEM INT EDIT, V59, P12178, DOI 10.1002/anie.202005432; Qi JP, 2018, P NATL ACAD SCI USA, V115, pE5467, DOI 10.1073/pnas.1719905115; Raj D, 2019, GUT, V68, P1052, DOI 10.1136/gutjnl-2018-316595; Rennert P, 2019, BLOOD, V134, DOI 10.1182/blood-2019-130654; Rodgers DT, 2016, P NATL ACAD SCI USA, V113, pE459, DOI 10.1073/pnas.1524155113; Sahillioglu AC, 2022, CURR OPIN IMMUNOL, V74, P190, DOI 10.1016/j.coi.2021.07.002; Schmid DA, 2010, J IMMUNOL, V184, P4936, DOI 10.4049/jimmunol.1000173; Shabani M, 2015, EXPERT OPIN THER TAR, V19, P941, DOI 10.1517/14728222.2015.1025753; Srivastava S, 2021, CANCER CELL, V39, P193, DOI 10.1016/j.ccell.2020.11.005; Srivastava S, 2019, CANCER CELL, V35, P489, DOI 10.1016/j.ccell.2019.02.003; Townsend MH, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0817-0; Viaud S, 2018, P NATL ACAD SCI USA, V115, pE10898, DOI 10.1073/pnas.1810060115; Wang ML., 2022, N ENGL J MED EVID, V1, P1; Wang XL, 2011, BLOOD, V118, P1255, DOI 10.1182/blood-2011-02-337360; Wu CY, 2015, SCIENCE, V350, DOI 10.1126/science.aab4077; Yam PY, 2002, MOL THER, V5, P479, DOI 10.1006/mthe.2002.0558; Yang JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021018; Zahnd C, 2004, J BIOL CHEM, V279, P18870, DOI 10.1074/jbc.M309169200; Zhao YM, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.680834	63	1	1	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene												10.1038/541388-022-02416-5	http://dx.doi.org/10.1038/541388-022-02416-5		JUL 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D9PU	35859167				2022-12-17	WOS:000829626500001
J	Quek, LE; van Geldermalsen, M; Guan, YF; Wahi, K; Mayoh, C; Balaban, S; Pang, A; Wang, Q; Cowley, MJ; Brown, KK; Turner, N; Hoy, AJ; Holst, J				Quek, Lake-Ee; van Geldermalsen, Michelle; Guan, Yi Fang; Wahi, Kanu; Mayoh, Chelsea; Balaban, Seher; Pang, Angel; Wang, Qian; Cowley, Mark J.; Brown, Kristin K.; Turner, Nigel; Hoy, Andrew J.; Holst, Jeff			Glutamine addiction promotes glucose oxidation in triple-negative breast cancer	ONCOGENE			English	Article							METABOLISM; CELLS; GROWTH; INHIBITOR; PROTEINS; STRESS; ACID	Glutamine is a conditionally essential nutrient for many cancer cells, but it remains unclear how consuming glutamine in excess of growth requirements confers greater fitness to glutamine-addicted cancers. By contrasting two breast cancer subtypes with distinct glutamine dependencies, we show that glutamine-indispensable triple-negative breast cancer (TNBC) cells rely on a non-canonical glutamine-to-glutamate overflow, with glutamine carbon routed once through the TCA cycle. Importantly, this single-pass glutaminolysis increases TCA cycle fluxes and replenishes TCA cycle intermediates in TNBC cells, a process that achieves net oxidation of glucose but not glutamine. The coupling of glucose and glutamine catabolism appears hard-wired via a distinct TNBC gene expression profile biased to strip and then sequester glutamine nitrogen, but hampers the ability of TNBC cells to oxidise glucose when glutamine is limiting. Our results provide a new understanding of how metabolically rigid TNBC cells are sensitive to glutamine deprivation and a way to select vulnerable TNBC subtypes that may be responsive to metabolic-targeted therapies.	[Quek, Lake-Ee] Univ Sydney, Sch Math & Stat, Camperdown, NSW, Australia; [van Geldermalsen, Michelle] Univ Sydney, Centenary Inst, Origins Canc Program, Camperdown, NSW, Australia; [van Geldermalsen, Michelle] Univ Sydney, Sydney Med Sch, Camperdown, NSW, Australia; [Guan, Yi Fang; Wahi, Kanu; Pang, Angel; Wang, Qian; Holst, Jeff] UNSW Sydney, Sch Med Sci, Kensington, NSW, Australia; [Guan, Yi Fang; Wahi, Kanu; Pang, Angel; Wang, Qian; Holst, Jeff] UNSW Sydney, Sch Clin Med, Kensington, NSW, Australia; [Mayoh, Chelsea; Cowley, Mark J.] UNSW Sydney, Childrens Canc Inst, Lowy Canc Ctr, Kensington, NSW, Australia; [Mayoh, Chelsea; Cowley, Mark J.] UNSW Sydney, Sch Womens & Childrens Hlth, Kensington, NSW, Australia; [Balaban, Seher; Hoy, Andrew J.] Univ Sydney, Charles Perkins Ctr, Sch Med Sci, Camperdown, NSW, Australia; [Brown, Kristin K.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Brown, Kristin K.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Brown, Kristin K.] Univ Melbourne, Dept Biochem & Pharmacol, Melbourne, Vic, Australia; [Turner, Nigel] UNSW Sydney, Dept Pharmacol, Sch Med Sci, Kensington, NSW, Australia	University of Sydney; University of Sydney; Centenary Institute; University of Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; University of Sydney; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; University of New South Wales Sydney	Quek, LE (corresponding author), Univ Sydney, Sch Math & Stat, Camperdown, NSW, Australia.; Holst, J (corresponding author), UNSW Sydney, Sch Med Sci, Kensington, NSW, Australia.; Holst, J (corresponding author), UNSW Sydney, Sch Clin Med, Kensington, NSW, Australia.	lake-ee.quek@sydney.edu.au; j.holst@unsw.edu.au	; Hoy, Andrew/J-2289-2017	Cowley, Mark/0000-0002-9519-5714; BROWN, KRISTIN/0000-0002-4991-8870; Hoy, Andrew/0000-0003-3922-1137; Pang, Angel/0000-0003-1001-5102	National Breast Cancer Foundation [ECF-12-05]; Cancer Council NSW [RG18-06]; Cancer Institute NSW; Australian Cancer Research Foundation (Tumour Metabolism Laboratory); Robinson Fellowship; University of Sydney; Luminesce Alliance: Innovation for Children's Health; Victorian Cancer Agency; Susan G. Komen; Sydney Catalyst	National Breast Cancer Foundation; Cancer Council NSW(Cancer Council New South Wales); Cancer Institute NSW; Australian Cancer Research Foundation (Tumour Metabolism Laboratory); Robinson Fellowship; University of Sydney(University of Sydney); Luminesce Alliance: Innovation for Children's Health; Victorian Cancer Agency; Susan G. Komen(Susan G. Komen Breast Cancer Foundation); Sydney Catalyst	This work was supported by grants from the National Breast Cancer Foundation (ECF-12-05 to JH); Cancer Council NSW (RG18-06 to JH); Cancer Institute NSW and Sydney Catalyst (MvG, LEQ and JH); and the Australian Cancer Research Foundation (Tumour Metabolism Laboratory to JH). AJH is supported by a Robinson Fellowship and funding from The University of Sydney. MJC is supported by Luminesce Alliance: Innovation for Children's Health. KKB is supported by grants from The Victorian Cancer Agency and Susan G. Komen. Metabolomics was facilitated by access to Sydney Mass Spectrometry, a core research facility at the University of Sydney and the Bioanalytical Mass Spectrometry Facility within the Mark Wainwright Analytical Centre of the University of New South Wales.	Ahn WS, 2013, METAB ENG, V15, P34, DOI 10.1016/j.ymben.2012.10.001; Brown KK, 2017, CANCER DISCOV, V7, P391, DOI 10.1158/2159-8290.CD-16-0611; Brunk E, 2018, NAT BIOTECHNOL, V36, P272, DOI 10.1038/nbt.4072; Budczies J, 2015, INT J CANCER, V136, P1619, DOI 10.1002/ijc.29152; Cantor JR, 2017, CELL, V169, P258, DOI 10.1016/j.cell.2017.03.023; Cao MD, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-941; Centenera MM, 2013, NAT REV UROL, V10, P483, DOI 10.1038/nrurol.2013.126; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Craze ML, 2019, BREAST CANCER RES TR, V174, P79, DOI 10.1007/s10549-018-5060-z; Davidson SM, 2016, CELL METAB, V23, P517, DOI 10.1016/j.cmet.2016.01.007; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; dos Reis LM, 2019, J BIOL CHEM, V294, P9342, DOI 10.1074/jbc.RA119.008180; Fan J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.65; Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870; Hosios AM, 2016, DEV CELL, V36, P540, DOI 10.1016/j.devcel.2016.02.012; Hui S, 2017, NATURE, V551, P115, DOI 10.1038/nature24057; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Jeon YJ, 2015, CANCER CELL, V27, P354, DOI 10.1016/j.ccell.2015.02.006; Kim S, 2013, TUMOR BIOL, V34, P2683, DOI 10.1007/s13277-013-0819-7; Knott SRV, 2018, NATURE, V554, P378, DOI 10.1038/nature25465; Kung HN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002229; Lampa M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185092; Lanning NJ, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0168-x; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Lee P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14374-1; Li HX, 2019, NAT MED, V25, P850, DOI 10.1038/s41591-019-0404-8; Li XX, 2022, NAT METAB, V4, P141, DOI 10.1038/s42255-021-00517-1; Liao CH, 2022, CANCER RES, V82, P665, DOI 10.1158/0008-5472.CAN-21-2745; Martin SD, 2019, CANCER METAB, V7, DOI 10.1186/s40170-019-0207-x; Martinez-Reyes I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13668-3; Mendez-Lucas A, 2020, NAT METAB, V2, P335, DOI 10.1038/s42255-020-0195-8; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Osanai-Sasakawa A, 2018, AM J CANCER RES, V8, P1499; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Quek Lake-Ee, 2014, Methods Mol Biol, V1191, P209, DOI 10.1007/978-1-4939-1170-7_13; Shin CS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15074; Simoes RV, 2015, NEOPLASIA, V17, P671, DOI 10.1016/j.neo.2015.08.005; Smith B, 2016, CELL REP, V17, P821, DOI 10.1016/j.celrep.2016.09.045; Spinelli JB, 2017, SCIENCE, V358, P941, DOI 10.1126/science.aam9305; Tardito S, 2015, NAT CELL BIOL, V17, P1556, DOI 10.1038/ncb3272; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; van Geldermalsen M, 2016, ONCOGENE, V35, P3201, DOI 10.1038/onc.2015.381; van Geldermalsen M, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4599-8; Vatrinet R, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0165-0; Vettore L, 2020, BRIT J CANCER, V122, P150, DOI 10.1038/s41416-019-0620-5; Voorde JV, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau7314; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wu Q, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18020-8; Yang CS, 2018, EMBO REP, V19, DOI 10.15252/embr.201643577; Zhang J, 2012, NAT PROTOC, V7, P1068, DOI 10.1038/nprot.2012.048	50	1	1	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2022	41	34					4066	4078		10.1038/s41388-022-02408-5	http://dx.doi.org/10.1038/s41388-022-02408-5		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3W0LE	35851845	Green Published, hybrid			2022-12-17	WOS:000826844200003
J	Horiguchi, H; Kadomatsu, T; Yumoto, S; Masuda, T; Miyata, K; Yamamura, S; Sato, M; Morinaga, J; Ohtsuki, S; Baba, H; Moroishi, T; Oike, Y				Horiguchi, Haruki; Kadomatsu, Tsuyoshi; Yumoto, Shinsei; Masuda, Takeshi; Miyata, Keishi; Yamamura, Shuji; Sato, Michio; Morinaga, Jun; Ohtsuki, Sumio; Baba, Hideo; Moroishi, Toshiro; Oike, Yuichi			Tumor cell-derived ANGPTL2 promotes beta-catenin-driven intestinal tumorigenesis	ONCOGENE			English	Article							ANGIOPOIETIN-LIKE PROTEIN-2; CANCER CELLS; OB-CADHERIN; STEM-CELLS; EXPRESSION; WNT; MUTATIONS; COLON; GENE; PROLIFERATION	Uncontrolled proliferation of intestinal epithelial cells caused by mutations in genes of the WNT/beta-catenin pathway is associated with development of intestinal cancers. We previously reported that intestinal stromal cell-derived angiopoietin-like protein 2 (ANGPTL2) controls epithelial regeneration and intestinal immune responses. However, the role of tumor cell-derived ANGPTL2 in intestinal tumorigenesis remained unclear. Here, we show that tumor cell-derived ANGPTL2 promotes beta-catenin-driven intestinal tumorigenesis. ANGPTL2 deficiency suppressed intestinal tumor development in an experimental mouse model of sporadic colon cancer. We also found that increased ANGPTL2 expression in colorectal cancer (CRC) cells augments beta-catenin pathway signaling and promotes tumor cell proliferation. Relevant to mechanism, our findings suggest that tumor cell-derived ANGPTL2 upregulates expression of OB-cadherin, which then interacts with beta-catenin, blocking destruction complex-independent proteasomal degradation of beta-catenin proteins. Moreover, our observations support a model whereby ANGPTL2-induced OB-cadherin expression in CRC cells is accompanied by decreased cell surface integrin alpha 5 beta 1 expression. These findings overall provide novel insight into mechanisms of beta-catenin-driven intestinal tumorigenesis.	[Horiguchi, Haruki; Kadomatsu, Tsuyoshi; Yumoto, Shinsei; Miyata, Keishi; Yamamura, Shuji; Sato, Michio; Morinaga, Jun; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Kumamoto 8608556, Japan; [Horiguchi, Haruki; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Dept Aging & Geriatr Med, Kumamoto 8608556, Japan; [Kadomatsu, Tsuyoshi; Miyata, Keishi; Moroishi, Toshiro; Oike, Yuichi] Kumamoto Univ, Ctr Metab Regulat Hlth Aging CMHA, Grad Sch Med Sci, Kumamoto 8608556, Japan; [Yumoto, Shinsei; Baba, Hideo] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto 8608556, Japan; [Masuda, Takeshi; Ohtsuki, Sumio] Kumamoto Univ, Fac Life Sci, Dept Pharmaceut Microbiol, Kumamoto 8608556, Japan; [Moroishi, Toshiro] Kumamoto Univ, Fac Life Sci, Dept Cell Signaling & Metab Med, Kumamoto 8608556, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University	Kadomatsu, T; Oike, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Kumamoto 8608556, Japan.; Oike, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Aging & Geriatr Med, Kumamoto 8608556, Japan.; Kadomatsu, T; Oike, Y (corresponding author), Kumamoto Univ, Ctr Metab Regulat Hlth Aging CMHA, Grad Sch Med Sci, Kumamoto 8608556, Japan.	tkado@gpo.kumamoto-u.ac.jp; oike@gpo.kumamoto-u.ac.jp	Ohtsuki, Sumio/S-4360-2016; Miyata, Keishi/HGF-1876-2022	Ohtsuki, Sumio/0000-0003-4634-7133; Miyata, Keishi/0000-0003-0336-1859; SATO, MICHIO/0000-0001-9339-1642	Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [21K07101, 21K15508]; Takeda Science Foundation; Tasaki Memorial Research Grant	Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Takeda Science Foundation(Takeda Science Foundation (TSF)); Tasaki Memorial Research Grant	We thank Kiyoka Tabu, Noriko Shirai, and Sayomi Iwaki for technical assistance. This work was supported by the Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (grant 21K07101 to TK and grant 21K15508 to HH), the Takeda Science Foundation (HH, TK), and Tasaki Memorial Research Grant for 2021 (HH).	Aoi J, 2011, CANCER RES, V71, P7502, DOI 10.1158/0008-5472.CAN-11-1758; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Cheng J, 2019, BMC EVOL BIOL, V19, DOI 10.1186/s12862-019-1477-1; Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077; Endo M, 2012, CANCER RES, V72, P1784, DOI 10.1158/0008-5472.CAN-11-3878; Feltes CM, 2002, CANCER RES, V62, P6688; Halbleib JM, 2007, MOL BIOL CELL, V18, P4261, DOI 10.1091/mbc.E07-04-0308; Hato T, 2008, TRENDS CARDIOVAS MED, V18, P6, DOI 10.1016/j.tcm.2007.10.003; HOFFMANN I, 1995, DEV BIOL, V169, P337, DOI 10.1006/dbio.1995.1148; Horiguchi H, 2021, ONCOGENE, V40, P55, DOI 10.1038/s41388-020-01505-7; Horiguchi H, 2019, GENE DEV, V33, P1641, DOI 10.1101/gad.329417.119; Horiguchi H, 2017, EMBO J, V36, P409, DOI 10.15252/embj.201695690; Horiguchi H, 2014, CANCER SCI, V105, P1550, DOI 10.1111/cas.12554; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Kadomatsu T, 2014, TRENDS ENDOCRIN MET, V25, P245, DOI 10.1016/j.tem.2014.03.012; Kaur H, 2012, MOL CANCER RES, V10, P293, DOI 10.1158/1541-7786.MCR-11-0457; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koshida S, 2005, DEV CELL, V8, P587, DOI 10.1016/j.devcel.2005.03.006; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Kumawat K, 2014, EXPERT OPIN THER TAR, V18, P1023, DOI 10.1517/14728222.2014.934813; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Masuda T, 2015, SCI REP-UK, V5, DOI 10.1038/srep09170; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427; Motokawa I, 2016, AM J PHYSIOL-LUNG C, V311, pL704, DOI 10.1152/ajplung.00005.2016; Munro SB, 1995, EXP MOL PATHOL, V62, P118, DOI 10.1006/exmp.1995.1013; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Odagiri H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004612; Oike Y, 2003, P NATL ACAD SCI USA, V100, P9494, DOI 10.1073/pnas.1531901100; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Osumi H, 2020, CANCER SCI, V111, P1241, DOI 10.1111/cas.14337; Oudhoff MJ, 2016, DEV CELL, V37, P47, DOI 10.1016/j.devcel.2016.03.002; Pishvaian MJ, 1999, CANCER RES, V59, P947; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Satriyo PB, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020148; Shibata T, 1996, CANCER LETT, V99, P147, DOI 10.1016/0304-3835(95)04047-1; Starchenko A, 2017, MOL BIOL CELL, V28, P1288, DOI 10.1091/mbc.E16-12-0852; Su YY, 2008, MOL CELL, V32, P652, DOI 10.1016/j.molcel.2008.10.023; Tabata M, 2009, CELL METAB, V10, P178, DOI 10.1016/j.cmet.2009.08.003; Takahashi M, 1998, CANCER RES, V58, P42; Tomita K, 2000, CANCER RES, V60, P3650; van Es JH, 2001, EXP CELL RES, V264, P126, DOI 10.1006/excr.2000.5142; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhui QQ, 2018, ONCOL LETT, V15, P1417, DOI 10.3892/ol.2017.7458	50	1	1	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2022	41	33					4028	4041		10.1038/s41388-022-02405-8	http://dx.doi.org/10.1038/s41388-022-02405-8		JUL 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3T2HP	35831580				2022-12-17	WOS:000824241600001
J	Meng, Q; Lu, YX; Wei, C; Wang, ZX; Lin, JF; Liao, K; Luo, XJ; Yu, K; Han, Y; Li, JJ; Tan, YT; Li, H; Zeng, ZL; Li, B; Xu, RH; Ju, HQ				Meng, Qi; Lu, Yun-Xin; Wei, Chen; Wang, Zi-Xian; Lin, Jin-Fei; Liao, Kun; Luo, Xiao-Jing; Yu, Kai; Han, Yi; Li, Jia-Jun; Tan, Yue-Tao; Li, Hao; Zeng, Zhao-Lei; Li, Bo; Xu, Rui-Hua; Ju, Huai-Qiang			Arginine methylation of MTHFD1 by PRMT5 enhances anoikis resistance and cancer metastasis	ONCOGENE			English	Article							PHOSPHORYLATION; DETACHMENT; METABOLISM; SURVIVAL; TARGET	Metastasis accounts for the major cause of cancer-related mortality. How disseminated tumor cells survive under suspension conditions and avoid anoikis is largely unknown. Here, using a metabolic enzyme-centered CRISPR-Cas9 genetic screen, we identified methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1 (MTHFD1) as a novel suppressor of anoikis. MTHFD1 depletion obviously restrained the capacity of cellular antioxidant defense and inhibited tumor distant metastasis. Mechanistically, MTHFD1 was found to bind the protein arginine methyltransferase 5 (PRMT5) and then undergo symmetric dimethylation on R173 by PRMT5. Under suspension conditions, the interaction between MTHFD1 and PRMT5 was strengthened, which increased the symmetric dimethylation of MTHFD1. The elevated methylation of MTHFD1 largely augmented its metabolic activity to generate NADPH, therefore leading to anoikis resistance and distant organ metastasis. Therapeutically, genetic depletion or pharmacological inhibition of PRMT5 declined tumor distant metastasis. And R173 symmetric dimethylation status was associated with metastasis and prognosis of ESCC patients. In conclusion, our study uncovered a novel regulatory role and therapeutic implications of PRMT5/MTHFD1 axis in facilitating anoikis resistance and cancer metastasis.	[Meng, Qi; Lu, Yun-Xin; Wei, Chen; Wang, Zi-Xian; Lin, Jin-Fei; Liao, Kun; Luo, Xiao-Jing; Yu, Kai; Han, Yi; Li, Jia-Jun; Tan, Yue-Tao; Li, Hao; Zeng, Zhao-Lei; Xu, Rui-Hua; Ju, Huai-Qiang] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, State Key Lab Oncol,South China Collaborat Innova, Guangzhou 510060, Peoples R China; [Meng, Qi; Lu, Yun-Xin; Wei, Chen; Wang, Zi-Xian; Lin, Jin-Fei; Luo, Xiao-Jing; Yu, Kai; Han, Yi; Li, Jia-Jun; Tan, Yue-Tao; Zeng, Zhao-Lei; Xu, Rui-Hua; Ju, Huai-Qiang] Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou 510060, Peoples R China; [Liao, Kun; Li, Bo] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem & Mol Biol, Guangzhou 510080, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Sun Yat Sen University	Xu, RH; Ju, HQ (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, State Key Lab Oncol,South China Collaborat Innova, Guangzhou 510060, Peoples R China.; Xu, RH; Ju, HQ (corresponding author), Chinese Acad Med Sci, Res Unit Precis Diag & Treatment Gastrointestinal, Guangzhou 510060, Peoples R China.	xurh@sysucc.org.cn; juhq@sysucc.org.cn	xu, rui/GRX-5734-2022		National Natural Science Foundation of China [81802452, 82002465]; Natural Science Foundation of Guangdong Province [2019A1515010233]; Science and Technology Program of Guangdong [2019B020227002]; Guangdong Esophageal Cancer Institute Science and Technology Program [M202003]; Bureau of Education of Guangzhou Municipality [202032801]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2019-I2M-5-036]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Program of Guangdong; Guangdong Esophageal Cancer Institute Science and Technology Program; Bureau of Education of Guangzhou Municipality; CAMS Innovation Fund for Medical Sciences (CIFMS)	This research was supported by the National Natural Science Foundation of China (82022052, 82073112 and 81930065), Natural Science Foundation of Guangdong Province (2019A1515010233), Science and Technology Program of Guangdong (2019B020227002), Guangdong Esophageal Cancer Institute Science and Technology Program (M202003), National Natural Science Foundation of China (81802452, 82002465), Bureau of Education of Guangzhou Municipality (202032801) and CAMS Innovation Fund for Medical Sciences (CIFMS) (2019-I2M-5-036).	Antonysamy S, 2017, SUBCELL BIOCHEM, V83, P185, DOI 10.1007/978-3-319-46503-6_7; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Cai CC, 2021, ADV SCI, V8, DOI 10.1002/advs.202003047; Cai Z, 2020, MOL CELL, V80, P263, DOI 10.1016/j.molcel.2020.09.018; Chen H, 2006, NUCLEIC ACIDS RES, V34, pW249, DOI 10.1093/nar/gkl233; Cheng TY, 2018, ONCOGENE, V37, P1730, DOI 10.1038/s41388-017-0086-y; Deng WK, 2017, BRIEF BIOINFORM, V18, P647, DOI 10.1093/bib/bbw041; Du SC, 2021, ONCOGENE, V40, P5764, DOI 10.1038/s41388-021-01988-y; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Guccione E, 2019, NAT REV MOL CELL BIO, V20, P642, DOI 10.1038/s41580-019-0155-x; Gustafsson R, 2017, CANCER RES, V77, P937, DOI 10.1158/0008-5472.CAN-16-1476; Hitosugi T, 2014, ONCOGENE, V33, P4279, DOI 10.1038/onc.2013.406; Hoxhaj G, 2019, SCIENCE, V363, P1088, DOI 10.1126/science.aau3903; Hu D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9419; Hwang JW, 2021, EXP MOL MED, V53, P788, DOI 10.1038/s12276-021-00613-y; Jarrold J, 2019, TRENDS MOL MED, V25, P993, DOI 10.1016/j.molmed.2019.05.007; Ju HQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00326-0; Ju HQ, 2019, JNCI-J NATL CANCER I, V111, P584, DOI 10.1093/jnci/djy160; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Li G, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2019822118; Li W, 2021, NAT METAB, V3, P75, DOI 10.1038/s42255-020-00330-2; Li W, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0843-6; Liang C, 2020, GUT, V69, P888, DOI 10.1136/gutjnl-2018-317163; Lu YX, 2018, CANCER RES, V78, P1972, DOI 10.1158/0008-5472.CAN-17-3155; Mason JA, 2017, TRENDS CANCER, V3, P475, DOI 10.1016/j.trecan.2017.04.009; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Rao XJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9468; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; TheUniProtConsortium, 2017, Nucleic Acids Res, V45, pD158, DOI 10.1093/nar/gkw1099; Wang B, 2020, EMBO REP, V21, DOI 10.15252/embr.201948183; Wang GH, 2019, NAT CELL BIOL, V21, P214, DOI 10.1038/s41556-018-0266-1; Wang XY, 2021, CELL DEATH DIFFER, V28, P2931, DOI 10.1038/s41418-021-00793-0; Wang YN, 2018, ONCOGENE, V37, P6025, DOI 10.1038/s41388-018-0384-z; Wang YQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02951-4; Wei QY, 2020, ONCOGENE, V39, P6139, DOI 10.1038/s41388-020-01432-7; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Yu H, 2019, FUTURE ONCOL, V15, P1771, DOI 10.2217/fon-2018-0606; Zhang HF, 2021, CANCER DISCOV, V11, P2884, DOI 10.1158/2159-8290.CD-20-1690; Zhang J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13732; Zhou LS, 2016, EMBO REP, V17, P811, DOI 10.15252/embr.201541643; Zhu YH, 2020, MOL CELL, V77, P138, DOI 10.1016/j.molcel.2019.10.015	43	1	1	12	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2022	41	32					3912	3924		10.1038/s41388-022-02387-7	http://dx.doi.org/10.1038/s41388-022-02387-7		JUL 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3O2GY	35798877				2022-12-17	WOS:000821721300005
J	You, A; Wei,; Yuan, HF; Gu, LK; Zhou, J; Deng, DJ				You, Abin; Tian, Wei; Yuan, Hongfan; Gu, Liankun; Zhou, Jing; Deng, Dajun			TTC22 promotes m6A-mediated WTAP expression and colon cancer metastasis in an RPL4 binding-dependent pattern	ONCOGENE			English	Article							MESSENGER-RNA METHYLATION; GENE-EXPRESSION; PROTEIN L4; M(6)A; N-6-METHYLADENOSINE; COMPLEX	WTAP, an essential component of the RNA N-6-methyladenosine (m6A) modification complex, guides METLL3-METLL14 heteroduplexes to target RNAs in the nuclear speckles of mammalian cells. Here, we show that TTC22 is widely coexpressed with WTAP and FTO in many human tissues by mining Genotype-Tissue Expression (GTEx) datasets. Our results indicate that the direct interaction of TTC22 with 60S ribosomal protein L4 (RPL4) promotes the binding of WTAP mRNA to RPL4, enhances the stability and translation efficiency of WTAP mRNA, and consequently increases the level of WTAP protein. Also, WTAP mRNA itself is an m6A target and YTHDF1 is characterized as an essential m6A binding protein interacting with m6A-modified WTAP mRNA. TTC22 triggers a positive feedback loop between WTAP expression and WTAP mRNA m6A modification, leading to an increased m6A level in total RNA. The knockdown of RPL4, WTAP, or YTHDF1 expression diminishes the TTC22-induced increase in the m6A level of total RNA. Thus, TTC22 caused dramatic expression changes in genes related to metabolic pathways, ribosomal biogenesis, the RNA spliceosome, and microorganism infections. Importantly, TTC22 upregulates the expression of SNAI1 by increasing m6A level and thus promotes lung metastases of colon cancer cells in mice. In conclusion, our study showed that TTC22 upregulates WTAP and SNAI1 expression, which contributes to TTC22-induced colon cancer metastasis.	[You, Abin; Tian, Wei; Yuan, Hongfan; Gu, Liankun; Zhou, Jing; Deng, Dajun] Peking Univ Canc Hosp & Inst, Div Etiol, Key Lab Carcinogenesis & Translat Res MOE Beijing, Beijing 100142, Peoples R China; [You, Abin] Xiamen Univ, Affiliated Hosp 1, Xiamen Key Lab Antitumor Drug Transformat Res, Dept Med Oncol, Xiamen 361003, Fujian, Peoples R China; [Deng, Dajun] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing 211166, Peoples R China	Xiamen University; Nanjing Medical University	Wei,; Deng, DJ (corresponding author), Peking Univ Canc Hosp & Inst, Div Etiol, Key Lab Carcinogenesis & Translat Res MOE Beijing, Beijing 100142, Peoples R China.; Deng, DJ (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing 211166, Peoples R China.	tianwei@bjmu.edu.cn; dengdajun@bjmu.edu.cn	Deng, Dajun/D-4605-2009	Deng, Dajun/0000-0001-5161-5943	National Natural Science Foundation of China [81372592]; Beijing Hospitals Authority' Mission Plan [SML20191101]; Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation; Fundamental Research Funds for the Central Universities [BMU2020PY005]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Hospitals Authority' Mission Plan; Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by grants from the National Natural Science Foundation of China (81372592) and from Beijing Hospitals Authority' Mission Plan (SML20191101) to DD and by a grant from the Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation and the Fundamental Research Funds for the Central Universities (BMU2020PY005) to WT. An Open access license has not been selected.	Agarwala SD, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002732; Capalbo L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12507-9; Chung DD, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107696; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; Dominissini D, 2013, NAT PROTOC, V8, P176, DOI 10.1038/nprot.2012.148; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Frye M, 2018, SCIENCE, V361, P1346, DOI 10.1126/science.aau1646; Geula S, 2015, SCIENCE, V347, P1002, DOI 10.1126/science.1261417; He X, 2016, ONCOTARGET, V7, P16217, DOI 10.18632/oncotarget.7479; Horiuchi K, 2013, J BIOL CHEM, V288, P33292, DOI 10.1074/jbc.M113.500397; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Li A, 2017, CELL RES, V27, P444, DOI 10.1038/cr.2017.10; Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Ma WR, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01150-4; McFadden MJ, 2021, TRENDS BIOCHEM SCI, V46, P366, DOI 10.1016/j.tibs.2020.11.008; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Miao CG, 2015, IMMUNOL LETT, V166, P45, DOI 10.1016/j.imlet.2015.05.011; Niu Yamei, 2013, Genomics Proteomics & Bioinformatics, V11, P8, DOI 10.1016/j.gpb.2012.12.002; Panneerdoss S, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar8263; Pillet B, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005565; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Pringle Eric S, 2019, Curr Protoc Mol Biol, V125, pe79, DOI 10.1002/cpmb.79; Schwartz S, 2014, CELL REP, V8, P284, DOI 10.1016/j.celrep.2014.05.048; Shen B, 2013, CELL RES, V23, P720, DOI 10.1038/cr.2013.46; Shen CL, 2016, P NATL ACAD SCI USA, V113, P2229, DOI 10.1073/pnas.1525444113; Shi YL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12801-6; Soerensen M, 2019, BIOGERONTOLOGY, V20, P627, DOI 10.1007/s10522-019-09818-1; Sorci M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0843-z; Stransky N, 2015, NATURE, V528, P84, DOI 10.1038/nature15736; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tian W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0925-y; Wang X, 2017, RNA BIOL, V14, P300, DOI 10.1080/15476286.2017.1282025; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Xiang MY, 2020, EPIGENOMICS-UK, V12, P801, DOI 10.2217/epi-2019-0358; Yang YCT, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1273-2; Zeytuni N, 2012, STRUCTURE, V20, P397, DOI 10.1016/j.str.2012.01.006; Zhao B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09060-w; Zhao BXS, 2017, NAT REV MOL CELL BIO, V18, P31, DOI 10.1038/nrm.2016.132; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015	43	1	1	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2022	41	32					3925	3938		10.1038/s41388-022-02402-x	http://dx.doi.org/10.1038/s41388-022-02402-x		JUL 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3O2GY	35798874	Green Submitted			2022-12-17	WOS:000821721300003
J	Shen, J; Huang, QW; Jia, WY; Feng, SJ; Liu, L; Li, XL; Tao, DD; Xie, DX				Shen, Jie; Huang, Qingwen; Jia, Weiyi; Feng, Shengjie; Liu, Liang; Li, Xiaolan; Tao, Deding; Xie, Daxing			YAP1 induces invadopodia formation by transcriptionally activating TIAM1 through enhancer in breast cancer	ONCOGENE			English	Article							NUCLEOTIDE EXCHANGE FACTOR; HIPPO SIGNALING PATHWAY; METASTASIS; CORTACTIN; BINDING; ASSOCIATION; PODOSOMES; MOLECULE; INVASION; COMPLEX	Yes-associated protein 1 (YAP1), a central component of the Hippo pathway, plays an important role in tumor metastasis; however, the underlying mechanism remains to be elucidated. Invadopodia are actin-rich protrusions containing multiple proteases and have been widely reported to promote cell invasiveness by degrading the extracellular matrix. In the present study, we report that YAP1 induces invadopodia formation and promotes tumor metastasis in breast cancer cells. We also identify TIAM1, a guanine nucleotide exchange factor, as a target of the YAP1-TEAD4 complex. Our results demonstrate that YAP1 could promote TEAD4 binding to the enhancer region of TIAM1, which activates TIAM1 expression, subsequently increasing RAC1 activity and inducing invadopodia formation. These findings reveal the functional role of Hippo signaling in the regulation of invadopodia and provide potential molecular targets for preventing tumor metastasis in breast cancer.	[Shen, Jie; Huang, Qingwen; Jia, Weiyi; Feng, Shengjie; Liu, Liang; Li, Xiaolan; Tao, Deding; Xie, Daxing] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Mol Med Ctr, Wuhan, Peoples R China; [Shen, Jie; Huang, Qingwen; Jia, Weiyi; Feng, Shengjie; Liu, Liang; Xie, Daxing] Huazhong Univ Sci & Technol, Tongji Hosp, Dept GI Surg, Tongji Med Coll, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Xie, DX (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Mol Med Ctr, Wuhan, Peoples R China.; Xie, DX (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept GI Surg, Tongji Med Coll, Wuhan, Peoples R China.	dxxie@tjh.tjmu.edu.cn		Shen, Jie/0000-0002-8442-7268	National Natural Science Foundation of China [81572861, 81773053]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (Grant numbers: 81572861, 81773053).	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Alonso DF, 2011, CURR PHARM BIOTECHNO, V12, P1974; Baik M, 2019, METHODSX, V6, P718, DOI 10.1016/j.mex.2019.03.024; Benjamin DC, 2020, CANCER RES, V80, P3867, DOI 10.1158/0008-5472.CAN-20-0212; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Boissier P, 2014, CELL SIGNAL, V26, P483, DOI 10.1016/j.cellsig.2013.11.034; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Caldon CE, 2012, MOL CANCER THER, V11, P1488, DOI 10.1158/1535-7163.MCT-11-0963; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Diamantopoulou Z, 2017, CANCER CELL, V31, P621, DOI 10.1016/j.ccell.2017.03.007; Diaz B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000368; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; Feldker N, 2020, EMBO J, V39, DOI 10.15252/embj.2019103209; Feng SJ, 2022, CANCER LETT, V532, DOI 10.1016/j.canlet.2022.215588; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Galouzis CC, 2022, CURR OPIN CELL BIOL, V75, DOI 10.1016/j.ceb.2022.01.010; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Harper K, 2010, CANCER RES, V70, P4634, DOI 10.1158/0008-5472.CAN-09-3813; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; Khan A, 2018, NUCLEIC ACIDS RES, V46, pD260, DOI 10.1093/nar/gkx1126; Kudlik G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218117; Lin KC, 2017, TRENDS BIOCHEM SCI, V42, P862, DOI 10.1016/j.tibs.2017.09.003; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lohmer LL, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005786; Lohmer LL, 2014, CELL ADHES MIGR, V8, P246, DOI 10.4161/cam.28406; Maugeri-Sacca M, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.12; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Pocaterra A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.230425; Qadir MI, 2015, CHEM BIOL DRUG DES, V86, P432, DOI 10.1111/cbdd.12556; Qiao YT, 2017, CELL REP, V19, P1495, DOI 10.1016/j.celrep.2017.04.075; Revach OY, 2016, EXP CELL RES, V343, P82, DOI 10.1016/j.yexcr.2016.02.003; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rosenberg BJ, 2017, MOL BIOL CELL, V28, P1347, DOI 10.1091/mbc.E16-12-0885; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sabatier R, 2011, BREAST CANCER RES TR, V126, P407, DOI 10.1007/s10549-010-0897-9; Seano G, 2015, CELL CYCLE, V14, P1370, DOI 10.1080/15384101.2015.1026523; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Shen J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0850-z; Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun X, 2020, NUCLEIC ACIDS RES, V48, P7182, DOI 10.1093/nar/gkaa482; Surviladze Z., 2010, PROBE REPORTS NIH MO; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Tong M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02240-6; Vinci M, 2015, JOVE-J VIS EXP, DOI 10.3791/52686; Wang ZY, 2014, P NATL ACAD SCI USA, V111, pE89, DOI 10.1073/pnas.1319190110; Wang ZQ, 2016, METHODS MOL BIOL, V1406, P203, DOI 10.1007/978-1-4939-3444-7_18; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Yang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109980; Yu HX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051239; Zagryazhskaya-Masson A, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201910132; Zanconato F, 2018, NAT MED, V24, P1599, DOI 10.1038/s41591-018-0158-8; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhu C, 2019, MOL CELL, V75, P791, DOI 10.1016/j.molcel.2019.06.010	67	1	1	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2022	41	31					3830	3845		10.1038/s41388-022-02344-4	http://dx.doi.org/10.1038/s41388-022-02344-4		JUN 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3I9OZ	35773411	hybrid, Green Published, Green Submitted			2022-12-17	WOS:000819316500002
J	Huang, C; Lv, XM; Chen, PC; Liu, JY; He, CB; Chen, L; Wang, HB; Moness, ML; Dong, JX; Rueda, BR; Davis, JS; Wang, C				Huang, Cong; Lv, Xiangmin; Chen, Peichao; Liu, Jiyuan; He, Chunbo; Chen, Li; Wang, Hongbo; Moness, Madelyn L.; Dong, Jixin; Rueda, Bo R.; Davis, John S.; Wang, Cheng			Human papillomavirus targets the YAP1-LATS2 feedback loop to drive cervical cancer development	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; HIPPO SIGNALING PATHWAY; CELLULAR SENESCENCE; NATURAL-HISTORY; HPV INFECTION; EXPRESSION; WORLDWIDE; ESTROGEN; YAP/TAZ; P53	Human papillomavirus (HPV) infection is very common in sexually active women, but cervical cancer only develops in a small fraction of HPV-infected women, suggesting that unknown intrinsic factors associated with the unique genetic/genomic background of the high-risk population play a critical role in cervical carcinogenesis. Although our previous studies have identified the hyperactivated YAP1 oncogene as a critical contributor to cervical cancer, the molecular mechanism by which YAP1 drives cervical cancer is unknown. In the present study, we found that although the hyperactivated YAP1 caused a malignant transformation of immortalized cervical epithelial cells, it induced cellular senescence in cultures of primary human cervical epithelial cells (HCvECs). However, the hyperactivated YAP1 induced malignant transformation of HCvECs in the presence of high-risk HPV E6/E7 proteins, suggesting that the hyperactivated YAP1 synergizes with HPV to initiate cervical cancer development. Our mechanistic studies demonstrate that YAP1, via up-regulating LATS2, formed a YAP1-LATS2 negative feedback loop in cervical epithelial cells to maintain homeostasis of cervical tissue. Intriguingly, we found that high-risk HPV targets LATS2 to disrupt the feedback loop leading to the malignant transformation of cervical epithelial cells. Finally, we report that mitomycin C, an FDA-approved drug that could upregulate LATS2 and drive cellular senescence in vitro and in vivo, induced a regression of cervical cancer in a pre-clinial animal model. Thus, high-risk HPV targeting the YAP1-LATS2 feedback loop represents a new mechanism of cervical cancer development.	[Huang, Cong; Lv, Xiangmin; Chen, Peichao; Liu, Jiyuan; He, Chunbo; Chen, Li; Wang, Hongbo; Moness, Madelyn L.; Rueda, Bo R.; Wang, Cheng] Harvard Med Sch, Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Vincent Ctr Reprod Biol, Boston, MA 02114 USA; [Chen, Peichao] Wenzhou Univ, Coll Life & Environm Sci, Wenzhou 325035, Zhejiang, Peoples R China; [He, Chunbo; Dong, Jixin; Davis, John S.] Univ Nebraska Med Ctr, Fred & Pamela Canc Ctr, Omaha, NE 68198 USA; [Chen, Li] Chinese Acad Sci, Key Lab Anim Ecol & Conservat Biol, Beijing 100101, Peoples R China; [Davis, John S.] Univ Nebraska Med Ctr, Dept Obstet & Gynecol, Olson Ctr Womens Hlth, Omaha, NE 68198 USA; [Davis, John S.] Vet Adm Nebraska Western Iowa Healthcare Syst, Omaha, NE 68105 USA; [Huang, Cong] Peking Univ Shenzhen Hosp, Shenzhen Peking Univ Hong Kong Univ Sci & Technol, Dept Dermatol, Shenzhen 518036, Peoples R China	Harvard University; Harvard Medical School; Massachusetts General Hospital; Wenzhou University; University of Nebraska System; University of Nebraska Medical Center; Chinese Academy of Sciences; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; Hong Kong University of Science & Technology; Peking University	Wang, C (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Vincent Ctr Reprod Biol, Boston, MA 02114 USA.	cwang34@mgh.harvard.edu		Rueda, Bo/0000-0001-9489-8699	National Cancer Institute/National Institute of Health [1R01CA197976, 1R01CA201500]; Vincent Memorial Hospital Foundation/Vincent Center for Reproductive Biology, Colleen's Dream Foundation; Ruggles Family Foundation; Veterans Administration Senior Research Career Scientist Award; Nile Albright Research Foundation	National Cancer Institute/National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Vincent Memorial Hospital Foundation/Vincent Center for Reproductive Biology, Colleen's Dream Foundation; Ruggles Family Foundation; Veterans Administration Senior Research Career Scientist Award; Nile Albright Research Foundation	This work was supported by the National Cancer Institute/National Institute of Health (1R01CA197976, 1R01CA201500), the Vincent Memorial Hospital Foundation/Vincent Center for Reproductive Biology, Colleen's Dream Foundation (no number), and the Ruggles Family Foundation. JSD is the recipient of a Veterans Administration Senior Research Career Scientist Award. BR was supported by the Nile Albright Research Foundation.	Arbyn M, 2020, LANCET GLOB HEALTH, V8, pE191, DOI 10.1016/S2214-109X(19)30482-6; Billman GE, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00200; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Boyer SN, 1996, CANCER RES, V56, P4620; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Brandman O, 2008, SCIENCE, V322, P390, DOI 10.1126/science.1160617; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Castellsague X, 2006, JNCI-J NATL CANCER I, V98, P303, DOI 10.1093/jnci/djj067; Castellsague X, 2008, GYNECOL ONCOL, V110, pS4, DOI 10.1016/j.ygyno.2008.07.045; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000; Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005; Chung SH, 2008, CANCER RES, V68, P9928, DOI 10.1158/0008-5472.CAN-08-2051; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Dai XM, 2015, CELL RES, V25, P1175, DOI 10.1038/cr.2015.101; Dey A, 2020, NAT REV DRUG DISCOV, V19, P480, DOI 10.1038/s41573-020-0070-z; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Ferrell JE, 2013, CURR OPIN CELL BIOL, V25, P676, DOI 10.1016/j.ceb.2013.07.007; Fu D, 2014, ENDOCR-RELAT CANCER, V21, P297, DOI 10.1530/ERC-13-0339; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; HARVEY M, 1995, CANCER RES, V55, P1146; He CB, 2019, CELL REP, V26, P2636, DOI 10.1016/j.celrep.2019.02.004; He CB, 2019, EMBO REP, V20, DOI 10.15252/embr.201744948; He CB, 2015, EMBO MOL MED, V7, P1426, DOI 10.15252/emmm.201404976; Howlader N, 2012, SEER CANC STAT REV 1; Hua G, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.207; Korotkevich G., 2016, BIORXIV; Koutsky Laura, 1997, American Journal of Medicine, V102, P3; Kulasingam SL, 2002, JAMA-J AM MED ASSOC, V288, P1749, DOI 10.1001/jama.288.14.1749; Lee S, 2019, NAT CELL BIOL, V21, P94, DOI 10.1038/s41556-018-0249-2; Li XM, 2013, INT J MOL SCI, V14, P2431, DOI 10.3390/ijms14022431; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu XL, 2018, ACTA PHARMACOL SIN, V39, P1553, DOI 10.1038/aps.2017.198; Lv XM, 2017, MOL CANCER THER, V16, P1080, DOI 10.1158/1535-7163.MCT-16-0626; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Modell H, 2015, ADV PHYSIOL EDUC, V39, P259, DOI 10.1152/advan.00107.2015; Molano M, 2003, AM J EPIDEMIOL, V158, P486, DOI 10.1093/aje/kwg171; Moroishi T, 2015, GENE DEV, V29, P1271, DOI 10.1101/gad.262816.115; Moya IM, 2019, NAT REV MOL CELL BIO, V20, P211, DOI 10.1038/s41580-018-0086-y; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Perez-Plasencia C., 2008, INT ARCH MED, V1; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Riley RR, 2003, CANCER RES, V63, P4862; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rosty C, 2005, ONCOGENE, V24, P7094, DOI 10.1038/sj.onc.1208854; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schiffman Mark H, 2003, J Natl Cancer Inst, V95, pE2; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Shah R, 2020, J WOMENS HEALTH, V29, P799, DOI 10.1089/jwh.2019.7858; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Stelzle D, 2021, LANCET GLOB HEALTH, V9, pE161, DOI 10.1016/S2214-109X(20)30459-9; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Turrigiano G, 2007, CURR OPIN NEUROBIOL, V17, P318, DOI 10.1016/j.conb.2007.04.004; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.397; Wang C, 2019, MOL CELL ONCOL, V6, DOI 10.1080/23723556.2019.1612677; Wang C, 2010, ENDOCRINOLOGY, V151, P2319, DOI 10.1210/en.2009-1489; Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050; Wyld L, 2020, CANCERS, V12, DOI 10.3390/cancers12082134; Xing BY, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.606335; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang Y, 2021, GENOME RES, V31, DOI 10.1101/gr.275193.120	71	1	1	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2022	41	30					3761	3777		10.1038/s41388-022-02390-y	http://dx.doi.org/10.1038/s41388-022-02390-y		JUN 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	3D1SP	35761037				2022-12-17	WOS:000817034400001
J	Zeng, ZC; Xu, SW; Wang, FF; Peng, X; Zhang, WN; Zhan, YZ; Ding, YQ; Liu, ZG; Liang, L				Zeng, Zhicheng; Xu, Shaowan; Wang, Feifei; Peng, Xin; Zhang, Wanning; Zhan, Yizhi; Ding, Yanqing; Liu, Ziguang; Liang, Li			HAO1-mediated oxalate metabolism promotes lung pre-metastatic niche formation by inducing neutrophil extracellular traps	ONCOGENE			English	Article							GLYCOLATE OXIDASE; MOUSE MODEL; RECOGNITION; ACTIVATION; CELLS; RNAS	Metabolic reprogramming has been shown to be involved in cancer-induced pre-metastatic niche (PMN) formation, but the underlying mechanisms have been insufficiently explored. Here, we showed that hydroxyacid oxidase 1 (HAO1), a rate-limiting enzyme of oxalate synthesis, was upregulated in the alveolar epithelial cells of mice bearing metastatic breast cancer cells at the pre-metastatic stage, leading to oxalate accumulation in lung tissue. Lung oxalate accumulation induced neutrophil extracellular trap (NET) formation by activating NADPH oxidase, which facilitated the formation of pre-metastatic niche. In addition, lung oxalate accumulation promoted the proliferation of metastatic cancer cells by activating the MAPK signaling pathway. Pharmacologic inhibition of HAO1 could effectively suppress the lung oxalate accumulation induced by primary cancer, consequently dampening lung metastasis of breast cancer. Breast cancer cells induced HAO1 expression and oxalate accumulation in alveolar epithelial cells by activating TLR3-IRF3 signaling. Collectively, these findings underscore the role of HAO1-mediated oxalate metabolism in cancer-induced lung PMN formation and metastasis. HAO1 could be an appealing therapeutic target for preventing lung metastasis of cancer.	[Zeng, Zhicheng; Liu, Ziguang] Southern Med Univ, Peoples Hosp Shunde Foshan 1, Shunde Hosp, Dept Pathol, Foshan, Guangdong, Peoples R China; [Zeng, Zhicheng; Xu, Shaowan; Wang, Feifei; Peng, Xin; Zhang, Wanning; Zhan, Yizhi; Ding, Yanqing; Liang, Li] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Peoples R China; [Zeng, Zhicheng; Xu, Shaowan; Wang, Feifei; Peng, Xin; Zhang, Wanning; Zhan, Yizhi; Ding, Yanqing; Liang, Li] Southern Med Univ, Basic Med Coll, Guangzhou 510515, Peoples R China; [Zeng, Zhicheng; Xu, Shaowan; Wang, Feifei; Peng, Xin; Zhang, Wanning; Zhan, Yizhi; Ding, Yanqing; Liang, Li] Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Liang, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Peoples R China.; Liang, L (corresponding author), Southern Med Univ, Basic Med Coll, Guangzhou 510515, Peoples R China.; Liang, L (corresponding author), Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China.	lli@smu.edu.cn			National Key R&D Program of China [2017YFC1309002]; National Natural Science Foundation of China [81672821, 81472313, 81773101, 81903002, 82003059]; China Postdoctoral Science Foundation [2019M652963, 2020M682624]; Cancer Research UK [A3655]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Cancer Research UK(Cancer Research UK)	This work was supported by the National Key R&D Program of China (2017YFC1309002), National Natural Science Foundation of China (81672821, 81472313, 81773101, 81903002, 82003059), China Postdoctoral Science Foundation (2019M652963, 2020M682624), Cancer Research UK grant A3655.	Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Baker PRS, 2004, AM J PHYSIOL-CELL PH, V287, pC1359, DOI 10.1152/ajpcell.00238.2004; Bourhis JM, 2009, ACTA CRYSTALLOGR F, V65, P1246, DOI 10.1107/S1744309109041670; Castellaro AM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1747-2; Cools-Lartigue J, 2013, J CLIN INVEST, V123, P3446, DOI 10.1172/JCI67484; Dutta C, 2016, MOL THER, V24, P770, DOI 10.1038/mt.2016.4; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Forte G, 2012, J IMMUNOL, V188, P5357, DOI 10.4049/jimmunol.1103811; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Jablonska J, 2017, ONCOTARGET, V8, P112132, DOI 10.18632/oncotarget.22792; Jorch SK, 2017, NAT MED, V23, P279, DOI 10.1038/nm.4294; Joshi S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/462361; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Lee W, 2019, AGING-US, V11, P6624, DOI 10.18632/aging.102258; Liebow A, 2017, J AM SOC NEPHROL, V28, P494, DOI 10.1681/ASN.2016030338; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Martin-Higueras C, 2016, MOL THER, V24, P719, DOI 10.1038/mt.2015.224; Milara J, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0179-5; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Robertson DS, 2011, CLIN CHEM LAB MED, V49, P1405, DOI 10.1515/CCLM.2011.238; Schnedler N, 2011, J HEPATOL, V54, P513, DOI 10.1016/j.jhep.2010.07.036; Simoes RV, 2015, NEOPLASIA, V17, P671, DOI 10.1016/j.neo.2015.08.005; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Tavora B, 2020, NATURE, V586, P299, DOI 10.1038/s41586-020-2774-y; Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001; Tsuji H, 2016, WORLD J UROL, V34, P89, DOI 10.1007/s00345-015-1563-y; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Whitsett JA, 2015, NAT IMMUNOL, V16, P27, DOI 10.1038/ni.3045; Wu ZM, 2015, CELL STEM CELL, V17, P47, DOI 10.1016/j.stem.2015.05.016; Yang LB, 2020, NATURE, V583, P133, DOI 10.1038/s41586-020-2394-6; Yang XY, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.703640; Yuan JM, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00949-4; Zabaleta N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07827-1; Zeng ZC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07810-w; Zhu JN, 2019, FREE RADICAL BIO MED, V134, P9, DOI 10.1016/j.freeradbiomed.2018.12.033	37	1	1	5	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2022	41	29					3719	3731		10.1038/s41388-022-02248-3	http://dx.doi.org/10.1038/s41388-022-02248-3		JUN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y6YE	35739335	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000814926700001
J	Buschhaus, JM; Rajendran, S; Humphries, BA; Cutter, AC; Muniz, AJ; Ciavattone, NG; Buschhaus, AM; Caneque, T; Nwosu, ZC; Sahoo, D; Bevoor, AS; Shah, YM; Lyssiotis, CA; Ghosh, P; Wicha, MS; Rodriguez, R; Luker, GD				Buschhaus, Johanna M.; Rajendran, Shrila; Humphries, Brock A.; Cutter, Alyssa C.; Muniz, Ayse J.; Ciavattone, Nicholas G.; Buschhaus, Alexander M.; Caneque, Tatiana; Nwosu, Zeribe C.; Sahoo, Debashis; Bevoor, Avinash S.; Shah, Yatrik M.; Lyssiotis, Costas A.; Ghosh, Pradipta; Wicha, Max S.; Rodriguez, Raphael; Luker, Gary D.			Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer	ONCOGENE			English	Article							ENDOCRINE RESISTANCE; DOWN-REGULATION; SALINOMYCIN; SENSITIVITY; INHIBITION; EXPRESSION; TUMORS	Patients with estrogen receptor-positive (ER+) breast cancer, the most common subtype, remain at risk for lethal metastatic disease years after diagnosis. Recurrence arises partly because tumor cells in bone marrow become resistant to estrogen-targeted therapy. Here, we utilized a co-culture model of bone marrow mesenchymal stem cells (MSCs) and ER+ breast cancer cells to recapitulate interactions of cancer cells in bone marrow niches. ER+ breast cancer cells in direct contact with MSCs acquire cancer stem-like (CSC) phenotypes with increased resistance to standard antiestrogenic drugs. We confirmed that co-culture with MSCs increased labile iron in breast cancer cells, a phenotype associated with CSCs and disease progression. Clinically approved iron chelators and in-house lysosomal iron-targeting compounds restored sensitivity to antiestrogenic therapy. These findings establish iron modulation as a mechanism to reverse MSC-induced drug resistance and suggest iron modulation in combination with estrogen-targeted therapy as a promising, translatable strategy to treat ER+ breast cancer.	[Buschhaus, Johanna M.; Luker, Gary D.] Univ Michigan, Dept Biomed Engn, 2200 Bonisteel, Ann Arbor, MI 48109 USA; [Buschhaus, Johanna M.; Rajendran, Shrila; Humphries, Brock A.; Cutter, Alyssa C.; Ciavattone, Nicholas G.; Buschhaus, Alexander M.; Bevoor, Avinash S.; Luker, Gary D.] Univ Michigan, Ctr Mol Imaging, Dept Radiol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA; [Muniz, Ayse J.] Univ Michigan, Macromol Sci & Engn & Biointerfaces Inst, Ann Arbor, MI 48109 USA; [Caneque, Tatiana; Rodriguez, Raphael] PSL Res Univ, Inst Curie, Chem Biol Canc Lab, CNRS UMR 3666,INSERM U1143, Paris, France; [Nwosu, Zeribe C.; Shah, Yatrik M.; Lyssiotis, Costas A.] Univ Michigan, Med Sch, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Sahoo, Debashis] Univ Calif San Diego, Pediat & Comp Sci & Engn, La Jolla, CA 92093 USA; [Shah, Yatrik M.] Univ Michigan, Med Sch, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA; [Shah, Yatrik M.] Univ Michigan, Med Sch, Rogel Canc Ctr, Ann Arbor, MI 48109 USA; [Lyssiotis, Costas A.] Univ Michigan, Med Sch, Dept Internal Med, Ann Arbor, MI 48109 USA; [Ghosh, Pradipta] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Ghosh, Pradipta] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Wicha, Max S.] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA; [Luker, Gary D.] Univ Michigan, Dept Microbiol & Immunol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; University of Michigan System; University of Michigan; University of California System; University of California San Diego; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Luker, GD (corresponding author), Univ Michigan, Dept Biomed Engn, 2200 Bonisteel, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Ctr Mol Imaging, Dept Radiol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.; Luker, GD (corresponding author), Univ Michigan, Dept Microbiol & Immunol, 109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	gluker@med.umich.edu		Caneque, Tatiana/0000-0002-1110-0643; luker, gary/0000-0001-6832-2581; Nwosu, Zeribe/0000-0003-1641-2045	University of Michigan Rogel Cancer Center through National Institutes of Health [P30CA046592]; NIH [R01CA100768, R01CA238042, R01GM138385, R01CA148828, R01CA245546, R01DK095201, R01CA248160, R35CA197585, R01CA2449310, U01CA210152, R01CA238023, R33CA225549, R50CA221807, R37CA222563]; Breast Cancer Research Foundation [BCRF-18-173]; European Research Council under the European Union [647973]; Foundation Charles Defforey-Institut de France; Ligue Contre le Cancer Equipe Labellisee; National Science Foundation Graduate Research Fellowship [DGE 1256260]; American Cancer Society -Michigan Cancer Research Fund Postdoctoral Fellowship [PF-18-236-01-CCG]; Michigan Postdoctoral Pioneer Program at the University of Michigan Medical School	University of Michigan Rogel Cancer Center through National Institutes of Health; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; European Research Council under the European Union(European Research Council (ERC)); Foundation Charles Defforey-Institut de France; Ligue Contre le Cancer Equipe Labellisee; National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF)); American Cancer Society -Michigan Cancer Research Fund Postdoctoral Fellowship(American Cancer Society); Michigan Postdoctoral Pioneer Program at the University of Michigan Medical School	We acknowledge support to the University of Michigan Rogel Cancer Center through National Institutes of Health grant P30CA046592 for flow cytometry and animal imaging studies. The authors acknowledge funding from NIH grants R01CA100768, R01CA238042, R01GM138385, R01CA148828, R01CA245546, R01DK095201, R01CA248160, R35CA197585, R01CA2449310, U01CA210152, R01CA238023, R33CA225549, R50CA221807, and R37CA222563 and funding from the Breast Cancer Research Foundation grant BCRF-18-173. RR lab is funded by the European Research Council under the European Union's Horizon 2020 research and innovation programme grant agreement No 647973 (R.R.), the Foundation Charles Defforey-Institut de France, and Ligue Contre le Cancer Equipe Labellisee. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE 1256260 (JMB and AJM). BAH, Ph.D., was supported by an American Cancer Society -Michigan Cancer Research Fund Postdoctoral Fellowship, PF-18-236-01-CCG. ZCN is supported by the Michigan Postdoctoral Pioneer Program at the University of Michigan Medical School.	Adamo A, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.584232; Amanatullah DF, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0910-x; Blanchette-Farra N, 2018, ONCOGENE, V37, P4013, DOI 10.1038/s41388-018-0243-y; Brown RAM, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00476; Buschhaus JM, TARGETING DISSEMINAT; Buschhaus JM, 2018, METHODS MOL BIOL, V1686, P201, DOI 10.1007/978-1-4939-7371-2_15; Bystrom LM, 2014, ANTIOXID REDOX SIGN, V20, P1917, DOI 10.1089/ars.2012.5014; Cavnar SP, 2016, TOMOGRAPHY, V2, P146, DOI 10.18383/j.tom.2016.00157; Chanvorachote P, 2016, AM J PHYSIOL-CELL PH, V310, pC728, DOI 10.1152/ajpcell.00322.2015; Chen Dar-Ren, 2014, Biomed Res Int, V2014, P532161, DOI 10.1155/2014/532161; Chirillo R, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00698; Colacino JA, 2018, STEM CELL REP, V10, P1596, DOI 10.1016/j.stemcr.2018.03.001; Eckley SS, 2019, TOMOGRAPHY, V5, P346, DOI 10.18383/j.tom.2019.00019; El Hout M, 2018, SEMIN CANCER BIOL, V53, P125, DOI 10.1016/j.semcancer.2018.07.009; Forciniti S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062257; Ge SX, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2486-6; Goto W, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07673-9; Graham N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041121; Houthuijzen J, 2012, BRIT J CANCER, V106, P1901, DOI 10.1038/bjc.2012.201; Hu JJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep17426; Huang J, 2017, BREAST CANCER RES TR, V161, P229, DOI 10.1007/s10549-016-4052-0; Huczynski A, 2012, BIOORG MED CHEM LETT, V22, P7146, DOI 10.1016/j.bmcl.2012.09.068; Humphries BA, 2019, MOL CANCER RES, V17, P1142, DOI 10.1158/1541-7786.MCR-18-0836; Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Katsura Y, 2019, CANCERS, V11, DOI 10.3390/cancers11020177; Katzenellenbogen JA, 2018, NAT REV CANCER, V18, P377, DOI 10.1038/s41568-018-0001-z; Kucerova L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-535; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Leimberg MJ, 2008, J CELL BIOCHEM, V103, P1211, DOI 10.1002/jcb.21499; Liang W, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.626812; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Luo M, 2018, CELL METAB, V28, P69, DOI 10.1016/j.cmet.2018.06.006; Luo M, 2015, CURR PHARM DESIGN, V21, P1301, DOI 10.2174/1381612821666141211120604; Magnani L, 2013, P NATL ACAD SCI USA, V110, pE1490, DOI 10.1073/pnas.1219992110; Mody K, 2019, INVEST NEW DRUG, V37, P684, DOI 10.1007/s10637-018-0703-9; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muller S, 2020, NAT CHEM, V12, P929, DOI 10.1038/s41557-020-0513-5; Muluhngwi P, 2015, ENDOCR-RELAT CANCER, V22, pR279, DOI 10.1530/ERC-15-0355; Oren B, 2016, J PATHOL, V239, P274, DOI 10.1002/path.4724; Pantel Klaus, 2014, Bonekey Rep, V3, P584, DOI 10.1038/bonekey.2014.79; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Patel SA, 2011, ONCOL REV, V5, P93, DOI 10.1007/s12156-010-0071-y; Plava J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0960-z; Pogribny IP, 2013, INT J ONCOL, V42, P1822, DOI 10.3892/ijo.2013.1855; Raggi C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17804-1; Ray P, 2015, ONCOGENE, V34, P2043, DOI 10.1038/onc.2014.157; Recalcati S, 2019, FREE RADICAL BIO MED, V133, P216, DOI 10.1016/j.freeradbiomed.2018.07.015; Rodriguez R, 2022, MOL CELL, V82, P728, DOI 10.1016/j.molcel.2021.12.001; Saeki I, 2016, WORLD J GASTROENTERO, V22, P8967, DOI 10.3748/wjg.v22.i40.8967; Sarmiento-Castro A, 2020, STEM CELL REP, V15, P307, DOI 10.1016/j.stemcr.2020.06.020; Savci-Heijink CD, 2015, BREAST CANCER RES TR, V150, P547, DOI 10.1007/s10549-015-3352-0; Schonberg DL, 2015, CANCER CELL, V28, P441, DOI 10.1016/j.ccell.2015.09.002; Shi Z, 2012, BREAST CANCER RES TR, V135, P737, DOI 10.1007/s10549-012-2196-0; Shiozawa Y, 2011, CLIN CANCER RES, V17, P5553, DOI 10.1158/1078-0432.CCR-10-2505; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Mai TT, 2017, NAT CHEM, V9, P1025, DOI [10.1038/nchem.2778, 10.1038/NCHEM.2778]; Tury S, 2018, J PATHOL, V246, P103, DOI 10.1002/path.5104; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Yeh WL, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0630-2; Yousef GM, 2004, BRIT J CANCER, V90, P167, DOI 10.1038/sj.bjc.6601451	61	1	1	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2022	41	29					3705	3718		10.1038/s41388-022-02385-9	http://dx.doi.org/10.1038/s41388-022-02385-9		JUN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y6YE	35732800				2022-12-17	WOS:000814460500001
J	Zhang, TZ; Wang, Z; Liu, MH; Liu, L; Yang, X; Zhang, Y; Bie, JT; Li, YT; Ren, MM; Song, C; Wang, WG; Tan, HY; Luo, JY				Zhang, Tianzhuo; Wang, Zhe; Liu, Minghui; Liu, Lu; Yang, Xin; Zhang, Yu; Bie, Juntao; Li, Yutong; Ren, Mengmeng; Song, Chen; Wang, Wengong; Tan, Hongyu; Luo, Jianyuan			Acetylation dependent translocation of EWSR1 regulates CHK2 alternative splicing in response to DNA damage	ONCOGENE			English	Article							EWINGS-SARCOMA PROTEIN; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; BIOCHEMICAL-PROPERTIES; KINASE; GENE; ATM; EWS-FLI1; CANCER; DOMAIN	Ewing sarcoma breakpoint region 1 (EWSR1) is a member of FET (FUS/EWSR1/TAF15) RNA-binding family of proteins. The Ewing sarcoma oncoprotein EWS-FLI1 has been extensively studied, while much less is known about EWSR1 itself, especially the potential role of EWSR1 in response to DNA damage. Here, we found that UV irradiation induces acetylation of EWSR1, which is required for its nucleoli translocation. We identified K423, K432, K438, K640, and K643 as the major acetylation sites, p300/CBP and HDAC3/HDAC10 as the major acetyltransferases and deacetylases, respectively. Mechanically, UV-induced EWSR1 acetylation repressed its interaction with spliceosomal component U1C, which caused abnormal splicing of CHK2, suppressing the activity of CHK2 in response to UV irradiation. Taken together, our findings uncover acetylation as a novel regulatory modification of EWSR1, and is essential for its function in DNA damage response.	[Zhang, Tianzhuo; Wang, Zhe; Liu, Minghui; Liu, Lu; Yang, Xin; Zhang, Yu; Bie, Juntao; Li, Yutong; Ren, Mengmeng; Song, Chen; Luo, Jianyuan] Peking Univ, Ctr Med Genet, Dept Med Genet, Hlth Sci Ctr, Beijing 100191, Peoples R China; [Zhang, Tianzhuo; Wang, Wengong; Luo, Jianyuan] Peking Univ, Dept Biochem & Biophys, Beijing Key Lab Prot Posttranslat Modificat & Cel, Hlth Sci Ctr, Beijing 100191, Peoples R China; [Tan, Hongyu] Peking Univ, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Dept Anesthesiol,Canc Hosp & Inst, Beijing 100142, Peoples R China	Peking University; Peking University; Peking University	Luo, JY (corresponding author), Peking Univ, Ctr Med Genet, Dept Med Genet, Hlth Sci Ctr, Beijing 100191, Peoples R China.; Luo, JY (corresponding author), Peking Univ, Dept Biochem & Biophys, Beijing Key Lab Prot Posttranslat Modificat & Cel, Hlth Sci Ctr, Beijing 100191, Peoples R China.; Tan, HY (corresponding author), Peking Univ, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Dept Anesthesiol,Canc Hosp & Inst, Beijing 100142, Peoples R China.	maggitan@yeah.net; luojianyuan@bjmu.edu.cn		Yang, Xin/0000-0003-0222-5839	National Natural Science Foundation of China [81874147, 82172959]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from National Natural Science Foundation of China (81874147, 82172959). We thank core facility at Peking University Health Science Center for experiment help.	Alex D, 2005, NUCLEIC ACIDS RES, V33, P1323, DOI 10.1093/nar/gki270; Araya N, 2005, BIOCHEM BIOPH RES CO, V329, P653, DOI 10.1016/j.bbrc.2005.02.018; Bachmaier R, 2009, ONCOGENE, V28, P1280, DOI 10.1038/onc.2008.484; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Berge EO, 2010, BBA-MOL CELL RES, V1803, P386, DOI 10.1016/j.bbamcr.2010.01.005; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Da Costa IC, 2020, ESSAYS BIOCHEM, V64, P737, DOI 10.1042/EBC20190095; Das S, 2013, FEBS LETT, V587, P417, DOI 10.1016/j.febslet.2013.01.035; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; Du HS, 2002, NATURE, V419, P86, DOI 10.1038/nature00947; Dutertre M, 2010, NAT STRUCT MOL BIOL, V17, P1358, DOI 10.1038/nsmb.1912; Dutto I, 2018, CELL MOL LIFE SCI, V75, P1325, DOI 10.1007/s00018-017-2717-4; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Grunewald TGP, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0003-x; Guinamard R, 1997, SCAND J IMMUNOL, V45, P587, DOI 10.1046/j.1365-3083.1997.d01-447.x; Han CJ, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abj8357; HARDIN JD, 1995, CELL IMMUNOL, V165, P44, DOI 10.1006/cimm.1995.1185; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; Hurov KE, 2010, GENE DEV, V24, P1939, DOI 10.1101/gad.1934210; Kim J, 1999, P NATL ACAD SCI USA, V96, P14300, DOI 10.1073/pnas.96.25.14300; Kim J, 2000, FEBS LETT, V474, P121, DOI 10.1016/S0014-5793(00)01590-8; Kim JD, 2008, INT J MOL MED, V22, P309, DOI 10.3892/ijmm_00000024; Klevernic IV, 2009, BIOCHEM J, V418, P625, DOI 10.1042/BJ20082097; Knoop LL, 2000, J BIOL CHEM, V275, P24865, DOI 10.1074/jbc.M001661200; Lee SG, 2020, EMBO REP, V21, DOI 10.15252/embr.201948676; Li HJ, 2007, J CLIN INVEST, V117, P1314, DOI 10.1172/JCI31222; Li K, 2008, J BIOL CHEM, V283, P7590, DOI 10.1074/jbc.M709707200; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Munoz MJ, 2009, CELL, V137, P708, DOI 10.1016/j.cell.2009.03.010; Mustofa MK, 2020, ENVIRON MOL MUTAGEN, V61, P730, DOI 10.1002/em.22397; Muto Y, 2004, J MOL BIOL, V341, P185, DOI 10.1016/j.jmb.2004.04.078; Paronetto MP, 2011, MOL CELL, V43, P353, DOI 10.1016/j.molcel.2011.05.035; Paronetto Maria Paola, 2013, Int J Cell Biol, V2013, P642853, DOI 10.1155/2013/642853; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Ren XL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2640-8; Rosel TD, 2011, EMBO J, V30, P1965, DOI 10.1038/emboj.2011.106; Schwartz JC, 2015, ANNU REV BIOCHEM, V84, P355, DOI 10.1146/annurev-biochem-060614-034325; Shandilya J, 2009, MOL CELL BIOL, V29, P5115, DOI 10.1128/MCB.01969-08; Spahn L, 2002, CANCER RES, V62, P4583; Srivastava A, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.600682; Staalesen V, 2004, ONCOGENE, V23, P8535, DOI 10.1038/sj.onc.1207928; Sun YL, 2007, MOL CELL BIOL, V27, P8502, DOI 10.1128/MCB.01382-07; Takahama K, 2011, FEBS J, V278, P988, DOI 10.1111/j.1742-4658.2011.08020.x; Tanoue Y, 2018, J INVEST DERMATOL, V138, P2550, DOI 10.1016/j.jid.2018.05.015; Zannini L, 2014, J MOL CELL BIOL, V6, P442, DOI 10.1093/jmcb/mju045	51	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2022	41	29					3694	3704		10.1038/s41388-022-02383-x	http://dx.doi.org/10.1038/s41388-022-02383-x		JUN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y6YE	35732801				2022-12-17	WOS:000814460500002
J	Datta, J; Bianchi, A; Silva, ID; Deshpande, NU; Cao, LL; Mehra, S; Singh, S; Rafie, C; Sun, XD; Chen, X; Dai, XZ; Colaprico, A; Sharma, P; Dosch, AR; Pillai, A; Hosein, PJ; Nagathihalli, NS; Komanduri, KV; Wilson, JM; Ban, YG; Merchant, NB				Datta, Jashodeep; Bianchi, Anna; Silva, Iago De Castro; Deshpande, Nilesh U.; Cao, Long Long; Mehra, Siddharth; Singh, Samara; Rafie, Christine; Sun, Xiaodian; Chen, Xi; Dai, Xizi; Colaprico, Antonio; Sharma, Prateek; Dosch, Austin R.; Pillai, Asha; Hosein, Peter J.; Nagathihalli, Nagaraj S.; Komanduri, Krishna, V; Wilson, Julie M.; Ban, Yuguang; Merchant, Nipun B.			Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer	ONCOGENE			English	Article							GENOMIC CHARACTERIZATION; ONCOGENIC KRAS; ADENOCARCINOMA; COOPERATE; PATHWAY; HETEROGENEITY; KRAS(G12D)	Co-occurrent KRAS and TP53 mutations define a majority of patients with pancreatic ductal adenocarcinoma (PDAC) and define its pro-metastatic proclivity. Here, we demonstrate that KRAS-TP53 co-alteration is associated with worse survival compared with either KRAS-alone or TP53-alone altered PDAC in 245 patients with metastatic disease treated at a tertiary referral cancer center, and validate this observation in two independent molecularly annotated datasets. Compared with non-TP53 mutated KRAS-altered tumors, KRAS-TP53 co-alteration engenders disproportionately innate immune-enriched and CD8(+) T-cell-excluded immune signatures. Leveraging in silico, in vitro, and in vivo models of human and murine PDAC, we discover a novel intersection between KRAS-TP53 co-altered transcriptomes, TP63-defined squamous trans-differentiation, and myeloid-cell migration into the tumor microenvironment. Comparison of single-cell transcriptomes between KRAS-TP53 co-altered and KRAS-altered/TP53(WT) tumors revealed cancer cell-autonomous transcriptional programs that orchestrate innate immune trafficking and function. Moreover, we uncover granulocyte-derived inflammasome activation and TNF signaling as putative paracrine mediators of innate immunoregulatory transcriptional programs in KRAS-TP53 co-altered PDAC. Immune subtyping of KRAS-TP53 co-altered PDAC reveals conflation of intratumor heterogeneity with progenitor-like stemness properties. Coalescing these distinct molecular characteristics into a KRAS-TP53 co-altered "immunoregulatory program" predicts chemoresistance in metastatic PDAC patients enrolled in the COMPASS trial, as well as worse overall survival.	[Datta, Jashodeep; Bianchi, Anna; Silva, Iago De Castro; Deshpande, Nilesh U.; Cao, Long Long; Mehra, Siddharth; Singh, Samara; Rafie, Christine; Dai, Xizi; Dosch, Austin R.; Nagathihalli, Nagaraj S.; Merchant, Nipun B.] Univ Miami, Miller Sch Med, Div Surg Oncol, Dept Surg, Miami, FL 33136 USA; [Datta, Jashodeep; Pillai, Asha; Hosein, Peter J.; Nagathihalli, Nagaraj S.; Komanduri, Krishna, V; Merchant, Nipun B.] Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Sun, Xiaodian; Chen, Xi; Colaprico, Antonio; Ban, Yuguang] Univ Miami, Miller Sch Med, Biostat & Bioinformat Shared Resource, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Sharma, Prateek] Univ Nebraska, Dept Surg, Omaha, NE USA; [Pillai, Asha] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA; [Pillai, Asha] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Hosein, Peter J.; Komanduri, Krishna, V] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Wilson, Julie M.] Ontario Inst Canc Res, PanCuRx Translat Res Initiat, Toronto, ON, Canada	University of Miami; University of Miami; University of Nebraska System; University of Miami; University of Miami; University of Miami; Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates	Datta, J (corresponding author), Univ Miami, Miller Sch Med, Div Surg Oncol, Dept Surg, Miami, FL 33136 USA.; Datta, J (corresponding author), Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.	jash.datta@med.miami.edu		Datta, Jashodeep/0000-0003-2869-1571	Miami CTSI under NIH Award [UL1TR002736]; Stanley Glaser Foundation; American College of Surgeons Franklin Martin Career Development Award; Association for Academic Surgery Joel J. Roslyn Faculty Award; NIH [R01 CA161976]; NCI/NIH Award [P30CA240139]	Miami CTSI under NIH Award; Stanley Glaser Foundation; American College of Surgeons Franklin Martin Career Development Award; Association for Academic Surgery Joel J. Roslyn Faculty Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI/NIH Award	This work was supported by KL2 career development grant from Miami CTSI under NIH Award UL1TR002736, Stanley Glaser Foundation, American College of Surgeons Franklin Martin Career Development Award, and Association for Academic Surgery Joel J. Roslyn Faculty Award (to JD); NIH R01 CA161976 (to NBM); and NCI/NIH Award P30CA240139 (to JD and NBM).	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; [Anonymous], 2014, GENOME BIOL, DOI DOI 10.1186/S13059-014-0550-8; Aung KL, 2018, CLIN CANCER RES, V24, P1344, DOI 10.1158/1078-0432.CCR-17-2994; Bailey JM, 2016, ONCOGENE, V35, P4282, DOI 10.1038/onc.2015.441; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Balachandran VP, 2019, GASTROENTEROLOGY, V156, P2056, DOI 10.1053/j.gastro.2018.12.038; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Blagih J, 2020, CELL REP, V30, P481, DOI 10.1016/j.celrep.2019.12.028; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Chakravarty D, 2017, JCO PRECIS ONCOL, V1; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Cui Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111942; Datta J, 2022, ANN SURG, V276, pE474, DOI 10.1097/SLA.0000000000004613; Datta J, 2020, CLIN CANCER RES, V26, P1077, DOI 10.1158/1078-0432.CCR-19-2390; Dosch Austin R, 2021, Oncotarget, V12, P2104, DOI 10.18632/oncotarget.27983; Dosch Austin R, 2020, Oncoscience, V7, P26, DOI 10.18632/oncoscience.503; Fan J, 2016, NAT METHODS, V13, P241, DOI [10.1038/NMETH.3734, 10.1038/nmeth.3734]; Gillet JP, 2012, CLIN CANCER RES, V18, P3197, DOI 10.1158/1078-0432.CCR-12-0056; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Gu ZG, 2014, BIOINFORMATICS, V30, P2811, DOI 10.1093/bioinformatics/btu393; Hamarsheh S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19288-6; Hamarsheh S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01444; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hosein AN, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129212; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; KATO H, 1979, JPN CIRC J, V43, P343, DOI 10.1253/jcj.43.343; Kim MP, 2021, CANCER DISCOV, V11, P2094, DOI 10.1158/2159-8290.CD-20-1228; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Kuhn DJ, 2005, FRONT BIOSCI-LANDMRK, V10, P1462, DOI 10.2741/1631; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Li JY, 2018, IMMUNITY, V49, P178, DOI 10.1016/j.immuni.2018.06.006; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Maddalena M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2025631118; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Miao YR, 2020, ADV SCI, V7, DOI 10.1002/advs.201902880; Mukherjee A, 2019, CANCER RES, V79, P3185, DOI 10.1158/0008-5472.CAN-19-0542; Nirmal AJ, 2018, CANCER IMMUNOL RES, V6, P1388, DOI 10.1158/2326-6066.CIR-18-0342; O'Kane GM, 2020, CLIN CANCER RES, V26, P4901, DOI 10.1158/1078-0432.CCR-19-3724; Oh JY, 2010, POULTRY SCI, V89, P2116, DOI 10.3382/ps.2010-00918; Pan Y, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0822-6; Rogan PK, 2019, MOL GENET METAB, V128, P45, DOI 10.1016/j.ymgme.2019.08.005; Rose Dianne, 2002, South Med J, V95, P621; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sharif PM, 2020, CYTOKINE, V130, DOI 10.1016/j.cyto.2020.155066; Smith JJ, 2019, CANCER MED-US, V8, P6538, DOI 10.1002/cam4.2415; Somerville TDD, 2020, ELIFE, V9, DOI 10.7554/eLife.53381; Tavassoly I, 2019, MOL ONCOL, V13, P1725, DOI 10.1002/1878-0261.12521; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Tomkiewicz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047170; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhou Y, 2019, NAT COMMUN, V10, DOI [DOI 10.1038/S41467-019-09234-6, 10.1038/s41467-019-09234-6]	59	1	1	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2022	41	28					3640	3654		10.1038/s41388-022-02368-w	http://dx.doi.org/10.1038/s41388-022-02368-w		JUN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y2ND	35701533	Green Submitted			2022-12-17	WOS:000810849500002
J	Morimoto, Y; Fushimi, A; Yamashita, N; Hagiwara, M; Bhattacharya, A; Cheng, JW; Frost, TC; Ahmad, R; Daimon, T; Huang, L; Hata, T; Takahashi, H; Yamamoto, M; Suzuki, Y; DeCaprio, JA; Kufe, D				Morimoto, Yoshihiro; Fushimi, Atsushi; Yamashita, Nami; Hagiwara, Masayuki; Bhattacharya, Atrayee; Cheng, Jingwei; Frost, Thomas C.; Ahmad, Rehan; Daimon, Tatsuaki; Huang, Lei; Hata, Tsuyoshi; Takahashi, Hidekazu; Yamamoto, Masaaki; Suzuki, Yozo; DeCaprio, James A.; Kufe, Donald			Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment	ONCOGENE			English	Article							GENE-EXPRESSION; TRANSCRIPTION; ONCOPROTEIN; GROWTH; MYC	Merkel cell carcinoma (MCC) is an aggressive malignancy with neuroendocrine (NE) features, limited treatment options, and a lack of druggable targets. There is no reported involvement of the MUC1-C oncogenic protein in MCC progression. We show here that MUC1-C is broadly expressed in MCCs and at higher levels in Merkel cell polyomavirus (MCPyV)-positive (MCCP) relative to MCPyV-negative (MCCN) tumors. Our results further demonstrate that MUC1-C is expressed in MCCP, as well as MCCN, cell lines and regulates common sets of signaling pathways related to RNA synthesis, processing, and transport in both subtypes. Mechanistically, MUC1-C (i) interacts with MYCL, which drives MCC progression, (ii) is necessary for expression of the OCT4, SOX2, KLF4, MYC, and NANOG pluripotency factors, and (iii) induces the NEUROD1, BRN2 and ATOH1 NE lineage dictating transcription factors. We show that MUC1-C is also necessary for MCCP and MCCN cell survival by suppressing DNA replication stress, the p53 pathway, and apoptosis. In concert with these results, targeting MUC1-C genetically and pharmacologically inhibits MCC self-renewal capacity and tumorigenicity. These findings demonstrate that MCCP and MCCN cells are addicted to MUC1-C and identify MUC1-C as a potential target for MCC treatment.	[Morimoto, Yoshihiro; Fushimi, Atsushi; Yamashita, Nami; Hagiwara, Masayuki; Bhattacharya, Atrayee; Cheng, Jingwei; Frost, Thomas C.; Ahmad, Rehan; Daimon, Tatsuaki; Hata, Tsuyoshi; Takahashi, Hidekazu; Yamamoto, Masaaki; Suzuki, Yozo; DeCaprio, James A.; Kufe, Donald] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Cheng, Jingwei] Univ New Hampshire, Dept Mol Cellular & Biomed Sci, Durham, NH 03824 USA; [Huang, Lei] Shanghai Jiao Tong Univ, Shanghai Key Lab Reprod Med, Chinese Minist Educ,Sch Med, Dept Histoembryol Genet & Dev Biol,Key Lab Cell D, Shanghai, Peoples R China; [Hagiwara, Masayuki] Keio Univ, Dept Urol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan; [Hata, Tsuyoshi; Takahashi, Hidekazu; Yamamoto, Masaaki; Suzuki, Yozo] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka 5650871, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University System Of New Hampshire; University of New Hampshire; Shanghai Jiao Tong University; Keio University; Osaka University	Kufe, D (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu	Ahmad, R/J-3509-2019	Frost, Thomas/0000-0002-7855-1000	National Cancer Institute of the National Institutes of Health [CA97098, CA166480, CA233084]; US Public Health Service [R35CA232128, P01CA203655]	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service)	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under grant numbers CA97098, CA166480, and CA233084 awarded to DK and also in part by US Public Health Service grants R35CA232128 and P01CA203655 awarded to JAD.	Angeles CV, 2021, J SURG ONCOL, V123, P775, DOI 10.1002/jso.26319; Becker JC, 2018, CANCER IMMUNOL IMMUN, V67, P341, DOI 10.1007/s00262-017-2099-3; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhattacharya A, 2022, MOL CANCER RES, V20, P556, DOI 10.1158/1541-7786.MCR-21-0672; Bian X, 2019, CANCERS, V11, DOI 10.3390/cancers11091289; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Cheng JW, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006668; Chteinberg E, 2018, NEOPLASIA, V20, P1227, DOI 10.1016/j.neo.2018.10.003; Daily K, 2015, J INVEST DERMATOL, V135, P1138, DOI 10.1038/jid.2014.518; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; DeCaprio JA, 2021, ANNU REV PATHOL-MECH, V16, P69, DOI 10.1146/annurev-pathmechdis-012419-032817; Fan KJ, 2020, J INVEST DERMATOL, V140, P56, DOI 10.1016/j.jid.2019.06.135; Fernandez-Flores A, 2016, APPL IMMUNOHISTO M M, V24, pE9, DOI 10.1097/PAI.0000000000000148; Hagiwara M, 2021, ONCOGENE, V40, P4930, DOI 10.1038/s41388-021-01899-y; Hagiwara M, 2021, CANCER RES, V81, P1111, DOI 10.1158/0008-5472.CAN-20-2588; Harold A, 2019, P NATL ACAD SCI USA, V116, P20104, DOI 10.1073/pnas.1907154116; Hata T, 2019, CANCER RES, V79, P5711, DOI 10.1158/0008-5472.CAN-19-1034; Hata T, 2019, MOL CANCER THER, V18, P1744, DOI 10.1158/1535-7163.MCT-19-0156; Hiraki M, 2017, ONCOGENE, V36, P2791, DOI 10.1038/onc.2016.439; Huang Lei, 2010, Genes Cancer, V1, P239; Jiang LY, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005895; Kreis NN, 2019, CANCERS, V11, DOI 10.3390/cancers11070989; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2020, CARCINOGENESIS, V41, P1173, DOI 10.1093/carcin/bgaa082; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Li W, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137112; Maricich SM, 2009, SCIENCE, V324, P1580, DOI 10.1126/science.1172890; McCubrey James A., 2017, Advances in Biological Regulation, V63, P32, DOI 10.1016/j.jbior.2016.10.001; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Park DE, 2020, NAT CELL BIOL, V22, P603, DOI 10.1038/s41556-020-0503-2; Park DE, 2019, P NATL ACAD SCI USA, V116, P1027, DOI 10.1073/pnas.1818798116; Petroni G, 2022, NAT REV DRUG DISCOV, V21, P440, DOI 10.1038/s41573-022-00415-5; Rajabi H, 2018, ONCOGENE, V37, P2079, DOI 10.1038/s41388-017-0096-9; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Shamloo B, 2019, CANCERS, V11, DOI 10.3390/cancers11081178; Shao Q, 2014, CANCER RES, V74, P7090, DOI 10.1158/0008-5472.CAN-14-0305; Starrett GJ, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00727-4; Stewart CA, 2020, NAT CANCER, V1, P423, DOI 10.1038/s43018-019-0020-z; Takahashi K, 2016, NAT REV MOL CELL BIO, V17, P183, DOI 10.1038/nrm.2016.8; Thomas A, 2021, CANCER CELL, V39, P566, DOI 10.1016/j.ccell.2021.02.014; Thomas A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6282; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Wong SQ, 2015, CANCER RES, V75, P5228, DOI 10.1158/0008-5472.CAN-15-1877; Xiong J, 2022, ONCOL LETT, V23, DOI 10.3892/ol.2021.13139; Yamamoto M, 2019, CANCER RES, V79, P2031, DOI 10.1158/0008-5472.CAN-18-3259; Yasumizu Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14219-6; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Zhang W, 2016, INT J BIOL SCI, V12, P1372, DOI 10.7150/ijbs.16349; Zheng X, 2020, INT J BIOL SCI, V16, P2442, DOI 10.7150/ijbs.46751	50	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2022	41	27					3511	3523		10.1038/s41388-022-02361-3	http://dx.doi.org/10.1038/s41388-022-02361-3		JUN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2P6AJ	35688945	Green Published, hybrid			2022-12-17	WOS:000809307500003
J	Kumarasamy, V; Nambiar, R; Wang, JX; Rosenheck, H; Witkiewicz, AK; Knudsen, ES				Kumarasamy, Vishnu; Nambiar, Ram; Wang, Jianxin; Rosenheck, Hanna; Witkiewicz, Agnieszka K.; Knudsen, Erik S.			RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models	ONCOGENE			English	Article							ESTROGEN-RECEPTOR; RETINOBLASTOMA PROTEIN; POSTMENOPAUSAL WOMEN; CDK4/6 INHIBITION; MECHANISMS; PATHWAYS; CELLS; PI3K	The management of metastatic estrogen receptor (ER) positive HER2 negative breast cancer (ER+) has improved; however, therapeutic resistance and disease progression emerges in majority of cases. Using unbiased approaches, as expected PI3K and MTOR inhibitors emerge as potent inhibitors to delay proliferation of ER+ models harboring PIK3CA mutations. However, the cytostatic efficacy of these drugs is hindered due to marginal impact on the expression of cyclin D1. Different combination approaches involving the inhibition of ER pathway or cell cycle result in durable growth arrest via RB activation and subsequent inhibition of CDK2 activity. However, cell cycle alterations due to RB loss or ectopic CDK4/cyclin D1 activation yields resistance to these cytostatic combination treatments. To define means to counter resistance to targeted therapies imparted with RB loss; complementary drug screens were performed with RB-deleted isogenic cell lines. In this setting, RB loss renders ER+ breast cancer models more vulnerable to drugs that target DNA replication and mitosis. Pairwise combinations using these classes of drugs defines greater selectivity for RB deficiency. The combination of AURK and WEE1 inhibitors, yields synergistic cell death selectively in RB-deleted ER+ breast cancer cells via apoptosis and yields profound disease control in vivo. Through unbiased efforts the XIAP/CIAP inhibitor birinapant was identified as a novel RB-selective agent. Birinapant further enhances the cytotoxic effect of chemotherapies and targeted therapies used in the treatment of ER+ breast cancer models selectively in the RB-deficient setting. Using organoid culture and xenograft models, we demonstrate the highly selective use of birinapant based combinations for the treatment of RB-deficient tumors. Together, these data illustrate the critical role of RB-pathway in response to many agents used to treat ER+ breast cancer, whilst informing new therapeutic approaches that could be deployed against resistant disease.	[Kumarasamy, Vishnu; Nambiar, Ram; Wang, Jianxin; Rosenheck, Hanna; Witkiewicz, Agnieszka K.; Knudsen, Erik S.] Roswell Park Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Knudsen, ES (corresponding author), Roswell Park Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.	Erik.Knudsen@roswellpark.org			National Cancer Institute (NCI)	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank all members of the laboratory group and colleagues in the discussion and preparation of the manuscript. We thank Emily Schultz for acquiring the patient information and the genetic characteristics of the tumor tissues. Dr. Steven Pruitt provided the lentiviral vector for CDK2 sensor. Drug screening was performed through Small Molecule Screening facility at RoswellPark Cancer Center. We would like to thank Dr. Sandra Sexton, Facility director of Laboratory Animal Resources at Roswell Park for assisting us with xenografts. The research was supported by a grant to AKW and ESK from National Cancer Institute (NCI).	Ahmad A, 2019, ADV EXP MED BIOL, V1152, P1, DOI 10.1007/978-3-030-20301-6_1; Andre F, 2019, NEW ENGL J MED, V380, P1929, DOI 10.1056/NEJMoa1813904; Arnedos M, 2018, ANN ONCOL, V29, P1755, DOI 10.1093/annonc/mdy202; Asghar US, 2022, JCO PRECIS ONCOL, V6, DOI 10.1200/PO.21.00002; Bertucci F, 2019, NATURE, V569, P560, DOI 10.1038/s41586-019-1056-z; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; Condon SM, 2014, J MED CHEM, V57, P3666, DOI 10.1021/jm500176w; Condorelli R, 2018, ANN ONCOL, V29, P640, DOI 10.1093/annonc/mdx784; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Dean JL, 2012, J BIOL CHEM, V287, P29075, DOI 10.1074/jbc.M112.365494; Desmedt C, 2006, CELL CYCLE, V5, P2198, DOI 10.4161/cc.5.19.3254; Dickler MN, 2017, CLIN CANCER RES, V23, P5218, DOI 10.1158/1078-0432.CCR-17-0754; Dickson MA, 2014, CLIN CANCER RES, V20, P3379, DOI 10.1158/1078-0432.CCR-13-1551; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Dowsett M, 2013, J CLIN ONCOL, V31, P2783, DOI 10.1200/JCO.2012.46.1558; Elkabets M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005747; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Franco J, 2016, CELL REP, V14, P979, DOI 10.1016/j.celrep.2015.12.094; Gong XQ, 2019, CANCER DISCOV, V9, P248, DOI 10.1158/2159-8290.CD-18-0469; Guarducci C, 2018, NPJ BREAST CANCER, V4, DOI 10.1038/s41523-018-0092-4; Howell A, 2008, BEST PRACT RES CL EN, V22, P615, DOI 10.1016/j.beem.2008.09.002; Jensen EV, 2003, CLIN CANCER RES, V9, P1980; Knudsen Erik S, 2020, Am Soc Clin Oncol Educ Book, V40, P115, DOI 10.1200/EDBK_281085; Knudsen ES, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0873-9; Knudsen ES, 2019, TRENDS CANCER, V5, P308, DOI 10.1016/j.trecan.2019.03.005; Knudsen ES, 2019, ONCOGENE, V38, P3355, DOI 10.1038/s41388-018-0650-0; Knudsen ES, 2018, GUT, V67, P508, DOI 10.1136/gutjnl-2016-313133; Kumarasamy V, 2021, CANCER RES, V81, P1347, DOI 10.1158/0008-5472.CAN-20-2275; Kumarasamy V, 2020, ONCOGENE, V39, P1831, DOI 10.1038/s41388-019-1102-1; Lalaoui N, 2020, CELL DEATH DIFFER, V27, P2768, DOI 10.1038/s41418-020-0541-0; Lee JW, 2019, CLIN CANCER RES, V25, P3430, DOI 10.1158/1078-0432.CCR-18-0440; Li ZQ, 2018, CANCER CELL, V34, P893, DOI 10.1016/j.ccell.2018.11.006; Manna Subrata, 2016, Sign Transduct Insights, V5, P1; McKeage K, 2004, DRUGS, V64, P633, DOI 10.2165/00003495-200464060-00009; Michaloglou C, 2018, MOL CANCER THER, V17, P908, DOI 10.1158/1535-7163.MCT-17-0537; Mills JN, 2018, CURR OPIN PHARMACOL, V41, P59, DOI 10.1016/j.coph.2018.04.009; Mouridsen H, 2001, J CLIN ONCOL, V19, P2596, DOI 10.1200/JCO.2001.19.10.2596; O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264; O'Leary B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03215-x; Oser MG, 2019, CANCER DISCOV, V9, P230, DOI 10.1158/2159-8290.CD-18-0389; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Presti D, 2019, CANCERS, V11, DOI 10.3390/cancers11091242; Provenzano A, 2013, EXPERT REV ANTICANC, V13, P143, DOI [10.1586/ERA.12.173, 10.1586/era.12.173]; Pu MY, 2020, BREAST CANCER RES TR, V179, P197, DOI 10.1007/s10549-019-05446-y; Rawlinson R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-483; Rubin SM, 2013, TRENDS BIOCHEM SCI, V38, P12, DOI 10.1016/j.tibs.2012.10.007; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Thu KL, 2018, CELL CYCLE, V17, P1871, DOI 10.1080/15384101.2018.1502567; Turner NC, 2018, NEW ENGL J MED, V379, P1926, DOI 10.1056/NEJMoa1810527; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Wander SA, 2020, CANCER DISCOV, V10, P1174, DOI 10.1158/2159-8290.CD-19-1390; Webster JD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00365; Weigelt B, 2011, ONCOGENE, V30, P3222, DOI 10.1038/onc.2011.42; Witkiewicz AK, 2018, CELL REP, V22, P1185, DOI 10.1016/j.celrep.2018.01.022; Yardley DA, 2013, ADV THER, V30, P870, DOI 10.1007/s12325-013-0060-1; Yue G, 2017, SCI REP-UK, V7, DOI 10.1038/srep45411; Zanudo JGT, 2021, CANCER RES, V81, P4603, DOI 10.1158/0008-5472.CAN-21-1208	60	1	1	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2022	41	27					3524	3538		10.1038/s41388-022-02362-2	http://dx.doi.org/10.1038/s41388-022-02362-2		JUN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2P6AJ	35676324				2022-12-17	WOS:000807963600001
J	Liu, CA; Ng, SK; Ding, YQ; Lin, YF; Liu, WX; Wong, SH; Sung, JJY; Yu, J				Liu, Changan; Ng, Siu-Kin; Ding, Yanqiang; Lin, Yufeng; Liu, Weixin; Wong, Sunny Hei; Sung, Joseph Jao-Yiu; Yu, Jun			Meta-analysis of mucosal microbiota reveals universal microbial signatures and dysbiosis in gastric carcinogenesis	ONCOGENE			English	Article							HELICOBACTER-PYLORI; INTESTINAL METAPLASIA; CANCER; ERADICATION; DISCOVERY; INFECTION; DISEASE; RISK	The consistency of the associations between gastric mucosal microbiome and gastric cancer across studies remained unexamined. We aimed to identify universal microbial signatures in gastric carcinogenesis through a meta-analysis of gastric microbiome from multiple studies. Compositional and ecological profiles of gastric microbes across stages of gastric carcinogenesis were significantly altered. Meta-analysis revealed that opportunistic pathobionts Fusobacterium, Parvimonas, Veillonella, Prevotella and Peptostreptococcus were enriched in GC, while commensals Bifidobacterium, Bacillus and Blautia were depleted in comparison to SG. The co-occurring correlation strengths of GC-enriched bacteria were increased along disease progression while those of GC-depleted bacteria were decreased. Eight bacterial taxa, including Veillonella, Dialister, Granulicatella, Herbaspirillum, Comamonas, Chryseobacterium, Shewanella and Helicobacter, were newly identified by this study as universal biomarkers for robustly discriminating GC from SG, with an area under the curve (AUC) of 0.85. Moreover, H. pylori-positive samples exhibited reduced microbial diversity, altered microbiota community and weaker interactions among gastric microbes. Our meta-analysis demonstrated comprehensive and generalizable gastric mucosa microbial features associated with histological stages of gastric carcinogenesis, including GC associated bacteria, diagnostic biomarkers, bacterial network alteration and H. pylori influence.	[Liu, Changan; Ng, Siu-Kin; Ding, Yanqiang; Lin, Yufeng; Liu, Weixin; Wong, Sunny Hei; Sung, Joseph Jao-Yiu; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Peoples R China; [Liu, Changan; Ng, Siu-Kin; Ding, Yanqiang; Lin, Yufeng; Liu, Weixin; Wong, Sunny Hei; Sung, Joseph Jao-Yiu; Yu, Jun] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China; [Wong, Sunny Hei; Sung, Joseph Jao-Yiu] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore	Chinese University of Hong Kong; Chinese University of Hong Kong; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Jun, Yu/D-8569-2015	Jun, Yu/0000-0001-5008-2153; LIN, Yufeng/0000-0001-5705-0787	RGC Theme-based Res Scheme Hong Kong [T21-705/20-N]; National Key R&D Program of China [2020YFA0509200/2020YFA0509203]; RGC Collaborative Research Fund [C4039-19GF, C7065-18GF]; RGC-GRF Hong Kong [14163817]	RGC Theme-based Res Scheme Hong Kong; National Key R&D Program of China; RGC Collaborative Research Fund(Hong Kong Research Grants Council); RGC-GRF Hong Kong(Hong Kong Research Grants Council)	This study was supported by RGC Theme-based Res Scheme Hong Kong (T21-705/20-N), National Key R&D Program of China (No. 2020YFA0509200/2020YFA0509203), RGC Collaborative Research Fund (C4039-19GF, C7065-18GF), RGC-GRF Hong Kong (14163817), Vice-Chancellor's Discretionary Fund CUHK.	Ahn J, 2013, JNCI-J NATL CANCER I, V105, P1907, DOI 10.1093/jnci/djt300; Aviles-Jimenez F, 2014, SCI REP-UK, V4, DOI 10.1038/srep04202; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carding Simon, 2015, Microbial Ecology in Health and Disease, V26, P26191, DOI 10.3402/mehd.v26.26191; Castano-Rodriguez N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16289-2; Coker OO, 2018, GUT, V67, P1024, DOI 10.1136/gutjnl-2017-314281; CORREA P, 1992, CANCER RES, V52, P6735; Correa P, 2013, GASTROENTEROL CLIN N, V42, P211, DOI 10.1016/j.gtc.2013.01.002; Delgado S, 2013, MICROB ECOL, V65, P763, DOI 10.1007/s00248-013-0192-5; Devi TB, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.631140; Douglas GM, 2020, NAT BIOTECHNOL, V38, P685, DOI 10.1038/s41587-020-0548-6; ElOmar EM, 1997, GASTROENTEROLOGY, V113, P15, DOI 10.1016/S0016-5085(97)70075-1; Elshaghabee FMF, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01490; Eun CS, 2014, HELICOBACTER, V19, P407, DOI 10.1111/hel.12145; Feng X, 2020, EMBO J, V39, DOI 10.15252/embj.2019104036; Ferreira RM, 2018, GUT, V67, P226, DOI 10.1136/gutjnl-2017-314205; Fukase K, 2008, LANCET, V372, P392, DOI 10.1016/S0140-6736(08)61159-9; Geng JW, 2014, GUT PATHOG, V6, DOI 10.1186/1757-4749-6-26; Gevers D, 2014, CELL HOST MICROBE, V15, P382, DOI 10.1016/j.chom.2014.02.005; Guerrero-Preston R, 2016, ONCOTARGET, V7, P51320, DOI 10.18632/oncotarget.9710; Huang N, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2708-5; Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007; Larsen JM, 2017, IMMUNOLOGY, V151, P363, DOI 10.1111/imm.12760; Li P, 2020, CARCINOGENESIS, V41, P397, DOI 10.1093/carcin/bgaa013; Li TH, 2017, SCI REP-UK, V7, DOI 10.1038/srep44935; Liu XM, 2021, GUT MICROBES, V13, DOI 10.1080/19490976.2021.1875796; Lofgren JL, 2011, GASTROENTEROLOGY, V140, P210, DOI 10.1053/j.gastro.2010.09.048; Morita E, 2003, CANCER SCI, V94, P492, DOI 10.1111/j.1349-7006.2003.tb01471.x; Nada HG, 2020, PHARMANUTRITION, V14, DOI 10.1016/j.phanu.2020.100219; Naffouje R, 2019, CANCERS, V11, DOI 10.3390/cancers11091346; Nakatsu G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9727; Nwizu N, 2020, PERIODONTOL 2000, V83, P213, DOI 10.1111/prd.12329; Plottel CS, 2011, CELL HOST MICROBE, V10, P324, DOI 10.1016/j.chom.2011.10.003; Sasaki H, 1998, CANCER RES, V58, P2991; Schulz C, 2018, GUT, V67, P216, DOI 10.1136/gutjnl-2016-312904; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Sheh A, 2013, GUT MICROBES, V4, P505, DOI 10.4161/gmic.26205; Suarez G, 2015, CANCER RES, V75, P1749, DOI 10.1158/0008-5472.CAN-14-2291; Sung JJY, 2020, GUT, V69, P1572, DOI 10.1136/gutjnl-2019-319826; Tang B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165701; Wen J, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9111680; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10; Yan XM, 2015, AM J CANCER RES, V5, P3111; Yang YZ, 2017, GASTROENTEROLOGY, V152, P851, DOI 10.1053/j.gastro.2016.11.018; Yin XH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149653; Yoneda M, 2016, J GASTROINTEST DIG S, V6; Yu GQ, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00302; Yu J, 2017, GUT, V66, P70, DOI 10.1136/gutjnl-2015-309800	50	1	1	4	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2022	41	28					3599	3610		10.1038/s41388-022-02377-9	http://dx.doi.org/10.1038/s41388-022-02377-9		JUN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2Y2ND	35680985	hybrid, Green Published			2022-12-17	WOS:000808419000001
J	Pan, X; Li, X; Sun, J; Xiong, ZY; Hu, HY; Ning, SW; Zhi, H				Pan, Xu; Li, Xin; Sun, Jie; Xiong, Zhiying; Hu, Haoyu; Ning, Shangwei; Zhi, Hui			Enhancer methylation dynamics drive core transcriptional regulatory circuitry in pan-cancer	ONCOGENE			English	Article							DNA METHYLATION; GENE-EXPRESSION; LANDSCAPES; REVEALS	Accumulating evidence has demonstrated that enhancer methylation has strong and dynamic regulatory effects on gene expression. Some transcription factors (TFs) can auto- and cross-regulate in a feed-forward manner, and cooperate with their enhancers to form core transcriptional regulatory circuitries (CRCs). However, the elaborated regulatory mechanism between enhancer methylation and CRC remains the tip of the iceberg. Here, we revealed that DNA methylation could drive the tissue-specific enhancer basal transcription and target gene expression in human cancers. By integrating methylome, transcriptome, and 3D genomic data, we identified enhancer methylation triplets (enhancer methylation-enhancer transcription-target gene expression) and dissected potential regulatory patterns within them. Moreover, we observed that cancer-specific core TFs regulated by enhancers were able to shape their enhancer methylation forming the enhancer methylation-driven CRCs (emCRCs). Further parsing of clinical implications showed rewired emCRCs could serve as druggable targets and prognostic risk markers. In summary, the integrative analysis of enhancer methylation regulome would facilitate portraying the cancer epigenomics landscape and developing the epigenetic anti-cancer approaches.	[Pan, Xu; Li, Xin; Sun, Jie; Xiong, Zhiying; Hu, Haoyu; Ning, Shangwei; Zhi, Hui] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China; [Li, Xin] Cent South Univ, Xiangya Hosp, Hunan Engn Res Ctr Skin Hlth & Dis, Hunan Key Lab Skin Canc & Psoriasis,Dept Dermatol, Changsha 410008, Hunan, Peoples R China	Harbin Medical University; Central South University	Ning, SW; Zhi, H (corresponding author), Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China.	ningsw@ems.hrbmu.edu.cn; zhihui@ems.hrbmu.edu.cn		Zhi, Hui/0000-0001-9103-8642	Natural Science Foundation of Heilongjiang Province, China [LH2020C05]; National Natural Science Foundation of China [32170674, 32070672]	Natural Science Foundation of Heilongjiang Province, China(Natural Science Foundation of Heilongjiang Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Natural Science Foundation of Heilongjiang Province, China [LH2020C05]; the National Natural Science Foundation of China [32170674 and 32070672].	Aguilo F, 2016, CELL REP, V14, P479, DOI 10.1016/j.celrep.2015.12.043; Baek SJ, 2016, ONCOTARGET, V7, P25620, DOI 10.18632/oncotarget.8239; Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335; Barnett KR, 2020, MOL CELL, V77, P1350, DOI 10.1016/j.molcel.2020.01.004; Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; Bell RE, 2016, GENOME RES, V26, P601, DOI 10.1101/gr.197194.115; Benner C, 2015, P NATL ACAD SCI USA, V112, P12776, DOI 10.1073/pnas.1512995112; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chakravarty D, 2017, JCO PRECIS ONCOL, V1; Chen H, 2018, CELL, V173, P386, DOI 10.1016/j.cell.2018.03.027; Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143; Davis CA, 2018, NUCLEIC ACIDS RES, V46, pD794, DOI 10.1093/nar/gkx1081; Decaesteker B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06699-9; Domcke S, 2015, NATURE, V528, P575, DOI 10.1038/nature16462; Feldmann A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003994; Gutierrez-Arcelus M, 2013, ELIFE, V2, DOI 10.7554/eLife.00523; Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013; Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Hatzi K, 2013, CELL REP, V4, P578, DOI 10.1016/j.celrep.2013.06.016; Hawkins RD, 2010, CELL STEM CELL, V6, P479, DOI 10.1016/j.stem.2010.03.018; Hegde AN, 2019, LEARN MEMORY, V26, P307, DOI 10.1101/lm.048769.118; Home P, 2012, P NATL ACAD SCI USA, V109, P7362, DOI 10.1073/pnas.1201595109; Kent LN, 2016, J CLIN INVEST, V126, P2955, DOI 10.1172/JCI85506; Kim S, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2016.140; Li J, 2015, CANCER RES, V75, P3728, DOI 10.1158/0008-5472.CAN-15-0273; Mei SL, 2017, CANCER RES, V77, pE19, DOI 10.1158/0008-5472.CAN-17-0327; Miao YF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02113-y; Moore JE, 2020, NATURE, V583, P699, DOI 10.1038/s41586-020-2493-4; Niculescu RS, 2006, J MACH LEARN RES, V7, P1357; Paralkar VR, 2016, MOL CELL, V62, P104, DOI 10.1016/j.molcel.2016.02.029; Petell CJ, 2016, NUCLEIC ACIDS RES, V44, P7605, DOI 10.1093/nar/gkw426; Priness I, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-111; Qian MX, 2017, GENOME RES, V27, P185, DOI 10.1101/gr.209163.116; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Saint-Andre V, 2016, GENOME RES, V26, P385, DOI 10.1101/gr.197590.115; Sanda T, 2012, CANCER CELL, V22, P209, DOI 10.1016/j.ccr.2012.06.007; Sato N, 2006, BIOCHEM BIOPH RES CO, V344, P845, DOI 10.1016/j.bbrc.2006.04.007; Schadt EE, 2005, NAT GENET, V37, P710, DOI 10.1038/ng1589; Schuijers J, 2018, CELL REP, V23, P349, DOI 10.1016/j.celrep.2018.03.056; Sladky VC, 2020, DEV CELL, V52, P335, DOI 10.1016/j.devcel.2019.12.016; Sondka Z, 2018, NAT REV CANCER, V18, P696, DOI 10.1038/s41568-018-0060-1; Song YL, 2019, MOL CELL, V75, P905, DOI 10.1016/j.molcel.2019.06.045; Steuer R, 2002, BIOINFORMATICS, V18, pS231, DOI 10.1093/bioinformatics/18.suppl_2.S231; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki T, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0169-6; Symmons O, 2014, GENOME RES, V24, P390, DOI 10.1101/gr.163519.113; Tong Y, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1442-0; Tsamardinos I, 2010, LECT NOTES ARTIF INT, V6323, P322, DOI 10.1007/978-3-642-15939-8_21; Vanzan L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23630-x; Chung VY, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0506-3; Wagenmakers EJ, 2004, PSYCHON B REV, V11, P192, DOI 10.3758/BF03206482; Wiench M, 2011, EMBO J, V30, P3028, DOI 10.1038/emboj.2011.210; Xiong L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08245-z; Xu QH, 2016, MODERN PATHOL, V29, P546, DOI 10.1038/modpathol.2016.60; Yao LJ, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0668-3; Zhang Y, 2016, NAT GENET, V48, P1003, DOI 10.1038/ng.3635; Zhao Y, 2016, CELL REP, V15, P599, DOI 10.1016/j.celrep.2016.03.038; Zhou Y, 2019, NAT COMMUN, V10, DOI [DOI 10.1038/S41467-019-09234-6, 10.1038/s41467-019-09234-6]; Zhu H, 2016, NAT REV GENET, V17, P551, DOI 10.1038/nrg.2016.83	61	1	1	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2022	41	26					3474	3484		10.1038/s41388-022-02359-x	http://dx.doi.org/10.1038/s41388-022-02359-x		JUN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2J2QW	35655092				2022-12-17	WOS:000805097900001
J	Kerr, A; Baxter, RC				Kerr, Aidan; Baxter, Robert C.			Noncoding RNA actions through IGFs and IGF binding proteins in cancer	ONCOGENE			English	Review							DOWN-REGULATION; PROMOTES PROLIFERATION; CLINICAL-SIGNIFICANCE; CELL-PROLIFERATION; BLADDER-CANCER; MESSENGER-RNAS; EMERGING ROLE; EXPRESSION; INVASION; PROGRESSION	The insulin-like growth factors (IGFs) and their regulatory proteins-IGF receptors and binding proteins-are strongly implicated in cancer progression and modulate cell survival and proliferation, migration, angiogenesis and metastasis. By regulating the bioavailability of the type-1 IGF receptor (IGF1R) ligands, IGF-1 and IGF-2, the IGF binding proteins (IGFBP-1 to -6) play essential roles in cancer progression. IGFBPs also influence cell communications through pathways that are independent of IGF1R activation. Noncoding RNAs (ncRNAs), which encompass a variety of RNA types including microRNAs (miRNAs) and long-noncoding RNAs (lncRNAs), have roles in multiple oncogenic pathways, but their many points of intersection with IGF axis functions remain to be fully explored. This review examines the functional interactions of miRNAs and lncRNAs with IGFs and their binding proteins in cancer, and reveals how the IGF axis may mediate ncRNA actions that promote or suppress cancer. A better understanding of the links between ncRNA and IGF pathways may suggest new avenues for prognosis and therapeutic intervention in cancer. Further, by exploring examples of intersecting ncRNA-IGF pathways in non-cancer conditions, it is proposed that new opportunities for future discovery in cancer control may be generated.	[Kerr, Aidan; Baxter, Robert C.] Univ Sydney, Royal North Shore Hosp, Fac Med & Hlth, Kolling Inst, Sydney, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Kerr, A; Baxter, RC (corresponding author), Univ Sydney, Royal North Shore Hosp, Fac Med & Hlth, Kolling Inst, Sydney, NSW 2065, Australia.	aidan.kerr1998@gmail.com; robert.baxter@sydney.edu.au			CAUL	CAUL	Open Access funding enabled and organized by CAUL and its Member Institutions.	An LF, 2020, ANTI-CANCER DRUG, V31, P473, DOI 10.1097/CAD.0000000000000888; Annunziata M, 2011, ACTA DIABETOL, V48, P1, DOI 10.1007/s00592-010-0227-z; Bai R, 2019, MOL CARCINOGEN, V58, P2254, DOI 10.1002/mc.23113; Baxter RC, 2014, NAT REV CANCER, V14, P329, DOI 10.1038/nrc3720; Beckwith H, 2015, MOL ENDOCRINOL, V29, P1549, DOI 10.1210/me.2015-1157; Brown J, 2009, VITAM HORM, V80, P699, DOI 10.1016/S0083-6729(08)00625-0; Cai HM, 2019, INT J CLIN EXP PATHO, V12, P2496; Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224; Cantile M, 2021, CANCERS, V13, DOI 10.3390/cancers13030570; Chai ZH, 2020, BIOL RES, V53, DOI 10.1186/s40659-020-00280-9; Chang YS, 2002, CLIN CANCER RES, V8, P3796; Chen BQ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121638; Chen C, 2021, CANCER LETT, V518, P169, DOI 10.1016/j.canlet.2021.07.005; Chen H, 2018, ONCOL LETT, V15, P6361, DOI 10.3892/ol.2018.8174; Chen PH, 2016, NEUROPHARMACOLOGY, V110, P362, DOI 10.1016/j.neuropharm.2016.07.038; Chen ZH, 2020, LIFE SCI, V243, DOI 10.1016/j.lfs.2020.117288; Chirshev E, 2021, CANCERS, V13, DOI 10.3390/cancers13184617; Chuang ST, 2008, J UROLOGY, V179, P445, DOI 10.1016/j.juro.2007.09.106; Coe EA, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008501; Cox OT, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00106; Cuciniello R, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02193-1; de Silva HC, 2019, CELL MOL LIFE SCI, V76, P2015, DOI 10.1007/s00018-019-03033-4; DiStefano JK, 2018, METHODS MOL BIOL, V1706, P91, DOI 10.1007/978-1-4939-7471-9_6; Fan Chuannan, 2019, Oncotarget, V10, P4192, DOI 10.18632/oncotarget.24115; Ferreira HJ, 2018, CANCER METAST REV, V37, P55, DOI 10.1007/s10555-017-9715-8; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Fukuhisa H, 2019, J HUM GENET, V64, P521, DOI 10.1038/s10038-019-0584-6; Gao LL, 2019, EBIOMEDICINE, V41, P395, DOI 10.1016/j.ebiom.2019.02.034; Gao ZH, 2002, J CLIN ENDOCR METAB, V87, P1170, DOI 10.1210/jc.87.3.1170; Ghaforui-Fard S, 2019, J CELL PHYSIOL, V234, P17100, DOI 10.1002/jcp.28464; Gil N, 2020, NAT REV GENET, V21, P102, DOI 10.1038/s41576-019-0184-5; Gleeson LM, 2001, J CLIN ENDOCR METAB, V86, P2484, DOI 10.1210/jc.86.6.2484; Goto K, 2016, ONCOGENE, V35, P3598, DOI 10.1038/onc.2015.445; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Hakuno F, 2018, J MOL ENDOCRINOL, V61, pT69, DOI 10.1530/JME-17-0311; Han N, 2020, AM J PHYSIOL-ENDOC M, V318, pE723, DOI 10.1152/ajpendo.00555.2018; Han S, 2014, BRIT J CANCER, V111, P1400, DOI 10.1038/bjc.2014.435; Hanafusa T, 2002, CANCER LETT, V176, P149, DOI 10.1016/S0304-3835(01)00736-4; Hong DVS, 2020, BRIT J CANCER, V122, P1630, DOI 10.1038/s41416-020-0802-1; Hu JH, 2016, FETAL PEDIATR PATHOL, V35, P287, DOI 10.1080/15513815.2016.1178360; Huang Y, 2021, IUBMB LIFE, V73, P118, DOI 10.1002/iub.2409; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Ivkovic TC, 2017, CANCER LETT, V407, P113, DOI 10.1016/j.canlet.2017.04.007; Ji YT, 2020, PLACENTA, V101, P185, DOI 10.1016/j.placenta.2020.09.015; Katayama H, 2017, SCI REP-UK, V7, DOI 10.1038/srep44498; Khodadadi-Jamayran Alireza, 2018, Oncotarget, V9, P12868, DOI 10.18632/oncotarget.24403; Khordadmehr M, 2019, J CELL PHYSIOL, V234, P16861, DOI 10.1002/jcp.28368; Kozomara A, 2019, NUCLEIC ACIDS RES, V47, pD155, DOI 10.1093/nar/gky1141; Kumar AS, 2018, RNA BIOL, V15, P320, DOI 10.1080/15476286.2017.1338240; Lecerf C, 2019, CELL MOL LIFE SCI, V76, P4673, DOI 10.1007/s00018-019-03240-z; Lee CC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173890; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Li CJ, 2020, INT J BIOL SCI, V16, P2271, DOI 10.7150/ijbs.46986; Li GQ, 2019, PATHOL RES PRACT, V215, P34, DOI 10.1016/j.prp.2018.10.008; Li SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150418; Li T, 2020, CANCER LETT, V477, P19, DOI 10.1016/j.canlet.2020.02.036; Li X, 2015, ONCOGENE, V34, P1619, DOI 10.1038/onc.2014.98; Li XY, 2020, AM J TRANSL RES, V12, P6314; Lin MZ, 2014, ONCOGENE, V33, P85, DOI 10.1038/onc.2012.538; Liu Hongyu, 2018, Onco Targets Ther, V11, P7197, DOI 10.2147/OTT.S175467; Liu JW, 2019, DIGEST DIS SCI, V64, P1523, DOI 10.1007/s10620-018-5424-6; Liu LY, 2015, BIOCHEM BIOPH RES CO, V457, P621, DOI 10.1016/j.bbrc.2015.01.037; Liu SJ, 2021, NAT REV CANCER, V21, P446, DOI 10.1038/s41568-021-00353-1; Liu XN, 2020, AM J PHYSIOL-ENDOC M, V319, pE34, DOI 10.1152/ajpendo.00528.2019; Long ZS, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01557-5; Lorenzatti G, 2011, J CELL SCI, V124, P1752, DOI 10.1242/jcs.084194; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; McDonald KL, 2007, J NEUROPATH EXP NEUR, V66, P405, DOI 10.1097/nen.0b013e31804567d7; Medley JC, 2021, WIRES RNA, V12, DOI 10.1002/wrna.1627; Mercer TR, 2022, TRENDS PHARMACOL SCI, V43, P269, DOI 10.1016/j.tips.2022.01.008; Morchikh M, 2017, MOL CELL, V67, P387, DOI 10.1016/j.molcel.2017.06.020; Niinuma T, 2017, ONCOL LETT, V14, P5703, DOI 10.3892/ol.2017.6911; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Osher E, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080895; Paul P, 2018, J CELL PHYSIOL, V233, P2007, DOI 10.1002/jcp.25854; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Poloznikov AA, 2019, B EXP BIOL MED+, V166, P641, DOI 10.1007/s10517-019-04409-z; Qi L, 2018, BIOMED PHARMACOTHER, V103, P1507, DOI 10.1016/j.biopha.2018.04.053; Qu SP, 2019, EUR REV MED PHARMACO, V23, P4850, DOI 10.26355/eurrev_201906_18072; Santosh V, 2010, CANCER EPIDEM BIOMAR, V19, P1399, DOI 10.1158/1055-9965.EPI-09-1213; Sehgal K, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143945; Seligson DB, 2013, HORM CANCER-US, V4, P12, DOI 10.1007/s12672-012-0124-8; Shen P, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-020-01705-x; Slack FJ, 2019, CELL, V179, P1033, DOI 10.1016/j.cell.2019.10.017; Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9; Sun Y, 2019, J CELL BIOCHEM, V120, P19406, DOI 10.1002/jcb.29055; Tan YL, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033820909125; Thin KZ, 2019, CLIN CHIM ACTA, V494, P38, DOI 10.1016/j.cca.2019.03.002; Tong L, 2021, ADV CLIN EXP MED, V30, P661, DOI 10.17219/acem/134833; Wa QD, 2018, ONCOL REP, V39, P81, DOI 10.3892/or.2017.6096; Wang HH, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694316; Wang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096472; Wang XY, 2020, BIOCHEM BIOPH RES CO, V531, P573, DOI 10.1016/j.bbrc.2020.08.008; Wu XG, 2020, LIFE SCI, V243, DOI 10.1016/j.lfs.2020.117287; Yan L, 2018, J CELL BIOCHEM, V119, P3989, DOI 10.1002/jcb.26553; Yang BY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0722-8; Yang CH, 2014, J BIOL CHEM, V289, P25079, DOI 10.1074/jbc.M114.593863; Yang DK, 2020, CANCER MED-US, V9, P700, DOI 10.1002/cam4.2650; Yin L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02785-3; Yu GQ, 2017, ONCOL REP, V37, P1123, DOI 10.3892/or.2016.5326; ZeinElAbdeen YA, 2022, J MAMMARY GLAND BIOL, V27, P79, DOI 10.1007/s10911-022-09511-z; Zhan JF, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12692; Zhang NN, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.1012; Zhang Q, 2020, J CELL MOL MED, V24, P8236, DOI 10.1111/jcmm.15499; Zhang T, 2019, ONCOL REP, V41, P279, DOI 10.3892/or.2018.6840; Zhang YY, 2016, NAT STRUCT MOL BIOL, V23, P522, DOI 10.1038/nsmb.3211; Zheng F, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0146-6; Zhou N, 2018, ONCOL REP, V40, P2710, DOI 10.3892/or.2018.6640; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	109	1	1	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3385	3393		10.1038/s41388-022-02353-3	http://dx.doi.org/10.1038/s41388-022-02353-3		MAY 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35597813	hybrid, Green Published			2022-12-17	WOS:000798470300001
J	Khandrika, L; Lieberman, R; Koul, S; Kumar, B; Maroni, P; Chandhoke, R; Meacham, RB; Koul, HK				Khandrika, Lakshmipathi; Lieberman, Rachel; Koul, Sweaty; Kumar, Binod; Maroni, Paul; Chandhoke, Ryan; Meacham, Randall B.; Koul, Hari K.			RETRACTION: Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1 alpha levels contribute to emergence of an aggressive phenotype in prostate cancer (Retraction of 10.1038/S41388-022-02357-Z, 2022)	ONCOGENE			English	Retraction												hari.koul@uchsc.edu						Khandrika L, 2022, ONCOGENE, V41, P3383, DOI 10.1038/s41388-022-02357-z	1	1	1	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3383	3383		10.1038/s41388-022-02357-z	http://dx.doi.org/10.1038/s41388-022-02357-z		MAY 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35589952	Bronze			2022-12-17	WOS:000799459800001
J	Hamad, SH; Montgomery, SA; Simon, JM; Bowman, BM; Spainhower, KB; Murphy, RM; Knudsen, ES; Fenton, SE; Randell, SH; Holt, JR; Hayes, DN; Witkiewicz, AK; Oliver, TG; Ben Major, M; Weissman, BE				Hamad, Samera H.; Montgomery, Stephanie A.; Simon, Jeremy M.; Bowman, Brittany M.; Spainhower, Kyle B.; Murphy, Ryan M.; Knudsen, Erik S.; Fenton, Suzanne E.; Randell, Scott H.; Holt, Jeremiah R.; Hayes, D. Neil; Witkiewicz, Agnieszka K.; Oliver, Trudy G.; Ben Major, M.; Weissman, Bernard E.			TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice	ONCOGENE			English	Article							KEAP1-NRF2 PATHWAY; 3Q AMPLIFICATION; MUTATIONS; CARCINOMA; NRF2; INACTIVATION; ACTIVATION; MECHANISMS; GENES; P63	Studies have shown that Nrf2(E79Q/+) is one of the most common mutations found in human tumors. To elucidate how this genetic change contributes to lung cancer, we compared lung tumor development in a genetically-engineered mouse model (GEMM) with dual Trp53/p16 loss, the most common mutations found in human lung tumors, in the presence or absence of Nrf2(E79Q/+). Trp53/p16-deficient mice developed combined-small cell lung cancer (C-SCLC), a mixture of pure-SCLC (P-SCLC) and large cell neuroendocrine carcinoma. Mice possessing the LSL-Nrf2(E79Q) mutation showed no difference in the incidence or latency of C-SCLC compared with Nrf2(+/+) mice. However, these tumors did not express NRF2 despite Cre-induced recombination of the LSL-Nrf2(E79Q) allele. Trp53/p16-deficient mice also developed P-SCLC, where activation of the NRF2(E79Q) mutation associated with a higher incidence of this tumor type. All C-SCLCs and P-SCLCs were positive for NE-markers, NKX1-2 (a lung cancer marker) and negative for P63 (a squamous cell marker), while only P-SCLC expressed NRF2 by immunohistochemistry. Analysis of a consensus NRF2 pathway signature in human NE+-lung tumors showed variable activation of NRF2 signaling. Our study characterizes the first GEMM that develops C-SCLC, a poorly-studied human cancer and implicates a role for NRF2 activation in SCLC development.	[Hamad, Samera H.; Montgomery, Stephanie A.; Simon, Jeremy M.; Bowman, Brittany M.; Ben Major, M.; Weissman, Bernard E.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Montgomery, Stephanie A.; Weissman, Bernard E.] Univ N Carolina, Dept Pathol & Lab Med, Sch Med, Chapel Hill, NC 27515 USA; [Simon, Jeremy M.] Univ N Carolina, Dept Genet, Sch Med, Chapel Hill, NC 27515 USA; [Simon, Jeremy M.] Univ N Carolina, UNC Neurosci Ctr, Sch Med, Chapel Hill, NC 27515 USA; [Spainhower, Kyle B.; Oliver, Trudy G.] Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT USA; [Murphy, Ryan M.] Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27515 USA; [Knudsen, Erik S.; Witkiewicz, Agnieszka K.] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA; [Fenton, Suzanne E.] NIEHS, Div Natl Toxicol Program, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Randell, Scott H.] Univ N Carolina, Sch Med, Marsico Lung Inst, Chapel Hill, NC 27515 USA; [Holt, Jeremiah R.; Hayes, D. Neil] Univ Tennessee, Hlth Sci Ctr Canc Res, Dept Med, Div Hematol & Oncol, Memphis, TN USA; [Ben Major, M.] Univ N Carolina, Dept Cell Biol & Physiol, Sch Med, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Utah System of Higher Education; University of Utah; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Tennessee System; University of Tennessee Health Science Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Ben Major, M; Weissman, BE (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.; Weissman, BE (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Sch Med, Chapel Hill, NC 27515 USA.; Ben Major, M (corresponding author), Univ N Carolina, Dept Cell Biol & Physiol, Sch Med, Chapel Hill, NC 27515 USA.	bmajor@wustl.edu; weissman@med.unc.edu	, Pathology Services Core/CEZ-2246-2022	Holt, Jeremiah/0000-0002-5201-5015	National Institutes of Environmental and Health Sciences [T32ES007126]; Golberg; National Cancer Institute [CA216051]; UNC Lineberger Clinical/Translational Research Award;  [5R01CA244841-02];  [5U01CA231844-04];  [5U24CA213274-05]	National Institutes of Environmental and Health Sciences; Golberg; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UNC Lineberger Clinical/Translational Research Award; ; ; 	This study was supported by a grant from the National Institutes of Environmental and Health Sciences (T32ES007126) (S.H.H), a Golberg Postdoctoral Fellow (S.H.H.), a grant from the National Cancer Institute (CA216051) (B.E.W, M.B.M.) and by grants 5R01CA244841-02, 5U01CA231844-04, and 5U24CA213274-05 (T.G.O.). These studies were also supported in part by a UNC Lineberger Clinical/Translational Research Award.	Alcala N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11276-9; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bowman BM, 2020, J PATHOL, V252, P125, DOI 10.1002/path.5504; Bryan HK, 2013, BIOCHEM PHARMACOL, V85, P705, DOI 10.1016/j.bcp.2012.11.016; Cancer Genome Atlas Research N, 2014, NATURE, V511, P50, DOI [10.1038/nature133851:CAS:528:DC%2BC2cXht1ChurnI, DOI 10.1038/NATURE133851:CAS:528:DC%2BC2CXHT1CHURNI]; Cescon DW, 2015, CLIN CANCER RES, V21, P2499, DOI 10.1158/1078-0432.CCR-14-2206; Cloer EW, 2019, CANCER RES, V79, P889, DOI 10.1158/0008-5472.CAN-18-2723; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; Demirhan O, 2010, CANCER EPIDEMIOL, V34, P472, DOI 10.1016/j.canep.2010.03.018; Desai A, 2016, CANCER BIOL MED, V13, P77, DOI 10.28092/j.issn.2095-3941.2016.0008; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Engel NW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166690; Fernandez-Cuesta L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4518; Gabriel AAG, 2020, GIGASCIENCE, V9, DOI 10.1093/gigascience/giaa112; George J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03099-x; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Hamad Samera H, 2017, Tob Regul Sci, V3, P459, DOI 10.18001/TRS.3.4.7; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Ireland AS, 2020, CANCER CELL, V38, P60, DOI 10.1016/j.ccell.2020.05.001; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001; Kazanets A, 2016, BBA-REV CANCER, V1865, P275, DOI 10.1016/j.bbcan.2016.04.001; Kerins MJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31281-0; Kim JH, 2017, ONCOTARGET, V8, P48248, DOI 10.18632/oncotarget.17594; Kodama T, 2014, MOL CANCER THER, V13, P2910, DOI 10.1158/1535-7163.MCT-14-0274; KOIKE K, 1990, J VIROL, V64, P3988, DOI 10.1128/JVI.64.8.3988-3991.1990; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Laddha SV, 2019, CANCER RES, V79, P4339, DOI 10.1158/0008-5472.CAN-19-0214; Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003; Leversha MA, 2003, J PATHOL, V200, P610, DOI 10.1002/path.1374; Li SY, 2016, J THORAC ONCOL, V11, P2129, DOI 10.1016/j.jtho.2016.08.142; Lubet R, 2005, EXP LUNG RES, V31, P117, DOI 10.1080/01902140490495499; Lubojemska A, 2016, VET COMP ONCOL, V14, pE70, DOI 10.1111/vco.12102; Maronpot RR, 1999, PATHOLOGY MOUSE REFE; Massion PP, 2003, CANCER RES, V63, P7113; McCaughan F, 2010, AM J RESP CRIT CARE, V182, P83, DOI 10.1164/rccm.201001-0005OC; McFadden DG, 2014, CELL, V156, P1298, DOI 10.1016/j.cell.2014.02.031; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Mollaoglu G, 2017, CANCER CELL, V31, P270, DOI 10.1016/j.ccell.2016.12.005; Mukhopadhyay S, 2011, AM J SURG PATHOL, V35, P15, DOI 10.1097/PAS.0b013e3182036d05; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Park KS, 2011, CELL CYCLE, V10, P2806, DOI 10.4161/cc.10.16.17012; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Perez-Moreno P, 2012, CLIN CANCER RES, V18, P2443, DOI 10.1158/1078-0432.CCR-11-2370; Qian J, 2008, J THORAC ONCOL, V3, P212, DOI 10.1097/JTO.0b013e3181663544; Rekhtman N, 2012, CLIN CANCER RES, V18, P1167, DOI 10.1158/1078-0432.CCR-11-2109; Reznik GK, 1994, IARC PUBL, P30524; Romero R, 2017, NAT MED, V23, P1362, DOI 10.1038/nm.4407; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Schaffer BE, 2010, CANCER RES, V70, P3877, DOI 10.1158/0008-5472.CAN-09-4228; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Siegel Rebecca L, 2019, CA Cancer J Clin, V69, P7, DOI 10.3322/caac.21551; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Snow AN, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472-6890-14-30; Society AC, 2019, CANC FACTS FIGURES 2; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Sonkin D, 2019, LUNG CANCER MANAG, V8, DOI 10.2217/lmt-2019-0005; Sutherland KD, 2011, CANCER CELL, V19, P754, DOI 10.1016/j.ccr.2011.04.019; Swanton C, 2016, NEW ENGL J MED, V374, P1864, DOI 10.1056/NEJMra1504688; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Travis WD, 2014, PATHOLOGE, V35, P188, DOI 10.1007/s00292-014-1974-3; Travis William D, 2009, Eur J Cancer, V45 Suppl 1, P251, DOI 10.1016/S0959-8049(09)70040-1; WAALKES MP, 1987, CANCER RES, V47, P2445; Wang SH, 2019, MAYO CLIN PROC, V94, P1599, DOI 10.1016/j.mayocp.2019.01.034; Wu MX, 2003, AM J CLIN PATHOL, V119, P696, DOI 10.1309/XCP6EWPB3BMRKA; Yamano S, 2016, CANCER SCI, V107, P123, DOI 10.1111/cas.12855; Zheng M, 2016, SURG ONCOL CLIN N AM, V25, P447, DOI 10.1016/j.soc.2016.02.003; Zhu Yanliang, 2008, Zhongguo Fei Ai Za Zhi, V11, P681, DOI 10.3779/j.issn.1009-3419.2008.05.009	69	1	1	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3423	3432		10.1038/s41388-022-02348-0	http://dx.doi.org/10.1038/s41388-022-02348-0		MAY 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35577980	Green Submitted			2022-12-17	WOS:000796348100001
J	Zhao, Y; Sun, HF; Zhao, YY; Liu, QQ; Liu, Y; Hou, YF; Jin, W				Zhao, Yang; Sun, Hefen; Zhao, Yuanyuan; Liu, Qiqi; Liu, Yang; Hou, Yifeng; Jin, Wei			NSrp70 suppresses metastasis in triple-negative breast cancer by modulating Numb/T beta R1/EMT axis	ONCOGENE			English	Article							SPECKLE-RELATED PROTEIN; ISOFORM; EXPRESSION; NUMB; ABERRANT	Alternative splicing of mRNA precursors allows cancer cells to create different protein isoforms that promote growth and survival. Compared to normal cells, cancer cells frequently exhibit a higher diversity of their transcriptomes. A comprehensive understanding of splicing regulation is required to correct the splicing alterations for the future precision oncology. A quantitative proteomic screen was performed to identify the regulators associated the metastasis in triple-negative breast cancer. Multiple in vitro and in vivo functional analyses were used to study the effects of NSrp70 on breast cancer metastasis. Next, transcriptomic sequencing (RNA-seq) and alternative splicing bioinformatics analysis was applied to screen the potential targets of NSrp70. Moreover, in vitro splicing assays, RNA pull-down, and RNA immunoprecipitation assay were used to confirm the specific binding between NSrp70 and downstream target genes. Furthermore, the prognostic value of NSrp70 was analyzed in a cohort of patients by performing IHC. We uncovered NSrp70 as a novel suppressor of breast cancer metastasis. We discovered that NSrp70 inhibited the skipped exon alternative splicing of NUMB, promoted the degradation of transforming growth factor receptor 1 through lysosome pathway, and regulated TGF beta/SMAD-mediated epithelial-mesenchymal transition phenotype in breast cancer cells. Furthermore, high NSrp70 expression correlated with a better prognosis in breast cancer patients. Our findings revealed that splicing regulator NSrp70 serves as a metastasis suppressor.	[Zhao, Yang; Sun, Hefen; Zhao, Yuanyuan; Liu, Qiqi; Liu, Yang; Hou, Yifeng; Jin, Wei] Fudan Univ, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Zhao, Yang; Sun, Hefen; Zhao, Yuanyuan; Liu, Qiqi; Hou, Yifeng; Jin, Wei] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Sun, HF; Jin, W (corresponding author), Fudan Univ, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Sun, HF; Jin, W (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.	sunhefen2006@163.com; jinwei@fudan.edu.cn	ZHAO, YUAN/HCI-5831-2022; jin, wei/M-4717-2018	jin, wei/0000-0001-8263-571X	National Natural Science Foundation of China [81972727]; Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines in Shanghai [2017BR028]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines in Shanghai	This work was supported by a grant from National Natural Science Foundation of China (81972727) and the Municipal Human Resources Development Program for Outstanding Leaders in Medical Disciplines in Shanghai (2017BR028). We gratefully acknowledge the help of professor Igor Vladimirovich Reshetov (I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation) for the support of clinical statistical analysis.	Bell MV, 1998, MOL CELL BIOL, V18, P5930, DOI 10.1128/MCB.18.10.5930; Cheng CH, 2006, GENE DEV, V20, P1715, DOI 10.1101/gad.1430906; Choi DB, 2014, LEUKEMIA RES, V38, P1252, DOI 10.1016/j.leukres.2014.08.001; Cooper TA, 2005, METHODS, V37, P331, DOI 10.1016/j.ymeth.2005.07.015; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Erb U, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-29; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Imamura T, 2012, BREAST CANCER-TOKYO, V19, P118, DOI 10.1007/s12282-011-0321-2; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Kandachar V, 2012, CURR OPIN CELL BIOL, V24, P534, DOI 10.1016/j.ceb.2012.06.006; Katz Y, 2010, NAT METHODS, V7, P1009, DOI 10.1038/NMETH.1528; Kim CH, 2016, J BIOL CHEM, V291, P6169, DOI 10.1074/jbc.M115.689414; Kim YD, 2011, NUCLEIC ACIDS RES, V39, P4300, DOI 10.1093/nar/gkq1267; Ladomery Michael, 2013, Int J Cell Biol, V2013, P463786, DOI 10.1155/2013/463786; Lee SH, 2016, BIOCHEM BIOPH RES CO, V479, P238, DOI 10.1016/j.bbrc.2016.09.051; Lee SCW, 2016, NAT MED, V22, P976, DOI 10.1038/nm.4165; Lee Y, 2015, ANNU REV BIOCHEM, V84, P291, DOI 10.1146/annurev-biochem-060614-034316; Li N, 2000, BJU INT, V85, P514, DOI 10.1046/j.1464-410x.2000.00483.x; Loh TJ, 2014, ONCOL REP, V31, P273, DOI 10.3892/or.2013.2812; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Misquitta-Ali CM, 2011, MOL CELL BIOL, V31, P138, DOI 10.1128/MCB.00709-10; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pece S, 2011, BBA-REV CANCER, V1815, P26, DOI 10.1016/j.bbcan.2010.10.001; Read A, 2018, ENDOCR-RELAT CANCER, V25, pR467, DOI 10.1530/ERC-18-0068; Reithmeier A, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3616-7; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; Spector DL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a000646; Stoss O, 1999, BRAIN RES PROTOC, V4, P383, DOI 10.1016/S1385-299X(99)00043-4; Sun HY, 2017, BIOCHEM BIOPH RES CO, V491, P780, DOI 10.1016/j.bbrc.2017.07.084; Sun HF, 2019, CANCER LETT, V440, P189, DOI 10.1016/j.canlet.2018.10.018; Townley-Tilson WHD, 2006, RNA, V12, P1853, DOI 10.1261/rna.76006; Tripathi V, 2012, MOL BIOL CELL, V23, P3694, DOI 10.1091/mbc.E12-03-0206; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang ZZ, 2010, CELL ADHES MIGR, V4, P176, DOI 10.4161/cam.4.2.10690; Xiao XY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-151; Xie J, 2015, NEUROSCIENCE, V310, P723, DOI 10.1016/j.neuroscience.2015.10.012; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zheng YZ, 2014, BREAST CANCER RES TR, V145, P349, DOI 10.1007/s10549-014-2967-x; Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289	42	1	1	5	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2022	41	25					3409	3422		10.1038/s41388-022-02349-z	http://dx.doi.org/10.1038/s41388-022-02349-z		MAY 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2E6DK	35568738	Green Submitted			2022-12-17	WOS:000795517600001
J	Moser, R; Gurley, KE; Nikolova, O; Qin, GR; Joshi, R; Mendez, E; Shmulevich, I; Ashley, A; Grandori, C; Kemp, CJ				Moser, Russell; Gurley, Kay E.; Nikolova, Olga; Qin, Guangrong; Joshi, Rashmi; Mendez, Eduardo; Shmulevich, Ilya; Ashley, Amanda; Grandori, Carla; Kemp, Christopher J.			Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; TUMOR-FORMATION; ONCOGENIC RAS; MALIGNANT PROGRESSION; THERAPEUTIC TARGETS; SKIN TUMORS; CANCER; MICE; PROMOTION; GROWTH	The oncogene Ras and the tumor suppressor gene p53 are frequently co-mutated in human cancer and mutations in Ras and p53 can cooperate to generate a more malignant cell state. To discover novel druggable targets for cancers carrying co-mutations in Ras and p53, we performed arrayed, kinome focused siRNA and oncology drug phenotypic screening utilizing a set of syngeneic Ras mutant squamous cell carcinoma (SCC) cell lines that also carried co-mutations in selected p53 pathway genes. These cell lines were derived from SCCs from carcinogen-treated inbred mice which harbored germline deletions or mutations in Trp53, p19(Arf), Atm, or Prkdc. Both siRNA and drug phenotypic screening converge to implicate the phosphoinositol kinases, receptor tyrosine kinases, MAP kinases, as well as cell cycle and DNA damage response genes as targetable dependencies in SCC. Differences in functional kinome profiles between Ras mutant cell lines reflect incomplete penetrance of Ras synthetic lethal kinases and indicate that co-mutations cause a rewiring of survival pathways in Ras mutant tumors. This study describes the functional kinomic landscape of Ras/p53 mutant chemically-induced squamous cell carcinoma in both the baseline unperturbed state and following DNA damage and nominates candidate therapeutic targets, including the Nek4 kinase, for further development.	[Moser, Russell; Gurley, Kay E.; Kemp, Christopher J.] Fred Hutchinson Canc Res Ctr, Div Human Biol, 1124 Columbia St, Seattle, WA 98104 USA; [Nikolova, Olga] Oregon Hlth & Sci Univ, Div Oncol Sci, Portland, OR 97201 USA; [Qin, Guangrong; Shmulevich, Ilya] Inst Syst Biol, Seattle, WA USA; [Joshi, Rashmi; Ashley, Amanda] New Mexico State Univ, Las Cruces, NM 88003 USA; [Mendez, Eduardo; Grandori, Carla] SEngine Precis Med, Seattle, WA USA	Fred Hutchinson Cancer Center; Oregon Health & Science University; Institute for Systems Biology (ISB); New Mexico State University	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, 1124 Columbia St, Seattle, WA 98104 USA.	cjkemp@fhcrc.org			NCI [U01 CA176303, U01 CA217883, U54 CA132381, R01 CA214428, R01 CA215647, 2P30CA015704]; ACS [123653-RSG-13-066]; Hartwell Fund	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS(American Cancer Society); Hartwell Fund	This work was supported by The Hartwell Fund, NCI U01 CA176303, U01 CA217883, U54 CA132381, R01 CA214428, R01 CA215647, 2P30CA015704, and ACS 123653-RSG-13-066. We acknowledge technical assistance from Slobodan Beronja in generating normal mouse keratinocytes and the use of data from the NCI's Cancer Target Discovery and Development Network, The Cancer Genome Atlas, and The Cell Line Encyclopedia.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Adhikari H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05692-6; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Bai YF, 2004, CANCER RES, V64, P8808, DOI 10.1158/0008-5472.CAN-04-3143; Bailey SL, 2008, MOL CANCER RES, V6, P1185, DOI 10.1158/1541-7786.MCR-07-2009; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Pavan ICB, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030507; Birmingham A, 2009, NAT METHODS, V6, P569, DOI 10.1038/nmeth.1351; Burke JE, 2018, MOL CELL, V71, P653, DOI 10.1016/j.molcel.2018.08.005; BURNS PA, 1991, ONCOGENE, V6, P2363; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Choi SY, 2015, BBA-MOL CELL BIOL L, V1851, P711, DOI 10.1016/j.bbalip.2015.01.009; Costa-Cabral S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149099; Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214; Dahlhoff M, 2017, J INVEST DERMATOL, V137, P921, DOI 10.1016/j.jid.2016.11.023; Dahlhoff M, 2015, MOL ONCOL, V9, P1825, DOI 10.1016/j.molonc.2015.06.007; Ding NH, 2018, J CELL MOL MED, V22, P5877, DOI 10.1111/jcmm.13857; Dlugosz AA, 1997, CANCER RES, V57, P3180; Doles J, 2010, CANCER RES, V70, P1033, DOI 10.1158/0008-5472.CAN-09-2113; Ehrenreiter K, 2009, CANCER CELL, V16, P149, DOI 10.1016/j.ccr.2009.06.008; Eyers PA, 2017, TRENDS CELL BIOL, V27, P284, DOI 10.1016/j.tcb.2016.11.002; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Fry AM, 2012, J CELL SCI, V125, P4423, DOI 10.1242/jcs.111195; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hahn WC, 2021, CELL, V184, P1142, DOI 10.1016/j.cell.2021.02.020; Hara T, 2005, CANCER RES, V65, P7356, DOI 10.1158/0008-5472.CAN-04-4241; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Jameson KL, 2013, NAT MED, V19, P626, DOI 10.1038/nm.3165; KEITH WN, 1990, CANCER RES, V50, P6841; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kemp CJ, 1999, CARCINOGENESIS, V20, P2051, DOI 10.1093/carcin/20.11.2051; Kemp CJ, 2014, MOUSE MODELS CANC LA, P5160; Kiessling MK, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3042-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Mackay HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Martin TD, 2017, CELL REP, V20, P427, DOI 10.1016/j.celrep.2017.06.061; McCreery MQ, 2015, NAT MED, V21, P1514, DOI 10.1038/nm.3979; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; Mendez E, 2018, CLIN CANCER RES, V24, P2740, DOI 10.1158/1078-0432.CCR-17-3796; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Moniz L, 2011, CELL DIV, V6, DOI 10.1186/1747-1028-6-18; Moore AR, 2020, NAT REV DRUG DISCOV, V19, P533, DOI 10.1038/s41573-020-0068-6; Moser R, 2014, CLIN CANCER RES, V20, P4274, DOI 10.1158/1078-0432.CCR-13-2858; Nassar D, 2015, NAT MED, V21, P946, DOI 10.1038/nm.3878; Nguyen CL, 2012, MOL CELL BIOL, V32, P3963, DOI 10.1128/MCB.00436-12; Nowak Jonathan A., 2009, V482, P215, DOI 10.1007/978-1-59745-060-7_14; Park SJ, 2016, ONCOTARGET, V7, P65957, DOI 10.18632/oncotarget.11781; Parker PJ, 2021, NAT REV CANCER, V21, P51, DOI 10.1038/s41568-020-00310-4; Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z; Prior IA, 2020, CANCER RES, V80, P2969, DOI 10.1158/0008-5472.CAN-19-3682; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Ryan CJ, 2018, TRENDS CANCER, V4, P671, DOI 10.1016/j.trecan.2018.08.003; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schneider G, 2017, NAT REV CANCER, V17, P239, DOI 10.1038/nrc.2017.5; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Sterneck E, 2006, ONCOGENE, V25, P1272, DOI 10.1038/sj.onc.1209144; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Tsunoda N, 2009, CANCER SCI, V100, P111, DOI 10.1111/j.1349-7006.2008.01007.x; Weinberg F, 2017, EBIOMEDICINE, V20, P79, DOI 10.1016/j.ebiom.2017.04.015; Xu C, 2018, CLIN CANCER RES, V24, P2828, DOI 10.1158/1078-0432.CCR-17-1339; Yadav V, 2011, MOL CARCINOGEN, V50, P346, DOI 10.1002/mc.20716; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	79	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3355	3369		10.1038/s41388-022-02330-w	http://dx.doi.org/10.1038/s41388-022-02330-w		MAY 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35538224				2022-12-17	WOS:000793037400002
J	Ehsani, M; Bartsch, S; Rasa, SMM; Dittmann, J; Pungsrinont, T; Neubert, L; Huettner, SS; Kotolloshi, R; Schindler, K; Ahmad, A; Mosig, AS; Adam, L; Ori, A; Neri, F; Berndt, A; Grimm, MO; Baniahmad, A				Ehsani, Marzieh; Bartsch, Sophie; Rasa, Seyed Mohammad Mahdi; Dittmann, Jessica; Pungsrinont, Thanakorn; Neubert, Laura; Huettner, Soeren S.; Kotolloshi, Roland; Schindler, Katrin; Ahmad, Aya; Mosig, Alexander S.; Adam, Lisa; Ori, Alessandro; Neri, Francesco; Berndt, Alexander; Grimm, Marc-Oliver; Baniahmad, Aria			The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR INTEGRIN ALPHA(V)BETA(3); MICROVESSEL DENSITY; CELLULAR SENESCENCE; PROGNOSTIC VALUE; RECEPTOR; EXPRESSION; ANTAGONIST; VEGF; SURVIVAL	Castration-resistant prostate cancer (CRPC) is an aggressive lethal form of prostate cancer (PCa). Atraric acid (AA) not only inhibits the wild-type androgen receptor (AR) but also those AR mutants that confer therapy resistance to other clinically used AR antagonists, indicating a different mode of AR antagonism. AA induces cellular senescence and inhibits CRPC tumour growth in in vivo xenograft mouse model associated with reduced neo-angiogenesis suggesting the repression of intratumoural neo-angiogenesis by AA. In line with this, the secretome of CRPC cells mediates neo-angiogenesis in an androgen-dependent manner, which is counteracted by AA. This was confirmed by two in vitro models using primary human endothelial cells. Transcriptome sequencing revealed upregulated angiogenic pathways by androgen, being however VEGF-independent, and pointing to the pro-angiogenic factor angiopoietin 2 (ANGPT2) as a key driver of neo-angiogenesis induced by androgens and repressed by AA. In agreement with this, AA treatment of native patient-derived PCa tumour samples ex vivo inhibits ANGPT2 expression. Mechanistically, in addition to AA, immune-depletion of ANGPT2 from secretome or blocking ANGPT2-receptors inhibits androgen-induced angiogenesis. Taken together, we reveal a VEGF-independent ANGPT2-mediated angiogenic pathway that is inhibited by AA leading to repression of androgen-regulated neo-angiogenesis.	[Ehsani, Marzieh; Bartsch, Sophie; Dittmann, Jessica; Pungsrinont, Thanakorn; Neubert, Laura; Huettner, Soeren S.; Kotolloshi, Roland; Schindler, Katrin; Ahmad, Aya; Baniahmad, Aria] Jena Univ Hosp, Inst Human Genet, D-07740 Jena, Germany; [Rasa, Seyed Mohammad Mahdi; Adam, Lisa; Ori, Alessandro; Neri, Francesco] Leibniz Inst Aging, D-07745 Jena, Germany; [Mosig, Alexander S.] Jena Univ, Inst Biochem 2, D-07740 Jena, Germany; [Berndt, Alexander] Jena Univ Hosp, Inst Pathol, D-07740 Jena, Germany; [Grimm, Marc-Oliver] Jena Univ Hosp, Dept Adult & Pediat Urol, D-07740 Jena, Germany	Friedrich Schiller University of Jena; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Baniahmad, A (corresponding author), Jena Univ Hosp, Inst Human Genet, D-07740 Jena, Germany.	aria.baniahmad@med.uni-jena.de		Huttner, Soren/0000-0002-5054-0027	German Cancer Aid [70113814]; German Academic Exchange Service (DAAD) [91606773, 91644032]; Projekt DEAL	German Cancer Aid(Deutsche Krebshilfe); German Academic Exchange Service (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); Projekt DEAL	This work was supported by the German Cancer Aid (No. 70113814) to AB, the German Academic Exchange Service (DAAD) to ME (91606773), TP (91644032). Open Access funding enabled and organized by Projekt DEAL.	Albert JM, 2006, INT J RADIAT ONCOL, V65, P1536, DOI 10.1016/j.ijrobp.2006.04.036; Aparicio A, 2011, NAT REV UROL, V8, P562, DOI 10.1038/nrurol.2011.107; Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Balk Steven P, 2008, Nucl Recept Signal, V6, pe001, DOI 10.1621/nrs.06001; Bono AV, 2002, PROSTATE CANCER P D, V5, P123, DOI 10.1038/sj.pcan.4500572; Borre M, 1998, BRIT J CANCER, V78, P940, DOI 10.1038/bjc.1998.605; Breslin S, 2013, DRUG DISCOV TODAY, V18, P240, DOI 10.1016/j.drudis.2012.10.003; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02; Duque José Luis Ferreira, 2006, Clinics, V61, P401, DOI 10.1590/S1807-59322006000500006; Ehsani M, 2021, CANCERS, V13, DOI 10.3390/cancers13071534; Esmaeili M, 2016, J MOL MED, V94, P1167, DOI 10.1007/s00109-016-1440-1; Esmaeili M, 2016, J MOL CELL BIOL, V8, P207, DOI 10.1093/jmcb/mjw007; Felcht M, 2012, J CLIN INVEST, V122, P1991, DOI 10.1172/JCI58832; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685; Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Fromont G, 2005, INT J CANCER, V114, P174, DOI 10.1002/ijc.20704; Garcia J, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102017; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Gyftopoulos K, 2011, UROL INT, V87, P464, DOI 10.1159/000329289; Handa RJ, 2008, HORM BEHAV, V53, P741, DOI 10.1016/j.yhbeh.2007.09.012; He F, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181259; Helfrich I, 2009, CLIN CANCER RES, V15, P1384, DOI 10.1158/1078-0432.CCR-08-1615; Hessenkemper W, 2014, MOL ENDOCRINOL, V28, P1831, DOI 10.1210/me.2014-1170; Imanishi Y, 2007, CANCER RES, V67, P4254, DOI 10.1158/0008-5472.CAN-06-4100; Jia J, 2019, INT J ONCOL, V55, P157, DOI 10.3892/ijo.2019.4797; Johansen JA, 2007, J NEUROENDOCRINOL, V19, P823, DOI 10.1111/j.1365-2826.2007.01592.x; Khalili P, 2006, MOL CANCER THER, V5, P2271, DOI 10.1158/1535-7163.MCT-06-0100; Kim I, 2000, ONCOGENE, V19, P4549, DOI 10.1038/sj.onc.1203800; Korff T, 2004, 3 DIMENTIONAL IN VIT; Lecce L, 2014, MOL ENDOCRINOL, V28, P1487, DOI 10.1210/me.2013-1405; Li ZH, 2019, CHIN J NAT MEDICINES, V17, P241, DOI 10.1016/S1875-5364(19)30028-7; Liu ZQ, 2015, INT J CLIN EXP MED, V8, P2289; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; March B, 2020, NAT REV UROL, V17, P119, DOI 10.1038/s41585-019-0274-3; Max R, 1997, INT J CANCER, V71, P320, DOI 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.3.CO;2-3; Melegh Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112676; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morrissey C, 2010, PROSTATE, V70, P1799, DOI 10.1002/pros.21216; Mosaad EO, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18050-1; Nordby Y, 2015, PROSTATE, V75, P1682, DOI 10.1002/pros.23048; Papaioannou M, 2009, J CELL MOL MED, V13, P2210, DOI 10.1111/j.1582-4934.2008.00426.x; Pari AAA, 2020, CANCER RES, V80, P2586, DOI 10.1158/0008-5472.CAN-19-2660; Park JH, 2007, CHEST, V132, P200, DOI 10.1378/chest.06-2915; Perner S, 2015, ONCOTARGET, V6, P35542, DOI 10.18632/oncotarget.4689; Place RF, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-37; Raclaw KA, 2008, PROSTATE, V68, P1696, DOI 10.1002/pros.20844; Rigamonti N, 2014, CELL REP, V8, P696, DOI 10.1016/j.celrep.2014.06.059; Roediger J, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-214; Roell D, 2019, J STEROID BIOCHEM, V188, P59, DOI 10.1016/j.jsbmb.2018.12.005; Schleich S, 2006, PLANTA MED, V72, P547, DOI 10.1055/s-2006-941472; Scholz A, 2015, ANN NY ACAD SCI, V1347, P45, DOI 10.1111/nyas.12726; Semenas J, 2013, DRUG DES DEV THER, V7, P875, DOI 10.2147/DDDT.S45703; Sfiligoi C, 2003, INT J CANCER, V103, P466, DOI 10.1002/ijc.10851; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Stoeltzing O, 2003, INT J CANCER, V104, P496, DOI 10.1002/ijc.10958; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sui AL, 2018, MED SCI MONITOR, V24, P5860, DOI 10.12659/MSM.907446; Taplin ME, 1999, CANCER RES, V59, P2511; ten Hagen TLM, 2013, INT J CANCER, V132, P2694, DOI 10.1002/ijc.27940; Wang K, 2012, ASIAN PAC J CANCER P, V13, P5665, DOI 10.7314/APJCP.2012.13.11.5665; Xuan ZX, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0992-4; Yu XL, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020457; Yuan HT, 2009, MOL CELL BIOL, V29, P2011, DOI 10.1128/MCB.01472-08	66	1	1	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3263	3277		10.1038/s41388-022-02333-7	http://dx.doi.org/10.1038/s41388-022-02333-7		MAY 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35513564	hybrid, Green Published			2022-12-17	WOS:000791081400001
J	Sun, FF; Wang, XP; Hu, J; Liu, JM; Wang, X; Jia, WQ; Yu, ZY; Gao, L; Dou, BK; Zhao, R; Feng, TT; Wang, XL; Zhang, WB; Liu, H; Liu, KH; Shao, Y; Dong, XS; Han, B				Sun, Feifei; Wang, Xinpei; Hu, Jing; Liu, Junmei; Wang, Xin; Jia, Wenqiao; Yu, Zeyuan; Gao, Lin; Dou, Baokai; Zhao, Ru; Feng, Tingting; Wang, Xueli; Zhang, Wenbo; Liu, Hui; Liu, Kaihua; Shao, Yang; Dong, Xuesen; Han, Bo			RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway	ONCOGENE			English	Article							ANDROGEN-RECEPTOR; CANCER; PONTIN; COMPLEX; REPTIN; IDENTIFICATION; EXPRESSION; MECHANISM; COFACTOR; ATPASES	Although enzalutamide improves the overall survival of patients with metastatic prostate cancers, enzalutamide resistance (ENZR) will be inevitably developed. Emerging evidence support that alternative oncogenic pathways may bypass the androgen receptor (AR) signaling to promote ENZR progression, however, the underpinning mechanisms remain poorly defined. Here, we report that the expression of RuvB like AAA ATPase 1 (RUVBL1) is upregulated in ENZR cells and xenograft models and prostate tumors in patients. Enzalutamide increases RUVBL1 accumulation in the cytoplasm, which in turn enhances the recruitment of CRAF proto-oncogene serine/threonine kinase protein to plexin A1 (PLXNA1) and the subsequent activation of the downstream MAPK pathway. Co-overexpression of RUVBL1 and PLXNA1 defines a subgroup of prostate cancer (PCa) patients with a poor prognosis. Furthermore, pharmacological inhibition of RUVBL1 by CB-6644 suppresses ENZR cell proliferation and xenograft growth and allows re-sensitization of ENZR cells and xenografts to enzalutamide, indicating that RUVBL1 may act to substitute the AR signaling to promote cancer cell survival and ENZR development. Together, these findings may lead to the identification of RUVBL1 as a potential therapeutic target for ENZR tumors.	[Sun, Feifei; Wang, Xinpei; Wang, Xin; Yu, Zeyuan; Gao, Lin; Zhao, Ru; Feng, Tingting; Zhang, Wenbo; Han, Bo] Shandong Univ, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Shandong, Peoples R China; [Sun, Feifei; Wang, Xinpei; Wang, Xin; Yu, Zeyuan; Gao, Lin; Zhao, Ru; Feng, Tingting; Zhang, Wenbo; Han, Bo] Shandong Univ, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Hu, Jing; Liu, Hui; Han, Bo] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Peoples R China; [Liu, Junmei] Sch Basic Med Sci, Dept Biochem & Mol Biol, Jinan 250012, Peoples R China; [Jia, Wenqiao] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Hlth Management Ctr, Jinan 250012, Peoples R China; [Dou, Baokai] Shandong First Med Univ, Dept Pharm, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China; [Wang, Xueli] Binzhou City Cent Hosp, Dept Pathol, Binzhou, Peoples R China; [Liu, Kaihua; Shao, Yang] Nanjing Geneseeq Technol Inc, Nanjing, Jiangsu, Peoples R China; [Dong, Xuesen] Vancouver Gen Hosp, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; [Dong, Xuesen] Univ British Columbia, Dept Urol Sci, Vancouver, BC V6H 3Z6, Canada	Shandong University; Shandong University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Geneseeq Technology Inc.; University of British Columbia; University of British Columbia	Han, B (corresponding author), Shandong Univ, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Shandong, Peoples R China.; Han, B (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Pathol, Jinan 250012, Shandong, Peoples R China.; Han, B (corresponding author), Shandong Univ, Qilu Hosp, Dept Pathol, Jinan 250012, Peoples R China.; Dong, XS (corresponding author), Vancouver Gen Hosp, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada.; Dong, XS (corresponding author), Univ British Columbia, Dept Urol Sci, Vancouver, BC V6H 3Z6, Canada.	xdong@prostatecentre.com; boh@sdu.edu.cn		Wang, Xin/0000-0003-1973-754X; Wang, Xinpei/0000-0002-2304-1580	Joint Research Fund of Natural Science, Shandong Province [ZR2019LZL014]; National Natural Science Foundation of China [81972416, 82172818]; Major Science and Technology Innovation Project of Shandong Province [2018CXGC1210]; National Key Research and Development Program of China [2018YFC0114703]; Fundamental Research Funds of Shandong University [2018JC016]	Joint Research Fund of Natural Science, Shandong Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Science and Technology Innovation Project of Shandong Province; National Key Research and Development Program of China; Fundamental Research Funds of Shandong University	This work was supported by the Joint Research Fund of Natural Science, Shandong Province (ZR2019LZL014), National Natural Science Foundation of China (Grant No. 81972416, 82172818), Major Science and Technology Innovation Project of Shandong Province (2018CXGC1210), the National Key Research and Development Program of China (2018YFC0114703), and The Fundamental Research Funds of Shandong University (2018JC016).	Advani SJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9154; Aramayo RJ, 2018, NAT STRUCT MOL BIOL, V25, P37, DOI 10.1038/s41594-017-0003-7; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Assimon VA, 2019, ACS CHEM BIOL, V14, P236, DOI 10.1021/acschembio.8b00904; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Bizarro J, 2014, J CELL BIOL, V207, P463, DOI 10.1083/jcb.201404160; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chen JA, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0947-9; Clarke TL, 2017, MOL CELL, V65, P900, DOI 10.1016/j.molcel.2017.01.019; Dauden MI, 2021, CURR OPIN STRUC BIOL, V67, P78, DOI 10.1016/j.sbi.2020.08.010; Fan WJ, 2017, BBA-GEN SUBJECTS, V1861, P1788, DOI 10.1016/j.bbagen.2017.03.016; Gao L, 2021, CANCER RES, V81, P1026, DOI 10.1158/0008-5472.CAN-20-1965; Guo H, 2018, BIOCHEM BIOPH RES CO, V498, P932, DOI 10.1016/j.bbrc.2018.03.084; Hu J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1222-z; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huber O, 2008, CANCER RES, V68, P6873, DOI 10.1158/0008-5472.CAN-08-0547; Izumi N, 2012, CANCER SCI, V103, P50, DOI 10.1111/j.1349-7006.2011.02112.x; Lauscher JC, 2007, HUM PATHOL, V38, P978, DOI 10.1016/j.humpath.2007.01.005; Li SZ, 2019, CANCER RES, V79, P2580, DOI 10.1158/0008-5472.CAN-18-2812; Mao YQ, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00058; Mello T, 2020, INT J CANCER, V146, P3410, DOI 10.1002/ijc.32787; Mostaghel EA, 2019, CLIN CANCER RES, V25, P426, DOI 10.1158/1078-0432.CCR-18-1431; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Qi M, 2018, ONCOGENE, V37, P1075, DOI 10.1038/onc.2017.380; Ren SC, 2018, EUR UROL, V73, P322, DOI 10.1016/j.eururo.2017.08.027; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Runge JS, 2018, G3-GENES GENOM GENET, V8, P1095, DOI 10.1534/g3.117.300504; Taniuchi K, 2014, INT J ONCOL, V44, P1945, DOI 10.3892/ijo.2014.2380; Tellman TV, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22063218; Thomas C, 2013, MOL CANCER THER, V12, P2342, DOI 10.1158/1535-7163.MCT-13-0032; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Venteicher AS, 2008, CELL, V132, P945, DOI 10.1016/j.cell.2008.01.019; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; Wang L, 2013, PROSTATE CANCER P D, V16, P301, DOI 10.1038/pcan.2013.25; Wang L, 2017, CANCER RES, V77, P5755, DOI 10.1158/0008-5472.CAN-17-0150; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Yenerall P, 2020, CELL CHEM BIOL, V27, P105, DOI 10.1016/j.chembiol.2019.12.005; Yuan XS, 2016, TUMOR BIOL, V37, P16015, DOI 10.1007/s13277-016-5452-9; Zhang A, 2015, CELL REP, V13, P209, DOI 10.1016/j.celrep.2015.08.069; Zhang JX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23025-y; Zhang XX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138820; Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111	44	1	1	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3239	3250		10.1038/s41388-022-02332-8	http://dx.doi.org/10.1038/s41388-022-02332-8		MAY 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35508542				2022-12-17	WOS:000790621800002
J	Chen, J; Li, ZQ; Jia, X; Song, WF; Wu, H; Zhu, H; Xuan, ZF; Du, YH; Zhu, XX; Song, GY; Dong, HJ; Bian, SC; Wang, S; Zhao, YC; Xie, HY; Zheng, SS; Song, PH				Chen, Jian; Li, Zequn; Jia, Xing; Song, Wenfeng; Wu, Hao; Zhu, Hai; Xuan, Zefeng; Du, Yehui; Zhu, Xingxin; Song, Guangyuan; Dong, Haijiang; Bian, Suchen; Wang, Shuo; Zhao, Yongchao; Xie, Haiyang; Zheng, Shusen; Song, Penghong			Targeting anillin inhibits tumorigenesis and tumor growth in hepatocellular carcinoma via impairing cytokinesis fidelity	ONCOGENE			English	Article							ANLN; CANCER; PLAYS; RHOA	Targeting cytokinesis can suppress tumor growth by blocking cell division and promoting apoptosis. We aimed to characterize key cytokinesis regulator in hepatocellular carcinoma (HCC) progression, providing insights into identifying promising HCC therapeutic targets. The unbiased bioinformatic screening identified Anillin actin binding protein (ANLN) as a critical cytokinesis regulator involved in HCC development. Functional assay demonstrated that knockdown of ANLN inhibited HCC growth by inducing cytokinesis failure and DNA damage, leading to multinucleation and mitotic catastrophe. Mechanistically, ANLN acts as a scaffold to strengthen interaction between RACGAP1 and PLK1. ANLN promotes PLK1-mediated RACGAP1 phosphorylation and RhoA activation to ensure cytokinesis fidelity. To explore the function of ANLN in HCC tumorigenesis, we hydrodynamically transfected c-Myc and NRAS plasmids into Anln(+/+), Anln(+/-), and Anln(-/-) mice through tail vein injection. Hepatic Anln ablation significantly impaired c-Myc/NRAS-driven hepatocarcinogenesis. Moreover, enhanced hepatic polyploidization was observed in Anln ablation mice, manifesting as increasing proportion of cellular and nuclear polyploidy. Clinically, ANLN is upregulated in human HCC tissues and high level of ANLN is correlated with poor patients' prognosis. Additionally, the proportion of cellular polyploidy decreases during HCC progression and ANLN level is significantly correlated with cellular polyploidy proportion in human HCC samples. In conclusion, ANLN is identified as a key cytokinesis regulator contributing to HCC initiation and progression. Our findings revealed a novel mechanism of ANLN in the regulation of cytokinesis to promote HCC tumorigenesis and growth, suggesting targeting ANLN to inhibit cytokinesis may be a promising therapeutic strategy for HCC.	[Chen, Jian; Li, Zequn; Jia, Xing; Song, Wenfeng; Wu, Hao; Zhu, Hai; Zhu, Xingxin; Song, Guangyuan; Dong, Haijiang; Bian, Suchen; Wang, Shuo; Xie, Haiyang; Zheng, Shusen; Song, Penghong] Zhejiang Univ, Affiliated Hosp 1, Dept Surg, Div Hepatobiliary & Pancreat Surg,Sch Med, Hangzhou, Peoples R China; [Chen, Jian; Li, Zequn; Jia, Xing; Song, Wenfeng; Wu, Hao; Zhu, Hai; Zhu, Xingxin; Song, Guangyuan; Dong, Haijiang; Bian, Suchen; Zhao, Yongchao; Xie, Haiyang; Zheng, Shusen; Song, Penghong] NHC Key Lab Combined Multiorgan Transplantat, Hangzhou, Peoples R China; [Chen, Jian; Li, Zequn; Jia, Xing; Song, Wenfeng; Wu, Hao; Zhu, Hai; Zhu, Xingxin; Song, Guangyuan; Dong, Haijiang; Bian, Suchen; Xie, Haiyang; Zheng, Shusen; Song, Penghong] Chinese Acad Med Sci 2019RU019, Res Unit Collaborat Diag & Treatment Hepatobiliar, Key Lab Diag & Treatment Organ Transplantat, Hangzhou, Peoples R China; [Chen, Jian; Li, Zequn; Jia, Xing; Song, Wenfeng; Wu, Hao; Zhu, Hai; Zhu, Xingxin; Song, Guangyuan; Dong, Haijiang; Bian, Suchen; Xie, Haiyang; Zheng, Shusen; Song, Penghong] Res Ctr Diag & Treatment Hepatobiliary Dis, Key Lab Organ Transplantat, Hangzhou, Zhejiang, Peoples R China; [Xuan, Zefeng] Zhejiang Univ, Affiliated Hosp 1, Div Breast Surg, Sch Med, Hangzhou, Peoples R China; [Du, Yehui] Zhejiang Univ, Affiliated Hosp 1, Div Thyroid Surg, Sch Med, Hangzhou, Peoples R China; [Zhao, Yongchao] Zhejiang Univ, Inst Translat Med, Sch Med, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University	Zheng, SS; Song, PH (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Dept Surg, Div Hepatobiliary & Pancreat Surg,Sch Med, Hangzhou, Peoples R China.; Zheng, SS; Song, PH (corresponding author), NHC Key Lab Combined Multiorgan Transplantat, Hangzhou, Peoples R China.; Zheng, SS; Song, PH (corresponding author), Chinese Acad Med Sci 2019RU019, Res Unit Collaborat Diag & Treatment Hepatobiliar, Key Lab Diag & Treatment Organ Transplantat, Hangzhou, Peoples R China.; Zheng, SS; Song, PH (corresponding author), Res Ctr Diag & Treatment Hepatobiliary Dis, Key Lab Organ Transplantat, Hangzhou, Zhejiang, Peoples R China.	shusenzheng@zju.edu.cn; songpenghong@zju.edu.cn			Key Research and Development Plan of Zhejiang Province [2019C03050]; National Natural Science Foundation of China [81870434, 82070652]; Innovative Research Groups of National Natural Science Foundation of China [81721091]	Key Research and Development Plan of Zhejiang Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovative Research Groups of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the grants from the Key Research and Development Plan of Zhejiang Province (No. 2020C04003), the National Natural Science Foundation of China (No. 81870434 and No. 82070652), the Innovative Research Groups of National Natural Science Foundation of China (No. 81721091) and the Key Research and Development Plan of Zhejiang Province (No. 2019C03050).	Basant A, 2018, CURR BIOL, V28, pR570, DOI 10.1016/j.cub.2018.03.045; Budnar S, 2019, DEV CELL, V49, P894, DOI 10.1016/j.devcel.2019.04.031; Burkard ME, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000111; Chaikovsky AC, 2021, NATURE, V592, P794, DOI 10.1038/s41586-021-03474-7; Chen J, 2021, BIOCHEM PHARMACOL, V188, DOI 10.1016/j.bcp.2021.114494; Chen J, 2021, ONCOGENE, V40, P163, DOI 10.1038/s41388-020-01522-6; Donne R, 2020, NAT REV GASTRO HEPAT, V17, P391, DOI 10.1038/s41575-020-0284-x; Duncan AW, 2010, NATURE, V467, P707, DOI 10.1038/nature09414; Gentric G, 2014, AM J PATHOL, V184, P322, DOI 10.1016/j.ajpath.2013.06.035; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Lens SMA, 2019, NAT REV CANCER, V19, P32, DOI 10.1038/s41568-018-0084-6; Li Z, 2019, HEPATOB PANCREAT DIS, V18, P303, DOI 10.1016/j.hbpd.2019.05.013; Lian YF, 2018, AGING-US, V10, P1884, DOI 10.18632/aging.101510; Lin Heng, 2021, Nat Commun, V12, P645, DOI 10.1038/s41467-020-20572-8; Lulli M, 2021, CANCER RES, V81, P2861, DOI 10.1158/0008-5472.CAN-20-3134; Ma H, 2022, HEPATOLOGY, DOI 10.1002/hep.32335; Maiani E, 2021, NATURE, V592, P799, DOI 10.1038/s41586-021-03422-5; Matsumoto T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-20916-y; Pallavicini G, 2018, CANCER RES, V78, P4599, DOI 10.1158/0008-5472.CAN-17-4060; Piekny AJ, 2010, SEMIN CELL DEV BIOL, V21, P881, DOI 10.1016/j.semcdb.2010.08.002; Qiao YT, 2021, EXP BIOL MED, V246, P1343, DOI 10.1177/15353702211008380; Rebouissou S, 2020, J HEPATOL, V72, P215, DOI 10.1016/j.jhep.2019.08.017; Sarveazad A, 2019, J RES MED SCI, V24, DOI 10.4103/jrms.JRMS_1017_18; Simoneschi D, 2021, NATURE, V592, P789, DOI 10.1038/s41586-021-03445-y; Su KC, 2011, DEV CELL, V21, P1104, DOI 10.1016/j.devcel.2011.11.003; Suzuki C, 2005, CANCER RES, V65, P11314, DOI 10.1158/0008-5472.CAN-05-1507; Tuan NM, 2020, CANCERS, V12, DOI 10.3390/cancers12061600; Wang AB, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1340-7; Wilkinson PD, 2019, HEPATOLOGY, V69, P1242, DOI 10.1002/hep.30286; Wolfe BA, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000110; Xu M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1020-4; Yang XM, 2018, GASTROENTEROLOGY, V155, P1233, DOI 10.1053/j.gastro.2018.07.010; Zhang L, 2010, CURR BIOL, V20, pR135, DOI 10.1016/j.cub.2009.12.017; Zhang SY, 2018, GASTROENTEROLOGY, V154, P1421, DOI 10.1053/j.gastro.2017.12.013; Zhang SY, 2018, DEV CELL, V44, P447, DOI 10.1016/j.devcel.2018.01.010; Zhao WM, 2005, P NATL ACAD SCI USA, V102, P13158, DOI 10.1073/pnas.0504145102; Zhou WB, 2015, MOL CELL BIOCHEM, V398, P11, DOI 10.1007/s11010-014-2200-6	38	1	1	5	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3118	3130		10.1038/s41388-022-02274-1	http://dx.doi.org/10.1038/s41388-022-02274-1		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35477750				2022-12-17	WOS:000794881300001
J	Pang, Z; Dong, XR; Deng, HY; Wang, CZ; Liao, XD; Liao, CH; Liao, YH; Tian, WD; Cheng, JK; Chen, GQ; Yi, HY; Huang, L				Pang, Zhi; Dong, Xinran; Deng, Huayun; Wang, Chengzhi; Liao, Xiaodong; Liao, Chunhua; Liao, Yahui; Tian, Weidong; Cheng, Jinke; Chen, Guoqiang; Yi, Haiying; Huang, Lei			MUC1 triggers lineage plasticity of Her2 positive mammary tumors	ONCOGENE			English	Article							SIGNALING PATHWAYS; BREAST; ONCOPROTEIN; ACTIVATION; OVEREXPRESSION; AMPLIFICATION; TUMORIGENESIS; EXPRESSION; RESISTANCE; MUTATIONS	Aberrant overexpression of mucin 1 (MUC1) and human epidermal growth factor receptor 2 (HER2) are often observed in breast cancer. However, the role of concomitant MUC1/HER2 in the development of breast cancer has not been fully illustrated. Following analysis of public microarray datasets that revealed a correlation between double MUC1 and HER2 positivity and a worse clinical outcome, we generated a mouse model overexpressing both Her2 and MUC1 cytoplasmic domain (MUC1-CD) to investigate their interaction in mammary carcinogenesis. Coexpression of Her2 and MUC1-CD conferred a growth advantage and promoted the development of spontaneous mammary tumors. Genomic analysis revealed that enforced expression of MUC1-CD and Her2 induces mammary tumor lineage plasticity, which is supported by gene reprogramming and mammary stem cell enrichment. Through gain- and loss-of-function strategies, we show that coexpression of Her2 and MUC1-CD is associated with downregulation of tricarboxylic acid (TCA) cycle genes in tumors. Importantly, the reduction in TCA cycle genes induced by MUC1-CD was found to be significantly connected to poor prognosis in HER2(+) breast cancer patients. In addition, MUC1 augments the Her2 signaling pathway by inducing Her2/Egfr dimerization. These findings collectively demonstrate the vital role of MUC1-CD/Her2 collaboration in shaping the mammary tumor landscape and highlight the prognostic and therapeutic implications of MUC1 in patients with HER2(+) breast cancer.	[Pang, Zhi; Deng, Huayun; Wang, Chengzhi; Liao, Xiaodong; Liao, Chunhua; Cheng, Jinke; Chen, Guoqiang; Huang, Lei] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Reprod Med,Dept Histoembryol Gen, Chinese Minist Educ,Key Lab Cell Differentiat & A, Shanghai, Peoples R China; [Pang, Zhi] Fudan Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Liver Canc Inst,Zhongshan Hosp, Shanghai, Peoples R China; [Dong, Xinran; Tian, Weidong] Fudan Univ, Ctr Mol Med, Childrens Hosp, Shanghai, Peoples R China; [Liao, Yahui] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Pharm,Huangpu Branch, Shanghai, Peoples R China; [Tian, Weidong] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, Dept Computat Biol,State Key Lab Genet Engn, Shanghai, Peoples R China; [Yi, Haiying] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Breast Surg,Huangpu Branch, Shanghai, Peoples R China	Shanghai Jiao Tong University; Fudan University; Fudan University; Shanghai Jiao Tong University; Fudan University; Shanghai Jiao Tong University	Huang, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Reprod Med,Dept Histoembryol Gen, Chinese Minist Educ,Key Lab Cell Differentiat & A, Shanghai, Peoples R China.; Yi, HY (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Dept Breast Surg,Huangpu Branch, Shanghai, Peoples R China.	yihaiying@163.com; leihuang@shsmu.edu.cn		Cheng, Jinke/0000-0002-4344-5363; Liao, Xiaodong/0000-0001-9230-5220; chen, guo qiang/0000-0003-4936-2363; Pang, Zhi/0000-0001-8677-9008	National Natural Science Foundation of China [81874197, 82073111]; Science and Technology Commission of Shanghai Municipality [21S11901600]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by the National Natural Science Foundation of China (grant numbers 81874197 and 82073111), Science and Technology Commission of Shanghai Municipality (grant number 21S11901600) to Huang L. The authors appreciate Dr. Shuhai Lin for constructive suggestions.	Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Arkhipov A, 2013, ELIFE, V2, DOI 10.7554/eLife.00708; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Barberan S, 2019, SEMIN CELL DEV BIOL, V87, P45, DOI 10.1016/j.semcdb.2018.05.011; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; [程布凯 Cheng Bukai], 2014, [中国科学. 生命科学, Scientia Sinica Vitae], V44, P143; Cho HJ, 2018, ONCOGENE, V37, P861, DOI 10.1038/onc.2017.386; Chung SS, 2014, INT J ONCOL, V44, P403, DOI 10.3892/ijo.2013.2195; D'Amato V, 2015, CANCER TREAT REV, V41, P877, DOI 10.1016/j.ctrv.2015.08.001; El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017; Fishbein L, 2017, CANCER CELL, V31, P181, DOI 10.1016/j.ccell.2017.01.001; Garcia-Heredia JM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071693; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gimm O, 2000, CANCER RES, V60, P6822; Guo JX, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.644857; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Gyorffy B, 2021, COMPUT STRUCT BIOTEC, V19, P4101, DOI 10.1016/j.csbj.2021.07.014; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Harrell JC, 2012, BREAST CANCER RES TR, V132, P523, DOI 10.1007/s10549-011-1619-7; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Hynes NE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003186; Janiszewska M, 2015, NAT GENET, V47, P1212, DOI 10.1038/ng.3391; Johnson S., 2013, BIOPROTOC, V3, pe326; Khodarev NN, 2009, CANCER RES, V69, P2833, DOI 10.1158/0008-5472.CAN-08-4513; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2020, CARCINOGENESIS, V41, P1173, DOI 10.1093/carcin/bgaa082; Lacunza E, 2010, CANCER GENET CYTOGEN, V201, P102, DOI 10.1016/j.cancergencyto.2010.05.015; Li Y, 2018, ONCOTARGET, V9, P3446, DOI 10.18632/oncotarget.23316; Li Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019102; Marquez J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122161; Mehla K, 2014, BBA-REV CANCER, V1845, P126, DOI 10.1016/j.bbcan.2014.01.001; Meier-Abt F, 2014, TRENDS MOL MED, V20, P143, DOI 10.1016/j.molmed.2013.11.002; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Nassar A, 2014, INT J CLIN EXP PATHO, V7, P6254; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Raimundo N, 2011, TRENDS MOL MED, V17, P641, DOI 10.1016/j.molmed.2011.06.001; Raina D, 2014, ONCOGENE, V33, P3422, DOI 10.1038/onc.2013.308; Rajabi H, 2018, ONCOGENE, V37, P2079, DOI 10.1038/s41388-017-0096-9; Sawai Y, 2003, J HEPATOL, V39, P991, DOI 10.1016/S0168-8278(03)00498-7; Schneider MR, 2016, ONCOGENE, V35, P2949, DOI 10.1038/onc.2015.372; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Tanaka H, 2013, J NEURO-ONCOL, V111, P273, DOI 10.1007/s11060-012-1027-9; Vermeer PD, 2013, CANCER RES, V73, P5787, DOI 10.1158/0008-5472.CAN-13-0760; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Wang DS, 2019, CELL RES, V29, P832, DOI 10.1038/s41422-019-0225-9; Weerts MJA, 2016, ONCOTARGET, V7, P29166, DOI 10.18632/oncotarget.8688; Wei T, 2017, VISUALIZATION CORREL; Wu BW, 2020, CELL METAB, V32, DOI 10.1016/j.cmet.2020.10.025; Yasumizu Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14219-6; Zhou ZQ, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010016	58	1	1	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3064	3078		10.1038/s41388-022-02320-y	http://dx.doi.org/10.1038/s41388-022-02320-y		APR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35461328				2022-12-17	WOS:000785962300002
J	Tsai, YT; Li, CY; Huang, YH; Chang, TS; Lin, CY; Chuang, CH; Wang, CY; Anuraga, G; Chang, TH; Shih, TC; Lin, ZY; Chen, YL; Chung, I; Lee, KH; Chang, CC; Sung, SY; Yang, KH; Tsui, WL; Yap, CV; Wu, MH				Tsai, Yao-Tsung; Li, Chih-Yi; Huang, Yen-Hua; Chang, Te-Sheng; Lin, Chung-Yen; Chuang, Chia-Hsien; Wang, Chih-Yang; Anuraga, Gangga; Chang, Tzu-Hao; Shih, Tsung-Chieh; Lin, Zu-Yau; Chen, Yuh-Ling; Chung, Ivy; Lee, Kuen-Haur; Chang, Che-Chang; Sung, Shian-Ying; Yang, Kai-Huei; Tsui, Wan-Lin; Yap, Chee-Voon; Wu, Ming-Heng			Galectin-1 orchestrates an inflammatory tumor-stroma crosstalk in hepatoma by enhancing TNFR1 protein stability and signaling in carcinoma-associated fibroblasts	ONCOGENE			English	Article							FACTOR RECEPTOR 1; DISINTEGRIN; SORAFENIB	Most cases of hepatocellular carcinoma (HCC) arise with the fibrotic microenvironment where hepatic stellate cells (HSCs) and carcinoma-associated fibroblasts (CAFs) are critical components in HCC progression. Therefore, CAF normalization could be a feasible therapy for HCC. Galectin-1 (Gal-1), a beta-galactoside-binding lectin, is critical for HSC activation and liver fibrosis. However, few studies has evaluated the pathological role of Gal-1 in HCC stroma and its role in hepatic CAF is unclear. Here we showed that Gal-1 mainly expressed in HCC stroma, but not cancer cells. High expression of Gal-1 is correlated with CAF markers and poor prognoses of HCC patients. In co-culture systems, targeting Gal-1 in CAFs or HSCs, using small hairpin (sh)RNAs or an therapeutic inhibitor (LLS30), downregulated plasminogen activator inhibitor-2 (PAI-2) production which suppressed cancer stem-like cell properties and invasion ability of HCC in a paracrine manner. The Gal-1-targeting effect was mediated by increased a disintegrin and metalloprotease 17 (ADAM17)-dependent TNF-receptor 1 (TNFR1) shedding/cleavage which inhibited the TNF-alpha -> JNK -> c-Jun/ATF2 signaling axis of pro-inflammatory gene transcription. Silencing Gal-1 in CAFs inhibited CAF-augmented HCC progression and reprogrammed the CAF-mediated inflammatory responses in a co-injection xenograft model. Taken together, the findings uncover a crucial role of Gal-1 in CAFs that orchestrates an inflammatory CSC niche supporting HCC progression and demonstrate that targeting Gal-1 could be a potential therapy for fibrosis-related HCC.	[Tsai, Yao-Tsung; Li, Chih-Yi; Chang, Che-Chang; Sung, Shian-Ying; Yang, Kai-Huei; Tsui, Wan-Lin; Yap, Chee-Voon; Wu, Ming-Heng] Taipei Med Univ, Int PhD Program Translat Sci, Taipei, Taiwan; [Tsai, Yao-Tsung; Li, Chih-Yi; Huang, Yen-Hua; Chang, Che-Chang; Sung, Shian-Ying; Yang, Kai-Huei; Tsui, Wan-Lin; Yap, Chee-Voon; Wu, Ming-Heng] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Translat Med, Taipei, Taiwan; [Huang, Yen-Hua] Taipei Med Univ, Dept Biochem & Mol Cell Biol, Taipei, Taiwan; [Huang, Yen-Hua] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan; [Huang, Yen-Hua; Wu, Ming-Heng] Taipei Med Univ, Ctr Cell Therapy & Regenerat Med, Taipei, Taiwan; [Chang, Te-Sheng] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Chang, Te-Sheng] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Chiayi, Taiwan; [Lin, Chung-Yen; Chuang, Chia-Hsien] Acad Sinica, Inst Informat Sci, Taipei, Taiwan; [Wang, Chih-Yang; Anuraga, Gangga; Lee, Kuen-Haur] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan; [Chang, Tzu-Hao] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Biomed Informat, Taipei, Taiwan; [Shih, Tsung-Chieh] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Lin, Zu-Yau] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan; [Lin, Zu-Yau] Kaohsiung Med Univ, Coll Med, Sch Med, Fac Internal Med, Kaohsiung, Taiwan; [Chen, Yuh-Ling] Natl Cheng Kung Univ, Coll Med, Inst Oral Med, Tainan, Taiwan; [Chung, Ivy] Univ Malaya, Fac Med, Canc Res Inst, Kuala Lumpur 50603, Malaysia; [Chung, Ivy] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia; [Wu, Ming-Heng] TMU Res Ctr Canc Translat Med, Taipei, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University; Chang Gung University; Chang Gung Memorial Hospital; Academia Sinica - Taiwan; Taipei Medical University; Taipei Medical University; University of California System; University of California Davis; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; National Cheng Kung University; Universiti Malaya; Universiti Malaya	Wu, MH (corresponding author), Taipei Med Univ, Int PhD Program Translat Sci, Taipei, Taiwan.; Wu, MH (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Translat Med, Taipei, Taiwan.; Wu, MH (corresponding author), Taipei Med Univ, Ctr Cell Therapy & Regenerat Med, Taipei, Taiwan.; Wu, MH (corresponding author), TMU Res Ctr Canc Translat Med, Taipei, Taiwan.	mhwu1015@tmu.edu.tw	Anuraga, Gangga/AAE-8623-2021	Anuraga, Gangga/0000-0002-0902-3968; Huang, Yen-Hua/0000-0001-6020-9998; Chuang, Chia-Hsien/0000-0002-3639-4684; Wang, Chih-Yang/0000-0002-4137-5074	Chang Gung Memorial Hospital (Chiayi, Taiwan); "TMU Research Center of Cancer Translational Medicine" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan	Chang Gung Memorial Hospital (Chiayi, Taiwan)(Chang Gung Memorial Hospital); "TMU Research Center of Cancer Translational Medicine" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan	We thank the National RNAi Core Facility at Academia Sinica, Taiwan for providing shRNA reagents and related services. We thank the Image and Bioinformatics Core Facility of Taipei Medical University for confocal microscopy and the microarray analysis. Human samples were from the Human Tumor Tissue Bank, Chang Gung Memorial Hospital (Chiayi, Taiwan). This work was financially supported by the "TMU Research Center of Cancer Translational Medicine" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.	Abolarinwa BA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184624; Bernot D, 2011, J CELL SCI, V124, P1224, DOI 10.1242/jcs.079889; Biffi G, 2021, PHYSIOL REV, V101, P147, DOI 10.1152/physrev.00048.2019; Boulaftali Y, 2013, ARTERIOSCL THROM VAS, V33, P1647, DOI 10.1161/ATVBAHA.113.301494; Castello-Cros R, 2011, CELL CYCLE, V10, P2021, DOI 10.4161/cc.10.12.16002; Chen PC, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.625943; Chen ZY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01286; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Cousin JM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091566; Deng M, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005548; Dominguez CX, 2020, CANCER DISCOV, V10, P232, DOI 10.1158/2159-8290.CD-19-0644; Donisi C, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.601240; Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Gao Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0448-6; Izaguirre G, 2019, BIOCHEMISTRY-US, V58, P1679, DOI 10.1021/acs.biochem.8b01295; Lei T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22135-w; Leung Z, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1402-x; Lin ZY, 2012, BIOMED PHARMACOTHER, V66, P525, DOI 10.1016/j.biopha.2012.02.001; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Lockett AD, 2013, AM J RESP CELL MOL, V49, P143, DOI 10.1165/rcmb.2012-0515OC; Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Martinez-Bosch N, 2020, ADV EXP MED BIOL, V1259, P17, DOI 10.1007/978-3-030-43093-1_2; Monteran L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01835; Ngo MHT, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041931; Nurmik M, 2020, INT J CANCER, V146, P895, DOI 10.1002/ijc.32193; Potikha T, 2019, FASEB J, V33, P7995, DOI 10.1096/fj.201900017R; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Sakimoto T, 2009, INVEST OPHTH VIS SCI, V50, P4618, DOI 10.1167/iovs.08-2669; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shih TC, 2018, CLIN CANCER RES, V24, P4319, DOI 10.1158/1078-0432.CCR-18-0157; Spano D, 2010, MOL MED, V16, P102, DOI 10.2119/molmed.2009.00119; Tarrats N, 2011, HEPATOLOGY, V54, P319, DOI 10.1002/hep.24388; Toegel S, 2016, J IMMUNOL, V196, P1910, DOI 10.4049/jimmunol.1501165; Wu H, 2012, J GASTROEN HEPATOL, V27, P1312, DOI 10.1111/j.1440-1746.2012.07130.x; Wu MH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11212-1; Yeh CC, 2015, MOL CELL PROTEOMICS, V14, P1527, DOI 10.1074/mcp.M114.046417; Zhang PF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.324	40	1	1	4	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					3011	3023		10.1038/s41388-022-02309-7	http://dx.doi.org/10.1038/s41388-022-02309-7		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35459781				2022-12-17	WOS:000787474100003
J	Gao, P; Hao, JL; Xie, QW; Han, GQ; Xu, BB; Hu, H; Sa, NE; Du, XW; Tang, HL; Yan, J; Dong, XM				Gao, Ping; Hao, Jing-Lan; Xie, Qian-Wen; Han, Gui-Qin; Xu, Bin-Bing; Hu, Hang; Sa, Na-Er; Du, Xiao-Wen; Tang, Hai-Long; Yan, Jian; Dong, Xiao-Ming			PELO facilitates PLK1-induced the ubiquitination and degradation of Smad4 and promotes the progression of prostate cancer	ONCOGENE			English	Article							INHIBITORS	PLK1 and Smad4 are two important factors in prostate cancer initiation and progression. They have been reported to play the opposite role in Pten-deleted mice, one is an oncogene, the other is a tumor suppressor. Moreover, they could reversely regulate the PI3K/AKT/mTOR pathway and the activation of MYC. However, the connections between PLK1 and Smad4 have never been studied. Here, we showed that PLK1 could interact with Smad4 and promote the ubiquitination and degradation of Smad4 in PCa cells. PLK1 and PELO could bind to different domains of Smad4 and formed a protein complex. PELO facilitated the degradation of Smad4 through cooperating with PLK1, thereby resulting in proliferation and metastasis of prostate cancer cell. Changes in protein levels of Smad4 led to the alteration of biological function that caused by PLK1 in prostate cancer cells. Further studies showed that PELO upregulation was positively associated with high grade PCa and knockdown of PELO expression significantly decreased PCa cell proliferation and metastasis in vitro and vivo. PELO knockdown in PCa cells could enhance the tumor suppressive role of PLK1 inhibitor. In addition, blocking the interaction between PELO and Smad4 by using specific peptide could effectively inhibit PCa cell metastasis ability in vitro and vivo. Overall, these findings identified a novel regulatory relationship among PLK1, Smad4 and PELO, and provided a potential therapeutic strategy for advanced PCa therapy by co-targeting PLK1 and PELO.	[Gao, Ping; Hao, Jing-Lan; Xie, Qian-Wen; Han, Gui-Qin; Xu, Bin-Bing; Hu, Hang; Sa, Na-Er; Du, Xiao-Wen; Dong, Xiao-Ming] Shaanxi Normal Univ, Coll Life Sci, Xian 710119, Peoples R China; [Tang, Hai-Long] Fourth Mil Med Univ, Xijing Hosp, Dept Hematol, Xian 710032, Peoples R China; [Yan, Jian] Northwest Univ, Sch Med, Xian 710069, Peoples R China; [Yan, Jian] City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China	Shaanxi Normal University; Air Force Military Medical University; Northwest University Xi'an; City University of Hong Kong	Gao, P; Dong, XM (corresponding author), Shaanxi Normal Univ, Coll Life Sci, Xian 710119, Peoples R China.	ping.gao2016@outlook.com; xiaomingdong@snnu.edu.cn	; Yan, Jian/B-2631-2018	gao, ping/0000-0003-1383-3290; Dong, xiao-ming/0000-0003-2413-8541; Yan, Jian/0000-0002-1267-2870	College of Life Sciences at Shaanxi Normal University - National Natural Science Foundation of China [81972417]; "1000 Young Scholars" Program of Shaanxi Province; Natural Science Foundation of Shaanxi Province [2020JM-292, 2020JQ-430]; Fundamental Research Funds for the Central Universities [GK201902002, GK201903061]; College Students' Innovative Entrepreneurial Training Plan Program [S202110718036]	College of Life Sciences at Shaanxi Normal University - National Natural Science Foundation of China; "1000 Young Scholars" Program of Shaanxi Province; Natural Science Foundation of Shaanxi Province(Natural Science Foundation of Shaanxi Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); College Students' Innovative Entrepreneurial Training Plan Program	We thank the College of Life Sciences at Shaanxi Normal University for the sharing platform of laboratory apparatus. This work was funded by the National Natural Science Foundation of China (81972417), The "1000 Young Scholars" Program of Shaanxi Province, Natural Science Foundation of Shaanxi Province (2020JM-292, 2020JQ-430), Fundamental Research Funds for the Central Universities (GK201902002, GK201903061) and College Students' Innovative Entrepreneurial Training Plan Program (S202110718036).	Adham IM, 2003, MOL CELL BIOL, V23, P1470, DOI 10.1128/MCB.23.4.1470-1476.2003; Garcia IA, 2020, MUTAT RES-FUND MOL M, V821, DOI 10.1016/j.mrfmmm.2020.111693; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen SQ, 2012, BIOORG MED CHEM LETT, V22, P1247, DOI 10.1016/j.bmcl.2011.11.052; Davis L, 1998, GENETICS, V149, P45; Demagny H, 2014, CELL REP, V9, P688, DOI 10.1016/j.celrep.2014.09.020; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Dong XM, 2020, FASEB J, V34, P8416, DOI 10.1096/fj.201902946R; Drucker DJ, 2020, NAT REV DRUG DISCOV, V19, P277, DOI 10.1038/s41573-019-0053-0; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gheghiani L, 2021, CANCER RES, V81, P1293, DOI 10.1158/0008-5472.CAN-20-1377; Goroshchuk O, 2019, ONCOGENE, V38, P1, DOI 10.1038/s41388-018-0443-5; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; KUMAR S, 2015, BIOMED RES INT, V2015, DOI DOI 10.1155/2015/705745; Liakath-Ali K, 2018, NATURE, V556, P376, DOI 10.1038/s41586-018-0032-3; Liu XS, 2011, J BIOL CHEM, V286, P35795, DOI 10.1074/jbc.C111.269050; Ogawa R, 2019, CLIN CANCER RES, V25, P2887, DOI 10.1158/1078-0432.CCR-18-3684; Olmos D, 2011, CLIN CANCER RES, V17, P3420, DOI 10.1158/1078-0432.CCR-10-2946; Pedersen K, 2014, ONCOGENE, V33, P1190, DOI 10.1038/onc.2013.35; Roelen BAJ, 2003, AM J PHYSIOL-CELL PH, V285, pC823, DOI 10.1152/ajpcell.00053.2003; Shi CX, 2021, ONCOGENE, V40, P937, DOI 10.1038/s41388-020-01580-w; Song B, 2019, J CLIN INVEST, V129, P569, DOI 10.1172/JCI122367; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595; van der Toom EE, 2019, NAT REV UROL, V16, P7, DOI 10.1038/s41585-018-0119-5; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; Whittaker SR, 2017, PHARMACOL THERAPEUT, V173, P83, DOI 10.1016/j.pharmthera.2017.02.008; Yao YS, 2020, EXP BIOL MED, V245, P777, DOI 10.1177/1535370220916709; Zhang M, 2017, CANCER LETT, V392, P71, DOI 10.1016/j.canlet.2017.01.024; Zhang Z, 2014, CANCER RES, V74, P6635, DOI 10.1158/0008-5472.CAN-14-1916	33	1	1	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2022	41	21					2945	2957		10.1038/s41388-022-02316-8	http://dx.doi.org/10.1038/s41388-022-02316-8		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1L8MU	35437307	Green Submitted			2022-12-17	WOS:000784068300001
J	Magrin, L; Fanale, D; Brando, C; Corsini, LR; Randazzo, U; Di Piazza, M; Gurrera, V; Pedone, E; Russo, TDB; Vieni, S; Pantuso, G; Russo, A; Bazan, V				Magrin, Luigi; Fanale, Daniele; Brando, Chiara; Corsini, Lidia Rita; Randazzo, Ugo; Di Piazza, Marianna; Gurrera, Vittorio; Pedone, Erika; Bazan Russo, Tancredi Didier; Vieni, Salvatore; Pantuso, Gianni; Russo, Antonio; Bazan, Viviana			MUTYH-associated tumor syndrome: The other face of MAP	ONCOGENE			English	Review							BASE-EXCISION-REPAIR; FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE COLORECTAL ADENOMA; GERMLINE MUTATIONS; MYH GENE; FUNCTIONAL CONSEQUENCES; INHERITED VARIANTS; DUODENAL ADENOMAS; THYROID-CANCER; BREAST-CANCER	MUTYH gene is involved in the base excision repair (BER) mechanism and its pathogenic alterations are associated with colorectal polyposis and cancer. MUTYH-associated polyposis (MAP) is a condition which is inherited in an autosomal recessive manner. MAP patients, beyond colorectal cancer (CRC), may develop other types of tumors, including duodenal, breast, ovarian, pancreatic, bladder and skin cancers. Carriers of biallelic MUTYH likely pathogenic/pathogenic variants exhibit a high lifetime risk of CRC, though cancer risk evidence becomes less clear when monoallelic carriers and extraintestinal tumors are considered. However, several studies recently reported an increased genetic susceptibility to cancer also for carriers of germline monoallelic MUTYH mutations. Moreover, experimental evidence highlighted the MUTYH involvement in many other biological functions. In future, MUTYH mutation carriers might benefit from new target therapies involving the use of PD-1 or KRAS inhibitors. Therefore, "MUTYH-associated tumor syndrome" might be the most appropriate term, due to the multiplicity of tumors observed in MAP patients and different biological contexts in which MUTYH acts as a "playmaker". In this Review, we will investigate the impact of germline mono- and biallelic MUTYH mutations on cancer risk, providing a proposal for clinical surveillance of mutation carriers.	[Magrin, Luigi; Fanale, Daniele; Brando, Chiara; Corsini, Lidia Rita; Randazzo, Ugo; Di Piazza, Marianna; Gurrera, Vittorio; Pedone, Erika; Russo, Antonio] Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, I-90127 Palermo, Italy; [Bazan Russo, Tancredi Didier] Univ Palermo, Med & Surg Sch, I-90127 Palermo, Italy; [Vieni, Salvatore; Pantuso, Gianni] Univ Palermo, Div Gen & Oncol Surg, Dept Surg Oncol & Oral Sci, I-90127 Palermo, Italy; [Bazan, Viviana] Univ Palermo, Dept Biomed Neurosci & Adv Diagno, I-90127 Palermo, Italy	University of Palermo; University of Palermo; University of Palermo; University of Palermo	Russo, A (corresponding author), Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, I-90127 Palermo, Italy.	antonio.russo@usa.net						Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Aretz S, 2014, EUR J HUM GENET, V22, P923, DOI 10.1038/ejhg.2012.309; Balaguer F, 2007, CLIN GASTROENTEROL H, V5, P379, DOI 10.1016/j.cgh.2006.12.025; Blair HA, 2021, DRUGS, V81, P1573, DOI 10.1007/s40265-021-01574-2; Bono M, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100235; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bulow S, 2004, GUT, V53, P381, DOI 10.1136/gut.2003.027771; Castillejo A, 2014, EUR J CANCER, V50, P2241, DOI 10.1016/j.ejca.2014.05.022; Caswell-Jin JL, 2018, GENET MED, V20, P234, DOI 10.1038/gim.2017.96; Chen JW, 2019, FREE RADICAL BIO MED, V143, P482, DOI 10.1016/j.freeradbiomed.2019.09.005; Chmiel NH, 2003, J MOL BIOL, V327, P431, DOI 10.1016/S0022-2836(03)00124-4; Colas C, 2020, EUR J MED GENET, V63, DOI 10.1016/j.ejmg.2020.104078; Croitoru ME, 2004, JNCI-J NATL CANCER I, V96, P1631, DOI 10.1093/jnci/djh288; Curia MC, 2020, WORLD J CLIN ONCOL, V11, P428, DOI 10.5306/wjco.v11.i7.428; Daans CG, 2020, FAM CANCER, V19, P183, DOI 10.1007/s10689-020-00162-9; El Hachem N, 2019, DIS COLON RECTUM, V62, P470, DOI 10.1097/DCR.0000000000001323; Fanale D, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.827822; Fanale D, 2020, CANCERS, V12, DOI 10.3390/cancers12092415; Farrington SM, 2005, AM J HUM GENET, V77, P112, DOI 10.1086/431213; Filipe B, 2009, CLIN GENET, V76, P242, DOI 10.1111/j.1399-0004.2009.01241.x; Fulk K, 2019, FAM CANCER, V18, P197, DOI 10.1007/s10689-018-00114-4; Grasel RS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.571330; Grolleman JE, 2019, CANCER CELL, V35, P256, DOI 10.1016/j.ccell.2018.12.011; Grover S, 2012, JAMA-J AM MED ASSOC, V308, P485, DOI 10.1001/jama.2012.8780; Gupta S, 2019, J NATL COMPR CANC NE, V17, P1033, DOI 10.6004/jnccn.2019.0044; Halford SER, 2003, AM J PATHOL, V162, P1545, DOI 10.1016/S0002-9440(10)64288-5; Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239; Hong DS., 2021, J CLIN ONCOL, V39, DOI [10.1200/JCO.2021.39.15_suppl.TPS2669, DOI 10.1200/JCO.2021.39.15_SUPPL.TPS2669, 10.1200/jco.2021.39.15_suppl.tps2669]; Hutchcraft ML, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11010084; Ishida H, 2022, CRIT REV ONCOL HEMAT, V172, DOI 10.1016/j.critrevonc.2022.103648; Jenkins MA, 2006, CANCER EPIDEM BIOMAR, V15, P312, DOI 10.1158/1055-9965.EPI-05-0793; Jones N, 2009, GASTROENTEROLOGY, V137, P489, DOI 10.1053/j.gastro.2009.04.047; Jones S, 2002, HUM MOL GENET, V11, P2961, DOI 10.1093/hmg/11.23.2961; Kacerovska D, 2016, AM J DERMATOPATH, V38, P915, DOI 10.1097/DAD.0000000000000649; Kasahara M, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-49; Kdissa A, 2020, CANCER GENET-NY, V240, P45, DOI 10.1016/j.cancergen.2019.10.007; Kim CJ, 2004, ONCOGENE, V23, P6820, DOI 10.1038/sj.onc.1207574; Krokan HE, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012583; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lipton L, 2003, CANCER RES, V63, P7595; Lipton L, 2004, CLIN GASTROENTEROL H, V2, P633, DOI 10.1016/S1542-3565(04)00286-1; Lubbe SJ, 2009, J CLIN ONCOL, V27, P3975, DOI 10.1200/JCO.2008.21.6853; Ma XY, 2014, GUT, V63, P326, DOI 10.1136/gutjnl-2012-304121; Magrin L, 2021, ONCOGENE, V40, P5893, DOI 10.1038/s41388-021-01984-2; Maguire S, 2021, JNCI-J NATL CANCER I, V113, P453, DOI 10.1093/jnci/djaa101; Mazzei F, 2013, MUTAT RES-FUND MOL M, V743, P33, DOI 10.1016/j.mrfmmm.2013.03.003; Miyaishi A, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-10; Monahan KJ, 2020, GUT, V69, P411, DOI 10.1136/gutjnl-2019-319915; Moscatello C, 2021, MOL CLIN ONCOL, V14, DOI 10.3892/mco.2020.2177; Nielsen M, 2007, CLIN GENET, V71, P427, DOI 10.1111/j.1399-0004.2007.00766.x; Nielsen M, 2009, GASTROENTEROLOGY, V136, P471, DOI 10.1053/j.gastro.2008.10.056; Nieuwenhuis MH, 2012, GUT, V61, P734, DOI 10.1136/gut.2010.229104; Nones K, 2019, ANN ONCOL, V30, P1071, DOI 10.1093/annonc/mdz132; Out AA, 2010, HUM MUTAT, V31, P1205, DOI 10.1002/humu.21343; Patel R, 2020, COLORECTAL DIS, V22, P1271, DOI 10.1111/codi.15078; Pervaiz MA, 2010, FAM CANCER, V9, P595, DOI 10.1007/s10689-010-9366-1; Picelli S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072091; Picelli S, 2010, EUR J CANCER, V46, P1041, DOI 10.1016/j.ejca.2010.01.013; Pilati C, 2017, J PATHOL, V242, P10, DOI 10.1002/path.4880; Ponti G, 2005, CLIN GENET, V68, P442, DOI 10.1111/j.1399-0004.2005.00519.x; Pope MA, 2005, DNA REPAIR, V4, P315, DOI 10.1016/j.dnarep.2004.10.003; Raetz AG, 2019, DNA REPAIR, V80, P16, DOI 10.1016/j.dnarep.2019.05.005; Rennert G, 2012, CANCER-AM CANCER SOC, V118, P1989, DOI 10.1002/cncr.26506; Rizzolo P, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00583; Ruggieri V, 2013, ONCOGENE, V32, P4500, DOI 10.1038/onc.2012.479; Saha T, 2010, CELL CYCLE, V9, P2471, DOI 10.4161/cc.9.13.12084; Samadder NJ, 2021, JAMA ONCOL, V7, P230, DOI 10.1001/jamaoncol.2020.6252; Santos LS, 2012, ONCOL REP, V28, P1859, DOI 10.3892/or.2012.1975; Scarpa A, 2017, NATURE, V543, P65, DOI 10.1038/nature21063; Schubert SA, 2020, GENE CHROMOSOME CANC, V59, P697, DOI 10.1002/gcc.22883; Schubert SA, 2020, MUTAGENESIS, V35, P221, DOI 10.1093/mutage/gez027; Barreiro RAS, 2022, J PATHOL, V256, P214, DOI 10.1002/path.5829; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Silva SN, 2021, BREAST CANCER RES TR, V188, P295, DOI 10.1007/s10549-021-06159-x; Singh A, 2019, PATHOL ONCOL RES, V25, P1327, DOI 10.1007/s12253-017-0372-6; Skates SJ, 2017, CLIN CANCER RES, V23, P3628, DOI 10.1158/1078-0432.CCR-15-2750; Stjepanovic N, 2019, ANN ONCOL, V30, P1558, DOI 10.1093/annonc/mdz233; Sutcliffe EG, 2019, FAM CANCER, V18, P203, DOI 10.1007/s10689-018-00116-2; Syngal S, 2015, AM J GASTROENTEROL, V110, P223, DOI 10.1038/ajg.2014.435; Takao M, 2018, INT J CLIN ONCOL, V23, P497, DOI 10.1007/s10147-017-1234-7; Tenesa A, 2006, BRIT J CANCER, V95, P239, DOI 10.1038/sj.bjc.6603239; Theodoratou E, 2010, BRIT J CANCER, V103, P1875, DOI 10.1038/sj.bjc.6605966; Thibodeau ML, 2019, CSH MOL CASE STUD, V5, DOI 10.1101/mcs.a003681; Thomas LE, 2021, GASTROENTEROLOGY, V160, P952, DOI 10.1053/j.gastro.2020.10.038; Thomas LE, 2017, CLIN CANCER RES, V23, P6721, DOI 10.1158/1078-0432.CCR-17-1269; Thompson, FAM CANCER, V2022; Ukaegbu C, 2021, FAM CANCER, V20, P111, DOI 10.1007/s10689-020-00198-x; Urso EDL, 2021, DIGEST LIVER DIS, V53, P409, DOI 10.1016/j.dld.2020.11.018; van Leerdam ME, 2019, ENDOSCOPY, V51, P877, DOI 10.1055/a-0965-0605; Vasen HFA, 2008, GUT, V57, DOI 10.1136/gut.2007.136127; Vidal AF, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08089-9; Viel A, 2017, EBIOMEDICINE, V20, P39, DOI 10.1016/j.ebiom.2017.04.022; Vogt S, 2009, GASTROENTEROLOGY, V137, P1976, DOI 10.1053/j.gastro.2009.08.052; Volkov NM, 2020, INVEST NEW DRUG, V38, P894, DOI 10.1007/s10637-019-00842-z; Wallace SS, 2012, CANCER LETT, V327, P73, DOI 10.1016/j.canlet.2011.12.038; Walton SJ, 2016, CLIN GASTROENTEROL H, V14, P986, DOI 10.1016/j.cgh.2016.02.020; Wang MB, 2021, ORAL ONCOL, V112, DOI 10.1016/j.oraloncology.2020.104987; Wasielewski M, 2010, BREAST CANCER RES TR, V124, P635, DOI 10.1007/s10549-010-0801-7; Win AK, 2016, INT J CANCER, V139, P1557, DOI 10.1002/ijc.30197; Win AK, 2014, GASTROENTEROLOGY, V146, P1208, DOI 10.1053/j.gastro.2014.01.022; Win AK, 2011, INT J CANCER, V129, P2256, DOI 10.1002/ijc.25870; Yanus GA, 2018, CLIN GENET, V93, P1015, DOI 10.1111/cge.13228; Zhang YW, 2006, CANCER EPIDEM BIOMAR, V15, P353, DOI 10.1158/1055-9965.EPI-05-0653	103	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2531	2539		10.1038/s41388-022-02304-y	http://dx.doi.org/10.1038/s41388-022-02304-y		APR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35422474				2022-12-17	WOS:000782543300003
J	Guo, P; Chen, Q; Peng, KS; Xie, JY; Liu, JJ; Ren, WJ; Tong, ZW; Li, M; Xu, JM; Zhang, YY; Yu, CD; Mo, PL				Guo, Peng; Chen, Qiang; Peng, Kesong; Xie, Jianyuan; Liu, Junjia; Ren, Wenjing; Tong, Zhangwei; Li, Ming; Xu, Jianming; Zhang, Yongyou; Yu, Chundong; Mo, Pingli			Nuclear receptor coactivator SRC-1 promotes colorectal cancer progression through enhancing GLI2-mediated Hedgehog signaling	ONCOGENE			English	Article							COREGULATORS; INHIBITION; GENE; TIF2; METASTASIS; DISRUPTION; EXPRESSION; PROTEINS; SURVIVAL; PATHWAY	Overexpression of nuclear coactivator steroid receptor coactivator 1 (SRC-1) and aberrant activation of the Hedgehog (Hh) signaling pathway are associated with various tumorigenesis; however, the significance of SRC-1 in colorectal cancer (CRC) and its contribution to the activation of Hh signaling are unclear. Here, we identified a conserved Hh signaling signature positively correlated with SRC-1 expression in CRC based on TCGA database; SRC-1 deficiency significantly inhibited the proliferation, survival, migration, invasion, and tumorigenesis of both human and mouse CRC cells, and SRC-1 knockout significantly suppressed azoxymethane/dextran sodium sulfate (AOM/DSS)-induced CRC in mice. Mechanistically, SRC-1 promoted the expression of GLI family zinc finger 2 (GLI2), a major downstream transcription factor of Hh pathway, and cooperated with GLI2 to enhance multiple Hh-regulated oncogene expression, including Cyclin D1, Bcl-2, and Slug. Pharmacological blockages of SRC-1 and Hh signaling retarded CRC progression in human CRC cell xenograft mouse model. Together, our studies uncover an SRC-1/GLI2-regulated Hh signaling looping axis that promotes CRC tumorigenesis, offering an attractive strategy for CRC treatment.	[Guo, Peng; Chen, Qiang; Peng, Kesong; Xie, Jianyuan; Liu, Junjia; Ren, Wenjing; Tong, Zhangwei; Li, Ming; Zhang, Yongyou; Yu, Chundong; Mo, Pingli] Xiamen Univ, Innovat Ctr Cell Signaling Network, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China; [Peng, Kesong] Fudan Univ, Sch Basic Med Sci, Dept Cellular & Genet Med, Shanghai 200433, Peoples R China; [Liu, Junjia; Zhang, Yongyou] Xiamen Univ, Res Ctr Mol Diagnost, Sch Life Sci, Natl Inst Data Sci Hlth & Med Engn,Minist Educ, Xiamen 361102, Fujian, Peoples R China; [Xu, Jianming] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Xiamen University; Fudan University; Xiamen University; Baylor College of Medicine	Zhang, YY; Yu, CD; Mo, PL (corresponding author), Xiamen Univ, Innovat Ctr Cell Signaling Network, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China.; Zhang, YY (corresponding author), Xiamen Univ, Res Ctr Mol Diagnost, Sch Life Sci, Natl Inst Data Sci Hlth & Med Engn,Minist Educ, Xiamen 361102, Fujian, Peoples R China.	yongyouzhang@xmu.edu.cn; cdyu@xmu.edu.cn; mop@xmu.edu.cn		Li, Ming/0000-0002-9700-1282; zhang, yongyou/0000-0003-2413-9106; Peng, Kesong/0000-0001-9035-3421; Xu, Jianming/0000-0002-8208-9162	National Natural Science Foundation of China [81970485, 81772942, 81772539]; Fundamental Research Funds for the Central Universities [20720180048]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We would like to thank Shiwen Luo (Nanchang University) for providing GLI2 expression plasmid and Hedgehog signaling reporter 8xGLI. We also thank Dr. Mingxia Zhu for technical support. This work was supported by the National Natural Science Foundation of China (Nos. 81970485 and 81772942 to Chundong Yu, and No. 81772539 to Yongyou Zhang), and the Fundamental Research Funds for the Central Universities (No. 20720180048 to Yongyou Zhang).	Berlin J, 2013, CLIN CANCER RES, V19, P258, DOI 10.1158/1078-0432.CCR-12-1800; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Catenacci DVT, 2015, J CLIN ONCOL, V33, P4284, DOI 10.1200/JCO.2015.62.8719; Chen Q, 2022, ONCOGENE, V41, P1421, DOI 10.1038/s41388-021-02173-x; Datta A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26811-w; Dlugosz A, 2012, NAT REV DRUG DISCOV, V11, P437, DOI 10.1038/nrd3753; Du K, 2018, GASTROENTEROLOGY, V154, P1465, DOI 10.1053/j.gastro.2017.12.022; Duteil D, 2010, CELL METAB, V12, P496, DOI 10.1016/j.cmet.2010.09.016; Fattahi S, 2018, J CELL PHYSIOL, V233, P5726, DOI 10.1002/jcp.26506; Giudici M, 2016, HANDB EXP PHARMACOL, V233, P95, DOI 10.1007/164_2015_5; Hsia EY, 2010, ADV DRUG DELIVER REV, V62, P1227, DOI 10.1016/j.addr.2010.09.016; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Jain S, 2017, ONCOTARGETS THER, V10, DOI 10.2147/OTT.S130910; Kangwan N, 2016, ONCOTARGET, V7, P7667, DOI 10.18632/oncotarget.6765; Kato S, 2011, TRENDS BIOCHEM SCI, V36, P272, DOI 10.1016/j.tibs.2011.01.001; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Lin JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25684-3; Lonard DM, 2012, NAT REV ENDOCRINOL, V8, P598, DOI 10.1038/nrendo.2012.100; Louet JF, 2010, CELL METAB, V12, P606, DOI 10.1016/j.cmet.2010.11.009; Madison BB, 2005, DEVELOPMENT, V132, P279, DOI 10.1242/dev.01576; Mark M, 2004, P NATL ACAD SCI USA, V101, P4453, DOI 10.1073/pnas.0400234101; Meerson A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2938-1; Mo P, 2015, ONCOGENE, V34, P3935, DOI 10.1038/onc.2014.324; Myers E, 2005, CLIN CANCER RES, V11, P2111, DOI 10.1158/1078-0432.CCR-04-1192; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223; Papadopoulos V, 2016, CLIN COLORECTAL CANC, V15, P116, DOI 10.1016/j.clcc.2016.02.010; Peng KS, 2020, ONCOGENE, V39, P7076, DOI 10.1038/s41388-020-01483-w; Peng KS, 2019, GASTROENTEROLOGY, V156, P1112, DOI 10.1053/j.gastro.2018.11.036; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Qin L, 2014, CANCER RES, V74, P3477, DOI 10.1158/0008-5472.CAN-13-2639; Qin L, 2011, CANCER RES, V71, P1742, DOI 10.1158/0008-5472.CAN-10-3453; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Raleigh DR, 2018, J CLIN INVEST, V128, P120, DOI 10.1172/JCI92710; Russo L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17088-5; Sang YZ, 2018, CANCER RES, V78, P1792, DOI 10.1158/0008-5472.CAN-17-2774; Sari IN, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110208; Seba V, 2021, POLYMERS-BASEL, V13, DOI 10.3390/polym13162611; Tong ZW, 2015, J BIOL CHEM, V290, P18596, DOI 10.1074/jbc.M115.640490; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Walsh CA, 2014, CANCER RES, V74, P2533, DOI 10.1158/0008-5472.CAN-13-2133; Walsh CA, 2012, INT J BIOL SCI, V8, P470, DOI 10.7150/ijbs.4125; Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105; Wang Y, 2014, CANCER RES, V74, P1506, DOI 10.1158/0008-5472.CAN-13-2939; Wang Y, 2011, MOL ENDOCRINOL, V25, P2041, DOI 10.1210/me.2011-1222; Xin MH, 2018, MED RES REV, V38, P870, DOI 10.1002/med.21482; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648; Zeng X, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082279; Zhao C, 2017, SCIENCE, V356, DOI 10.1126/science.aal3485; Zhuo MH, 2020, ONCOGENE, V39, P3336, DOI 10.1038/s41388-020-1219-2	55	1	1	8	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2846	2859		10.1038/s41388-022-02308-8	http://dx.doi.org/10.1038/s41388-022-02308-8		APR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35418691				2022-12-17	WOS:000783468200006
J	Kidger, AM; Saville, MK; Rushworth, LK; Davidson, J; Stellzig, J; Ono, M; Kuebelsbeck, LA; Janssen, KP; Holzmann, B; Morton, JP; Sansom, OJ; Caunt, CJ; Keyse, SM				Kidger, Andrew M.; Saville, Mark K.; Rushworth, Linda K.; Davidson, Jane; Stellzig, Julia; Ono, Motoharu; Kuebelsbeck, Ludwig A.; Janssen, Klaus-Peter; Holzmann, Bernhard; Morton, Jennifer P.; Sansom, Owen J.; Caunt, Christopher J.; Keyse, Stephen M.			Suppression of mutant Kirsten-RAS (KRAS(G12D))-driven pancreatic carcinogenesis by dual-specificity MAP kinase phosphatases 5 and 6	ONCOGENE			English	Article							DOWN-REGULATION; POTENTIAL-ROLE; GROWTH-FACTORS; K-RAS; CANCER; DUSP6; PROGRESSION; PROTEIN; PROLIFERATION; DUSP6/MKP-3	The cytoplasmic phosphatase DUSP6 and its nuclear counterpart DUSP5 are negative regulators of RAS/ERK signalling. Here we use deletion of either Dusp5 or Dusp6 to explore the roles of these phosphatases in a murine model of KRAS(G12D)-driven pancreatic cancer. By 56-days, loss of either DUSP5 or DUSP6 causes a significant increase in KRAS(G12D)-driven pancreatic hyperplasia. This is accompanied by increased pancreatic acinar to ductal metaplasia (ADM) and the development of pre-neoplastic pancreatic intraepithelial neoplasia (PanINs). In contrast, by 100-days, pancreatic hyperplasia is reversed with significant atrophy of pancreatic tissue and weight loss observed in animals lacking either DUSP5 or DUSP6. On further ageing, Dusp6(-/-) mice display accelerated development of metastatic pancreatic ductal adenocarcinoma (PDAC), while in Dusp5(-/-) animals, although PDAC development is increased this process is attenuated by atrophy of pancreatic acinar tissue and severe weight loss in some animals before cancer could progress. Our data suggest that despite a common target in the ERK MAP kinase, DUSP5 and DUSP6 play partially non-redundant roles in suppressing oncogenic KRAS(G12D) signalling, thus retarding both tumour initiation and progression. Our data suggest that loss of either DUSP5 or DUSP6, as observed in certain human tumours, including the pancreas, could promote carcinogenesis.	[Kidger, Andrew M.; Saville, Mark K.; Rushworth, Linda K.; Davidson, Jane; Stellzig, Julia; Ono, Motoharu; Keyse, Stephen M.] Univ Dundee, Jacqui Wood Canc Ctr, Sch Med, Div Cellular & Syst Med,Stress Response Lab, Dundee DD1 9SY, Scotland; [Kuebelsbeck, Ludwig A.; Janssen, Klaus-Peter; Holzmann, Bernhard] Tech Univ Munich, Sch Med, Dept Surg, Klinikum Rechts Isar, Munich, Germany; [Morton, Jennifer P.; Sansom, Owen J.] Inst Canc Sci, Garscube Estate,Switchback Rd, Glasgow G61 1QH, Lanark, Scotland; [Morton, Jennifer P.; Sansom, Owen J.] CRUK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland; [Caunt, Christopher J.] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of Dundee; Technical University of Munich; University of Glasgow; Beatson Institute; University of Bath	Keyse, SM (corresponding author), Univ Dundee, Jacqui Wood Canc Ctr, Sch Med, Div Cellular & Syst Med,Stress Response Lab, Dundee DD1 9SY, Scotland.	s.m.keyse@dundee.ac.uk		Sansom, Owen J./0000-0001-9540-3010; Kubelsbeck, Ludwig/0000-0002-2888-6558	Cancer Research UK [C8227/A12053, A25142, A17196, A21139, A29996, A25233]; MRC Research Grant [MR/N020790/1]; Dundee Cancer Centre Studentship; Deutsche Krebshilfe e.V. (German Cancer Aid) [111822]; German Research Council (DFG) through collaborative Research Centre 1321 [SFB1321]	Cancer Research UK(Cancer Research UK); MRC Research Grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Dundee Cancer Centre Studentship; Deutsche Krebshilfe e.V. (German Cancer Aid)(Deutsche Krebshilfe); German Research Council (DFG) through collaborative Research Centre 1321(German Research Foundation (DFG))	We would like to thank the staff of the Biological Resources Unit (Ninewells Hospital) and The Biological Services Unit (CRUK Beatson Institute, Glasgow) for animal husbandry and technical assistance. Tayside Tissue Bank (Mairi Lennie and Sharon King) for tissue sectioning and slide scanning. Richard Odle (Babraham Institute, Cambridge) for IHC scoring. Catherine Winchester (CRUK Beatson Institute, Glasgow) for critical reading of the manuscript, Ian Rosewell, Linda Groom, David Williams and Susanne Van Schelven for technical assistance during the early stages of this project. SMK was supported by a Cancer Research UK Programme Grant (C8227/A12053), an MRC Research Grant (MR/N020790/1 to SMK and CJC) and a Dundee Cancer Centre Studentship (to AMK), JPM and OJS are supported by Cancer Research UK (A25142, A17196, A21139, A29996 and A25233). BH and K-PJ are supported by grant 111822 from Deutsche Krebshilfe e.V. (German Cancer Aid) and LAK is supported by the German Research Council (DFG) through collaborative Research Centre 1321 (SFB1321). We dedicate this manuscript to the memory of our friend and colleague CJC.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Beaudry K, 2019, J CELL PHYSIOL, V234, P6731, DOI 10.1002/jcp.27420; Belo J, 2013, STEM CELLS DEV, V22, P2935, DOI 10.1089/scd.2013.0106; Buffet C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184861; Cai C, 2015, INT J CLIN EXP MED, V8, P4186; Caunt CJ, 2013, FEBS J, V280, P489, DOI 10.1111/j.1742-4658.2012.08716.x; Cheung EC, 2020, CANCER CELL, V37, P168, DOI 10.1016/j.ccell.2019.12.012; Collisson EA, 2012, CANCER DISCOV, V2, P685, DOI 10.1158/2159-8290.CD-11-0347; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Ekerot M, 2008, BIOCHEM J, V412, P287, DOI 10.1042/BJ20071512; Furukawa T, 2005, MODERN PATHOL, V18, P1034, DOI 10.1038/modpathol.3800383; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Guerra C, 2013, MOL ONCOL, V7, P232, DOI 10.1016/j.molonc.2013.02.002; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Harris NLE, 2017, ONCOGENE, V36, P4288, DOI 10.1038/onc.2017.63; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Holmes DA, 2015, EMBO J, V34, P218, DOI 10.15252/embj.201489456; Holzenberger M, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.21.e92; Karlsson M, 2004, J BIOL CHEM, V279, P41882, DOI 10.1074/jbc.M406720200; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kidger AM, 2017, P NATL ACAD SCI USA, V114, pE317, DOI 10.1073/pnas.1614684114; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Kucharska A, 2009, CELL SIGNAL, V21, P1794, DOI 10.1016/j.cellsig.2009.07.015; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Maillet M, 2008, J BIOL CHEM, V283, P31246, DOI 10.1074/jbc.M806085200; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Means AL, 2005, DEVELOPMENT, V132, P3767, DOI 10.1242/dev.01925; Messina S, 2011, ONCOGENE, V30, P3813, DOI 10.1038/onc.2011.99; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Nagdas S, 2019, CELL REP, V28, P1845, DOI 10.1016/j.celrep.2019.07.031; Okudela K, 2009, AM J PATHOL, V175, P867, DOI 10.2353/ajpath.2009.080489; Packer LM, 2009, PIGM CELL MELANOMA R, V22, P785, DOI 10.1111/j.1755-148X.2009.00618.x; Rushworth LK, 2014, P NATL ACAD SCI USA, V111, P18267, DOI 10.1073/pnas.1420159112; Seternes OM, 2019, BBA-MOL CELL RES, V1866, P124, DOI 10.1016/j.bbamcr.2018.09.002; Shin SH, 2013, AM J PATHOL, V182, P1275, DOI 10.1016/j.ajpath.2013.01.004; Shojaee S, 2015, CANCER CELL, V28, P114, DOI 10.1016/j.ccell.2015.05.008; Togel L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20176-9; Tonnetti L, 2008, CANCER RES, V68, P5648, DOI 10.1158/0008-5472.CAN-07-5850; Tuveson DA, 2005, COLD SH Q B, V70, P65, DOI 10.1101/sqb.2005.70.040; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Vartanian S, 2013, J BIOL CHEM, V288, P2403, DOI 10.1074/jbc.M112.394130; von Figura G, 2014, NAT CELL BIOL, V16, P255, DOI 10.1038/ncb2916; Wittig-Blaich S, 2017, ONCOTARGET, V8, P23760, DOI 10.18632/oncotarget.15863; Wojtukiewicz MZ, 2001, THROMB HAEMOSTASIS, V86, P1416; Xu SH, 2005, J HUM GENET, V50, P159, DOI 10.1007/s10038-005-0235-y; Xue A, 2008, PANCREAS, V36, P160, DOI 10.1097/MPA.0b013e31815750f0; Yan XB, 2016, AM J CANCER RES, V6, P2323; Zhou HM, 2001, CANCER RES, V61, P970	56	1	1	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2022	41	20					2811	2823		10.1038/s41388-022-02302-0	http://dx.doi.org/10.1038/s41388-022-02302-0		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1F4TJ	35418690	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000783468200005
J	Chen, S; Cheng, JH; Zhong, YH; Liu, RM; Lu, ZX; Luo, XY				Chen, Shuai; Cheng, Jianghong; Zhong, Yanhong; Liu, Ruimin; Lu, Zhongxian; Luo, Xianyang			Liver-specific overexpression of Gab2 accelerates hepatocellular carcinoma progression by activating immunosuppression of myeloid-derived suppressor cells	ONCOGENE			English	Article							CANCER; AMPLIFICATION; CARCINOGENESIS; TARGET	GRB2-associated-binding protein 2 (Gab2) deletion has a preventive effect of on chronic liver inflammation and hepatocellular carcinoma. This study was aimed to elaborate Gab2-initiated immunoregulation during hepatocarcinogenesis. Compared to wild-type group, liver-specific overexpression of Gab2 mice (L-Gab2) displayed early hepatocarcinogenesis after 5-month diethylnitrosamine (DEN) induction, and accelerated tumor growth after 9-month DEN challenge. More myeloid-derived suppressor cells (MDSCs) were observed in DEN-challenged L-Gab2 mice than that in DEN-treated wild-type mice. Additionally, MDSCs activation-induced tumor angiogenesis capability and immunosuppression function were exceedingly activated in DEN-exposed L-Gab2 mice, which reflected in the increased platelet endothelial cell adhesion molecule (PECAM) and vascular endothelial growth factor (VEGF), and the decreased cytotoxic T lymphocytes. Mechanistically, DEN-challenged L-Gab2 mice produced more IL-6, and IL-6 depletion significantly deprived Gab2-overexpression-mediated tumor-promotion phenomena, accompanied by the impairment of MDSCs-initiated immunosuppression function. MDSCs isolated from IL-6-depleted L-Gab2 mice or inactivating MDSCs partly restored the immune function of cytotoxic T cells. Of note, MDSCs gene signatures had a significant association with the increased Gab2 or IL6 in hepatoma specimens. Collectively, L-Gab2 mice accelerated hepatoma progression possibly through activating IL-6-initiated the activation of MDSCs. This study provides a novel insights for exploring the role of Gab2 in autoimmune tolerance during hepatocarcinogenesis.	[Chen, Shuai; Luo, Xianyang] Xiamen Univ, Affiliated Hosp 1, Sch Med, Dept Otolaryngol Head & Neck Surg, Xiamen 361003, Peoples R China; [Cheng, Jianghong] Xian Med Univ, Xian Key Lab Pathogen Microorganism & Tumor Immun, Xian 710021, Peoples R China; [Zhong, Yanhong; Liu, Ruimin; Lu, Zhongxian] Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Pharmaceut Sci, Xiamen 361005, Fujian, Peoples R China; [Luo, Xianyang] Xiamen Key Lab Otolaryngol Head & Neck Surg, Xiamen 361003, Peoples R China	Xiamen University; Xi'an Medical University; Xiamen University	Luo, XY (corresponding author), Xiamen Univ, Affiliated Hosp 1, Sch Med, Dept Otolaryngol Head & Neck Surg, Xiamen 361003, Peoples R China.; Lu, ZX (corresponding author), Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Pharmaceut Sci, Xiamen 361005, Fujian, Peoples R China.; Luo, XY (corresponding author), Xiamen Key Lab Otolaryngol Head & Neck Surg, Xiamen 361003, Peoples R China.	zhongxian@xmu.edu.cn; luoxianyang126@126.com		Lu, zhongxian/0000-0002-1682-7147	Natural Science Foundation of China [81802332, 8210115473]; Natural Science Foundation of Fujian Province [2020J05302, 2021J011358]; Science Foundation of the Fujian provincial Commission of Health and Family Planning [2021GGB026]; Natural Science Basic Research Program of Shaanxi Province [2021JQ-780]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); Science Foundation of the Fujian provincial Commission of Health and Family Planning; Natural Science Basic Research Program of Shaanxi Province	We thank the Gene Expression Profiling Interactive Analysis 2.0 online database (GEPIA2). This work was supported by the grants from Natural Science Foundation of China (81802332 and 8210115473), Natural Science Foundation of Fujian Province (2020J05302 and 2021J011358), Science Foundation of the Fujian provincial Commission of Health and Family Planning (2021GGB026) and Natural Science Basic Research Program of Shaanxi Province (2021JQ-780).	Arihara F, 2013, CANCER IMMUNOL IMMUN, V62, P1421, DOI 10.1007/s00262-013-1447-1; Atretkhany KSN, 2016, BIOCHEMISTRY-MOSCOW+, V81, P1274, DOI 10.1134/S0006297916110055; Beury DW, 2014, J LEUKOCYTE BIOL, V96, P1109, DOI 10.1189/jlb.3A0414-210R; Bocanegra M, 2010, ONCOGENE, V29, P774, DOI 10.1038/onc.2009.364; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brodaczewska KK, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12704; Chang Wen-Chi L, 2017, World J Gastrointest Pharmacol Ther, V8, P47, DOI 10.4292/wjgpt.v8.i1.47; Chen S, 2016, J MOL CELL BIOL, V8, P492, DOI 10.1093/jmcb/mjw028; Chen ZQ, 2020, AM J CANCER RES, V10, P2993; Cheng JH, 2017, FASEB J, V31, P5530, DOI 10.1096/fj.201700120RR; Chernoff KA, 2009, CLIN CANCER RES, V15, P4288, DOI 10.1158/1078-0432.CCR-09-0280; Choo YW, 2018, ACS NANO, V12, P8977, DOI 10.1021/acsnano.8b02446; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; De Cicco P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01680; Deng Y, 2017, ONCOGENE, V36, P1090, DOI 10.1038/onc.2016.273; Ding CB, 2015, MOL MED REP, V12, P4007, DOI 10.3892/mmr.2015.3951; Ding CB, 2015, INT J CLIN EXP PATHO, V8, P2779; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Groth C, 2019, BRIT J CANCER, V120, P16, DOI 10.1038/s41416-018-0333-1; Guo XH, 2017, J BIOL CHEM, V292, P14003, DOI 10.1074/jbc.M117.802066; Hernandez-Gea V, 2013, GASTROENTEROLOGY, V144, P512, DOI 10.1053/j.gastro.2013.01.002; Herr R, 2018, ONCOGENE, V37, P1576, DOI 10.1038/s41388-017-0063-5; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Horst B, 2009, AM J PATHOL, V174, P1524, DOI 10.2353/ajpath.2009.080543; Kapanadze T, 2013, J HEPATOL, V59, P1007, DOI 10.1016/j.jhep.2013.06.010; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Lee AW, 2011, MOL CELL BIOL, V31, P4563, DOI 10.1128/MCB.05706-11; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Lu LC, 2019, J HEPATOCELL CARCINO, V6, P71, DOI 10.2147/JHC.S159693; Park YR, 2017, J KOREAN MED SCI, V32, P1784, DOI 10.3346/jkms.2017.32.11.1784; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Ribechini E, 2010, MED MICROBIOL IMMUN, V199, P273, DOI 10.1007/s00430-010-0151-4; Saviano A, 2019, MOL TRANSL MED, P317, DOI 10.1007/978-3-030-21540-8_15; Schrader J, 2013, J HEPATOL, V59, P921, DOI 10.1016/j.jhep.2013.08.003; Triantafyllou E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02948; Urakawa S, 2019, CANCER IMMUNOL IMMUN, V68, P1341, DOI 10.1007/s00262-019-02366-0; Waldron TJ, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24117; Yang Y, 2013, ONCOGENE, V32, P3627, DOI 10.1038/onc.2012.367; Zanconato F, 2019, NAT REV CANCER, V19, P454, DOI 10.1038/s41568-019-0168-y; Zatkova A, 2006, GENE CHROMOSOME CANC, V45, P798, DOI 10.1002/gcc.20344; Zhang YS, 2018, CANCER BIOL THER, V19, P735, DOI 10.1080/15384047.2018.1453971; Zhao F, 2012, IMMUNOLOGY, V136, P176, DOI 10.1111/j.1365-2567.2012.03566.x	43	1	1	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2022	41	24					3316	3327		10.1038/s41388-022-02298-7	http://dx.doi.org/10.1038/s41388-022-02298-7		APR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	2A3BO	35411035				2022-12-17	WOS:000780668900001
J	Li, XK; Chen, HC; Zhang, LZ; Chen, L; Wei, W; Gao, SG; Xue, Q; Li, Y; Wang, B; Li, JG; Gao, YS; Lin, YL				Li, Xingkai; Chen, Hengchi; Zhang, Lizhen; Chen, Li; Wei, Wei; Gao, Shugeng; Xue, Qi; Li, Yue; Wang, Bing; Li, Jiagen; Gao, Yushun; Lin, Yanliang			27-hydroxycholesterol linked high cholesterol diet to lung adenocarcinoma metastasis	ONCOGENE			English	Article							CANCER; 25-HYDROXYCHOLESTEROL; LIPIDS	Dietary cholesterol has been implicated to promote lung cancer. Lung adenocarcinoma (LAC) is a main type of lung cancer, whereas the functional mechanism of cholesterol in LAC remained largely unknown. In the present study, we evidenced that cholesterol promoted cell proliferation and invasion of LAC in vitro as well as LAC metastasis in vivo. Cyp27A1 knockdown reduced the cholesterol-induced LAC cells proliferation and invasion. In contrast, Cyp7B1 knockdown enhanced the effect of cholesterol on LAC cells proliferation and invasion. Furthermore, Cyp27A1 deficiency remarkably reduced high cholesterol-induced LAC metastasis in vivo. Mechanism investigation demonstrated that exposure of LAC cells to 27-hydroxycholesterol induced the phosphorylation of AKT and NF kappa B p65, and promoted the expression of peptidylprolyl isomerase B (PPIB), especially in the coculture with THP1-derived macrophage. Meanwhile, 27-hydroxycholesterol induced the secretion of FGF2 and IL-6, which contributed to the expression of snail and vimentin. Luciferase report assay and ChIP assay confirmed that NF kappa B p65 controlled the transcription of PPIB. Inhibiting NF kappa B p65 activation reduced PPIB expression. PPIB inhibition reduced 27-hydroxycholesterol-induced expression of snail and vimentin. These results indicated that 27-hydroxycholesterol linked high cholesterol and LAC metastasis by regulating NF kappa B/PPIB axis and the secretion of FGF2 and IL-6.	[Li, Xingkai; Chen, Hengchi; Gao, Shugeng; Xue, Qi; Wang, Bing; Li, Jiagen; Gao, Yushun] Chinese Acad Med Sci & Peking Union Med Coll, Dept Thorac Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China; [Zhang, Lizhen; Lin, Yanliang] Shandong First Med Univ, Dept Cent Lab, Shandong Prov Hosp, Jinan, Peoples R China; [Chen, Li; Lin, Yanliang] Shandong Univ, Dept Cent Lab, Shandong Prov Hosp, Jinan, Peoples R China; [Wei, Wei] Shandong Prov Ecoenvironm Monitoring Ctr, Jinan, Peoples R China; [Li, Yue] Peking Univ Third Hosp, Dept Anesthesiol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Peking University	Gao, YS (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Dept Thorac Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China.; Lin, YL (corresponding author), Shandong First Med Univ, Dept Cent Lab, Shandong Prov Hosp, Jinan, Peoples R China.; Lin, YL (corresponding author), Shandong Univ, Dept Cent Lab, Shandong Prov Hosp, Jinan, Peoples R China.	1027david@sohu.com; yanlianglin@aliyun.com			National Natural Science Foundation of China [81572272, 81972177]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (Grant No. 81572272; 81972177).	Baek AE, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00910-z; Cagno V, 2017, REDOX BIOL, V12, P522, DOI 10.1016/j.redox.2017.03.016; CARPENTER KLH, 1995, BBA-LIPID LIPID MET, V1256, P141, DOI 10.1016/0005-2760(94)00247-V; Chen L, 2017, BIOCHEM BIOPH RES CO, V484, P857, DOI 10.1016/j.bbrc.2017.02.003; Choi TG, 2018, J PATHOL, V246, P115, DOI 10.1002/path.5107; De Stefani E, 2002, LUNG CANCER-J IASLC, V35, P43, DOI 10.1016/S0169-5002(01)00281-1; Hiramitsu S, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00470; Kurimoto R, 2016, INT J ONCOL, V48, P1825, DOI 10.3892/ijo.2016.3419; Lin XJ, 2018, NUTRIENTS, V10, DOI 10.3390/nu10020185; Lin XJ, 2017, J CLIN LIPIDOL, V11, P1073, DOI 10.1016/j.jacl.2017.05.004; Llaverias G, 2010, AM J PATHOL, V177, P3180, DOI 10.2353/ajpath.2010.100568; Ma JB, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.281; Nelson ER, 2018, MOL CELL ENDOCRINOL, V466, P73, DOI 10.1016/j.mce.2017.09.021; Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908; Raza S, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0422-x; Rossin D, 2019, FREE RADICAL BIO MED, V136, P35, DOI 10.1016/j.freeradbiomed.2019.03.020; SHEKELLE RB, 1991, AM J EPIDEMIOL, V134, P480, DOI 10.1093/oxfordjournals.aje.a116119; Wang JS, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0705-9; Williams PD, 2011, NEOPLASIA, V13, P1122, DOI 10.1593/neo.111398; Wu Q, 2013, CELL REP, V5, P637, DOI 10.1016/j.celrep.2013.10.006; Wu YF, 2015, BIOCHEM BIOPH RES CO, V457, P614, DOI 10.1016/j.bbrc.2015.01.035; Yang ZZ, 2017, EBIOMEDICINE, V19, P49, DOI 10.1016/j.ebiom.2017.04.017; Zhang YW, 2017, INT J CANCER, V140, P1645, DOI 10.1002/ijc.30581; Zhao ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095884	24	1	1	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2685	2695		10.1038/s41388-022-02285-y	http://dx.doi.org/10.1038/s41388-022-02285-y		APR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35379924	hybrid, Green Published			2022-12-17	WOS:000778745900001
J	Baker, K; O'Donnell, C; Bendix, M; Keogh, S; Byrne, J; O'Riordain, M; Neary, P; Houston, A; Brint, E				Baker, Kevin; O'Donnell, Charlotte; Bendix, Maura; Keogh, Samuel; Byrne, James; O'Riordain, Michael; Neary, Peter; Houston, Aileen; Brint, Elizabeth			IL-36 signalling enhances a pro-tumorigenic phenotype in colon cancer cells with cancer cell growth restricted by administration of the IL-36R antagonist	ONCOGENE			English	Article							ULCERATIVE-COLITIS; EXPRESSION; INTERLEUKIN-36; RECEPTOR; FAMILY; ROLES	The IL-36 cytokines are a recently described subset of the IL-1 family of cytokines, shown to play a role in the pathogenesis of intestinal diseases such as Inflammatory Bowel Disease (IBD). Given the link between IBD and colitis -associated cancer, as well as the involvement of other IL-1 family members in intestinal tumorigenesis, the aim of this work was to investigate whether IL-36 cytokines play a role in the pathogenesis of colon cancer. Whilst research to date has focused on the role of IL-36 family members in augmenting the immune response to induce tumour rejection, very little remains known about IL-36R signalling in tumour cells in this context. In this study we demonstrate that expression of IL-36 family member mRNA and protein are significantly increased in colorectal cancer tissue compared to adjacent non-tumour. In vitro assays showed stimulation of colon cancer cell lines with IL-36R agonists resulted in the activation of the pro-tumorigenic phenotypes of increased cellular migration, invasion and proliferation in both 2D and 3D models. In addition, the IL-36 cytokines induced strong expression of pro-inflammatory chemokines in both human and murine cell lines. Intraperitoneal injection of IL-36Ra significantly reduced tumour burden using the subcutaneous CT26 tumour model in syngeneic Balb/mice, and this was associated with a decrease in Ki-67 expression by tumour cells in the IL-36Ra- treated group relative to untreated, suggesting the inhibition of the pro-proliferative signalling of IL-36 agonists resulted in the decreased tumour size. Moreover, colon cancer cells lacking the IL-36R also showed reduced tumour growth and reduced Ki-67 expression in vivo. Taken together, this data suggests that targeting IL-36R signalling may be a useful targeted therapy for colorectal cancer patients with IL-36R(+) tumour cells.	[Baker, Kevin; Bendix, Maura; Keogh, Samuel; Byrne, James; Brint, Elizabeth] Univ Coll Cork, Dept Pathol, Cork, Ireland; [Baker, Kevin; Houston, Aileen; Brint, Elizabeth] Univ Coll Cork, APC Microbiome Ireland, Cork, Ireland; [O'Donnell, Charlotte; Houston, Aileen] Univ Coll Cork, Dept Med, Cork, Ireland; [Bendix, Maura] Univ Coll Cork, Canc Res UCC, Cork, Ireland; [O'Riordain, Michael] Mercy Univ Hosp, Cork, Ireland; [Neary, Peter] Waterford Univ Hosp, Waterford, Ireland	University College Cork; University College Cork; University College Cork; University College Cork; University College Cork	Brint, E (corresponding author), Univ Coll Cork, Dept Pathol, Cork, Ireland.; Brint, E (corresponding author), Univ Coll Cork, APC Microbiome Ireland, Cork, Ireland.	e.brint@ucc.ie		Houston, Aileen/0000-0003-1362-5256; Bendix, Maura/0000-0001-8883-2677; Brint, Elizabeth/0000-0001-9214-149X	Government of Ireland [GOIPG/2018/2974]; IReL Consortium	Government of Ireland; IReL Consortium	This work was funded by a grant from the Government of Ireland postgraduate scholarship scheme GOIPG/2018/2974. Open Access funding provided by the IReL Consortium.	Aldinucci D, 2020, CANCERS, V12, DOI 10.3390/cancers12071765; Baker KJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01197; Bassoy EY, 2018, IMMUNOL REV, V281, P169, DOI 10.1111/imr.12610; Byrne J, 2021, CELL MOL LIFE SCI, V78, P6215, DOI 10.1007/s00018-021-03909-4; Chun E, 2015, CELL REP, V12, P244, DOI 10.1016/j.celrep.2015.06.024; Diaz-Maroto NG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094960; Ding LP, 2018, ONCOTARGET, V9, P2895, DOI 10.18632/oncotarget.22814; Dunn E, 2001, TRENDS IMMUNOL, V22, P533, DOI 10.1016/S1471-4906(01)02034-8; Duronio Robert J, 2013, Cold Spring Harb Perspect Biol, V5, pa008904, DOI 10.1101/cshperspect.a008904; Fernandes P, 2014, J IMMUNOL, V193, P6103, DOI 10.4049/jimmunol.1303083; Fonseca-Camarillo G, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5140691; Frick VO, 2016, WORLD J GASTROENTERO, V22, P833, DOI 10.3748/wjg.v22.i2.833; Gabay C, 2015, J LEUKOCYTE BIOL, V97, P645, DOI 10.1189/jlb.3RI1014-495R; Gelfo V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176009; Holen I, 2016, ONCOTARGET, V7, P75571, DOI 10.18632/oncotarget.12289; Ko HBM, 2015, MODERN PATHOL, V28, P1584, DOI 10.1038/modpathol.2015.111; Kobelt D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00980; Le Rolle AF, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0555-4; Leon G, 2021, INFLAMM BOWEL DIS, V27, P440, DOI 10.1093/ibd/izaa232; Liu Q, 2020, INT J BIOL SCI, V16, P1023, DOI 10.7150/ijbs.40535; Mao DL, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819883633; McCombs JE, 2021, AM J RESP CELL MOL, V64, P153, DOI 10.1165/rcmb.2020-0461ED; Medina-Contreras O, 2016, J IMMUNOL, V196, P34, DOI 10.4049/jimmunol.1501312; Najdaghi S, 2020, CYTOKINE, V135, DOI 10.1016/j.cyto.2020.155205; Nishida A, 2016, INFLAMM BOWEL DIS, V22, P303, DOI 10.1097/MIB.0000000000000654; O'Donnell C, 2016, BRIT J CANCER, V114, P37, DOI 10.1038/bjc.2015.433; Pijuan J, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00107; Qu QX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00634; Queen D, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00317; Ridker PM, 2017, LANCET, V390, P1833, DOI 10.1016/S0140-6736(17)32247-X; Russell SE, 2016, MUCOSAL IMMUNOL, V9, P1193, DOI 10.1038/mi.2015.134; Swindell WR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00080; Uppala R, 2021, CELL MOL IMMUNOL, V18, P307, DOI 10.1038/s41423-020-0519-3; Wang D, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0701-2; Wang XF, 2015, CANCER CELL, V28, P296, DOI 10.1016/j.ccell.2015.07.014; Weinstein AM, 2019, CANCER IMMUNOL IMMUN, V68, P109, DOI 10.1007/s00262-018-2259-0; Weinstein AM, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1322238; Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z; Yang W, ADV SCI, V2022; Yashiro M, 2014, WORLD J GASTROENTERO, V20, P16389, DOI 10.3748/wjg.v20.i44.16389; Zhao X, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01803	41	1	1	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2672	2684		10.1038/s41388-022-02281-2	http://dx.doi.org/10.1038/s41388-022-02281-2		APR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35365751	Green Published, hybrid			2022-12-17	WOS:000777275200001
J	Cui, YM; Jiao, HL; Ye, YP; Chen, CM; Wang, JX; Tang, N; Li, TT; Lin, J; Qi, L; Wu, P; Wang, SY; He, MR; Liang, L; Bian, XW; Liao, WT; Ding, YQ				Cui, Y-M; Jiao, H-L; Ye, Y-P; Chen, C-M; Wang, J-X; Tang, N.; Li, T-T; Lin, J.; Qi, L.; Wu, P.; Wang, S-Y; He, M-R; Liang, L.; Bian, X-W; Liao, W-T; Ding, Y-Q			RETRACTION: FOXC2 promotes colorectal cancer metastasis by directly targeting MET (Retraction of Vol 34, Pg 4379, 2015)	ONCOGENE			English	Retraction												liaowt2002@gmail.com; dyqgz@126.com						Cui YM, 2015, ONCOGENE, V34, P4379, DOI 10.1038/onc.2014.368; Cui YM, 2014, CANCER LETT, V353, P87, DOI 10.1016/j.canlet.2014.07.008	2	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2529	2529		10.1038/s41388-022-02287-w	http://dx.doi.org/10.1038/s41388-022-02287-w		APR 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35365752	Bronze			2022-12-17	WOS:000777275200002
J	Tu, JJ; Fang, YL; Han, DF; Tan, XW; Xu, Z; Jiang, HF; Wang, XM; Hong, WM; Wei, W				Tu, Jiajie; Fang, Yilong; Han, Dafei; Tan, Xuewen; Xu, Zhen; Jiang, Haifeng; Wang, Xinming; Hong, Wenming; Wei, Wei			MicroRNA-22 represses glioma development via activation of macrophage-mediated innate and adaptive immune responses (Mar, 10.1038/s41388-022-02236-7, 2022)	ONCOGENE			English	Correction												524594636@qq.com; wwei@ahmu.edu.cn		hong, wenming/0000-0002-1143-8046				Tu JJ, 2022, ONCOGENE, V41, P2444, DOI 10.1038/s41388-022-02236-7	1	1	1	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2526	2527		10.1038/s41388-022-02282-1	http://dx.doi.org/10.1038/s41388-022-02282-1		MAR 2022	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35354907	Bronze			2022-12-17	WOS:000775854500001
J	Wang, C; Leavenworth, J; Zhang, C; Liu, ZC; Yuan, KY; Wang, YC; Zhang, GX; Wang, SB; Cui, XL; Zhang, Y; Bae, S; Zhou, JB; Wang, LZ; Liu, RH				Wang, Chao; Leavenworth, Jonathan; Zhang, Chao; Liu, Zhichao; Yuan, Katherine Y.; Wang, Yicun; Zhang, Guangxin; Wang, Shuaibin; Cui, Xuelian; Zhang, Yue; Bae, Sejong; Zhou, Jiangbing; Wang, Lizhong; Liu, Runhua			Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer	ONCOGENE			English	Article							TRANSLATION INITIATION; GENE-EXPRESSION	In prostate cancers, elongation initiation factor 4A1 (eIF4A1) supports an oncogenic translation program and is highly expressed, but its role remains elusive. By the use of human specimens and cell models, we addressed the role of eIF4A1 in prostate cancer in vitro and in vivo. EIF4A1 expression, as determined by mRNA and protein levels, was higher in primary prostate cancers relative to normal prostate tissue. Also, for primary prostate cancers, elevated mRNA levels of EIF4A1 correlated with DNA hypomethylation levels in the CpG-rich island of EIF4A1. Using a DNMT3a CRISPR-Cas9-based tool for specific targeting of DNA methylation, we characterized, in human prostate cancer cells, the epigenetic regulation of EIF4A1 transcripts through DNA methylation in the CpG-rich island of EIF4A1. Next, we investigated the oncogenic effect of EIF4A1 on cancer cell proliferation in vitro and tumor growth in vivo. For prostate cancer cells, EIF4A1 heterozygous knockout or knockdown inhibited protein translation and tumor growth. In addition, using RNA immunoprecipitation with RNA sequencing, we discovered the eIF4A1-mediated translational regulation of the oncogene BRD2, which contains the most enriched eIF4A1-binding motifs in its 5 ' untranslated region, establishing an eIF4A1-BRD2 axis for oncogenic translation. Finally, we found a positive correlation between expression levels of eIF4A1 and BRD2 in primary prostate cancers. Our results demonstrate, for prostate cancer cells, epigenetic regulation of EIF4A1 transcripts through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling.	[Wang, Chao; Leavenworth, Jonathan; Zhang, Chao; Liu, Zhichao; Yuan, Katherine Y.; Wang, Yicun; Zhang, Guangxin; Wang, Shuaibin; Cui, Xuelian; Zhang, Yue; Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35487 USA; [Bae, Sejong; Wang, Lizhong; Liu, Runhua] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35487 USA; [Bae, Sejong] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Zhou, Jiangbing] Yale Univ, Dept Neurosurg, New Haven, CT USA; [Zhou, Jiangbing] Yale Univ, Dept Biomed Engn, New Haven, CT USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Yale University; Yale University	Wang, LZ; Liu, RH (corresponding author), Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35487 USA.; Wang, LZ; Liu, RH (corresponding author), Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL 35487 USA.	lwang12@uab.edu; runhua@uab.edu		Zhang, Yue/0000-0003-3817-8253; bae, sejong/0000-0001-9982-3223; Leavenworth, Jonathan/0000-0002-6120-8185	Department of Defense [W81XWH-15-1-0323, W81XWH-20-1-0426, W81XWH-21-1-0100]; National Cancer Institute [CA118948]; Mike Slive Foundation for Prostate Cancer Research	Department of Defense(United States Department of Defense); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Mike Slive Foundation for Prostate Cancer Research	We thank Dr Donald Hill for editorial assistance in preparing this paper. This work was supported by grants from the Department of Defense (W81XWH-15-1-0323 and W81XWH-20-1-0426 for RL and W81XWH-21-1-0100 for LW), the National Cancer Institute (CA118948 for LW), and the Mike Slive Foundation for Prostate Cancer Research (RL).	Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Chan K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13086-5; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 1999, MOL CELL BIOL, V19, P1; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; de la Parra C, 2018, CURR OPIN GENET DEV, V48, P82, DOI 10.1016/j.gde.2017.11.001; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Faivre EJ, 2020, NATURE, V578, P306, DOI 10.1038/s41586-020-1930-8; Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101; Gao CC, 2020, ACTA BIOCH BIOPH SIN, V52, P310, DOI 10.1093/abbs/gmz168; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jin C, 2013, ONCOGENE, V32, P2179, DOI 10.1038/onc.2012.236; Kregel S, 2019, CLIN CANCER RES, V25, P4038, DOI 10.1158/1078-0432.CCR-18-3776; Kumar A, 2021, ELIFE, V10, DOI [10.7554/eLife.72873, 10.7554/eLife.72873.sa1, 10.7554/eLife.72873.sa2]; Leppek K, 2018, NAT REV MOL CELL BIO, V19, P158, DOI 10.1038/nrm.2017.103; Liu XS, 2016, CELL, V167, P233, DOI 10.1016/j.cell.2016.08.056; Malina A, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012377; Malka-Mahieu H, 2017, CLIN CANCER RES, V23, P21, DOI 10.1158/1078-0432.CCR-14-2362; Modelska A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.542; Muhar M, 2018, SCIENCE, V360, P800, DOI 10.1126/science.aao2793; Quinn CM, 1999, GENOMICS, V62, P468, DOI 10.1006/geno.1999.6031; Ramamurthy VP, 2017, CURR OPIN ONCOL, V29, P210, DOI 10.1097/CCO.0000000000000367; Raman D, 2020, CANCER REP-US, DOI 10.1002/cnr2.1299; Remondini D, 2005, P NATL ACAD SCI USA, V102, P6902, DOI 10.1073/pnas.0502081102; Rubio CA, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0476-1; Schrecengost R, 2013, SEMIN ONCOL, V40, P244, DOI 10.1053/j.seminoncol.2013.04.001; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Sridharan S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01311; Urbanucci A, 2017, CELL REP, V19, P2045, DOI 10.1016/j.celrep.2017.05.049; Waldron JA, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1901-2; Waldron JA, 2018, NUCLEIC ACIDS RES, V46, P3075, DOI 10.1093/nar/gky108; Wolfe AL, 2014, NATURE, V513, P65, DOI 10.1038/nature13485; Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	35	1	1	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2022	41	19					2778	2785		10.1038/s41388-022-02272-3	http://dx.doi.org/10.1038/s41388-022-02272-3		MAR 2022	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1A5QI	35361883	Green Accepted			2022-12-17	WOS:000777357500001
J	Lu, CW; Yang, DF; Klement, JD; Colson, YL; Oberlies, NH; Pearce, CJ; Colby, AH; Grinstaff, MW; Liu, ZQ; Shi, HD; Ding, HF; Liu, KB				Lu, Chunwan; Yang, Dafeng; Klement, John D.; Colson, Yolonda L.; Oberlies, Nicholas H.; Pearce, Cedric J.; Colby, Aaron H.; Grinstaff, Mark W.; Liu, Zhuoqi; Shi, Huidong; Ding, Han-Fei; Liu, Kebin			H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth	ONCOGENE			English	Article							OXIDATIVE STRESS; LACTATE-DEHYDROGENASE; CELL-CYCLE; CANCER; METABOLISM; APOPTOSIS; INHIBITION; ACTIVATION; G9A; METHYLATION	The role of glucose-6-phosphate dehydrogenase (G6PD) in human cancer is incompletely understood. In a metabolite screening, we observed that inhibition of H3K9 methylation suppressed aerobic glycolysis and enhances the PPP in human mesothelioma cells. Genome-wide screening identified G6PD as an H3K9me3 target gene whose expression is correlated with increased tumor cell apoptosis. Inhibition of aerobic glycolysis enzyme LDHA and G6PD had no significant effects on tumor cell survival. Ablation of G6PD had no significant effect on human mesothelioma and colon carcinoma xenograft growth in athymic mice. However, activation of G6PD with the G6PD-selective activator AG1 induced tumor cell death. AG1 increased tumor cell ROS production and the resultant extrinsic and intrinsic death pathways, mitochondrial processes, and unfolded protein response in tumor cells. Consistent with increased tumor cell death in vitro, AG1 suppressed human mesothelioma xenograft growth in a dose-dependent manner in vivo. Furthermore, AG1 treatment significantly increased tumor-bearing mouse survival in an intra-peritoneum xenograft athymic mouse model. Therefore, in human mesothelioma and colon carcinoma, G6PD is not essential for tumor growth. G6PD acts as a metabolic checkpoint to control metabolic flux towards the PPP to promote tumor cell apoptosis, and its expression is repressed by its promotor H3K9me3 deposition.	[Lu, Chunwan] Tianjin Univ, Sch Life Sci, Tianjin 300072, Peoples R China; [Lu, Chunwan; Yang, Dafeng; Klement, John D.; Liu, Kebin] Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Yang, Dafeng; Klement, John D.; Liu, Zhuoqi; Shi, Huidong; Ding, Han-Fei; Liu, Kebin] Med Coll Georgia, Georgia Canc Ctr, Augusta, GA 30912 USA; [Yang, Dafeng; Klement, John D.; Liu, Kebin] Charlie Norwood VA Med Ctr, Augusta, GA 30904 USA; [Colson, Yolonda L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Div Thorac Surg, Boston, MA 02114 USA; [Oberlies, Nicholas H.] Univ North Carolina Greensboro, Dept Chem & Biochem, Greensboro, NC 27402 USA; [Pearce, Cedric J.] Mycosynthetix Inc, Hillsborough, NC 27278 USA; [Colby, Aaron H.; Grinstaff, Mark W.] Ion Pharmaceut, Brookline, MA 02445 USA; [Colby, Aaron H.; Grinstaff, Mark W.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Tianjin University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Harvard Medical School; Massachusetts General Hospital; University of North Carolina; University of North Carolina Greensboro; Boston University	Lu, CW (corresponding author), Tianjin Univ, Sch Life Sci, Tianjin 300072, Peoples R China.; Lu, CW (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	Chunwanlu@tju.edu.cn	Grinstaff, Mark/U-2829-2017; Oberlies, Nicholas/D-8162-2011	Grinstaff, Mark/0000-0002-5453-3668; Shi, Huidong/0000-0003-1137-3390; Oberlies, Nicholas/0000-0002-0354-8464; Ding, Han-Fei/0000-0001-5702-3439	National Cancer Institute [R01 CA227433, R01CA133085, P01 CA125066, R01CA190429, R01CA236890, F30CA236436]; US Department of Veterans Affairs Award [CX001364]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US Department of Veterans Affairs Award(US Department of Veterans Affairs)	We thank Dr. Roni Bollag at the Georgia Cancer Center Biorepository for providing the human mesothelioma specimen and for pathological analysis. We also thank Dr. Natasha Savage for tumor specimen analysis and Dr. Kimya Jones for immunohistochemical analysis of tumor specimen. This work was supported by the National Cancer Institute grants R01 CA227433 (to MWG, YLC, NHO, KL), R01CA133085 (to KL), P01 CA125066 (to NHO), R01CA190429, and R01CA236890 (to H-FD), F30CA236436 (to JDK), and the US Department of Veterans Affairs Award CX001364 (to KL).	Abbosh PH, 2006, CANCER RES, V66, P5582, DOI 10.1158/0008-5472.CAN-05-3575; Aggarwal BB, 2012, BLOOD, V119, P651, DOI 10.1182/blood-2011-04-325225; Amrine CSM, 2018, J IND MICROBIOL BIOT, V45, P1053, DOI 10.1007/s10295-018-2083-8; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Chen L, 2019, NAT METAB, V1, P404, DOI 10.1038/s42255-019-0043-x; Cui WY, 2021, CANCER TREAT REV, V100, DOI 10.1016/j.ctrv.2021.102265; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Dick TP, 2015, MOL CELL, V59, P519, DOI 10.1016/j.molcel.2015.08.002; Ding H., 2021, SCI ADV, V7, P1; Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004; Fiehn O, 2008, PLANT J, V53, P691, DOI 10.1111/j.1365-313X.2007.03387.x; Figueroa M, 2012, J ANTIBIOT, V65, P559, DOI 10.1038/ja.2012.69; Fritsch L, 2010, MOL CELL, V37, P46, DOI 10.1016/j.molcel.2009.12.017; Ge TX, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00365; Ghergurovich JM, 2020, CANCER RES, V80, P3820, DOI 10.1158/0008-5472.CAN-19-2486; Ghergurovich JM, 2020, NAT CHEM BIOL, V16, P731, DOI 10.1038/s41589-020-0533-x; Gu Y., 2014, CELL DEATH DIS, V5; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hotta K, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000461; Hwang S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06447-z; Iurlaro R, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00479-16; Jian SL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.192; Koo SJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00202; Kowalik MA, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00087; Kuehne A, 2015, MOL CELL, V59, P359, DOI 10.1016/j.molcel.2015.06.017; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Lemoine J, 2021, CLIN CANCER RES, V27, P6298, DOI 10.1158/1078-0432.CCR-21-1559; Li W, 2021, NAT METAB, V3, P75, DOI 10.1038/s42255-020-00330-2; Liu B, 2019, ACS CHEM NEUROSCI, V10, P2332, DOI 10.1021/acschemneuro.8b00644; Lu CW, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-003543; Lu CW, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002624; Lu CW, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001365; Lu CW, 2020, CANCER LETT, V476, P87, DOI 10.1016/j.canlet.2020.02.004; Lu CW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw283; Matei D, 2020, CANCER RES, V80, P3775, DOI 10.1158/0008-5472.CAN-19-3837; McCambridge AJ, 2018, J THORAC ONCOL, V13, P606, DOI 10.1016/j.jtho.2018.02.021; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Menon DR, 2020, THERANOSTICS, V10, P6261, DOI 10.7150/thno.42523; Monteiro-Reis S, 2020, CANCERS, V12, DOI 10.3390/cancers12051066; Mozzetta C, 2014, MOL CELL, V53, P277, DOI 10.1016/j.molcel.2013.12.005; Muller MM, 2016, NAT CHEM BIOL, V12, P188, DOI [10.1038/NCHEMBIO.2008, 10.1038/nchembio.2008]; Nagashio R, 2019, BBA-PROTEINS PROTEOM, V1867, P38, DOI 10.1016/j.bbapap.2018.05.005; Nakajima EC, 2022, CLIN CANCER RES, V28, P446, DOI 10.1158/1078-0432.CCR-21-1466; Nakamura M, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001679; Nicetto D, 2019, SCIENCE, V363, P294, DOI 10.1126/science.aau0583; Olcina MM, 2016, ONCOGENE, V35, P793, DOI 10.1038/onc.2015.134; Oshima N, 2020, CELL REP, V30, P1798, DOI 10.1016/j.celrep.2020.01.039; Paschall AV, 2015, GENOM DATA, V5, P189, DOI 10.1016/j.gdata.2015.05.043; Paschall AV, 2015, J IMMUNOL, V195, P1868, DOI 10.4049/jimmunol.1402243; Pathria G, 2018, EMBO J, V37, DOI 10.15252/embj.201899735; Pinton G, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.678447; Raub AG, 2019, CHEMMEDCHEM, V14, P1321, DOI 10.1002/cmdc.201900341; Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI 10.1016/j.bbamcr.2016.09.012; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Salvi A, 2020, MOL CANCER THER, V19, P89, DOI 10.1158/1535-7163.MCT-19-0205; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Stomper J., 2021, CLIN EPIGENETICS, P13; Tu DZ, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1659-1; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Williams D, 2019, CLIN EXP METASTAS, V36, P211, DOI 10.1007/s10585-019-09967-0; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Wu SR, 2018, CANCER RES, V78, P4549, DOI 10.1158/0008-5472.CAN-17-4047; Yeung C, 2019, CANCER RES, V79, P5060, DOI 10.1158/0008-5472.CAN-19-0217; Zhang XM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.85	66	1	1	7	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2651	2662		10.1038/s41388-022-02283-0	http://dx.doi.org/10.1038/s41388-022-02283-0		MAR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35351997	Green Accepted			2022-12-17	WOS:000774697300001
J	Yang, YS; Jia, XZ; Lu, QY; Cai, SL; Huang, XT; Yang, SH; Wood, C; Wang, YH; Zhou, JJ; Chen, YD; Yang, JS; Yang, WJ				Yang, Yao-Shun; Jia, Xi-Zheng; Lu, Qian-Yun; Cai, Sun-Li; Huang, Xue-Ting; Yang, Shu-Hua; Wood, Chris; Wang, Yue-Hong; Zhou, Jiao-Jiao; Chen, Yi-Ding; Yang, Jin-Shu; Yang, Wei-Jun			Exosomal DEK removes chemoradiotherapy resistance by triggering quiescence exit of breast cancer stem cells	ONCOGENE			English	Article							PREDICTS POOR-PROGNOSIS; PROTEIN; ONCOPROTEIN; GENE; DNA; OVEREXPRESSION; CHROMATIN; HETEROGENEITY; EXPRESSION; INHIBITOR	Tumor therapeutics often target the primary tumor bulk but fail to eradicate therapy-resistant cancer stem cells (CSCs) in quiescent state. These can then become activated to initiate recurrence and/or metastasis beyond therapy. Here, we identified and isolated chemoradiotherapy-resistant CSCs in quiescent state with high capacity of tumor-initiation and tumorsphere formation from three types of breast tumors in mice. Experiments of knockdown and rescue revealed DEK, a nuclear protein, as essential for CSC activation. Exogenous DEK was then used to trigger quiescence exit of CSCs. ChIP-seq and ATAC-seq showed that DEK directly binds to chromatin, facilitating its genome-wide accessibility. The resulting epigenetic events upregulate the expression of cellular activation-related genes including MYC targets, whereas cellular quiescence-related genes including the p53 signaling pathway are silenced. However, twinned with DEK-induced activation, formerly resistant CSCs were then destroyed by chemotherapy in vitro. In mice, traditional chemoradiotherapy concurrent with the injection of DEK-containing exosomes resulted in eradication of primary tumors together with formerly resistant CSCs without recurrence or metastasis. Our findings advance knowledge of the mechanism of quiescent CSC activation and may provide novel clinical opportunities for removal of quiescence-linked therapy resistance.	[Yang, Yao-Shun; Jia, Xi-Zheng; Lu, Qian-Yun; Cai, Sun-Li; Huang, Xue-Ting; Yang, Shu-Hua; Wood, Chris; Yang, Jin-Shu; Yang, Wei-Jun] Zhejiang Univ, Coll Life Sci, MOE Lab Biosyst Homeostasis & Protect, Hangzhou 310058, Peoples R China; [Wang, Yue-Hong] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Resp Med, Hangzhou, Peoples R China; [Zhou, Jiao-Jiao; Chen, Yi-Ding] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Surg Oncol, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Yang, WJ (corresponding author), Zhejiang Univ, Coll Life Sci, MOE Lab Biosyst Homeostasis & Protect, Hangzhou 310058, Peoples R China.	w_jyang@zju.edu.cn	Huang, Xueting/HGT-9440-2022	Wood, Christopher/0000-0002-5517-9496; Yang, Shuhua/0000-0002-1125-8088; Huang, Xueting/0000-0001-7893-168X; Cai, Sunli/0000-0003-3784-7048; Jia, Xi-Zheng/0000-0002-6656-0997	National Major Research and Development Project [2016YFA0101201]; National Natural Science Foundation of China [31730084]	National Major Research and Development Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Major Research and Development Project (2016YFA0101201) and the National Natural Science Foundation of China (Project No. 31730084).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bajaj J, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201911053; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Boichuk S, 2013, CANCER RES, V73, P5120, DOI 10.1158/0008-5472.CAN-13-0579; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Capitano ML, 2019, J CLIN INVEST, V129, P2555, DOI 10.1172/JCI127460; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Dai L, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00453-16; Damen MPF, 2021, FEBS J, V288, P6286, DOI 10.1111/febs.15626; Ewton DZ, 2011, MOL CANCER THER, V10, P2104, DOI 10.1158/1535-7163.MCT-11-0498; Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hacker KE, 2018, NEOPLASIA, V20, P1209, DOI 10.1016/j.neo.2018.10.005; Hidayat M, 2019, BOSNIAN J BASIC MED, V19, P355, DOI 10.17305/bjbms.2019.4227; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Hu HG, 2007, BIOCHEM BIOPH RES CO, V358, P1008, DOI 10.1016/j.bbrc.2007.05.019; Hua Y, 2009, SCI CHINA SER C, V52, P637, DOI 10.1007/s11427-009-0088-2; Jia WH, 2019, BIOCHEM J, V476, P1753, DOI 10.1042/BCJ20190169; Johnsen KB, 2014, BBA-REV CANCER, V1846, P75, DOI 10.1016/j.bbcan.2014.04.005; Kavanaugh GM, 2011, NUCLEIC ACIDS RES, V39, P7465, DOI 10.1093/nar/gkr454; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Khodadoust MS, 2009, CANCER RES, V69, P6405, DOI 10.1158/0008-5472.CAN-09-1063; Khoo WH, 2019, BLOOD, V134, P30, DOI 10.1182/blood.2018880930; Koleva RI, 2012, BLOOD, V119, P4878, DOI 10.1182/blood-2011-10-383083; LEE MS, 1991, P NATL ACAD SCI USA, V88, P9675, DOI 10.1073/pnas.88.21.9675; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu SP, 2012, PATHOL INT, V62, P176, DOI 10.1111/j.1440-1827.2011.02775.x; Marusyk A, 2020, CANCER CELL, V37, P471, DOI 10.1016/j.ccell.2020.03.007; Mor-Vaknin N, 2006, MOL CELL BIOL, V26, P9484, DOI 10.1128/MCB.01030-06; Najafi M, 2019, LIFE SCI, V234, DOI 10.1016/j.lfs.2019.116781; Piao JJ, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-67; Recasens A, 2019, TRENDS PHARMACOL SCI, V40, P128, DOI 10.1016/j.tips.2018.12.004; Saha AK, 2013, P NATL ACAD SCI USA, V110, P6847, DOI 10.1073/pnas.1220751110; Saito Y, 2010, NAT BIOTECHNOL, V28, P275, DOI 10.1038/nbt.1607; Sanden C, 2015, LEUKEMIA, V29, P1632, DOI 10.1038/leu.2015.72; Sanden C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-215; Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442; Sistigu A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02166; Steinbichler TB, 2018, SEMIN CANCER BIOL, V53, P156, DOI 10.1016/j.semcancer.2018.11.006; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun J, 2017, ONCOL REP, V37, P857, DOI 10.3892/or.2016.5302; Teng Y, 2018, CURR CANCER DRUG TAR, V18, P256, DOI 10.2174/1568009617666170522094730; Vinnedge LMP, 2015, ONCOGENE, V34, P2325, DOI 10.1038/onc.2014.173; Waldmann T, 2004, GENE, V343, P1, DOI 10.1016/j.gene.2004.08.029; Waldmann T, 2002, J BIOL CHEM, V277, P24988, DOI 10.1074/jbc.M204045200; Wang XY, 2014, INT J CLIN EXP PATHO, V7, P5016; Wise-Draper TM, 2005, J VIROL, V79, P14309, DOI 10.1128/JVI.79.22.14309-14317.2005; Ye S, 2019, CANCER RES, V79, P4729, DOI 10.1158/0008-5472.CAN-19-1084; Yi HC, 2015, MOL MED REP, V11, P1318, DOI 10.3892/mmr.2014.2781; Zeng X., 2021, PHARM RES-DORDR, V163	52	1	1	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2624	2637		10.1038/s41388-022-02278-x	http://dx.doi.org/10.1038/s41388-022-02278-x		MAR 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35351996				2022-12-17	WOS:000774697100001
J	Shirakihara, T; Yamaguchi, H; Kondo, T; Yashiro, M; Sakai, R				Shirakihara, Takuya; Yamaguchi, Hideki; Kondo, Tadashi; Yashiro, Masakazu; Sakai, Ryuichi			Transferrin receptor 1 promotes the fibroblast growth factor receptor-mediated oncogenic potential of diffused-type gastric cancer	ONCOGENE			English	Article							FGF RECEPTORS; CELL-LINES; K-SAM; PHOSPHORYLATION; CARCINOMA; SEQUENCE; MET; EXPRESSION; INHIBITOR; BINDING	Diffuse-type gastric cancer (DGC) is a highly invasive subtype of gastric adenocarcinoma that frequently exhibits scattered peritoneal metastasis. Previous studies have shown that the genes of receptor tyrosine kinases (RTKs), such as fibroblast growth factor receptor 2 (FGFR2) or Met, are amplified in some DGC cell lines, leading to the constitutive activation of corresponding RTKs. In these cell lines, the survival of cancer cells appears to be dependent on the activation of RTKs. To gain novel insights into the downstream signaling pathways of RTKs specific to DGC, phosphotyrosine-containing proteins associated with activated FGFR2 were purified through two sequential rounds of immunoprecipitation from the lysates of two DGC cell lines. As a result, transferrin receptor 1 (TfR1) was identified as the binding partner of FGFR2. Biochemical analysis confirmed that TfR1 protein binds to FGFR2 and is phosphorylated at tyrosine 20 (Tyr20) in an FGFR2 kinase activity-dependent manner. The knockdown of TfR1 and treatment with an inhibitor of FGFR2 caused significant impairment in iron uptake and suppression of cellular proliferation in vitro. Moreover, the suppression of expression levels of TfR1 in the DGC cells significantly reduced their tumorigenicity and potency of peritoneal dissemination. It was indicated that TfR1, when phosphorylated by the binding partner FGFR2 in DGC cells, promotes proliferation and tumorigenicity of these cancer cells. These results suggest that the control of TfR1 function may serve as a therapeutic target in DGC with activated FGFR2.	[Shirakihara, Takuya; Sakai, Ryuichi] Kitasato Univ, Sch Med, Dept Biochem, Sagamihara, Kanagawa, Japan; [Yamaguchi, Hideki] Sasaki Fdn, Sasaki Inst, Dept Canc Cell Res, Tokyo, Japan; [Kondo, Tadashi] Natl Canc Ctr, Div Rare Canc Res, Tokyo, Japan; [Yashiro, Masakazu] Osaka City Univ, Grad Sch Med, Mol Oncol & Therapeut, Osaka, Japan	Kitasato University; National Cancer Center - Japan; Osaka Metropolitan University	Sakai, R (corresponding author), Kitasato Univ, Sch Med, Dept Biochem, Sagamihara, Kanagawa, Japan.	rsakai@kitasato-u.ac.jp		Sakai, Ryuichi/0000-0001-6833-1103; Shirakihara, Takuya/0000-0002-6222-0143; Yamaguchi, Hideki/0000-0003-2125-9655	JSPS KAKENHI [JP17K08648, JP18K07242, JP21K07105]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr. Kazuyoshi Yanagihara (National Cancer Center, Japan) for providing 44As3 and 58As9 cell lines. This work was supported by JSPS KAKENHI Grants Numbers JP17K08648, JP18K07242, and JP21K07105.	Aisen P, 2004, INT J BIOCHEM CELL B, V36, P2137, DOI 10.1016/j.biocel.2004.02.007; Bottcher RT, 2004, NAT CELL BIOL, V6, P38, DOI 10.1038/ncb1082; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010; Daniels TR, 2012, BBA-GEN SUBJECTS, V1820, P291, DOI 10.1016/j.bbagen.2011.07.016; Dieci MV, 2013, CANCER DISCOV, V3, P264, DOI 10.1158/2159-8290.CD-12-0362; FAULK WP, 1980, LANCET, V2, P390; GALBRAITH GMP, 1980, CELL IMMUNOL, V49, P215, DOI 10.1016/0008-8749(80)90072-6; GATTER KC, 1983, J CLIN PATHOL, V36, P539, DOI 10.1136/jcp.36.5.539; Hattori Y, 1996, CLIN CANCER RES, V2, P1373; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212; Jabara HH, 2016, NAT GENET, V48, P74, DOI 10.1038/ng.3465; Jian JL, 2011, J BIOL CHEM, V286, P35708, DOI 10.1074/jbc.M111.271585; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kawabata H, 2001, BLOOD, V98, P2714, DOI 10.1182/blood.V98.9.2714; Kovalenko D, 2003, J BIOL CHEM, V278, P14087, DOI 10.1074/jbc.C200606200; Kuang YB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1528-y; Kumar N, 2007, PLOS COMPUT BIOL, V3, P35, DOI 10.1371/journal.pcbi.0030004; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Liu YJ, 2014, BRIT J CANCER, V110, P1169, DOI 10.1038/bjc.2014.61; Mattiuzzi C, 2019, J EPIDEMIOL GLOB HEA, V9, P217, DOI 10.2991/jegh.k.191008.001; Nakamura K, 2006, GASTROENTEROLOGY, V131, P1530, DOI 10.1053/j.gastro.2006.08.030; NAKATANI H, 1990, JPN J CANCER RES, V81, P707, DOI 10.1111/j.1349-7006.1990.tb02631.x; NECKERS LM, 1986, CANCER INVEST, V4, P461, DOI 10.3109/07357908609017524; Porebska N, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010007; Qiu H, 2009, CANCER SCI, V100, P181, DOI 10.1111/j.1349-7006.2008.01004.x; Shen Y, 2018, AM J CANCER RES, V8, P916; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; TAETLE R, 1986, CANCER RES, V46, P1759; Torti SV, 2020, CANCER RES, V80, P5435, DOI 10.1158/0008-5472.CAN-20-2017; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Xue X, 2016, CELL METAB, V24, P447, DOI 10.1016/j.cmet.2016.07.015; Yamaguchi H, 2014, CANCER SCI, V105, P528, DOI 10.1111/cas.12387; Yanagihara K, 2005, CANCER SCI, V96, P323, DOI 10.1111/j.1349-7006.2005.00054.x; Yashiro M, 1996, CLIN EXP METASTAS, V14, P43, DOI 10.1007/BF00157685	45	1	1	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2587	2596		10.1038/s41388-022-02270-5	http://dx.doi.org/10.1038/s41388-022-02270-5		MAR 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35338344				2022-12-17	WOS:000780349900001
J	Tu, YM; Xu, L; Xu, J; Bao, ZY; Tian, W; Ye, YF; Sun, GC; Miao, Z; Chao, HL; You, YP; Liu, N; Ji, J				Tu, Yiming; Xu, Lei; Xu, Jia; Bao, Zhongyuan; Tian, Wei; Ye, Yangfan; Sun, Guangchi; Miao, Zong; Chao, Honglu; You, Yongping; Liu, Ning; Ji, Jing			Loss of deubiquitylase USP2 triggers development of glioblastoma via TGF-beta signaling	ONCOGENE			English	Article							CELL-PROLIFERATION; SMAD7; UBIQUITINATION; DEGRADATION; METHYLATION; SIGNATURE; PROTEIN	Glioblastoma (GBM) is the most aggressive primary brain tumor as one of the deadliest cancers. The TGF-beta signaling acts as an oncogenic factor in GBM, and plays vital roles in development of GBM. SMAD7 is a major inhibitor of TGF-beta signaling, while the deubiquitination of SMAD7 has been poorly studied in GBM. Here, we found USP2 as a new prominent candidate that could regulate SMAD7 stability. USP2 was lost in GBM, leading to the poor prognosis in patients. Moreover, aberrant DNA methylation mediated by DNMT3A induced the low expression of USP2 in GBM. USP2 depletion induced TGF-beta signaling and progression of GBM. In contrast, overexpressed USP2 suppressed TGF-beta signaling and GBM development. Specifically, USP2 interacted with SMAD7 and prevented SMAD7 ubiquitination. USP2 directly cleaved Lys27- and Lys48-linked poly-ubiquitin chains of SMAD7, and Lys27-linked poly-ubiquitin chains of SMAD7 K185 mediated the recruitment of SMAD7 to HERC3, which regulated Lys63-linked poly-ubiquitination of SMAD7. Moreover, we demonstrated that the DNMT3A inhibitor SGI-1027 induced USP2, suppressed TGF-beta signaling and GBM development. Thus, USP2 repressed development of GBM by inhibition TGF-beta signaling pathway via the deubiquitination of SMAD7.	[Tu, Yiming; Xu, Lei; Xu, Jia; Bao, Zhongyuan; Tian, Wei; Ye, Yangfan; Sun, Guangchi; Miao, Zong; Chao, Honglu; You, Yongping; Liu, Ning; Ji, Jing] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China; [You, Yongping; Ji, Jing] Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Inst Brain Tumors, Nanjing, Jiangsu, Peoples R China; [Ji, Jing] Nanjing Med Univ, Gusu Sch, Suzhou, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Ji, J (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China.; Ji, J (corresponding author), Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Inst Brain Tumors, Nanjing, Jiangsu, Peoples R China.; Ji, J (corresponding author), Nanjing Med Univ, Gusu Sch, Suzhou, Peoples R China.	jijing@njmu.edu.cn			National Natural Science Foundation of China [82120108018, 81972153]; China Postdoctoral Science Foundation [2021M701495]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) [JX10231803]; Gusu School, Nanjing Medical University [GSKY202201010]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Gusu School, Nanjing Medical University	This study was supported by grants from the National Natural Science Foundation of China (82120108018 and 81972153), China Postdoctoral Science Foundation (2021M701495), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, Grant No. JX10231803), and Gusu School, Nanjing Medical University (GSKY202201010).	Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Behnan J, 2019, BRAIN, V142, P847, DOI 10.1093/brain/awz044; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Chai RC, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01124-z; De Boeck M, 2012, UPSALA J MED SCI, V117, P153, DOI 10.3109/03009734.2012.654858; Dixit D, 2021, CANCER DISCOV, V11, P480, DOI 10.1158/2159-8290.CD-20-0331; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Gu XH, 2018, AM J TRANSL RES, V10, P2834; He JB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1512-6; Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270; Imamura T, 2013, J BIOCHEM, V154, P481, DOI 10.1093/jb/mvt097; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jiang T, 2021, CANCER LETT, V499, P60, DOI 10.1016/j.canlet.2020.10.050; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Koinuma D, 2003, EMBO J, V22, P6458, DOI 10.1093/emboj/cdg632; Li H, 2019, CLIN CANCER RES, V25, P3602, DOI 10.1158/1078-0432.CCR-18-3791; Lui SKL, 2017, EMBO REP, V18, P797, DOI 10.15252/embr.201643270; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Niederlander C, 2001, NATURE, V410, P830, DOI 10.1038/35071103; Park SH, 2015, MOL CELLS, V38, P20, DOI 10.14348/molcells.2015.2120; Qu Q, 2015, TUMOR BIOL, V36, P5415, DOI 10.1007/s13277-015-3207-7; Sanai N, 2018, CLIN CANCER RES, V24, P3820, DOI 10.1158/1078-0432.CCR-17-3348; Song B, 2019, J CLIN INVEST, V129, P569, DOI 10.1172/JCI122367; Song YF, 2020, NEURO-ONCOLOGY, V22, P46, DOI 10.1093/neuonc/noz136; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tang YL, 2019, GASTROENTEROLOGY, V156, P692, DOI 10.1053/j.gastro.2018.10.023; Tong L, 2020, CELL DEATH DIFFER, V27, P1795, DOI 10.1038/s41418-019-0459-6; Tu YM, 2020, CLIN CANCER RES, V26, P1749, DOI 10.1158/1078-0432.CCR-19-1515; Wang QH, 2018, CANCER CELL, V33, P152, DOI 10.1016/j.ccell.2017.12.012; Wang QX, 2018, THERANOSTICS, V8, P4733, DOI 10.7150/thno.26550; Wiesner S, 2007, CELL, V130, P651, DOI 10.1016/j.cell.2007.06.050; Wu X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12145-1; Xu TH, 2020, NATURE, V586, P151, DOI 10.1038/s41586-020-2747-1; Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018; Yin Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09844-0; Zhang JR, 2020, CELL DEATH DIFFER, V27, P2710, DOI 10.1038/s41418-020-0538-8; Zhang QT, 2019, NAT CELL BIOL, V21, P179, DOI 10.1038/s41556-018-0264-3; Zhang SP, 2007, MOL CELL BIOL, V27, P4488, DOI 10.1128/MCB.01636-06; Zhang ZK, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02029-7; Zhao YG, 2011, J BIOL CHEM, V286, P40520, DOI 10.1074/jbc.M111.292961	41	1	1	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2597	2608		10.1038/s41388-022-02275-0	http://dx.doi.org/10.1038/s41388-022-02275-0		MAR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35332268				2022-12-17	WOS:000772732900001
J	Liu, Z; Li, JH; Ding, Y; Ma, M; Chen, J; Lei, W; Li, L; Yao, YY; Yu, X; Zhong, M; Liao, Q; Fang, WD; Fan, LW; Huang, CY; Zhong, HG; Wen, Q; Fang, Z; Chen, JY; Huang, SS; Xiong, JP; Xiang, XJ; Deng, J				Liu, Zhen; Li, Junhe; Ding, Yun; Ma, Mei; Chen, Jun; Lei, Wan; Li, Li; Yao, Yangyang; Yu, Xin; Zhong, Min; Liao, Quan; Fang, Weidan; Fan, Linwei; Huang, Chunye; Zhong, Hongguang; Wen, Qin; Fang, Zi; Chen, Jingyi; Huang, Shanshan; Xiong, Jianpin; Xiang, Xiaojun; Deng, Jun			USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer	ONCOGENE			English	Article							HIPPO PATHWAY; GROWTH; CHEMORESISTANCE; PROLIFERATION; MECHANISMS; LATS	The importance of the Hippo-Yes-associated protein 1 (YAP1) pathway in gastric carcinogenesis and metastasis has attracted considerable research attention; however, the regulatory network of YAP1 in gastric cancer (GC) is not completely understood. In this study, ubiquitin-specific peptidase 49 (USP49) was identified as a novel deubiquitinase of YAP1, knockdown of USP49 inhibited the proliferation, metastasis, chemoresistance, and peritoneal metastasis of GC cells. Overexpression of USP49 showed opposing biological effects. Moreover, USP49 was transcriptionally activated by the YAP1/TEAD4 complex, which formed a positive feedback loop with YAP1 to promote the malignant progression of GC cells. Finally, we collected tissue samples and clinical follow-up information from 482 GC patients. The results showed that USP49 expression was high in GC cells and positively correlated with the expression of YAP1 and its target genes, connective tissue growth factor (CTGF) and cysteine-rich angiogenic inducer 61 (CYR61). Survival and Cox regression analysis showed that high USP49 expression was associated with poor prognosis and was an independent prognostic factor. Moreover, patients with high USP49 and YAP1 expression had extremely short overall survival. The findings of this study reveal that the aberrant activation of the USP49/YAP1 positive feedback loop plays a critical role in the malignant progression of GC, thus providing potential novel prognostic factors and therapeutic targets for GC.	[Liu, Zhen; Li, Junhe; Ding, Yun; Ma, Mei; Chen, Jun; Lei, Wan; Li, Li; Yao, Yangyang; Yu, Xin; Zhong, Min; Liao, Quan; Fang, Weidan; Fan, Linwei; Huang, Chunye; Zhong, Hongguang; Wen, Qin; Fang, Zi; Chen, Jingyi; Huang, Shanshan; Xiong, Jianpin; Xiang, Xiaojun; Deng, Jun] Nanchang Univ, Dept Oncol, Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China; [Liu, Zhen; Ding, Yun; Ma, Mei; Yu, Xin; Zhong, Min; Liao, Quan; Fang, Weidan; Fan, Linwei; Fang, Zi] Jiangxi Key Lab Individual Canc Therapy, 17 Yongwai St, Nanchang 330006, Jiangxi, Peoples R China	Nanchang University	Huang, SS; Xiong, JP (corresponding author), Nanchang Univ, Dept Oncol, Affiliated Hosp 1, Nanchang 330006, Jiangxi, Peoples R China.	923834857@qq.com; Jpxiong0630@outlook.com; xjxiang_nc@ncu.edu.cn; dengjun19871106@ncu.edu.cn			JiangXi Province General Projects [20202BBGL73036]; National Natural Science Foundation of China [81760432, 8216100370]; Key Laboratory Fund of Jiangxi Province [20202BCD42011]; Jiangxi Provincial Outstanding Young Talents projects [2019BCB23020]; Science and Technology Department of Jiangxi Province [20202BBGL73055, 20202BAB216028]; Jiangxi Provincial Young Talents projects [20204BCJ23016]; Jiangxi Provincial Outstanding Youth projects [2018ACB21037]; CSCO-Bayer Cancer Research Fund [Y-bayer202001/zb-0007]; Department of Health of Jiangxi Province Projects [2019A058]	JiangXi Province General Projects; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Laboratory Fund of Jiangxi Province; Jiangxi Provincial Outstanding Young Talents projects; Science and Technology Department of Jiangxi Province; Jiangxi Provincial Young Talents projects; Jiangxi Provincial Outstanding Youth projects; CSCO-Bayer Cancer Research Fund; Department of Health of Jiangxi Province Projects	This work was supported by JiangXi Province General Projects (grant 20202BBGL73036), the National Natural Science Foundation of China (grant 81760432), Key Laboratory Fund of Jiangxi Province (grant number: 20202BCD42011), Jiangxi Provincial Outstanding Young Talents projects (grant 2019BCB23020), the Science and Technology Department of Jiangxi Province (grant 20202BBGL73055), Jiangxi Provincial Young Talents projects (grant 20204BCJ23016), the National Natural Science Foundation of China (grant 8216100370), Jiangxi Provincial Outstanding Youth projects (grant 2018ACB21037), the CSCO-Bayer Cancer Research Fund (grant Y-bayer202001/zb-0007), the Science and Technology Department of Jiangxi Province (grant 20202BAB216028), and the Department of Health of Jiangxi Province Projects (grant 2019A058).	Ajani JA, 2021, GUT, V70, P55, DOI 10.1136/gutjnl-2019-319748; An LW, 2020, J EXP MED, V217, DOI 10.1084/jem.20191817; D'Arcy P, 2014, CLIN CANCER RES, V20, P3908, DOI 10.1158/1078-0432.CCR-14-0568; Deng J, 2016, ONCOTARGET, V7, P10037, DOI 10.18632/oncotarget.7048; Fang ZL, 2018, ELIFE, V7, DOI 10.7554/eLife.31275; Harrigan JA, 2018, NAT REV DRUG DISCOV, V17, P57, DOI 10.1038/nrd.2017.152; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Huang SS, 2020, J CELL MOL MED, V24, P11133, DOI 10.1111/jcmm.15613; Jiao S, 2018, J EXP MED, V215, P699, DOI 10.1084/jem.20171116; Kategaya L, 2017, NATURE, V550, P534, DOI 10.1038/nature24006; Li L, 2018, GENE, V641, P240, DOI 10.1016/j.gene.2017.09.071; Liu Z, 2018, BIOCHEM BIOPH RES CO, V505, P843, DOI 10.1016/j.bbrc.2018.09.191; Liu Z, 2018, BIOCHEM BIOPH RES CO, V503, P2370, DOI 10.1016/j.bbrc.2018.06.163; Luo KT, 2017, EMBO J, V36, P1434, DOI 10.15252/embj.201695669; Ma XJ, 2017, P NATL ACAD SCI USA, V114, P1934, DOI 10.1073/pnas.1621359114; Marti P, 2015, HEPATOLOGY, V62, P1497, DOI 10.1002/hep.27992; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Mevissen TET, 2017, ANNU REV BIOCHEM, V86, P159, DOI 10.1146/annurev-biochem-061516-044916; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Pan BQ, 2020, PROTEIN CELL, V11, P138, DOI 10.1007/s13238-019-00674-w; Pan T, 2019, ELIFE, V8, DOI 10.7554/eLife.48318; Qian WL, 2020, ONCOGENE, V39, P6802, DOI 10.1038/s41388-020-01471-0; Shah MA, 2015, J CLIN ONCOL, V33, P1760, DOI 10.1200/JCO.2014.60.1799; Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5; Sun TS, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01262-x; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Tang Y, 2020, CANCER CELL, V38, P115, DOI 10.1016/j.ccell.2020.05.019; Togasaki K, 2021, GASTROENTEROLOGY, V160, P823, DOI 10.1053/j.gastro.2020.10.047; Toloczko A, 2017, CANCER RES, V77, P4921, DOI 10.1158/0008-5472.CAN-16-3413; Tu RF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0475-3; Yang LB, 2020, MOL CELL BIOCHEM, V474, P263, DOI 10.1007/s11010-020-03850-3; Yao F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04620-y; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang ZK, 2019, MOL CELL, V73, P7, DOI 10.1016/j.molcel.2018.10.030; Zhang Z, 2013, GENE DEV, V27, P1581, DOI 10.1101/gad.211037.112; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhou ZA, 2020, CANCER RES, V80, P2550, DOI 10.1158/0008-5472.CAN-19-3718; Zhu H, 2020, CANCER RES, V80, P2204, DOI 10.1158/0008-5472.CAN-19-2388; Zhu LL, 2020, GENE, V742, DOI 10.1016/j.gene.2020.144556; Zhu WJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.698751; Zhuang YY, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00494-0	42	1	1	7	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2022	41	18					2555	2570		10.1038/s41388-022-02267-0	http://dx.doi.org/10.1038/s41388-022-02267-0		MAR 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0W4LA	35318441				2022-12-17	WOS:000771890400001
J	Chen, XX; Wang, ZY; Zhao, XG; Zhang, LL; Zhou, L; Li, XX; Ge, C; Zhao, FY; Chen, TY; Xie, HY; Cui, Y; Tian, H; Li, H; Yao, M; Li, JJ				Chen, Xiaoxia; Wang, Zhenyu; Zhao, Xinge; Zhang, Lili; Zhou, Lianer; Li, Xianxian; Ge, Chao; Zhao, Fangyu; Chen, Taoyang; Xie, Haiyang; Cui, Ying; Tian, Hua; Li, Hong; Yao, Ming; Li, Jinjun			STAT5A modulates CDYL2/SLC7A6 pathway to inhibit the proliferation and invasion of hepatocellular carcinoma by targeting to mTORC1	ONCOGENE			English	Article							CDYL; CANCER; TRIMETHYLATION; ACTIVATION; EXPRESSION; PROMOTES	Chromodomain Y-like 2 (CDYL2), as a member of CDY family known to be involved in spermatogenesis, has been reported to participate in breast cancer development recently, but its exact biological role in hepatocellular carcinoma (HCC) remains unclear. Here, we observed that CDYL2 was down-regulated in human primary HCC tissues and the low levels of CDYL2 expression were correlated with poor survival. Gain- and loss-of-function experiments showed that CDYL2 inhibited the proliferation and metastasis of HCC cells in vitro and in vivo. Mechanistically, CDYL2 down-regulates solute carrier family 7 member 6 (SLC7A6) by decreasing the enrichment of H3K4me3 on the promoter region of SLC7A6. Additionally, we also found that signal transducer and activator of transcription 5A (STAT5A) could directly and positively regulate the expression of CDYL2. Thus, CDYL2 was regulated by STAT5A, and suppressed the amino acid transportation through down-regulation of SLC7A6, and then inhibits the mTORC1/S6K pathway, a master regulator of cell growth. Consistently, CDYL2 expression correlated significantly with STAT5A and SLC7A6 expression in HCC. Collectively, we propose a model for a STAT5A/CDYL2/SLC7A6 axis that provides novel insight into CDYL2, which may serve as a potential factor for predicting prognosis and a therapeutic target for HCC patients.	[Chen, Xiaoxia; Li, Jinjun] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Biomed Engn, Shanghai 200032, Peoples R China; [Chen, Xiaoxia; Wang, Zhenyu; Zhao, Xinge; Zhou, Lianer; Li, Xianxian; Ge, Chao; Zhao, Fangyu; Tian, Hua; Li, Hong; Yao, Ming; Li, Jinjun] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, Sch Med, Shanghai 200032, Peoples R China; [Zhang, Lili] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Oncol, Sch Med, Shanghai 200080, Peoples R China; [Chen, Taoyang] Qi Dong Liver Canc Inst, Qi Dong 226200, Peoples R China; [Xie, Haiyang] Zhejiang Univ, Dept Gen Surg, Affiliated Hosp 1, Sch Med, Hangzhou 310000, Peoples R China; [Cui, Ying] Canc Inst Guangxi, Nanning 530027, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Zhejiang University	Li, JJ (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Biomed Engn, Shanghai 200032, Peoples R China.; Li, JJ (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, Sch Med, Shanghai 200032, Peoples R China.	jjli@shsci.org			National Natural Science Foundation of China [82173331, 81972580, 81773152]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The authors are grateful to Dr. Daqiang Li for donating pLVX-CDYL2 vector. This work was supported by the National Natural Science Foundation of China [Grant number 82173331, 81972580, 81773152].	Abu-Zhayia ER, 2018, J MOL CELL BIOL, V10, P341, DOI 10.1093/jmcb/mjx050; Audia JE, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019521; Bernaciak TM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2341; Dorus S, 2003, HUM MOL GENET, V12, P1643, DOI 10.1093/hmg/ddg185; Escamilla-Del-Arenal M, 2013, MOL CELL BIOL, V33, P5005, DOI 10.1128/MCB.00866-13; Gunasekaran G, 2021, HEPATOLOGY, V73, P128, DOI 10.1002/hep.31325; Jewell JL, 2013, NAT REV MOL CELL BIO, V14, P133, DOI 10.1038/nrm3522; Jiang YB, 2021, MOL ONCOL, V15, P710, DOI 10.1002/1878-0261.12846; Kandasamy P, 2018, TRENDS BIOCHEM SCI, V43, P752, DOI 10.1016/j.tibs.2018.05.003; Kollmann S, 2019, LEUKEMIA, V33, P1583, DOI 10.1038/s41375-018-0369-5; Lahn BT, 2002, P NATL ACAD SCI USA, V99, P8707, DOI 10.1073/pnas.082248899; Lee TK, 2006, CANCER RES, V66, P9948, DOI 10.1158/0008-5472.CAN-06-1092; Liu P, 2017, HEPATOLOGY, V66, P167, DOI 10.1002/hep.29183; Liu SM, 2017, MOL CELL, V67, P853, DOI 10.1016/j.molcel.2017.07.011; McGlynn KA, 2021, HEPATOLOGY, V73, P4, DOI 10.1002/hep.31288; Menezes ME, 2016, ADV CANCER RES, V132, P1, DOI 10.1016/bs.acr.2016.07.001; Milewski K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112308; Mulligan P, 2008, MOL CELL, V32, P718, DOI 10.1016/j.molcel.2008.10.025; Qiu ZG, 2019, THERANOSTICS, V9, P4717, DOI 10.7150/thno.33680; Rask-Andersen M, 2013, MOL ASPECTS MED, V34, P702, DOI 10.1016/j.mam.2012.07.015; Rotoli BM, 2020, J CELL MOL MED, V24, P921, DOI 10.1111/jcmm.14801; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Shen E, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0514; Siouda M, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101141; Tang JZ, 2010, ENDOCRINOLOGY, V151, P43, DOI 10.1210/en.2009-0651; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; Wang A, 2008, ANIM GENET, V39, P207, DOI 10.1111/j.1365-2052.2008.01706.x; Wang Q, 2015, AM J CANCER RES, V5, P1281; Wu H, 2013, GENE CHROMOSOME CANC, V52, P644, DOI 10.1002/gcc.22060; Xia XY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1455-y; Yang J, 2019, THERANOSTICS, V9, P5810, DOI 10.7150/thno.34973; Yang LF, 2020, THERANOSTICS, V10, P5242, DOI 10.7150/thno.43744; Yu JH, 2012, HEPATOLOGY, V56, P2375, DOI 10.1002/hep.25900; Yu JH, 2010, HEPATOLOGY, V52, P1808, DOI 10.1002/hep.23882; Yue M, 2017, CELL REP, V21, P3819, DOI 10.1016/j.celrep.2017.12.002; Zhang LL, 2020, CANCER RES, V80, P2599, DOI 10.1158/0008-5472.CAN-19-3226; Zhang Y, 2011, J BIOL CHEM, V286, P42414, DOI 10.1074/jbc.M111.271064	37	1	1	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2492	2504		10.1038/s41388-022-02273-2	http://dx.doi.org/10.1038/s41388-022-02273-2		MAR 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35314791				2022-12-17	WOS:000771325000002
J	Gu, YH; Guo, YY; Gao, N; Fang, Y; Xu, C; Hu, GM; Guo, MX; Ma, YX; Zhang, YF; Zhou, J; Luo, YL; Zhang, HF; Wen, Q; Qiao, HL				Gu, Yuhan; Guo, Yuanyuan; Gao, Na; Fang, Yan; Xu, Chen; Hu, Guiming; Guo, Mengxue; Ma, Yaxing; Zhang, Yunfei; Zhou, Jun; Luo, Yanlin; Zhang, Haifeng; Wen, Qiang; Qiao, Hailing			The proteomic characterization of the peritumor microenvironment in human hepatocellular carcinoma	ONCOGENE			English	Article							THYMIDINE PHOSPHORYLASE EXPRESSION; PROTEOGENOMIC CHARACTERIZATION; CANCER; HETEROGENEITY; PROGRESSION; PROGNOSIS; DATABASE; DENSITY; EVASION; TARGET	The tumor microenvironment (TME) was usually studied in tumor tissue and in relation to only tumor progression, with little involved in occurrence, recurrence and metastasis of tumor. Thus, a new concept "peritumor microenvironment (PME)" was proposed in the proteomic characterization of peritumor liver tissues in human hepatocellular carcinoma (HCC). The PME for occurrence (PME-O) and progression (PME-P) were almost totally different at proteome composition and function. Proteins for occurrence and progression rarely overlapped and crossed. Immunity played a central role in PME-O, whereas inflammation, angiogenesis and metabolism were critical in PME-P. Proteome profiling identified three PME subtypes with different features of HCC. Thymidine phosphorylase (TYMP) was validated as an antiangiogenic target in an orthotopic HCC mouse model. Overall, the proteomic characterization of the PME revealed that the entire processes of HCC occurrence and progression differ substantially. These findings could enable advances in cancer biology, diagnostics and therapeutics.	[Gu, Yuhan; Guo, Yuanyuan; Gao, Na; Fang, Yan; Xu, Chen; Hu, Guiming; Guo, Mengxue; Ma, Yaxing; Zhang, Haifeng; Wen, Qiang; Qiao, Hailing] Zhengzhou Univ, Inst Clin Pharmacol, Zhengzhou, Peoples R China; [Guo, Yuanyuan] Zhengzhou Univ, Dept Pharm, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Zhang, Yunfei; Luo, Yanlin] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China; [Zhou, Jun] Zhengzhou Univ, Affiliated Peoples Hosp, Zhengzhou, Peoples R China	Zhengzhou University; Zhengzhou University; Zhengzhou University; Zhengzhou University	Qiao, HL (corresponding author), Zhengzhou Univ, Inst Clin Pharmacol, Zhengzhou, Peoples R China.	qiaohl@zzu.edu.cn		Gu, yuhan/0000-0002-6021-7215	National Natural Science Foundation of China (NSFC) [81473279, 81673507, 81872931, 82073930]; Zhengzhou Major Scientific and Technological Innovation Projects [2020CXZX0076]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Zhengzhou Major Scientific and Technological Innovation Projects	This work was supported by National Natural Science Foundation of China (NSFC) (Nos. 81473279, 81673507, 81872931 and 82073930), Zhengzhou Major Scientific and Technological Innovation Projects (No.2020CXZX0076). We thank Prof. Xiaohong Qian and Yangjun Zhang (State Key Laboratory of Proteomics) for technical support of mass spectrometry detection and suggestions for data processing.	Affo S, 2017, ANNU REV PATHOL-MECH, V12, P153, DOI 10.1146/annurev-pathol-052016-100322; Archer TC, 2018, CANCER CELL, V34, P396, DOI 10.1016/j.ccell.2018.08.004; Billan S, 2020, LANCET ONCOL, V21, pE463, DOI 10.1016/S1470-2045(20)30328-4; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Casanova E, 2006, J MED CHEM, V49, P5562, DOI 10.1021/jm0605379; Chakrabarti S, 2021, PHARMACOL THERAPEUT, V224, DOI 10.1016/j.pharmthera.2021.107823; Chapouly C, 2015, BRAIN, V138, P1548, DOI 10.1093/brain/awv077; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; De Clercq E, 2011, MED RES REV, V31, P118, DOI 10.1002/med.20179; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; Forget A, 2019, ADV MATER, V31, DOI 10.1002/adma.201808050; FURUKAWA T, 1992, NATURE, V356, P668, DOI 10.1038/356668a0; Furukawa T, 2018, PHARMACOL RES, V132, P15, DOI 10.1016/j.phrs.2018.03.019; Gao J, 2018, MOL CARCINOGEN, V57, P1371, DOI 10.1002/mc.22851; Gao J, 2018, J PHARMACOL EXP THER, V365, P398, DOI 10.1124/jpet.117.245555; Gao N, 2016, EUR J PHARM SCI, V92, P86, DOI 10.1016/j.ejps.2016.06.015; Gao Q, 2019, CELL, V179, P561, DOI 10.1016/j.cell.2019.08.052; Ge S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03121-2; Goliwas KF, 2021, PHYSIOL REV, V101, P417, DOI 10.1152/physrev.00008.2020; Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962; Imazono Y, 1997, J CLIN ONCOL, V15, P2570, DOI 10.1200/JCO.1997.15.7.2570; Javaid S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225056; Jiang LH, 2020, CELL, V183, P269, DOI 10.1016/j.cell.2020.08.036; Jiang Y, 2019, NATURE, V567, P257, DOI 10.1038/s41586-019-0987-8; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Lawson KA, 2020, NATURE, V586, P120, DOI 10.1038/s41586-020-2746-2; Li W, 2018, TRENDS CARDIOVAS MED, V28, P157, DOI 10.1016/j.tcm.2017.10.003; Li W, 2014, CIRC RES, V115, P997, DOI 10.1161/CIRCRESAHA.115.304591; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liekens S, 2004, J BIOL CHEM, V279, P29598, DOI 10.1074/jbc.M402602200; Liekens S, 2006, MOL PHARMACOL, V70, P501, DOI 10.1124/mol.105.021188; Lin C, 2019, GUT, V68, P1764, DOI 10.1136/gutjnl-2018-316324; Mascaux C, 2019, NATURE, V571, P570, DOI 10.1038/s41586-019-1330-0; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; McLaughlin M, 2020, NAT REV CANCER, V20, P203, DOI 10.1038/s41568-020-0246-1; Ortmayr K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09695-9; PAGET S, 1989, CANCER METAST REV, V8, P98; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Toi M, 1999, CLIN CANCER RES, V5, P1131; Toi M, 2005, LANCET ONCOL, V6, P158, DOI 10.1016/S1470-2045(05)01766-3; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958; Yao YX, 2001, CLIN CANCER RES, V7, P4021; Yoshihama S, 2016, P NATL ACAD SCI USA, V113, P5999, DOI 10.1073/pnas.1602069113; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438; Zhang HF, 2016, J PHARMACOL EXP THER, V358, P83, DOI 10.1124/jpet.116.233635; Zhang HF, 2015, SCI REP-UK, V5, DOI 10.1038/srep17671; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	59	1	1	8	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2480	2491		10.1038/s41388-022-02264-3	http://dx.doi.org/10.1038/s41388-022-02264-3		MAR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35314790	hybrid, Green Published			2022-12-17	WOS:000771325000001
J	Lee, WK; Zhu, XG; Park, S; Zhu, YJ; Zhao, L; Meltzer, P; Cheng, SY				Lee, Woo Kyung; Zhu, Xuguang; Park, Sunmi; Zhu, Yuelin Jack; Zhao, Li; Meltzer, Paul; Cheng, Sheue-Yann			Regulation of cancer stem cell activity by thyroid hormone receptor beta	ONCOGENE			English	Article							TR-BETA; EXPRESSION; CARCINOMA; GENE; MUTATION; IDENTIFICATION; TUMORIGENESIS; ASSOCIATION; INHIBITION; PATHWAY	Increasing numbers of cancer stem cell markers have been recently identified. It is not known, however, whether a member of the nuclear receptor superfamily, thyroid hormone receptor beta (TR beta), can function to regulate cancer stem cell (CSC) activity. Using anaplastic thyroid cancer cells (ATC) as a model, we highlight the role of TR beta in CSC activity. ATC is one of the most aggressive solid cancers in humans and is resistant to currently available therapeutics. Recent studies provide evidence that CSC activity underlies aggressiveness and therapeutic resistance of ATC. Here we show that TR beta inhibits CSC activity by suppressing tumor-sphere formation of human ATC cells and their tumor-initiating capacity. TR beta suppresses the expression of CSC regulators, including ALDH, KLF2, SOX2, b-catenin, and ABCG2, in ATC cell-induced xenograft tumors. Single-cell transcriptomic analysis shows that TR beta reduces CSC population in ATC-induced xenograft tumors. Analysis of The Cancer Genome Atlas (TCGA) database demonstrates that the inhibition of CSC capacity by TR beta contributes to favorable clinical outcomes in human cancer. Our studies show that TR beta is a newly identified transcription regulator that acts to suppress CSC activity and that TR beta could be considered as a molecular target for therapeutic intervention of ATC.	[Lee, Woo Kyung; Zhu, Xuguang; Park, Sunmi; Zhao, Li; Cheng, Sheue-Yann] NCI, Lab Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Zhu, Yuelin Jack; Meltzer, Paul] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cheng, SY (corresponding author), NCI, Lab Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	chengs@mail.nih.gov	Doolittle, Woo Kyung Lee/CAJ-0252-2022	Doolittle, Woo Kyung Lee/0000-0002-6737-3173	Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health	Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research is supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health.	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ando S, 2001, J CLIN ENDOCR METAB, V86, P5572, DOI 10.1210/jc.86.11.5572; Aranda A, 2009, TRENDS ENDOCRIN MET, V20, P318, DOI 10.1016/j.tem.2009.03.011; Ayob AZ, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0426-4; Bolf EL, 2020, MOL CANCER RES, V18, P1443, DOI 10.1158/1541-7786.MCR-20-0282; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Carr FE, 2016, ENDOCRINOLOGY, V157, P3278, DOI 10.1210/en.2015-2046; Enomoto K, 2017, J CLIN ENDOCR METAB, V102, P2268, DOI 10.1210/jc.2016-3771; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Guigon CJ, 2011, ONCOGENE, V30, P3381, DOI 10.1038/onc.2011.50; Haghpanah V, 2016, LIFE SCI, V146, P34, DOI 10.1016/j.lfs.2015.12.057; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Iwasaki Y, 2010, ANN SURG ONCOL, V17, P2222, DOI 10.1245/s10434-010-0956-9; Jazdzewski K, 2011, J CLIN ENDOCR METAB, V96, pE546, DOI 10.1210/jc.2010-1594; Jean E, 2011, J CELL MOL MED, V15, P119, DOI 10.1111/j.1582-4934.2009.00942.x; Jerzak KJ, 2018, BREAST CANCER RES TR, V171, P709, DOI 10.1007/s10549-018-4844-5; Joseph B, 2007, J CLIN ENDOCR METAB, V92, P4766, DOI 10.1210/jc.2007-0812; Kim WG, 2014, THYROID, V24, P260, DOI 10.1089/thy.2013.0054; Kim WG, 2013, BBA-GEN SUBJECTS, V1830, P3928, DOI 10.1016/j.bbagen.2012.04.002; Kim WG, 2013, ENDOCRINOLOGY, V154, P25, DOI 10.1210/en.2012-1728; Lee CH, 2016, ONCOTARGET, V7, P1215, DOI 10.18632/oncotarget.6261; Lee WK., 2021, J CANC METASTASIS TR, V7, P27; Lee WK, 2020, ENDOCR-RELAT CANCER, V27, P209, DOI 10.1530/ERC-19-0482; Lee WK, 2019, EUR J ENDOCRINOL, V181, P139, DOI 10.1530/EJE-18-1025; Lee WK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102867; Li W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065095; Li Z, 2002, CANCER RES, V62, P1939; Lopez-Mateo I, 2020, THYROID, V30, P116, DOI 10.1089/thy.2019.0175; Mabbott NA, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-632; Marlow LA, 2010, J CLIN ENDOCR METAB, V95, P5338, DOI 10.1210/jc.2010-1421; Molinaro E, 2017, NAT REV ENDOCRINOL, V13, P644, DOI 10.1038/nrendo.2017.76; Park JW, 2013, AM J CANCER RES, V3, P302; Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015; Ravi N, 2020, CANCERS, V12, DOI 10.3390/cancers12030680; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Silva JM, 2002, ONCOGENE, V21, P4307, DOI 10.1038/sj.onc.1205534; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smallridge RC, 2012, THYROID, V22, P1104, DOI 10.1089/thy.2012.0302; Smallridge RC, 2012, J CLIN ENDOCR METAB, V97, P2566, DOI 10.1210/jc.2012-1314; Subbiah V, 2018, J CLIN ONCOL, V36, P7, DOI 10.1200/JCO.2017.73.6785; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Tiedje V, 2018, ENDOCR-RELAT CANCER, V25, pR153, DOI 10.1530/ERC-17-0435; Tuttle RM, 2017, THYROID, V27, P751, DOI 10.1089/thy.2017.0102	45	1	1	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2315	2325		10.1038/s41388-022-02242-9	http://dx.doi.org/10.1038/s41388-022-02242-9		MAR 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35256781	Green Accepted			2022-12-17	WOS:000765674100004
J	Wang, CH; Zhang, SS; Ma, BY; Fu, Y; Luo, YZ				Wang, Caihong; Zhang, Shaosen; Ma, Boyuan; Fu, Yan; Luo, Yongzhang			TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression	ONCOGENE			English	Article							RAB-COUPLING PROTEIN; MUTANT P53; CELL; GAIN; INVASION; GENE; ACTIVATION; INTEGRIN	Mutant p53 (mtp53) can exert cancer-promoting activities via "gain-of-function", which has become a popular research target. Although lots of researchers focus on the tumor-suppressor role for p53, the regulation of mutant p53 remains unknown. Here, we report a mechanism by which mtp53 regulate the transcription of Rab coupling protein (RCP) to influence lung cancer behavior. First, we show that RCP is specifically expressed at high levels in lung cancer tissues and cells, and RCP knockout suppresses tumor growth and metastasis. Further mass spectrometry and functional analysis identify that Sp1, Sp3 and Stat3 are the transcriptional activators of RCP. Moreover, p53 is involved in modulating RCP expression in an Sp1/3 dependent manner. Mechanistically, in contrast to wild-type p53 suppression of RCP transcription by decreasing Sp1/3 proteins, TP53 mutations have changed on Sp1/3 expression via "loss-of-function". Surprisingly, the DNA contact mutants of p53 further robustly enhance their binding ability with Sp1/3 to drive RCP expression through the "gain-of-function" activity. Collectively, we reveal a mechanism by which p53 regulating the transcription of RCP to influence lung cancer progression, which provides new insights for treating p53 mutant lung cancer.	[Wang, Caihong] Capital Med Univ, Beijing Friendship Hosp, Beijing Inst Trop Med, Beijing 100050, Peoples R China; [Wang, Caihong; Zhang, Shaosen; Ma, Boyuan; Fu, Yan; Luo, Yongzhang] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China; [Wang, Caihong; Zhang, Shaosen; Ma, Boyuan; Fu, Yan; Luo, Yongzhang] Tsinghua Univ, Natl Engn Res Ctr Prot Technol, Beijing 100084, Peoples R China; [Wang, Caihong; Zhang, Shaosen; Ma, Boyuan; Fu, Yan; Luo, Yongzhang] Tsinghua Univ, Beijing Key Lab Prot Therapeut, Beijing 100084, Peoples R China; [Zhang, Shaosen] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Etiol & Carcinogenesis, Beijing 100021, Peoples R China	Capital Medical University; Tsinghua University; Tsinghua University; Tsinghua University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	Luo, YZ (corresponding author), Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China.; Luo, YZ (corresponding author), Tsinghua Univ, Natl Engn Res Ctr Prot Technol, Beijing 100084, Peoples R China.; Luo, YZ (corresponding author), Tsinghua Univ, Beijing Key Lab Prot Therapeut, Beijing 100084, Peoples R China.	yluo@tsinghua.edu.cn		Zhang, Shaosen/0000-0003-0010-1445	National Natural Science Foundation of China [82103071]; National Major Scientific and Technological Special Project for "Significant New Drugs Development" [20181821569]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Major Scientific and Technological Special Project for "Significant New Drugs Development"	This work was supported by the National Natural Science Foundation of China (No. 82103071 to CW) and the National Major Scientific and Technological Special Project for "Significant New Drugs Development" (No. 20181821569 to YL).	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Balsara BR, 1997, CANCER RES, V57, P2116; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Cho KH, 2019, ARCH PHARM RES, V42, P101, DOI 10.1007/s12272-019-01129-w; Choe SR, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0078-1; Dai YZ, 2012, ONCOL LETT, V3, P1231, DOI 10.3892/ol.2012.652; Donehower LA, 2019, CELL REP, V28, P1370, DOI 10.1016/j.celrep.2019.07.001; Escoll M, 2017, ONCOGENE, V36, P3515, DOI 10.1038/onc.2016.518; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gettinger SN, 2012, J CLIN ONCOL, V30; Ghosh M, 2021, CANCER CELL, V39, P494, DOI 10.1016/j.ccell.2021.01.003; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Gundry C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14646; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hwang CI, 2011, P NATL ACAD SCI USA, V108, P14240, DOI 10.1073/pnas.1017536108; Hwang MH, 2017, ONCOGENE, V36, P1102, DOI 10.1038/onc.2016.277; Jacquemet G, 2013, J CELL BIOL, V202, P917, DOI 10.1083/jcb.201302041; Kim JY, 2020, EXP MOL MED, V52, P1152, DOI 10.1038/s12276-020-0474-1; Kim MP, 2018, CELL DEATH DIFFER, V25, P161, DOI 10.1038/cdd.2017.185; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Kurppa KJ, 2020, CANCER CELL, V37, P104, DOI 10.1016/j.ccell.2019.12.006; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Lindsay AJ, 2017, ONCOTARGET, V8, P104717, DOI 10.18632/oncotarget.10513; Lozano G, 2007, CURR OPIN GENET DEV, V17, P66, DOI 10.1016/j.gde.2006.12.003; Mills GB, 2009, J CLIN INVEST, V119, P2123, DOI 10.1172/JCI40256; Mollaoglu G, 2017, CANCER CELL, V31, P270, DOI 10.1016/j.ccell.2016.12.005; Monteleone E, 2019, CANCERS, V11, DOI 10.3390/cancers11010101; Morello V, 2011, ONCOGENE, V30, P4087, DOI 10.1038/onc.2011.107; Muller PAJ, 2013, ONCOGENE, V32, P1252, DOI 10.1038/onc.2012.148; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Novo D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07339-y; Oduah EI, 2020, CANCER BIOL THER, V21, P293, DOI 10.1080/15384047.2019.1702403; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Phatak V, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03497-y; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Schuette W, 2005, J CLIN ONCOL, V23, P8389, DOI 10.1200/JCO.2005.02.3739; Su HW, 2009, AM J PHYSIOL-CELL PH, V296, pC13, DOI 10.1152/ajpcell.00263.2008; Suske G, 2005, GENOMICS, V85, P551, DOI 10.1016/j.ygeno.2005.01.005; Tang QS, 2021, EMBO REP, V22, DOI 10.15252/embr.201948351; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; van 't Veer LJ, 2008, NATURE, V452, P564, DOI 10.1038/nature06915; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Xu SR, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1442-3; Zhang J, 2019, P NATL ACAD SCI USA, V116, P24259, DOI 10.1073/pnas.1913919116; Zhang JQ, 2009, J CLIN INVEST, V119, P2171, DOI 10.1172/JCI37622; Zhang L, 2010, J BIOL CHEM, V285, P38463, DOI 10.1074/jbc.M110.153999; Zhang SS, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107879; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	54	1	1	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2357	2371		10.1038/s41388-022-02260-7	http://dx.doi.org/10.1038/s41388-022-02260-7		MAR 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35256783				2022-12-17	WOS:000765674100001
J	Wang, H; Zhang, DY; Cui, XX; Dai, YB; Wang, CC; Feng, WL; Lv, XQ; Li, YF; Wang, LN; Ru, YX; Zhang, YC; Ren, Q; Zheng, GG				Wang, Hao; Zhang, Dongyue; Cui, Xiaoxi; Dai, Yibo; Wang, Chenchen; Feng, Wenli; Lv, Xiaoqian; Li, Yifei; Wang, Lina; Ru, Yongxin; Zhang, Yingchi; Ren, Qian; Zheng, Guoguang			Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion	ONCOGENE			English	Article							BLOOD-BRAIN-BARRIER; STEM-CELLS; TRANSCRIPTION FACTORS; BONE METASTASIS; CANCER CELLS; MODEL; ESTABLISHMENT; CHALLENGES; REGULATOR; FAMILY	Interferon regulatory factor 7 (IRF7) is widely studied in inflammatory models. Its effects on malignant progression have been documented mainly from the perspective of the microenvironment. However, its role in leukemia has not been established. Here we used MLL-AF9-induced acute myeloid leukemia (AML) mouse models with IRF7 knockout or overexpression and xenograft mouse models to explore the intrinsic effects of IRF7 in AML. AML-IRF7(-/-) mice exhibited accelerated disease progression with intracerebral invasion of AML cells. AML-IRF7(-/-) cells showed increased proliferation and elevated leukemia stem cell (LSC) levels. Overexpression of IRF7 in AML cells decreased cell proliferation and LSC levels. Furthermore, overexpression of transforming growth-interacting factor 1 (TGIF1) rescued the enhanced proliferation and high LSC levels caused by IRF7 deficiency. Moreover, upregulation of vascular cell adhesion molecule 1 (VCAM1), which correlated with high LSC levels, was detected in AML-IRF7(-/-) cells. In addition, blocking VCAM1-very late antigen 4 (VLA-4) axis delayed disease progression and attenuated intracerebral invasion of AML cells. Therefore, our findings uncover the intrinsic effects of IRF7 in AML and provide a potential strategy to control central nervous system myeloid leukemia.	[Wang, Hao; Zhang, Dongyue; Cui, Xiaoxi; Dai, Yibo; Wang, Chenchen; Feng, Wenli; Lv, Xiaoqian; Li, Yifei; Wang, Lina; Ru, Yongxin; Zhang, Yingchi; Ren, Qian; Zheng, Guoguang] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp,Haihe Lab Cell Ecos, 288 Nanjing Rd, Tianjin 300020, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Peking Union Medical College	Zheng, GG (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp,Haihe Lab Cell Ecos, 288 Nanjing Rd, Tianjin 300020, Peoples R China.	zhengggtjchn@aliyun.com		Wang, Chenchen/0000-0003-3329-0756	National Natural Science Foundation of China (NSFC) [81970155, 82170174, 81770183]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2021-I<INF>2</INF>M-1-041]; Graduate Student Innovation Fund of Peking Union Medical College [2018-0710-08]; New Century Excellent Talents in University [NCET-08-0329]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS); Graduate Student Innovation Fund of Peking Union Medical College; New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET))	This work was supported by grants 81970155, 82170174, and 81770183 from the National Natural Science Foundation of China (NSFC); program 2021-I<INF>2</INF>M-1-041 from the CAMS Innovation Fund for Medical Sciences (CIFMS); and the grant 2018-0710-08 from the Graduate Student Innovation Fund of Peking Union Medical College. Z.GG. is a recipient of the New Century Excellent Talents in University (NCET-08-0329).	Bakst RL, 2011, BLOOD, V118, P3785, DOI 10.1182/blood-2011-04-347229; Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830; Chen XM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12850-x; Chen YY, 2021, STEM CELLS, V39, P183, DOI 10.1002/stem.3308; Chen Z, 2021, ONCOGENE, V40, P3786, DOI 10.1038/s41388-021-01818-1; Chu YJ, 2020, ONCOGENE, V39, P7239, DOI 10.1038/s41388-020-01495-6; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Felix A, 2018, J PEDIAT HEMATOL ONC, V40, P43, DOI 10.1097/MPH.0000000000001034; Feng WL, 2021, HAEMATOLOGICA, V106, P1278, DOI 10.3324/haematol.2019.243360; Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004; Greenwood J, 2011, NEUROPATH APPL NEURO, V37, P24, DOI 10.1111/j.1365-2990.2010.01140.x; Grove RA, 2013, EUR J NEUROL, V20, P1032, DOI 10.1111/ene.12097; Guca E, 2018, NUCLEIC ACIDS RES, V46, P9220, DOI 10.1093/nar/gky680; Hamid R, 2009, MOL ONCOL, V3, P451, DOI 10.1016/j.molonc.2009.07.004; Hayakawa Y, 2015, CANCER CELL, V28, P800, DOI 10.1016/j.ccell.2015.10.003; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hu GH, 2020, CL LYMPH MYELOM LEUK, V20, pE813, DOI 10.1016/j.clml.2020.06.009; Kim TH, 2020, GENES-BASEL, V11, DOI 10.3390/genes11040385; Kinstrie R, 2020, LEUKEMIA, V34, P1613, DOI 10.1038/s41375-019-0684-5; Lan Q, 2019, ONCOGENE, V38, P2814, DOI 10.1038/s41388-018-0624-2; Li DF, 2014, ONCOL REP, V32, P684, DOI 10.3892/or.2014.3254; Li YP, 2015, CELL PROLIFERAT, V48, P643, DOI 10.1111/cpr.12223; Li ZJ, 2006, EUR J HAEMATOL, V77, P128, DOI 10.1111/j.1600-0609.2006.00686.x; Li ZZ, 2017, J CANCER, V8, P207, DOI 10.7150/jca.16415; Litzow MR, 2015, BLOOD, V126, P833, DOI 10.1182/blood-2014-10-551895; Liu YX, 2021, INT J ONCOL, V58, P371, DOI 10.3892/ijo.2021.5180; LYNCH RG, 1975, J NATL CANCER I, V55, P611, DOI 10.1093/jnci/55.3.611; Negishi H, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028423; Parajuli P, 2019, EMBO J, V38, DOI 10.15252/embj.2018101067; Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925; Puhalla S, 2015, NEURO-ONCOLOGY, V17, P639, DOI 10.1093/neuonc/nov023; Pui CH, 2008, LANCET ONCOL, V9, P257, DOI 10.1016/S1470-2045(08)70070-6; Ransohoff RM, 2003, NAT REV IMMUNOL, V3, P569, DOI 10.1038/nri1130; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Si MY, 2018, CANCER MANAG RES, V10, P305, DOI 10.2147/CMAR.S152419; Soto MS, 2014, NEURO-ONCOLOGY, V16, P541, DOI 10.1093/neuonc/not222; Takeshita Y, 2012, IMMUNOL REV, V248, P228, DOI 10.1111/j.1600-065X.2012.01127.x; Tamura T, 2008, ANNU REV IMMUNOL, V26, P535, DOI 10.1146/annurev.immunol.26.021607.090400; Wang DY, 2020, STEM CELL REP, V14, P1093, DOI 10.1016/j.stemcr.2020.05.012; Wang R, 2020, CANCER LETT, V469, P151, DOI 10.1016/j.canlet.2019.10.032; Willer A, 2015, LEUKEMIA, V29, P1018, DOI 10.1038/leu.2014.307; Wu MH, 2019, ANN RHEUM DIS, V78, P1583, DOI 10.1136/annrheumdis-2019-215208; Yan L, 2020, J CELL MOL MED, V24, P13472, DOI 10.1111/jcmm.15977; Yan L, 2013, MOL CELL BIOL, V33, P4824, DOI 10.1128/MCB.01076-13; Yanai H, 2012, ONCOIMMUNOLOGY, V1, P1376, DOI 10.4161/onci.22475; Yang Q, 2017, ONCOGENE, V36, P2969, DOI 10.1038/onc.2016.448; Yang X, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412910; Yu X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07384-7; Zhao Y, 2017, ONCOL RES, V25, P511, DOI 10.3727/096504016X14756226781802; Zhou XX, 2015, BLOOD, V126, P1433, DOI 10.1182/blood-2015-01-624833; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845	51	1	1	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2022	41	16					2303	2314		10.1038/s41388-022-02233-w	http://dx.doi.org/10.1038/s41388-022-02233-w		MAR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0N1NW	35256780	Green Published, hybrid			2022-12-17	WOS:000765674100002
J	Baumer, N; Tiemann, J; Scheller, A; Meyer, T; Wittmann, L; Suburu, MEG; Greune, L; Peipp, M; Kellmann, N; Gumnior, A; Brand, C; Hartmann, W; Rossig, C; Muller-Tidow, C; Neri, D; Strassert, CA; Ruter, C; Dersch, P; Lenz, G; Koeffler, HP; Berdel, WE; Baumer, S				Baeumer, Nicole; Tiemann, Jessica; Scheller, Annika; Meyer, Theresa; Wittmann, Lisa; Suburu, Matias Ezequiel Gutierrez; Greune, Lilo; Peipp, Matthias; Kellmann, Neele; Gumnior, Annika; Brand, Caroline; Hartmann, Wolfgang; Rossig, Claudia; Muller-Tidow, Carsten; Neri, Dario; Strassert, Cristian A.; Rueter, Christian; Dersch, Petra; Lenz, Georg; Koeffler, H. Phillip; Berdel, Wolfgang E.; Baeumer, Sebastian			Targeted siRNA nanocarrier: a platform technology for cancer treatment	ONCOGENE			English	Article							SMALL INTERFERING RNAS; PROTAMINE; DELIVERY; AGGREGATION; RESISTANCE; DRUGS	The small arginine-rich protein protamine condenses complete genomic DNA into the sperm head. Here, we applied its high RNA binding capacity for spontaneous electrostatic assembly of therapeutic nanoparticles decorated with tumour-cell-specific antibodies for efficiently targeting siRNA. Fluorescence microscopy and DLS measurements of these nanocarriers revealed the formation of a vesicular architecture that requires presence of antibody-protamine, defined excess of free SMCC-protamine, and anionic siRNA to form. Only these complex nanoparticles were efficient in the treatment of non-small-cell lung cancer (NSCLC) xenograft models, when the oncogene KRAS was targeted via EGFR-mediated delivery. To show general applicability, we used the modular platform for IGF1R-positive Ewing sarcomas. Anti-IGR1R-antibodies were integrated into an antibody-protamine nanoparticle with an siRNA specifically against the oncogenic translocation product EWS/FLI1. Using these nanoparticles, EWS/FLI1 knockdown blocked in vitro and in vivo growth of Ewing sarcoma cells. We conclude that these antibody-protamine-siRNA nanocarriers provide a novel platform technology to specifically target different cell types and yet undruggable targets in cancer therapy by RNAi.	[Baeumer, Nicole; Tiemann, Jessica; Scheller, Annika; Wittmann, Lisa; Kellmann, Neele; Gumnior, Annika; Brand, Caroline; Lenz, Georg; Berdel, Wolfgang E.; Baeumer, Sebastian] Univ Munster, Dept Med A, Hematol Oncol, Munster, Germany; [Meyer, Theresa; Greune, Lilo; Rueter, Christian; Dersch, Petra] Univ Munster, Ctr Mol Biol Inflammat ZMBE, Inst Infectiol, Munster, Germany; [Suburu, Matias Ezequiel Gutierrez; Strassert, Cristian A.] Univ Munster, Inst Inorgan & Analyt Chem, Munster, Germany; [Peipp, Matthias] Univ Kiel, Div Stem Cell Transplantat & Immunotherapy, Kiel, Germany; [Hartmann, Wolfgang] Univ Munster, Gerhard Domagk Inst Pathol, Munster, Germany; [Rossig, Claudia] Univ Childrens Hosp Munster, Dept Pediat Hematol & Oncol, Munster, Germany; [Muller-Tidow, Carsten] Heidelberg Univ, Dept Med 5, Heidelberg, Germany; [Neri, Dario] Swiss Fed Inst Technol, Inst Pharmaceut Sci, Zurich, Switzerland; [Koeffler, H. Phillip] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA	University of Munster; University of Munster; University of Munster; University of Kiel; University of Munster; University of Munster; Ruprecht Karls University Heidelberg; Swiss Federal Institutes of Technology Domain; ETH Zurich; Cedars Sinai Medical Center; University of California System; University of California Los Angeles	Baumer, S (corresponding author), Univ Munster, Dept Med A, Hematol Oncol, Munster, Germany.	baumers@uni-muenster.de	Baeumer, Sebastian/GYU-0544-2022; Peipp, Matthias/A-8775-2013	Tiemann, Jessica/0000-0002-1804-0348; Meyer, Theresa/0000-0001-7748-9084; Gutierrez Suburu, Matias Ezequiel/0000-0002-9133-3614	Deutsche Krebshilfe [70112282]; Wilhelm Sander-Stiftung [2014.054.1, 2017.071.1]; Innovative Medical Research of the University of Munster Medical School [111418, 211502, 121314, 111501, 121802]; Cedars-Sinai Cancer (CSC) Developmental Funds; Deutsche Forschungsgemeinschaft [6103/3-1, DFG CRC1009B03, DFG EXC1003]; Interdisciplinary Centre for Clinical Research (IZKF Munster) [Bau2/009/19]; Sanford Burnham Prebys (SBP) Cancer Center	Deutsche Krebshilfe(Deutsche Krebshilfe); Wilhelm Sander-Stiftung; Innovative Medical Research of the University of Munster Medical School; Cedars-Sinai Cancer (CSC) Developmental Funds; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Interdisciplinary Centre for Clinical Research (IZKF Munster); Sanford Burnham Prebys (SBP) Cancer Center	We thank Annette Westermann and Mara Apel for excellent technical support. This study was funded by Deutsche Krebshilfe (No. 70112282, NB and SB), Wilhelm Sander-Stiftung (2014.054.1 and 2017.071.1, WEB and SB), Innovative Medical Research of the University of Munster Medical School (111418, SB; 211502, SB; 121314, NB; 111501 and 121802, SB and NB), Sanford Burnham Prebys (SBP) Cancer Center and Cedars-Sinai Cancer (CSC) Developmental Funds to HPK, and Deutsche Forschungsgemeinschaft (DFG EXC1003, WEB and GL; 6103/3-1, SB; DFG CRC1009B03, CR). SB and NB gratefully acknowledge the Interdisciplinary Centre for Clinical Research (IZKF Munster, Bau2/009/19).	Baumer N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200163; Baumer N, 2016, NAT PROTOC, V11, P22, DOI 10.1038/nprot.2015.137; Baumer S, 2015, CLIN CANCER RES, V21, P1383, DOI 10.1158/1078-0432.CCR-13-2017; Balhorn R, 2000, MOL REPROD DEV, V56, P230, DOI 10.1002/(SICI)1098-2795(200006)56:2+<230::AID-MRD3>3.3.CO;2-M; Carr JA, 1999, J CARDIOVASC SURG, V40, P659; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Delgado D, 2011, EUR J PHARM BIOPHARM, V79, P495, DOI 10.1016/j.ejpb.2011.06.005; Dohjima T, 2003, MOL THER, V7, P811, DOI 10.1016/S1525-0016(03)00101-1; Dolgin E, 2020, NAT BIOTECHNOL, V38, P385, DOI 10.1038/s41587-020-0481-8; Doody JF, 2007, MOL CANCER THER, V6, P2642, DOI 10.1158/1535-7163.MCT-06-0506; Einstein A, 1905, ANN PHYS-BERLIN, V17, P549, DOI 10.1002/andp.19053220806; HED J, 1987, J IMMUNOL METHODS, V101, P119, DOI 10.1016/0022-1759(87)90224-9; Ladenstein R, 2010, J CLIN ONCOL, V28, P3284, DOI 10.1200/JCO.2009.22.9864; Mochizuki T, 1998, ANESTH ANALG, V87, P781, DOI 10.1097/00000539-199810000-00008; Naing A, 2012, CLIN CANCER RES, V18, P2625, DOI 10.1158/1078-0432.CCR-12-0061; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; ROSSMANN P, 1982, VIRCHOWS ARCH B, V40, P81, DOI 10.1007/BF02932853; Rotow J, 2017, NAT REV CANCER, V17, P637, DOI 10.1038/nrc.2017.84; SMULL CE, 1962, J BACTERIOL, V84, P1035, DOI 10.1128/JB.84.5.1035-1040.1962; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Vasimalai N, 2013, J MATER CHEM B, V1, P5620, DOI 10.1039/c3tb20991a; Wang MN, 2021, NAT MED, V27, P1345, DOI 10.1038/s41591-021-01450-2; Yoo H, 2015, ARCH PHARM RES, V38, P129, DOI 10.1007/s12272-014-0359-8	23	1	1	8	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2210	2224		10.1038/s41388-022-02241-w	http://dx.doi.org/10.1038/s41388-022-02241-w		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35220407	hybrid, Green Published			2022-12-17	WOS:000761831800001
J	Landras, A; de Moura, CR; Villoutreix, BO; Battistella, M; Sadoux, A; Dumaz, N; Menashi, S; Fernandez-Recio, J; Lebbe, C; Mourah, S				Landras, Alexandra; de Moura, Coralie Reger; Villoutreix, Bruno O.; Battistella, Maxime; Sadoux, Aurelie; Dumaz, Nicolas; Menashi, Suzanne; Fernandez-Recio, Juan; Lebbe, Celeste; Mourah, Samia			Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction	ONCOGENE			English	Article							METASTATIC MELANOMA; GROWTH-FACTOR; OPEN-LABEL; PHASE-II; MEK INHIBITORS; BRAF; STAT3; MULTICENTER; BIOMARKER; SURVIVAL	More than 70% of human NRAS(mut) melanomas are resistant to MEK inhibitors highlighting the crucial need for efficient therapeutic strategies for these tumors. CD147, a membrane receptor, is overexpressed in most cancers including melanoma and is associated with poor prognosis. We show here that CD147i, a specific inhibitor of CD147/VEGFR-2 interaction represents a potential therapeutic strategy for NRAS(mut) melanoma cells. It significantly inhibited the malignant properties of NRAS(mut) melanomas ex vivo and in vivo. Importantly, NRAS(mut) patient's-derived xenografts, which were resistant to MEKi, became sensitive when combined with CD147i leading to decreased proliferation ex vivo and tumor regression in vivo. Mechanistic studies revealed that CD147i effects were mediated through STAT3 pathway. These data bring a proof of concept on the impact of the inhibition of CD147/VEGFR-2 interaction on melanoma progression and represents a new therapeutic opportunity for NRAS(mut) melanoma when combined with MEKi.	[Landras, Alexandra; de Moura, Coralie Reger; Battistella, Maxime; Dumaz, Nicolas; Lebbe, Celeste; Mourah, Samia] Univ Paris, UMR S976, INSERM, F-75010 Paris, France; [de Moura, Coralie Reger; Sadoux, Aurelie; Menashi, Suzanne; Mourah, Samia] Hop St Louis, AP HP, Pharmacogen Dept, F-75010 Paris, France; [Villoutreix, Bruno O.] Hop Robert Debre, UMR S1141, INSERM, F-75019 Paris, France; [Battistella, Maxime] Hop St Louis, AP HP, Pathol Dept, F-75010 Paris, France; [Fernandez-Recio, Juan] Univ La Rioja, Inst Ciencias & Vino ICVV, CSIC, Gobierno La Rioja, Logrono, Spain; [Lebbe, Celeste] Hop St Louis, AP HP, Dermatol Dept, F-75010 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de La Rioja; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Mourah, S (corresponding author), Univ Paris, UMR S976, INSERM, F-75010 Paris, France.; Mourah, S (corresponding author), Hop St Louis, AP HP, Pharmacogen Dept, F-75010 Paris, France.	samia.mourah@aphp.fr	Landras, Alexandra/GNP-5158-2022; Battistella, Maxime/K-2949-2012; Dumaz, Nicolas/B-5907-2008	Battistella, Maxime/0000-0002-7053-7431; Reger de Moura, Coralie/0000-0002-3728-6722; Dumaz, Nicolas/0000-0003-3511-2160; Mourah, Samia/0000-0002-9283-1068; Villoutreix, Bruno/0000-0002-6456-7730	La Ligue Nationale contre le Cancer; Institut National de la Sante et de la Recherche Medicale (INSERM); La Societe Francaise de Dermatologie; Spanish Ministry of Science and Innovation [PID2019-110167RB-I00]; Ligue Nationale contre le Cancer	La Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); La Societe Francaise de Dermatologie; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	This work was supported by La Ligue Nationale contre le Cancer, the Institut National de la Sante et de la Recherche Medicale (INSERM) and La Societe Francaise de Dermatologie. AL was supported by a PhD funding from La Ligue Nationale contre le Cancer and the Spanish Ministry of Science and Innovation (PID2019-110167RB-I00). We thank technological platform of the Institut Recherche Saint-Louis (IRSL) for confocal microscopy analyses and Dr Benoit Souquet for technical support.	Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Ascierto PA, 2013, LANCET ONCOL, V14, P249, DOI 10.1016/S1470-2045(13)70024-X; Boespflug A, 2017, THER ADV MED ONCOL, V9, P481, DOI 10.1177/1758834017708160; Bougatef F, 2009, BLOOD, V114, P5547, DOI 10.1182/blood-2009-04-217380; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Caudron A, 2016, EXP DERMATOL, V25, P618, DOI 10.1111/exd.13022; Chapman PB, 2017, ANN ONCOL, V28, P2581, DOI 10.1093/annonc/mdx339; Chen SH, 2008, CANCER BIOL THER, V7, P1994, DOI 10.4161/cbt.7.12.6967; Davis EJ, 2018, CANCER-AM CANCER SOC, V124, P3490, DOI 10.1002/cncr.31345; de Moura CR, 2020, TRANSL ONCOL, V13, P275, DOI 10.1016/j.tranon.2019.10.003; Decoster L, 2015, ANTICANCER RES, V35, P6893; Delord JP, 2017, CLIN CANCER RES, V23, P5339, DOI 10.1158/1078-0432.CCR-16-2923; Delyon J, 2018, J INVEST DERMATOL, V138, P58, DOI 10.1016/j.jid.2017.07.839; Delyon J, 2016, ONCOTARGET, V7, P13069, DOI 10.18632/oncotarget.7541; Dummer R, 2017, LANCET ONCOL, V18, P435, DOI 10.1016/S1470-2045(17)30180-8; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Echevarria-Vargas IM, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708446; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Favier B, 2006, BLOOD, V108, P1243, DOI 10.1182/blood-2005-11-4447; Fedorenko IV, 2013, ONCOGENE, V32, P3009, DOI 10.1038/onc.2012.453; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Fu ZG, 2016, ONCOTARGET, V7, P9430, DOI 10.18632/oncotarget.6990; Graells J, 2004, J INVEST DERMATOL, V123, P1151, DOI 10.1111/j.0022-202X.2004.23460.x; Grass GD, 2013, J BIOL CHEM, V288, P26089, DOI 10.1074/jbc.M113.497685; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hayes TK, 2019, CANCER RES, V79, P2352, DOI 10.1158/0008-5472.CAN-18-2711; Hillion J, 2008, CANCER RES, V68, P10121, DOI 10.1158/0008-5472.CAN-08-2121; Ivy SP, 2009, NAT REV CLIN ONCOL, V6, P569, DOI 10.1038/nrclinonc.2009.130; Jiang TX, 2012, BLOOD, V120, P2330, DOI 10.1182/blood-2012-01-406108; Jouve N, 2015, INT J CANCER, V137, P50, DOI 10.1002/ijc.29370; Khayati F, 2015, ONCOTARGET, V6, P9766, DOI 10.18632/oncotarget.2870; Kim J, 2020, CANCERS, V12, DOI 10.3390/cancers12010119; Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9; Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502; Landras A, 2019, CANCERS, V11, DOI 10.3390/cancers11111803; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Lebbe C, 2020, CANCERS, V12, DOI 10.3390/cancers12071727; LOCKSHIN A, 1985, CANCER RES, V45, P345; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Mahapatra DK, 2017, EXPERT OPIN THER PAT, V27, P887, DOI 10.1080/13543776.2017.1339688; Mandala M, 2014, CRIT REV ONCOL HEMAT, V92, P107, DOI 10.1016/j.critrevonc.2014.05.005; Munoz-Couselo E, 2017, ONCOTARGETS THER, V10, P3941, DOI 10.2147/OTT.S117121; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Oladipupo SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33037-2; Posch C, 2013, P NATL ACAD SCI USA, V110, P4015, DOI 10.1073/pnas.1216013110; Robinson JP, 2017, MELANOMA RES, V27, P545, DOI 10.1097/CMR.0000000000000403; Sarkisian S, 2018, DRUG DES DEV THER, V12, P2553, DOI 10.2147/DDDT.S131721; Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010; Tang Y, 2005, CANCER RES, V65, P3193, DOI 10.1158/0008-5472.CAN-04-3605; Tremmel M, 2009, BLOOD, V114, P5236, DOI 10.1182/blood-2009-04-219204; Trojaniello C, 2019, EXPERT REV CLIN PHAR, V12, P259, DOI 10.1080/17512433.2019.1570847; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wu PK, 2015, SEMIN ONCOL, V42, P849, DOI 10.1053/j.seminoncol.2015.09.023; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818	54	1	1	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2254	2264		10.1038/s41388-022-02244-7	http://dx.doi.org/10.1038/s41388-022-02244-7		FEB 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35217792				2022-12-17	WOS:000761868000002
J	Yoshida, A; Phillips-Mason, P; Tarallo, V; Avril, S; Koivisto, C; Leone, G; Diehl, JA				Yoshida, Akihiro; Phillips-Mason, Polly; Tarallo, Vincenzo; Avril, Stefanie; Koivisto, Christopher; Leone, Gustavo; Diehl, J. Alan			Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss	ONCOGENE			English	Article							KAPPA-B; PROTEOLYSIS; CANCER; PRMT5; EXPRESSION; SUBUNIT; MTOR	Cyclin D1 is a regulatory subunit of -Cyclin Dependent Kinases 4 and 6 (CDK4/6) and regulates progression from G1 to S phase of the cell cycle. Dysregulated cyclin D1-CDK4/6 contributes to abnormal cell proliferation and tumor development. Phosphorylation of threonine 286 of cyclin D1 is necessary for ubiquitin-dependent degradation. Non-phosphorylatable cyclin D1 mutants are stabilized and concentrated in the nucleus, contributing to genomic instability and tumor development. Studies investigating the tumor-promoting functions of cyclin D1 mutants have focused on the use of artificial promoters to drive the expression which unfortunately may not accurately reflect tumorigenic functions of mutant cyclin D1 in cancer development. We have generated a conditional knock-in mouse model where cyclin D1T286A is expressed under the control of its endogenous promoter following Cre-dependent excision of a lox-stop-lox sequence. Acute expression of cyclin D1T286A following tamoxifen-inducible Cre recombinase triggers inflammation, lymphocyte abnormality and ultimately mesenteric tumors in the intestine. Tissue-specific expression of cyclin D1T286A in the uterus and endometrium cooperates with Pten loss to drive endometrial hyperplasia and cancer. Mechanistically, cyclin D1T286A mutant activates NF-kappa B signaling, augments inflammation, and contributes to tumor development. These results indicate that mutation of cyclin D1 at threonine 286 has a critical role in regulating inflammation and tumor development.	[Yoshida, Akihiro] Univ Hosp Cleveland, Dept Dermatol, Med Ctr, Cleveland, OH 44106 USA; [Yoshida, Akihiro; Avril, Stefanie] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Yoshida, Akihiro; Phillips-Mason, Polly; Tarallo, Vincenzo; Diehl, J. Alan] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; [Yoshida, Akihiro; Avril, Stefanie; Diehl, J. Alan] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Avril, Stefanie] Univ Hosp Cleveland, Dept Pathol, Med Ctr, Cleveland, OH 44106 USA; [Koivisto, Christopher] Med Univ South Carolina, Dept Biochem, Charleston, SC 29425 USA; [Leone, Gustavo] Med Coll Wisconsin, Canc Ctr, Dept Biochem, Wauwatosa, WI 53226 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Medical University of South Carolina; Medical College of Wisconsin	Yoshida, A (corresponding author), Univ Hosp Cleveland, Dept Dermatol, Med Ctr, Cleveland, OH 44106 USA.; Yoshida, A (corresponding author), Case Western Reserve Univ, Cleveland, OH 44106 USA.; Yoshida, A; Diehl, JA (corresponding author), Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA.; Yoshida, A; Diehl, JA (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.	axy234@case.edu; jad283@case.edu		Tarallo, Vincenzo/0000-0001-8158-1326; , J. Alan/0000-0001-9854-5049; Yoshida, Akihiro/0000-0002-9785-9035	National Cancer Institute [R01 CA093237, P01 CA098101, R01 CA121275]; Advancing a Healthier Wisconsin Endowment Award	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Advancing a Healthier Wisconsin Endowment Award	This work was supported by grants from National Cancer Institute: R01 CA093237 and P01 CA098101 (JAD); R01 CA121275 and Advancing a Healthier Wisconsin Endowment Award (GL).	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Caserta E, 2015, GENE DEV, V29, P1707, DOI 10.1101/gad.262568.115; Contreras CM, 2010, DIS MODEL MECH, V3, P181, DOI 10.1242/dmm.004440; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Gladden AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147; GU L, 2004, BLOOD, V104, P4438, DOI DOI 10.1182/BLOOD.V104.11.4438.4438; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Kwon HJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11686; Li Y, 2015, CANCER DISCOV, V5, P288, DOI 10.1158/2159-8290.CD-14-0625; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Masclef L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00106; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Pontano LL, 2008, MOL CELL BIOL, V28, P7245, DOI 10.1128/MCB.01085-08; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Tian YQ, 2019, AGING CELL, V18, DOI 10.1111/acel.12858; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Wei H, 2013, P NATL ACAD SCI USA, V110, P13516, DOI 10.1073/pnas.1311784110; Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105	30	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2187	2195		10.1038/s41388-022-02243-8	http://dx.doi.org/10.1038/s41388-022-02243-8		FEB 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35210557				2022-12-17	WOS:000761270800001
J	Humbert, PO; Pryjda, TZ; Pranjic, B; Farrell, A; Fujikura, K; Simoes, RD; Karim, R; Kozieradzki, I; Cronin, SJF; Neely, GG; Meyer, TF; Hagelkruys, A; Richardson, HE; Penninger, JM				Humbert, Patrick O.; Pryjda, Tamara Zoranovic; Pranjic, Blanka; Farrell, Andrew; Fujikura, Kohei; de Matos Simoes, Ricardo; Karim, Rezaul; Kozieradzki, Ivona; Cronin, Shane J. F.; Neely, G. Gregory; Meyer, Thomas F.; Hagelkruys, Astrid; Richardson, Helena E.; Penninger, Josef M.			TSPAN6 is a suppressor of Ras-driven cancer	ONCOGENE			English	Article							CELL POLARITY; EXPRESSION; TETRASPANINS; ACTIVATION; MUTATIONS; JUNCTIONS; RESPONSES; INVASION; MODULE; GROWTH	Oncogenic mutations in the small GTPase RAS contribute to similar to 30% of human cancers. In a Drosophila genetic screen, we identified novel and evolutionary conserved cancer genes that affect Ras-driven tumorigenesis and metastasis in Drosophila including confirmation of the tetraspanin Tsp29Fb. However, it was not known whether the mammalian Tsp29Fb orthologue, TSPAN6, has any role in RAS-driven human epithelial tumors. Here we show that TSPAN6 suppressed tumor growth and metastatic dissemination of human RAS activating mutant pancreatic cancer xenografts. Whole-body knockout as well as tumor cell autonomous inactivation using floxed alleles of Tspan6 in mice enhanced Kras(G12D)-driven lung tumor initiation and malignant progression. Mechanistically, TSPAN6 binds to the EGFR and blocks EGFR-induced RAS activation. Moreover, we show that inactivation of TSPAN6 induces an epithelial-to-mesenchymal transition and inhibits cell migration in vitro and in vivo. Finally, low TSPAN6 expression correlates with poor prognosis of patients with lung and pancreatic cancers with mesenchymal morphology. Our results uncover TSPAN6 as a novel tumor suppressor receptor that controls epithelial cell identify and restrains RAS-driven epithelial cancer.	[Humbert, Patrick O.; Farrell, Andrew; Richardson, Helena E.] La Trobe Univ, Sch Mol Sci, Dept Biochem Genet, Bundoora, Vic 3086, Australia; [Humbert, Patrick O.; Pryjda, Tamara Zoranovic; Pranjic, Blanka; Karim, Rezaul; Kozieradzki, Ivona; Cronin, Shane J. F.; Neely, G. Gregory; Hagelkruys, Astrid; Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohrgasse 3, A-1030 Vienna, Austria; [Pryjda, Tamara Zoranovic; Meyer, Thomas F.] Max Planck Inst Infect Biol, Charite Pl 1, D-10117 Berlin, Germany; [Fujikura, Kohei; Kozieradzki, Ivona; Penninger, Josef M.] Univ British Columbia, Inst Life Sci, Dept Med Genet, Vancouver, BC, Canada; [de Matos Simoes, Ricardo] Ctr Integrat Bioinformat Vienna, Max F Perusetz Labs, Dr Bohr Gasse 9-6, A-1030 Vienna, Austria; [Neely, G. Gregory] Univ Sydney, Sch Life & Environm Sci, Dr John & Anne Chong Lab Funct Genom, Charles Perkins Ctr, Sydney, NSW 2006, Australia; [Meyer, Thomas F.] Christian Albrechts Univ Kiel, Inst Clin Mol Biol, Lab Infect Oncol, Kiel, Germany; [Pryjda, Tamara Zoranovic; Pranjic, Blanka] Univ Hosp Schleswig Holstein Campus Kiel, Kiel, Germany	La Trobe University; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Max Planck Society; University of British Columbia; University of Sydney; University of Kiel; University of Kiel; Schleswig Holstein University Hospital	Humbert, PO; Richardson, HE (corresponding author), La Trobe Univ, Sch Mol Sci, Dept Biochem Genet, Bundoora, Vic 3086, Australia.; Humbert, PO; Penninger, JM (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohrgasse 3, A-1030 Vienna, Austria.; Penninger, JM (corresponding author), Univ British Columbia, Inst Life Sci, Dept Med Genet, Vancouver, BC, Canada.	P.Humbert@latrobe.edu.au; H.Richardson@latrobe.edu.au; josef.penninger@ubc.ca	; Humbert, Patrick/L-4264-2016; Penninger, Josef/I-6860-2013	zoranovic, tamara/0000-0002-5369-6385; Humbert, Patrick/0000-0002-1366-6691; Penninger, Josef/0000-0002-8194-3777	IMBA; ERC Advanced Investigator grant; Era of Hope; T. von Zastrow foundation; Canada 150 Chair in Functional Genetics; Marie Curie Excellence grant; Infla-Care grant; Infect-ERA grant; Invest [RD0412515]; Cancer Council Victoria (Australia); National Health & Medical Research Council (NHMRC), Australia; La Trobe University	IMBA; ERC Advanced Investigator grant; Era of Hope; T. von Zastrow foundation; Canada 150 Chair in Functional Genetics; Marie Curie Excellence grant(European Commission); Infla-Care grant; Infect-ERA grant; Invest; Cancer Council Victoria (Australia)(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); National Health & Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); La Trobe University	We thank all members of our laboratories for helpful discussions as well as VDRC and IMP/IMBA core facilities for excellent technical support. We also acknowledge Life Science Editors for editorial support (www.lifescienceeditors.com).JMP was supported by IMBA, ERC Advanced Investigator grant, an Innovator Award from Era of Hope, the T. von Zastrow foundation, and a Canada 150 Chair in Functional Genetics. TZP was supported by a Marie Curie Excellence grant. RK was supported by Infla-Care and Infect-ERA grants. RdMS was supported by a grant from Invest NI RD0412515. AF was supported from funds from the Cancer Council Victoria (Australia) to HER, POH, and JMP. HER and POH were supported by fellowships from the National Health & Medical Research Council (NHMRC), Australia, and by funds from La Trobe University.	Andrijes R, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2011411118; Aubrey BJ, 2018, CELL DEATH DIFFER, V25, P104, DOI 10.1038/cdd.2017.169; Balagurunathan Y, 2008, MOL CANCER THER, V7, P3071, DOI 10.1158/1535-7163.MCT-08-0402; Bar-Sagi D, 1992, Semin Cell Biol, V3, P93; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Caddy J, 2010, DEV CELL, V19, P138, DOI 10.1016/j.devcel.2010.06.008; Charrin S, 2014, J CELL SCI, V127, P3641, DOI 10.1242/jcs.154906; Chen JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026104; Chen SJ, 2019, CURR PHARM DESIGN, V25, P1105, DOI 10.2174/1381612825666190506122228; Cho JH, 2020, CELL DEATH DIFFER, V27, P2681, DOI 10.1038/s41418-020-0537-9; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; DeNicola Gina M, 2009, Eur J Cancer, V45 Suppl 1, P211, DOI 10.1016/S0959-8049(09)70036-X; DiMauro T, 2010, CURR CANCER DRUG TAR, V10, P869, DOI 10.2174/156800910793357998; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Elsum I, 2012, ESSAYS BIOCHEM, V53, P141, DOI [10.1042/BSE0530141, 10.1042/bse0530141]; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Fox RM, 2015, BIOL OPEN, V4, P317, DOI 10.1242/bio.201411205; Garcia-Espana A, 2008, GENOMICS, V91, P326, DOI 10.1016/j.ygeno.2007.12.005; Hemler ME, 2014, NAT REV CANCER, V14, P49, DOI 10.1038/nrc3640; Hobbs GA, 2016, J CELL SCI, V129, P1287, DOI 10.1242/jcs.182873; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Kummer D, 2020, MED MICROBIOL IMMUN, V209, P397, DOI 10.1007/s00430-020-00673-3; Kuner R, 2009, LUNG CANCER, V63, P32, DOI 10.1016/j.lungcan.2008.03.033; La Marca JE, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00042; Lang T, 2020, CURR BIOL, V30, pR204, DOI 10.1016/j.cub.2020.01.007; Leong GR, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-62; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Rizzotto D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910883; Rubinstein E, 2011, BIOCHEM SOC T, V39, P501, DOI 10.1042/BST0390501; Sacco E, 2012, EXPERT OPIN THER PAT, V22, P1263, DOI 10.1517/13543776.2012.728586; Schramek D, 2011, TRENDS ENDOCRIN MET, V22, P188, DOI 10.1016/j.tem.2011.02.007; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Stephens R, 2018, J MOL BIOL, V430, P3585, DOI 10.1016/j.jmb.2018.01.011; Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208; Tepass U, 2012, ANNU REV CELL DEV BI, V28, P655, DOI 10.1146/annurev-cellbio-092910-154033; Termini CM, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00034; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Xu CW, 2019, CELL REP, V26, P670, DOI 10.1016/j.celrep.2018.12.079; Yamamoto M, 2017, NATURE, V542, P246, DOI 10.1038/nature21033; Yanez-Mo M, 2009, TRENDS CELL BIOL, V19, P434, DOI 10.1016/j.tcb.2009.06.004; Young A, 2009, ADV CANCER RES, V102, P1, DOI 10.1016/S0065-230X(09)02001-6; Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543; Zoranovic T, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007688	51	1	1	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2095	2105		10.1038/s41388-022-02223-y	http://dx.doi.org/10.1038/s41388-022-02223-y		FEB 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35184157	Green Published, hybrid			2022-12-17	WOS:000757918900001
J	Qiao, GL; Kone, LB; Phillips, EH; Lee, SSY; Brown, GE; Khetani, SR; Thakur, A; Lum, LG; Prabhakar, BS; Maker, AV				Qiao, Guilin; Kone, Lyonell B.; Phillips, Evan H.; Lee, Steve Seung-Young; Brown, Grace E.; Khetani, Salman R.; Thakur, Archana; Lum, Lawrence G.; Prabhakar, Bellur S.; Maker, Ajay, V			LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer	ONCOGENE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; COLORECTAL-CANCER; PROGNOSTIC-FACTOR; CYTOLYTIC ACTIVITY; IMMUNE CELLS; HIGH-RISK; SURVIVAL; ERADICATION; METASTASIS; BLOCKADE	Increased tumor infiltrating lymphocytes (TIL) are associated with improved patient responses to immunotherapy. As a result, there is interest in enhancing lymphocyte trafficking particularly to colon cancers since the majority are checkpoint blockade-resistant and microsatellite stable. Here, we demonstrate that activated T-cells (ATC) armed with anti-CD3 x anti-EGFR bispecific antibody increases TIL and mediate anti-tumor cytotoxicity while decreasing tumor cell viability. Furthermore, treatment induces endogenous anti-tumor immunity that resisted tumor rechallenge and increased memory T-cell subsets in the tumor. When combined with targeted tumor expression of the tumor necrosis factor superfamily member LIGHT, activated T-cell proliferation and infiltration were further enhanced, and human colorectal tumor regressions were observed. Our data indicate that tumor-targeted armed bispecific antibody increases TIL trafficking and is a potentially potent strategy that can be paired with combination immunotherapy to battle microsatellite stable colon cancer. Significance Enhancing trafficking of tumor infiltrating lymphocytes (TILs) to solid tumors has been shown to improve outcomes. Unfortunately, few strategies have been successful in the clinical setting for solid tumors, particularly for "cold" microsatellite stable colon cancers. In order to address this gap in knowledge, this study combined TNFSF14/LIGHT immunomodulation with a bispecific antibody armed with activated T-cells targeted to the tumor. This unique T-cell trafficking strategy successfully generated anti-tumor immunity in a microsatellite stable colon cancer model, stimulated T-cell infiltration, and holds promise as a combination immunotherapy for treating advanced and metastatic colorectal cancer.	[Qiao, Guilin; Maker, Ajay, V] Univ Calif San Francisco, Dept Surg, Div Surg Oncol, San Francisco, CA 94143 USA; [Kone, Lyonell B.; Maker, Ajay, V] Univ Illinois, Coll Med, Dept Surg, Div Surg Oncol, Chicago, IL 60612 USA; [Phillips, Evan H.; Lee, Steve Seung-Young] Univ Illinois, Coll Pharm, Dept Pharmaceut Sci, Chicago, IL 60612 USA; [Brown, Grace E.; Khetani, Salman R.] Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA; [Thakur, Archana; Lum, Lawrence G.] Univ Virginia, Dept Med, Div Hematol Oncol, Canc Ctr, Charlottesville, VA USA; [Prabhakar, Bellur S.; Maker, Ajay, V] Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of California System; University of California San Francisco; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Virginia; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Maker, AV (corresponding author), Univ Calif San Francisco, Dept Surg, Div Surg Oncol, San Francisco, CA 94143 USA.; Maker, AV (corresponding author), Univ Illinois, Coll Med, Dept Surg, Div Surg Oncol, Chicago, IL 60612 USA.; Maker, AV (corresponding author), Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA.	Ajay.Maker@ucsf.edu		Prabhakar, Bellur S./0000-0001-9815-9850	 [R37CA238435];  [K08CA190855];  [R00EB022636];  [R01CA140314];  [R01CA092344];  [P30CA044579]	; ; ; ; ; 	R37CA238435 (AVM), K08CA190855 (AVM); R00EB022636 (SSYL); R01CA140314, R01CA092344, P30CA044579 (LGL).	Bhutani D, 2015, CURR OPIN HEMATOL, V22, P476, DOI 10.1097/MOH.0000000000000176; Bibeau F, 2006, VIRCHOWS ARCH, V449, P281, DOI 10.1007/s00428-006-0247-9; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Camus M, 2009, CANCER RES, V69, P2685, DOI 10.1158/0008-5472.CAN-08-2654; Chiba T, 2004, BRIT J CANCER, V91, P1711, DOI 10.1038/sj.bjc.6602201; Chung KY, 2010, J CLIN ONCOL, V28, P3485, DOI 10.1200/JCO.2010.28.3994; Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003; Correale P, 2012, CLIN CANCER RES, V18, P850, DOI 10.1158/1078-0432.CCR-10-3186; Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760; Flaherty DC, 2016, J AM COLL SURGEONS, V223, P134, DOI 10.1016/j.jamcollsurg.2016.03.003; Gajewski TF, 2013, CURR OPIN IMMUNOL, V25, P268, DOI 10.1016/j.coi.2013.02.009; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Giordano G, 2019, CANCERS, V11, DOI 10.3390/cancers11081089; Grabert RC, 2006, CLIN CANCER RES, V12, P569, DOI 10.1158/1078-0432.CCR-05-2005; Halama N, 2011, CANCER RES, V71, P5670, DOI 10.1158/0008-5472.CAN-11-0268; Huang CW, 2017, ONCOTARGET, V8, P114663, DOI 10.18632/oncotarget.23072; Katz SC, 2013, ANN SURG ONCOL, V20, P946, DOI 10.1245/s10434-012-2668-9; Klebanoff CA, 2005, P NATL ACAD SCI USA, V102, P9571, DOI 10.1073/pnas.0503726102; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lee SSY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16987-x; Lee WS, 2010, CANCER-AM CANCER SOC, V116, P5188, DOI 10.1002/cncr.25293; Lin Christine, 2017, Curr Protoc Toxicol, V72, DOI 10.1002/cptx.23; Lum LG, 2014, BONE MARROW TRANSPL, V49, P73, DOI 10.1038/bmt.2013.133; Lum LG, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.4108; Lum LG, 2016, BIOL BLOOD MARROW TR, V22, P869, DOI 10.1016/j.bbmt.2015.12.030; Lum Lawrence G, 2003, Clin Breast Cancer, V4, P212, DOI 10.3816/CBC.2003.n.028; Lum LG, 2013, BIOL BLOOD MARROW TR, V19, P925, DOI 10.1016/j.bbmt.2013.03.010; Lum LG, 2011, BIODRUGS, V25, P365, DOI 10.2165/11595950-000000000-00000; Maker AV, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1069937; Maker AV, 2015, CANCER IMMUNOL RES, V3, P380, DOI 10.1158/2326-6066.CIR-14-0212; Maker AV, 2005, ANN SURG ONCOL, V12, P1005, DOI 10.1245/ASO.2005.03.536; Naito Y, 1998, CANCER RES, V58, P3491; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; Prall F, 2004, HUM PATHOL, V35, P808, DOI 10.1016/j.humpath.2004.01.022; Qiao GL, 2017, CANCER RES, V77, P1880, DOI 10.1158/0008-5472.CAN-16-1655; Qin JZ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-70; Qin JZ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.473; Reusch U, 2006, CLIN CANCER RES, V12, P183, DOI 10.1158/1078-0432.CCR-05-1855; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Sen M, 2001, J HEMATOTH STEM CELL, V10, P247, DOI 10.1089/15258160151134944; Shibutani M, 2018, IN VIVO, V32, P151, DOI 10.21873/invivo.11218; Siegel RL, 2017, JAMA-J AM MED ASSOC, V318, P572, DOI 10.1001/jama.2017.7630; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun ZC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11782-w; Thakur A, 2018, BLOOD REV, V32, P339, DOI 10.1016/j.blre.2018.02.004; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Vasu C, 2003, INT IMMUNOL, V15, P641, DOI 10.1093/intimm/dxg061; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Yankelevich M, 2012, PEDIATR BLOOD CANCER, V59, P1198, DOI 10.1002/pbc.24237; Yu P, 2004, NAT IMMUNOL, V5, P141, DOI 10.1038/ni1029; Yu P, 2008, CYTOKINE GROWTH F R, V19, P285, DOI 10.1016/j.cytogfr.2008.04.004; Zboralski D, 2017, CANCER IMMUNOL RES, V5, P950, DOI 10.1158/2326-6066.CIR-16-0303; Zitron IM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-83; Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180	56	1	1	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2054	2068		10.1038/s41388-022-02209-w	http://dx.doi.org/10.1038/s41388-022-02209-w		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35177811	hybrid, Green Published			2022-12-17	WOS:000757138900001
J	Zeng, Z; Zhang, X; Jiang, CQ; Zhang, YG; Wu, X; Li, J; Tang, S; Li, L; Gu, LJ; Xie, XY; Jiang, YA				Zeng, Zhi; Zhang, Xu; Jiang, Cong-Qing; Zhang, Yong-Gang; Wu, Xue; Li, Jin; Tang, Shan; Li, Lang; Gu, Li-Juan; Xie, Xiao-Yu; Jiang, Ying-An			Identifying novel therapeutic targets in gastric cancer using genome-wide CRISPR-Cas9 screening	ONCOGENE			English	Article							CRISPR/CAS9 LIBRARY; GENETIC SCREENS; PROMOTES; CARCINOMA	Genome-scale CRISPR-Cas9 screening technology is a powerful tool to systematically identify genes essential for cancer cell survival. Herein, TKOv3, a genome-scale CRISPR-Cas9 knock-out library, was screened in the gastric cancer (GC) cells, and relevant validation experiments were performed. We obtained 854 essential genes for the AGS cell line, and 184 were novel essential genes. After knocking down essential genes: SPC25, DHX37, ABCE1, SNRPB, TOP3A, RUVBL1, CIT, TACC3 and MTBP, cell viability and proliferation were significantly decreased. Then, we analysed the detected essential genes at different time points and proved more characteristic genes might appear with the extension of selection. After progressive selection using a series of open datasets, 41 essential genes were identified as potential drug targets. Among them, methyltransferase 1 (METTL1) was over expressed in GC tissues. High METTL1 expression was associated with poor prognosis among 3 of 6 GC cohorts. Furthermore, GC cells growth was significantly inhibited after the down-regulation of METTL1 in vitro and in vivo. Function analysis revealed that METTL1 might play a role in the cell cycle through AKT/STAT3 pathways. In conclusion, compared with existing genome-scale screenings, we obtained 184 novel essential genes. Among them, METTL1 was validated as a potential therapeutic target of GC.	[Zeng, Zhi] Wuhan Univ, Dept Pathol, Renmin Hosp, Wuhan, Hubei, Peoples R China; [Zhang, Xu; Zhang, Yong-Gang; Gu, Li-Juan] Wuhan Univ, Cent Lab, Renmin Hosp, Wuhan, Hubei, Peoples R China; [Jiang, Cong-Qing; Xie, Xiao-Yu] Wuhan Univ, Dept Colorectal & Anal Surg, Zhongnan Hosp, Wuhan, Hubei, Peoples R China; [Wu, Xue; Li, Jin; Tang, Shan; Li, Lang] Ohio State Univ, Dept Biomed Informat, Columbus, OH USA; [Jiang, Ying-An] Wuhan Univ, Dept Infect Dis, Renmin Hosp, Wuhan, Hubei, Peoples R China	Wuhan University; Wuhan University; Wuhan University; University System of Ohio; Ohio State University; Wuhan University	Xie, XY (corresponding author), Wuhan Univ, Dept Colorectal & Anal Surg, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.; Jiang, YA (corresponding author), Wuhan Univ, Dept Infect Dis, Renmin Hosp, Wuhan, Hubei, Peoples R China.	ZN004356@whu.edu.cn; jiangya_cn@aliyun.com		Tang, Shan/0000-0002-8224-2809; Zeng, Zhi/0000-0003-4131-050X				Balusamy SR, 2018, BIOMED PHARMACOTHER, V108, P1835, DOI 10.1016/j.biopha.2018.10.028; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen ZY, 2018, BIOCHEM BIOPH RES CO, V498, P579, DOI 10.1016/j.bbrc.2018.03.022; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Costa R, 2016, ONCOTARGET, V7, P55924, DOI 10.18632/oncotarget.10482; Evers B, 2016, NAT BIOTECHNOL, V34, P631, DOI 10.1038/nbt.3536; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Hart T, 2017, G3-GENES GENOM GENET, V7, P2719, DOI 10.1534/g3.117.041277; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Ho SWT, 2019, CANCER SCI, V110, P3405, DOI 10.1111/cas.14191; Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288; Kurata M, 2018, J HUM GENET, V63, P179, DOI 10.1038/s10038-017-0376-9; Li CS, 2016, GENE, V587, P42, DOI 10.1016/j.gene.2016.04.029; Lin SB, 2018, MOL CELL, V71, P244, DOI 10.1016/j.molcel.2018.06.001; Liu Y, 2020, LIFE SCI, V249, DOI 10.1016/j.lfs.2020.117480; Lu X, 2019, ONCOTARGETS THER, V12, P7489, DOI 10.2147/OTT.S208848; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Marcotte R, 2012, CANCER DISCOV, V2, P172, DOI 10.1158/2159-8290.CD-11-0224; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Morgens DW, 2016, NAT BIOTECHNOL, V34, P634, DOI 10.1038/nbt.3567; Okamoto M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004639; Orellana EA, 2021, MOL CELL, V81, P3323, DOI 10.1016/j.molcel.2021.06.031; Pandolfini L, 2019, MOL CELL, V74, P1278, DOI 10.1016/j.molcel.2019.03.040; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shang WJ, 2021, J PATHOL, V253, P148, DOI 10.1002/path.5568; Sheng Y, 2018, CANCER MANAG RES, V10, P6205, DOI 10.2147/CMAR.S176147; Tao JQ, 2014, TUMOR BIOL, V35, P4389, DOI 10.1007/s13277-013-1578-1; Tian QH, 2019, J MOL MED, V97, P1535, DOI 10.1007/s00109-019-01830-9; Tsai MM, 2012, CANCER SCI, V103, P1136, DOI 10.1111/j.1349-7006.2012.02243.x; Tzelepis K, 2016, CELL REP, V17, P1193, DOI 10.1016/j.celrep.2016.09.079; Venerito M, 2019, HELICOBACTER, V24, DOI 10.1111/hel.12643; Wang BB, 2019, NAT PROTOC, V14, P756, DOI 10.1038/s41596-018-0113-7; Wang C, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12591; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; Yuan L, 2021, WORLD J GASTROENTERO, V27, P1785, DOI 10.3748/wjg.v27.i16.1785; Zhou YX, 2014, NATURE, V509, P487, DOI 10.1038/nature13166	38	1	1	7	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2069	2078		10.1038/s41388-022-02177-1	http://dx.doi.org/10.1038/s41388-022-02177-1		FEB 2022	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35177812				2022-12-17	WOS:000757138900002
J	Hochnadel, I; Hoenicke, L; Petriv, N; Neubert, L; Reinhard, E; Hirsch, T; Alfonso, JCL; Suo, HZ; Longerich, T; Geffers, R; Lichtinghagen, R; Guzman, CA; Wedemeyer, H; Lenzen, H; Manns, MP; Bruder, D; Yevsa, T				Hochnadel, Inga; Hoenicke, Lisa; Petriv, Nataliia; Neubert, Lavinia; Reinhard, Elena; Hirsch, Tatjana; Alfonso, Juan Carlos Lopez; Suo, Huizhen; Longerich, Thomas; Geffers, Robert; Lichtinghagen, Ralf; Guzman, Carlos Alberto; Wedemeyer, Heiner; Lenzen, Henrike; Manns, Michael Peter; Bruder, Dunja; Yevsa, Tetyana			Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers	ONCOGENE			English	Article							IMMUNE-RESPONSES; SURVEILLANCE; CELLS; MANAGEMENT; SORAFENIB; FIBROSIS	Primary liver cancer (PLC) comprising hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) represents the third deadliest cancer worldwide with still insufficient treatment options. We have previously found that CD4 T helper 1 (Th1) response is indispensable for the protection against PLC. In the present research, we aimed to test the potent inducers of Th1 responses, live-attenuated Listeria monocytogenes Delta actA/Delta inlB strain as preventive/therapeutic vaccine candidate in liver fibrosis, HCC, and CCA. Studies were performed using autochthonous models of HCC and CCA, highly reflecting human disease. L monocytogenes Delta actA/Delta inlB demonstrated strong safety/efficacy in premalignant and malignant liver diseases. The protective mechanism relied on the induction of strong tumor-specific immune responses that keep the development of hepatobiliary cancers under control. Combination therapy, comprising Listeria vaccination and a checkpoint inhibitor blockade significantly extended the survival of HCC-bearing mice even at the advanced stages of the disease. This is the first report on the safety and efficacy of Listeria-based vaccine in liver fibrosis, as well as the first proof of principle study on Listeria-based vaccines in CCA. Our study paves the way for the use of live-attenuated Listeria as safe and efficient vaccine and a potent inducer of protective immune responses in liver fibrosis and hepatobiliary malignancies.	[Hochnadel, Inga; Hoenicke, Lisa; Petriv, Nataliia; Suo, Huizhen; Wedemeyer, Heiner; Lenzen, Henrike; Manns, Michael Peter; Yevsa, Tetyana] Hannover Med Sch MHH, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany; [Neubert, Lavinia] MHH, Inst Pathol, Hannover, Germany; [Reinhard, Elena; Guzman, Carlos Alberto] Helmholtz Ctr Infect Res HZI, Dept Vaccinol & Appl Microbiol, Braunschweig, Germany; [Hirsch, Tatjana; Bruder, Dunja] HZI, Immune Regulat Grp, Braunschweig, Germany; [Hirsch, Tatjana; Bruder, Dunja] Otto von Guericke Univ, Inst Med Microbiol & Hosp Hyg, Infect Immunol Grp, Magdeburg, Germany; [Alfonso, Juan Carlos Lopez] Tech Univ Carolo Wilhelmina Braunschweig, Dept Syst Immunol, Braunschweig, Germany; [Alfonso, Juan Carlos Lopez] HZI, Braunschweig, Germany; [Longerich, Thomas] Heidelberg Univ Hosp, Inst Pathol, Heidelberg, Germany; [Geffers, Robert] HZI, Genome Analyt, Braunschweig, Germany; [Lichtinghagen, Ralf] MHH, Dept Clin Chem, Hannover, Germany	Hannover Medical School; Hannover Medical School; Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; Otto von Guericke University; Braunschweig University of Technology; Helmholtz Association; Helmholtz-Center for Infection Research; Ruprecht Karls University Heidelberg; Helmholtz Association; Helmholtz-Center for Infection Research; Hannover Medical School	Yevsa, T (corresponding author), Hannover Med Sch MHH, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany.	Yevsa.Tetyana@mh-hannover.de		Hoenicke, Lisa/0000-0003-0613-8337	German Research Foundation (DFG) [YE 151/21, AOBJ: 618426]; Young Academy MHH; Ellen Schmidt Program MHH; Niedersachsische Krebsgesellschaft e.V.; DFG [LO-1676/4-1, SFB/TR209]; German Academic Exchange Service (DAAD) [91736778]; Fritz Thyssen Foundation [REF.10.16.1.031MN]; Wilhelm-Sander Foundation [2013.107.1]; Gilead Sciences International Research Scholars Program in Liver Disease; Projekt DEAL; HiLFII MHH	German Research Foundation (DFG)(German Research Foundation (DFG)); Young Academy MHH; Ellen Schmidt Program MHH; Niedersachsische Krebsgesellschaft e.V.; DFG(German Research Foundation (DFG)); German Academic Exchange Service (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); Fritz Thyssen Foundation; Wilhelm-Sander Foundation; Gilead Sciences International Research Scholars Program in Liver Disease; Projekt DEAL; HiLFII MHH	This work was supported by the German Research Foundation (DFG) (grant YE 151/21, AOBJ: 618426) (TY), Young Academy MHH (TY), HiLFII MHH (TY), Ellen Schmidt Program MHH (TY) and by a grant support of Niedersachsische Krebsgesellschaft e.V. TL acknowledges the support by the DFG (LO-1676/4-1 and SFB/TR209 project B08). NP acknowledges the funding of the German Academic Exchange Service (DAAD) in the scope of the Doctoral Program in Germany (Project-ID 91736778). This work was supported in part by: Fritz Thyssen Foundation (grant REF.10.16.1.031MN) (TY), Wilhelm-Sander Foundation (grant 2013.107.1) (TY, MPM), Gilead Sciences International Research Scholars Program in Liver Disease (Research Award to TY). Open Access funding enabled and organized by Projekt DEAL.	Brockstedt DG, 2004, P NATL ACAD SCI USA, V101, P13832, DOI 10.1073/pnas.0406035101; Buonaguro L, 2019, ANN HEPATOL, V18, P291, DOI 10.1016/j.aohep.2019.04.003; Chen Y, 2012, ONCOGENE, V31, P2140, DOI 10.1038/onc.2011.395; Crowther MD, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071588; Cui M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.613530; Dauch D, 2016, NAT MED, V22, P744, DOI 10.1038/nm.4107; Deng WW, 2018, P NATL ACAD SCI USA, V115, P8179, DOI 10.1073/pnas.1801910115; DiLillo DJ, 2008, J IMMUNOL, V180, P361, DOI 10.4049/jimmunol.180.1.361; Eggert T, 2016, CANCER CELL, V30, P533, DOI 10.1016/j.ccell.2016.09.003; European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Flickinger JC, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030048; Garaud S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02660; Gilley Ryan P, 2020, Oncotarget, V11, P740, DOI 10.18632/oncotarget.27490; Gu Y, 2019, NAT MED, V25, P312, DOI 10.1038/s41591-018-0309-y; Hochnadel I, 2017, HUM VACC IMMUNOTHER, V13, P2931, DOI 10.1080/21645515.2017.1359362; Hoenicke L, 2012, CARCINOGENESIS, V33, P1123, DOI 10.1093/carcin/bgs124; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kim VM, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0601-5; Kramer ES, 2009, DIGEST DIS SCI, V54, P2016, DOI 10.1007/s10620-009-0867-4; Le DT, 2019, CLIN CANCER RES, V25, P5493, DOI 10.1158/1078-0432.CCR-18-2992; Le DT, 2015, J CLIN ONCOL, V33, P1325, DOI 10.1200/JCO.2014.57.4244; Lee HW, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e11; Ley C., 2019, ONKOL HEUTE, V11, P51; Liau LM, 2002, CANCER RES, V62, P2287; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213; Nault JC, 2020, J HEPATOL, V72, P209, DOI 10.1016/j.jhep.2019.11.006; O'Rourke JM, 2018, WORLD J GASTROENTERO, V24, P4436, DOI 10.3748/wjg.v24.i39.4436; Petriv N, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1874159; Roni DA, 2013, ADV VIROL, V2013, DOI 10.1155/2013/196704; Rudalska R, 2014, NAT MED, V20, P1138, DOI 10.1038/nm.3679; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Seavey MM, 2009, J IMMUNOL, V182, P5537, DOI 10.4049/jimmunol.0803742; Seehawer M, 2018, NATURE, V562, P69, DOI 10.1038/s41586-018-0519-y; Shalapour S, 2017, NATURE, V551, P340, DOI 10.1038/nature24302; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Valle JW, 2016, ANN ONCOL, V27, pv28, DOI 10.1093/annonc/mdw324; Walcher L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01280; Wallecha A, 2009, CLIN VACCINE IMMUNOL, V16, P96, DOI 10.1128/CVI.00274-08; Wang J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.227; WHO, 2021, CANC; Xu GL, 2020, ONCOGENE, V39, P1429, DOI 10.1038/s41388-019-1072-3; Yang Y, 2014, CELL MOL IMMUNOL, V11, P184, DOI 10.1038/cmi.2013.64; Yevsa T, 2012, ONCOIMMUNOLOGY, V1, P397, DOI 10.4161/onci.19128; Zenewicz LA, 2007, MICROBES INFECT, V9, P1208, DOI 10.1016/j.micinf.2007.05.008	48	1	2	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2039	2053		10.1038/s41388-022-02222-z	http://dx.doi.org/10.1038/s41388-022-02222-z		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35173308	hybrid, Green Published			2022-12-17	WOS:000756457400004
J	Sun, T; Wu, ZK; Wang, XF; Wang, YL; Hu, XY; Qin, WN; Lu, SX; Xu, DP; Wu, YT; Chen, QC; Ding, XY; Guo, H; Li, YL; Wang, YH; Fu, BS; Yao, WF; Wei, MJ; Wu, HZ				Sun, Tong; Wu, Zhikun; Wang, Xiufang; Wang, Yilin; Hu, Xiaoyun; Qin, Wenyan; Lu, Senxu; Xu, Dongping; Wu, Yutong; Chen, Qiuchen; Ding, Xiangyu; Guo, Hao; Li, Yalun; Wang, Yuanhe; Fu, Boshi; Yao, Weifan; Wei, Minjie; Wu, Huizhe			LNC942 promoting METTL14-mediated m 6 A methylation in breast cancer cell proliferation and progression (vol 39, pg 5358, 2020)	ONCOGENE			English	Correction												mjwei@cmu.edu.cn; wuhz@cmu.edu.cn	Hu, Xiao/GQI-0007-2022	Hu, Xiao/0000-0003-1128-4099				Sun T, 2020, ONCOGENE, V39, P5358, DOI 10.1038/s41388-020-1338-9	1	1	1	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1677	1677		10.1038/s41388-022-02194-0	http://dx.doi.org/10.1038/s41388-022-02194-0		FEB 2022	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35169255	Bronze			2022-12-17	WOS:000755405100002
J	Zhang, XC; Hu, YB; Pan, YL; Xiong, YX; Zhang, YX; Han, MZ; Dong, KS; Song, J; Liang, HF; Ding, ZY; Zhang, XW; Zhu, H; Liu, QM; Lu, X; Feng, YD; Chen, XP; Zhang, ZG; Zhang, BX				Zhang, Xiaochao; Hu, Yabing; Pan, Yonglong; Xiong, Yixiao; Zhang, Yuxin; Han, Mengzhen; Dong, Keshuai; Song, Jia; Liang, Huifang; Ding, Zeyang; Zhang, Xuewu; Zhu, He; Liu, Qiumeng; Lu, Xun; Feng, Yongdong; Chen, Xiaoping; Zhang, Zhanguo; Zhang, Bixiang			DDR1 promotes hepatocellular carcinoma metastasis through recruiting PSD4 to ARF6	ONCOGENE			English	Article							DOMAIN RECEPTOR 1; TYROSINE KINASES; GROWTH-FACTOR; DISCOIDIN; EXPRESSION; INHIBITION; OVEREXPRESSION; ACTIVATION; SURVIVAL; ROLES	Discoidin domain receptor 1 (DDR1) is a member of the receptor tyrosine kinase family, and its ligand is collagen. Previous studies demonstrated that DDR1 is highly expressed in many tumors. However, its role in hepatocellular carcinoma (HCC) remains obscure. In this study, we found that DDR1 was upregulated in HCC tissues, and the expression of DDR1 in TNM stage II-IV was higher than that in TNM stage I in HCC tissues, and high DDR1 expression was associated with poor prognosis. Gene expression analysis showed that DDR1 target genes were functionally involved in HCC metastasis. DDR1 positively regulated the migration and invasion of HCC cells and promoted lung metastasis. Human Phospho-Kinase Array showed that DDR1 activated ERK/MAPK signaling pathway. Mechanically, DDR1 interacted with ARF6 and activated ARF6 through recruiting PSD4. The kinase activity of DDR1 was required for ARF6 activation and its role in metastasis. High expression of PSD4 was associated with poor prognosis in HCC. In summary, our findings indicate that DDR1 promotes HCC metastasis through collagen induced DDR1 signaling mediated PSD4/ARF6 signaling, suggesting that DDR1 and ARF6 may serve as novel prognostic biomarkers and therapeutic targets for metastatic HCC.	[Zhang, Xiaochao; Hu, Yabing; Pan, Yonglong; Xiong, Yixiao; Zhang, Yuxin; Han, Mengzhen; Dong, Keshuai; Song, Jia; Liang, Huifang; Ding, Zeyang; Zhang, Xuewu; Zhu, He; Liu, Qiumeng; Lu, Xun; Chen, Xiaoping; Zhang, Zhanguo; Zhang, Bixiang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China; [Zhang, Xiaochao; Pan, Yonglong; Xiong, Yixiao; Zhang, Yuxin; Han, Mengzhen; Dong, Keshuai; Song, Jia; Liang, Huifang; Ding, Zeyang; Zhang, Xuewu; Zhu, He; Liu, Qiumeng; Lu, Xun; Chen, Xiaoping; Zhang, Zhanguo; Zhang, Bixiang] ChinaClin Med Res Ctr Hepat Surg Hubei Prov, Wuhan, Peoples R China; [Zhang, Xiaochao; Pan, Yonglong; Xiong, Yixiao; Zhang, Yuxin; Han, Mengzhen; Dong, Keshuai; Song, Jia; Liang, Huifang; Ding, Zeyang; Zhang, Xuewu; Zhu, He; Liu, Qiumeng; Lu, Xun; Chen, Xiaoping; Zhang, Zhanguo; Zhang, Bixiang] Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Zhang, Xiaochao; Pan, Yonglong; Xiong, Yixiao; Zhang, Yuxin; Han, Mengzhen; Dong, Keshuai; Song, Jia; Liang, Huifang; Ding, Zeyang; Zhang, Xuewu; Zhu, He; Liu, Qiumeng; Lu, Xun; Chen, Xiaoping; Zhang, Zhanguo; Zhang, Bixiang] Natl Hlth Commiss, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Zhang, Xiaochao; Pan, Yonglong; Xiong, Yixiao; Zhang, Yuxin; Han, Mengzhen; Dong, Keshuai; Song, Jia; Liang, Huifang; Ding, Zeyang; Zhang, Xuewu; Zhu, He; Liu, Qiumeng; Lu, Xun; Chen, Xiaoping; Zhang, Zhanguo; Zhang, Bixiang] Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan, Peoples R China; [Zhang, Xiaochao] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dermatol, Wuhan, Peoples R China; [Hu, Yabing] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Biochem & Mol Biol, Wuhan, Hubei, Peoples R China; [Feng, Yongdong] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Canc Res Inst, Wuhan 430030, Hubei, Peoples R China	Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zhang, ZG; Zhang, BX (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China.; Zhang, ZG; Zhang, BX (corresponding author), ChinaClin Med Res Ctr Hepat Surg Hubei Prov, Wuhan, Peoples R China.; Zhang, ZG; Zhang, BX (corresponding author), Minist Educ, Key Lab Organ Transplantat, Wuhan, Peoples R China.; Zhang, ZG; Zhang, BX (corresponding author), Natl Hlth Commiss, Key Lab Organ Transplantat, Wuhan, Peoples R China.; Zhang, ZG; Zhang, BX (corresponding author), Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan, Peoples R China.	zhanguo_tjh@hust.edu.cn; bixiangzhang@163.com	yuxin, Zhang/GNH-2283-2022; Ding, Ze-yang/HHC-6329-2022	Ding, Ze-yang/0000-0001-5826-0970; Liang, Huifang/0000-0001-6874-3634	National Natural Science Foundation of China [81372327, 81874149, 81874189, 81572855, 81572427, 81874065]; State Key Project on Infection Disease of China [2018ZX10723204-003]; National Key Research and Development Program of China [2018YFA0208904]; Hepato-BiliaryPancreatic Investigation Fund of Chen Xiaoping Foundation for the Development of Science and Technology of Hubei Province [CXPJJH11800001-2018356]; HCP project of Huazhong University of Science and Technology [5001540059, 5001540006]; Major Technological Innovation Projects of Hubei Province [2018ACA137]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Project on Infection Disease of China; National Key Research and Development Program of China; Hepato-BiliaryPancreatic Investigation Fund of Chen Xiaoping Foundation for the Development of Science and Technology of Hubei Province; HCP project of Huazhong University of Science and Technology; Major Technological Innovation Projects of Hubei Province	This research was supported by grants from the National Natural Science Foundation of China (No.81372327, 81874149, 81874189, 81572855, 81572427, 81874065), the State Key Project on Infection Disease of China (No. 2018ZX10723204-003), the National Key Research and Development Program of China (2018YFA0208904), the Hepato-BiliaryPancreatic Investigation Fund of Chen Xiaoping Foundation for the Development of Science and Technology of Hubei Province (CXPJJH11800001-2018356), the HCP project of Huazhong University of Science and Technology (No. 5001540059, 5001540006), Major Technological Innovation Projects of Hubei Province (2018ACA137).	Agarwal G, 2007, J MOL BIOL, V367, P443, DOI 10.1016/j.jmb.2006.12.073; Aguilera KY, 2017, MOL CANCER THER, V16, P2473, DOI 10.1158/1535-7163.MCT-16-0834; ALVES F, 1995, ONCOGENE, V10, P609; Ambrogio C, 2016, NAT MED, V22, P270, DOI 10.1038/nm.4041; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Cox R, 2004, MOL BIOL CELL, V15, P1487, DOI 10.1091/mbc.E03-06-0443; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Dai W, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00563-x; Ding ZY, 2014, HEPATOLOGY, V60, P1620, DOI 10.1002/hep.27273; Ding ZY, 2013, CELL SIGNAL, V25, P1981, DOI 10.1016/j.cellsig.2013.05.027; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Gao H, 2016, CELL, V166, P47, DOI 10.1016/j.cell.2016.06.009; Grossmann AH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003398; Hashimoto S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10656; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Hongu T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8925; Hu B, 2009, CANCER RES, V69, P794, DOI 10.1158/0008-5472.CAN-08-2110; Hunzicker-Dunn M, 2002, FEBS LETT, V521, P3, DOI 10.1016/S0014-5793(02)02822-3; Jeitany M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201707918; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P10891, DOI 10.1073/pnas.90.22.10891; Juin A, 2014, J CELL BIOL, V207, P517, DOI 10.1083/jcb.201404079; Leitinger B, 2014, INT REV CEL MOL BIO, V310, P39, DOI 10.1016/B978-0-12-800180-6.00002-5; Meng ZP, 2010, HEPATOLOGY, V52, P2148, DOI 10.1002/hep.23915; Morishige M, 2008, NAT CELL BIOL, V10, P85, DOI 10.1038/ncb1672; Muralidharan-Chari V, 2009, CANCER RES, V69, P2201, DOI 10.1158/0008-5472.CAN-08-1301; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Romayor I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75395-w; Tsochatzis EA, 2012, NEW ENGL J MED, V366, P92, DOI 10.1056/NEJMc1112501; Valencia K, 2012, CLIN CANCER RES, V18, P969, DOI 10.1158/1078-0432.CCR-11-1686; Vehlow A, 2019, CELL REP, V26, P3672, DOI 10.1016/j.celrep.2019.02.096; Villalba M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51066-3; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Wei S, 2012, CARCINOGENESIS, V33, P538, DOI 10.1093/carcin/bgr319; Weiner HL, 2000, NEUROSURGERY, V47, P1400, DOI 10.1097/00006123-200012000-00028; Yang J, 2017, SCI REP-UK, V7, DOI 10.1038/srep40358; Yang J, 2019, THERANOSTICS, V9, P5810, DOI 10.7150/thno.34973; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yoo JH, 2016, CANCER CELL, V29, P889, DOI 10.1016/j.ccell.2016.04.015; Zangari J, 2014, CANCER RES, V74, P5493, DOI 10.1158/0008-5472.CAN-14-0298; Zhavoronkov A, 2019, NAT BIOTECHNOL, V37, P1038, DOI 10.1038/s41587-019-0224-x; Zhou L, 2008, WORLD J SURG, V32, P1748, DOI 10.1007/s00268-008-9615-8	44	1	1	10	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1821	1834		10.1038/s41388-022-02212-1	http://dx.doi.org/10.1038/s41388-022-02212-1		FEB 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35140331	Green Published, hybrid			2022-12-17	WOS:000753256900001
J	Jeong, HS; Lee, DH; Kim, SH; Lee, CH; Shin, HM; Kim, HR; Cho, CH				Jeong, Han-Seok; Lee, Da-Hye; Kim, Seung-Hoon; Lee, Chang-Han; Shin, Hyun Mu; Kim, Hang-Rae; Cho, Chung-Hyun			Hyperglycemia-induced oxidative stress promotes tumor metastasis by upregulating vWF expression in endothelial cells through the transcription factor GATA1	ONCOGENE			English	Article							VON-WILLEBRAND-FACTOR; TIGHT JUNCTION PROTEINS; VASCULAR-PERMEABILITY; STAT3 ACTIVATION; PLASMA-LEVELS; CANCER; SECRETION; INFLAMMATION; PLATELETS; INSIGHTS	Diabetes mellitus (DM) characterized by hyperglycemia is a chronic metabolic disorder that leads to many symptoms and vascular complications. Despite the close association between DM and cancer progression, the response and role of endothelial cells (ECs) under diabetic conditions in tumor metastasis remain to be elucidated. In this study, we sought to determine whether and how ECs under diabetic conditions contribute to tumor metastasis. We have taken advantage of syngeneic mouse tumor models of Lewis lung carcinoma (LLC) and melanoma (B16F10) cells and a streptozotocin (STZ)-induced hyperglycemia model. We demonstrated that hyperglycemia increased the metastasis of LLC and B16F10 cells in an experimental metastasis model with an intravenous injection of the tumor cells. We also found that hyperglycemia promoted lung metastasis of tumor cells by increasing the adhesiveness of ECs to facilitate the adhesion of tumor cells to ECs rather than affecting the metastatic behavior of tumor cells themselves. From the analysis of gene expression in primary lung ECs from STZ-treated mice, we identified that vWF promoted the adhesion of tumor cells to ECs and the transendothelial migration of tumor cells. Mechanistically, hyperglycemia-induced oxidative stress in ECs, and increased oxidative stress enhanced vWF expression in ECs through an increase in the transcription factor GATA1. These results provide evidence for the role of vWF in ECs in promoting hyperglycemia-induced tumor metastasis and potential therapeutic targets for the regulation of vWF expression in ECs and hyperglycemia-induced tumor metastasis.	[Jeong, Han-Seok; Lee, Da-Hye; Kim, Seung-Hoon; Lee, Chang-Han; Shin, Hyun Mu; Kim, Hang-Rae; Cho, Chung-Hyun] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 03080, South Korea; [Jeong, Han-Seok; Lee, Da-Hye; Kim, Seung-Hoon; Lee, Chang-Han; Cho, Chung-Hyun] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 03080, South Korea; [Shin, Hyun Mu] Seoul Natl Univ, Coll Med, Wide River Inst Immunol, Hongcheon 25159, South Korea; [Kim, Hang-Rae] Seoul Natl Univ, Dept Anat & Cell Biol, Seoul 03080, South Korea; [Cho, Chung-Hyun] Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul 03080, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Cho, CH (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 03080, South Korea.; Cho, CH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 03080, South Korea.; Cho, CH (corresponding author), Seoul Natl Univ, Coll Med, Ischem Hypox Dis Inst, Seoul 03080, South Korea.	iamhyun@snu.ac.kr		Kim, Hang-Rae/0000-0002-3983-6193	National Research Foundation of Korea - Korea government [2020R1A2C1008008]; SNUH Research Fund [0420210290]	National Research Foundation of Korea - Korea government(National Research Foundation of KoreaKorean Government); SNUH Research Fund	We appreciate Dr. Kyong Soo Park for technical assistance in insulin supplementation experiments. This work is supported by funding from the National Research Foundation of Korea grant funded by the Korea government (2020R1A2C1008008 to CHC) and the SNUH Research Fund (0420210290 to CHC).	Aghajanian A, 2008, J THROMB HAEMOST, V6, P1453, DOI 10.1111/j.1538-7836.2008.03087.x; Avdonin PV, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020196; Basta G, 2004, CARDIOVASC RES, V63, P582, DOI 10.1016/j.cardiores.2004.05.001; Blann AD, 2011, PROSTATE, V71, P1047, DOI 10.1002/pros.21319; Carstensen B, 2016, DIABETOLOGIA, V59, P980, DOI 10.1007/s00125-016-3884-9; Chan Norman N, 2003, Med Sci Monit, V9, pCR297; Chan SHH, 2009, CIRC RES, V105, P886, DOI 10.1161/CIRCRESAHA.109.199018; Coller BS, 2008, BLOOD, V112, P3011, DOI 10.1182/blood-2008-06-077891; De Ceunynck K, 2013, BLOOD, V121, P270, DOI 10.1182/blood-2012-07-442285; Dmitrieva NI, 2014, P NATL ACAD SCI USA, V111, P6485, DOI 10.1073/pnas.1404809111; Drummond GR, 2014, TRENDS ENDOCRIN MET, V25, P452, DOI 10.1016/j.tem.2014.06.012; Dymkowska D, 2014, ARCH BIOCHEM BIOPHYS, V542, P7, DOI 10.1016/j.abb.2013.11.008; Fainsod-Levi T, 2017, CELL REP, V21, P2384, DOI 10.1016/j.celrep.2017.11.010; Fan C, 2009, J BIOL CHEM, V284, P23331, DOI 10.1074/jbc.M109.036079; Foda HD, 2001, DRUG DISCOV TODAY, V6, P478, DOI 10.1016/S1359-6446(01)01752-4; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Franchini M, 2013, THROMB RES, V131, P290, DOI 10.1016/j.thromres.2013.01.015; Franses JW, 2013, INT J CANCER, V133, P1334, DOI 10.1002/ijc.28146; GADDUCCI A, 1994, GYNECOL ONCOL, V53, P352, DOI 10.1006/gyno.1994.1146; Garcia-Roman J, 2013, CANCER LETT, V335, P259, DOI 10.1016/j.canlet.2013.03.005; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; Gorin Y, 2013, CLIN SCI, V125, P361, DOI 10.1042/CS20130065; He H, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01531; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Ikemura M, 2017, ANTICANCER RES, V37, P5463, DOI 10.21873/anticanres.11975; Ikemura M, 2013, J CONTROL RELEASE, V170, P191, DOI 10.1016/j.jconrel.2013.05.028; Jafar N, 2016, AM J MED SCI, V351, P201, DOI 10.1016/j.amjms.2015.11.011; Jeon HY, 2019, FASEB J, V33, P750, DOI 10.1096/fj.201800723R; KARPATKIN S, 1988, J CLIN INVEST, V81, P1012, DOI 10.1172/JCI113411; Kim KJ, 2017, ONCOGENE, V36, P5445, DOI 10.1038/onc.2017.148; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Li NL, 2016, INT J CANCER, V138, P2078, DOI 10.1002/ijc.29847; Li WJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1309-6; Liu J, 2009, J THROMB HAEMOST, V7, P1384, DOI 10.1111/j.1538-7836.2009.03501.x; Lou ZK, 2018, MOL MED REP, V17, P2479, DOI 10.3892/mmr.2017.8124; Marini A, 2018, P NATL ACAD SCI USA, V115, P6219, DOI 10.1073/pnas.1718531115; MORDES DB, 1983, DIABETES, V32, P876, DOI 10.2337/diabetes.32.9.876; Morganti M, 2000, BIOMED PHARMACOTHER, V54, P431, DOI 10.1016/S0753-3322(00)00006-8; NICHOLS TC, 1995, P NATL ACAD SCI USA, V92, P2455, DOI 10.1073/pnas.92.7.2455; Noh Y, 2019, INT J CANCER, V144, P1530, DOI 10.1002/ijc.31870; O'Sullivan JM, 2018, SEMIN THROMB HEMOST, V44, P159, DOI 10.1055/s-0037-1607352; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Pilch J, 2002, J BIOL CHEM, V277, P21930, DOI 10.1074/jbc.M201630200; Rohsig LM, 2001, BRAZ J MED BIOL RES, V34, P1125; Sadler JE, 2013, BLOOD, V121, P2583, DOI 10.1182/blood-2013-02-482000; Scappaticcio L, 2017, ENDOCRINE, V56, P231, DOI 10.1007/s12020-016-1216-y; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; Seligman BGS, 2000, DIABETES CARE, V23, P1395, DOI 10.2337/diacare.23.9.1395; Spratt DE, 2016, INT J RADIAT ONCOL, V94, P523, DOI 10.1016/j.ijrobp.2015.11.007; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Takano M, 2002, AM J PHYSIOL-HEART C, V283, pH2054, DOI 10.1152/ajpheart.01001.2001; Terraube V, 2006, J THROMB HAEMOST, V4, P519, DOI 10.1111/j.1538-7836.2005.01770.x; Terraube V, 2007, THROMB RES, V120, pS64, DOI 10.1016/S0049-3848(07)70132-9; Umetani M, 2001, ARTERIOSCL THROM VAS, V21, P917, DOI 10.1161/01.ATV.21.6.917; VISCHER UM, 1995, BLOOD, V85, P3164, DOI 10.1182/blood.V85.11.3164.bloodjournal85113164; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; Wang JP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37130-4; Wang WS, 2005, WORLD J GASTROENTERO, V11, P2166, DOI 10.3748/wjg.v11.i14.2166; Xiang YZ, 2015, BLOOD, V125, P3377, DOI 10.1182/blood-2015-01-620278; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yun JH, 2021, J CELL PHYSIOL, V236, P7058, DOI 10.1002/jcp.30373; Yun JH, 2017, J CELL PHYSIOL, V232, P1123, DOI 10.1002/jcp.25575; Zheng Y, 2016, AM J PATHOL, V186, P1081, DOI 10.1016/j.ajpath.2015.12.020	64	1	1	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1634	1646		10.1038/s41388-022-02207-y	http://dx.doi.org/10.1038/s41388-022-02207-y		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35094008				2022-12-17	WOS:000750486500003
J	Meinhardt, AL; Munkhbaatar, E; Hockendorf, U; Dietzen, M; Dechant, M; Anton, M; Jacob, A; Steiger, K; Weichert, W; Brcic, L; McGranahan, N; Branca, C; Kaufmann, T; Dengler, MA; Jost, PJ				Meinhardt, Anna-Lena; Munkhbaatar, Enkhtsetseg; Hockendorf, Ulrike; Dietzen, Michelle; Dechant, Marta; Anton, Martina; Jacob, Anne; Steiger, Katja; Weichert, Wilko; Brcic, Luka; McGranahan, Nicholas; Branca, Caterina; Kaufmann, Thomas; Dengler, Michael A.; Jost, Philipp J.			The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner	ONCOGENE			English	Article							APOPTOSIS; CELLS; PROLIFERATION; EXPRESSION; MUTATIONS; ENABLES; BAX	A variety of cancer entities are driven by KRAS mutations, which remain difficult to target clinically. Survival pathways, such as resistance to cell death, may represent a promising treatment approach in KRAS mutated cancers. Based on the frequently observed genomic deletions of BCL-2-related ovarian killer (BOK) in cancer patients, we explored the function of BOK in a mutant Kras(G12D)-driven murine model of lung cancer. Using Kras(G12D/+)Bok(-/-) mice, we observed an overall tumor-promoting function of BOK in vivo. Specifically, loss of BOK reduced proliferation both in cell lines in vitro as well as in Kras(G12D)-driven tumor lesions in vivo. During tumor development in vivo, loss of BOK resulted in a lower tumor burden, with fewer, smaller, and less advanced tumors. Using Kras(G12D/+)Tp53(Delta/Delta)Bok(-/-) mice, we identified that this phenotype was entirely dependent on the presence of functional p53. Furthermore, analysis of a human dataset of untreated early-stage lung tumors did not identify any common deletion of the BOK locus, independently of the TP53 status or the histopathological classification. Taken together our data indicate that BOK supports tumor progression in Kras-driven lung cancer.	[Meinhardt, Anna-Lena; Munkhbaatar, Enkhtsetseg; Hockendorf, Ulrike; Dechant, Marta; Branca, Caterina; Jost, Philipp J.] Tech Univ Munich, TUM Sch Med, Dept Med 3, Klinikum Rechts Isar, Munich, Germany; [Dietzen, Michelle; McGranahan, Nicholas] UCL, Canc Inst, Canc Res UK Lung Canc Ctr Excellence, Paul OGorman Bldg, London, England; [Dietzen, Michelle; McGranahan, Nicholas] UCL, Canc Inst, Canc Genome Evolut Res Grp, London, England; [Dietzen, Michelle] Francis Crick Inst, Canc Evolut & Genome Instabil Lab, London, England; [Anton, Martina] Tech Univ Munich, Sch Med, Inst Mol Immunol & Expt Oncol, Munich, Germany; [Jacob, Anne; Steiger, Katja; Weichert, Wilko] Tech Univ Munich, Inst Pathol, Munich, Germany; [Steiger, Katja; Weichert, Wilko; Jost, Philipp J.] German Canc Consortium DKTK, Partner Site Munich, Munich, Germany; [Brcic, Luka] Med Univ Graz, Diagnost & Res Inst Pathol, Diagnost & Res Ctr Mol BioMed, Graz, Austria; [Kaufmann, Thomas] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Dengler, Michael A.; Jost, Philipp J.] Med Univ Graz, Dept Med, Div Clin Oncol, Graz, Austria; [Meinhardt, Anna-Lena] Rutgers New Jersey Med Sch, Dept Med, Newark, NJ USA; [Munkhbaatar, Enkhtsetseg] Tech Univ Munich, Sch Med, Dept Surg, Munich, Germany	Technical University of Munich; Cancer Research UK; University of London; University College London; University of London; University College London; Francis Crick Institute; Technical University of Munich; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Medical University of Graz; University of Bern; Medical University of Graz; Rutgers State University New Brunswick; Rutgers State University Medical Center; Technical University of Munich	Jost, PJ (corresponding author), Tech Univ Munich, TUM Sch Med, Dept Med 3, Klinikum Rechts Isar, Munich, Germany.; Jost, PJ (corresponding author), German Canc Consortium DKTK, Partner Site Munich, Munich, Germany.; Dengler, MA; Jost, PJ (corresponding author), Med Univ Graz, Dept Med, Div Clin Oncol, Graz, Austria.	michael.dengler@medunigraz.at; philipp.jost@medunigraz.at	Dengler, Michael/AFR-3509-2022; Jost, Philipp J./S-4962-2016	Jost, Philipp J./0000-0003-2454-0362; Dietzen, Michelle/0000-0002-6853-7563; Steiger, Katja/0000-0002-7269-5433; Dengler, Michael/0000-0002-1693-1761; Anton, Martina/0000-0001-5290-5213; Kaufmann, Thomas/0000-0001-9906-874X; Brcic, Luka/0000-0002-9098-8416; Hockendorf, Ulrike/0000-0002-8218-3343	Deutsche Krebshilfe for AM (Doktorandenstipendium) [112066]; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [FOR 2036, SFB 1335, 360372040]; German Consortium for Translational Cancer Research (DKTK); Swiss National Science Foundation [31003A_173006]; Wellcome Trust; Royal Society [211179/Z/18/Z]; Cancer Research UK Lung Cancer Center of Excellence; NIHR BRC at University College London Hospitals; Rosetrees	Deutsche Krebshilfe for AM (Doktorandenstipendium)(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)(German Research Foundation (DFG)); German Consortium for Translational Cancer Research (DKTK); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Wellcome Trust(Wellcome Trust); Royal Society(Royal Society of London); Cancer Research UK Lung Cancer Center of Excellence; NIHR BRC at University College London Hospitals; Rosetrees(Rosetrees Trust)	We thank the members of the TRACERx consortium for participating in this study. The authors thank Bettina Flasch for excellent technical assistance. Grant support by Deutsche Krebshilfe for AM (Doktorandenstipendium 112066); the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation - FOR 2036, SFB 1335 (Project-ID 360372040)), German Consortium for Translational Cancer Research (DKTK) to KS and PJJ; Support by the Swiss National Science Foundation (project grant #31003A_173006) to TK; NM is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (Grant Number 211179/Z/18/Z), and also receives funding from Cancer Research UK Lung Cancer Center of Excellence, Rosetrees, and the NIHR BRC at University College London Hospitals.	Alenzi FQB, 2004, BRIT J BIOMED SCI, V61, P99, DOI 10.1080/09674845.2004.11732652; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brock CK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09010-6; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Carpio MA, 2015, P NATL ACAD SCI USA, V112, P7201, DOI 10.1073/pnas.1421063112; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Echeverry N, 2013, CELL DEATH DIFFER, V20, P785, DOI 10.1038/cdd.2013.10; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Ichim G, 2016, NAT REV CANCER, V16, P539, DOI 10.1038/nrc.2016.58; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Janic A, 2018, NAT MED, V24, P947, DOI 10.1038/s41591-018-0043-5; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Ke F, 2012, CELL DEATH DIFFER, V19, P915, DOI 10.1038/cdd.2011.210; Ke FFS, 2018, CELL, V173, P1217, DOI 10.1016/j.cell.2018.04.036; Lieschke E, 2019, J MOL CELL BIOL, V11, P212, DOI 10.1093/jmcb/mjy077; Llambi F, 2016, CELL, V165, P421, DOI 10.1016/j.cell.2016.02.026; Marino S, 2000, GENE DEV, V14, P994; Moravcikova E, 2017, INT J CANCER, V141, P2050, DOI 10.1002/ijc.30906; Munkhbaatar E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18372-1; Naim S, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.574338; Rabachini T, 2018, CELL DEATH DIFFER, V25, P706, DOI 10.1038/s41418-017-0008-0; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ray JE, 2010, CELL DEATH DIFFER, V17, P846, DOI 10.1038/cdd.2009.167; Srivastava R, 2019, P NATL ACAD SCI USA, V116, P15469, DOI 10.1073/pnas.1904523116; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Zhang F, 2019, MED SCI MONITOR, V25, P5356, DOI 10.12659/MSM.913706; Zheng JH, 2018, CELL REP, V23, P2083, DOI 10.1016/j.celrep.2018.04.060	33	1	1	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1376	1382		10.1038/s41388-021-02161-1	http://dx.doi.org/10.1038/s41388-021-02161-1		JAN 2022	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35091677	Green Published, hybrid			2022-12-17	WOS:000749073200002
J	Yi, Y; Li, YQ; Li, C; Wu, LX; Zhao, DY; Li, FX; Fazli, LD; Wang, R; Wang, L; Dong, XS; Zhao, W; Chen, KF; Cao, Q				Yi, Yang; Li, Yanqiang; Li, Chao; Wu, Longxiang; Zhao, Dongyu; Li, Fuxi; Fazli, Ladan; Wang, Rui; Wang, Long; Dong, Xuesen; Zhao, Wei; Chen, Kaifu; Cao, Qi			Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE EZH2; GENE-EXPRESSION; PROTEIN EZH2; POLYCOMB; RECEPTOR; PROGRESSION; PACKAGE; GROWTH; CELLS	Cell division cycle-associated 8 (CDCA8) is a component of chromosomal passenger complex (CPC) that participates in mitotic regulation. Although cancer-related CDCA8 hyperactivation has been widely observed, its molecular mechanism remains elusive. Here, we report that CDCA8 overexpression maintains tumorigenicity and is associated with poor clinical outcome in patients with prostate cancer (PCa). Notably, enhancer of zeste homolog 2 (EZH2) is identified to be responsible for CDCA8 activation in PCa. Genome-wide assays revealed that EZH2-induced H3K27 trimethylation represses let-7b expression and thus protects the let-7b-targeting CDCA8 transcripts. More importantly, EZH2 facilitates the self-activation of E2F1 by recruiting E2F1 to its own promoter region in a methylation-independent manner. The high level of E2F1 further promotes transcription of CDCA8 along with the other CPC subunits. Taken together, our study suggests that EZH2-mediated cell cycle regulation in PCa relies on both its methyltransferase and non-methyltransferase activities.	[Yi, Yang; Li, Chao; Wu, Longxiang; Wang, Rui; Cao, Qi] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA; [Yi, Yang; Li, Chao; Cao, Qi] Houston Methodist Res Inst, Ctr Inflammat & Epigenet, Houston, TX 77030 USA; [Li, Yanqiang; Zhao, Dongyu; Chen, Kaifu] Boston Childrens Hosp, Dept Cardiol, Basic & Translat Res Div, Boston, MA 02115 USA; [Li, Yanqiang; Zhao, Dongyu; Chen, Kaifu] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [Li, Chao; Wang, Long] Cent South Univ, Xiangya Hosp 3, Dept Urol, Changsha 410013, Peoples R China; [Wu, Longxiang] Cent South Univ, Dept Urol, Xiangya Hosp, Changsha 410008, Peoples R China; [Li, Fuxi; Zhao, Wei] Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Guangzhou 510080, Peoples R China; [Fazli, Ladan; Dong, Xuesen] Vancouver Gen Hosp, Vancouver Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; [Fazli, Ladan; Dong, Xuesen] Univ British Columbia, Dept Urol Sci, Vancouver, BC V6H 3Z6, Canada; [Chen, Kaifu] Dana Farber Harvard Canc Ctr, Prostate Canc Program, 450 Brookline Ave,BP332A, Boston, MA 02215 USA; [Cao, Qi] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Central South University; Central South University; Sun Yat Sen University; University of British Columbia; University of British Columbia; Harvard University; Dana-Farber Cancer Institute; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Cao, Q (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA.; Cao, Q (corresponding author), Houston Methodist Res Inst, Ctr Inflammat & Epigenet, Houston, TX 77030 USA.; Chen, KF (corresponding author), Boston Childrens Hosp, Dept Cardiol, Basic & Translat Res Div, Boston, MA 02115 USA.; Chen, KF (corresponding author), Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.; Chen, KF (corresponding author), Dana Farber Harvard Canc Ctr, Prostate Canc Program, 450 Brookline Ave,BP332A, Boston, MA 02215 USA.; Cao, Q (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA.	kaifu.chen@childrens.harvard.edu; qi.cao@northwestern.edu	Dong, Xuesen/AGF-9228-2022; Cao, Qi/A-5517-2010	Cao, Qi/0000-0002-5140-3681; Dong, Xuesen/0000-0002-3115-3371; Yi, Yang/0000-0002-1958-7249	American Cancer Society [RSG-15-192-01]; Northwestern University; Northwestern University, U.S. Department of Defense [W81XWH-17-1-0357, W81XWH-19-1-0563, W81XWH-20-1-0504]; NIH/NCI [R01CA208257, R01CA256741]; Prostate SPORE [P50CA180995]; Polsky Urologic Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital	American Cancer Society(American Cancer Society); Northwestern University; Northwestern University, U.S. Department of Defense; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Prostate SPORE; Polsky Urologic Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital	This work was supported by American Cancer Society (RSG-15-192-01) and a startup funding provided by the Northwestern University. Part of effort for QC was supported by Northwestern University, U.S. Department of Defense (W81XWH-17-1-0357, W81XWH-19-1-0563 and W81XWH-20-1-0504), NIH/NCI (R01CA208257, R01CA256741 and Prostate SPORE P50CA180995 Development Research Program) and Polsky Urologic Cancer Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Asenjo HG, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay4768; Ben-Salem S, 2021, ENDOCR-RELAT CANCER, V28, pR141, DOI 10.1530/ERC-20-0517; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carmena M, 2012, NAT REV MOL CELL BIO, V13, P789, DOI 10.1038/nrm3474; Chen KF, 2013, GENOME RES, V23, P341, DOI 10.1101/gr.142067.112; Chirshev E, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0240-y; Chun JN, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2019.188336; Dai C, 2015, J BIOL CHEM, V290, P22423, DOI 10.1074/jbc.M115.642710; Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043; Fillmore CM, 2015, NATURE, V520, P239, DOI 10.1038/nature14122; Gao X, 2020, PEERJ, V8, DOI 10.7717/peerj.9078; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433; Gonzalez ME, 2011, CANCER RES, V71, P2360, DOI 10.1158/0008-5472.CAN-10-1933; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hernandez J, 2004, CANCER-AM CANCER SOC, V101, P894, DOI 10.1002/cncr.20480; Huang HY, 2020, NUCLEIC ACIDS RES, V48, pD148, DOI 10.1093/nar/gkz896; Ishak CA, 2016, MOL CELL, V64, P1074, DOI 10.1016/j.molcel.2016.10.021; Jeon T, 2021, CANCERS, V13, DOI 10.3390/cancers13051055; Kim J, 2018, CELL REP, V25, P2808, DOI 10.1016/j.celrep.2018.11.035; Kong DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033729; Koyen AE, 2020, ONCOGENE, V39, P4798, DOI 10.1038/s41388-020-1332-2; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Liu T, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.608393; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Michaelis M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019705; Park SH, 2021, ONCOGENE, V40, P5788, DOI 10.1038/s41388-021-01982-4; Park SH, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe2261; Qi Gonghua, 2021, Am J Cancer Res, V11, P389; Rastgoo N, 2018, LEUKEMIA, V32, P2471, DOI 10.1038/s41375-018-0140-y; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Sullivan M, 2007, NAT REV MOL CELL BIO, V8, P894, DOI 10.1038/nrm2276; Tabbal H, 2019, BRIT J CANCER, V121, P384, DOI 10.1038/s41416-019-0538-y; Tang C, 2021, BIOL REPROD, V105, P267, DOI 10.1093/biolre/ioab062; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Wu Z, 2011, CELL DEATH DIFFER, V18, P1771, DOI 10.1038/cdd.2011.48; Xie N, 2015, INT J CANCER, V136, pE27, DOI 10.1002/ijc.29147; Xu H, 2016, MOL CANCER RES, V14, P163, DOI 10.1158/1541-7786.MCR-15-0313; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang Q, 2019, ACM T INTEL SYST TEC, V10, DOI 10.1145/3298981; Yi Y, 2021, NAT CELL BIOL, V23, P341, DOI 10.1038/s41556-021-00653-6; Yin HL, 2020, THERANOSTICS, V10, P8494, DOI 10.7150/thno.44849; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu Y, 2015, PROSTATE, V75, P1043, DOI 10.1002/pros.22988; Zhao DY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18913-8; Zhuang CB, 2016, INT J ONCOL, V48, P1195, DOI 10.3892/ijo.2016.3336	54	1	1	5	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1610	1621		10.1038/s41388-022-02208-x	http://dx.doi.org/10.1038/s41388-022-02208-x		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35094010				2022-12-17	WOS:000750486500001
J	Chen, TC; Yao, CY; Chen, YR; Yuan, CT; Lin, CC; Hsu, YC; Chuang, PH; Kao, CJ; Li, YH; Hou, HA; Chou, WC; Tien, HF				Chen, Tsung-Chih; Yao, Chi-Yuan; Chen, Yu-Ren; Yuan, Chang-Tsu; Lin, Chien-Chin; Hsu, Yueh-Chwen; Chuang, Po-Han; Kao, Chein-Jun; Li, Yi-Hung; Hou, Hsin-An; Chou, Wen-Chien; Tien, Hwei-Fang			Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; NETWORKS; ATM	The pathogenesis of acute leukemia involves interaction among genetic alterations. Mutations of IDH1/2 and PHF6 are common and co-exist in some patients of hematopoietic malignancies, but their cooperative effects remain unexplored. In this study, we addressed the question by characterizing the hematopoietic phenotypes of mice harboring neither, Phf6 knockout, Idh2 R172K, or combined mutations. We found that the combined Phf6(KO)Idh2(R172K) mice showed biased hematopoietic differentiation toward myeloid lineages and reduced long-term hematopoietic stem cells. They rapidly developed neoplasms of myeloid and lymphoid lineages, with much shorter survival compared with single mutated and wild-type mice. The marrow and spleen cells of the combined mutated mice produced a drastically increased amount of 2-hydroxyglutarate compared with mice harboring Idh2 R172K. Single-cell RNA sequencing revealed distinct patterns of transcriptome of the hematopoietic stem/progenitor cells from the combined mutated mice, including aberrant expression of metabolic enzymes, increased expression of several oncogenes, and impairment of DNA repairs, as confirmed by the enhanced gamma H2AX expression in the marrow and spleen cells. We conclude that Idh2 and Phf6 mutations are synergistic in leukemogenesis, at least through overproduction of 2-hydroxyglutarate and impairment of DNA repairs.	[Chen, Tsung-Chih] Taichung Vet Gen Hosp, Dept Internal Med, Div Hematol Med Oncol, Taichung, Taiwan; [Chen, Tsung-Chih; Yao, Chi-Yuan; Yuan, Chang-Tsu; Lin, Chien-Chin; Chuang, Po-Han] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan; [Yao, Chi-Yuan; Chen, Yu-Ren; Lin, Chien-Chin; Hsu, Yueh-Chwen; Chuang, Po-Han; Kao, Chein-Jun; Chou, Wen-Chien] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan; [Yuan, Chang-Tsu; Chou, Wen-Chien] Natl Taiwan Univ, Dept Pathol, Canc Ctr, Taipei, Taiwan; [Yuan, Chang-Tsu] Natl Taiwan Univ Hosp, Dept Pathol, Taipei, Taiwan; [Li, Yi-Hung] Chinese Culture Univ, Dept Anim Sci, Taipei, Taiwan; [Hou, Hsin-An; Tien, Hwei-Fang] Natl Taiwan Univ Hosp, Dept Internal Med, Div Hematol, Taipei, Taiwan	Taichung Veterans General Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Chinese Culture University; National Taiwan University; National Taiwan University Hospital	Chou, WC (corresponding author), Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan.; Chou, WC (corresponding author), Natl Taiwan Univ, Dept Pathol, Canc Ctr, Taipei, Taiwan.	wchou@ntu.edu.tw		CHOU, WEN-CHIEN/0000-0003-2967-698X; Yuan, Chang-Tsu/0000-0003-1438-9187; LIN, CHIEN-CHIN/0000-0001-7160-2285	Ministry of Science and Technology of Taiwan [MOST 106-2314-B-002-224-MY3, MOST 106-2314-B-002-152-, MOST 107-2314-B-075A-010-, MOST 108-2314-B-075A-007-, MOST 109-2314-B-002 -221-, MOST 109-2314-B-075A-008-MY2]; Ministry of Health and Welfare [MOHW109-TDU-B-211-134009];  [TCVGH-1093702B];  [TCVGH-1103701B]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan); ; 	We thank the technical services provided by the Transgenic Mouse Model Core Facility of the National Core Facility Program for Biotechnology, Ministry of Science and Technology, the Animal Resources Laboratory of National Taiwan University Centers of Genomic and Precision Medicine, the Metabolomics Core Laboratory of National Taiwan University Center of Genomic Medicine, and the National Center for Genome Medicine. We thank the technical help from the Genomics Core Facility of the Institute of Molecular Biology, Academia Sinica. We would like to acknowledge the service provided by the Flow Cytometric Analyzing and Sorting Core Facilities at National Taiwan University Hospital and First Core Laboratory of National Taiwan University College of Medicine. The study was supported by research grants including TCVGH-1093702B, TCVGH-1103701B, Ministry of Science and Technology of Taiwan (MOST 106-2314-B-002-224-MY3, MOST 106-2314-B-002-152-, MOST 107-2314-B-075A-010-, MOST 108-2314-B-075A-007-, MOST 109-2314-B-002 -221- and MOST 109-2314-B-075A-008-MY2-), and Ministry of Health and Welfare (MOHW109-TDU-B-211-134009).	Abelson S, 2018, NATURE, V559, P400, DOI 10.1038/s41586-018-0317-6; Amson R, 2012, NAT MED, V18, P91, DOI 10.1038/nm.2546; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bommer UA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071632; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Chan SM, 2015, NAT MED, V21, P178, DOI 10.1038/nm.3788; Chen C, 2013, GENE DEV, V27, P1974, DOI 10.1101/gad.226613.113; Corces-Zimmerman MR, 2014, P NATL ACAD SCI USA, V111, P2548, DOI 10.1073/pnas.1324297111; Dahlin JS, 2018, BLOOD, V131, pE1, DOI 10.1182/blood-2017-12-821413; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; de Rooij JDE, 2016, BRIT J HAEMATOL, V175, P967, DOI 10.1111/bjh.13891; Dekker LJM, 2020, FASEB J, V34, P3646, DOI 10.1096/fj.201902352R; Desai P, 2018, NAT MED, V24, P1015, DOI 10.1038/s41591-018-0081-z; Duan L, 2019, CANCER BIOL THER, V20, P252, DOI 10.1080/15384047.2018.1523858; Gan LH, 2020, CELL REP, V30, P3717, DOI 10.1016/j.celrep.2020.02.085; Holmfeldt L, 2010, PEDIATR BLOOD CANCER, V55, P595, DOI 10.1002/pbc.22661; Hsu YC, 2019, BLOOD ADV, V3, P2355, DOI 10.1182/bloodadvances.2019000391; Inoue S, 2016, CANCER CELL, V30, P337, DOI 10.1016/j.ccell.2016.05.018; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Lemonnier F, 2016, P NATL ACAD SCI USA, V113, P15084, DOI 10.1073/pnas.1617929114; Lin CC, 2014, AM J HEMATOL, V89, P137, DOI 10.1002/ajh.23596; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McRae HM, 2019, BLOOD, V133, P1729, DOI 10.1182/blood-2018-07-860726; Miyagi S, 2019, BLOOD, V133, P2495, DOI 10.1182/blood.2019000468; Molenaar RJ, 2018, ONCOGENE, V37, P1949, DOI 10.1038/s41388-017-0077-z; Mori T, 2016, LEUKEMIA, V30, P2270, DOI 10.1038/leu.2016.212; Nestorowa S, 2016, BLOOD, V128, pE20, DOI 10.1182/blood-2016-05-716480; Notta F, 2016, SCIENCE, V351, P139, DOI 10.1126/science.aab2116; Oh S, 2020, NUCLEIC ACIDS RES, V48, P9037, DOI 10.1093/nar/gkaa626; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Pellin D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10291-0; Psaila B, 2020, MOL CELL, V78, P477, DOI 10.1016/j.molcel.2020.04.008; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038; Soto-Feliciano YM, 2017, GENE DEV, V31, P973, DOI 10.1101/gad.295857.117; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Van Vlierberghe P, 2011, LEUKEMIA, V25, P130, DOI 10.1038/leu.2010.247; Van Vlierberghe P, 2010, NAT GENET, V42, P338, DOI 10.1038/ng.542; Wang JD, 2013, J BIOL CHEM, V288, P3174, DOI 10.1074/jbc.M112.414839; Wang P, 2015, CELL REP, V13, P2353, DOI 10.1016/j.celrep.2015.11.029; Wang Q, 2011, HAEMATOL-HEMATOL J, V96, P1808, DOI 10.3324/haematol.2011.043083; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Warmerdam DO, 2020, EMBO REP, V21, DOI 10.15252/embr.201948460; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wendorff AA, 2019, CANCER DISCOV, V9, P436, DOI 10.1158/2159-8290.CD-18-1005; Xia D, 2017, LEUKEMIA LYMPHOMA, V58, P2208, DOI 10.1080/10428194.2017.1287358; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Ye D, 2018, TRENDS CANCER, V4, P151, DOI 10.1016/j.trecan.2017.12.005; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang H, 2013, CANCER CELL, V24, P575, DOI 10.1016/j.ccr.2013.09.018; Zhang XT, 2020, BLOOD, V135, P845, DOI 10.1182/blood.2019003330; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944; Zhou C, 2017, LEUKEMIA, V31, P1196, DOI 10.1038/leu.2016.329	56	1	1	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1576	1588		10.1038/s41388-022-02193-1	http://dx.doi.org/10.1038/s41388-022-02193-1		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35091680				2022-12-17	WOS:000749073300002
J	Ma, Y; Zhang, HB; Chen, C; Liu, LX; Ding, T; Wang, Y; Ma, DC; Ling, XL; Chen, XH; Li, JP; Zhong, GS; Ru, GQ; Zhang, L; Tang, JM				Ma, Yan; Zhang, Haibo; Chen, Cheng; Liu, Lixin; Ding, Ting; Wang, Ying; Ma, Dachang; Ling, Xiaoling; Chen, Xiaohua; Li, Jianping; Zhong, Guansheng; Ru, Guoqing; Zhang, Lei; Tang, Jianming			TRIM32 promotes radioresistance by disrupting TC45-STAT3 interaction in triple-negative breast cancer	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; UBIQUITIN LIGASE TRIM32; STAT3; PHOSPHORYLATION; PROLIFERATION; RADIOTHERAPY; DEGRADATION; ACTIVATION; PROGNOSIS; ENZYME	Radioresistance is common in the treatment of triple-negative breast cancer (TNBC), but the molecular mechanisms involved remain unclear. Herein, we reveal that tripartite motif-containing protein 32 (TRIM32) is upregulated in TNBC and is negatively associated with survival of TNBC patients. Radiotherapy resulted in enhanced expression of TRIM32, whereas TRIM32 depletion reduced TNBC radioresistance in vitro and in vivo. Mechanistically, radiotherapy promoted the association between TRIM32 and nuclear STAT3, which suppressed TC45-induced dephosphorylation of STAT3, resulting in increased STAT3 transcriptional activation and TNBC radioresistance. Finally, we demonstrated that TRIM32 and STAT3 phosphorylation are co-expressed in TNBC tissues. Moreover, high expression of TRIM32 and STAT3 phosphorylation is positively linked to poor prognosis of TNBC patients. Our study demonstrates that TRIM32 is a novel target for predicting radioresistance in TNBC patients.	[Ma, Yan; Chen, Xiaohua; Tang, Jianming] Lanzhou Univ, Hosp 1, Dept Radiat Oncol, Lanzhou 730000, Gansu, Peoples R China; [Zhang, Haibo; Wang, Ying] Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Oncol Ctr,Dept Radiat Oncol, Hangzhou 310014, Zhejiang, Peoples R China; [Chen, Cheng; Ma, Dachang] Lanzhou Univ, Hosp 1, Dept Breast Surg, Lanzhou 730000, Gansu, Peoples R China; [Liu, Lixin] Lanzhou Univ, Hosp 1, Dept Thorac Surg, Lanzhou 730000, Gansu, Peoples R China; [Ding, Ting] Yiyang Cent Hosp, Dept Endocrinol, Yiyang 413000, Hunan, Peoples R China; [Ling, Xiaoling] Lanzhou Univ, Hosp 1, Dept Oncol, Lanzhou 730000, Gansu, Peoples R China; [Li, Jianping] Shanghai Bioegene Co Ltd, Shanghai 200003, Peoples R China; [Zhong, Guansheng] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Breast Surg, Hangzhou 310003, Zhejiang, Peoples R China; [Ru, Guoqing] Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Dept Pathol, Hangzhou 310014, Zhejiang, Peoples R China; [Zhang, Lei] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Radiat Oncol, Shanghai 200127, Peoples R China	Lanzhou University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Lanzhou University; Lanzhou University; Lanzhou University; Zhejiang University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Shanghai Jiao Tong University	Tang, JM (corresponding author), Lanzhou Univ, Hosp 1, Dept Radiat Oncol, Lanzhou 730000, Gansu, Peoples R China.; Zhang, L (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Radiat Oncol, Shanghai 200127, Peoples R China.	hrbmuzl@126.com; 15900792812@163.com	Li, Jing/GYU-5036-2022; LI, JIAN/GRY-2197-2022; li, jian/GSE-0245-2022	Zhang, Haibo/0000-0002-5134-4167	National Natural Science Foundation of China [82003236]; Zhejiang Provincial Nature Science Foundation of China [LY20H160044]; Gansu Provincial National Science Foundation for Distinguished Young Scholars [21JR7RA389]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Nature Science Foundation of China; Gansu Provincial National Science Foundation for Distinguished Young Scholars	This study was supported, in part, by grants from the National Natural Science Foundation of China (Grant number: 82003236 to Haibo Zhang), Zhejiang Provincial Nature Science Foundation of China (Grant number: LQ20H160063 to Jianming Tang), Gansu Provincial National Science Foundation for Distinguished Young Scholars (Grant number: 21JR7RA389 to Jianming Tang), Zhejiang Provincial Nature Science Foundation of China (Grant number: LY20H160044 to Ying Wang).	Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; Bi ZF, 2020, ADV SCI, V7, DOI 10.1002/advs.202000915; Brett-Morris A, 2014, CANCER RES, V74, P6925, DOI 10.1158/0008-5472.CAN-14-1249; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Cui XP, 2016, MOL CELL BIOCHEM, V421, P127, DOI 10.1007/s11010-016-2793-z; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004; Gillison ML, 2019, LANCET, V393, P40, DOI 10.1016/S0140-6736(18)32779-X; Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002; He KY, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003900; He L, 2019, CANCER MANAG RES, V11, P5765, DOI 10.2147/CMAR.S213663; He MY, 2018, CRIT REV ONCOL HEMAT, V131, P96, DOI 10.1016/j.critrevonc.2018.09.004; Horn EJ, 2004, CARCINOGENESIS, V25, P157, DOI 10.1093/carcin/bgh003; Ikeda O, 2009, BIOCHEM BIOPH RES CO, V384, P71, DOI 10.1016/j.bbrc.2009.04.076; Kano S, 2008, CANCER RES, V68, P5572, DOI 10.1158/0008-5472.CAN-07-6231; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kudryashova E, 2009, HUM MOL GENET, V18, P1353, DOI 10.1093/hmg/ddp036; Lazzari E, 2016, INT J BIOCHEM CELL B, V79, P469, DOI 10.1016/j.biocel.2016.07.023; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu J, 2014, CELL DEATH DIFFER, V21, P1792, DOI 10.1038/cdd.2014.121; Lu L, 2018, ONCOGENE, V37, P5292, DOI 10.1038/s41388-018-0340-y; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Okawa T, 1999, Gan To Kagaku Ryoho, V26 Suppl 1, P15; Park SY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1405-7; Qiu LY, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-03021-y; Sang YZ, 2018, CANCER RES, V78, P1792, DOI 10.1158/0008-5472.CAN-17-2774; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Wang J, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7297631; Wang ML, 2020, CELL DEATH DIFFER, V27, P1286, DOI 10.1038/s41418-019-0415-5; Wang XH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01120; Wang YM, 2014, MOL CELL, V53, P752, DOI 10.1016/j.molcel.2014.01.020; Wang Y, 2020, CELL DEATH DIFFER, V27, P695, DOI 10.1038/s41418-019-0381-y; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yin HM, 2019, J CELL BIOCHEM, V120, P5232, DOI 10.1002/jcb.27798; Zhao TT, 2018, J CANCER, V9, P1349, DOI 10.7150/jca.22390; Zhou ZC, 2014, GASTROENTEROLOGY, V147, P1043, DOI 10.1053/j.gastro.2014.07.021	36	1	1	6	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1589	1599		10.1038/s41388-022-02204-1	http://dx.doi.org/10.1038/s41388-022-02204-1		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35091679				2022-12-17	WOS:000749073300004
J	Saliba, J; Coutaud, B; Makhani, K; Roth, NE; Jackson, J; Park, JY; Gagnon, N; Costa, P; Jeyakumar, T; Bury, M; Beauchemin, N; Mann, KK; Blank, V				Saliba, James; Coutaud, Baptiste; Makhani, Kiran; Roth, Noam Epstein; Jackson, Jennie; Park, Joo Yeoun; Gagnon, Natascha; Costa, Paolo; Jeyakumar, Thiviya; Bury, Marina; Beauchemin, Nicole; Mann, Koren K.; Blank, Volker			Loss of NFE2L3 protects against inflammation-induced colorectal cancer through modulation of the tumor microenvironment	ONCOGENE			English	Article							ERYTHROID 2-LIKE 3; MAST-CELLS; NUCLEAR FACTOR; COLON-CANCER; METASTASIS; EXPRESSION; CARCINOMA; IL-33; ACTIVATION; CONTRIBUTE	We investigated the role of the NFE2L3 transcription factor in inflammation-induced colorectal cancer. Our studies revealed that Nfe2l3(-/-) mice exhibit significantly less inflammation in the colon, reduced tumor size and numbers, and skewed localization of tumors with a more pronounced decrease of tumors in the distal colon. CIBERSORT analysis of RNA-seq data from normal and tumor tissue predicted a reduction in mast cells in Nfe2l3(-/-) animals, which was confirmed by toluidine blue staining. Concomitantly, the transcript levels of Il33 and Rab27a, both important regulators of mast cells, were reduced and increased, respectively, in the colorectal tumors of Nfe2l3(-/-) mice. Furthermore, we validated NFE2L3 binding to the regulatory sequences of the IL33 and RAB27A loci in human colorectal carcinoma cells. Using digital spatial profiling, we found that Nfe2l3(-/-) mice presented elevated FOXP3 and immune checkpoint markers CTLA4, TIM3, and LAG3, suggesting an increase in Treg counts. Staining for CD3 and FOXP3 confirmed a significant increase in immunosuppressive Tregs in the colon of Nfe2l3(-/-) animals. Also, Human Microbiome Project (HMP2) data showed that NFE2L3 transcript levels are higher in the rectum of ulcerative colitis patients. The observed changes in the tumor microenvironment provide new insights into the molecular differences regarding colon cancer sidedness. This may be exploited for the treatment of early-onset colorectal cancer as this emerging subtype primarily displays distal/left-sided tumors.	[Saliba, James; Coutaud, Baptiste; Makhani, Kiran; Roth, Noam Epstein; Jackson, Jennie; Park, Joo Yeoun; Gagnon, Natascha; Costa, Paolo; Bury, Marina; Mann, Koren K.; Blank, Volker] Lady Davis Inst Med Res, Montreal, PQ, Canada; [Saliba, James; Makhani, Kiran; Roth, Noam Epstein; Jeyakumar, Thiviya; Beauchemin, Nicole; Blank, Volker] McGill Univ, Dept Med, Montreal, PQ, Canada; [Jeyakumar, Thiviya; Beauchemin, Nicole] McGill Univ, Goodman Canc Inst, Montreal, PQ, Canada; [Jeyakumar, Thiviya; Beauchemin, Nicole] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Jeyakumar, Thiviya; Beauchemin, Nicole] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Mann, Koren K.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada; [Blank, Volker] McGill Univ, Dept Physiol, Montreal, PQ, Canada; [Jackson, Jennie] Univ British Columbia, Life Sci Inst, Vancouver, BC, Canada; [Jackson, Jennie] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC, Canada; [Bury, Marina] UCLouvain, De Duve Inst, Brussels, Belgium	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; McGill University; University of British Columbia; University of British Columbia; Universite Catholique Louvain	Blank, V (corresponding author), Lady Davis Inst Med Res, Montreal, PQ, Canada.; Blank, V (corresponding author), McGill Univ, Dept Med, Montreal, PQ, Canada.; Blank, V (corresponding author), McGill Univ, Dept Physiol, Montreal, PQ, Canada.	volker.blank@mcgill.ca		Jackson, Jennie/0000-0003-2890-4047	SEG (Lebanon) studentship; McGill Integrated Cancer Research Training Program (MICRTP) studentship; LDI/TD bank fellowship; Gordon Phillip Studentship; Division of Experimental Medicine, McGilll University; Lady Davis Institute/TB bank studentship; Biotalent Canada; MICRTP studentship; Donner Canada Foundation; MICRTP; FRQS; Cole Foundation fellowship; Canadian Institutes of Health Research (CIHR) [MOP-97932, PJT-152937]	SEG (Lebanon) studentship; McGill Integrated Cancer Research Training Program (MICRTP) studentship; LDI/TD bank fellowship; Gordon Phillip Studentship; Division of Experimental Medicine, McGilll University; Lady Davis Institute/TB bank studentship; Biotalent Canada; MICRTP studentship; Donner Canada Foundation; MICRTP(Canadian Institutes of Health Research (CIHR)); FRQS; Cole Foundation fellowship; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	We would like to thank Steven Hebert and Claudia Kleinman for bioinformatics analyses and expertise, and Ulrich Blank for advice on mast cells. JS was supported by SEG (Lebanon) and McGill Integrated Cancer Research Training Program (MICRTP) studentships. KM obtained a studentship from LDI/TD bank fellowship and Gordon Phillip Studentship, NER was supported by a recruitment award (Division of Experimental Medicine, McGilll University) and a Lady Davis Institute/TB bank studentship, JJ received support from Biotalent Canada, JYP was supported by a MICRTP studentship and TJ from Donner Canada Foundation, MB was supported by MICRTP, FRQS and a Cole Foundation fellowship. The study was supported by the Canadian Institutes of Health Research (CIHR) MOP-97932 and PJT-152937 grants to VB.	Akimoto N, 2021, NAT REV CLIN ONCOL, V18, P230, DOI 10.1038/s41571-020-00445-1; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Aono S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133344; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Baran B, 2018, GASTROENTEROL RES, V11, P264, DOI 10.14740/gr1062w; Blank V, 2008, J MOL BIOL, V376, P913, DOI 10.1016/j.jmb.2007.11.074; Blatner NR, 2010, P NATL ACAD SCI USA, V107, P6430, DOI 10.1073/pnas.0913683107; Bleeker JS, 2020, J CLIN ONCOL, V38; Bury M, 2019, CELL REP, V29, P1469, DOI 10.1016/j.celrep.2019.09.087; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Chen LB, 2019, GENE, V692, P119, DOI 10.1016/j.gene.2019.01.001; Chenais B, 2005, MOL ENDOCRINOL, V19, P125, DOI 10.1210/me.2003-0379; Cheon EC, 2011, CANCER RES, V71, P1627, DOI 10.1158/0008-5472.CAN-10-1923; Chevillard G, 2011, CELL MOL LIFE SCI, V68, P3337, DOI 10.1007/s00018-011-0747-x; Chevillard G, 2011, BLOOD, V117, P2005, DOI 10.1182/blood-2010-02-271460; Chowdhury A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42725; Cui GL, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00561; Danelli L, 2015, CANCER IMMUNOL RES, V3, P85, DOI 10.1158/2326-6066.CIR-14-0102; De Oliveira T, 2019, ONCOGENE, V38, P1787, DOI 10.1038/s41388-018-0551-2; Dong WW, 2015, DISCOV MED, V20, P357; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Fodil N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01381-y; Fukuda M, 2013, TRAFFIC, V14, P949, DOI 10.1111/tra.12083; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Gounaris E, 2007, P NATL ACAD SCI USA, V104, P19977, DOI 10.1073/pnas.0704620104; Gulubova MV, 2012, INT J COLORECTAL DIS, V27, P159, DOI 10.1007/s00384-011-1334-1; Heijmans J, 2012, BBA-MOL BASIS DIS, V1822, P9, DOI 10.1016/j.bbadis.2010.12.001; Hodzic Z, 2017, CYTOKINE, V100, P1, DOI 10.1016/j.cyto.2017.06.017; Johnson CM, 2013, CANCER CAUSE CONTROL, V24, P1207, DOI 10.1007/s10552-013-0201-5; Joulia R, 2017, J ALLERGY CLIN IMMUN, V140, P497, DOI 10.1016/j.jaci.2016.09.049; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kannan MB, 2015, J BIOL CHEM, V290, P26292, DOI 10.1074/jbc.M115.666446; Keller DS, 2019, TECH COLOPROCTOL, V23, P3, DOI 10.1007/s10151-019-1926-2; Kitaya K, 2007, INT J MOL MED, V20, P689; Kolde Raivo, 2019, CRAN; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li YK, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0839-7; Li ZY, 2015, CELL MOL IMMUNOL, V12, P558, DOI 10.1038/cmi.2015.10; Liu XJ, 2014, BIOCHEM BIOPH RES CO, V453, P486, DOI 10.1016/j.bbrc.2014.09.106; Loomans-Kropp HA, 2019, J CANCER EPIDEMIOL, V2019, DOI 10.1155/2019/9841295; Low EE, 2020, GASTROENTEROLOGY, V159, P492, DOI 10.1053/j.gastro.2020.01.004; Lunderius-Andersson C, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00082; Mauri G, 2019, MOL ONCOL, V13, P109, DOI 10.1002/1878-0261.12417; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]; Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000; Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26; Proctor LM, 2019, NATURE, V569, P641, DOI 10.1038/s41586-019-1238-8; Ren YG, 2020, J CANCER, V11, P6939, DOI 10.7150/jca.48100; Ribatti D, 2018, INT ARCH ALLERGY IMM, V176, P55, DOI 10.1159/000487538; Rigoni A, 2015, CANCER RES, V75, P3760, DOI 10.1158/0008-5472.CAN-14-3767; Saluja R, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0076-5; Shi CB, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0303-3; Singh RK, 2013, FEBS J, V280, P892, DOI 10.1111/febs.12081; Slenter DN, 2018, NUCLEIC ACIDS RES, V46, pD661, DOI 10.1093/nar/gkx1064; Sun JG, 2019, ONCOTARGETS THER, V12, P3019, DOI 10.2147/OTT.S197409; Suzuki R, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-84; Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x; Thaker Ameet I, 2012, J Vis Exp, DOI 10.3791/4100; Van Der Kraak L, 2010, ONCOTARGET, V1, P436; Vuik FER, 2019, GUT, V68, P1820, DOI 10.1136/gutjnl-2018-317592; Vukman KV., 2014, BIOPROTOC, V4, pe1053; Wang CJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90651; Wang H, 2018, CELL CYCLE, V17, P2164, DOI 10.1080/15384101.2018.1520558; Wang J, 2019, J CANCER, V10, P6726, DOI 10.7150/jca.35641; Ward-Hartstonge KA, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.43; Weller CL, 2005, J EXP MED, V201, P1961, DOI 10.1084/jem.20042407; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu MM, 2019, WORLD J GASTROENTERO, V25, P1210, DOI 10.3748/wjg.v25.i10.1210; Yu YX, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1504729; Zhang LH, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/2829798; Zhang Z, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00017	78	1	1	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1563	1575		10.1038/s41388-022-02192-2	http://dx.doi.org/10.1038/s41388-022-02192-2		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35091681	hybrid, Green Published			2022-12-17	WOS:000749073300003
J	Mo, J; Moye, SL; McKay, RM; Le, LQ				Mo, Juan; Moye, Stefanie L.; McKay, Renee M.; Le, Lu Q.			Neurofibromin and suppression of tumorigenesis: beyond the GAP	ONCOGENE			English	Review							GENE-PRODUCT NEUROFIBROMIN; NF1 TUMOR-SUPPRESSOR; NERVE SHEATH TUMORS; EPITHELIAL-MESENCHYMAL TRANSITION; GENOTYPE-PHENOTYPE CORRELATION; SMALL-MOLECULE INHIBITORS; STEM-CELL PROLIFERATION; TYPE-1 GENE; SCHWANN-CELLS; PLEXIFORM NEUROFIBROMAS	Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disease and one of the most common inherited tumor predisposition syndromes, affecting 1 in 3000 individuals worldwide. The NF1 gene encodes neurofibromin, a large protein with RAS GTP-ase activating (RAS-GAP) activity, and loss of NF1 results in increased RAS signaling. Neurofibromin contains many other domains, and there is considerable evidence that these domains play a role in some manifestations of NF1. Investigating the role of these domains as well as the various signaling pathways that neurofibromin regulates and interacts with will provide a better understanding of how neurofibromin acts to suppress tumor development and potentially open new therapeutic avenues. In this review, we discuss what is known about the structure of neurofibromin, its interactions with other proteins and signaling pathways, its role in development and differentiation, and its function as a tumor suppressor. Finally, we discuss the latest research on potential therapeutics for neurofibromin-deficient neoplasms.	[Mo, Juan; Moye, Stefanie L.; McKay, Renee M.; Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, ODonnell Brain Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, ODonnell Brain Inst, Dallas, TX 75390 USA.	lu.le@utsouthwestern.edu		Le, Lu/0000-0003-2817-5382; McKay, Renee/0000-0001-5976-1996	US Department of Defense [W81XWH1910687]; Burroughs Wellcome Fund; National Cancer Institute of the NIH [R01 CA166593]; Developmental and Hyperactive RAS Tumor SPORE [U54 CA196519]; Neurofibromatosis Therapeutic Acceleration Program; NF1 Research Consortium Fund; Giorgio Foundation	US Department of Defense(United States Department of Defense); Burroughs Wellcome Fund(Burroughs Wellcome Fund); National Cancer Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Developmental and Hyperactive RAS Tumor SPORE; Neurofibromatosis Therapeutic Acceleration Program; NF1 Research Consortium Fund; Giorgio Foundation	JM is the recipient of the Early Investigator Research Award from the US Department of Defense (W81XWH1910687). LQL held a Career Award for Medical Scientists from the Burroughs Wellcome Fund and is the Thomas L. Shield, M.D. endowed Professor in Dermatology. He is supported by funding from the US Department of Defense, the National Cancer Institute of the NIH (R01 CA166593) and the Developmental and Hyperactive RAS Tumor SPORE (U54 CA196519); the Neurofibromatosis Therapeutic Acceleration Program; the NF1 Research Consortium Fund; and the Giorgio Foundation.	Afridi SK, 2015, AM J MED GENET A, V167, P2282, DOI 10.1002/ajmg.a.37186; Amano M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008704; Amirnasr A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59789-4; Anastasaki C, 2020, STEM CELL REP, V14, P541, DOI 10.1016/j.stemcr.2020.03.007; Anastasaki C, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00115; Anastasaki C, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000192; Anastasaki C, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000169; Anastasaki C, 2015, HUM MOL GENET, V24, P3518, DOI 10.1093/hmg/ddv103; ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; Antony-Debre I, 2017, J CLIN INVEST, V127, P4297, DOI 10.1172/JCI92504; Aras S, 2017, BRIT J CANCER, V117, P1583, DOI 10.1038/bjc.2017.356; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; Arima Y, 2010, EXP DERMATOL, V19, pE136, DOI 10.1111/j.1600-0625.2009.01017.x; Arkin MR, 2014, CHEM BIOL, V21, P1102, DOI 10.1016/j.chembiol.2014.09.001; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Arthur LL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14112; Arun V, 2013, FEBS LETT, V587, P1466, DOI 10.1016/j.febslet.2013.03.035; Arun V, 2013, J NEUROSCI RES, V91, P494, DOI 10.1002/jnr.23189; Assunto A, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1223-1; Atak ZK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038463; Bai RY, 2019, GENE THER, V26, P277, DOI 10.1038/s41434-019-0080-9; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Baralle FE, 2017, NAT REV MOL CELL BIO, V18, P437, DOI 10.1038/nrm.2017.27; Barron VA, 2012, BIOSCIENCE REP, V32, P131, DOI 10.1042/BSR20110060; Bausch B, 2007, J CLIN ENDOCR METAB, V92, P2784, DOI 10.1210/jc.2006-2833; Bayik D, 2021, NAT REV CANCER, V21, P526, DOI 10.1038/s41568-021-00366-w; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Bell RJA, 2015, SCIENCE, V348, P1036, DOI 10.1126/science.aab0015; Bellampalli SS, 2019, PAIN, V160, P1007, DOI 10.1097/j.pain.0000000000001486; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bertucci F, 2019, NATURE, V569, P560, DOI 10.1038/s41586-019-1056-z; Biayna J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83152-w; Bodempudi V, 2009, MOL CELL BIOL, V29, P3964, DOI 10.1128/MCB.01153-08; Bolcekova A, 2013, NEOPLASMA, V60, P655, DOI 10.4149/neo_2013_084; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; Boregowda RK, 2016, ONCOTARGET, V7, P29689, DOI 10.18632/oncotarget.8822; Boudry-Labis E, 2013, AM J HEMATOL, V88, P306, DOI 10.1002/ajh.23403; Boyanapalli M, 2006, BIOCHEM BIOPH RES CO, V340, P1200, DOI 10.1016/j.bbrc.2005.12.129; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Brems H, 2007, NAT GENET, V39, P1120, DOI 10.1038/ng2113; Brosseau JP, 2020, BRIT J CANCER, V123, P178, DOI 10.1038/s41416-020-0903-x; Brosseau JP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07452-y; Brown JA, 2010, J NEUROSCI, V30, P5579, DOI 10.1523/JNEUROSCI.3994-09.2010; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Buono FD, 2019, J PAIN RES, V12, P2555, DOI 10.2147/JPR.S209540; Caravagna G, 2018, NAT METHODS, V15, P707, DOI 10.1038/s41592-018-0108-x; Cehajic-Kapetanovic J, 2020, NAT MED, V26, P354, DOI 10.1038/s41591-020-0763-1; Cerezo M, 2018, NAT MED, V24, P1877, DOI 10.1038/s41591-018-0217-1; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chai GL, 2010, CANCER SCI, V101, P1997, DOI 10.1111/j.1349-7006.2010.01616.x; Chan EM, 2019, NATURE, V568, P551, DOI 10.1038/s41586-019-1102-x; Chen A, 2020, TRENDS MOL MED, V26, P508, DOI 10.1016/j.molmed.2020.01.004; Chen Y, 2021, NAT REV CLIN ONCOL, V18, P792, DOI 10.1038/s41571-021-00546-5; Chen YH, 2015, GENE DEV, V29, P1677, DOI 10.1101/gad.261677.115; Chen ZG, 2019, CANCER DISCOV, V9, P114, DOI 10.1158/2159-8290.CD-18-0151; Chen ZG, 2014, CANCER CELL, V26, P695, DOI 10.1016/j.ccell.2014.09.009; Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073; Choi K, 2017, SCI REP-UK, V7, DOI 10.1038/srep43315; Cooke SL, 2010, ONCOGENE, V29, P4905, DOI 10.1038/onc.2010.245; Costa RM, 2001, NAT GENET, V27, P399, DOI 10.1038/86898; Cui Y, 2019, HUM MUTAT, V40, P187, DOI 10.1002/humu.23681; Cui YJ, 2008, CELL, V135, P549, DOI 10.1016/j.cell.2008.09.060; D'Angelo I, 2006, EMBO REP, V7, P174, DOI 10.1038/sj.embor.7400602; Daginakatte GC, 2007, HUM MOL GENET, V16, P1098, DOI 10.1093/hmg/ddm059; Dang I, 2011, NEUROCHEM RES, V36, P1697, DOI 10.1007/s11064-011-0433-2; Dasgupta B, 2005, J NEUROSCI, V25, P5584, DOI 10.1523/JNEUROSCI.4693-04.2005; Dasgupta B, 2005, CANCER RES, V65, P2755, DOI 10.1158/0008-5472.CAN-04-4058; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; De Schepper S, 2008, J INVEST DERMATOL, V128, P1050, DOI 10.1038/sj.jid.5701095; De Schepper S, 2006, J INVEST DERMATOL, V126, P653, DOI 10.1038/sj.jid.5700087; Della Corte CM, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0776-2; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Delpu Y, 2013, INT J MOL SCI, V14, P15029, DOI 10.3390/ijms140715029; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943; Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672; Dunzendorfer-Matt T, 2016, P NATL ACAD SCI USA, V113, P7497, DOI 10.1073/pnas.1607298113; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Faden DL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170348; Fadhlullah SFB, 2019, ONCOGENE, V38, P5367, DOI 10.1038/s41388-019-0809-3; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Farschtschi S, 2016, CANCER IMMUNOL IMMUN, V65, P1113, DOI 10.1007/s00262-016-1871-0; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Fisher MJ, 2021, NAT MED, V27, P165, DOI 10.1038/s41591-020-01193-6; Fisher MJ, 2018, AM J MED GENET A, V176, P1258, DOI 10.1002/ajmg.a.38675; Fletcher JS, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.98601; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Fotouhi N, 2005, CURR TOP MED CHEM, V5, P159, DOI 10.2174/1568026053507705; Friedman J.M., 1993, GENEREVIEWS; Friedmann-Morvinski D, 2014, EMBO REP, V15, P244, DOI 10.1002/embr.201338254; Furukawa K, 2003, SURG TODAY, V33, P323, DOI 10.1007/s005950300074; Geist RT, 1996, NEUROSCI LETT, V211, P85, DOI 10.1016/0304-3940(96)12730-0; Genovese P, 2014, NATURE, V510, P235, DOI 10.1038/nature13420; Ghadimi MP, 2012, MOL CANCER THER, V11, P1758, DOI 10.1158/1535-7163.MCT-12-0015; Gong M, 2012, NEURO-ONCOLOGY, V14, P1007, DOI 10.1093/neuonc/nos124; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gorringe KL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011408; Gouzi JY, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002281; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V19, P265, DOI 10.1007/BF01233074; Gross AM, 2020, NEW ENGL J MED, V382, P1430, DOI 10.1056/NEJMoa1912735; Guo HF, 2000, NATURE, V403, P895, DOI 10.1038/35002593; Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1995, CELL GROWTH DIFFER, V6, P315; GUTMANN DH, 1993, HUM MOL GENET, V2, P989; Haferlach C, 2012, LEUKEMIA, V26, P834, DOI 10.1038/leu.2011.296; Hall A, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau8389; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hiatt K, 2004, AM J PATHOL, V164, P1471, DOI 10.1016/S0002-9440(10)63233-6; Hinman MN, 2014, MOL CELL BIOL, V34, P2188, DOI 10.1128/MCB.00019-14; Hirata Y, 2016, J BIOL CHEM, V291, P3124, DOI 10.1074/jbc.M115.703710; Ho IS, 2007, J NEUROSCI, V27, P6852, DOI 10.1523/JNEUROSCI.0933-07.2007; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Holzel M, 2010, CELL, V142, P218, DOI 10.1016/j.cell.2010.06.004; Hsueh YP, 2001, J NEUROSCI, V21, P3764, DOI 10.1523/JNEUROSCI.21-11-03764.2001; Huang A, 2020, NAT REV DRUG DISCOV, V19, P23, DOI 10.1038/s41573-019-0046-z; Hutter S, 2016, HUM GENET, V135, P469, DOI 10.1007/s00439-016-1646-x; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Ismat FA, 2006, J CLIN INVEST, V116, P2378, DOI 10.1172/JCI28341; Itani S, 2012, J CANCER RES CLIN, V138, P1501, DOI 10.1007/s00432-012-1223-1; Izawa I, 1996, FEBS LETT, V382, P53, DOI 10.1016/0014-5793(96)00137-8; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jecrois ES, 2021, DEV CELL, V56, P2871, DOI 10.1016/j.devcel.2021.08.004; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Johansson G, 2008, MOL CANCER THER, V7, P1237, DOI 10.1158/1535-7163.MCT-07-2335; Jones DL, 2008, NAT REV MOL CELL BIO, V9, P11, DOI 10.1038/nrm2319; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones RE, 2017, ONCOTARGET, V8, P40132, DOI 10.18632/oncotarget.16981; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kaufmann D, 2002, BIOCHEM BIOPH RES CO, V294, P496, DOI 10.1016/S0006-291X(02)00501-6; Kehrer-Sawatzki H, 2017, HUM GENET, V136, P349, DOI 10.1007/s00439-017-1766-y; Kim HA, 2001, J NEUROSCI, V21, P1110; Kluwe L, 1999, GENE CHROMOSOME CANC, V24, P283, DOI 10.1002/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koczkowska M, 2020, HUM MUTAT, V41, P299, DOI 10.1002/humu.23929; Koczkowska M, 2019, GENET MED, V21, P867, DOI 10.1038/s41436-018-0269-0; Koczkowska M, 2018, AM J HUM GENET, V102, P69, DOI 10.1016/j.ajhg.2017.12.001; Koliou X, 2016, J NEUROCHEM, V136, P78, DOI 10.1111/jnc.13401; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Larizza L, 2009, CURR MOL MED, V9, P634, DOI 10.2174/156652409788488801; Le LQ, 2007, ONCOGENE, V26, P4609, DOI 10.1038/sj.onc.1210261; Le LQ, 2011, CANCER RES, V71, P4686, DOI 10.1158/0008-5472.CAN-10-4577; Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535; Lee K, 2017, NAT BIOMED ENG, V1, P889, DOI 10.1038/s41551-017-0137-2; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Li CJ, 2001, DEV BRAIN RES, V130, P231, DOI 10.1016/S0165-3806(01)00190-0; Liao CP, 2018, J CLIN INVEST, V128, P2848, DOI 10.1172/JCI99424; Lin YL, 2007, J CELL BIOL, V177, P829, DOI 10.1083/jcb.200608121; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Liu JY, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01901; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Luo G, 2014, CELL CYCLE, V13, P2780, DOI 10.4161/15384101.2015.945870; Mamcarz E, 2019, NEW ENGL J MED, V380, P1525, DOI 10.1056/NEJMoa1815408; Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; Marjanovic ND, 2013, CLIN CHEM, V59, P168, DOI 10.1373/clinchem.2012.184655; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Mautner VF, 2003, NEURORADIOLOGY, V45, P618, DOI 10.1007/s00234-003-0964-6; Melloni G, 2019, CANCERS, V11, DOI 10.3390/cancers11121838; Meyers RM, 2017, NAT GENET, V49, P1779, DOI 10.1038/ng.3984; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Mo J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139807; Mohammad HP, 2019, NAT MED, V25, P403, DOI 10.1038/s41591-019-0376-8; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Moutal A, 2017, PAIN, V158, P2203, DOI 10.1097/j.pain.0000000000001026; Murthy V, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007765; Nadim WD, 2016, P NATL ACAD SCI USA, V113, P12310, DOI 10.1073/pnas.1600914113; Nevedomskaya E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051359; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Opocher G, 2010, BEST PRACT RES CL EN, V24, P943, DOI 10.1016/j.beem.2010.05.001; Ozawa T, 2005, J BIOL CHEM, V280, P39524, DOI 10.1074/jbc.M503707200; Pacot L, 2021, CANCERS, V13, DOI 10.3390/cancers13122963; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Paria N, 2014, J BONE MINER RES, V29, P2636, DOI 10.1002/jbmr.2298; Parkin B, 2010, CLIN CANCER RES, V16, P4135, DOI 10.1158/1078-0432.CCR-09-2639; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pasmant E, 2009, J MED GENET, V46, P425, DOI 10.1136/jmg.2008.065243; Patrakitkomjorn S, 2008, J BIOL CHEM, V283, P9399, DOI 10.1074/jbc.M708206200; Patwardhan PP, 2014, CLIN CANCER RES, V20, P3146, DOI 10.1158/1078-0432.CCR-13-2576; Pawlak M, 2012, CURR TOP MED CHEM, V12, P486, DOI 10.2174/156802612799436641; Pearson A, 2020, CLIN CANCER RES, V26, P608, DOI 10.1158/1078-0432.CCR-18-4044; Pemov A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-194; Perrin GQ, 2019, BLOOD, V133, P407, DOI 10.1182/blood-2018-07-820720; Peta C, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112348; Philpott C, 2017, HUM GENOMICS, V11, DOI 10.1186/s40246-017-0109-3; Pinna V, 2015, EUR J HUM GENET, V23, P1068, DOI 10.1038/ejhg.2014.243; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Presneau N, 2013, BRIT J CANCER, V108, P964, DOI 10.1038/bjc.2012.518; Prunier C, 2017, ONCOTARGET, V8, P41749, DOI 10.18632/oncotarget.16978; Qureshy Zoya, 2020, J Cancer Metastasis Treat, V6; Rakhra K, 2010, CANCER CELL, V18, P485, DOI 10.1016/j.ccr.2010.10.002; Rao UNM, 1997, HUM PATHOL, V28, P1066, DOI 10.1016/S0046-8177(97)90060-5; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Rischin A, 2019, RHEUMATOLOGY, V58, P1111, DOI 10.1093/rheumatology/kez012; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Rodriguez FJ, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0792-5; Rojnueangnit K, 2015, HUM MUTAT, V36, P1052, DOI 10.1002/humu.22832; Ross JS, 2014, MODERN PATHOL, V27, P271, DOI 10.1038/modpathol.2013.135; Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8; Sanchez-Ortiz E, 2014, GENE DEV, V28, P2407, DOI 10.1101/gad.246603.114; Sangha N, 2008, NEOPLASIA, V10, P1362, DOI 10.1593/neo.08784; Santoro C, 2015, EUR J HUM GENET, V23, P1460, DOI 10.1038/ejhg.2015.93; Scadden DT, 2014, CELL, V157, P41, DOI 10.1016/j.cell.2014.02.013; Scala M, 2021, CANCERS, V13, DOI 10.3390/cancers13081879; Sell S, 2010, AM J PATHOL, V176, P2584, DOI 10.2353/ajpath.2010.091064; Semenova G, 2017, BIOCHIMIE, V135, P1, DOI 10.1016/j.biochi.2017.01.001; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Serra G, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-019-0718-7; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shapira S, 2007, CELL DEATH DIFFER, V14, P895, DOI 10.1038/sj.cdd.4402057; Sharif S, 2011, J MED GENET, V48, P256, DOI 10.1136/jmg.2010.081760; Sherekar M, 2020, J BIOL CHEM, V295, P1105, DOI 10.1074/jbc.RA119.010934; Shukla V, 2008, MUTAT RES-FUND MOL M, V637, P1, DOI 10.1016/j.mrfmmm.2007.07.012; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smith BA, 2015, P NATL ACAD SCI USA, V112, pE6544, DOI 10.1073/pnas.1518007112; Steinmann K, 2009, J INVEST DERMATOL, V129, P615, DOI 10.1038/jid.2008.274; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Stowe IB, 2012, GENE DEV, V26, P1421, DOI 10.1101/gad.190876.112; Subramanian S, 2010, J PATHOL, V220, P58, DOI 10.1002/path.2633; Summers MA, 2015, J MUSCULOSKEL NEURON, V15, P161; Tabata MM, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136262; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; Thomas SL, 2006, BIOCHEM BIOPH RES CO, V348, P971, DOI 10.1016/j.bbrc.2006.07.159; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; Trauger JW, 1996, NATURE, V382, P559, DOI 10.1038/382559a0; Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010; Upadhyaya M, 2007, AM J HUM GENET, V80, P140, DOI 10.1086/510781; Vallee B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047283; Vandenbroucke I, 2004, FEBS LETT, V560, P98, DOI 10.1016/S0014-5793(04)00078-X; Vandenbroucke I, 2002, FEBS LETT, V522, P71, DOI 10.1016/S0014-5793(02)02887-9; Volta M, 2010, BIOCHEM BIOPH RES CO, V391, P1216, DOI 10.1016/j.bbrc.2009.12.043; Walker JA, 2018, EXPERT OPIN THER TAR, V22, P419, DOI 10.1080/14728222.2018.1465931; Walker James A, 2014, Rare Dis, V2, pe28341, DOI 10.4161/rdis.28341; Wang HF, 2011, J CLIN INVEST, V121, P4820, DOI 10.1172/JCI45677; Wang JW, 2021, CANCER RES, V81, P747, DOI 10.1158/0008-5472.CAN-20-1992; Wang S, 2014, P NATL ACAD SCI USA, V111, P4251, DOI 10.1073/pnas.1322198111; Wang WX, 2011, HUM MOL GENET, V20, P3910, DOI 10.1093/hmg/ddr310; Warrington NM, 2010, CANCER RES, V70, P5717, DOI 10.1158/0008-5472.CAN-09-3769; Wegscheid ML, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109315; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Weiss B, 2015, NEURO-ONCOLOGY, V17, P596, DOI 10.1093/neuonc/nou235; Weiss B, 2014, PEDIATR BLOOD CANCER, V61, P982, DOI 10.1002/pbc.24873; Weiss JB, 2017, BEHAV BRAIN RES, V332, P337, DOI 10.1016/j.bbr.2017.06.024; Welander J, 2012, HUM MOL GENET, V21, P5406, DOI 10.1093/hmg/dds402; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Widemann Brigitte C., 2019, Sarcoma, V2019, P7656747, DOI 10.1155/2019/7656747; Wiesner T, 2015, AM J SURG PATHOL, V39, P1357, DOI 10.1097/PAS.0000000000000451; Williams KB, 2020, GENES-BASEL, V11, DOI 10.3390/genes11050477; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433; Wolman MA, 2014, CELL REP, V8, P1265, DOI 10.1016/j.celrep.2014.07.054; Wolters PL, 2015, AM J MED GENET A, V167, P2103, DOI 10.1002/ajmg.a.37123; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Wu JQ, 2016, CELL REP, V14, P1979, DOI 10.1016/j.celrep.2016.01.074; Wu LMN, 2018, CANCER CELL, V33, P292, DOI 10.1016/j.ccell.2018.01.005; Xie KQ, 2016, CURR BIOL, V26, P2992, DOI 10.1016/j.cub.2016.09.010; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; Xu M, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00270; Xu YC, 2019, NAT MED, V25, P301, DOI 10.1038/s41591-018-0321-2; Yan WP, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107909; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Yang FC, 2006, HUM MOL GENET, V15, P2421, DOI 10.1093/hmg/ddl165; Yang JL, 2011, CLIN CANCER RES, V17, P7563, DOI 10.1158/1078-0432.CCR-11-1707; Yang K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2703-x; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yunoue S, 2003, J BIOL CHEM, V278, P26958, DOI 10.1074/jbc.M209413200; Zheng ZY, 2020, CANCER CELL, V37, P387, DOI 10.1016/j.ccell.2020.02.003; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101	286	1	1	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1235	1251		10.1038/s41388-021-02156-y	http://dx.doi.org/10.1038/s41388-021-02156-y		JAN 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35066574	Green Accepted			2022-12-17	WOS:000745605800001
J	Journo, S; Goldberg, AK; Sokol, ES; Zinger, L; Pasmanik-Chor, M; Sarvin, B; Simkin, D; Fuchs, S; Shlomi, T; Wolf, I; Rubinek, T				Journo, Shani; Goldberg, Anat Klein; Sokol, Ethan S.; Zinger, Lotem; Pasmanik-Chor, Metsada; Sarvin, Boris; Simkin, Dor; Fuchs, Sivan; Shlomi, Tomer; Wolf, Ido; Rubinek, Tami			Genomic alterations drive metastases formation in pancreatic ductal adenocarcinoma cancer: deciphering the role of CDKN2A and CDKN2B in mediating liver tropism	ONCOGENE			English	Article							KINASE-4 INHIBITOR GENE; GLUTAMINE-METABOLISM; SOMATIC MUTATIONS; DELETIONS; AMMONIA	Metastases are often the direct cause of death from pancreatic ductal adenocarcinoma (PDAC). The role of genomic alterations (GA) in mediating tropism and metastasis formation by PDAC cells is currently unknown. We aimed to identify GAs predisposing colonization of PDAC cells to the liver and decipher mechanisms enabling this process. In order to reveal specific genes, we studied the frequency of GA in 8,880 local and 7,983 metastatic PDAC samples. We observed differential pattern of GA in the local tumor and specific metastatic sites, with liver metastases characterized by deletion of CDKN2A/B (encoding p16/p15, respectively). The role of CDKN2A/B in promoting liver metastasis was evidenced by enhanced tumorigenic phenotype of p15/p16-deleted PDAC cells when exposed to hepatocytes conditioned media. The liver is characterized by high-ammonia low-glutamine environment and transcriptomic assays indicated unique adaptation of PDAC cells to these conditions, including regulation of genes leading to reduced glutaminolysis, like overexpression of GLUL and reduction in GLS2. Furthermore, metabolic assays indicated an increase in glutamate derived from [U-C-13]-glucose in p15/p16-deleted cells. Importantly, these cells thrived under high ammonia condition. These data suggest a unique role for genomic alterations in mediating tropism of PDAC. Among these alterations, p15/16 deletion was identified as a promoter of liver metastases. Further studies indicated a unique role for p15/16 in regulating glutaminolysis. These findings reveal vulnerabilities in PDAC cells, which may pave the way for the development of novel therapeutic strategies aiming at the prevention of liver metastases formation.	[Journo, Shani; Goldberg, Anat Klein; Zinger, Lotem; Simkin, Dor; Fuchs, Sivan; Wolf, Ido; Rubinek, Tami] Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel; [Journo, Shani; Zinger, Lotem; Wolf, Ido; Rubinek, Tami] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Sokol, Ethan S.] Fdn Med Inc, Cambridge, MA 02141 USA; [Pasmanik-Chor, Metsada] Tel Aviv Univ, Fac Life Sci, Bioinformat Unit, Tel Aviv, Israel; [Sarvin, Boris; Shlomi, Tomer] Technion, Fac Comp Sci, Haifa, Israel; [Sarvin, Boris; Shlomi, Tomer] Technion, Fac Biol, Haifa, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Foundation Medicine; Tel Aviv University; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Wolf, I; Rubinek, T (corresponding author), Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel.; Wolf, I; Rubinek, T (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	wolf-i@inter.net.il; rubinekt@gmail.com			Israel Science Foundation [1320/14]; Israel Cancer Association [20160053]; Margaret Stultz foundation for Pancreatic Cancer Research; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; TASMC excellence fund	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; Margaret Stultz foundation for Pancreatic Cancer Research; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; TASMC excellence fund	This work was financially supported by the Israel Science Foundation to I.W. (grant no. 1320/14); the Israel Cancer Association to I.W. (grant no. 20160053); The Margaret Stultz foundation for Pancreatic Cancer Research, the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; and TASMC excellence fund. The funding sources had no implications on the study design, collections, analysis, and interpretation of data or writing the manuscript. Israel Cancer Association, ISF, Pancreatic Cancer Foundation	Boldes T, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07005-x; Bott AJ, 2019, CELL REP, V29, P1287, DOI 10.1016/j.celrep.2019.09.056; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Cluntun AA, 2017, TRENDS CANCER, V3, P169, DOI 10.1016/j.trecan.2017.01.005; Connor AA, 2019, CANCER CELL, V35, P267, DOI 10.1016/j.ccell.2018.12.010; Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963; Edwards Mina, 2013, Methods Mol Biol, V987, P283, DOI 10.1007/978-1-62703-321-3_24; Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Haussinger D, 2007, FRONT BIOSCI-LANDMRK, V12, P371, DOI 10.2741/2070; Hao Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13934; Hatting M, 2018, ANN NY ACAD SCI, V1411, P21, DOI 10.1111/nyas.13435; Haussinger D, 2001, J NUTR, V131, p2509S, DOI 10.1093/jn/131.9.2509S; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Kent OA, 2016, MOL CANCER RES, V14, P267, DOI 10.1158/1541-7786.MCR-15-0456; Kietzmann T, 1997, BIOCHEM J, V321, P17, DOI 10.1042/bj3210017; Kim GW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041701; Kumar A, 2018, BIOCHEM BIOPH RES CO, V500, P731, DOI 10.1016/j.bbrc.2018.04.144; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Melamud E, 2010, ANAL CHEM, V82, P9818, DOI 10.1021/ac1021166; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Pokorny AMJ, 2018, INTERN MED J, V48, P637, DOI 10.1111/imj.13810; Reiter JG, 2018, SCIENCE, V361, P1033, DOI 10.1126/science.aat7171; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sipos B, 2003, VIRCHOWS ARCH, V442, P444, DOI 10.1007/s00428-003-0784-4; Spinelli JB, 2017, SCIENCE, V358, P941, DOI 10.1126/science.aam9305; Tanaka M, 2019, BRIT J SURG, V106, P1590, DOI 10.1002/bjs.11295; Walker V, 2014, ADV CLIN CHEM, V67, P73, DOI 10.1016/bs.acc.2014.09.002; Watford M, 2000, J NUTR, V130, p983S, DOI 10.1093/jn/130.4.983S; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Yachida S, 2012, CLIN CANCER RES, V18, P6339, DOI 10.1158/1078-0432.CCR-12-1215; Yang LF, 2014, MOL SYST BIOL, V10, DOI 10.1002/msb.20134892; Yu T, 2018, BIOMED PHARMACOTHER, V108, P1162, DOI 10.1016/j.biopha.2018.09.132; Yuan LQ, 2015, ENDOCR-RELAT CANCER, V22, P577, DOI 10.1530/ERC-15-0192; Zinger L, 2019, CLIN CANCER RES, V25, P2900, DOI 10.1158/1078-0432.CCR-18-1505	43	1	1	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1468	1481		10.1038/s41388-022-02184-2	http://dx.doi.org/10.1038/s41388-022-02184-2		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35064215				2022-12-17	WOS:000745402900001
J	He, XS; Ye, WL; Zhang, YJ; Yang, XQ; Liu, F; Wang, JR; Ding, XL; Yang, Y; Zhang, RN; Zhao, YY; Bi, HX; Guo, LC; Gan, WJ; Wu, H				He, Xiao-Shun; Ye, Wen-Long; Zhang, Yu-Juan; Yang, Xiao-Qin; Liu, Feng; Wang, Jing-Ru; Ding, Xiao-Lu; Yang, Yun; Zhang, Ruo-Nan; Zhao, Yuan-Yuan; Bi, Hai-Xia; Guo, Ling-Chuan; Gan, Wen-Juan; Wu, Hua			Oncogenic potential of BEST4 in colorectal cancer via activation of PI3K/Akt signaling	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; PIK3CA GENE; HIGH-FREQUENCY; HUMAN COLON; EXPRESSION; PTEN; MUTATIONS; PATHWAY; FAMILY; STABILIZATION	BEST4 is a member of the bestrophin protein family that plays a critical role in human intestinal epithelial cells. However, its role and mechanism in colorectal cancer (CRC) remain largely elusive. Here, we investigated the role and clinical significance of BEST4 in CRC. Our results demonstrate that BEST4 expression is upregulated in clinical CRC samples and its high-level expression correlates with advanced TNM (tumor, lymph nodes, distant metastasis) stage, LNM (lymph node metastasis), and poor survival. Functional studies revealed that ectopic expression of BEST4 promoted CRC cell proliferation and metastasis, whereas the depletion of BEST4 had the opposite effect both in vitro and in vivo. Mechanistically, BEST4 binds to the p85 alpha regulatory subunit of phosphatidylinositol-3-kinase (PI3K) and promotes p110 kinase activity; this leads to activation of Akt signaling and expression of MYC and CCND1, which are critical regulators of cell proliferation and metastasis. In clinical samples, the expression of BEST4 is positively associated with the expression of phosphorylated Akt, MYC and CCND1. Pharmacological inhibition of Akt activity markedly repressed BEST4-mediated Akt signaling and proliferation and metastasis of CRC cells. Importantly, the interaction between BEST4 and p85 alpha was also enhanced by epidermal growth factor (EGF) in CRC cells. Therapeutically, BEST4 suppression effectively sensitized CRC cells to gefitinib treatment in vivo. Taken together, our findings indicate the oncogenic potential of BEST4 in colorectal carcinogenesis and metastasis by modulating BEST4/PI3K/Akt signaling, highlighting a potential strategy for CRC therapy.	[He, Xiao-Shun; Ye, Wen-Long; Zhang, Yu-Juan; Wang, Jing-Ru; Ding, Xiao-Lu; Yang, Yun; Zhang, Ruo-Nan; Zhao, Yuan-Yuan; Bi, Hai-Xia; Guo, Ling-Chuan; Wu, Hua] Soochow Univ, Med Coll, Dept Pathol, Suzhou 215123, Peoples R China; [He, Xiao-Shun; Ye, Wen-Long; Zhang, Yu-Juan; Wang, Jing-Ru; Ding, Xiao-Lu; Yang, Yun; Zhang, Ruo-Nan; Zhao, Yuan-Yuan; Bi, Hai-Xia; Guo, Ling-Chuan; Wu, Hua] Soochow Univ, Affiliated Hosp 1, Suzhou 215123, Peoples R China; [Yang, Xiao-Qin] Soochow Univ, Med Coll, Dept Bioinformat, Suzhou 215123, Peoples R China; [Liu, Feng] Canglang Hosp Suzhou, Dept Gen Surg, Suzhou 215009, Peoples R China; [Gan, Wen-Juan; Wu, Hua] Soochow Univ, Dept Pathol, Dushu Lake Hosp, Suzhou 215124, Peoples R China; [Gan, Wen-Juan] Soochow Univ, Med Ctr, Dept Pathol, Suzhou 215124, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China	Guo, LC; Wu, H (corresponding author), Soochow Univ, Med Coll, Dept Pathol, Suzhou 215123, Peoples R China.; Guo, LC; Wu, H (corresponding author), Soochow Univ, Affiliated Hosp 1, Suzhou 215123, Peoples R China.; Gan, WJ; Wu, H (corresponding author), Soochow Univ, Dept Pathol, Dushu Lake Hosp, Suzhou 215124, Peoples R China.; Gan, WJ (corresponding author), Soochow Univ, Med Ctr, Dept Pathol, Suzhou 215124, Peoples R China.	szglc@hotmail.com; ganwenjuan@suda.edu.cn; wuhua@suda.edu.cn	ZHAO, YUAN/HCI-5831-2022; wang, jing/GVT-8700-2022; Wu, Jing/GZK-5063-2022; Wang, Jin/GYA-2019-2022		Natural Science Foundation of Jiangsu Province [BK20190042, BK20181434, BK20190182]; National Natural Science Foundation of China [82022050, 81972601, 81772541]; Science and Technology Foundation of Suzhou [SYS2019034, SKJY2021070]; Fujian Provincial Key Laboratory of Innovative Drug Target Research; Tang Scholar Funds; Priority Academic Program Development of Jiangsu Higher Education Institutions	Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Foundation of Suzhou; Fujian Provincial Key Laboratory of Innovative Drug Target Research; Tang Scholar Funds; Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported by the Natural Science Foundation of Jiangsu Province (BK20190042, BK20181434, and BK20190182), National Natural Science Foundation of China (82022050, 81972601, and 81772541), and the Science and Technology Foundation of Suzhou (SYS2019034, SKJY2021070). This work was also supported by the Fujian Provincial Key Laboratory of Innovative Drug Target Research, the Tang Scholar Funds, and the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Dieterle AM, 2014, ONCOGENE, V33, P3043, DOI 10.1038/onc.2013.266; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Guo PD, 2016, CANCER RES, V76, P3813, DOI 10.1158/0008-5472.CAN-15-2882; He XS, 2017, ONCOTARGET, V8, P68696, DOI 10.18632/oncotarget.19827; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Ito G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079693; Jacobsen K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00450-6; Ji CY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54892-7; Kaneko T, 2008, FRONT BIOSCI-LANDMRK, V13, P4938, DOI 10.2741/3053; Kramer F, 2004, CYTOGENET GENOME RES, V105, P107, DOI 10.1159/000078016; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Liu YN, 2021, ACTA PHARM SIN B, V11, P1412, DOI 10.1016/j.apsb.2020.12.003; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Noorolyai S, 2019, GENE, V698, P120, DOI 10.1016/j.gene.2019.02.076; Papa A, 2014, CELL, V157, P595, DOI 10.1016/j.cell.2014.03.027; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; RAJAGOPAL S, 1995, INT J CANCER, V62, P661, DOI 10.1002/ijc.2910620603; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Stohr H, 2002, EUR J HUM GENET, V10, P281, DOI 10.1038/sj.ejhg.5200796; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Thorpe LM, 2017, P NATL ACAD SCI USA, V114, P7095, DOI 10.1073/pnas.1704706114; Triscott J, 2018, CANCER DISCOV, V8, P682, DOI 10.1158/2159-8290.CD-18-0369; Tsunenari T, 2003, J BIOL CHEM, V278, P41114, DOI 10.1074/jbc.M306150200; Tsunenari T, 2006, J GEN PHYSIOL, V127, P749, DOI 10.1085/jgp.200609527; Wang JR, 2014, CARCINOGENESIS, V35, P2474, DOI 10.1093/carcin/bgu157; Wu H, 2016, J PATHOL, V238, P457, DOI 10.1002/path.4670; Wu L., 2016, SCI REP-UK, V6; Xing C, 2016, CANCER RES, V76, P83, DOI 10.1158/0008-5472.CAN-14-3595; Yan TD, 2010, CANCER RES, V70, P2285, DOI 10.1158/0008-5472.CAN-09-2968; Yang J, 2019, MOL THER-NUCL ACIDS, V18, P1, DOI 10.1016/j.omtn.2019.08.003; Yang JL, 2004, GUT, V53, P123, DOI 10.1136/gut.53.1.123; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu K, 2010, J CLIN INVEST, V120, P1722, DOI 10.1172/JCI41129; Zhou H, 2010, CANCER CELL, V17, P560, DOI 10.1016/j.ccr.2010.04.023	43	1	1	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1166	1177		10.1038/s41388-021-02160-2	http://dx.doi.org/10.1038/s41388-021-02160-2		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35058597				2022-12-17	WOS:000744835400001
J	Han, AN; Chua, V; Baqai, U; Purwin, TJ; Bechtel, N; Hunter, E; Tiago, M; Seifert, E; Speicher, DW; Schug, ZT; Harbour, JW; Aplin, AE				Han, Anna; Chua, Vivian; Baqai, Usman; Purwin, Timothy J.; Bechtel, Nelisa; Hunter, Emily; Tiago, Manoela; Seifert, Erin; Speicher, David W.; Schug, Zachary T.; Harbour, J. William; Aplin, Andrew E.			Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma	ONCOGENE			English	Article							TCA CYCLE; METABOLISM; GENE; PHOSPHORYLATION; VALIDATION; EXPRESSION; UTILITY; KRAS	Effective therapeutic options are still lacking for uveal melanoma (UM) patients who develop metastasis. Metastatic traits of UM are linked to BRCA1-associated protein 1 (BAP1) mutations. Cell metabolism is re-programmed in UM with BAP1 mutant UM, but the underlying mechanisms and opportunities for therapeutic intervention remain unclear. BAP1 mutant UM tumors have an elevated glycolytic gene expression signature, with increased expression of pyruvate dehydrogenase (PDH) complex and PDH kinase (PDHK1). Furthermore, BAP1 mutant UM cells showed higher levels of phosphorylated PDHK1 and PDH that was associated with an upregulated glycolytic profile compared to BAP1 wild-type UM cells. Suppressing PDHK1-PDH phosphorylation decreased glycolytic capacity and cell growth, and induced cell cycle arrest of BAP1 mutant UM cells. Our results suggest that PDHK1-PDH phosphorylation is a causative factor of glycolytic phenotypes found in BAP1 mutant UM and propose a therapeutic opportunity for BAP1 mutant UM patients.	[Han, Anna; Chua, Vivian; Baqai, Usman; Purwin, Timothy J.; Bechtel, Nelisa; Hunter, Emily; Tiago, Manoela; Aplin, Andrew E.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA; [Han, Anna] Jeonbuk Natl Univ, Dept Food Sci & Human Nutr, Jeonju 54896, Jeollabuk Do, South Korea; [Seifert, Erin] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; [Speicher, David W.] Wistar Inst Anat & Biol, Prote & Metabol Facil, Philadelphia, PA 19104 USA; [Speicher, David W.; Schug, Zachary T.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; [Harbour, J. William] Univ Miami, Sylvester Comprehens Canc Ctr, Bascom Palmer Eye Inst, Miami, FL 33146 USA; [Harbour, J. William] Univ Miami, Interdisciplinary Stem Cell Inst, Miller Sch Med, Miami, FL 33146 USA; [Harbour, J. William] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dept Ophthalmol, Dallas, TX 75390 USA; [Aplin, Andrew E.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jeonbuk National University; Jeonbuk National University Hospital; Jefferson University; The Wistar Institute; The Wistar Institute; Bascom Palmer Eye Institute; University of Miami; University of Miami; University of Texas System; University of Texas Southwestern Medical Center Dallas; Jefferson University	Aplin, AE (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA.	Andrew.Aplin@Jefferson.edu		Purwin, Timothy/0000-0002-7053-8039; Schug, Zachary/0000-0003-4197-8227	Cancer Center Support Grant [5P30CA056036-17]; National Institutes of Health (NIH)/National Cancer Institute (NCI) [R01 CA196278, R01 CA253977, P01 CA114046]; Melanoma Research Alliance team science award [559058]; American Association for Cancer Research (AACR)/Ocular Melanoma Foundation (OMF);  [P30CA010815];  [P01CA140043];  [S10OD023586]	Cancer Center Support Grant; National Institutes of Health (NIH)/National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Melanoma Research Alliance team science award; American Association for Cancer Research (AACR)/Ocular Melanoma Foundation (OMF); ; ; 	The Cancer Center Support Grant 5P30CA056036-17 to the SKCC supported the Microscopy Shared Resource facility. We thank Dr. Bruce Ksander (Schepens Eye Research Institute, Boston, MA), Dr. Martine Jager (Leiden University, Leiden, The Netherlands), and Dr. Sergio Roman-Roman (Institute Curie, Paris, France) for cell lines. We are grateful to Dr. Michael Durante (University of Miami Miller School of Medicine, Miami, FL) for his help with single-cell RNA-Seq data and Dr. Hsin-Yao Tang (The Wistar Institute, Philadelphia, PA) for metabolomic analyses. This work was supported by National Institutes of Health (NIH)/National Cancer Institute (NCI) grants R01 CA196278, R01 CA253977, and P01 CA114046 to AEA. This work also was supported by a Melanoma Research Alliance team science award (#559058) to AEA and JWH. The Wistar Proteomics and Metabolomics Facility was supported by P30CA010815, P01CA140043, and S10OD023586. Further support was from the American Association for Cancer Research (AACR)/Ocular Melanoma Foundation (OMF) awarded to AH.	Agarwal E, 2019, J BIOL CHEM, V294, P10407, DOI 10.1074/jbc.AC119.008656; Amirouchene-Angelozzi N, 2014, MOL ONCOL, V8, P1508, DOI 10.1016/j.molonc.2014.06.004; [Anonymous], 2014, GENOME BIOL, DOI DOI 10.1186/S13059-014-0550-8; Attrill H, 2019, DATABASE-OXFORD, DOI 10.1093/database/baz007; Baughman JM, 2016, CELL REP, V16, P583, DOI 10.1016/j.celrep.2016.05.096; Bononi A, 2017, CELL DEATH DIFFER, V24, P1694, DOI 10.1038/cdd.2017.95; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cai Z, 2020, MOL CELL, V80, P263, DOI 10.1016/j.molcel.2020.09.018; Carbone M, 2020, CANCER DISCOV, V10, P1103, DOI 10.1158/2159-8290.CD-19-1220; Carvajal RD, 2018, J CLIN ONCOL, V36, P1232, DOI 10.1200/JCO.2017.74.1090; Chattopadhyay C, 2019, INVEST OPHTH VIS SCI, V60, P4187, DOI 10.1167/iovs.19-28082; Chen CY, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00338; Cheng HY, 2017, MOL CANCER THER, V16, P516, DOI 10.1158/1535-7163.MCT-16-0552; Chua V, 2022, PIGM CELL MELANOMA R, V35, P78, DOI 10.1111/pcmr.13007; Chua V, 2021, CLIN CANCER RES, V27, P28, DOI 10.1158/1078-0432.CCR-20-2536; Chua V, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809081; Chua V, 2018, CURR OPIN ONCOL, V30, P134, DOI 10.1097/CCO.0000000000000425; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Di Nunno V, 2019, FUTURE ONCOL, V15, P2151, DOI 10.2217/fon-2018-0915; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Durante MA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14256-1; Eldredge-Hindy H, 2016, AM J CLIN ONCOL-CANC, V39, P189, DOI 10.1097/COC.0000000000000033; Field MG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02428-w; Forma E, 2014, CELL MOL BIOL LETT, V19, P438, DOI 10.2478/s11658-014-0204-6; Han A, 2021, TRENDS CANCER, V7, P671, DOI 10.1016/j.trecan.2021.05.005; Han A, 2021, CANCER RES, V81, P2807, DOI 10.1158/0008-5472.CAN-20-3430; Han AN, 2021, ONCOGENE, V40, P618, DOI 10.1038/s41388-020-01554-y; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Hebert L, 2017, ONCOTARGET, V8, P72513, DOI 10.18632/oncotarget.19872; Heppt MV, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0800-0; Hutton JE, 2016, MOL CELL PROTEOMICS, V15, P2924, DOI 10.1074/mcp.M116.058925; Johansson PA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16276-8; Kalirai H, 2014, BRIT J CANCER, V111, P1373, DOI 10.1038/bjc.2014.417; Karlsson J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15606-0; Kennedy BE, 2019, CANCER RES, V79, P3824, DOI 10.1158/0008-5472.CAN-18-2414; Krantz BA, 2017, CLIN OPHTHALMOL, V11, P279, DOI 10.2147/OPTH.S89591; Kreuzaler P, 2020, MOL METAB, V33, P83, DOI 10.1016/j.molmet.2019.08.021; Lapadula D, 2019, MOL CANCER RES, V17, P963, DOI 10.1158/1541-7786.MCR-18-0574; Li J, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aaz8240; Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Meir T, 2007, INVEST OPHTH VIS SCI, V48, P4890, DOI 10.1167/iovs.07-0215; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Nguyen GK, 2018, RADIOLOGY, V287, P884, DOI 10.1148/radiol.2018171504; Nie H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13601-8; Pascual G, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032920; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Ruan HB, 2012, CELL METAB, V16, P226, DOI 10.1016/j.cmet.2012.07.006; Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564; Nanda CS, 2020, BRIT J CANCER, V122, P136, DOI 10.1038/s41416-019-0663-7; Shain AH, 2019, NAT GENET, V51, P1123, DOI 10.1038/s41588-019-0440-9; Singh Arun D, 2005, Ophthalmol Clin North Am, V18, P75, DOI 10.1016/j.ohc.2004.07.002; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Wang A, 2016, J CLIN PATHOL, V69, P750, DOI 10.1136/jclinpath-2016-203866; Wei QY, 2020, ONCOGENE, V39, P6139, DOI 10.1038/s41388-020-01432-7; Zachar Z, 2011, J MOL MED, V89, P1137, DOI 10.1007/s00109-011-0785-8; Zhang S, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-10; Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325; Zhang YL, 2018, NAT CELL BIOL, V20, P1181, DOI 10.1038/s41556-018-0178-0	64	1	1	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1129	1139		10.1038/s41388-021-02154-0	http://dx.doi.org/10.1038/s41388-021-02154-0		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35046531	Green Accepted			2022-12-17	WOS:000744391200001
J	Xu, LF; Zhao, B; Butler, W; Xu, H; Song, N; Chen, XF; Hauck, JS; Gao, X; Zhang, H; Groth, J; Yang, Q; Zhao, Y; Moon, D; George, D; Zhou, YL; He, YP; Huang, JT				Xu, Lingfan; Zhao, Bing; Butler, William; Xu, Huan; Song, Nan; Chen, Xufeng; Hauck, J. Spencer; Gao, Xia; Zhang, Hong; Groth, Jeff; Yang, Qing; Zhao, Yue; Moon, David; George, Daniel; Zhou, Yinglu; He, Yiping; Huang, Jiaoti			Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer	ONCOGENE			English	Article							CELL; PTEN	Advanced and aggressive prostate cancer (PCa) depends on glutamine for survival and proliferation. We have previously shown that inhibition of glutaminase 1, which catalyzes the rate-limiting step of glutamine catabolism, achieves significant therapeutic effect; however, therapy resistance is inevitable. Here we report that while the glutamine carbon is critical to PCa survival, a parallel pathway of glutamine nitrogen catabolism that actively contributes to pyrimidine assembly is equally important for PCa cells. Importantly, we demonstrate a reciprocal feedback mechanism between glutamine carbon and nitrogen pathways which leads to therapy resistance when one of the two pathways is inhibited. Combination treatment to inhibit both pathways simultaneously yields better clinical outcome for advanced PCa patients.	[Xu, Lingfan; Zhao, Bing; Butler, William; Xu, Huan; Song, Nan; Chen, Xufeng; Hauck, J. Spencer; Zhang, Hong; Groth, Jeff; Zhao, Yue; Moon, David; He, Yiping; Huang, Jiaoti] Duke Univ, Dept Pathol, Sch Med, Durham, NC 27710 USA; [Gao, Xia; Huang, Jiaoti] Duke Univ, Dept Pharmacol & Canc Biol, Sch Med, Durham, NC 27710 USA; [Gao, Xia] Duke Univ, Duke Mol Physiol Inst, Sch Med, Durham, NC USA; [Yang, Qing] Duke Univ, Duke Sch Nursing, Durham, NC USA; [Zhao, Yue] China Med Univ, Coll Basic Med Sci, Dept Pathol, Shenyang, Peoples R China; [Zhao, Yue] China Med Univ, Affiliated Hosp 1, Shenyang, Peoples R China; [George, Daniel] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; [George, Daniel; Huang, Jiaoti] Duke Univ, Duke Canc Inst, Sch Med, Durham, NC 27710 USA; [Zhou, Yinglu] Dana Farber Canc Inst, Dept Data Sci, Boston, MA USA; [Xu, Huan] Shanghai Ninth Peoples Hosp, Dept Urol, Shanghai, Peoples R China; [Song, Nan] Capital Med Univ, Beijing Shijitan Hosp, Dept Urol, Beijing, Peoples R China	Duke University; Duke University; Duke University; Duke University; China Medical University; China Medical University; Duke University; Duke University; Harvard University; Dana-Farber Cancer Institute; Shanghai Jiao Tong University; Capital Medical University	Huang, JT (corresponding author), Duke Univ, Dept Pathol, Sch Med, Durham, NC 27710 USA.; Huang, JT (corresponding author), Duke Univ, Dept Pharmacol & Canc Biol, Sch Med, Durham, NC 27710 USA.; Huang, JT (corresponding author), Duke Univ, Duke Canc Inst, Sch Med, Durham, NC 27710 USA.	jiaoti.huang@duke.edu	Zhao, Yue/AGZ-4412-2022	Zhao, Yue/0000-0002-0110-0359; Gao, Xia/0000-0003-0979-9990; Hauck, J. Spencer/0000-0003-1722-8709; xu, lingfan/0000-0003-2465-241X; Zhao, Bing/0000-0001-5423-971X; Butler, William/0000-0001-7274-6352; Yang, Qing/0000-0003-4844-4690	Prostate Cancer Foundation Movember Valor Challenge Award (2018);  [DOD-W81XWH-19-1-0411];  [DOD-W81XWH2110034];  [K99-K99CA237618]	Prostate Cancer Foundation Movember Valor Challenge Award (2018); ; ; 	This work was supported by DOD-W81XWH-19-1-0411 (JH), DOD-W81XWH2110034 (LX), K99-K99CA237618 (XG), Prostate Cancer Foundation Movember Valor Challenge Award (2018).	Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Ben-Sahra I, 2013, SCIENCE, V339, P1323, DOI 10.1126/science.1228792; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Biancur DE, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15965; Bott AJ, 2019, CANCERS, V11, DOI 10.3390/cancers11060770; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chen M, 2018, NAT GENET, V50, P206, DOI 10.1038/s41588-017-0027-2; Cluntun AA, 2017, TRENDS CANCER, V3, P169, DOI 10.1016/j.trecan.2017.01.005; Crumbaker M, 2017, CANCERS, V9, DOI 10.3390/cancers9040034; Davidson SM, 2016, CELL METAB, V23, P517, DOI 10.1016/j.cmet.2016.01.007; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Kodama M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15136-9; Lane AN, 2015, NUCLEIC ACIDS RES, V43, P2466, DOI 10.1093/nar/gkv047; Li YJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax0428; Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078-0432.CCR-13-3296; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Oizel K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2523-z; Park JH, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102308; Park JW, 2016, P NATL ACAD SCI USA, V113, P4482, DOI 10.1073/pnas.1603645113; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Quigley DA, 2018, CELL, V174, P758, DOI 10.1016/j.cell.2018.06.039; Rawla P, 2019, WORLD J ONCOL, V10, P63, DOI 10.14740/wjon1191; Robitaille AM, 2013, SCIENCE, V339, P1320, DOI 10.1126/science.1228771; Spetsieris N, 2020, CANCERS, V12, DOI 10.3390/cancers12123792; Swami U, 2020, TRENDS CANCER, V6, P702, DOI 10.1016/j.trecan.2020.04.010; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Wang XX, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau4972; Wang YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08033-9; Wang ZF, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.589508; Xu LF, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2012748118; Yang LF, 2016, CELL METAB, V24, P685, DOI 10.1016/j.cmet.2016.10.011; Yin Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0941-2; Yoo HC, 2020, EXP MOL MED, V52, P1496, DOI 10.1038/s12276-020-00504-8; Yu X, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00394; Zhang J, 2017, EMBO J, V36, P1302, DOI 10.15252/embj.201696151	38	1	1	5	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1140	1154		10.1038/s41388-021-02155-z	http://dx.doi.org/10.1038/s41388-021-02155-z		JAN 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35046532				2022-12-17	WOS:000744388700001
J	Takagane, K; Umakoshi, M; Itoh, G; Kuriyama, S; Goto, A; Tanaka, M				Takagane, Kurara; Umakoshi, Michinobu; Itoh, Go; Kuriyama, Sei; Goto, Akiteru; Tanaka, Masamitsu			SKAP2 suppresses inflammation-mediated tumorigenesis by regulating SHP-1 and SHP-2	ONCOGENE			English	Article							TYROSINE-PHOSPHATASE; CYTOKINE PRODUCTION; KAPPA-B; RECEPTOR; SHPS-1; TOLL-LIKE-RECEPTOR-4; PHOSPHORYLATION; INTERFERON; MECHANISMS; INDUCTION	Inflammatory bowel diseases, like ulcerative colitis and Crohn's disease are frequently accompanied by colorectal cancers. However, the mechanisms underlying colitis-associated cancers are not fully understood. Src Kinase Associated Phosphoprotein 2 (SKAP2), a substrate of Src family kinases, is highly expressed in macrophages. Here, we examined the effects of SKAP2 on inflammatory responses in a mouse model of tumorigenesis with colitis induced by azoxymethane/dextran sulfate sodium. SKAP2 knockout increased the severity of colitis and tumorigenesis, as well as lipopolysaccharide (LPS) induced acute inflammation. SKAP2 attenuated inflammatory signaling in macrophages induced by uptake of cancer cell-derived exosomes. SKAP2(-/-) mice were characterized by the activation of NF-kappa B signaling and the upregulation and release of cytokines including TNF alpha, IL-1 beta, IL-6, CXCL-9/-10/-13, and sICAM1; SKAP2 overexpression attenuated NF-kappa B activation. Mechanistically, SKAP2 formed a complex with the SHP-1 tyrosine phosphatase via association with the Sirp alpha transmembrane receptor. SKAP2 also physically associated with the TIR domain of MyD88, TIRAP, and TRAM, adaptors of toll-like receptor 4 (TLR4). SKAP2-mediated recruitment of the Sirp alpha/SHP-1 complex to TLR4 attenuated inflammatory responses, whereas direct interaction of SKAP2 with SHP-2 decreased SHP-2 activation. SHP-2 is required for efficient NF-kappa B activation and suppresses the TRAM/TRIF-INF beta pathway; therefore, SKAP2-mediated SHP-2 inhibition affected two signaling axes from TLR4. The present findings indicate that SKAP2 prevents excess inflammation by inhibiting the TLR4-NF-kappa B pathway, and it activates the TLR4-IFN beta pathway through SHP-1 and SHP-2, thereby suppressing inflammation-mediated tumorigenesis.	[Takagane, Kurara; Itoh, Go; Kuriyama, Sei; Tanaka, Masamitsu] Akita Univ, Dept Mol Med & Biochem, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan; [Takagane, Kurara] Akita Univ, Tech Div, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan; [Umakoshi, Michinobu; Goto, Akiteru] Akita Univ, Dept Cellular & Organ Pathol, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan	Akita University; Akita University; Akita University	Tanaka, M (corresponding author), Akita Univ, Dept Mol Med & Biochem, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan.	mastanak@med.akita-u.ac.jp		Tanaka, Masamitsu/0000-0002-4823-9737; Kuriyama, Sei/0000-0002-5502-7177	JSPS KAKENHI [19H03495, 19K07681, 21K07090, 20H01094, 19K07454]; Takeda Science Foundation; Princess Takamatsu Cancer Research Fund [19-25123]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Princess Takamatsu Cancer Research Fund	This work was supported by JSPS KAKENHI grants (19H03495 to M. Tanaka, 19K07681 to G. Itoh, 21K07090 to S. Kuriyama, 20H01094 to K. Takagane, and 19K07454 to A. Goto), the Takeda Science Foundation grants (to M. Tanaka and G. Itoh), and a Research Grant from the Princess Takamatsu Cancer Research Fund (19-25123 to M. Tanaka).	Alenghat FJ, 2012, J CELL SCI, V125, P5535, DOI 10.1242/jcs.111260; An HZ, 2006, IMMUNITY, V25, P919, DOI 10.1016/j.immuni.2006.10.014; Antwi-Baffour SS, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0174-7; Barichello T, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/371465; Boras M, 2017, J EXP MED, V214, P851, DOI 10.1084/jem.20160647; Bourette RP, 2005, CELL SIGNAL, V17, P941, DOI 10.1016/j.cellsig.2004.11.009; Bretz NP, 2013, J BIOL CHEM, V288, P36691, DOI 10.1074/jbc.M113.512806; Bui TM, 2020, J LEUKOCYTE BIOL, V108, P787, DOI 10.1002/JLB.2MR0220-549R; Buwitt-Beckmann U, 2005, EUR J IMMUNOL, V35, P282, DOI 10.1002/eji.200424955; Chattopadhyay S, 2014, CYTOKINE GROWTH F R, V25, P533, DOI 10.1016/j.cytogfr.2014.06.002; Chaudhary A, 2007, IMMUNOL CELL BIOL, V85, P249, DOI 10.1038/sj.icb7100030; Chen R., 2012, BIO-PROTOCOL, V2; Chow A, 2014, SCI REP-UK, V4, DOI 10.1038/srep05750; Ciardiello C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020175; CORRIN B, 1980, J CLIN PATHOL, V33, P891, DOI 10.1136/jcp.33.9.891; Feng JR, 2019, ADV EXP MED BIOL, V1111, P19, DOI 10.1007/5584_2018_236; Floyel T, 2021, DIABETES, V70, P464, DOI 10.2337/db20-0092; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Fukata M, 2009, INFLAMM BOWEL DIS, V15, P997, DOI 10.1002/ibd.20880; Hoogland ICM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0332-6; Jakopin Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174265; Kagan JC, 2008, NAT IMMUNOL, V9, P361, DOI 10.1038/ni1569; Khaled AR, 1998, CELL IMMUNOL, V185, P49, DOI 10.1006/cimm.1998.1272; Kim EJ, 2013, INFLAMM RES, V62, P377, DOI 10.1007/s00011-013-0589-0; Kuzmich NN, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040034; Li P, 2019, BIOCHEM BIOPH RES CO, V508, P169, DOI 10.1016/j.bbrc.2018.11.074; Lu RZ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002597; Marongiu L, 2019, J LEUKOCYTE BIOL, V106, P147, DOI 10.1002/JLB.3MIR1218-483RR; Massa PT, 1998, J INTERF CYTOK RES, V18, P499, DOI 10.1089/jir.1998.18.499; Medvedev AE, 2007, J BIOL CHEM, V282, P16042, DOI 10.1074/jbc.M606781200; Miyake A, 2008, GENES CELLS, V13, P209, DOI 10.1111/j.1365-2443.2007.01161.x; Nguyen GT, 2020, ELIFE, V9, DOI 10.7554/eLife.56656; Niogret C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02468; Oshima K, 2002, FEBS LETT, V519, P1, DOI 10.1016/S0014-5793(02)02703-5; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Paschon V, 2016, MOL NEUROBIOL, V53, P2016, DOI 10.1007/s12035-015-9142-1; Pashenkov MV, 2019, J LEUKOCYTE BIOL, V105, P669, DOI 10.1002/JLB.2RU0718-290R; Qian ZR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/649161; Ramachandran IR, 2011, J IMMUNOL, V186, P3934, DOI 10.4049/jimmunol.1001675; Reinhold A, 2009, J LEUKOCYTE BIOL, V86, P61, DOI [10.1189/JLB.0608344, 10.1189/jlb.0608344]; Rosadini CV, 2017, CURR OPIN IMMUNOL, V44, P14, DOI 10.1016/j.coi.2016.10.005; Rosso M, 2011, CRIT REV IMMUNOL, V31, P379, DOI 10.1615/CritRevImmunol.v31.i5.20; Shaban L, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008576; Shi L, 2020, WORLD J GASTROENTERO, V26, DOI 10.3748/wjg.v26.i39.5983; Shimamura S, 2013, J BIOL CHEM, V288, P1171, DOI 10.1074/jbc.M112.386722; Snider AJ, 2016, METHODS MOL BIOL, V1438, P245, DOI 10.1007/978-1-4939-3661-8_14; Steinbichler TB, 2017, SEMIN CANCER BIOL, V44, P170, DOI 10.1016/j.semcancer.2017.02.006; Swanson KD, 2008, MOL CELL, V32, P564, DOI 10.1016/j.molcel.2008.09.022; Tanaka M, 2016, CANCER RES, V76, P358, DOI 10.1158/0008-5472.CAN-15-1879; Timms JF, 1999, CURR BIOL, V9, P927, DOI 10.1016/S0960-9822(99)80401-1; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5; van Heel DA, 2005, LANCET, V365, P1794, DOI 10.1016/S0140-6736(05)66582-8; Waldner MJ, 2015, CELL MOL GASTROENTER, V1, P6, DOI 10.1016/j.jcmgh.2014.11.006; Yashiro M, 2014, WORLD J GASTROENTERO, V20, P16389, DOI 10.3748/wjg.v20.i44.16389; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Zhang X, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0898-6	57	1	1	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1087	1099		10.1038/s41388-021-02153-1	http://dx.doi.org/10.1038/s41388-021-02153-1		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35034964				2022-12-17	WOS:000743007800002
J	Smalling, RV; Bechard, ME; Duryea, J; Kingsley, PJ; Roberts, ER; Marnett, LJ; Bilbao, D; Stauffer, SR; McDonald, OG				Smalling, Rana, V; Bechard, Matthew E.; Duryea, Jeff; Kingsley, Philip J.; Roberts, Evan R.; Marnett, Lawrence J.; Bilbao, Daniel; Stauffer, Shaun R.; McDonald, Oliver G.			Aminopyridine analogs selectively target metastatic pancreatic cancer	ONCOGENE			English	Article							DISTANT METASTASIS; 6-AMINONICOTINAMIDE; HETEROGENEITY; ADENOCARCINOMA; METABOLISM; CELLS	Metastatic outgrowth is supported by metabolic adaptations that may differ from the primary tumor of origin. However, it is unknown if such adaptations are therapeutically actionable. Here we report a novel aminopyridine compound that targets a unique Phosphogluconate Dehydrogenase (PGD)-dependent metabolic adaptation in distant metastases from pancreatic cancer patients. Compared to structurally similar analogs, 6-aminopicolamine (6AP) potently and selectively reversed PGD-dependent metastatic properties, including intrinsic tumorigenic capacity, excess glucose consumption, and global histone hyperacetylation. 6AP acted as a water-soluble prodrug that was converted into intracellular bioactive metabolites that inhibited PGD in vitro, and 6AP monotherapy demonstrated anti-metastatic efficacy with minimal toxicity in vivo. Collectively, these studies identify 6AP and possibly other 6-aminopyridines as well-tolerated prodrugs with selectivity for metastatic pancreatic cancers. If unique metabolic adaptations are a common feature of metastatic or otherwise aggressive human malignancies, then such dependencies could provide a largely untapped pool of druggable targets for patients with advanced cancers.	[Smalling, Rana, V; Bechard, Matthew E.; McDonald, Oliver G.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; [Duryea, Jeff; Roberts, Evan R.; Bilbao, Daniel; McDonald, Oliver G.] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol & Lab Med, Miller Sch Med, Miami, FL 33136 USA; [Kingsley, Philip J.; Marnett, Lawrence J.] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN USA; [Stauffer, Shaun R.] Vanderbilt Univ, Dept Pharmacol, Med Ctr, Nashville, TN USA; [Stauffer, Shaun R.] Cleveland Clin, Ctr Therapeut Discovery, Cleveland, OH USA	Vanderbilt University; University of Miami; Vanderbilt University; Vanderbilt University; Cleveland Clinic Foundation	McDonald, OG (corresponding author), Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA.; McDonald, OG (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol & Lab Med, Miller Sch Med, Miami, FL 33136 USA.	ogm443@miami.edu		McDonald, Oliver/0000-0002-6602-7535; Kingsley, Philip/0000-0002-5470-4340	National Institutes of Health [R01 CA222594, 5P30 DK058404]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institutes of Health grants R01 CA222594 (OGM) and 5P30 DK058404 (OGM).	Balachandran VP, 2019, GASTROENTEROLOGY, V156, P2056, DOI 10.1053/j.gastro.2018.12.038; Bechard ME, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17839-5; Bechard ME, 2018, ONCOGENE, V37, P5248, DOI 10.1038/s41388-018-0346-5; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Daneshmandi S, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108831; DIETRICH LS, 1958, J BIOL CHEM, V233, P964; Embuscado EE, 2005, CANCER BIOL THER, V4, P548, DOI 10.4161/cbt.4.5.1663; Fendt SM, 2020, CANCER DISCOV, V10, P1797, DOI 10.1158/2159-8290.CD-20-0844; Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387; Hayashi A, 2021, NAT REV GASTRO HEPAT, V18, P469, DOI 10.1038/s41575-021-00463-z; HERKEN H, 1976, N-S ARCH PHARMACOL, V293, P245, DOI 10.1007/BF00507347; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Iacobuzio-Donahue CA, 2020, NAT CANCER, V1, P3, DOI 10.1038/s43018-019-0002-1; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; JOHNSON WJ, 1955, SCIENCE, V122, P834, DOI 10.1126/science.122.3174.834; Ju HQ, 2016, CANCER LETT, V379, P1, DOI 10.1016/j.canlet.2016.05.024; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; KOHLER E, 1970, FEBS LETT, V6, P225, DOI 10.1016/0014-5793(70)80063-1; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Makohon-Moore AP, 2017, NAT GENET, V49, P358, DOI 10.1038/ng.3764; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McDonald OG, 2020, MOL CELL ONCOL, V7, DOI 10.1080/23723556.2020.1825910; McDonald OG, 2017, NAT GENET, V49, P367, DOI 10.1038/ng.3753; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Recouvreux MV, 2020, J EXP MED, V217, DOI 10.1084/jem.20200388; Reiter JG, 2018, SCIENCE, V361, P1033, DOI 10.1126/science.aat7171; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Roe JS, 2017, CELL, V170, P875, DOI 10.1016/j.cell.2017.07.007; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Soares Kevin C, 2014, J Vis Exp, P51677, DOI 10.3791/51677; Storz P, 2020, GASTROENTEROLOGY, V158, P2072, DOI 10.1053/j.gastro.2020.02.059; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Walker DL, 1999, BIOCHEM PHARMACOL, V58, P1057, DOI 10.1016/S0006-2952(99)00179-3; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yoshida T, 2020, BIOCHEM BIOPH RES CO, V522, P633, DOI 10.1016/j.bbrc.2019.11.130	40	1	1	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1518	1525		10.1038/s41388-022-02183-3	http://dx.doi.org/10.1038/s41388-022-02183-3		JAN 2022	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35031771	Green Accepted			2022-12-17	WOS:000742613600002
J	Madrazo, E; Gonzalez-Novo, R; Ortiz-Placin, C; de Lacoba, MG; Gonzalez-Murillo, A; Ramirez, M; Redondo-Munoz, J				Madrazo, Elena; Gonzalez-Novo, Raquel; Ortiz-Placin, Candido; Garcia de Lacoba, Mario; Gonzalez-Murillo, Africa; Ramirez, Manuel; Redondo-Munoz, Javier			Fast H3K9 methylation promoted by CXCL12 contributes to nuclear changes and invasiveness of T-acute lymphoblastic leukemia cells	ONCOGENE			English	Article							MIGRATION; KINASE; CXCR4; INFILTRATION; CHROMATIN; PATHOGENESIS; PHOSPHORYLATION; DEFORMATION; STRATEGIES; ORIGINS	T-acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that comprises the accumulation of malignant T-cells. Despite current therapies, failure to conventional treatments and relapse are frequent in children with T-ALL. It is known that the chemokine CXCL12 modulates leukemia survival and dissemination; however, our understanding of molecular mechanisms used by T-ALL cells to infiltrate and respond to leukemia cells-microenvironment interactions is still vague. In the present study, we showed that CXCL12 promoted H3K9 methylation in cell lines and primary T-ALL cells within minutes. We thus identified that CXCL12-mediated H3K9 methylation affected the global chromatin configuration and the nuclear mechanics of T-ALL cells. Importantly, we characterized changes in the genomic profile of T-ALL cells associated with rapid CXCL12 stimulation. We showed that blocking CXCR4 and protein kinase C (PKC) impaired the H3K9 methylation induced by CXCL12 in T-ALL cells. Finally, blocking H3K9 methyltransferases reduced the efficiency of T-ALL cells to deform their nuclei, migrate across confined spaces, and home to spleen and bone marrow in vivo models. Together, our data show novel functions for CXL12 as a master regulator of nuclear deformability and epigenetic changes in T-ALL cells, and its potential as a promising pharmacological target against T-ALL dissemination.	[Madrazo, Elena; Gonzalez-Novo, Raquel; Ortiz-Placin, Candido; Redondo-Munoz, Javier] Ctr Invest Biol Margarita Salas CIB Margarita Sal, Dept Mol Med, Madrid, Spain; [Garcia de Lacoba, Mario] Ctr Invest Biol Margarita Salas CIB Margarita Sal, Bioinformat & Biostat Unit, Madrid, Spain; [Gonzalez-Murillo, Africa; Ramirez, Manuel] Hosp Univ Nino Jesus, Dept Paediat Haematol & Oncol, Madrid, Spain; [Gonzalez-Murillo, Africa; Ramirez, Manuel] Hlth Res Inst La Princesa, Madrid, Spain		Redondo-Munoz, J (corresponding author), Ctr Invest Biol Margarita Salas CIB Margarita Sal, Dept Mol Med, Madrid, Spain.	Javier.redondo@cib.csic.es	; Gonzalez, Africa/M-3426-2014	Gonzalez-Novo, Raquel/0000-0002-3796-2751; Redondo-Munoz, Javier/0000-0003-0607-2171; Ortiz Placin, Candido/0000-0003-0529-4047; Gonzalez, Africa/0000-0001-7747-1204	FPI Scholarship 2018 (Ministerio de Ciencia e Innovacion/MICINN); FPI Scholarship 2018 (Agencia Estatal de Investigacion/AEI); FPI Scholarship 2018 (Fondo Europeo de Desarrollo Regional/FEDER); undergraduate fellowship "Beca de Introduccion a la Investigacion" (Asociacion Espanola Contra el Cancer); Asociacion Pablo Ugarte; Gilead Sciences International Scholar in Hematology/Oncology (Gilead); 2020 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation); Ministerio de Ciencia e Innovacion/MICINN [SAF2017-86327-R]; Agencia Estatal de Investigacion/AEI [SAF2017-86327-R]; Fondo Europeo de Desarrollo Regional/FEDER [SAF2017-86327-R]	FPI Scholarship 2018 (Ministerio de Ciencia e Innovacion/MICINN); FPI Scholarship 2018 (Agencia Estatal de Investigacion/AEI); FPI Scholarship 2018 (Fondo Europeo de Desarrollo Regional/FEDER); undergraduate fellowship "Beca de Introduccion a la Investigacion" (Asociacion Espanola Contra el Cancer); Asociacion Pablo Ugarte; Gilead Sciences International Scholar in Hematology/Oncology (Gilead); 2020 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation); Ministerio de Ciencia e Innovacion/MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Agencia Estatal de Investigacion/AEI; Fondo Europeo de Desarrollo Regional/FEDER(European CommissionSpanish Government)	The authors thank the Microscopy Unit and the Flow Cytometry Core Unit of Instituto de Investigacion Biosanitaria Gregorio Maranon (IiSGM) for assistance with confocal, videomicroscopy and flow cytometry analyses. The UCM-Genomic CAI Unit for their assistance with the microarray experiments. We thank Dr. Ignacio Casal, Joaquin Teixido, Alicia Garcia-Arroyo and Maria Montoya for insightful and critical comments. This research was supported by a FPI Scholarship 2018 (Ministerio de Ciencia e Innovacion/MICINN, Agencia Estatal de Investigacion/AEI y Fondo Europeo de Desarrollo Regional/FEDER) to R. G.N.; an undergraduate fellowship "Beca de Introduccion a la Investigacion" (Asociacion Espanola Contra el Cancer) to C.O.P.; and by grants from Asociacion Pablo Ugarte to M.R., Gilead Sciences International Scholar in Hematology/Oncology (Gilead), 2020 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation) and SAF2017-86327-R (Ministerio de Ciencia e Innovacion/MICINN, Agencia Estatal de Investigacion/AEI y Fondo Europeo de Desarrollo Regional/FEDER) to J.R.M.	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Almamun M, 2015, EPIGENETICS-US, V10, P882, DOI 10.1080/15592294.2015.1078050; Alsadeq A, 2017, HAEMATOLOGICA, V102, P346, DOI 10.3324/haematol.2016.147744; Altman A, 2016, ANNU REV IMMUNOL, V34, P511, DOI 10.1146/annurev-immunol-041015-055347; Apaolaza I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00555-y; Bao Y, 2019, ONCOGENE, V38, P881, DOI 10.1038/s41388-018-0452-4; Barbieri F, 2016, EXPERT OPIN DRUG DIS, V11, P1093, DOI 10.1080/17460441.2016.1233176; Bendall LJ, 2005, CANCER RES, V65, P3290, DOI 10.1158/0008-5472.CAN-04-3402; Bradstock KF, 2000, LEUKEMIA, V14, P882, DOI 10.1038/sj.leu.2401729; Cancilla D, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01672; Cannon JL, 2017, ONCOTARGET, V8, P84626, DOI 10.18632/oncotarget.21394; Melo RDC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085926; Crazzolara R, 2001, BRIT J HAEMATOL, V115, P545, DOI 10.1046/j.1365-2141.2001.03164.x; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Edens LJ, 2017, MOL BIOL CELL, V28, P1389, DOI 10.1091/mbc.E16-11-0786; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Friedl P, 2011, CURR OPIN CELL BIOL, V23, P55, DOI 10.1016/j.ceb.2010.10.015; Frishman-Levy L, 2017, BRIT J HAEMATOL, V176, P157, DOI 10.1111/bjh.14411; Gerlitz G, 2010, J CELL SCI, V123, P2207, DOI 10.1242/jcs.058271; Gomez AM, 2015, BLOOD CELL MOL DIS, V55, P220, DOI 10.1016/j.bcmd.2015.07.001; Guinamard R, 1999, J EXP MED, V189, P1461, DOI 10.1084/jem.189.9.1461; Hong ZX, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01060-y; Irianto J, 2017, BIOPHYS J, V112, P446, DOI 10.1016/j.bpj.2016.09.047; Isham CR, 2007, BLOOD, V109, P2579, DOI 10.1182/blood-2006-07-027326; Jost TR, 2016, J LEUKOCYTE BIOL, V99, P1077, DOI 10.1189/jlb.5MA0915-394R; Jung HJ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.15; Kato I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027042; Kidiyoor GR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18580-9; Konopleva MY, 2011, J CLIN ONCOL, V29, P591, DOI 10.1200/JCO.2010.31.0904; Kuang SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061807; Lai YS, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.37; Le Berre M, 2012, INTEGR BIOL-UK, V4, P1406, DOI 10.1039/c2ib20056b; Levoye A, 2009, BLOOD, V113, P6085, DOI 10.1182/blood-2008-12-196618; Lu CW, 2020, CANCER LETT, V476, P87, DOI 10.1016/j.canlet.2020.02.004; Madrazo E, 2018, CANCERS, V10, DOI 10.3390/cancers10090325; Makhija E, 2016, P NATL ACAD SCI USA, V113, pE32, DOI 10.1073/pnas.1513189113; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nava MM, 2020, CELL, V181, P800, DOI 10.1016/j.cell.2020.03.052; Pajerowski JD, 2007, P NATL ACAD SCI USA, V104, P15619, DOI 10.1073/pnas.0702576104; Passaro D, 2015, CANCER CELL, V27, P769, DOI 10.1016/j.ccell.2015.05.003; Perim AD, 2015, CELL MOL LIFE SCI, V72, P1715, DOI 10.1007/s00018-014-1830-x; Petit I, 2005, J CLIN INVEST, V115, P168, DOI 10.1172/JCI200521773; Pfeifer CR, 2019, ADV EXP MED BIOL, V1146, P117, DOI 10.1007/978-3-030-17593-1_8; Pfeifer CR, 2018, MOL BIOL CELL, V29, P1948, DOI 10.1091/mbc.E18-02-0079; Pitt LA, 2015, CANCER CELL, V27, P755, DOI 10.1016/j.ccell.2015.05.002; Poli A, 2018, FASEB J, V32, P681, DOI 10.1096/fj.201700690R; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Pui CH, 2007, NAT REV DRUG DISCOV, V6, P149, DOI 10.1038/nrd2240; Randhawa S, 2016, BRIT J HAEMATOL, V174, P425, DOI 10.1111/bjh.14075; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Redondo-Munoz J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00156; Schumann K, 2010, IMMUNITY, V32, P703, DOI 10.1016/j.immuni.2010.04.017; Scupoli MT, 2008, HAEMATOLOGICA, V93, P524, DOI 10.3324/haematol.12098; Sison EAR, 2015, ONCOTARGET, V6, P30902, DOI 10.18632/oncotarget.5094; Song ZY, 2019, ONCOGENE, V38, P1560, DOI 10.1038/s41388-018-0519-2; Stephens AD, 2019, CURR OPIN CELL BIOL, V58, P76, DOI 10.1016/j.ceb.2019.02.006; Stephens AD, 2017, MOL BIOL CELL, V28, P1984, DOI 10.1091/mbc.E16-09-0653; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Vadillo E, 2018, BLOOD REV, V32, P36, DOI 10.1016/j.blre.2017.08.006; Vargas P, 2014, JOVE-J VIS EXP, DOI 10.3791/51099; Velazquez-Avila M, 2019, LEUKEMIA, V33, P1337, DOI 10.1038/s41375-018-0333-4; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; Wei SY, 2014, J MOL CELL BIOL, V6, P458, DOI 10.1093/jmcb/mju050; Yokoyama M, 2017, ONCOTARGET, V8, P21315, DOI 10.18632/oncotarget.15528; Zhang XH, 2016, NUCLEIC ACIDS RES, V44, P3031, DOI 10.1093/nar/gkv1348	66	1	1	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1324	1336		10.1038/s41388-021-02168-8	http://dx.doi.org/10.1038/s41388-021-02168-8		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	34999734	Green Published			2022-12-17	WOS:000740423700002
J	Li, H; Roy, M; Liang, L; Cao, WJ; Hu, B; Li, YA; Xiao, XJ; Wang, HQ; Ye, M; Sun, SM; Zhang, B; Liu, J				Li, Hui; Roy, Mridul; Liang, Long; Cao, Wenjie; Hu, Bin; Li, Yanan; Xiao, Xiaojuan; Wang, Haiqin; Ye, Mao; Sun, Shuming; Zhang, Bin; Liu, Jing			Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; APOPTOSIS; DISEASE; CELLS	Despite the establishment of novel therapeutic interventions, multiple myeloma (MM) remains invariably incurable due to development of drug resistance and subsequent relapse, which are attributed to activation of oncogenic pathways such as autophagy. Deubiquitinating enzymes (DUBs) are promising targets to overcome resistance to proteasome inhibitor-based treatment. Ubiquitin-specific protease-12 (USP12) is a DUB with a known prognostic value in several cancers. We found that USP12 protein levels were significantly higher in myeloma patient samples than in non-cancerous human samples. Depletion of USP12 suppressed cell growth and clonogenicity and inhibited autophagy. Mechanistic studies showed that USP12 interacted with, deubiquitylated and stabilized the critical autophagy mediator HMGB1 (high mobility group box-1) protein. Knockdown of USP12 decreased the level of HMGB1 and suppressed HMGB1-mediated autophagy in MM. Furthermore, basal autophagy activity associated with USP12/HMGB1 was elevated in bortezomib (BTZ)-resistant MM cell lines. USP12 depletion, concomitant with a reduced expression of HMGB1, suppressed autophagy and increased the sensitivity of resistant cells to BTZ. Collectively, our findings have identified an important role of the deubiquitylase USP12 in pro-survival autophagy and resultant BTZ resistance in MM by stabilizing HMGB1, suggesting that the USP12/HMGB1 axis might be pursued as a potential diagnostic and therapeutic target in human MM.	[Li, Hui; Roy, Mridul; Ye, Mao] Hunan Univ, Coll Biol, Coll Chem & Chem Engn,State Key Lab Chemo Biosens, Collaborat Innovat Ctr Chem & Mol Med,Mol Sci & B, Changsha 410082, Hunan, Peoples R China; [Li, Hui; Roy, Mridul; Hu, Bin; Li, Yanan; Xiao, Xiaojuan; Wang, Haiqin; Sun, Shuming; Liu, Jing] Cent South Univ, Ctr Med Genet, Sch Life Sci,Mol Biol Res Ctr, Hunan Prov Key Lab Basic & Appl Hematol, Changsha 410078, Peoples R China; [Li, Hui; Liang, Long] Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha 410008, Hunan, Peoples R China; [Cao, Wenjie; Zhang, Bin] Cent South Univ, Xiangya Sch Med, Dept Histol & Embryol, Changsha 410013, Peoples R China	Hunan University; Central South University; Central South University; Central South University	Ye, M (corresponding author), Hunan Univ, Coll Biol, Coll Chem & Chem Engn,State Key Lab Chemo Biosens, Collaborat Innovat Ctr Chem & Mol Med,Mol Sci & B, Changsha 410082, Hunan, Peoples R China.; Sun, SM; Liu, J (corresponding author), Cent South Univ, Ctr Med Genet, Sch Life Sci,Mol Biol Res Ctr, Hunan Prov Key Lab Basic & Appl Hematol, Changsha 410078, Peoples R China.; Zhang, B (corresponding author), Cent South Univ, Xiangya Sch Med, Dept Histol & Embryol, Changsha 410013, Peoples R China.	goldleaf@hnu.edu.cn; sunshuming203@163.com; coolzhangbin22@163.com; jingliucsu@hotmail.com		Ye, Mao/0000-0002-4798-1825; Li, Hui/0000-0003-1086-0402; Cao, Wenjie/0000-0002-7877-4079	National Key Research and Development Program of China [2018YFA0107800]; National Natural Science Foundation of China [21890744, 81672760, 82003286, 81970195, 81920108004, 81772496, 82073099]; Natural Science Foundation of Hunan Province [2021JJ40054, 2019JJ40391]; China Postdoctoral Science Foundation [2020M672474, 2021T140195, 2018M630896]; Hunan Provincial Key Research and Development Plan [2018SK2128]; Changsha Municipal Natural Science Foundation [kq2014041, kq2014042, kq2001012]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Hunan Provincial Key Research and Development Plan; Changsha Municipal Natural Science Foundation	This study was supported by grants from the National Key Research and Development Program of China (2018YFA0107800), the National Natural Science Foundation of China (Nos. 21890744, 81672760, 82003286, 81970195, 81920108004, 81772496 and 82073099), the Natural Science Foundation of Hunan Province (No. 2021JJ40054, 2019JJ40391), the China Postdoctoral Science Foundation (2020M672474, 2021T140195 and 2018M630896), the Hunan Provincial Key Research and Development Plan (2018SK2128), the Changsha Municipal Natural Science Foundation (kq2014041, kq2014042 and kq2001012).	Arnold J, 2016, CELL DEATH DIFFER, V23, P853, DOI 10.1038/cdd.2015.149; Aron R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05653-z; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Boutouja F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122541; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; D'Eliseo Donatella, 2017, Genes Cancer, V8, P426, DOI 10.18632/genesandcancer.131; Gao D, 2017, J CELL BIOCHEM, V118, P3341, DOI 10.1002/jcb.25987; Guo X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0883-3; Hanna J, 2006, CELL, V127, P99, DOI 10.1016/j.cell.2006.07.038; Hussain S, 2015, ONCOTARGET, V6, P40704, DOI 10.18632/oncotarget.5727; Inoue Y, 2013, THROMB RES, V132, P493, DOI 10.1016/j.thromres.2013.08.020; Jacomin AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143078; Jahan AS, 2016, P NATL ACAD SCI USA, V113, pE705, DOI 10.1073/pnas.1521763113; Jarauta V, 2016, CANCER LETT, V382, P1, DOI 10.1016/j.canlet.2016.08.019; Joo HY, 2011, J BIOL CHEM, V286, P7190, DOI 10.1074/jbc.M110.158311; Kane RC, 2003, ONCOLOGIST, V8, P508, DOI 10.1634/theoncologist.8-6-508; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kumar SK, 2014, LEUKEMIA, V28, P1122, DOI 10.1038/leu.2013.313; Kumar SK, 2016, CLIN CANCER RES, V22, P5453, DOI 10.1158/1078-0432.CCR-16-0868; Liu J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008215; Lu YC, 2018, CANCER SCI, V109, P2706, DOI 10.1111/cas.13711; Mah Li Yen, 2012, Cold Spring Harb Perspect Biol, V4, pa008821, DOI 10.1101/cshperspect.a008821; McClurg UL, 2018, ONCOGENE, V37, P4679, DOI 10.1038/s41388-018-0283-3; Milan E, 2016, J CLIN IMMUNOL, V36, pS18, DOI 10.1007/s10875-016-0254-9; Moretti J, 2012, J BIOL CHEM, V287, P29429, DOI 10.1074/jbc.M112.366807; Nakada S, 2010, NATURE, V466, P941, DOI 10.1038/nature09297; Nayak TKS, 2017, BIOCHEM BIOPH RES CO, V483, P69, DOI 10.1016/j.bbrc.2017.01.004; Nomura S, 2018, J BLOOD MED, V9, P1, DOI 10.2147/JBM.S147743; Pengo N, 2013, NAT IMMUNOL, V14, P298, DOI 10.1038/ni.2524; Pinto V, 2020, CANCERS, V12, DOI 10.3390/cancers12020407; Rajkumar SV, 2009, CURR PROB CANCER, V33, P7, DOI 10.1016/j.currproblcancer.2009.01.001; Roy M, 2016, THERANOSTICS, V6, P2209, DOI 10.7150/thno.15584; Salminen A, 2013, PROG NEUROBIOL, V106, P33, DOI 10.1016/j.pneurobio.2013.06.002; Sridhar S, 2012, J PATHOL, V226, P255, DOI 10.1002/path.3025; Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078; Tian Z, 2014, BLOOD, V123, P706, DOI 10.1182/blood-2013-05-500033; Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264; Xia JL, 2020, MOL ONCOL, V14, P763, DOI 10.1002/1878-0261.12641; Yuan SL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00920-3; Zhang HM, 2018, ONCOL RES, V26, P421, DOI 10.3727/096504017X15049221237147; Zhang MJ, 2015, ONCOTARGET, V6, P8567, DOI 10.18632/oncotarget.3251; Zhang XD, 2014, MOL CELL BIOCHEM, V385, P265, DOI 10.1007/s11010-013-1835-z; Zhuang Y, 2017, LEUKEMIA RES, V59, P97, DOI 10.1016/j.leukres.2017.06.002	43	1	1	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1298	1308		10.1038/s41388-021-02167-9	http://dx.doi.org/10.1038/s41388-021-02167-9		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	34997217				2022-12-17	WOS:000740148500001
J	Huang, WC; Yen, JH; Sung, YW; Tung, SL; Chen, PM; Chu, PY; Shih, YC; Chi, HC; Huang, YC; Huang, SJ; Wang, LH				Huang, Wei-Chieh; Yen, Jia-Hau; Sung, Yu-Wen; Tung, Shiao-Lin; Chen, Po-Ming; Chu, Pei-Yi; Shih, Ya-Chi; Chi, Hsiang-Cheng; Huang, Yi-Ching; Huang, Shih-Jei; Wang, Lu-Hai			Novel function of THEMIS2 in the enhancement of cancer stemness and chemoresistance by releasing PTP1B from MET	ONCOGENE			English	Article							PROTEIN-TYROSINE PHOSPHATASES; C-MET; CELLS; EXPRESSION; RECEPTOR; OVARIAN; ICB-1; ONCOGENE; PATHWAYS; TARGETS	Triple negative breast cancer (TNBC) possesses poor prognosis mainly due to lack of effective endocrine or targeted therapies, aggressive nature and high rate of chemoresistance. Cancer stem cells (CSCs) are considered to play critical roles in cancer recurrence and chemoresistance. THEMIS2 was identified as the sole common elevated gene in three triple negative breast cancer (TNBC) and two ovarian CSC lines. We discovered an intrinsic signaling scaffold function of THEMIS2, which acts as a novel regulator of cancer stemness in promoting multiple cancer stemness properties including sphere formation, stemness markers expression, chemoresistance and tumorigenicity with low numbers of cancer cells implantation. For the first time, we demonstrated that THEMIS2 specifically enhanced MET activating phosphorylation by suppressing the association of protein-tyrosine phosphatases 1B (PTP1B) with p-MET and MET, which accounted mainly for THEMIS2-mediated effect on cancer stemness and chemoresistance. Increased THEMIS2 expression was associated with poor survival in TNBC patients and in patients from our breast cancer cohort. We found that non-cytotoxic dosages of cryptotanshinone (CPT) could potently inhibit cancer stemness, chemoresistance and tumorigenicity by suppressing expression of THEMIS2. Notably, stable overexpression of THEMIS2 is associated with enhanced sensitivity toward Capmatinib and CPT treatment. Expression levels of THEMIS2 and p-MET protein were positively correlated in the 465 breast cancer specimens. Our study revealed the novel oncogenic role of THEMIS2 and its underlying mechanism via suppressing PTP1B association with MET and thus leading to its activation. Our findings suggest that THEMIS2 could be a biomarker for MET targeted therapy and also provide a potential clinical application using low dosages of CPT for treatment of THEMIS2 positive TNBC.	[Huang, Wei-Chieh; Chen, Po-Ming; Shih, Ya-Chi; Chi, Hsiang-Cheng; Huang, Yi-Ching; Huang, Shih-Jei; Wang, Lu-Hai] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan; [Huang, Wei-Chieh; Shih, Ya-Chi; Chi, Hsiang-Cheng; Huang, Shih-Jei; Wang, Lu-Hai] China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan; [Yen, Jia-Hau] China Med Univ Hosp, Res Canc Ctr Tradit Chinese Med, Dept Med Res, Taichung, Taiwan; [Sung, Yu-Wen] China Med Univ Hosp, Dept Obstet & Gynecol, Taichung, Taiwan; [Tung, Shiao-Lin] Ton Yen Gen Hosp, Dept Hematol & Oncol, Zhubei City, Hsinchu County, Taiwan; [Tung, Shiao-Lin] Hsin Sheng Jr Coll Med Care & Management, Dept Nursing, Taoyuan, Taiwan; [Chu, Pei-Yi] Show Chwan Mem Hosp, Dept Pathol, Chung Shang Rd, Changhua, Changhua County, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Show Chwan Memorial Hospital	Wang, LH (corresponding author), China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.; Wang, LH (corresponding author), China Med Univ, Chinese Med Res Ctr, Taichung, Taiwan.	luhaiwang@mail.cmu.edu.tw		Tung, Shiao-Lin/0000-0002-6241-6293	Ministry of Science and Technology, Taiwan [MOST 107-2320-B-039-059-MY3, MOST 107-2320-B-039-065, MOST 109-2320-B-039 -067, MOST 110-2320-B-039 -061]; China Medical University, Taiwan [CMU107-TU-11, CMU110-Z-06, CMU110-MF-26, CMU110-N-02]; "Chinese Medicine Research Center, China Medical University" from The Featured Areas Research Center Program within Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan [CMRC-CENTER-0]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, TaiwanMinistry of Science, ICT & Future Planning, Republic of Korea); China Medical University, Taiwan(China Medical University); "Chinese Medicine Research Center, China Medical University" from The Featured Areas Research Center Program within Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan	This work were supported by the Ministry of Science and Technology, Taiwan (MOST 107-2320-B-039-059-MY3, MOST 107-2320-B-039-065, MOST 109-2320-B-039 -067, MOST 110-2320-B-039 -061), and China Medical University, Taiwan (CMU107-TU-11, CMU110-Z-06, CMU110-MF-26 and CMU110-N-02), and the "Chinese Medicine Research Center, China Medical University" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (CMRC-CENTER-0).	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Al Moustafa AE, 2013, CELL ADHES MIGR, V7, P424, DOI 10.4161/cam.26728; Bollmann J, 2008, J STEROID BIOCHEM, V109, P16, DOI 10.1016/j.jsbmb.2007.12.007; Chan SH, 2014, ONCOGENE, V33, P4496, DOI 10.1038/onc.2014.10; Cheng D, 2017, NAT IMMUNOL, V18, P205, DOI 10.1038/ni.3642; Cortazar P, 2019, LANCET, V393, P986; El Darsa Haidar, 2020, J Exp Pharmacol, V12, P349, DOI 10.2147/JEP.S242958; Firuzi O, 2019, CANCERS, V11, DOI 10.3390/cancers11050638; Garajova Ingrid, 2015, Transl Oncogenomics, V7, P13, DOI 10.4137/TOG.S30534; Hage C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.158; Hodgkinson CL, 2014, NAT MED, V20, P897, DOI 10.1038/nm.3600; Huang WC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1091-5; Huang X, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00152; Kakazu A, 2008, INVEST OPHTH VIS SCI, V49, P2927, DOI 10.1167/iovs.07-0709; Karamboulas C, 2013, BBA-GEN SUBJECTS, V1830, P2481, DOI 10.1016/j.bbagen.2012.11.008; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Konwisorz A, 2010, ENDOCR-RELAT CANCER, V17, P147, DOI 10.1677/ERC-09-0095; Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923; Lee GD, 2017, J THORAC ONCOL, V12, P1233, DOI 10.1016/j.jtho.2017.04.031; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Liang H, 2020, ONCOTARGETS THER, V13, P2491, DOI 10.2147/OTT.S231257; Liu XD, 2011, CLIN CANCER RES, V17, P7127, DOI 10.1158/1078-0432.CCR-11-1157; Luo Susan Y, 2013, Transl Respir Med, V1, P6, DOI 10.1186/2213-0802-1-6; Luvero D, 2014, THER ADV MED ONCOL, V6, P229, DOI 10.1177/1758834014544121; Matsumura A, 2013, INT J ONCOL, V42, P535, DOI 10.3892/ijo.2012.1728; Ng YP, 2006, J BIOL CHEM, V281, P15636, DOI 10.1074/jbc.M601863200; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; O'Conor CJ, 2018, BIOMARK MED, V12, P813, DOI 10.2217/bmm-2017-0398; O'Reilly EA, 2015, BBA CLIN, V3, P257, DOI 10.1016/j.bbacli.2015.03.003; Peirce MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011465; Riedmeier M, 2021, ARCH GYNECOL OBSTET, V304, P203, DOI 10.1007/s00404-020-05902-x; Sangwan V, 2011, J BIOL CHEM, V286, P45000, DOI 10.1074/jbc.M111.270934; Sangwan V, 2008, J BIOL CHEM, V283, P34374, DOI 10.1074/jbc.M805916200; Shin DS, 2009, CANCER RES, V69, P193, DOI 10.1158/0008-5472.CAN-08-2575; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Stoker AW, 2005, J ENDOCRINOL, V185, P19, DOI 10.1677/joe.1.06069; Treeck O, 2012, J CELL BIOCHEM, V113, P2979, DOI 10.1002/jcb.24175; Tung SL, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.25; Verma N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7064; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Wang H, 2017, ONCOL LETT, V14, P5890, DOI 10.3892/ol.2017.6959; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Wolf J, 2020, NEW ENGL J MED, V383, P944, DOI 10.1056/NEJMoa2002787; Wu YL, 2021, CANCER TREAT REV, V95, DOI 10.1016/j.ctrv.2021.102173; Zagouri F, 2013, BRIT J CANCER, V108, P1100, DOI 10.1038/bjc.2013.31; Zhang Y, 2016, ONCOL LETT, V11, P3803, DOI 10.3892/ol.2016.4444	46	1	1	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					997	1010		10.1038/s41388-021-02136-2	http://dx.doi.org/10.1038/s41388-021-02136-2		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34974522	Green Published, hybrid			2022-12-17	WOS:000736941300001
J	Nan, G; Zhao, SH; Wang, T; Chao, D; Tian, RF; Wang, WJ; Fu, X; Lin, P; Guo, T; Wang, B; Sun, XX; Chen, X; Chen, ZN; Wang, SJ; Cui, HY				Nan, Gang; Zhao, Shu-Hua; Wang, Ting; Chao, Dong; Tian, Ruo-Fei; Wang, Wen-Jing; Fu, Xin; Lin, Peng; Guo, Ting; Wang, Bin; Sun, Xiu-Xuan; Chen, Xi; Chen, Zhi-Nan; Wang, Shi-Jie; Cui, Hong-Yong			CD147 supports paclitaxel resistance via interacting with RanBP1	ONCOGENE			English	Article							OVARIAN-CANCER CELLS; TAXOL RESISTANCE; BETA; INHIBITION; APOPTOSIS; MUTATIONS; CHEMOSENSITIVITY; HAB18G/CD147; MECHANISMS; EXPRESSION	Though the great success of paclitaxel, the variable response of patients to the drug limits its clinical utility and the precise mechanisms underlying the variable response to paclitaxel remain largely unknown. This study aims to verify the role and the underlying mechanisms of CD147 in paclitaxel resistance. Immunostaining was used to analyze human non-small-cell lung cancer (NSCLC) and ovarian cancer tissues. RNA-sequencing was used to identify downstream effectors. Annexin V-FITC/propidium iodide and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining were used to detect apoptosis. Co-immunoprecipitation (Co-IP), fluorescence resonance energy transfer (FRET) and surface plasmon resonance (SPR) were performed to determine protein interactions. Fluorescence recovery after photobleaching (FRAP) was performed to measure the speed of microtubule turnover. Xenograft tumor model was established to evaluate sensitivity of cancer cells to paclitaxel in vivo. In vitro and in vivo assays showed that silencing CD147 sensitized the cancer cells to paclitaxel treatment. CD147 protected cancer cells from paclitaxel-induced caspase-3 mediated apoptosis regardless of p53 status. Truncation analysis showed that the intracellular domain of CD147 (CD147(ICD)) was indispensable for CD147-regulated sensitivity to paclitaxel. Via screening the interacting proteins of CD147(ICD), Ran binding protein 1 (RanBP1) was identified to interact with CD147(ICD) via its C-terminal tail. Furthermore, we showed that RanBP1 mediated CD147-regulated microtubule stability and dynamics as well as response to paclitaxel treatment. These results demonstrated that CD147 regulated paclitaxel response by interacting with the C-terminal tail of RanBP1 and targeting CD147 may be a promising strategy for preventing paclitaxel resistant.	[Nan, Gang; Tian, Ruo-Fei; Wang, Wen-Jing; Fu, Xin; Lin, Peng; Guo, Ting; Wang, Bin; Sun, Xiu-Xuan; Chen, Zhi-Nan; Wang, Shi-Jie; Cui, Hong-Yong] Fourth Mil Med Univ, Natl Translat Sci Ctr Mol Med, Xian 710032, Peoples R China; [Nan, Gang; Tian, Ruo-Fei; Wang, Wen-Jing; Fu, Xin; Lin, Peng; Guo, Ting; Wang, Bin; Sun, Xiu-Xuan; Chen, Zhi-Nan; Wang, Shi-Jie; Cui, Hong-Yong] Fourth Mil Med Univ, Dept Cell Biol, Xian 710032, Peoples R China; [Zhao, Shu-Hua] Fourth Mil Med Univ, Xijing Hosp, Dept Obstet & Gynecol, Xian 710032, Peoples R China; [Wang, Ting] Fourth Mil Med Univ, Dept Biochem & Mol Biol, Xian 710032, Peoples R China; [Chao, Dong] 940th Hosp Joint Logist Support Force Chinese Peo, Dept Thorac Surg, Lanzhou 730050, Peoples R China; [Chen, Xi] Northwest Univ, Coll Chem & Mat Sci, Xian 710127, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Northwest University Xi'an	Chen, ZN; Wang, SJ; Cui, HY (corresponding author), Fourth Mil Med Univ, Natl Translat Sci Ctr Mol Med, Xian 710032, Peoples R China.; Chen, ZN; Wang, SJ; Cui, HY (corresponding author), Fourth Mil Med Univ, Dept Cell Biol, Xian 710032, Peoples R China.	znchen@fmmu.edu.cn; kola_519@163.com; cui-hongyong@163.com		Chen, Zhi-Nan/0000-0001-5512-4623	National Key Research and Development Program of China [2018YFA0109000]; National Postdoctoral Program for Innovative Talents [BX20180376]; State Key Laboratory of Cancer Biology [CBSKL2019ZZ16]; Discipline Promotion Foundation of Xijing Hospital [XJZT18MJ92]; Natural Science Foundation of Shaanxi Province [2020SF-252]; Basic Research Plan of Natural Science in Shaanxi Province [2020JM-326]; National Natural Science Foundation of China [31601127, 82103360, 82173244]	National Key Research and Development Program of China; National Postdoctoral Program for Innovative Talents; State Key Laboratory of Cancer Biology; Discipline Promotion Foundation of Xijing Hospital; Natural Science Foundation of Shaanxi Province(Natural Science Foundation of Shaanxi Province); Basic Research Plan of Natural Science in Shaanxi Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Key Research and Development Program of China (2018YFA0109000), the National Postdoctoral Program for Innovative Talents (BX20180376), the State Key Laboratory of Cancer Biology (CBSKL2019ZZ16), the Discipline Promotion Foundation of Xijing Hospital (XJZT18MJ92), the Natural Science Foundation of Shaanxi Province (2020SF-252), the Basic Research Plan of Natural Science in Shaanxi Province (2020JM-326) and the National Natural Science Foundation of China (31601127, 82103360 and 82173244). We thank Ms Rui-Rui Yao and Ms. Wen Wen for paraffin section, Ms Tian-Jiao Zhang for mouse model establishment.	Als AB, 2007, CLIN CANCER RES, V13, P4407, DOI 10.1158/1078-0432.CCR-07-0109; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Cavazza T, 2016, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00082; Chen YK, 2009, CANCER LETT, V278, P113, DOI 10.1016/j.canlet.2009.01.004; Cui HY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00677-2; Cui HY, 2016, ONCOTARGET, V7, P5613, DOI 10.18632/oncotarget.6723; Dasso M, 2002, CURR BIOL, V12, pR502, DOI 10.1016/S0960-9822(02)00970-3; Fan XY, 2019, AM J TRANSL RES, V11, P3543; Fruehauf J P, 1994, Contrib Gynecol Obstet, V19, P39; Gao J, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0920-9; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Gonzalez-Garay ML, 1999, J BIOL CHEM, V274, P23875, DOI 10.1074/jbc.274.34.23875; Gou XC, 2009, CANCER SCI, V100, P837, DOI 10.1111/j.1349-7006.2009.01113.x; Gulluni F, 2017, CANCER CELL, V32, P444, DOI 10.1016/j.ccell.2017.09.002; He LF, 2001, MOL CANCER THER, V1, P3; Hu Yun, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P192, DOI 10.3969/j.issn.1672-7347.2011.03.002; Inoue S, 2001, Hum Cell, V14, P211; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Kanakkanthara A, 2013, CANCER TREAT REV, V39, P161, DOI 10.1016/j.ctrv.2012.07.005; Kang MJ, 2013, PROTEOMICS, V13, P1714, DOI 10.1002/pmic.201200511; Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803; Kuang YH, 2008, J PROTEOME RES, V7, P4784, DOI 10.1021/pr800355b; Kuang YH, 2009, CANCER LETT, V276, P189, DOI 10.1016/j.canlet.2008.11.010; Li Y, 2009, HISTOPATHOLOGY, V54, P677, DOI 10.1111/j.1365-2559.2009.03280.x; Liang Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102496; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Milross CG, 1996, JNCI-J NATL CANCER I, V88, P1308, DOI 10.1093/jnci/88.18.1308; Muramatsu T, 2016, J BIOCHEM, V159, P481, DOI 10.1093/jb/mvv127; Nami B, 2018, CANCERS, V10, DOI 10.3390/cancers10080274; Newman JR, 2008, ARCH OTOLARYNGOL, V134, P1218, DOI 10.1001/archotol.134.11.1218; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang J, 2012, CELL DEATH DIFFER, V19, P1779, DOI 10.1038/cdd.2012.60; Wang SJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01647-2; Wu B, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.251; Xu J, 2007, HEPATOLOGY, V45, P269, DOI 10.1002/hep.21465; Yau KC, 2020, CELL CYCLE, V19, P1899, DOI 10.1080/15384101.2020.1782036; Yin SH, 2007, MOL CANCER THER, V6, P2798, DOI 10.1158/1535-7163.MCT-06-0791; Yin SH, 2012, PHARM RES-DORDR, V29, P2994, DOI 10.1007/s11095-012-0794-5; Yin SH, 2010, MOL CANCER THER, V9, P327, DOI 10.1158/1535-7163.MCT-09-0674; Yong YL, 2019, J PATHOL, V249, P255, DOI 10.1002/path.5316; Yu Y, 2015, CANCER CELL, V28, P82, DOI 10.1016/j.ccell.2015.05.009; Zheng YY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02811-7; Zou W, 2007, CANCER LETT, V248, P211, DOI 10.1016/j.canlet.2006.07.005	47	1	1	5	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					983	996		10.1038/s41388-021-02143-3	http://dx.doi.org/10.1038/s41388-021-02143-3		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34974521	hybrid, Green Published			2022-12-17	WOS:000736941300002
J	Desi, N; Teh, V; Tong, QY; Lim, CY; Tabatabaeian, H; Chew, XH; Sanchez-Mejias, A; Chan, JJ; Zhang, B; Pitcheshwar, P; Siew, BE; Wang, S; Lee, KC; Chong, CS; Cheong, WK; Lieske, B; Tan, IJW; Tan, KK; Tay, Y				Desi, Ng; Teh, Velda; Tong, Qing Yun; Lim, Chun You; Tabatabaeian, Hossein; Chew, Xiao Hong; Sanchez-Mejias, Avencia; Chan, Jia Jia; Zhang, Bin; Pitcheshwar, Priyankaa; Siew, Bei-En; Wang, Shi; Lee, Kuok-Chung; Chong, Choon-Seng; Cheong, Wai-Kit; Lieske, Bettina; Tan, Ian Jse-Wei; Tan, Ker-Kan; Tay, Yvonne			MiR-138 is a potent regulator of the heterogenous MYC transcript population in cancers	ONCOGENE			English	Article							C-MYC; CELL-PROLIFERATION; EXPRESSION; INHIBITION; DELIVERY; TARGET; GENE; OVEREXPRESSION; IDENTIFICATION; AMPLIFICATION	3 ' UTR shortening in cancer has been shown to activate oncogenes, partly through the loss of microRNA-mediated repression. This suggests that many reported microRNA-oncogene target interactions may not be present in cancer cells. One of the most well-studied oncogenes is the transcription factor MYC, which is overexpressed in more than half of all cancers. MYC overexpression is not always accompanied by underlying genetic aberrations. In this study, we demonstrate that the MYC 3 ' UTR is shortened in colorectal cancer (CRC). Using unbiased computational and experimental approaches, we identify and validate microRNAs that target the MYC coding region. In particular, we show that miR-138 inhibits MYC expression and suppresses tumor growth of CRC and hepatocellular carcinoma (HCC) cell lines. Critically, the intravenous administration of miR-138 significantly impedes MYC-driven tumor growth in vivo. Taken together, our results highlight the previously uncharacterized shortening of the MYC 3 ' UTR in cancer, and identify miR-138 as a potent regulator of the heterogenous MYC transcript population.	[Desi, Ng; Teh, Velda; Tong, Qing Yun; Lim, Chun You; Tabatabaeian, Hossein; Chew, Xiao Hong; Sanchez-Mejias, Avencia; Chan, Jia Jia; Zhang, Bin; Pitcheshwar, Priyankaa; Chong, Choon-Seng; Tay, Yvonne] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore; [Desi, Ng; Tay, Yvonne] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117597, Singapore; [Siew, Bei-En; Chong, Choon-Seng; Lieske, Bettina; Tan, Ker-Kan] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore, Singapore; [Wang, Shi] Natl Univ Hlth Syst, Dept Pathol, Singapore, Singapore; [Lee, Kuok-Chung; Chong, Choon-Seng; Cheong, Wai-Kit; Lieske, Bettina; Tan, Ian Jse-Wei; Tan, Ker-Kan] Univ Surg Cluster, Natl Univ Hlth Syst, Div Colorectal Surg, Singapore, Singapore; [Sanchez-Mejias, Avencia] Pompeu Fabra Univ, Dept Expt & Hlth Sci, Barcelona 08003, Spain	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; Pompeu Fabra University	Tay, Y (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore.; Tay, Y (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117597, Singapore.	yvonnetay@nus.edu.sg		Ng, Desi/0000-0001-8167-3925; zhang, bin/0000-0001-8835-8370	Singapore National Research Foundation Fellowship; National University of Singapore; NMRC OF-IRG; NUS Research Scholarship; National Research Foundation Singapore; Singapore Ministry of Education under its Research Centres of Excellence initiative; RNA Biology Center at the Cancer Science Institute of Singapore, NUS, Singapore Ministry of Education's AcRF Tier 3 grant [MOE2014-T3-1-006]; NCIS; NUS Cancer Programme Seed Grant	Singapore National Research Foundation Fellowship(National Research Foundation, Singapore); National University of Singapore(National University of Singapore); NMRC OF-IRG; NUS Research Scholarship(National University of Singapore); National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under its Research Centres of Excellence initiative(Ministry of Education, Singapore); RNA Biology Center at the Cancer Science Institute of Singapore, NUS, Singapore Ministry of Education's AcRF Tier 3 grant; NCIS; NUS Cancer Programme Seed Grant	We thank all past and present YT lab members for their constructive feedback on this project. We also thank MiRXES for the high-throughput qPCR analysis. We apologize to all colleagues whose work could not be cited due to space constraints. YT is funded by a Singapore National Research Foundation Fellowship, a National University of Singapore President's Assistant Professorship, a NMRC OF-IRG, and a Joint NCIS and NUS Cancer Programme Seed Grant. ND is supported by the NUS Research Scholarship. This research is supported by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative, as well as the RNA Biology Center at the Cancer Science Institute of Singapore, NUS, as part of funding under the Singapore Ministry of Education's AcRF Tier 3 grants, Grant number MOE2014-T3-1-006.	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; Akman BH, 2012, NUCLEIC ACIDS RES, V40, P10679, DOI 10.1093/nar/gks855; Avci CB, 2013, CELL BIOL INT, V37, P1205, DOI 10.1002/cbin.10157; Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637-016-0407-y; Berkovits BD, 2015, NATURE, V522, P363, DOI 10.1038/nature14321; Chan KL, 2004, HUM PATHOL, V35, P1324, DOI 10.1016/j.humpath.2004.06.012; Chan XHD, 2012, CELL REP, V2, P591, DOI 10.1016/j.celrep.2012.07.012; Chu-Tan JA, 2020, MOL VIS, V26, P48; Conde J, 2016, NAT MATER, V15, P353, DOI [10.1038/NMAT4497, 10.1038/nmat4497]; Cui JK, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1448330; Dell Ralph B, 2002, ILAR J, V43, P207; Desi N, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121634; Endo-Takahashi Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep03883; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fu Y., 2019, EXRNA, V1, P24, DOI [DOI 10.1186/S41544-019-0024-Y, 10.1186/S41544-019-0024-Y,20191:1.1]; FUJIWARA Y, 1993, CANCER RES, V53, P857; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Gao SQ, 2015, ACTA BIOMATER, V25, P184, DOI 10.1016/j.actbio.2015.07.020; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Huang Z, 2014, GUT, V63, P1247, DOI 10.1136/gutjnl-2012-304213; Jackstadt R, 2015, BBA-GENE REGUL MECH, V1849, P544, DOI 10.1016/j.bbagrm.2014.04.003; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KOZMA L, 1994, CANCER LETT, V81, P165, DOI 10.1016/0304-3835(94)90198-8; Lal A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002363; Li DF, 2017, RSC ADV, V7, P52030, DOI 10.1039/c7ra09042k; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Lin F, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-58; Long LM, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-275; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Migliore C, 2012, CLIN CANCER RES, V18, P737, DOI 10.1158/1078-0432.CCR-11-1699; Mihailovich M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9725; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Misiewicz-Krzeminska I, 2016, CLIN CANCER RES, V22, P207, DOI 10.1158/1078-0432.CCR-14-2796; Miyazaki Y, 2012, NAT MED, V18, P1136, DOI 10.1038/nm.2791; Mohammed A, 2019, ONCOL REP, V41, P973, DOI 10.3892/or.2018.6857; Nama S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49155-4; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ouyang M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1151-y; Park HJ, 2018, NAT GENET, V50, P783, DOI 10.1038/s41588-018-0118-8; Qiu SW, 2013, BBA-MOL BASIS DIS, V1832, P1697, DOI 10.1016/j.bbadis.2013.05.015; Ramanujam D, 2016, MOL THER, V24, P1939, DOI 10.1038/mt.2016.166; Reid G, 2013, ANN ONCOL, V24, P3128, DOI 10.1093/annonc/mdt412; Rochlitz CF, 1996, ONCOLOGY, V53, P448; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Seto AG, 2018, BRIT J HAEMATOL, V183, P428, DOI 10.1111/bjh.15547; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shams R, 2020, CANCER MANAG RES, V12, P2393, DOI 10.2147/CMAR.S245872; SMITH DR, 1993, BRIT J CANCER, V68, P407, DOI 10.1038/bjc.1993.350; Wang YY, 2017, THERANOSTICS, V7, P1360, DOI 10.7150/thno.16532; Wang YB, 2018, J CELL BIOCHEM, V119, P1702, DOI 10.1002/jcb.26330; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xie F, 2017, ONCOTARGETS THER, V10, P885, DOI 10.2147/OTT.S122992; Xu XS, 2015, ONCOTARGET, V6, P3988, DOI 10.18632/oncotarget.2905; Xu Y, 2018, EUR REV MED PHARMACO, V22, P8664, DOI 10.26355/eurrev_201812_16631; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Yoon JH, 2012, METHODS, V58, P81, DOI 10.1016/j.ymeth.2012.07.004; You CX, 2019, ONCOL LETT, V17, P2271, DOI 10.3892/ol.2018.9864; Zhang QY, 2015, J CONTROL RELEASE, V197, P208, DOI 10.1016/j.jconrel.2014.11.010; Zhang S, 2021, DRUG DES DEV THER, V15, P721, DOI 10.2147/DDDT.S288859; Zhao L, 2016, ONCOTARGET, V7, P45370, DOI 10.18632/oncotarget.9659	62	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1178	1189		10.1038/s41388-021-02084-x	http://dx.doi.org/10.1038/s41388-021-02084-x		DEC 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	34937878	hybrid, Green Published			2022-12-17	WOS:000733868400001
J	Frey, P; Devisme, A; Rose, K; Schrempp, M; Freihen, V; Andrieux, G; Boerries, M; Hecht, A				Frey, Patrick; Devisme, Antoine; Rose, Katja; Schrempp, Monika; Freihen, Vivien; Andrieux, Geoffroy; Boerries, Melanie; Hecht, Andreas			SMAD4 mutations do not preclude epithelial-mesenchymal transition in colorectal cancer	ONCOGENE			English	Article							CONSENSUS MOLECULAR SUBTYPES; EPHB3 TUMOR-SUPPRESSOR; SNAIL TRANSCRIPTION; EXPRESSION; GENE; PROGRESSION	Transforming growth factor beta (TGF beta) superfamily signaling is a prime inducer of epithelial-mesenchymal transitions (EMT) that foster cancer cell invasion and metastasis, a major cause of cancer-related deaths. Yet, TGF beta signaling is frequently inactivated in human tumor entities including colorectal cancer (CRC) and pancreatic adenocarcinoma (PAAD) with a high proportion of mutations incapacitating SMAD4, which codes for a transcription factor (TF) central to canonical TGF beta and bone morphogenetic protein (BMP) signaling. Beyond its role in initiating EMT, SMAD4 was reported to crucially contribute to subsequent gene regulatory events during EMT execution. It is therefore widely assumed that SMAD4-mutant (SMAD4(mut)) cancer cells are unable to undergo EMT. Here, we scrutinized this notion and probed for potential SMAD4-independent EMT execution using SMAD4(mut) CRC cell lines. We show that SMAD4(mut) cells exhibit morphological changes, become invasive, and regulate EMT marker genes upon induction of the EMT-TF SNAIL1. Furthermore, SNAIL1-induced EMT in SMAD4(mut) cells was found to be entirely independent of TGF beta/BMP receptor activity. Global assessment of the SNAIL1-dependent transcriptome confirmed the manifestation of an EMT gene regulatory program in SMAD4(mut) cells highly related to established EMT signatures. Finally, analyses of human tumor transcriptomes showed that SMAD4 mutations are not underrepresented in mesenchymal tumor samples and that expression patterns of EMT-associated genes are similar in SMAD4(mut) and SMAD4 wild-type (SMAD4(wt)) cases. Altogether, our findings suggest that alternative TFs take over the gene regulatory functions of SMAD4 downstream of EMT-TFs, arguing for considerable plasticity of gene regulatory networks operating in EMT execution. Further, they establish that EMT is not categorically precluded in SMAD4(mut) tumors, which is relevant for their diagnostic and therapeutic evaluation.	[Frey, Patrick; Rose, Katja; Schrempp, Monika; Freihen, Vivien; Hecht, Andreas] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany; [Frey, Patrick; Hecht, Andreas] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Freiburg, Germany; [Frey, Patrick; Devisme, Antoine; Hecht, Andreas] Univ Freiburg, Fac Biol, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] Univ Freiburg, Fac Med, Med Ctr, Inst Med Bioinformat & Syst Med, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] German Canc Consortium DKTK, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] German Canc Res Ctr, Heidelberg, Germany; [Hecht, Andreas] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg	Hecht, A (corresponding author), Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, Fac Biol, Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany.	andreas.hecht@mol-med.uni-freiburg.de			Excellence Initiative of the German Research Foundation [GSC-4]; Ministry for Science, Research and Arts of the State of Baden-Wuerttemberg; Deutsche Forschungsgemeinschaft (DFG) [CRC-850]; German Federal Ministry of Education and Research by MIRACUM within the Medical Informatics Funding Scheme [FKZ 01ZZ1801B]; DFG [CRC-1479, 441891347-S1, CRC-1160, CRC-1453, 431984000-S1, TRR167]	Excellence Initiative of the German Research Foundation(German Research Foundation (DFG)); Ministry for Science, Research and Arts of the State of Baden-Wuerttemberg; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Federal Ministry of Education and Research by MIRACUM within the Medical Informatics Funding Scheme; DFG(German Research Foundation (DFG))	The authors wish to thank the team at the Lighthouse Core Facility Freiburg, Germany for cell sorting assistance, M. Bewerunge-Hudler and her team from the Genomics and Proteomics Core Facility at the German Cancer Research Center (DKFZ), Heidelberg, Germany for their microarray services, and all members of the Hecht laboratory for critical reading of the manuscript. The results shown here are in part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.This study was supported in part by the Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School) and in part by the Ministry for Science, Research and Arts of the State of Baden-Wuerttemberg. Additional financial support was obtained from the Deutsche Forschungsgemeinschaft (DFG) (CRC-850 subprojects B5 to AH; C9 and Z1 to MB). MB received further funding from the German Federal Ministry of Education and Research by MIRACUM within the Medical Informatics Funding Scheme (FKZ 01ZZ1801B), and from the DFG within the following consortia: CRC-1479 (Project ID: 441891347-S1), CRC-1160 (Project Z02), CRC-1453 (Project ID 431984000-S1), and TRR167 (Project Z01).	Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Beyes S, 2019, ONCOGENE, V38, P6647, DOI 10.1038/s41388-019-0905-4; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Cook DP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16066-2; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eide PW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16747-x; Feldker N, 2020, EMBO J, V39, DOI 10.15252/embj.2019103209; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Freihen V, 2020, INT J CANCER, V146, P2229, DOI 10.1002/ijc.32644; Frey P, 2020, CANCERS, V12, DOI 10.3390/cancers12041019; Groger CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051136; Guerrero-Martinez JA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19877-5; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Haeussler M, 2019, NUCLEIC ACIDS RES, V47, pD853, DOI 10.1093/nar/gky1095; Hayashi Y, 2011, CANCER SCI, V102, P1228, DOI 10.1111/j.1349-7006.2011.01910.x; Herwig R, 2016, NAT PROTOC, V11, P1889, DOI 10.1038/nprot.2016.117; Inamoto S, 2016, CLIN CANCER RES, V22, P492, DOI 10.1158/1078-0432.CCR-15-0726; Jagle S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007109; Jagle S, 2014, P NATL ACAD SCI USA, V111, P4886, DOI 10.1073/pnas.1314523111; Ji Q, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1119-y; Khan FM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00268-2; Kolmykov S, 2021, NUCLEIC ACIDS RES, V49, pD104, DOI 10.1093/nar/gkaa1057; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Linnekamp JF, 2018, CELL DEATH DIFFER, V25, P616, DOI 10.1038/s41418-017-0011-5; Ma CQ, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0212-5; Ma ZQ, 2018, SEMIN CANCER BIOL, V50, P21, DOI 10.1016/j.semcancer.2018.02.004; Mak MP, 2016, CLIN CANCER RES, V22, P609, DOI 10.1158/1078-0432.CCR-15-0876; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; McFaline-Figueroa JL, 2019, NAT GENET, V51, P1389, DOI 10.1038/s41588-019-0489-5; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Mei Z, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4298-5; Meyer-Schaller N, 2019, DEV CELL, V48, P539, DOI 10.1016/j.devcel.2018.12.023; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pires BRB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169622; Ramirez D, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00054; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ronsch K, 2015, MOL ONCOL, V9, P335, DOI 10.1016/j.molonc.2014.08.016; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395; Stanisavljevic J, 2011, J CELL SCI, V124, P4159, DOI 10.1242/jcs.078824; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tascilar M, 2001, CLIN CANCER RES, V7, P4115; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Voorneveld PW, 2014, GASTROENTEROLOGY, V147, P196, DOI 10.1053/j.gastro.2014.03.052; Wang GH, 2018, PATHOL RES PRACT, V214, P1362, DOI 10.1016/j.prp.2018.06.018; Wang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056664; Wang Y, 2021, LAB INVEST, V101, P463, DOI 10.1038/s41374-020-00517-x; Wendt Michael K, 2014, JAKSTAT, V3, pe28975, DOI 10.4161/jkst.28975; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Wu WS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18101-7; Yan P, 2016, CLIN CANCER RES, V22, P3037, DOI 10.1158/1078-0432.CCR-15-0939; Zhang B, 2014, BRIT J CANCER, V110, P946, DOI 10.1038/bjc.2013.789; Zhang JY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005304; Zhang YE, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022129; Zhang Y, 2019, BIOMED PHARMACOTHER, V110, P400, DOI 10.1016/j.biopha.2018.11.112	64	1	1	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					824	837		10.1038/s41388-021-02128-2	http://dx.doi.org/10.1038/s41388-021-02128-2		DEC 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34857888	hybrid, Green Published			2022-12-17	WOS:000725388800001
J	Page, EC; Heatley, SL; Eadie, LN; McClure, BJ; de Bock, CE; Omari, S; Yeung, DT; Hughes, TP; Thomas, PQ; White, DL				Page, Elyse C.; Heatley, Susan L.; Eadie, Laura N.; McClure, Barbara J.; de Bock, Charles E.; Omari, Sofia; Yeung, David T.; Hughes, Timothy P.; Thomas, Paul Q.; White, Deborah L.			HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; MURINE XENOGRAFT MODELS; CHILDREN; TRANSCRIPTION; INHIBITION; PI3K/MTOR; TRANSFORMATION; ACTIVATION; EXPRESSION; MUTATIONS	The genetic basis of the predisposition for Down Syndrome (DS) patients to develop cytokine receptor-like factor 2 rearranged (CRLF2r) acute lymphoblastic leukemia (ALL) is currently unknown. Genes located on chromosome 21 and expressed in hematopoietic cells are likely candidates for investigation of CRLF2r DS-ALL pathogenesis. We explored the high-mobility group nucleosome-binding protein 1 (HMGN1), located in the DS critical region, in an inducible CRISPR/Cas9 knockout (KO) xenograft model to assess the effect of HMGN1 loss of function on the leukemic burden. We demonstrated HMGN1 KO-mitigated leukemic phenotypes including hepatosplenomegaly, thrombocytopenia, and anemia, commonly observed in leukemia patients, and significantly increased survival in vivo. HMGN1 overexpression in murine stem cells and Ba/F3 cells in vitro, in combination with P2RY8-CRLF2, resulted in cytokine-independent transformation and upregulation of cell signaling pathways associated with leukemic development. Finally, in vitro screening demonstrated successful targeting of P2RY8-CRLF2 and HMGN1 co-expressing cell lines and patient samples with fedratinib (JAK2 inhibitor), and GSK-J4 (demethylase inhibitor) in combination. Together, these data provide critical insight into the development and persistence of CRLF2r DS-ALL and identify HMGN1 as a potential therapeutic target to improve outcomes and reduce toxicity in this high-risk cohort of young patients.	[Page, Elyse C.; Heatley, Susan L.; Eadie, Laura N.; McClure, Barbara J.; Yeung, David T.; Hughes, Timothy P.; White, Deborah L.] South Australian Hlth & Med Res Inst, Canc Program, Precis Med Theme, Adelaide, SA, Australia; [Page, Elyse C.; White, Deborah L.] Univ Adelaide, Fac Sci, Adelaide, SA, Australia; [Heatley, Susan L.; Eadie, Laura N.; McClure, Barbara J.; Yeung, David T.; Hughes, Timothy P.; Thomas, Paul Q.; White, Deborah L.] Univ Adelaide, Discipline Med, Adelaide, SA, Australia; [Page, Elyse C.; White, Deborah L.] Australian & New Zealand Childrens Haematol Oncol, Sydney, NSW, Australia; [de Bock, Charles E.; Omari, Sofia] UNSW Sydney, Lowy Canc Res Ctr, Childrens Canc Inst, Sydney, NSW, Australia; [de Bock, Charles E.; Omari, Sofia] UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW, Australia; [Yeung, David T.; Hughes, Timothy P.; White, Deborah L.] Australasian Leukaemia & Lymphoma Grp, Melbourne, Vic, Australia; [Yeung, David T.; Hughes, Timothy P.] Royal Adelaide Hosp, Dept Haematol, Adelaide, SA, Australia; [Yeung, David T.; Hughes, Timothy P.] SA Pathol, Adelaide, SA, Australia; [Yeung, David T.] Univ South Australia, Sch Pharm & Med Sci, Adelaide, SA, Australia; [Thomas, Paul Q.] South Australian Hlth & Med Res Inst, Gene Editing Program, Precis Med Theme, Adelaide, SA, Australia; [White, Deborah L.] Australian Genom Hlth Alliance AGHA, Sydney, NSW, Australia	South Australian Health & Medical Research Institute (SAHMRI); University of Adelaide; University of Adelaide; Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; Royal Adelaide Hospital; SA Pathology; University of South Australia; South Australian Health & Medical Research Institute (SAHMRI)	White, DL (corresponding author), South Australian Hlth & Med Res Inst, Canc Program, Precis Med Theme, Adelaide, SA, Australia.; White, DL (corresponding author), Univ Adelaide, Fac Sci, Adelaide, SA, Australia.; White, DL (corresponding author), Univ Adelaide, Discipline Med, Adelaide, SA, Australia.; White, DL (corresponding author), Australian & New Zealand Childrens Haematol Oncol, Sydney, NSW, Australia.; White, DL (corresponding author), Australasian Leukaemia & Lymphoma Grp, Melbourne, Vic, Australia.; White, DL (corresponding author), Australian Genom Hlth Alliance AGHA, Sydney, NSW, Australia.	Deborah.white@sahmri.com	de Bock, Charles/H-7699-2019; Heatley, Susan/AGP-2179-2022	de Bock, Charles/0000-0001-5182-8535; McClure, Barbara/0000-0002-5201-4127; Omari, Sofia/0000-0003-0345-5601; Heatley, Susan/0000-0001-7497-6477; White, Deborah/0000-0003-4844-333X	Detmold Hoopman Group; Australian Cancer Research Foundation; Australian Government through the Zero Childhood Cancer Program; NHMRC; Beat Cancer; RTP University of Adelaide scholarship	Detmold Hoopman Group; Australian Cancer Research Foundation; Australian Government through the Zero Childhood Cancer Program; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Beat Cancer; RTP University of Adelaide scholarship	Flow cytometry analysis and cell sorting were performed at the South Australian Health Medical Research Institute (SAHMRI) in the ACRF Cellular Imaging and Cytometry Core Facility. The Facility is generously supported by the Detmold Hoopman Group, Australian Cancer Research Foundation, and the Australian Government through the Zero Childhood Cancer Program. Animal models were performed in the Bioresources Core Facility at SAHMRI and we would like to acknowledge the technical support provided. The authors acknowledge the facilities and scientific and technical assistance of the National Imaging Facility, a National Collaborative Research Infrastructure Strategy (NCRIS) capability, at the Preclinical Imaging and Research Laboratories/Bioresources, South Australian Health and Medical Research Institute. This study has been performed as partial fulfillment of the requirement for a Ph.D. degree from the University of Adelaide Faculty of Sciences for E.C.P. Funding for this study was provided by NHMRC, Beat Cancer, and L.F.A. E.C.P. was supported by an RTP University of Adelaide scholarship.	Adikusuma F, 2018, NATURE, V560, pE8, DOI 10.1038/s41586-018-0380-z; Antonarakis SE, 2017, NAT REV GENET, V18, P147, DOI 10.1038/nrg.2016.154; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Buitenkamp TD, 2012, LEUKEMIA, V26, P2204, DOI 10.1038/leu.2012.84; Buitenkamp TD, 2014, BLOOD, V123, P70, DOI 10.1182/blood-2013-06-509463; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P431, DOI 10.1016/S0968-0004(01)01855-2; Cabal-Hierro L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15221-z; Caruso C, 2019, CANCER DISCOV, V9, P1332, DOI 10.1158/2159-8290.CD-NB2019-102; Catez F, 2002, EMBO REP, V3, P760, DOI 10.1093/embo-reports/kvf156; Cho SW, 2014, GENOME RES, V24, P132, DOI 10.1101/gr.162339.113; Den Boer ML, 2009, LANCET ONCOL, V10, P125, DOI 10.1016/S1470-2045(08)70339-5; Figueroa ME, 2013, J CLIN INVEST, V123, P3099, DOI 10.1172/JCI66203; Ghosh S, 2009, AM J MED GENET A, V149A, P1415, DOI 10.1002/ajmg.a.32932; Gozgit JM, 2008, J BIOL CHEM, V283, P32334, DOI 10.1074/jbc.M803813200; Hama A, 2008, BRIT J HAEMATOL, V140, P552, DOI 10.1111/j.1365-2141.2007.06971.x; Heerema NA, 2007, GENE CHROMOSOME CANC, V46, P684, DOI 10.1002/gcc.20451; Hertzberg L, 2010, BLOOD, V115, P1006, DOI 10.1182/blood-2009-08-235408; Hurtz C, 2020, J CLIN INVEST, V130, P3637, DOI 10.1172/JCI134424; Izraeli S, 2014, BLOOD, V123, P35, DOI 10.1182/blood-2013-07-453480; Lane AA, 2014, NAT GENET, V46, P618, DOI 10.1038/ng.2949; Lee P, 2016, LEUKEMIA, V30, P1816, DOI 10.1038/leu.2016.164; Li Q, 2018, ONCOL LETT, V15, P4517, DOI 10.3892/ol.2018.7898; Li WP, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0761-2; Li YN, 2018, J CANCER RES CLIN, V144, P1065, DOI 10.1007/s00432-018-2631-7; Lim JH, 2004, MOL CELL, V15, P573, DOI 10.1016/j.molcel.2004.08.006; Maude SL, 2015, BLOOD, V125, P1759, DOI 10.1182/blood-2014-06-580480; Meyr F, 2013, BRIT J HAEMATOL, V162, P98, DOI 10.1111/bjh.12348; Mowery CT, 2018, CELL REP, V25, P1898, DOI 10.1016/j.celrep.2018.10.061; Mullally A, 2020, BLOOD ADV, V4, P1792, DOI 10.1182/bloodadvances.2019000954; Mullighan CG, 2009, NAT GENET, V41, P1243, DOI 10.1038/ng.469; Mullighan CG, 2009, P NATL ACAD SCI USA, V106, P9414, DOI 10.1073/pnas.0811761106; Page EC, 2018, CANCER LETT, V432, P69, DOI 10.1016/j.canlet.2018.05.045; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Roberts I, 2014, BRIT J HAEMATOL, V167, P587, DOI 10.1111/bjh.13096; Roberts KG, 2014, NEW ENGL J MED, V371, P1005, DOI 10.1056/NEJMoa1403088; Rochman M, 2011, NUCLEIC ACIDS RES, V39, P4076, DOI 10.1093/nar/gkq1343; Russell LJ, 2009, BLOOD, V114, P2688, DOI 10.1182/blood-2009-03-208397; Sandhofer N, 2015, LEUKEMIA, V29, P828, DOI 10.1038/leu.2014.305; Tasian SK, 2017, BLOOD, V129, P177, DOI 10.1182/blood-2016-05-707653; Tasian SK, 2012, BLOOD, V120, P833, DOI 10.1182/blood-2011-12-389932; Tasian Sarah K., 2011, Critical Reviews in Oncogenesis, V16, P13; Vesely C, 2017, LEUKEMIA, V31, P1491, DOI 10.1038/leu.2016.365; Whitlock JA, 2006, BRIT J HAEMATOL, V135, P595, DOI 10.1111/j.1365-2141.2006.06337.x; Yoda A, 2010, P NATL ACAD SCI USA, V107, P252, DOI 10.1073/pnas.0911726107; Zhu N, 2007, MOL CELL BIOL, V27, P8859, DOI 10.1128/MCB.01724-07	45	1	1	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					797	808		10.1038/s41388-021-02126-4	http://dx.doi.org/10.1038/s41388-021-02126-4		DEC 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34857887				2022-12-17	WOS:000725389500001
J	Sun, LZ; Xi, SY; Zhou, ZD; Zhang, FF; Hu, PC; Cui, YZ; Wu, SS; Wang, Y; Wu, SY; Wang, YC; Du, YY; Zheng, JY; Yang, H; Chen, M; Yan, Q; Yu, DD; Shi, CR; Zhang, Y; Xie, D; Guan, XY; Li, Y				Sun, Liangzhan; Xi, Shaoyan; Zhou, Zhengdong; Zhang, Feifei; Hu, Pengchao; Cui, Yuzhu; Wu, Shasha; Wang, Ying; Wu, Shayi; Wang, Yanchen; Du, Yuyang; Zheng, Jingyi; Yang, Hui; Chen, Miao; Yan, Qian; Yu, Dandan; Shi, Chaoran; Zhang, Yu; Xie, Dan; Guan, Xin-Yuan; Li, Yan			Elevated expression of RIT1 hyperactivates RAS/MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor	ONCOGENE			English	Article							INITIATION-FACTOR; PATHWAY; KINASE; ACTIVATION; EIF4E	Hyperactivation of RAS/MAPK signaling is commonly observed in hepatocellular carcinoma (HCC). Gain-of-function mutations of canonical RAS genes, however, are rarely detected and it remains unclear how the activity of this pathway is turned on during hepatocarcinogenesis. We performed a comprehensive analysis of RAS superfamily genetic alterations across ten subfamilies, 152 members in 377 HCC patients from the Cancer Genome Atlas database. RIT1 (Ras-like without CAAX 1) was the most frequently altered RAS member amplified in 13% of the HCC cohort. Both genomic amplification and CREB-mediated transcriptional activation contributed to the elevated RIT1 expression, and its overexpression correlated with RAS/MAPK activation and poor prognosis. Then, we found that RIT1-induced angiogenesis via the MEK/ERK/EIF4E/HIF1-alpha/VEGFA axis. MAP3K11 and MAP3K12, in addition to CRAF, could mediate this process by binding to RIT1. Moreover, RIT1 increased the phosphorylation of p38 MAPK and AKT to promote cell survival under reactive oxygen species stress. Based on this mechanistic understanding, we treated RIT1-overexpressing HCC with combined regimen sorafenib plus AKT inhibitor, and achieved enhanced antitumor effects in vivo. Our study reveals RAS "orphan" member RIT1 as the most common genetic alteration of RAS family in HCC and combination of sorafenib with AKT inhibitor might be a promising treatment strategy for RIT1-overexpressing HCC.	[Sun, Liangzhan; Zhou, Zhengdong; Hu, Pengchao; Wu, Shasha; Wang, Yanchen; Du, Yuyang; Zheng, Jingyi; Yang, Hui; Yu, Dandan; Li, Yan] Southern Univ Sci & Technol, Sch Life Sci, Dept Biol, Shenzhen, Peoples R China; [Sun, Liangzhan; Zhang, Feifei; Cui, Yuzhu; Wu, Shayi; Chen, Miao; Yan, Qian; Yu, Dandan; Shi, Chaoran; Zhang, Yu; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China; [Sun, Liangzhan; Yan, Qian; Yu, Dandan; Guan, Xin-Yuan] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China; [Xi, Shaoyan] Sun Yat Sen Univ, Dept Pathol, Canc Ctr, Guangzhou, Peoples R China; [Xi, Shaoyan; Wang, Ying; Xie, Dan; Guan, Xin-Yuan] Sun Yat Sen Univ, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China; [Xi, Shaoyan; Wang, Ying; Xie, Dan; Guan, Xin-Yuan] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China; [Wang, Ying] Sun Yat Sen Univ, Dept Radiat Oncol, Canc Ctr, Guangzhou, Peoples R China; [Guan, Xin-Yuan] Univ Hong Kong, Shenzhen Hosp, Shenzhen, Peoples R China	Southern University of Science & Technology; University of Hong Kong; University of Hong Kong; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; University of Hong Kong	Li, Y (corresponding author), Southern Univ Sci & Technol, Sch Life Sci, Dept Biol, Shenzhen, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China.; Guan, XY (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China.; Guan, XY (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, Shenzhen Hosp, Shenzhen, Peoples R China.	xyguan@hku.hk; liy33@sustech.edu			National Natural Science Foundation of China [82073127]; Shenzhen Fundamental Research Programs [JCYJ20190809145215160]; Shenzhen Science and Technology Innovation Commission [KYTDPT20181011104005, KQTD2018041118502879]; Guangdong Innovative Research Team Fund [2016ZT06S172]; Hong Kong Research Grant Council [17143716, C7065-18GF, C7026-18GF, T12-704/16-R]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Fundamental Research Programs; Shenzhen Science and Technology Innovation Commission; Guangdong Innovative Research Team Fund; Hong Kong Research Grant Council(Hong Kong Research Grants Council)	This work was supported by the National Natural Science Foundation of China (82073127), Shenzhen Fundamental Research Programs (JCYJ20190809145215160), Shenzhen Science and Technology Innovation Commission (KYTDPT20181011104005 and KQTD2018041118502879), and Guangdong Innovative Research Team Fund (No. 2016ZT06S172). Hong Kong Research Grant Council grants including GRF (17143716), Collaborative Research Funds (C7065-18GF and C7026-18GF) and Theme-based Research Scheme (T12-704/16-R).	Al-Salama ZT, 2019, DRUGS, V79, P665, DOI 10.1007/s40265-019-01116-x; Aoki Y, 2013, AM J HUM GENET, V93, P173, DOI 10.1016/j.ajhg.2013.05.021; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Cai WK, 2011, MOL BIOL CELL, V22, P3231, DOI 10.1091/mbc.E11-05-0400; Calcagni G, 2017, INT J CARDIOL, V245, P92, DOI 10.1016/j.ijcard.2017.07.068; Cao J, 2014, BIOCHEM PHARMACOL, V89, P20, DOI 10.1016/j.bcp.2013.12.002; Castel P, 2019, SCIENCE, V363, P1226, DOI 10.1126/science.aav1444; Chadee DN, 2013, CAN J PHYSIOL PHARM, V91, P268, DOI 10.1139/cjpp-2012-0258; Delire B, 2015, EUR J CLIN INVEST, V45, P609, DOI 10.1111/eci.12441; Fang JH, 2018, HEPATOLOGY, V68, P1459, DOI 10.1002/hep.29920; Fang ZH, 2016, J BIOL CHEM, V291, P15641, DOI 10.1074/jbc.M116.714196; Feng YF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0979-x; Grabocka E, 2014, CANCER CELL, V25, P243, DOI 10.1016/j.ccr.2014.01.005; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; Harrison SMW, 2005, DEV DYNAM, V232, P817, DOI 10.1002/dvdy.20346; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Huang YWA, 2017, CELL, V168, P427, DOI 10.1016/j.cell.2016.12.044; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Li Jin-Tian, 2003, Ai Zheng, V22, P695; Li N, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3478305; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Roth GS, 2017, MOL CANCER THER, V16, P2157, DOI 10.1158/1535-7163.MCT-16-0602-T; Ryan MB, 2018, NAT REV CLIN ONCOL, V15, P709, DOI 10.1038/s41571-018-0105-0; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Shi GX, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.384248; Shi GX, 2005, MOL CELL BIOL, V25, P830, DOI 10.1128/MCB.25.2.830-846.2005; Shveygert M, 2010, MOL CELL BIOL, V30, P5160, DOI 10.1128/MCB.00448-10; Song Z, 2019, CANCER LETT, V460, P96, DOI 10.1016/j.canlet.2019.06.016; Taketomi A, 2013, SURG TODAY, V43, P289, DOI 10.1007/s00595-012-0462-8; Waters AM, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031435; Xu FJ, 2015, INT J CLIN EXP PATHO, V8, P10315; Zhang PP, 2019, CANCER LETT, V442, P53, DOI 10.1016/j.canlet.2018.10.035	35	1	2	4	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					732	744		10.1038/s41388-021-02130-8	http://dx.doi.org/10.1038/s41388-021-02130-8		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34845378				2022-12-17	WOS:000723571700001
J	Demetriadou, C; Raoukka, A; Charidemou, E; Mylonas, C; Michael, C; Parekh, S; Koufaris, C; Skourides, P; Papageorgis, P; Tessarz, P; Kirmizis, A				Demetriadou, Christina; Raoukka, Anastasia; Charidemou, Evelina; Mylonas, Constantine; Michael, Christina; Parekh, Swati; Koufaris, Costas; Skourides, Paris; Papageorgis, Panagiotis; Tessarz, Peter; Kirmizis, Antonis			Histone N-terminal acetyltransferase NAA40 links one-carbon metabolism to chemoresistance	ONCOGENE			English	Article							CANCER; EPIGENETICS; TRANSCRIPTION; GUIDELINES; MECHANISMS	Aberrant function of epigenetic modifiers plays an important role not only in the progression of cancer but also the development of drug resistance. N-alpha-acetyltransferase 40 (NAA40) is a highly specific epigenetic enzyme catalyzing the transfer of an acetyl moiety at the N-terminal end of histones H4 and H2A. Recent studies have illustrated the essential oncogenic role of NAA40 in various cancer types but its role in chemoresistance remains unclear. Here, using transcriptomic followed by metabolomic analysis in colorectal cancer (CRC) cells, we demonstrate that NAA40 controls key one-carbon metabolic genes and corresponding metabolites. In particular, through its acetyltransferase activity NAA40 regulates the methionine cycle thereby affecting global histone methylation and CRC cell survival. Importantly, NAA40-mediated metabolic rewiring promotes resistance of CRC cells to antimetabolite chemotherapy in vitro and in xenograft models. Specifically, NAA40 stimulates transcription of the one-carbon metabolic gene thymidylate synthase (TYMS), whose product is targeted by 5-fluorouracil (5-FU) and accordingly in primary CRC tumours NAA40 expression associates with TYMS levels and poorer 5-FU response. Mechanistically, NAA40 activates TYMS by preventing enrichment of repressive H2A/H4S1ph at the nuclear periphery. Overall, these findings define a novel regulatory link between epigenetics and cellular metabolism mediated by NAA40, which is harnessed by cancer cells to evade chemotherapy.	[Demetriadou, Christina; Raoukka, Anastasia; Charidemou, Evelina; Koufaris, Costas; Skourides, Paris; Kirmizis, Antonis] Univ Cyprus, Dept Biol Sci, CY-2109 Nicosia, Cyprus; [Mylonas, Constantine; Parekh, Swati; Tessarz, Peter] Max Planck Inst Biol Ageing, Cologne, Germany; [Michael, Christina; Papageorgis, Panagiotis] European Univ Cyprus, Dept Life Sci, CY-2404 Nicosia, Cyprus; [Tessarz, Peter] Cologne Excellence Cluster Stress Responses Agein, Joseph Stelzmann Str 26, D-50931 Cologne, Germany	University of Cyprus; Max Planck Society; European University Cyprus	Kirmizis, A (corresponding author), Univ Cyprus, Dept Biol Sci, CY-2109 Nicosia, Cyprus.	kirmizis@ucy.ac.cy	Koufaris, Costas/ABW-5036-2022; Tessarz, Peter/I-9035-2014	Koufaris, Costas/0000-0002-1222-5130; CHARIDEMOU, EVELINA/0000-0002-2299-9471; Tessarz, Peter/0000-0002-6953-9835				Benson A, 2018, J NATL COMPR CANC NE, V16, P874, DOI 10.6004/jnccn.2018.0061; Buchwalter A, 2019, NAT REV GENET, V20, P39, DOI 10.1038/s41576-018-0063-5; Campbell SL, 2018, MOL CELL, V71, P398, DOI 10.1016/j.molcel.2018.07.015; Carrer A, 2015, CURR OPIN BIOTECH, V34, P23, DOI 10.1016/j.copbio.2014.11.012; Dai ZW, 2020, NAT REV GENET, V21, P737, DOI 10.1038/s41576-020-0270-8; Dai ZW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04426-y; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Demetriadou C, 2020, EPIGENET CHROMATIN, V13, DOI 10.1186/s13072-020-00352-w; Demetriadou C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1487-3; Deng Y, 2021, NOVEL BISUBSTRATE IN, DOI 10.1101/2021.01.24.427995; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Farria A, 2015, ONCOGENE, V34, P4901, DOI 10.1038/onc.2014.453; Finlan LE, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000039; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Goldman M, 2019, UCSC XENA PLATFORM P, DOI DOI 10.1101/326470; Hole K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024713; Ju JY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00988-5; Karoutas A, 2021, NAT CELL BIOL, V23, P116, DOI 10.1038/s41556-020-00630-5; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Koufaris C, 2020, CANCERS, V12, DOI 10.3390/cancers12092631; Lee S, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1936-4; Liu Z, 2009, INT J BIOCHEM CELL B, V41, P2528, DOI 10.1016/j.biocel.2009.08.009; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lund E, 2013, GENOME RES, V23, P1580, DOI 10.1101/gr.159400.113; Magin RS, 2015, STRUCTURE, V23, P332, DOI 10.1016/j.str.2014.10.025; Marine JC, 2020, NAT REV CANCER, V20, P743, DOI 10.1038/s41568-020-00302-4; Mentch SJ, 2015, CELL METAB, V22, P861, DOI 10.1016/j.cmet.2015.08.024; Nacev BA, 2019, NATURE, V567, P473, DOI 10.1038/s41586-019-1038-1; Shyh-Chang N, 2013, SCIENCE, V339, P222, DOI 10.1126/science.1226603; Reddy KL, 2008, NATURE, V452, P243, DOI 10.1038/nature06727; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Roy DG, 2020, CELL METAB, V31, P250, DOI 10.1016/j.cmet.2020.01.006; Salvarani N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09929-w; Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236; Serefidou M, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00764; Shiraki N, 2014, CELL METAB, V19, P780, DOI 10.1016/j.cmet.2014.03.017; Shuvalov O, 2017, ONCOTARGET, V8, P23955, DOI 10.18632/oncotarget.15053; Suh EJ, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-12-r121; Ulanovskaya OA, 2013, NAT CHEM BIOL, V9, P300, DOI [10.1038/NCHEMBIO.1204, 10.1038/nchembio.1204]; Varghese V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38017-0; Wakasa K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123076; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Ye CQ, 2018, TRENDS ENDOCRIN MET, V29, P626, DOI 10.1016/j.tem.2018.06.002; Ye CQ, 2017, MOL CELL, V66, P180, DOI 10.1016/j.molcel.2017.02.026; Zhang Y, 2004, J BIOL CHEM, V279, P21866, DOI 10.1074/jbc.M400099200	48	1	1	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					571	585		10.1038/s41388-021-02113-9	http://dx.doi.org/10.1038/s41388-021-02113-9		NOV 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34785778	hybrid, Green Published			2022-12-17	WOS:000719277200004
J	Yu, L; Lang, Y; Hsu, CC; Chen, WM; Chiang, JC; Hsieh, JT; Story, MD; Shang, ZF; Chen, BPC; Saha, D				Yu, Lan; Lang, Yue; Hsu, Ching-Cheng; Chen, Wei-Min; Chiang, Jui-Chung; Hsieh, Jer-Tsong; Story, Michael D.; Shang, Zeng-Fu; Chen, Benjamin P. C.; Saha, Debabrata			Mitotic phosphorylation of tumor suppressor DAB2IP maintains spindle assembly checkpoint and chromosomal stability through activating PLK1-Mps1 signal pathway and stabilizing mitotic checkpoint complex	ONCOGENE			English	Article							PROSTATE-CANCER; ANAPHASE; CDC20; MPS1; DRIVES; CELLS; UBIQUITINATION; LOCALIZATION; INACTIVATION; INSTABILITY	Chromosomal instability (CIN) is a driving force for cancer development. The most common causes of CIN include the dysregulation of the spindle assembly checkpoint (SAC), which is a surveillance mechanism that prevents premature chromosome separation during mitosis by targeting anaphase-promoting complex/cyclosome (APC/C). DAB2IP is frequently silenced in advanced prostate cancer (PCa) and is associated with aggressive phenotypes of PCa. Our previous study showed that DAB2IP activates PLK1 and functions in mitotic regulation. Here, we report the novel mitotic phosphorylation of DAB2IP by Cdks, which mediates DAB2IP's interaction with PLK1 and the activation of the PLK1-Mps1 pathway. DAB2IP interacts with Cdc20 in a phosphorylation-independent manner. However, the phosphorylation of DAB2IP inhibits the ubiquitylation of Cdc20 in response to SAC, and blocks the premature release of the APC/C-MCC. The PLK1-Mps1 pathway plays an important role in mitotic checkpoint complex (MCC) assembly. It is likely that DAB2IP acts as a scaffold to aid PLK1-Mps1 in targeting Cdc20. Depletion or loss of the Cdks-mediated phosphorylation of DAB2IP destabilizes the MCC, impairs the SAC, and increases chromosome missegregation and subsequent CIN, thus contributing to tumorigenesis. Collectively, these results demonstrate the mechanism of DAB2IP in SAC regulation and provide a rationale for targeting the SAC to cause lethal CIN against DAB2IP-deficient aggressive PCa, which exhibits a weak SAC.	[Yu, Lan; Hsu, Ching-Cheng; Chen, Wei-Min; Chiang, Jui-Chung; Story, Michael D.; Shang, Zeng-Fu; Chen, Benjamin P. C.; Saha, Debabrata] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA; [Yu, Lan] Nanjing Med Univ, Suzhou Digest Dis & Nutr Res Ctr, Affiliated Suzhou Hosp, Suzhou 215008, Peoples R China; [Lang, Yue; Shang, Zeng-Fu] Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Med Coll, State Key Lab Radiat Med & Protect,Sch Radiat Med, Suzhou 215123, Peoples R China; [Hsieh, Jer-Tsong] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Hsieh, Jer-Tsong; Story, Michael D.; Chen, Benjamin P. C.; Saha, Debabrata] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Hsieh, Jer-Tsong] Natl Taiwan Univ, Dept Oncol, Natl Taiwan Univ Hosp, Coll Med, Taipei 10048, Taiwan	University of Texas System; University of Texas Southwestern Medical Center Dallas; Nanjing Medical University; Soochow University - China; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Taiwan University; National Taiwan University Hospital	Shang, ZF; Chen, BPC; Saha, D (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA.; Shang, ZF (corresponding author), Soochow Univ, Collaborat Innovat Ctr Radiat Med Jiangsu Higher, Med Coll, State Key Lab Radiat Med & Protect,Sch Radiat Med, Suzhou 215123, Peoples R China.; Chen, BPC; Saha, D (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA.	zengfu.shang@utsouthwestern.edu; benjamin.chen@utsouthwestern.edu; debabrata.saha@utsouthwestern.edu		Saha, Debabrata/0000-0003-3477-4111; HSU, CHING-CHENG/0000-0002-8804-6171; Chen, Benjamin/0000-0001-6958-8816; Chen, Wei-min/0000-0002-5247-7826; Chiang, Jui-Chung/0000-0001-9979-8347; Shang, Zeng-Fu/0000-0002-2396-1416	National Institutes of Health [CA233594, CA175879]; National Natural Science Foundation of China [81872546]; Natural Science Foundation of Jiangsu Province [BK20181180]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province)	The authors are grateful to Jonathan Feinberg and John Squire for editing the manuscript. National Institutes of Health [CA175879] to DS; National Institutes of Health [CA233594] to BPC; National Natural Science Foundation of China [#81872546] and Natural Science Foundation of Jiangsu Province [BK20181180] to LY.	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Combes G, 2017, ONCOGENE, V36, P4819, DOI 10.1038/onc.2017.113; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; de Carcer G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05429-5; Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013; Eytan E, 2014, P NATL ACAD SCI USA, V111, P12019, DOI 10.1073/pnas.1412901111; Faesen AC, 2017, NATURE, V542, P498, DOI 10.1038/nature21384; Foster SA, 2012, MOL CELL, V47, P921, DOI 10.1016/j.molcel.2012.07.031; Gao YF, 2011, NAT CELL BIOL, V13, P924, DOI 10.1038/ncb2287; Giam M, 2015, CELL DIV, V10, DOI 10.1186/s13008-015-0009-7; Guo ZY, 2021, ONCOGENE, V40, P1821, DOI 10.1038/s41388-020-01601-8; Ji ZJ, 2017, ELIFE, V6, DOI 10.7554/eLife.22513; Jia LY, 2013, TRENDS BIOCHEM SCI, V38, P302, DOI 10.1016/j.tibs.2013.03.004; Kang JS, 2007, P NATL ACAD SCI USA, V104, P20232, DOI 10.1073/pnas.0710519105; Kong ZL, 2010, CANCER RES, V70, P2829, DOI 10.1158/0008-5472.CAN-09-2919; London N, 2012, CURR BIOL, V22, P900, DOI 10.1016/j.cub.2012.03.052; Lowery DM, 2005, ONCOGENE, V24, P248, DOI 10.1038/sj.onc.1208280; Mansfeld J, 2011, NAT CELL BIOL, V13, P1234, DOI 10.1038/ncb2347; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Miniowitz-Shemtov S, 2012, P NATL ACAD SCI USA, V109, P8056, DOI 10.1073/pnas.1204081109; Moura M, 2017, ELIFE, V6, DOI 10.7554/eLife.25366; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Musacchio A, 2012, NAT STRUCT MOL BIOL, V19, P1059, DOI 10.1038/nsmb.2429; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Orr B, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00164; Palframan WJ, 2006, SCIENCE, V313, P680, DOI 10.1126/science.1127205; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Plumb LA, 2004, METH MOLEC MED, V88, P165; Reddy SK, 2007, NATURE, V446, P921, DOI 10.1038/nature05734; Shepperd LA, 2012, CURR BIOL, V22, P891, DOI 10.1016/j.cub.2012.03.051; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Teichner A, 2011, P NATL ACAD SCI USA, V108, P3187, DOI 10.1073/pnas.1100023108; Uzunova K, 2012, NAT STRUCT MOL BIOL, V19, P1116, DOI 10.1038/nsmb.2412; Vanoosthuyse V, 2009, CURR BIOL, V19, P1176, DOI 10.1016/j.cub.2009.05.060; Varetti G, 2011, MOL CELL, V44, P710, DOI 10.1016/j.molcel.2011.11.014; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; von Schubert C, 2015, CELL REP, V12, P66, DOI 10.1016/j.celrep.2015.06.007; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; Westhorpe FG, 2011, J CELL SCI, V124, P3905, DOI 10.1242/jcs.093286; Wu KJ, 2013, CLIN CANCER RES, V19, P4740, DOI 10.1158/1078-0432.CCR-13-0954; Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107; Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106; Yamagishi Y, 2012, NAT CELL BIOL, V14, P746, DOI 10.1038/ncb2515; Yu L, 2016, NUCLEIC ACIDS RES, V44, P8842, DOI 10.1093/nar/gkw746; Yu L, 2012, NEOPLASIA, V14, P1203, DOI 10.1593/neo.121310; Yun EJ, 2015, ONCOGENE, V34, P2741, DOI 10.1038/onc.2014.215; Yun EJ, 2019, CLIN CANCER RES, V25, P4542, DOI 10.1158/1078-0432.CCR-18-3004	51	1	1	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					489	501		10.1038/s41388-021-02106-8	http://dx.doi.org/10.1038/s41388-021-02106-8		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34775484	Green Published, hybrid			2022-12-17	WOS:000718063600001
J	Boice, AG; Lopez, KE; Pandita, RK; Parsons, MJ; Charendoff, CI; Charaka, V; Carisey, AF; Pandita, TK; Bouchier-Hayes, L				Boice, Ashley G.; Lopez, Karla E.; Pandita, Raj K.; Parsons, Melissa J.; Charendoff, Chloe, I; Charaka, Vijay; Carisey, Alexandre F.; Pandita, Tej K.; Bouchier-Hayes, Lisa			Caspase-2 regulates S-phase cell cycle events to protect from DNA damage accumulation independent of apoptosis	ONCOGENE			English	Article							GENOMIC INSTABILITY; REPLICATION FORKS; LICENSING FACTOR; ATM; CHECKPOINT; ACTIVATION; PHOSPHORYLATION; PIDDOSOME; KINASE; CHK2	In addition to its classical role in apoptosis, accumulating evidence suggests that caspase-2 has non-apoptotic functions, including regulation of cell division. Loss of caspase-2 is known to increase proliferation rates but how caspase-2 is regulating this process is currently unclear. We show that caspase-2 is activated in dividing cells in G1-phase of the cell cycle. In the absence of caspase-2, cells exhibit numerous S-phase defects including delayed exit from S-phase, defects in repair of chromosomal aberrations during S-phase, and increased DNA damage following S-phase arrest. In addition, caspase-2-deficient cells have a higher frequency of stalled replication forks, decreased DNA fiber length, and impeded progression of DNA replication tracts. This indicates that caspase-2 protects from replication stress and promotes replication fork protection to maintain genomic stability. These functions are independent of the pro-apoptotic function of caspase-2 because blocking caspase-2-induced cell death had no effect on cell division, DNA damage-induced cell cycle arrest, or DNA damage. Thus, our data supports a model where caspase-2 regulates cell cycle and DNA repair events to protect from the accumulation of DNA damage independently of its pro-apoptotic function.	[Boice, Ashley G.; Lopez, Karla E.; Parsons, Melissa J.; Charendoff, Chloe, I; Bouchier-Hayes, Lisa] Baylor Coll Med, Dept Pediat, Sect Hematol Oncol, Houston, TX 77030 USA; [Boice, Ashley G.; Lopez, Karla E.; Charendoff, Chloe, I; Carisey, Alexandre F.; Bouchier-Hayes, Lisa] Texas Childrens Hosp William T Shearer Ctr Human, Houston, TX 77030 USA; [Boice, Ashley G.; Lopez, Karla E.; Pandita, Raj K.; Pandita, Tej K.; Bouchier-Hayes, Lisa] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Pandita, Raj K.; Pandita, Tej K.] Texas A&M Inst Biosci & Technol, Houston, TX 77030 USA; [Charaka, Vijay; Pandita, Tej K.] Houston Methodist Res Inst, Dept Radiat Oncol, Houston, TX 77030 USA; [Carisey, Alexandre F.] Baylor Coll Med, Dept Pediat, Sect Allergy & Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine	Bouchier-Hayes, L (corresponding author), Baylor Coll Med, Dept Pediat, Sect Hematol Oncol, Houston, TX 77030 USA.; Bouchier-Hayes, L (corresponding author), Texas Childrens Hosp William T Shearer Ctr Human, Houston, TX 77030 USA.; Bouchier-Hayes, L (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	bouchier@bcm.edu	Carisey, Alexandre F/A-5026-2015	Carisey, Alexandre F/0000-0003-1326-2205; Lopez, Karla/0000-0001-7301-5260; Bouchier-Hayes, Lisa/0000-0003-3886-5977	NIH/NIGMS [R01GM121389, T32GM008231]; NIH/NCI [R21CA256606]; Cytometry and Cell Sorting Core at Baylor College of Medicine; NIH [P30 AI036211, P30 CA125123, S10 RR024574]; Texas Children's Hospital William T. Shearer Center for Human Immunobiology	NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cytometry and Cell Sorting Core at Baylor College of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Texas Children's Hospital William T. Shearer Center for Human Immunobiology	We would like to thank Jennifer Martinez (NIEHS) for careful reading of this paper. Funding for this project includes NIH/NIGMS R01GM121389 (LBH), NIH/NCI R21CA256606 (LBH) and NIH/NIGMS T32GM008231 (KEL). This project was supported by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the NIH (P30 AI036211, P30 CA125123, and S10 RR024574) and the expert assistance of J. M. Sederstrom. We would like to acknowledge the Texas Children's Hospital William T. Shearer Center for Human Immunobiology for their generous support for this research and the expert assistance of Rebecca Kairis.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Andersen JL, 2009, EMBO J, V28, P3216, DOI 10.1038/emboj.2009.253; Ando K, 2017, J CELL BIOL, V216, P1795, DOI 10.1083/jcb.201608095; Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Baptiste-Okoh N, 2008, P NATL ACAD SCI USA, V105, P1937, DOI 10.1073/pnas.0711800105; Beck H, 2012, MOL CELL BIOL, V32, P4226, DOI 10.1128/MCB.00412-12; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Boice A, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2020.118688; Bonzon C, 2006, MOL BIOL CELL, V17, P2150, DOI 10.1091/mbc.E05-12-1107; Bouchier-Hayes L, 2012, CELL DEATH DIFFER, V19, P51, DOI 10.1038/cdd.2011.157; Bouchier-Hayes L, 2010, J CELL MOL MED, V14, P1212, DOI 10.1111/j.1582-4934.2010.01037.x; Bouchier-Hayes L, 2009, MOL CELL, V35, P830, DOI 10.1016/j.molcel.2009.07.023; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Ceccaldi R, 2016, NAT REV MOL CELL BIO, V17, P337, DOI 10.1038/nrm.2016.48; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Couch FB, 2013, GENE DEV, V27, P1610, DOI 10.1101/gad.214080.113; Dawar S, 2017, ONCOGENE, V36, P2704, DOI 10.1038/onc.2016.423; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Fava LL, 2017, GENE DEV, V31, P34, DOI 10.1101/gad.289728.116; Gao ZH, 2005, J BIOL CHEM, V280, P38271, DOI 10.1074/jbc.M506488200; Gatei M, 2000, CANCER RES, V60, P3299; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goldwasser F, 1996, CANCER RES, V56, P4430; Gundry MC, 2016, CELL REP, V17, P1453, DOI 10.1016/j.celrep.2016.09.092; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Henry CM, 2017, MOL CELL, V65, P715, DOI 10.1016/j.molcel.2017.01.022; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; HOWARD A, 1986, INT J RADIAT BIOL, V49, P207, DOI 10.1080/09553008514552501; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Ismail IH, 2005, J BIOL CHEM, V280, P4649, DOI 10.1074/jbc.M411588200; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Krull A, 2019, PROC CVPR IEEE, P2124, DOI 10.1109/CVPR.2019.00223; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; Lapytsko A, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0816-5; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lim Y, 2021, CELL DEATH DIFFER, V28, P349, DOI 10.1038/s41418-020-00604-y; Lin YF, 2018, NUCLEIC ACIDS RES, V46, P1847, DOI 10.1093/nar/gkx1298; Liu SZ, 2011, MOL CELL, V43, P192, DOI 10.1016/j.molcel.2011.06.019; Lopez-Garcia C, 2017, CANCER CELL, V31, P79, DOI 10.1016/j.ccell.2016.11.001; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Manzl C, 2009, J CELL BIOL, V185, P291, DOI 10.1083/jcb.200811105; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mattoo AR, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00535-16; Moreno-Mateos MA, 2015, NAT METHODS, V12, P982, DOI [10.1038/NMETH.3543, 10.1038/nmeth.3543]; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nishitani H, 2004, J BIOL CHEM, V279, P30807, DOI 10.1074/jbc.M312644200; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Oliver TG, 2011, MOL CELL, V43, P57, DOI 10.1016/j.molcel.2011.06.012; Pan Y, 2009, CANCER BIOL THER, V8, P1559, DOI 10.4161/cbt.8.16.8955; Parsons MJ, 2013, CELL DEATH DIFFER, V20, P1174, DOI 10.1038/cdd.2013.38; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Puccini J, 2013, P NATL ACAD SCI USA, V110, P19920, DOI 10.1073/pnas.1311947110; Ren KQ, 2012, J BIOL CHEM, V287, P14792, DOI 10.1074/jbc.M112.347625; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robeson AC, 2018, EMBO J, V37, DOI 10.15252/embj.201797072; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Saldivar JC, 2017, NAT REV MOL CELL BIO, V18, P622, DOI 10.1038/nrm.2017.67; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sharma GG, 2003, MOL CELL BIOL, V23, P8363, DOI 10.1128/MCB.23.22.8363-8376.2003; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Singh DK, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00484-17; Singh M, 2013, MOL CELL BIOL, V33, P1210, DOI 10.1128/MCB.01676-12; Stringer C, 2021, NAT METHODS, V18, P100, DOI 10.1038/s41592-020-01018-x; Terry MR, 2015, CELL DEATH DIFFER, V22, P719, DOI 10.1038/cdd.2014.159; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; von Chamier L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22518-0; Wang HY, 2004, CANCER RES, V64, P7139, DOI 10.1158/0008-5472.CAN-04-1289; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhong Y, 2013, J CELL BIOL, V201, P373, DOI 10.1083/jcb.201208060; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	80	1	1	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					204	219		10.1038/s41388-021-02085-w	http://dx.doi.org/10.1038/s41388-021-02085-w		OCT 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34718349	Green Accepted, Green Submitted			2022-12-17	WOS:000712941800001
J	Zhang, JN; Zhang, L; Nie, J; Lin, Y; Li, Y; Xu, W; Zhao, JY; Zhao, SM; Wang, CJ				Zhang, Jianong; Zhang, Liang; Nie, Ji; Lin, Yan; Li, Yao; Xu, Wei; Zhao, Jian-Yuan; Zhao, Shi-Min; Wang, Chenji			Calcineurin inactivation inhibits pyruvate dehydrogenase complex activity and induces the Warburg effect	ONCOGENE			English	Article							PHOSPHATASE; PHOSPHORYLATION; PROMOTES; BINDING; PROTEIN; KINASE; OVEREXPRESSION; CYCLOSPORINE; DEFICIENCY; ACTIVATION	Calcineurin is a calcium- and calmodulin-dependent serine/threonine protein phosphatase that connects the Ca2+-dependent signalling to multiple cellular responses. Calcineurin inhibitors (CNIs) have been widely used to suppress immune response in allograft patients. However, CNIs significantly increase cancer incidence in transplant recipients compared with the general population. Accumulating evidence suggests that CNIs may promote the malignant transformation of cancer cells in addition to its role in immunosuppression, but the underlying mechanisms remain poorly understood. Here, we show that calcineurin interacts with pyruvate dehydrogenase complex (PDC), a mitochondrial gatekeeper enzyme that connects two key metabolic pathways of cells, glycolysis and the tricarboxylic acid cycle. Mitochondrial-localized calcineurin dephosphorylates PDHA1 at Ser232, Ser293 and Ser300, and thus enhances PDC enzymatic activity, remodels cellular glycolysis and oxidative phosphorylation, and suppresses cancer cell proliferation. Hypoxia attenuates mitochondrial translocation of calcineurin to promote PDC inactivation. Moreover, CNIs promote metabolic remodelling and the Warburg effect by blocking calcineurin-mediated PDC activation in cancer cells. Our findings indicate that calcineurin is a critical regulator of mitochondrial metabolism and suggest that CNIs may promote tumorigenesis through inhibition of the calcineurin-PDC pathway.	[Zhang, Jianong; Zhang, Liang; Nie, Ji; Lin, Yan; Li, Yao; Zhao, Shi-Min; Wang, Chenji] Fudan Univ, Key Lab Reprod Regulat NPFPC, State Key Lab Genet Engn,SIPPR,IRD,Sch Life Sci, MOE Engn Res Ctr Gene Technol,Obstet & Gynecol Ho, Shanghai 200438, Peoples R China; [Xu, Wei] Fudan Univ, Shanghai Peoples Hosp 5, Shanghai 200032, Peoples R China; [Xu, Wei] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China; [Zhao, Jian-Yuan] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200438, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Zhao, SM; Wang, CJ (corresponding author), Fudan Univ, Key Lab Reprod Regulat NPFPC, State Key Lab Genet Engn,SIPPR,IRD,Sch Life Sci, MOE Engn Res Ctr Gene Technol,Obstet & Gynecol Ho, Shanghai 200438, Peoples R China.	zhaosm@fudan.edu.cn; chenjiwang@fudan.edu.cn		Zhao, Jian-Yuan/0000-0001-9861-0330; wang, chenji/0000-0002-5752-6439	National Science Foundation of China [91957125, 81972396, 31330023, 3182100, 291753207, 31930062, 81722021, 81771627, 31521003, 31671483, 31871432]; Shanghai Rising-Star Program [18QA1400300]; National Key R&D Program of China [2018YFA0800300, 2019YFA0801900, 2018YFA0801300, 2018YFC1004700]; Science and Technology Municipal Commission of Shanghai, China [16JC1405301]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Rising-Star Program; National Key R&D Program of China; Science and Technology Municipal Commission of Shanghai, China	This work was supported by grants from the National Science Foundation of China (No. 91957125, 81972396 to CJW, No. 31330023, 3182100, 291753207, 31930062 to SMZ; No. 81722021, 81771627, 31521003 to JYZ; No. 31671483, 31871432 to WX), Shanghai Rising-Star Program (No. 18QA1400300 to WX), National Key R&D Program of China (No. 2018YFA0800300 to SMZ; 2019YFA0801900 to JYZ; 2018YFA0801300, 2018YFC1004700 to WX); Science and Technology Municipal Commission of Shanghai, China (No. 16JC1405301 to SMZ).	Basu A, 2008, CANCER RES, V68, P5689, DOI 10.1158/0008-5472.CAN-07-6603; Basu A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023919; Cereghetti GM, 2010, CELL DEATH DIFFER, V17, P1785, DOI 10.1038/cdd.2010.61; Charni-Natan Meital, 2020, STAR Protoc, V1, P100086, DOI 10.1016/j.xpro.2020.100086; Chen GL, 1996, J BIOL CHEM, V271, P28064, DOI 10.1074/jbc.271.45.28064; Datta D, 2009, CANCER RES, V69, P8902, DOI 10.1158/0008-5472.CAN-09-1404; Dougherty MK, 2009, MOL CELL, V34, P652, DOI 10.1016/j.molcel.2009.06.001; Duan LL, 2010, P NATL ACAD SCI USA, V107, P22314, DOI 10.1073/pnas.1016630108; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Fan J, 2014, J BIOL CHEM, V289, P26533, DOI 10.1074/jbc.M114.593970; Fan J, 2014, MOL CELL, V53, P534, DOI 10.1016/j.molcel.2013.12.026; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; Golias T, 2019, INT J CANCER, V144, P674, DOI 10.1002/ijc.31812; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Han WN, 2012, CANCER PREV RES, V5, P1155, DOI 10.1158/1940-6207.CAPR-12-0185-T; Han Z, 2008, J BIOL CHEM, V283, P237, DOI 10.1074/jbc.M704748200; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Karpova T, 2003, BBA-PROTEINS PROTEOM, V1652, P126, DOI 10.1016/j.bbapap.2003.08.010; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kinoshita E, 2006, MOL CELL PROTEOMICS, V5, P749, DOI 10.1074/mcp.T500024-MCP200; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kung L, 2000, TRANSPLANTATION, V70, P327, DOI 10.1097/00007890-200007270-00017; Li B, 2013, CLIN CANCER RES, V19, P5835, DOI 10.1158/1078-0432.CCR-12-3629; Li HM, 2011, TRENDS CELL BIOL, V21, P91, DOI 10.1016/j.tcb.2010.09.011; Liu LL, 2005, MOL BIOL REP, V32, P41, DOI 10.1007/s11033-004-4250-4; Maj MC, 2006, MOL CELL ENDOCRINOL, V249, P1, DOI 10.1016/j.mce.2006.02.003; Maluccio M, 2003, TRANSPLANTATION, V76, P597, DOI 10.1097/01.TP.0000081399.75231.3B; McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200; Medina DL, 2015, NAT CELL BIOL, V17, P288, DOI 10.1038/ncb3114; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; MURAMATSU T, 1992, BIOCHEM BIOPH RES CO, V188, P265, DOI 10.1016/0006-291X(92)92379-C; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Park J, 2013, MOL CELL, V50, P919, DOI 10.1016/j.molcel.2013.06.001; Patel MS, 2014, J BIOL CHEM, V289, P16615, DOI 10.1074/jbc.R114.563148; Pfluger PT, 2015, CELL METAB, V22, P838, DOI 10.1016/j.cmet.2015.08.022; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Shan CL, 2014, J BIOL CHEM, V289, P21413, DOI 10.1074/jbc.M114.581124; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Sutendra G, 2014, CELL, V158, P84, DOI 10.1016/j.cell.2014.04.046; Ume AC, 2020, PHOTODERMATOL PHOTO, V36, P433, DOI 10.1111/phpp.12600; Yu XK, 2008, STRUCTURE, V16, P104, DOI 10.1016/j.str.2007.10.024	45	1	1	4	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6692	6702		10.1038/s41388-021-02065-0	http://dx.doi.org/10.1038/s41388-021-02065-0		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34667275				2022-12-17	WOS:000708806900002
J	Cao, CH; Ling, H; Han, K; Lu, XP; Cai, MY; Cao, JH; Zhou, J; Xiang, ZC; Chen, JW; Li, S; Lin, JL; Duan, JL; Luo, J; Fang, YJ; Pan, ZZ; Liang, L; Wang, F; Xie, D; Wang, FW				Cao, Chen-Hui; Ling, Han; Han, Kai; Lu, Xiao-Peng; Cai, Mu-Yan; Cao, Jing-Hua; Zhou, Jie; Xiang, Zhi-Cheng; Chen, Jie-Wei; Li, Si; Lin, Jin-Long; Duan, Jin-Ling; Luo, Jie; Fang, Yu-Jing; Pan, Zhi-Zhong; Liang, Li; Wang, Feng; Xie, Dan; Wang, Feng-Wei			PPIP5K2 promotes colorectal carcinoma pathogenesis through facilitating DNA homologous recombination repair	ONCOGENE			English	Article							NUCLEAR EXPORT; C-ABL; PROTEIN; PHOSPHORYLATION; CANCER; PATHWAYS; COMPLEX; HEALTH; CELLS; AKT	Colorectal carcinoma (CRC) is the second most deadly cancer worldwide. Therapies that take advantage of DNA repair defects have been explored in various tumors but not yet systematically in CRC. Here, we found that Diphosphoinositol Pentakisphosphate Kinase 2 (PPIP5K2), an inositol pyrophosphate kinase, was highly expressed in CRC and associated with a poor prognosis of CRC patients. In vitro and in vivo functional studies demonstrated that PPIP5K2 could promote the proliferation and migration ability of CRC cells independent of its inositol pyrophosphate kinase activity. Mechanically, S1006 dephosphorylation of PPIP5K2 could accelerate its dissociation with 14-3-3 in the cytoplasm, resulting in more nuclear distribution. Moreover, DNA damage treatments such as doxorubicin (DOX) or irradiation (IR) could induce nuclear translocation of PPIP5K2, which subsequently promoted homologous recombination (HR) repair by binding and recruiting RPA70 to the DNA damage site as a novel scaffold protein. Importantly, we verified that S1006 dephosphorylation of PPIP5K2 could significantly enhance the DNA repair ability of CRC cells through a series of DNA repair phenotype assays. In conclusion, PPIP5K2 is critical for enhancing the survival of CRC cells via facilitating DNA HR repair. Our findings revealed an unrecognized biological function and mechanism model of PPIP5K2 dependent on S1006 phosphorylation and provided a potential therapeutic target for CRC patients.	[Cao, Chen-Hui; Ling, Han; Han, Kai; Cai, Mu-Yan; Cao, Jing-Hua; Zhou, Jie; Xiang, Zhi-Cheng; Chen, Jie-Wei; Li, Si; Lin, Jin-Long; Duan, Jin-Ling; Luo, Jie; Fang, Yu-Jing; Pan, Zhi-Zhong; Wang, Feng; Xie, Dan; Wang, Feng-Wei] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510060, Peoples R China; [Han, Kai; Fang, Yu-Jing; Pan, Zhi-Zhong] Sun Yat Sen Univ, Dept Colorectal Surg, Ctr Canc, Guangzhou 510060, Peoples R China; [Lu, Xiao-Peng] Shenzhen Univ, Sch Med, Dept Biochem & Mol Biol, Guangdong Key Lab Genome Instabil & Human Dis Pre, Shenzhen 518055, Peoples R China; [Cai, Mu-Yan; Chen, Jie-Wei; Xie, Dan] Sun Yat Sen Univ, Dept Pathol, Ctr Canc, Guangzhou 510060, Peoples R China; [Liang, Li] Southern Med Univ, Dept Pathol, Guangzhou 510060, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Shenzhen University; Sun Yat Sen University; Southern Medical University - China	Xie, D; Wang, FW (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510060, Peoples R China.; Xie, D (corresponding author), Sun Yat Sen Univ, Dept Pathol, Ctr Canc, Guangzhou 510060, Peoples R China.	xiedan@sysucc.org.cn; wangfengw@sysucc.org.cn		Cao, Chenhui/0000-0002-8119-0613	National Key R&D Program of China [2017YFC1309000]; National Natural Science Foundation of China [81972227, 81730072, 82072608, 81872001, 82002467]; Natural Science Foundation of Guangdong [2020A151501021, 2020A1515011020]; Guangzhou Science and Technology Plan Projects [201904020044]; China Postdoctoral Science Foundation [2020M672999]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Plan Projects; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from the National Key R&D Program of China [grant number 2017YFC1309000]; the National Natural Science Foundation of China [grant numbers 81972227, 81730072, 82072608, 81872001, and 82002467]; the Natural Science Foundation of Guangdong [grant numbers 2020A151501021 and 2020A1515011020]; the Guangzhou Science and Technology Plan Projects [grant number 201904020044] and the China Postdoctoral Science Foundation (2020M672999).	Aghazadeh Y, 2016, DRUG DISCOV TODAY, V21, P278, DOI 10.1016/j.drudis.2015.09.012; Ashworth A, 2018, NAT REV CLIN ONCOL, V15, P564, DOI 10.1038/s41571-018-0055-6; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bhat KP, 2018, NAT STRUCT MOL BIOL, V25, P446, DOI 10.1038/s41594-018-0075-z; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai MY, 2020, CELL REP, V30, P2402, DOI 10.1016/j.celrep.2020.01.052; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Chakraborty A, 2018, BIOL REV, V93, P1203, DOI 10.1111/brv.12392; Chen Huarong, 2017, Oncotarget, V8, P95054, DOI 10.18632/oncotarget.10982; Cremolini C, 2015, NAT REV CLIN ONCOL, V12, P607, DOI 10.1038/nrclinonc.2015.129; Fanning E, 2006, NUCLEIC ACIDS RES, V34, P4126, DOI 10.1093/nar/gkl550; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Gao SS, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba7822; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Gu CF, 2017, P NATL ACAD SCI USA, V114, P11968, DOI 10.1073/pnas.1702370114; Han K, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01184-8; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Hou ZY, 2010, CANCER RES, V70, P4385, DOI 10.1158/0008-5472.CAN-10-0070; Jadav RS, 2016, CELL SIGNAL, V28, P1124, DOI 10.1016/j.cellsig.2016.04.011; Khaled ML, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55866-5; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Liu HP, 2018, NATURE, V563, P131, DOI 10.1038/s41586-018-0629-6; Liu J, 2010, NAT STRUCT MOL BIOL, V17, P1260, DOI 10.1038/nsmb.1904; Lo MC, 2004, CELL, V117, P95, DOI 10.1016/S0092-8674(04)00203-X; Machkalyan Gayane, 2016, J Mol Signal, V11, P4, DOI 10.5334/1750-2187-11-4; Marechal A, 2015, CELL RES, V25, P9, DOI 10.1038/cr.2014.147; Moon S, 2017, EMBO REP, V18, P61, DOI 10.15252/embr.201642683; Morrison BH, 2002, ONCOGENE, V21, P1882, DOI 10.1038/sj.onc.1205265; Nihira K, 2008, ONCOGENE, V27, P7285, DOI 10.1038/onc.2008.334; Pendergast AM, 2005, NAT CELL BIOL, V7, P213, DOI 10.1038/ncb0305-213; Pohlmann J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004586; Pulloor NK, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003981; Randall Thomas A., 2020, Advances in Biological Regulation, V75, P100674, DOI 10.1016/j.jbior.2019.100674; Romanova LY, 2004, ONCOGENE, V23, P9025, DOI 10.1038/sj.onc.1207982; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Thota SG, 2015, J BIOSCIENCES, V40, P593, DOI 10.1007/s12038-015-9549-x; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Wang HC, 2014, CHEM BIOL, V21, P689, DOI 10.1016/j.chembiol.2014.03.009; Wang HC, 2012, NAT CHEM BIOL, V8, P111, DOI 10.1038/nchembio.733; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang QY, 2017, P NATL ACAD SCI USA, V114, pE6054, DOI 10.1073/pnas.1700694114; Yong ST, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860-015-0063-7; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yousaf RW, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007297	48	1	1	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6680	6691		10.1038/s41388-021-02052-5	http://dx.doi.org/10.1038/s41388-021-02052-5		OCT 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34645979				2022-12-17	WOS:000706949900002
J	Liang, SK; Hsu, CC; Song, HL; Huang, YC; Kuo, CW; Yao, X; Li, CC; Yang, HC; Hung, YL; Chao, SY; Wu, SC; Tsai, FR; Chen, JK; Liao, WN; Cheng, SC; Tsou, TC; Wang, IC				Liang, Sheng-Kai; Hsu, Chia-Chan; Song, Hsiang-Lin; Huang, Yu-Chi; Kuo, Chun-Wei; Yao, Xiang; Li, Chien-Cheng; Yang, Hui-Chen; Hung, Yu-Ling; Chao, Sheng-Yang; Wu, Shun-Chi; Tsai, Feng-Ren; Chen, Jen-Kun; Liao, Wei-Neng; Cheng, Shih-Chin; Tsou, Tsui-Chun; Wang, I-Ching			FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis (vol 40, pg 4847, 2021)	ONCOGENE			English	Correction												icwang@life.nthu.edu.tw		Wang, I-Ching/0000-0003-4398-2975				Liang SK, 2021, ONCOGENE, V40, P4847, DOI 10.1038/s41388-021-01895-2	1	1	1	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6705	6705		10.1038/s41388-021-02044-5	http://dx.doi.org/10.1038/s41388-021-02044-5		OCT 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34642501	Bronze			2022-12-17	WOS:000706593200001
J	Garcia-Valverde, A; Rosell, J; Sayols, S; Gomez-Peregrina, D; Pilco-Janeta, DF; Olivares-Rivas, I; de Alava, E; Maurel, J; Rubio-Casadevall, J; Esteve, A; Gut, M; Valverde, C; Barretina, J; Carles, J; Demetri, GD; Fletcher, JA; Arribas, J; Serrano, C				Garcia-Valverde, Alfonso; Rosell, Jordi; Sayols, Sergi; Gomez-Peregrina, David; Pilco-Janeta, Daniel F.; Olivares-Rivas, Ivan; de Alava, Enrique; Maurel, Joan; Rubio-Casadevall, Jordi; Esteve, Anna; Gut, Marta; Valverde, Claudia; Barretina, Jordi; Carles, Joan; Demetri, George D.; Fletcher, Jonathan A.; Arribas, Joaquin; Serrano, Cesar			E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor	ONCOGENE			English	Article							IMATINIB MESYLATE; KINASE INHIBITOR; MECHANISMS; SURVIVAL; FBXO32; FOXO3A; TUMORIGENESIS; QUIESCENCE; SUPPRESSOR; MUTATIONS	KIT/PDGFRA oncogenic tyrosine kinase signaling is the central oncogenic event in most gastrointestinal stromal tumors (GIST), which are human malignant mesenchymal neoplasms that often feature myogenic differentiation. Although targeted inhibition of KIT/PDGFRA provides substantial clinical benefit, GIST cells adapt to KIT/PDGFRA driver suppression and eventually develop resistance. The specific molecular events leading to adaptive resistance in GIST remain unclear. By using clinically representative in vitro and in vivo GIST models and GIST patients' samples, we found that the E3 ubiquitin ligase Atrogin-1 (FBXO32)-the main effector of muscular atrophy in cachexia-resulted in the most critical gene derepressed in response to KIT inhibition, regardless the type of KIT primary or secondary mutation. Atrogin-1 in GISTs is transcriptionally controlled by the KIT-FOXO3a axis, thus indicating overlap with Atrogin-1 regulation mechanisms in nonneoplastic muscle cells. Further, Atrogin-1 overexpression was a GIST-cell-specific pro-survival mechanism that enabled the adaptation to KIT-targeted inhibition by apoptosis evasion through cell quiescence. Buttressed on these findings, we established in vitro and in vivo the preclinical proof-of-concept for co-targeting KIT and the ubiquitin pathway to maximize the therapeutic response to first-line imatinib treatment.	[Garcia-Valverde, Alfonso; Rosell, Jordi; Gomez-Peregrina, David; Pilco-Janeta, Daniel F.; Olivares-Rivas, Ivan; Serrano, Cesar] Vall Hebron Inst Oncol VHIO, Sarcoma Translat Res Lab, Barcelona, Spain; [Sayols, Sergi] Inst Mol Biol, Mainz, Germany; [Pilco-Janeta, Daniel F.; Fletcher, Jonathan A.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Pilco-Janeta, Daniel F.; Demetri, George D.; Fletcher, Jonathan A.] Harvard Med Sch, Boston, MA 02115 USA; [de Alava, Enrique] Univ Seville, CIBERONC, CSIC, Virgen Rocio Univ Hosp,Inst Biomed Sevilla IBiS, Seville, Spain; [de Alava, Enrique] Univ Seville, Sch Med, Dept Normal & Pathol Cytol & Histol, Seville, Spain; [Maurel, Joan] Univ Barcelona, IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Hosp Clin Barcelona,Med Oncol Dept, Barcelona, Spain; [Rubio-Casadevall, Jordi] Inst Catala Oncoi, Med Oncol Serv, Girona, Spain; [Esteve, Anna; Gut, Marta] Barcelona Inst Sci & Technol BIST, Ctr Genom Regulat, CNAG CRG, Barcelona, Spain; [Esteve, Anna; Gut, Marta] Univ Pompeu Fabra UPF, Barcelona, Spain; [Valverde, Claudia; Carles, Joan; Serrano, Cesar] Vail Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain; [Barretina, Jordi] Inst Catala Oncoi, Inst Invest Ciencies Salut Germans Trias & Pujol, Badalona, Spain; [Demetri, George D.] Dana Farber Canc Inst, Sarcoma & Bone Canc Treatment Ctr, Boston, MA 02115 USA; [Demetri, George D.] Harvard Med Sch, Ludwig Ctr Harvard, Boston, MA 02115 USA; [Arribas, Joaquin] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain; [Arribas, Joaquin] Vail Hebron Inst Oncol VHIO, Growth Factors Lab, Barcelona, Spain; [Arribas, Joaquin] CIBERONC, Barcelona, Spain	Vall d'Hebron Institut d'Oncologia (VHIO); Institute of Molecular Biology (IMB); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; University of Sevilla; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Hospital Universitari Vall d'Hebron; Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol (IGTP); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; ICREA; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC	Serrano, C (corresponding author), Vall Hebron Inst Oncol VHIO, Sarcoma Translat Res Lab, Barcelona, Spain.; Serrano, C (corresponding author), Vail Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain.	cserrano@vhio.net	de Alava, Enrique/GOH-0368-2022; Esteve-Codina, Anna/M-9614-2015	de Alava, Enrique/0000-0001-8400-046X; Esteve-Codina, Anna/0000-0003-0361-2873; Sayols, Sergi/0000-0002-3877-4170; Rubio-Casadevall, Jordi/0000-0002-3516-6970; Pilco-Janeta, Daniel Fernando/0000-0003-3640-0498	2014 SARC International Career Development Award (SARC Sarcoma Spore) [1U54CA168512-01]; Fundacion Mari Paz Jimenez Casado; FERO Foundation; Spanish Society of Medical Oncology (SEOM); PERIS [SLT006/17/221]; ISCIII [PI16/01371, PI19/01271, FI20/00275, PT17/0009/0019]; FEDER	2014 SARC International Career Development Award (SARC Sarcoma Spore); Fundacion Mari Paz Jimenez Casado; FERO Foundation; Spanish Society of Medical Oncology (SEOM); PERIS; ISCIII(Instituto de Salud Carlos III); FEDER(European Commission)	This project was funded by the 2014 SARC International Career Development Award (SARC Sarcoma Spore 1U54CA168512-01), Fundacion Mari Paz Jimenez Casado, FERO Foundation, Spanish Society of Medical Oncology (SEOM), PERIS SLT006/17/221, ISCIII PI16/01371 and PI19/01271, all to C.S. ISCIII FI20/00275 (to DG-P), and a Ph.D. fellowship from the National Secretary for Higher Education, Science, Technology and Innovation of Ecuador (SENESCYT) (to DFP-J). AE-C is funded by ISCIII PT17/0009/0019 and co-funded by FEDER. We thank the Cellex Foundation for providing facilities and equipment.	Bardia A, 2020, ONCOLOGIST, V25, pE160, DOI 10.1634/theoncologist.2019-0297; Bauer S, 2007, ONCOGENE, V26, P7560, DOI 10.1038/sj.onc.1210558; Boichuk S, 2013, CANCER RES, V73, P5120, DOI 10.1158/0008-5472.CAN-13-0579; Bosbach B, 2017, P NATL ACAD SCI USA, V114, pE8448, DOI 10.1073/pnas.1711449114; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chi P, 2010, NATURE, V467, P849, DOI 10.1038/nature09409; Chou JL, 2010, LAB INVEST, V90, P414, DOI 10.1038/labinvest.2009.138; Ciarapica R, 2014, ONCOGENE, V33, P4173, DOI 10.1038/onc.2013.471; Cohen NA, 2015, CANCER RES, V75, P2061, DOI 10.1158/0008-5472.CAN-14-2564; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Demetri George D, 2010, J Natl Compr Canc Netw, V8 Suppl 2, pS1; Dolly SO, 2016, CLIN CANCER RES, V22, P2874, DOI 10.1158/1078-0432.CCR-15-2225; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Frolov A, 2003, MOL CANCER THER, V2, P699; Garcia-Valverde A, 2020, MOL CANCER THER, V19, P1289, DOI 10.1158/1535-7163.MCT-19-1069; Garner AP, 2014, CLIN CANCER RES, V20, P5745, DOI 10.1158/1078-0432.CCR-14-1397; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Grunewald S, 2021, CANCER DISCOV, V11, P108, DOI 10.1158/2159-8290.CD-20-0487; Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461; Hemming ML, 2018, P NATL ACAD SCI USA, V115, pE5746, DOI 10.1073/pnas.1802079115; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hyer ML, 2018, NAT MED, V24, P186, DOI 10.1038/nm.4474; Jin JP, 2007, NATURE, V447, P1135, DOI 10.1038/nature05902; Lagirand-Cantaloube J, 2008, EMBO J, V27, P1266, DOI 10.1038/emboj.2008.52; Li F, 2015, CANCER DISCOV, V5, P438, DOI 10.1158/2159-8290.CD-14-0763; Liegl B, 2008, J PATHOL, V216, P64, DOI 10.1002/path.2382; Liu Y, 2008, CANCER RES, V68, P9015, DOI 10.1158/0008-5472.CAN-08-1935; Maurel J, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569-016-0050-6; Pascual-Reguant L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05912-z; Ran LL, 2018, CANCER DISCOV, V8, P234, DOI 10.1158/2159-8290.CD-17-0468; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Serrano C, 2020, CLIN CANCER RES, V26, P5078, DOI 10.1158/1078-0432.CCR-20-1706; Serrano C, 2019, CLIN CANCER RES, V25, P7287, DOI 10.1158/1078-0432.CCR-19-2150; Serrano C, 2019, BRIT J CANCER, V120, P612, DOI 10.1038/s41416-019-0389-6; Skurk C, 2005, J BIOL CHEM, V280, P20814, DOI 10.1074/jbc.M500528200; Taylor BS, 2011, NAT REV CANCER, V11, P541, DOI 10.1038/nrc3087; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; Vitiello GA, 2019, J CLIN INVEST, V129, P1863, DOI 10.1172/JCI124108; Wang D, 2012, ANN SURG ONCOL, V19, P1074, DOI 10.1245/s10434-011-2190-5; Wang YX, 2014, NAT GENET, V46, P601, DOI 10.1038/ng.2974; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Zhou H, 2017, ONCOGENE, V36, P3312, DOI 10.1038/onc.2016.479; Zhu MJ, 2007, ONCOGENE, V26, P6386, DOI 10.1038/sj.onc.1210464	50	1	1	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6614	6626		10.1038/s41388-021-02049-0	http://dx.doi.org/10.1038/s41388-021-02049-0		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34621020				2022-12-17	WOS:000704524600001
J	Kyjacova, L; Saup, R; Ronsch, K; Wallbaum, S; Dukowic-Schulze, S; Foss, A; Scherer, SD; Rothley, M; Neeb, A; Grau, N; Thiele, W; Thaler, S; Cremers, N; Sticht, C; Gretz, N; Garvalov, BK; Utikal, J; Sleeman, JP				Kyjacova, Lenka; Saup, Rafael; Roensch, Kerstin; Wallbaum, Sabine; Dukowic-Schulze, Stefanie; Foss, Amelia; Scherer, Sandra D.; Rothley, Melanie; Neeb, Antje; Grau, Nicole; Thiele, Wilko; Thaler, Sonja; Cremers, Natascha; Sticht, Carsten; Gretz, Norbert; Garvalov, Boyan K.; Utikal, Jochen; Sleeman, Jonathan P.			IER2-induced senescence drives melanoma invasion through osteopontin	ONCOGENE			English	Article							IMMEDIATE-EARLY GENE; ONCOGENE-INDUCED SENESCENCE; EARLY RESPONSE PROTEIN-2; CELLULAR SENESCENCE; ECDYSONE RECEPTOR; PREMATURE SENESCENCE; SECRETORY PHENOTYPE; POOR SURVIVAL; TUMOR-GROWTH; HUMAN-CELLS	Expression of the immediate-early response gene IER2 has been associated with the progression of several types of cancer, but its functional role is poorly understood. We found that increased IER2 expression in human melanoma is associated with shorter overall survival, and subsequently investigated the mechanisms through which IER2 exerts this effect. In experimental melanoma models, sustained expression of IER2 induced senescence in a subset of melanoma cells in a p53/MAPK/AKT-dependent manner. The senescent cells produced a characteristic secretome that included high levels of the extracellular phosphoglycoprotein osteopontin. Nuclear localization of the IER2 protein was critical for both the induction of senescence and osteopontin secretion. Osteopontin secreted by IER2-expressing senescent cells strongly stimulated the migration and invasion of non-senescent melanoma cells. Consistently, we observed coordinate expression of IER2, p53/p21, and osteopontin in primary human melanomas and metastases, highlighting the pathophysiological relevance of IER2-mediated senescence in melanoma progression. Together, our study reveals that sustained IER2 expression drives melanoma invasion and progression through stimulating osteopontin secretion via the stochastic induction of senescence.	[Kyjacova, Lenka; Saup, Rafael; Roensch, Kerstin; Dukowic-Schulze, Stefanie; Foss, Amelia; Scherer, Sandra D.; Thiele, Wilko; Thaler, Sonja; Garvalov, Boyan K.; Sleeman, Jonathan P.] Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci ECAS, Dept Microvasc Biol & Pathobiol, Mannheim, Germany; [Roensch, Kerstin; Wallbaum, Sabine; Dukowic-Schulze, Stefanie; Scherer, Sandra D.; Rothley, Melanie; Neeb, Antje; Grau, Nicole; Thiele, Wilko; Cremers, Natascha; Sleeman, Jonathan P.] Karlsruhe Inst Technol KIT, Inst Biol & Chem Syst Biol Informat Proc IBCS BIP, Campus Nord, Karlsruhe, Germany; [Sticht, Carsten; Gretz, Norbert] Heidelberg Univ, Med Fac Mannheim, Med Res Ctr, Mannheim, Germany; [Utikal, Jochen] German Canc Res Ctr, Skin Canc Unit, Heidelberg, Germany; [Utikal, Jochen] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Dermatol Venereol & Allergol, Mannheim, Germany; [Roensch, Kerstin] Eurofins GATC Biotech GmbH, Constance, Germany; [Grau, Nicole] Heidelberg Univ Hosp, Dept Radiat Oncol, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; Karlsruhe Institute of Technology; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Sleeman, JP (corresponding author), Heidelberg Univ, Med Fac Mannheim, European Ctr Angiosci ECAS, Dept Microvasc Biol & Pathobiol, Mannheim, Germany.; Sleeman, JP (corresponding author), Karlsruhe Inst Technol KIT, Inst Biol & Chem Syst Biol Informat Proc IBCS BIP, Campus Nord, Karlsruhe, Germany.	jonathan.sleeman@medma.uni-heidelberg.de	Thaler, Sonja/AAC-4784-2020		Projekt DEAL	Projekt DEAL	Open Access funding enabled and organized by Projekt DEAL.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Astle MV, 2012, ONCOGENE, V31, P1949, DOI 10.1038/onc.2011.394; Bahrami Shahram, 2016, Advances in Biological Regulation, V62, P37, DOI 10.1016/j.jbior.2016.05.001; Bandopadhyay M, 2014, EXPERT OPIN THER TAR, V18, P883, DOI 10.1517/14728222.2014.925447; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Budczies J, 2015, ONCOTARGET, V6, P570, DOI 10.18632/oncotarget.2677; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Celton-Morizur S, 2009, J CLIN INVEST, V119, P1880, DOI 10.1172/JCI38677; CHARLES CH, 1990, MOL CELL BIOL, V10, P6769, DOI 10.1128/MCB.10.12.6769; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Damsky William E, 2010, Cancers (Basel), V3, P126, DOI 10.3390/cancers3010126; Dang JJ, 2002, CANCER RES, V62, P1222; Angelini PD, 2013, CANCER RES, V73, P450, DOI 10.1158/0008-5472.CAN-12-2301; Davie JR, 2010, ADV ENZYME REGUL, V50, P135, DOI 10.1016/j.advenzreg.2009.10.008; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dunn KL, 2005, ONCOGENE, V24, P3492, DOI 10.1038/sj.onc.1208521; Ebert R, 2015, STEM CELL RES, V15, P231, DOI 10.1016/j.scr.2015.06.008; Eggert T, 2016, CANCER CELL, V30, P533, DOI 10.1016/j.ccell.2016.09.003; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Fava LL, 2017, GENE DEV, V31, P34, DOI 10.1101/gad.289728.116; Flanagan KC, 2018, ONCOTARGET, V9, P21, DOI 10.18632/oncotarget.22940; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Haapajarvi T, 1999, CELL GROWTH DIFFER, V10, P163; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; He SH, 2017, CELL, V169, P1000, DOI 10.1016/j.cell.2017.05.015; Healy S, 2013, PHARMACOL THERAPEUT, V137, P64, DOI 10.1016/j.pharmthera.2012.09.001; Herranz N, 2018, J CLIN INVEST, V128, P1238, DOI 10.1172/JCI95148; Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225; Hoare M, 2016, NAT CELL BIOL, V18, P979, DOI 10.1038/ncb3397; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hong SK, 2009, P NATL ACAD SCI USA, V106, P2230, DOI 10.1073/pnas.0812880106; Hsu CH, 2019, CELL, V178, P361, DOI 10.1016/j.cell.2019.05.041; Huun J, 2017, BMC CELL BIOL, V18, DOI 10.1186/s12860-017-0134-z; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jager K, 2019, CANCERS, V11, DOI 10.3390/cancers11010076; Karzenowski D, 2005, BIOTECHNIQUES, V39, P191, DOI 10.2144/05392ST01; Kato M, 1998, ONCOGENE, V17, P1885, DOI 10.1038/sj.onc.1202077; Kauko O, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1093; Kim EK, 2014, CANCER RES, V74, P6705, DOI 10.1158/0008-5472.CAN-14-1482; Knappe N, 2016, STEM CELLS, V34, P832, DOI 10.1002/stem.2284; Kolesnichenko M, 2012, CELL CYCLE, V11, P2391, DOI 10.4161/cc.20683; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lens SMA, 2019, NAT REV CANCER, V19, P32, DOI 10.1038/s41568-018-0084-6; Levine MS, 2018, GENE DEV, V32, P620, DOI 10.1101/gad.314351.118; Li JH, 2019, J CELL MOL MED, V23, P3867, DOI 10.1111/jcmm.14234; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Loaiza N, 2016, BBA-REV CANCER, V1865, P155, DOI 10.1016/j.bbcan.2016.01.007; Mannava S, 2012, ONCOGENE, V31, P1484, DOI 10.1038/onc.2011.339; McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045; Milanovic M, 2018, TRENDS CELL BIOL, V28, P1049, DOI 10.1016/j.tcb.2018.09.001; Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167; MILLER FR, 1983, INVAS METAST, V3, P22; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Neeb A, 2012, ONCOGENE, V31, P3796, DOI 10.1038/onc.2011.535; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Palli SR, 2003, EUR J BIOCHEM, V270, P1308, DOI 10.1046/j.1432-1033.2003.03501.x; Paluncic J, 2016, BBA-MOL CELL RES, V1863, P770, DOI 10.1016/j.bbamcr.2016.01.025; Panopoulos A, 2014, MOL BIOL CELL, V25, P3105, DOI 10.1091/mbc.E14-03-0844; Pazolli E, 2012, CANCER RES, V72, P2251, DOI 10.1158/0008-5472.CAN-11-3386; Pazolli E, 2009, CANCER RES, V69, P1230, DOI 10.1158/0008-5472.CAN-08-2970; Prasad R, 2014, ONCOTARGET, V5, P10636, DOI 10.18632/oncotarget.2527; Purvis JE, 2012, SCIENCE, V336, P1440, DOI 10.1126/science.1218351; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Sadaie M, 2015, MOL BIOL CELL, V26, P2971, DOI 10.1091/mbc.E15-01-0003; Saker M, 2016, ARTERIOSCL THROM VAS, V36, P1879, DOI 10.1161/ATVBAHA.116.307839; Saleh T, 2019, BIOCHEM PHARMACOL, V162, P202, DOI 10.1016/j.bcp.2018.12.013; Sangaletti S, 2014, CANCER RES, V74, P4706, DOI 10.1158/0008-5472.CAN-13-3334; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; SCOTT JL, 1994, J CELL BIOCHEM, V54, P135, DOI 10.1002/jcb.240540202; Sensi M, 2006, ONCOGENE, V25, P3357, DOI 10.1038/sj.onc.1209379; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharon Y, 2015, CANCER RES, V75, P963, DOI 10.1158/0008-5472.CAN-14-1990; SHIMIZU N, 1991, J BIOL CHEM, V266, P12157; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takaya T, 2009, BIOSCI BIOTECH BIOCH, V73, P1653, DOI 10.1271/bbb.90162; Ueda T, 2019, CELL SIGNAL, V55, P81, DOI 10.1016/j.cellsig.2018.12.012; van Deursen JM, 2019, SCIENCE, V364, P636, DOI 10.1126/science.aaw1299; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wagner NB, 2015, INT J CANCER, V137, P2607, DOI 10.1002/ijc.29619; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wallbaum H, 2009, BAUINGENIEUR-GERMANY, V84, P291; Wallbaum S, 2009, BIOTECHNIQUES, V46, P433, DOI 10.2144/000113121; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x; Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011; Wu WJ, 2015, INT J MOL MED, V36, P1104, DOI 10.3892/ijmm.2015.2310; Wu WJ, 2015, AM J CANCER RES, V5, P1435; Xu X, 2020, NEOPLASMA, V67, P614, DOI 10.4149/neo_2020_190818N781; Xu YX, 2014, TRENDS BIOCHEM SCI, V39, P268, DOI 10.1016/j.tibs.2014.04.004; Xu ZX, 2017, ONCOL REP, V37, P259, DOI 10.3892/or.2016.5215; Yang LX, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.49; Zhao HL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0391-6; Zhou YW, 2005, J INVEST DERMATOL, V124, P1044, DOI 10.1111/j.0022-202X.2005.23680.x; Zlobec I, 2006, MODERN PATHOL, V19, P1236, DOI 10.1038/modpathol.3800642	106	1	1	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6494	6512		10.1038/s41388-021-02027-6	http://dx.doi.org/10.1038/s41388-021-02027-6		OCT 2021	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34611309	hybrid, Green Published			2022-12-17	WOS:000703836100002
J	Li, MY; Li, XY; Goldsmith, JR; Shi, SL; Zhang, L; Zamani, A; Wan, L; Sun, HH; Li, T; Yu, JY; Etwebi, Z; Bou-Dargham, MJ; Chen, YHH				Li, Mingyue; Li, Xinyuan; Goldsmith, Jason R.; Shi, Songlin; Zhang, Li; Zamani, Ali; Wan, Lin; Sun, Honghong; Li, Ting; Yu, Jiyeon; Etwebi, Zienab; Bou-Dargham, Mayassa J.; Chen, Youhai H.			Decoupling tumor cell metastasis from growth by cellular pilot protein TNFAIP8	ONCOGENE			English	Article							HIPPO-YAP PATHWAY; ORGAN SIZE; COMPENSATORY PROLIFERATION; NEGATIVE REGULATOR; CANCER; OVEREXPRESSION; TUMORIGENESIS; INFLAMMATION; MIGRATION; MOLECULE	Cancer metastasis accounts for nearly 90% of all cancer deaths. Metastatic cancer progression requires both cancer cell migration to the site of the metastasis and subsequent proliferation after colonization. However, it has long been recognized that cancer cell migration and proliferation can be uncoupled; but the mechanism underlying this paradox is not well understood. Here we report that TNFAIP8 (tumor necrosis factor-alpha-induced protein 8), a "professional" transfer protein of phosphoinositide second messengers, promotes cancer cell migration or metastasis but inhibits its proliferation or cancer growth. TNFAIP8-deficient mice developed larger tumors, but TNFAIP8-deficient tumor cells completely lost their ability to migrate toward chemoattractants and were defective in colonizing lung tissues as compared to wild-type counterparts. Mechanistically, TNFAIP8 served as a cellular "pilot" of tumor cell migration by locally amplifying PI3K-AKT and Rac signals on the cell membrane facing chemoattractant; at the same time, TNFAIP8 also acted as a global inhibitor of tumor cell growth and proliferation by regulating Hippo signaling pathway. These findings help explain the migration-proliferation paradox of cancer cells that characterizes many cancers.	[Li, Mingyue; Li, Xinyuan; Goldsmith, Jason R.; Shi, Songlin; Zhang, Li; Zamani, Ali; Wan, Lin; Sun, Honghong; Li, Ting; Yu, Jiyeon; Etwebi, Zienab; Bou-Dargham, Mayassa J.; Chen, Youhai H.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Chen, Youhai H.] CAS Shenzhen Inst Adv Technol, Fac Pharmaceut Sci, Shenzhen, Peoples R China; [Zhang, Li] Shandong First Med Univ, Dept Clin Lab Med, Affiliated Hosp 1, Jinan, Shandong, Peoples R China; [Zhang, Li] Shandong Prov Qianfoshan Hosp, Jinan, Shandong, Peoples R China	University of Pennsylvania; Pennsylvania Medicine; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences	Li, MY; Chen, YHH (corresponding author), Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA.; Chen, YHH (corresponding author), CAS Shenzhen Inst Adv Technol, Fac Pharmaceut Sci, Shenzhen, Peoples R China.	Mingyue.Li@pennmedicine.upenn.edu; yhc@pennmedicine.upenn.edu		Shi, Song-Lin/0000-0003-1213-0550; Bou-Dargham, Mayassa/0000-0002-1551-8887	National Institutes of Health (NIH), USA [R01AI143676, R01AI1136945]	National Institutes of Health (NIH), USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by grants from the National Institutes of Health (NIH), USA (R01AI143676 and R01AI1136945).	Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Briata P, 2012, CELL DEATH DIFFER, V19, P478, DOI 10.1038/cdd.2011.117; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Day TF, 2019, MOL CANCER RES, V17, P1207, DOI 10.1158/1541-7786.MCR-18-0731; Devalaraja S, 2020, CELL, V180, P1098, DOI 10.1016/j.cell.2020.02.042; Fayngerts SA, 2017, NAT IMMUNOL, V18, P1353, DOI 10.1038/ni.3866; Goldsmith JR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16379-2; Goldsmith JR, 2017, CELL MOL IMMUNOL, V14, P482, DOI 10.1038/cmi.2017.4; Hadisaputri YE, 2012, ANN SURG ONCOL, V19, pS589, DOI 10.1245/s10434-011-2097-1; Han Y, 2018, MOL CARCINOGEN, V57, P159, DOI 10.1002/mc.22740; Haugh JM, 2018, LYSOPHOSPHATIDIC ACI, V2019, DOI [10.1101/355610, DOI 10.1101/355610]; Kango-Singh M, 2009, DEV DYNAM, V238, P1627, DOI 10.1002/dvdy.21996; Kohrman AQ, 2017, TRENDS CELL BIOL, V27, P12, DOI 10.1016/j.tcb.2016.08.003; Kumar D, 2004, ONCOGENE, V23, P612, DOI 10.1038/sj.onc.1207123; Laliberte B, 2010, J CELL PHYSIOL, V225, P865, DOI 10.1002/jcp.22297; Leung HW, 2015, BBA-MOL CELL RES, V1853, P1827, DOI 10.1016/j.bbamcr.2015.04.020; Li T, 2020, NAT CANCER, V1, DOI 10.1038/s43018-020-0061-3; Liu T, 2013, BRIT J CANCER, V109, P1685, DOI 10.1038/bjc.2013.501; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Miller E, 2012, CHEM BIOL, V19, P955, DOI 10.1016/j.chembiol.2012.07.005; Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005; Niture S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010009; Padmavathi G, 2018, CANCER LETT, V432, P260, DOI 10.1016/j.canlet.2018.06.017; Sakurai T, 2008, CANCER CELL, V14, P156, DOI 10.1016/j.ccr.2008.06.016; Schreiber TH, 2009, BRIT J CANCER, V101, P381, DOI 10.1038/sj.bjc.6605198; Sun HH, 2008, CELL, V133, P415, DOI 10.1016/j.cell.2008.03.026; Sun HH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63629-w; Sun HH, 2015, J IMMUNOL, V194, P5736, DOI 10.4049/jimmunol.1401986; Svensson S, 2003, CANCER RES, V63, P1737; Swann JB, 2008, P NATL ACAD SCI USA, V105, P652, DOI 10.1073/pnas.0708594105; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Wang ZJ, 2012, P NATL ACAD SCI USA, V109, P15413, DOI 10.1073/pnas.1204525109; Watt KI, 2010, BIOCHEM BIOPH RES CO, V393, P619, DOI 10.1016/j.bbrc.2010.02.034; Wettschureck N, 2005, PHYSIOL REV, V85, P1159, DOI 10.1152/physrev.00003.2005; Xie Y, 2018, EXP THER MED, V16, P4975, DOI 10.3892/etm.2018.6819; Xing Y, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0254-x; Yang M, 2014, HISTOPATHOLOGY, V65, P517, DOI 10.1111/his.12413; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037846; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001; Zhong MY, 2020, J CANCER, V11, P3061, DOI 10.7150/jca.40191	43	1	1	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2021	40	46					6456	6468		10.1038/s41388-021-02035-6	http://dx.doi.org/10.1038/s41388-021-02035-6		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA1UG	34608264	Green Accepted			2022-12-17	WOS:000703526900001
J	Fountain, DM; Smith, MJ; O'Leary, C; Pathmanaban, ON; Roncaroli, F; Bobola, N; King, AT; Evans, DG				Fountain, Daniel M.; Smith, Miriam J.; O'Leary, Claire; Pathmanaban, Omar N.; Roncaroli, Federico; Bobola, Nicoletta; King, Andrew T.; Evans, Dafydd Gareth			The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges (vol 40, pg 875, 2021)	ONCOGENE			English	Correction												Daniel.fountain@nhs.net	Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784; Fountain, Daniel/0000-0001-6227-9930	National Institute for Health Research (NIHR); Cancer Research UK (CRUK) Predoctoral Research Bursary [C72069/A30348, IS-BRC-1215-20007]	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Cancer Research UK (CRUK) Predoctoral Research Bursary	DMF is supported by the National Institute for Health Research (NIHR) and a Cancer Research UK (CRUK) Predoctoral Research Bursary (C72069/A30348). DGE and MJS are supported by the all Manchester National Institute for Health Research Biomedical Research Centre (IS-BRC-1215-20007).	Fountain DM, 2021, ONCOGENE, V40, P875, DOI 10.1038/s41388-020-01568-6	1	1	1	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6139	6139		10.1038/s41388-021-01700-0	http://dx.doi.org/10.1038/s41388-021-01700-0		SEP 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34522010	hybrid, Green Published			2022-12-17	WOS:000695769700001
J	Leonard, MK; Puts, GS; Pamidimukkala, N; Adhikary, G; Xu, YL; Kwok, E; Jin, YX; Snyder, D; Matsangos, N; Novak, M; Mahurkar, A; Shetty, AC; Slominski, RM; De Fabo, EC; Noonan, FP; Day, CP; Rigi, M; Slominski, AT; Webb, MG; Craig, DW; Merlino, G; Eckert, RL; Carpten, JD; Manojlovic, Z; Kaetzel, DM				Leonard, M. Kathryn; Puts, Gemma S.; Pamidimukkala, Nidhi; Adhikary, Gautam; Xu, Yili; Kwok, Eric; Jin, Yuxin; Snyder, Devin; Matsangos, Nicolette; Novak, Marian; Mahurkar, Anup; Shetty, Amol C.; Slominski, Radomir M.; De Fabo, Edward C.; Noonan, Frances P.; Day, Chi-Ping; Rigi, Mohammed; Slominski, Andrzej T.; Webb, Michelle G.; Craig, David W.; Merlino, Glenn; Eckert, Richard L.; Carpten, John D.; Manojlovic, Zarko; Kaetzel, David M.			Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients	ONCOGENE			English	Article							NM23/NUCLEOSIDE DIPHOSPHATE-KINASE; SUPPRESSOR FUNCTION; PROSTATE-CANCER; CTLA-4 BLOCKADE; UVEAL MELANOMA; CELL MOTILITY; MUTATIONS; NM23-H1; ABERRATIONS; REPAIR	Hepatocyte growth factor-overexpressing mice that harbor a deletion of the Ink4a/p16 locus (HP mice) form melanomas with low metastatic potential in response to UV irradiation. Here we report that these tumors become highly metastatic following hemizygous deletion of the Nme1 and Nme2 metastasis suppressor genes (HPN mice). Whole-genome sequencing of melanomas from HPN mice revealed a striking increase in lung metastatic activity that is associated with missense mutations in eight signature genes (Arhgap35, Atp8b4, Brca1, Ift172, Kif21b, Nckap5, Pcdha2, and Zfp869). RNA-seq analysis of transcriptomes from HP and HPN primary melanomas identified a 32-gene signature (HPN lung metastasis signature) for which decreased expression is strongly associated with lung metastatic potential. Analysis of transcriptome data from The Cancer Genome Atlas revealed expression profiles of these genes that predict improved survival of patients with cutaneous or uveal melanoma. Silencing of three representative HPN lung metastasis signature genes (ARRDC3, NYNRIN, RND3) in human melanoma cells resulted in increased invasive activity, consistent with roles for these genes as mediators of the metastasis suppressor function of NME1 and NME2. In conclusion, our studies have identified a family of genes that mediate suppression of melanoma lung metastasis, and which may serve as prognostic markers and/or therapeutic targets for clinical management of metastatic melanoma.	[Leonard, M. Kathryn; Puts, Gemma S.; Pamidimukkala, Nidhi; Adhikary, Gautam; Snyder, Devin; Matsangos, Nicolette; Novak, Marian; Eckert, Richard L.; Kaetzel, David M.] Univ Maryland Baltimore, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Leonard, M. Kathryn; Puts, Gemma S.; Pamidimukkala, Nidhi; Adhikary, Gautam; Snyder, Devin; Eckert, Richard L.; Kaetzel, David M.] Univ Maryland Baltimore, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Sch Med, Baltimore, MD 21201 USA; [Xu, Yili; Kwok, Eric; Jin, Yuxin; Webb, Michelle G.; Craig, David W.; Carpten, John D.; Manojlovic, Zarko] Univ Southern Calif, Keck Sch Med, Dept Translat Genom, Los Angeles, CA 90007 USA; [Mahurkar, Anup; Shetty, Amol C.] Univ Maryland Baltimore, Sch Med, Inst Genome Sci, Baltimore, MD USA; [Slominski, Radomir M.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA; [De Fabo, Edward C.; Noonan, Frances P.] George Washington Univ, Med Ctr, Washington, DC 20037 USA; [Day, Chi-Ping; Merlino, Glenn] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA; [Rigi, Mohammed; Slominski, Andrzej T.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Kaetzel, David M.] VA Maryland Hlth Care Syst, Res & Dev Serv, Baltimore, MD 21201 USA; [Leonard, M. Kathryn] Amer Assoc Canc Res, Philadelphia, PA USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Southern California; University System of Maryland; University of Maryland Baltimore; University of Alabama System; University of Alabama Birmingham; George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Birmingham	Kaetzel, DM (corresponding author), Univ Maryland Baltimore, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.; Kaetzel, DM (corresponding author), Univ Maryland Baltimore, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Sch Med, Baltimore, MD 21201 USA.; Kaetzel, DM (corresponding author), VA Maryland Hlth Care Syst, Res & Dev Serv, Baltimore, MD 21201 USA.	DKaetzel@som.umaryland.edu		Matsangos, Nicolette/0000-0002-3542-2612; Xu, Yili/0000-0001-8508-4706; Snyder, Devin/0000-0001-8528-7538; LEONARD, M. Kathryn/0000-0002-8432-6803	National Institutes of Health/National Cancer Institute [R01 CA83237, R01 CA159871, R01 CA159871-S1, R01 CA211909, P30 CA134274, T32 CA154274]; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01 AR071189]; National Institutes of Health/National Institute of General Medical Sciences [R25 GM055036]; Maryland Stem Cell Research Foundation [MSCRFI-1638]; Veterans Administration (VA Merit Grant) [1I01BX004293]; Baltimore Research and Education Foundation, VA Maryland Health Care System	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institutes of Health/National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Maryland Stem Cell Research Foundation; Veterans Administration (VA Merit Grant)(US Department of Veterans Affairs); Baltimore Research and Education Foundation, VA Maryland Health Care System	The authors gratefully acknowledge the expert technical assistance of A. Greenawalt and B. Hazzard, and to I. Violich for providing guidance in development of the mouse computational pipeline. This work was supported by the National Institutes of Health/National Cancer Institute through research grants R01 CA83237, R01 CA159871 and R01 CA159871-S1 (DMK), R01 CA211909 (RLE), center core grant P30 CA134274 and training grant T32 CA154274, by research grant R01 AR071189 (ATS) from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, and by education grant R25 GM055036 from the National Institutes of Health/National Institute of General Medical Sciences. The study was also supported by funding from the Maryland Stem Cell Research Foundation (MSCRFI-1638, DMK), the Veterans Administration (VA Merit Grant 1I01BX004293, ATS), and the Baltimore Research and Education Foundation, VA Maryland Health Care System.	Aaron KA, 2020, OTOL NEUROTOL, V41, P522, DOI 10.1097/MAO.0000000000002580; Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451; Ahn A, 2017, MOL CANCER THER, V16, P1002, DOI 10.1158/1535-7163.MCT-16-0535; [Anonymous], 2014, GENOME BIOL, DOI DOI 10.1186/S13059-014-0550-8; Arakaki AKS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071886; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Bektic J, 2005, PROSTATE, V64, P332, DOI 10.1002/pros.20243; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Boissan M, 2005, JNCI-J NATL CANCER I, V97, P836, DOI 10.1093/jnci/dji143; Boissan M, 2012, B CANCER, V99, P431, DOI 10.1684/bdc.2012.1550; Chen DC, 2019, ONCOGENE, V38, P6429, DOI 10.1038/s41388-019-0891-6; Chen LH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028222; Diskin SJ, 2006, GENOME RES, V16, P1149, DOI 10.1101/gr.5076506; Draheim KM, 2010, ONCOGENE, V29, P5032, DOI 10.1038/onc.2010.250; Ekizoglu S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4381-y; Fei F, 2017, ONCOTARGET, V8, P73219, DOI 10.18632/oncotarget.18016; Fisher ML, 2017, ONCOTARGET, V8, P110257, DOI 10.18632/oncotarget.22628; Garibyan L, 2010, CURR ONCOL REP, V12, P319, DOI 10.1007/s11912-010-0119-y; Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568-018-0038-z; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; Heraud C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040351; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Horak CE, 2007, CANCER RES, V67, P11751, DOI 10.1158/0008-5472.CAN-07-3175; Horak CE, 2007, CANCER RES, V67, P7238, DOI 10.1158/0008-5472.CAN-07-0962; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Johansson P, 2016, ONCOTARGET, V7, P4624, DOI 10.18632/oncotarget.6614; Kaetzel DM, 2015, N-S ARCH PHARMACOL, V388, P199, DOI 10.1007/s00210-014-1010-4; Kandasamy S, 2020, MOL CANCER RES, V18, P343, DOI 10.1158/1541-7786.MCR-19-0914; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Klein RM, 2009, CANCER RES, V69, P2224, DOI 10.1158/0008-5472.CAN-08-3201; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Leonard MK, 2019, EXP CELL RES, V374, P85, DOI 10.1016/j.yexcr.2018.11.010; Leonard MK, 2018, LAB INVEST, V98, P327, DOI 10.1038/labinvest.2017.108; LEONE A, 1993, ONCOGENE, V8, P2325; Liang WS, 2017, GENOME RES, V27, P524, DOI 10.1101/gr.213348.116; Mahamdallie S, 2019, LANCET CHILD ADOLESC, V3, P322, DOI 10.1016/S2352-4642(19)30018-5; Manojlovic Z, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007087; Marino N, 2012, CANCER METAST REV, V31, P593, DOI 10.1007/s10555-012-9374-8; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656; Molina-Ortiz I, 2009, J BIOL CHEM, V284, P15147, DOI 10.1074/jbc.M807834200; Morrison GJ, 2020, INT J CANCER, V146, P2845, DOI 10.1002/ijc.32915; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; Pamidimukkala N, 2021, BRIT J CANCER, V124, P161, DOI 10.1038/s41416-020-01096-w; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Paysan L, 2016, MOL CANCER RES, V14, P1033, DOI 10.1158/1541-7786.MCR-16-0164; Perez-Guijarro E, 2020, NAT MED, V26, P781, DOI 10.1038/s41591-020-0818-3; Popova T, 2012, CANCER RES, V72, P5454, DOI 10.1158/0008-5472.CAN-12-1470; Postel EH, 2009, DEV DYNAM, V238, P775, DOI 10.1002/dvdy.21887; Recio JA, 2002, CANCER RES, V62, P6724; Roberts A, 2013, NAT METHODS, V10, P71, DOI [10.1038/nmeth.2251, 10.1038/NMETH.2251]; Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r22; Rubenstein NM, 2005, EXP CELL RES, V305, P74, DOI 10.1016/j.yexcr.2004.12.010; Shain AH, 2015, NAT GENET, V47, P1194, DOI 10.1038/ng.3382; Sheng Y, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4592-2; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Snyder D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58996-3; Soung YH, 2014, SCI REP-UK, V4, DOI 10.1038/srep03846; Spivak G, 2016, ARCH TOXICOL, V90, P2583, DOI 10.1007/s00204-016-1820-x; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Tamura K, 2009, CANCER RES, V69, P8133, DOI 10.1158/0008-5472.CAN-09-0775; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Xiao JT, 2018, AM J CANCER RES, V8, P132; Xue RY, 2019, DNA REPAIR, V77, P27, DOI 10.1016/j.dnarep.2019.03.003; Yang MM, 2009, MUTAT RES-FUND MOL M, V660, P74, DOI 10.1016/j.mrfmmm.2008.09.015; Yang ZY, 2020, J CELL MOL MED, V24, P4510, DOI 10.1111/jcmm.15109; Zhang KM, 2016, J INVEST DERMATOL, V136, P464, DOI 10.1016/j.jid.2015.11.006; Zhang QB, 2011, INT J CANCER, V128, P40, DOI 10.1002/ijc.25307; Zheng Y, 2017, CURR MOL MED, V17, P221, DOI 10.2174/1566524017666170807144711	76	1	1	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6329	6342		10.1038/s41388-021-01998-w	http://dx.doi.org/10.1038/s41388-021-01998-w		AUG 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34433909	Green Accepted			2022-12-17	WOS:000688395700002
J	Miller, AK; Tavera, G; Dominguez, RL; Camargo, MC; Waterboer, T; Wilson, KT; Williams, SM; Morgan, DR				Miller, Anna K.; Tavera, Gloria; Dominguez, Ricardo L.; Camargo, M. Constanza; Waterboer, Tim; Wilson, Keith T.; Williams, Scott M.; Morgan, Douglas R.			Ornithine decarboxylase (ODC1) gene variant (rs2302615) is associated with gastric cancer independently of Helicobacter pylori CagA serostatus	ONCOGENE			English	Article							CHRONIC ATROPHIC GASTRITIS; INCREASED RISK; MACROPHAGE ACTIVATION; INFECTION; SUSCEPTIBILITY; POLYMORPHISMS; INFLAMMATION; METAANALYSIS; ADENOCARCINOMA; PREVALENCE	The primary cause of gastric cancer is chronic infection with Helicobacter pylori (H. pylori), particularly the high-risk genotype cagA, and risk modification by human genetic variants. We studied 94 variants in 54 genes for association with gastric cancer, including rs2302615 in ornithine decarboxylase (ODC1), which may affect response to chemoprevention with the ODC inhibitor, eflornithine (difluoromethylornithine; DFMO). Our population-based, case-control study included 1366 individuals (664 gastric cancer cases and 702 controls) from Western Honduras, a high incidence region of Latin America. CagA seropositivity was strongly associated with cancer (OR = 3.6; 95% CI: 2.6, 5.1). The ODC1 variant rs2302615 was associated with gastric cancer (OR = 1.36; p = 0.018) in a model adjusted for age, sex, and CagA serostatus. Two additional single nucleotide polymorphisms (SNPs) in CASP1 (rs530537) and TLR4 (rs1927914) genes were also associated with gastric cancer in univariate models as well as models adjusted for age, sex, and CagA serostatus. The ODC1 SNP association with gastric cancer was stronger in individuals who carried the TT genotype at the associating TLR4 polymorphism, rs1927914 (OR = 1.77; p = 1.85 x 10(-3)). In conclusion, the ODC1 variant, rs2302615, is associated with gastric cancer and supports chemoprevention trials with DFMO, particularly in individuals homozygous for the T allele at rs1927914.	[Miller, Anna K.; Williams, Scott M.] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA; [Tavera, Gloria; Williams, Scott M.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Dominguez, Ricardo L.] Minist Hlth, Hosp Occidente, Santa Rosa De Copan, Copan, Honduras; [Camargo, M. Constanza] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA; [Waterboer, Tim] German Canc Res Ctr, Infect & Canc Epidemiol, Heidelberg, Germany; [Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Div Gastroenterol Hepatol & Nutr, Nashville, TN USA; [Wilson, Keith T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA; [Morgan, Douglas R.] Univ Alabama Birmingham UAB, UAB Div Gastroenterol & Hepatol, Birmingham, AL 35294 USA	Case Western Reserve University; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Helmholtz Association; German Cancer Research Center (DKFZ); Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of Alabama System; University of Alabama Birmingham	Williams, SM (corresponding author), Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH 44106 USA.; Williams, SM (corresponding author), Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH 44106 USA.; Morgan, DR (corresponding author), Univ Alabama Birmingham UAB, UAB Div Gastroenterol & Hepatol, Birmingham, AL 35294 USA.	smw154@case.edu; drmorgan@uabmc.edu	Williams, Scott/Q-4812-2019; Camargo, M. Constanza/R-9891-2016	Williams, Scott/0000-0002-4835-9544; Camargo, M. Constanza/0000-0002-1065-2198; Miller, Anna/0000-0003-0504-6510; Wilson, Keith/0000-0003-4421-1830	U.S. National Cancer Institute [P01CA028842, R01CA190612, K07 CA125588, PAR-15-155, P30CA068485, P01CA116087]; Veterans Affairs Merit Review grant [I01CX002171]; Department of Defense [W81XWH-18-1-0301]; NIH [T32HL007567]; National Library of Medicine [1R01LM010098]	U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs Merit Review grant(US Department of Veterans Affairs); Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	This study was funded in part by the U.S. National Cancer Institute (P01CA028842 (DRM, KTW, SMW), R01CA190612 (DRM, KTW), K07 CA125588 (DRM), PAR-15-155 (DRM), P30CA068485 (DRM, KTW), P01CA116087 (KTW)), Veterans Affairs Merit Review grant I01CX002171 (KTW), Department of Defense grant W81XWH-18-1-0301 (KTW), NIH T32HL007567 (AKM), and National Library of Medicine 1R01LM010098 (SMW). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the paper. SBR, RLD, RM, and DRM had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. DRM had final responsibility for the decision to submit for publication.	Abnet CC, 2010, NAT GENET, V42, P764, DOI 10.1038/ng.649; Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Asim M, 2010, J BIOL CHEM, V285, P20343, DOI 10.1074/jbc.M110.116988; Auton A., 2015, NATURE, V7571, P68, DOI 10.1038/nature15393; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BLASER MJ, 1995, CANCER RES, V55, P2111; Bonder MJ, 2016, NAT GENET, V48, P1407, DOI 10.1038/ng.3663; Bonequi P, 2013, CANCER CAUSE CONTROL, V24, P217, DOI 10.1007/s10552-012-0110-z; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burucoa C, 2017, HELICOBACTER, V22, DOI 10.1111/hel.12403; Butt J, 2020, CANCER CAUSE CONTROL, V31, P601, DOI 10.1007/s10552-020-01295-z; Cai H, 2016, INT J EPIDEMIOL, V45, P774, DOI 10.1093/ije/dyw078; Camargo MC, 2012, CANCER EPIDEM BIOMAR, V21, P20, DOI 10.1158/1055-9965.EPI-11-0834; Castano-Rodriguez N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098899; Chaturvedi R, 2015, ONCOGENE, V34, P3429, DOI 10.1038/onc.2014.273; Cheng Y, 2005, J BIOL CHEM, V280, P22492, DOI 10.1074/jbc.C500122200; Cho LY, 2015, GASTRIC CANCER, V18, P495, DOI 10.1007/s10120-014-0396-5; Correa P, 1996, CANCER EPIDEM BIOMAR, V5, P477; de Martel C, 2006, DIGEST DIS SCI, V51, P2292, DOI 10.1007/s10620-006-9210-5; de Martel C, 2020, LANCET GLOB HEALTH, V8, pE180, DOI 10.1016/S2214-109X(19)30488-7; Dominguez RL, 2013, CANCER CAUSE CONTROL, V24, P233, DOI 10.1007/s10552-012-0109-5; El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Epplein M, 2012, CANCER EPIDEM BIOMAR, V21, P2185, DOI 10.1158/1055-9965.EPI-12-0792-T; Fox JG, 2007, J CLIN INVEST, V117, P60, DOI 10.1172/JCI30111; Gao L, 2009, CANCER RES, V69, P2973, DOI 10.1158/0008-5472.CAN-08-3477; Gong YF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149629; Gonzalez-Hormazabal P, 2020, MOL BIOL REP, V47, P9239, DOI 10.1007/s11033-020-05943-0; Greene CS, 2015, NAT GENET, V47, P569, DOI 10.1038/ng.3259; Haley KP, 2016, GASTROENT RES PRACT, V2016, DOI 10.1155/2016/3019362; Hardbower DM, 2017, ONCOGENE, V36, P3807, DOI 10.1038/onc.2017.23; Hardbower DM, 2017, P NATL ACAD SCI USA, V114, pE751, DOI 10.1073/pnas.1614958114; Hardbower DM, 2014, J LEUKOCYTE BIOL, V96, P201, DOI 10.1189/jlb.4BT0214-099R; Hardbower DM, 2013, GUT MICROBES, V4, P475, DOI 10.4161/gmic.25583; Hitzler I, 2012, J IMMUNOL, V188, P3594, DOI 10.4049/jimmunol.1103212; Jakszyn P, 2006, CARCINOGENESIS, V27, P1497, DOI 10.1093/carcin/bgl019; Jensen Klaus Hojgaard, 2018, Oncotarget, V9, P9043, DOI 10.18632/oncotarget.24138; Jin JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106580; Kavermann H, 2003, J EXP MED, V197, P813, DOI 10.1084/jem.20021531; Kim JJ, 2002, GASTROENTEROLOGY, V123, P542, DOI 10.1053/gast.2002.34751; Koch KN, 2015, GUT MICROBES, V6, P382, DOI 10.1080/19490976.2015.1105427; Koch KN, 2015, J CLIN INVEST, V125, P3297, DOI 10.1172/JCI79337; Kodaman N, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00290; Kodaman N, 2014, P NATL ACAD SCI USA, V111, P1455, DOI 10.1073/pnas.1318093111; Kolde R, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0515-8; Kupfer SS, 2017, GASTROENTEROLOGY, V152, P926, DOI 10.1053/j.gastro.2017.02.026; Kurilshikov A, 2017, TRENDS IMMUNOL, V38, P633, DOI 10.1016/j.it.2017.06.003; La Torre G, 2009, TUMORI, V95, P13; Li W, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18452-1; Li X, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftu024; Martinez ME, 2003, P NATL ACAD SCI USA, V100, P7859, DOI 10.1073/pnas.1332465100; Michel A, 2009, HELICOBACTER, V14, P525, DOI 10.1111/j.1523-5378.2009.00723.x; Miller KD, 2018, CA-CANCER J CLIN, V68, P425, DOI 10.3322/caac.21494; Mondaca S, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.03.27; Morgan DR, 2006, CLIN GASTROENTEROL H, V4, P1103, DOI 10.1016/j.cgh.2006.05.025; Pabla BS, 2020, CLIN GASTROENTEROL H, V18, P347, DOI 10.1016/j.cgh.2019.05.032; Park JY, 2018, TOXINS, V10, DOI 10.3390/toxins10040163; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Peek RM, 1995, LAB INVEST, V73, P760; Pegg AE, 2006, J BIOL CHEM, V281, P14529, DOI 10.1074/jbc.R500031200; Pegg AE, 2009, IUBMB LIFE, V61, P880, DOI 10.1002/iub.230; Pormohammad A, 2018, MICROB PATHOGENESIS, V118, P214, DOI 10.1016/j.micpath.2018.03.004; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; REPLOGLE ML, 1995, AM J EPIDEMIOL, V142, P856, DOI 10.1093/oxfordjournals.aje.a117725; Rolig AS, 2013, INFECT IMMUN, V81, P1382, DOI 10.1128/IAI.00044-13; Rowland M, 2006, GASTROENTEROLOGY, V130, P65, DOI 10.1053/j.gastro.2005.11.004; Sakamoto H, 2008, NAT GENET, V40, P730, DOI 10.1038/ng.152; Shi YY, 2011, NAT GENET, V43, P1215, DOI 10.1038/ng.978; Sierra JC, 2020, ONCOGENE, V39, P4465, DOI 10.1038/s41388-020-1304-6; Sierra JC, 2019, P NATL ACAD SCI USA, V116, P5077, DOI 10.1073/pnas.1814497116; Singh K, 2018, CANCER RES, V78, P4303, DOI 10.1158/0008-5472.CAN-18-0116; Smith Sinead M, 2014, World J Gastrointest Pathophysiol, V5, P133, DOI 10.4291/wjgp.v5.i3.133; Snaith Ailsa, 2008, Expert Rev Gastroenterol Hepatol, V2, P577, DOI 10.1586/17474124.2.4.577; Song HR, 2013, MOL CARCINOGEN, V52, P155, DOI 10.1002/mc.22063; Su B, 2003, INFECT IMMUN, V71, P3496, DOI 10.1128/IAI.71.6.3496-3502.2003; Takenaka R, 2004, MICROBIOL-SGM, V150, P3913, DOI 10.1099/mic.0.27527-0; Tavera G, 2018, CURR GENET MED REP, V6, P199, DOI 10.1007/s40142-018-0153-x; Terlizzi M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00670; Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109; Tian J, 2019, CANCER BIOL MED, V16, P361, DOI 10.20892/j.issn.2095-3941.2018.0290; Torres J, 2013, CANCER CAUSE CONTROL, V24, P249, DOI 10.1007/s10552-012-0114-8; Varga MG, 2021, GUT MICROBES, V13, P1, DOI 10.1080/19490976.2020.1862613; Venerito M, 2018, HELICOBACTER, V23, DOI 10.1111/hel.12518; Wang TR, 2014, INT J CLIN EXP PATHO, V7, P6950; Weck MN, 2009, EPIDEMIOLOGY, V20, P569, DOI 10.1097/EDE.0b013e3181a3d5f4; Wilson KT, 2007, GASTROENTEROLOGY, V133, P288, DOI 10.1053/j.gastro.2007.05.008; Yang JC, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/248585; Zambon CF, 2005, CYTOKINE, V29, P141, DOI 10.1016/j.cyto.2004.10.013; Zell JA, 2010, J NATL CANCER I, V102, P1513, DOI 10.1093/jnci/djq325; Zell JA, 2009, CLIN CANCER RES, V15, P6208, DOI 10.1158/1078-0432.CCR-09-0592; Zhu YL, 2017, EXP THER MED, V14, P3304, DOI 10.3892/etm.2017.4904	91	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5963	5969		10.1038/s41388-021-01981-5	http://dx.doi.org/10.1038/s41388-021-01981-5		AUG 2021	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34376808	Green Submitted, Green Accepted			2022-12-17	WOS:000683685200001
J	Sun, J; Gaidosh, G; Xu, Y; Mookhtiar, A; Man, N; Cingaram, PR; Blumenthal, E; Shiekhattar, R; Goka, ET; Nimer, SD; Lippman, ME				Sun, Jun; Gaidosh, Gabriel; Xu, Ye; Mookhtiar, Adnan; Man, Na; Cingaram, Pradeep Reddy; Blumenthal, Ezra; Shiekhattar, Ramin; Goka, Erik T.; Nimer, Stephen D.; Lippman, Marc E.			RAC1 plays an essential role in estrogen receptor alpha function in breast cancer cells	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; ENDOCRINE THERAPY; GENE-EXPRESSION; GTPASE; DEGRADATION; COACTIVATOR; LOCALIZATION; MUTATIONS; MECHANISM; EHT-1864	The activity of Rho family GTPase protein, RAC1, which plays important normal physiological functions, is dysregulated in multiple cancers. RAC1 is expressed in both estrogen receptor alpha (ER)-positive and ER-negative breast cancer (BC) cells. However, ER-positive BC is more sensitive to RAC1 inhibition. We have determined that reducing RAC1 activity, using siRNA or EHT 1864 (a small molecule Rac inhibitor), leads to rapid ER protein degradation. RAC1 interacts with ER within the ER complex and RAC1 localizes to chromatin binding sites for ER upon estrogen treatment. RAC1 activity is important for RNA Pol II function at both promoters and enhancers of ER target genes and ER-regulated gene transcription is blocked by EHT 1864, in a dose-dependent manner. Having identified that RAC1 is an essential ER cofactor for ER protein stability and ER transcriptional activity, we report that RAC1 inhibition could be an effective therapeutic approach for ER-positive BC.	[Sun, Jun; Xu, Ye; Nimer, Stephen D.; Lippman, Marc E.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Sun, Jun; Xu, Ye; Mookhtiar, Adnan; Man, Na; Shiekhattar, Ramin; Nimer, Stephen D.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Gaidosh, Gabriel; Cingaram, Pradeep Reddy; Blumenthal, Ezra; Shiekhattar, Ramin] Univ Miami, Dept Human Genet, Miami, FL USA; [Goka, Erik T.] Geneyus LLC, Miami, FL USA; [Nimer, Stephen D.] Univ Miami, Dept Biochem & Mol Biol, Miami, FL 33101 USA; [Lippman, Marc E.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA	University of Miami; University of Miami; University of Miami; University of Miami; Georgetown University	Nimer, SD; Lippman, ME (corresponding author), Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA.; Nimer, SD (corresponding author), Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.; Nimer, SD (corresponding author), Univ Miami, Dept Biochem & Mol Biol, Miami, FL 33101 USA.; Lippman, ME (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.	snimer@med.miami.edu; mlippman@med.miami.edu	Cingaram, Pradeep Reddy/AAG-7322-2019	Cingaram, Pradeep Reddy/0000-0002-9643-9725; Blumenthal, Ezra/0000-0001-7607-088X	National Cancer Institute (NCI) [5R01CA166835, 1P30CA240139]	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by a generous gift from the Lampert family (MEL), National Cancer Institute (NCI) grants 5R01CA166835 (SDN), and 1P30CA240139 (the Sylvester Comprehensive Cancer Center). We thank the Oncogenomics Shared Resource of the Sylvester Comprehensive Cancer Center for providing expertize and guidance on next generation sequencing services. Xue Xiao and Justin Sun provided assistance in figure generation.	Akbar H, 2006, METHOD ENZYMOL, V406, P554, DOI 10.1016/S0076-6879(06)06043-5; AlFakeeh A, 2018, CURR ONCOL, V25, pS18, DOI 10.3747/co.25.3752; Bates M, 2007, SCIENCE, V317, P1749, DOI 10.1126/science.1146598; Beckedorff F, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107917; BRUNNER N, 1993, CANCER RES, V53, P3229; Buongiorno P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-73; Chu I, 2007, J CLIN INVEST, V117, P2205, DOI 10.1172/JCI21739; Daly B, 2017, JAMA ONCOL, V3, P928, DOI 10.1001/jamaoncol.2016.6380; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Goka ET, 2015, ONCOGENE, V34, P5395, DOI 10.1038/onc.2014.468; Goka ET, 2019, MOL CANCER THER, V18, P957, DOI 10.1158/1535-7163.MCT-18-0955; Hajdo-Milasinovic A, 2007, J CELL SCI, V120, P555, DOI 10.1242/jcs.03364; Hampsch RA, 2017, ONCOTARGET, V8, P21806, DOI 10.18632/oncotarget.15586; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hein AL, 2016, ONCOGENE, V35, P6319, DOI 10.1038/onc.2016.163; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Jamieson C, 2015, J CELL SCI, V128, P3933, DOI 10.1242/jcs.167742; Johnson AB, 2012, MOL CELL ENDOCRINOL, V348, P430, DOI 10.1016/j.mce.2011.04.021; Kazanietz MG, 2017, CANCER RES, V77, P5445, DOI 10.1158/0008-5472.CAN-17-1456; Korkmaz G, 2016, NAT BIOTECHNOL, V34, P192, DOI 10.1038/nbt.3450; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Kurdi AT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13048; Kwapisz D, 2017, BREAST CANCER RES TR, V166, P41, DOI 10.1007/s10549-017-4385-3; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lanning CC, 2004, J BIOL CHEM, V279, P44197, DOI 10.1074/jbc.M404977200; Levet F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10007-4; Liang J, 2013, ANNU REV PHYSIOL, V75, P225, DOI 10.1146/annurev-physiol-030212-183708; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; LIPPMAN ME, 1975, NATURE, V256, P592, DOI 10.1038/256592a0; Liu F, 2020, NUCLEIC ACIDS RES, V48, P2956, DOI 10.1093/nar/gkaa065; Lupien M, 2009, MOL CELL BIOL, V29, P3413, DOI 10.1128/MCB.00020-09; Maldonado MD, 2018, CANCER RES, V78, P3101, DOI 10.1158/0008-5472.CAN-18-0619; Nagase M, 2013, NAT REV NEPHROL, V9, P86, DOI 10.1038/nrneph.2012.282; Narumiya S, 2018, FEBS LETT, V592, P1763, DOI 10.1002/1873-3468.13087; Navarro-Lerida I, 2015, DEV CELL, V32, P318, DOI 10.1016/j.devcel.2014.12.019; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nonclercq D, 2004, MOL CELL ENDOCRINOL, V227, P53, DOI 10.1016/j.mce.2004.07.003; Oesterreich S, 2001, CANCER RES, V61, P5771; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Paulsen MT, 2013, P NATL ACAD SCI USA, V110, P2240, DOI 10.1073/pnas.1219192110; Payapilly A, 2018, CURR OPIN CELL BIOL, V54, P50, DOI 10.1016/j.ceb.2018.04.009; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Reinbolt RE, 2015, SEMIN ONCOL NURS, V31, P146, DOI 10.1016/j.soncn.2015.02.002; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rosenblatt AE, 2011, ENDOCR-RELAT CANCER, V18, P207, DOI 10.1677/ERC-10-0049; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shen L, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-284; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sugihara K, 1998, ONCOGENE, V17, P3427, DOI 10.1038/sj.onc.1202595; Szostakowska M, 2019, BREAST CANCER RES TR, V173, P489, DOI 10.1007/s10549-018-5023-4; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Walker MP, 2011, ONCOGENE, V30, P1984, DOI 10.1038/onc.2010.583; Yang CF, 2006, MOL CELL BIOL, V26, P831, DOI 10.1128/MCB.26.3.831-842.2006; Yi P, 2017, MOL CELL, V67, P733, DOI 10.1016/j.molcel.2017.07.026; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	61	1	1	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5950	5962		10.1038/s41388-021-01985-1	http://dx.doi.org/10.1038/s41388-021-01985-1		AUG 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34373577	hybrid, Green Published			2022-12-17	WOS:000683273100001
J	Zhang, Y; Yan, Q; Gong, LQ; Xu, H; Liu, BL; Fang, XN; Yu, DD; Li, L; Wei, T; Wang, Y; Wong, CN; Lyu, Z; Tang, Y; Sham, PC; Guan, XY				Zhang, Yu; Yan, Qian; Gong, Lanqi; Xu, Hang; Liu, Beilei; Fang, Xiaona; Yu, Dandan; Li, Lei; Wei, Ting; Wang, Ying; Wong, Ching Ngar; Lyu, Zhaojie; Tang, Ying; Sham, Pak Chung; Guan, Xin-Yuan			C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism (vol 40, pg 1147, 2021)	ONCOGENE			English	Correction												xyguan@hku.hk						Zhang Y, 2021, ONCOGENE, V40, P1147, DOI 10.1038/s41388-020-01593-5	1	1	1	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5451	5453		10.1038/s41388-021-01942-y	http://dx.doi.org/10.1038/s41388-021-01942-y		JUL 2021	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34312489	Green Published, hybrid			2022-12-17	WOS:000678988300001
J	Kanumuri, R; Chelluboyina, AK; Biswal, J; Vignesh, R; Pandian, J; Venu, A; Vaishnavi, B; Leena, DJ; Jeyaraman, J; Ganesan, K; Aradhyam, GK; Venkatraman, G; Rayala, SK				Kanumuri, Rahul; Chelluboyina, Aruna Kumar; Biswal, Jayashree; Vignesh, Ravichandran; Pandian, Jaishree; Venu, Akkanapally; Vaishnavi, B.; Leena, D. J.; Jeyaraman, Jeyakanthan; Ganesan, Kumaresan; Aradhyam, Gopala Krishna; Venkatraman, Ganesh; Rayala, Suresh K.			Small peptide inhibitor from the sequence of RUNX3 disrupts PAK1-RUNX3 interaction and abrogates its phosphorylation-dependent oncogenic function	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; STRUCTURE PREDICTION; PEP-FOLD; PROTEIN; EXPRESSION; CELLS; APOPTOSIS; REVERSES; GROWTH; SERVER	P21 Activated Kinase 1 (PAK1) is an oncogenic serine/threonine kinase known to play a significant role in the regulation of cytoskeleton and cell morphology. Runt-related transcription factor 3 (RUNX3) was initially known for its tumor suppressor function, but recent studies have reported the oncogenic role of RUNX3 in various cancers. Previous findings from our laboratory provided evidence that Threonine 209 phosphorylation of RUNX3 acts as a molecular switch in dictating the tissue-specific dualistic functions of RUNX3 for the first time. Based on these proofs and to explore the translational significance of these findings, we designed a small peptide (RMR) from the protein sequence of RUNX3 flanking the Threonine 209 phosphorylation site. The selection of this specific peptide from multiple possible peptides was based on their binding energies, hydrogen bonding, docking efficiency with the active site of PAK1 and their ability to displace PAK1-RUNX3 interaction in our prediction models. We found that this peptide is stable both in in vitro and in vivo conditions, not toxic to normal cells and inhibits the Threonine 209 phosphorylation in RUNX3 by PAK1. We also tested the efficacy of this peptide to block the RUNX3 Threonine 209 phosphorylation mediated tumorigenic functions in in vitro cell culture models, patient-derived explant (PDE) models and in in vivo tumor xenograft models. These results proved that this peptide has the potential to be developed as an efficient therapeutic molecule for targeting RUNX3 Threonine 209 phosphorylation-dependent tumor phenotypes.	[Kanumuri, Rahul; Chelluboyina, Aruna Kumar; Vignesh, Ravichandran; Aradhyam, Gopala Krishna; Rayala, Suresh K.] Indian Inst Technol Madras IITM, Dept Biotechnol, Chennai, Tamil Nadu, India; [Kanumuri, Rahul; Venu, Akkanapally; Vaishnavi, B.; Venkatraman, Ganesh] Sri Ramachandra Inst Higher Educ & Res Deemed Uni, Dept Human Genet, Sri Ramachandra Fac Biomed Sci & Technol, Chennai, Tamil Nadu, India; [Biswal, Jayashree; Jeyaraman, Jeyakanthan] Alagappa Univ, Dept Bioinformat, Struct Biol & Biocomp Lab, Sci Block, Karaikkudi, Tamil Nadu, India; [Pandian, Jaishree; Ganesan, Kumaresan] Madurai Kamaraj Univ, Unit Excellence Canc Genet, Dept Genet, Ctr Excellence Genom Sci,Sch Biol Sci, Madurai, Tamil Nadu, India; [Leena, D. J.] Sri Ramachandra Inst Higher Educ & Res Deemed Uni, Dept Pathol, Chennai, Tamil Nadu, India; [Chelluboyina, Aruna Kumar] Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Case Comprehens Canc Ctr, Cleveland, OH USA	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Madras; Sri Ramachandra Institute of Higher Education & Research; Alagappa University; Madurai Kamaraj University; Sri Ramachandra Institute of Higher Education & Research; Case Western Reserve University	Rayala, SK (corresponding author), Indian Inst Technol Madras IITM, Dept Biotechnol, Chennai, Tamil Nadu, India.; Venkatraman, G (corresponding author), Sri Ramachandra Inst Higher Educ & Res Deemed Uni, Dept Human Genet, Sri Ramachandra Fac Biomed Sci & Technol, Chennai, Tamil Nadu, India.	ganeshv@sriramachandra.edu.in; rayala@iitm.ac.in	CHELLUBOYINA, ARUNA KUMAR/GZL-7536-2022; Kanumuri, Rahul Sankrityayan/AGF-8012-2022; CHELLUBOYINA, ARUNA KUMAR/GXG-8165-2022	CHELLUBOYINA, ARUNA KUMAR/0000-0001-7201-3810; Kanumuri, Rahul Sankrityayan/0000-0001-6039-461X; CHELLUBOYINA, ARUNA KUMAR/0000-0001-7201-3810; , Ravichandran Vignesh/0000-0001-7024-6717	DAE-BRNS [35/14/41/2014-BRNS/2045]; DBT Government of India [BT/PR14340/NNT/28/860/2015]; DST-INDO TAIWAN [GITA/DST/TWN/P-86/2019]; Board of Research in Nuclear Sciences (BRNS) [35/14/02/2018 BRNS/35009]; DST-Fund for Improvement of S&T Infrastructure in Universities & Higher Educational Institutions (FIST) [SR/FST/LSI-667/2016]; DST-Promotion of University Research and Scientific Excellence (PURSE) [SR/PURSE Phase 2/38 (G)]; UGC OBC National Fellowship [F./2015-16/NFO-2015-17-OBC-PON-29027]	DAE-BRNS(Department of Atomic Energy (DAE)Board of Research in Nuclear Sciences (BRNS)); DBT Government of India(Department of Biotechnology (DBT) India); DST-INDO TAIWAN; Board of Research in Nuclear Sciences (BRNS)(Department of Atomic Energy (DAE)Board of Research in Nuclear Sciences (BRNS)); DST-Fund for Improvement of S&T Infrastructure in Universities & Higher Educational Institutions (FIST); DST-Promotion of University Research and Scientific Excellence (PURSE); UGC OBC National Fellowship	The authors thank Dr. Sanjay kumar and Franklin, Department of Biotechnology, Christian Medical College, Vellore, India for helping in peptide uptake studies using animal imaging. We thank Dr. Vidhyarani Shyamsunder, Balaji Dental College, India for the help in establishing Head & Neck PDE model. We thank Bamdeb Patra, Khwajah Mohinudeen, Dr. Ram Prasad, and Srikanth Swamy Swaroop, Indian Institute of Technology-Madras, India for helping in Flow-cytometry experiments, Mass spectrometry experiment, Serum stability assay and for protein expression study, respectively. We thank Dr. Yogesh and Anand, Centre for Toxicology and Developmental Research (CEFT), Sri Ramachandra Institute of Higher Education and Research, India for animal studies. We thank DAE-BRNS (35/14/41/2014-BRNS/2045), DBT (BT/PR14340/NNT/28/860/2015) Government of India for financial support to SKR and the Department of Biotechnology, Indian Institute of Technology Madras (IITM) for infrastructural facilities. JJ thank the DST-INDO TAIWAN (GITA/DST/TWN/P-86/2019 dated: 04.03.2020), Board of Research in Nuclear Sciences (BRNS) (35/14/02/2018 BRNS/35009), DST-Fund for Improvement of S&T Infrastructure in Universities & Higher Educational Institutions (FIST) (SR/FST/LSI-667/2016) (C), DST-Promotion of University Research and Scientific Excellence (PURSE) (No. SR/PURSE Phase 2/38 (G), 2017 and JB is grateful to the UGC OBC National Fellowship (F./2015-16/NFO-2015-17-OBC-PON-29027).	Aljohani AI, 2020, BREAST CANCER RES TR, V181, P541, DOI 10.1007/s10549-020-05646-x; Alqaeisoom N, 2019, INT J PEPT RES THER, V25, P447, DOI 10.1007/s10989-018-9689-6; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049; Beard H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082849; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bird GH, 2010, P NATL ACAD SCI USA, V107, P14093, DOI 10.1073/pnas.1002713107; Cao LQ, 2019, MOL MED REP, V19, P5097, DOI 10.3892/mmr.2019.10212; Chen FF, 2016, ONCOL REP, V35, P1227, DOI 10.3892/or.2015.4515; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Coto-Llerena M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00979; Damdinsuren A, 2015, LEUKEMIA RES, V39, P1405, DOI 10.1016/j.leukres.2015.09.009; Solano-Iturri JD, 2020, AGING-US, V12, P10337, DOI 10.18632/aging.103261; Date Y, 2020, MOL CELLS, V43, P176, DOI 10.14348/molcells.2019.0285; DelGiorno KE, 2016, CELL, V25, P289; Deng WM, 2012, ANGIOGENESIS, V15, P71, DOI 10.1007/s10456-011-9244-y; Douchi D, 2015, CANCER LETT, V365, P132, DOI 10.1016/j.canlet.2015.05.023; Eldar-Finkelman H, 2009, CURR PHARM DESIGN, V15, P2463, DOI 10.2174/138161209788682253; Gao L, 2016, ONCOTARGET, V7, P87037, DOI 10.18632/oncotarget.13523; George A, 2010, CANCER BIOMARK, V7, P275, DOI 10.3233/CBM-2010-0191; Goh YM, 2010, J BIOL CHEM, V285, P10122, DOI 10.1074/jbc.M109.071381; He WG, 2007, MOL IMMUNOL, V44, P2850, DOI 10.1016/j.molimm.2007.01.022; Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q; Hu K, 2019, SCI REPORTS, V9, P1, DOI DOI 10.1038/s41598-018-37186-2; Jagadeeshan S, 2016, ANN ONCOL, V27, P1546, DOI 10.1093/annonc/mdw184; Jiang Z, 2010, MOL BIOL REP, V37, P3029, DOI 10.1007/s11033-009-9873-z; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; Kim J, 2008, BONE, V23, P1; Kudo Y, 2011, J CELL BIOCHEM, V112, P387, DOI 10.1002/jcb.22967; Kumar A, 2016, ONCOGENE, V35, P4857, DOI 10.1038/onc.2016.18; Kumar Arun, 2019, Small GTPases, V10, P264, DOI 10.1080/21541248.2017.1322667; Lee ACL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102383; Lee CWL, 2011, GYNECOL ONCOL, V122, P410, DOI 10.1016/j.ygyno.2011.04.044; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Lim KJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066084; Manandhar S, 2018, BMB REP, V51, P174, DOI 10.5483/BMBRep.2018.51.4.033; Mendes O, 2005, CLIN EXP METASTAS, V22, P237, DOI 10.1007/s10585-005-8115-6; Mevel R, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.148296; Moreira IS, 2007, J COMPUT CHEM, V28, P644, DOI 10.1002/jcc.20566; Otvos L, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00062; Pan JY, 2020, CANCER MED-US, V9, P3829, DOI 10.1002/cam4.2898; Powley IR, 2020, BRIT J CANCER, V122, P735, DOI 10.1038/s41416-019-0672-6; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Raines RT, 2015, METHODS MOL BIOL, V1278, P323, DOI 10.1007/978-1-4939-2425-7_19; Raj GV, 2017, ELIFE, V6, DOI 10.7554/eLife.26857; Saboia TM, 2015, ARCH ORAL BIOL, V60, P223, DOI 10.1016/j.archoralbio.2014.10.002; Salto-Tellez M, 2006, ONCOGENE, V25, P7646, DOI 10.1038/sj.onc.1209739; Sauter W, 2008, CANCER EPIDEM BIOMAR, V17, P1127, DOI 10.1158/1055-9965.EPI-07-2840; Selvarajan V, 2017, LEUKEMIA, V31, P2219, DOI 10.1038/leu.2017.40; Shen YM, 2014, J CHEM THEORY COMPUT, V10, P4745, DOI 10.1021/ct500592m; Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018; Sung HJ, 2011, J PROTEOME RES, V10, P1383, DOI 10.1021/pr101154j; Takehara M, 2020, CANCER SCI, V111, P2883, DOI 10.1111/cas.14527; Tanaka S, 2012, INT J CANCER, V131, P2537, DOI 10.1002/ijc.27575; Thangaretnam KP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07482-4; Thevenet P, 2012, NUCLEIC ACIDS RES, V40, pW288, DOI 10.1093/nar/gks419; Tsunematsu T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005892; van Wijnen AJ, 2008, BONE, V23, P1; van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014; Voon DCC, 2012, STEM CELLS, V30, P2088, DOI 10.1002/stem.1183; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Zagani R, 2015, ONCOTARGET, V6, P28282, DOI 10.18632/oncotarget.5061; Zhang XL, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0029084, 10.1371/journal.pone.0031868]; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40	66	1	1	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5327	5341		10.1038/s41388-021-01927-x	http://dx.doi.org/10.1038/s41388-021-01927-x		JUL 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34253860				2022-12-17	WOS:000672308900001
J	Majhi, PD; Griner, NB; Mayfield, JA; Compton, S; Kane, JJ; Baptiste, TA; Dunphy, KA; Roberts, AL; Schneider, SS; Savage, EM; Patel, D; Blackburn, AC; Maurus, KJ; Wiesmuller, L; Jerry, DJ				Majhi, Prabin Dhangada; Griner, Nicholas B.; Mayfield, Jacob A.; Compton, Shannon; Kane, Jeffrey J.; Baptiste, Trevor A.; Dunphy, Karen A.; Roberts, Amy L.; Schneider, Sallie S.; Savage, Evan M.; Patel, Divyen; Blackburn, Anneke C.; Maurus, Kim Joana; Wiesmueller, Lisa; Jerry, D. Joseph			Genetic modifiers regulating DNA replication and double-strand break repair are associated with differences in mammary tumors in mouse models of Li-Fraumeni syndrome	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY GENES; CANCER; RADIATION; MICE; P53; APOPTOSIS; TUMORIGENESIS; MUTATION; ALLELES	Breast cancer is the most common tumor among women with inherited variants in the TP53 tumor suppressor, but onset varies widely suggesting interactions with genetic or environmental factors. Rodent models haploinsufficent for Trp53 also develop a wide variety of malignancies associated with Li-Fraumeni syndrome, but BALB/c mice are uniquely susceptible to mammary tumors and is genetically linked to the Suprmam1 locus on chromosome 7. To define mechanisms that interact with deficiencies in p53 to alter susceptibility to mammary tumors, we fine mapped the Suprmam1 locus in females from an N2 backcross of BALB/cMed and C57BL/6J mice. A major modifier was localized within a 10 cM interval on chromosome 7. The effect of the locus on DNA damage responses was examined in the parental strains and mice that are congenic for C57BL/6J alleles on the BALB/cMed background (SM1-Trp53(+/-)). The mammary epithelium of C57BL/6J-Trp53(+/-) females exhibited little radiation-induced apoptosis compared to BALB/cMed-Trp53(+/-) and SM1-Trp53(+/-) females indicating that the Suprmam1(B6/B6) alleles could not rescue repair of radiation-induced DNA double-strand breaks mostly relying on non-homologous end joining. In contrast, the Suprmam1(B6/B6) alleles in SM1-Trp53(+/-) mice were sufficient to confer the C57BL/6J-Trp53(+/-) phenotypes in homology-directed repair and replication fork progression. The Suprmam1(B6/B6) alleles in SM1-Trp53(+/-) mice appear to act in trans to regulate a panel of DNA repair and replication genes which lie outside the locus.	[Majhi, Prabin Dhangada; Griner, Nicholas B.; Compton, Shannon; Baptiste, Trevor A.; Dunphy, Karen A.; Roberts, Amy L.; Jerry, D. Joseph] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; [Majhi, Prabin Dhangada] Ravenshaw Univ, Dept Bot, Cuttack, Odisha, India; [Mayfield, Jacob A.] Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, 75 Francis St, Boston, MA 02115 USA; [Kane, Jeffrey J.] Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA; [Schneider, Sallie S.] Univ Massachusetts, Med Sch Baystate, Dept Surg, Springfield, MA USA; [Schneider, Sallie S.; Jerry, D. Joseph] Pioneer Valley Life Sci Inst, Springfield, MA 01199 USA; [Savage, Evan M.; Patel, Divyen] Genome Explorat, Memphis, TN USA; [Blackburn, Anneke C.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT, Australia; [Maurus, Kim Joana; Wiesmueller, Lisa] Ulm Univ, Dept Obstet & Gynecol, Ulm, Germany	University of Massachusetts System; University of Massachusetts Amherst; Ravenshaw University; Harvard University; Brigham & Women's Hospital; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; Australian National University; John Curtin School of Medical Research; Ulm University	Jerry, DJ (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA.; Jerry, DJ (corresponding author), Pioneer Valley Life Sci Inst, Springfield, MA 01199 USA.; Wiesmuller, L (corresponding author), Ulm Univ, Dept Obstet & Gynecol, Ulm, Germany.	lisa.wiesmueller@uni-ulm.de; jjerry@vasci.umass.edu		Roberts, Amy/0000-0003-0178-1737; Mayfield, Jacob/0000-0002-5762-6755; Compton, Shannon/0000-0001-9372-1891	National Institute of Environmental Health Sciences of the National Institutes of Health [R01CA105452, U01ES026140]; Department of Defense [W81XWH-15-1-0217]; Rays of Hope Center for Breast Cancer Research; University Grants Commission (India); German Research Foundation (DFG, Research Training Group 2554); DFG	National Institute of Environmental Health Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Department of Defense(United States Department of Defense); Rays of Hope Center for Breast Cancer Research; University Grants Commission (India)(University Grants Commission, India); German Research Foundation (DFG, Research Training Group 2554)(German Research Foundation (DFG)); DFG(German Research Foundation (DFG))	Research reported in this publication was supported, in part, by the National Institute of Environmental Health Sciences of the National Institutes of Health under award number R01CA105452 (DJJ), U01ES026140 (DJJ, SSS), the Department of Defense under contract #W81XWH-15-1-0217 (DJJ) and the Rays of Hope Center for Breast Cancer Research (DJJ), University Grants Commission (India) for Raman Fellowship for post-doctoral research (PDM) as well as by the German Research Foundation (DFG, Research Training Group 2554 to LW) and by the DFG-funded Graduate School of Molecular Medicine, Ulm University (PhD fellowship to KJM).	Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Amadou A, 2018, CURR OPIN ONCOL, V30, P23, DOI 10.1097/CCO.0000000000000423; Backlund MG, 2001, CANCER RES, V61, P6577; Becker KA, 2005, ONCOGENE, V24, P6345, DOI 10.1038/sj.onc.1208787; Blackburn AC, 2003, CANCER RES, V63, P2364; Blackburn AC, 2007, AM J PATHOL, V170, P2030, DOI 10.2353/ajpath.2007.060512; Bohringer M, 2013, ONCOGENE, V32, P5458, DOI 10.1038/onc.2013.38; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Bowman-Colin C, 2013, P NATL ACAD SCI USA, V110, P8632, DOI 10.1073/pnas.1305362110; Broman KW, 2003, BIOINFORMATICS, V19, P889, DOI 10.1093/bioinformatics/btg112; Chang HHY, 2017, NAT REV MOL CELL BIO, V18, P495, DOI 10.1038/nrm.2017.48; Chen JJ, 1999, CANCER RES, V59, p1752S; Deniz M, 2017, ONCOTARGET, V8, P98660, DOI 10.18632/oncotarget.21720; Didion JP, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-34; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Donehower LA, 2019, CELL REP, V28, P3010, DOI 10.1016/j.celrep.2019.08.061; Dudgeon C, 2014, GENE DEV, V28, P2613, DOI 10.1101/gad.252148.114; Fletcher O, 2011, JNCI-J NATL CANCER I, V103, P425, DOI 10.1093/jnci/djq563; Fortuno C, 2018, HUM MUTAT, V39, P1764, DOI 10.1002/humu.23656; Hansen SA, 2016, DIS MODEL MECH, V9, P1139, DOI 10.1242/dmm.025767; Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jalan M, 2019, CANCERS, V11, DOI 10.3390/cancers11071038; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Karanam K, 2012, MOL CELL, V47, P320, DOI 10.1016/j.molcel.2012.05.052; Keimling M, 2012, FASEB J, V26, P2094, DOI 10.1096/fj.11-200790; Koch JG, 2007, MAMM GENOME, V18, P300, DOI 10.1007/s00335-007-9028-2; Kolishovski G, 2019, MAMM GENOME, V30, P353, DOI 10.1007/s00335-019-09821-4; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li YR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14261-4; Majhi PD, 2020, ENVIRON HEALTH PERSP, V128, DOI 10.1289/EHP5221; Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563; Milne RL, 2016, ENDOCR-RELAT CANCER, V23, pT69, DOI 10.1530/ERC-16-0277; Mori N, 1995, GENOMICS, V30, P553, DOI 10.1006/geno.1995.1276; MORI N, 1995, GENOMICS, V25, P609, DOI 10.1016/0888-7543(95)80001-3; Okayasu R, 2000, CANCER RES, V60, P4342; Ramos EM, 2014, EUR J HUM GENET, V22, P144, DOI 10.1038/ejhg.2013.96; Ratnadiwakara M, 2019, J STEROID BIOCHEM, V188, P48, DOI 10.1016/j.jsbmb.2018.12.004; Sasaki H, 2001, AM J PATHOL, V159, P359, DOI 10.1016/S0002-9440(10)61702-6; Schoenfelder S, 2019, NAT REV GENET, V20, P437, DOI 10.1038/s41576-019-0128-0; Scully R, 2019, NAT REV MOL CELL BIO, V20, P698, DOI 10.1038/s41580-019-0152-0; Snijders AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045394; Tchatchou S, 2010, HUM MUTAT, V31, P60, DOI 10.1002/humu.21134; Ullrich RL, 1996, RADIAT RES, V146, P353, DOI 10.2307/3579468; Wang JR, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S3-S13; Weil MM, 1997, GENOMICS, V45, P626, DOI 10.1006/geno.1997.4999; Weil MM, 2001, GENOMICS, V72, P73, DOI 10.1006/geno.2000.6465; Wendt C, 2019, ACTA ONCOL, V58, P135, DOI 10.1080/0284186X.2018.1529428; Xu J., 2005, CURR PROTOC MOL BIOL; Yan HX, 2012, CARCINOGENESIS, V33, P2001, DOI 10.1093/carcin/bgs238; Yu YJ, 2001, CANCER RES, V61, P1820; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	54	1	1	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					5026	5037		10.1038/s41388-021-01892-5	http://dx.doi.org/10.1038/s41388-021-01892-5		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34183771	Green Accepted			2022-12-17	WOS:000667587200001
J	Shapira, S; Boustanai, I; Kazanov, D; Ben Shimon, M; Fokra, A; Arber, N				Shapira, Shiran; Boustanai, Ilana; Kazanov, Dina; Ben Shimon, Marina; Fokra, Ahmad; Arber, Nadir			Innovative dual system approach for selective eradication of cancer cells using viral-based delivery of natural bacterial toxin-antitoxin system	ONCOGENE			English	Article							MUTANT P53; GENE-THERAPY; MUTATIONS; DNA	The inactivation of p53, a tumor suppressor, and the activation of the RAS oncogene are the most frequent genetic alterations in cancer. We have shown that a unique E. coli MazF-MazE toxin-antitoxin (TA) system can be used for selective and effective eradication of RAS-mutated cancer cells. This out of the box strategy holds great promise for effective cancer treatment and management. We provide proof of concept for a novel platform to selectively eradicate cancer cells using an adenoviral delivery system based on the adjusted natural bacterial system. We generated adenoviral vectors carrying the mazF toxin (pAdEasy-Py4-SV40mP-mCherry-MazF) and the antitoxin mazE (pAdEasy-RGC-SV40mP-MazE-IRES-GFP) under the regulation of RAS and p53, resp. The control vector carries the toxin without the RAS-responsive element (pAdEasy-Delta Py4-SV40mP-mCherry-MazF). In vitro, the mazF-mazE TA system (Py4-SV40mP-mCherry-MazF+RGC-SV40mP-MazE-IRES-GFP) induced massive, dose-dependent cell death, at 69% compared to 19% for the control vector, in a co-infected HCT116 cell line. In vivo, the system caused significant tumor growth inhibition of HCT116 (KRAS(mut)/p53(mut)) tumors at 73 and 65% compared to PBS and Delta PY4 control groups, resp. In addition, we demonstrate 65% tumor growth inhibition in HCT116 (KRAS(mut)/p53(wt)) cells, compared to the other two control groups, indicating a contribution of the antitoxin in blocking system leakage in WT RAS cells. These data provide evidence of the feasibility of using mutations in the p53 and RAS pathway to efficiently kill cancer cells. The platform, through its combination of the antitoxin (mazE) with the toxin (mazF), provides effective protection of normal cells from basal low activity or leakage of mazF.	[Shapira, Shiran; Boustanai, Ilana; Kazanov, Dina; Ben Shimon, Marina; Fokra, Ahmad; Arber, Nadir] Tel Aviv Sourasky Med Ctr, Integrated Canc Prevent Ctr, Tel Aviv, Israel; [Shapira, Shiran; Boustanai, Ilana; Kazanov, Dina; Ben Shimon, Marina; Fokra, Ahmad; Arber, Nadir] Tel Aviv Sourasky Med Ctr, Hlth Promot Ctr, Tel Aviv, Israel; [Shapira, Shiran; Boustanai, Ilana; Fokra, Ahmad; Arber, Nadir] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Arber, N (corresponding author), Tel Aviv Sourasky Med Ctr, Integrated Canc Prevent Ctr, Tel Aviv, Israel.; Arber, N (corresponding author), Tel Aviv Sourasky Med Ctr, Hlth Promot Ctr, Tel Aviv, Israel.; Arber, N (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	nadira@tlvmc.gov.il						Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bykov VJN, 2018, NAT REV CANCER, V18, P89, DOI 10.1038/nrc.2017.109; Crystal RG, 2014, HUM GENE THER, V25, P3, DOI 10.1089/hum.2013.2527; Davis TB, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27584-x; Do PM, 2012, GENE DEV, V26, P830, DOI 10.1101/gad.181685.111; Duffy MJ, 2017, EUR J CANCER, V83, P258, DOI 10.1016/j.ejca.2017.06.023; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Dvory-Sobol H, 2005, BIOMED PHARMACOTHER, V59, pS370, DOI 10.1016/S0753-3322(05)80081-2; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jeng HH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2173; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kodaz H, 2017, EURASIAN J MED ONCOL, V1, P1, DOI 10.14744/ejmo.2017.22931; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Ledford H, 2015, NATURE, V528, P317, DOI 10.1038/528317a; Lee CS, 2017, GENES DIS, V4, P43, DOI 10.1016/j.gendis.2017.04.001; Lisiansky V, 2012, CANCER GENE THER, V19, P862, DOI 10.1038/cgt.2012.73; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Naumov I, 2012, EXP CELL RES, V318, P160, DOI 10.1016/j.yexcr.2011.09.015; Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622; Sagiv E, 2006, GASTROENTEROLOGY, V131, P630, DOI 10.1053/j.gastro.2006.04.028; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shapira S, 2017, ONCOTARGET, V8, P38581, DOI 10.18632/oncotarget.16934; Shima F, 2013, P NATL ACAD SCI USA, V110, P8182, DOI 10.1073/pnas.1217730110; Soussi T, 2015, CELL DEATH DIFFER, V22, P1239, DOI 10.1038/cdd.2015.53; Stites EC, 2018, CPT-PHARMACOMET SYST, V7, P342, DOI 10.1002/psp4.12291; Tomasini P, 2016, ONCOLOGIST, V21, P1450, DOI 10.1634/theoncologist.2015-0084; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; Yue XT, 2017, J MOL BIOL, V429, P1595, DOI 10.1016/j.jmb.2017.03.030; Zenonos K, 2013, WORLD J GASTRO ONCOL, V5, P97, DOI 10.4251/wjgo.v5.i5.97	32	1	1	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					4967	4979		10.1038/s41388-021-01792-8	http://dx.doi.org/10.1038/s41388-021-01792-8		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34172933	Green Published, hybrid			2022-12-17	WOS:000667360400001
J	Alonso-Maranon, J; Villanueva, A; Piulats, JM; Martinez-Iniesta, M; Sole, L; Martin-Liberal, J; Segura, S; Pujol, RM; Iglesias, M; Bigas, A; Gallardo, F; Espinosa, L				Alonso-Maranon, Josune; Villanueva, Alberto; Piulats, Josep Maria; Martinez-Iniesta, Maria; Sole, Laura; Martin-Liberal, Juan; Segura, Sonia; Pujol, Ramon M.; Iglesias, Mar; Bigas, Anna; Gallardo, Fernando; Espinosa, Lluis			Combination of chemotherapy with BRAF inhibitors results in effective eradication of malignant melanoma by preventing ATM-dependent DNA repair	ONCOGENE			English	Article								Invasive malignant melanoma (MM) is an aggressive tumor with no curative therapy in advanced stages. Chemotherapy has not demonstrated its efficacy in MM and current treatment for tumors carrying the most frequent BRAFV600E mutation consists of BRAF inhibitors alone or in combination with MAPK pathway inhibitors. We previously found that BRAF inhibition prevents activation of the DNA-damage repair (DDR) pathway in colorectal cancer thus potentiating the effect of chemotherapy. We now show that different chemotherapy agents inflict DNA damage in MM cells, which is efficiently repaired, associated with activation of the ATM-dependent DDR machinery. Pharmacologic inhibition of BRAF impairs ATM and DDR activation in these cells, leading to sustained DNA damage. Combination treatments involving DNA-damaging agents and BRAF inhibitors increase tumor cell death in vitro and in vivo, and impede MM regrowth after treatment cessation. We propose to reconsider the use of chemotherapy in combination with BRAF inhibitors for MM treatment.	[Alonso-Maranon, Josune; Sole, Laura; Bigas, Anna; Espinosa, Lluis] CIBERONC, Stem Cells & Canc Res Lab IMIM, Barcelona, Spain; [Alonso-Maranon, Josune; Sole, Laura; Pujol, Ramon M.; Bigas, Anna; Gallardo, Fernando; Espinosa, Lluis] Hosp del Mar Med Res Inst IMIM, Canc Res Program, Barcelona, Spain; [Villanueva, Alberto; Martinez-Iniesta, Maria] IDIBELL, Grp Chemoresistance & Predict Factors, Subprogram Canc Therapeut Resistance ProCURE, ICO,Oncobell Program, Barcelona, Spain; [Piulats, Josep Maria; Martin-Liberal, Juan] CIBERONC, Med Oncol Dept, Catalan Inst Canc ICO, IDIBELL OncoBell, Barcelona, Spain; [Segura, Sonia; Pujol, Ramon M.; Gallardo, Fernando] Inst Hosp del Mar Investigac Med IMIM, Dept Dermatol, Barcelona, Spain; [Segura, Sonia; Pujol, Ramon M.; Gallardo, Fernando] Univ Autonoma Barcelona, Barcelona, Spain; [Iglesias, Mar] Univ Autonoma Barcelona, Inst Mar Investigac Med, Dept Pathol, CIBERONC, Barcelona, Spain; [Bigas, Anna] Inst Josep Carreras Leucemia IJC, Barcelona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Catalan Institute of Oncology; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Autonomous University of Barcelona; Autonomous University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC	Bigas, A; Espinosa, L (corresponding author), CIBERONC, Stem Cells & Canc Res Lab IMIM, Barcelona, Spain.; Bigas, A; Gallardo, F; Espinosa, L (corresponding author), Hosp del Mar Med Res Inst IMIM, Canc Res Program, Barcelona, Spain.; Villanueva, A (corresponding author), IDIBELL, Grp Chemoresistance & Predict Factors, Subprogram Canc Therapeut Resistance ProCURE, ICO,Oncobell Program, Barcelona, Spain.; Gallardo, F (corresponding author), Inst Hosp del Mar Investigac Med IMIM, Dept Dermatol, Barcelona, Spain.; Gallardo, F (corresponding author), Univ Autonoma Barcelona, Barcelona, Spain.; Bigas, A (corresponding author), Inst Josep Carreras Leucemia IJC, Barcelona, Spain.	avillanueva@iconcologia.net; abigas@imim.es; fgallardo@parcdesalutmar.cat; lespinosa@imim.es	Piulats, Josep M/F-2862-2019	Piulats, Josep M/0000-0002-3606-1724; Alonso, Josune/0000-0001-6783-5166; Bigas, Anna/0000-0003-4801-6899; Sole Font, Laura/0000-0002-3195-0565; Martinez-Iniesta, Maria/0000-0001-6252-6671	Instituto de Salud Carlos III FEDER [PI19/00013, PI19/01320, PI19/01210]; Generalitat de Catalunya [2017SGR135]; Pla Director d'Oncologia de Catalunya (XBTC); Fundacion hna; Javier Lamas Miralles grant	Instituto de Salud Carlos III FEDER(Instituto de Salud Carlos IIIEuropean Commission); Generalitat de Catalunya(Generalitat de Catalunya); Pla Director d'Oncologia de Catalunya (XBTC); Fundacion hna; Javier Lamas Miralles grant	We want to thank the Bigas' and Espinosa's lab members for constructive discussions and suggestions and technical support. This work was funded by grants from Instituto de Salud Carlos III FEDER PI19/00013 to LE, PI19/01320 to AV and PI19/01210 to JM-L, Generalitat de Catalunya 2017SGR135 and the "Xarxa de Bancs de tumors sponsored by Pla Director d'Oncologia de Catalunya (XBTC) and Fundacion hna to AV research team in the development of orthoxenografts/PDOX. JA-M is a recipient of Javier Lamas Miralles grant.	Buecher B, 2010, FAM CANCER, V9, P663, DOI 10.1007/s10689-010-9379-9; Colombino M, 2012, J CLIN ONCOL, V30, P2522, DOI 10.1200/JCO.2011.41.2452; Colomer C, 2019, MOL CELL, V75, P669, DOI 10.1016/j.molcel.2019.05.036; Colomer C, 2018, BRIT J CANCER, V118, P839, DOI 10.1038/bjc.2017.459; Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Gallardo F, 2015, ONCOTARGET, V6, P9284, DOI 10.18632/oncotarget.3252; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Luke JJ, 2013, CLIN DERMATOL, V31, P290, DOI 10.1016/j.clindermatol.2012.08.016; Luo JL, 2007, NATURE, V446, P690, DOI 10.1038/nature05656; Margalef P, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005886; Margalef P, 2012, CELL REP, V2, P840, DOI 10.1016/j.celrep.2012.08.028; Monahan KB, 2010, ONCOGENE, V29, P5809, DOI 10.1038/onc.2010.314; Nogueira C, 2010, ONCOGENE, V29, P6222, DOI 10.1038/onc.2010.349; Planchard D, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.107; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Robb R, 2019, CLIN CANCER RES, V25, P4749, DOI 10.1158/1078-0432.CCR-18-3625; Schreck KC, 2018, ONCOLOGY-NY, V32, P555; Toll A, 2015, ARCH DERMATOL RES, V307, P721, DOI 10.1007/s00403-015-1579-6; Wilson MA, 2016, CANCER TREAT RES, V167, P209, DOI 10.1007/978-3-319-22539-5_8; Zaman A, 2019, CANCERS, V11, DOI 10.3390/cancers11081197; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982	23	1	1	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					5042	5048		10.1038/s41388-021-01879-2	http://dx.doi.org/10.1038/s41388-021-01879-2		JUN 2021	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34140639				2022-12-17	WOS:000662838900006
J	Snigdha, K; Singh, A; Kango-Singh, M				Snigdha, Kirti; Singh, Amit; Kango-Singh, Madhuri			Yorkie-Cactus (I kappa B alpha)-JNK axis promotes tumor growth and progression in Drosophila	ONCOGENE			English	Article							CELL POLARITY; ONCOGENIC RAS; MATRIX METALLOPROTEINASES; TISSUE OVERGROWTH; IMMUNE-RESPONSE; NECROSIS-FACTOR; HIPPO PATHWAY; JNK; RECEPTOR; CANCER	Presence of inflammatory factors in the tumor microenvironment is well-documented yet their specific role in tumorigenesis is elusive. The core inflammatory pathways like the Toll-Like Receptor (TLR) and the Tumor Necrosis Factor (TNF) pathway are conserved in Drosophila. We induced GFP-marked epithelial tumors by expressing activated oncogenic forms of Ras(V12) or Yorkie (Yki(3SA), mammalian YAP) in scribble deficient cells (scrib(RNAi), mammalian SCRIB) to study the role of inflammatory factors in tumorigenesis. Similar to Ras(V12)scrib(RNAi), we found that Yki(3SA)scrib(RNAi) form invasive neoplastic lethal tumors that induce a systemic inflammatory response. We identified Cactus (Cact, mammalian I kappa B alpha), the negative regulator of TLR, as a key player in tumor growth. Cact accumulates in the cytoplasm in Drosophila tumor models, similar to squamous cell carcinoma in mice models and human patients where cytoplasmic I kappa B alpha favors oncogenic transformation. Further, cact is transcriptionally upregulated in tumors, and downregulation of Cact affects tumor growth. We investigated if TLR or TNF pathway affect tumor growth through activation of Jun N-terminal Kinase (JNK) pathway and its target Matrix Metalloprotease1 (MMP1). Genetically manipulating levels of TLR components or TNF receptors showed that Cact acts upstream of JNK signaling and regulates JNK via a non-canonical mechanism during tumorigenesis. Further, Hippo coactivator Yki transcriptionally regulates cact expression, and downregulation of Yki or Cact is sufficient to cause downregulation of JNK-mediated signaling that promotes tumorigenesis. Here, we report a link between Hippo, I kappa B alpha and JNK signaling that may induce inflammation and innate immune response in tumorigenesis.	[Snigdha, Kirti; Singh, Amit; Kango-Singh, Madhuri] Univ Dayton, Dept Biol, Dayton, OH 45469 USA; [Singh, Amit; Kango-Singh, Madhuri] Univ Dayton, Ctr Tissue Regenerat & Engn Dayton TREND, Dayton, OH 45469 USA; [Singh, Amit; Kango-Singh, Madhuri] Univ Dayton, Premed Programs, Dayton, OH 45469 USA; [Singh, Amit; Kango-Singh, Madhuri] Univ Dayton, Integrat Sci & Engn Ctr ISE, Dayton, OH 45469 USA	University of Dayton; University of Dayton; University of Dayton; University of Dayton	Kango-Singh, M (corresponding author), Univ Dayton, Dept Biol, Dayton, OH 45469 USA.; Kango-Singh, M (corresponding author), Univ Dayton, Ctr Tissue Regenerat & Engn Dayton TREND, Dayton, OH 45469 USA.; Kango-Singh, M (corresponding author), Univ Dayton, Premed Programs, Dayton, OH 45469 USA.; Kango-Singh, M (corresponding author), Univ Dayton, Integrat Sci & Engn Ctr ISE, Dayton, OH 45469 USA.	mkangosingh1@udayton.edu		Kango-Singh, Madhuri/0000-0003-2447-6997; Singh, Amit/0000-0002-2962-2255; SNIGDHA, KIRTI/0000-0002-8618-1628	Graduate Program of University of Dayton; Schuellein Endowed Chair in Biology from University of Dayton; NIH [1R15 GM124654-1, R01CA183991]; University of Dayton	Graduate Program of University of Dayton; Schuellein Endowed Chair in Biology from University of Dayton; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Dayton	We would like to thank the anonymous reviewers for their helpful comments that have helped make this manuscript better. We thank Dr. A. Bergmann, Dr. Stephen Cohen, the Bloomington Drosophila Stock Center, and the Drosophila Studies Hybridoma Bank for flies and antibodies. KS acknowledges the Teaching Assistantship and Graduate Student Summer Fellowship from the Graduate Program of University of Dayton. AS is supported by funding from Start-up research funds, the Schuellein Endowed Chair in Biology from the University of Dayton, and NIH 1R15 GM124654-1. MKS is supported by start-up research funds from the University of Dayton, and a subaward from NIH grant R01CA183991 (PI Nakano).	Andersen DS, 2015, NATURE, V522, P482, DOI 10.1038/nature14298; Arefin B, 2017, G3-GENES GENOM GENET, V7, P2139, DOI 10.1534/g3.117.039487; Atkins M, 2016, CURR BIOL, V26, P2101, DOI 10.1016/j.cub.2016.06.035; Beaucher M, 2007, DEV BIOL, V303, P625, DOI 10.1016/j.ydbio.2006.12.001; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; BIREMBAUT P, 1985, J PATHOL, V145, P283, DOI 10.1002/path.1711450402; Bretscher AJ, 2015, BIOL OPEN, V4, P355, DOI 10.1242/bio.201410595; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Bunker BD, 2015, ELIFE, V4, DOI 10.7554/eLife.03189; Byun PK, 2019, CURR BIOL, V29, P2790, DOI 10.1016/j.cub.2019.07.012; Mulero MC, 2013, CANCER CELL, V24, P151, DOI 10.1016/j.ccr.2013.06.003; Cellurale C, 2011, MOL CELL BIOL, V31, P1565, DOI 10.1128/MCB.01122-10; Chen CL, 2012, P NATL ACAD SCI USA, V109, P484, DOI 10.1073/pnas.1113882109; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Dominguez M, 2014, SEMIN CELL DEV BIOL, V28, P78, DOI 10.1016/j.semcdb.2014.04.012; Enomoto M, 2015, DEV BIOL, V403, P162, DOI 10.1016/j.ydbio.2015.05.001; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; Germani F, 2018, GENETICS, V208, P473, DOI 10.1534/genetics.117.300256; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hauling T, 2014, BIOL OPEN, V3, P250, DOI 10.1242/bio.20146494; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Hong X, 2014, EMBO J, V33, P2447, DOI 10.15252/embj.201489385; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Ito K, 1997, DEVELOPMENT, V124, P761; Kanda H, 2002, J BIOL CHEM, V277, P28372, DOI 10.1074/jbc.C200324200; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Kango-Singh M, 2003, DEV BIOL, V256, P48, DOI 10.1016/S0012-1606(02)00123-9; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kauppila S, 2003, ONCOGENE, V22, P4860, DOI 10.1038/sj.onc.1206715; Kulshammer E, 2015, DIS MODEL MECH, V8, P1279, DOI 10.1242/dmm.020719; La Marca JE, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00042; Liu B, 2016, CELL, V164, P406, DOI 10.1016/j.cell.2015.12.029; Ma X, 2016, ONCOGENE, V35, P846, DOI 10.1038/onc.2015.137; Ma XJ, 2015, P NATL ACAD SCI USA, V112, P1065, DOI 10.1073/pnas.1415020112; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mao YP, 2017, ONCOTARGET, V8, P110877, DOI 10.18632/oncotarget.22865; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Martinelli C, 2005, J ENDOTOXIN RES, V11, P243, DOI 10.1179/09680510SX37411; Mishra-Gorur K, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039727; Morimoto Kenta, 2017, J Vis Exp, DOI 10.3791/55901; Muzzopappa M, 2017, P NATL ACAD SCI USA, V114, pE7291, DOI 10.1073/pnas.1701791114; Villegas SN, 2018, CELL REP, V22, P2541, DOI 10.1016/j.celrep.2018.02.049; Oh H, 2009, DEV BIOL, V335, P188, DOI 10.1016/j.ydbio.2009.08.026; Ohsawa S, 2011, DEV CELL, V20, P315, DOI 10.1016/j.devcel.2011.02.007; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Parisi F, 2014, CELL REP, V6, P855, DOI 10.1016/j.celrep.2014.01.039; Parvy JP, 2019, ELIFE, V8, DOI 10.7554/eLife.45061; Patel PH, 2015, NAT CELL BIOL, V17, P1182, DOI 10.1038/ncb3214; Ramet M, 2002, DEV BIOL, V241, P145, DOI 10.1006/dbio.2001.0502; ROTH S, 1991, DEVELOPMENT, V112, P371; Rudrapatna VA, 2014, ONCOGENE, V33, P2801, DOI 10.1038/onc.2013.232; Shaukat Z, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/369286; Snigdha K, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00085; Sun GP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004324; Sun GP, 2011, DEV BIOL, V350, P139, DOI 10.1016/j.ydbio.2010.11.036; Tournier Cathy, 2013, Genes Cancer, V4, P397, DOI 10.1177/1947601913486349; Tremmel DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067789; Tzou P, 2000, IMMUNITY, V13, P737, DOI 10.1016/S1074-7613(00)00072-8; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Valanne S, 2011, J IMMUNOL, V186, P649, DOI 10.4049/jimmunol.1002302; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Verghese S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047173; Vidal M, 2007, CANCER RES, V67, P10278, DOI 10.1158/0008-5472.CAN-07-1376; Waghmare I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158081; Wang X, 2008, ACTA PHARMACOL SIN, V29, P1275, DOI 10.1111/j.1745-7254.2008.00889.x; Willsey HR, 2016, ELIFE, V5, DOI 10.7554/eLife.11491; Yang CC, 2015, P NATL ACAD SCI USA, V112, P1785, DOI 10.1073/pnas.1420850112; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049	80	1	1	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4124	4136		10.1038/s41388-021-01831-4	http://dx.doi.org/10.1038/s41388-021-01831-4		MAY 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34017079				2022-12-17	WOS:000652439200003
J	Hu, YM; Liu, FF; Jia, XC; Wang, PL; Gu, TX; Liu, H; Liu, TT; Wei, HF; Chen, HY; Zhao, JZ; Yang, R; Chen, YY; Dong, ZG; Liu, KD				Hu, Yamei; Liu, Fangfang; Jia, Xuechao; Wang, Penglei; Gu, Tingxuan; Liu, Hui; Liu, Tingting; Wei, Huifang; Chen, Hanyong; Zhao, Jiuzhou; Yang, Ran; Chen, Yingying; Dong, Zigang; Liu, Kangdong			Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3	ONCOGENE			English	Article							TYROSINE PHOSPHORYLATION; CANCER; ACTIVATION; INHIBITOR; APOPTOSIS; PATHWAY; JAK1	The mortality rate of esophageal squamous cell carcinoma (ESCC) is higher than that of other cancers worldwide owing to a lack of therapeutic targets and related drugs. This study aimed to find new drugs by targeting an efficacious therapeutic target in ESCC patients. Signal transducer and activator of transcription 3 (STAT3) is hyperactive in ESCC. Herein, we identified a novel STAT3 inhibitor, periplogenin, which strongly inhibited phosphorylation of STAT3 at Tyr705. Docking models and pull-down assays revealed that periplogenin bound directly and specifically to STAT3, leading to significant suppression of subsequent dimerization, nuclear import, and transcription activities. In addition, STAT3 knockdown cell lines were insensitive to periplogenin, whereas in contrast, STAT3-overexpressing cells were more sensitive to periplogenin, indicating that STAT3 was a target of periplogenin. Intraperitoneally administered periplogenin exhibited efficacious therapeutic effects in ESCC patient-derived xenograft models and dramatically impaired the phosphorylation of STAT3 and expression levels of STAT3-mediated downstream genes. Thus, our study demonstrated that periplogenin acted as a new STAT3 inhibitor, suppressing the growth of ESCC in vitro and in vivo, providing a basis for its potential application in ESCC treatment and prevention.	[Hu, Yamei; Liu, Fangfang; Jia, Xuechao; Wang, Penglei; Gu, Tingxuan; Liu, Hui; Liu, Tingting; Wei, Huifang; Chen, Yingying; Dong, Zigang; Liu, Kangdong] Zhengzhou Univ, Acad Med Sci, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China; [Hu, Yamei; Liu, Fangfang; Jia, Xuechao; Wang, Penglei; Gu, Tingxuan; Liu, Hui; Liu, Tingting; Wei, Huifang; Yang, Ran; Dong, Zigang; Liu, Kangdong] China US Henan Hormel Canc Inst, Zhengzhou 450008, Henan, Peoples R China; [Liu, Kangdong] Zhengzhou Univ, Prov Cooperat Innovat Ctr Canc Chemoprevent, Zhengzhou, Henan, Peoples R China; [Liu, Kangdong] Canc Chemoprevent Int Collaborat Lab, Zhengzhou, Henan, Peoples R China; [Dong, Zigang; Liu, Kangdong] State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Henan, Peoples R China; [Chen, Hanyong] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Zhao, Jiuzhou] Zhengzhou Univ, Affiliated Canc Hosp, Dept Mol Pathol, Zhengzhou 450008, Henan, Peoples R China	Zhengzhou University; Zhengzhou University; University of Minnesota System; Zhengzhou University	Dong, ZG; Liu, KD (corresponding author), Zhengzhou Univ, Acad Med Sci, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China.; Dong, ZG; Liu, KD (corresponding author), China US Henan Hormel Canc Inst, Zhengzhou 450008, Henan, Peoples R China.; Liu, KD (corresponding author), Zhengzhou Univ, Prov Cooperat Innovat Ctr Canc Chemoprevent, Zhengzhou, Henan, Peoples R China.; Liu, KD (corresponding author), Canc Chemoprevent Int Collaborat Lab, Zhengzhou, Henan, Peoples R China.; Dong, ZG; Liu, KD (corresponding author), State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Henan, Peoples R China.	zgdong@hci-cn.org; kdliu@zzu.edu.cn			National Science Foundation of China [81872335]; Henan Key Science and Technology Program [161100510300]; National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program", China [2018ZX09711002]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Henan Key Science and Technology Program; National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program", China	This work was supported by a grant from the National Science Foundation of China (No. 81872335); Henan Key Science and Technology Program 161100510300; National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program", China (No. 2018ZX09711002). We thank Kyle Vaughn Laster, PhD, from China-US (Henan) Hormel Cancer Institute for polishing parts of this manuscript.	Bai LC, 2019, CANCER CELL, V36, P498, DOI 10.1016/j.ccell.2019.10.002; Banerjee K, 2016, INT J CANCER, V138, P2570, DOI 10.1002/ijc.29923; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buenz EJ, 2018, ANNU REV PHARMACOL, V58, P509, DOI 10.1146/annurev-pharmtox-010617-052703; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chung SY, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0084-z; Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David B, 2015, PHYTOCHEM REV, V14, P299, DOI 10.1007/s11101-014-9367-z; Gadina M, 2018, J LEUKOCYTE BIOL, V104, P499, DOI 10.1002/JLB.5RI0218-084R; Han N, 2010, PLANTA MED, V76, P561, DOI 10.1055/s-0029-1240600; Hindley C, 2013, BIOCHEM J, V451, P135, DOI 10.1042/BJ20121627; Hong D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5272; Horiguchi A, 2010, BRIT J CANCER, V102, P1592, DOI 10.1038/sj.bjc.6605691; Hussain SF, 2007, CANCER RES, V67, P9630, DOI 10.1158/0008-5472.CAN-07-1243; Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Jonker DJ, 2018, LANCET GASTROENTEROL, V3, P263, DOI 10.1016/S2468-1253(18)30009-8; Kato K, 2014, ESOPHAGUS-TOKYO, V11, P183, DOI 10.1007/s10388-014-0427-7; Khazaei S, 2018, INT J CANCER MANAG, V11, DOI 10.5812/ijcm.10059; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112; Li Z, 2019, INT J ANAL CHEM, V2019, DOI 10.1155/2019/1639619; Liu H, 2020, THERANOSTICS, V10, P6201, DOI 10.7150/thno.46137; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Lohberger B, 2018, PHYTOMEDICINE, V51, P162, DOI 10.1016/j.phymed.2018.10.008; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8; Nobili S, 2009, PHARMACOL RES, V59, P365, DOI 10.1016/j.phrs.2009.01.017; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Okines A, 2010, NAT REV CLIN ONCOL, V7, P231, DOI 10.1038/nrclinonc.2010.20; Pan R, 2017, INT J CANCER, V141, P1315, DOI 10.1002/ijc.30825; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Phillips TJ, 2018, BLOOD, V132, P293, DOI 10.1182/blood-2017-10-812701; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Redell MS, 2011, BLOOD, V117, P5701, DOI 10.1182/blood-2010-04-280123; Silva KAS, 2015, J BIOL CHEM, V290, P11177, DOI 10.1074/jbc.M115.641514; Shen ZY, 2002, INT J MOL MED, V10, P641; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Smyth EC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.48; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Spera D, 2007, PLANTA MED, V73, P384, DOI 10.1055/s-2007-967133; Tai WT, 2014, HEPATOLOGY, V59, P190, DOI 10.1002/hep.26640; Van Rompaey L, 2013, J IMMUNOL, V191, P3568, DOI 10.4049/jimmunol.1201348; van Rossum PSN, 2018, NAT REV GASTRO HEPAT, V15, P235, DOI 10.1038/nrgastro.2017.162; Xiong AL, 2014, CANCERS, V6, P926, DOI 10.3390/cancers6020926; Yang JB, 2008, CELL RES, V18, P443, DOI 10.1038/cr.2008.41; Yang YJ, 2021, ANTI-CANCER AGENT ME, V21, P61, DOI 10.2174/1871520620666200708104559; Ye HX, 2020, J BIOMED NANOTECHNOL, V16, P1406, DOI 10.1166/jbn.2020.2978; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yuan Q, 2019, AGING-US, V11, P9530, DOI 10.18632/aging.102402; Zhang HY, 2016, INT J PHARMACEUT, V502, P98, DOI 10.1016/j.ijpharm.2016.02.024; Zhang T, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.305; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	59	1	2	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					3942	3958		10.1038/s41388-021-01817-2	http://dx.doi.org/10.1038/s41388-021-01817-2		MAY 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33986510				2022-12-17	WOS:000650146400001
J	Bajpai, D; Mehdizadeh, S; Uchiyama, A; Inoue, Y; Sawaya, A; Overmiller, A; Brooks, SR; Hasneen, K; Kellett, M; Palazzo, E; Motegi, S; Yuspa, SH; Cataisson, C; Morasso, MI				Bajpai, Deepti; Mehdizadeh, Spencer; Uchiyama, Akihiko; Inoue, Yuta; Sawaya, Andrew; Overmiller, Andrew; Brooks, Stephen R.; Hasneen, Kowser; Kellett, Meghan; Palazzo, Elisabetta; Motegi, Sei-ichiro; Yuspa, Stuart H.; Cataisson, Christophe; Morasso, Maria, I			Loss of DLX3 tumor suppressive function promotes progression of SCC through EGFR-ERBB2 pathway	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; HOMEOBOX GENE-EXPRESSION; TREATED MOUSE EPIDERMIS; SKIN TUMORS; HOX GENES; LUNG-CANCER; KERATIN; DIFFERENTIATION; CARCINOGENESIS; INFLAMMATION	Cutaneous squamous cell carcinoma (cSCC) ranks second in the frequency of all skin cancers. The balance between keratinocyte proliferation and differentiation is disrupted in the pathological development of cSCC. DLX3 is a homeobox transcription factor which plays pivotal roles in embryonic development and epidermal homeostasis. To investigate the impact of DLX3 expression on cSCC prognosis, we carried out clinicopathologic analysis of DLX3 expression which showed statistical correlation between tumors of higher pathologic grade and levels of DLX3 protein expression. Further, Kaplan-Meier survival curve analysis demonstrated that low DLX3 expression correlated with poor patient survival. To model the function of Dlx3 in skin tumorigenesis, a two-stage dimethylbenzanthracene (DMBA)/12-O-tetradecanoylphorbol 13-acetate (TPA) study was performed on mice genetically depleted of Dlx3 in skin epithelium (Dlx3cKO). Dlx3cKO mice developed significantly more tumors, with more rapid tumorigenesis compared to control mice. In Dlx3cKO mice treated only with DMBA, tumors developed after similar to 16 weeks suggesting that loss of Dlx3 has a tumor promoting effect. Whole transcriptome analysis of tumor and skin tissue from our mouse model revealed spontaneous activation of the EGFR-ERBB2 pathway in the absence of Dlx3. Together, our findings from human and mouse model system support a tumor suppressive function for DLX3 in skin and underscore the efficacy of therapeutic approaches that target EGFR-ERBB2 pathway.	[Bajpai, Deepti; Mehdizadeh, Spencer; Sawaya, Andrew; Overmiller, Andrew; Hasneen, Kowser; Kellett, Meghan; Palazzo, Elisabetta; Morasso, Maria, I] NIAMSD, Lab Skin Biol, NIH, Bethesda, MD 20892 USA; [Uchiyama, Akihiko; Inoue, Yuta; Motegi, Sei-ichiro] Gunma Univ, Dept Dermatol, Grad Sch Med, Maebashi, Gumma, Japan; [Brooks, Stephen R.] NIAMSD, Biodata Min & Discovery Sect, NIH, Bethesda, MD 20892 USA; [Yuspa, Stuart H.; Cataisson, Christophe] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Gunma University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Morasso, MI (corresponding author), NIAMSD, Lab Skin Biol, NIH, Bethesda, MD 20892 USA.	morassom@mail.nih.gov	BAJPAI, DEEPTI/AGZ-6770-2022; PALAZZO, ELISABETTA/J-5287-2016	BAJPAI, DEEPTI/0000-0001-5701-8218; PALAZZO, ELISABETTA/0000-0002-0812-5524	Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH [ZIA-AR041124]	Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH (ZIA-AR041124 to MIM). We thank Gutierrez-Cruz and S. Dell'Orso of the NIAMS Genome Analysis Core Facility and members of the NIAMS Light Imaging Core Facility. This work used the computational resources of the NIH High-Performance Computing Biowulf Cluster. We also thank all members of our laboratories for their continuous support. BioRender was used to create experimental design schematic.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Bhattacharya S, 2018, J INVEST DERMATOL, V138, P1052, DOI 10.1016/j.jid.2017.11.033; Cataisson C, 2009, CANCER RES, V69, P319, DOI 10.1158/0008-5472.CAN-08-2490; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; Dahlhoff M, 2017, J INVEST DERMATOL, V137, P921, DOI 10.1016/j.jid.2016.11.023; Dahlhoff M, 2015, MOL ONCOL, V9, P1825, DOI 10.1016/j.molonc.2015.06.007; Dahlhoff M, 2011, EXP DERMATOL, V20, P290, DOI 10.1111/j.1600-0625.2010.01192.x; Darwiche N, 2007, ONCOGENE, V26, P6885, DOI 10.1038/sj.onc.1210491; El-Abaseri TB, 2005, CANCER RES, V65, P3958, DOI 10.1158/0008-5472.CAN-04-2204; Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534; GIMENEZCONTI I, 1990, CARCINOGENESIS, V11, P1995, DOI 10.1093/carcin/11.11.1995; Herbst RS, 2002, CANCER-AM CANCER SOC, V94, P1593, DOI 10.1002/cncr.10372; Hwang J, 2008, DEVELOPMENT, V135, P3149, DOI 10.1242/dev.022202; Hwang J, 2011, P NATL ACAD SCI USA, V108, P11566, DOI 10.1073/pnas.1019658108; Karia PS, 2013, J AM ACAD DERMATOL, V68, P957, DOI 10.1016/j.jaad.2012.11.037; Kiguchi K, 1998, MOL CARCINOGEN, V22, P73, DOI 10.1002/(SICI)1098-2744(199806)22:2<73::AID-MC2>3.3.CO;2-B; Kiguchi K, 2010, CANCER PREV RES, V3, P940, DOI 10.1158/1940-6207.CAPR-10-0010; Lallas A, 2015, BRIT J DERMATOL, V172, P1308, DOI 10.1111/bjd.13510; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo ZF, 2019, CANCERS, V11, DOI 10.3390/cancers11030323; Morasso Maria I., 2005, Birth Defects Research, V75, P163, DOI 10.1002/bdrc.20047; Mueller MM, 2006, EUR J CANCER, V42, P735, DOI 10.1016/j.ejca.2006.01.014; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; Nyati MK, 2006, NAT REV CANCER, V6, P876, DOI 10.1038/nrc1953; Palazzo E, 2016, ONCOGENE, V35, P3114, DOI 10.1038/onc.2015.380; Palazzo E, 2017, CELL DEATH DIFFER, V24, P717, DOI 10.1038/cdd.2017.5; Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857; Que SKT, 2018, J AM ACAD DERMATOL, V78, P237, DOI 10.1016/j.jaad.2017.08.059; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Samuel S, 2005, EUR J CANCER, V41, P2428, DOI 10.1016/j.ejca.2005.08.014; Schneider MR, 2016, ONCOGENE, V35, P2949, DOI 10.1038/onc.2015.372; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Subramanian J, 2019, ONCOLOGIST, V24, pE1303, DOI 10.1634/theoncologist.2018-0845; Sun YQ, 2018, CANCER CELL, V34, P643, DOI 10.1016/j.ccell.2018.08.018; TOFTGARD R, 1985, CANCER RES, V45, P5845; Wheeler DL, 2013, J SKIN CANCER, V2013, DOI 10.1155/2013/971495; Wilker E, 2005, MOL CARCINOGEN, V44, P137, DOI 10.1002/mc.20132; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; Xian WJ, 1997, ONCOGENE, V14, P1435, DOI 10.1038/sj.onc.1200980	44	1	1	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3680	3694		10.1038/s41388-021-01802-9	http://dx.doi.org/10.1038/s41388-021-01802-9		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33947961	Green Accepted			2022-12-17	WOS:000647084500001
J	Kumagai, K; Takanashi, M; Ohno, S; Harada, Y; Fujita, K; Oikawa, K; Sudo, K; Ikeda, S; Nishi, H; Oikawa, K; Kuroda, M				Kumagai, Katsuyoshi; Takanashi, Masakatsu; Ohno, Shin-ichiro; Harada, Yuichirou; Fujita, Koji; Oikawa, Keiki; Sudo, Katsuko; Ikeda, Shun-ichi; Nishi, Hirotaka; Oikawa, Kosuke; Kuroda, Masahiko			WAPL induces cervical intraepithelial neoplasia modulated with estrogen signaling without HPV E6/E7	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS E6; SISTER-CHROMATID COHESION; RECEPTOR-ALPHA; PROGESTERONE-RECEPTOR; CANCER; CARCINOGENESIS; EXPRESSION; ONCOGENE; PROMOTES; SORORIN	Since cervical cancer still afflicts women around the world, it is necessary to understand the underlying mechanism of cervical cancer development. Infection with HPV is essential for the development of cervical intraepithelial neoplasia (CIN). In addition, estrogen receptor signaling is implicated in the development of cervical cancer. Previously, we have isolated human wings apart-like (WAPL), which is expected to cause chromosomal instability in the process of HPV-infected precancerous lesions to cervical cancer. However, the role of WAPL in the development of CIN is still unknown. In this study, in order to elucidate the role of WAPL in the early lesion, we established WAPL overexpressing mice (WAPL Tg mice) and HPV E6/E7 knock-in (KI) mice. WAPL Tg mice developed CIN lesion without HPV E6/E7. Interestingly, in WAPL Tg mice estrogen receptor 1 (ESR1) showed reduction as compared with the wild type, but cell growth factors MYC and Cyclin D1 controlled by ESR1 expressed at high levels. These results suggested that WAPL facilitates sensitivity of ESR1 mediated by some kind of molecule, and as a result, affects the expression of MYC and Cyclin D1 in cervical cancer cells. To detect such molecules, we performed microarray analysis of the uterine cervix in WAPL Tg mice, and focused MACROD1, a co-activator of ESR1. MACROD1 expression was increased in WAPL Tg mice compared with the wild type. In addition, knockdown of WAPL induced the downregulation of MACROD1, MYC, and Cyclin D1 but not ESR1 expression. Furthermore, ESR1 sensitivity assay showed lower activity in WAPL or MACROD1 downregulated cells than control cells. These data suggested that WAPL increases ESR1 sensitivity by activating MACROD1, and induces the expression of MYC and Cyclin D1. Therefore, we concluded that WAPL not only induces chromosomal instability in cervical cancer tumorigenesis, but also plays a key role in activating estrogen receptor signaling in early tumorigenesis.	[Kumagai, Katsuyoshi; Sudo, Katsuko] Tokyo Med Univ, Preclin Res Ctr, Tokyo, Japan; [Takanashi, Masakatsu; Ohno, Shin-ichiro; Harada, Yuichirou; Fujita, Koji; Oikawa, Keiki; Kuroda, Masahiko] Tokyo Med Univ, Dept Mol Pathol, Tokyo, Japan; [Ikeda, Shun-ichi] Kohseichuo Gen Hosp, Dept Obstet & Gynecol, Tokyo, Japan; [Nishi, Hirotaka] Tokyo Med Univ, Dept Obstet & Gynecol, Tokyo, Japan; [Oikawa, Kosuke] Wakayama Med Univ, Dept Pathol, Wakayama, Japan	Tokyo Medical University; Tokyo Medical University; Tokyo Medical University; Wakayama Medical University	Kuroda, M (corresponding author), Tokyo Med Univ, Dept Mol Pathol, Tokyo, Japan.	kuroda@tokyo-med.ac.jp	慎一郎, 大野/AAI-7736-2021	Kuroda, Masahiko/0000-0001-7052-4289; Takanashi, Masakatsu/0000-0002-7127-1153; Ohno, Shin-ichiro/0000-0003-1064-4750	Tokyo Medical University Foundation Cancer Research Fund;  [20K09654]	Tokyo Medical University Foundation Cancer Research Fund; 	We thank Dr. Shouichirou Mineo of Tokyo Medical University and Dr. Shinichi Miyagawa of Tokyo University of Science for their technical assistance and advice regarding the experiments. We appreciate Dr. Tohru Kiyono of the National Cancer Center Research Institute for his donating of pDONR201-16E6E7 vector. This work was partly supported by the Grants-in-Aid for Scientific Research of Education, Culture, Sports, Science and Technology, Japan (MEXT Grant), Grant number: (20K09654 to KK) and the Tokyo Medical University Foundation Cancer Research Fund.	Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chen M, 2019, CANCER SCI, V110, P2794, DOI 10.1111/cas.14140; Chen Q, 2016, ONCOTARGET, V7, P36115, DOI 10.18632/oncotarget.8741; Chen Q, 2014, ONCOTARGET, V5, P9092, DOI 10.18632/oncotarget.2377; Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005; Chung SH, 2009, P NATL ACAD SCI USA, V106, P19467, DOI 10.1073/pnas.0911436106; Chung SH, 2008, CANCER RES, V68, P9928, DOI 10.1158/0008-5472.CAN-08-2051; den Boon JA, 2015, P NATL ACAD SCI USA, V112, pE3255, DOI 10.1073/pnas.1509322112; Duensing S, 2004, INT J CANCER, V109, P157, DOI 10.1002/ijc.11691; Duensing S, 2002, CANCER RES, V62, P7075; Gandhi R, 2006, CURR BIOL, V16, P2406, DOI 10.1016/j.cub.2006.10.061; Goldman JM, 2007, BIRTH DEFECTS RES B, V80, P84, DOI 10.1002/bdrb.20106; Gu TT, 2012, AM J PATHOL, V181, P652, DOI 10.1016/j.ajpath.2012.04.008; Han WD, 2007, ENDOCR-RELAT CANCER, V14, P741, DOI 10.1677/ERC-06-0082; Hara K, 2014, NAT STRUCT MOL BIOL, V21, P864, DOI 10.1038/nsmb.2880; Hong K, 2018, BMB REP, V51, P225, DOI 10.5483/BMBRep.2018.51.5.045; Hong MK, 2017, INT J GYNECOL CANCER, V27, P1247, DOI 10.1097/IGC.0000000000001004; Jin GX, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00147; Kobayashi D, 2011, INT J ONCOL, V38, P933, DOI 10.3892/ijo.2011.929; Kueng S, 2006, CELL, V127, P955, DOI 10.1016/j.cell.2006.09.040; Kurita T, 2010, DIFFERENTIATION, V80, P99, DOI 10.1016/j.diff.2010.06.007; Kuroda M, 2005, BRIT J CANCER, V92, P290, DOI 10.1038/sj.bjc.6602329; Kwasniewska A, 2011, ONCOL REP, V26, P153, DOI 10.3892/or.2011.1256; Ladurner R, 2016, EMBO J, V35, P635, DOI 10.15252/embj.201592532; Li A, 2015, ONCOGENE, V34, P63, DOI 10.1038/onc.2013.529; Li SF, 2007, BIRTH DEFECTS RES B, V80, P246, DOI 10.1002/bdrb.20120; Li XJ, 2012, CHINESE MED J-PEKING, V125, P1695, DOI 10.3760/cma.j.issn.0366-6999.2012.10.004; Li YJ, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1225-6; Masuda S, 2013, NEW ENGL J MED, V369, P1171, DOI 10.1056/NEJMc1308785; Merkwitz C, 2016, LAB ANIM-UK, V50, P344, DOI 10.1177/0023677215617387; Miyagawaa S, 2015, P NATL ACAD SCI USA, V112, P12986, DOI 10.1073/pnas.1513550112; Nam Eun Ji, 2008, J Gynecol Oncol, V19, P162, DOI 10.3802/jgo.2008.19.3.162; Narisawa-Saito M, 2007, CANCER SCI, V98, P1505, DOI 10.1111/j.1349-7006.2007.00546.x; Nishiyama T, 2010, CELL, V143, P737, DOI 10.1016/j.cell.2010.10.031; Ohbayashi T, 2007, BIOCHEM BIOPH RES CO, V356, P699, DOI 10.1016/j.bbrc.2007.03.037; Oikawa K, 2004, CANCER RES, V64, P3545, DOI 10.1158/0008-5472.CAN-03-3822; Riley RR, 2003, CANCER RES, V63, P4862; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shai A, 2007, CANCER RES, V67, P1626, DOI 10.1158/0008-5472.CAN-06-3344; Snijders PJF, 2006, J PATHOL, V208, P152, DOI 10.1002/path.1866; Son J, 2018, J PATHOL, V245, P147, DOI 10.1002/path.5069; Son J, 2014, CARCINOGENESIS, V35, P489, DOI 10.1093/carcin/bgt350; Steenbergen RDM, 2014, NAT REV CANCER, V14, P395, DOI 10.1038/nrc3728; Tian LY, 2009, J ENDOCRINOL, V202, P167, DOI 10.1677/JOE-09-0054; Tsoumpou I, 2009, CANCER TREAT REV, V35, P210, DOI 10.1016/j.ctrv.2008.10.005; Yong KJ, 2016, ONCOTARGET, V7, P75425, DOI 10.18632/oncotarget.12251; Yuan X, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.69; Zang Li, 2018, Cell Physiol Biochem, V51, P2591, DOI 10.1159/000495931; Zhai YL, 2010, AM J PATHOL, V177, P884, DOI 10.2353/ajpath.2010.091166; Zhang NG, 2012, CELL CYCLE, V11, P2073, DOI 10.4161/cc.20241; Zhong PP, 2015, INT J CLIN EXP PATHO, V8, P2979; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	55	1	1	6	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3695	3706		10.1038/s41388-021-01787-5	http://dx.doi.org/10.1038/s41388-021-01787-5		MAY 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33947962	hybrid, Green Published			2022-12-17	WOS:000647084500004
J	Zhang, Q; Tang, Q; Liu, WY; Hu, CP; Liu, XY; Liu, YL; Zhou, M; Lai, WJ; Sheng, FF; Yang, HB; Huang, JB; Li, GB				Zhang, Qian; Tang, Qin; Liu, Wuyi; Hu, Changpeng; Liu, Xiaoyu; Liu, Yali; Zhou, Min; Lai, Wenjing; Sheng, Fangfang; Yang, Haibo; Huang, Jingbin; Li, Guobing			Novel role of CAP1 in regulation RNA polymerase II-mediated transcription elongation depends on its actin-depolymerization activity in nucleoplasm	ONCOGENE			English	Article								Lung cancer is one of the most intractable diseases with high incidence and mortality worldwide. Adenylate cyclase-associated protein 1 (CAP1), a well-known actin depolymerization factor, is recently reported to be an oncogene accelerating cancer cell proliferation. However, the physiological significance of CAP1 in lung cancer is incompletely understood and the novel functions of CAP1 in transcriptional regulation remain unknown. Here we found that CAP1 was highly expressed in lung cancer tissues and cells, which was also negatively associated with prognosis in lung cancer patients. Moreover, CAP1 promoted A549 cells proliferation by promoting protein synthesis to accelerate cell cycle progression. Mechanistically, we revealed that CAP1 facilitated cyclin-dependent kinase 9 (CDK9)-mediated RNA polymerases (Pol) II-Ser2 phosphorylation and subsequent transcription elongation, and CAP1 performed its function in this progress depending on its actin-depolymerization activity in nucleoplasm. Furthermore, our in vivo findings confirmed that CAP1-promoted A549 xenograft tumor growth was associated with CDK9-mediated Pol II-Ser2 phosphorylation. Our study elucidates a novel role of CAP1 in modulating transcription by promoting polymerase II phosphorylation and suggests that CAP1 is a newly identified biomarker for lung cancer treatment and prognosis prediction.	[Zhang, Qian; Tang, Qin; Liu, Wuyi; Hu, Changpeng; Liu, Xiaoyu; Liu, Yali; Zhou, Min; Lai, Wenjing; Sheng, Fangfang; Yang, Haibo; Huang, Jingbin; Li, Guobing] Army Med Univ, Affiliated Hosp 2, Dept Pharm, Chongqing, Peoples R China	Army Medical University	Huang, JB; Li, GB (corresponding author), Army Med Univ, Affiliated Hosp 2, Dept Pharm, Chongqing, Peoples R China.	hjb20091364@126.com; guobingl@126.com		Hu, Changpeng/0000-0002-3033-4023	National Natural Science Foundation of China [81874357]; Youth Talent Project of Army Medical University [2019R050]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Talent Project of Army Medical University	This work was supported by National Natural Science Foundation of China (Grant No. 81874357) and the Youth Talent Project of Army Medical University (Grant No. 2019R050).	Almuzzaini B, 2016, FASEB J, V30, P2860, DOI 10.1096/fj.201600280R; Arimbasseri AG, 2016, TRENDS BIOCHEM SCI, V41, P546, DOI 10.1016/j.tibs.2016.03.003; Bertling E, 2004, MOL BIOL CELL, V15, P2324, DOI 10.1091/mbc.E04-01-0048; Blank HM, 2017, CELL CYCLE, V16, P905, DOI 10.1080/15384101.2017.1312851; Bock FJ, 2015, MOL CELL, V58, P959, DOI 10.1016/j.molcel.2015.01.037; BOGOMOLETZ WV, 1990, EUR J CANCER, V26, P1042, DOI 10.1016/0277-5379(90)90047-W; Brar GA, 2015, NAT REV MOL CELL BIO, V16, P651, DOI 10.1038/nrm4069; Buratowski S, 2009, MOL CELL, V36, P541, DOI 10.1016/j.molcel.2009.10.019; Chen F, 2015, GENE DEV, V29, P39, DOI 10.1101/gad.246173.114; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; Fan HT, 2017, NUCLEIC ACIDS RES, V45, P11043, DOI 10.1093/nar/gkx719; Fomproix N, 2004, EXP CELL RES, V294, P140, DOI 10.1016/j.yexcr.2003.10.028; FREEMAN NL, 1995, J BIOL CHEM, V270, P5680, DOI 10.1074/jbc.270.10.5680; Gieni RS, 2009, BIOCHEM CELL BIOL, V87, P283, DOI 10.1139/O08-133; Gilchrist DA, 2008, GENE DEV, V22, P1921, DOI 10.1101/gad.1643208; Hasan R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112653; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Hoeffer CA, 2011, P NATL ACAD SCI USA, V108, P3383, DOI 10.1073/pnas.1013063108; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; Hu P, 2004, GENE DEV, V18, P3010, DOI 10.1101/gad.1250804; Kolegova ES, 2019, B EXP BIOL MED+, V167, P393, DOI 10.1007/s10517-019-04534-9; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Larsen JE, 2011, CLIN CHEST MED, V32, P703, DOI 10.1016/j.ccm.2011.08.003; Lee MJ, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a005918; Liang H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14771; Liu YH, 2014, PATHOL RES PRACT, V210, P169, DOI 10.1016/j.prp.2013.11.011; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Lu HS, 2018, NATURE, V558, P318, DOI 10.1038/s41586-018-0174-3; Moriyama K, 2002, J CELL SCI, V115, P1591; Obrdlik A, 2011, NUCLEUS-PHILA, V2, P72, DOI 10.4161/nucl.2.1.14508; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Olausson KH, 2014, J BIOL CHEM, V289, P34601, DOI 10.1074/jbc.M114.569244; Pawlus MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072358; Percipalle P, 2006, J CELL BIOL, V172, P967, DOI 10.1083/jcb.200512083; Percipalle P, 2013, NUCLEUS-AUSTIN, V4, P43, DOI 10.4161/nucl.22798; Perez-Ortin JE, 2013, J MOL BIOL, V425, P3750, DOI 10.1016/j.jmb.2013.02.029; Philimonenko VV, 2004, NAT CELL BIOL, V6, P1165, DOI 10.1038/ncb1190; Proudfoot NJ, 2016, SCIENCE, V352, DOI 10.1126/science.aad9926; Qi TY, 2011, J BIOL CHEM, V286, P15171, DOI 10.1074/jbc.M110.184374; Riss TL, 2011, METHODS MOL BIOL, V740, P103, DOI 10.1007/978-1-61779-108-6_12; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Serebryannyy LA, 2016, J CELL SCI, V129, P3412, DOI 10.1242/jcs.195867; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith ER, 2008, P NATL ACAD SCI USA, V105, P8575, DOI 10.1073/pnas.0804379105; Srivastava R, 2015, BIOTECHNOL ADV, V33, P856, DOI 10.1016/j.biotechadv.2015.07.008; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Tan M, 2013, ONCOL REP, V30, P1639, DOI 10.3892/or.2013.2607; Van Der Kelen K, 2009, CRIT REV BIOCHEM MOL, V44, P143, DOI 10.1080/10409230902882090; Vieu E, 2006, NAT CELL BIOL, V8, P650, DOI 10.1038/ncb0706-650; Wang J, 2016, J BIOL CHEM, V291, P25239, DOI 10.1074/jbc.M116.735886; White-Gilbertson S, 2009, MOL ONCOL, V3, P402, DOI 10.1016/j.molonc.2009.05.003; Wu LP, 2003, EUKARYOT CELL, V2, P256, DOI 10.1128/EC.2.2.256-264.2003; Xie SS, 2018, J CANCER, V9, P2825, DOI 10.7150/jca.25993; Yamaguchi K, 2005, J BIOL CHEM, V280, P32569, DOI 10.1074/jbc.M503201200; Ye J, 2008, GENE DEV, V22, P322, DOI 10.1101/gad.455908; Yee NS, 2012, BIOL OPEN, V1, P295, DOI 10.1242/bio.2012539; Yoo YD, 2007, J BIOL CHEM, V282, P7616, DOI 10.1074/jbc.M607596200; Zhang HT, 2013, J BIOL CHEM, V288, P20966, DOI 10.1074/jbc.M113.484535; Zhang YF, 2017, BBA-GENE REGUL MECH, V1860, P246, DOI 10.1016/j.bbagrm.2016.10.010; Zhou Q, 2012, ANNU REV BIOCHEM, V81, P119, DOI 10.1146/annurev-biochem-052610-095910	61	1	1	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3492	3509		10.1038/s41388-021-01789-3	http://dx.doi.org/10.1038/s41388-021-01789-3		APR 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33911205				2022-12-17	WOS:000645202500001
J	Ko, YS; Bae, JA; Kim, KY; Kim, SJ; Sun, EG; Lee, KH; Kim, N; Kang, H; Seo, YW; Kim, H; Chung, IJ; Kim, KK				Ko, Yoo-Seung; Bae, Jeong A.; Kim, Keon Young; Kim, Sung Jin; Sun, Eun Gene; Lee, Kyung Hwa; Kim, Nacksung; Kang, Hyuno; Seo, Young-Woo; Kim, Hangun; Chung, Ik Joo; Kim, Kyung Keun			MYO1D binds with kinase domain of the EGFR family to anchor them to plasma membrane before their activation and contributes carcinogenesis (vol 38, 7416, 2019)	ONCOGENE			English	Correction								A Correction to this paper has been published: https://doi.org/10.1038/s41388-021-01675-y	[Ko, Yoo-Seung; Bae, Jeong A.; Kim, Keon Young; Kim, Sung Jin; Kim, Nacksung; Kim, Kyung Keun] Chonnam Natl Univ Med Sch, Departments Pharmacol, Gwangju, South Korea; [Sun, Eun Gene; Chung, Ik Joo] Chonnam Natl Univ Med Sch, Departments Hematol, Oncology, Gwangju, South Korea; [Lee, Kyung Hwa] Chonnam Natl Univ Med Sch, Departments Pathol, Gwangju, South Korea; [Kang, Hyuno; Seo, Young-Woo] Korea Basic Sci Inst, Gwangju Ctr, Gwangju, South Korea; [Kim, Hangun] Sunchon Natl Univ, Coll Pharm, Sunchon, North Korea	Chonnam National University; Chonnam National University; Chonnam National University; Korea Basic Science Institute (KBSI)	Kim, KK (corresponding author), Chonnam Natl Univ Med Sch, Departments Pharmacol, Gwangju, South Korea.	kimkk@chonnam.ac.kr						Ko YS, 2019, ONCOGENE, V38, P7416, DOI 10.1038/s41388-019-0954-8	1	1	1	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3471	3472		10.1038/s41388-021-01675-y	http://dx.doi.org/10.1038/s41388-021-01675-y		APR 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33883693	Bronze			2022-12-17	WOS:000642072200002
J	Turgu, B; Zhang, F; El-Naggar, A; Negri, GL; Kogler, M; Tortola, L; Johnson, F; Ng, T; Li, A; Yapp, D; Lockwood, W; Martinez, D; Maris, JM; Daugaard, M; Penninger, JM; Hughes, CS; Sorensen, PH				Turgu, Busra; Zhang, Fan; El-Naggar, Amal; Negri, Gian Luca; Kogler, Melanie; Tortola, Luigi; Johnson, Fraser; Ng, Tony; Li, Amy; Yapp, Donald; Lockwood, William; Martinez, Daniel; Maris, John M.; Daugaard, Mads; Penninger, Josef M.; Hughes, Christopher S.; Sorensen, Poul H.			HACE1 blocks HIF1 alpha accumulation under hypoxia in a RAC1 dependent manner	ONCOGENE			English	Article								Uncovering the mechanisms that underpin how tumor cells adapt to microenvironmental stress is essential to better understand cancer progression. The HACE1 (HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase) gene is a tumor suppressor that inhibits the growth, invasive capacity, and metastasis of cancer cells. However, the direct regulatory pathways whereby HACE1 confers this tumor-suppressive effect remain to be fully elucidated. In this report, we establish a link between HACE1 and the major stress factor, hypoxia-inducible factor 1 alpha (HIF1 alpha). We find that HACE1 blocks the accumulation of HIF1 alpha during cellular hypoxia through decreased protein stability. This property is dependent on HACE1 E3 ligase activity and loss of Ras-related C3 botulinum toxin substrate 1 (RAC1), an established target of HACE1 mediated ubiquitinylation and degradation. In vivo, genetic deletion of Rac1 reversed the increased HIF1 alpha expression observed in Hace1(-/-) mice in murine KRas(G12D)-driven lung tumors. An inverse relationship was observed between HACE1 and HIF1 alpha levels in tumors compared to patient-matched normal kidney tissues, highlighting the potential pathophysiological significance of our findings. Together, our data uncover a previously unrecognized function for the HACE1 tumor suppressor in blocking HIF1 alpha accumulation under hypoxia in a RAC1-dependent manner.	[Turgu, Busra; El-Naggar, Amal; Johnson, Fraser; Li, Amy; Hughes, Christopher S.; Sorensen, Poul H.] British Columbia Canc Res Ctr, Dept Mol Oncol, Vancouver, BC, Canada; [Turgu, Busra] Univ British Columbia, Interdisciplinary Oncol Grad Program, Fac Med, Vancouver, BC, Canada; [Zhang, Fan; Daugaard, Mads] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada; [El-Naggar, Amal; Ng, Tony; Lockwood, William; Sorensen, Poul H.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [El-Naggar, Amal] Menoufia Univ, Dept Pathol, Fac Med, Shibin Al Kawm, Egypt; [Negri, Gian Luca] Canadas Michael Smith Genome Sci Ctr, BC Canc, Vancouver, BC, Canada; [Kogler, Melanie; Tortola, Luigi; Penninger, Josef M.] Austrian Acad Sci, Inst Mol Biotechnol, Vienna, Austria; [Tortola, Luigi] Swiss Fed Inst Technol, Inst Mol Hlth Sci, Dept Biol, Zurich, Switzerland; [Yapp, Donald] British Columbia Canc Res Ctr, Dept Expt Therapeut, Vancouver, BC, Canada; [Lockwood, William] British Columbia Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC, Canada; [Martinez, Daniel] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA; [Maris, John M.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Maris, John M.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA; [Penninger, Josef M.] Univ British Columbia, Life Sci Inst, Dept Med Genet, Vancouver, BC, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia; Egyptian Knowledge Bank (EKB); Menofia University; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Swiss Federal Institutes of Technology Domain; ETH Zurich; British Columbia Cancer Agency; British Columbia Cancer Agency; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of British Columbia	Sorensen, PH (corresponding author), British Columbia Canc Res Ctr, Dept Mol Oncol, Vancouver, BC, Canada.; Sorensen, PH (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada.	psor@mail.ubc.ca	Penninger, Josef M/I-6860-2013; EL-Naggar, Amal/AAE-5565-2022; Daugaard, Mads/Y-6483-2018	Penninger, Josef M/0000-0002-8194-3777; EL-Naggar, Amal/0000-0002-3202-6171; Daugaard, Mads/0000-0001-8383-055X; Negri, Gian Luca/0000-0001-7722-8888; Tortola, Luigi/0000-0002-8480-2080; Turgu, Busra/0000-0002-0207-1115	Canada Institutes of Health Research (CIHR); Michael Smith Foundation for Health Research; CIHR Foundation [FDN-143280]; British Columbia Cancer Foundation; IMBA; Austrian Ministry of Sciences; Austrian Academy of Sciences; European Research Council (ERC) Advanced Grant; Era of Hope Innovator award; Canada 150 Grant; Swiss National Science Foundation [PBEZP3_145993]; Canadian Institutes of Health Research (CIHR) [377771]	Canada Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); CIHR Foundation(Canadian Institutes of Health Research (CIHR)); British Columbia Cancer Foundation; IMBA; Austrian Ministry of Sciences; Austrian Academy of Sciences; European Research Council (ERC) Advanced Grant(European Research Council (ERC)); Era of Hope Innovator award; Canada 150 Grant; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	The authors thank Joan Mathers, Michelle Pollard and Dr Karl Mechtler for helpful discussions; Dr Michael Ohh (University of Toronto) for providing the VHL-null RCC4 cell line; Dr. Thilo Hagen (National University of Singapore) for mutant HIF1 alpha plasmids; and Dr. Peggy Olive (British Columbia Cancer Research Center) for HRE-GFP plasmids. FZ was supported by fellowships from the Canada Institutes of Health Research (CIHR) and the Michael Smith Foundation for Health Research. This work is supported in part by a grant to PHS from CIHR Foundation [Grant#: FDN-143280], and by the British Columbia Cancer Foundation through generous donations from Team Finn and other riders in the Ride to Conquer Cancer. JMP is supported by grants from IMBA, the Austrian Ministry of Sciences, the Austrian Academy of Sciences, a European Research Council (ERC) Advanced Grant, an Era of Hope Innovator award, and a Canada 150 Grant. LT is supported by the Swiss National Science Foundation [Grant#: PBEZP3_145993]. MD is supported by the Canadian Institutes of Health Research (CIHR) [Grant#: 377771].	Acosta MI, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19471-2; Anglesio MS, 2004, HUM MOL GENET, V13, P2061, DOI 10.1093/hmg/ddh215; Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130; Bouzelfen A, 2017, LEUKEMIA RES, V60, P53, DOI 10.1016/j.leukres.2017.06.006; Cardama GA, 2017, INT J ONCOL, V51, P1025, DOI 10.3892/ijo.2017.4093; Castillo-Lluva S, 2013, ONCOGENE, V32, P1735, DOI 10.1038/onc.2012.189; Chen HY, 2013, EMBO MOL MED, V5, P723, DOI 10.1002/emmm.201202140; D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200; Daugaard M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3180; Day GJ, 1998, MOL CELL BIOL, V18, P7444, DOI 10.1128/MCB.18.12.7444; Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205; Diebold I, 2010, ANTIOXID REDOX SIGN, V13, P399, DOI 10.1089/ars.2009.3013; Du J, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0025213, 10.1371/journal.pone.0026204]; Duran RV, 2012, EMBO REP, V13, P121, DOI 10.1038/embor.2011.257; El-Naggar AM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1276-4; El-Naggar AM, 2015, CANCER CELL, V27, P682, DOI 10.1016/j.ccell.2015.04.003; Fernandez CV, 2001, CANCER GENET CYTOGEN, V129, P165, DOI 10.1016/S0165-4608(01)00445-9; Goka ET, 2015, ONCOGENE, V34, P5395, DOI 10.1038/onc.2014.468; Gonzalez N, 2017, CELL SIGNAL, V30, P154, DOI 10.1016/j.cellsig.2016.12.002; Hibi K, 2008, ANTICANCER RES, V28, P1581; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Huang YL, 2010, BLOOD, V115, P1226, DOI 10.1182/blood-2009-05-221275; Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032; Kaluz S, 2008, J CELL BIOCHEM, V104, P536, DOI 10.1002/jcb.21644; Karakashev SV, 2015, CANCER MANAG RES, V7, P253, DOI 10.2147/CMAR.S58285; Katoh H, 2006, J CELL SCI, V119, P56, DOI 10.1242/jcs.02720; Kenneth NS, 2008, BIOCHEM J, V414, P19, DOI 10.1042/BJ20081055; Kim I, 2019, ONCOGENE, V38, P3651, DOI 10.1038/s41388-019-0676-y; Kimbro KS, 2006, ENDOCR-RELAT CANCER, V13, P739, DOI 10.1677/erc.1.00728; Kogler M, 2020, CANCER RES, V80, P3009, DOI 10.1158/0008-5472.CAN-19-2270; Kohn KW, 2004, MOL BIOL CELL, V15, P3042, DOI 10.1091/mbc.E03-12-0897; Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Maldonado MD, 2018, CANCER RES, V78, P3101, DOI 10.1158/0008-5472.CAN-18-0619; Masson N, 2003, J CELL SCI, V116, P3041, DOI 10.1242/jcs.00655; Mettouchi Amel, 2012, Small GTPases, V3, P102, DOI 10.4161/sgtp.19221; Moroz E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005077; Ohh M, 2006, NEOPLASIA, V8, P623, DOI 10.1593/neo.06442; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Qutub AA, 2006, J CELL SCI, V119, P3467, DOI 10.1242/jcs.03087; Rohwer N, 2009, BRIT J CANCER, V100, P772, DOI 10.1038/sj.bjc.6604919; Rosenblatt AE, 2011, ENDOCR-RELAT CANCER, V18, P207, DOI 10.1677/ERC-10-0049; Rundqvist H, 2010, CURR TOP MICROBIOL, V345, P121, DOI 10.1007/82_2010_77; Sakata M, 2009, ANTICANCER RES, V29, P2231; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shuin T, 2006, JPN J CLIN ONCOL, V36, P337, DOI 10.1093/jjco/hyl052; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Slade I, 2010, J MED GENET, V47, P342, DOI 10.1136/jmg.2009.072983; Stewenius Y, 2008, GENE CHROMOSOME CANC, V47, P845, DOI 10.1002/gcc.20587; Sufan RI, 2006, NEOPLASIA, V8, P956, DOI 10.1593/neo.06520; Thelander EF, 2008, LEUKEMIA LYMPHOMA, V49, P477, DOI 10.1080/10428190701817282; Torrino S, 2011, DEV CELL, V21, P959, DOI 10.1016/j.devcel.2011.08.015; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Van Welden S, 2017, NAT REV GASTRO HEPAT, V14, P596, DOI 10.1038/nrgastro.2017.101; Wang YY, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0180-y; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009; Yu ZJ, 2019, ONCOL LETT, V17, P4361, DOI 10.3892/ol.2019.10139; Zhang L, 2007, NAT MED, V13, P1060, DOI 10.1038/nm1621; Zhong H, 2004, CANCER DETECT PREV, V28, P88, DOI 10.1016/j.cdp.2003.12.009	63	1	1	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					1988	2001		10.1038/s41388-021-01680-1	http://dx.doi.org/10.1038/s41388-021-01680-1		FEB 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603169	hybrid, Green Published			2022-12-17	WOS:000619433100001
J	Scalia, P; Pandini, G; Carnevale, V; Giordano, A; Williams, SJ				Scalia, Pierluigi; Pandini, Giuseppe; Carnevale, Vincenzo; Giordano, Antonio; Williams, Stephen J.			Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma (vol 38, pg 5987, 2019)	ONCOGENE			English	Correction												pscalia@isoprog.org	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X					1	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1551	1551		10.1038/s41388-020-01609-0	http://dx.doi.org/10.1038/s41388-020-01609-0		JAN 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452463	hybrid, Green Published			2022-12-17	WOS:000607998600001
J	Zhang, H; Wong, CCL; Wei, H; Gilkes, DM; Korangath, P; Chaturvedi, P; Schito, L; Chen, J; Krishnamachary, B; Winnard, PT; Raman, V; Zhen, L; Mitzner, WA; Sukumar, S; Semenza, GL				Zhang, H.; Wong, C. C. L.; Wei, H.; Gilkes, D. M.; Korangath, P.; Chaturvedi, P.; Schito, L.; Chen, J.; Krishnamachary, B.; Winnard, P. T., Jr.; Raman, V.; Zhen, L.; Mitzner, W. A.; Sukumar, S.; Semenza, G. L.			HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs (vol 31, pg 1757, 2012)	ONCOGENE			English	Correction								A Correction to this paper has been published: https://doi.org/10.1038/s41388-020-01618-z				gsemenza@jhmi.edu	Gilkes, Daniele M/AAI-8133-2020	Gilkes, Daniele M/0000-0003-3984-9338				Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365	1	1	1	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1552	1553		10.1038/s41388-020-01618-z	http://dx.doi.org/10.1038/s41388-020-01618-z		JAN 2021	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452464	Bronze			2022-12-17	WOS:000607998600009
J	Garofalo, M; Quintavalle, C; Di Leva, G; Zanca, C; Romano, G; Taccioli, C; Liu, CG; Croce, CM; Condorelli, G				Garofalo, M.; Quintavalle, C.; Di Leva, G.; Zanca, C.; Romano, G.; Taccioli, C.; Liu, C. G.; Croce, C. M.; Condorelli, G.			MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer (vol 27, pg 3845, 2008)	ONCOGENE			English	Correction								A Correction to this paper has been published: https://doi.org/10.1038/s41388-020-01608-1.				gecondor@unina.it						Garofalo M, 2008, ONCOGENE, V27, P3845, DOI 10.1038/onc.2008.6	1	1	1	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1204	1204		10.1038/s41388-020-01608-1	http://dx.doi.org/10.1038/s41388-020-01608-1		JAN 2021	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33398039	Bronze			2022-12-17	WOS:000604794200001
J	de Pedro, I; Galan-Vidal, J; Freije, A; de Diego, E; Gandarillas, A				de Pedro, Isabel; Galan-Vidal, Jesus; Freije, Ana; de Diego, Ernesto; Gandarillas, Alberto			p21CIP1 controls the squamous differentiation response to replication stress	ONCOGENE			English	Article							CELL-CYCLE EXIT; HUMAN KERATINOCYTES; DNA-REPLICATION; P21 EXPRESSION; MITOTIC EXIT; C-MYC; P53; P21(WAF1/CIP1); CANCER; SKIN	The control of cell fate is critical to homeostasis and cancer. Cell cycle cdk inhibitor p21CIP1 has a central and paradoxical role in the regulatory crossroads leading to senescence, apoptosis, or differentiation. p21 is an essential target of tumor suppressor p53, but it also is regulated independently. In squamous self-renewal epithelia continuously exposed to mutagenesis, p21 controls cell fate by mechanisms still intriguing. We previously identified a novel epidermoid DNA damage-differentiation response. We here show that p21 intervenes in the mitosis block that is required for the squamous differentiation response to cell cycle deregulation and replication stress. The inactivation of endogenous p21 in human primary keratinocytes alleviated the differentiation response to oncogenic loss of p53 or overexpression of the DNA replication major regulator Cyclin E. The bypass of p21-induced mitotic block involving upregulation of Cyclin B allowed DNA damaged cells to escape differentiation and continue to proliferate. In addition, loss of p21 drove keratinocytes from differentiation to apoptosis upon moderate UV irradiation. The results show that p21 is required to drive keratinocytes towards differentiation in response to genomic stress and shed light into its dual and paradoxical role in carcinogenesis.	[de Pedro, Isabel; Galan-Vidal, Jesus; Freije, Ana; de Diego, Ernesto; Gandarillas, Alberto] Inst Res Marques de Valdecilla IDIVAL, Cell Cycle Stem Cell Fate & Canc Lab France Suppl, Santander 39011, Spain; [de Diego, Ernesto] Hosp Univ Marques de Valdecilla, Paediat Surg, Santander 39008, Spain; [Gandarillas, Alberto] INSERM, Languedoc Roussillon, F-34394 Montpellier, France	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Institut National de la Sante et de la Recherche Medicale (Inserm)	Gandarillas, A (corresponding author), Inst Res Marques de Valdecilla IDIVAL, Cell Cycle Stem Cell Fate & Canc Lab France Suppl, Santander 39011, Spain.; Gandarillas, A (corresponding author), INSERM, Languedoc Roussillon, F-34394 Montpellier, France.	agandarillas@idival.org	Vidal, Jesús Galán/AAN-3015-2021	Galan Vidal, Jesus/0000-0001-9105-2401	Instituto de Salud Carlos III/FEDER (AG; Spain) [PI14/00900, PI17/01307]; ISCIII-FEDER [PI1400900]; IFC (Industrial Farmaceutica Cantabria); Asociacion Espanola Contra el Cancer (AECC; Spain) [PRDCA19003GALA]	Instituto de Salud Carlos III/FEDER (AG; Spain); ISCIII-FEDER(Spanish Government); IFC (Industrial Farmaceutica Cantabria); Asociacion Espanola Contra el Cancer (AECC; Spain)	This work was funded by Instituto de Salud Carlos III/FEDER (AG; Spain), grants PI14/00900 and PI17/01307. IdP was in part supported by lab resources, by ISCIII-FEDER PI1400900 and by a scholarship from IFC (Industrial Farmaceutica Cantabria, currently Cantabria Labs; Spain). JG is recipient of a predoctoral scholarship from Asociacion Espanola Contra el Cancer (AECC; Spain), PRDCA19003GALA. We thank Jeannette G. Cook for the doxycycline-inducible Cyclin E construct.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Alonso-Lecue P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.259; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; Aylon Y, 2011, MOL ONCOL, V5, P315, DOI 10.1016/j.molonc.2011.07.007; Borowiec AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077507; Brash DE, 2006, BRIT J DERMATOL, V154, P8, DOI 10.1111/j.1365-2133.2006.07230.x; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; de Pedro I, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1130-8; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; El-Deiry WS, 2016, CANCER RES, V76, P5189, DOI 10.1158/0008-5472.CAN-16-2055; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Freije A, 2012, ONCOGENE, V31, P5180, DOI 10.1038/onc.2012.22; Freije A, 2020, METHODS MOL BIOL, V2109, P113, DOI 10.1007/7651_2019_238; Freije A, 2014, CELL REP, V9, P1349, DOI 10.1016/j.celrep.2014.10.012; Galanos P, 2016, NAT CELL BIOL, V18, P777, DOI 10.1038/ncb3378; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gandarillas A, 2012, CELL CYCLE, V11, P4507, DOI 10.4161/cc.22529; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harvat BL, 1998, J CELL SCI, V111, P1185; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Kolly C, 2005, J INVEST DERMATOL, V124, P1014, DOI 10.1111/j.0022-202X.2005.23655.x; Kreis NN, 2015, ONCOGENE, V34, P1758, DOI 10.1038/onc.2014.133; Kumar MG, 1999, ARCH DERMATOL RES, V291, P37, DOI 10.1007/s004030050381; le Pelletier F, 2001, J INVEST DERMATOL, V117, P1324; Liu M, 1999, J INVEST DERMATOL, V113, P283, DOI 10.1046/j.1523-1747.1999.00657.x; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Matson JP, 2017, ELIFE, V6, DOI 10.7554/eLife.30473; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Molinuevo R, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202001063; Mullers E, 2014, CELL CYCLE, V13, P2733, DOI 10.4161/15384101.2015.945831; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; PONTEN J, 1995, INT J CANCER, V60, P1, DOI 10.1002/ijc.2910600102; Potapova TA, 2006, NATURE, V440, P954, DOI 10.1038/nature04652; Ren ZP, 1997, AM J PATHOL, V150, P1791; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; Ritchie A, 2009, CELL DEATH DIFFER, V16, P838, DOI 10.1038/cdd.2009.13; Sanz-Gomez N, 2020, METHODS MOL BIOL, V2109, P83, DOI 10.1007/7651_2019_237; Sanz-Gomez N, 2020, CELL DEATH DIFFER, V27, P2451, DOI 10.1038/s41418-020-0515-2; Sanz-Gomez N, 2018, HEAD NECK-J SCI SPEC, V40, P2487, DOI 10.1002/hed.25376; SHEA CR, 1992, AM J PATHOL, V141, P25; Teixeira LK, 2017, ADV EXP MED BIOL, V1042, P527, DOI 10.1007/978-981-10-6955-0_22; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Weinberg WC, 2002, CRIT REV ORAL BIOL M, V13, P453, DOI 10.1177/154411130201300603; Yook JI, 1998, ORAL ONCOL, V34, P198, DOI 10.1016/S1368-8375(97)00091-2; Zanet J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015701; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	51	1	1	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					152	162		10.1038/s41388-020-01520-8	http://dx.doi.org/10.1038/s41388-020-01520-8		OCT 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33097856				2022-12-17	WOS:000582109700002
J	Totani, H; Shinjo, K; Suzuki, M; Katsushima, K; Mase, S; Masaki, A; Ito, A; Ri, M; Kusumoto, S; Komatsu, H; Ishida, T; Inagaki, H; Iida, S; Kondo, Y				Totani, Haruhito; Shinjo, Keiko; Suzuki, Miho; Katsushima, Keisuke; Mase, Shoko; Masaki, Ayako; Ito, Asahi; Ri, Masaki; Kusumoto, Shigeru; Komatsu, Hirokazu; Ishida, Takashi; Inagaki, Hiroshi; Iida, Shinsuke; Kondo, Yutaka			Autocrine HGF/c-Met signaling pathway confers aggressiveness in lymph node adult T-cell leukemia/lymphoma	ONCOGENE			English	Article							LEUKEMIA-LYMPHOMA; EXPRESSION; GROWTH; LINE; IDENTIFICATION; MOGAMULIZUMAB; INVOLVEMENT; TAX	Adult T-cell leukemia/lymphoma (ATL) is an aggressive T-cell neoplasm. While ATL cells in peripheral blood (PB-ATL) are sensitive to anti-CC chemokine receptor 4 treatment, non-PB-ATLs, including lymph node ATLs (LN-ATLs), are more aggressive and resistant. We examined characteristic cytokines and growth factors that allow non-PB-ATLs to proliferate and invade compared with PB-ATLs. Protein array analysis revealed hepatocyte growth factor (HGF) and C-C motif chemokine 2 (CCL2) were significantly upregulated in non-PB-ATLs compared with PB-ATLs. The HGF membrane receptor, c-Met, was expressed in PB-ATL and non-PB-ATL cell lines, but CCR2, a CCL2 receptor, was not. Immunohistochemical analysis in clinical ATLs revealed high HGF expression in LNs, pharynx, bone marrow, and tonsils. The HGF/c-Met signaling pathway was active downstream in non-PB-ATLs. Downregulation of HGF/c-Met by siRNA or chemical inhibitors decreased in vitro and in vivo proliferation and invasion by non-PB-ATLs. Treatment with bromodomain and extra-terminal motif inhibitor suppressed HGF expression and decreased levels of histone H3 lysine 27 acetylation (H3K27Ac) and bromodomain-containing protein 4 (BRD4) binding promoter and enhancer regions, suppressing non-PB-ATL cellular growth. Our data indicate H3K27Ac/BRD4 epigenetics regulates the HGF/c-MET pathway in ATLs; targeting this pathway may improve treatment of aggressive non-PB-ATLs.	[Totani, Haruhito; Shinjo, Keiko; Suzuki, Miho; Katsushima, Keisuke; Mase, Shoko; Kondo, Yutaka] Nagoya Univ, Grad Sch Med, Div Canc Biol, Nagoya, Aichi, Japan; [Totani, Haruhito; Masaki, Ayako; Ito, Asahi; Ri, Masaki; Kusumoto, Shigeru; Komatsu, Hirokazu; Iida, Shinsuke] Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Nagoya, Aichi, Japan; [Masaki, Ayako; Inagaki, Hiroshi] Nagoya City Univ, Grad Sch Med Sci, Dept Pathol & Mol Diagnost, Nagoya, Aichi, Japan; [Ri, Masaki] Nagoya City Univ Hosp, Dept Blood Transfus & Cell Therapy, Nagoya, Aichi, Japan; [Ishida, Takashi] Nagoya Univ, Grad Sch Med, Dept Immunol, Nagoya, Aichi, Japan	Nagoya University; Nagoya City University; Nagoya City University; Nagoya City University; Nagoya University	Kondo, Y (corresponding author), Nagoya Univ, Grad Sch Med, Div Canc Biol, Nagoya, Aichi, Japan.	ykondo@med.nagoya-u.ac.jp	katsushima, keisuke/AAD-5945-2019; 石田, 高司/GRS-3184-2022	katsushima, keisuke/0000-0001-7770-432X; 石田, 高司/0000-0002-1060-0777	Japan Society for the Promotion of Science [25290048, 19K16752]; National Cancer Center Research and Development Fund [29-A-3]	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); National Cancer Center Research and Development Fund(National Cancer Center - Japan)	This study was performed as research program with a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (25290048, YK; 19K16752, HT) and the National Cancer Center Research and Development Fund (29-A-3, SI).	Bonanno G, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-247; Choi YL, 2007, ONCOGENE, V26, P1245, DOI 10.1038/sj.onc.1209898; Ding XS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0922-1; Fujikawa D, 2016, BLOOD, V127, P1790, DOI 10.1182/blood-2015-08-662593; Hartmann S, 2016, CLIN CANCER RES, V22, P4005, DOI 10.1158/1078-0432.CCR-16-0951; Hieshima K, 2008, J IMMUNOL, V180, P931, DOI 10.4049/jimmunol.180.2.931; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Imaizumi Y, 2003, CLIN CANCER RES, V9, P181; Ishida T, 2017, CANCER SCI, V108, P2022, DOI 10.1111/cas.13343; Ishida T, 2015, BRIT J HAEMATOL, V169, P672, DOI 10.1111/bjh.13338; Ishida T, 2012, J CLIN ONCOL, V30, P837, DOI 10.1200/JCO.2011.37.3472; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; Katsuya H, 2015, BLOOD, V126, P2570, DOI 10.1182/blood-2015-03-632489; Kwon Y, 2015, ONCOGENE, V34, P144, DOI 10.1038/onc.2013.539; Masaki A, 2015, CLIN CANCER RES, V21, P2830, DOI 10.1158/1078-0432.CCR-14-2275; MIYOSHI I, 1980, GANN, V71, P155; Murashima A, 2019, J BIOCHEM, V166, P41, DOI 10.1093/jb/mvz007; Nakagawa M, 2018, CANCER CELL, V34, P286, DOI 10.1016/j.ccell.2018.06.014; NAOE T, 1988, CANCER GENET CYTOGEN, V34, P77, DOI 10.1016/0165-4608(88)90171-9; Oki S, 2018, EMBO REP, V19, DOI 10.15252/embr.201846255; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Onimaru Y, 2008, INT J ONCOL, V33, P697, DOI 10.3892/ijo_00000055; Oshiro A, 2006, BLOOD, V107, P4500, DOI 10.1182/blood-2005-09-3801; Piekarz RL, 2011, BLOOD, V117, P5827, DOI 10.1182/blood-2010-10-312603; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Rutella S, 2006, BLOOD, V108, P218, DOI 10.1182/blood-2005-08-3141; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Skibinski G, 2001, EUR J CANCER, V37, P1562, DOI 10.1016/S0959-8049(01)00164-2; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; Suzuki S, 2012, CANCER SCI, V103, P1764, DOI 10.1111/j.1349-7006.2012.02371.x; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Umino A, 2011, BLOOD, V117, P5473, DOI 10.1182/blood-2010-12-327791; Xu CH, 2012, HAEMATOL-HEMATOL J, V97, P572, DOI 10.3324/haematol.2011.056101; Yamada Y, 1997, LEUKEMIA LYMPHOMA, V26, P327, DOI 10.3109/10428199709051782; Yamagishi M, 2019, CELL REP, V29, P2321, DOI 10.1016/j.celrep.2019.10.083; Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015; Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505	38	1	1	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5782	5794		10.1038/s41388-020-01393-x	http://dx.doi.org/10.1038/s41388-020-01393-x		AUG 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32747750				2022-12-17	WOS:000555362200001
J	Arnold, JM; Gu, FL; Ambati, CR; Rasaily, U; Ramirez-Pena, E; Joseph, R; Manikkam, M; Martin, RS; Charles, C; Pan, YH; Chatterjee, SS; Den Hollander, P; Zhang, WJ; Nagi, C; Sikora, AG; Rowley, D; Putluri, N; Zhang, XHF; Karanam, B; Mani, SA; Sreekumar, A				Arnold, James M.; Gu, Franklin; Ambati, Chandrashekar R.; Rasaily, Uttam; Ramirez-Pena, Esmeralda; Joseph, Robiya; Manikkam, Mohan; Martin, Rebeca San; Charles, Christy; Pan, Yinghong; Chatterjee, Sujash S.; Den Hollander, Petra; Zhang, Weijie; Nagi, Chandandeep; Sikora, Andrew G.; Rowley, David; Putluri, Nagireddy; Zhang, Xiang H. -F.; Karanam, Balasubramanyam; Mani, Sendurai A.; Sreekumar, Arun			UDP-glucose 6-dehydrogenase regulates hyaluronic acid production and promotes breast cancer progression (Jul, 10.1038/s41388-019-0885-4, 2019)	ONCOGENE			English	Correction												sreekuma@bcm.edu	; Mani, Sendurai/A-7244-2009	Zhang, Weijie/0000-0002-6462-6067; Putluri, Nagireddy/0000-0003-4488-7400; Joseph, Robiya/0000-0003-3214-890X; Mani, Sendurai/0000-0002-5918-4276	NCI NIH HHS [R01 CA216426, R01 CA220297] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnold JM, 2020, ONCOGENE, V39, P3089, DOI 10.1038/s41388-019-0885-4	1	1	2	4	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3226	3228		10.1038/s41388-020-1252-1	http://dx.doi.org/10.1038/s41388-020-1252-1		MAR 2020	3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32214199	Bronze			2022-12-17	WOS:000521526300002
J	Bonetti, P; Climent, M; Panebianco, F; Tordonato, C; Santoro, A; Marzi, MJ; Pelicci, PG; Ventura, A; Nicassio, F				Bonetti, Paola; Climent, Montserrat; Panebianco, Fabiana; Tordonato, Chiara; Santoro, Angela; Marzi, Matteo Jacopo; Pelicci, Pier Giuseppe; Ventura, Andrea; Nicassio, Francesco			Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer (vol 38, pg 360, 2019)	ONCOGENE			English	Correction								An amendment to this paper has been published and can be accessed via a link at the top of the paper.	[Bonetti, Paola; Climent, Montserrat; Panebianco, Fabiana; Marzi, Matteo Jacopo; Nicassio, Francesco] Ist Italiano Tecnol, Ctr Genom Sci IIT SEMM, I-20139 Milan, Italy; [Tordonato, Chiara] FIRC Inst Mol Oncol Fdn, IFOM, I-20139 Milan, Italy; [Santoro, Angela; Pelicci, Pier Giuseppe] European Inst Oncol IRCCS, Dept Expt Oncol, IEO, Via Adamello 16, I-20139 Milan, Italy; [Pelicci, Pier Giuseppe] Univ Milan, Dipartimento Sci Salute, I-20100 Milan, Italy; [Ventura, Andrea] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA	Istituto Italiano di Tecnologia - IIT; IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Milan; Memorial Sloan Kettering Cancer Center	Bonetti, P; Nicassio, F (corresponding author), Ist Italiano Tecnol, Ctr Genom Sci IIT SEMM, I-20139 Milan, Italy.	paola.bonetti@iit.it; francesco.nicassio@iit.it	Pelicci, Pier Giuseppe/AAL-6572-2020; Climent, Montserrat/K-6490-2019	Climent, Montserrat/0000-0002-9029-7914; bonetti, paola/0000-0002-8805-9837; tordonato, chiara/0000-0001-6556-1747; nicassio, francesco/0000-0002-5954-5318				Bonetti P, 2019, ONCOGENE, V38, P360, DOI 10.1038/s41388-018-0445-3	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2228	2228		10.1038/s41388-019-1094-x	http://dx.doi.org/10.1038/s41388-019-1094-x			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31705063	hybrid, Green Published			2022-12-17	WOS:000518584000017
J	Elias, D; Vever, H; Laenkholm, AV; Gjerstorff, MF; Yde, CW; Lykkesfeldt, AE; Ditzel, HJ				Elias, D.; Vever, H.; Laenkholm, A. -V.; Gjerstorff, M. F.; Yde, C. W.; Lykkesfeldt, A. E.; Ditzel, H. J.			Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (vol 34, pg 1919, 2019)	ONCOGENE			English	Correction												delias@health.sdu.dk; hditzel@health.sdu.dk		Laenkholm, Anne-Vibeke/0000-0003-2166-8686				Elias D, 2018, ONCOGENE, V37, P5585, DOI 10.1038/s41388-018-0495-6	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2229	2230		10.1038/s41388-019-1096-8	http://dx.doi.org/10.1038/s41388-019-1096-8			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31712727	Green Published, hybrid			2022-12-17	WOS:000518584000018
J	Kouzi, F; Zibara, K; Bourgeais, J; Picou, F; Gallay, N; Brossaud, J; Dakik, H; Roux, B; Hamard, S; Le Nail, LR; Hleihel, R; Foucault, A; Ravalet, N; Rouleux-Bonnin, F; Gouilleux, F; Mazurier, F; Bene, MC; Akl, H; Gyan, E; Domenech, J; El-Sabban, M; Herault, O				Kouzi, Farah; Zibara, Kazem; Bourgeais, Jerome; Picou, Frederic; Gallay, Nathalie; Brossaud, Julie; Dakik, Hassan; Roux, Benjamin; Hamard, Sophie; Le Nail, Louis-Romee; Hleihel, Rita; Foucault, Amelie; Ravalet, Noemie; Rouleux-Bonnin, Florence; Gouilleux, Fabrice; Mazurier, Frederic; Bene, Marie C.; Akl, Haidar; Gyan, Emmanuel; Domenech, Jorge; El-Sabban, Marwan; Herault, Olivier			Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells (vol 39, pg 1198, 2020)	ONCOGENE			English	Correction								The original version of this Article omitted the following from the Acknowledgements: This research was also supported by grants to KZ (UL and L-CNRS). This has now been corrected in both the PDF and HTML versions of the Article.	[Kouzi, Farah; Bourgeais, Jerome; Picou, Frederic; Gallay, Nathalie; Dakik, Hassan; Roux, Benjamin; Hamard, Sophie; Foucault, Amelie; Ravalet, Noemie; Rouleux-Bonnin, Florence; Gouilleux, Fabrice; Mazurier, Frederic; Gyan, Emmanuel; Domenech, Jorge; Herault, Olivier] CNRS ERL7001 LNOx Leukem Niche & Redox Metab, Tours, France; [Kouzi, Farah; Bourgeais, Jerome; Picou, Frederic; Gallay, Nathalie; Dakik, Hassan; Roux, Benjamin; Hamard, Sophie; Foucault, Amelie; Ravalet, Noemie; Rouleux-Bonnin, Florence; Gouilleux, Fabrice; Mazurier, Frederic; Gyan, Emmanuel; Domenech, Jorge; Herault, Olivier] Univ Tours, Fac Med, EA7501 GICC, Tours, France; [Kouzi, Farah; Zibara, Kazem; Akl, Haidar] Lebanese Univ, PRASE, DSST, Beirut, Lebanon; [Zibara, Kazem; Akl, Haidar] Lebanese Univ, Fac Sci, Biol Dept, Beirut, Lebanon; [Bourgeais, Jerome; Picou, Frederic; Gallay, Nathalie; Roux, Benjamin; Foucault, Amelie; Ravalet, Noemie; Domenech, Jorge; Herault, Olivier] Tours Univ Hosp, Dept Biol Hematol, Tours, France; [Brossaud, Julie] Bordeaux Univ Hosp, Dept Nucl Med, Pessac, France; [Le Nail, Louis-Romee] Tours Univ Hosp, Dept Surg Orthopedia, Tours, France; [Hleihel, Rita; El-Sabban, Marwan] Amer Univ Beirut, Dept Anat Cell Biol & Physiol Sci, Fac Med, Beirut, Lebanon; [Hleihel, Rita] Amer Univ Beirut, Fac Med, Dept Internal Med, Beirut, Lebanon; [Bene, Marie C.] Nantes Univ Hosp, Dept Biol Hematol, CRCINA, Nantes, France; [Gyan, Emmanuel] Tours Univ Hosp, Dept Hematol & Cell Therapy, Tours, France	Universite de Tours; Lebanese University; Lebanese University; CHU Tours; CHU Bordeaux; CHU Tours; American University of Beirut; American University of Beirut; Nantes Universite; CHU de Nantes; CHU Tours	Herault, O (corresponding author), CNRS ERL7001 LNOx Leukem Niche & Redox Metab, Tours, France.; Herault, O (corresponding author), Univ Tours, Fac Med, EA7501 GICC, Tours, France.; Herault, O (corresponding author), Tours Univ Hosp, Dept Biol Hematol, Tours, France.	olivier.herault@univ-tours.fr	Ravalet, Noémie/AAC-7874-2022; Rouleux, Florence/AFT-8675-2022; PICOU, FREDERIC/AAC-4695-2022; Le Nail, Louis-Romée/CAH-0851-2022; Hleihel, Rita/GON-7341-2022	Ravalet, Noémie/0000-0001-5779-337X; PICOU, FREDERIC/0000-0002-2066-2146; Zibara, Kazem/0000-0002-9887-072X; Hamard, Sophie/0000-0002-8537-2713; Foucault, Amelie/0000-0003-4225-2006	UL; L-CNRS	UL; L-CNRS	This research was also supported by grants to KZ (UL and L-CNRS).	Kouzi F, 2020, ONCOGENE, V39, P1198, DOI 10.1038/s41388-019-1069-y	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2227	2227		10.1038/s41388-019-1089-7	http://dx.doi.org/10.1038/s41388-019-1089-7			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31700154	Green Published, hybrid			2022-12-17	WOS:000518584000016
J	Suzuki, N; Idogawa, M; Tange, S; Ohashi, T; Sasaki, Y; Nakase, H; Tokino, T				Suzuki, Natsumi; Idogawa, Masashi; Tange, Shoichiro; Ohashi, Tomoko; Sasaki, Yasushi; Nakase, Hiroshi; Tokino, Takashi			p53-induced ARVCF modulates the splicing landscape and supports the tumor suppressive function of p53	ONCOGENE			English	Article							TRANSCRIPTIONAL TARGET; APOPTOSIS	p53 is one of the most important tumor suppressor genes, and the exploration of p53-target genes is important for elucidation of its functional mechanisms. In this study, we identified Armadillo Repeat gene deleted in Velo-Cardio-Facial syndrome (ARVCF) as a direct target of p53 through ChIP-sequencing analysis. Activated p53 protein was found to bind to two distinct sites in the ARVCF gene, resulting in induction of ARVCF expression at both the mRNA and protein levels. We revealed that the knockdown of ARVCF inhibited p53-induced apoptosis. Interestingly, ARVCF interacted with hnRNPH2, which is involved in pre-mRNA splicing, and ARVCF knockdown induced dynamic changes in alternative splicing patterns. These results suggest that p53-induced ARVCF indirectly, but not directly, regulates p53 target selectivity through splicing alterations of specific genes. Thus, we demonstrated that the induction of ARVCF expression contributed to the tumor suppressive function of p53. Recently, it has been reported that many tumors have thousands of alternative splicing events that are not detectable in normal samples. ARVCF may play a role in alternative splicing events in cancer and may provide clues to explore novel approaches for cancer diagnosis and therapy.	[Suzuki, Natsumi; Idogawa, Masashi; Tange, Shoichiro; Ohashi, Tomoko; Tokino, Takashi] Sapporo Med Univ, Res Inst Frontier Med, Dept Med Genome Sci, Sch Med, Sapporo, Hokkaido, Japan; [Idogawa, Masashi; Nakase, Hiroshi] Sapporo Med Univ, Dept Gastroenterol & Hepatol, Sch Med, Sapporo, Hokkaido, Japan; [Sasaki, Yasushi] Sapporo Med Univ, Ctr Med Educ, Dept Liberal Arts & Sci, Biol, Sapporo, Hokkaido, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University	Idogawa, M; Tokino, T (corresponding author), Sapporo Med Univ, Res Inst Frontier Med, Dept Med Genome Sci, Sch Med, Sapporo, Hokkaido, Japan.; Idogawa, M (corresponding author), Sapporo Med Univ, Dept Gastroenterol & Hepatol, Sch Med, Sapporo, Hokkaido, Japan.	idogawa@sapmed.ac.jp; tokino@sapmed.ac.jp	Nakase, Hiroshi/AAZ-4425-2020; Tange, Shoichiro/AAJ-5265-2020; Idogawa, Masashi/B-5208-2008; Tokino, Takashi/AAI-9887-2021	Tange, Shoichiro/0000-0002-2126-6938; Idogawa, Masashi/0000-0002-8507-1726; Sasaki, Yasushi/0000-0002-3500-8059	JSPS KAKENHI [19K08372, 19K07645, 16K09285, 16K07122]; Takeda Science Foundation	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF))	This work was supported by JSPS KAKENHI (grant numbers: 19K08372, 19K07645, 16K09285, and 16K07122) and Takeda Science Foundation.	Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Chang GS, 2014, CELL REP, V8, P513, DOI 10.1016/j.celrep.2014.06.030; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Idogawa M, 2019, J ONCOL, V2019, DOI 10.1155/2019/4368068; Idogawa M, 2017, INT J CANCER, V140, P2785, DOI 10.1002/ijc.30689; Idogawa M, 2014, ONCOTARGET, V5, P7540, DOI 10.18632/oncotarget.2272; Idogawa M, 2014, HUM MOL GENET, V23, P2847, DOI 10.1093/hmg/ddt673; Idogawa M, 2009, CLIN CANCER RES, V15, P3725, DOI 10.1158/1078-0432.CCR-08-2396; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Katz Y, 2010, NAT METHODS, V7, P1009, DOI 10.1038/NMETH.1528; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; McCrea PD, 2007, BBA-MOL CELL RES, V1773, P17, DOI 10.1016/j.bbamcr.2006.06.009; Ohashi T, 2017, CANCER LETT, V390, P58, DOI 10.1016/j.canlet.2016.12.034; Ohashi T, 2013, MOL CANCER RES, V11, P1554, DOI 10.1158/1541-7786.MCR-13-0330-T; Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196; Rappe U, 2014, J BIOL CHEM, V289, P12421, DOI 10.1074/jbc.M113.530717; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang B, 2014, CELL DEATH DIFFER, V21, P521, DOI 10.1038/cdd.2013.132; Zhang D, 2015, MOL CARCINOGEN, V54, pE185, DOI 10.1002/mc.22281	21	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2202	2211		10.1038/s41388-019-1133-7	http://dx.doi.org/10.1038/s41388-019-1133-7			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31827232				2022-12-17	WOS:000518584000013
J	Guan, CJ; He, L; Chang, ZY; Gu, XJ; Liang, J; Liu, R				Guan, Chengjian; He, Lin; Chang, Zhenyu; Gu, Xinjin; Liang, Jing; Liu, Rong			ZNF774 is a potent suppressor of hepatocarcinogenesis through dampening the NOTCH2 signaling (vol 325, pg 127, 2019)	ONCOGENE			English	Correction															Capital Health Research and Special Development [2016-1-1111]; National Key Technologies RD Program [2015BAI13B09]; Beijing Municipal Administration of Hospitals Incubator Program [PX2016001, PX2019004]; "Miaopu" Innovation Foundation of the Chinese PLA General Hospital [17KMM07]	Capital Health Research and Special Development; National Key Technologies RD Program(National Key Technology R&D Program); Beijing Municipal Administration of Hospitals Incubator Program; "Miaopu" Innovation Foundation of the Chinese PLA General Hospital	This paper was supported by Capital Health Research and Special Development (No. 2016-1-1111), National Key Technologies R&D Program (No. 2015BAI13B09), Beijing Municipal Administration of Hospitals Incubator Program (Nos. PX2016001 and PX2019004) and "Miaopu" Innovation Foundation of the Chinese PLA General Hospital (No. 17KMM07).	Guan CJ, 2020, ONCOGENE, V39, P1665, DOI 10.1038/s41388-019-1075-0	1	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2844	2844		10.1038/s41388-020-1180-0	http://dx.doi.org/10.1038/s41388-020-1180-0		FEB 2020	1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32015484	Bronze			2022-12-17	WOS:000510820900003
J	Barak, AF; Lewinsky, H; Perpinial, M; Huber, V; Radomir, L; Kramer, MP; Sever, L; Wolf, Y; Shapiro, M; Herishanu, Y; Jung, S; Becker-Herman, S; Shachar, I				Barak, Avital F.; Lewinsky, Hadas; Perpinial, Michal; Huber, Victoria; Radomir, Lihi; Kramer, Mattias P.; Sever, Lital; Wolf, Yochai; Shapiro, Mika; Herishanu, Yair; Jung, Steffen; Becker-Herman, Shirly; Shachar, Idit			Bone marrow dendritic cells support the survival of chronic lymphocytic leukemia cells in a CD84 dependent manner	ONCOGENE			English	Article							IMMUNE SUPPRESSION; B-CELLS; RECEPTOR; MICROENVIRONMENT; MONOCYTES; MOUSE; CLL; PATHOGENESIS; APOPTOSIS; DEPLETION	Chronic lymphocytic leukemia (CLL) is a malignancy of mature B lymphocytes. The microenvironment of the CLL cells is a vital element in the regulation of the survival of these malignant cells. CLL cell longevity is dependent on external signals, originating from cells in their microenvironment including secreted and surface-bound factors. Dendritic cells (DCs) play an important part in tumor microenvironment, but their role in the CLL bone marrow (BM) niche has not been studied. We show here that CLL cells induce accumulation of bone marrow dendritic cells (BMDCs). Depletion of this population attenuates disease expansion. Our results show that the support of the microenvironment is partly dependent on CD84, a cell surface molecule belonging to the Signaling Lymphocyte Activating Molecule (SLAM) family of immunoreceptors. Our results suggest a novel therapeutic strategy whereby eliminating BMDCs or blocking the CD84 expressed on these cells may reduce the tumor load.	[Barak, Avital F.; Lewinsky, Hadas; Perpinial, Michal; Huber, Victoria; Radomir, Lihi; Kramer, Mattias P.; Sever, Lital; Wolf, Yochai; Jung, Steffen; Becker-Herman, Shirly; Shachar, Idit] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; [Shapiro, Mika; Herishanu, Yair] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Dept Hematol, Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Shachar, I (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	idit.shachar@weizmann.ac.il	Jung, Steffen/K-1409-2012	Jung, Steffen/0000-0003-4290-5716; Kramer, Matthias P/0000-0002-0289-5261; Wolf, Yochai/0000-0003-0270-2025	DKFZ-MOST cooperation in cancer research; ERA-NET TRANSCAN-2 program JTC 2014-project FIRE-CLL; Binational Science Foundation (BSF) [711979]; Israel Science Foundation	DKFZ-MOST cooperation in cancer research; ERA-NET TRANSCAN-2 program JTC 2014-project FIRE-CLL; Binational Science Foundation (BSF)(US-Israel Binational Science Foundation); Israel Science Foundation(Israel Science Foundation)	The authors wish to thank members of the Shachar lab for fruitful discussion and support. IS is the incumbent of the Dr Morton and Ann Kleiman Professorial Chair. This research was supported by the DKFZ-MOST cooperation in cancer research, ERA-NET TRANSCAN-2 program JTC 2014-project FIRE-CLL and the Binational Science Foundation (BSF) grant no 711979. This research was performed without the support of the Israel Science Foundation.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; BINET JL, 1977, CANCER-AM CANCER SOC, V40, P855, DOI 10.1002/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1; Binsky-Ehrenreich I, 2014, ONCOGENE, V33, P1006, DOI 10.1038/onc.2013.31; Birnberg T, 2008, IMMUNITY, V29, P986, DOI 10.1016/j.immuni.2008.10.012; Brockschniedier D, 2006, GENESIS, V44, P322, DOI 10.1002/dvg.20218; Burger JA, 2007, LEUKEMIA RES, V31, P887, DOI 10.1016/j.leukres.2006.12.004; Cabanas C, 1999, J BIOL REG HOMEOS AG, V13, P134; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Calpe S, 2008, ADV IMMUNOL, V97, P177, DOI 10.1016/S0065-2776(08)00004-7; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Engelhardt JJ, 2012, CANCER CELL, V21, P402, DOI 10.1016/j.ccr.2012.01.008; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; GALE RP, 1994, LEUKEMIA, V8, P1610; Galletti G, 2016, CELL REP, V14, P1748, DOI 10.1016/j.celrep.2016.01.042; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671; Greaves P, 2013, BLOOD, V121, P734, DOI 10.1182/blood-2012-10-385591; Hanna BS, 2016, LEUKEMIA, V30, P570, DOI 10.1038/leu.2015.305; Hofbauer JP, 2011, LEUKEMIA, V25, P1452, DOI 10.1038/leu.2011.111; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Karthaus N, 2012, AM J PATHOL, V181, P733, DOI 10.1016/j.ajpath.2012.05.012; Kipps T J, 1998, Curr Opin Hematol, V5, P244; Klein U, 2010, SEMIN CANCER BIOL, V20, P377, DOI 10.1016/j.semcancer.2010.10.012; Krempski J, 2011, J IMMUNOL, V186, P6905, DOI 10.4049/jimmunol.1100274; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; Lagneaux L, 1998, BLOOD, V91, P2387, DOI 10.1182/blood.V91.7.2387.2387_2387_2396; Lewinsky H, 2018, J CLIN INVEST, V128, P5465, DOI 10.1172/JCI96610; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marom A, 2017, ONCOGENE, V36, P628, DOI 10.1038/onc.2016.238; Martin M, 2001, J IMMUNOL, V167, P3668, DOI 10.4049/jimmunol.167.7.3668; Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016; Montserrat E, 2008, ANN ONCOL, V19, P320, DOI 10.1093/annonc/mdn460; Nicholas NS, 2016, BBA-MOL CELL RES, V1863, P471, DOI 10.1016/j.bbamcr.2015.11.003; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; Ramsay AD, 2013, BRIT J HAEMATOL, V162, P15, DOI 10.1111/bjh.12344; Romero X, 2005, J IMMUNOL, V174, P7033, DOI 10.4049/jimmunol.174.11.7033; Sapoznikov A, 2008, IMMUNOL CELL BIOL, V86, P409, DOI 10.1038/icb.2008.23; Sapoznikov A, 2008, NAT IMMUNOL, V9, P388, DOI 10.1038/ni1571; Saulep-Easton D, 2014, LEUKEMIA, V28, P2005, DOI 10.1038/leu.2014.105; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011; Yan QR, 2007, P NATL ACAD SCI USA, V104, P10583, DOI 10.1073/pnas.0703893104; Yang JY, 2014, BIOMARK RES, V2, DOI 10.1186/2050-7771-2-1; Zlotnikov-Klionsky Y, 2015, IMMUNITY, V43, P776, DOI 10.1016/j.immuni.2015.08.015	48	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1997	2008		10.1038/s41388-019-1121-y	http://dx.doi.org/10.1038/s41388-019-1121-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31772329				2022-12-17	WOS:000516579800013
J	Jin, Y; Bao, H; Le, XN; Fan, XJ; Tang, M; Shi, X; Zhao, J; Yan, JR; Xu, Y; Quek, K; Elamin, YY; Zhang, JH; Futreal, PA; Wistuba, II; Heymach, JV; Lou, GY; Shao, L; He, Q; Lin, C; Wu, X; Shao, YW; Wang, XN; He, JH; Chen, YM; Stebbing, J; Chen, M; Zhang, JJ; Yu, XM				Jin, Ying; Bao, Hua; Le, Xiuning; Fan, Xiaojun; Tang, Ming; Shi, Xun; Zhao, Jun; Yan, Junrong; Xu, Yang; Quek, Kelly; Elamin, Yasir Y.; Zhang, Jianhua; Futreal, P. Andrew; Wistuba, Ignacio I.; Heymach, John V.; Lou, Guangyuan; Shao, Lan; He, Qiong; Lin, Chen; Wu, Xue; Shao, Yang W.; Wang, Xiaonan; He, Jiachen; Chen, Yamei; Stebbing, Justin; Chen, Ming; Zhang, Jianjun; Yu, Xinmin			Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation (vol 39, pg 1846, 2020)	ONCOGENE			English	Correction								The original version of this Article omitted the following from the Acknowledgements: Professor Stebbing sits on SABs for Celltrion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with Lansdowne partners, Vitruvian and Social Impact Capital and Chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare. This has now been corrected in both the PDF and HTML versions of the Article.				chenming@zjcc.org.cn; jzhang20@mdanderson.org; yuxm@zjcc.org.cn	Chen, Ming/GYE-1379-2022	Chen, Ming/0000-0001-5041-9342; Yan, Junrong/0000-0001-9750-7518; Stebbing, Justin/0000-0002-1117-6947	Department of Health [NIHR-RP-011-053] Funding Source: Medline	Department of Health		Jin Y, 2020, ONCOGENE, V39, P1846, DOI 10.1038/s41388-019-1104-z	1	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					2027	2027		10.1038/s41388-019-1143-5	http://dx.doi.org/10.1038/s41388-019-1143-5			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31831835	Bronze			2022-12-17	WOS:000516579800016
J	Marcus, J; Bejerano-Sagie, M; Patterson, N; Bagchi, S; Verkhusha, VV; Connolly, D; Goldberg, GL; Golden, A; Sharma, VP; Condeelis, J; Montagna, C				Marcus, Jenna; Bejerano-Sagie, Michal; Patterson, Nicole; Bagchi, Susmita; Verkhusha, Vladislav V.; Connolly, Diana; Goldberg, Gary L.; Golden, Aaron; Sharma, Ved P.; Condeelis, John; Montagna, Cristina			Septin 9 isoforms promote tumorigenesis in mammary epithelial cells by increasing migration and ECM degradation through metalloproteinase secretion at focal adhesions (vol 38, pg 5839, 2019)	ONCOGENE			English	Correction								The original version of this Article contained an error in the author affiliations. Vladislav V. Verkhusha was incorrectly associated with the School of Mathematics, Statistics & Applied Mathematics, National University of Ireland Galway, Galway, Ireland. The correct affiliation is Anatomy and Structural Biology, Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, USA.	[Marcus, Jenna; Goldberg, Gary L.] Yeshiva Univ, Dept Obstet & Gynecol, Albert Einstein Coll Med, Bronx, NY USA; [Marcus, Jenna; Goldberg, Gary L.] Yeshiva Univ, Dept Womens Hlth, Albert Einstein Coll Med, Bronx, NY USA; [Bejerano-Sagie, Michal; Patterson, Nicole; Bagchi, Susmita; Connolly, Diana; Golden, Aaron; Montagna, Cristina] Yeshiva Univ, Genet, Albert Einstein Coll Med, Bronx, NY 10461 USA; [Verkhusha, Vladislav V.; Sharma, Ved P.; Condeelis, John] Yeshiva Univ, Anat & Struct Biol, Albert Einstein Coll Med, Bronx, NY USA; [Golden, Aaron] Natl Univ Ireland Galway, Sch Math Stat & Appl Math, Galway, Ireland; [Sharma, Ved P.; Condeelis, John] Yeshiva Univ, Gruss Lipper Biophoton Ctr, Albert Einstein Coll Med, Bronx, NY USA; [Montagna, Cristina] Yeshiva Univ, Pathol, Albert Einstein Coll Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Ollscoil na Gaillimhe-University of Galway; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Montagna, C (corresponding author), Yeshiva Univ, Genet, Albert Einstein Coll Med, Bronx, NY 10461 USA.; Montagna, C (corresponding author), Yeshiva Univ, Pathol, Albert Einstein Coll Med, Bronx, NY 10461 USA.	cristina.montagna@einstein.yu.edu	Marcus, Jenna/AAK-7334-2021; Marcus, Jenna/GQP-7232-2022; Verkhusha, Vladislav/AAU-7784-2020	Verkhusha, Vladislav/0000-0002-2083-8121				Marcus J, 2019, ONCOGENE, V38, P5839, DOI 10.1038/s41388-019-0844-0	1	1	1	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1830	1830		10.1038/s41388-019-1039-4	http://dx.doi.org/10.1038/s41388-019-1039-4			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31576012	Bronze			2022-12-17	WOS:000514923000016
J	Szmyd, R; Niska-Blakie, J; Diril, MK; Nunes, PR; Tzelepis, K; Lacroix, A; van Hul, N; Deng, LW; Matos, J; Dreesen, O; Bisteau, X; Kaldis, P				Szmyd, Radoslaw; Niska-Blakie, Joanna; Diril, M. Kasim; Nunes, Patricia Renck; Tzelepis, Konstantinos; Lacroix, Aurelie; van Hul, Noemi; Deng, Lih-Wen; Matos, Joao; Dreesen, Oliver; Bisteau, Xavier; Kaldis, Philipp			Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality (vol 38, pg 998, 2019)	ONCOGENE			English	Correction								An amendment to this paper has been published and can be accessed via a link at the top of the paper.	[van Hul, Noemi] Dokuz Eylul Univ, Izmir Biomed & Genom Ctr, Hlth Campus, TR-35340 Izmir, Turkey	Dokuz Eylul University	van Hul, N (corresponding author), Dokuz Eylul Univ, Izmir Biomed & Genom Ctr, Hlth Campus, TR-35340 Izmir, Turkey.	kaldis@imcb.a-star.edu.sg	Dreesen, Oliver/AAJ-2132-2020; Bisteau, Xavier/Q-7239-2018; Bisteau, Xavier/AAH-6744-2021	Bisteau, Xavier/0000-0002-8896-5098; 				Szmyd R, 2019, ONCOGENE, V38, P998, DOI 10.1038/s41388-018-0464-0	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					2030	2030		10.1038/s41388-019-1114-x	http://dx.doi.org/10.1038/s41388-019-1114-x			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31754212	hybrid, Green Published			2022-12-17	WOS:000516579800019
J	Wang, JY; Nagy, N; Masucci, MG				Wang, Jiayu; Nagy, Noemi; Masucci, Maria G.			The Epstein-Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization (vol 39, pg 603, 2020)	ONCOGENE			English	Correction								This article was originally published under Springer Nature's License to Publish, but has now been made available under a CC BY 4.0 license. The PDF and HTML versions of the paper have been modified accordingly.	[Wang, Jiayu; Nagy, Noemi; Masucci, Maria G.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.	maria.masucci@ki.se		Masucci, Maria/0000-0002-5541-2809				Wang JY, 2020, ONCOGENE, V39, P603, DOI 10.1038/s41388-019-1003-3	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					2028	2028		10.1038/s41388-019-1066-1	http://dx.doi.org/10.1038/s41388-019-1066-1			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31649332	Green Published, hybrid			2022-12-17	WOS:000516579800017
J	Zhou, BJ; Zong, SM; Zhong, WL; Tian, YX; Wang, LM; Zhang, Q; Zhang, RY; Li, L; Wang, W; Zhao, JM; Chen, X; Feng, YJ; Zhai, BH; Sun, T; Liu, YR				Zhou, Bijiao; Zong, Shumin; Zhong, Weilong; Tian, Yixuan; Wang, Lumeng; Zhang, Qian; Zhang, Renya; Li, Lei; Wang, Wei; Zhao, Jianmin; Chen, Xin; Feng, Yaju; Zhai, Binghui; Sun, Tao; Liu, Yanrong			Interaction between laminin-5 gamma 2 and integrin beta 1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins (vol 38, pg 872, 2020)	ONCOGENE			English	Correction									Tianjin Med Univ, Gen Hosp, Dept Gastroenterol & Hepatol, Tianjin 300052, Peoples R China	Tianjin Medical University		sunrockmia@hotmail.com; liuyanrong1984@163.com						Zhou BJ, 2020, ONCOGENE, V39, P1527, DOI 10.1038/s41388-019-1082-1	1	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1617	1617		10.1038/s41388-019-1113-y	http://dx.doi.org/10.1038/s41388-019-1113-y			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31801971	Bronze			2022-12-17	WOS:000513289600016
J	Zhang, D; Jin, N; Sun, W; Li, X; Liu, B; Xie, Z; Qu, J; Xu, J; Yang, X; Su, Y; Tang, S; Han, H; Chen, D; Ding, J; Tan, M; Huang, M; Geng, M				Zhang, D.; Jin, N.; Sun, W.; Li, X.; Liu, B.; Xie, Z.; Qu, J.; Xu, J.; Yang, X.; Su, Y.; Tang, S.; Han, H.; Chen, D.; Ding, J.; Tan, M.; Huang, M.; Geng, M.			Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity (vol 36, pg 2900, 2020)	ONCOGENE			English	Correction																		Zhang D, 2017, ONCOGENE, V36, P2900, DOI 10.1038/onc.2016.446	1	1	1	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2451	2452		10.1038/s41388-019-1148-0	http://dx.doi.org/10.1038/s41388-019-1148-0		JAN 2020	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31900417	Green Published, hybrid			2022-12-17	WOS:000508754300001
J	Cai, L; Lin, SY; Girard, L; Zhou, YY; Yang, L; Ci, B; Zhou, QB; Luo, DN; Yao, B; Tang, H; Allen, J; Huffman, K; Gazdar, A; Heymach, J; Wistuba, I; Xiao, GH; Minna, J; Xie, Y				Cai, Ling; Lin, ShinYi; Girard, Luc; Zhou, Yunyun; Yang, Lin; Ci, Bo; Zhou, Qinbo; Luo, Danni; Yao, Bo; Tang, Hao; Allen, Jeffrey; Huffman, Kenneth; Gazdar, Adi; Heymach, John; Wistuba, Ignacio; Xiao, Guanghua; Minna, John; Xie, Yang			LCE: an open web portal to explore gene expression and clinical associations in lung cancer (vol 45, pg 717, 2019)	ONCOGENE			English	Correction									[Cai, Ling; Zhou, Yunyun; Yang, Lin; Ci, Bo; Yao, Bo; Tang, Hao; Allen, Jeffrey; Xiao, Guanghua; Xie, Yang] UT Southwestern Med Ctr, Quantitat Biomed Res Ctr, Dept Clin Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Cai, Ling] UT Southwestern Med Ctr, Childrens Med Ctr, Res Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Lin, ShinYi; Zhou, Qinbo; Luo, Danni; Yao, Bo; Xiao, Guanghua; Xie, Yang] UT Southwestern Med Ctr, Bioinformat Core Facil, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Girard, Luc; Huffman, Kenneth; Gazdar, Adi; Minna, John] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Zhou, Yunyun] Univ Mississippi, Med Ctr, Dept Data Sci, 2500N State St, Jackson, MS 39216 USA; [Yang, Lin] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Dept Pathol, Beijing 100021, Peoples R China; [Yang, Lin] Peking Union Med Coll, Beijing 100021, Peoples R China; [Gazdar, Adi] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Heymach, John] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77005 USA; [Wistuba, Ignacio] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Xiao, Guanghua; Minna, John; Xie, Yang] Univ Texas Southwestern Med Ctr Dallas, Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Minna, John] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Minna, John] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Mississippi; University of Mississippi Medical Center; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Xiao, GH; Xie, Y (corresponding author), UT Southwestern Med Ctr, Quantitat Biomed Res Ctr, Dept Clin Sci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Xiao, GH; Xie, Y (corresponding author), UT Southwestern Med Ctr, Bioinformat Core Facil, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Minna, J (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Xiao, GH; Minna, J; Xie, Y (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Minna, J (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.; Minna, J (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Guanghua.Xiao@UTSouthwestern.edu; John.Minna@UTSouthwestern.edu; Yang.Xie@UTSouthwestern.edu		Yang, Lin/0000-0002-7594-3770				Cai L, 2019, ONCOGENE, V38, P2551, DOI 10.1038/s41388-018-0588-2	1	1	1	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					718	719		10.1038/s41388-019-1000-6	http://dx.doi.org/10.1038/s41388-019-1000-6			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31501522	Bronze, Green Published			2022-12-17	WOS:000509718300017
J	Chang, YW; Tseng, CF; Wang, MY; Chang, WC; Lee, CC; Chen, LT; Hung, MC; Su, JL				Chang, Y. W.; Tseng, C. F.; Wang, M. Y.; Chang, W. C.; Lee, C. C.; Chen, L. T.; Hung, M. C.; Su, J. L.			Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer (vol 39, pg 946, 2019)	ONCOGENE			English	Correction								An amendment to this paper has been published and can be accessed via a link at the top of the paper.	[Chang, Y. W.; Tseng, C. F.; Chen, L. T.; Su, J. L.] Natl Inst Canc Res, Natl Hlth Res Inst, Zhunan, Taiwan; [Tseng, C. F.] Natl Tsing Hua Univ, Coll Life Sci, Grad Program Biotechnol Med, Hsinchu, Taiwan; [Wang, M. Y.] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Chang, W. C.; Su, J. L.] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Lee, C. C.] Acad Sinica, Core Facil Prot Struct Anal, Taipei, Taiwan; [Hung, M. C.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Su, J. L.] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Su, J. L.] Asia Univ, Dept Biotechnol, Taichung, Taiwan	National Health Research Institutes - Taiwan; National Tsing Hua University; National Taiwan University; National Taiwan University Hospital; China Medical University Taiwan; Academia Sinica - Taiwan; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan	Su, JL (corresponding author), Natl Inst Canc Res, Natl Hlth Res Inst, Zhunan, Taiwan.; Su, JL (corresponding author), China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan.; Su, JL (corresponding author), China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan.; Su, JL (corresponding author), Asia Univ, Dept Biotechnol, Taichung, Taiwan.	hansoneblack@gmail.com	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				CHNG YW, 2019, ONCOGENE, V39, P946, DOI DOI 10.1038/0NC.2015.214	1	1	1	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					946	949		10.1038/s41388-019-0981-5	http://dx.doi.org/10.1038/s41388-019-0981-5			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31537904	Bronze			2022-12-17	WOS:000509197200015
J	Rajabi, H; Hata, T; Li, W; Long, MD; Hu, Q; Liu, S; Raina, D; Kui, L; Yasumizu, Y; Hong, DL; Samur, M; Kufe, D				Rajabi, Hasan; Hata, Tsuyoshi; Li, Wei; Long, Mark D.; Hu, Qiang; Liu, Song; Raina, Deepak; Kui, Ling; Yasumizu, Yota; Hong, Deli; Samur, Mehmet; Kufe, Donald			MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells (vol 38, pg 7266, 2019)	ONCOGENE			English	Correction									[Rajabi, Hasan; Hata, Tsuyoshi; Li, Wei; Raina, Deepak; Kui, Ling; Yasumizu, Yota; Hong, Deli; Samur, Mehmet; Kufe, Donald] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Long, Mark D.; Hu, Qiang; Liu, Song] Roswell Park Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA; [Raina, Deepak] Genus Oncol, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu	Hong, Deli/AAG-2565-2021; Wei, Li/AAE-9938-2020; wei, li/GSD-3630-2022	Long, Mark/0000-0003-1120-8176; Hu, Qiang/0000-0002-4090-5539				Rajabi H, 2019, ONCOGENE, V38, P7266, DOI 10.1038/s41388-019-0940-1	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7278	7278		10.1038/s41388-019-1038-5	http://dx.doi.org/10.1038/s41388-019-1038-5			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31576011	Green Published, hybrid			2022-12-17	WOS:000497989400007
J	Yang, HN				Yang, Haining			Mesothelioma early detection and prevention-are we there yet?	ONCOGENE			English	Meeting Abstract	2nd International Symposium of Norges-Teknisk-Naturvitenskapelige-Universitet (NTNU) - Biomarkers in Precision Diagnosis and Treatment	JUN 14-15, 2018	Trondheim, NORWAY	Norges Teknisk Naturvitenskapelige Univ			ASBESTOS; CARCINOGENESIS; BIOMARKERS; HMGB1		[Yang, Haining] Univ Hawaii, Honolulu, HI 96822 USA	University of Hawaii System					NATIONAL CANCER INSTITUTE [F31CA213627] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carbone M, 2012, CLIN CANCER RES, V18, P598, DOI 10.1158/1078-0432.CCR-11-2259; Chen ZJ, 2017, TRANSL LUNG CANCER R, V6, P259, DOI 10.21037/tlcr.2017.05.06; Jube S, 2012, CANCER RES, V72, P3290, DOI 10.1158/0008-5472.CAN-11-3481; Napolitano A, 2016, CLIN CANCER RES, V22, P3087, DOI 10.1158/1078-0432.CCR-15-1130; Yang H, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.153; Yang HN, 2010, P NATL ACAD SCI USA, V107, P12611, DOI 10.1073/pnas.1006542107; Yang HN, 2008, CURR TREAT OPTION ON, V9, P147, DOI 10.1007/s11864-008-0067-z	7	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2019	38			S		D2-06	5	6						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JZ5TS					2022-12-17	WOS:000505166200008
J	Lee, E; Ouzounova, M; Piranlioglu, R; Ma, MT; Guzel, M; Marasco, D; Chadli, A; Gestwicki, JE; Cowell, JK; Wicha, MS; Hassan, KA; Korkaya, H				Lee, Eunmi; Ouzounova, Maria; Piranlioglu, Raziye; Minh Thu Ma; Guzel, Mustafa; Marasco, Daniela; Chadli, Ahmed; Gestwicki, Jason E.; Cowell, John K.; Wicha, Max S.; Hassan, Khaled A.; Korkaya, Hasan			The pleiotropic effects of TNF alpha in breast cancer subtypes is regulated by TNFAIP3/A20 (vol 38, pg 469, 2018)	ONCOGENE			English	Correction									[Lee, Eunmi; Ouzounova, Maria; Piranlioglu, Raziye; Minh Thu Ma; Chadli, Ahmed; Cowell, John K.; Korkaya, Hasan] Augusta Univ, Georgia Canc Ctr, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Guzel, Mustafa] Medipol Univ, Regenerat & Restorat Res Ctr REMER, Istanbul, Turkey; [Marasco, Daniela] Univ Naples Federico II, Dept Pharm, I-80134 Naples, Italy; [Gestwicki, Jason E.; Hassan, Khaled A.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Wicha, Max S.] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA; [Ouzounova, Maria] CRCL, Dept Canc Cell Plast, Lyon, France	University System of Georgia; Augusta University; Istanbul Medipol University; University of Naples Federico II; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL)	Korkaya, H (corresponding author), Augusta Univ, Georgia Canc Ctr, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	hkorkaya@augusta.edu	Wicha, Max/AAE-7268-2019; Korkaya, Hasan/GRY-1016-2022; Ouzounova, Maria/B-7189-2014	Ouzounova, Maria/0000-0001-8934-3461; Korkaya, Hasan/0000-0002-0719-5862; Guzel, Prof. Mustafa/0000-0002-1423-0435	Georgia Cancer Center; American Cancer Society Institutional fund; Augusta University Research Inc.; Forbes Institute research fund;  [R35CA197585]	Georgia Cancer Center; American Cancer Society Institutional fund(American Cancer Society); Augusta University Research Inc.; Forbes Institute research fund; 	We gratefully acknowledge the generous help from Flow Cytometry, Genomics Core facilities and Laboratory of Animal Services. This work was supported by startup funds to H. K. by Georgia Cancer Center. Additional research fundings to H. K. provided by American Cancer Society Institutional fund, Augusta University Research Inc. Bridge funding Forbes Institute research fund and R35CA197585 funding is to M. S. W.	Lee E, 2019, ONCOGENE, V38, P469, DOI 10.1038/s41388-018-0472-0	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5749	5749		10.1038/s41388-019-0838-y	http://dx.doi.org/10.1038/s41388-019-0838-y			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31197211	Bronze			2022-12-17	WOS:000474845100020
J	Lu, CH; Yeh, DW; Lai, CY; Liu, YL; Huang, LR; Lee, AYL; Jin, SLC; Chuang, TH				Lu, Chih-Hao; Yeh, Da-Wei; Lai, Chao-Yang; Liu, Yi-Ling; Huang, Li-Rung; Lee, Alan Yueh-Luen; Jin, S. -L. Catherine; Chuang, Tsung-Hsien			USP17 mediates macrophage-promoted inflammation and stemness in lung cancer cells by regulating TRAF2/TRAF3 complex formation (vol 37, pg 6327, 2018)	ONCOGENE			English	Correction									[Lu, Chih-Hao; Yeh, Da-Wei; Lai, Chao-Yang; Liu, Yi-Ling; Chuang, Tsung-Hsien] Natl Hlth Res Inst, Immunol Res Ctr, Miaoli, Taiwan; [Lu, Chih-Hao; Jin, S. -L. Catherine] Natl Cent Univ, Dept Life Sci, Taoyuan, Taiwan; [Huang, Li-Rung] Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan; [Lee, Alan Yueh-Luen] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan; [Chuang, Tsung-Hsien] Kaohsiung Med Univ, Program Environm & Occupat Med, Kaohsiung, Taiwan	National Health Research Institutes - Taiwan; National Central University; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Kaohsiung Medical University	Chuang, TH (corresponding author), Natl Hlth Res Inst, Immunol Res Ctr, Miaoli, Taiwan.; Chuang, TH (corresponding author), Kaohsiung Med Univ, Program Environm & Occupat Med, Kaohsiung, Taiwan.	thchuang@nhri.org.tw	Chuang, Tsung-Hsien/F-9679-2010	Lee, Alan Yueh-Luen/0000-0003-0252-0571				Hu B, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040297; Jin X, 2018, MOL CELL, V71, P592, DOI 10.1016/j.molcel.2018.06.036; Liu TZ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13923; Lu CH, 2018, ONCOGENE, V37, P6327, DOI 10.1038/s41388-018-0411-0; McFarlane C, 2013, ONCOTARGET, V4, P1836, DOI 10.18632/oncotarget.1282; Mehic M, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.45; Wu XW, 2019, P NATL ACAD SCI USA, V116, P2961, DOI 10.1073/pnas.1814742116; Wu YD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14228	8	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5742	5743		10.1038/s41388-019-0831-5	http://dx.doi.org/10.1038/s41388-019-0831-5			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31147601	hybrid, Green Published			2022-12-17	WOS:000474845100015
J	Oue, N; Naito, Y; Hayashi, T; Takigahira, M; Kawano-Nagatsuma, A; Sentani, K; Sakamoto, N; Oo, HZ; Uraoka, N; Yanagihara, K; Ochiai, A; Sasaki, H; Yasui, W				Oue, N.; Naito, Y.; Hayashi, T.; Takigahira, M.; Kawano-Nagatsuma, A.; Sentani, K.; Sakamoto, N.; Oo, H. Z.; Uraoka, N.; Yanagihara, K.; Ochiai, A.; Sasaki, H.; Yasui, W.			Signal peptidase complex 18, encoded by SEC11A, contributes to progression via TGF-alpha secretion in gastric cancer (vol 33, pg 3918, 2014)	ONCOGENE			English	Correction									[Oue, N.; Naito, Y.; Hayashi, T.; Sentani, K.; Sakamoto, N.; Oo, H. Z.; Uraoka, N.; Yasui, W.] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Mol Pathol, Hiroshima, Japan; [Takigahira, M.] Natl Canc Ctr Hosp East, Res Ctr Innovat Oncol, Investigat Treatment Div, Kashiwa, Chiba, Japan; [Kawano-Nagatsuma, A.; Ochiai, A.] Natl Canc Ctr Hosp East, Pathol Div, Kashiwa, Chiba, Japan; [Kawano-Nagatsuma, A.; Ochiai, A.] Natl Canc Ctr Hosp East, Res Ctr Innovat Oncol, Kashiwa, Chiba, Japan; [Yanagihara, K.] Natl Canc Ctr Hosp East, Res Ctr Innovat Oncol, Div Translat Res, Kashiwa, Chiba, Japan; [Sasaki, H.] Natl Canc Ctr, Res Inst, Div Genet, Tokyo, Japan	Hiroshima University; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan	Yasui, W (corresponding author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Mol Pathol, Hiroshima, Japan.	wyasui@hiroshima-u.ac.jp						Oue N, 2014, ONCOGENE, V33, P3918, DOI 10.1038/onc.2013.364	1	1	1	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5748	5748		10.1038/s41388-019-0837-z	http://dx.doi.org/10.1038/s41388-019-0837-z			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31175341	Bronze			2022-12-17	WOS:000474845100019
J	Short, SP; Barrett, CW; Stengel, KR; Revetta, FL; Choksi, YA; Coburn, LA; Lintel, MK; McDonough, EM; Washington, MK; Wilson, KT; Prokhortchouk, E; Chen, X; Hiebert, SW; Reynolds, AB; Williams, CS				Short, Sarah P.; Barrett, Caitlyn W.; Stengel, Kristy R.; Revetta, Frank L.; Choksi, Yash A.; Coburn, Lori A.; Lintel, Mary K.; McDonough, Elizabeth M.; Washington, M. Kay; Wilson, Keith T.; Prokhortchouk, Egor; Chen, Xi; Hiebert, Scott W.; Reynolds, Albert B.; Williams, Christopher S.			Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma (vol 38, pg 5091, 2019)	ONCOGENE			English	Correction									[Short, Sarah P.; Barrett, Caitlyn W.; Choksi, Yash A.; Coburn, Lori A.; Lintel, Mary K.; McDonough, Elizabeth M.; Wilson, Keith T.; Williams, Christopher S.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol, Nashville, TN 37232 USA; [Short, Sarah P.; Barrett, Caitlyn W.; Choksi, Yash A.; Wilson, Keith T.; Reynolds, Albert B.; Williams, Christopher S.] Vanderbilt Univ, Program Canc Biol, Nashville, TN 37232 USA; [Stengel, Kristy R.; Hiebert, Scott W.] Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; [Revetta, Frank L.; Washington, M. Kay; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Choksi, Yash A.; Coburn, Lori A.; Wilson, Keith T.; Williams, Christopher S.] Vet Affairs Tennessee Valley Hlth Care Syst, Nashville, TN 37232 USA; [Coburn, Lori A.; Wilson, Keith T.; Williams, Christopher S.] Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA; [McDonough, Elizabeth M.] Our Lady Lake Childrens Hosp, Div Gastroenterol, Dept Pediat, Baton Rouge, TN 70808 USA; [Wilson, Keith T.; Hiebert, Scott W.; Reynolds, Albert B.; Williams, Christopher S.] Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Prokhortchouk, Egor] Russian Acad Sci, Res Ctr Biotechnol, Inst Bioengn, Moscow, Russia; [Chen, Xi] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Chen, Xi] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Research Center of Biotechnology RAS; Russian Academy of Sciences; University of Miami; University of Miami	Williams, CS (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol, Nashville, TN 37232 USA.; Williams, CS (corresponding author), Vanderbilt Univ, Program Canc Biol, Nashville, TN 37232 USA.; Williams, CS (corresponding author), Vet Affairs Tennessee Valley Hlth Care Syst, Nashville, TN 37232 USA.; Williams, CS (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA.; Williams, CS (corresponding author), Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	Christopher.williams@vanderbilt.edu		Williams, Christopher/0000-0002-1541-579X; Coburn, Lori/0000-0003-3249-9806; Wilson, Keith/0000-0003-4421-1830				Short SP, 2019, ONCOGENE, V38, P5091, DOI 10.1038/s41388-019-0777-7	1	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5107	5107		10.1038/s41388-019-0829-z	http://dx.doi.org/10.1038/s41388-019-0829-z			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	31068667	Bronze			2022-12-17	WOS:000472145900016
J	Rua, WM; Venkatachalam, G; Sobota, RM; Chen, LY; Wang, LC; Jacobson, A; Paramasivam, K; Surana, U				Rua, Weimei; Venkatachalam, Gireedhar; Sobota, Radoslaw Mikolaj; Chen, Liyan; Wang, Loo Chien; Jacobson, Alena; Paramasivam, Kathirvel; Surana, Uttam			Resistance to anti-microtubule drug-induced cell death is determined by regulation of BimEL expression	ONCOGENE			English	Article							APOPTOSIS RESISTANCE; DEGRADATION; PHOSPHORYLATION; TRANSCRIPTION; MECHANISMS; TAXOL; B1	Anti-microtubule agents are frequently used as anticancer therapeutics. Cell death induced by these agents is considered to be due to sustained mitotic arrest caused by the activation of spindle assembly checkpoint (SAC). However, some cell types are resistant to mitotic cell death. Cells' ability to escape mitotic arrest (mitotic slippage) is thought to be a major mechanism contributing to this resistance. Here, we show that resistance to cell death induced by anti-mitotic agents is not linked to cells' capacity to undergo mitotic slippage as generally believed but is dependent on the state of BimEL regulation during mitosis. While transcriptional repression of BimEL in the mitotic death-resistant cells involves polycomb repressive complex 2 (PRC2)-mediated histone trimethylation, the BimEL protein is destabilized by cullin 1/4A-beta TrCP-dependent degradation involving activation of cullin 1/4A by neddylation. These results imply that pharmacological augmentation of BimEL activity in anti-microtubule drug-resistant tumors may have important therapeutic implications.	[Rua, Weimei; Venkatachalam, Gireedhar; Sobota, Radoslaw Mikolaj; Chen, Liyan; Wang, Loo Chien; Jacobson, Alena; Paramasivam, Kathirvel; Surana, Uttam] ASTAR, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore; [Surana, Uttam] ASTAR, Bioproc Technol Inst, Singapore, Singapore; [Surana, Uttam] Natl Univ Singapore, Dept Pharmacol, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Bioprocessing Technology Institute (BTI); National University of Singapore	Surana, U (corresponding author), ASTAR, Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.; Surana, U (corresponding author), ASTAR, Bioproc Technol Inst, Singapore, Singapore.; Surana, U (corresponding author), Natl Univ Singapore, Dept Pharmacol, Singapore, Singapore.	mcbucs@imcb.a-star.edu.sg		Surana, Uttam/0000-0002-4785-6514; Ruan, Weimei/0000-0002-3459-5837; Sobota, Radoslaw/0000-0002-2455-2526; Chen, Liyan/0000-0002-5255-0296	Biomedical Research Council of A* STAR (Agency for Science, Technology and Research), Singapore	Biomedical Research Council of A* STAR (Agency for Science, Technology and Research), Singapore(Agency for Science Technology & Research (A*STAR))	We thank the members of the US laboratory for helpful discussions and the mouse model unit (IMCB, Singapore) for kindly providing the PLKO. 1 vector and lentiviral packaging vectors. The U.S. lab is supported by the Biomedical Research Council of A* STAR (Agency for Science, Technology and Research), Singapore.	Bah N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.251; Balachandran RS, 2016, J CELL BIOL, V215, P151, DOI 10.1083/jcb.201601083; Brito DA, 2009, CELL MOTIL CYTOSKEL, V66, P437, DOI 10.1002/cm.20316; Chan KS, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.148; Cheung CHA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012564; Chumduri C, 2015, J MOL MED, V93, P559, DOI 10.1007/s00109-014-1242-2; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; Harley ME, 2010, EMBO J, V29, P2407, DOI 10.1038/emboj.2010.112; Haschka MD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7891; He YJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157558; Huang S, 2016, ONCOTARGET, V7, P38718, DOI 10.18632/oncotarget.9586; Jiang LY, 2011, J BIOL CHEM, V286, P6971, DOI 10.1074/jbc.M110.186494; KNEHR M, 1995, EXP CELL RES, V217, P546, DOI 10.1006/excr.1995.1121; Kutuk O, 2010, CELL DEATH DIFFER, V17, P1624, DOI 10.1038/cdd.2010.41; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Manchado E, 2012, CELL DEATH DIFFER, V19, P369, DOI 10.1038/cdd.2011.197; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Pathan N, 2001, NEOPLASIA, V3, P550, DOI 10.1038/sj.neo.7900213; Ridinger-Saison M, 2013, CELL DEATH DIFFER, V20, P1268, DOI 10.1038/cdd.2013.88; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Sinnott R, 2014, CANCER RES, V74, P3857, DOI 10.1158/0008-5472.CAN-13-3398; Terrano DT, 2010, MOL CELL BIOL, V30, P640, DOI 10.1128/MCB.00882-09; Thomas Y, 2010, CELL CYCLE, V9, P4338, DOI 10.4161/cc.9.21.13593; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wan LX, 2014, DEV CELL, V29, P377, DOI 10.1016/j.devcel.2014.04.022; Wu N, 2017, ONCOL LETT, V13, P1826, DOI 10.3892/ol.2017.5660; Xu ZJ, 2017, ONCOL LETT, V14, P345, DOI 10.3892/ol.2017.6149; Yamaguchi H, 2004, J BIOL CHEM, V279, P39431, DOI 10.1074/jbc.M401530200; Zhang WZ, 2008, J BIOL CHEM, V283, P16416, DOI 10.1074/jbc.M802360200	31	1	1	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4352	4365		10.1038/s41388-019-0727-4	http://dx.doi.org/10.1038/s41388-019-0727-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30770899				2022-12-17	WOS:000469339100011
J	Perotti, V; Baldassari, P; Molla, A; Vegetti, C; Bersani, I; Maurichi, A; Santinami, M; Anichini, A; Mortarini, R				Perotti, V.; Baldassari, P.; Molla, A.; Vegetti, C.; Bersani, I.; Maurichi, A.; Santinami, M.; Anichini, A.; Mortarini, R.			NFATc2 is an intrinsic regulator of melanoma dedifferentiation (vol 35, pg 2862, 2016)	ONCOGENE			English	Correction									[Perotti, V.; Baldassari, P.; Molla, A.; Vegetti, C.; Bersani, I.; Anichini, A.; Mortarini, R.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Human Tumors Immunobiol Unit, Milan, Italy; [Maurichi, A.; Santinami, M.] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Melanoma & Sarcoma Unit, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Mortarini, R (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Human Tumors Immunobiol Unit, Milan, Italy.	roberta.mortarini@istitutotumori.mi.it	Santinami, Mario/I-3795-2017; Anichini, Andrea/K-1434-2016; Perotti, Valentina/C-1049-2017	Santinami, Mario/0000-0001-8436-4757; Anichini, Andrea/0000-0001-5096-5538; Perotti, Valentina/0000-0003-4506-2363				Perotti V, 2016, ONCOGENE, V35, P2862, DOI 10.1038/onc.2015.355	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3763	3764		10.1038/s41388-019-0679-8	http://dx.doi.org/10.1038/s41388-019-0679-8			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30692631	hybrid, Green Published			2022-12-17	WOS:000467379600015
J	Iida, M; Brand, TM; Campbell, DA; Li, C; Wheeler, DL				Iida, M.; Brand, T. M.; Campbell, D. A.; Li, C.; Wheeler, D. L.			Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor (vol 32, pg 759, 2013)	ONCOGENE			English	Correction									[Iida, M.; Brand, T. M.; Campbell, D. A.; Li, C.; Wheeler, D. L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Wheeler, DL (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI 53706 USA.	dlwheeler@wisc.edu						Iida M, 2013, ONCOGENE, V32, P759, DOI 10.1038/onc.2012.90	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2435	2435		10.1038/s41388-018-0572-x	http://dx.doi.org/10.1038/s41388-018-0572-x			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30518873	Bronze			2022-12-17	WOS:000462588000016
J	Lujambio, A; Portela, A; Liz, J; Melo, SA; Rossi, S; Spizzo, R; Croce, CM; Calin, GA; Esteller, M				Lujambio, A.; Portela, A.; Liz, J.; Melo, S. A.; Rossi, S.; Spizzo, R.; Croce, C. M.; Calin, G. A.; Esteller, M.			CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer (vol 29, pg 6390, 2010)	ONCOGENE			English	Correction									[Lujambio, A.; Portela, A.; Liz, J.; Melo, S. A.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08907, Spain; [Rossi, S.; Spizzo, R.; Calin, G. A.] Texas State Univ, Univ Texas MD Anderson Canc Ctr, Expt Therapeut & Canc Genet, Houston, TX USA; [Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Texas State University System; Texas State University San Marcos; University of Texas System; UTMD Anderson Cancer Center; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; ICREA	Esteller, M (corresponding author), Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08907, Spain.; Esteller, M (corresponding author), ICREA, Barcelona, Catalonia, Spain.	mesteller@iconcologia.net	Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Calin, George/0000-0002-7427-0578; Calin, George/0000-0001-6704-5615				Lujambio A, 2010, ONCOGENE, V29, P6390, DOI 10.1038/onc.2010.361	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					765	766		10.1038/s41388-018-0560-1	http://dx.doi.org/10.1038/s41388-018-0560-1			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30397238	Green Published, hybrid			2022-12-17	WOS:000457300300011
J	Lee, KM; Choi, WI; Koh, DI; Kim, YJ; Jeon, BN; Yoon, JH; Lee, CE; Kim, SH; Oh, J; Hur, MW				Lee, K. M.; Choi, W. I.; Koh, D. I.; Kim, Y. J.; Jeon, B. N.; Yoon, J. H.; Lee, C. E.; Kim, S. H.; Oh, J.; Hur, M. W.			The proto-oncoprotein KR-POK represses transcriptional activation of CDKN1A by MIZ-1 through competitive binding (vol 31, pg 1442, 2012)	ONCOGENE			English	Correction															Basic Science Research Grant [314-2008-1-E00030]; MRC from the National Research Foundation of Korea [R13-2002-054-05002-0]; Faculty Research Grant from Yonsei University School of Medicine [6-2007-0105]	Basic Science Research Grant; MRC from the National Research Foundation of Korea(National Research Foundation of Korea); Faculty Research Grant from Yonsei University School of Medicine	This work was mainly funded by a Basic Science Research Grant (314-2008-1-E00030 to MW Hur and CE Lee) and MRC (R13-2002-054-05002-0) from the National Research Foundation of Korea, and also by a Faculty Research Grant (6-2007-0105 to MW Hur) from Yonsei University School of Medicine.	Lee KM, 2012, ONCOGENE, V31, P1442, DOI 10.1038/onc.2011.331	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4951	4951		10.1038/onc.2017.115	http://dx.doi.org/10.1038/onc.2017.115			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28604745	Bronze			2022-12-17	WOS:000408234400011
J	Vinyoles, M; Del Valle-Perez, B; Curto, J; Padilla, M; Villarroel, A; Yang, J; de Herreros, AG; Dunach, M				Vinyoles, M.; Del Valle-Perez, B.; Curto, J.; Padilla, M.; Villarroel, A.; Yang, J.; de Herreros, A. G.; Dunach, M.			Activation of CK1 epsilon by PP2A/PR61 epsilon is required for the initiation of Wnt signaling (vol 36, pg 429, 2017)	ONCOGENE			English	Correction													Dunach, Mireia/E-3604-2015	Dunach, Mireia/0000-0001-9844-5603				Vinyoles M, 2017, ONCOGENE, V36, P429, DOI 10.1038/onc.2016.209	1	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4670	4670		10.1038/onc.2017.84	http://dx.doi.org/10.1038/onc.2017.84			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368396	Bronze			2022-12-17	WOS:000407246200014
J	Shen, J; Vakifahmetoglu, H; Stridh, H; Zhivotovsky, B; Wiman, KG				Shen, J.; Vakifahmetoglu, H.; Stridh, H.; Zhivotovsky, B.; Wiman, K. G.			PRIMA-1Met induces mitochondrial apoptosis through activation of caspase-2 (vol 27, pg 6571, 2008)	ONCOGENE			English	Correction													Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X				Shen J, 2008, ONCOGENE, V27, P6571, DOI 10.1038/onc.2008.249	1	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6446	6446		10.1038/onc.2016.210	http://dx.doi.org/10.1038/onc.2016.210			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27375019	Bronze			2022-12-17	WOS:000390247600009
J	Lin, KT; Shann, YJ; Chau, GY; Hsu, CN; Huang, CYF				Lin, K-T; Shann, Y-J; Chau, G-Y; Hsu, C-N; Huang, C-Y F.			Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing (vol 33, pg 4786, 2014)	ONCOGENE			English	Correction																		Lin KT, 2014, ONCOGENE, V33, P4786, DOI 10.1038/onc.2013.424	1	1	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5078	5078		10.1038/onc.2016.62	http://dx.doi.org/10.1038/onc.2016.62			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	27477694	Bronze			2022-12-17	WOS:000383965300012
J	Wu, DW; Lee, MC; Hsu, NY; Wu, TC; Wu, JY; Wang, YC; Cheng, YW; Chen, CY; Lee, H				Wu, D-W; Lee, M-C; Hsu, N-Y; Wu, T-C; Wu, J-Y; Wang, Y-C; Cheng, Y-W; Chen, C-Y; Lee, H.			FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-kappa B/Slug-mediated PUMA reduction (vol 34, pg 2505, 2015)	ONCOGENE			English	Correction									[Lee, M-C] Taichung Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taichung, Taiwan	Taichung Veterans General Hospital								Wu DW, 2015, ONCOGENE, V34, P2505, DOI 10.1038/onc.2014.184	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2546	2546		10.1038/onc.2014.465	http://dx.doi.org/10.1038/onc.2014.465			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	25950371	Bronze			2022-12-17	WOS:000354190400013
J	Philips, ST; Hildenbrand, ZL; Oravecz-Wilson, KI; Foley, SB; Mgbemena, VE; Ross, TS				Philips, S. T.; Hildenbrand, Z. L.; Oravecz-Wilson, K. I.; Foley, S. B.; Mgbemena, V. E.; Ross, T. S.			Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells	ONCOGENE			English	Article						myeloproliferation; Imatinib; arsenic	HEMATOPOIETIC STEM-CELLS; CHRONIC MYELOID-LEUKEMIA; HUNTINGTIN-INTERACTING PROTEIN-1; CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; HISTONE DEACETYLASE INHIBITORS; RECEPTOR-BETA; CML PATIENTS; QUIESCENT; GENE	Myeloproliferative neoplasms (MPNs) such as chronic myelogenous (CML) and chronic myelomonocytic leukemias (CMML) are frequently induced by tyrosine kinase oncogenes. Although these MPNs are sensitive to tyrosine kinase inhibitors such as imatinib, patients often relapse upon withdrawal of therapy. We used a model of MPN, which is induced by co-expression of the oncoproteins HIP1/PDGFbR (H/P) and AML1/ETO from their endogenous loci, to examine the mechanisms of disease development and recurrence following imatinib withdrawal. Although the MPN displayed a full hematologic response to imatinib, 100% of the diseased mice relapsed upon drug withdrawal. MPN persistence was not due to imatinib resistance mutations in the H/P oncogene or massive gene expression changes. Within 1 week of imatinib treatment, more than 98% of gene expression changes induced by the oncogenes in isolated hematopoietic stem and progenitor cells (lineage(-)Sca-1(+)c-Kit(+) immunophenotype) normalized. Supplementation of imatinib with granulocyte colony-stimulating factor or arsenic trioxide reduced MPN-initiating cell frequencies and the combination of imatinib with arsenic trioxide cured a large fraction of mice with MPNs. In contrast, no mice in the imatinibtreated control cohorts were cured. These data suggest that treatment with a combination of arsenic trioxide and imatinib can eliminate refractory MPN-initiating cells and reduce disease relapse.	[Philips, S. T.; Hildenbrand, Z. L.; Foley, S. B.; Mgbemena, V. E.; Ross, T. S.] Univ Texas Dallas, SW Med Ctr, Dept Internal Med, Div Hematol Oncol, Dallas, TX 75390 USA; [Oravecz-Wilson, K. I.] Univ Michigan, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Michigan System; University of Michigan	Ross, TS (corresponding author), Univ Texas Dallas, SW Med Ctr, Dept Internal Med, Div Hematol Oncol, 5323 Harry Hines Blvd,ND3-214, Dallas, TX 75390 USA.	Theo.Ross@utsouthwestern.edu		Ross, Theodora/0000-0002-9166-1802	Burroughs Wellcome Fund Clinical Scientist Award in Translational Research; TSR holds the Jeanne Ann Plitt Professorship in Breast Cancer Research; H Ben and Isabelle T Decherd Chair in Internal Medicine at UT Southwestern Medical Center; Leukemia and Lymphoma Society Scholar;  [CBTG CA009676];  [R01 CA82363-03];  [R01 CA098730-01]; NATIONAL CANCER INSTITUTE [T32CA124334, R01CA098730, R01CA082363, T32CA009676] Funding Source: NIH RePORTER	Burroughs Wellcome Fund Clinical Scientist Award in Translational Research(Burroughs Wellcome Fund); TSR holds the Jeanne Ann Plitt Professorship in Breast Cancer Research; H Ben and Isabelle T Decherd Chair in Internal Medicine at UT Southwestern Medical Center; Leukemia and Lymphoma Society Scholar(Leukemia and Lymphoma Society); ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bob Rooney, Luke Peterson, Phil (Zhe) Guan, Ivan Maillard, Yipin Wu and Alice Gauvin for their intellectual input and technical assistance. This work was supported by the following grants: CBTG CA009676 (STP), R01 CA82363-03 (TSR) and R01 CA098730-01 (TSR), and a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research (TSR). TSR holds the Jeanne Ann Plitt Professorship in Breast Cancer Research and the H Ben and Isabelle T Decherd Chair in Internal Medicine at UT Southwestern Medical Center. TSR was supported as a Leukemia and Lymphoma Society Scholar during the time this work was completed.	Agarwal A, 2012, BLOOD, V120, P2658, DOI 10.1182/blood-2011-05-355396; Ames HM, 2013, MOL CELL BIOL, V33, P3580, DOI 10.1128/MCB.00473-13; Antman KH, 2001, ONCOLOGIST, V6, P1, DOI 10.1634/theoncologist.6-suppl_2-1; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Boissel N, 2006, LEUKEMIA, V20, P965, DOI 10.1038/sj.leu.2404188; Connor RF, 2006, LEUKEMIA RES, V30, P1249, DOI 10.1016/j.leukres.2006.02.020; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; Cortes J, 2004, BLOOD, V104, P2204, DOI 10.1182/blood-2004-04-1335; David M, 2007, BLOOD, V109, P61, DOI 10.1182/blood-2006-05-024828; DiPersio JF, 2009, BLOOD, V113, P5720, DOI 10.1182/blood-2008-08-174946; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Drummond MW, 2009, LEUKEMIA, V23, P1199, DOI 10.1038/leu.2009.43; Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815; Forsberg EC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008785; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Grand FH, 2004, CANCER RES, V64, P7216, DOI 10.1158/0008-5472.CAN-04-2005; Graves CW, 2008, CANCER RES, V68, P1064, DOI 10.1158/0008-5472.CAN-07-5892; Grossmann V, 2011, LEUKEMIA, V25, P557, DOI 10.1038/leu.2010.298; Higashi T, 2004, AM J HEMATOL, V76, P275, DOI 10.1002/ajh.20096; Holtz M, 2007, CANCER RES, V67, P1113, DOI 10.1158/0008-5472.CAN-06-2014; Huang HJ, 1999, CANCER RES, V59, P2981; Irizarry RA, 2006, BIOINFORMATICS, V22, P789, DOI 10.1093/bioinformatics/btk046; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Jaiswal S, 2003, P NATL ACAD SCI USA, V100, P10002, DOI 10.1073/pnas.1633833100; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Jones AV, 2004, CELL MOL LIFE SCI, V61, P2912, DOI 10.1007/s00018-004-4272-z; Jorgensen HG, 2006, CLIN CANCER RES, V12, P626, DOI 10.1158/1078-0432.CCR-05-0429; Kavalerchik E, 2008, J CLIN ONCOL, V26, P2911, DOI 10.1200/JCO.2008.17.5745; Kiel MJ, 2007, NATURE, V449, P238, DOI 10.1038/nature06115; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lee KH, 2000, J IMMUNOL, V165, P4970, DOI 10.4049/jimmunol.165.9.4970; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mauro MJ, 2004, LEUKEMIA RES, V28, pS71, DOI 10.1016/j.leukres.2003.10.017; Morrison SJ, 1997, P NATL ACAD SCI USA, V94, P1908, DOI 10.1073/pnas.94.5.1908; Oravecz-Wilson KI, 2009, CANCER CELL, V16, P137, DOI 10.1016/j.ccr.2009.06.007; Preudhomme C, 2010, NEW ENGL J MED, V363, P2511, DOI 10.1056/NEJMoa1004095; Provenzano JD, 2013, CASE REP HEMATOL, V2013, DOI 10.1155/2013/709164; Roberts KG, 2012, CANCER CELL, V22, P153, DOI 10.1016/j.ccr.2012.06.005; Ross TS, 1998, BLOOD, V91, P4419, DOI 10.1182/blood.V91.12.4419.412k43_4419_4426; Savona M, 2008, NAT REV CANCER, V8, P341, DOI 10.1038/nrc2368; Strout MP, 1999, ANN HEMATOL, V78, P251, DOI 10.1007/s002770050511; Tefferi A, 2008, LEUKEMIA, V22, P14, DOI 10.1038/sj.leu.2404955; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Vainio P, 2011, ONCOTARGET, V2, P1176; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang B, 2010, CANCER CELL, V17, P427, DOI 10.1016/j.ccr.2010.03.011; Zuccolo J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009369	49	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2014	33	46					5379	5390		10.1038/onc.2013.484	http://dx.doi.org/10.1038/onc.2013.484			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MF	24240679	Green Accepted			2022-12-17	WOS:000345120600008
J	Lin, A; Yao, J; Zhuang, L; Wang, D; Han, J; Lam, EWF; Gan, B				Lin, A.; Yao, J.; Zhuang, L.; Wang, D.; Han, J.; Lam, E. W-F; Gan, B.			The FoxO-BNIP3 axis exerts a unique regulation of mTORC1 and cell survival under energy stress (vol 33, pg 3183, 2014)	ONCOGENE			English	Correction																		Lin A, 2014, ONCOGENE, V33, P3183, DOI 10.1038/onc.2013.273	1	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5310	5310		10.1038/onc.2014.330	http://dx.doi.org/10.1038/onc.2014.330			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD		Bronze			2022-12-17	WOS:000345120400009
J	Tait, S				Tait, S.			DNA: leukemia's secret weapon of bone mass destruction	ONCOGENE			English	Editorial Material							MYB	Interaction of tumour cells with their microenvironment impacts on all aspects of cancer, ranging from development through to treatment response. In this issue, Dvorak and colleagues(1) reveal a novel tumour/microevironment relationship that may drive leukemia pathogenesis. Specifically, they find that leukemic cells secrete chromatin-complexed DNA that, in turn, triggers a variety of harmful effects, including cell death, in neighbouring stromal cells. Through this toxicity, DNA-mediated bone marrow destruction could promote disease progression by allowing leukemic cells to exit the bone marrow into the circulation.	Univ Glasgow, Beatson Inst Canc Res, Inst Canc Sci, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow	Tait, S (corresponding author), Univ Glasgow, Beatson Inst Canc Res, Inst Canc Sci, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	stephen.tait@glasgow.ac.uk		Tait, Stephen/0000-0001-7697-132X				Dvorakova M, 2013, ONCOGENE, V32, P5201, DOI 10.1038/onc.2012.553; Dvorakova M, 2001, BLOOD CELL MOL DIS, V27, P437, DOI 10.1006/bcmd.2001.0402; Gahan PB, 2010, CELL BIOCHEM FUNCT, V28, P529, DOI 10.1002/cbf.1690; Karafiat V, 2001, BLOOD, V98, P3668, DOI 10.1182/blood.V98.13.3668; Nickel W, 2010, CURR OPIN BIOTECH, V21, P621, DOI 10.1016/j.copbio.2010.06.004; Pattabiraman DR, 2013, LEUKEMIA, V27, P269, DOI 10.1038/leu.2012.225	6	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5199	5200		10.1038/onc.2012.639	http://dx.doi.org/10.1038/onc.2012.639			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23353820				2022-12-17	WOS:000326497100002
J	Ng, T; Irshad, S; Stebbing, J				Ng, T.; Irshad, S.; Stebbing, J.			BRCA1 mutations and luminal-basal transformation	ONCOGENE			English	Editorial Material							DIFFERENTIATION; PROLIFERATION; EXPRESSION; TARGET; BREAST	The multifunctional roles of BRCA1 include its ability to regulate transcriptional processes that control differentiation at multiple levels, as well as functioning as a tumor suppressor. Data herein demonstrate that germline mutations in Brca1 impair luminal cell lineage and mammary development, with its deficiency converting ER-positive luminal tumors into basal-like cancers. Heterozygous mutations in Brca1 lead to downregulation of a number of luminal differentiation genes, explaining how it suppresses basal-like tumors, also highlighting its importance outside of its known highly publicized role in DNA repair.	[Ng, T.; Irshad, S.] Kings Coll London, Richard Dimbleby Dept Canc Res, Randall Div, London WC2R 2LS, England; [Ng, T.; Irshad, S.] Kings Coll London, Div Canc Studies, London WC2R 2LS, England; [Ng, T.; Irshad, S.] Kings Coll London, Breakthrough Breast Canc Res Unit, London WC2R 2LS, England; [Stebbing, J.] Univ London Imperial Coll Sci Technol & Med, Dept Med Oncol, London W12 0NN, England	University of London; King's College London; University of London; King's College London; University of London; King's College London; Imperial College London	Stebbing, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Med Oncol, Hammersmith Campus, London W12 0NN, England.	j.stebbing@imperial.ac.uk	Irshad, Sheeba/ABE-9417-2021	Irshad, Sheeba/0000-0002-4419-7162; Stebbing, Justin/0000-0002-1117-6947; Ng, Tony/0000-0003-3894-5619	Cancer Research UK [14549, 16463] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish; Breast Cancer Now [KCL-Q1] Funding Source: researchfish; Department of Health [NIHR-RP-011-053] Funding Source: Medline	Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); Breast Cancer Now; Department of Health		Bai F, 2013, ONCOGENE, V32, P2715, DOI 10.1038/onc.2012.293; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Coene ED, 2011, J CELL BIOL, V192, P497, DOI 10.1083/jcb.201004136; Deans AJ, 2006, CANCER RES, V66, P8219, DOI 10.1158/0008-5472.CAN-05-3945; Drost R, 2011, CANCER CELL, V20, P797, DOI 10.1016/j.ccr.2011.11.014; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Kubista M, 2002, ONCOGENE, V21, P4747, DOI 10.1038/sj.onc.1205580; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Morris JR, 2009, NATURE, V462, P886, DOI 10.1038/nature08593; Pei XH, 2009, CANCER CELL, V15, P389, DOI 10.1016/j.ccr.2009.03.004; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Taghavi N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-138; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61	16	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2712	2714		10.1038/onc.2012.379	http://dx.doi.org/10.1038/onc.2012.379			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22926516				2022-12-17	WOS:000319808000002
J	Yang, MH; Lin, BR; Chang, CH; Chen, ST; Lin, SK; Kuo, MYP; Jeng, YM; Kuo, ML; Chang, CC				Yang, M-H; Lin, B-R; Chang, C-H; Chen, S-T; Lin, S-K; Kuo, M. Y-P; Jeng, Y-M; Kuo, M-L; Chang, C-C			Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling (vol 31, pg 240, 2012)	ONCOGENE			English	Correction													Yang, Muh-Hwa/AAE-4691-2020	KUO, MIN-LIANG/0000-0002-7139-0144; CHANG, CHIA-HSUIN/0000-0003-0024-6177; Chen, Szu-Ta/0000-0002-9715-1221; LIN, SZE-KWAN/0000-0002-7969-0280; LIN, BEEN-REN/0000-0001-8354-1758				Yang MH, 2012, ONCOGENE, V31, P2401, DOI 10.1038/onc.2011.423	1	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2013	32	5					670	670		10.1038/onc.2012.559	http://dx.doi.org/10.1038/onc.2012.559			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ		Bronze			2022-12-17	WOS:000316164700014
J	Zhang, P; Yang, Y; Nolo, R; Zweidler-McKay, PA; Hughes, DPM				Zhang, P.; Yang, Y.; Nolo, R.; Zweidler-McKay, P. A.; Hughes, D. P. M.			Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness (vol 29, pg 2916, 2010)	ONCOGENE			English	Correction														Zweidler-McKay, Patrick/0000-0001-6621-523X				Hua YQ, 2012, CANCER-AM CANCER SOC, V118, P5140, DOI 10.1002/cncr.27496; Hughes DPM, 2004, CANCER RES, V64, P2047, DOI 10.1158/0008-5472.CAN-03-3096; Zhang P, 2010, ONCOGENE, V29, P2916, DOI 10.1038/onc.2010.62	3	1	1	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	44					4732	4732		10.1038/onc.2012.429	http://dx.doi.org/10.1038/onc.2012.429			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW		Bronze			2022-12-17	WOS:000310724400009
J	Doyle, KR; Mitchell, MA; Roberts, CL; James, S; Johnson, JE; Zhou, Y; von Mehren, M; Lev, D; Kipling, D; Broccoli, D				Doyle, K. R.; Mitchell, M. A.; Roberts, C. L.; James, S.; Johnson, J. E.; Zhou, Y.; von Mehren, M.; Lev, D.; Kipling, D.; Broccoli, D.			Validating a gene expression signature proposed to differentiate liposarcomas that use different telomere maintenance mechanisms	ONCOGENE			English	Letter							SARCOMAS; ALT		[Doyle, K. R.; Mitchell, M. A.; Roberts, C. L.; James, S.; Broccoli, D.] Mem Univ Med Ctr, Curtis & Elizabeth Anderson Canc Inst, Dept Lab Oncol Res, Savannah, GA USA; [Johnson, J. E.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Zhou, Y.] Fox Chase Canc Ctr, Bioinformat Facil, Philadelphia, PA 19111 USA; [von Mehren, M.] Fox Chase Canc Ctr, Dept Med Oncol, Div Populat Sci, Philadelphia, PA 19111 USA; [von Mehren, M.] Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; [Lev, D.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Kipling, D.] Cardiff Univ, Sch Med, Dept Pathol, Cardiff, S Glam, Wales	University of Pennsylvania; Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Cardiff University	Doyle, KR (corresponding author), Mem Univ Med Ctr, Curtis & Elizabeth Anderson Canc Inst, Dept Lab Oncol Res, Savannah, GA USA.	broccdo1@memorialhealth.com						Cairney CJ, 2008, BRIT J CANCER, V98, P1467, DOI 10.1038/sj.bjc.6604328; Lafferty-Whyte K, 2009, ONCOGENE, V28, P3765, DOI 10.1038/onc.2009.238; Matushansky I, 2008, AM J PATHOL, V172, P1069, DOI 10.2353/ajpath.2008.070284; Montgomery E, 2004, AM J PATHOL, V164, P1523, DOI 10.1016/S0002-9440(10)63710-8; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Ulaner GA, 2004, GENE CHROMOSOME CANC, V41, P155, DOI 10.1002/gcc.20074	6	1	1	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	2					265	266		10.1038/onc.2011.225	http://dx.doi.org/10.1038/onc.2011.225			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21706060	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000299307400011
J	Li, Y; Cai, L; Wang, H; Wu, P; Gu, W; Chen, Y; Hao, H; Tang, K; Yi, P; Liu, M; Miao, S; Ye, D				Li, Y.; Cai, L.; Wang, H.; Wu, P.; Gu, W.; Chen, Y.; Hao, H.; Tang, K.; Yi, P.; Liu, M.; Miao, S.; Ye, D.			Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2 (vol 30, pg 3887, 2011)	ONCOGENE			English	Correction														Li, Yongsheng/0000-0003-2175-9449				Li Y, 2011, ONCOGENE, V30, P4373, DOI 10.1038/onc.2011.413	1	1	1	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	42					4373	4374		10.1038/onc.2011.413	http://dx.doi.org/10.1038/onc.2011.413			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HP		Bronze			2022-12-17	WOS:000296356400008
J	Pan, J; Nakade, K; Huang, YC; Zhu, ZW; Masuzaki, S; Hasegawa, H; Murata, T; Yoshiki, A; Yamaguchi, N; Lee, CH; Yang, WC; Tsai, EM; Obata, Y; Yokoyama, KK				Pan, J.; Nakade, K.; Huang, Y-C; Zhu, Z-W; Masuzaki, S.; Hasegawa, H.; Murata, T.; Yoshiki, A.; Yamaguchi, N.; Lee, C-H; Yang, W-C; Tsai, E-M; Obata, Y.; Yokoyama, K. K.			Suppression of cell-cycle progression by Jun dimerization protein-2 (JDP2) involves downregulation of cyclin-A2 (vol 29, pg 6245, 2010)	ONCOGENE			English	Correction													Obata, Yuichi/A-5300-2016; Yoshiki, Atsushi/A-6036-2016	Obata, Yuichi/0000-0003-1839-4709; Yoshiki, Atsushi/0000-0002-9450-5151				Pan J, 2010, ONCOGENE, V29, P6245, DOI 10.1038/onc.2010.355	1	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	33					3648	3648		10.1038/onc.2011.285	http://dx.doi.org/10.1038/onc.2011.285			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL		Bronze, Green Published, Green Accepted			2022-12-17	WOS:000294005100008
J	Jie, X; Lang, C; Jian, Q; Chaoqun, L; Dehua, Y; Yi, S; Yanping, J; Luokun, X; Qiuping, Z; Hui, W; Feili, G; Boquan, J; Youxin, J; Jinquan, T				Jie, X.; Lang, C.; Jian, Q.; Chaoqun, L.; Dehua, Y.; Yi, S.; Yanping, J.; Luokun, X.; Qiuping, Z.; Hui, W.; Feili, G.; Boquan, J.; Youxin, J.; Jinquan, T.			Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells (Retraction of vol 30, pg 5741, 2007)	ONCOGENE			English	Correction																		Jie X, 2007, ONCOGENE, V26, P5741, DOI 10.1038/sj.onc.1210362	1	1	1	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	24					2798	2798		10.1038/onc.2011.66	http://dx.doi.org/10.1038/onc.2011.66			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB		Bronze			2022-12-17	WOS:000291678500010
J	Cheli, Y; Giuliano, S; Botton, T; Rocchi, S; Hofman, V; Hofman, P; Bahadoran, P; Bertolotto, C; Ballotti, R				Cheli, Y.; Giuliano, S.; Botton, T.; Rocchi, S.; Hofman, V.; Hofman, P.; Bahadoran, P.; Bertolotto, C.; Ballotti, R.			Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny (vol 30, pg 2307, 2011)	ONCOGENE			English	Correction													Cheli, Yann/O-5783-2016; Rocchi, Stephane/O-4152-2016; Hofman, Paul/P-7654-2018	Cheli, Yann/0000-0001-9839-4332; Rocchi, Stephane/0000-0002-0943-1304; Hofman, Paul/0000-0003-0431-9353; veronique, HOFMAN/0000-0003-0943-1627				Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	20					2390	2390		10.1038/onc.2011.143	http://dx.doi.org/10.1038/onc.2011.143			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF		Bronze			2022-12-17	WOS:000290789200010
J	Takizawa, M; Kim, JS; Tessarollo, L; McNeil, N; Waldschmidt, TJ; Casellas, R; Ried, T; Janz, S				Takizawa, M.; Kim, J. S.; Tessarollo, L.; McNeil, N.; Waldschmidt, T. J.; Casellas, R.; Ried, T.; Janz, S.			Genetic reporter system for oncogenic Igh-Myc translocations in mice	ONCOGENE			English	Article						mouse plasmacytoma T(12;15) translocation; human Burkitt lymphoma t(8;14)(q24;q32) translocation; green fluorescence protein	CLASS SWITCH RECOMBINATION; C-MYC; CHROMOSOMAL TRANSLOCATIONS; B-CELL; BALB/C PLASMACYTOMAS; DNA-REPAIR; IN-VIVO; T(12/15); AID; HYPERMUTATION	The Myc-deregulating chromosomal T(12; 15)(Igh-Myc) translocation, the hallmark mutation of inflammation-and interleukin 6-dependent mouse plasmacytoma (PCT), is the premier model of cancer-associated chromosomal translocations because it is the only translocation in mice that occurs spontaneously (B lymphocyte lineage) and with predictably high incidence (similar to 85% of PCT), and has a direct counterpart in humans: Burkitt lymphoma t(8;14)(q24;q32) translocation. Here, we report on the development of a genetic system for the detection of T(12;15)(Igh-Myc) translocations in plasma cells of a mouse strain in which an enhanced green fluorescent protein (GFP)-encoding reporter gene has been targeted to Myc. Four of the PCTs that developed in the newly generated translocation reporter mice, designated iGFP(5/Myc), expressed GFP consequent to naturally occurring T(12;15) translocation. GFP expression did not interfere with tumor development or the deregulation of Myc on derivative 12 of translocation, der (12), because the reporter gene was allocated to the reciprocal product of translocation, der (15). Although the described reporter gene approach requires refinement before T(12;15) translocations can be quantitatively detected in vivo, including in B lymphocyte lineage cells that have not yet completed malignant transformation, our findings provide proof of principle that reporter gene tagging of oncogenes in gene-targeted mice can be used to elucidate unresolved questions on the occurrence, distribution and trafficking of cells that have acquired cancer-causing chromosomal translocations of great relevance for humans. Oncogene (2010) 29, 4113-4120; doi:10.1038/onc.2010.150; published online 10 May 2010	[Waldschmidt, T. J.; Janz, S.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pathol, Iowa City, IA 52246 USA; [Takizawa, M.; Kim, J. S.] NCI, Genet Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Takizawa, M.; Casellas, R.] Natl Inst Arthrit & Musculoskeletal Dis, Bethesda, MD USA; [Tessarollo, L.] NCI, Mouse Canc Genet Program, CCR, Bethesda, MD 20892 USA; [McNeil, N.; Ried, T.] NCI, Genet Branch, CCR, NIH, Bethesda, MD 20892 USA	University of Iowa; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Janz, S (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pathol, 500 Newton Rd,1046C ML, Iowa City, IA 52246 USA.	siegfried-janz@uiowa.edu		Waldschmidt, Thomas/0000-0001-6147-6991; McNeil, Nicole/0000-0003-1440-6880	NIH; National Cancer Institute [P50CA097274]; NATIONAL CANCER INSTITUTE [ZICBC011265, ZIABC010836, R01CA151354, P50CA097274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041149, ZIAAR041148, Z01AR041149] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank our colleagues from NCI and NIAID, NIH for their contributions to this project: Tina Willington, Vaishali Jarral and Wendy DuBois for genotyping and assistance with the mouse experiments; Eileen Southon for gene targeting; Dr Alexander L Kovalchuk for advice on PCR analysis and providing primers; Drs Sung Sup Park and Santiago Silva for contributions to early stages of this project; and Drs Michael Potter and Beverly Mock for stimulating discussion and laboratory support. For assistance with transfer, cryopreservation, maintenance and rederivation of mice under SPF conditions, we thank: Ling Hu, CCOM, Iowa City, Iowa; the staff of the Jackson Laboratory, Bar Harbor, Maine; and the Office of Animal Resources, CCOM, particularly Dr Kem Singletary and James Hynes. We also thank Lorraine Tygrett, CCOM for assistance with flow cytometry. This work was supported, in part, by the Intramural Research Program of the NIH (LT, RC, TR) and Award Number P50CA097274 from the National Cancer Institute (SJ).	ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; Cheng HL, 2009, P NATL ACAD SCI USA, V106, P2717, DOI 10.1073/pnas.0812304106; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Germain RN, 2005, SEMIN IMMUNOL, V17, P431, DOI 10.1016/j.smim.2005.09.003; Gostissa M, 2009, NATURE, V462, P803, DOI 10.1038/nature08633; Gostissa M, 2009, P NATL ACAD SCI USA, V106, P2265, DOI 10.1073/pnas.0812763106; JANZ S, 1993, P NATL ACAD SCI USA, V90, P7361, DOI 10.1073/pnas.90.15.7361; Janz S, 2006, DNA REPAIR, V5, P1213, DOI 10.1016/j.dnarep.2006.05.017; Kovalchuk AL, 2000, LEUKEMIA, V14, P1127, DOI 10.1038/sj.leu.2401767; Kovalchuk AL, 1997, ONCOGENE, V15, P2369, DOI 10.1038/sj.onc.1201409; Kovalchuk AL, 2000, LEUKEMIA, V14, P909, DOI 10.1038/sj.leu.2401676; Kovalchuk AL, 2003, ONCOGENE, V22, P2842, DOI 10.1038/sj.onc.1206345; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Muller JR, 1996, CANCER RES, V56, P419; Muller JR, 1997, BLOOD, V89, P291, DOI 10.1182/blood.V89.1.291.291_291_296; Muller JR, 1997, CURR TOP MICROBIOL, V224, P251; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Silva S, 2003, CANCER RES, V63, P8656; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Wang JH, 2009, NATURE, V460, P231, DOI 10.1038/nature08159; Wessels JT, 2007, CYTOM PART A, V71A, P542, DOI 10.1002/cyto.a.20419; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822	31	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4113	4120		10.1038/onc.2010.150	http://dx.doi.org/10.1038/onc.2010.150			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20453890	Green Accepted			2022-12-17	WOS:000279892400011
J	Gascoyne, DM; Dunne, J; Behjati, S; Sebire, NJ; Anderson, J; Latchman, DS				Gascoyne, D. M.; Dunne, J.; Behjati, S.; Sebire, N. J.; Anderson, J.; Latchman, D. S.			EWS/ETS proteins promote expression and regulate function of the homeodomain transcription factor BRN3A	ONCOGENE			English	Article						EWS/ETS; Ewing's sarcoma; EFT; BRN3A; POU4F1	EWINGS-SARCOMA; DNA-BINDING; GENE-EXPRESSION; FUSION PROTEIN; NEUROECTODERMAL TUMORS; INHIBITS PROLIFERATION; EWS-FLI1 ONCOPROTEIN; SENSORY NEURONS; TARGET GENE; CELL-LINES	Ewing's sarcoma family tumors (ESFTs or EFTs) express neuronal markers, which indicates they may originate from cells at least partly committed to neuronal lineage. However, recent publications suggest EFT originates in mesenchymal stem cells, and EWS/ETS fusion proteins characteristic of EFT activate neuronal marker expression to confer a neural phenotype on EFT. Here we show that the neuronal marker BRN3A/POU4F1 is expressed abundantly at the protein level in primary EFT but not in rhabdomyosarcoma and neuroblastoma, and EFT cells exhibit high activity of the BRN3A proximal autoregulatory region. EWS/FLI-1 siRNA reduces BRN3A expression and promoter activity and EWS/ETS proteins are bound to the BRN3A locus, suggesting a direct function for EWS/ETS proteins in control of BRN3A expression. Differentiation-associated and autoregulatory activities of BRN3A are respectively impaired and altered in EFT cells, and EWS/FLI-1 siRNA can restore some BRN3A function. A potentially novel function for BRN3A in EFT cells is identified. These results extend the hypothesis that EWS/ETS proteins induce expression of neuronal markers such as BRN3A in EFT by showing that the function of those same markers may be restricted or controlled in an EWS/ETS-dependent manner. Oncogene (2010) 29, 3134-3145; doi: 10.1038/onc.2010.72; published online 29 March 2010	[Gascoyne, D. M.; Behjati, S.; Anderson, J.] UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London, England; [Dunne, J.] Barts & London Queen Marys Sch Med & Dent, Canc Res UK Med Oncol Lab, London, England; [Sebire, N. J.] Great Ormond St Hosp Sick Children, Dept Paediat Pathol, London WC1N 3JH, England; [Latchman, D. S.] Univ London, Birkbeck Coll, London, England	University of London; University College London; Cancer Research UK; University of London; Queen Mary University London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; Birkbeck University London	Gascoyne, DM (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Level 4 Acad Block, Oxford OX3 9DU, England.	duncan.gascoyne@ndcls.ox.ac.uk		Sebire, Neil/0000-0001-5348-9063; Anderson, William/0000-0001-7509-3203	MRC; BBSRC; CR-UK; Great Ormond Street Hospital Childrens Charity [V0907] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); CR-UK(Cancer Research UK); Great Ormond Street Hospital Childrens Charity	We thank Sue Burchill (Leeds, UK) and Peter Houghton (Memphis, USA) for cell lines, Eric Turner (San Diego, USA) for alpha-Brn3a antiserum, Seong-Jin Kim (Bethesda, USA) for TGFbRII (-1670/+36), Sian Gibson and Dyanne Rampling for technical assistance and James Diss for PC-3 cells and useful discussions. Funding was provided by MRC and BBSRC (DMG and DSL), and CR-UK (JD).	Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Baird K, 2005, CANCER RES, V65, P9226, DOI 10.1158/0008-5472.CAN-05-1699; Beauchamp E, 2009, J BIOL CHEM, V284, P9074, DOI 10.1074/jbc.M806233200; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Eliazer S, 2003, MOL CELL BIOL, V23, P482, DOI 10.1128/MCB.23.2.482-492.2003; Eng SR, 2001, J NEUROSCI, V21, P541, DOI 10.1523/JNEUROSCI.21-02-00541.2001; Ensor E, 2001, J BIOL CHEM, V276, P5204, DOI 10.1074/jbc.M007068200; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; Frass B, 2002, BBA-GENE STRUCT EXPR, V1579, P207, DOI 10.1016/S0167-4781(02)00540-7; Fukuma M, 2003, ONCOGENE, V22, P1, DOI 10.1038/sj.onc.1206055; Gascoyne DM, 2004, ONCOGENE, V23, P3830, DOI 10.1038/sj.onc.1207497; Gonzalez I, 2004, CLIN CANCER RES, V10, P751, DOI 10.1158/1078-0432.CCR-0778-03; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hippenmeyer S, 2005, PLOS BIOL, V3, P878, DOI 10.1371/journal.pbio.0030159; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; Kim S, 2006, MOL CELL BIOL, V26, P2467, DOI 10.1128/MCB.26.7.2467-2478.2006; Landuzzi L, 2000, AM J PATHOL, V157, P2123, DOI 10.1016/S0002-9440(10)64850-X; Lanier J, 2007, DEV BIOL, V302, P703, DOI 10.1016/j.ydbio.2006.10.050; LeblondFrancillard M, 1997, J CLIN ENDOCR METAB, V82, P89, DOI 10.1210/jc.82.1.89; Manara MC, 2007, CLIN CANCER RES, V13, P1322, DOI 10.1158/1078-0432.CCR-06-1518; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Perez-Sanchez C, 2002, NUCLEIC ACIDS RES, V30, P4872, DOI 10.1093/nar/gkf610; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Radig K, 1998, PATHOL RES PRACT, V194, P157, DOI 10.1016/S0344-0338(98)80016-2; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; THIELE CJ, 1990, CANCER INVEST, V8, P629, DOI 10.3109/07357909009018932; Torchia EC, 2003, CANCER RES, V63, P3464; Trieu M, 1999, J NEUROSCI, V19, P6549; Trieu M, 2003, DEVELOPMENT, V130, P111, DOI 10.1242/dev.00194; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Yamaki K, 2005, MENT RETARD, V43, P1, DOI 10.1352/0047-6765(2005)43<1:BWSAAW>2.0.CO;2; Yeny CT, 2005, CANCER RES, V65, P8698, DOI 10.1158/0008-5472.CAN-05-1704; Zhang JS, 2004, CANCER RES, V64, P6026, DOI 10.1158/0008-5472.CAN-03-2594	50	1	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3134	3145		10.1038/onc.2010.72	http://dx.doi.org/10.1038/onc.2010.72			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20348952				2022-12-17	WOS:000278133100010
J	Pillaire, MJ; Selves, J; Gordien, K; Gourraud, PA; Gentil, C; Danjoux, M; Do, C; Negre, V; Bieth, A; Guimbaud, R; Trouche, D; Pasero, P; Mechali, M; Hoffmann, JS; Cazaux, C				Pillaire, M-J; Selves, J.; Gordien, K.; Gourraud, P-A; Gentil, C.; Danjoux, M.; Do, C.; Negre, V.; Bieth, A.; Guimbaud, R.; Trouche, D.; Pasero, P.; Mechali, M.; Hoffmann, J-S; Cazaux, C.			A 'DNA replication' signature of progression and negative outcome in colorectal cancer (vol 29, pg 876, 2009)	ONCOGENE			English	Correction													Gourraud, Pierre-Antoine FD/O-3024-2015; Pillaire, Marie-Jeanne/P-1579-2014; Pasero, Philippe/O-2340-2018; GUIMBAUD, Rosine/M-7503-2014; Hoffmann, Jean-Sebastien/O-9183-2014	Pillaire, Marie-Jeanne/0000-0001-6866-7416; Pasero, Philippe/0000-0001-5891-0822; Hoffmann, Jean-Sebastien/0000-0003-2222-354X				PILLAIRE MJ, 2009, ONCOGENE, V29, P876, DOI DOI 10.1038/0NC.2009.378	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2010	29	14					2160	2160		10.1038/onc.2010.66	http://dx.doi.org/10.1038/onc.2010.66			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX		Bronze			2022-12-17	WOS:000276402800014
J	Kato, M; Paranjape, T; Muller, RU; Nallur, S; Gillespie, E; Keane, K; Esquela-Kerscher, A; Weidhaas, JB; Slack, FJ				Kato, M.; Paranjape, T.; Mueller, R. U.; Nallur, S.; Gillespie, E.; Keane, K.; Esquela-Kerscher, A.; Weidhaas, J. B.; Slack, F. J.			The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells (vol 28, pg 2419, 2009)	ONCOGENE			English	Correction													Müller, Roman-Ulrich/AAK-3493-2021	Müller, Roman-Ulrich/0000-0001-6910-0745; Weidhaas, Joanne/0000-0002-5096-3281; Slack, Frank/0000-0001-8263-0409				Kato M, 2009, ONCOGENE, V28, P2419, DOI 10.1038/onc.2009.106	1	1	1	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	2009	28	33					3008	3008		10.1038/onc.2009.218	http://dx.doi.org/10.1038/onc.2009.218			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA		Bronze			2022-12-17	WOS:000269142800009
J	Wischermann, K; Popp, S; Moshir, S; Scharffetter-Kochanek, K; Wlaschek, M; de Gruijl, F; Hartschuh, W; Greinert, R; Volkmer, B; Faust, A; Rapp, A; Schmezer, P; Boukamp, P				Wischermann, K.; Popp, S.; Moshir, S.; Scharffetter-Kochanek, K.; Wlaschek, M.; de Gruijl, F.; Hartschuh, W.; Greinert, R.; Volkmer, B.; Faust, A.; Rapp, A.; Schmezer, P.; Boukamp, P.			UVA radiation causes DNA strand breaks, chromosomal aberrations and tumorigenic transformation in HaCaT skin keratinocytes (vol 27, pg 4269, 2008)	ONCOGENE			English	Correction																		Wischermann K, 2008, ONCOGENE, V27, P4269, DOI 10.1038/onc.2008.70	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2008	27	53					6790	6790		10.1038/onc.2008.375	http://dx.doi.org/10.1038/onc.2008.375			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO		Bronze			2022-12-17	WOS:000260866200009
J	Suprynowicz, FA; Disbrow, GL; Krawczyk, E; Simic, V; Lantzky, K; Schlegel, R				Suprynowicz, F. A.; Disbrow, G. L.; Krawczyk, E.; Simic, V.; Lantzky, K.; Schlegel, R.			HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells (vol 27, pg 1071, 2008)	ONCOGENE			English	Correction																		Suprynowicz FA, 2008, ONCOGENE, V27, P1071, DOI 10.1038/sj.onc.1210725	1	1	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	49					6396	6396		10.1038/onc.2008.357	http://dx.doi.org/10.1038/onc.2008.357			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK		Bronze			2022-12-17	WOS:000260263400009
J	Leder, A; McMenamin, J; Zhou, F; Moran, JL; Beier, D; Leder, P				Leder, A.; McMenamin, J.; Zhou, F.; Moran, J. L.; Beier, D. R.; Leder, P.			Genome-wide SNP analysis of Tg.AC transgenic mice reveals an oncogenic collaboration between v-Ha-ras and Ink4a, which is absent in p53 deficiency	ONCOGENE			English	Article						Tg.AC; SNP screen; ras; ink4a (cdkn2a); ink4b (cdkn2b); p53	TUMOR-SUPPRESSOR LOCUS; CELLULAR SENESCENCE; MOUSE; P16(INK4A); PATHWAYS; P16; RETINOBLASTOMA; INHIBITION; P15(INK4B); MUTATIONS	Oncogenesis is a progressive process often involving collaboration between various oncogenes and tumor suppressors. To identify those genes that collaborate with oncogenic ras, we took advantage of the Tg. AC transgenic mouse, a line that harbors the v- Ha- ras transgene and spontaneously develops an array of malignant tumors. By crossing Tg. AC mice on an inbred FVB background to other inbred strains, F1 mice were created that could be analysed using genome wide, single nucleotide polymorphism ( SNP) screens. Loss of heterozygosity ( LOH) in tumors and tumor cell lines marked a somatic event, possibly the inactivation of tumor suppressor gene( s). LOH could also represent DNA damage, a sign of genomic instability in the pretransformed cell. Nonetheless, the screens showed no evidence of such generalized genomic instability. Instead, they revealed a single region of LOH on chromosome 4 that occurred via somatic recombination/ gene conversion, generating a region of isoparental disomy. This LOH provided a clue that linked v- Ha- ras to the inactivation of the Ink4a locus in 25 of 32 tumor cell lines. This collaboration is seen regardless of tumor type or genetic background. In contrast, tumors that develop in bitransgenic mice bearing both the v- Ha- ras gene and a heterozygous mutant p53 allele tend to retain the Ink4a locus and instead lose the p53 wild- type allele. This suggests that different strategies can be selected to collaborate with v- Ha- ras in tumorigenesis.	[Leder, A.; McMenamin, J.; Zhou, F.; Leder, P.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Moran, J. L.; Beier, D. R.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Leder, P (corresponding author), Harvard Univ, Sch Med, Dept Genet, NRB 356B,77 Ave Louis Pasteur, Boston, MA 02115 USA.	leder@genetics.med.harvard.edu		Moran, Jennifer/0000-0002-5664-4716				Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Berger JH, 2007, CURR MOL MED, V7, P63, DOI 10.2174/156652407779940477; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Guan RJ, 1999, GASTROENTEROLOGY, V116, P1063, DOI 10.1016/S0016-5085(99)70009-0; Humble MC, 2005, ONCOGENE, V24, P8217, DOI 10.1038/sj.onc.1209000; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084; Leder A, 1997, BLOOD, V90, P1275, DOI 10.1182/blood.V90.3.1275.1275_1275_1282; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Moran JL, 2006, GENOME RES, V16, P436, DOI 10.1101/gr.4563306; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721; Uhrbom L, 2002, CANCER RES, V62, P5551	32	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2456	2465		10.1038/sj.onc.1210866	http://dx.doi.org/10.1038/sj.onc.1210866			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17952114				2022-12-17	WOS:000254844900010
J	Begum, S; Emami, N; Cheung, A; Wilkins, O; Der, S; Hamel, PA				Begum, S.; Emami, N.; Cheung, A.; Wilkins, O.; Der, S.; Hamel, P. A.			Cell type-specific regulation of distinct sets of gene targets by Pax3 and Pax3/FKHR (vol 24, pg 1860, 2005)	ONCOGENE			English	Correction													Wilkins, Olivia/AGG-7629-2022	Wilkins, Olivia/0000-0001-9762-7069				Begum S, 2005, ONCOGENE, V24, P1860, DOI 10.1038/sj.onc.1208315	1	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1812	1812		10.1038/onc.2008.12	http://dx.doi.org/10.1038/onc.2008.12			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF		Bronze			2022-12-17	WOS:000253962100018
J	Brandes, JC; Carraway, H; Herman, JG				Brandes, J. C.; Carraway, H.; Herman, J. G.			Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter (Vol 26, pg 6229, 2007)	ONCOGENE			English	Correction													Carraway, Hetty/AAR-4977-2020	Carraway, Hetty/0000-0001-5241-3614; Brandes, Johann/0000-0002-1815-8311				Brandes JC, 2007, ONCOGENE, V26, P6684, DOI 10.1038/sj.onc.1210781	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6684	6684		10.1038/sj.onc.1210781	http://dx.doi.org/10.1038/sj.onc.1210781			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT		Bronze			2022-12-17	WOS:000250081500011
J	Nandi, S; Reinert, LS; Hachem, A; Mazan-Mamczarz, K; Hsu, HL; Hagner, P; He, H; Gartenhaus, RB				Nandi, S.; Reinert, L. S.; Hachem, A.; Mazan-Mamczarz, K.; Hsu, H. L.; Hagner, P.; He, H.; Gartenhaus, R. B.			Phosphorylation of MCT-1 by p44/42 MAPKis required for its stabilization in response to DNA damage (vol 26, pg 2283, 2007)	ONCOGENE			English	Correction									Natl Hlth Res Inst, Zhunan Towan, Miaoli County, Taiwan	National Health Research Institutes - Taiwan	Nandi, S (corresponding author), Natl Hlth Res Inst, Zhunan Towan, Miaoli County, Taiwan.		Hsu, Hsin-Ling/E-3672-2010	Reinert, Line/0000-0002-8317-0886				Nandi S, 2007, ONCOGENE, V26, P2674, DOI 10.1038/sj.onc.1210447	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2674	2674		10.1038/sj.onc.1210447	http://dx.doi.org/10.1038/sj.onc.1210447			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI		Bronze			2022-12-17	WOS:000245831200015
J	Tong, S; Liss, AS; You, M; Bose, HR				Tong, S.; Liss, A. S.; You, M.; Bose, H. R., Jr.			The activation of TC10, a Rho small GTPase, contributes to v-Rel-mediated transformation	ONCOGENE			English	Article						v-Rel; NF-kappa B; TC10; Rho; GTPase; transformation	STIMULATED GLUT4 TRANSLOCATION; KAPPA-B FAMILY; C-REL; DNA-BINDING; CELL-TRANSFORMATION; PROTEINS; CDC42; EXPRESSION; MUTATIONS; GENES	v-Rel is the oncogenic member of the Rel/NF-kappa B family of transcription factors and transforms hematopoietic cells and fibroblasts. Differential display was employed to identify target genes that exhibit altered expression in v-Rel transformed cells. One of the cDNAs identified encodes the chicken ortholog of TC10, a member of the Rho small GTPase family. The expression of TC10 was increased in v-Rel-transformed chicken embryonic fibroblasts (CEFs) 3 to 6-fold relative to control cells at both the RNA and protein levels. An elevated level of active, GTP-bound TC10 was also detected in v-Rel-transformed cells relative to control cells. Expression of a dominant-negative TC10 mutant (TC10T32N) decreased the colony formation potential of v-Rel-transformed cells. Furthermore, overexpression of wild-type TC10 or a gain-of-function mutant (TC10Q76L) greatly enhanced the ability of v-Rel transformed CEFs to form colonies in soft agar. In addition to enhance the transformation potential of v-Rel, the overexpression of wild-type TC10 or the gain-of-function mutant alone enhanced the saturation density of CEFs and was sufficient for their anchorage-independent growth in vitro. These results indicate that elevated TC10 activity contributes to v-Rel-mediated transformation of CEFs and demonstrate for the first time that a Rho factor alone is capable of inducing the in vitro transformation of primary cells.	Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Bose, HR (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, 1 Univ Stn A5000, Austin, TX 78712 USA.	bose@mail.utexas.edu	Liss, Andrew/L-9696-2019		NCI NIH HHS [CA33192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham MT, 2001, LARYNGOSCOPE, V111, P1285, DOI 10.1097/00005537-200107000-00027; AKIYAMA Y, 1974, BIKEN J, V17, P105; Anastasiadis PZ, 2001, J BIOL CHEM, V276, P9050, DOI 10.1074/jbc.M006570200; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; Benard V, 2002, METHOD ENZYMOL, V345, P349; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bernards A, 2005, GROWTH FACTORS, V23, P143, DOI 10.1080/08977190500130480; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; Chang L, 2002, P NATL ACAD SCI USA, V99, P12835, DOI 10.1073/pnas.202495599; Chen J, 2005, J BIOL CHEM, V280, P29912, DOI 10.1074/jbc.M504516200; Chiang SH, 2002, J BIOL CHEM, V277, P13067, DOI 10.1074/jbc.M109471200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; del Peso L, 1997, ONCOGENE, V15, P3047; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; Dransart E, 2005, TRAFFIC, V6, P957, DOI 10.1111/j.1600-0854.2005.00335.x; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Frame MC, 2002, CURR OPIN GENET DEV, V12, P36, DOI 10.1016/S0959-437X(01)00261-1; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; FRYKBERG L, 1987, ONCOGENE, V1, P415; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hrdlickova R, 2006, J VIROL, V80, P281, DOI 10.1128/JVI.80.1.281-295.2006; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P308; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HRDLICKOVA R, 1999, ENCY VIROLOGY, V3, P1496; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Keely PJ, 2001, LANCET, V358, P1744, DOI 10.1016/S0140-6736(01)06840-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; MOSCOW JA, 1994, ONCOGENE, V9, P189; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; Murphy GA, 2001, CELL GROWTH DIFFER, V12, P157; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; NAZERIAN K, 1977, AVIAN DIS, V21, P69, DOI 10.2307/1589365; Nehyba J, 2002, MOL CELL BIOL, V22, P3942, DOI 10.1128/MCB.22.11.3942-3957.2002; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; OKUNO H, 1991, ONCOGENE, V6, P1491; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; PERONA R, 1993, ONCOGENE, V8, P1285; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAO A, 1990, CANCER RES, V50, P4764; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Ridley AJ, 1997, INT J BIOCHEM CELL B, V29, P1225, DOI 10.1016/S1357-2725(97)00052-6; ROMERO P, 1995, J VIROL, V69, P301, DOI 10.1128/JVI.69.1.301-307.1995; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Tanabe K, 2000, J NEUROSCI, V20, P4138; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; van Golen KL, 2000, CANCER RES, V60, P5832; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WARBURG O, 1930, METABOLISM TUMORS; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Whitmire KH, 1998, ADV ORGANOMET CHEM, V42, P1, DOI 10.1016/S0065-3055(08)60542-0; You MJ, 1998, METHODS, V16, P373, DOI 10.1006/meth.1998.0692; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806; ZHANG JY, 1989, J VIROL, V63, P1107, DOI 10.1128/JVI.63.3.1107-1115.1989; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	88	1	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2318	2329		10.1038/sj.onc.1210023	http://dx.doi.org/10.1038/sj.onc.1210023			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016434				2022-12-17	WOS:000245466000008
J	Deppert, W				Deppert, Wolfgang			Guest editor	ONCOGENE			English	Editorial Material																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	2007	26	15					2141	2141		10.1038/sj.onc.1210275	http://dx.doi.org/10.1038/sj.onc.1210275			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE		Bronze			2022-12-17	WOS:000245394800001
J	Cerone, MA; Londono-Vallejo, JA; Autexier, C				Cerone, M. A.; Londono-Vallejo, J. A.; Autexier, C.			Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance (vol 25, pg 7411, 2006)	ONCOGENE			English	Correction													Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Cerone MA, 2007, ONCOGENE, V26, P1983, DOI 10.1038/sj.onc.1210192	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1983	1983		10.1038/sj.onc.1210192	http://dx.doi.org/10.1038/sj.onc.1210192			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE		Bronze			2022-12-17	WOS:000245117700016
J	Duesbery, NS; Teh, BT				Duesbery, N. S.; Teh, B. T.			Cancer: biology and therapeutics - A tribute to George Vande Woude	ONCOGENE			English	Biographical-Item									Van Andel Res Inst, Lab Canc & Dev Cell Biol, Grand Rapids, MI 49503 USA	Van Andel Institute	Duesbery, NS (corresponding author), Van Andel Res Inst, Lab Canc & Dev Cell Biol, 333 Boostwick Ave,NE, Grand Rapids, MI 49503 USA.	duesbery@vai.org		Teh, Bin Tean/0000-0003-1514-1124; DUESBERY, NICK/0000-0002-4258-5655; Duesbery, Nicholas/0000-0002-5708-4984					0	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2007	26	9					1258	1259		10.1038/sj.onc.1210257	http://dx.doi.org/10.1038/sj.onc.1210257			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322909				2022-12-17	WOS:000244558700001
J	Hamai, A; Richon, C; Meslin, F; Faure, F; Kauffmann, A; Lecluse, Y; Jalil, A; Larue, L; Avril, MF; Chouaib, S; Mehrpour, M				Hamai, A.; Richon, C.; Meslin, F.; Faure, F.; Kauffmann, A.; Lecluse, Y.; Jalil, A.; Larue, L.; Avril, M. F.; Chouaib, S.; Mehrpour, M.			Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation (vol 25, pg 7618, 2006)	ONCOGENE			English	Correction													Chouaib, Salem/F-7939-2016; Larue, Lionel/F-7355-2013; faure, florence/P-9064-2016	faure, florence/0000-0002-8359-4283				Hamai A, 2007, ONCOGENE, V26, P1256, DOI 10.1038/sj.onc.1210213	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1256	1256		10.1038/sj.onc.1210213	http://dx.doi.org/10.1038/sj.onc.1210213			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG		Bronze			2022-12-17	WOS:000244406400016
J	Winograd-Katz, SE; Levitzki, A				Winograd-Katz, S. E.; Levitzki, A.			Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor (vol 25, pg 7381, 2006)	ONCOGENE			English	Correction																		Winograd-Katz SE, 2006, ONCOGENE, V25, P7381, DOI 10.1038/sj.onc.1209737	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	5					788	788		10.1038/sj.onc.1210160	http://dx.doi.org/10.1038/sj.onc.1210160			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM		Bronze			2022-12-17	WOS:000243902200016
J	O'Keefe, LV; Liu, Y; Perkins, A; Dayan, S; Saint, R; Richards, RI				O'Keefe, L. V.; Liu, Y.; Perkins, A.; Dayan, S.; Saint, R.; Richards, R. I.			FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila (vol 24, pg 6590, 2005)	ONCOGENE			English	Correction													Saint, Robert/A-4190-2008; O'Keefe, Louise V/B-9856-2008; Dayan, Sonia/U-9400-2017; Dayan, Sonia/D-7960-2013; Richards, Robert/ABE-6423-2020	Saint, Robert/0000-0002-7989-6043; Dayan, Sonia/0000-0002-5616-7542; Dayan, Sonia/0000-0002-5616-7542; Richards, Robert Ian/0000-0002-5978-6453				O'Keefe LV, 2005, ONCOGENE, V24, P6590, DOI 10.1038/sj.onc.1208806	1	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2006	25	58					7662	7662		10.1038/sj.onc.1210119	http://dx.doi.org/10.1038/sj.onc.1210119			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU		Bronze			2022-12-17	WOS:000242655500011
J	Bienz, M				Bienz, M.			Bio-sketch for oncogene review issue on Wnt signalling - M Bienz	ONCOGENE			English	Biographical-Item									MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bienz, M (corresponding author), MRC, Mol Biol Lab, Cambridge CB2 2QH, England.							BIENZ M, PUBLICATION LIST; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8	2	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2006	25	57					7441	7441		10.1038/sj.onc.1210062	http://dx.doi.org/10.1038/sj.onc.1210062			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143287	Bronze			2022-12-17	WOS:000242514900001
J	Lai, SY; Childs, EE; Xi, SC; Coppelli, FM; Gooding, WE; Wells, A; Ferris, RL; Grandis, JR				Lai, SY; Childs, EE; Xi, SC; Coppelli, FM; Gooding, WE; Wells, A; Ferris, RL; Grandis, JR			Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma (vol 24, pg 4442, 2005)	ONCOGENE			English	Correction														Lai, Stephen/0000-0001-8301-7286				Lai SY, 2005, ONCOGENE, V24, P8216, DOI 10.1038/sj.onc.1209224	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2005	24	55					8216	8216		10.1038/sj.onc.1209224	http://dx.doi.org/10.1038/sj.onc.1209224			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL		Bronze			2022-12-17	WOS:000233809400015
J	Sukezane, T; Oneyama, C; Kakumoto, K; Shibutani, K; Hanafusa, H; Akagi, T				Sukezane, T; Oneyama, C; Kakumoto, K; Shibutani, K; Hanafusa, H; Akagi, T			Human diploid broblasts are resistant to MEK/ERK-mediated disruption of the actin cytoskeleton and invasiveness stimulated by Ras (vol 24, pg 8216, 2005)	ONCOGENE			English	Correction																		Sukezane T, 2005, ONCOGENE, V24, P8216, DOI 10.1038/sj.onc.1209223	1	1	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2005	24	55					8216	8216		10.1038/sj.onc.1209223	http://dx.doi.org/10.1038/sj.onc.1209223			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL		Bronze			2022-12-17	WOS:000233809400014
J	Yoshida, M; Jeang, KT				Yoshida, M; Jeang, KT			Preface to 25 years of HTLV-1 and ATL research	ONCOGENE			English	Editorial Material							T-CELL LEUKEMIA; RETROVIRUS		Banyu Tsukuba Res Inst, Tsukuba, Ibaraki, Japan; NIAID, Mol Virol Sect, LMM, NIH, Bethesda, MD 20892 USA	Merck & Company; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Yoshida, M (corresponding author), Banyu Tsukuba Res Inst, Tsukuba, Ibaraki, Japan.		Jeang, Kuan-Teh/A-2424-2008					Gallo RC, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-17; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Takatsuki K, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-16; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	6	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2005	24	39					5925	5925		10.1038/sj.onc.1208967	http://dx.doi.org/10.1038/sj.onc.1208967			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH					2022-12-17	WOS:000231623400001
J	Asano, T; Yao, YX; Zhu, JJ; Li, DH; Abbruzzese, JL; Reddy, SAG				Asano, T; Yao, YX; Zhu, JJ; Li, DH; Abbruzzese, JL; Reddy, SAG			The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappa B and c-Myc in pancreatic cancer cells (vol 23, pg 8517, 2004)	ONCOGENE			English	Correction																		Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902	1	1	2	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 16	2005	24	26					4320	4320		10.1038/sj.onc.1208766	http://dx.doi.org/10.1038/sj.onc.1208766			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY		Bronze			2022-12-17	WOS:000229815300019
J	Ohali, A; Avigad, S; Zaizov, R; Ophir, R; Horn-Saban, S; Cohen, IJ; Meller, I; Kollender, Y; Issakov, J; Yaniv, I				Ohali, A; Avigad, S; Zaizov, R; Ophir, R; Horn-Saban, S; Cohen, IJ; Meller, I; Kollender, Y; Issakov, J; Yaniv, I			Prediction of high-risk Ewing's sarcoma by gene expression profiling (vol 23, pg 8997, 2004)	ONCOGENE			English	Correction													Cohen, Ian/H-3358-2013					Ohali A, 2004, ONCOGENE, V23, P8997, DOI 10.1038/sj.onc.1208060	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 16	2005	24	26					4319	4319		10.1038/sj.onc.1208765	http://dx.doi.org/10.1038/sj.onc.1208765			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY		Bronze			2022-12-17	WOS:000229815300017
J	[Anonymous]				[Anonymous]			A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer(vol 24, pg 4163, 2005)	ONCOGENE			English	Correction														Parish, Christopher/0000-0001-7740-0430					0	1	1	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4163	4163						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA					2022-12-17	WOS:000229680300016
J	Herbst, A; Salghetti, SE; Kim, SY; Tansey, WP				Herbst, A; Salghetti, SE; Kim, SY; Tansey, WP			Multiple cell-type-specific elements regulate Myc protein stability (vol 23, pg 3863, 2004)	ONCOGENE			English	Correction																		Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492	1	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2004	23	58					9448	9448		10.1038/sj.onc.1208362	http://dx.doi.org/10.1038/sj.onc.1208362			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT		Bronze			2022-12-17	WOS:000225764100019
J	Kamio, M; Yoshida, T; Ogata, H; Douchi, T; Nagata, Y; Inoue, M; Hasegawa, M; Yonemitsu, Y; Yoshimura, A				Kamio, M; Yoshida, T; Ogata, H; Douchi, T; Nagata, Y; Inoue, M; Hasegawa, M; Yonemitsu, Y; Yoshimura, A			SOC1 inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein (vol 23, pg 3107, 2004)	ONCOGENE			English	Correction																		Kamio M, 2004, ONCOGENE, V23, P3107, DOI 10.1038/sj.onc.1207453	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2004	23	58					9449	9449		10.1038/sj.onc.1208310	http://dx.doi.org/10.1038/sj.onc.1208310			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT		Bronze			2022-12-17	WOS:000225764100022
J	Ward, KR; Zhang, KX; Somasiri, AM; Roskelley, CD; Schrader, JW				Ward, KR; Zhang, KX; Somasiri, AM; Roskelley, CD; Schrader, JW			Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and tumorigenesis (vol 23, pg 1187, 2004)	ONCOGENE			English	Correction																		Ward KR, 2004, ONCOGENE, V23, P1187, DOI 10.1038/sj.onc.1207226	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	2004	23	54					8858	8858		10.1038/sj.onc.1207865	http://dx.doi.org/10.1038/sj.onc.1207865			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ		Bronze			2022-12-17	WOS:000225165100018
J	Chiba, S; Ishikawa, F; Miyazono, K				Chiba, S; Ishikawa, F; Miyazono, K			Dr Hisamaru Hirai - Obituary	ONCOGENE			English	Biographical-Item									Univ Tokyo, Dept Cell Therapy & Transplantat Med, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo, Japan; Kyoto Univ, Grad Sch Biostudies, Lab Cell Cycle Regulat, Dept Gene Mech, Kyoto, Japan	University of Tokyo; University of Tokyo; Kyoto University	Chiba, S (corresponding author), Univ Tokyo, Dept Cell Therapy & Transplantat Med, Tokyo, Japan.							HIRAI H, PUBLICATION LIST	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2004	23	24					4196	4197		10.1038/sj.onc.1207626	http://dx.doi.org/10.1038/sj.onc.1207626			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ		Bronze			2022-12-17	WOS:000221586000001
J	Kang, AD; Park, G; Kim, YH; Oh, IH				Kang, AD; Park, G; Kim, YH; Oh, IH			Differential modulation of Myb family genes by Ets-2	ONCOGENE			English	Article						myb family gene; ets-2; transcriptional cooperation	MURINE A-MYB; C-MYB; B-MYB; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL DOMAINS; EXPRESSION; ONCOGENE; PHOSPHORYLATION; PROTEINS; DISTINCT	The myb family of genes encodes highly homologous nuclear transcription factors that play distinct roles in the development of breast, germ cells and hematoid organs. While the mechanisms associated with the regulation of these genes remain unknown, the transactivation of c-Myb was previously shown to be upregulated by transcriptional cooperation with Ets-2. The present study examines the transactivation potential of the myb gene family in cooperation with Ets-2. A-Myb and c-Myb showed similar transcriptional cooperation with Ets-2, but not with Ets-1. Interestingly, B-Myb showed no cooperative activity with Ets-2 or Ets-1. Additionally, deletion mutants of A-Myb or c-Myb, where the C-terminal negative regulatory domain was deleted, did not abrogate their ability to cooperate with Ets-2. However, the deletion mutant of B-Myb, where the C-terminal positive regulatory domain was deleted, restored its ability to cooperate with Ets-2. Furthermore, studies using a series of 'domain-swapped' mutants between c-Myb and B-Myb revealed that the C-terminus of B-Myb, which is responsible for the protein's transactivation potential, blocks transcriptional cooperation with Ets-2. These results suggest that the myb gene family can be differentially modulated by Ets-2, and that the C-terminus is the domain that regulates this activity.	Catholic Univ Korea, Cell & Gene Therapy Inst, Dept Cellular Med & Biol, Seoul 137701, South Korea; Catholic Univ Korea, Dept Clin Pathol, Seoul 137701, South Korea; Korea Univ, Seoul 136701, South Korea	Catholic University of Korea; Catholic University of Korea; Korea University	Oh, IH (corresponding author), Catholic Univ Korea, Cell & Gene Therapy Inst, Dept Cellular Med & Biol, 505 Banpo Dong, Seoul 137701, South Korea.	iho@catholic.ac.kr		Kim, Yeul Hong/0000-0002-2555-2333				BALUDA MA, 1994, ONCOGENE, V9, P2761; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; KALKBRENNER F, 1990, ONCOGENE, V5, P657; METTUS RV, 1994, ONCOGENE, V9, P3077; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Patel G, 1996, ONCOGENE, V13, P1197; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	25	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4177	4181		10.1038/sj.onc.1207537	http://dx.doi.org/10.1038/sj.onc.1207537			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064740				2022-12-17	WOS:000221520200017
J	Janz, C; Susse, S; Wiesmuller, L				Janz, C; Susse, S; Wiesmuller, L			P53 and recombination intermediates: role of tetramerization at DNA junctions in complex formation and exonucleolytic degradation (vol 21, pg 2130, 2002)	ONCOGENE			English	Correction									Univ Frauenklin & Poliklin, D-89075 Ulm, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Ulm University; Heinrich Pette Institute; University of Hamburg	Janz, C (corresponding author), Univ Frauenklin & Poliklin, Prittwitzstr 43, D-89075 Ulm, Germany.							Janz C, 2003, ONCOGENE, V22, P2856, DOI 10.1038/sj.onc.1206591	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2856	2856		10.1038/sj.onc.1206591	http://dx.doi.org/10.1038/sj.onc.1206591			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ		Bronze			2022-12-17	WOS:000182569300018
J	Zink, D; Mayr, C; Janz, C; Wiesmuller, L				Zink, D; Mayr, C; Janz, C; Wiesmuller, L			Association of P53 and MSH2 with recombinative repair complexes during S-phase (vol 21, pg 4788, 2002)	ONCOGENE			English	Correction									LMU Munchen, Inst Anthropol & Humangenet, D-80336 Munich, Germany; Univ Frauenklin & Poliklin, D-89075 Ulm, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	University of Munich; Ulm University; Heinrich Pette Institute; University of Hamburg	Zink, D (corresponding author), LMU Munchen, Inst Anthropol & Humangenet, Goethestr 31, D-80336 Munich, Germany.		Zink, Daniele/A-8181-2015					Zink D, 2003, ONCOGENE, V22, P2856, DOI 10.1038/sj.onc.1206590	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2856	2856		10.1038/sj.onc.1206590	http://dx.doi.org/10.1038/sj.onc.1206590			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ		Bronze			2022-12-17	WOS:000182569300017
J	Chang, BY; Harte, RA; Cartwright, CA				Chang, BY; Harte, RA; Cartwright, CA			RACK1: a novel substrate for the Src protein-tyrosine kinase (vol 22, pg 1748, 2003)	ONCOGENE			English	Correction																		Chang BY, 2003, ONCOGENE, V22, P1748, DOI 10.1038/sj.onc.1206276	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1748	1748		10.1038/sj.onc.1206276	http://dx.doi.org/10.1038/sj.onc.1206276			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH		Bronze			2022-12-17	WOS:000181580500018
J	Peschiaroli, A; Figliola, R; Coltella, L; Strom, A; Valentini, A; D'Agnano, I; Maione, R				Peschiaroli, A; Figliola, R; Coltella, L; Strom, A; Valentini, A; D'Agnano, I; Maione, R			MyoD induces apoptosis in the absence of RB function through a p21(WAF1)-dependent relocalization of cyclin/cdk complexes to the nucleus (vol 22, pg 1747, 2003)	ONCOGENE			English	Correction													Coltella, Luana/AAA-5263-2020; D'Agnano, Igea/AAR-7282-2020	D'Agnano, Igea/0000-0002-2646-9224; PESCHIAROLI, ANGELO/0000-0001-6311-2382				Peschiaroli A, 2003, ONCOGENE, V22, P1747, DOI 10.1038/sj.onc.1206275	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1747	1747		10.1038/sj.onc.1206275	http://dx.doi.org/10.1038/sj.onc.1206275			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH		Bronze			2022-12-17	WOS:000181580500017
J	Dunican, DS; McWilliam, P; Tighe, O; Parle-McDermott, A; Croke, DT				Dunican, DS; McWilliam, P; Tighe, O; Parle-McDermott, A; Croke, DT			Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization (vol 21, pg 3253, 2002)	ONCOGENE			English	Correction													Tighe, Orna P/D-6223-2012; Dunican, Donncha/A-8147-2011	Tighe, Orna/0000-0003-0931-1254; Croke, David/0000-0003-2718-3583				Dunican DS, 2002, ONCOGENE, V21, P3253, DOI 10.1038/sj.onc.1205431	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 7	2002	21	51					7912	7912		10.1038/sj.onc.1205655	http://dx.doi.org/10.1038/sj.onc.1205655			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT		Bronze			2022-12-17	WOS:000178946000017
J	Sidransky, D				Sidransky, D			Untitled	ONCOGENE			English	Editorial Material																			0	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	2002	21	48					7283	7283		10.1038/sj.onc.1205811	http://dx.doi.org/10.1038/sj.onc.1205811			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW		Bronze			2022-12-17	WOS:000178618000001
J	Corey, DR				Corey, DR			Telomerase inhibition, oligonucleotides, and clinical trials (vol 21, pg 631, 2002)	ONCOGENE			English	Correction																		Corey DR, 2002, ONCOGENE, V21, P6557, DOI 10.1038/sj.onc.1205721	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6557	6557		10.1038/sj.onc.1205721	http://dx.doi.org/10.1038/sj.onc.1205721			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD		Bronze			2022-12-17	WOS:000177925300016
J	Lee, SH; Zhang, W; Choi, JJ; Cho, YS; Oh, SH; Kim, JW; Hu, LM; Xu, J; Liu, JS; Lee, JH				Lee, SH; Zhang, W; Choi, JJ; Cho, YS; Oh, SH; Kim, JW; Hu, LM; Xu, J; Liu, JS; Lee, JH			Qverexpression of the thymosin beta-10 gene in human ovarian cancer cells disrupts F-actin stress fiber and leads to apoptosis (vol 21, pg 5822, 2002)	ONCOGENE			English	Correction														Kim, Jung-whan/0000-0002-7829-1480				Lee SH, 2002, ONCOGENE, V21, P5822, DOI 10.1038/sj.onc.1205714	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5822	5822		10.1038/sj.onc.1205714	http://dx.doi.org/10.1038/sj.onc.1205714			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL		Bronze			2022-12-17	WOS:000177463400019
J	Guil, S; Darzynkiewicz, E; Bach-Elias, M				Guil, S; Darzynkiewicz, E; Bach-Elias, M			Study of the 2719 mutant of the c-H-ras oncogene in a bi-intronic alternative splicing system	ONCOGENE			English	Article						splicing; H-ras; 2719 H-ras mutant; CBC; mini-exon; terminal exon	SITE-DIRECTED MUTAGENESIS; SR PROTEINS; IN-VITRO; U1 SNRNP; EXPRESSION; MODULATION	C-H-ras proto-oncogene forms part of the signal transduction pathway of numerous external stimuli. This proto-oncogene is regulated by alternative splicing within its intron D due to the presence of the alternative intron D exon (IDX). The alternative splicing produces mRNA which encodes for the putative p19 protein, that lacks transforming potential. Herein, we demonstrated that SR proteins regulate the intron D splicing. Moreover, we studied the 2719 mutation of H-ras which has higher transforming potential than Ile12 and Val12 H-ras mutants and is also known to affect the 5' splice site of the IDX. However, here we show that the 2719 mutant can still be spliced when the upstream 5' splice-site is blocked. During these later studies, additionally, we generated a short 11 nucleotides 5' terminal exon that was fully defined and spliced in a bi-intronic pre-mRNA. The definition of this mini-exon was also addressed in this work.	CSIC, IIBB, Dept PMT, Unidad Biol & Farmacol Mol Canc, ES-08034 Barcelona, Spain; Univ Warsaw, Dept Biophys, Inst Expt Phys, PL-02089 Warsaw, Poland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Warsaw	Bach-Elias, M (corresponding author), CSIC, IIBB, Dept PMT, Unidad Biol & Farmacol Mol Canc, C-Jorge Girona Salgado 18-26, ES-08034 Barcelona, Spain.		Guil, Sonia/M-8036-2015	Guil, Sonia/0000-0002-2257-3331				Codony C, 2001, ONCOGENE, V20, P3683, DOI 10.1038/sj.onc.1204473; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; CRISPINO JD, 1994, SCIENCE, V265, P1866, DOI 10.1126/science.8091213; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Huang MY, 1997, ONCOL RES, V9, P611; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; Lewis JD, 1997, EUR J BIOCHEM, V247, P461, DOI 10.1111/j.1432-1033.1997.00461.x; Lewis JD, 1996, GENE DEV, V10, P1683, DOI 10.1101/gad.10.13.1683; MacMillan AM, 1997, P NATL ACAD SCI USA, V94, P133, DOI 10.1073/pnas.94.1.133; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; Vogel J, 1997, NUCLEIC ACIDS RES, V25, P2030, DOI 10.1093/nar/25.10.2030; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zhu L, 1996, Methods Mol Biol, V57, P13	16	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	2002	21	36					5649	5653		10.1038/sj.onc.1205722	http://dx.doi.org/10.1038/sj.onc.1205722			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165864				2022-12-17	WOS:000177442000015
J	Paumelle, R; Tulasne, D; Kherrouche, Z; Plaza, S; Leroy, C; Reveneau, S; Vandenbunder, B; Fafeur, V				Paumelle, R; Tulasne, D; Kherrouche, Z; Plaza, S; Leroy, C; Reveneau, S; Vandenbunder, B; Fafeur, V			Hepatocyte growth factor scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway (vol 21, pg 2309, 2002)	ONCOGENE			English	Correction													Paumelle, Réjane/R-6675-2018; Tulasne, David/A-8705-2008; KHERROUCHE, Zoulika/HHN-0213-2022; Fafeur, Veronique/L-9072-2018; Tulasne, David/AAR-5287-2020	Paumelle, Réjane/0000-0002-4489-0717; Tulasne, David/0000-0002-6764-7242				Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297	1	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4872	4872		10.1038/sj.onc.1205607	http://dx.doi.org/10.1038/sj.onc.1205607			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ		Bronze			2022-12-17	WOS:000176716300018
J	Krutovskikh, VA; Piccoli, C; Yamasaki, H				Krutovskikh, VA; Piccoli, C; Yamasaki, H			Gap junction intercellular communication propagates cell death in cancerous cells (vol 21, pg 1989, 2002)	ONCOGENE			English	Correction																		Krutovskikh VA, 2002, ONCOGENE, V21, P1989, DOI 10.1038/sj.onc.1205187	1	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2002	21	28					4471	4471		10.1038/sj.onc.1205567	http://dx.doi.org/10.1038/sj.onc.1205567			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA		Bronze			2022-12-17	WOS:000176317100012
J	Herbert, BS; Pongracz, K; Shay, JW; Gryaznov, SM				Herbert, BS; Pongracz, K; Shay, JW; Gryaznov, SM			Oligonucleotide N3 '-> P5 ' phosphoramidates as efficient telomerase inhibitors (vol 21, pg 638, 2002)	ONCOGENE			English	Correction													Shay, Jerry W/F-7878-2011					Shea-Herbert B, 2002, ONCOGENE, V21, P638, DOI 10.1038/sj.onc.1205064	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2774	2774		10.1038/sj.onc.1205403	http://dx.doi.org/10.1038/sj.onc.1205403			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA		Bronze			2022-12-17	WOS:000174996500018
J	Latonen, L; Taya, Y; Laiho, M				Latonen, L; Taya, Y; Laiho, M			UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts (vol 20, pg 6784, 2001)	ONCOGENE			English	Correction																		Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883	1	1	1	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8165	8165		10.1038/sj.onc.1205057	http://dx.doi.org/10.1038/sj.onc.1205057			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ		Bronze			2022-12-17	WOS:000172396800015
J	Fueyo, J; Gomez-Manzano, C; Alemany, R; Lee, PSN; McDonnell, TJ; Mitlianga, P; Shi, YX; Levin, VA; Yung, WKA; Kyritsis, AP				Fueyo, J; Gomez-Manzano, C; Alemany, R; Lee, PSN; McDonnell, TJ; Mitlianga, P; Shi, YX; Levin, VA; Yung, WKA; Kyritsis, AP			A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo (vol 19, pg 2, 2000)	ONCOGENE			English	Correction													Mitlianga, Paraskevi/AAU-1541-2020	Mitlianga, Paraskevi/0000-0003-3145-5596; Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335				Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251	1	1	1	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 12	2000	19	43					5038	5038		10.1038/sj.onc.1203884	http://dx.doi.org/10.1038/sj.onc.1203884			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363KF		Bronze			2022-12-17	WOS:000089834300012
J	Wunder, JS				Wunder, JS			Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas (vol 18, pg 783, 1999)	ONCOGENE			English	Correction																		Wunder JS, 1999, ONCOGENE, V18, P783, DOI 10.1038/sj.onc.1202346	1	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1734	1734						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG					2022-12-17	WOS:000086083800016
J	Kaneko				Kaneko			Cell cycle-dependent and ATM-independent expression of human Chk1 kinase (vol 18, pg 3673, 1999)	ONCOGENE			English	Correction																		Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706	1	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	1999	18	37					5246	5246						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE					2022-12-17	WOS:000082555700014
J	Mitchell, PJ				Mitchell, PJ			Characterization and chromosome mapping of the human non receptor tyrosine kinase gene (vol 15, pg 1497, 1997)	ONCOGENE			English	Correction													Mitchell, Philip J/F-6393-2013					Mitchell PJ, 1997, ONCOGENE, V15, P1497, DOI 10.1038/sj.onc.1201292	1	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					129	129						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936					2022-12-17	WOS:000074677800015
J	Hahn, SL; Criqui-Filipe, P				Hahn, SL; Criqui-Filipe, P			Modulation of ETS-1 transcriptional activity by hullBC9, an ubiquitin-conjugating enzyme (vol 15, pg 1489, 1997)	ONCOGENE			English	Correction																		Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301	1	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					691	691						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376					2022-12-17	WOS:000071816600017
J	Albor, A; Thraves, PJ; Dritschilo, A; Notario, V				Albor, A; Thraves, PJ; Dritschilo, A; Notario, V			Oncogenic activation of the tyrosine kinase domain of the human trk protooncogene by fusion to a cell adhesion molecule	ONCOGENE			English	Article						radiation transformation; human keratinocytes; beta-1,4-galactosyltransferase; tumorigenicity assays; cosmid cloning	HUMAN EPIDERMAL-KERATINOCYTES; PAPILLARY THYROID CARCINOMAS; HAMSTER-EMBRYO FIBROBLASTS; NEOPLASTIC TRANSFORMATION; DNA REARRANGEMENT; POINT MUTATION; PROTO-ONCOGENE; GROWTH-FACTOR; GENE; GALACTOSYLTRANSFERASE	To investigate the mechanisms of radiation-induced neoplastic conversion, DNA from X-ray transformed human epidermal keratinocytes (RHEK-1) was used in sequential cycles of NM3T3 transfection followed by nude mice tumorigenicity assays. NM3T3-derived transformants retained discrete DNA fragments hybridizing to human alu probes. Pour clones were isolated from a cosmid library prepared from one of these transformants (49-7G) using human DNA as the probe. Analyses of DNAs from 49-7G cells and the four cosmid clones with probes for a number of human oncogenes demonstrated that the cloned sequences were related to the trk oncogene. Transfection of NM3T3 cells with the cosmid DNAs did not result in the appearance of transformed foci when the murine fibroblasts were cultured on plastic. However, foci developed when transfected cells were cultured on plates coated with various extracellular matrix (ECM) components. Neomycin-resistant cosmid-transfected NIH3T3 cells did induce tumors in nude mice, and their tumorigenicity correlated with their level of trk expression. Nucleotide sequence analyses of cDNA clones isolated from a 49-7G library with a human trk probe revealed that the cloned sequences resulted from the fusion between 5' sequences from the human beta-1,4-galactosyltransferase gene, which encodes a membrane protein involved in cell-cell and cell-matrix interactions, and 3' sequences from the human trk proto-oncogene. The 76 kDa protein product of the chimeric gene, designated bgt-trk, has been identified in NM3T3 cells transfected with cosmid 19/2 or with bgt-trk cDNA expression constructs, and its phosphorylation in tyrosine has been found to increase when the transfected cells were seeded on plates coated with ECM components which also elicited foci formation in NIH3T3 transformation assays. The fusion of the trk tyrosine kinase domain to a cell adhesion molecule may explain tbe ECM dependence for the expression of the full transforming potential of the resulting oncogene product.	GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,WASHINGTON,DC 20007	Georgetown University			/AAB-6461-2022; /AFP-0764-2022		NATIONAL CANCER INSTITUTE [R01CA052954] Funding Source: NIH RePORTER; NCI NIH HHS [CA52954] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBOR A, 1994, CANCER RES, V54, P4502; ALBOR A, 1994, MOL CARCINOG, V11, P1339; AVILA MA, 1995, ONCOGENE, V10, P963; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARCELLOSHOFF MH, 1992, EXP CELL RES, V201, P225, DOI 10.1016/0014-4827(92)90367-H; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BAYNA EM, 1988, CELL, V53, P145, DOI 10.1016/0092-8674(88)90496-5; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BUTTI MG, 1995, GENOMICS, V28, P15, DOI 10.1006/geno.1995.1100; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOPER GM, 1982, SCIENCE, V218, P801; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; DUNCAN AMV, 1986, BIOCHEM BIOPH RES CO, V141, P1185, DOI 10.1016/S0006-291X(86)80169-3; ECKSTEIN DJ, 1992, EXP CELL RES, V201, P83, DOI 10.1016/0014-4827(92)90350-H; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GONG XH, 1995, SCIENCE, V269, P1718, DOI 10.1126/science.7569899; GRECO A, 1995, MOL CELL BIOL, V15, P6118; GRECO A, 1992, ONCOGENE, V7, P237; GRECO A, 1993, GENOMICS, V18, P397, DOI 10.1006/geno.1993.1482; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; NOTARIO V, 1990, ONCOGENE, V5, P1425; OHUCHI T, 1992, ONCOGENE, V7, P331; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPER NL, 1986, SOMAT CELL MOLEC GEN, V12, P633, DOI 10.1007/BF01671948; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; THRAVES P, 1990, P NATL ACAD SCI USA, V87, P1174, DOI 10.1073/pnas.87.3.1174; THRAVES P, 1991, MECH CARCINOGENESIS, P93; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	46	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1755	1763						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895522				2022-12-17	WOS:A1996VM88700021
J	Korhonen, J; Polvi, A; Partanen, J; Alitalo, K				Korhonen, J; Polvi, A; Partanen, J; Alitalo, K			The mouse tie receptor tyrosine kinase gene: Expression during embryonic angiogenesis (vol 9, pg 395, 1994)	ONCOGENE			English	Correction, Addition																		KORHONEN J, 1994, ONCOGENE, V9, P395	1	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					943	943						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686					2022-12-17	WOS:A1996TW68600027
J	Storey, A; Massini, P; Dawson, K; Banks, L				Storey, A; Massini, P; Dawson, K; Banks, L			Conditional immortalization of primary cells by human papillomavirus type 18 E6 and E5-ras defines an E6 activity in G(0)/G(1) phase which can be substituted for by mutations in p53 (vol 11, pg 653, 1995)	ONCOGENE			English	Correction, Addition														Storey, Alan/0000-0003-2001-9772				STOREY A, 1995, ONCOGENE, V11, P653	1	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					945	945						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686					2022-12-17	WOS:A1996TW68600028
J	FELIX, CA; WASSERMAN, R; CESANO, A; NOWELL, PC; HOSLER, MR; MASTERSON, M; POPLACK, DG; SANTOLI, D				FELIX, CA; WASSERMAN, R; CESANO, A; NOWELL, PC; HOSLER, MR; MASTERSON, M; POPLACK, DG; SANTOLI, D			CLONAL EXPANSION OF GERMLINE B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA IN SEVERE COMBINED IMMUNODEFICIENT MICE	ONCOGENE			English	Article						CDR3; POLYMERASE CHAIN REACTION; SOUTHERN BLOT ANALYSIS; DIFFERENTIATION; SUBCLONE	IMMUNOGLOBULIN HEAVY-CHAIN; T-CELL; GENE REARRANGEMENT; RESIDUAL DISEASE; ALL-1 GENE; CHILDHOOD; DIFFERENTIATION; EXPRESSION; PATTERNS; ORIGIN	CD19(+) B lineage acute lymphoblastic leukemias (ALLs) with unrearranged Ig and TCR genes are designated germline B lineage ALLS. We used CDR3 PCR to determine whether pediatric germline B lineage ALLs contain minor subclones with rearranged Ig H V genes. In six of seven cases there were no PCR detectable CDR3 rearrangements. One case with a smear pattern on CDR3 PCR contained multiple unique CDR3 sequences at frequencies of 1-2 per 2 600, suggesting that polyclonal B cells were present at low frequency. To verify that the germline patterns were from leukemic cells and evaluate in vivo subclone differentiation, a germline B lineage ALL with the t(4;11) translocation was propagated in severe combined immunodeficient (SCID) mice. The Ig and TCR genes in the leukemic cells recovered from mouse tissues were germline by Southern blot analysis except for single rearrangements that suggested subclone evolution at the Ig H and lambda loci in addition to the germline population. No CDR3 sequences were detected, indicating that the observed Ig H gene rearrangement most likely was a DJ joining. This study suggests that the transformed cell ingermline B lineage ALL represents an early pro-B cell with limited tendency to further differentiate.	UNIV PENN,SCH MED,WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV CINCINNATI,CHILDRENS HOSP,MED CTR,DEPT PEDIAT,CINCINNATI,OH 45229; TEXAS CHILDRENS HOSP,BAYLOR COLL MED,HEMATOL ONCOL SERV,HOUSTON,TX 77030	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Baylor College of Medicine	FELIX, CA (corresponding author), UNIV PENN,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,DIV ONCOL,PHILADELPHIA,PA 19104, USA.				NCI NIH HHS [CA-42232] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042232] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANVRET M, 1984, NUCLEIC ACIDS RES, V12, P1149, DOI 10.1093/nar/12.2.1149; BEISHUIZEN A, 1994, BLOOD, V83, P2238, DOI 10.1182/blood.V83.8.2238.bloodjournal8382238; BEISHUIZEN A, 1991, LEUKEMIA, V5, P657; BEISHUIZEN A, 1992, LEUKEMIA, V6, P60; BIONDI A, 1989, BLOOD, V73, P2133; BIRD J, 1988, J EXP MED, V168, P229, DOI 10.1084/jem.168.1.229; BORIES JC, 1991, BLOOD, V78, P2053, DOI 10.1182/blood.V78.8.2053.bloodjournal7882053; CESANO A, 1991, BLOOD, V77, P2463; CESANO A, 1992, ONCOGENE, V7, P827; DAVEY MP, 1986, P NATL ACAD SCI USA, V83, P8759, DOI 10.1073/pnas.83.22.8759; DEANE M, 1991, LEUKEMIA, V5, P832; EHRLICH A, 1993, CELL, V72, P695; FELIX CA, 1993, CANCER RES, V53, P2954; FELIX CA, 1987, J CLIN INVEST, V80, P545, DOI 10.1172/JCI113103; FELIX CA, 1987, BLOOD, V70, P536; FELIX CA, 1990, J CLIN ONCOL, V8, P431, DOI 10.1200/JCO.1990.8.3.431; FELIX CA, 1994, LEUKEMIA, V8, P963; FOA R, 1984, J CLIN INVEST, V74, P1756, DOI 10.1172/JCI111594; GREENBERG JM, 1986, J IMMUNOL, V137, P2043; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HARA J, 1988, J CLIN INVEST, V82, P1974, DOI 10.1172/JCI113817; HUNGER SP, 1993, BLOOD, V81, P3197; JANSEN B, 1992, CANCER RES, V52, P406; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; KITCHINGMAN GR, 1986, BLOOD, V67, P698; KITCHINGMAN GR, 1993, BLOOD, V81, P775; KIYOI H, 1992, J CLIN INVEST, V89, P739, DOI 10.1172/JCI115650; KORSMEYER SJ, 1983, J CLIN INVEST, V71, P301, DOI 10.1172/JCI110770; LEBIEN TW, 1990, HEMATOL ONCOL CLIN N, V4, P835, DOI 10.1016/S0889-8588(18)30470-2; MIRRO J, 1986, BLOOD, V67, P689; NADLER LM, 1984, J CLIN INVEST, V74, P332, DOI 10.1172/JCI111428; RAIMONDI SC, 1993, BLOOD, V81, P2237; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; STEENBERGEN EJ, 1993, BLOOD, V82, P581, DOI 10.1182/blood.V82.2.581.bloodjournal822581; TYCKO B, 1992, BLOOD, V79, P481; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1988, BLOOD, V71, P13; VANDONGEN JJM, 1987, J IMMUNOL, V138, P1260; WASSERMAN R, 1992, BLOOD, V79, P223; YAMADA M, 1989, P NATL ACAD SCI USA, V86, P5123, DOI 10.1073/pnas.86.13.5123; YAMADA M, 1991, J EXP MED, V173, P395, DOI 10.1084/jem.173.2.395; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705; YONEDA N, 1993, BLOOD, V82, P207, DOI 10.1182/blood.V82.1.207.bloodjournal821207	43	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1753	1759						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478603				2022-12-17	WOS:A1995TD09400010
J	BUIJS				BUIJS			TRANSLOCATION (12-22)(P13-Q11) IN MYELOPROLIFERATIVE DISORDERS RESULTS IN FUSION OF THE ETS-LIKE TEL GENE ON 12P13 TO THE MN1 GENE ON 22Q11 (VOL 10, PG 1511, 1995)	ONCOGENE			English	Correction, Addition																		BUIJS, 1995, ONCOGENE, V10, P1511	1	1	1	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					809	809						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469					2022-12-17	WOS:A1995RQ46900025
J	LEIBOVITCH, MP; SOLHONNE, B; GUILLIER, M; VERRELLE, P; LEIBOVITCH, SA				LEIBOVITCH, MP; SOLHONNE, B; GUILLIER, M; VERRELLE, P; LEIBOVITCH, SA			DIRECT RELATIONSHIP BETWEEN THE EXPRESSION OF TUMOR-SUPPRESSOR H19 MESSENGER-RNA AND C-MOS PROTOONCOGENE DURING MYOGENESIS (VOL 10, PG 251, 1995)	ONCOGENE			English	Correction, Addition									CTR JEAN PERRIN,SERV RADIOTHERAPIE,F-63011 CLERMONT FERRAND,FRANCE	UNICANCER; Centre Jean Perrin	LEIBOVITCH, MP (corresponding author), INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 126,UA 1158,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.							LEIBOVITCH MP, 1995, ONCOGENE, V10, P251	1	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					605	605						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530					2022-12-17	WOS:A1995RN53000023
J	HEIGHWAY, J; WHITE, GRM; HARTLEY, AL; BIRCH, JM; SANTIBANEZKOREF, MF				HEIGHWAY, J; WHITE, GRM; HARTLEY, AL; BIRCH, JM; SANTIBANEZKOREF, MF			RARE VARIANT (GLU TO LYS) IN THE LEUCINE-ZIPPER REGION OF CHOP (GADD153)	ONCOGENE			English	Note							GENE; TRANSCRIPTION; LIPOSARCOMA; PROTEIN; FUSION	CHOP (GADD153) has been shown to be a dominant negative inhibitor of specific transcription factors. Direct sequencing of the gene, amplified from the DNA of a Li-Fraumeni family index case (liposarcoma, breast cancer) revealed a constitutional variant within the coding region. This alteration, though not responsible for the Li-Fraumeni phenotype, resulted in a glutamic acid to lysine switch within the leucine zipper domain, at a residue conserved between CHOP and its potential target molecules and between the human and hamster sequences. The variant created a Tag I restriction fragment length polymorphism (RFLP) facilitating screening. Analysis of 159 breast tumour DNA samples detected two encoding variant alleles (tumour and constitutional DNA).	CHRISTIE CRC RES CTR,CRC,PAEDIAT & FAMILIAL RES GRP,MANCHESTER,LANCS,ENGLAND		HEIGHWAY, J (corresponding author), CHRISTIE CRC RES CTR,PATERSON INST CANC RES,CRC,DEPT CANC GENET,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.							AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; BIRCH JM, 1994, CANCER RES, V54, P1298; BRUGIERES L, 1993, CANCER RES, V53, P452; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439	9	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2737	2738						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058339				2022-12-17	WOS:A1994PC05400037
J	BOCCO, JL; REIMUND, B; CHATTON, B; KEDINGER, C				BOCCO, JL; REIMUND, B; CHATTON, B; KEDINGER, C			RB MAY ACT AS A TRANSCRIPTIONAL COACTIVATOR IN UNDIFFERENTIATED F9 CELLS (VOL 8, PG 2977, 1993)	ONCOGENE			English	Correction, Addition													CHATTON, Bruno/R-3813-2019					BOCCO, 1993, ONCOGENE, V8, P2977	1	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					999	999						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551					2022-12-17	WOS:A1994MW55100042
J	BOTTAZZI, ME; GOODENOW, MM; MOSCOVICI, MG; MOSCOVICI, C				BOTTAZZI, ME; GOODENOW, MM; MOSCOVICI, MG; MOSCOVICI, C			BM2L IS A SPONTANEOUS LEUKEMOGENIC VARIANT OF A NON-LEUKEMOGENIC V-MYB-TRANSFORMED MYELOID CELL-LINE	ONCOGENE			English	Article							C-MYB; ONCOGENE; LEUKEMIA; VIRUSES; DIFFERENTIATION; SEQUENCES	Leukemogenesis is a complex process involving an accumulation of genetic lesions affecting both growth and differentiation in cells of the hematopoietic lineage. Our laboratory has established a non-producer v-myb-transformed cell line (BM2/C3A) which, when injected into the chicken embryo, does not produce leukemia. Recently, a spontaneous variant of this cell line, called BM2L, was obtained from in vivo experiments. BM2L produces an acute monoblastic leukemia when injected into the chicken embryo. BM2L cells do not differentiate in vivo or in vitro, but continue to proliferate under conditions in culture that allow for the differentiation of BM2/C3A cells into macrophages. In addition, BM2L cells have reduced requirements for exogenous growth factors. BM2L cells contain the v-myh allele and express v-Myb protein, but leukemogenicity does not involve point mutations in v-myb. The BM2 model, consisting of two non-producer cell lines differing in vivo in their leukemogenicity, provides a novel system for identifying genes that play a role in the induction or suppression of leukemogenesis.	UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT PATHOL,GAINESVILLE,FL 32610; VET ADM MED CTR,DEPT PEDIAT,DIV IMMUNOL,GAINESVILLE,FL 32602; VET ADM MED CTR,CTR MAMMALIAN GENET,GAINESVILLE,FL 32602; VET ADM MED CTR,TUMOR VIROL LAB,GAINESVILLE,FL 32602	State University System of Florida; University of Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)				Bottazzi, Maria Elena/0000-0002-8429-0476	NATIONAL CANCER INSTITUTE [R01CA010697] Funding Source: NIH RePORTER; NCI NIH HHS [CA10697] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAER MR, 1991, ANNU REV MED, V42, P381, DOI 10.1146/annurev.me.42.020191.002121; CHEN JH, 1980, VIROLOGY, V103, P112, DOI 10.1016/0042-6822(80)90130-0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GOODENOW MM, 1987, J VIROL, V61, P2489, DOI 10.1128/JVI.61.8.2489-2498.1987; GOUGH NM, 1989, CANCER CELL-MON REV, V1, P77; GRIMES HL, 1992, NUCLEIC ACIDS RES, V20, P1511, DOI 10.1093/nar/20.7.1511; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KIM WK, 1988, ONCOGENE RES, V3, P147; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOSCOVICI C, 1976, VIROLOGY, V73, P181, DOI 10.1016/0042-6822(76)90072-6; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI C, 1982, EXPRESSION DIFFERENT; MOSCOVICI C, 1982, ADV VIRAL ONCOLOGY, V1; MOSCOVICI MG, 1980, IN VIVO IN VITRO ERY, P503; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHUU RER, 1991, ONCOGENE, V6, P1409; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0	25	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					731	736						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437856				2022-12-17	WOS:A1993KN00800025
J	STEUER, B; STOPPLER, H; BREUER, B; ALONSO, A				STEUER, B; STOPPLER, H; BREUER, B; ALONSO, A			TRANSCRIPTION OF BPV-1 GENES IN TRANSFECTED F9 CELLS	ONCOGENE			English	Article							BOVINE PAPILLOMAVIRUS TYPE-1; MURINE TERATOCARCINOMA CELLS; EMBRYONAL CARCINOMA-CELLS; STEM-CELLS; DNA; DIFFERENTIATION; EXPRESSION; KERATINOCYTES; ANTIGEN; INVITRO	In F9 cells transformed with bovine papillomavirus type 1 (BPV-1) sequences two different phenotypes can be recognized. One cell type shows the characteristics of the parental stem cell line, whereas the other comprises cells with spindle-like morphology that do not adhere to each other, similar to retinoic acid-treated F9 embryonal carcinoma cells. The phenotypically altered cells plate more efficiently than the stem cells, grow well in soft agar and show an extended lifespan in the differentiated stage. Both types of cells contain BPV-1 DNA sequences as episomes, but only the non-stem-like cells have RNA transcripts for the unspliced E5 reading frame as well as for the spliced E6/E4.	GERMAN CANC RES CTR,NEUENHEIMER FELD 280,W-6900 HEIDELBERG 1,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								BREUER B, 1989, GENE, V81, P307, DOI 10.1016/0378-1119(89)90191-1; DURST M, 1987, ONCOGENE, V1, P251; Hogan B. L. M, 1983, CANCER SURV, V2, P115; LAMBERT PF, 1988, ANNU REV GENET, V22, P235, DOI 10.1146/annurev.ge.22.120188.001315; LAW MF, 1981, P NATL ACAD SCI-BIOL, V78, P2727, DOI 10.1073/pnas.78.5.2727; LEVINE RA, 1984, MOL CELL BIOL, V4, P2142, DOI 10.1128/MCB.4.10.2142; LINNENBACH A, 1980, P NATL ACAD SCI-BIOL, V77, P4875, DOI 10.1073/pnas.77.8.4875; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; ROSENSTRAUS MJ, 1982, DEV BIOL, V89, P516, DOI 10.1016/0012-1606(82)90340-2; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SWARTZENDRUBER DE, 1975, J CELL PHYSIOL, V85, P179, DOI 10.1002/jcp.1040850204; TIENARI J, 1987, DEV BIOL, V123, P566, DOI 10.1016/0012-1606(87)90415-5; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030	18	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1875	1878						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323821				2022-12-17	WOS:A1992JJ37600025
J	HADDOW, S				HADDOW, S			CORRECTION	ONCOGENE			English	Correction, Addition																		HADDOW S, 1991, ONCOGENE, V6, P1465	1	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2377	2377						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735					2022-12-17	WOS:A1991GX73500030
J	SCHUUR, ER; BALUDA, MA				SCHUUR, ER; BALUDA, MA			PROTOONCOGENE EXPRESSION IN AVIAN HEMATOPOIETIC TISSUES	ONCOGENE			English	Article							MURINE SARCOMA VIRUS-3611; C-MYB PROTEIN; NF-KAPPA-B; V-MYB; MYELOBLASTOSIS VIRUS; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; TRANSFORMING GENE; PROTOONCOGENE EXPRESSION	Previous findings from this laboratory (Kim & Baluda, 1988) have shown that the proto-oncogenes ETS, FPS, MHT (RAF), MYC and REL are expressed in avian myeloblastosis virus (AMV)-transformed cells, whereas the MYB gene is repressed. In this study five different chicken hematopoietic tissues which contained varying concentrations of target cells for AMV transformation were analyzed to determine whether the expression of these proto-oncogenes resulted from, or was altered by, v-myb-induced leukemogenesis. Poly-A+ RNA from hematopoietic cells of 11-13 day yolk sac, 16 day embryonic spleen, 1 day post-hatch bursa of Fabricius, bone marrow and thymus, as well as from chicken embryonic fibroblasts (CEF) was examined by Northern blot analysis. All five proto-oncogenes were found to be expressed in the normal hematopoietic tissues. The ETS, MHT (RAF), MYC, and REL genes, but not FPS, were expressed in CEF. The expression of these five proto-oncogenes was not quantitatively or qualitatively altered in AMV-transformed myeloid cells as compared with their normal counterparts. While their expression is part of the hematopoietic phenotype of the target cells and as such is necessary for susceptibility to AMV transformation, it is not sufficient because thymocytes with a high level of expression are not transformed. This is in contrast to MYB expression, which is totally repressed in leukemic cells but probably not as a result of v-myb expression.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [R01 CA 10197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA010197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENDER TP, 1987, J IMMUNOL, V139, P3822; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DIETERLENLIEVRE F, 1986, VERTEBRATE BLOOD CEL; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLORDELLIS CS, 1985, VIROLOGY, V141, P267, DOI 10.1016/0042-6822(85)90257-0; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HUANG CC, 1984, J VIROL, V50, P125, DOI 10.1128/JVI.50.1.125-131.1984; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; KIM WK, 1988, ONCOGENE RES, V3, P147; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LEE WH, 1980, P NATL ACAD SCI-BIOL, V77, P2018, DOI 10.1073/pnas.77.4.2018; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LIPSICK JS, 1984, CANCER CELLS, V2, P143; MCKEON C, 1988, CANCER RES, V48, P4307; Moscovici C., 1973, Methods Cell Biol, V7, P313; MOSCOVICI MG, 1979, IN VIVO IN VITRO ERY; NUNN M, 1984, VIROLOGY, V139, P330, DOI 10.1016/0042-6822(84)90378-7; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; PREISLER HD, 1987, LEUKEMIA RES, V11, P923, DOI 10.1016/0145-2126(87)90138-X; ROMANOFF A, 1961, AVIAN EMBRYO; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; THOMPSON CB, 1986, NATURE, V319, P380; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984	62	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1409	1415						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886713				2022-12-17	WOS:A1991GX27200017
J	SOPCHAK, L; THRUSH, GR; LERMAN, SP; KING, SR				SOPCHAK, L; THRUSH, GR; LERMAN, SP; KING, SR			LOSS OF MYB EXPRESSION IN AN AGGRESSIVE SJL/J B-CELL LYMPHOMA	ONCOGENE			English	Article							C-MYB; NUCLEOTIDE-SEQUENCE; ONCOGENE ACTIVATION; V-MYB; DNA; SARCOMAS; TUMORS; GENES; MICE; AMPLIFICATION	SJL mice spontaneously develop B-cell lymphomas that can be propagated by transplantation into syngeneic mice. These tumors usually have an indolent phenotype and require at least several weeks to produce morbidity following transplantation. However an aggressive lymphoma (RCS5) has been found that produces morbidity within days of transplantation. RCS5 cells fail to express the H-2D(s) class I major histocompatibility complex antigen, whereas indolent tumors express H-2D(s). To identify genetic factors that may contribute to the tumorigenicity of B-cell lymphomas in SJL mice, tumor genomes were analyzed for mutations in cellular oncogenes. No rearrangements were detected by Southern hybridization analysis in tumors at the abl, myc, mhcl-2, Ha-ras, Ki-ras and raf loci. Indolent tumors were not rearranged at the myb oncogene, however alterations were detected in both myb alleles in RCS5. Northern hybridization analysis on RNA from in vivo-derived tumor preparations failed to detect any myb transcripts in RCS5. The loss of normal myb expression could directly contribute to the aggressive phenotype of RCS5. Alternatively, expression of the RCS5 myb allele may have contributed to early stages of tumor development. The possibilities that the observed myb mutations affect tumor aggressiveness and H-2D(s) expression are discussed.	WAYNE STATE UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,DETROIT,MI 48201	Wayne State University			King, Steven/AAE-2526-2019		NCI NIH HHS [CA22453, CA52603] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052603, P30CA022453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER TP, 1987, J IMMUNOL, V139, P3822; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BONAVIDA B, 1985, SURV IMMUNOL RES, V4, P271; BUTCH AW, 1986, 6TH INT C IMM, P397; CAVENEE W, 1989, RECESSIVE ONCOGENES; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; GRUNWALD DJ, 1982, J VIROL, V43, P92, DOI 10.1128/JVI.43.1.92-103.1982; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MURPHY ED, 1969, J NATL CANCER I, V42, P797; NAKAUCHI H, 1987, J IMMUNOL, V139, P2803; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; Ponzio N M, 1986, Int Rev Immunol, V1, P273, DOI 10.3109/08830188609056610; PONZIO NM, 1977, CELL IMMUNOL, V32, P10, DOI 10.1016/0008-8749(77)90178-2; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROSLONIEC EF, 1984, J IMMUNOL, V132, P945; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; Sambrook J., 1989, MOL CLONING LAB MANU; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SOPCHAK L, 1989, CANCER RES, V49, P665; STAVNEZER J, 1989, EUR J IMMUNOL, V19, P1063, DOI 10.1002/eji.1830190616; WIRSCHUBSKY Z, 1984, INT J CANCER, V33, P477, DOI 10.1002/ijc.2910330410; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	34	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1335	1338						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886709				2022-12-17	WOS:A1991GX27200006
J	VANDEWOUDE, GF; REDDY, EP				VANDEWOUDE, GF; REDDY, EP			ONCOGENES AND THE NOBEL-PRIZE	ONCOGENE			English	Editorial Material									WISTAR INST, PHILADELPHIA, PA 19104 USA	The Wistar Institute	VANDEWOUDE, GF (corresponding author), FREDERICK CANC RES FACIL, BLDG 469, FREDERICK, MD 21701 USA.		Reddy, E. Premkumar/F-6233-2011					BADER JP, 1972, J VIROL, V10, P267, DOI 10.1128/JVI.10.2.267-276.1972; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; DUESBERG PH, 1970, P NATL ACAD SCI USA, V67, P1673, DOI 10.1073/pnas.67.4.1673; HANAFUSA H, 1977, J EXP MED, V146, P1735, DOI 10.1084/jem.146.6.1735; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; LAI MMC, 1973, P NATL ACAD SCI USA, V70, P2266, DOI 10.1073/pnas.70.8.2266; MARTIN GS, 1970, NATURE, V227, P1021, DOI 10.1038/2271021a0; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0	11	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1990	5	1					3	3						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2320371				2022-12-17	WOS:A1990CM62000001
J	THEILLET				THEILLET			CORRECTION	ONCOGENE			English	Correction, Addition																		THEILLET, 1989, ONCOGENE, V4, P915	1	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1537	1537						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659					2022-12-17	WOS:A1989CB65900020
J	HARVEY, RC				HARVEY, RC			CORRECTION	ONCOGENE			English	Correction, Addition																		HARVEY RC, 1989, ONCOGENE, V4, P341	1	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					1057	1057						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297					2022-12-17	WOS:A1989AJ29700018
J	LAGARDE, AE				LAGARDE, AE			METASTATIC CONVERSION OF FACTOR-DEPENDENT LUNG FIBROBLASTS (CCL39) REQUIRES OVER-EXPRESSION OF ONCOGENES WHICH INDUCE HIGH-RATE OF AUTONOMOUS REPLICATION	ONCOGENE			English	Article									UNIV TORONTO,DEPT MED GENET,TORONTO M5G 1X5,ONTARIO,CANADA	University of Toronto	LAGARDE, AE (corresponding author), MT SINAI HOSP,RES INST,DIV CANC & CELL BIOL,ROOM 876,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA.							ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BAUER EA, 1985, P NATL ACAD SCI USA, V82, P4132, DOI 10.1073/pnas.82.12.4132; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; CHADWICK DE, 1988, J NATL CANCER I, V80, P318, DOI 10.1093/jnci/80.5.318; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHUA CC, 1985, J BIOL CHEM, V260, P5213; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COLLARD JG, 1987, CANCER RES, V47, P754; DENHARDT DT, 1987, ONCOGENE, V2, P55; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; GARBISA S, 1987, CANCER RES, V47, P1523; GREENBERG AH, 1987, CANCER RES, V47, P4801; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; GRIMALDI G, 1986, EMBO J, V5, P855, DOI 10.1002/j.1460-2075.1986.tb04295.x; HANNINK M, 1984, SCIENCE, V226, P1197, DOI 10.1126/science.6095451; HILL SA, 1988, J NATL CANCER I, V80, P484, DOI 10.1093/jnci/80.7.484; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MACHIDA CM, 1988, MOL CELL BIOL, V8, P2479, DOI 10.1128/MCB.8.6.2479; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; OWEN RD, 1987, MOL CELL BIOL, V7, P2512, DOI 10.1128/MCB.7.7.2512; PEREZRODRIGUEZ R, 1981, J CELL PHYSIOL, V109, P387, DOI 10.1002/jcp.1041090303; PEREZRODRIGUEZ R, 1982, INT J CANCER, V29, P309, DOI 10.1002/ijc.2910290314; PICHON F, 1988, ONCOGENE, V3, P373; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; RADINSKY R, 1987, P NATL ACAD SCI USA, V84, P5143, DOI 10.1073/pnas.84.15.5143; RENWICK DE, 1986, JNCI-J NATL CANCER I, V77, P105; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SADOWSKI I, 1988, ONCOGENE, V2, P241; SALO T, 1985, J BIOL CHEM, V260, P8526; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STORER RD, 1988, ONCOGENE, V2, P141; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; VANOBBERGHENSCHILLING E, 1983, J CELL PHYSIOL, V115, P123, DOI 10.1002/jcp.1041150204; VANOBBERGHENSCHILLING E, 1983, EXP CELL RES, V147, P369, DOI 10.1016/0014-4827(83)90219-7; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WAGHORNE C, 1987, ONCOGENE, V1, P149; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917	51	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					889	895						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2755702				2022-12-17	WOS:A1989AE58400011
J	MANNE, V				MANNE, V			A NOVEL CANDIDATE FOR RECEPTOR-COUPLED PHOSPHOLIPASE-C PURIFIED FROM HUMAN-PLATELETS	ONCOGENE			English	Article											MANNE, V (corresponding author), WISTAR INST ANAT & BIOL,36TH ST & SPRUCE,PHILADELPHIA,PA 19104, USA.		manne, veeraswamy/B-1954-2010	manne, veeraswamy/0000-0002-1179-5529	PHS HHS [21124] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANNO Y, 1986, BIOCHEM BIOPH RES CO, V136, P713, DOI 10.1016/0006-291X(86)90498-5; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILLAH MM, 1980, J BIOL CHEM, V255, P227; CHAU LY, 1982, BIOCHIM BIOPHYS ACTA, V713, P344; COCKCROFT S, 1984, BIOCHEM J, V221, P477, DOI 10.1042/bj2210477; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; DAWSON RMC, 1973, FORM FUNCTION PHOSPH, P97; DECKMYN H, 1986, J BIOL CHEM, V261, P6553; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; HAKATA H, 1982, J BIOCHEM-TOKYO, V92, P929, DOI 10.1093/oxfordjournals.jbchem.a134008; HIRASAWA K, 1982, BIOCHEM J, V205, P437, DOI 10.1042/bj2050437; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; IRVINE RF, 1982, CELL CALCIUM, V3, P295, DOI 10.1016/0143-4160(82)90018-5; IRVINE RF, 1984, BIOCHEM J, V218, P177, DOI 10.1042/bj2180177; JACKOWSKI S, 1986, J BIOL CHEM, V261, P4978; KATAN M, 1987, EUR J BIOCHEM, V168, P413, DOI 10.1111/j.1432-1033.1987.tb13435.x; LENSTRA R, 1984, BIOCHIM BIOPHYS ACTA, V792, P199, DOI 10.1016/0005-2760(84)90223-6; LITOSCH I, 1985, J BIOL CHEM, V260, P5464; LOW MG, 1983, BIOCHEM J, V215, P325, DOI 10.1042/bj2150325; LOW MG, 1986, BIOCHEM J, V237, P139, DOI 10.1042/bj2370139; MAJERUS PW, 1984, CELL, V37, P701, DOI 10.1016/0092-8674(84)90405-7; MANNE V, 1987, BIOCHEM J, V243, P763, DOI 10.1042/bj2430763; MANNE V, 1987, ONCOGENE, V2, P49; NAKAMURA K, 1985, THROMB RES, V38, P513, DOI 10.1016/0049-3848(85)90184-7; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; REBECCHI MJ, 1987, BIOCHEM J, V245, P49, DOI 10.1042/bj2450049; RUGGIERO M, 1985, BIOCHEM BIOPH RES CO, V131, P1198, DOI 10.1016/0006-291X(85)90218-9; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; RYU SH, 1986, BIOCHEM BIOPH RES CO, V136, P713; SIESS W, 1983, BIOCHIM BIOPHYS ACTA, V752, P329, DOI 10.1016/0005-2760(83)90131-5; SMITH CD, 1985, J BIOL CHEM, V260, P5875; WILCHEK M, 1984, METHOD ENZYMOL, V104, P3	35	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					579	585						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2856255				2022-12-17	WOS:A1988R516300015
J	GANGULY, S				GANGULY, S			DESCRIPTION OF A HUMAN PLACENTAL ANTI-INSULIN RECEPTOR POLYCLONAL ANTIBODY THAT ACTIVATES INSULIN BINDING TO THE RECEPTOR INVITRO	ONCOGENE			English	Article									YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine								CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; DAS M, 1984, EUR J BIOCHEM, V141, P429, DOI 10.1111/j.1432-1033.1984.tb08209.x; DEUTSCH PJ, 1983, P NATL ACAD SCI-BIOL, V80, P133, DOI 10.1073/pnas.80.1.133; FREDMAN P, 1983, J BIOL CHEM, V258, P1206; GANGULY S, 1987, FEBS LETT, V224, P198, DOI 10.1016/0014-5793(87)80447-7; GANGULY S, 1985, CURR TOP CELL REGUL, V27, P83; HEDO JA, 1981, P NATL ACAD SCI-BIOL, V78, P4791, DOI 10.1073/pnas.78.8.4791; IKEDA Y, 1976, J BIOL CHEM, V251, P6135; JACOBS S, 1978, SCIENCE, V200, P1283, DOI 10.1126/science.663609; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KASUGA M, 1981, DIABETES, V30, P354, DOI 10.2337/diabetes.30.4.354; KHAN CR, 1976, NEW ENGL J MED, V294, P739; KULL FC, 1982, BIOCHEM BIOPH RES CO, V106, P1019, DOI 10.1016/0006-291X(82)91813-7; MORGAN D, 1986, BIOCHEMISTRY, V25, P1371; PETRUZZELLI LM, 1982, P NATL ACAD SCI-BIOL, V79, P6792, DOI 10.1073/pnas.79.22.6792; PONZIO G, 1987, EMBO J, V6, P333, DOI 10.1002/j.1460-2075.1987.tb04759.x; ROTH RA, 1982, P NATL ACAD SCI-BIOL, V79, P7312, DOI 10.1073/pnas.79.23.7312; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; SIEGEL TW, 1981, J BIOL CHEM, V256, P9266; ZICK Y, 1984, J BIOL CHEM, V259, P4396	20	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					341	344						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3144692				2022-12-17	WOS:A1988Q436700014
